Word	Tag	Begin-End
A	O	0-1
common	O	2-8
human	O	9-14
skin	B	15-19
tumour	I	20-26
is	O	27-29
caused	O	30-36
by	O	37-39
activating	O	40-50
mutations	O	51-60
in	O	61-63
beta	O	64-68
-	O	68-69
catenin	O	69-76
.	O	76-77

WNT	O	78-81
signalling	O	82-92
orchestrates	O	93-105
a	O	106-107
number	O	108-114
of	O	115-117
developmental	O	118-131
programs	O	132-140
.	O	140-141

In	O	142-144
response	O	145-153
to	O	154-156
this	O	157-161
stimulus	O	162-170
,	O	170-171
cytoplasmic	O	172-183
beta	O	184-188
-	O	188-189
catenin	O	189-196
(	O	197-198
encoded	O	198-205
by	O	206-208
CTNNB1	O	209-215
)	O	215-216
is	O	217-219
stabilized	O	220-230
,	O	230-231
enabling	O	232-240
downstream	O	241-251
transcriptional	O	252-267
activation	O	268-278
by	O	279-281
members	O	282-289
of	O	290-292
the	O	293-296
LEF	O	297-300
/	O	300-301
TCF	O	301-304
family	O	305-311
.	O	311-312

One	O	313-316
of	O	317-319
the	O	320-323
target	O	324-330
genes	O	331-336
for	O	337-340
beta	O	341-345
-	O	345-346
catenin	O	346-353
/	O	353-354
TCF	O	354-357
encodes	O	358-365
c	O	366-367
-	O	367-368
MYC	O	368-371
,	O	371-372
explaining	O	373-383
why	O	384-387
constitutive	O	388-400
activation	O	401-411
of	O	412-414
the	O	415-418
WNT	O	419-422
pathway	O	423-430
can	O	431-434
lead	O	435-439
to	O	440-442
cancer	B	443-449
,	O	449-450
particularly	O	451-463
in	O	464-466
the	O	467-470
colon	O	471-476
.	O	476-477

Most	O	478-482
colon	B	483-488
cancers	I	489-496
arise	O	497-502
from	O	503-507
mutations	O	508-517
in	O	518-520
the	O	521-524
gene	O	525-529
encoding	O	530-538
adenomatous	B	539-550
polyposis	I	551-560
coli	I	561-565
(	O	566-567
APC	B	567-570
)	O	570-571
,	O	571-572
a	O	573-574
protein	O	575-582
required	O	583-591
for	O	592-595
ubiquitin	O	596-605
-	O	605-606
mediated	O	606-614
degradation	O	615-626
of	O	627-629
beta	O	630-634
-	O	634-635
catenin	O	635-642
,	O	642-643
but	O	644-647
a	O	648-649
small	O	650-655
percentage	O	656-666
of	O	667-669
colon	B	670-675
and	I	676-679
some	I	680-684
other	I	685-690
cancers	I	691-698
harbour	O	699-706
beta	O	707-711
-	O	711-712
catenin	O	712-719
-	O	711-712
stabilizing	O	720-731
mutations	O	732-741
.	O	741-742

Recently	O	743-751
,	O	751-752
we	O	753-755
discovered	O	756-766
that	O	767-771
transgenic	O	772-782
mice	O	783-787
expressing	O	788-798
an	O	799-801
activated	O	802-811
beta	O	812-816
-	O	816-817
catenin	O	817-824
are	O	825-828
predisposed	O	829-840
to	O	841-843
developing	O	844-854
skin	B	855-859
tumours	I	860-867
resembling	O	868-878
pilomatricomas	B	879-893
.	O	893-894

Given	O	895-900
that	O	901-905
the	O	906-909
skin	O	910-914
of	O	915-917
these	O	918-923
adult	O	924-929
mice	O	930-934
also	O	935-939
exhibits	O	940-948
signs	O	949-954
of	O	955-957
de	O	958-960
novo	O	961-965
hair	O	966-970
-	O	970-971
follicle	O	971-979
morphogenesis	O	980-993
,	O	993-994
we	O	995-997
wondered	O	998-1006
whether	O	1007-1014
human	O	1015-1020
pilomatricomas	B	1021-1035
might	O	1036-1041
originate	O	1042-1051
from	O	1052-1056
hair	O	1057-1061
matrix	O	1062-1068
cells	O	1069-1074
and	O	1075-1078
whether	O	1079-1086
they	O	1087-1091
might	O	1092-1097
possess	O	1098-1105
beta	O	1106-1110
-	O	1110-1111
catenin	O	1111-1118
-	O	1110-1111
stabilizing	O	1119-1130
mutations	O	1131-1140
.	O	1140-1141

Here	O	1142-1146
,	O	1146-1147
we	O	1148-1150
explore	O	1151-1158
the	O	1159-1162
cell	O	1163-1167
origin	O	1168-1174
and	O	1175-1178
aetiology	O	1179-1188
of	O	1189-1191
this	O	1192-1196
common	O	1197-1203
human	O	1204-1209
skin	B	1210-1214
tumour	I	1215-1221
.	O	1221-1222

We	O	1223-1225
found	O	1226-1231
nuclear	O	1232-1239
LEF	O	1240-1243
-	O	1243-1244
1	O	1244-1245
in	O	1246-1248
the	O	1249-1252
dividing	O	1253-1261
tumour	B	1262-1268
cells	O	1269-1274
,	O	1274-1275
providing	O	1276-1285
biochemical	O	1286-1297
evidence	O	1298-1306
that	O	1307-1311
pilomatricomas	B	1312-1326
are	O	1327-1330
derived	O	1331-1338
from	O	1339-1343
hair	O	1344-1348
matrix	O	1349-1355
cells	O	1356-1361
.	O	1361-1362

At	O	1363-1365
least	O	1366-1371
75	O	1372-1374
%	O	1374-1375
of	O	1376-1378
these	O	1379-1384
tumours	B	1385-1392
possess	O	1393-1400
mutations	O	1401-1410
affecting	O	1411-1420
the	O	1421-1424
amino	O	1425-1430
-	O	1430-1431
terminal	O	1431-1439
segment	O	1440-1447
,	O	1447-1448
normally	O	1449-1457
involved	O	1458-1466
in	O	1467-1469
phosphorylation	O	1470-1485
-	O	1485-1486
dependent	O	1486-1495
,	O	1495-1496
ubiquitin	O	1497-1506
-	O	1506-1507
mediated	O	1507-1515
degradation	O	1516-1527
of	O	1528-1530
the	O	1531-1534
protein	O	1535-1542
.	O	1542-1543

This	O	1544-1548
percentage	O	1549-1559
of	O	1560-1562
CTNNB1	O	1563-1569
mutations	O	1570-1579
is	O	1580-1582
greater	O	1583-1590
than	O	1591-1595
in	O	1596-1598
all	O	1599-1602
other	O	1603-1608
human	O	1609-1614
tumours	B	1615-1622
examined	O	1623-1631
thus	O	1632-1636
far	O	1637-1640
,	O	1640-1641
and	O	1642-1645
directly	O	1646-1654
implicates	O	1655-1665
beta	O	1666-1670
-	O	1670-1671
catenin	O	1671-1678
/	O	1678-1679
LEF	O	1679-1682
misregulation	O	1683-1696
as	O	1697-1699
the	O	1700-1703
major	O	1704-1709
cause	O	1710-1715
of	O	1716-1718
hair	O	1719-1723
matrix	O	1724-1730
cell	O	1731-1735
tumorigenesis	O	1736-1749
in	O	1750-1752
humans	O	1753-1759
.	O	1759-1760
.	O	1759-1760

HFE	O	0-3
mutations	O	4-13
analysis	O	14-22
in	O	23-25
711	O	26-29
hemochromatosis	B	30-45
probands	O	46-54
:	O	54-55
evidence	O	56-64
for	O	65-68
S65C	O	69-73
implication	O	74-85
in	O	86-88
mild	O	89-93
form	O	94-98
of	O	99-101
hemochromatosis	B	102-117
.	O	117-118

Hereditary	B	119-129
hemochromatosis	I	130-145
(	O	146-147
HH	B	147-149
)	O	149-150
is	O	151-153
a	O	154-155
common	O	156-162
autosomal	B	163-172
recessive	I	173-182
genetic	I	183-190
disorder	I	191-199
of	O	200-202
iron	O	203-207
metabolism	O	208-218
.	O	218-219

The	O	220-223
HFE	O	224-227
candidate	O	228-237
gene	O	238-242
encoding	O	243-251
an	O	252-254
HLA	O	255-258
class	O	259-264
I	O	265-266
-	O	266-267
like	O	267-271
protein	O	272-279
involved	O	280-288
in	O	289-291
HH	B	292-294
was	O	295-298
identified	O	299-309
in	O	310-312
1996	O	313-317
.	O	317-318

Two	O	319-322
missense	O	323-331
mutations	O	332-341
have	O	342-346
been	O	347-351
described	O	352-361
C282Y	O	363-368
,	O	368-369
accounting	O	370-380
for	O	381-384
80	O	385-387
%	O	387-388
to	O	389-391
90	O	392-394
%	O	394-395
of	O	396-398
HH	B	399-401
chromosomes	O	402-413
,	O	413-414
and	O	415-418
H63D	O	419-423
,	O	423-424
which	O	425-430
is	O	431-433
associated	O	434-444
with	O	445-449
a	O	450-451
milder	O	452-458
form	O	459-463
of	O	464-466
the	O	467-470
disease	O	471-478
representing	O	479-491
40	O	492-494
%	O	494-495
to	O	496-498
70	O	499-501
%	O	501-502
of	O	503-505
non	O	506-509
-	O	509-510
C282Y	O	510-515
HH	B	516-518
chromosomes	O	519-530
.	O	530-531

We	O	532-534
report	O	535-541
here	O	542-546
on	O	547-549
the	O	550-553
analysis	O	554-562
of	O	563-565
C282Y	O	566-571
,	O	571-572
H63D	O	573-577
,	O	577-578
and	O	579-582
the	O	583-586
193A	O	587-591
-	O	591-592
-	O	591-592
>	O	594-595
T	O	596-597
substitution	O	598-610
leading	O	611-618
to	O	619-621
the	O	622-625
S65C	O	626-630
missense	O	631-639
substitution	O	640-652
in	O	653-655
a	O	656-657
large	O	658-663
series	O	664-670
of	O	671-673
probands	O	674-682
and	O	683-686
controls	O	687-695
.	O	695-696

The	O	697-700
results	O	701-708
confirm	O	709-716
that	O	717-721
the	O	722-725
C282Y	O	726-731
substitution	O	732-744
was	O	745-748
the	O	749-752
main	O	753-757
mutation	O	758-766
involved	O	767-775
in	O	776-778
hemochromatosis	B	779-794
,	O	794-795
accounting	O	796-806
for	O	807-810
85	O	811-813
%	O	813-814
of	O	815-817
carrier	O	818-825
chromosomes	O	826-837
,	O	837-838
whereas	O	839-846
the	O	847-850
H63D	O	851-855
substitution	O	856-868
represented	O	869-880
39	O	881-883
%	O	883-884
of	O	885-887
the	O	888-891
HH	B	892-894
chromosomes	O	895-906
that	O	907-911
did	O	912-915
not	O	916-919
carry	O	920-925
the	O	926-929
C282Y	O	930-935
mutation	O	936-944
.	O	944-945

In	O	946-948
addition	O	949-957
,	O	957-958
our	O	959-962
screening	O	963-972
showed	O	973-979
that	O	980-984
the	O	985-988
S65C	O	989-993
substitution	O	994-1006
was	O	1007-1010
significantly	O	1011-1024
enriched	O	1025-1033
in	O	1034-1036
probands	O	1037-1045
with	O	1046-1050
at	O	1051-1053
least	O	1054-1059
one	O	1060-1063
chromosome	O	1064-1074
without	O	1075-1082
an	O	1083-1085
assigned	O	1086-1094
mutation	O	1095-1103
.	O	1103-1104

This	O	1105-1109
substitution	O	1110-1122
accounted	O	1123-1132
for	O	1133-1136
7	O	1137-1138
.	O	1138-1139
8	O	1140-1141
%	O	1141-1142
of	O	1143-1145
HH	B	1146-1148
chromosomes	O	1149-1160
that	O	1161-1165
were	O	1166-1170
neither	O	1171-1178
C282Y	O	1179-1184
nor	O	1185-1188
H63D	O	1189-1193
.	O	1193-1194

This	O	1195-1199
enrichment	O	1200-1210
of	O	1211-1213
S65C	O	1214-1218
among	O	1219-1224
HH	B	1225-1227
chromosomes	O	1228-1239
suggests	O	1240-1248
that	O	1249-1253
the	O	1254-1257
S65C	O	1258-1262
substitution	O	1263-1275
is	O	1276-1278
associated	O	1279-1289
with	O	1290-1294
the	O	1295-1298
mild	O	1299-1303
form	O	1304-1308
of	O	1309-1311
hemochromatosis	B	1312-1327
.	O	1327-1328

Germline	O	0-8
BRCA1	O	9-14
alterations	O	15-26
in	O	27-29
a	O	30-31
population	O	32-42
-	O	42-43
based	O	43-48
series	O	49-55
of	O	56-58
ovarian	B	59-66
cancer	I	67-73
cases	O	74-79
.	O	79-80

The	O	81-84
objective	O	85-94
of	O	95-97
this	O	98-102
study	O	103-108
was	O	109-112
to	O	113-115
provide	O	116-123
more	O	124-128
accurate	O	129-137
frequency	O	138-147
estimates	O	148-157
of	O	158-160
breast	B	161-167
cancer	I	168-174
susceptibility	O	175-189
gene	O	190-194
1	O	195-196
(	O	197-198
BRCA1	O	198-203
)	O	203-204
germline	O	205-213
alterations	O	214-225
in	O	226-228
the	O	229-232
ovarian	B	233-240
cancer	I	241-247
population	O	248-258
.	O	258-259

To	O	260-262
achieve	O	263-270
this	O	271-275
,	O	275-276
we	O	277-279
determined	O	280-290
the	O	291-294
prevalence	O	295-305
of	O	306-308
BRCA1	O	309-314
alterations	O	315-326
in	O	327-329
a	O	330-331
population	O	332-342
-	O	342-343
based	O	343-348
series	O	349-355
of	O	356-358
consecutive	O	359-370
ovarian	B	371-378
cancer	I	379-385
cases	O	386-391
.	O	391-392

This	O	393-397
is	O	398-400
the	O	401-404
first	O	405-410
population	O	411-421
-	O	421-422
based	O	422-427
ovarian	B	428-435
cancer	I	436-442
study	O	443-448
reporting	O	449-458
BRCA1	O	459-464
alterations	O	465-476
derived	O	477-484
from	O	485-489
a	O	490-491
comprehensive	O	492-505
screen	O	506-512
of	O	513-515
the	O	516-519
entire	O	520-526
coding	O	527-533
region	O	534-540
.	O	540-541

One	O	542-545
hundred	O	546-553
and	O	554-557
seven	O	558-563
ovarian	B	564-571
cancer	I	572-578
cases	O	579-584
were	O	585-589
analyzed	O	590-598
for	O	599-602
BRCA1	O	603-608
alterations	O	609-620
using	O	621-626
the	O	627-630
RNase	O	631-636
mismatch	O	637-645
cleavage	O	646-654
assay	O	655-660
followed	O	661-669
by	O	670-672
direct	O	673-679
sequencing	O	680-690
.	O	690-691

Two	O	692-695
truncating	O	696-706
mutations	O	707-716
,	O	716-717
962del4	O	718-725
and	O	726-729
3600del11	O	730-739
,	O	739-740
were	O	741-745
identified	O	746-756
.	O	756-757

Both	O	758-762
patients	O	763-771
had	O	772-775
a	O	776-777
family	O	778-784
history	O	785-792
of	O	793-795
breast	B	796-802
or	I	803-805
ovarian	I	806-813
cancer	I	814-820
.	O	820-821

Several	O	822-829
novel	O	830-835
as	O	836-838
well	O	839-843
as	O	844-846
previously	O	847-857
reported	O	858-866
uncharacterized	O	867-882
variants	O	883-891
were	O	892-896
also	O	897-901
identified	O	902-912
,	O	912-913
some	O	914-918
of	O	919-921
which	O	922-927
were	O	928-932
associated	O	933-943
with	O	944-948
a	O	949-950
family	O	951-957
history	O	958-965
of	O	966-968
cancer	B	969-975
.	O	975-976

The	O	977-980
frequency	O	981-990
distribution	O	991-1003
of	O	1004-1006
common	O	1007-1013
polymorphisms	O	1014-1027
was	O	1028-1031
determined	O	1032-1042
in	O	1043-1045
the	O	1046-1049
91	O	1050-1052
Caucasian	O	1053-1062
cancer	B	1063-1069
cases	O	1070-1075
in	O	1076-1078
this	O	1079-1083
series	O	1084-1090
and	O	1091-1094
24	O	1095-1097
sister	O	1098-1104
controls	O	1105-1113
using	O	1114-1119
allele	O	1120-1126
-	O	1126-1127
specific	O	1127-1135
amplification	O	1136-1149
.	O	1149-1150

The	O	1151-1154
rare	O	1155-1159
form	O	1160-1164
of	O	1165-1167
the	O	1168-1171
Q356R	O	1172-1177
polymorphism	O	1178-1190
was	O	1191-1194
significantly	O	1195-1208
(	O	1209-1210
P	O	1210-1211
=	O	1212-1213
0	O	1214-1215
.	O	1215-1216
03	O	1217-1219
)	O	1219-1220
associated	O	1221-1231
with	O	1232-1236
a	O	1237-1238
family	O	1239-1245
history	O	1246-1253
of	O	1254-1256
ovarian	B	1257-1264
cancer	I	1265-1271
,	O	1271-1272
suggesting	O	1273-1283
that	O	1284-1288
this	O	1289-1293
polymorphism	O	1294-1306
may	O	1307-1310
influence	O	1311-1320
ovarian	B	1321-1328
cancer	I	1329-1335
risk	O	1336-1340
.	O	1340-1341

In	O	1342-1344
summary	O	1345-1352
,	O	1352-1353
our	O	1354-1357
data	O	1358-1362
suggest	O	1363-1370
a	O	1371-1372
role	O	1373-1377
for	O	1378-1381
some	O	1382-1386
uncharacterized	O	1387-1402
variants	O	1403-1411
and	O	1412-1415
rare	O	1416-1420
forms	O	1421-1426
of	O	1427-1429
polymorphisms	O	1430-1443
in	O	1444-1446
determining	O	1447-1458
ovarian	B	1459-1466
cancer	I	1467-1473
risk	O	1474-1478
,	O	1478-1479
and	O	1480-1483
highlight	O	1484-1493
the	O	1494-1497
necessity	O	1498-1507
to	O	1508-1510
screen	O	1511-1517
for	O	1518-1521
missense	O	1522-1530
alterations	O	1531-1542
as	O	1543-1545
well	O	1546-1550
as	O	1551-1553
truncating	O	1554-1564
mutations	O	1565-1574
in	O	1575-1577
this	O	1578-1582
population	O	1583-1593
.	O	1593-1594

Identification	O	0-14
of	O	15-17
APC2	O	18-22
,	O	22-23
a	O	24-25
homologue	O	26-35
of	O	36-38
the	O	39-42
adenomatous	B	43-54
polyposis	I	55-64
coli	I	65-69
tumour	I	70-76
suppressor	O	77-87
.	O	87-88

The	O	89-92
adenomatous	B	93-104
polyposis	I	105-114
coli	I	115-119
(	I	120-121
APC	I	121-124
)	I	124-125
tumour	I	126-132
-	O	132-133
suppressor	O	133-143
protein	O	144-151
controls	O	152-160
the	O	161-164
Wnt	O	165-168
signalling	O	169-179
pathway	O	180-187
by	O	188-190
forming	O	191-198
a	O	199-200
complex	O	201-208
with	O	209-213
glycogen	O	214-222
synthase	O	223-231
kinase	O	232-238
3beta	O	239-244
(	O	245-246
GSK	O	246-249
-	O	249-250
3beta	O	250-255
)	O	255-256
,	O	256-257
axin	O	258-262
/	O	262-263
conductin	O	263-272
and	O	273-276
betacatenin	O	277-288
.	O	288-289

Complex	O	290-297
formation	O	298-307
induces	O	308-315
the	O	316-319
rapid	O	320-325
degradation	O	326-337
of	O	338-340
betacatenin	O	341-352
.	O	352-353

In	O	354-356
colon	B	357-362
carcinoma	I	363-372
cells	O	373-378
,	O	378-379
loss	O	380-384
of	O	385-387
APC	O	388-391
leads	O	392-397
to	O	398-400
the	O	401-404
accumulation	O	405-417
of	O	418-420
betacatenin	O	421-432
in	O	433-435
the	O	436-439
nucleus	O	440-447
,	O	447-448
where	O	449-454
it	O	455-457
binds	O	458-463
to	O	464-466
and	O	467-470
activates	O	471-480
the	O	481-484
Tcf	O	485-488
-	O	488-489
4	O	489-490
transcription	O	491-504
factor	O	505-511
(	O	512-513
reviewed	O	513-521
in	O	522-524
[	O	525-526
1	O	526-527
]	O	527-528
[	O	529-530
2	O	530-531
]	O	531-532
)	O	532-533
.	O	533-534

Here	O	535-539
,	O	539-540
we	O	541-543
report	O	544-550
the	O	551-554
identification	O	555-569
and	O	570-573
genomic	O	574-581
structure	O	582-591
of	O	592-594
APC	O	595-598
homologues	O	599-609
.	O	609-610

Mammalian	O	611-620
APC2	O	621-625
,	O	625-626
which	O	627-632
closely	O	633-640
resembles	O	641-650
APC	O	651-654
in	O	655-657
overall	O	658-665
domain	O	666-672
structure	O	673-682
,	O	682-683
was	O	684-687
functionally	O	688-700
analyzed	O	701-709
and	O	710-713
shown	O	714-719
to	O	720-722
contain	O	723-730
two	O	731-734
SAMP	O	735-739
domains	O	740-747
,	O	747-748
both	O	749-753
of	O	754-756
which	O	757-762
are	O	763-766
required	O	767-775
for	O	776-779
binding	O	780-787
to	O	788-790
conductin	O	791-800
.	O	800-801

Like	O	802-806
APC	O	807-810
,	O	810-811
APC2	O	812-816
regulates	O	817-826
the	O	827-830
formation	O	831-840
of	O	841-843
active	O	844-850
betacatenin	O	851-862
-	O	862-863
Tcf	O	863-866
complexes	O	867-876
,	O	876-877
as	O	878-880
demonstrated	O	881-893
using	O	894-899
transient	O	900-909
transcriptional	O	910-925
activation	O	926-936
assays	O	937-943
in	O	944-946
APC	O	947-950
-	O	951-952
/	O	952-953
-	O	951-952
colon	B	955-960
carcinoma	I	961-970
cells	O	971-976
.	O	976-977

Human	O	978-983
APC2	O	984-988
maps	O	989-993
to	O	994-996
chromosome	O	997-1007
19p13	O	1008-1013
.	O	1013-1014

3	O	1015-1016
.	O	1016-1017
APC	O	1018-1021
and	O	1022-1025
APC2	O	1026-1030
may	O	1031-1034
therefore	O	1035-1044
have	O	1045-1049
comparable	O	1050-1060
functions	O	1061-1070
in	O	1071-1073
development	O	1074-1085
and	O	1086-1089
cancer	B	1090-1096
.	O	1096-1097

Familial	B	0-8
deficiency	I	9-19
of	I	20-22
the	I	23-26
seventh	I	27-34
component	I	35-44
of	I	45-47
complement	I	48-58
associated	O	59-69
with	O	70-74
recurrent	O	75-84
bacteremic	B	85-95
infections	I	96-106
due	I	107-110
to	I	111-113
Neisseria	I	114-123
.	O	123-124

The	O	125-128
serum	O	129-134
of	O	135-137
a	O	138-139
29	O	140-142
-	O	142-143
year	O	143-147
old	O	148-151
woman	O	152-157
with	O	158-162
a	O	163-164
recent	O	165-171
episode	O	172-179
of	O	180-182
disseminated	B	183-195
gonococcal	I	196-206
infection	I	207-216
and	O	217-220
a	O	221-222
history	O	223-230
of	O	231-233
meningococcal	B	234-247
meningitis	I	248-258
and	O	259-262
arthritis	B	263-272
as	O	273-275
a	O	276-277
child	O	278-283
was	O	284-287
found	O	288-293
to	O	294-296
lack	O	297-301
serum	O	302-307
hemolytic	O	308-317
complement	O	318-328
activity	O	329-337
.	O	337-338

The	O	339-342
seventh	O	343-350
component	O	351-360
of	O	361-363
complement	O	364-374
(	O	375-376
C7	O	376-378
)	O	378-379
was	O	380-383
not	O	384-387
detected	O	388-396
by	O	397-399
functional	O	400-410
or	O	411-413
immunochemical	O	414-428
assays	O	429-435
,	O	435-436
whereas	O	437-444
other	O	445-450
components	O	451-461
were	O	462-466
normal	O	467-473
by	O	474-476
hemolytic	O	477-486
and	O	487-490
immunochemical	O	491-505
assessment	O	506-516
.	O	516-517

Her	O	518-521
fresh	O	522-527
serum	O	528-533
lacked	O	534-540
complement	O	541-551
-	O	551-552
mediated	O	552-560
bactericidal	O	561-573
activity	O	574-582
against	O	583-590
Neisseria	O	591-600
gonorrhoeae	O	601-612
,	O	612-613
but	O	614-617
the	O	618-621
addition	O	622-630
of	O	631-633
fresh	O	634-639
normal	O	640-646
serum	O	647-652
or	O	653-655
purified	O	656-664
C7	O	665-667
restored	O	668-676
bactericidal	O	677-689
activity	O	690-698
as	O	699-701
well	O	702-706
as	O	707-709
hemolytic	O	710-719
activity	O	720-728
.	O	728-729

The	O	730-733
absence	B	734-741
of	I	742-744
functional	I	745-755
C7	I	756-758
activity	O	759-767
could	O	768-773
not	O	774-777
be	O	778-780
accounted	O	781-790
for	O	791-794
on	O	795-797
the	O	798-801
basis	O	802-807
of	O	808-810
an	O	811-813
inhibitor	O	814-823
.	O	823-824

Opsonization	O	825-837
and	O	838-841
generation	O	842-852
of	O	853-855
chemotactic	O	856-867
activity	O	868-876
functioned	O	877-887
normally	O	888-896
.	O	896-897

Complete	B	898-906
absence	I	907-914
of	I	915-917
C7	I	918-920
was	O	921-924
also	O	925-929
found	O	930-935
in	O	936-938
one	O	939-942
sibling	O	943-950
who	O	951-954
had	O	955-958
the	O	959-962
clinical	O	963-971
syndrome	O	972-980
of	O	981-983
meningococcal	B	984-997
meningitis	I	998-1008
and	O	1009-1012
arthritis	B	1013-1022
as	O	1024-1026
a	O	1027-1028
child	O	1029-1034
and	O	1035-1038
in	O	1039-1041
this	O	1042-1046
siblings	O	1047-1055
clinically	O	1056-1066
well	O	1067-1071
eight	O	1072-1077
-	O	1077-1078
year	O	1078-1082
-	O	1077-1078
old	O	1083-1086
son	O	1087-1090
.	O	1090-1091

HLA	O	1092-1095
histocompatibility	O	1096-1114
typing	O	1115-1121
of	O	1122-1124
the	O	1125-1128
family	O	1129-1135
members	O	1136-1143
did	O	1144-1147
not	O	1148-1151
demonstrate	O	1152-1163
evidence	O	1164-1172
for	O	1173-1176
genetic	O	1177-1184
linkage	O	1185-1192
of	O	1193-1195
C7	B	1196-1198
deficiency	I	1199-1209
with	O	1210-1214
the	O	1215-1218
major	O	1219-1224
histocompatibility	O	1225-1243
loci	O	1244-1248
.	O	1248-1249

This	O	1250-1254
report	O	1255-1261
represents	O	1262-1272
the	O	1273-1276
first	O	1277-1282
cases	O	1283-1288
of	O	1289-1291
C7	B	1292-1294
deficiency	I	1295-1305
associated	O	1306-1316
with	O	1317-1321
infectious	O	1322-1332
complications	O	1333-1346
and	O	1347-1350
suggests	O	1351-1359
that	O	1360-1364
bactericidal	O	1365-1377
activity	O	1378-1386
may	O	1387-1390
be	O	1391-1393
important	O	1394-1403
in	O	1404-1406
host	O	1407-1411
defense	O	1412-1419
against	O	1420-1427
bacteremic	B	1428-1438
neisseria	I	1439-1448
infections	I	1449-1459
.	O	1459-1460

GCH1	O	0-4
mutation	O	5-13
in	O	14-16
a	O	17-18
patient	O	19-26
with	O	27-31
adult	O	32-37
-	O	37-38
onset	O	38-43
oromandibular	B	44-57
dystonia	I	58-66
.	O	66-67

The	O	68-71
authors	O	72-79
report	O	80-86
a	O	87-88
mutation	O	89-97
in	O	98-100
exon	O	101-105
5	O	106-107
of	O	108-110
GCH1	O	111-115
in	O	116-118
a	O	119-120
patient	O	121-128
with	O	129-133
adult	O	134-139
-	O	139-140
onset	O	140-145
oromandibular	B	146-159
dystonia	I	160-168
and	O	169-172
no	O	173-175
obvious	O	176-183
family	O	184-190
history	O	191-198
of	O	199-201
dystonia	B	202-210
.	O	210-211

The	O	212-215
patient	O	216-223
responded	O	224-233
positively	O	234-244
to	O	245-247
treatment	O	248-257
with	O	258-262
L	O	263-264
-	O	264-265
dopa	O	265-269
.	O	269-270

These	O	271-276
findings	O	277-285
demonstrate	O	286-297
that	O	298-302
GCH1	O	303-307
mutations	O	308-317
must	O	318-322
be	O	323-325
considered	O	326-336
even	O	337-341
in	O	342-344
patients	O	345-353
with	O	354-358
dystonic	B	359-367
symptoms	O	368-376
not	O	377-380
typical	O	381-388
of	O	389-391
dopa	B	392-396
-	I	396-397
responsive	I	397-407
dystonia	I	408-416
.	O	416-417

The	O	0-3
hereditary	B	4-14
hemochromatosis	I	15-30
protein	O	31-38
,	O	38-39
HFE	O	40-43
,	O	43-44
specifically	O	45-57
regulates	O	58-67
transferrin	O	68-79
-	O	79-80
mediated	O	80-88
iron	O	89-93
uptake	O	94-100
in	O	101-103
HeLa	O	104-108
cells	O	109-114
.	O	114-115

HFE	O	116-119
is	O	120-122
the	O	123-126
protein	O	127-134
product	O	135-142
of	O	143-145
the	O	146-149
gene	O	150-154
mutated	O	155-162
in	O	163-165
the	O	166-169
autosomal	B	170-179
recessive	I	180-189
disease	I	190-197
hereditary	B	198-208
hemochromatosis	I	209-224
(	O	225-226
Feder	O	226-231
,	O	231-232
J	O	233-234
.	O	234-235
N	O	236-237
.	O	237-238
,	O	238-239
Gnirke	O	240-246
,	O	246-247
A	O	248-249
.	O	249-250
,	O	250-251
Thomas	O	252-258
,	O	258-259
W	O	260-261
.	O	261-262
,	O	262-263
Tsuchihashi	O	264-275
,	O	275-276
Z	O	277-278
.	O	278-279
,	O	279-280
Ruddy	O	281-286
,	O	286-287
D	O	288-289
.	O	289-290
A	O	291-292
.	O	292-293
,	O	293-294
Basava	O	295-301
,	O	301-302
A	O	303-304
.	O	304-305
,	O	305-306
Dormishian	O	307-317
,	O	317-318
F	O	319-320
.	O	320-321
,	O	321-322
Domingo	O	323-330
,	O	330-331
R	O	332-333
.	O	333-334
J	O	335-336
.	O	336-337
,	O	337-338
Ellis	O	339-344
,	O	344-345
M	O	346-347
.	O	347-348
C	O	349-350
.	O	350-351
,	O	351-352
Fullan	O	353-359
,	O	359-360
A	O	361-362
.	O	362-363
,	O	363-364
Hinton	O	365-371
,	O	371-372
L	O	373-374
.	O	374-375
M	O	376-377
.	O	377-378
,	O	378-379
Jones	O	380-385
,	O	385-386
N	O	387-388
.	O	388-389
L	O	390-391
.	O	391-392
,	O	392-393
Kimmel	O	394-400
,	O	400-401
B	O	402-403
.	O	403-404
E	O	405-406
.	O	406-407
,	O	407-408
Kronmal	O	409-416
,	O	416-417
G	O	418-419
.	O	419-420
S	O	421-422
.	O	422-423
,	O	423-424
Lauer	O	425-430
,	O	430-431
P	O	432-433
.	O	433-434
,	O	434-435
Lee	O	436-439
,	O	439-440
V	O	441-442
.	O	442-443
K	O	444-445
.	O	445-446
,	O	446-447
Loeb	O	448-452
,	O	452-453
D	O	454-455
.	O	455-456
B	O	457-458
.	O	458-459
,	O	459-460
Mapa	O	461-465
,	O	465-466
F	O	467-468
.	O	468-469
A	O	470-471
.	O	471-472
,	O	472-473
McClelland	O	474-484
,	O	484-485
E	O	486-487
.	O	487-488
,	O	488-489
Meyer	O	490-495
,	O	495-496
N	O	497-498
.	O	498-499
C	O	500-501
.	O	501-502
,	O	502-503
Mintier	O	504-511
,	O	511-512
G	O	513-514
.	O	514-515
A	O	516-517
.	O	517-518
,	O	518-519
Moeller	O	520-527
,	O	527-528
N	O	529-530
.	O	530-531
,	O	531-532
Moore	O	533-538
,	O	538-539
T	O	540-541
.	O	541-542
,	O	542-543
Morikang	O	544-552
,	O	552-553
E	O	554-555
.	O	555-556
,	O	556-557
Prasss	O	558-564
,	O	564-565
C	O	566-567
.	O	567-568
E	O	569-570
.	O	571-572
,	O	572-573
Quintana	O	574-582
,	O	582-583
L	O	584-585
.	O	585-586
,	O	586-587
Starnes	O	588-595
,	O	595-596
S	O	597-598
.	O	598-599
M	O	600-601
.	O	602-603
,	O	603-604
Schatzman	O	605-614
,	O	614-615
R	O	616-617
.	O	617-618
C	O	619-620
.	O	621-622
,	O	622-623
Brunke	O	624-630
,	O	630-631
K	O	632-633
.	O	633-634
J	O	635-636
.	O	637-638
,	O	638-639
Drayna	O	640-646
,	O	646-647
D	O	648-649
.	O	649-650
T	O	651-652
.	O	652-653
,	O	653-654
Risch	O	655-660
,	O	660-661
N	O	662-663
.	O	663-664
J	O	665-666
.	O	667-668
,	O	668-669
Bacon	O	670-675
,	O	675-676
B	O	677-678
.	O	678-679
R	O	680-681
.	O	682-683
,	O	683-684
and	O	685-688
Wolff	O	689-694
,	O	694-695
R	O	696-697
.	O	697-698
R	O	699-700
.	O	701-702

(	O	703-704
1996	O	704-708
)	O	708-709
Nat	O	710-713
.	O	713-714

Genet	O	715-720
.	O	720-721

13	O	722-724
,	O	724-725
399	O	726-729
-	O	729-730
408	O	730-733
)	O	733-734
.	O	734-735

At	O	736-738
the	O	739-742
cell	O	743-747
surface	O	748-755
,	O	755-756
HFE	O	757-760
complexes	O	761-770
with	O	771-775
transferrin	O	776-787
receptor	O	788-796
(	O	797-798
TfR	O	798-801
)	O	801-802
,	O	802-803
increasing	O	804-814
the	O	815-818
dissociation	O	819-831
constant	O	832-840
of	O	841-843
transferrin	O	844-855
(	O	856-857
Tf	O	857-859
)	O	859-860
for	O	861-864
its	O	865-868
receptor	O	869-877
10	O	878-880
-	O	880-881
fold	O	881-885
(	O	886-887
Gross	O	887-892
,	O	892-893
C	O	894-895
.	O	895-896
N	O	897-898
.	O	899-900
,	O	900-901
Irrinki	O	902-909
,	O	909-910
A	O	911-912
.	O	912-913
,	O	913-914
Feder	O	915-920
,	O	920-921
J	O	922-923
.	O	923-924
N	O	925-926
.	O	927-928
,	O	928-929
and	O	930-933
Enns	O	934-938
,	O	938-939
C	O	940-941
.	O	941-942
A	O	943-944
.	O	945-946

(	O	947-948
1998	O	948-952
)	O	952-953
J	O	954-955
.	O	955-956
Biol	O	957-961
.	O	961-962

Chem	O	963-967
.	O	967-968

273	O	969-972
,	O	972-973
22068	O	974-979
-	O	979-980
22074	O	980-985
;	O	985-986
Feder	O	987-992
,	O	992-993
J	O	994-995
.	O	995-996
N	O	997-998
.	O	998-999
,	O	999-1000
Penny	O	1001-1006
,	O	1006-1007
D	O	1008-1009
.	O	1009-1010
M	O	1011-1012
.	O	1012-1013
,	O	1013-1014
Irrinki	O	1015-1022
,	O	1022-1023
A	O	1024-1025
.	O	1025-1026
,	O	1026-1027
Lee	O	1028-1031
,	O	1031-1032
V	O	1033-1034
.	O	1034-1035
K	O	1036-1037
.	O	1037-1038
,	O	1038-1039
Lebron	O	1040-1046
,	O	1046-1047
J	O	1048-1049
.	O	1049-1050
A	O	1051-1052
.	O	1052-1053
,	O	1053-1054
Watson	O	1055-1061
,	O	1061-1062
N	O	1063-1064
.	O	1064-1065
,	O	1065-1066
Tsuchihashi	O	1067-1078
,	O	1078-1079
Z	O	1080-1081
.	O	1081-1082
,	O	1082-1083
Sigal	O	1084-1089
,	O	1089-1090
E	O	1091-1092
.	O	1092-1093
,	O	1093-1094
Bjorkman	O	1095-1103
,	O	1103-1104
P	O	1105-1106
.	O	1106-1107
J	O	1108-1109
.	O	1109-1110
,	O	1110-1111
and	O	1112-1115
Schatzman	O	1116-1125
,	O	1125-1126
R	O	1127-1128
.	O	1128-1129
C	O	1130-1131
.	O	1131-1132
(	O	1133-1134
1998	O	1134-1138
)	O	1138-1139
Proc	O	1140-1144
.	O	1144-1145

Natl	O	1146-1150
.	O	1151-1152

Acad	O	1153-1157
.	O	1157-1158

Sci	O	1159-1162
.	O	1162-1163

U	O	1164-1165
S	O	1166-1167
A	O	1168-1169
95	O	1170-1172
,	O	1172-1173
1472	O	1174-1178
-	O	1178-1179
1477	O	1179-1183
)	O	1183-1184
.	O	1184-1185

HFE	O	1186-1189
does	O	1190-1194
not	O	1195-1198
remain	O	1199-1205
at	O	1206-1208
the	O	1209-1212
cell	O	1213-1217
surface	O	1218-1225
,	O	1225-1226
but	O	1227-1230
traffics	O	1231-1239
with	O	1240-1244
TfR	O	1245-1248
to	O	1249-1251
Tf	O	1252-1254
-	O	1254-1255
positive	O	1255-1263
internal	O	1264-1272
compartments	O	1273-1285
(	O	1286-1287
Gross	O	1287-1292
et	O	1293-1295
al	O	1296-1298
.	O	1298-1299
,	O	1299-1300
1998	O	1301-1305
)	O	1305-1306
.	O	1306-1307

Using	O	1308-1313
a	O	1314-1315
HeLa	O	1316-1320
cell	O	1321-1325
line	O	1326-1330
in	O	1331-1333
which	O	1334-1339
the	O	1340-1343
expression	O	1344-1354
of	O	1355-1357
HFE	O	1358-1361
is	O	1362-1364
controlled	O	1365-1375
by	O	1376-1378
tetracycline	O	1379-1391
,	O	1391-1392
we	O	1393-1395
show	O	1396-1400
that	O	1401-1405
the	O	1406-1409
expression	O	1410-1420
of	O	1421-1423
HFE	O	1424-1427
reduces	O	1428-1435
55Fe	O	1436-1440
uptake	O	1441-1447
from	O	1448-1452
Tf	O	1453-1455
by	O	1456-1458
33	O	1459-1461
%	O	1461-1462
but	O	1463-1466
does	O	1467-1471
not	O	1472-1475
affect	O	1476-1482
the	O	1483-1486
endocytic	O	1487-1496
or	O	1497-1499
exocytic	O	1500-1508
rates	O	1509-1514
of	O	1515-1517
TfR	O	1518-1521
cycling	O	1522-1529
.	O	1529-1530

Therefore	O	1531-1540
,	O	1540-1541
HFE	O	1542-1545
appears	O	1546-1553
to	O	1554-1556
reduce	O	1557-1563
cellular	O	1564-1572
acquisition	O	1573-1584
of	O	1585-1587
iron	O	1588-1592
from	O	1593-1597
Tf	O	1598-1600
within	O	1601-1607
endocytic	O	1608-1617
compartments	O	1618-1630
.	O	1630-1631

HFE	O	1632-1635
specifically	O	1636-1648
reduces	O	1649-1656
iron	O	1657-1661
uptake	O	1662-1668
from	O	1669-1673
Tf	O	1674-1676
,	O	1676-1677
as	O	1678-1680
non	O	1681-1684
-	O	1684-1685
Tf	O	1685-1687
-	O	1684-1685
mediated	O	1688-1696
iron	O	1697-1701
uptake	O	1702-1708
from	O	1709-1713
Fe	O	1714-1716
-	O	1716-1717
nitrilotriacetic	O	1717-1733
acid	O	1734-1738
is	O	1739-1741
not	O	1742-1745
altered	O	1746-1753
.	O	1753-1754

These	O	1755-1760
results	O	1761-1768
explain	O	1769-1776
the	O	1777-1780
decreased	O	1781-1790
ferritin	O	1791-1799
levels	O	1800-1806
seen	O	1807-1811
in	O	1812-1814
our	O	1815-1818
HeLa	O	1819-1823
cell	O	1824-1828
system	O	1829-1835
and	O	1836-1839
demonstrate	O	1840-1851
the	O	1852-1855
specific	O	1856-1864
control	O	1865-1872
of	O	1873-1875
HFE	O	1876-1879
over	O	1880-1884
the	O	1885-1888
Tf	O	1889-1891
-	O	1891-1892
mediated	O	1892-1900
pathway	O	1901-1908
of	O	1909-1911
iron	O	1912-1916
uptake	O	1917-1923
.	O	1923-1924

These	O	1925-1930
results	O	1931-1938
also	O	1939-1943
have	O	1944-1948
implications	O	1949-1961
for	O	1962-1965
the	O	1966-1969
understanding	O	1970-1983
of	O	1984-1986
cellular	O	1987-1995
iron	O	1996-2000
homeostasis	O	2001-2012
in	O	2013-2015
organs	O	2016-2022
such	O	2023-2027
as	O	2028-2030
the	O	2031-2034
liver	O	2035-2040
,	O	2040-2041
pancreas	O	2042-2050
,	O	2050-2051
heart	O	2052-2057
,	O	2057-2058
and	O	2059-2062
spleen	O	2063-2069
that	O	2070-2074
are	O	2075-2078
iron	O	2079-2083
loaded	O	2084-2090
in	O	2091-2093
hereditary	B	2094-2104
hemochromatotic	I	2105-2120
individuals	O	2121-2132
lacking	O	2133-2140
functional	O	2141-2151
HFE	O	2152-2155
.	O	2155-2156

Mutation	O	0-8
and	O	9-12
haplotype	O	13-22
studies	O	23-30
of	O	31-33
familial	B	34-42
Mediterranean	I	43-56
fever	I	57-62
reveal	O	63-69
new	O	70-73
ancestral	O	74-83
relationships	O	84-97
and	O	98-101
evidence	O	102-110
for	O	111-114
a	O	115-116
high	O	117-121
carrier	O	122-129
frequency	O	130-139
with	O	140-144
reduced	O	145-152
penetrance	O	153-163
in	O	164-166
the	O	167-170
Ashkenazi	O	171-180
Jewish	O	181-187
population	O	188-198
.	O	198-199

Familial	B	200-208
Mediterranean	I	209-222
fever	I	223-228
(	O	229-230
FMF	B	230-233
)	O	233-234
is	O	235-237
a	O	238-239
recessive	B	240-249
disorder	I	250-258
characterized	O	259-272
by	O	273-275
episodes	O	276-284
of	O	285-287
fever	O	288-293
with	O	294-298
serositis	B	299-308
or	O	309-311
synovitis	B	312-321
.	O	321-322

The	O	323-326
FMF	B	327-330
gene	O	331-335
(	O	336-337
MEFV	O	337-341
)	O	341-342
was	O	343-346
cloned	O	347-353
recently	O	354-362
,	O	362-363
and	O	364-367
four	O	368-372
missense	O	373-381
mutations	O	382-391
were	O	392-396
identified	O	397-407
.	O	407-408

Here	O	409-413
we	O	414-416
present	O	417-424
data	O	425-429
from	O	430-434
non	O	435-438
-	O	438-439
Ashkenazi	O	439-448
Jewish	O	449-455
and	O	456-459
Arab	O	460-464
patients	O	465-473
in	O	474-476
whom	O	477-481
we	O	482-484
had	O	485-488
not	O	489-492
originally	O	493-503
found	O	504-509
mutations	O	510-519
and	O	520-523
from	O	524-528
a	O	529-530
new	O	531-534
,	O	534-535
more	O	536-540
ethnically	O	541-551
diverse	O	552-559
panel	O	560-565
.	O	565-566

Among	O	567-572
90	O	573-575
symptomatic	O	576-587
mutation	O	588-596
-	O	596-597
positive	O	597-605
individuals	O	606-617
,	O	617-618
11	O	619-621
mutations	O	622-631
accounted	O	632-641
for	O	642-645
79	O	646-648
%	O	648-649
of	O	650-652
carrier	O	653-660
chromosomes	O	661-672
.	O	672-673

Of	O	674-676
the	O	677-680
two	O	681-684
mutations	O	685-694
that	O	695-699
are	O	700-703
novel	O	704-709
,	O	709-710
one	O	711-714
alters	O	715-721
the	O	722-725
same	O	726-730
residue	O	731-738
(	O	739-740
680	O	740-743
)	O	743-744
as	O	745-747
a	O	748-749
previously	O	750-760
known	O	761-766
mutation	O	767-775
,	O	775-776
and	O	777-780
the	O	781-784
other	O	785-790
(	O	791-792
P369S	O	792-797
)	O	797-798
is	O	799-801
located	O	802-809
in	O	810-812
exon	O	813-817
3	O	818-819
.	O	819-820
Consistent	O	821-831
with	O	832-836
another	O	837-844
recent	O	845-851
report	O	852-858
,	O	858-859
the	O	860-863
E148Q	O	864-869
mutation	O	870-878
was	O	879-882
observed	O	883-891
in	O	892-894
patients	O	895-903
of	O	904-906
several	O	907-914
ethnicities	O	915-926
and	O	927-930
on	O	931-933
multiple	O	934-942
microsatellite	O	943-957
haplotypes	O	958-968
,	O	968-969
but	O	970-973
haplotype	O	974-983
data	O	984-988
indicate	O	989-997
an	O	998-1000
ancestral	O	1001-1010
relationships	O	1011-1024
between	O	1025-1032
non	O	1033-1036
-	O	1036-1037
Jewish	O	1037-1043
Italian	O	1044-1051
and	O	1052-1055
Ashkenazi	O	1056-1065
Jewish	O	1066-1072
patients	O	1073-1081
with	O	1082-1086
FMF	B	1087-1090
and	O	1091-1094
other	O	1095-1100
affected	O	1101-1109
populations	O	1110-1121
.	O	1121-1122

Among	O	1123-1128
approximately	O	1129-1142
200	O	1143-1146
anonymous	O	1147-1156
Ashkenazi	O	1157-1166
Jewish	O	1167-1173
DNA	O	1174-1177
samples	O	1178-1185
,	O	1185-1186
the	O	1187-1190
MEFV	O	1191-1195
carrier	O	1196-1203
frequency	O	1204-1213
was	O	1214-1217
21	O	1218-1220
%	O	1220-1221
,	O	1221-1222
with	O	1223-1227
E148Q	O	1228-1233
the	O	1234-1237
most	O	1238-1242
common	O	1243-1249
mutation	O	1250-1258
.	O	1258-1259

Several	O	1260-1267
lines	O	1268-1273
of	O	1274-1276
evidence	O	1277-1285
indicate	O	1286-1294
reduced	O	1295-1302
penetrance	O	1303-1313
among	O	1314-1319
Ashkenazi	O	1320-1329
Jews	O	1330-1334
,	O	1334-1335
especially	O	1336-1346
for	O	1347-1350
E148Q	O	1351-1356
,	O	1356-1357
P369S	O	1358-1363
,	O	1363-1364
and	O	1365-1368
K695R	O	1369-1374
.	O	1374-1375

Nevertheless	O	1376-1388
,	O	1388-1389
E148Q	O	1390-1395
helps	O	1396-1401
account	O	1402-1409
for	O	1410-1413
recessive	O	1414-1423
inheritance	O	1424-1435
in	O	1436-1438
an	O	1439-1441
Ashkenazi	O	1442-1451
family	O	1452-1458
previously	O	1459-1469
reported	O	1470-1478
as	O	1479-1481
an	O	1482-1484
unusual	O	1485-1492
case	O	1493-1497
of	O	1498-1500
dominantly	O	1501-1511
inherited	O	1512-1521
FMF	B	1522-1525
.	O	1525-1526

The	O	1527-1530
presence	O	1531-1539
of	O	1540-1542
three	O	1543-1548
frequent	O	1549-1557
MEFV	O	1558-1562
mutations	O	1563-1572
in	O	1573-1575
multiple	O	1576-1584
Mediterranean	O	1585-1598
populations	O	1599-1610
strongly	O	1611-1619
suggests	O	1620-1628
a	O	1629-1630
heterozygote	O	1631-1643
advantage	O	1644-1653
in	O	1654-1656
this	O	1657-1661
geographic	O	1662-1672
region	O	1673-1679
.	O	1679-1680

Autoimmune	B	0-10
lymphoproliferative	I	11-30
syndrome	I	31-39
with	O	41-45
defective	O	46-55
Fas	O	56-59
:	O	59-60
genotype	O	61-69
influences	O	70-80
penetrance	O	81-91
.	O	91-92

Autoimmune	B	93-103
lymphoproliferative	I	104-123
syndrome	I	124-132
(	O	133-134
ALPS	B	134-138
)	O	138-139
is	O	140-142
a	O	143-144
disorder	B	145-153
of	I	154-156
lymphocyte	I	157-167
homeostasis	I	168-179
and	I	180-183
immunological	I	184-197
tolerance	I	198-207
.	O	207-208

Most	O	209-213
patients	O	214-222
have	O	223-227
a	O	228-229
heterozygous	O	230-242
mutation	O	243-251
in	O	252-254
the	O	255-258
APT1	O	259-263
gene	O	264-268
,	O	268-269
which	O	270-275
encodes	O	276-283
Fas	O	284-287
(	O	288-289
CD95	O	289-293
,	O	293-294
APO	O	295-298
-	O	298-299
1	O	299-300
)	O	300-301
,	O	301-302
mediator	O	303-311
of	O	312-314
an	O	315-317
apoptotic	O	318-327
pathway	O	328-335
crucial	O	336-343
to	O	344-346
lymphocyte	O	347-357
homeostasis	O	358-369
.	O	369-370

Of	O	371-373
17	O	374-376
unique	O	377-383
APT1	O	384-388
mutations	O	389-398
in	O	399-401
unrelated	O	402-411
ALPS	B	412-416
probands	O	417-425
,	O	425-426
12	O	427-429
(	O	430-431
71	O	431-433
%	O	433-434
)	O	434-435
occurred	O	436-444
in	O	445-447
exons	O	448-453
7	O	454-455
-	O	455-456
9	O	456-457
,	O	457-458
which	O	459-464
encode	O	465-471
the	O	472-475
intracellular	O	476-489
portion	O	490-497
of	O	498-500
Fas	O	501-504
.	O	504-505

In	O	506-508
vitro	O	509-514
,	O	514-515
activated	O	516-525
lymphocytes	O	526-537
from	O	538-542
all	O	543-546
17	O	547-549
patients	O	550-558
showed	O	559-565
apoptotic	O	566-575
defects	O	576-583
when	O	584-588
exposed	O	589-596
to	O	597-599
an	O	600-602
anti	O	603-607
-	O	607-608
Fas	O	608-611
agonist	O	612-619
monoclonal	O	620-630
antibody	O	631-639
.	O	639-640

Similar	O	641-648
defects	O	649-656
were	O	657-661
found	O	662-667
in	O	668-670
a	O	671-672
Fas	O	673-676
-	O	676-677
negative	O	677-685
cell	O	686-690
line	O	691-695
transfected	O	696-707
with	O	708-712
cDNAs	O	713-718
bearing	O	719-726
each	O	727-731
of	O	732-734
the	O	735-738
mutations	O	739-748
.	O	748-749

In	O	750-752
cotransfection	O	753-767
experiments	O	768-779
,	O	779-780
Fas	O	781-784
constructs	O	785-795
with	O	796-800
either	O	801-807
intra	O	808-813
-	O	813-814
or	O	815-817
extracellular	O	818-831
mutations	O	832-841
caused	O	842-848
dominant	O	849-857
inhibition	O	858-868
of	O	869-871
apoptosis	O	872-881
mediated	O	882-890
by	O	891-893
wild	O	894-898
-	O	898-899
type	O	899-903
Fas	O	904-907
.	O	907-908

Two	O	909-912
missense	O	913-921
Fas	O	922-925
variants	O	926-934
,	O	934-935
not	O	936-939
restricted	O	940-950
to	O	951-953
patients	O	954-962
with	O	963-967
ALPS	B	968-972
,	O	972-973
were	O	974-978
identified	O	979-989
.	O	989-990

Variant	O	991-998
A	O	999-1000
(	O	1001-1002
-	O	1002-1003
1	O	1003-1004
)	O	1004-1005
T	O	1006-1007
at	O	1008-1010
the	O	1011-1014
Fas	O	1015-1018
signal	O	1019-1025
-	O	1025-1026
sequence	O	1026-1034
cleavage	O	1035-1043
site	O	1044-1048
,	O	1048-1049
which	O	1050-1055
mediates	O	1056-1064
apoptosis	O	1065-1074
less	O	1075-1079
well	O	1080-1084
than	O	1085-1089
wild	O	1090-1094
-	O	1094-1095
type	O	1095-1099
Fas	O	1100-1103
and	O	1104-1107
is	O	1108-1110
partially	O	1111-1120
inhibitory	O	1121-1131
,	O	1131-1132
was	O	1133-1136
present	O	1137-1144
in	O	1145-1147
13	O	1148-1150
%	O	1150-1151
of	O	1152-1154
African	O	1155-1162
American	O	1163-1171
alleles	O	1172-1179
.	O	1179-1180

Among	O	1181-1186
the	O	1187-1190
ALPS	B	1191-1195
-	O	1195-1196
associated	O	1196-1206
Fas	O	1207-1210
mutants	O	1211-1218
,	O	1218-1219
dominant	O	1220-1228
inhibition	O	1229-1239
of	O	1240-1242
apoptosis	O	1243-1252
was	O	1253-1256
much	O	1257-1261
more	O	1262-1266
pronounced	O	1267-1277
in	O	1278-1280
mutants	O	1281-1288
affecting	O	1289-1298
the	O	1299-1302
intracellular	O	1303-1316
,	O	1316-1317
versus	O	1318-1324
extracellular	O	1325-1338
,	O	1338-1339
portion	O	1340-1347
of	O	1348-1350
the	O	1351-1354
Fas	O	1355-1358
receptor	O	1359-1367
.	O	1367-1368

Mutations	O	1369-1378
causing	O	1379-1386
disruption	O	1387-1397
of	O	1398-1400
the	O	1401-1404
intracellular	O	1405-1418
Fas	O	1419-1422
death	O	1423-1428
domain	O	1429-1435
also	O	1436-1440
showed	O	1441-1447
a	O	1448-1449
higher	O	1450-1456
penetrance	O	1457-1467
of	O	1468-1470
ALPS	B	1471-1475
phenotype	O	1476-1485
features	O	1486-1494
in	O	1495-1497
mutation	O	1498-1506
-	O	1506-1507
bearing	O	1507-1514
relatives	O	1515-1524
.	O	1524-1525

Significant	O	1526-1537
ALPS	B	1538-1542
-	O	1542-1543
related	O	1543-1550
morbidity	O	1551-1560
occurred	O	1561-1569
in	O	1570-1572
44	O	1573-1575
%	O	1575-1576
of	O	1577-1579
relatives	O	1580-1589
with	O	1590-1594
intracellular	O	1595-1608
mutations	O	1609-1618
,	O	1618-1619
versus	O	1620-1626
0	O	1627-1628
%	O	1628-1629
of	O	1630-1632
relatives	O	1633-1642
with	O	1643-1647
extracellular	O	1648-1661
mutations	O	1662-1671
.	O	1671-1672

Thus	O	1673-1677
,	O	1677-1678
the	O	1679-1682
location	O	1683-1691
of	O	1692-1694
mutations	O	1695-1704
within	O	1705-1711
APT1	O	1712-1716
strongly	O	1717-1725
influences	O	1726-1736
the	O	1737-1740
development	O	1741-1752
and	O	1753-1756
the	O	1757-1760
severity	O	1761-1769
of	O	1770-1772
ALPS	B	1773-1777
.	O	1777-1778

Mutational	O	0-10
analysis	O	11-19
and	O	20-23
genotype	O	24-32
-	O	32-33
phenotype	O	33-42
correlation	O	43-54
of	O	55-57
29	O	58-60
unrelated	O	61-70
Japanese	O	71-79
patients	O	80-88
with	O	89-93
X	B	94-95
-	I	95-96
linked	I	96-102
adrenoleukodystrophy	I	103-123
.	O	123-124
BACKGROUND	O	125-135
X	B	137-138
-	I	138-139
linked	I	139-145
adrenoleukodystrophy	I	146-166
(	O	167-168
ALD	B	168-171
)	O	171-172
is	O	173-175
an	O	176-178
inherited	B	179-188
disease	I	189-196
characterized	O	197-210
by	O	211-213
progressive	O	214-225
neurologic	B	226-236
dysfunction	I	237-248
,	O	248-249
occasionally	O	250-262
associated	O	263-273
with	O	274-278
adrenal	B	279-286
insufficiency	I	287-300
.	O	300-301

The	O	302-305
classic	O	306-313
form	O	314-318
of	O	319-321
ALD	B	322-325
usually	O	326-333
has	O	334-337
onset	O	338-343
in	O	344-346
childhood	O	347-356
(	O	357-358
childhood	B	358-367
cerebral	I	368-376
ALD	I	377-380
)	O	380-381
,	O	381-382
with	O	383-387
rapid	O	388-393
neurologic	B	394-404
deterioration	I	405-418
leading	O	419-426
to	O	427-429
a	O	430-431
vegetative	O	432-442
state	O	443-448
.	O	448-449

Adult	O	450-455
-	O	455-456
onset	O	456-461
cerebral	B	462-470
ALD	I	471-474
also	O	475-479
presents	O	480-488
with	O	489-493
rapidly	O	494-501
progressive	O	502-513
neurologic	B	514-524
dysfunction	I	525-536
.	O	536-537

Milder	O	538-544
phenotypes	O	545-555
such	O	556-560
as	O	561-563
adrenomyeloneuropathy	B	564-585
and	O	586-589
Addison	B	590-597
disease	I	598-605
only	O	606-610
also	O	611-615
have	O	616-620
been	O	621-625
recognized	O	626-636
.	O	636-637

Despite	O	638-645
discovery	O	646-655
of	O	656-658
the	O	659-662
causative	O	663-672
gene	O	673-677
,	O	677-678
a	O	679-680
molecular	O	681-690
basis	O	691-696
for	O	697-700
the	O	701-704
diverse	O	705-712
clinical	O	713-721
presentations	O	722-735
remains	O	736-743
to	O	744-746
be	O	747-749
elucidated	O	750-760
.	O	760-761

OBJECTIVES	O	762-772
To	O	774-776
conduct	O	777-784
mutational	O	785-795
analyses	O	796-804
in	O	805-807
29	O	808-810
Japanese	O	811-819
patients	O	820-828
with	O	829-833
ALD	B	834-837
from	O	838-842
29	O	843-845
unrelated	O	846-855
families	O	856-864
,	O	864-865
to	O	866-868
obtain	O	869-875
knowledge	O	876-885
of	O	886-888
the	O	889-892
spectrum	O	893-901
of	O	902-904
mutations	O	905-914
in	O	915-917
this	O	918-922
gene	O	923-927
,	O	927-928
and	O	929-932
to	O	933-935
study	O	936-941
genotype	O	942-950
-	O	950-951
phenotype	O	951-960
correlations	O	961-973
in	O	974-976
Japanese	O	977-985
patients	O	986-994
.	O	994-995

METHODS	O	996-1003
The	O	1005-1008
29	O	1009-1011
patients	O	1012-1020
comprised	O	1021-1030
13	O	1031-1033
patients	O	1034-1042
with	O	1043-1047
childhood	B	1048-1057
cerebral	I	1058-1066
ALD	I	1067-1070
,	O	1070-1071
11	O	1072-1074
patients	O	1075-1083
with	O	1084-1088
adult	O	1089-1094
-	O	1094-1095
onset	O	1095-1100
cerebral	B	1101-1109
ALD	I	1110-1113
,	O	1113-1114
and	O	1115-1118
5	O	1119-1120
patients	O	1121-1129
with	O	1130-1134
adrenomyeloneuropathy	B	1135-1156
.	O	1156-1157

We	O	1158-1160
conducted	O	1161-1170
detailed	O	1171-1179
mutational	O	1180-1190
analyses	O	1191-1199
of	O	1200-1202
29	O	1203-1205
unrelated	O	1206-1215
Japanese	O	1216-1224
patients	O	1225-1233
with	O	1234-1238
ALD	B	1239-1242
by	O	1243-1245
genomic	O	1246-1253
Southern	O	1254-1262
blot	O	1263-1267
analysis	O	1268-1276
and	O	1277-1280
direct	O	1281-1287
nucleotide	O	1288-1298
sequence	O	1299-1307
analysis	O	1308-1316
of	O	1317-1319
reverse	O	1320-1327
transcriptase	O	1328-1341
-	O	1341-1342
polymerase	O	1342-1352
chain	O	1353-1358
reaction	O	1359-1367
products	O	1368-1376
derived	O	1377-1384
from	O	1385-1389
total	O	1390-1395
RNA	O	1396-1399
that	O	1400-1404
was	O	1405-1408
extracted	O	1409-1418
from	O	1419-1423
cultured	O	1424-1432
skin	O	1433-1437
fibroblasts	O	1438-1449
,	O	1449-1450
lymphoblastoid	O	1451-1465
cells	O	1466-1471
,	O	1471-1472
or	O	1473-1475
peripheral	O	1476-1486
blood	O	1487-1492
leukocytes	O	1493-1503
.	O	1503-1504

RESULTS	O	1505-1512
Three	O	1514-1519
patients	O	1520-1528
with	O	1529-1533
adult	O	1534-1539
-	O	1539-1540
onset	O	1540-1545
cerebral	B	1546-1554
ALD	I	1555-1558
were	O	1559-1563
identified	O	1564-1574
as	O	1575-1577
having	O	1578-1584
large	O	1585-1590
genomic	O	1591-1598
rearrangements	O	1599-1613
.	O	1613-1614

The	O	1615-1618
remaining	O	1619-1628
26	O	1629-1631
patients	O	1632-1640
were	O	1641-1645
identified	O	1646-1656
as	O	1657-1659
having	O	1660-1666
21	O	1667-1669
independent	O	1670-1681
mutations	O	1682-1691
,	O	1691-1692
including	O	1693-1702
12	O	1703-1705
novel	O	1706-1711
mutations	O	1712-1721
resulting	O	1722-1731
in	O	1732-1734
small	O	1735-1740
nucleotide	O	1741-1751
alterations	O	1752-1763
in	O	1764-1766
the	O	1767-1770
ALD	B	1771-1774
gene	O	1775-1779
.	O	1779-1780

Eighteen	O	1781-1789
(	O	1790-1791
69	O	1791-1793
%	O	1793-1794
)	O	1794-1795
of	O	1796-1798
26	O	1799-1801
mutations	O	1802-1811
were	O	1812-1816
missense	O	1817-1825
mutations	O	1826-1835
.	O	1835-1836

Most	O	1837-1841
missense	O	1842-1850
mutations	O	1851-1860
involved	O	1861-1869
amino	O	1870-1875
acids	O	1876-1881
conserved	O	1882-1891
in	O	1892-1894
homologous	O	1895-1905
gene	O	1906-1910
products	O	1911-1919
,	O	1919-1920
including	O	1921-1930
PMP70	O	1931-1936
,	O	1936-1937
mALDRP	O	1938-1944
,	O	1944-1945
and	O	1946-1949
Pxa1p	O	1950-1955
.	O	1955-1956

The	O	1957-1960
AG	O	1961-1963
dinucleotide	O	1964-1976
deletion	O	1977-1985
at	O	1986-1988
position	O	1989-1997
1081	O	1998-2002
-	O	2002-2003
1082	O	2003-2007
,	O	2007-2008
which	O	2009-2014
has	O	2015-2018
been	O	2019-2023
reported	O	2024-2032
previously	O	2033-2043
to	O	2044-2046
be	O	2047-2049
the	O	2050-2053
most	O	2054-2058
common	O	2059-2065
mutation	O	2066-2074
in	O	2075-2077
white	O	2078-2083
patients	O	2084-2092
(	O	2093-2094
12	O	2094-2096
%	O	2096-2097
-	O	2098-2099
17	O	2099-2101
%	O	2101-2102
)	O	2102-2103
,	O	2103-2104
was	O	2105-2108
also	O	2109-2113
identified	O	2114-2124
as	O	2125-2127
the	O	2128-2131
most	O	2132-2136
common	O	2137-2143
mutation	O	2144-2152
in	O	2153-2155
Japanese	O	2156-2164
patients	O	2165-2173
(	O	2174-2175
12	O	2175-2177
%	O	2177-2178
)	O	2178-2179
.	O	2179-2180

All	O	2181-2184
phenotypes	O	2185-2195
were	O	2196-2200
associated	O	2201-2211
with	O	2212-2216
mutations	O	2217-2226
resulting	O	2227-2236
in	O	2237-2239
protein	O	2240-2247
truncation	O	2248-2258
or	O	2259-2261
subtle	O	2262-2268
amino	O	2269-2274
acid	O	2275-2279
changes	O	2280-2287
.	O	2287-2288

There	O	2289-2294
were	O	2295-2299
no	O	2300-2302
differences	O	2303-2314
in	O	2315-2317
phenotypic	O	2318-2328
expressions	O	2329-2340
between	O	2341-2348
missense	O	2349-2357
mutations	O	2358-2367
involving	O	2368-2377
conserved	O	2378-2387
amino	O	2388-2393
acids	O	2394-2399
and	O	2400-2403
those	O	2404-2409
involving	O	2410-2419
nonconserved	O	2420-2432
amino	O	2433-2438
acids	O	2439-2444
.	O	2444-2445

CONCLUSIONS	O	2446-2457
There	O	2459-2464
are	O	2465-2468
no	O	2469-2471
obvious	O	2472-2479
correlations	O	2480-2492
between	O	2493-2500
the	O	2501-2504
phenotypes	O	2505-2515
of	O	2516-2518
patients	O	2519-2527
with	O	2528-2532
ALD	B	2533-2536
and	O	2537-2540
their	O	2541-2546
genotypes	O	2547-2556
,	O	2556-2557
suggesting	O	2558-2568
that	O	2569-2573
other	O	2574-2579
genetic	O	2580-2587
or	O	2588-2590
environmental	O	2591-2604
factors	O	2605-2612
modify	O	2613-2619
the	O	2620-2623
phenotypic	O	2624-2634
expressions	O	2635-2646
of	O	2647-2649
ALD	B	2650-2653
.	O	2653-2654
.	O	2653-2654

Absence	B	0-7
of	I	8-10
the	I	11-14
seventh	I	15-22
component	I	23-32
of	I	33-35
complement	I	36-46
in	O	47-49
a	O	50-51
patient	O	52-59
with	O	60-64
chronic	B	65-72
meningococcemia	I	73-88
presenting	O	89-99
as	O	100-102
vasculitis	B	103-113
.	O	113-114

A	O	115-116
previously	O	117-127
healthy	O	128-135
40	O	136-138
-	O	138-139
year	O	139-143
-	O	138-139
old	O	144-147
man	O	148-151
presenting	O	152-162
with	O	163-167
fever	B	168-173
,	O	173-174
arthritis	B	175-184
,	O	184-185
and	O	186-189
cutaneous	B	190-199
vasculitis	I	200-210
was	O	211-214
found	O	215-220
to	O	221-223
have	O	224-228
chronic	B	229-236
meningococcemia	I	237-252
.	O	252-253

Evaluation	O	254-264
of	O	265-267
his	O	268-271
complement	O	272-282
system	O	283-289
showed	O	290-296
an	O	297-299
absence	O	300-307
of	O	308-310
functional	O	311-321
and	O	322-325
antigenic	O	326-335
C7	O	336-338
,	O	338-339
compatible	O	340-350
with	O	351-355
a	O	356-357
complete	O	358-366
deficiency	B	367-377
of	I	378-380
the	I	381-384
seventh	I	385-392
component	I	393-402
of	I	403-405
complement	I	406-416
.	O	416-417

Study	O	418-423
of	O	424-426
the	O	427-430
patients	O	431-439
family	O	440-446
spanning	O	447-455
four	O	456-460
generations	O	461-472
showed	O	473-479
heterozygous	O	480-492
deficiency	B	493-503
of	I	504-506
C7	I	507-509
in	O	510-512
five	O	513-517
members	O	518-525
.	O	525-526

Chronic	B	527-534
neisserial	I	535-545
infection	I	546-555
can	O	556-559
be	O	560-562
associated	O	563-573
with	O	574-578
C7	B	579-581
deficiency	I	582-592
and	O	593-596
must	O	597-601
be	O	602-604
distinguished	O	605-618
from	O	619-623
other	O	624-629
causes	O	630-636
of	O	637-639
cutaneous	B	640-649
vasculitis	I	650-660
.	O	660-661
.	O	660-661

Genotype	O	0-8
and	O	9-12
phenotype	O	13-22
in	O	23-25
patients	O	26-34
with	O	35-39
dihydropyrimidine	B	40-57
dehydrogenase	I	58-71
deficiency	I	72-82
.	O	82-83

Dihydropyrimidine	B	84-101
dehydrogenase	I	102-115
(	I	116-117
DPD	I	117-120
)	I	120-121
deficiency	I	122-132
is	O	133-135
an	O	136-138
autosomal	B	139-148
recessive	I	149-158
disease	I	159-166
characterised	O	167-180
by	O	181-183
thymine	O	184-191
-	O	191-192
uraciluria	O	192-202
in	O	203-205
homozygous	O	206-216
deficient	O	217-226
patients	O	227-235
and	O	236-239
has	O	240-243
been	O	244-248
associated	O	249-259
with	O	260-264
a	O	265-266
variable	O	267-275
clinical	O	276-284
phenotype	O	285-294
.	O	294-295

In	O	296-298
order	O	299-304
to	O	305-307
understand	O	308-318
the	O	319-322
genetic	O	323-330
and	O	331-334
phenotypic	O	335-345
basis	O	346-351
for	O	352-355
DPD	B	356-359
deficiency	I	360-370
,	O	370-371
we	O	372-374
have	O	375-379
reviewed	O	380-388
17	O	389-391
families	O	392-400
presenting	O	401-411
22	O	412-414
patients	O	415-423
with	O	424-428
complete	O	429-437
deficiency	B	438-448
of	I	449-451
DPD	I	452-455
.	O	455-456

In	O	457-459
this	O	460-464
group	O	465-470
of	O	471-473
patients	O	474-482
,	O	482-483
7	O	484-485
different	O	486-495
mutations	O	496-505
have	O	506-510
been	O	511-515
identified	O	516-526
,	O	526-527
including	O	528-537
2	O	538-539
deletions	O	540-549
[	O	550-551
295	O	551-554
-	O	554-555
298delTCAT	O	555-565
,	O	565-566
1897delC	O	567-575
]	O	575-576
,	O	576-577
1	O	578-579
splice	O	580-586
-	O	586-587
site	O	587-591
mutation	O	592-600
[	O	601-602
IVS14	O	602-607
+	O	608-609
1G	O	610-612
>	O	613-614
A	O	615-616
)	O	616-617
]	O	617-618
and	O	619-622
4	O	623-624
missense	O	625-633
mutations	O	634-643
(	O	644-645
85T	O	645-648
>	O	649-650
C	O	651-652
,	O	652-653
703C	O	654-658
>	O	659-660
T	O	661-662
,	O	662-663
2658G	O	664-669
>	O	670-671
A	O	672-673
,	O	673-674
2983G	O	675-680
>	O	681-682
T	O	683-684
)	O	684-685
.	O	685-686

Analysis	O	687-695
of	O	696-698
the	O	699-702
prevalence	O	703-713
of	O	714-716
the	O	717-720
various	O	721-728
mutations	O	729-738
among	O	739-744
DPD	B	745-748
patients	O	749-757
has	O	758-761
shown	O	762-767
that	O	768-772
the	O	773-776
G	O	777-778
-	O	778-779
-	O	778-779
>	O	781-782
A	O	783-784
point	O	785-790
mutation	O	791-799
in	O	800-802
the	O	803-806
invariant	O	807-816
splice	O	817-823
donor	O	824-829
site	O	830-834
is	O	835-837
by	O	838-840
far	O	841-844
the	O	845-848
most	O	849-853
common	O	854-860
(	O	861-862
52	O	862-864
%	O	864-865
)	O	865-866
,	O	866-867
whereas	O	868-875
the	O	876-879
other	O	880-885
six	O	886-889
mutations	O	890-899
are	O	900-903
less	O	904-908
frequently	O	909-919
observed	O	920-928
.	O	928-929

A	O	930-931
large	O	932-937
phenotypic	O	938-948
variability	O	949-960
has	O	961-964
been	O	965-969
observed	O	970-978
,	O	978-979
with	O	980-984
convulsive	B	985-995
disorders	I	996-1005
,	O	1005-1006
motor	B	1007-1012
retardation	I	1013-1024
and	O	1025-1028
mental	B	1029-1035
retardation	I	1036-1047
being	O	1048-1053
the	O	1054-1057
most	O	1058-1062
abundant	O	1063-1071
manifestations	O	1072-1086
.	O	1086-1087

A	O	1088-1089
clear	O	1090-1095
correlation	O	1096-1107
between	O	1108-1115
the	O	1116-1119
genotype	O	1120-1128
and	O	1129-1132
phenotype	O	1133-1142
has	O	1143-1146
not	O	1147-1150
been	O	1151-1155
established	O	1156-1167
.	O	1167-1168

An	O	1169-1171
altered	O	1172-1179
beta	O	1180-1184
-	O	1184-1185
alanine	O	1185-1192
,	O	1192-1193
uracil	O	1194-1200
and	O	1201-1204
thymine	O	1205-1212
homeostasis	O	1213-1224
might	O	1225-1230
underlie	O	1231-1239
the	O	1240-1243
various	O	1244-1251
clinical	B	1252-1260
abnormalities	I	1261-1274
encountered	O	1275-1286
in	O	1287-1289
patients	O	1290-1298
with	O	1299-1303
DPD	B	1304-1307
deficiency	I	1308-1318
.	O	1318-1319

Molecular	O	0-9
characterization	O	10-26
of	O	27-29
glucose	B	30-37
-	I	37-38
6	I	38-39
-	I	37-38
phosphate	I	40-49
dehydrogenase	I	50-63
(	I	64-65
G6PD	I	65-69
)	I	69-70
deficiency	I	71-81
by	O	82-84
natural	O	85-92
and	O	93-96
amplification	O	97-110
created	O	111-118
restriction	O	119-130
sites	O	131-136
:	O	136-137
five	O	138-142
mutations	O	143-152
account	O	153-160
for	O	161-164
most	O	165-169
G6PD	B	170-174
deficiency	I	175-185
cases	O	186-191
in	O	192-194
Taiwan	O	195-201
.	O	201-202

We	O	203-205
have	O	206-210
developed	O	211-220
a	O	221-222
rapid	O	223-228
and	O	229-232
simple	O	233-239
method	O	240-246
to	O	247-249
diagnose	O	250-258
the	O	259-262
molecular	O	263-272
defects	O	273-280
of	O	281-283
glucose	B	284-291
-	I	291-292
6	I	292-293
-	I	291-292
phosphate	I	294-303
dehydrogenase	I	304-317
(	I	318-319
G6PD	I	319-323
)	I	323-324
deficiency	I	325-335
in	O	336-338
Chinese	O	339-346
in	O	347-349
Taiwan	O	350-356
.	O	356-357

This	O	358-362
method	O	363-369
involves	O	370-378
the	O	379-382
selective	O	383-392
amplification	O	393-406
of	O	407-409
a	O	410-411
DNA	O	412-415
fragment	O	416-424
from	O	425-429
human	O	430-435
G6PD	O	436-440
gene	O	441-445
with	O	446-450
specific	O	451-459
oligonucleotide	O	460-475
primers	O	476-483
followed	O	484-492
by	O	493-495
digestion	O	496-505
with	O	506-510
restriction	O	511-522
enzymes	O	523-530
that	O	531-535
recognize	O	536-545
artificially	O	546-558
created	O	559-566
or	O	567-569
naturally	O	570-579
occurring	O	580-589
restriction	O	590-601
sites	O	602-607
.	O	607-608

Ninety	O	609-615
-	O	615-616
four	O	616-620
Chinese	O	621-628
males	O	629-634
with	O	635-639
G6PD	B	640-644
deficiency	I	645-655
were	O	656-660
studied	O	661-668
.	O	668-669

The	O	670-673
results	O	674-681
show	O	682-686
that	O	687-691
50	O	692-694
%	O	694-695
(	O	696-697
47	O	697-699
of	O	700-702
94	O	703-705
)	O	705-706
were	O	707-711
G	O	712-713
to	O	714-716
T	O	717-718
mutation	O	719-727
at	O	728-730
nucleotide	O	731-741
(	O	742-743
nt	O	743-745
)	O	745-746
1376	O	747-751
,	O	751-752
21	O	753-755
.	O	755-756
3	O	757-758
%	O	758-759
(	O	760-761
20	O	761-763
of	O	764-766
94	O	767-769
)	O	769-770
were	O	771-775
G	O	776-777
to	O	778-780
A	O	781-782
mutation	O	783-791
at	O	792-794
nt	O	795-797
1388	O	798-802
,	O	802-803
7	O	804-805
.	O	805-806
4	O	807-808
%	O	808-809
(	O	810-811
7	O	811-812
of	O	813-815
94	O	816-818
)	O	818-819
were	O	820-824
A	O	825-826
to	O	827-829
G	O	830-831
mutation	O	832-840
at	O	841-843
nt	O	844-846
493	O	847-850
,	O	850-851
7	O	852-853
.	O	853-854
4	O	855-856
%	O	856-857
(	O	858-859
7	O	859-860
of	O	861-863
94	O	864-866
)	O	866-867
were	O	868-872
A	O	873-874
to	O	875-877
G	O	878-879
mutation	O	880-888
at	O	889-891
nt	O	892-894
95	O	895-897
,	O	897-898
4	O	899-900
.	O	900-901
2	O	902-903
%	O	903-904
(	O	905-906
4	O	906-907
of	O	908-910
94	O	911-913
)	O	913-914
were	O	915-919
C	O	920-921
to	O	922-924
T	O	925-926
mutation	O	927-935
at	O	936-938
nt	O	939-941
1024	O	942-946
,	O	946-947
1	O	948-949
.	O	949-950
1	O	951-952
%	O	952-953
(	O	954-955
1	O	955-956
of	O	957-959
94	O	960-962
)	O	962-963
was	O	964-967
G	O	968-969
to	O	970-972
T	O	973-974
mutation	O	975-983
at	O	984-986
nt	O	987-989
392	O	990-993
,	O	993-994
and	O	995-998
1	O	999-1000
.	O	1000-1001
1	O	1002-1003
%	O	1003-1004
(	O	1005-1006
1	O	1006-1007
of	O	1008-1010
94	O	1011-1013
)	O	1013-1014
was	O	1015-1018
G	O	1019-1020
to	O	1021-1023
A	O	1024-1025
mutation	O	1026-1034
at	O	1035-1037
nt	O	1038-1040
487	O	1041-1044
.	O	1044-1045

These	O	1046-1051
results	O	1052-1059
show	O	1060-1064
that	O	1065-1069
the	O	1070-1073
former	O	1074-1080
five	O	1081-1085
mutations	O	1086-1095
account	O	1096-1103
for	O	1104-1107
more	O	1108-1112
than	O	1113-1117
90	O	1118-1120
%	O	1120-1121
of	O	1122-1124
G6PD	B	1125-1129
deficiency	I	1130-1140
cases	O	1141-1146
in	O	1147-1149
Taiwan	O	1150-1156
.	O	1156-1157

Aside	O	1158-1163
from	O	1164-1168
showing	O	1169-1176
that	O	1177-1181
G	O	1182-1183
to	O	1184-1186
T	O	1187-1188
change	O	1189-1195
at	O	1196-1198
nt	O	1199-1201
1376	O	1202-1206
is	O	1207-1209
the	O	1210-1213
most	O	1214-1218
common	O	1219-1225
mutation	O	1226-1234
,	O	1234-1235
our	O	1236-1239
research	O	1240-1248
indicates	O	1249-1258
that	O	1259-1263
nt	O	1264-1266
493	O	1267-1270
mutation	O	1271-1279
is	O	1280-1282
a	O	1283-1284
frequent	O	1285-1293
mutation	O	1294-1302
among	O	1303-1308
Chinese	O	1309-1316
in	O	1317-1319
Taiwan	O	1320-1326
.	O	1326-1327

We	O	1328-1330
compared	O	1331-1339
G6PD	O	1340-1344
activity	O	1345-1353
among	O	1354-1359
different	O	1360-1369
mutations	O	1370-1379
,	O	1379-1380
without	O	1381-1388
discovering	O	1389-1400
significant	O	1401-1412
differences	O	1413-1424
between	O	1425-1432
them	O	1433-1437
.	O	1437-1438

Homozygous	B	0-10
hypobetalipoproteinemia	I	11-34
:	O	34-35
a	O	36-37
disease	O	38-45
distinct	O	46-54
from	O	55-59
abetalipoproproteinemia	B	60-83
at	O	84-86
the	O	87-90
molecular	O	91-100
level	O	101-106
.	O	106-107

apoB	O	108-112
DNA	O	113-116
,	O	116-117
RNA	O	118-121
,	O	121-122
and	O	123-126
protein	O	127-134
from	O	135-139
two	O	140-143
patients	O	144-152
with	O	153-157
homozygous	B	158-168
hypobetalipoproteinemia	I	169-192
(	O	193-194
HBL	B	194-197
)	O	197-198
were	O	199-203
evaluated	O	204-213
and	O	214-217
compared	O	218-226
with	O	227-231
normal	O	232-238
individuals	O	239-250
.	O	250-251

Southern	O	252-260
blot	O	261-265
analysis	O	266-274
with	O	275-279
10	O	280-282
different	O	283-292
cDNA	O	293-297
probes	O	298-304
revealed	O	305-313
a	O	314-315
normal	O	316-322
gene	O	323-327
without	O	328-335
major	O	336-341
insertions	O	342-352
,	O	352-353
deletions	O	354-363
,	O	363-364
or	O	365-367
rearrangements	O	368-382
.	O	382-383

Northern	O	384-392
and	O	393-396
slot	O	397-401
blot	O	402-406
analyses	O	407-415
of	O	416-418
total	O	419-424
liver	O	425-430
mRNA	O	431-435
from	O	436-440
HBL	B	441-444
patients	O	445-453
documented	O	454-464
a	O	465-466
normal	O	467-473
size	O	474-478
apoB	O	479-483
mRNA	O	484-488
that	O	489-493
was	O	494-497
present	O	498-505
in	O	506-508
greatly	O	509-516
reduced	O	517-524
quantities	O	525-535
.	O	535-536

ApoB	O	537-541
protein	O	542-549
was	O	550-553
detected	O	554-562
within	O	563-569
HBL	B	570-573
hepatocytes	O	574-585
utilizing	O	586-595
immunohistochemical	O	596-615
techniques	O	616-626
;	O	626-627
however	O	628-635
,	O	635-636
it	O	637-639
was	O	640-643
markedly	O	644-652
reduced	O	653-660
in	O	661-663
quantity	O	664-672
when	O	673-677
compared	O	678-686
with	O	687-691
control	O	692-699
samples	O	700-707
.	O	707-708

No	O	709-711
apoB	O	712-716
was	O	717-720
detectable	O	721-731
in	O	732-734
the	O	735-738
plasma	O	739-745
of	O	746-748
HBL	B	749-752
individuals	O	753-764
with	O	765-769
an	O	770-772
ELISA	O	773-778
assay	O	779-784
.	O	784-785

These	O	786-791
data	O	792-796
are	O	797-800
most	O	801-805
consistent	O	806-816
with	O	817-821
a	O	822-823
mutation	O	824-832
in	O	833-835
the	O	836-839
coding	O	840-846
portion	O	847-854
of	O	855-857
the	O	858-861
apoB	O	862-866
gene	O	867-871
in	O	872-874
HBL	B	875-878
patients	O	879-887
,	O	887-888
leading	O	889-896
to	O	897-899
an	O	900-902
abnormal	O	903-911
apoB	O	912-916
protein	O	917-924
and	O	925-928
apoB	O	929-933
mRNA	O	934-938
instability	O	939-950
.	O	950-951

These	O	952-957
results	O	958-965
are	O	966-969
distinct	O	970-978
from	O	979-983
those	O	984-989
previously	O	990-1000
noted	O	1001-1006
in	O	1007-1009
abetalipoproteinemia	B	1010-1030
,	O	1030-1031
which	O	1032-1037
was	O	1038-1041
characterized	O	1042-1055
by	O	1056-1058
an	O	1059-1061
elevated	O	1062-1070
level	O	1071-1076
of	O	1077-1079
hepatic	O	1080-1087
apoB	O	1088-1092
mRNA	O	1093-1097
and	O	1098-1101
accumulation	O	1102-1114
of	O	1115-1117
intracellular	O	1118-1131
hepatic	O	1132-1139
apoB	O	1140-1144
protein	O	1145-1152
.	O	1152-1153
.	O	1152-1153

A	O	0-1
population	O	2-12
-	O	12-13
based	O	13-18
study	O	19-24
of	O	25-27
the	O	28-31
clinical	O	32-40
expression	O	41-51
of	O	52-54
the	O	55-58
hemochromatosis	B	59-74
gene	O	75-79
.	O	79-80

BACKGROUND	O	81-91
AND	O	92-95
METHODS	O	96-103
Hereditary	B	105-115
hemochromatosis	I	116-131
is	O	132-134
associated	O	135-145
with	O	146-150
homozygosity	O	151-163
for	O	164-167
the	O	168-171
C282Y	O	172-177
mutation	O	178-186
in	O	187-189
the	O	190-193
hemochromatosis	B	194-209
(	O	210-211
HFE	O	211-214
)	O	214-215
gene	O	216-220
on	O	221-223
chromosome	O	224-234
6	O	235-236
,	O	236-237
elevated	O	238-246
serum	O	247-252
transferrin	O	253-264
saturation	O	265-275
,	O	275-276
and	O	277-280
excess	B	281-287
iron	I	288-292
deposits	I	293-301
throughout	O	302-312
the	O	313-316
body	O	317-321
.	O	321-322

To	O	323-325
assess	O	326-332
the	O	333-336
prevalence	O	337-347
and	O	348-351
clinical	O	352-360
expression	O	361-371
of	O	372-374
the	O	375-378
HFE	O	379-382
gene	O	383-387
,	O	387-388
we	O	389-391
conducted	O	392-401
a	O	402-403
population	O	404-414
-	O	414-415
based	O	415-420
study	O	421-426
in	O	427-429
Busselton	O	430-439
,	O	439-440
Australia	O	441-450
.	O	450-451

In	O	452-454
1994	O	455-459
,	O	459-460
we	O	461-463
obtained	O	464-472
blood	O	473-478
samples	O	479-486
for	O	487-490
the	O	491-494
determination	O	495-508
of	O	509-511
serum	O	512-517
transferrin	O	518-529
saturation	O	530-540
and	O	541-544
ferritin	O	545-553
levels	O	554-560
and	O	561-564
the	O	565-568
presence	O	569-577
or	O	578-580
absence	O	581-588
of	O	589-591
the	O	592-595
C282Y	O	596-601
mutation	O	602-610
and	O	611-614
the	O	615-618
H63D	O	619-623
mutation	O	624-632
(	O	633-634
which	O	634-639
may	O	640-643
contribute	O	644-654
to	O	655-657
increased	O	658-667
hepatic	O	668-675
iron	O	676-680
levels	O	681-687
)	O	687-688
in	O	689-691
3011	O	692-696
unrelated	O	697-706
white	O	707-712
adults	O	713-719
.	O	719-720

We	O	721-723
evaluated	O	724-733
all	O	734-737
subjects	O	738-746
who	O	747-750
had	O	751-754
persistently	O	755-767
elevated	O	768-776
transferrin	O	777-788
-	O	788-789
saturation	O	789-799
values	O	800-806
(	O	807-808
45	O	808-810
percent	O	811-818
or	O	819-821
higher	O	822-828
)	O	828-829
or	O	830-832
were	O	833-837
homozygous	O	838-848
for	O	849-852
the	O	853-856
C282Y	O	857-862
mutation	O	863-871
.	O	871-872

We	O	873-875
recommended	O	876-887
liver	O	888-893
biopsy	O	894-900
for	O	901-904
subjects	O	905-913
with	O	914-918
serum	O	919-924
ferritin	O	925-933
levels	O	934-940
of	O	941-943
300	O	944-947
ng	O	948-950
per	O	951-954
milliliter	O	955-965
or	O	966-968
higher	O	969-975
.	O	975-976

The	O	977-980
subjects	O	981-989
were	O	990-994
followed	O	995-1003
for	O	1004-1007
up	O	1008-1010
to	O	1011-1013
four	O	1014-1018
years	O	1019-1024
.	O	1024-1025

RESULTS	O	1026-1033
Sixteen	O	1035-1042
of	O	1043-1045
the	O	1046-1049
subjects	O	1050-1058
(	O	1059-1060
0	O	1060-1061
.	O	1061-1062
5	O	1063-1064
percent	O	1065-1072
)	O	1072-1073
were	O	1074-1078
homozygous	O	1079-1089
for	O	1090-1093
the	O	1094-1097
C282Y	O	1098-1103
mutation	O	1104-1112
,	O	1112-1113
and	O	1114-1117
424	O	1118-1121
(	O	1122-1123
14	O	1123-1125
.	O	1125-1126
1	O	1127-1128
percent	O	1129-1136
)	O	1136-1137
were	O	1138-1142
heterozygous	O	1143-1155
.	O	1155-1156

The	O	1157-1160
serum	O	1161-1166
transferrin	O	1167-1178
saturation	O	1179-1189
was	O	1190-1193
45	O	1194-1196
percent	O	1197-1204
or	O	1205-1207
higher	O	1208-1214
in	O	1215-1217
15	O	1218-1220
of	O	1221-1223
the	O	1224-1227
16	O	1228-1230
who	O	1231-1234
were	O	1235-1239
homozygous	O	1240-1250
;	O	1250-1251
in	O	1252-1254
1	O	1255-1256
subject	O	1257-1264
it	O	1265-1267
was	O	1268-1271
43	O	1272-1274
percent	O	1275-1282
.	O	1282-1283

Four	O	1284-1288
of	O	1289-1291
the	O	1292-1295
homozygous	O	1296-1306
subjects	O	1307-1315
had	O	1316-1319
previously	O	1320-1330
been	O	1331-1335
given	O	1336-1341
a	O	1342-1343
diagnosis	O	1344-1353
of	O	1354-1356
hemochromatosis	B	1357-1372
,	O	1372-1373
and	O	1374-1377
12	O	1378-1380
had	O	1381-1384
not	O	1385-1388
.	O	1388-1389

Seven	O	1390-1395
of	O	1396-1398
these	O	1399-1404
12	O	1405-1407
patients	O	1408-1416
had	O	1417-1420
elevated	O	1421-1429
serum	O	1430-1435
ferritin	O	1436-1444
levels	O	1445-1451
in	O	1452-1454
1994	O	1455-1459
;	O	1459-1460
6	O	1461-1462
of	O	1463-1465
the	O	1466-1469
7	O	1470-1471
had	O	1472-1475
further	O	1476-1483
increases	O	1484-1493
in	O	1494-1496
1998	O	1497-1501
,	O	1501-1502
and	O	1503-1506
1	O	1507-1508
had	O	1509-1512
a	O	1513-1514
decrease	O	1515-1523
,	O	1523-1524
although	O	1525-1533
the	O	1534-1537
value	O	1538-1543
remained	O	1544-1552
elevated	O	1553-1561
.	O	1561-1562

The	O	1563-1566
serum	O	1567-1572
ferritin	O	1573-1581
levels	O	1582-1588
in	O	1589-1591
the	O	1592-1595
four	O	1596-1600
other	O	1601-1606
homozygous	O	1607-1617
patients	O	1618-1626
remained	O	1627-1635
in	O	1636-1638
the	O	1639-1642
normal	O	1643-1649
range	O	1650-1655
.	O	1655-1656

Eleven	O	1657-1663
of	O	1664-1666
the	O	1667-1670
16	O	1671-1673
homozygous	O	1674-1684
subjects	O	1685-1693
underwent	O	1694-1703
liver	O	1704-1709
biopsy	O	1710-1716
;	O	1716-1717
3	O	1718-1719
had	O	1720-1723
hepatic	B	1724-1731
fibrosis	I	1732-1740
,	O	1740-1741
and	O	1742-1745
1	O	1746-1747
,	O	1747-1748
who	O	1749-1752
had	O	1753-1756
a	O	1757-1758
history	O	1759-1766
of	O	1767-1769
excessive	B	1770-1779
alcohol	I	1780-1787
consumption	I	1788-1799
,	O	1799-1800
had	O	1801-1804
cirrhosis	B	1805-1814
and	O	1815-1818
mild	O	1819-1823
microvesicular	B	1824-1838
steatosis	I	1839-1848
.	O	1848-1849

Eight	O	1850-1855
of	O	1856-1858
the	O	1859-1862
16	O	1863-1865
homozygous	O	1866-1876
subjects	O	1877-1885
had	O	1886-1889
clinical	O	1890-1898
findings	O	1899-1907
that	O	1908-1912
were	O	1913-1917
consistent	O	1918-1928
with	O	1929-1933
the	O	1934-1937
presence	O	1938-1946
of	O	1947-1949
hereditary	B	1950-1960
hemochromatosis	I	1961-1976
,	O	1976-1977
such	O	1978-1982
as	O	1983-1985
hepatomegaly	B	1986-1998
,	O	1998-1999
skin	B	2000-2004
pigmentation	I	2005-2017
,	O	2017-2018
and	O	2019-2022
arthritis	B	2023-2032
.	O	2032-2033

CONCLUSIONS	O	2034-2045
In	O	2047-2049
a	O	2050-2051
population	O	2052-2062
of	O	2063-2065
white	O	2066-2071
adults	O	2072-2078
of	O	2079-2081
northern	O	2082-2090
European	O	2091-2099
ancestry	O	2100-2108
,	O	2108-2109
0	O	2110-2111
.	O	2111-2112
5	O	2113-2114
percent	O	2115-2122
were	O	2123-2127
homozygous	O	2128-2138
for	O	2139-2142
the	O	2143-2146
C282Y	O	2147-2152
mutation	O	2153-2161
in	O	2162-2164
the	O	2165-2168
HFE	O	2169-2172
gene	O	2173-2177
.	O	2177-2178

However	O	2179-2186
,	O	2186-2187
only	O	2188-2192
half	O	2193-2197
of	O	2198-2200
those	O	2201-2206
who	O	2207-2210
were	O	2211-2215
homozygous	O	2216-2226
had	O	2227-2230
clinical	O	2231-2239
features	O	2240-2248
of	O	2249-2251
hemochromatosis	B	2252-2267
,	O	2267-2268
and	O	2269-2272
one	O	2273-2276
quarter	O	2277-2284
had	O	2285-2288
serum	O	2289-2294
ferritin	O	2295-2303
levels	O	2304-2310
that	O	2311-2315
remained	O	2316-2324
normal	O	2325-2331
over	O	2332-2336
a	O	2337-2338
four	O	2339-2343
-	O	2343-2344
year	O	2344-2348
period	O	2349-2355
.	O	2355-2356

Overexpression	O	0-14
of	O	15-17
DM20	O	18-22
messenger	O	23-32
RNA	O	33-36
in	O	37-39
two	O	40-43
brothers	O	44-52
with	O	53-57
Pelizaeus	B	58-67
-	I	67-68
Merzbacher	I	68-78
disease	I	79-86
.	O	86-87

Pelizaeus	B	88-97
-	I	97-98
Merzbacher	I	98-108
disease	I	109-116
is	O	117-119
a	O	120-121
rare	B	122-126
,	I	126-127
sex	I	128-131
-	I	131-132
linked	I	132-138
recessive	I	139-148
,	I	148-149
dysmyelinating	I	150-164
disease	I	165-172
of	I	173-175
the	I	176-179
central	I	180-187
nervous	I	188-195
system	I	196-202
that	O	203-207
has	O	208-211
been	O	212-216
associated	O	217-227
with	O	228-232
mutations	O	233-242
in	O	243-245
the	O	246-249
myelin	O	250-256
proteolipid	O	257-268
protein	O	269-276
(	O	277-278
PLP	O	278-281
)	O	281-282
gene	O	283-287
.	O	287-288

Only	O	289-293
25	O	294-296
%	O	296-297
of	O	298-300
patients	O	301-309
studied	O	310-317
with	O	318-322
Pelizaeus	B	323-332
-	I	332-333
Merzbacher	I	333-343
disease	I	344-351
have	O	352-356
exonic	O	357-363
mutations	O	364-373
in	O	374-376
this	O	377-381
gene	O	382-386
,	O	386-387
the	O	388-391
underlying	O	392-402
cause	O	403-408
of	O	409-411
the	O	412-415
disease	O	416-423
in	O	424-426
the	O	427-430
remaining	O	431-440
patients	O	441-449
is	O	450-452
unknown	O	453-460
.	O	460-461

The	O	462-465
PLP	O	466-469
gene	O	470-474
encodes	O	475-482
two	O	483-486
major	O	487-492
alternatively	O	493-506
spliced	O	507-514
transcripts	O	515-526
called	O	527-533
PLP	O	534-537
and	O	538-541
DM20	O	542-546
.	O	546-547

PLP	O	548-551
messenger	O	552-561
RNA	O	562-565
is	O	566-568
specifically	O	569-581
expressed	O	582-591
in	O	592-594
central	O	595-602
nervous	O	603-610
system	O	611-617
tissue	O	618-624
,	O	624-625
whereas	O	626-633
DM20	O	634-638
messenger	O	639-648
RNA	O	649-652
is	O	653-655
found	O	656-661
in	O	662-664
central	O	665-672
nervous	O	673-680
system	O	681-687
,	O	687-688
cardiac	O	689-696
,	O	696-697
and	O	698-701
other	O	702-707
tissues	O	708-715
.	O	715-716

We	O	717-719
studied	O	720-727
cultured	O	728-736
skin	O	737-741
fibroblasts	O	742-753
from	O	754-758
2	O	759-760
brothers	O	761-769
with	O	770-774
Pelizaeus	B	775-784
-	I	784-785
Merzbacher	I	785-795
disease	I	796-803
who	O	804-807
exhibited	O	808-817
no	O	818-820
detectable	O	821-831
exonic	O	832-838
mutation	O	839-847
of	O	848-850
the	O	851-854
PLP	O	855-858
gene	O	859-863
.	O	863-864

Examination	O	865-876
of	O	877-879
RNA	O	880-883
from	O	884-888
these	O	889-894
cells	O	895-900
showed	O	901-907
that	O	908-912
the	O	913-916
level	O	917-922
of	O	923-925
DM20	O	926-930
messenger	O	931-940
RNA	O	941-944
is	O	945-947
elevated	O	948-956
sixfold	O	957-964
relative	O	965-973
to	O	974-976
male	O	977-981
control	O	982-989
skin	O	990-994
fibroblasts	O	995-1006
.	O	1006-1007

An	O	1008-1010
unrelated	O	1011-1020
female	O	1021-1027
carrier	O	1028-1035
,	O	1035-1036
also	O	1037-1041
with	O	1042-1046
no	O	1047-1049
detectable	O	1050-1060
exonic	O	1061-1067
mutation	O	1068-1076
,	O	1076-1077
showed	O	1078-1084
a	O	1085-1086
threefold	O	1087-1096
increase	O	1097-1105
in	O	1106-1108
DM20	O	1109-1113
messenger	O	1114-1123
RNA	O	1124-1127
in	O	1128-1130
cultured	O	1131-1139
skin	O	1140-1144
fibroblasts	O	1145-1156
.	O	1156-1157

Our	O	1158-1161
findings	O	1162-1170
suggest	O	1171-1178
that	O	1179-1183
in	O	1184-1186
some	O	1187-1191
patients	O	1192-1200
,	O	1200-1201
Pelizaeus	B	1202-1211
-	I	1211-1212
Merzbacher	I	1212-1222
disease	I	1223-1230
is	O	1231-1233
caused	O	1234-1240
by	O	1241-1243
overexpression	O	1244-1258
of	O	1259-1261
PLP	O	1262-1265
gene	O	1266-1270
transcripts	O	1271-1282
,	O	1282-1283
and	O	1284-1287
that	O	1288-1292
in	O	1293-1295
these	O	1296-1301
families	O	1302-1310
a	O	1311-1312
50	O	1313-1315
%	O	1315-1316
increase	O	1317-1325
of	O	1326-1328
DM20	O	1329-1333
messenger	O	1334-1343
RNA	O	1344-1347
in	O	1348-1350
females	O	1351-1358
,	O	1358-1359
relative	O	1360-1368
to	O	1369-1371
the	O	1372-1375
increase	O	1376-1384
in	O	1385-1387
affected	O	1388-1396
males	O	1397-1402
,	O	1402-1403
can	O	1404-1407
identify	O	1408-1416
a	O	1417-1418
female	O	1419-1425
carrier	O	1426-1433
.	O	1433-1434
.	O	1433-1434

Homozygosity	O	0-12
for	O	13-16
a	O	17-18
novel	O	19-24
DTDST	O	25-30
mutation	O	31-39
in	O	40-42
a	O	43-44
child	O	45-50
with	O	51-55
a	O	56-57
'	O	58-59
broad	O	59-64
bone	O	65-69
-	O	69-70
platyspondylic	O	70-84
'	O	84-85
variant	O	86-93
of	O	94-96
diastrophic	B	97-108
dysplasia	I	109-118
.	O	118-119

Atypical	O	120-128
or	O	129-131
variant	O	132-139
forms	O	140-145
of	O	146-148
well	O	149-153
-	O	153-154
known	O	154-159
chondrodysplasias	B	160-177
may	O	178-181
pose	O	182-186
diagnostic	O	187-197
problems	O	198-206
.	O	206-207

We	O	208-210
report	O	211-217
on	O	218-220
a	O	221-222
girl	O	223-227
with	O	228-232
clinical	O	233-241
features	O	242-250
suggesting	O	251-261
diastrophic	B	262-273
dysplasia	I	274-283
but	O	284-287
with	O	288-292
unusual	O	293-300
radiographic	O	301-313
features	O	314-322
including	O	323-332
severe	O	333-339
platyspondyly	B	340-353
,	O	353-354
wide	O	355-359
metaphyses	O	360-370
,	O	370-371
and	O	372-375
fibular	O	376-383
overgrowth	O	384-394
,	O	394-395
which	O	396-401
are	O	402-405
partially	O	406-415
reminiscent	O	416-427
of	O	428-430
metatropic	B	431-441
dysplasia	I	442-451
.	O	451-452

The	O	453-456
diagnosis	O	457-466
was	O	467-470
clarified	O	471-480
by	O	481-483
molecular	O	484-493
analysis	O	494-502
of	O	503-505
the	O	506-509
DTDST	O	510-515
gene	O	516-520
,	O	520-521
which	O	522-527
revealed	O	528-536
homozygosity	O	537-549
for	O	550-553
a	O	554-555
previously	O	556-566
undescribed	O	567-578
mutation	O	579-587
leading	O	588-595
to	O	596-598
a	O	599-600
Q454P	O	601-606
substitution	O	607-619
in	O	620-622
the	O	623-626
10th	O	627-631
transmembrane	O	632-645
domain	O	646-652
of	O	653-655
the	O	656-659
DTDST	O	660-665
sulfate	O	666-673
transporter	O	674-685
.	O	685-686

Molecular	O	687-696
analysis	O	697-705
may	O	706-709
be	O	710-712
of	O	713-715
particular	O	716-726
value	O	727-732
in	O	733-735
such	O	736-740
atypical	O	741-749
cases	O	750-755
.	O	755-756
.	O	755-756

Carrier	O	0-7
detection	O	8-17
and	O	18-21
prenatal	O	22-30
diagnosis	O	31-40
of	O	41-43
Pelizaeus	B	44-53
-	I	53-54
Merzbacher	I	54-64
disease	I	65-72
using	O	73-78
a	O	79-80
combination	O	81-92
of	O	93-95
anonymous	O	96-105
DNA	O	106-109
polymorphisms	O	110-123
and	O	124-127
the	O	128-131
proteolipid	O	132-143
protein	O	144-151
(	O	152-153
PLP	O	153-156
)	O	156-157
gene	O	158-162
cDNA	O	163-167
.	O	167-168

We	O	169-171
report	O	172-178
carrier	O	179-186
identification	O	187-201
and	O	202-205
a	O	206-207
prenatal	O	208-216
diagnosis	O	217-226
using	O	227-232
DNA	O	233-236
polymorphisms	O	237-250
in	O	251-253
2	O	254-255
families	O	256-264
with	O	265-269
X	B	270-271
-	I	271-272
linked	I	272-278
Pelizaeus	I	279-288
-	I	288-289
Merzbacher	I	289-299
disease	I	300-307
(	O	308-309
PMD	B	309-312
)	O	312-313
.	O	313-314

In	O	315-317
both	O	318-322
families	O	323-331
,	O	331-332
the	O	333-336
proteolipid	O	337-348
protein	O	349-356
(	O	357-358
PLP	O	358-361
)	O	361-362
gene	O	363-367
in	O	368-370
the	O	371-374
single	O	375-381
affected	O	382-390
male	O	391-395
could	O	396-401
be	O	402-404
traced	O	405-411
back	O	412-416
to	O	417-419
his	O	420-423
unaffected	O	424-434
maternal	O	435-443
grandfather	O	444-455
.	O	455-456

Therefore	O	457-466
,	O	466-467
each	O	468-472
family	O	473-479
contains	O	480-488
a	O	489-490
new	O	491-494
mutation	O	495-503
.	O	503-504

In	O	505-507
the	O	508-511
case	O	512-516
of	O	517-519
the	O	520-523
prenatal	O	524-532
diagnosis	O	533-542
,	O	542-543
the	O	544-547
fetus	O	548-553
was	O	554-557
shown	O	558-563
by	O	564-566
cytogenetic	O	567-578
analysis	O	579-587
to	O	588-590
be	O	591-593
a	O	594-595
female	O	596-602
,	O	602-603
who	O	604-607
we	O	608-610
predict	O	611-618
will	O	619-623
be	O	624-626
a	O	627-628
noncarrier	O	629-639
of	O	640-642
PMD	B	643-646
based	O	647-652
on	O	653-655
her	O	656-659
genotype	O	660-668
with	O	669-673
the	O	674-677
PLP	O	678-681
intragenic	O	682-692
polymorphism	O	693-705
.	O	705-706
.	O	705-706

Gardner	B	0-7
syndrome	I	8-16
in	O	17-19
a	O	20-21
boy	O	22-25
with	O	26-30
interstitial	O	31-43
deletion	O	44-52
of	O	53-55
the	O	56-59
long	O	60-64
arm	O	65-68
of	O	69-71
chromosome	O	72-82
5	O	83-84
.	O	84-85

We	O	86-88
described	O	89-98
a	O	99-100
15	O	101-103
-	O	103-104
year	O	104-108
-	O	103-104
old	O	109-112
boy	O	113-116
with	O	117-121
Gardner	B	122-129
syndrome	I	130-138
(	O	139-140
GS	B	140-142
)	O	142-143
,	O	143-144
mental	B	145-151
retardation	I	152-163
,	O	163-164
and	O	165-168
craniofacial	B	169-181
abnormalities	I	182-195
.	O	195-196

High	O	197-201
-	O	201-202
resolution	O	202-212
banding	O	213-220
analysis	O	221-229
showed	O	230-236
an	O	237-239
interstitial	O	240-252
deletion	O	253-261
of	O	262-264
the	O	265-268
long	O	269-273
arm	O	274-277
of	O	278-280
chromosome	O	281-291
5	O	292-293
(	O	294-295
q22	O	295-298
.	O	298-299

1	O	300-301
-	O	301-302
-	O	301-302
-	O	301-302
-	O	301-302
q31	O	305-308
1	O	309-310
-	O	310-311
-	O	310-311
-	O	310-311
-	O	310-311
q31	O	314-317
.	O	317-318

1	O	319-320
)	O	320-321
.	O	321-322

The	O	323-326
breakpoints	O	327-338
in	O	339-341
the	O	342-345
present	O	346-353
case	O	354-358
and	O	359-362
in	O	363-365
3	O	366-367
previously	O	368-378
reported	O	379-387
5q	O	388-390
-	O	390-391
patients	O	392-400
with	O	401-405
adenomatous	B	406-417
polyposis	I	418-427
coli	I	428-432
suggest	O	433-440
that	O	441-445
the	O	446-449
gene	O	450-454
responsible	O	455-466
for	O	467-470
GS	B	471-473
/	O	473-474
or	O	474-476
familial	B	477-485
polyposis	I	486-495
coli	I	496-500
(	O	501-502
FPC	B	502-505
)	O	505-506
is	O	507-509
in	O	510-512
the	O	513-516
5q22	O	517-521
region	O	522-528
,	O	528-529
a	O	530-531
result	O	532-538
consistent	O	539-549
with	O	550-554
the	O	555-558
findings	O	559-567
of	O	568-570
linkage	O	571-578
studies	O	579-586

Type	B	0-4
I	I	5-6
human	I	7-12
complement	I	13-23
C2	I	24-26
deficiency	I	27-37
.	O	37-38

A	O	39-40
28	O	41-43
-	O	43-44
base	O	44-48
pair	O	49-53
gene	O	54-58
deletion	O	59-67
causes	O	68-74
skipping	O	75-83
of	O	84-86
exon	O	87-91
6	O	92-93
during	O	94-100
RNA	O	101-104
splicing	O	105-113
.	O	113-114

Two	O	115-118
variants	O	119-127
of	O	128-130
a	O	131-132
genetic	O	133-140
deficiency	B	141-151
of	I	152-154
complement	I	155-165
protein	I	166-173
C2	I	174-176
(	O	177-178
C2D	O	178-181
)	O	181-182
have	O	183-187
been	O	188-192
previously	O	193-203
identified	O	204-214
.	O	214-215

No	O	216-218
C2	O	219-221
protein	O	222-229
translation	O	230-241
is	O	242-244
detected	O	245-253
in	O	254-256
type	O	257-261
I	O	262-263
deficiency	O	264-274
,	O	274-275
while	O	276-281
type	O	282-286
II	O	287-289
deficiency	O	290-300
is	O	301-303
characterized	O	304-317
by	O	318-320
a	O	321-322
selective	O	323-332
block	O	333-338
in	O	339-341
C2	O	342-344
secretion	O	345-354
.	O	354-355

Type	B	356-360
I	I	361-362
C2	I	363-365
deficiency	I	366-376
was	O	377-380
described	O	381-390
in	O	391-393
a	O	394-395
family	O	396-402
in	O	403-405
which	O	406-411
the	O	412-415
C2	O	416-418
null	O	419-423
allele	O	424-430
(	O	431-432
C2Q0	O	432-436
)	O	436-437
is	O	438-440
associated	O	441-451
with	O	452-456
the	O	457-460
major	O	461-466
histocompatibility	O	467-485
haplotype	O	486-495
/	O	495-496
complotype	O	496-506
HLA	O	507-510
-	O	510-511
A25	O	511-514
,	O	514-515
B18	O	516-519
,	O	519-520
C2Q0	O	521-525
,	O	525-526
BfS	O	527-530
,	O	530-531
C4A4	O	532-536
,	O	536-537
C4B2	O	538-542
,	O	542-543
Drw2	O	544-548
;	O	548-549
this	O	550-554
extended	O	555-563
haplotype	O	564-573
occurs	O	574-580
in	O	581-583
over	O	584-588
90	O	589-591
%	O	591-592
of	O	593-595
C2	B	596-598
-	I	598-599
deficient	I	599-608
individuals	O	609-620
(	O	621-622
common	O	622-628
complotype	O	629-639
/	O	639-640
haplotype	O	640-649
)	O	649-650
.	O	650-651

To	O	652-654
determine	O	655-664
the	O	665-668
molecular	O	669-678
basis	O	679-684
of	O	685-687
type	B	688-692
I	I	693-694
C2	I	695-697
deficiency	I	698-708
,	O	708-709
the	O	710-713
C2	O	714-716
gene	O	717-721
and	O	722-725
cDNA	O	726-730
were	O	731-735
characterized	O	736-749
from	O	750-754
a	O	755-756
homozygous	O	757-767
type	B	768-772
I	I	773-774
C2	I	775-777
-	I	777-778
deficient	I	778-787
individual	O	788-798
with	O	799-803
the	O	804-807
common	O	808-814
associated	O	815-825
haplotype	O	826-835
/	O	835-836
complotype	O	836-846
.	O	846-847

We	O	848-850
found	O	851-856
a	O	857-858
28	O	859-861
-	O	861-862
base	O	862-866
pair	O	867-871
deletion	O	872-880
in	O	881-883
the	O	884-887
type	O	888-892
I	O	893-894
C2Q0	O	895-899
gene	O	900-904
,	O	904-905
beginning	O	906-915
9	O	916-917
base	O	918-922
pairs	O	923-928
upstream	O	929-937
of	O	938-940
the	O	941-944
3	O	945-946
-	O	946-947
end	O	947-950
of	O	951-953
exon	O	954-958
6	O	959-960
,	O	960-961
that	O	962-966
generates	O	967-976
a	O	977-978
C2	O	979-981
transcript	O	982-992
with	O	993-997
a	O	998-999
complete	O	1000-1008
deletion	O	1009-1017
of	O	1018-1020
exon	O	1021-1025
6	O	1026-1027
(	O	1028-1029
134	O	1029-1032
base	O	1033-1037
pair	O	1038-1042
)	O	1042-1043
and	O	1044-1047
a	O	1048-1049
premature	O	1050-1059
termination	O	1060-1071
codon	O	1072-1077
.	O	1077-1078

In	O	1079-1081
studies	O	1082-1089
of	O	1090-1092
eight	O	1093-1098
kindred	O	1099-1106
,	O	1106-1107
the	O	1108-1111
28	O	1112-1114
-	O	1114-1115
base	O	1115-1119
pair	O	1120-1124
deletion	O	1125-1133
was	O	1134-1137
observed	O	1138-1146
in	O	1147-1149
all	O	1150-1153
C2Q0	O	1154-1158
alleles	O	1159-1166
associated	O	1167-1177
with	O	1178-1182
the	O	1183-1186
common	O	1187-1193
type	O	1194-1198
I	O	1199-1200
deficient	O	1201-1210
complotype	O	1211-1221
/	O	1221-1222
haplotype	O	1222-1231
;	O	1231-1232
this	O	1233-1237
deletion	O	1238-1246
was	O	1247-1250
not	O	1251-1254
present	O	1255-1262
in	O	1263-1265
normal	O	1266-1272
C2	O	1273-1275
nor	O	1276-1279
in	O	1280-1282
type	B	1283-1287
II	I	1288-1290
C2	I	1291-1293
-	I	1293-1294
deficient	I	1294-1303
genes	O	1304-1309
.	O	1309-1310

These	O	1311-1316
data	O	1317-1321
demonstrate	O	1322-1333
that	O	1334-1338
1	O	1340-1341
)	O	1341-1342
type	B	1343-1347
I	I	1348-1349
human	I	1350-1355
complement	I	1356-1366
C2	I	1367-1369
deficiency	I	1370-1380
is	O	1381-1383
caused	O	1384-1390
by	O	1391-1393
a	O	1394-1395
28	O	1396-1398
-	O	1398-1399
base	O	1399-1403
pair	O	1404-1408
genomic	O	1409-1416
deletion	O	1417-1425
that	O	1426-1430
causes	O	1431-1437
skipping	O	1438-1446
of	O	1447-1449
exon	O	1450-1454
6	O	1455-1456
during	O	1457-1463
RNA	O	1464-1467
splicing	O	1468-1476
,	O	1476-1477
resulting	O	1478-1487
in	O	1488-1490
generation	O	1491-1501
of	O	1502-1504
a	O	1505-1506
premature	O	1507-1516
termination	O	1517-1528
codon	O	1529-1534
,	O	1534-1535
2	O	1536-1537
)	O	1537-1538
the	O	1539-1542
28	O	1543-1545
-	O	1545-1546
base	O	1546-1550
pair	O	1551-1555
deletion	O	1556-1564
in	O	1565-1567
the	O	1568-1571
type	O	1572-1576
I	O	1577-1578
C2Q0	O	1579-1583
gene	O	1584-1588
is	O	1589-1591
strongly	O	1592-1600
associated	O	1601-1611
with	O	1612-1616
the	O	1617-1620
HLA	O	1621-1624
haplotype	O	1625-1634
/	O	1634-1635
complotype	O	1635-1645
A25	O	1646-1649
,	O	1649-1650
B18	O	1651-1654
,	O	1654-1655
C2Q0	O	1656-1660
,	O	1660-1661
BfS	O	1662-1665
,	O	1665-1666
C4A4	O	1667-1671
,	O	1671-1672
C4B2	O	1673-1677
,	O	1677-1678
Drw2	O	1679-1683
,	O	1683-1684
suggesting	O	1685-1695
that	O	1696-1700
all	O	1701-1704
C2	B	1705-1707
-	I	1707-1708
deficient	I	1708-1717
individuals	O	1718-1729
with	O	1730-1734
this	O	1735-1739
haplotype	O	1740-1749
/	O	1749-1750
complotype	O	1750-1760
will	O	1761-1765
harbor	O	1766-1772
the	O	1773-1776
28	O	1777-1779
-	O	1779-1780
base	O	1780-1784
pair	O	1785-1789
C2	O	1790-1792
gene	O	1793-1797
deletion	O	1798-1806
,	O	1806-1807
and	O	1808-1811
3	O	1812-1813
)	O	1813-1814
type	B	1815-1819
II	I	1820-1822
C2	I	1823-1825
deficiency	I	1826-1836
is	O	1837-1839
caused	O	1840-1846
by	O	1847-1849
a	O	1850-1851
different	O	1852-1861
,	O	1861-1862
as	O	1863-1865
yet	O	1866-1869
uncharacterized	O	1870-1885
,	O	1885-1886
molecular	O	1887-1896
genetic	B	1897-1904
defect	I	1905-1911
.	O	1911-1912
.	O	1911-1912

(	O	0-1
Over	O	1-5
)	O	5-6
correction	O	6-16
of	O	17-19
FMR1	B	20-24
deficiency	I	25-35
with	O	36-40
YAC	O	41-44
transgenics	O	45-56
:	O	56-57
behavioral	O	58-68
and	O	69-72
physical	O	73-81
features	O	82-90
.	O	90-91

Fragile	B	92-99
X	I	100-101
syndrome	I	102-110
is	O	111-113
a	O	114-115
common	O	116-122
cause	O	123-128
of	O	129-131
mental	B	132-138
retardation	I	139-150
involving	O	151-160
loss	O	161-165
of	O	166-168
expression	O	169-179
of	O	180-182
the	O	183-186
FMR1	O	187-191
gene	O	192-196
.	O	196-197

The	O	198-201
role	O	202-206
of	O	207-209
FMR1	O	210-214
remains	O	215-222
undetermined	O	223-235
but	O	236-239
the	O	240-243
protein	O	244-251
appears	O	252-259
to	O	260-262
be	O	263-265
involved	O	266-274
in	O	275-277
RNA	O	278-281
metabolism	O	282-292
.	O	292-293

Fmr1	O	294-298
knockout	O	299-307
mice	O	308-312
exhibit	O	313-320
a	O	321-322
phenotype	O	323-332
with	O	333-337
some	O	338-342
similarities	O	343-355
to	O	356-358
humans	O	359-365
,	O	365-366
such	O	367-371
as	O	372-374
macroorchidism	B	375-389
and	O	390-393
behavioral	O	394-404
abnormalities	O	405-418
.	O	418-419

As	O	420-422
a	O	423-424
step	O	425-429
toward	O	430-436
understanding	O	437-450
the	O	451-454
function	O	455-463
of	O	464-466
FMR1	O	467-471
and	O	472-475
the	O	476-479
determination	O	480-493
of	O	494-496
the	O	497-500
potential	O	501-510
for	O	511-514
therapeutic	O	515-526
approaches	O	527-537
to	O	538-540
fragile	B	541-548
X	I	549-550
syndrome	I	551-559
,	O	559-560
yeast	O	561-566
artificial	O	567-577
chromosome	O	578-588
(	O	589-590
YAC	O	590-593
)	O	593-594
transgenic	O	595-605
mice	O	606-610
were	O	611-615
generated	O	616-625
in	O	626-628
order	O	629-634
to	O	635-637
determine	O	638-647
whether	O	648-655
the	O	656-659
Fmr1	O	660-664
knockout	O	665-673
mouse	O	674-679
phenotype	O	680-689
could	O	690-695
be	O	696-698
rescued	O	699-706
.	O	706-707

Several	O	708-715
transgenic	O	716-726
lines	O	727-732
were	O	733-737
generated	O	738-747
that	O	748-752
carried	O	753-760
the	O	761-764
entire	O	765-771
FMR1	O	772-776
locus	O	777-782
with	O	783-787
extensive	O	788-797
amounts	O	798-805
of	O	806-808
flanking	O	809-817
sequence	O	818-826
.	O	826-827

We	O	828-830
observed	O	831-839
that	O	840-844
the	O	845-848
YAC	O	849-852
transgene	O	853-862
supported	O	863-872
production	O	873-883
of	O	884-886
the	O	887-890
human	O	891-896
protein	O	897-904
(	O	905-906
FMRP	O	906-910
)	O	910-911
which	O	912-917
was	O	918-921
present	O	922-929
at	O	930-932
levels	O	933-939
10	O	940-942
to	O	943-945
15	O	946-948
times	O	949-954
that	O	955-959
of	O	960-962
endogenous	O	963-973
protein	O	974-981
and	O	982-985
was	O	986-989
expressed	O	990-999
in	O	1000-1002
a	O	1003-1004
cell	O	1005-1009
-	O	1009-1010
and	O	1011-1014
tissue	O	1015-1021
-	O	1021-1022
specific	O	1022-1030
manner	O	1031-1037
.	O	1037-1038

Macro	O	1039-1044
-	O	1044-1045
orchidism	O	1045-1054
was	O	1055-1058
absent	O	1059-1065
in	O	1066-1068
knockout	O	1069-1077
mice	O	1078-1082
carrying	O	1083-1091
the	O	1092-1095
YAC	O	1096-1099
transgene	O	1100-1109
indicating	O	1110-1120
functional	O	1121-1131
rescue	O	1132-1138
by	O	1139-1141
the	O	1142-1145
human	O	1146-1151
protein	O	1152-1159
.	O	1159-1160

Given	O	1161-1166
the	O	1167-1170
complex	O	1171-1178
behavioral	O	1179-1189
phenotype	O	1190-1199
in	O	1200-1202
fragile	B	1203-1210
X	I	1211-1212
patients	O	1213-1221
and	O	1222-1225
the	O	1226-1229
mild	O	1230-1234
phenotype	O	1235-1244
previously	O	1245-1255
reported	O	1256-1264
for	O	1265-1268
the	O	1269-1272
Fmr1	O	1273-1277
knockout	O	1278-1286
mouse	O	1287-1292
,	O	1292-1293
we	O	1294-1296
performed	O	1297-1306
a	O	1307-1308
more	O	1309-1313
thorough	O	1314-1322
evaluation	O	1323-1333
of	O	1334-1336
the	O	1337-1340
Fmr1	O	1341-1345
knockout	O	1346-1354
phenotype	O	1355-1364
using	O	1365-1370
additional	O	1371-1381
behavioral	O	1382-1392
assays	O	1393-1399
that	O	1400-1404
had	O	1405-1408
not	O	1409-1412
previously	O	1413-1423
been	O	1424-1428
reported	O	1429-1437
for	O	1438-1441
this	O	1442-1446
animal	O	1447-1453
model	O	1454-1459
.	O	1459-1460

The	O	1461-1464
mouse	O	1465-1470
displayed	O	1471-1480
reduced	O	1481-1488
anxiety	B	1489-1496
-	O	1496-1497
related	O	1497-1504
responses	O	1505-1514
with	O	1515-1519
increased	O	1520-1529
exploratory	O	1530-1541
behavior	O	1542-1550
.	O	1550-1551

FMR1	O	1552-1556
YAC	O	1557-1560
transgenic	O	1561-1571
mice	O	1572-1576
overexpressing	O	1577-1591
the	O	1592-1595
human	O	1596-1601
protein	O	1602-1609
did	O	1610-1613
produce	O	1614-1621
opposing	O	1622-1630
behavioral	O	1631-1641
responses	O	1642-1651
and	O	1652-1655
additional	O	1656-1666
abnormal	O	1667-1675
behaviors	O	1676-1685
were	O	1686-1690
also	O	1691-1695
observed	O	1696-1704
.	O	1704-1705

These	O	1706-1711
findings	O	1712-1720
have	O	1721-1725
significant	O	1726-1737
implications	O	1738-1750
for	O	1751-1754
gene	O	1755-1759
therapy	O	1760-1767
for	O	1768-1771
fragile	B	1772-1779
X	I	1780-1781
syndrome	I	1782-1790
since	O	1791-1796
overexpression	O	1797-1811
of	O	1812-1814
the	O	1815-1818
gene	O	1819-1823
may	O	1824-1827
harbor	O	1828-1834
its	O	1835-1838
own	O	1839-1842
phenotype	O	1843-1852
.	O	1852-1853
.	O	1852-1853

Fabry	B	0-5
disease	I	6-13
:	O	13-14
identification	O	15-29
of	O	30-32
novel	O	33-38
alpha	O	39-44
-	O	44-45
galactosidase	O	45-58
A	O	59-60
mutations	O	61-70
and	O	71-74
molecular	O	75-84
carrier	O	85-92
detection	O	93-102
by	O	103-105
use	O	106-109
of	O	110-112
fluorescent	O	113-124
chemical	O	125-133
cleavage	O	134-142
of	O	143-145
mismatches	O	146-156
.	O	156-157

Fabry	B	158-163
disease	I	164-171
(	O	172-173
FD	B	173-175
)	O	175-176
(	O	177-178
angiokeratoma	B	178-191
corporis	I	192-200
diffusum	I	201-209
)	O	209-210
is	O	211-213
an	O	214-216
X	B	217-218
-	I	218-219
linked	I	219-225
inborn	I	226-232
error	I	233-238
of	I	239-241
glycosphingolipid	I	242-259
metabolism	I	260-270
caused	O	271-277
by	O	278-280
defects	O	281-288
in	O	289-291
the	O	292-295
lysosomal	O	296-305
alpha	O	306-311
-	O	311-312
galactosidase	O	312-325
A	O	326-327
gene	O	328-332
(	O	333-334
GLA	O	334-337
)	O	337-338
.	O	338-339

The	O	340-343
enzymatic	O	344-353
defect	O	354-360
leads	O	361-366
to	O	367-369
the	O	370-373
systemic	O	374-382
accumulation	O	383-395
of	O	396-398
neutral	O	399-406
glycosphingolipids	O	407-425
with	O	426-430
terminal	O	431-439
alpha	O	440-445
-	O	445-446
galactosyl	O	446-456
moieties	O	457-465
.	O	465-466

Clinically	O	467-477
,	O	477-478
affected	O	479-487
hemizygous	O	488-498
males	O	499-504
have	O	505-509
angiokeratoma	B	510-523
,	O	523-524
severe	B	525-531
acroparesthesia	I	532-547
,	O	547-548
renal	B	549-554
failure	I	555-562
,	O	562-563
and	O	564-567
vasculopathy	B	568-580
of	I	581-583
the	I	584-587
heart	I	588-593
and	I	594-597
brain	I	598-603
.	O	603-604

While	O	605-610
demonstration	O	611-624
of	O	625-627
alpha	B	628-633
-	I	633-634
galactosidase	I	634-647
deficiency	I	648-658
in	O	659-661
leukocytes	O	662-672
is	O	673-675
diagnostic	O	676-686
in	O	687-689
affected	O	690-698
males	O	699-704
,	O	704-705
enzymatic	O	706-715
detection	O	716-725
of	O	726-728
female	O	729-735
carriers	O	736-744
is	O	745-747
often	O	748-753
inconclusive	O	754-766
,	O	766-767
due	O	768-771
to	O	772-774
random	O	775-781
X	O	782-783
-	O	783-784
chromosomal	O	784-795
inactivation	O	796-808
,	O	808-809
underlining	O	810-821
the	O	822-825
need	O	826-830
of	O	831-833
molecular	O	834-843
investigations	O	844-858
for	O	859-862
accurate	O	863-871
genetic	O	872-879
counseling	O	880-890
.	O	890-891

By	O	892-894
use	O	895-898
of	O	899-901
chemical	O	902-910
cleavage	O	911-919
of	O	920-922
mismatches	O	923-933
adapted	O	934-941
to	O	942-944
fluorescence	O	945-957
-	O	957-958
based	O	958-963
detection	O	964-973
systems	O	974-981
,	O	981-982
we	O	983-985
have	O	986-990
characterized	O	991-1004
the	O	1005-1008
mutations	O	1009-1018
underlying	O	1019-1029
alpha	B	1030-1035
-	I	1035-1036
Gal	I	1036-1039
A	I	1040-1041
deficiency	I	1042-1052
in	O	1053-1055
16	O	1056-1058
individuals	O	1059-1070
from	O	1071-1075
six	O	1076-1079
unrelated	O	1080-1089
families	O	1090-1098
with	O	1099-1103
FD	B	1104-1106
.	O	1106-1107

The	O	1108-1111
mutational	O	1112-1122
spectrum	O	1123-1131
included	O	1132-1140
five	O	1141-1145
missense	O	1146-1154
mutations	O	1155-1164
(	O	1165-1166
C202W	O	1166-1171
,	O	1171-1172
C223G	O	1173-1178
,	O	1178-1179
N224D	O	1180-1185
,	O	1185-1186
R301Q	O	1187-1192
,	O	1192-1193
and	O	1194-1197
Q327K	O	1198-1203
)	O	1203-1204
and	O	1205-1208
one	O	1209-1212
splice	O	1213-1219
-	O	1219-1220
site	O	1220-1224
mutation	O	1225-1233
[	O	1234-1235
IVS3	O	1235-1239
G	O	1240-1241
(	O	1242-1243
-	O	1243-1244
1	O	1244-1245
)	O	1245-1246
-	O	1247-1248
-	O	1247-1248
>	O	1250-1251
C	O	1252-1253
]	O	1253-1254
.	O	1254-1255

Studies	O	1256-1263
at	O	1264-1266
the	O	1267-1270
mRNA	O	1271-1275
level	O	1276-1281
showed	O	1282-1288
that	O	1289-1293
the	O	1294-1297
latter	O	1298-1304
led	O	1305-1308
to	O	1309-1311
altered	O	1312-1319
pre	O	1320-1323
-	O	1323-1324
mRNA	O	1324-1328
splicing	O	1329-1337
with	O	1338-1342
consequent	O	1343-1353
alteration	O	1354-1364
of	O	1365-1367
the	O	1368-1371
mRNA	O	1372-1376
translational	O	1377-1390
reading	O	1391-1398
frame	O	1399-1404
and	O	1405-1408
generation	O	1409-1419
of	O	1420-1422
a	O	1423-1424
premature	O	1425-1434
termination	O	1435-1446
codon	O	1447-1452
of	O	1453-1455
translation	O	1456-1467
.	O	1467-1468

By	O	1469-1471
use	O	1472-1475
of	O	1476-1478
this	O	1479-1483
strategy	O	1484-1492
,	O	1492-1493
carrier	O	1494-1501
status	O	1502-1508
was	O	1509-1512
accurately	O	1513-1523
assessed	O	1524-1532
in	O	1533-1535
all	O	1536-1539
seven	O	1540-1545
at	O	1546-1548
-	O	1548-1549
risk	O	1549-1553
females	O	1554-1561
tested	O	1562-1568
,	O	1568-1569
whereas	O	1570-1577
enzymatic	O	1578-1587
dosages	O	1588-1595
failed	O	1596-1602
to	O	1603-1605
diagnose	O	1606-1614
or	O	1615-1617
exclude	O	1618-1625
heterozygosity	O	1626-1640
.	O	1640-1641
.	O	1640-1641

Evidence	O	0-8
for	O	9-12
linkage	O	13-20
of	O	21-23
bipolar	B	24-31
disorder	I	32-40
to	O	41-43
chromosome	O	44-54
18	O	55-57
with	O	58-62
a	O	63-64
parent	O	65-71
-	O	71-72
of	O	72-74
-	O	71-72
origin	O	75-81
effect	O	82-88
.	O	88-89

A	O	90-91
susceptibility	O	92-106
gene	O	107-111
on	O	112-114
chromosome	O	115-125
18	O	126-128
and	O	129-132
a	O	133-134
parent	O	135-141
-	O	141-142
of	O	142-144
-	O	141-142
origin	O	145-151
effect	O	152-158
have	O	159-163
been	O	164-168
suggested	O	169-178
for	O	179-182
bipolar	B	183-190
affective	I	191-200
disorder	I	201-209
(	O	210-211
BPAD	B	211-215
)	O	215-216
.	O	216-217

We	O	218-220
have	O	221-225
studied	O	226-233
28	O	234-236
nuclear	O	237-244
families	O	245-253
selected	O	254-262
for	O	263-266
apparent	O	267-275
unilineal	O	276-285
transmission	O	286-298
of	O	299-301
the	O	302-305
BPAD	B	306-310
phenotype	O	311-320
,	O	320-321
by	O	322-324
using	O	325-330
31	O	331-333
polymorphic	O	334-345
markers	O	346-353
spanning	O	354-362
chromosome	O	363-373
18	O	374-376
.	O	376-377

Evidence	O	378-386
for	O	387-390
linkage	O	391-398
was	O	399-402
tested	O	403-409
with	O	410-414
affected	O	415-423
-	O	423-424
sib	O	424-427
-	O	423-424
pair	O	428-432
and	O	433-436
LOD	O	437-440
score	O	441-446
methods	O	447-454
under	O	455-460
two	O	461-464
definitions	O	465-476
of	O	477-479
the	O	480-483
affected	O	484-492
phenotype	O	493-502
.	O	502-503

The	O	504-507
affected	O	508-516
-	O	516-517
sibpair	O	517-524
analyses	O	525-533
indicated	O	534-543
excess	O	544-550
allele	O	551-557
sharing	O	558-565
for	O	566-569
markers	O	570-577
on	O	578-580
18p	O	581-584
within	O	585-591
the	O	592-595
region	O	596-602
reported	O	603-611
previously	O	612-622
.	O	622-623

The	O	624-627
greatest	O	628-636
sharing	O	637-644
was	O	645-648
at	O	649-651
D18S37	O	652-658
64	O	660-662
%	O	662-663
in	O	664-666
bipolar	O	667-674
and	O	675-678
recurrent	O	679-688
unipolar	O	689-697
(	O	698-699
RUP	O	699-702
)	O	702-703
sib	O	704-707
pairs	O	708-713
(	O	714-715
P	O	715-716
=	O	717-718
.	O	718-719
0006	O	720-724
)	O	724-725
.	O	725-726

In	O	727-729
addition	O	730-738
,	O	738-739
excess	O	740-746
sharing	O	747-754
of	O	755-757
the	O	758-761
paternally	O	762-772
,	O	772-773
but	O	774-777
not	O	778-781
maternally	O	782-792
,	O	792-793
transmitted	O	794-805
alleles	O	806-813
was	O	814-817
observed	O	818-826
at	O	827-829
three	O	830-835
markers	O	836-843
on	O	844-846
18q	O	847-850
at	O	852-854
D18S41	O	855-861
,	O	861-862
51	O	863-865
bipolar	O	866-873
and	O	874-877
RUP	O	878-881
sib	O	882-885
pairs	O	886-891
were	O	892-896
concordant	O	897-907
for	O	908-911
paternally	O	912-922
transmitted	O	923-934
alleles	O	935-942
,	O	942-943
and	O	944-947
21	O	948-950
pairs	O	951-956
were	O	957-961
discordant	O	962-972
(	O	973-974
P	O	974-975
=	O	976-977
0004	O	978-982
)	O	982-983
.	O	983-984

The	O	985-988
evidence	O	989-997
for	O	998-1001
linkage	O	1002-1009
to	O	1010-1012
loci	O	1013-1017
on	O	1018-1020
both	O	1021-1025
18p	O	1026-1029
and	O	1030-1033
18q	O	1034-1037
was	O	1038-1041
strongest	O	1042-1051
in	O	1052-1054
the	O	1055-1058
11	O	1059-1061
paternal	O	1062-1070
pedigrees	O	1071-1080
,	O	1080-1081
i	O	1082-1083
.	O	1083-1084
e	O	1085-1086
e	O	1087-1088
.	O	1088-1089
,	O	1089-1090
those	O	1091-1096
in	O	1097-1099
which	O	1100-1105
the	O	1106-1109
father	O	1110-1116
or	O	1117-1119
one	O	1120-1123
of	O	1124-1126
the	O	1127-1130
fathers	O	1131-1138
sibs	O	1139-1143
is	O	1144-1146
affected	O	1147-1155
.	O	1155-1156

In	O	1157-1159
these	O	1160-1165
pedigrees	O	1166-1175
,	O	1175-1176
the	O	1177-1180
greatest	O	1181-1189
allele	O	1190-1196
sharing	O	1197-1204
(	O	1205-1206
81	O	1206-1208
%	O	1208-1209
;	O	1209-1210
P	O	1211-1212
=	O	1213-1214
.	O	1214-1215
00002	O	1216-1221
)	O	1221-1222
and	O	1223-1226
the	O	1227-1230
highest	O	1231-1238
LOD	O	1239-1242
score	O	1243-1248
(	O	1249-1250
3	O	1250-1251
.	O	1251-1252

51	O	1253-1255
;	O	1255-1256
phi	O	1257-1260
=	O	1261-1262
0	O	1263-1264
.	O	1264-1265
0	O	1266-1267
)	O	1267-1268
were	O	1269-1273
observed	O	1274-1282
at	O	1283-1285
D18S41	O	1286-1292
.	O	1292-1293

Our	O	1294-1297
results	O	1298-1305
provide	O	1306-1313
further	O	1314-1321
support	O	1322-1329
for	O	1330-1333
linkage	O	1334-1341
of	O	1342-1344
BPAD	B	1345-1349
to	O	1350-1352
chromosome	O	1353-1363
18	O	1364-1366
and	O	1367-1370
the	O	1371-1374
first	O	1375-1380
molecular	O	1381-1390
evidence	O	1391-1399
for	O	1400-1403
a	O	1404-1405
parent	O	1406-1412
-	O	1412-1413
of	O	1413-1415
-	O	1412-1413
origin	O	1416-1422
effect	O	1423-1429
operating	O	1430-1439
in	O	1440-1442
this	O	1443-1447
disorder	O	1448-1456
.	O	1456-1457

The	O	1458-1461
number	O	1462-1468
of	O	1469-1471
loci	O	1472-1476
involved	O	1477-1485
,	O	1485-1486
and	O	1487-1490
their	O	1491-1496
precise	O	1497-1504
location	O	1505-1513
,	O	1513-1514
require	O	1515-1522
further	O	1523-1530
study	O	1531-1536

BRCA1	O	0-5
mutations	O	6-15
in	O	16-18
a	O	19-20
population	O	21-31
-	O	31-32
based	O	32-37
sample	O	38-44
of	O	45-47
young	O	48-53
women	O	54-59
with	O	60-64
breast	B	65-71
cancer	I	72-78
.	O	78-79

BACKGROUND	O	80-90
.	O	90-91

Inherited	O	92-101
mutations	O	102-111
in	O	112-114
the	O	115-118
BRCA1	O	119-124
gene	O	125-129
are	O	130-133
associated	O	134-144
with	O	145-149
a	O	150-151
high	O	152-156
risk	O	157-161
of	O	162-164
breast	B	165-171
and	I	172-175
ovarian	I	176-183
cancer	I	184-190
in	O	191-193
some	O	194-198
families	O	199-207
.	O	207-208

However	O	209-216
,	O	216-217
little	O	218-224
is	O	225-227
known	O	228-233
about	O	234-239
the	O	240-243
contribution	O	244-256
of	O	257-259
BRCA1	O	260-265
mutations	O	266-275
to	O	276-278
breast	B	279-285
cancer	I	286-292
in	O	293-295
the	O	296-299
general	O	300-307
population	O	308-318
.	O	318-319

We	O	320-322
analyzed	O	323-331
DNA	O	332-335
samples	O	336-343
from	O	344-348
women	O	349-354
enrolled	O	355-363
in	O	364-366
a	O	367-368
population	O	369-379
-	O	379-380
based	O	380-385
study	O	386-391
of	O	392-394
early	O	395-400
-	O	400-401
onset	O	401-406
breast	B	407-413
cancer	I	414-420
to	O	421-423
assess	O	424-430
the	O	431-434
spectrum	O	435-443
and	O	444-447
frequency	O	448-457
of	O	458-460
germ	O	461-465
-	O	465-466
line	O	466-470
BRCA1	O	471-476
mutations	O	477-486
in	O	487-489
young	O	490-495
women	O	496-501
with	O	502-506
breast	B	507-513
cancer	I	514-520
.	O	520-521

METHODS	O	522-529
.	O	529-530

We	O	531-533
studied	O	534-541
80	O	542-544
women	O	545-550
in	O	551-553
whom	O	554-558
breast	B	559-565
cancer	I	566-572
was	O	573-576
diagnosed	O	577-586
before	O	587-593
the	O	594-597
age	O	598-601
of	O	602-604
35	O	605-607
,	O	607-608
and	O	609-612
who	O	613-616
were	O	617-621
not	O	622-625
selected	O	626-634
on	O	635-637
the	O	638-641
basis	O	642-647
of	O	648-650
family	O	651-657
history	O	658-665
.	O	665-666

Genomic	O	667-674
DNA	O	675-678
was	O	679-682
studied	O	683-690
for	O	691-694
BRCA1	O	695-700
mutations	O	701-710
by	O	711-713
analysis	O	714-722
involving	O	723-732
single	O	733-739
-	O	739-740
strand	O	740-746
conformation	O	747-759
polymorphisms	O	760-773
and	O	774-777
with	O	778-782
allele	O	783-789
-	O	789-790
specific	O	790-798
assays	O	799-805
.	O	805-806

Alterations	O	807-818
were	O	819-823
defined	O	824-831
by	O	832-834
DNA	O	835-838
sequencing	O	839-849
.	O	849-850

RESULTS	O	851-858
.	O	858-859

Germ	O	860-864
-	O	864-865
line	O	865-869
BRCA1	O	870-875
mutations	O	876-885
were	O	886-890
identified	O	891-901
in	O	902-904
6	O	905-906
of	O	907-909
the	O	910-913
80	O	914-916
women	O	917-922
.	O	922-923

Four	O	924-928
additional	O	929-939
rare	O	940-944
sequence	O	945-953
variants	O	954-962
of	O	963-965
unknown	O	966-973
functional	O	974-984
importance	O	985-995
were	O	996-1000
also	O	1001-1005
identified	O	1006-1016
.	O	1016-1017

Two	O	1018-1021
of	O	1022-1024
the	O	1025-1028
mutations	O	1029-1038
and	O	1039-1042
three	O	1043-1048
of	O	1049-1051
the	O	1052-1055
rare	O	1056-1060
sequence	O	1061-1069
variants	O	1070-1078
were	O	1079-1083
found	O	1084-1089
among	O	1090-1095
the	O	1096-1099
39	O	1100-1102
women	O	1103-1108
who	O	1109-1112
reported	O	1113-1121
no	O	1122-1124
family	O	1125-1131
history	O	1132-1139
of	O	1140-1142
breast	B	1143-1149
or	I	1150-1152
ovarian	I	1153-1160
cancer	I	1161-1167
.	O	1167-1168

None	O	1169-1173
of	O	1174-1176
the	O	1177-1180
mutations	O	1181-1190
and	O	1191-1194
only	O	1195-1199
one	O	1200-1203
of	O	1204-1206
the	O	1207-1210
rare	O	1211-1215
variants	O	1216-1224
was	O	1225-1228
identified	O	1229-1239
in	O	1240-1242
a	O	1243-1244
reference	O	1245-1254
population	O	1255-1265
of	O	1266-1268
73	O	1269-1271
unrelated	O	1272-1281
subjects	O	1282-1290
.	O	1290-1291

CONCLUSIONS	O	1292-1303
.	O	1303-1304

Alterations	O	1305-1316
in	O	1317-1319
BRCA1	O	1320-1325
were	O	1326-1330
identified	O	1331-1341
in	O	1342-1344
approximately	O	1345-1358
10	O	1359-1361
percent	O	1362-1369
of	O	1370-1372
this	O	1373-1377
cohort	O	1378-1384
of	O	1385-1387
young	O	1388-1393
women	O	1394-1399
with	O	1400-1404
breast	B	1405-1411
cancer	I	1412-1418
.	O	1418-1419

The	O	1420-1423
risk	O	1424-1428
of	O	1429-1431
harboring	O	1432-1441
a	O	1442-1443
mutation	O	1444-1452
was	O	1453-1456
not	O	1457-1460
limited	O	1461-1468
to	O	1469-1471
women	O	1472-1477
with	O	1478-1482
family	O	1483-1489
histories	O	1490-1499
of	O	1500-1502
breast	B	1503-1509
or	I	1510-1512
ovarian	I	1513-1520
cancer	I	1521-1527
.	O	1527-1528

These	O	1529-1534
results	O	1535-1542
represent	O	1543-1552
a	O	1553-1554
minimal	O	1555-1562
estimate	O	1563-1571
of	O	1572-1574
the	O	1575-1578
frequency	O	1579-1588
of	O	1589-1591
BRCA1	O	1592-1597
mutations	O	1598-1607
in	O	1608-1610
this	O	1611-1615
population	O	1616-1626
.	O	1626-1627

Comprehensive	O	1628-1641
methods	O	1642-1649
of	O	1650-1652
identifying	O	1653-1664
BRCA1	O	1665-1670
mutations	O	1671-1680
and	O	1681-1684
understanding	O	1685-1698
their	O	1699-1704
importance	O	1705-1715
will	O	1716-1720
be	O	1721-1723
needed	O	1724-1730
before	O	1731-1737
testing	O	1738-1745
of	O	1746-1748
women	O	1749-1754
in	O	1755-1757
the	O	1758-1761
general	O	1762-1769
population	O	1770-1780
can	O	1781-1784
be	O	1785-1787
undertaken	O	1788-1798
.	O	1798-1799
.	O	1798-1799

Retinoschisin	O	0-13
,	O	13-14
the	O	15-18
X	B	19-20
-	I	20-21
linked	I	21-27
retinoschisis	I	28-41
protein	O	42-49
,	O	49-50
is	O	51-53
a	O	54-55
secreted	O	56-64
photoreceptor	O	65-78
protein	O	79-86
,	O	86-87
and	O	88-91
is	O	92-94
expressed	O	95-104
and	O	105-108
released	O	109-117
by	O	118-120
Weri	O	121-125
-	O	125-126
Rb1	O	126-129
cells	O	130-135
.	O	135-136

X	B	137-138
-	I	138-139
linked	I	139-145
retinoschisis	I	146-159
is	O	160-162
characterized	O	163-176
by	O	177-179
microcystic	O	180-191
-	O	191-192
like	O	192-196
changes	O	197-204
of	O	205-207
the	O	208-211
macular	O	212-219
region	O	220-226
and	O	227-230
schisis	O	231-238
within	O	239-245
the	O	246-249
inner	O	250-255
retinal	O	256-263
layers	O	264-270
,	O	270-271
leading	O	272-279
to	O	280-282
visual	B	283-289
deterioration	I	290-303
in	O	304-306
males	O	307-312
.	O	312-313

Many	O	314-318
missense	O	319-327
and	O	328-331
protein	O	332-339
-	O	339-340
truncating	O	340-350
mutations	O	351-360
of	O	361-363
the	O	364-367
causative	O	368-377
gene	O	378-382
RS1	O	383-386
have	O	387-391
now	O	392-395
been	O	396-400
identified	O	401-411
and	O	412-415
are	O	416-419
thought	O	420-427
to	O	428-430
be	O	431-433
inactivating	O	434-446
.	O	446-447

RS1	O	448-451
encodes	O	452-459
a	O	460-461
224	O	462-465
amino	O	466-471
acid	O	472-476
protein	O	477-484
,	O	484-485
retinoschisin	O	486-499
,	O	499-500
which	O	501-506
contains	O	507-515
a	O	516-517
discoidin	O	518-527
domain	O	528-534
but	O	535-538
is	O	539-541
of	O	542-544
unknown	O	545-552
function	O	553-561
.	O	561-562

We	O	563-565
have	O	566-570
generated	O	571-580
a	O	581-582
polyclonal	O	583-593
antibody	O	594-602
against	O	603-610
a	O	611-612
peptide	O	613-620
from	O	621-625
a	O	626-627
unique	O	628-634
region	O	635-641
within	O	642-648
retinoschisin	O	649-662
,	O	662-663
which	O	664-669
detects	O	670-677
a	O	678-679
protein	O	680-687
of	O	688-690
approximately	O	691-704
28	O	705-707
kDa	O	708-711
in	O	712-714
retinal	O	715-722
samples	O	723-730
reduced	O	731-738
with	O	739-743
dithiothreitol	O	744-758
,	O	758-759
but	O	760-763
multimers	O	764-773
sized	O	774-779
>	O	780-781
40	O	782-784
kDa	O	785-788
under	O	789-794
non	O	795-798
-	O	798-799
reducing	O	799-807
conditions	O	808-818
.	O	818-819

A	O	820-821
screen	O	822-828
of	O	829-831
human	O	832-837
tissues	O	838-845
with	O	846-850
this	O	851-855
antibody	O	856-864
reveals	O	865-872
retinoschisin	O	873-886
to	O	887-889
be	O	890-892
retina	O	893-899
specific	O	900-908
and	O	909-912
the	O	913-916
antibody	O	917-925
detects	O	926-933
a	O	934-935
protein	O	936-943
of	O	944-946
similar	O	947-954
size	O	955-959
in	O	960-962
bovine	O	963-969
and	O	970-973
murine	O	974-980
retinae	O	981-988
.	O	988-989

We	O	990-992
investigated	O	993-1005
the	O	1006-1009
expression	O	1010-1020
pattern	O	1021-1028
in	O	1029-1031
the	O	1032-1035
retina	O	1036-1042
of	O	1043-1045
both	O	1046-1050
RS1	O	1051-1054
mRNA	O	1055-1059
(	O	1060-1061
using	O	1061-1066
in	O	1067-1069
situ	O	1070-1074
hybridization	O	1075-1088
with	O	1089-1093
riboprobes	O	1094-1104
)	O	1104-1105
and	O	1106-1109
retinoschisin	O	1110-1123
(	O	1124-1125
using	O	1125-1130
immunohistochemistry	O	1131-1151
)	O	1151-1152
.	O	1152-1153

The	O	1154-1157
antisense	O	1158-1167
riboprobe	O	1168-1177
detected	O	1178-1186
RS1	O	1187-1190
mRNA	O	1191-1195
only	O	1196-1200
in	O	1201-1203
the	O	1204-1207
photoreceptor	O	1208-1221
layer	O	1222-1227
but	O	1228-1231
the	O	1232-1235
protein	O	1236-1243
product	O	1244-1251
of	O	1252-1254
the	O	1255-1258
gene	O	1259-1263
was	O	1264-1267
present	O	1268-1275
both	O	1276-1280
in	O	1281-1283
the	O	1284-1287
photoreceptors	O	1288-1302
and	O	1303-1306
within	O	1307-1313
the	O	1314-1317
inner	O	1318-1323
portions	O	1324-1332
of	O	1333-1335
the	O	1336-1339
retina	O	1340-1346
.	O	1346-1347

Furthermore	O	1348-1359
,	O	1359-1360
differentiated	O	1361-1375
retinoblastoma	B	1376-1390
cells	O	1391-1396
(	O	1397-1398
Weri	O	1398-1402
-	O	1402-1403
Rb1	O	1403-1406
cells	O	1407-1412
)	O	1412-1413
were	O	1414-1418
found	O	1419-1424
to	O	1425-1427
express	O	1428-1435
RS1	O	1436-1439
mRNA	O	1440-1444
and	O	1445-1448
to	O	1449-1451
release	O	1452-1459
retinoschisin	O	1460-1473
.	O	1473-1474

These	O	1475-1480
results	O	1481-1488
suggest	O	1489-1496
that	O	1497-1501
retinoschisin	O	1502-1515
is	O	1516-1518
released	O	1519-1527
by	O	1528-1530
photo	O	1531-1536
-	O	1536-1537
receptors	O	1537-1546
and	O	1547-1550
has	O	1551-1554
functions	O	1555-1564
within	O	1565-1571
the	O	1572-1575
inner	O	1576-1581
retinal	O	1582-1589
layers	O	1590-1596
.	O	1596-1597

Thus	O	1598-1602
,	O	1602-1603
X	B	1604-1605
-	I	1605-1606
linked	I	1606-1612
retinoschisis	I	1613-1626
is	O	1627-1629
caused	O	1630-1636
by	O	1637-1639
abnormalities	O	1640-1653
in	O	1654-1656
a	O	1657-1658
putative	O	1659-1667
secreted	O	1668-1676
photoreceptor	O	1677-1690
protein	O	1691-1698
and	O	1699-1702
is	O	1703-1705
the	O	1706-1709
first	O	1710-1715
example	O	1716-1723
of	O	1724-1726
a	O	1727-1728
secreted	O	1729-1737
photo	O	1738-1743
-	O	1743-1744
receptor	O	1744-1752
protein	O	1753-1760
associated	O	1761-1771
with	O	1772-1776
a	O	1777-1778
retinal	B	1779-1786
dystrophy	I	1787-1796
.	O	1796-1797
.	O	1796-1797

Aberrant	O	0-8
splicing	O	9-17
of	O	18-20
the	O	21-24
CHM	B	25-28
gene	O	29-33
is	O	34-36
a	O	37-38
significant	O	39-50
cause	O	51-56
of	O	57-59
choroideremia	B	60-73
.	O	73-74

Choroideremia	B	75-88
(	O	89-90
CHM	B	90-93
)	O	93-94
is	O	95-97
an	O	98-100
X	B	101-102
-	I	102-103
linked	I	103-109
progressive	I	110-121
degeneration	I	122-134
of	I	135-137
the	I	138-141
choroid	I	142-149
and	I	150-153
retina	I	154-160
.	O	160-161

12	O	162-164
%	O	164-165
of	O	166-168
unrelated	O	169-178
male	O	179-183
patients	O	184-192
carry	O	193-198
deletions	O	199-208
of	O	209-211
the	O	212-215
partially	O	216-225
cloned	O	226-232
CHM	B	233-236
gene	O	237-241
.	O	241-242

In	O	243-245
Finland	O	246-253
,	O	253-254
there	O	255-260
are	O	261-264
more	O	265-269
than	O	270-274
120	O	275-278
living	O	279-285
CHM	B	286-289
patients	O	290-298
belonging	O	299-308
to	O	309-311
eight	O	312-317
apparently	O	318-328
unrelated	O	329-338
pedigrees	O	339-348
.	O	348-349

Molecular	O	350-359
deletions	O	360-369
involving	O	370-379
the	O	380-383
CHM	B	384-387
gene	O	388-392
have	O	393-397
been	O	398-402
detected	O	403-411
in	O	412-414
three	O	415-420
families	O	421-429
.	O	429-430

We	O	431-433
have	O	434-438
screened	O	439-447
the	O	448-451
remaining	O	452-461
five	O	462-466
families	O	467-475
for	O	476-479
point	O	480-485
mutations	O	486-495
.	O	495-496

In	O	497-499
one	O	500-503
large	O	504-509
family	O	510-516
a	O	517-518
single	O	519-525
nucleotide	O	526-536
(	O	537-538
T	O	538-539
)	O	539-540
insertion	O	541-550
into	O	551-555
the	O	556-559
donor	O	560-565
splice	O	566-572
site	O	573-577
of	O	578-580
exon	O	581-585
C	O	586-587
leads	O	588-593
to	O	594-596
two	O	597-600
aberrantly	O	601-611
spliced	O	612-619
mRNAs	O	620-625
both	O	626-630
producing	O	631-640
a	O	641-642
premature	O	643-652
stop	O	653-657
codon	O	658-663
.	O	663-664

The	O	665-668
mutation	O	669-677
can	O	678-681
be	O	682-684
assayed	O	685-692
easily	O	693-699
by	O	700-702
amplification	O	703-716
and	O	717-720
digestion	O	721-730
with	O	731-735
Msel	O	736-740
.	O	740-741

Our	O	742-745
findings	O	746-754
provide	O	755-762
additional	O	763-773
evidence	O	774-782
for	O	783-786
the	O	787-790
pathogenetic	O	791-803
role	O	804-808
of	O	809-811
CHM	B	812-815
mutations	O	816-825
and	O	826-829
provide	O	830-837
a	O	838-839
diagnostic	O	840-850
tool	O	851-855
for	O	856-859
one	O	860-863
fifth	O	864-869
of	O	870-872
the	O	873-876
worlds	O	877-883
known	O	884-889
CHM	B	890-893
patients	O	894-902
.	O	902-903
.	O	902-903

X	B	0-1
-	I	1-2
linked	I	2-8
adrenoleukodystrophy	I	9-29
(	O	30-31
ALD	B	31-34
)	O	34-35
:	O	35-36
a	O	37-38
novel	O	39-44
mutation	O	45-53
of	O	54-56
the	O	57-60
ALD	B	61-64
gene	O	65-69
in	O	70-72
6	O	73-74
members	O	75-82
of	O	83-85
a	O	86-87
family	O	88-94
presenting	O	95-105
with	O	106-110
5	O	111-112
different	O	113-122
phenotypes	O	123-133
.	O	133-134

Fragments	O	135-144
of	O	145-147
the	O	148-151
adrenoleukodystrophy	B	152-172
(	O	173-174
ALD	B	174-177
)	O	177-178
cDNA	O	179-183
from	O	184-188
a	O	189-190
patient	O	191-198
with	O	199-203
adolescent	B	204-214
ALD	I	215-218
were	O	219-223
amplified	O	224-233
by	O	234-236
polymerase	O	237-247
chain	O	248-253
reaction	O	254-262
and	O	263-266
subcloned	O	267-276
.	O	276-277

Bidirectional	O	278-291
sequencing	O	292-302
of	O	303-305
the	O	306-309
entire	O	310-316
coding	O	317-323
ALD	B	324-327
gene	O	328-332
disclosed	O	333-342
a	O	343-344
cytosine	O	345-353
to	O	354-356
guanine	O	357-364
transversion	O	365-377
at	O	378-380
nucleotide	O	381-391
1451	O	392-396
in	O	397-399
exon	O	400-404
five	O	405-409
,	O	409-410
resulting	O	411-420
in	O	421-423
substitution	O	424-436
of	O	437-439
proline	O	440-447
484	O	448-451
by	O	452-454
arginine	O	455-463
.	O	463-464

Five	O	465-469
of	O	470-472
nine	O	473-477
siblings	O	478-486
of	O	487-489
the	O	490-493
patient	O	494-501
,	O	501-502
comprising	O	503-513
two	O	514-517
cerebral	B	518-526
ALD	I	527-530
,	O	530-531
one	O	532-535
adrenomyeloneuropathy	B	536-557
,	O	557-558
one	O	559-562
Addison	B	563-570
only	I	571-575
as	O	576-578
well	O	579-583
as	O	584-586
the	O	587-590
symptomatic	O	591-602
mother	O	603-609
(	O	610-611
all	O	611-614
accumulating	O	615-627
very	O	628-632
long	O	633-637
chain	O	638-643
fatty	O	644-649
acids	O	650-655
)	O	655-656
carried	O	657-664
this	O	665-669
mutation	O	670-678
,	O	678-679
which	O	680-685
was	O	686-689
not	O	690-693
found	O	694-699
in	O	700-702
the	O	703-706
unaffected	O	707-717
persons	O	718-725
,	O	725-726
in	O	727-729
five	O	730-734
unrelated	O	735-744
ALD	B	745-748
patients	O	749-757
,	O	757-758
and	O	759-762
in	O	763-765
twenty	O	766-772
controls	O	773-781
.	O	781-782

We	O	783-785
propose	O	786-793
that	O	794-798
this	O	799-803
missense	O	804-812
mutation	O	813-821
generated	O	822-831
the	O	832-835
disease	O	836-843
per	O	844-847
se	O	848-850
as	O	851-853
well	O	854-858
as	O	859-861
the	O	862-865
metabolic	O	866-875
defect	O	876-882
;	O	882-883
the	O	884-887
different	O	888-897
phenotypes	O	898-908
,	O	908-909
however	O	910-917
,	O	917-918
must	O	919-923
have	O	924-928
originated	O	929-939
by	O	940-942
means	O	943-948
of	O	949-951
additional	O	952-962
pathogenetic	O	963-975
factors	O	976-983
.	O	983-984
.	O	983-984

Statistical	O	0-11
analysis	O	12-20
of	O	21-23
the	O	24-27
two	O	28-31
stage	O	32-37
mutation	O	38-46
model	O	47-52
in	O	53-55
von	B	56-59
Hippel	I	60-66
-	I	66-67
Lindau	I	67-73
disease	I	74-81
,	O	81-82
and	O	83-86
in	O	87-89
sporadic	B	90-98
cerebellar	I	99-109
haemangioblastoma	I	110-127
and	O	128-131
renal	B	132-137
cell	I	138-142
carcinoma	I	143-152
.	O	152-153

Analysis	O	154-162
of	O	163-165
the	O	166-169
age	O	170-173
incidence	O	174-183
curves	O	184-190
for	O	191-194
unilateral	B	195-205
and	I	206-209
bilateral	I	210-219
retinoblastoma	I	220-234
led	O	235-238
Knudson	O	239-246
to	O	247-249
propose	O	250-257
that	O	258-262
hereditary	B	263-273
tumours	I	274-281
may	O	282-285
arise	O	286-291
by	O	292-294
a	O	295-296
single	O	297-303
event	O	304-309
and	O	310-313
sporadic	B	314-322
tumours	I	323-330
by	O	331-333
a	O	334-335
two	O	336-339
stage	O	340-345
mutation	O	346-354
process	O	355-362
.	O	362-363

It	O	364-366
has	O	367-370
been	O	371-375
suggested	O	376-385
recently	O	386-394
that	O	395-399
sporadic	B	400-408
renal	I	409-414
cell	I	415-419
carcinoma	I	420-429
may	O	430-433
arise	O	434-439
from	O	440-444
a	O	445-446
two	O	447-450
stage	O	451-456
mutation	O	457-465
process	O	466-473
.	O	473-474

We	O	475-477
analysed	O	478-486
the	O	487-490
age	O	491-494
incidence	O	495-504
curves	O	505-511
for	O	512-515
symptomatic	O	516-527
renal	B	528-533
cell	I	534-538
carcinoma	I	539-548
(	O	549-550
n	O	550-551
=	O	552-553
26	O	554-556
)	O	556-557
and	O	558-561
cerebellar	B	562-572
haemangioblastoma	I	573-590
(	O	591-592
n	O	592-593
=	O	594-595
68	O	596-598
)	O	598-599
in	O	600-602
109	O	603-606
patients	O	607-615
with	O	616-620
von	B	621-624
Hippel	I	625-631
-	I	631-632
Lindau	I	632-638
(	I	639-640
VHL	I	640-643
)	I	643-644
disease	I	645-652
,	O	652-653
and	O	654-657
compared	O	658-666
them	O	667-671
to	O	672-674
104	O	675-678
patients	O	679-687
with	O	688-692
sporadic	B	693-701
renal	I	702-707
cell	I	708-712
carcinoma	I	713-722
and	O	723-726
43	O	727-729
patients	O	730-738
with	O	739-743
sporadic	B	744-752
cerebellar	I	753-763
haemangioblastoma	I	764-781
.	O	781-782

The	O	783-786
age	O	787-790
incidence	O	791-800
curves	O	801-807
for	O	808-811
renal	B	812-817
cell	I	818-822
carcinoma	I	823-832
and	O	833-836
cerebellar	B	837-847
haemangioblastoma	I	848-865
in	O	866-868
VHL	B	869-872
disease	I	873-880
were	O	881-885
compatible	O	886-896
with	O	897-901
a	O	902-903
single	O	904-910
mutation	O	911-919
model	O	920-925
,	O	925-926
whereas	O	927-934
the	O	935-938
age	O	939-942
incidence	O	943-952
curves	O	953-959
for	O	960-963
sporadic	B	964-972
renal	I	973-978
cell	I	979-983
carcinoma	I	984-993
and	O	994-997
cerebellar	B	998-1008
haemangioblastoma	I	1009-1026
suggested	O	1027-1036
a	O	1037-1038
two	O	1039-1042
stage	O	1043-1048
mutation	O	1049-1057
process	O	1058-1065
.	O	1065-1066

These	O	1067-1072
data	O	1073-1077
are	O	1078-1081
compatible	O	1082-1092
with	O	1093-1097
the	O	1098-1101
VHL	B	1102-1105
gene	O	1106-1110
functioning	O	1111-1122
as	O	1123-1125
a	O	1126-1127
recessive	O	1128-1137
tumour	B	1138-1144
suppressor	O	1145-1155
gene	O	1156-1160
.	O	1160-1161

Sporadic	B	1162-1170
cerebellar	I	1171-1181
haemangioblastoma	I	1182-1199
and	O	1200-1203
some	O	1204-1208
renal	B	1209-1214
cell	I	1215-1219
carcinoma	I	1220-1229
may	O	1230-1233
arise	O	1234-1239
from	O	1240-1244
somatic	O	1245-1252
mutations	O	1253-1262
inactivating	O	1263-1275
both	O	1276-1280
alleles	O	1281-1288
at	O	1289-1291
the	O	1292-1295
VHL	B	1296-1299
locus	O	1300-1305
.	O	1305-1306
.	O	1305-1306

Characterization	O	0-16
of	O	17-19
a	O	20-21
germline	O	22-30
mosaicism	O	31-40
in	O	41-43
families	O	44-52
with	O	53-57
Lowe	B	58-62
syndrome	I	63-71
,	O	71-72
and	O	73-76
identification	O	77-91
of	O	92-94
seven	O	95-100
novel	O	101-106
mutations	O	107-116
in	O	117-119
the	O	120-123
OCRL1	O	124-129
gene	O	130-134
.	O	134-135

The	O	136-139
oculocerebrorenal	B	140-157
syndrome	I	158-166
of	I	167-169
Lowe	I	170-174
(	O	175-176
OCRL	B	176-180
)	O	180-181
is	O	182-184
an	O	185-187
X	B	188-189
-	I	189-190
linked	I	190-196
disorder	I	197-205
characterized	O	206-219
by	O	220-222
major	O	223-228
abnormalities	B	229-242
of	I	243-245
eyes	I	246-250
,	I	250-251
nervous	I	252-259
system	I	260-266
,	I	266-267
and	I	268-271
kidneys	I	272-279
.	O	279-280

Mutations	O	281-290
in	O	291-293
the	O	294-297
OCRL1	O	298-303
gene	O	304-308
have	O	309-313
been	O	314-318
associated	O	319-329
with	O	330-334
the	O	335-338
disease	O	339-346
.	O	346-347

OCRL1	O	348-353
encodes	O	354-361
a	O	362-363
phosphatidylinositol	O	364-384
4	O	385-386
,	O	386-387
5	O	388-389
-	O	389-390
biphosphate	O	390-401
(	O	402-403
PtdIns	O	403-409
[	O	410-411
4	O	411-412
,	O	412-413
5	O	414-415
]	O	415-416
P2	O	417-419
)	O	419-420
5	O	421-422
-	O	422-423
phosphatase	O	423-434
.	O	434-435

We	O	436-438
have	O	439-443
examined	O	444-452
the	O	453-456
OCRL1	O	457-462
gene	O	463-467
in	O	468-470
eight	O	471-476
unrelated	O	477-486
patients	O	487-495
with	O	496-500
OCRL	B	501-505
and	O	506-509
have	O	510-514
found	O	515-520
seven	O	521-526
new	O	527-530
mutations	O	531-540
and	O	541-544
one	O	545-548
recurrent	O	549-558
in	O	559-561
-	O	561-562
frame	O	562-567
deletion	O	568-576
.	O	576-577

Among	O	578-583
the	O	584-587
new	O	588-591
mutations	O	592-601
,	O	601-602
two	O	603-606
nonsense	O	607-615
mutations	O	616-625
(	O	626-627
R317X	O	627-632
and	O	633-636
E558X	O	637-642
)	O	642-643
and	O	644-647
three	O	648-653
other	O	654-659
frameshift	O	660-670
mutations	O	671-680
caused	O	681-687
premature	O	688-697
termination	O	698-709
of	O	710-712
the	O	713-716
protein	O	717-724
.	O	724-725

A	O	726-727
missense	O	728-736
mutation	O	737-745
,	O	745-746
R483G	O	747-752
,	O	752-753
was	O	754-757
located	O	758-765
in	O	766-768
the	O	769-772
highly	O	773-779
conserved	O	780-789
PtdIns	O	790-796
(	O	797-798
4	O	798-799
,	O	799-800
5	O	801-802
)	O	802-803
P2	O	804-806
5	O	807-808
-	O	808-809
phosphatase	O	809-820
domain	O	821-827
.	O	827-828

Finally	O	829-836
,	O	836-837
one	O	838-841
frameshift	O	842-852
mutation	O	853-861
,	O	861-862
2799delC	O	863-871
,	O	871-872
modifies	O	873-881
the	O	882-885
C	O	886-887
-	O	887-888
terminal	O	888-896
part	O	897-901
of	O	902-904
OCRL1	O	905-910
,	O	910-911
with	O	912-916
an	O	917-919
extension	O	920-929
of	O	930-932
six	O	933-936
amino	O	937-942
acids	O	943-948
.	O	948-949

Altogether	O	950-960
,	O	960-961
70	O	962-964
%	O	964-965
of	O	966-968
missense	O	969-977
mutations	O	978-987
are	O	988-991
located	O	992-999
in	O	1000-1002
exon	O	1003-1007
15	O	1008-1010
,	O	1010-1011
and	O	1012-1015
52	O	1016-1018
%	O	1018-1019
of	O	1020-1022
all	O	1023-1026
mutations	O	1027-1036
cluster	O	1037-1044
in	O	1045-1047
exons	O	1048-1053
11	O	1054-1056
-	O	1056-1057
15	O	1057-1059
.	O	1059-1060

We	O	1061-1063
also	O	1064-1068
identified	O	1069-1079
two	O	1080-1083
new	O	1084-1087
microsatellite	O	1088-1102
markers	O	1103-1110
for	O	1111-1114
the	O	1115-1118
OCRL1	O	1119-1124
locus	O	1125-1130
,	O	1130-1131
and	O	1132-1135
we	O	1136-1138
detected	O	1139-1147
a	O	1148-1149
germline	O	1150-1158
mosaicism	O	1159-1168
in	O	1169-1171
one	O	1172-1175
family	O	1176-1182
.	O	1182-1183

This	O	1184-1188
observation	O	1189-1200
has	O	1201-1204
direct	O	1205-1211
implications	O	1212-1224
for	O	1225-1228
genetic	O	1229-1236
counseling	O	1237-1247
of	O	1248-1250
Lowe	B	1251-1255
syndrome	I	1256-1264
families	O	1265-1273
.	O	1273-1274
.	O	1273-1274

Aminoglycoside	O	0-14
antibiotics	O	15-26
restore	O	27-34
dystrophin	O	35-45
function	O	46-54
to	O	55-57
skeletal	O	58-66
muscles	O	67-74
of	O	75-77
mdx	O	78-81
mice	O	82-86
.	O	86-87

Duchenne	B	88-96
muscular	I	97-105
dystrophy	I	106-115
(	O	116-117
DMD	B	117-120
)	O	120-121
is	O	122-124
caused	O	125-131
by	O	132-134
mutations	O	135-144
in	O	145-147
the	O	148-151
dystrophin	O	152-162
gene	O	163-167
,	O	167-168
leading	O	169-176
to	O	177-179
the	O	180-183
absence	O	184-191
of	O	192-194
the	O	195-198
dystrophin	O	199-209
protein	O	210-217
in	O	218-220
striated	O	221-229
muscle	O	230-236
.	O	236-237

A	O	238-239
significant	O	240-251
number	O	252-258
of	O	259-261
these	O	262-267
mutations	O	268-277
are	O	278-281
premature	O	282-291
stop	O	292-296
codons	O	297-303
.	O	303-304

On	O	305-307
the	O	308-311
basis	O	312-317
of	O	318-320
the	O	321-324
observation	O	325-336
that	O	337-341
aminoglycoside	O	342-356
treatment	O	357-366
can	O	367-370
suppress	O	371-379
stop	O	380-384
codons	O	385-391
in	O	392-394
cultured	O	395-403
cells	O	404-409
,	O	409-410
we	O	411-413
tested	O	414-420
the	O	421-424
effect	O	425-431
of	O	432-434
gentamicin	O	435-445
on	O	446-448
cultured	O	449-457
muscle	O	458-464
cells	O	465-470
from	O	471-475
the	O	476-479
mdx	O	480-483
mouse	O	484-489
-	O	490-491
an	O	492-494
animal	O	495-501
model	O	502-507
for	O	508-511
DMD	B	512-515
that	O	516-520
possesses	O	521-530
a	O	531-532
premature	O	533-542
stop	O	543-547
codon	O	548-553
in	O	554-556
the	O	557-560
dystrophin	O	561-571
gene	O	572-576
.	O	576-577

Exposure	O	578-586
of	O	587-589
mdx	O	590-593
myotubes	O	594-602
to	O	603-605
gentamicin	O	606-616
led	O	617-620
to	O	621-623
the	O	624-627
expression	O	628-638
and	O	639-642
localization	O	643-655
of	O	656-658
dystrophin	O	659-669
to	O	670-672
the	O	673-676
cell	O	677-681
membrane	O	682-690
.	O	690-691

We	O	692-694
then	O	695-699
evaluated	O	700-709
the	O	710-713
effects	O	714-721
of	O	722-724
differing	O	725-734
dosages	O	735-742
of	O	743-745
gentamicin	O	746-756
on	O	757-759
expression	O	760-770
and	O	771-774
functional	O	775-785
protection	O	786-796
of	O	797-799
the	O	800-803
muscles	O	804-811
of	O	812-814
mdx	O	815-818
mice	O	819-823
.	O	823-824

We	O	825-827
identified	O	828-838
a	O	839-840
treatment	O	841-850
regimen	O	851-858
that	O	859-863
resulted	O	864-872
in	O	873-875
the	O	876-879
presence	O	880-888
of	O	889-891
dystrophin	O	892-902
in	O	903-905
the	O	906-909
cell	O	910-914
membrane	O	915-923
in	O	924-926
all	O	927-930
striated	O	931-939
muscles	O	940-947
examined	O	948-956
and	O	957-960
that	O	961-965
provided	O	966-974
functional	O	975-985
protection	O	986-996
against	O	997-1004
muscular	B	1005-1013
injury	I	1014-1020
.	O	1020-1021

To	O	1022-1024
our	O	1025-1028
knowledge	O	1029-1038
,	O	1038-1039
our	O	1040-1043
results	O	1044-1051
are	O	1052-1055
the	O	1056-1059
first	O	1060-1065
to	O	1066-1068
demonstrate	O	1069-1080
that	O	1081-1085
aminoglycosides	O	1086-1101
can	O	1102-1105
suppress	O	1106-1114
stop	O	1115-1119
codons	O	1120-1126
not	O	1127-1130
only	O	1131-1135
in	O	1136-1138
vitro	O	1139-1144
but	O	1145-1148
also	O	1149-1153
in	O	1154-1156
vivo	O	1157-1161
.	O	1161-1162

Furthermore	O	1163-1174
,	O	1174-1175
these	O	1176-1181
results	O	1182-1189
raise	O	1190-1195
the	O	1196-1199
possibility	O	1200-1211
of	O	1212-1214
a	O	1215-1216
novel	O	1217-1222
treatment	O	1223-1232
regimen	O	1233-1240
for	O	1241-1244
muscular	B	1245-1253
dystrophy	I	1254-1263
and	O	1264-1267
other	O	1268-1273
diseases	O	1274-1282
caused	O	1283-1289
by	O	1290-1292
premature	O	1293-1302
stop	O	1303-1307
codon	O	1308-1313
mutations	O	1314-1323
.	O	1323-1324

This	O	1325-1329
treatment	O	1330-1339
could	O	1340-1345
prove	O	1346-1351
effective	O	1352-1361
in	O	1362-1364
up	O	1365-1367
to	O	1368-1370
15	O	1371-1373
%	O	1373-1374
of	O	1375-1377
patients	O	1378-1386
with	O	1387-1391
DMD	B	1392-1395
.	O	1395-1396
.	O	1395-1396

Molecular	O	0-9
and	O	10-13
metabolic	O	14-23
basis	O	24-29
for	O	30-33
the	O	34-37
metabolic	B	38-47
disorder	I	48-56
normotriglyceridemic	B	57-77
abetalipoproteinemia	I	78-98
.	O	98-99

We	O	100-102
have	O	103-107
previously	O	108-118
described	O	119-128
a	O	129-130
disorder	O	131-139
,	O	139-140
normotriglyceridemic	B	141-161
abetalipoproteinemia	I	162-182
,	O	182-183
that	O	184-188
is	O	189-191
characterized	O	192-205
by	O	206-208
the	O	209-212
virtual	O	213-220
absence	O	221-228
of	O	229-231
plasma	O	232-238
low	O	239-242
density	O	243-250
lipoproteins	O	251-263
and	O	264-267
complete	O	268-276
absence	O	277-284
of	O	285-287
apoB	O	288-292
-	O	292-293
100	O	293-296
,	O	296-297
but	O	298-301
with	O	302-306
apparently	O	307-317
normal	O	318-324
secretion	O	325-334
of	O	335-337
triglyceride	O	338-350
-	O	350-351
rich	O	351-355
lipoproteins	O	356-368
containing	O	369-379
apoB	O	380-384
-	O	384-385
48	O	385-387
.	O	387-388

The	O	389-392
patients	O	393-401
plasma	O	402-408
lipoproteins	O	409-421
were	O	422-426
shown	O	427-432
on	O	433-435
polyacrylamide	O	436-450
gels	O	451-455
and	O	456-459
by	O	460-462
antibody	O	463-471
mapping	O	472-479
to	O	480-482
have	O	483-487
a	O	488-489
new	O	490-493
truncated	O	494-503
apoB	O	504-508
variant	O	509-516
,	O	516-517
apoB	O	518-522
-	O	522-523
50	O	523-525
,	O	525-526
circulating	O	527-538
along	O	539-544
with	O	545-549
her	O	550-553
apoB	O	554-558
-	O	558-559
48	O	559-561
.	O	561-562

We	O	563-565
have	O	566-570
found	O	571-576
this	O	577-581
individual	O	582-592
to	O	593-595
be	O	596-598
homozygous	O	599-609
for	O	610-613
a	O	614-615
single	O	616-622
C	O	623-624
-	O	624-625
to	O	625-627
-	O	624-625
T	O	628-629
nucleotide	O	630-640
substitution	O	641-653
at	O	654-656
apoB	O	657-661
codon	O	662-667
2252	O	668-672
,	O	672-673
which	O	674-679
produces	O	680-688
a	O	689-690
premature	O	691-700
in	O	701-703
-	O	703-704
frame	O	704-709
stop	O	710-714
codon	O	715-720
.	O	720-721

Thus	O	722-726
,	O	726-727
this	O	728-732
is	O	733-735
a	O	736-737
rare	O	738-742
example	O	743-750
of	O	751-753
homozygous	B	754-764
hypobetalipoproteinemia	I	765-788
.	O	788-789
Electron	O	790-798
photomicrographs	O	799-815
revealed	O	816-824
that	O	825-829
the	O	830-833
diameters	O	834-843
of	O	844-846
particles	O	847-856
in	O	857-859
the	O	860-863
d	O	864-865
less	O	866-870
than	O	871-875
1	O	876-877
.	O	877-878
006	O	879-882
g	O	883-884
/	O	884-885
ml	O	885-887
lipoprotein	O	888-899
fraction	O	900-908
,	O	908-909
in	O	910-912
both	O	913-917
the	O	918-921
postprandial	O	922-934
and	O	935-938
postabsorptive	O	939-953
state	O	954-959
,	O	959-960
are	O	961-964
bimodally	O	965-974
distributed	O	975-986
.	O	986-987

The	O	988-991
molar	O	992-997
ratio	O	998-1003
of	O	1004-1006
apoE	O	1007-1011
to	O	1012-1014
apoB	O	1015-1019
in	O	1020-1022
these	O	1023-1028
particles	O	1029-1038
is	O	1039-1041
3	O	1042-1043
.	O	1043-1044
5	O	1045-1046
1	O	1048-1049
,	O	1049-1050
similar	O	1051-1058
to	O	1059-1061
normal	O	1062-1068
VLDL	O	1069-1073
.	O	1073-1074

The	O	1075-1078
plasma	O	1079-1085
LDL	O	1086-1089
interval	O	1090-1098
contains	O	1099-1107
both	O	1108-1112
spherical	O	1113-1122
and	O	1123-1126
cuboidal	O	1127-1135
particles	O	1136-1145
.	O	1145-1146

Autologous	O	1147-1157
reinfusion	O	1158-1168
of	O	1169-1171
labeled	O	1172-1179
d	O	1180-1181
less	O	1182-1186
than	O	1187-1191
1	O	1192-1193
.	O	1193-1194
006	O	1195-1198
g	O	1199-1200
/	O	1200-1201
ml	O	1201-1203
lipoproteins	O	1204-1216
showed	O	1217-1223
exponential	O	1224-1235
disappearance	O	1236-1249
from	O	1250-1254
plasma	O	1255-1261
,	O	1261-1262
with	O	1263-1267
an	O	1268-1270
apparent	O	1271-1279
half	O	1280-1284
-	O	1284-1285
removal	O	1285-1292
time	O	1293-1297
of	O	1298-1300
50	O	1301-1303
min	O	1304-1307
,	O	1307-1308
somewhat	O	1309-1317
slower	O	1318-1324
than	O	1325-1329
for	O	1330-1333
normal	O	1334-1340
chylomicrons	O	1341-1353
but	O	1354-1357
within	O	1358-1364
the	O	1365-1368
normal	O	1369-1375
range	O	1376-1381
for	O	1382-1385
VLDL	O	1386-1390
.	O	1390-1391

The	O	1392-1395
calculated	O	1396-1406
production	O	1407-1417
rate	O	1418-1422
for	O	1423-1426
apoB	O	1427-1431
was	O	1432-1435
within	O	1436-1442
the	O	1443-1446
normal	O	1447-1453
range	O	1454-1459
in	O	1460-1462
this	O	1463-1467
subject	O	1468-1475
.	O	1475-1476

von	B	0-3
Willebrand	I	4-14
disease	I	15-22
type	I	23-27
B	I	28-29
:	O	29-30
a	O	31-32
missense	O	33-41
mutation	O	42-50
selectively	O	51-62
abolishes	O	63-72
ristocetin	O	73-83
-	O	83-84
induced	O	84-91
von	B	92-95
Willebrand	I	96-106
factor	O	107-113
binding	O	114-121
to	O	122-124
platelet	O	125-133
glycoprotein	O	134-146
Ib	O	147-149
.	O	149-150
von	B	151-154
Willebrand	I	155-165
factor	O	166-172
(	O	173-174
vWF	O	174-177
)	O	177-178
is	O	179-181
a	O	182-183
multimeric	O	184-194
glycoprotein	O	195-207
that	O	208-212
mediates	O	213-221
the	O	222-225
adhesion	O	226-234
of	O	235-237
platelets	O	238-247
to	O	248-250
the	O	251-254
subendothelium	O	255-269
by	O	270-272
binding	O	273-280
to	O	281-283
platelet	O	284-292
glycoprotein	O	293-305
Ib	O	306-308
.	O	308-309

For	O	310-313
human	O	314-319
vWF	O	320-323
,	O	323-324
this	O	325-329
interaction	O	330-341
can	O	342-345
be	O	346-348
induced	O	349-356
in	O	357-359
vitro	O	360-365
by	O	366-368
the	O	369-372
antibiotic	O	373-383
ristocetin	O	384-394
or	O	395-397
the	O	398-401
snake	O	402-407
venom	O	408-413
protein	O	414-421
botrocetin	O	422-432
.	O	432-433

A	O	434-435
missense	O	436-444
mutation	O	445-453
,	O	453-454
Gly	O	455-458
-	O	458-459
561	O	459-462
-	O	458-459
-	O	458-459
>	O	465-466
Ser	O	467-470
,	O	470-471
was	O	472-475
identified	O	476-486
within	O	487-493
the	O	494-497
proposed	O	498-506
glycoprotein	O	507-519
Ib	O	520-522
binding	O	523-530
domain	O	531-537
of	O	538-540
vWF	O	541-544
in	O	545-547
the	O	548-551
proband	O	552-559
with	O	560-564
von	B	565-568
Willebrand	I	569-579
disease	I	580-587
type	I	588-592
B	I	593-594
,	O	594-595
a	O	596-597
unique	O	598-604
variant	O	605-612
characterized	O	613-626
by	O	627-629
no	O	630-632
ristocetin	O	633-643
-	O	643-644
induced	O	644-651
,	O	651-652
but	O	653-656
normal	O	657-663
botrocetin	O	664-674
-	O	674-675
induced	O	675-682
,	O	682-683
binding	O	684-691
to	O	692-694
glycoprotein	O	695-707
Ib	O	708-710
.	O	710-711

The	O	712-715
corresponding	O	716-729
mutant	O	730-736
recombinant	O	737-748
protein	O	749-756
,	O	756-757
rvWF	O	758-762
(	O	763-764
G561S	O	764-769
)	O	769-770
,	O	770-771
formed	O	772-778
normal	O	779-785
multimers	O	786-795
and	O	796-799
exhibited	O	800-809
the	O	810-813
same	O	814-818
functional	O	819-829
defect	O	830-836
as	O	837-839
the	O	840-843
patients	O	844-852
plasma	O	853-859
vWF	O	860-863
,	O	863-864
confirming	O	865-875
that	O	876-880
this	O	881-885
mutation	O	886-894
causes	O	895-901
von	B	902-905
Willebrand	I	906-916
disease	I	917-924
type	I	925-929
B	I	930-931
.	O	931-932
These	O	933-938
data	O	939-943
show	O	944-948
that	O	949-953
botrocetin	O	954-964
and	O	965-968
ristocetin	O	969-979
cofactor	O	980-988
activities	O	989-999
of	O	1000-1002
vWF	O	1003-1006
can	O	1007-1010
be	O	1011-1013
dissociated	O	1014-1025
by	O	1026-1028
a	O	1029-1030
point	O	1031-1036
mutation	O	1037-1045
and	O	1046-1049
confirm	O	1050-1057
that	O	1058-1062
these	O	1063-1068
mediators	O	1069-1078
promote	O	1079-1086
vWF	O	1087-1090
binding	O	1091-1098
to	O	1099-1101
platelets	O	1102-1111
by	O	1112-1114
different	O	1115-1124
mechanisms	O	1125-1135
.	O	1135-1136

The	O	1137-1140
normal	O	1141-1147
botrocetin	O	1148-1158
-	O	1158-1159
induced	O	1159-1166
binding	O	1167-1174
and	O	1175-1178
the	O	1179-1182
defective	O	1183-1192
ristocetin	O	1193-1203
-	O	1203-1204
induced	O	1204-1211
binding	O	1212-1219
of	O	1220-1222
rvWF	O	1223-1227
(	O	1228-1229
G561S	O	1229-1234
)	O	1234-1235
suggest	O	1236-1243
that	O	1244-1248
the	O	1249-1252
primary	O	1253-1260
defect	O	1261-1267
in	O	1268-1270
von	B	1271-1274
Willebrand	I	1275-1285
disease	I	1286-1293
type	I	1294-1298
B	I	1299-1300
may	O	1301-1304
be	O	1305-1307
a	O	1308-1309
failure	O	1310-1317
of	O	1318-1320
normal	O	1321-1327
allosteric	O	1328-1338
regulation	O	1339-1349
of	O	1350-1352
the	O	1353-1356
glycoprotein	O	1357-1369
Ib	O	1370-1372
binding	O	1373-1380
function	O	1381-1389
of	O	1390-1392
vWF	O	1393-1396
.	O	1396-1397
.	O	1396-1397

A	O	0-1
high	O	2-6
incidence	O	7-16
of	O	17-19
BRCA1	O	20-25
mutations	O	26-35
in	O	36-38
20	O	39-41
breast	B	42-48
-	I	48-49
ovarian	I	49-56
cancer	I	57-63
families	O	64-72
.	O	72-73

We	O	74-76
have	O	77-81
analyzed	O	82-90
20	O	91-93
breast	B	94-100
-	I	100-101
ovarian	I	101-108
cancer	I	109-115
families	O	116-124
,	O	124-125
the	O	126-129
majority	O	130-138
of	O	139-141
which	O	142-147
show	O	148-152
positive	O	153-161
evidence	O	162-170
of	O	171-173
linkage	O	174-181
to	O	182-184
chromosome	O	185-195
17q12	O	196-201
for	O	202-205
germ	O	206-210
-	O	210-211
line	O	211-215
mutations	O	216-225
in	O	226-228
the	O	229-232
BRCA1	O	233-238
gene	O	239-243
.	O	243-244

BRCA1	O	245-250
mutations	O	251-260
cosegregating	O	261-274
with	O	275-279
breast	B	280-286
and	I	287-290
ovarian	I	291-298
cancer	I	299-305
susceptibility	O	306-320
were	O	321-325
identified	O	326-336
in	O	337-339
16	O	340-342
families	O	343-351
,	O	351-352
including	O	353-362
1	O	363-364
family	O	365-371
with	O	372-376
a	O	377-378
case	O	379-383
of	O	384-386
male	B	387-391
breast	I	392-398
cancer	I	399-405
.	O	405-406

Nine	O	407-411
of	O	412-414
these	O	415-420
mutations	O	421-430
have	O	431-435
not	O	436-439
been	O	440-444
reported	O	445-453
previously	O	454-464
.	O	464-465

The	O	466-469
majority	O	470-478
of	O	479-481
mutations	O	482-491
were	O	492-496
found	O	497-502
to	O	503-505
generate	O	506-514
a	O	515-516
premature	O	517-526
stop	O	527-531
codon	O	532-537
leading	O	538-545
to	O	546-548
the	O	549-552
formation	O	553-562
of	O	563-565
a	O	566-567
truncated	O	568-577
BRCA1	O	578-583
protein	O	584-591
of	O	592-594
2	O	595-596
%	O	596-597
-	O	598-599
88	O	599-601
%	O	601-602
of	O	603-605
the	O	606-609
expected	O	610-618
normal	O	619-625
length	O	626-632
.	O	632-633

Two	O	634-637
mutations	O	638-647
altered	O	648-655
the	O	656-659
RING	O	660-664
finger	O	665-671
domain	O	672-678
.	O	678-679

Sequencing	O	680-690
of	O	691-693
genomic	O	694-701
DNA	O	702-705
led	O	706-709
to	O	710-712
the	O	713-716
identification	O	717-731
of	O	732-734
a	O	735-736
mutation	O	737-745
in	O	746-748
the	O	749-752
coding	O	753-759
region	O	760-766
of	O	767-769
BRCA1	O	770-775
in	O	776-778
12	O	779-781
families	O	782-790
,	O	790-791
and	O	792-795
cDNA	O	796-800
analysis	O	801-809
revealed	O	810-818
an	O	819-821
abnormal	O	822-830
or	O	831-833
missing	O	834-841
BRCA1	O	842-847
transcript	O	848-858
in	O	859-861
4	O	862-863
of	O	864-866
the	O	867-870
8	O	871-872
remaining	O	873-882
families	O	883-891
.	O	891-892

A	O	893-894
total	O	895-900
of	O	901-903
eight	O	904-909
mutations	O	910-919
were	O	920-924
associated	O	925-935
with	O	936-940
a	O	941-942
reduced	O	943-950
quantity	O	951-959
of	O	960-962
BRCA1	O	963-968
transcript	O	969-979
.	O	979-980

We	O	981-983
were	O	984-988
unable	O	989-995
to	O	996-998
detect	O	999-1005
BRCA1	O	1006-1011
mutations	O	1012-1021
in	O	1022-1024
4	O	1025-1026
of	O	1027-1029
the	O	1030-1033
20	O	1034-1036
families	O	1037-1045
,	O	1045-1046
but	O	1047-1050
only	O	1051-1055
1	O	1056-1057
of	O	1058-1060
these	O	1061-1066
was	O	1067-1070
clearly	O	1071-1078
linked	O	1079-1085
to	O	1086-1088
BRCA1	O	1089-1094
.	O	1094-1095

It	O	1096-1098
is	O	1099-1101
expected	O	1102-1110
that	O	1111-1115
the	O	1116-1119
majority	O	1120-1128
of	O	1129-1131
clear	O	1132-1137
examples	O	1138-1146
of	O	1147-1149
the	O	1150-1153
breast	B	1154-1160
-	I	1160-1161
ovarian	I	1161-1168
syndrome	I	1169-1177
will	O	1178-1182
be	O	1183-1185
associated	O	1186-1196
with	O	1197-1201
germ	O	1202-1206
-	O	1206-1207
line	O	1207-1211
mutations	O	1212-1221
in	O	1222-1224
the	O	1225-1228
coding	O	1229-1235
region	O	1236-1242
of	O	1243-1245
BRCA1	O	1246-1251
.	O	1251-1252
.	O	1251-1252

Assignment	O	0-10
of	O	11-13
the	O	14-17
human	O	18-23
Na	O	24-26
+	O	26-27
/	O	27-28
glucose	O	28-35
cotransporter	O	36-49
gene	O	50-54
SGLT1	O	55-60
to	O	61-63
chromosome	O	64-74
22q13	O	75-80
.	O	80-81
1	O	78-79
.	O	80-81

The	O	84-87
Na	O	88-90
+	O	91-92
/	O	92-93
glucose	O	93-100
cotransporter	O	101-114
gene	O	115-119
SGLT1	O	120-125
encodes	O	126-133
the	O	134-137
primary	O	138-145
carrier	O	146-153
protein	O	154-161
responsible	O	162-173
for	O	174-177
the	O	178-181
uptake	O	182-188
of	O	189-191
the	O	192-195
dietary	O	196-203
sugars	O	204-210
glucose	O	211-218
and	O	219-222
galactose	O	223-232
from	O	233-237
the	O	238-241
intestinal	O	242-252
lumen	O	253-258
.	O	258-259

SGLT1	O	260-265
transport	O	266-275
activity	O	276-284
is	O	285-287
currently	O	288-297
exploited	O	298-307
in	O	308-310
oral	O	311-315
rehydration	O	316-327
therapy	O	328-335
.	O	335-336

The	O	337-340
75	O	341-343
-	O	343-344
kDa	O	344-347
glycoprotein	O	348-360
is	O	361-363
localized	O	364-373
in	O	374-376
the	O	377-380
brush	O	381-386
border	O	387-393
of	O	394-396
the	O	397-400
intestinal	O	401-411
epithelium	O	412-422
and	O	423-426
is	O	427-429
predicted	O	430-439
to	O	440-442
comprise	O	443-451
12	O	452-454
membrane	O	455-463
spans	O	464-469
.	O	469-470

In	O	471-473
two	O	474-477
patients	O	478-486
with	O	487-491
the	O	492-495
autosomal	B	496-505
recessive	I	506-515
disease	I	516-523
glucose	I	524-531
/	I	531-532
galactose	I	532-541
malabsorption	I	542-555
,	O	555-556
the	O	557-560
underlying	O	561-571
cause	O	572-577
was	O	578-581
found	O	582-587
to	O	588-590
be	O	591-593
a	O	594-595
missense	O	596-604
mutation	O	605-613
in	O	614-616
SGLT1	O	617-622
,	O	622-623
and	O	624-627
the	O	628-631
Asp28	O	632-637
-	O	637-638
-	O	637-638
>	O	640-641
Asn	O	642-645
change	O	646-652
was	O	653-656
demonstrated	O	657-669
in	O	670-672
vitro	O	673-678
to	O	679-681
eliminate	O	682-691
SGLT1	O	692-697
transport	O	698-707
activity	O	708-716
.	O	716-717

The	O	718-721
SGLT1	O	722-727
gene	O	728-732
was	O	733-736
previously	O	737-747
shown	O	748-753
to	O	754-756
reside	O	757-763
on	O	764-766
the	O	767-770
distal	O	771-777
q	O	778-779
arm	O	780-783
of	O	784-786
chromosome	O	787-797
22	O	798-800
(	O	801-802
11	O	802-804
.	O	804-805

2	O	806-807
-	O	807-808
-	O	807-808
>	O	810-811
qter	O	812-816
)	O	816-817
.	O	817-818

We	O	819-821
have	O	822-826
used	O	827-831
a	O	832-833
cosmid	O	834-840
probe	O	841-846
for	O	847-850
fluorescence	O	851-863
in	O	864-866
situ	O	867-871
hybridization	O	872-885
,	O	885-886
which	O	887-892
refines	O	893-900
the	O	901-904
localization	O	905-917
to	O	918-920
22q13	O	921-926
.	O	926-927
1	O	928-929
,	O	929-930
and	O	931-934
provide	O	935-942
an	O	943-945
example	O	946-953
of	O	954-956
the	O	957-960
utility	O	961-968
of	O	969-971
the	O	972-975
SGLT1	O	976-981
probe	O	982-987
as	O	988-990
a	O	991-992
diagnostic	O	993-1003
for	O	1004-1007
genetic	B	1008-1015
diseases	I	1016-1024
associated	O	1025-1035
with	O	1036-1040
translocations	O	1041-1055
of	O	1056-1058
chromosome	O	1059-1069
22	O	1070-1072
.	O	1072-1073

A	O	0-1
pseudodeficiency	O	2-18
allele	O	19-25
common	O	26-32
in	O	33-35
non	O	36-39
-	O	39-40
Jewish	O	40-46
Tay	B	47-50
-	I	50-51
Sachs	I	51-56
carriers	O	57-65
:	O	65-66
implications	O	67-79
for	O	80-83
carrier	O	84-91
screening	O	92-101
.	O	101-102

Deficiency	B	103-113
of	I	114-116
beta	I	117-121
-	I	121-122
hexosaminidase	I	122-136
A	I	137-138
(	O	139-140
Hex	O	140-143
A	O	144-145
)	O	145-146
activity	O	147-155
typically	O	156-165
results	O	166-173
in	O	174-176
Tay	B	177-180
-	I	180-181
Sachs	I	181-186
disease	I	187-194
.	O	194-195

However	O	196-203
,	O	203-204
healthy	O	205-212
subjects	O	213-221
found	O	222-227
to	O	228-230
be	O	231-233
deficient	B	234-243
in	I	244-246
Hex	I	247-250
A	I	251-252
activity	O	253-261
(	O	262-263
i	O	263-264
.	O	264-265

e	O	266-267
.	O	267-268
,	O	268-269
pseudodeficient	O	270-285
)	O	285-286
by	O	287-289
means	O	290-295
of	O	296-298
in	O	299-301
vitro	O	302-307
biochemical	O	308-319
tests	O	320-325
have	O	326-330
been	O	331-335
described	O	336-345
.	O	345-346

We	O	347-349
analyzed	O	350-358
the	O	359-362
HEXA	O	363-367
gene	O	368-372
of	O	373-375
one	O	376-379
pseudodeficient	O	380-395
subject	O	396-403
and	O	404-407
identified	O	408-418
both	O	419-423
a	O	424-425
C739	O	426-430
-	O	430-431
to	O	431-433
-	O	430-431
T	O	434-435
substitution	O	436-448
that	O	449-453
changes	O	454-461
Arg247	O	462-468
-	O	468-469
-	O	468-469
-	O	468-469
-	O	468-469
Trp	O	472-475
on	O	476-478
one	O	479-482
allele	O	483-489
and	O	490-493
a	O	494-495
previously	O	496-506
identified	O	507-517
Tay	B	518-521
-	I	521-522
Sachs	I	522-527
disease	I	528-535
mutation	O	536-544
on	O	545-547
the	O	548-551
second	O	552-558
allele	O	559-565
.	O	565-566

Six	O	567-570
additional	O	571-581
pseudodeficient	O	582-597
subjects	O	598-606
were	O	607-611
found	O	612-617
to	O	618-620
have	O	621-625
the	O	626-629
C739	O	630-634
-	O	634-635
to	O	635-637
-	O	634-635
T	O	638-639
mutation	O	640-648
.	O	648-649

This	O	650-654
allele	O	655-661
accounted	O	662-671
for	O	672-675
32	O	676-678
%	O	678-679
(	O	680-681
20	O	681-683
/	O	683-684
62	O	684-686
)	O	686-687
of	O	688-690
non	O	691-694
-	O	694-695
Jewish	O	695-701
enzyme	O	702-708
-	O	708-709
defined	O	709-716
Tay	B	717-720
-	I	720-721
Sachs	I	721-726
disease	I	727-734
carriers	O	735-743
but	O	744-747
for	O	748-751
none	O	752-756
of	O	757-759
36	O	760-762
Jewish	O	763-769
enzyme	O	770-776
-	O	776-777
defined	O	777-784
carriers	O	785-793
who	O	794-797
did	O	798-801
not	O	802-805
have	O	806-810
one	O	811-814
of	O	815-817
three	O	818-823
known	O	824-829
mutations	O	830-839
common	O	840-846
to	O	847-849
this	O	850-854
group	O	855-860
.	O	860-861

The	O	862-865
C739	O	866-870
-	O	870-871
to	O	871-873
-	O	870-871
T	O	874-875
allele	O	876-882
,	O	882-883
together	O	884-892
with	O	893-897
a	O	898-899
"	O	900-901
true	O	902-906
"	O	907-908
Tay	B	909-912
-	I	912-913
Sachs	I	913-918
disease	I	919-926
allele	O	927-933
,	O	933-934
causes	O	935-941
Hex	O	942-945
A	O	946-947
pseudodeficiency	O	948-964
.	O	964-965

Given	O	966-971
both	O	972-976
the	O	977-980
large	O	981-986
proportion	O	987-997
of	O	998-1000
non	O	1001-1004
-	O	1004-1005
Jewish	O	1005-1011
carriers	O	1012-1020
with	O	1021-1025
this	O	1026-1030
allele	O	1031-1037
and	O	1038-1041
that	O	1042-1046
standard	O	1047-1055
biochemical	O	1056-1067
screening	O	1068-1077
cannot	O	1078-1084
differentiate	O	1085-1098
between	O	1099-1106
heterozygotes	O	1107-1120
for	O	1121-1124
the	O	1125-1128
C739	O	1129-1133
-	O	1133-1134
to	O	1134-1136
-	O	1133-1134
T	O	1137-1138
mutations	O	1139-1148
and	O	1149-1152
Tay	B	1153-1156
-	I	1156-1157
Sachs	I	1157-1162
disease	I	1163-1170
carriers	O	1171-1179
,	O	1179-1180
DNA	O	1181-1184
testing	O	1185-1192
for	O	1193-1196
this	O	1197-1201
mutation	O	1202-1210
in	O	1211-1213
at	O	1214-1216
-	O	1216-1217
risk	O	1217-1221
couples	O	1222-1229
is	O	1230-1232
essential	O	1233-1242
.	O	1242-1243

The	O	0-3
presence	O	4-12
of	O	13-15
two	O	16-19
different	O	20-29
infantile	O	30-39
Tay	B	40-43
-	I	43-44
Sachs	I	44-49
disease	I	50-57
mutations	O	58-67
in	O	68-70
a	O	71-72
Cajun	O	73-78
population	O	79-89
.	O	89-90

A	O	91-92
study	O	93-98
was	O	99-102
undertaken	O	103-113
to	O	114-116
characterize	O	117-129
the	O	130-133
mutation	O	134-142
(	O	143-144
s	O	144-145
)	O	145-146
responsible	O	147-158
for	O	159-162
Tay	B	163-166
-	I	166-167
Sachs	I	167-172
disease	I	173-180
(	O	181-182
TSD	B	182-185
)	O	185-186
in	O	187-189
a	O	190-191
Cajun	O	192-197
population	O	198-208
in	O	209-211
southwest	O	212-221
Louisiana	O	222-231
and	O	232-235
to	O	236-238
identify	O	239-247
the	O	248-251
origins	O	252-259
of	O	260-262
these	O	263-268
mutations	O	269-278
.	O	278-279

Eleven	O	280-286
of	O	287-289
12	O	290-292
infantile	O	293-302
TSD	B	303-306
alleles	O	307-314
examined	O	315-323
in	O	324-326
six	O	327-330
families	O	331-339
had	O	340-343
the	O	344-347
beta	O	348-352
-	O	352-353
hexosaminidase	O	353-367
A	O	368-369
(	O	370-371
Hex	O	371-374
A	O	375-376
)	O	376-377
alpha	O	378-383
-	O	383-384
subunit	O	384-391
exon	O	392-396
11	O	397-399
insertion	O	400-409
mutation	O	410-418
that	O	419-423
is	O	424-426
present	O	427-434
in	O	435-437
approximately	O	438-451
70	O	452-454
%	O	454-455
of	O	456-458
Ashkenazi	O	459-468
Jewish	O	469-475
TSD	B	476-479
heterozygotes	O	480-493
.	O	493-494

The	O	495-498
mutation	O	499-507
in	O	508-510
the	O	511-514
remaining	O	515-524
allele	O	525-531
was	O	532-535
a	O	536-537
single	O	538-544
-	O	544-545
base	O	545-549
transition	O	550-560
in	O	561-563
the	O	564-567
donor	O	568-573
splice	O	574-580
site	O	581-585
of	O	586-588
the	O	589-592
alpha	O	593-598
-	O	598-599
subunit	O	599-606
intron	O	607-613
9	O	614-615
.	O	615-616
To	O	617-619
determine	O	620-629
the	O	630-633
origins	O	634-641
of	O	642-644
these	O	645-650
two	O	651-654
mutations	O	655-664
in	O	665-667
the	O	668-671
Cajun	O	672-677
population	O	678-688
,	O	688-689
the	O	690-693
TSD	B	694-697
carrier	O	698-705
status	O	706-712
was	O	713-716
enzymatically	O	717-730
determined	O	731-741
for	O	742-745
90	O	746-748
members	O	749-756
of	O	757-759
four	O	760-764
of	O	765-767
the	O	768-771
six	O	772-775
families	O	776-784
,	O	784-785
and	O	786-789
extensive	O	790-799
pedigrees	O	800-809
were	O	810-814
constructed	O	815-826
for	O	827-830
all	O	831-834
carriers	O	835-843
.	O	843-844

A	O	845-846
single	O	847-853
ancestral	O	854-863
couple	O	864-870
from	O	871-875
France	O	876-882
was	O	883-886
found	O	887-892
to	O	893-895
be	O	896-898
common	O	899-905
to	O	906-908
most	O	909-913
of	O	914-916
the	O	917-920
carriers	O	921-929
of	O	930-932
the	O	933-936
exon	O	937-941
11	O	942-944
insertion	O	945-954
.	O	954-955

Pedigree	O	956-964
data	O	965-969
suggest	O	970-977
that	O	978-982
this	O	983-987
mutation	O	988-996
has	O	997-1000
been	O	1001-1005
in	O	1006-1008
the	O	1009-1012
Cajun	O	1013-1018
population	O	1019-1029
since	O	1030-1035
its	O	1036-1039
founding	O	1040-1048
over	O	1049-1053
2	O	1054-1055
centuries	O	1056-1065
ago	O	1066-1069
and	O	1070-1073
that	O	1074-1078
it	O	1079-1081
may	O	1082-1085
be	O	1086-1088
widely	O	1089-1095
distributed	O	1096-1107
within	O	1108-1114
the	O	1115-1118
population	O	1119-1129
.	O	1129-1130

In	O	1131-1133
contrast	O	1134-1142
,	O	1142-1143
the	O	1144-1147
intron	O	1148-1154
9	O	1155-1156
mutation	O	1157-1165
apparently	O	1166-1176
was	O	1177-1180
introduced	O	1181-1191
within	O	1192-1198
the	O	1199-1202
last	O	1203-1207
century	O	1208-1215
and	O	1216-1219
probably	O	1220-1228
is	O	1229-1231
limited	O	1232-1239
to	O	1240-1242
a	O	1243-1244
few	O	1245-1248
Louisiana	O	1249-1258
families	O	1259-1267
.	O	1267-1268
.	O	1267-1268

Canavan	B	0-7
disease	I	8-15
:	O	15-16
genomic	O	17-24
organization	O	25-37
and	O	38-41
localization	O	42-54
of	O	55-57
human	O	58-63
ASPA	O	64-68
to	O	69-71
17p13	O	72-77
-	O	77-78
ter	O	78-81
and	O	82-85
conservation	O	86-98
of	O	99-101
the	O	102-105
ASPA	O	106-110
gene	O	111-115
during	O	116-122
evolution	O	123-132
.	O	132-133

Canavan	B	134-141
disease	I	142-149
,	O	149-150
or	O	151-153
spongy	B	154-160
degeneration	I	161-173
of	I	174-176
the	I	177-180
brain	I	181-186
,	O	186-187
is	O	188-190
a	O	191-192
severe	O	193-199
leukodystrophy	B	200-214
caused	O	215-221
by	O	222-224
the	O	225-228
deficiency	B	229-239
of	I	240-242
aspartoacylase	I	243-257
(	O	258-259
ASPA	O	259-263
)	O	263-264
.	O	264-265

Recently	O	266-274
,	O	274-275
a	O	276-277
missense	O	278-286
mutation	O	287-295
was	O	296-299
identified	O	300-310
in	O	311-313
human	O	314-319
ASPA	O	320-324
coding	O	325-331
sequence	O	332-340
from	O	341-345
patients	O	346-354
with	O	355-359
Canavan	B	360-367
disease	I	368-375
.	O	375-376

The	O	377-380
human	O	381-386
ASPA	O	387-391
gene	O	392-396
has	O	397-400
been	O	401-405
cloned	O	406-412
and	O	413-416
found	O	417-422
to	O	423-425
span	O	426-430
29	O	431-433
kb	O	434-436
of	O	437-439
the	O	440-443
genome	O	444-450
.	O	450-451

Human	O	452-457
aspartoacylase	O	458-472
is	O	473-475
coded	O	476-481
by	O	482-484
six	O	485-488
exons	O	489-494
intervened	O	495-505
by	O	506-508
five	O	509-513
introns	O	514-521
.	O	521-522

The	O	523-526
exons	O	527-532
vary	O	533-537
from	O	538-542
94	O	543-545
(	O	546-547
exon	O	547-551
III	O	552-555
)	O	555-556
to	O	557-559
514	O	560-563
(	O	564-565
exon	O	565-569
VI	O	570-572
)	O	572-573
bases	O	574-579
.	O	579-580

The	O	581-584
exon	O	585-589
/	O	589-590
intron	O	590-596
splice	O	597-603
junction	O	604-612
sites	O	613-618
follow	O	619-625
the	O	626-629
gt	O	630-632
/	O	632-633
ag	O	633-635
consensus	O	636-645
sequence	O	646-654
rule	O	655-659
.	O	659-660

Southern	O	661-669
blot	O	670-674
analysis	O	675-683
of	O	684-686
genomic	O	687-694
DNA	O	695-698
from	O	699-703
human	O	704-709
/	O	709-710
mouse	O	710-715
somatic	O	716-723
cell	O	724-728
hybrid	O	729-735
cell	O	736-740
lines	O	741-746
localized	O	747-756
ASPA	O	757-761
to	O	762-764
human	O	765-770
chromosome	O	771-781
17	O	782-784
.	O	784-785

The	O	786-789
human	O	790-795
ASPA	O	796-800
locus	O	801-806
was	O	807-810
further	O	811-818
mapped	O	819-825
in	O	826-828
the	O	829-832
17p13	O	833-838
-	O	838-839
ter	O	839-842
region	O	843-849
by	O	850-852
fluorescence	O	853-865
in	O	866-868
situ	O	869-873
hybridization	O	874-887
.	O	887-888

The	O	889-892
bovine	O	893-899
aspa	O	900-904
gene	O	905-909
has	O	910-913
also	O	914-918
been	O	919-923
cloned	O	924-930
,	O	930-931
and	O	932-935
its	O	936-939
exon	O	940-944
/	O	944-945
intron	O	945-951
organization	O	952-964
is	O	965-967
identical	O	968-977
to	O	978-980
that	O	981-985
of	O	986-988
the	O	989-992
human	O	993-998
gene	O	999-1003
.	O	1003-1004

The	O	1005-1008
500	O	1009-1012
-	O	1012-1013
base	O	1013-1017
sequence	O	1018-1026
upstream	O	1027-1035
of	O	1036-1038
the	O	1039-1042
initiator	O	1043-1052
ATG	O	1053-1056
codon	O	1057-1062
in	O	1063-1065
the	O	1066-1069
human	O	1070-1075
gene	O	1076-1080
and	O	1081-1084
that	O	1085-1089
in	O	1090-1092
the	O	1093-1096
bovine	O	1097-1103
gene	O	1104-1108
are	O	1109-1112
77	O	1113-1115
%	O	1115-1116
identical	O	1117-1126
.	O	1126-1127

Human	O	1128-1133
ASPA	O	1134-1138
coding	O	1139-1145
sequences	O	1146-1155
cross	O	1156-1161
-	O	1161-1162
hybridize	O	1162-1171
with	O	1172-1176
genomic	O	1177-1184
DNA	O	1185-1188
from	O	1189-1193
yeast	O	1194-1199
,	O	1199-1200
chicken	O	1201-1208
,	O	1208-1209
rabbit	O	1210-1216
,	O	1216-1217
cow	O	1218-1221
,	O	1221-1222
dog	O	1223-1226
,	O	1226-1227
mouse	O	1228-1233
,	O	1233-1234
rat	O	1235-1238
,	O	1238-1239
and	O	1240-1243
monkey	O	1244-1250
.	O	1250-1251

The	O	1252-1255
specificity	O	1256-1267
of	O	1268-1270
cross	O	1271-1276
-	O	1276-1277
species	O	1277-1284
hybridization	O	1285-1298
of	O	1299-1301
coding	O	1302-1308
sequences	O	1309-1318
suggests	O	1319-1327
that	O	1328-1332
aspartoacylase	O	1333-1347
has	O	1348-1351
been	O	1352-1356
conserved	O	1357-1366
during	O	1367-1373
evolution	O	1374-1383
.	O	1383-1384

It	O	1385-1387
should	O	1388-1394
now	O	1395-1398
be	O	1399-1401
possible	O	1402-1410
to	O	1411-1413
identify	O	1414-1422
mutations	O	1423-1432
in	O	1433-1435
the	O	1436-1439
noncoding	O	1440-1449
genomic	O	1450-1457
sequences	O	1458-1467
that	O	1468-1472
lead	O	1473-1477
to	O	1478-1480
Canavan	B	1481-1488
disease	I	1489-1496
and	O	1497-1500
to	O	1501-1503
study	O	1504-1509
the	O	1510-1513
regulation	O	1514-1524
of	O	1525-1527
ASPA	O	1528-1532
.	O	1532-1533
.	O	1532-1533

Adrenoleukodystrophy	B	0-20
:	O	20-21
survey	O	22-28
of	O	29-31
303	O	32-35
cases	O	36-41
:	O	41-42
biochemistry	O	43-55
,	O	55-56
diagnosis	O	57-66
,	O	66-67
and	O	68-71
therapy	O	72-79
.	O	79-80

Adrenoleukodystrophy	B	81-101
(	O	102-103
ALD	B	103-106
)	O	106-107
is	O	108-110
a	O	111-112
genetically	O	113-124
determined	O	125-135
disorder	O	136-144
associated	O	145-155
with	O	156-160
progressive	B	161-172
central	I	173-180
demyelination	I	181-194
and	O	195-198
adrenal	B	199-206
cortical	I	207-215
insufficiency	I	216-229
.	O	229-230

All	O	231-234
affected	O	235-243
persons	O	244-251
show	O	252-256
increased	O	257-266
levels	O	267-273
of	O	274-276
saturated	O	277-286
unbranched	O	287-297
very	O	298-302
-	O	302-303
long	O	303-307
-	O	302-303
chain	O	308-313
fatty	O	314-319
acids	O	320-325
,	O	325-326
particularly	O	327-339
hexacosanoate	O	340-353
(	O	354-355
C26	O	355-358
0	O	360-361
)	O	361-362
,	O	362-363
because	O	364-371
of	O	372-374
impaired	O	375-383
capacity	O	384-392
to	O	393-395
degrade	O	396-403
these	O	404-409
acids	O	410-415
.	O	415-416

This	O	417-421
degradation	O	422-433
normally	O	434-442
takes	O	443-448
place	O	449-454
in	O	455-457
a	O	458-459
subcellular	O	460-471
organelle	O	472-481
called	O	482-488
the	O	489-492
peroxisome	O	493-503
,	O	503-504
and	O	505-508
ALD	B	509-512
,	O	512-513
together	O	514-522
with	O	523-527
Zellwegers	B	528-538
cerebrohepatorenal	I	539-557
syndrome	I	558-566
,	O	566-567
is	O	568-570
now	O	571-574
considered	O	575-585
to	O	586-588
belong	O	589-595
to	O	596-598
the	O	599-602
newly	O	603-608
formed	O	609-615
category	O	616-624
of	O	625-627
peroxisomal	B	628-639
disorders	I	640-649
.	O	649-650

Biochemical	O	651-662
assays	O	663-669
permit	O	670-676
prenatal	O	677-685
diagnosis	O	686-695
,	O	695-696
as	O	697-699
well	O	700-704
as	O	705-707
identification	O	708-722
of	O	723-725
most	O	726-730
heterozygotes	O	731-744
.	O	744-745

We	O	746-748
have	O	749-753
identified	O	754-764
303	O	765-768
patients	O	769-777
with	O	778-782
ALD	B	783-786
in	O	787-789
217	O	790-793
kindreds	O	794-802
.	O	802-803

These	O	804-809
patients	O	810-818
show	O	819-823
a	O	824-825
wide	O	826-830
phenotypic	O	831-841
variation	O	842-851
.	O	851-852

Sixty	O	853-858
percent	O	859-866
of	O	867-869
patients	O	870-878
had	O	879-882
childhood	O	883-892
ALD	B	893-896
and	O	897-900
17	O	901-903
%	O	903-904
adrenomyeloneuropathy	B	905-926
,	O	926-927
both	O	928-932
of	O	933-935
which	O	936-941
are	O	942-945
X	O	946-947
-	O	947-948
linked	O	948-954
,	O	954-955
with	O	956-960
the	O	961-964
gene	O	965-969
mapped	O	970-976
to	O	977-979
Xq28	O	980-984
.	O	984-985

Neonatal	B	986-994
ALD	I	995-998
,	O	998-999
a	O	1000-1001
distinct	O	1002-1010
entity	O	1011-1017
with	O	1018-1022
autosomal	O	1023-1032
recessive	O	1033-1042
inheritance	O	1043-1054
and	O	1055-1058
points	O	1059-1065
of	O	1066-1068
resemblance	O	1069-1080
to	O	1081-1083
Zellwegers	B	1084-1094
syndrome	I	1095-1103
,	O	1103-1104
accounted	O	1105-1114
for	O	1115-1118
7	O	1119-1120
%	O	1120-1121
of	O	1122-1124
the	O	1125-1128
cases	O	1129-1134
.	O	1134-1135

Although	O	1136-1144
excess	O	1145-1151
C26	O	1152-1155
0	O	1157-1158
in	O	1159-1161
the	O	1162-1165
brain	O	1166-1171
of	O	1172-1174
patients	O	1175-1183
with	O	1184-1188
ALD	B	1189-1192
is	O	1193-1195
partially	O	1196-1205
of	O	1206-1208
dietary	O	1209-1216
origin	O	1217-1223
,	O	1223-1224
dietary	O	1225-1232
C26	O	1233-1236
0	O	1238-1239
restriction	O	1240-1251
did	O	1252-1255
not	O	1256-1259
produce	O	1260-1267
clear	O	1268-1273
benefit	O	1274-1281
.	O	1281-1282

Bone	O	1283-1287
marrow	O	1288-1294
transplant	O	1295-1305
lowered	O	1306-1313
the	O	1314-1317
plasma	O	1318-1324
C26	O	1325-1328
0	O	1330-1331
level	O	1332-1337
but	O	1338-1341
failed	O	1342-1348
to	O	1349-1351
arrest	O	1352-1358
neurological	O	1359-1371
progression	O	1372-1383
.	O	1383-1384
.	O	1383-1384

French	O	0-6
Machado	B	7-14
-	I	14-15
Joseph	I	15-21
disease	I	22-29
patients	O	30-38
do	O	39-41
not	O	42-45
exhibit	O	46-53
gametic	O	54-61
segregation	O	62-73
distortion	O	74-84
:	O	84-85
a	O	86-87
sperm	O	88-93
typing	O	94-100
analysis	O	101-109
.	O	109-110

Segregation	O	111-122
distortion	O	123-133
has	O	134-137
been	O	138-142
reported	O	143-151
to	O	152-154
occur	O	155-160
in	O	161-163
a	O	164-165
number	O	166-172
of	O	173-175
the	O	176-179
trinucleotide	B	180-193
repeat	I	194-200
disorders	I	201-210
.	O	210-211

On	O	212-214
the	O	215-218
basis	O	219-224
of	O	225-227
a	O	228-229
sperm	O	230-235
typing	O	236-242
study	O	243-248
performed	O	249-258
in	O	259-261
patients	O	262-270
of	O	271-273
Japanese	O	274-282
descent	O	283-290
with	O	291-295
Machado	B	296-303
-	I	303-304
Joseph	I	304-310
disease	I	311-318
(	O	319-320
MJD	B	320-323
)	O	323-324
,	O	324-325
it	O	326-328
was	O	329-332
reported	O	333-341
that	O	342-346
disease	O	347-354
alleles	O	355-362
are	O	363-366
preferentially	O	367-381
transmitted	O	382-393
during	O	394-400
meiosis	O	401-408
.	O	408-409

We	O	410-412
performed	O	413-422
a	O	423-424
sperm	O	425-430
typing	O	431-437
study	O	438-443
of	O	444-446
five	O	447-451
MJD	B	452-455
patients	O	456-464
of	O	465-467
French	O	468-474
descent	O	475-482
and	O	483-486
analysis	O	487-495
of	O	496-498
the	O	499-502
pooled	O	503-509
data	O	510-514
shows	O	515-520
a	O	521-522
ratio	O	523-528
of	O	529-531
mutant	O	532-538
to	O	539-541
normal	O	542-548
alleles	O	549-556
of	O	557-559
379	O	560-563
436	O	565-568
(	O	569-570
46	O	570-572
.	O	572-573
5	O	574-575
53	O	577-579
.	O	579-580

5	O	581-582
%	O	582-583
)	O	583-584
,	O	584-585
which	O	586-591
does	O	592-596
not	O	597-600
support	O	601-608
meiotic	O	609-616
segregation	O	617-628
distortion	O	629-639
.	O	639-640

To	O	641-643
confirm	O	644-651
these	O	652-657
results	O	658-665
,	O	665-666
sperm	O	667-672
typing	O	673-679
analysis	O	680-688
was	O	689-692
also	O	693-697
performed	O	698-707
using	O	708-713
a	O	714-715
polymorphic	O	716-727
marker	O	728-734
,	O	734-735
D14S1050	O	736-744
,	O	744-745
closely	O	746-753
linked	O	754-760
to	O	761-763
the	O	764-767
MJD1	O	768-772
gene	O	773-777
.	O	777-778

Among	O	779-784
910	O	785-788
sperm	O	789-794
analyzed	O	795-803
,	O	803-804
the	O	805-808
allele	O	809-815
linked	O	816-822
to	O	823-825
the	O	826-829
disease	O	830-837
chromosome	O	838-848
was	O	849-852
detected	O	853-861
in	O	862-864
50	O	865-867
.	O	867-868

3	O	869-870
%	O	870-871
of	O	872-874
the	O	875-878
samples	O	879-886
and	O	887-890
the	O	891-894
allele	O	895-901
linked	O	902-908
to	O	909-911
the	O	912-915
normal	O	916-922
chromosome	O	923-933
was	O	934-937
found	O	938-943
in	O	944-946
49	O	947-949
.	O	949-950

6	O	951-952
%	O	952-953
of	O	954-956
the	O	957-960
sperm	O	961-966
.	O	966-967

The	O	968-971
difference	O	972-982
in	O	983-985
frequency	O	986-995
of	O	996-998
these	O	999-1004
two	O	1005-1008
alleles	O	1009-1016
is	O	1017-1019
not	O	1020-1023
significant	O	1024-1035
(	O	1036-1037
P	O	1037-1038
=	O	1039-1040
0	O	1041-1042
.	O	1042-1043
8423	O	1044-1048
)	O	1048-1049
.	O	1049-1050

Likelihood	O	1051-1061
-	O	1061-1062
based	O	1062-1067
analysis	O	1068-1076
of	O	1077-1079
segregation	O	1080-1091
distortion	O	1092-1102
in	O	1103-1105
the	O	1106-1109
single	O	1110-1116
sperm	O	1117-1122
data	O	1123-1127
using	O	1128-1133
the	O	1134-1137
SPERMSEG	O	1138-1146
program	O	1147-1154
also	O	1155-1159
showed	O	1160-1166
no	O	1167-1169
support	O	1170-1177
for	O	1178-1181
segregation	O	1182-1193
distortion	O	1194-1204
at	O	1205-1207
the	O	1208-1211
gamete	O	1212-1218
level	O	1219-1224
in	O	1225-1227
this	O	1228-1232
patient	O	1233-1240
population	O	1241-1251
.	O	1251-1252

The	O	1253-1256
previous	O	1257-1265
report	O	1266-1272
on	O	1273-1275
the	O	1276-1279
Japanese	O	1280-1288
patients	O	1289-1297
also	O	1298-1302
suggested	O	1303-1312
that	O	1313-1317
disease	O	1318-1325
allele	O	1326-1332
stability	O	1333-1342
may	O	1343-1346
be	O	1347-1349
influenced	O	1350-1360
by	O	1361-1363
a	O	1364-1365
trans	O	1366-1371
effect	O	1372-1378
of	O	1379-1381
an	O	1382-1384
intragenic	O	1385-1395
polymorphism	O	1396-1408
(	O	1409-1410
987	O	1410-1413
G	O	1414-1415
/	O	1415-1416
C	O	1416-1417
)	O	1417-1418
in	O	1419-1421
the	O	1422-1425
wild	O	1426-1430
-	O	1430-1431
type	O	1431-1435
allele	O	1436-1442
.	O	1442-1443

All	O	1444-1447
of	O	1448-1450
the	O	1451-1454
French	O	1455-1461
patients	O	1462-1470
were	O	1471-1475
heterozygous	O	1476-1488
for	O	1489-1492
this	O	1493-1497
polymorphism	O	1498-1510
.	O	1510-1511

However	O	1512-1519
,	O	1519-1520
analysis	O	1521-1529
of	O	1530-1532
the	O	1533-1536
variance	O	1537-1545
in	O	1546-1548
repeat	O	1549-1555
number	O	1556-1562
in	O	1563-1565
sperm	O	1566-1571
from	O	1572-1576
the	O	1577-1580
French	O	1581-1587
MJD	B	1588-1591
patients	O	1592-1600
overlapped	O	1601-1611
significantly	O	1612-1625
with	O	1626-1630
the	O	1631-1634
variance	O	1635-1643
in	O	1644-1646
repeat	O	1647-1653
number	O	1654-1660
observed	O	1661-1669
in	O	1670-1672
the	O	1673-1676
C	O	1677-1678
/	O	1678-1679
C	O	1677-1678
homozygous	O	1681-1691
Japanese	O	1692-1700
patients	O	1701-1709
.	O	1709-1710

Nebulin	O	0-7
seen	O	8-12
in	O	13-15
DMD	B	16-19
males	O	20-25
including	O	26-35
one	O	36-39
patient	O	40-47
with	O	48-52
a	O	53-54
large	O	55-60
DNA	O	61-64
deletion	O	65-73
encompassing	O	74-86
the	O	87-90
DMD	B	91-94
gene	O	95-99
.	O	99-100

The	O	101-104
presence	O	105-113
of	O	114-116
nebulin	O	117-124
in	O	125-127
a	O	128-129
muscle	O	130-136
specimen	O	137-145
from	O	146-150
a	O	151-152
patient	O	153-160
with	O	161-165
Duchenne	B	166-174
muscular	I	175-183
dystrophy	I	184-193
(	O	194-195
DMD	B	195-198
)	O	198-199
due	O	200-203
to	O	204-206
a	O	207-208
large	O	209-214
deletion	O	215-223
precludes	O	224-233
the	O	234-237
possibility	O	238-249
that	O	250-254
this	O	255-259
protein	O	260-267
is	O	268-270
the	O	271-274
DMD	B	275-278
gene	O	279-283
product	O	284-291
.	O	291-292
.	O	291-292

The	O	0-3
human	O	4-9
gene	O	10-14
for	O	15-18
alkaptonuria	B	19-31
(	O	32-33
AKU	B	33-36
)	O	36-37
maps	O	38-42
to	O	43-45
chromosome	O	46-56
3q	O	57-59
.	O	59-60

Alkaptonuria	B	61-73
(	O	74-75
AKU	B	75-78
;	O	78-79
McKusick	O	80-88
no	O	89-91
.	O	91-92

203500	O	93-99
)	O	99-100
is	O	101-103
a	O	104-105
rare	O	106-110
autosomal	B	111-120
recessive	I	121-130
disorder	I	131-139
caused	O	140-146
by	O	147-149
the	O	150-153
lack	O	154-158
of	O	159-161
homogentisic	O	162-174
acid	O	175-179
oxidase	O	180-187
activity	O	188-196
.	O	196-197

Patients	O	198-206
excrete	O	207-214
large	O	215-220
amounts	O	221-228
of	O	229-231
homogentisic	O	232-244
acid	O	245-249
in	O	250-252
their	O	253-258
urine	O	259-264
and	O	265-268
a	O	269-270
black	O	271-276
ochronotic	O	277-287
pigment	O	288-295
is	O	296-298
deposited	O	299-308
in	O	309-311
their	O	312-317
cartilage	O	318-327
and	O	328-331
collagenous	O	332-343
tissues	O	344-351
.	O	351-352

Ochronosis	B	353-363
is	O	364-366
the	O	367-370
predominant	O	371-382
clinical	O	383-391
complication	O	392-404
of	O	405-407
the	O	408-411
disease	O	412-419
leading	O	420-427
to	O	428-430
ochronotic	B	431-441
arthropathy	I	442-453
,	O	453-454
dark	O	455-459
urine	O	460-465
,	O	465-466
pigment	O	467-474
changes	O	475-482
of	O	483-485
the	O	486-489
skin	O	490-494
,	O	494-495
and	O	496-499
other	O	500-505
clinical	O	506-514
features	O	515-523
.	O	523-524

A	O	525-526
mutation	O	527-535
causing	O	536-543
alkaptonuria	B	544-556
in	O	557-559
the	O	560-563
mouse	O	564-569
has	O	570-573
mapped	O	574-580
to	O	581-583
chromosome	O	584-594
16	O	595-597
.	O	597-598

Considering	O	599-610
conserved	O	611-620
synteny	O	621-628
,	O	628-629
we	O	630-632
were	O	633-637
able	O	638-642
to	O	643-645
map	O	646-649
the	O	650-653
human	O	654-659
gene	O	660-664
to	O	665-667
chromosome	O	668-678
3q	O	679-681
in	O	682-684
six	O	685-688
alkaptonuria	B	689-701
pedigrees	O	702-711
of	O	712-714
Slovak	O	715-721
origin	O	722-728
.	O	728-729
.	O	728-729

The	O	0-3
APC	B	4-7
gene	O	8-12
,	O	12-13
responsible	O	14-25
for	O	26-29
familial	B	30-38
adenomatous	I	39-50
polyposis	I	51-60
,	O	60-61
is	O	62-64
mutated	O	65-72
in	O	73-75
human	O	76-81
gastric	B	82-89
cancer	I	90-96
.	O	96-97

Although	O	98-106
gastric	B	107-114
cancer	I	115-121
is	O	122-124
the	O	125-128
most	O	129-133
common	O	134-140
cancer	B	141-147
in	O	148-150
the	O	151-154
world	O	155-160
,	O	160-161
genetic	O	162-169
changes	O	170-177
during	O	178-184
its	O	185-188
carcinogenesis	O	189-203
are	O	204-207
not	O	208-211
well	O	212-216
understood	O	217-227
.	O	227-228

Since	O	229-234
some	O	235-239
gastric	B	240-247
cancers	I	248-255
are	O	256-259
considered	O	260-270
to	O	271-273
originate	O	274-283
from	O	284-288
the	O	289-292
intestinal	O	293-303
metaplasia	O	304-314
,	O	314-315
it	O	316-318
is	O	319-321
likely	O	322-328
that	O	329-333
the	O	334-337
adenomatous	B	338-349
polyposis	I	350-359
coli	I	360-364
(	O	365-366
APC	B	366-369
)	O	369-370
gene	O	371-375
,	O	375-376
the	O	377-380
mutation	O	381-389
of	O	390-392
which	O	393-398
causes	O	399-405
adenomatous	B	406-417
polyps	I	418-424
in	I	425-427
the	I	428-431
colon	I	432-437
,	O	437-438
is	O	439-441
associated	O	442-452
with	O	453-457
carcinogenesis	O	458-472
of	O	473-475
gastric	B	476-483
cancer	I	484-490
.	O	490-491

Based	O	492-497
on	O	498-500
this	O	501-505
idea	O	506-510
,	O	510-511
DNAs	O	512-516
isolated	O	517-525
from	O	526-530
gastric	B	531-538
cancers	I	539-546
were	O	547-551
examined	O	552-560
by	O	561-563
means	O	564-569
of	O	570-572
a	O	573-574
RNase	O	575-580
protection	O	581-591
analysis	O	592-600
coupled	O	601-608
with	O	609-613
polymerase	O	614-624
chain	O	625-630
reaction	O	631-639
followed	O	640-648
by	O	649-651
sequencing	O	652-662
of	O	663-665
the	O	666-669
polymerase	O	670-680
chain	O	681-686
reaction	O	687-695
products	O	696-704
.	O	704-705

By	O	706-708
screening	O	709-718
nearly	O	719-725
one	O	726-729
-	O	729-730
half	O	730-734
of	O	735-737
the	O	738-741
coding	O	742-748
region	O	749-755
of	O	756-758
the	O	759-762
APC	B	763-766
gene	O	767-771
in	O	772-774
44	O	775-777
tumors	B	778-784
,	O	784-785
somatic	O	786-793
mutations	O	794-803
were	O	804-808
detected	O	809-817
in	O	818-820
three	O	821-826
tumors	B	827-833
a	O	835-836
missense	O	837-845
mutation	O	846-854
,	O	854-855
a	O	856-857
nonsense	O	858-866
mutation	O	867-875
,	O	875-876
and	O	877-880
a	O	881-882
5	O	883-884
-	O	884-885
base	O	885-889
pair	O	890-894
deletion	O	895-903
resulting	O	904-913
in	O	914-916
a	O	917-918
frame	O	919-924
shift	O	925-930
which	O	931-936
causes	O	937-943
truncation	O	944-954
of	O	955-957
the	O	958-961
gene	O	962-966
product	O	967-974
.	O	974-975

These	O	976-981
results	O	982-989
suggest	O	990-997
that	O	998-1002
the	O	1003-1006
mutation	O	1007-1015
of	O	1016-1018
the	O	1019-1022
APC	B	1023-1026
gene	O	1027-1031
also	O	1032-1036
plays	O	1037-1042
an	O	1043-1045
important	O	1046-1055
role	O	1056-1060
during	O	1061-1067
the	O	1068-1071
carcinogenesis	O	1072-1086
of	O	1087-1089
at	O	1090-1092
least	O	1093-1098
some	O	1099-1103
gastric	B	1104-1111
cancers	I	1112-1119
.	O	1119-1120
.	O	1119-1120

Molecular	O	0-9
epidemiology	O	10-22
of	O	23-25
C9	B	26-28
deficiency	I	29-39
heterozygotes	O	40-53
with	O	54-58
an	O	59-61
Arg95Stop	O	62-71
mutation	O	72-80
of	O	81-83
the	O	84-87
C9	O	88-90
gene	O	91-95
in	O	96-98
Japan	O	99-104
.	O	104-105

Deficiency	B	106-116
of	I	117-119
the	I	120-123
ninth	I	124-129
component	I	130-139
of	I	140-142
human	I	143-148
complement	I	149-159
(	O	160-161
C9	O	161-163
)	O	163-164
is	O	165-167
the	O	168-171
most	O	172-176
common	O	177-183
complement	B	184-194
deficiency	I	195-205
in	O	206-208
Japan	O	209-214
,	O	214-215
with	O	216-220
an	O	221-223
incidence	O	224-233
of	O	234-236
approximately	O	237-250
one	O	251-254
homozygote	O	255-265
in	O	266-268
1000	O	269-273
,	O	273-274
but	O	275-278
is	O	279-281
very	O	282-286
rare	O	287-291
in	O	292-294
other	O	295-300
countries	O	301-310
.	O	310-311

Genetic	O	312-319
analyses	O	320-328
of	O	329-331
Japanese	O	332-340
C9	B	341-343
deficiency	I	344-354
have	O	355-359
shown	O	360-365
that	O	366-370
a	O	371-372
C	O	373-374
-	O	374-375
to	O	375-377
-	O	374-375
T	O	378-379
transition	O	380-390
leading	O	391-398
to	O	399-401
TGA	O	402-405
stop	O	406-410
codon	O	411-416
for	O	417-420
Arg95	O	421-426
in	O	427-429
exon	O	430-434
4	O	435-436
of	O	437-439
the	O	440-443
C9	O	444-446
gene	O	447-451
(	O	452-453
Arg95Stop	O	453-462
)	O	462-463
is	O	464-466
common	O	467-473
in	O	474-476
Japanese	O	477-485
C9	B	486-488
deficiency	I	489-499
.	O	499-500

To	O	501-503
determine	O	504-513
the	O	514-517
prevalence	O	518-528
of	O	529-531
heterozygous	O	532-544
carriers	O	545-553
of	O	554-556
the	O	557-560
Arg95Stop	O	561-570
mutation	O	571-579
in	O	580-582
a	O	583-584
Japanese	O	585-593
population	O	594-604
,	O	604-605
we	O	606-608
collected	O	609-618
DNA	O	619-622
samples	O	623-630
from	O	631-635
300	O	636-639
individuals	O	640-651
in	O	652-654
two	O	655-658
of	O	659-661
the	O	662-665
four	O	666-670
main	O	671-675
islands	O	676-683
of	O	684-686
Japan	O	687-692
.	O	692-693

Heterozygote	O	694-706
detection	O	707-716
was	O	717-720
performed	O	721-730
with	O	731-735
an	O	736-738
allele	O	739-745
-	O	745-746
specific	O	746-754
polymerase	O	755-765
chain	O	766-771
reaction	O	772-780
(	O	781-782
PCR	O	782-785
)	O	785-786
system	O	787-793
designed	O	794-802
to	O	803-805
detect	O	806-812
exclusively	O	813-824
only	O	825-829
one	O	830-833
of	O	834-836
the	O	837-840
normal	O	841-847
and	O	848-851
mutant	O	852-858
alleles	O	859-866
,	O	866-867
followed	O	868-876
by	O	877-879
confirmation	O	880-892
with	O	893-897
PCR	O	898-901
/	O	901-902
single	O	902-908
-	O	908-909
strand	O	909-915
conformation	O	916-928
polymorphism	O	929-941
(	O	942-943
SSCP	O	943-947
)	O	947-948
analysis	O	949-957
and	O	958-961
direct	O	962-968
sequencing	O	969-979
.	O	979-980

Twenty	O	981-987
individuals	O	988-999
were	O	1000-1004
heterozygous	O	1005-1017
for	O	1018-1021
the	O	1022-1025
Arg95Stop	O	1026-1035
mutation	O	1036-1044
.	O	1044-1045

None	O	1046-1050
was	O	1051-1054
homozygous	O	1055-1065
.	O	1065-1066

The	O	1067-1070
prevalence	O	1071-1081
of	O	1082-1084
carriers	O	1085-1093
of	O	1094-1096
the	O	1097-1100
Arg95Stop	O	1101-1110
mutation	O	1111-1119
was	O	1120-1123
6	O	1124-1125
.	O	1125-1126
7	O	1127-1128
%	O	1128-1129
(	O	1130-1131
20	O	1131-1133
/	O	1133-1134
300	O	1134-1137
)	O	1137-1138
.	O	1138-1139

An	O	1140-1142
estimated	O	1143-1152
frequency	O	1153-1162
(	O	1163-1164
0	O	1164-1165
.	O	1165-1166
12	O	1167-1169
%	O	1169-1170
)	O	1170-1171
of	O	1172-1174
complete	O	1175-1183
C9	B	1184-1186
deficiency	I	1187-1197
due	O	1198-1201
to	O	1202-1204
homozygous	O	1205-1215
Arg95Stop	O	1216-1225
mutation	O	1226-1234
was	O	1235-1238
consistent	O	1239-1249
with	O	1250-1254
frequencies	O	1255-1266
determined	O	1267-1277
by	O	1278-1280
serological	O	1281-1292
studies	O	1293-1300

Molecular	O	0-9
analysis	O	10-18
of	O	19-21
a	O	22-23
female	O	24-30
Lesch	B	31-36
-	I	36-37
Nyhan	I	37-42
patient	O	43-50
.	O	50-51

We	O	52-54
report	O	55-61
the	O	62-65
identification	O	66-80
of	O	81-83
a	O	84-85
female	O	86-92
patient	O	93-100
with	O	101-105
the	O	106-109
X	O	110-111
-	O	111-112
linked	O	112-118
recessive	O	119-128
Lesch	B	129-134
-	I	134-135
Nyhan	I	135-140
syndrome	I	141-149
(	O	150-151
hypoxanthine	B	151-163
phosphoribosyltransferase	I	164-189
[	I	190-191
HPRT	I	191-195
]	I	195-196
deficiency	I	197-207
)	O	207-208
.	O	208-209

Cytogenetic	O	210-221
and	O	222-225
carrier	O	226-233
studies	O	234-241
revealed	O	242-250
structurally	O	251-263
normal	O	264-270
chromosomes	O	271-282
for	O	283-286
this	O	287-291
patient	O	292-299
and	O	300-303
her	O	304-307
parents	O	308-315
and	O	316-319
demonstrated	O	320-332
that	O	333-337
this	O	338-342
mutation	O	343-351
arose	O	352-357
through	O	358-365
a	O	366-367
de	O	368-370
novo	O	371-375
gametic	O	376-383
event	O	384-389
.	O	389-390

Comparison	O	391-401
of	O	402-404
this	O	405-409
patients	O	410-418
DNA	O	419-422
with	O	423-427
the	O	428-431
DNA	O	432-435
of	O	436-438
her	O	439-442
parents	O	443-450
revealed	O	451-459
that	O	460-464
a	O	465-466
microdeletion	O	467-480
,	O	480-481
which	O	482-487
occurred	O	488-496
within	O	497-503
a	O	504-505
maternal	O	506-514
gamete	O	515-521
and	O	522-525
involved	O	526-534
the	O	535-538
entire	O	539-545
HPRT	O	546-550
gene	O	551-555
,	O	555-556
was	O	557-560
partially	O	561-570
responsible	O	571-582
for	O	583-586
the	O	587-590
disease	O	591-598
in	O	599-601
this	O	602-606
patient	O	607-614
.	O	614-615

Somatic	O	616-623
cell	O	624-628
hybrids	O	629-636
,	O	636-637
generated	O	638-647
to	O	648-650
separate	O	651-659
maternal	O	660-668
and	O	669-672
paternal	O	673-681
X	O	682-683
chromosomes	O	684-695
,	O	695-696
showed	O	697-703
that	O	704-708
expression	O	709-719
of	O	720-722
two	O	723-726
additional	O	727-737
X	O	738-739
-	O	739-740
linked	O	740-746
enzymes	O	747-754
,	O	754-755
phosphoglycerate	O	756-772
kinase	O	773-779
and	O	780-783
glucose	O	784-791
-	O	791-792
6	O	792-793
-	O	791-792
phosphate	O	794-803
dehydrogenase	O	804-817
,	O	817-818
were	O	819-823
expressed	O	824-833
only	O	834-838
in	O	839-841
cells	O	842-847
that	O	848-852
contained	O	853-862
the	O	863-866
maternal	O	867-875
X	O	876-877
chromosome	O	878-888
,	O	888-889
suggesting	O	890-900
the	O	901-904
presence	O	905-913
of	O	914-916
a	O	917-918
functionally	O	919-931
inactive	O	932-940
paternal	O	941-949
X	O	950-951
chromosome	O	952-962
.	O	962-963

Furthermore	O	964-975
,	O	975-976
comparison	O	977-987
of	O	988-990
methylation	O	991-1002
patterns	O	1003-1011
within	O	1012-1018
a	O	1019-1020
region	O	1021-1027
of	O	1028-1030
the	O	1031-1034
HPRT	O	1035-1039
gene	O	1040-1044
known	O	1045-1050
to	O	1051-1053
be	O	1054-1056
important	O	1057-1066
in	O	1067-1069
gene	O	1070-1074
regulation	O	1075-1085
revealed	O	1086-1094
differences	O	1095-1106
between	O	1107-1114
DNA	O	1115-1118
from	O	1119-1123
the	O	1124-1127
father	O	1128-1134
and	O	1135-1138
the	O	1139-1142
patient	O	1143-1150
,	O	1150-1151
in	O	1152-1154
keeping	O	1155-1162
with	O	1163-1167
an	O	1168-1170
active	O	1171-1177
HPRT	O	1178-1182
locus	O	1183-1188
in	O	1189-1191
the	O	1192-1195
father	O	1196-1202
and	O	1203-1206
an	O	1207-1209
inactive	O	1210-1218
HPRT	O	1219-1223
locus	O	1224-1229
in	O	1230-1232
the	O	1233-1236
patient	O	1237-1244
.	O	1244-1245

Together	O	1246-1254
these	O	1255-1260
data	O	1261-1265
indicate	O	1266-1274
that	O	1275-1279
nonrandom	O	1280-1289
inactivation	O	1290-1302
of	O	1303-1305
the	O	1306-1309
cytogenetically	O	1310-1325
normal	O	1326-1332
paternal	O	1333-1341
X	O	1342-1343
chromosome	O	1344-1354
and	O	1355-1358
a	O	1359-1360
microdeletion	O	1361-1374
of	O	1375-1377
the	O	1378-1381
HPRT	O	1382-1386
gene	O	1387-1391
on	O	1392-1394
an	O	1395-1397
active	O	1398-1404
maternal	O	1405-1413
X	O	1414-1415
chromosome	O	1416-1426
were	O	1427-1431
responsible	O	1432-1443
for	O	1444-1447
the	O	1448-1451
absence	O	1452-1459
of	O	1460-1462
HPRT	O	1463-1467
in	O	1468-1470
this	O	1471-1475
patient	O	1476-1483
.	O	1483-1484
.	O	1483-1484

Changes	O	0-7
at	O	8-10
P183	O	11-15
of	O	16-18
emerin	O	19-25
weaken	O	26-32
its	O	33-36
protein	O	37-44
-	O	44-45
protein	O	37-44
interactions	O	53-65
resulting	O	66-75
in	O	76-78
X	B	79-80
-	I	80-81
linked	I	81-87
Emery	I	88-93
-	I	93-94
Dreifuss	I	94-102
muscular	I	103-111
dystrophy	I	112-121
.	O	121-122

Emery	B	123-128
-	I	128-129
Dreifuss	I	129-137
muscular	I	138-146
dystrophy	I	147-156
(	O	157-158
EDMD	B	158-162
)	O	162-163
is	O	164-166
an	O	167-169
X	B	170-171
-	I	171-172
linked	I	172-178
recessive	I	179-188
muscular	I	189-197
dystrophy	I	198-207
characterized	O	208-221
by	O	222-224
early	O	225-230
contractures	B	231-243
of	I	244-246
the	I	247-250
elbows	I	251-257
,	I	257-258
Achilles	I	259-267
tendons	I	268-275
and	I	276-279
spine	I	280-285
,	O	285-286
slowly	O	287-293
progressive	O	294-305
muscle	B	306-312
wasting	I	313-320
and	O	321-324
weakness	B	325-333
,	O	333-334
and	O	335-338
cardiomyopathy	B	339-353
associated	O	354-364
with	O	365-369
cardiac	B	370-377
conduction	I	378-388
defects	I	389-396
.	O	396-397

The	O	398-401
emerin	O	402-408
gene	O	409-413
has	O	414-417
been	O	418-422
mapped	O	423-429
to	O	430-432
Xq28	O	433-437
and	O	438-441
encodes	O	442-449
a	O	450-451
34	O	452-454
-	O	454-455
kDa	O	455-458
serine	O	459-465
-	O	465-466
rich	O	466-470
protein	O	471-478
,	O	478-479
emerin	O	480-486
,	O	486-487
which	O	488-493
has	O	494-497
been	O	498-502
localized	O	503-512
to	O	513-515
the	O	516-519
nuclear	O	520-527
envelope	O	528-536
in	O	537-539
a	O	540-541
wide	O	542-546
variety	O	547-554
of	O	555-557
tissues	O	558-565
,	O	565-566
including	O	567-576
skeletal	O	577-585
and	O	586-589
cardiac	O	590-597
muscle	O	598-604
.	O	604-605

Mutations	O	606-615
spanning	O	616-624
the	O	625-628
emerin	O	629-635
gene	O	636-640
have	O	641-645
been	O	646-650
identified	O	651-661
in	O	662-664
patients	O	665-673
with	O	674-678
EDMD	B	679-683
.	O	683-684

We	O	685-687
present	O	688-695
here	O	696-700
the	O	701-704
effect	O	705-711
,	O	711-712
on	O	713-715
emerin	O	716-722
protein	O	723-730
expression	O	731-741
,	O	741-742
of	O	743-745
two	O	746-749
missense	O	750-758
mutations	O	759-768
identified	O	769-779
in	O	780-782
unrelated	O	783-792
EDMD	B	793-797
patients	O	798-806
.	O	806-807

These	O	808-813
alterations	O	814-825
predict	O	826-833
the	O	834-837
replacement	O	838-849
of	O	850-852
a	O	853-854
proline	O	855-862
residue	O	863-870
at	O	871-873
position	O	874-882
183	O	883-886
with	O	887-891
either	O	892-898
a	O	899-900
histidine	O	901-910
or	O	911-913
a	O	914-915
threonine	O	916-925
.	O	925-926

Biochemical	O	927-938
analysis	O	939-947
has	O	948-951
demonstrated	O	952-964
that	O	965-969
the	O	970-973
mobility	O	974-982
and	O	983-986
expression	O	987-997
levels	O	998-1004
of	O	1005-1007
the	O	1008-1011
mutant	O	1012-1018
forms	O	1019-1024
of	O	1025-1027
emerin	O	1028-1034
are	O	1035-1038
indistinguishable	O	1039-1056
from	O	1057-1061
that	O	1062-1066
of	O	1067-1069
wild	O	1070-1074
-	O	1074-1075
type	O	1075-1079
emerin	O	1080-1086
,	O	1086-1087
but	O	1088-1091
that	O	1092-1096
they	O	1097-1101
have	O	1102-1106
weakened	O	1107-1115
interactions	O	1116-1128
with	O	1129-1133
nuclear	O	1134-1141
lamina	O	1142-1148
components	O	1149-1159
.	O	1159-1160

In	O	1161-1163
comparison	O	1164-1174
with	O	1175-1179
the	O	1180-1183
usual	O	1184-1189
EDMD	B	1190-1194
phenotype	O	1195-1204
,	O	1204-1205
patients	O	1206-1214
with	O	1215-1219
P183	O	1220-1224
missense	O	1225-1233
mutations	O	1234-1243
have	O	1244-1248
a	O	1249-1250
later	O	1251-1256
age	O	1257-1260
at	O	1261-1263
onset	O	1264-1269
of	O	1270-1272
first	O	1273-1278
symptoms	O	1279-1287
,	O	1287-1288
elbow	B	1289-1294
contractures	I	1295-1307
,	O	1307-1308
ankle	B	1309-1314
contractures	I	1315-1327
,	O	1327-1328
upper	B	1329-1334
limb	I	1335-1339
weakness	I	1340-1348
and	O	1349-1352
lower	B	1353-1358
limb	I	1359-1363
weakness	I	1364-1372
,	O	1372-1373
but	O	1374-1377
there	O	1378-1383
is	O	1384-1386
no	O	1387-1389
difference	O	1390-1400
for	O	1401-1404
the	O	1405-1408
age	O	1409-1412
at	O	1413-1415
onset	O	1416-1421
of	O	1422-1424
cardiac	B	1425-1432
involvement	I	1433-1444
.	O	1444-1445

This	O	1446-1450
is	O	1451-1453
the	O	1454-1457
first	O	1458-1463
report	O	1464-1470
of	O	1471-1473
protein	O	1474-1481
studies	O	1482-1489
on	O	1490-1492
patients	O	1493-1501
with	O	1502-1506
missense	O	1507-1515
mutations	O	1516-1525
resulting	O	1526-1535
in	O	1536-1538
the	O	1539-1542
clinical	O	1543-1551
features	O	1552-1560
of	O	1561-1563
EDMD	B	1564-1568
.	O	1568-1569

These	O	1570-1575
studies	O	1576-1583
demonstrate	O	1584-1595
the	O	1596-1599
importance	O	1600-1610
of	O	1611-1613
proline	O	1614-1621
183	O	1622-1625
for	O	1626-1629
the	O	1630-1633
proper	O	1634-1640
structure	O	1641-1650
/	O	1650-1651
function	O	1651-1659
of	O	1660-1662
emerin	O	1663-1669
.	O	1669-1670
.	O	1669-1670

Decreased	O	0-9
expression	O	10-20
of	O	21-23
BRCA1	O	24-29
accelerates	O	30-41
growth	O	42-48
and	O	49-52
is	O	53-55
often	O	56-61
present	O	62-69
during	O	70-76
sporadic	B	77-85
breast	I	86-92
cancer	I	93-99
progression	O	100-111
.	O	111-112

We	O	113-115
have	O	116-120
characterized	O	121-134
expression	O	135-145
of	O	146-148
the	O	149-152
familial	B	153-161
breast	I	162-168
and	I	169-172
ovarian	I	173-180
cancer	I	181-187
gene	O	188-192
,	O	192-193
BRCA1	O	194-199
,	O	199-200
in	O	201-203
cases	O	204-209
of	O	210-212
non	B	213-216
-	I	216-217
hereditary	I	217-227
(	I	228-229
sporadic	I	229-237
)	I	237-238
breast	I	239-245
cancer	I	246-252
and	O	253-256
analyzed	O	257-265
the	O	266-269
effect	O	270-276
of	O	277-279
antisense	O	280-289
inhibition	O	290-300
of	O	301-303
BRCA1	O	304-309
on	O	310-312
the	O	313-316
proliferative	O	317-330
rate	O	331-335
of	O	336-338
mammary	O	339-346
epithelial	O	347-357
cells	O	358-363
.	O	363-364

BRCA1	O	365-370
mRNA	O	371-375
levels	O	376-382
are	O	383-386
markedly	O	387-395
decreased	O	396-405
during	O	406-412
the	O	413-416
transition	O	417-427
from	O	428-432
carcinoma	B	433-442
in	I	443-445
situ	I	446-450
to	O	451-453
invasive	B	454-462
cancer	I	463-469
.	O	469-470

Experimental	O	471-483
inhibition	O	484-494
of	O	495-497
BRCA1	O	498-503
expression	O	504-514
with	O	515-519
antisense	O	520-529
oligonucleotides	O	530-546
produced	O	547-555
accelerated	O	556-567
growth	O	568-574
of	O	575-577
normal	O	578-584
and	O	585-588
malignant	O	589-598
mammary	O	599-606
cells	O	607-612
,	O	612-613
but	O	614-617
had	O	618-621
no	O	622-624
effect	O	625-631
on	O	632-634
non	O	635-638
-	O	638-639
mammary	O	639-646
epithelial	O	647-657
cells	O	658-663
.	O	663-664

These	O	665-670
studies	O	671-678
suggest	O	679-686
that	O	687-691
BRCA1	O	692-697
may	O	698-701
normally	O	702-710
serve	O	711-716
as	O	717-719
a	O	720-721
negative	O	722-730
regulator	O	731-740
of	O	741-743
mammary	O	744-751
epithelial	O	752-762
cell	O	763-767
growth	O	768-774
whose	O	775-780
function	O	781-789
is	O	790-792
compromised	O	793-804
in	O	805-807
breast	B	808-814
cancer	I	815-821
either	O	822-828
by	O	829-831
direct	O	832-838
mutation	O	839-847
or	O	848-850
alterations	O	851-862
in	O	863-865
gene	O	866-870
expression	O	871-881
.	O	881-882
.	O	881-882

Additional	O	0-10
copies	O	11-17
of	O	18-20
the	O	21-24
proteolipid	O	25-36
protein	O	37-44
gene	O	45-49
causing	O	50-57
Pelizaeus	B	58-67
-	I	67-68
Merzbacher	I	68-78
disease	I	79-86
arise	O	87-92
by	O	93-95
separate	O	96-104
integration	O	105-116
into	O	117-121
the	O	122-125
X	O	126-127
chromosome	O	128-138
.	O	138-139

The	O	140-143
proteolipid	O	144-155
protein	O	156-163
gene	O	164-168
(	O	169-170
PLP	O	170-173
)	O	173-174
is	O	175-177
normally	O	178-186
present	O	187-194
at	O	195-197
chromosome	O	198-208
Xq22	O	209-213
.	O	213-214

Mutations	O	215-224
and	O	225-228
duplications	O	229-241
of	O	242-244
this	O	245-249
gene	O	250-254
are	O	255-258
associated	O	259-269
with	O	270-274
Pelizaeus	B	275-284
-	I	284-285
Merzbacher	I	285-295
disease	I	296-303
(	O	304-305
PMD	B	305-308
)	O	308-309
.	O	309-310

Here	O	311-315
we	O	316-318
describe	O	319-327
two	O	328-331
new	O	332-335
families	O	336-344
in	O	345-347
which	O	348-353
males	O	354-359
affected	O	360-368
with	O	369-373
PMD	B	374-377
were	O	378-382
found	O	383-388
to	O	389-391
have	O	392-396
a	O	397-398
copy	O	399-403
of	O	404-406
PLP	O	407-410
on	O	411-413
the	O	414-417
short	O	418-423
arm	O	424-427
of	O	428-430
the	O	431-434
X	O	435-436
chromosome	O	437-447
,	O	447-448
in	O	449-451
addition	O	452-460
to	O	461-463
a	O	464-465
normal	O	466-472
copy	O	473-477
on	O	478-480
Xq22	O	481-485
.	O	485-486

In	O	487-489
the	O	490-493
first	O	494-499
family	O	500-506
,	O	506-507
the	O	508-511
extra	O	512-517
copy	O	518-522
was	O	523-526
first	O	527-532
detected	O	533-541
by	O	542-544
the	O	545-548
presence	O	549-557
of	O	558-560
heterozygosity	O	561-575
of	O	576-578
the	O	579-582
AhaII	O	583-588
dimorphism	O	589-599
within	O	600-606
the	O	607-610
PLP	O	611-614
gene	O	615-619
.	O	619-620

The	O	621-624
results	O	625-632
of	O	633-635
FISH	O	636-640
analysis	O	641-649
showed	O	650-656
an	O	657-659
additional	O	660-670
copy	O	671-675
of	O	676-678
PLP	O	679-682
in	O	683-685
Xp22	O	686-690
.	O	690-691
1	O	692-693
,	O	693-694
although	O	695-703
no	O	704-706
chromosomal	O	707-718
rearrangements	O	719-733
could	O	734-739
be	O	740-742
detected	O	743-751
by	O	752-754
standard	O	755-763
karyotype	O	764-773
analysis	O	774-782
.	O	782-783

Another	O	784-791
three	O	792-797
affected	O	798-806
males	O	807-812
from	O	813-817
the	O	818-821
family	O	822-828
had	O	829-832
similar	O	833-840
findings	O	841-849
.	O	849-850

In	O	851-853
a	O	854-855
second	O	856-862
unrelated	O	863-872
family	O	873-879
with	O	880-884
signs	O	885-890
of	O	891-893
PMD	B	894-897
,	O	897-898
cytogenetic	O	899-910
analysis	O	911-919
showed	O	920-926
a	O	927-928
pericentric	O	929-940
inversion	O	941-950
of	O	951-953
the	O	954-957
X	O	958-959
chromosome	O	960-970
.	O	970-971

In	O	972-974
the	O	975-978
inv	O	979-982
(	O	983-984
X	O	984-985
)	O	985-986
carried	O	987-994
by	O	995-997
several	O	998-1005
affected	O	1006-1014
family	O	1015-1021
members	O	1022-1029
,	O	1029-1030
FISH	O	1031-1035
showed	O	1036-1042
PLP	O	1043-1046
signals	O	1047-1054
at	O	1055-1057
Xp11	O	1058-1062
.	O	1062-1063
4	O	1064-1065
and	O	1066-1069
Xq22	O	1070-1074
.	O	1074-1075

A	O	1076-1077
third	O	1078-1083
family	O	1084-1090
has	O	1091-1094
previously	O	1095-1105
been	O	1106-1110
reported	O	1111-1119
,	O	1119-1120
in	O	1121-1123
which	O	1124-1129
affected	O	1130-1138
members	O	1139-1146
had	O	1147-1150
an	O	1151-1153
extra	O	1154-1159
copy	O	1160-1164
of	O	1165-1167
the	O	1168-1171
PLP	O	1172-1175
gene	O	1176-1180
detected	O	1181-1189
at	O	1190-1192
Xq26	O	1193-1197
in	O	1198-1200
a	O	1201-1202
chromosome	O	1203-1213
with	O	1214-1218
an	O	1219-1221
otherwise	O	1222-1231
normal	O	1232-1238
banding	O	1239-1246
pattern	O	1247-1254
.	O	1254-1255

The	O	1256-1259
identification	O	1260-1274
of	O	1275-1277
three	O	1278-1283
separate	O	1284-1292
families	O	1293-1301
in	O	1302-1304
which	O	1305-1310
PLP	O	1311-1314
is	O	1315-1317
duplicated	O	1318-1328
at	O	1329-1331
a	O	1332-1333
noncontiguous	O	1334-1347
site	O	1348-1352
suggests	O	1353-1361
that	O	1362-1366
such	O	1367-1371
duplications	O	1372-1384
could	O	1385-1390
be	O	1391-1393
a	O	1394-1395
relatively	O	1396-1406
common	O	1407-1413
but	O	1414-1417
previously	O	1418-1428
undetected	O	1429-1439
cause	O	1440-1445
of	O	1446-1448
genetic	B	1449-1456
disorders	I	1457-1466
.	O	1466-1467

Linkage	O	0-7
relationships	O	8-21
of	O	22-24
the	O	25-28
apolipoprotein	O	29-43
C1	O	44-46
gene	O	47-51
and	O	52-55
a	O	56-57
cytochrome	O	58-68
P450	O	69-73
gene	O	74-78
(	O	79-80
CYP2A	O	80-85
)	O	85-86
to	O	87-89
myotonic	B	90-98
dystrophy	I	99-108
.	O	108-109

We	O	110-112
have	O	113-117
studied	O	118-125
the	O	126-129
genetic	O	130-137
linkage	O	138-145
of	O	146-148
two	O	149-152
markers	O	153-160
,	O	160-161
the	O	162-165
apolipoprotein	O	166-180
C1	O	181-183
(	O	184-185
APOC1	O	185-190
)	O	190-191
gene	O	192-196
and	O	197-200
a	O	201-202
cytochrome	O	203-213
P450	O	214-218
(	O	219-220
CYP2A	O	220-225
)	O	225-226
gene	O	227-231
,	O	231-232
in	O	233-235
relation	O	236-244
to	O	245-247
the	O	248-251
gene	O	252-256
for	O	257-260
myotonic	B	261-269
dystrophy	I	270-279
(	O	280-281
DM	B	281-283
)	O	283-284
.	O	284-285

A	O	286-287
peak	O	288-292
lod	O	293-296
score	O	297-302
of	O	303-305
9	O	306-307
.	O	307-308
29	O	309-311
at	O	312-314
2	O	315-316
cM	O	317-319
was	O	320-323
observed	O	324-332
for	O	333-336
APOC1	O	337-342
-	O	342-343
DM	O	343-345
,	O	345-346
with	O	347-351
a	O	352-353
lod	O	354-357
score	O	358-363
of	O	364-366
8	O	367-368
.	O	368-369
55	O	370-372
at	O	373-375
4	O	376-377
cM	O	378-380
for	O	381-384
CYP2A	O	385-390
-	O	390-391
DM	O	391-393
.	O	393-394

These	O	395-400
two	O	401-404
markers	O	405-412
also	O	413-417
show	O	418-422
close	O	423-428
linkage	O	429-436
to	O	437-439
each	O	440-444
other	O	445-450
(	O	451-452
theta	O	452-457
max	O	458-461
=	O	462-463
0	O	464-465
.	O	465-466
05	O	467-469
,	O	469-470
Zmax	O	471-475
=	O	476-477
9	O	478-479
.	O	479-480
09	O	481-483
)	O	483-484
.	O	484-485

From	O	486-490
examination	O	491-502
of	O	503-505
the	O	506-509
genotypes	O	510-519
of	O	520-522
the	O	523-526
recombinant	O	527-538
individuals	O	539-550
,	O	550-551
CYP2A	O	552-557
appears	O	558-565
to	O	566-568
map	O	569-572
proximal	O	573-581
to	O	582-584
DM	O	585-587
because	O	588-595
in	O	596-598
one	O	599-602
recombinant	O	603-614
individual	O	615-625
CYP2A	O	626-631
,	O	631-632
APOC2	O	633-638
and	O	639-642
CKMM	O	643-647
had	O	648-651
all	O	652-655
recombined	O	656-666
with	O	667-671
DM	O	672-674
.	O	674-675

Evidence	O	676-684
from	O	685-689
another	O	690-697
CYP2A	O	698-703
-	O	703-704
DM	O	704-706
recombinant	O	707-718
individual	O	719-729
places	O	730-736
CYP2A	O	737-742
proximal	O	743-751
to	O	752-754
APOC2	O	755-760
and	O	761-764
CKMM	O	765-769
.	O	769-770

Localisation	O	771-783
of	O	784-786
CYP2A	O	787-792
on	O	793-795
a	O	796-797
panel	O	798-803
of	O	804-806
somatic	O	807-814
cell	O	815-819
hybrids	O	820-827
also	O	828-832
suggests	O	833-841
that	O	842-846
it	O	847-849
is	O	850-852
proximal	O	853-861
to	O	862-864
DM	O	865-867
and	O	868-871
APOC2	O	872-877
/	O	877-878
C1	O	878-880
/	O	877-878
E	O	881-882
gene	O	883-887
cluster	O	888-895
.	O	895-896

beta	O	0-4
-	O	4-5
galactosidase	O	5-18
gene	O	19-23
mutations	O	24-33
affecting	O	34-43
the	O	44-47
lysosomal	O	48-57
enzyme	O	58-64
and	O	65-68
the	O	69-72
elastin	O	73-80
-	O	80-81
binding	O	81-88
protein	O	89-96
in	O	97-99
GM1	B	100-103
-	I	103-104
gangliosidosis	I	104-118
patients	O	119-127
with	O	128-132
cardiac	B	133-140
involvement	I	141-152
.	O	152-153

GM1	B	154-157
-	I	157-158
gangliosidosis	I	158-172
is	O	173-175
a	O	176-177
lysosomal	B	178-187
storage	I	188-195
disorder	I	196-204
caused	O	205-211
by	O	212-214
deficiency	B	215-225
of	I	226-228
acid	I	229-233
beta	I	234-238
-	I	238-239
galactosidase	I	239-252
(	O	253-254
GLB1	O	254-258
)	O	258-259
.	O	259-260

We	O	261-263
report	O	264-270
five	O	271-275
new	O	276-279
beta	O	280-284
-	O	284-285
galactosidase	O	285-298
gene	O	299-303
mutations	O	304-313
in	O	314-316
nine	O	317-321
Italian	O	322-329
patients	O	330-338
and	O	339-342
one	O	343-346
fetus	O	347-352
,	O	352-353
segregating	O	354-365
in	O	366-368
seven	O	369-374
unrelated	O	375-384
families	O	385-393
.	O	393-394

Six	O	395-398
of	O	399-401
the	O	402-405
eight	O	406-411
patients	O	412-420
with	O	421-425
the	O	426-429
infantile	O	430-439
,	O	439-440
severe	O	441-447
form	O	448-452
of	O	453-455
the	O	456-459
disease	O	460-467
presented	O	468-477
cardiac	B	478-485
involvement	I	486-497
,	O	497-498
a	O	499-500
feature	O	501-508
rarely	O	509-515
associated	O	516-526
with	O	527-531
GM1	B	532-535
-	I	535-536
gangliosidosis	I	536-550
.	O	550-551

Molecular	O	552-561
analysis	O	562-570
of	O	571-573
the	O	574-577
patients	O	578-586
RNA	O	587-590
and	O	591-594
DNA	O	595-598
identified	O	599-609
two	O	610-613
new	O	614-617
RNA	O	618-621
splicing	O	622-630
defects	O	631-638
,	O	638-639
three	O	640-645
new	O	646-649
and	O	650-653
three	O	654-659
previously	O	660-670
described	O	671-680
amino	O	681-686
acid	O	687-691
substitutions	O	692-705
.	O	705-706

Interestingly	O	707-720
,	O	720-721
all	O	722-725
patients	O	726-734
with	O	735-739
cardiac	B	740-747
involvement	I	748-759
were	O	760-764
homozygous	O	765-775
for	O	776-779
one	O	780-783
of	O	784-786
these	O	787-792
mutations	O	793-802
R59H	O	804-808
,	O	808-809
Y591C	O	810-815
,	O	815-816
Y591N	O	817-822
,	O	822-823
or	O	824-826
IVS14	O	827-832
-	O	832-833
2A	O	833-835
>	O	836-837
G	O	838-839
.	O	839-840

In	O	841-843
contrast	O	844-852
,	O	852-853
all	O	854-857
other	O	858-863
patients	O	864-872
were	O	873-877
compound	O	878-886
heterozygous	O	887-899
for	O	900-903
one	O	904-907
of	O	908-910
the	O	911-914
following	O	915-924
mutations	O	925-934
R201H	O	936-941
,	O	941-942
R482H	O	943-948
,	O	948-949
G579D	O	950-955
,	O	955-956
IVS8	O	957-961
+	O	962-963
2T	O	964-966
>	O	967-968
C	O	969-970
.	O	970-971

Although	O	972-980
we	O	981-983
could	O	984-989
not	O	990-993
directly	O	994-1002
correlate	O	1003-1012
the	O	1013-1016
presence	O	1017-1025
of	O	1026-1028
cardiac	B	1029-1036
abnormalities	I	1037-1050
with	O	1051-1055
specific	O	1056-1064
genetic	B	1065-1072
lesions	I	1073-1080
,	O	1080-1081
the	O	1082-1085
mutations	O	1086-1095
identified	O	1096-1106
in	O	1107-1109
patients	O	1110-1118
with	O	1119-1123
cardiomyopathy	B	1124-1138
fell	O	1139-1143
in	O	1144-1146
the	O	1147-1150
GLB1	O	1151-1155
cDNA	O	1156-1160
region	O	1161-1167
common	O	1168-1174
to	O	1175-1177
the	O	1178-1181
lysosomal	O	1182-1191
enzyme	O	1192-1198
and	O	1199-1202
the	O	1203-1206
Hbeta	O	1207-1212
-	O	1212-1213
Gal	O	1213-1216
-	O	1212-1213
related	O	1217-1224
protein	O	1225-1232
,	O	1232-1233
also	O	1234-1238
known	O	1239-1244
as	O	1245-1247
the	O	1248-1251
elastin	O	1252-1259
binding	O	1260-1267
protein	O	1268-1275
(	O	1276-1277
EBP	O	1277-1280
)	O	1280-1281
.	O	1281-1282

Consequently	O	1283-1295
,	O	1295-1296
both	O	1297-1301
molecules	O	1302-1311
are	O	1312-1315
affected	O	1316-1324
by	O	1325-1327
the	O	1328-1331
mutations	O	1332-1341
,	O	1341-1342
and	O	1343-1346
they	O	1347-1351
may	O	1352-1355
contribute	O	1356-1366
differently	O	1367-1378
to	O	1379-1381
the	O	1382-1385
occurrence	O	1386-1396
of	O	1397-1399
specific	O	1400-1408
clinical	O	1409-1417
manifestations	O	1418-1432
.	O	1432-1433
.	O	1432-1433

Exclusion	O	0-9
of	O	10-12
linkage	O	13-20
between	O	21-28
familial	B	29-37
Mediterranean	I	38-51
fever	I	52-57
and	O	58-61
the	O	62-65
human	O	66-71
serum	O	72-77
amyloid	O	78-85
A	O	86-87
(	O	88-89
SAA	O	89-92
)	O	92-93
gene	O	94-98
cluster	O	99-106
.	O	106-107

We	O	108-110
studied	O	111-118
the	O	119-122
relationship	O	123-135
between	O	136-143
the	O	144-147
autosomal	O	148-157
recessive	O	158-167
trait	O	168-173
familial	B	174-182
Mediterranean	I	183-196
fever	I	197-202
(	O	203-204
FMF	B	204-207
)	O	207-208
and	O	209-212
the	O	213-216
serum	O	217-222
amyloid	O	223-230
A	O	231-232
(	O	233-234
SAA	O	234-237
)	O	237-238
genes	O	239-244
by	O	245-247
comparing	O	248-257
alleles	O	258-265
of	O	266-268
a	O	269-270
highly	O	271-277
polymorphic	O	278-289
dinucleotide	O	290-302
repeat	O	303-309
and	O	310-313
a	O	314-315
conventional	O	316-328
restriction	O	329-340
fragment	O	341-349
length	O	350-356
polymorphism	O	357-369
(	O	370-371
RFLP	O	371-375
)	O	375-376
in	O	377-379
the	O	380-383
SAA	O	384-387
gene	O	388-392
cluster	O	393-400
in	O	401-403
Israeli	O	404-411
FMF	B	412-415
kindreds	O	416-424
.	O	424-425

By	O	426-428
haplotype	O	429-438
analysis	O	439-447
,	O	447-448
our	O	449-452
data	O	453-457
indicate	O	458-466
a	O	467-468
minimum	O	469-476
crossover	O	477-486
frequency	O	487-496
of	O	497-499
22	O	500-502
%	O	502-503
between	O	504-511
the	O	512-515
SAA	O	516-519
gene	O	520-524
marker	O	525-531
and	O	532-535
FMF	B	536-539
.	O	539-540

By	O	541-543
conventional	O	544-556
linkage	O	557-564
analysis	O	565-573
this	O	574-578
eliminates	O	579-589
a	O	590-591
minimum	O	592-599
of	O	600-602
10	O	603-605
.	O	605-606
4	O	607-608
cM	O	609-611
including	O	612-621
and	O	622-625
surrounding	O	626-637
the	O	638-641
SAA	O	642-645
gene	O	646-650
cluster	O	651-658
as	O	659-661
the	O	662-665
site	O	666-670
of	O	671-673
the	O	674-677
FMF	B	678-681
mutation	O	682-690
although	O	691-699
SAA	O	700-703
proteins	O	704-712
are	O	713-716
prominent	O	717-726
physiologic	O	727-738
markers	O	739-746
of	O	747-749
the	O	750-753
acute	O	754-759
attacks	O	760-767
.	O	767-768

Mice	O	0-4
deficient	B	5-14
in	I	15-17
Six5	I	18-22
develop	O	23-30
cataracts	B	31-40
:	O	40-41
implications	O	42-54
for	O	55-58
myotonic	B	59-67
dystrophy	I	68-77
.	O	77-78

Expansion	O	79-88
of	O	89-91
a	O	92-93
CTG	O	94-97
trinucleotide	O	98-111
repeat	O	112-118
in	O	119-121
the	O	122-125
3	O	126-127
UTR	O	128-131
of	O	132-134
the	O	135-138
gene	O	139-143
DMPK	O	144-148
at	O	149-151
the	O	152-155
DM1	O	156-159
locus	O	160-165
on	O	166-168
chromosome	O	169-179
19	O	180-182
causes	O	183-189
myotonic	B	190-198
dystrophy	I	199-208
,	O	208-209
a	O	210-211
dominantly	B	212-222
inherited	I	223-232
disease	I	233-240
characterized	O	241-254
by	O	255-257
skeletal	O	258-266
muscle	B	267-273
dystrophy	I	274-283
and	O	284-287
myotonia	B	288-296
,	O	296-297
cataracts	B	298-307
and	O	308-311
cardiac	B	312-319
conduction	I	320-330
defects	I	331-338
.	O	338-339

Targeted	O	340-348
deletion	O	349-357
of	O	358-360
Dm15	O	361-365
,	O	365-366
the	O	367-370
mouse	O	371-376
orthologue	O	377-387
of	O	388-390
human	O	391-396
DMPK	O	397-401
,	O	401-402
produced	O	403-411
mice	O	412-416
with	O	417-421
a	O	422-423
mild	O	424-428
myopathy	B	429-437
and	O	438-441
cardiac	B	442-449
conduction	I	450-460
abnormalities	I	461-474
,	O	474-475
but	O	476-479
without	O	480-487
other	O	488-493
features	O	494-502
of	O	503-505
myotonic	B	506-514
dystrophy	I	515-524
,	O	524-525
such	O	526-530
as	O	531-533
myotonia	B	534-542
and	O	543-546
cataracts	B	547-556
.	O	556-557

We	O	558-560
,	O	560-561
and	O	562-565
others	O	566-572
,	O	572-573
have	O	574-578
demonstrated	O	579-591
that	O	592-596
repeat	O	597-603
expansion	O	604-613
decreases	O	614-623
expression	O	624-634
of	O	635-637
the	O	638-641
adjacent	O	642-650
gene	O	651-655
SIX5	O	656-660
(	O	661-662
refs	O	662-666
7	O	667-668
,	O	668-669
8	O	670-671
)	O	671-672
,	O	672-673
which	O	674-679
encodes	O	680-687
a	O	688-689
homeodomain	O	690-701
transcription	O	702-715
factor	O	716-722
.	O	722-723

To	O	724-726
determine	O	727-736
whether	O	737-744
SIX5	B	745-749
deficiency	I	750-760
contributes	O	761-772
to	O	773-775
the	O	776-779
myotonic	B	780-788
dystrophy	I	789-798
phenotype	O	799-808
,	O	808-809
we	O	810-812
disrupted	O	813-822
mouse	O	823-828
Six5	O	829-833
by	O	834-836
replacing	O	837-846
the	O	847-850
first	O	851-856
exon	O	857-861
with	O	862-866
a	O	867-868
beta	O	869-873
-	O	873-874
galactosidase	O	874-887
reporter	O	888-896
.	O	896-897

Six5	O	898-902
-	O	902-903
mutant	O	903-909
mice	O	910-914
showed	O	915-921
reporter	O	922-930
expression	O	931-941
in	O	942-944
multiple	O	945-953
tissues	O	954-961
,	O	961-962
including	O	963-972
the	O	973-976
developing	O	977-987
lens	O	988-992
.	O	992-993

Homozygous	O	994-1004
mutant	O	1005-1011
mice	O	1012-1016
had	O	1017-1020
no	O	1021-1023
apparent	O	1024-1032
abnormalities	B	1033-1046
of	I	1047-1049
skeletal	I	1050-1058
muscle	I	1059-1065
function	I	1066-1074
,	O	1074-1075
but	O	1076-1079
developed	O	1080-1089
lenticular	B	1090-1100
opacities	I	1101-1110
at	O	1111-1113
a	O	1114-1115
higher	O	1116-1122
rate	O	1123-1127
than	O	1128-1132
controls	O	1133-1141
.	O	1141-1142

Our	O	1143-1146
results	O	1147-1154
suggest	O	1155-1162
that	O	1163-1167
SIX5	B	1168-1172
deficiency	I	1173-1183
contributes	O	1184-1195
to	O	1196-1198
the	O	1199-1202
cataract	B	1203-1211
phenotype	O	1212-1221
in	O	1222-1224
myotonic	B	1225-1233
dystrophy	I	1234-1243
,	O	1243-1244
and	O	1245-1248
that	O	1249-1253
myotonic	B	1254-1262
dystrophy	I	1263-1272
represents	O	1273-1283
a	O	1284-1285
multigenic	B	1286-1296
disorder	I	1297-1305
.	O	1305-1306
.	O	1305-1306

Screening	O	0-9
for	O	10-13
germ	O	14-18
-	O	18-19
line	O	19-23
mutations	O	24-33
in	O	34-36
familial	B	37-45
adenomatous	I	46-57
polyposis	I	58-67
patients	O	68-76
:	O	76-77
61	O	78-80
new	O	81-84
patients	O	85-93
and	O	94-97
a	O	98-99
summary	O	100-107
of	O	108-110
150	O	111-114
unrelated	O	115-124
patients	O	125-133
.	O	133-134

We	O	135-137
report	O	138-144
here	O	145-149
the	O	150-153
result	O	154-160
of	O	161-163
a	O	164-165
screening	O	166-175
for	O	176-179
germ	O	180-184
-	O	184-185
line	O	185-189
mutations	O	190-199
in	O	200-202
the	O	203-206
adenomatous	B	207-218
polyposis	I	219-228
coli	I	229-233
(	O	234-235
APC	B	235-238
)	O	238-239
gene	O	240-244
in	O	245-247
61	O	248-250
new	O	251-254
familial	B	255-263
adenomatous	I	264-275
polyposis	I	276-285
(	O	286-287
FAP	B	287-290
)	O	290-291
patients	O	292-300
as	O	301-303
well	O	304-308
as	O	309-311
a	O	312-313
summary	O	314-321
of	O	322-324
the	O	325-328
results	O	329-336
of	O	337-339
150	O	340-343
patients	O	344-352
.	O	352-353

Examination	O	354-365
of	O	366-368
the	O	369-372
entire	O	373-379
coding	O	380-386
region	O	387-393
of	O	394-396
the	O	397-400
APC	B	401-404
gene	O	405-409
,	O	409-410
based	O	411-416
on	O	417-419
a	O	420-421
ribonuclease	O	422-434
protection	O	435-445
assay	O	446-451
coupled	O	452-459
with	O	460-464
the	O	465-468
polymerase	O	469-479
chain	O	480-485
reaction	O	486-494
(	O	495-496
PCR	O	496-499
)	O	499-500
,	O	500-501
disclosed	O	502-511
mutations	O	512-521
that	O	522-526
were	O	527-531
considered	O	532-542
to	O	543-545
cause	O	546-551
significant	O	552-563
defects	O	564-571
in	O	572-574
the	O	575-578
APC	B	579-582
product	O	583-590
in	O	591-593
97	O	594-596
of	O	597-599
150	O	600-603
unrelated	O	604-613
FAP	B	614-617
patients	O	618-626
.	O	626-627

Our	O	628-631
findings	O	632-640
revealed	O	641-649
the	O	650-653
following	O	654-663
characteristics	O	664-679
of	O	680-682
the	O	683-686
germ	O	687-691
-	O	691-692
line	O	692-696
mutations	O	697-706
of	O	707-709
APC	O	710-713
1	O	715-716
)	O	716-717
the	O	718-721
great	O	722-727
majority	O	728-736
of	O	737-739
the	O	740-743
mutations	O	744-753
were	O	754-758
found	O	759-764
to	O	765-767
truncate	O	768-776
the	O	777-780
APC	B	781-784
product	O	785-792
;	O	792-793
2	O	794-795
)	O	795-796
almost	O	797-803
all	O	804-807
of	O	808-810
the	O	811-814
mutations	O	815-824
were	O	825-829
located	O	830-837
within	O	838-844
the	O	845-848
first	O	849-854
half	O	855-859
of	O	860-862
the	O	863-866
coding	O	867-873
region	O	874-880
;	O	880-881
3	O	882-883
)	O	883-884
no	O	885-887
correlation	O	888-899
was	O	900-903
observed	O	904-912
between	O	913-920
the	O	921-924
locations	O	925-934
of	O	935-937
germ	O	938-942
-	O	942-943
line	O	943-947
mutations	O	948-957
and	O	958-961
extracolonic	O	962-974
manifestations	O	975-989
in	O	990-992
FAP	B	993-996
patients	O	997-1005
;	O	1005-1006
4	O	1007-1008
)	O	1008-1009
more	O	1010-1014
than	O	1015-1019
80	O	1020-1022
%	O	1022-1023
of	O	1024-1026
base	O	1027-1031
substitutions	O	1032-1045
in	O	1046-1048
the	O	1049-1052
APC	B	1053-1056
gene	O	1057-1061
were	O	1062-1066
from	O	1067-1071
cytosine	O	1072-1080
to	O	1081-1083
other	O	1084-1089
nucleotides	O	1090-1101
,	O	1101-1102
nearly	O	1103-1109
one	O	1110-1113
-	O	1113-1114
third	O	1114-1119
of	O	1120-1122
which	O	1123-1128
occurred	O	1129-1137
at	O	1138-1140
the	O	1141-1144
GpG	O	1145-1148
site	O	1149-1153
.	O	1153-1154

Our	O	1155-1158
results	O	1159-1166
provide	O	1167-1174
information	O	1175-1186
helpful	O	1187-1194
to	O	1195-1197
an	O	1198-1200
understanding	O	1201-1214
of	O	1215-1217
the	O	1218-1221
APC	B	1222-1225
gene	O	1226-1230
and	O	1231-1234
will	O	1235-1239
also	O	1240-1244
contribute	O	1245-1255
to	O	1256-1258
presymptomatic	O	1259-1273
diagnosis	O	1274-1283
of	O	1284-1286
members	O	1287-1294
in	O	1295-1297
FAP	B	1298-1301
families	O	1302-1310
.	O	1310-1311
.	O	1310-1311

Hereditary	O	0-10
deficiency	B	11-21
of	I	22-24
C5	I	25-27
in	O	28-30
association	O	31-42
with	O	43-47
discoid	B	48-55
lupus	I	56-61
erythematosus	I	62-75
.	O	75-76

A	O	77-78
29	O	79-81
-	O	81-82
year	O	82-86
-	O	81-82
old	O	87-90
woman	O	91-96
with	O	97-101
discoid	B	102-109
lupus	I	110-115
erythematosus	I	116-129
had	O	130-133
undetectable	O	134-146
classic	O	147-154
pathway	O	155-162
complement	O	163-173
activity	O	174-182
.	O	182-183

Hypocomplementemia	B	184-202
was	O	203-206
due	O	207-210
to	O	211-213
selective	O	214-223
deficiency	B	224-234
of	I	235-237
C5	I	238-240
.	O	240-241

One	O	242-245
of	O	246-248
her	O	249-252
children	O	253-261
was	O	262-265
also	O	266-270
deficient	O	271-280
.	O	280-281

To	O	282-284
our	O	285-288
knowledge	O	289-298
this	O	299-303
is	O	304-306
the	O	307-310
first	O	311-316
documented	O	317-327
case	O	328-332
of	O	333-335
an	O	336-338
association	O	339-350
between	O	351-358
discoid	B	359-366
lupus	I	367-372
erythematosus	I	373-386
and	O	387-390
C5	B	391-393
deficiency	I	394-404
.	O	404-405
.	O	404-405

Isolation	O	0-9
,	O	9-10
genomic	O	11-18
organization	O	19-31
,	O	31-32
and	O	33-36
expression	O	37-47
analysis	O	48-56
of	O	57-59
the	O	60-63
mouse	O	64-69
and	O	70-73
rat	O	74-77
homologs	O	78-86
of	O	87-89
MEFV	O	90-94
,	O	94-95
the	O	96-99
gene	O	100-104
for	O	105-108
familial	B	109-117
mediterranean	I	118-131
fever	I	132-137
.	O	137-138

Familial	B	139-147
Mediterranean	I	148-161
fever	I	162-167
(	O	168-169
FMF	B	169-172
)	O	172-173
is	O	174-176
a	O	177-178
recessive	B	179-188
disorder	I	189-197
characterized	O	198-211
by	O	212-214
episodes	O	215-223
of	O	224-226
fever	B	227-232
with	O	233-237
serositis	B	238-247
or	O	248-250
synovitis	B	251-260
.	O	260-261

Recently	O	262-270
the	O	271-274
FMF	B	275-278
gene	O	279-283
(	O	284-285
MEFV	O	285-289
)	O	289-290
was	O	291-294
cloned	O	295-301
;	O	301-302
the	O	303-306
protein	O	307-314
product	O	315-322
,	O	322-323
pyrin	O	324-329
/	O	329-330
marenostrin	O	330-341
,	O	341-342
is	O	343-345
thought	O	346-353
to	O	354-356
regulate	O	357-365
inflammation	O	366-378
in	O	379-381
myeloid	O	382-389
cells	O	390-395
.	O	395-396

In	O	397-399
this	O	400-404
manuscript	O	405-415
we	O	416-418
report	O	419-425
the	O	426-429
mouse	O	430-435
and	O	436-439
rat	O	440-443
homologs	O	444-452
of	O	453-455
MEFV	O	456-460
.	O	460-461

The	O	462-465
murine	O	466-472
gene	O	473-477
contains	O	478-486
ten	O	487-490
exons	O	491-496
with	O	497-501
a	O	502-503
coding	O	504-510
sequence	O	511-519
of	O	520-522
2304	O	523-527
bp	O	528-530
,	O	530-531
while	O	532-537
the	O	538-541
rat	O	542-545
homolog	O	546-553
has	O	554-557
nine	O	558-562
exons	O	563-568
with	O	569-573
a	O	574-575
coding	O	576-582
sequence	O	583-591
of	O	592-594
2253	O	595-599
bp	O	600-602
.	O	602-603

A	O	604-605
considerable	O	606-618
amino	O	619-624
acid	O	625-629
sequence	O	630-638
homology	O	639-647
was	O	648-651
observed	O	652-660
between	O	661-668
the	O	669-672
mouse	O	673-678
and	O	679-682
human	O	683-688
(	O	689-690
47	O	690-692
.	O	692-693

6	O	694-695
%	O	695-696
identity	O	697-705
and	O	706-709
65	O	710-712
.	O	712-713
5	O	714-715
%	O	715-716
similarity	O	717-727
)	O	727-728
and	O	729-732
between	O	733-740
the	O	741-744
mouse	O	745-750
and	O	751-754
rat	O	755-758
genes	O	759-764
(	O	765-766
73	O	766-768
.	O	768-769
5	O	770-771
%	O	771-772
identity	O	773-781
and	O	782-785
82	O	786-788
.	O	788-789

1	O	790-791
%	O	791-792
similarity	O	793-803
)	O	803-804
.	O	804-805

The	O	806-809
predicted	O	810-819
rodent	O	820-826
proteins	O	827-835
have	O	836-840
several	O	841-848
important	O	849-858
domains	O	859-866
and	O	867-870
signals	O	871-878
found	O	879-884
in	O	885-887
human	O	888-893
pyrin	O	894-899
,	O	899-900
including	O	901-910
a	O	911-912
B	O	913-914
-	O	914-915
box	O	915-918
zinc	O	919-923
finger	O	924-930
domain	O	931-937
,	O	937-938
Robbins	O	939-946
-	O	946-947
Dingwall	O	947-955
nuclear	O	956-963
localization	O	964-976
signal	O	977-983
,	O	983-984
and	O	985-988
coiled	O	989-995
-	O	995-996
coil	O	989-993
domain	O	1001-1007
.	O	1007-1008

However	O	1009-1016
,	O	1016-1017
perhaps	O	1018-1025
because	O	1026-1033
of	O	1034-1036
an	O	1037-1039
ancient	O	1040-1047
frame	O	1048-1053
-	O	1053-1054
shift	O	1054-1059
mutation	O	1060-1068
,	O	1068-1069
neither	O	1070-1077
the	O	1078-1081
mouse	O	1082-1087
nor	O	1088-1091
the	O	1092-1095
rat	O	1096-1099
protein	O	1100-1107
has	O	1108-1111
an	O	1112-1114
intact	O	1115-1121
C	O	1122-1123
-	O	1123-1124
terminal	O	1124-1132
B30	O	1133-1136
.	O	1136-1137
2	O	1138-1139
domain	O	1140-1146
,	O	1146-1147
in	O	1148-1150
which	O	1151-1156
most	O	1157-1161
FMF	B	1162-1165
-	O	1165-1166
associated	O	1166-1176
mutations	O	1177-1186
have	O	1187-1191
been	O	1192-1196
found	O	1197-1202
in	O	1203-1205
human	O	1206-1211
MEFV	O	1212-1216
.	O	1216-1217

Nevertheless	O	1218-1230
,	O	1230-1231
like	O	1232-1236
the	O	1237-1240
human	O	1241-1246
gene	O	1247-1251
,	O	1251-1252
mouse	O	1253-1258
Mefv	O	1259-1263
is	O	1264-1266
expressed	O	1267-1276
in	O	1277-1279
peripheral	O	1280-1290
blood	O	1291-1296
granulocytes	O	1297-1309
but	O	1310-1313
not	O	1314-1317
lymphocytes	O	1318-1329
.	O	1329-1330

Consistent	O	1331-1341
with	O	1342-1346
its	O	1347-1350
expression	O	1351-1361
in	O	1362-1364
granulocytes	O	1365-1377
,	O	1377-1378
Mefv	O	1379-1383
was	O	1384-1387
detected	O	1388-1396
at	O	1397-1399
high	O	1400-1404
levels	O	1405-1411
in	O	1412-1414
the	O	1415-1418
primary	O	1419-1426
follicles	O	1427-1436
and	O	1437-1440
marginal	O	1441-1449
zones	O	1450-1455
of	O	1456-1458
the	O	1459-1462
splenic	O	1463-1470
white	O	1471-1476
pulp	O	1477-1481
.	O	1481-1482

Mefv	O	1483-1487
is	O	1488-1490
localized	O	1491-1500
on	O	1501-1503
mouse	O	1504-1509
Chromosome	O	1510-1520
(	O	1521-1522
Chr	O	1522-1525
)	O	1525-1526
16	O	1527-1529
,	O	1529-1530
region	O	1531-1537
A3	O	1538-1540
-	O	1540-1541
B1	O	1541-1543
,	O	1543-1544
extending	O	1545-1554
a	O	1555-1556
region	O	1557-1563
of	O	1564-1566
synteny	O	1567-1574
with	O	1575-1579
human	O	1580-1585
Chr	O	1586-1589
16p13	O	1590-1595
.	O	1595-1596

3	O	1597-1598
.	O	1598-1599
Development	O	1600-1611
of	O	1612-1614
knockout	O	1615-1623
and	O	1624-1627
knockin	O	1628-1635
mouse	O	1636-1641
models	O	1642-1648
may	O	1649-1652
provide	O	1653-1660
further	O	1661-1668
insights	O	1669-1677
into	O	1678-1682
the	O	1683-1686
functional	O	1687-1697
evolution	O	1698-1707
of	O	1708-1710
this	O	1711-1715
gene	O	1716-1720
.	O	1720-1721

Analysis	O	0-8
of	O	9-11
X	O	12-13
-	O	13-14
chromosome	O	14-24
inactivation	O	25-37
and	O	38-41
presumptive	O	42-53
expression	O	54-64
of	O	65-67
the	O	68-71
Wiskott	B	72-79
-	I	79-80
Aldrich	I	80-87
syndrome	I	88-96
(	O	97-98
WAS	B	98-101
)	O	101-102
gene	O	103-107
in	O	108-110
hematopoietic	O	111-124
cell	O	125-129
lineages	O	130-138
of	O	139-141
a	O	142-143
thrombocytopenic	O	144-160
carrier	O	161-168
female	O	169-175
of	O	176-178
WAS	B	179-182
.	O	182-183

We	O	184-186
report	O	187-193
on	O	194-196
a	O	197-198
thrombocytopenic	B	199-215
female	O	216-222
belonging	O	223-232
to	O	233-235
a	O	236-237
pedigree	O	238-246
with	O	247-251
the	O	252-255
Wiskott	B	256-263
-	I	263-264
Aldrich	I	264-271
syndrome	I	272-280
(	O	281-282
WAS	B	282-285
)	O	285-286
.	O	286-287

Restriction	O	288-299
fragment	O	300-308
length	O	309-315
polymorphism	O	316-328
(	O	329-330
RFLP	O	330-334
)	O	334-335
analysis	O	336-344
with	O	345-349
probe	O	350-355
M27	O	356-359
beta	O	360-364
,	O	364-365
closely	O	366-373
linked	O	374-380
to	O	381-383
the	O	384-387
WAS	B	388-391
gene	O	392-396
,	O	396-397
demonstrated	O	398-410
that	O	411-415
she	O	416-419
is	O	420-422
a	O	423-424
carrier	O	425-432
of	O	433-435
WAS	B	436-439
.	O	439-440

Both	O	441-445
small	O	446-451
-	O	451-452
sized	O	452-457
and	O	458-461
normal	O	462-468
-	O	468-469
sized	O	469-474
platelets	O	475-484
were	O	485-489
present	O	490-497
,	O	497-498
suggesting	O	499-509
that	O	510-514
,	O	514-515
unlike	O	516-522
the	O	523-526
vast	O	527-531
majority	O	532-540
of	O	541-543
WAS	B	544-547
carriers	O	548-556
,	O	556-557
she	O	558-561
does	O	562-566
not	O	567-570
manifest	O	571-579
nonrandom	O	580-589
X	O	590-591
-	O	591-592
chromosome	O	592-602
inactivation	O	603-615
in	O	616-618
the	O	619-622
thrombopoietic	O	623-637
cell	O	638-642
lineage	O	643-650
.	O	650-651

Study	O	652-657
of	O	658-660
X	O	661-662
-	O	662-663
chromosome	O	663-673
inactivation	O	674-686
by	O	687-689
means	O	690-695
of	O	696-698
RFLP	O	699-703
and	O	704-707
methylation	O	708-719
analysis	O	720-728
demonstrated	O	729-741
that	O	742-746
the	O	747-750
pattern	O	751-758
of	O	759-761
X	O	762-763
-	O	763-764
chromosome	O	764-774
inactivation	O	775-787
was	O	788-791
nonrandom	O	792-801
in	O	802-804
T	O	805-806
lymphocytes	O	807-818
,	O	818-819
but	O	820-823
random	O	824-830
in	O	831-833
granulocytes	O	834-846
.	O	846-847

While	O	848-853
this	O	854-858
is	O	859-861
the	O	862-865
first	O	866-871
complete	O	872-880
report	O	881-887
on	O	888-890
the	O	891-894
occurrence	O	895-905
of	O	906-908
thrombocytopenia	B	909-925
in	O	926-928
a	O	929-930
carrier	O	931-938
female	O	939-945
of	O	946-948
WAS	B	949-952
as	O	953-955
the	O	956-959
result	O	960-966
of	O	967-969
atypical	O	970-978
lyonization	O	979-990
,	O	990-991
it	O	992-994
also	O	995-999
suggests	O	1000-1008
that	O	1009-1013
expression	O	1014-1024
of	O	1025-1027
the	O	1028-1031
WAS	B	1032-1035
gene	O	1036-1040
occurs	O	1041-1047
at	O	1048-1050
(	O	1051-1052
or	O	1052-1054
extends	O	1055-1062
up	O	1063-1065
to	O	1066-1068
)	O	1068-1069
a	O	1070-1071
later	O	1072-1077
stage	O	1078-1083
than	O	1084-1088
the	O	1089-1092
multipotent	O	1093-1104
stem	O	1105-1109
cell	O	1110-1114
along	O	1115-1120
the	O	1121-1124
hematopoietic	O	1125-1138
differentiation	O	1139-1154
pathway	O	1155-1162
.	O	1162-1163
.	O	1162-1163

hCds1	O	0-5
-	O	5-6
mediated	O	6-14
phosphorylation	O	15-30
of	O	31-33
BRCA1	O	34-39
regulates	O	40-49
the	O	50-53
DNA	O	54-57
damage	O	58-64
response	O	65-73
.	O	73-74

Mutations	O	75-84
in	O	85-87
the	O	88-91
BRCA1	O	92-97
(	O	98-99
ref	O	99-102
.	O	102-103
1	O	104-105
)	O	105-106
tumour	B	107-113
suppressor	O	114-124
gene	O	125-129
are	O	130-133
found	O	134-139
in	O	140-142
almost	O	143-149
all	O	150-153
of	O	154-156
the	O	157-160
families	O	161-169
with	O	170-174
inherited	B	175-184
breast	I	185-191
and	I	192-195
ovarian	I	196-203
cancers	I	204-211
and	O	212-215
about	O	216-221
half	O	222-226
of	O	227-229
the	O	230-233
families	O	234-242
with	O	243-247
only	O	248-252
breast	B	253-259
cancer	I	260-266
.	O	266-267

Although	O	268-276
the	O	277-280
biochemical	O	281-292
function	O	293-301
of	O	302-304
BRCA1	O	305-310
is	O	311-313
not	O	314-317
well	O	318-322
understood	O	323-333
,	O	333-334
it	O	335-337
is	O	338-340
important	O	341-350
for	O	351-354
DNA	O	355-358
damage	O	359-365
repair	O	366-372
and	O	373-376
cell	O	377-381
-	O	381-382
cycle	O	382-387
checkpoint	O	388-398
.	O	398-399

BRCA1	O	400-405
exists	O	406-412
in	O	413-415
nuclear	O	416-423
foci	O	424-428
but	O	429-432
is	O	433-435
hyperphosphorylated	O	436-455
and	O	456-459
disperses	O	460-469
after	O	470-475
DNA	O	476-479
damage	O	480-486
.	O	486-487

It	O	488-490
is	O	491-493
not	O	494-497
known	O	498-503
whether	O	504-511
BRCA1	O	512-517
phosphorylation	O	518-533
and	O	534-537
dispersion	O	538-548
and	O	549-552
its	O	553-556
function	O	557-565
in	O	566-568
DNA	O	569-572
damage	O	573-579
response	O	580-588
are	O	589-592
related	O	593-600
.	O	600-601

In	O	602-604
yeast	O	605-610
the	O	611-614
DNA	O	615-618
damage	O	619-625
response	O	626-634
and	O	635-638
the	O	639-642
replication	O	643-654
-	O	654-655
block	O	655-660
checkpoint	O	661-671
are	O	672-675
mediated	O	676-684
partly	O	685-691
through	O	692-699
the	O	700-703
Cds1	O	704-708
kinase	O	709-715
family	O	716-722
.	O	722-723

Here	O	724-728
we	O	729-731
report	O	732-738
that	O	739-743
the	O	744-747
human	O	748-753
Cds1	O	754-758
kinase	O	759-765
(	O	766-767
hCds1	O	767-772
/	O	772-773
Chk2	O	773-777
)	O	777-778
regulates	O	779-788
BRCA1	O	789-794
function	O	795-803
after	O	804-809
DNA	O	810-813
damage	O	814-820
by	O	821-823
phosphorylating	O	824-839
serine	O	840-846
988	O	847-850
of	O	851-853
BRCA1	O	854-859
.	O	859-860

We	O	861-863
show	O	864-868
that	O	869-873
hCds1	O	874-879
and	O	880-883
BRCA1	O	884-889
interact	O	890-898
and	O	899-902
co	O	903-905
-	O	905-906
localize	O	906-914
within	O	915-921
discrete	O	922-930
nuclear	O	931-938
foci	O	939-943
but	O	944-947
separate	O	948-956
after	O	957-962
gamma	O	963-968
irradiation	O	969-980
.	O	980-981

Phosphorylation	O	982-997
of	O	998-1000
BRCA1	O	1001-1006
at	O	1007-1009
serine	O	1010-1016
988	O	1017-1020
is	O	1021-1023
required	O	1024-1032
for	O	1033-1036
the	O	1037-1040
release	O	1041-1048
of	O	1049-1051
BRCA1	O	1052-1057
from	O	1058-1062
hCds1	O	1063-1068
.	O	1068-1069

This	O	1070-1074
phosphorylation	O	1075-1090
is	O	1091-1093
also	O	1094-1098
important	O	1099-1108
for	O	1109-1112
the	O	1113-1116
ability	O	1117-1124
of	O	1125-1127
BRCA1	O	1128-1133
to	O	1134-1136
restore	O	1137-1144
survival	O	1145-1153
after	O	1154-1159
DNA	O	1160-1163
damage	O	1164-1170
in	O	1171-1173
the	O	1174-1177
BRCA1	O	1178-1183
-	O	1183-1184
mutated	O	1184-1191
cell	O	1192-1196
line	O	1197-1201
HCC1937	O	1202-1209
.	O	1209-1210
.	O	1209-1210

Ataxin	O	0-6
-	O	6-7
3	O	7-8
with	O	9-13
an	O	14-16
altered	O	17-24
conformation	O	25-37
that	O	38-42
exposes	O	43-50
the	O	51-54
polyglutamine	O	55-68
domain	O	69-75
is	O	76-78
associated	O	79-89
with	O	90-94
the	O	95-98
nuclear	O	99-106
matrix	O	107-113
.	O	113-114

Spinocerebellar	B	115-130
ataxia	I	131-137
type	I	138-142
-	I	142-143
3	I	143-144
or	O	145-147
Machado	B	148-155
-	I	155-156
Joseph	I	156-162
disease	I	163-170
(	O	171-172
SCA3	B	172-176
/	O	176-177
MJD	B	177-180
)	O	180-181
is	O	182-184
a	O	185-186
member	O	187-193
of	O	194-196
the	O	197-200
CAG	B	201-204
/	I	204-205
polyglutamine	I	205-218
repeat	I	219-225
disease	I	226-233
family	O	234-240
.	O	240-241

In	O	242-244
this	O	245-249
family	O	250-256
of	O	257-259
disorders	O	260-269
,	O	269-270
a	O	271-272
normally	O	273-281
polymorphic	O	282-293
CAG	O	294-297
repeat	O	298-304
becomes	O	305-312
expanded	O	313-321
,	O	321-322
resulting	O	323-332
in	O	333-335
expression	O	336-346
of	O	347-349
an	O	350-352
expanded	O	353-361
polyglutamine	O	362-375
domain	O	376-382
in	O	383-385
the	O	386-389
disease	O	390-397
gene	O	398-402
product	O	403-410
.	O	410-411

Experimental	O	412-424
models	O	425-431
of	O	432-434
polyglutamine	B	435-448
disease	I	449-456
implicate	O	457-466
the	O	467-470
nucleus	O	471-478
in	O	479-481
pathogenesis	O	482-494
;	O	494-495
however	O	496-503
,	O	503-504
the	O	505-508
link	O	509-513
between	O	514-521
intranuclear	O	522-534
expression	O	535-545
of	O	546-548
expanded	O	549-557
polyglutamine	O	558-571
and	O	572-575
neuronal	B	576-584
dysfunction	I	585-596
remains	O	597-604
unclear	O	605-612
.	O	612-613

Here	O	614-618
we	O	619-621
demonstrate	O	622-633
that	O	634-638
ataxin	O	639-645
-	O	645-646
3	O	646-647
,	O	647-648
the	O	649-652
disease	O	653-660
protein	O	661-668
in	O	669-671
SCA3	B	672-676
/	O	676-677
MJD	B	677-680
,	O	680-681
adopts	O	682-688
a	O	689-690
unique	O	691-697
conformation	O	698-710
when	O	711-715
expressed	O	716-725
within	O	726-732
the	O	733-736
nucleus	O	737-744
of	O	745-747
transfected	O	748-759
cells	O	760-765
.	O	765-766

The	O	767-770
monoclonal	O	771-781
antibody	O	782-790
1C2	O	791-794
is	O	795-797
known	O	798-803
preferentially	O	804-818
to	O	819-821
bind	O	822-826
expanded	O	827-835
polyglutamine	O	836-849
,	O	849-850
but	O	851-854
we	O	855-857
find	O	858-862
that	O	863-867
it	O	868-870
also	O	871-875
binds	O	876-881
a	O	882-883
fragment	O	884-892
of	O	893-895
ataxin	O	896-902
-	O	902-903
3	O	903-904
containing	O	905-915
a	O	916-917
normal	O	918-924
glutamine	O	925-934
repeat	O	935-941
.	O	941-942

In	O	943-945
addition	O	946-954
,	O	954-955
expression	O	956-966
of	O	967-969
ataxin	O	970-976
-	O	976-977
3	O	977-978
within	O	979-985
the	O	986-989
nucleus	O	990-997
exposes	O	998-1005
the	O	1006-1009
glutamine	O	1010-1019
domain	O	1020-1026
of	O	1027-1029
the	O	1030-1033
full	O	1034-1038
-	O	1038-1039
length	O	1039-1045
non	O	1046-1049
-	O	1049-1050
pathological	O	1050-1062
protein	O	1063-1070
,	O	1070-1071
allowing	O	1072-1080
it	O	1081-1083
to	O	1084-1086
bind	O	1087-1091
the	O	1092-1095
monoclonal	O	1096-1106
antibody	O	1107-1115
1C2	O	1116-1119
.	O	1119-1120

Fractionation	O	1121-1134
and	O	1135-1138
immunochemical	O	1139-1153
experiments	O	1154-1165
indicate	O	1166-1174
that	O	1175-1179
this	O	1180-1184
novel	O	1185-1190
conformation	O	1191-1203
of	O	1204-1206
intranuclear	O	1207-1219
ataxin	O	1220-1226
-	O	1226-1227
3	O	1227-1228
is	O	1229-1231
not	O	1232-1235
due	O	1236-1239
to	O	1240-1242
proteolysis	O	1243-1254
,	O	1254-1255
suggesting	O	1256-1266
instead	O	1267-1274
that	O	1275-1279
association	O	1280-1291
with	O	1292-1296
nuclear	O	1297-1304
protein	O	1305-1312
(	O	1313-1314
s	O	1314-1315
)	O	1315-1316
alters	O	1317-1323
the	O	1324-1327
structure	O	1328-1337
of	O	1338-1340
full	O	1341-1345
-	O	1345-1346
length	O	1346-1352
ataxin	O	1353-1359
-	O	1359-1360
3	O	1360-1361
which	O	1362-1367
exposes	O	1368-1375
the	O	1376-1379
polyglutamine	O	1380-1393
domain	O	1394-1400
.	O	1400-1401

This	O	1402-1406
conformationally	O	1407-1423
altered	O	1424-1431
ataxin	O	1432-1438
-	O	1438-1439
3	O	1439-1440
is	O	1441-1443
bound	O	1444-1449
to	O	1450-1452
the	O	1453-1456
nuclear	O	1457-1464
matrix	O	1465-1471
.	O	1471-1472

The	O	1473-1476
pathological	O	1477-1489
form	O	1490-1494
of	O	1495-1497
ataxin	O	1498-1504
-	O	1504-1505
3	O	1505-1506
with	O	1507-1511
an	O	1512-1514
expanded	O	1515-1523
polyglutamine	O	1524-1537
domain	O	1538-1544
also	O	1545-1549
associates	O	1550-1560
with	O	1561-1565
the	O	1566-1569
nuclear	O	1570-1577
matrix	O	1578-1584
.	O	1584-1585

These	O	1586-1591
data	O	1592-1596
suggest	O	1597-1604
that	O	1605-1609
an	O	1610-1612
early	O	1613-1618
event	O	1619-1624
in	O	1625-1627
the	O	1628-1631
pathogenesis	O	1632-1644
of	O	1645-1647
SCA3	B	1648-1652
/	O	1652-1653
MJD	B	1653-1656
may	O	1657-1660
be	O	1661-1663
an	O	1664-1666
altered	O	1667-1674
conformation	O	1675-1687
of	O	1688-1690
ataxin	O	1691-1697
-	O	1697-1698
3	O	1698-1699
within	O	1700-1706
the	O	1707-1710
nucleus	O	1711-1718
that	O	1719-1723
exposes	O	1724-1731
the	O	1732-1735
polyglutamine	O	1736-1749
domain	O	1750-1756
.	O	1756-1757
.	O	1756-1757

A	O	0-1
zinc	O	2-6
finger	O	7-13
truncation	O	14-24
of	O	25-27
murine	O	28-34
WT1	O	35-38
results	O	39-46
in	O	47-49
the	O	50-53
characteristic	O	54-68
urogenital	B	69-79
abnormalities	I	80-93
of	O	94-96
Denys	B	97-102
-	I	102-103
Drash	I	103-108
syndrome	I	109-117
.	O	118-119

The	O	120-123
Wilms	B	124-129
tumor	I	130-135
-	O	136-137
suppressor	O	137-147
gene	O	148-152
,	O	152-153
WT1	O	154-157
,	O	157-158
plays	O	159-164
a	O	165-166
key	O	167-170
role	O	171-175
in	O	176-178
urogenital	O	179-189
development	O	190-201
,	O	201-202
and	O	203-206
WT1	B	207-210
dysfunction	I	211-222
is	O	223-225
implicated	O	226-236
in	O	237-239
both	O	240-244
neoplastic	B	245-255
(	O	256-257
Wilms	B	257-262
tumor	I	263-268
,	O	268-269
mesothelioma	B	270-282
,	O	282-283
leukemias	B	284-293
,	O	293-294
and	O	295-298
breast	B	299-305
cancer	I	306-312
)	O	312-313
and	O	314-317
nonneoplastic	B	318-331
(	O	332-333
glomerulosclerosis	B	333-351
)	O	351-352
disease	O	353-360
.	O	360-361

The	O	362-365
analysis	O	366-374
of	O	375-377
diseases	O	378-386
linked	O	387-393
specifically	O	394-406
with	O	407-411
WT1	O	412-415
mutations	O	416-425
,	O	425-426
such	O	427-431
as	O	432-434
Denys	B	435-440
-	I	440-441
Drash	I	441-446
syndrome	I	447-455
(	O	456-457
DDS	B	457-460
)	O	460-461
,	O	461-462
can	O	463-466
provide	O	467-474
valuable	O	475-483
insight	O	484-491
concerning	O	492-502
the	O	503-506
role	O	507-511
of	O	512-514
WT1	O	515-518
in	O	519-521
development	O	522-533
and	O	534-537
disease	O	538-545
.	O	545-546

DDS	B	547-550
is	O	551-553
a	O	554-555
rare	O	556-560
childhood	O	561-570
disease	O	571-578
characterized	O	579-592
by	O	593-595
a	O	596-597
nephropathy	B	598-609
involving	O	610-619
mesangial	B	620-629
sclerosis	I	630-639
,	O	639-640
XY	O	641-643
pseudohermaphroditism	B	644-665
,	O	665-666
and	O	667-670
/	O	670-671
or	O	671-673
Wilms	B	674-679
tumor	I	680-685
(	O	686-687
WT	B	687-689
)	O	689-690
.	O	690-691

DDS	B	692-695
patients	O	696-704
are	O	705-708
constitutionally	O	709-725
heterozygous	O	726-738
for	O	739-742
exonic	O	743-749
point	O	750-755
mutations	O	756-765
in	O	766-768
WT1	O	769-772
,	O	772-773
which	O	774-779
include	O	780-787
mutations	O	788-797
predicted	O	798-807
to	O	808-810
truncate	O	811-819
the	O	820-823
protein	O	824-831
within	O	832-838
the	O	839-842
C	O	843-844
-	O	844-845
terminal	O	845-853
zinc	O	854-858
finger	O	859-865
(	O	866-867
ZF	O	867-869
)	O	869-870
region	O	871-877
.	O	877-878

We	O	879-881
report	O	882-888
that	O	889-893
heterozygosity	O	894-908
for	O	909-912
a	O	913-914
targeted	O	915-923
murine	O	924-930
Wt1	O	931-934
allele	O	935-941
,	O	941-942
Wt1	O	943-946
(	O	947-948
tmT396	O	948-954
)	O	954-955
,	O	955-956
which	O	957-962
truncates	O	963-972
ZF3	O	973-976
at	O	977-979
codon	O	980-985
396	O	986-989
,	O	989-990
induces	O	991-998
mesangial	B	999-1008
sclerosis	I	1009-1018
characteristic	O	1019-1033
of	O	1034-1036
DDS	B	1037-1040
in	O	1041-1043
adult	O	1044-1049
heterozygous	O	1050-1062
and	O	1063-1066
chimeric	O	1067-1075
mice	O	1076-1080
.	O	1080-1081

Male	B	1082-1086
genital	I	1087-1094
defects	I	1095-1102
also	O	1103-1107
were	O	1108-1112
evident	O	1113-1120
and	O	1121-1124
there	O	1125-1130
was	O	1131-1134
a	O	1135-1136
single	O	1137-1143
case	O	1144-1148
of	O	1149-1151
Wilms	B	1152-1157
tumor	I	1158-1163
in	O	1164-1166
which	O	1167-1172
the	O	1173-1176
transcript	O	1177-1187
of	O	1188-1190
the	O	1191-1194
nontargeted	O	1195-1206
allele	O	1207-1213
showed	O	1214-1220
an	O	1221-1223
exon	O	1224-1228
9	O	1229-1230
skipping	O	1231-1239
event	O	1240-1245
,	O	1245-1246
implying	O	1247-1255
a	O	1256-1257
causal	O	1258-1264
link	O	1265-1269
between	O	1270-1277
Wt1	B	1278-1281
dysfunction	I	1282-1293
and	O	1294-1297
Wilms	B	1298-1303
tumorigenesis	I	1304-1317
in	O	1318-1320
mice	O	1321-1325
.	O	1325-1326

However	O	1327-1334
,	O	1334-1335
the	O	1336-1339
mutant	O	1340-1346
WT1	O	1347-1350
(	O	1351-1352
tmT396	O	1352-1358
)	O	1358-1359
protein	O	1360-1367
accounted	O	1368-1377
for	O	1378-1381
only	O	1382-1386
5	O	1387-1388
%	O	1388-1389
of	O	1390-1392
WT1	O	1393-1396
in	O	1397-1399
both	O	1400-1404
heterozygous	O	1405-1417
embryonic	O	1418-1427
stem	O	1428-1432
cells	O	1433-1438
and	O	1439-1442
the	O	1443-1446
WT	B	1447-1449
.	O	1449-1450

This	O	1451-1455
has	O	1456-1459
implications	O	1460-1472
regarding	O	1473-1482
the	O	1483-1486
mechanism	O	1487-1496
by	O	1497-1499
which	O	1500-1505
the	O	1506-1509
mutant	O	1510-1516
allele	O	1517-1523
exerts	O	1524-1530
its	O	1531-1534
effect	O	1535-1541
.	O	1541-1542

Heterogeneity	O	0-13
of	O	14-16
"	O	17-18
Mediterranean	O	18-31
type	O	32-36
"	O	36-37
glucose	B	38-45
-	I	45-46
6	I	46-47
-	I	45-46
phosphate	I	48-57
dehydrogenase	I	58-71
(	I	72-73
G6PD	I	73-77
)	I	77-78
deficiency	I	79-89
in	O	90-92
Spain	O	93-98
and	O	99-102
description	O	103-114
of	O	115-117
two	O	118-121
new	O	122-125
variants	O	126-134
associated	O	135-145
with	O	146-150
favism	B	151-157
.	O	157-158

Glucose	O	159-166
-	O	166-167
6	O	167-168
-	O	166-167
phosphate	O	169-178
dehydrogenase	O	179-192
(	O	193-194
G6PD	O	194-198
)	O	198-199
;	O	199-200
EC	O	201-203
1	O	204-205
.	O	205-206
1	O	207-208
.	O	208-209
1	O	210-211
.	O	211-212
49	O	213-215
from	O	216-220
thirty	O	221-227
-	O	227-228
six	O	228-231
unrelated	O	232-241
Spanish	O	242-249
males	O	250-255
was	O	256-259
partially	O	260-269
purified	O	270-278
from	O	279-283
blood	O	284-289
,	O	289-290
and	O	291-294
the	O	295-298
variants	O	299-307
were	O	308-312
characterized	O	313-326
biochemically	O	327-340
and	O	341-344
electrophoretically	O	345-364
according	O	365-374
to	O	375-377
the	O	378-381
methods	O	382-389
recommended	O	390-401
by	O	402-404
the	O	405-408
world	O	409-414
Health	O	415-421
Organization	O	422-434
.	O	434-435

Subjects	O	436-444
were	O	445-449
from	O	450-454
multiple	O	455-463
geographic	O	464-474
regions	O	475-482
within	O	483-489
Spain	O	490-495
,	O	495-496
and	O	497-500
all	O	501-504
suffered	O	505-513
from	O	514-518
hemolytic	B	519-528
anemia	I	529-535
,	O	535-536
either	O	537-543
acute	O	544-549
(	O	550-551
34	O	551-553
cases	O	554-559
)	O	559-560
or	O	561-563
chronic	O	564-571
nonspherocytic	O	572-586
(	O	587-588
2	O	588-589
cases	O	590-595
)	O	595-596
.	O	596-597

Almost	O	598-604
all	O	605-608
the	O	609-612
variants	O	613-621
studied	O	622-629
presented	O	630-639
residual	O	640-648
erythrocyte	O	649-660
G6PD	O	661-665
activity	O	666-674
ranging	O	675-682
from	O	683-687
0	O	688-689
to	O	690-692
10	O	693-695
%	O	695-696
of	O	697-699
normal	O	700-706
,	O	706-707
and	O	708-711
five	O	712-716
different	O	717-726
mutants	O	727-734
were	O	735-739
responsible	O	740-751
for	O	752-755
the	O	756-759
deficient	O	760-769
phenotype	O	770-779
.	O	779-780

Three	O	781-786
variants	O	787-795
were	O	796-800
similar	O	801-808
to	O	809-811
others	O	812-818
previously	O	819-829
described	O	830-839
G6PD	O	841-845
Mediterranean	O	846-859
(	O	860-861
11	O	861-863
cases	O	864-869
)	O	869-870
,	O	870-871
G6PD	O	872-876
Athens	O	877-883
-	O	883-884
like	O	884-888
(	O	889-890
3	O	890-891
cases	O	892-897
)	O	897-898
,	O	898-899
and	O	900-903
G6PD	O	904-908
Union	O	909-914
(	O	915-916
2	O	916-917
cases	O	918-923
)	O	923-924
.	O	924-925

The	O	926-929
remaining	O	930-939
variants	O	940-948
were	O	949-953
different	O	954-963
from	O	964-968
the	O	969-972
numerous	O	973-981
variants	O	982-990
already	O	991-998
reported	O	999-1007
and	O	1008-1011
have	O	1012-1016
been	O	1017-1021
considered	O	1022-1032
as	O	1033-1035
new	O	1036-1039
mutants	O	1040-1047
.	O	1047-1048

Provisionally	O	1049-1062
they	O	1063-1067
are	O	1068-1071
called	O	1072-1078
G6PD	O	1079-1083
Betica	O	1084-1090
(	O	1091-1092
19	O	1092-1094
cases	O	1095-1100
)	O	1100-1101
and	O	1102-1105
G6PD	O	1106-1110
Menorca	O	1111-1118
(	O	1119-1120
1	O	1120-1121
case	O	1122-1126
)	O	1126-1127
.	O	1127-1128

The	O	1129-1132
present	O	1133-1140
study	O	1141-1146
constitutes	O	1147-1158
the	O	1159-1162
first	O	1163-1168
attempt	O	1169-1176
to	O	1177-1179
characterize	O	1180-1192
the	O	1193-1196
deficient	B	1197-1206
G6PD	I	1207-1211
variants	O	1212-1220
found	O	1221-1226
in	O	1227-1229
Spain	O	1230-1235
and	O	1236-1239
supplies	O	1240-1248
new	O	1249-1252
data	O	1253-1257
on	O	1258-1260
the	O	1261-1264
relationship	O	1265-1277
between	O	1278-1285
molecular	O	1286-1295
characteristics	O	1296-1311
of	O	1312-1314
deficient	O	1315-1324
variants	O	1325-1333
and	O	1334-1337
their	O	1338-1343
clinical	O	1344-1352
manifestations	O	1353-1367
.	O	1367-1368

The	O	1369-1372
most	O	1373-1377
important	O	1378-1387
findings	O	1388-1396
can	O	1397-1400
be	O	1401-1403
summarized	O	1404-1414
as	O	1415-1417
follows	O	1418-1425
(	O	1427-1428
1	O	1428-1429
)	O	1429-1430
The	O	1431-1434
Spanish	O	1435-1442
population	O	1443-1453
is	O	1454-1456
characterized	O	1457-1470
by	O	1471-1473
an	O	1474-1476
important	O	1477-1486
heterogeneity	O	1487-1500
in	O	1501-1503
G6PD	B	1504-1508
deficiency	I	1509-1519
.	O	1519-1520

(	O	1521-1522
2	O	1522-1523
)	O	1523-1524
Although	O	1525-1533
G6PD	O	1534-1538
Mediterranean	O	1539-1552
is	O	1553-1555
very	O	1556-1560
frequent	O	1561-1569
,	O	1569-1570
it	O	1571-1573
presents	O	1574-1582
a	O	1583-1584
relatively	O	1585-1595
high	O	1596-1600
degree	O	1601-1607
of	O	1608-1610
polymorphism	O	1611-1623
.	O	1623-1624

(	O	1625-1626
3	O	1626-1627
)	O	1627-1628
Favism	B	1629-1635
has	O	1636-1639
been	O	1640-1644
observed	O	1645-1653
associated	O	1654-1664
with	O	1665-1669
all	O	1670-1673
kinds	O	1674-1679
of	O	1680-1682
variants	O	1683-1691
described	O	1692-1701
here	O	1702-1706
.	O	1706-1707

(	O	1708-1709
4	O	1709-1710
)	O	1710-1711
G6PD	O	1712-1716
Betica	O	1717-1723
,	O	1723-1724
which	O	1725-1730
is	O	1731-1733
the	O	1734-1737
most	O	1738-1742
frequent	O	1743-1751
variant	O	1752-1759
found	O	1760-1765
in	O	1766-1768
subjects	O	1769-1777
of	O	1778-1780
Southern	O	1781-1789
Spanish	O	1790-1797
origin	O	1798-1804
,	O	1804-1805
has	O	1806-1809
been	O	1810-1814
observed	O	1815-1823
associated	O	1824-1834
with	O	1835-1839
favism	B	1840-1846
in	O	1847-1849
all	O	1850-1853
cases	O	1854-1859
except	O	1860-1866
one	O	1867-1870
.	O	1870-1871

Early	O	0-5
onset	O	6-11
of	O	12-14
X	B	15-16
-	I	16-17
linked	I	17-23
Emery	I	24-29
-	I	29-30
Dreifuss	I	30-38
muscular	I	39-47
dystrophy	I	48-57
in	O	58-60
a	O	61-62
boy	O	63-66
with	O	67-71
emerin	O	72-78
gene	O	79-83
deletion	O	84-92
.	O	92-93

A	O	94-95
boy	O	96-99
developed	O	100-109
contractures	B	110-122
of	I	123-125
the	I	126-129
Achilles	I	130-138
tendons	I	139-146
at	O	147-149
3	O	150-151
years	O	152-157
and	O	158-161
of	O	162-164
the	O	165-168
postcervical	O	169-181
muscles	O	182-189
at	O	190-192
7	O	193-194
years	O	195-200
,	O	200-201
although	O	202-210
neither	O	211-218
contractures	B	219-231
of	I	232-234
the	I	235-238
elbows	I	239-245
nor	O	246-249
cardiac	B	250-257
abnormality	I	258-269
were	O	270-274
recognized	O	275-285
by	O	286-288
the	O	289-292
age	O	293-296
of	O	297-299
9	O	300-301
years	O	302-307
.	O	307-308

Muscle	O	309-315
computed	O	316-324
tomography	O	325-335
scanning	O	336-344
revealed	O	345-353
changes	O	354-361
characteristic	O	362-376
of	O	377-379
muscle	O	380-386
involvement	O	387-398
.	O	398-399

Emerin	O	400-406
was	O	407-410
not	O	411-414
detected	O	415-423
in	O	424-426
the	O	427-430
biopsied	O	431-439
muscle	O	440-446
,	O	446-447
and	O	448-451
RT	O	452-454
-	O	454-455
PCR	O	455-458
and	O	459-462
PCR	O	463-466
-	O	466-467
based	O	467-472
genomic	O	473-480
DNA	O	481-484
analyses	O	485-493
of	O	494-496
the	O	497-500
emerin	O	501-507
gene	O	508-512
demonstrated	O	513-525
no	O	526-528
amplification	O	529-542
product	O	543-550
in	O	551-553
the	O	554-557
patient	O	558-565
.	O	565-566

These	O	567-572
results	O	573-580
confirmed	O	581-590
the	O	591-594
diagnosis	O	595-604
of	O	605-607
X	B	608-609
-	I	609-610
linked	I	610-616
Emery	I	617-622
-	I	622-623
Dreifuss	I	623-631
muscular	I	632-640
dystrophy	I	641-650
(	O	651-652
EDMD	B	652-656
)	O	656-657
,	O	657-658
and	O	659-662
reinforce	O	663-672
the	O	673-676
necessity	O	677-686
of	O	687-689
molecular	O	690-699
genetic	O	700-707
diagnosis	O	708-717
of	O	718-720
the	O	721-724
membrane	O	725-733
protein	O	734-741
emerin	O	742-748
in	O	749-751
younger	O	752-759
patients	O	760-768
with	O	769-773
possible	O	774-782
EDMD	B	783-787
before	O	788-794
appearance	O	795-805
of	O	806-808
the	O	809-812
typical	O	813-820
symptoms	O	821-829
,	O	829-830
to	O	831-833
avoid	O	834-839
sudden	B	840-846
cardiac	I	847-854
death	I	855-860
.	O	860-861
.	O	860-861

PRAD1	O	0-5
,	O	5-6
a	O	7-8
candidate	O	9-18
BCL1	O	19-23
oncogene	O	24-32
:	O	32-33
mapping	O	34-41
and	O	42-45
expression	O	46-56
in	O	57-59
centrocytic	B	60-71
lymphoma	I	72-80
.	O	80-81

Rearrangement	O	82-95
of	O	96-98
the	O	99-102
BCL1	O	103-107
(	O	108-109
B	O	109-110
-	O	110-111
cell	O	111-115
lymphoma	O	116-124
1	O	125-126
)	O	126-127
region	O	128-134
on	O	135-137
chromosome	O	138-148
11q13	O	149-154
appears	O	155-162
to	O	163-165
be	O	166-168
highly	O	169-175
characteristic	O	176-190
of	O	191-193
centrocytic	B	194-205
lymphoma	I	206-214
and	O	215-218
also	O	219-223
is	O	224-226
found	O	227-232
infrequently	O	233-245
in	O	246-248
other	O	249-254
B	B	255-256
-	I	256-257
cell	I	257-261
neoplasms	I	262-271
.	O	271-272

Rearrangement	O	273-286
is	O	287-289
thought	O	290-297
to	O	298-300
deregulate	O	301-311
a	O	312-313
nearby	O	314-320
protooncogene	O	321-334
,	O	334-335
but	O	336-339
transcribed	O	340-351
sequences	O	352-361
in	O	362-364
the	O	365-368
immediate	O	369-378
vicinity	O	379-387
of	O	388-390
BCL1	O	391-395
breakpoints	O	396-407
had	O	408-411
not	O	412-415
been	O	416-420
identified	O	421-431
.	O	431-432

PRAD1	O	433-438
,	O	438-439
previously	O	440-450
designated	O	451-461
D11S287E	O	462-470
,	O	470-471
was	O	472-475
identified	O	476-486
on	O	487-489
11q13	O	490-495
as	O	496-498
a	O	499-500
chromosomal	O	501-512
breakpoint	O	513-523
region	O	524-530
rearranged	O	531-541
with	O	542-546
the	O	547-550
parathyroid	O	551-562
hormone	O	563-570
gene	O	571-575
in	O	576-578
a	O	579-580
subset	O	581-587
of	O	588-590
parathyroid	B	591-602
adenomas	I	603-611
;	O	611-612
this	O	613-617
highly	O	618-624
conserved	O	625-634
putative	O	635-643
oncogene	O	644-652
,	O	652-653
which	O	654-659
encodes	O	660-667
a	O	668-669
novel	O	670-675
cyclin	O	676-682
,	O	682-683
has	O	684-687
been	O	688-692
linked	O	693-699
to	O	700-702
BCL1	O	703-707
and	O	708-711
implicated	O	712-722
also	O	723-727
in	O	728-730
subsets	O	731-738
of	O	739-741
breast	B	742-748
and	I	749-752
squamous	I	753-761
cell	I	762-766
neoplasms	I	767-776
with	O	777-781
11q13	O	782-787
amplification	O	788-801
.	O	801-802

We	O	803-805
report	O	806-812
pulsed	O	813-819
-	O	819-820
field	O	820-825
gel	O	826-829
electrophoresis	O	830-845
data	O	846-850
showing	O	851-858
BCL1	O	859-863
and	O	864-867
PRAD1	O	868-873
to	O	874-876
be	O	877-879
no	O	880-882
more	O	883-887
than	O	888-892
130	O	893-896
kilobases	O	897-906
apart	O	907-912
.	O	912-913

PRAD1	O	914-919
mRNA	O	920-924
is	O	925-927
abundantly	O	928-938
expressed	O	939-948
in	O	949-951
seven	O	952-957
of	O	958-960
seven	O	961-966
centrocytic	B	967-978
lymphomas	I	979-988
(	O	989-990
Kiel	O	990-994
classification	O	995-1009
)	O	1009-1010
,	O	1010-1011
in	O	1012-1014
contrast	O	1015-1023
to	O	1024-1026
13	O	1027-1029
closely	O	1030-1037
related	O	1038-1045
but	O	1046-1049
noncentrocytic	B	1050-1064
lymphomas	I	1065-1074
.	O	1074-1075

Three	O	1076-1081
of	O	1082-1084
the	O	1085-1088
seven	O	1089-1094
centrocytic	B	1095-1106
lymphomas	I	1107-1116
had	O	1117-1120
detectable	O	1121-1131
BCL1	O	1132-1136
DNA	O	1137-1140
rearrangement	O	1141-1154
.	O	1154-1155

Also	O	1156-1160
,	O	1160-1161
two	O	1162-1165
unusual	O	1166-1173
cases	O	1174-1179
of	O	1180-1182
CLL	O	1183-1186
with	O	1187-1191
BCL1	O	1192-1196
rearrangement	O	1197-1210
overexpressed	O	1211-1224
PRAD1	O	1225-1230
,	O	1230-1231
in	O	1232-1234
contrast	O	1235-1243
to	O	1244-1246
five	O	1247-1251
CLL	O	1252-1255
controls	O	1256-1264
.	O	1264-1265

Thus	O	1266-1270
,	O	1270-1271
PRAD1	O	1272-1277
is	O	1278-1280
an	O	1281-1283
excellent	O	1284-1293
candidate	O	1294-1303
"	O	1304-1305
BCL1	O	1306-1310
oncogene	O	1311-1319
.	O	1319-1320

"	O	1321-1322
Its	O	1323-1326
overexpression	O	1327-1341
may	O	1342-1345
be	O	1346-1348
a	O	1349-1350
key	O	1351-1354
consequence	O	1355-1366
of	O	1367-1369
rearrangement	O	1370-1383
of	O	1384-1386
the	O	1387-1390
BCL1	O	1391-1395
vicinity	O	1396-1404
in	O	1405-1407
B	B	1408-1409
-	I	1409-1410
cell	I	1410-1414
neoplasms	I	1415-1424
and	O	1425-1428
a	O	1429-1430
unifying	O	1431-1439
pathogenetic	O	1440-1452
feature	O	1453-1460
in	O	1461-1463
centrocytic	B	1464-1475
lymphoma	I	1476-1484
.	O	1484-1485

Adrenoleukodystrophy	B	0-20
:	O	20-21
increased	O	22-31
plasma	O	32-38
content	O	39-46
of	O	47-49
saturated	O	50-59
very	O	60-64
long	O	65-69
chain	O	70-75
fatty	O	76-81
acids	O	82-87
.	O	87-88

With	O	89-93
a	O	94-95
new	O	96-99
method	O	100-106
we	O	107-109
measured	O	110-118
the	O	119-122
saturated	O	123-132
very	O	133-137
long	O	138-142
chain	O	143-148
fatty	O	149-154
acids	O	155-160
in	O	161-163
the	O	164-167
plasma	O	168-174
of	O	175-177
adrenoleukodystrophy	B	178-198
(	O	199-200
ALD	B	200-203
)	O	203-204
hemizygotes	O	205-216
,	O	216-217
ALD	B	218-221
heterozygotes	O	222-235
,	O	235-236
and	O	237-240
controls	O	241-249
.	O	249-250

ALD	B	251-254
hemizygotes	O	255-266
showed	O	267-273
increased	O	274-283
levels	O	284-290
of	O	291-293
hexacosanoate	O	294-307
(	O	308-309
C26	O	309-312
fatty	O	313-318
acid	O	319-323
)	O	323-324
which	O	325-330
represented	O	331-342
0	O	343-344
.	O	344-345
081	O	346-349
+	O	350-351
/	O	351-352
-	O	352-353
0	O	354-355
.	O	355-356
0066	O	357-361
%	O	361-362
(	O	363-364
SEM	O	364-367
)	O	367-368
of	O	369-371
total	O	372-377
fatty	O	378-383
acids	O	384-389
,	O	389-390
compared	O	391-399
to	O	400-402
0	O	403-404
.	O	404-405
015	O	406-409
+	O	410-411
/	O	411-412
-	O	412-413
0	O	414-415
.	O	415-416
0032	O	417-421
%	O	421-422
in	O	423-425
the	O	426-429
controls	O	430-438
.	O	438-439

C25	O	440-443
,	O	443-444
C24	O	445-448
,	O	448-449
and	O	450-453
C23	O	454-457
fatty	O	458-463
acids	O	464-469
were	O	470-474
also	O	475-479
increased	O	480-489
,	O	489-490
but	O	491-494
the	O	495-498
C22	O	499-502
and	O	503-506
C20	O	507-510
fatty	O	511-516
acids	O	517-522
were	O	523-527
normal	O	528-534
.	O	534-535

C26	O	536-539
levels	O	540-546
were	O	547-551
also	O	552-556
increased	O	557-566
in	O	567-569
most	O	570-574
ALD	B	575-578
heterozygotes	O	579-592
,	O	592-593
with	O	594-598
a	O	599-600
mean	O	601-605
level	O	606-611
0	O	612-613
.	O	613-614
057	O	615-618
+	O	619-620
/	O	620-621
-	O	621-622
0	O	623-624
.	O	624-625
0063	O	626-630
%	O	630-631
of	O	632-634
total	O	635-640
fatty	O	641-646
acids	O	647-652
.	O	652-653

The	O	654-657
technique	O	658-667
can	O	668-671
be	O	672-674
used	O	675-679
for	O	680-683
diagnosis	O	684-693
and	O	694-697
carrier	O	698-705
identification	O	706-720
,	O	720-721
and	O	722-725
in	O	726-728
the	O	729-732
evaluation	O	733-743
of	O	744-746
therapy	O	747-754
.	O	754-755

Glucose	B	0-7
-	I	7-8
6	I	8-9
-	I	7-8
phosphate	I	10-19
dehydrogenase	I	20-33
deficiency	I	34-44
inhibits	O	45-53
in	O	54-56
vitro	O	57-62
growth	O	63-69
of	O	70-72
Plasmodium	O	73-83
falciparum	O	84-94
.	O	94-95

Glucose	B	96-103
-	I	103-104
6	I	104-105
-	I	103-104
phosphate	I	106-115
dehydrogenase	I	116-129
(	I	130-131
G6PD	I	131-135
;	I	135-136
EC	I	137-139
1	I	140-141
.	I	141-142
1	I	143-144
.	I	144-145
1	I	146-147
.	I	147-148
49	I	149-151
)	I	151-152
-	I	153-154
deficient	I	154-163
red	O	164-167
blood	O	168-173
cells	O	174-179
from	O	180-184
male	O	185-189
hemizygotes	O	190-201
and	O	202-205
female	O	206-212
heterozygotes	O	213-226
from	O	227-231
the	O	232-235
island	O	236-242
of	O	243-245
Sardinia	O	246-254
were	O	255-259
studied	O	260-267
for	O	268-271
their	O	272-277
ability	O	278-285
to	O	286-288
support	O	289-296
growth	O	297-303
in	O	304-306
vitro	O	307-312
of	O	313-315
the	O	316-319
malaria	B	320-327
-	O	327-328
causing	O	328-335
organism	O	336-344
Plasmodium	O	345-355
falciparum	O	356-366
.	O	366-367

Parasite	O	368-376
growth	O	377-383
was	O	384-387
approximately	O	388-401
one	O	402-405
-	O	405-406
third	O	406-411
of	O	412-414
normal	O	415-421
in	O	422-424
both	O	425-429
hemi	O	430-434
-	O	434-435
and	O	436-439
heterozygotes	O	440-453
for	O	454-457
G6PD	B	458-462
deficiency	I	463-473
.	O	473-474

In	O	475-477
Sardinians	O	478-488
with	O	489-493
the	O	494-497
beta	O	498-502
0	O	503-504
-	O	504-505
thalassemia	O	505-516
trait	O	517-522
,	O	522-523
parasite	O	524-532
growth	O	533-539
was	O	540-543
normal	O	544-550
except	O	551-557
when	O	558-562
G6PD	B	563-567
deficiency	I	568-578
occurred	O	579-587
together	O	588-596
with	O	597-601
the	O	602-605
thalassemia	B	606-617
trait	O	618-623
.	O	623-624

The	O	625-628
data	O	629-633
support	O	634-641
the	O	642-645
hypothesis	O	646-656
that	O	657-661
G6PD	B	662-666
deficiency	I	667-677
may	O	678-681
confer	O	682-688
a	O	689-690
selective	O	691-700
advantage	O	701-710
in	O	711-713
a	O	714-715
malarious	B	716-725
area	O	726-730
;	O	730-731
the	O	732-735
female	O	736-742
heterozygote	O	743-755
may	O	756-759
be	O	760-762
at	O	763-765
a	O	766-767
particular	O	768-778
advantage	O	779-788
because	O	789-796
resistance	O	797-807
to	O	808-810
malaria	B	811-818
equals	O	819-825
that	O	826-830
of	O	831-833
male	O	834-838
hemizygotes	O	839-850
,	O	850-851
but	O	852-855
the	O	856-859
risk	O	860-864
of	O	865-867
fatal	B	868-873
hemolysis	I	874-883
may	O	884-887
be	O	888-890
less	O	891-895
.	O	895-896

However	O	897-904
,	O	904-905
more	O	906-910
female	O	911-917
heterozygotes	O	918-931
must	O	932-936
be	O	937-939
studied	O	940-947
to	O	948-950
confirm	O	951-958
this	O	959-963
hypothesis	O	964-974
.	O	974-975

No	O	976-978
protective	O	979-989
effect	O	990-996
of	O	997-999
beta	O	1000-1004
0	O	1005-1006
-	O	1006-1007
thalassemia	O	1007-1018
trait	O	1019-1024
could	O	1025-1030
be	O	1031-1033
demonstrated	O	1034-1046
in	O	1047-1049
vitro	O	1050-1055
.	O	1055-1056

Heterozygous	B	0-12
C2	I	13-15
deficiency	I	16-26
associated	O	27-37
with	O	38-42
angioedema	B	43-53
,	O	53-54
myasthenia	B	55-65
gravis	I	66-72
,	O	72-73
and	O	74-77
systemic	B	78-86
lupus	I	87-92
erythematosus	I	93-106
.	O	106-107

We	O	108-110
describe	O	111-119
a	O	120-121
patient	O	122-129
with	O	130-134
myasthenia	B	135-145
gravis	I	146-152
,	O	152-153
systemic	B	154-162
lupus	I	163-168
erythematosus	I	169-182
,	O	182-183
and	O	184-187
angioedema	B	188-198
associated	O	199-209
with	O	210-214
heterozygous	O	215-227
complement	B	228-238
factor	I	239-245
2	I	246-247
(	I	248-249
C2	I	249-251
)	I	251-252
deficiency	I	253-263
.	O	263-264

The	O	265-268
significance	O	269-281
of	O	282-284
this	O	285-289
association	O	290-301
is	O	302-304
controversial	O	305-318
,	O	318-319
though	O	320-326
the	O	327-330
association	O	331-342
of	O	343-345
C2	B	346-348
deficiency	I	349-359
with	O	360-364
certain	O	365-372
histocompatibility	O	373-391
antigens	O	392-400
suggests	O	401-409
possible	O	410-418
linkage	O	419-426
to	O	427-429
immune	O	430-436
response	O	437-445
genes	O	446-451
.	O	451-452

To	O	453-455
our	O	456-459
knowledge	O	460-469
this	O	470-474
is	O	475-477
the	O	478-481
first	O	482-487
report	O	488-494
of	O	495-497
heterozygous	O	498-510
C2	B	511-513
deficiency	I	514-524
in	O	525-527
association	O	528-539
with	O	540-544
this	O	545-549
combination	O	550-561
of	O	562-564
autoimmune	B	565-575
disorders	I	576-585
,	O	585-586
and	O	587-590
we	O	591-593
discuss	O	594-601
the	O	602-605
aetiological	O	606-618
implications	O	619-631
.	O	631-632
.	O	631-632

Inherited	O	0-9
C3	B	10-12
deficiency	I	13-23
with	O	24-28
recurrent	O	29-38
infections	O	39-49
and	O	50-53
glomerulonephritis	B	54-72
.	O	72-73

A	O	74-75
10	O	76-78
-	O	78-79
year	O	79-83
-	O	78-79
old	O	84-87
Laotian	O	88-95
boy	O	96-99
had	O	100-103
homozygous	O	104-114
deficiency	B	115-125
of	I	126-128
the	I	129-132
third	I	133-138
component	I	139-148
of	I	149-151
complement	I	152-162
and	O	163-166
recurrent	O	167-176
bacterial	B	177-186
infections	I	187-197
beginning	O	198-207
at	O	208-210
age	O	211-214
5	O	215-216
months	O	217-223
.	O	223-224

Cellular	O	225-233
and	O	234-237
humoral	O	238-245
immunity	O	246-254
were	O	255-259
normal	O	260-266
,	O	266-267
as	O	268-270
were	O	271-275
polymorphonuclear	O	276-293
leukocyte	O	294-303
chemotaxis	O	304-314
and	O	315-318
bactericidal	O	319-331
activities	O	332-342
.	O	342-343

Serum	O	344-349
complement	O	350-360
-	O	360-361
mediated	O	361-369
hemolytic	O	370-379
,	O	379-380
chemotactic	O	381-392
,	O	392-393
and	O	394-397
opsonic	O	398-405
activities	O	406-416
were	O	417-421
deficient	O	422-431
.	O	431-432

In	O	433-435
vitro	O	436-441
addition	O	442-450
of	O	451-453
purified	O	454-462
C3	O	463-465
to	O	466-468
patient	O	469-476
serum	O	477-482
restored	O	483-491
hemolytic	O	492-501
complement	O	502-512
to	O	513-515
normal	O	516-522
levels	O	523-529
,	O	529-530
and	O	531-534
plasma	O	535-541
infusion	O	542-550
during	O	551-557
each	O	558-562
of	O	563-565
four	O	566-570
episodes	O	571-579
of	O	580-582
pneumonia	B	583-592
significantly	O	593-606
enhanced	O	607-615
serum	O	616-621
opsonic	O	622-629
activity	O	630-638
for	O	639-642
as	O	643-645
long	O	646-650
as	O	651-653
36	O	654-656
hours	O	657-662
.	O	662-663

A	O	664-665
renal	O	666-671
biopsy	O	672-678
specimen	O	679-687
revealed	O	688-696
mesangiopathic	B	697-711
glomerulonephritis	I	712-730
,	O	730-731
although	O	732-740
significant	O	741-752
levels	O	753-759
of	O	760-762
circulating	O	763-774
IgG	O	775-778
immune	O	779-785
complexes	O	786-795
were	O	796-800
not	O	801-804
detected	O	805-813
.	O	813-814

These	O	815-820
findings	O	821-829
further	O	830-837
support	O	838-845
the	O	846-849
association	O	850-861
of	O	862-864
C3	B	865-867
deficiency	I	868-878
with	O	879-883
immune	B	884-890
-	I	890-891
complex	I	891-898
disease	I	899-906
and	O	907-910
suggest	O	911-918
that	O	919-923
plasma	O	924-930
infusion	O	931-939
may	O	940-943
be	O	944-946
an	O	947-949
adjunct	O	950-957
to	O	958-960
antibiotic	O	961-971
therapy	O	972-979
in	O	980-982
the	O	983-986
management	O	987-997
of	O	998-1000
severe	O	1001-1007
pyogenic	B	1008-1016
infections	I	1017-1027
in	O	1028-1030
patients	O	1031-1039
with	O	1040-1044
C3	B	1045-1047
deficiency	I	1048-1058
.	O	1058-1059
.	O	1058-1059

Southern	O	0-8
analysis	O	9-17
reveals	O	18-25
a	O	26-27
large	O	28-33
deletion	O	34-42
at	O	43-45
the	O	46-49
hypoxanthine	O	50-62
phosphoribosyltransferase	O	63-88
locus	O	89-94
in	O	95-97
a	O	98-99
patient	O	100-107
with	O	108-112
Lesch	B	113-118
-	I	118-119
Nyhan	I	119-124
syndrome	I	125-133
.	O	133-134

Whole	O	135-140
genomic	O	141-148
hprt	O	149-153
clones	O	154-160
were	O	161-165
used	O	166-170
in	O	171-173
Southern	O	174-182
analysis	O	183-191
to	O	192-194
screen	O	195-201
the	O	202-205
integrity	O	206-215
of	O	216-218
the	O	219-222
hprt	O	223-227
gene	O	228-232
in	O	233-235
a	O	236-237
family	O	238-244
that	O	245-249
includes	O	250-258
a	O	259-260
patient	O	261-268
with	O	269-273
HPRT	B	274-278
enzyme	I	279-285
deficiency	I	286-296
causal	O	297-303
to	O	304-306
Lesch	B	307-312
-	I	312-313
Nyhan	I	313-318
syndrome	I	319-327
.	O	327-328

A	O	329-330
5	O	331-332
kb	O	333-335
DNA	O	336-339
sequence	O	340-348
deletion	O	349-357
was	O	358-361
found	O	362-367
to	O	368-370
have	O	371-375
its	O	376-379
endpoints	O	380-389
in	O	390-392
the	O	393-396
first	O	397-402
and	O	403-406
third	O	407-412
introns	O	413-420
.	O	420-421

The	O	422-425
probes	O	426-432
identified	O	433-443
the	O	444-447
carrier	O	448-455
status	O	456-462
of	O	463-465
female	O	466-472
family	O	473-479
members	O	480-487
,	O	487-488
aided	O	489-494
by	O	495-497
an	O	498-500
RFLP	O	501-505
carried	O	506-513
by	O	514-516
the	O	517-520
mothers	O	521-528
normal	O	529-535
X	O	536-537
-	O	537-538
chromosome	O	538-548
.	O	548-549
.	O	548-549

Association	O	0-11
of	O	12-14
BRCA1	O	15-20
with	O	21-25
the	O	26-29
hRad50	O	30-36
-	O	36-37
hMre11	O	37-43
-	O	36-37
p95	O	44-47
complex	O	48-55
and	O	56-59
the	O	60-63
DNA	O	64-67
damage	O	68-74
response	O	75-83
.	O	83-84

BRCA1	O	85-90
encodes	O	91-98
a	O	99-100
tumor	B	101-106
suppressor	O	107-117
that	O	118-122
is	O	123-125
mutated	O	126-133
in	O	134-136
familial	B	137-145
breast	I	146-152
and	I	153-156
ovarian	I	157-164
cancers	I	165-172
.	O	172-173

Here	O	174-178
,	O	178-179
it	O	180-182
is	O	183-185
shown	O	186-191
that	O	192-196
BRCA1	O	197-202
interacts	O	203-212
in	O	213-215
vitro	O	216-221
and	O	222-225
in	O	226-228
vivo	O	229-233
with	O	234-238
hRad50	O	239-245
,	O	245-246
which	O	247-252
forms	O	253-258
a	O	259-260
complex	O	261-268
with	O	269-273
hMre11	O	274-280
and	O	281-284
p95	O	285-288
/	O	288-289
nibrin	O	289-295
.	O	295-296

Upon	O	297-301
irradiation	O	302-313
,	O	313-314
BRCA1	O	315-320
was	O	321-324
detected	O	325-333
in	O	334-336
discrete	O	337-345
foci	O	346-350
in	O	351-353
the	O	354-357
nucleus	O	358-365
,	O	365-366
which	O	367-372
colocalize	O	373-383
with	O	384-388
hRad50	O	389-395
.	O	395-396

Formation	O	397-406
of	O	407-409
irradiation	O	410-421
-	O	421-422
induced	O	422-429
foci	O	430-434
positive	O	435-443
for	O	444-447
BRCA1	O	448-453
,	O	453-454
hRad50	O	455-461
,	O	461-462
hMre11	O	463-469
,	O	469-470
or	O	471-473
p95	O	474-477
was	O	478-481
dramatically	O	482-494
reduced	O	495-502
in	O	503-505
HCC	O	506-509
/	O	509-510
1937	O	510-514
breast	B	515-521
cancer	I	522-528
cells	O	529-534
carrying	O	535-543
a	O	544-545
homozygous	O	546-556
mutation	O	557-565
in	O	566-568
BRCA1	O	569-574
but	O	575-578
was	O	579-582
restored	O	583-591
by	O	592-594
transfection	O	595-607
of	O	608-610
wild	O	611-615
-	O	615-616
type	O	616-620
BRCA1	O	621-626
.	O	626-627

Ectopic	O	628-635
expression	O	636-646
of	O	647-649
wild	O	650-654
-	O	654-655
type	O	655-659
,	O	659-660
but	O	661-664
not	O	665-668
mutated	O	669-676
,	O	676-677
BRCA1	O	678-683
in	O	684-686
these	O	687-692
cells	O	693-698
rendered	O	699-707
them	O	708-712
less	O	713-717
sensitive	O	718-727
to	O	728-730
the	O	731-734
DNA	O	735-738
damage	O	739-745
agent	O	746-751
,	O	751-752
methyl	O	753-759
methanesulfonate	O	760-776
.	O	776-777

These	O	778-783
data	O	784-788
suggest	O	789-796
that	O	797-801
BRCA1	O	802-807
is	O	808-810
important	O	811-820
for	O	821-824
the	O	825-828
cellular	O	829-837
responses	O	838-847
to	O	848-850
DNA	O	851-854
damage	O	855-861
that	O	862-866
are	O	867-870
mediated	O	871-879
by	O	880-882
the	O	883-886
hRad50	O	887-893
-	O	893-894
hMre11	O	894-900
-	O	893-894
p95	O	901-904
complex	O	905-912
.	O	912-913
.	O	912-913

Nebulin	O	0-7
and	O	8-11
titin	O	12-17
expression	O	18-28
in	O	29-31
Duchenne	B	32-40
muscular	I	41-49
dystrophy	I	50-59
appears	O	60-67
normal	O	68-74
.	O	74-75

Monoclonal	O	76-86
antibodies	O	87-97
which	O	98-103
recognize	O	104-113
different	O	114-123
epitopes	O	124-132
on	O	133-135
either	O	136-142
titin	O	143-148
or	O	149-151
nebulin	O	152-159
show	O	160-164
normal	O	165-171
staining	O	172-180
patterns	O	181-189
on	O	190-192
frozen	O	193-199
sections	O	200-208
of	O	209-211
three	O	212-217
muscle	O	218-224
biopsies	O	225-233
of	O	234-236
Duchenne	B	237-245
muscular	I	246-254
dystrophy	I	255-264
(	O	265-266
DMD	B	266-269
)	O	269-270
.	O	270-271

Gel	O	272-275
electrophoresis	O	276-291
and	O	292-295
immunoblotting	O	296-310
performed	O	311-320
on	O	321-323
two	O	324-327
of	O	328-330
these	O	331-336
muscle	O	337-343
biopsies	O	344-352
show	O	353-357
the	O	358-361
normal	O	362-368
pattern	O	369-376
of	O	377-379
titin	O	380-385
and	O	386-389
nebulin	O	390-397
polypeptides	O	398-410
.	O	410-411

Since	O	412-417
the	O	418-421
donor	O	422-427
of	O	428-430
one	O	431-434
of	O	435-437
these	O	438-443
biopsies	O	444-452
has	O	453-456
a	O	457-458
large	O	459-464
deletion	O	465-473
of	O	474-476
the	O	477-480
5	O	481-482
-	O	482-483
region	O	483-489
of	O	490-492
the	O	493-496
DMD	B	497-500
gene	O	501-505
,	O	505-506
our	O	507-510
results	O	511-518
argue	O	519-524
against	O	525-532
the	O	533-536
recent	O	537-543
proposal	O	544-552
that	O	553-557
nebulin	O	558-565
is	O	566-568
the	O	569-572
gene	O	573-577
mutated	O	578-585
in	O	586-588
DMD	B	589-592
.	O	592-593
.	O	592-593

Myotonic	B	0-8
dystrophy	I	9-18
kinase	O	19-25
is	O	26-28
a	O	29-30
component	O	31-40
of	O	41-43
neuromuscular	O	44-57
junctions	O	58-67
.	O	67-68

The	O	69-72
clinical	O	73-81
manifestation	O	82-95
of	O	96-98
myotonic	B	99-107
dystrophy	I	108-117
(	O	118-119
DM	B	119-121
)	O	121-122
is	O	123-125
correlated	O	126-136
to	O	137-139
the	O	140-143
extent	O	144-150
of	O	151-153
expansion	O	154-163
of	O	164-166
an	O	167-169
unstable	O	170-178
[	O	179-180
CTG	O	180-183
]	O	183-184
n	O	185-186
DNA	O	187-190
motif	O	191-196
.	O	196-197

Recent	O	198-204
studies	O	205-212
have	O	213-217
demonstrated	O	218-230
that	O	231-235
this	O	236-240
trinucleotide	O	241-254
motif	O	255-260
forms	O	261-266
part	O	267-271
of	O	272-274
the	O	275-278
last	O	279-283
,	O	283-284
3	O	285-286
untranslated	O	287-299
exon	O	300-304
of	O	305-307
a	O	308-309
gene	O	310-314
which	O	315-320
potentially	O	321-332
encodes	O	333-340
multiple	O	341-349
protein	O	350-357
isoforms	O	358-366
of	O	367-369
a	O	370-371
serine	O	372-378
/	O	378-379
threonine	O	379-388
protein	O	389-396
kinase	O	397-403
(	O	404-405
myotonic	B	405-413
dystrophy	I	414-423
protein	O	424-431
kinase	O	432-438
,	O	438-439
DM	O	440-442
-	O	442-443
PK	O	443-445
)	O	445-446
.	O	446-447

We	O	448-450
report	O	451-457
here	O	458-462
on	O	463-465
the	O	466-469
development	O	470-481
of	O	482-484
antisera	O	485-493
against	O	494-501
synthetic	O	502-511
DM	O	512-514
-	O	514-515
PK	O	515-517
peptide	O	518-525
antigens	O	526-534
and	O	535-538
their	O	539-544
use	O	545-548
in	O	549-551
biochemical	O	552-563
and	O	564-567
histochemical	O	568-581
studies	O	582-589
.	O	589-590

Immunoreactive	O	591-605
DM	O	606-608
-	O	608-609
kinase	O	609-615
protein	O	616-623
of	O	624-626
53	O	627-629
kD	O	630-632
is	O	633-635
present	O	636-643
at	O	644-646
low	O	647-650
levels	O	651-657
in	O	658-660
skeletal	O	661-669
and	O	670-673
cardiac	O	674-681
muscle	O	682-688
extracts	O	689-697
of	O	698-700
DM	B	701-703
patients	O	704-712
and	O	713-716
normal	O	717-723
controls	O	724-732
.	O	732-733

Immunohistochemical	O	734-753
staining	O	754-762
revealed	O	763-771
that	O	772-776
DM	O	777-779
-	O	779-780
PK	O	780-782
is	O	783-785
localised	O	786-795
prominently	O	796-807
at	O	808-810
sites	O	811-816
of	O	817-819
neuromuscular	O	820-833
and	O	834-837
myotendinous	O	838-850
junctions	O	851-860
(	O	861-862
NMJs	O	862-866
and	O	867-870
MTJs	O	871-875
)	O	875-876
of	O	877-879
human	O	880-885
and	O	886-889
rodent	O	890-896
skeletal	O	897-905
muscles	O	906-913
.	O	913-914

Furthermore	O	915-926
,	O	926-927
very	O	928-932
low	O	933-936
levels	O	937-943
of	O	944-946
immunoreactive	O	947-961
DM	O	962-964
-	O	964-965
PK	O	965-967
protein	O	968-975
are	O	976-979
present	O	980-987
in	O	988-990
the	O	991-994
sarcoplasm	O	995-1005
of	O	1006-1008
predominantly	O	1009-1022
type	O	1023-1027
I	O	1028-1029
fibres	O	1030-1036
in	O	1037-1039
various	O	1040-1047
muscles	O	1048-1055
.	O	1055-1056

Strikingly	O	1057-1067
,	O	1067-1068
presence	O	1069-1077
of	O	1078-1080
the	O	1081-1084
protein	O	1085-1092
can	O	1093-1096
also	O	1097-1101
be	O	1102-1104
demonstrated	O	1105-1117
for	O	1118-1121
NMJs	O	1122-1126
of	O	1127-1129
muscular	O	1130-1138
tissues	O	1139-1146
of	O	1147-1149
adult	O	1150-1155
and	O	1156-1159
congenital	O	1160-1170
cases	O	1171-1176
of	O	1177-1179
DM	B	1180-1182
,	O	1182-1183
with	O	1184-1188
no	O	1189-1191
gross	O	1192-1197
changes	O	1198-1205
in	O	1206-1208
structural	O	1209-1219
organisation	O	1220-1232
.	O	1232-1233

Our	O	1234-1237
findings	O	1238-1246
provide	O	1247-1254
a	O	1255-1256
basis	O	1257-1262
for	O	1263-1266
further	O	1267-1274
characterisation	O	1275-1291
of	O	1292-1294
the	O	1295-1298
role	O	1299-1303
of	O	1304-1306
the	O	1307-1310
kinase	O	1311-1317
in	O	1318-1320
protein	O	1321-1328
assembly	O	1329-1337
processes	O	1338-1347
or	O	1348-1350
signal	O	1351-1357
mediation	O	1358-1367
at	O	1368-1370
synaptic	O	1371-1379
sites	O	1380-1385
and	O	1386-1389
ultimately	O	1390-1400
for	O	1401-1404
the	O	1405-1408
understanding	O	1409-1422
of	O	1423-1425
the	O	1426-1429
complex	O	1430-1437
pathophysiology	O	1438-1453
of	O	1454-1456
DM	B	1457-1459
.	O	1459-1460
.	O	1459-1460

New	O	0-3
genetic	O	4-11
variants	O	12-20
of	O	21-23
glucose	O	24-31
6	O	32-33
-	O	33-34
phosphate	O	34-43
dehydrogenase	O	44-57
(	O	58-59
G6PD	O	59-63
)	O	63-64
in	O	65-67
Italy	O	68-73
.	O	73-74

Six	O	75-78
new	O	79-82
variants	O	83-91
of	O	92-94
human	O	95-100
erythrocyte	O	101-112
G6PD	O	113-117
have	O	118-122
been	O	123-127
characterized	O	128-141
.	O	141-142

All	O	143-146
of	O	147-149
them	O	150-154
were	O	155-159
found	O	160-165
in	O	166-168
Italian	O	169-176
males	O	177-182
and	O	183-186
all	O	187-190
were	O	191-195
associated	O	196-206
with	O	207-211
enzyme	B	212-218
deficiency	I	219-229
,	O	229-230
but	O	231-234
only	O	235-239
two	O	240-243
with	O	244-248
signs	O	249-254
of	O	255-257
haemolysis	B	258-268
.	O	268-269

These	O	270-275
and	O	276-279
other	O	280-285
variants	O	286-294
reported	O	295-303
in	O	304-306
the	O	307-310
literature	O	311-321
,	O	321-322
which	O	323-328
must	O	329-333
thus	O	334-338
far	O	339-342
be	O	343-345
regarded	O	346-354
as	O	355-357
sporadic	O	358-366
,	O	366-367
are	O	368-371
found	O	372-377
to	O	378-380
map	O	381-384
in	O	385-387
parts	O	388-393
of	O	394-396
Italy	O	397-402
where	O	403-408
common	O	409-415
types	O	416-421
of	O	422-424
G6PD	B	425-429
deficiency	I	430-440
are	O	441-444
also	O	445-449
prevalent	O	450-459
.	O	459-460
.	O	459-460

ATM	O	0-3
-	O	3-4
heterozygous	O	4-16
germline	O	17-25
mutations	O	26-35
contribute	O	36-46
to	O	47-49
breast	B	50-56
cancer	I	57-63
-	O	63-64
susceptibility	O	64-78
.	O	78-79

Approximately	O	80-93
0	O	94-95
.	O	95-96
5	O	97-98
%	O	98-99
-	O	100-101
1	O	101-102
%	O	102-103
of	O	104-106
the	O	107-110
general	O	111-118
population	O	119-129
has	O	130-133
been	O	134-138
estimated	O	139-148
to	O	149-151
be	O	152-154
heterozygous	O	155-167
for	O	168-171
a	O	172-173
germline	O	174-182
mutation	O	183-191
in	O	192-194
the	O	195-198
ATM	O	199-202
gene	O	203-207
.	O	207-208

Mutations	O	209-218
in	O	219-221
the	O	222-225
ATM	O	226-229
gene	O	230-234
are	O	235-238
responsible	O	239-250
for	O	251-254
the	O	255-258
autosomal	B	259-268
recessive	I	269-278
disorder	I	279-287
ataxia	B	288-294
-	I	294-295
telangiectasia	I	295-309
(	O	310-311
A	B	311-312
-	I	312-313
T	I	313-314
)	O	314-315
(	O	316-317
MIM	O	317-320
208900	O	321-327
)	O	327-328
.	O	328-329

The	O	330-333
finding	O	334-341
that	O	342-346
ATM	O	347-350
-	O	350-351
heterozygotes	O	351-364
have	O	365-369
an	O	370-372
increased	O	373-382
relative	O	383-391
risk	O	392-396
for	O	397-400
breast	B	401-407
cancer	I	408-414
was	O	415-418
supported	O	419-428
by	O	429-431
some	O	432-436
studies	O	437-444
but	O	445-448
not	O	449-452
confirmed	O	453-462
by	O	463-465
others	O	466-472
.	O	472-473

In	O	474-476
view	O	477-481
of	O	482-484
this	O	485-489
discrepancy	O	490-501
,	O	501-502
we	O	503-505
examined	O	506-514
the	O	515-518
frequency	O	519-528
of	O	529-531
ATM	O	532-535
germline	O	536-544
mutations	O	545-554
in	O	555-557
a	O	558-559
selected	O	560-568
group	O	569-574
of	O	575-577
Dutch	O	578-583
patients	O	584-592
with	O	593-597
breast	B	598-604
cancer	I	605-611
.	O	611-612

We	O	613-615
have	O	616-620
analyzed	O	621-629
ATM	O	630-633
germline	O	634-642
mutations	O	643-652
in	O	653-655
normal	O	656-662
blood	O	663-668
lymphocytes	O	669-680
,	O	680-681
using	O	682-687
the	O	688-691
protein	O	692-699
-	O	699-700
truncation	O	700-710
test	O	711-715
followed	O	716-724
by	O	725-727
genomic	O	728-735
-	O	735-736
sequence	O	736-744
analysis	O	745-753
.	O	753-754

A	O	755-756
high	O	757-761
percentage	O	762-772
of	O	773-775
ATM	O	776-779
germline	O	780-788
mutations	O	789-798
was	O	799-802
demonstrated	O	803-815
among	O	816-821
patients	O	822-830
with	O	831-835
sporadic	B	836-844
breast	I	845-851
cancer	I	852-858
.	O	858-859

The	O	860-863
82	O	864-866
patients	O	867-875
included	O	876-884
in	O	885-887
this	O	888-892
study	O	893-898
had	O	899-902
developed	O	903-912
breast	B	913-919
cancer	I	920-926
at	O	927-929
age	O	930-933
<	O	934-935
45	O	936-938
and	O	939-942
had	O	943-946
survived	O	947-955
>	O	956-957
/	O	957-958
=	O	958-959
5	O	960-961
years	O	962-967
(	O	968-969
mean	O	969-973
15	O	974-976
years	O	977-982
)	O	982-983
,	O	983-984
and	O	985-988
in	O	989-991
33	O	992-994
(	O	995-996
40	O	996-998
%	O	998-999
)	O	999-1000
of	O	1001-1003
the	O	1004-1007
patients	O	1008-1016
a	O	1017-1018
contralateral	O	1019-1032
breast	O	1033-1039
tumor	O	1040-1045
had	O	1046-1049
been	O	1050-1054
diagnosed	O	1055-1064
.	O	1064-1065

Among	O	1066-1071
these	O	1072-1077
patients	O	1078-1086
we	O	1087-1089
identified	O	1090-1100
seven	O	1101-1106
(	O	1107-1108
8	O	1108-1109
.	O	1109-1110
5	O	1111-1112
%	O	1112-1113
)	O	1113-1114
ATM	O	1115-1118
germline	O	1119-1127
mutations	O	1128-1137
,	O	1137-1138
of	O	1139-1141
which	O	1142-1147
five	O	1148-1152
are	O	1153-1156
distinct	O	1157-1165
.	O	1165-1166

One	O	1167-1170
splice	O	1171-1177
-	O	1177-1178
site	O	1178-1182
mutation	O	1183-1191
(	O	1192-1193
IVS10	O	1193-1198
-	O	1198-1199
6T	O	1199-1201
-	O	1198-1199
-	O	1198-1199
>	O	1204-1205
G	O	1206-1207
)	O	1207-1208
was	O	1209-1212
detected	O	1213-1221
three	O	1222-1227
times	O	1228-1233
in	O	1234-1236
our	O	1237-1240
series	O	1241-1247
.	O	1247-1248

Four	O	1249-1253
heterozygous	O	1254-1266
carriers	O	1267-1275
were	O	1276-1280
patients	O	1281-1289
with	O	1290-1294
bilateral	O	1295-1304
breast	O	1305-1311
cancer	O	1312-1318
.	O	1318-1319

Our	O	1320-1323
results	O	1324-1331
indicate	O	1332-1340
that	O	1341-1345
the	O	1346-1349
mutations	O	1350-1359
identified	O	1360-1370
in	O	1371-1373
this	O	1374-1378
study	O	1379-1384
are	O	1385-1388
"	O	1389-1390
A	O	1391-1392
-	O	1392-1393
T	O	1393-1394
disease	O	1395-1402
-	O	1402-1403
causing	O	1403-1410
"	O	1411-1412
mutations	O	1413-1422
that	O	1423-1427
might	O	1428-1433
be	O	1434-1436
associated	O	1437-1447
with	O	1448-1452
an	O	1453-1455
increased	O	1456-1465
risk	O	1466-1470
of	O	1471-1473
breast	O	1474-1480
cancer	O	1481-1487
in	O	1488-1490
heterozygotes	O	1491-1504
.	O	1504-1505

We	O	1506-1508
conclude	O	1509-1517
that	O	1518-1522
ATM	O	1523-1526
heterozygotes	O	1527-1540
have	O	1541-1545
an	O	1546-1548
approximately	O	1549-1562
ninefold	O	1563-1571
-	O	1571-1572
increased	O	1572-1581
risk	O	1582-1586
of	O	1587-1589
developing	O	1590-1600
a	O	1601-1602
type	O	1603-1607
of	O	1608-1610
breast	O	1611-1617
cancer	O	1618-1624
characterized	O	1625-1638
by	O	1639-1641
frequent	O	1642-1650
bilateral	O	1651-1660
occurrence	O	1661-1671
,	O	1671-1672
early	O	1673-1678
age	O	1679-1682
at	O	1683-1685
onset	O	1686-1691
,	O	1691-1692
and	O	1693-1696
long	O	1697-1701
-	O	1701-1702
term	O	1702-1706
survival	O	1707-1715
.	O	1715-1716

The	O	1717-1720
specific	O	1721-1729
characteristics	O	1730-1745
of	O	1746-1748
our	O	1749-1752
population	O	1753-1763
of	O	1764-1766
patients	O	1767-1775
may	O	1776-1779
explain	O	1780-1787
why	O	1788-1791
such	O	1792-1796
a	O	1797-1798
high	O	1799-1803
frequency	O	1804-1813
was	O	1814-1817
not	O	1818-1821
found	O	1822-1827
in	O	1828-1830
other	O	1831-1836
series	O	1837-1843
.	O	1843-1844

Autoimmune	B	0-10
lymphoproliferative	I	11-30
syndrome	I	31-39
(	O	40-41
ALPS	B	41-45
)	O	45-46
in	O	47-49
a	O	50-51
child	O	52-57
from	O	58-62
consanguineous	O	63-77
parents	O	78-85
:	O	85-86
a	O	87-88
dominant	O	89-97
or	O	98-100
recessive	O	101-110
disease	O	111-118
?	O	118-119

Autoimmune	B	120-130
lymphoproliferative	I	131-150
syndrome	I	151-159
(	O	160-161
ALPS	B	161-165
)	O	165-166
is	O	167-169
characterized	O	170-183
by	O	184-186
autoimmune	O	187-197
features	O	198-206
and	O	207-210
lymphoproliferations	O	211-231
and	O	232-235
is	O	236-238
generally	O	239-248
caused	O	249-255
by	O	256-258
defective	O	259-268
Fas	O	269-272
-	O	272-273
mediated	O	273-281
apoptosis	O	282-291
.	O	291-292

This	O	293-297
report	O	298-304
describes	O	305-314
a	O	315-316
child	O	317-322
with	O	323-327
clinical	O	328-336
features	O	337-345
of	O	346-348
ALPS	B	349-353
without	O	354-361
detectable	O	362-372
Fas	O	373-376
expression	O	377-387
on	O	388-390
freshly	O	391-398
isolated	O	399-407
blood	O	408-413
leukocytes	O	414-424
.	O	424-425

Detection	O	426-435
of	O	436-438
FAS	O	439-442
transcripts	O	443-454
via	O	455-458
real	O	459-463
-	O	463-464
time	O	464-468
quantitative	O	469-481
PCR	O	482-485
made	O	486-490
a	O	491-492
severe	O	493-499
transcriptional	O	500-515
defect	O	516-522
unlikely	O	523-531
.	O	531-532

Sequencing	O	533-543
of	O	544-546
the	O	547-550
FAS	O	551-554
gene	O	555-559
revealed	O	560-568
a	O	569-570
20	O	571-573
-	O	573-574
nucleotide	O	574-584
duplication	O	585-596
in	O	597-599
the	O	600-603
last	O	604-608
exon	O	609-613
affecting	O	614-623
the	O	624-627
cytoplasmic	O	628-639
signaling	O	640-649
domain	O	650-656
.	O	656-657

The	O	658-661
patient	O	662-669
was	O	670-673
homozygous	O	674-684
for	O	685-688
this	O	689-693
mutation	O	694-702
,	O	702-703
whereas	O	704-711
the	O	712-715
consanguineous	O	716-730
parents	O	731-738
and	O	739-742
the	O	743-746
siblings	O	747-755
were	O	756-760
heterozygous	O	761-773
.	O	773-774

The	O	775-778
patient	O	779-786
reported	O	787-795
here	O	796-800
is	O	801-803
a	O	804-805
human	O	806-811
homologue	O	812-821
of	O	822-824
the	O	825-828
Fas	O	829-832
-	O	832-833
null	O	833-837
mouse	O	838-843
,	O	843-844
inasmuch	O	845-853
as	O	854-856
she	O	857-860
carries	O	861-868
an	O	869-871
autosomal	O	872-881
homozygous	O	882-892
mutation	O	893-901
in	O	902-904
the	O	905-908
FAS	O	909-912
gene	O	913-917
and	O	918-921
she	O	922-925
shows	O	926-931
the	O	932-935
severe	O	936-942
and	O	943-946
accelerated	O	947-958
ALPS	B	959-963
phenotype	O	964-973
.	O	973-974

The	O	975-978
heterozygous	O	979-991
family	O	992-998
members	O	999-1006
did	O	1007-1010
not	O	1011-1014
have	O	1015-1019
the	O	1020-1023
ALPS	B	1024-1028
phenotype	O	1029-1038
,	O	1038-1039
indicating	O	1040-1050
that	O	1051-1055
the	O	1056-1059
disease	O	1060-1067
-	O	1067-1068
causing	O	1068-1075
FAS	O	1076-1079
mutation	O	1080-1088
in	O	1089-1091
this	O	1092-1096
family	O	1097-1103
is	O	1104-1106
autosomal	O	1107-1116
recessive	O	1117-1126
.	O	1126-1127
.	O	1126-1127

A	O	0-1
prevalent	O	2-11
mutation	O	12-20
for	O	21-24
galactosemia	B	25-37
among	O	38-43
black	O	44-49
Americans	O	50-59
.	O	59-60

OBJECTIVE	O	61-70
To	O	72-74
define	O	75-81
the	O	82-85
mutation	O	86-94
causing	O	95-102
galactosemia	B	103-115
in	O	116-118
patients	O	119-127
of	O	128-130
black	O	131-136
American	O	137-145
origin	O	146-152
who	O	153-156
have	O	157-161
no	O	162-164
galactose	O	165-174
-	O	174-175
1	O	175-176
-	O	174-175
phosphate	O	177-186
uridyltransferase	O	187-204
(	O	205-206
GALT	O	206-210
)	O	210-211
activity	O	212-220
in	O	221-223
erythrocytes	O	224-236
but	O	237-240
good	O	241-245
clinical	O	246-254
outcome	O	255-262
.	O	262-263

METHODS	O	264-271
We	O	273-275
discovered	O	276-286
a	O	287-288
mutation	O	289-297
caused	O	298-304
by	O	305-307
a	O	308-309
C	O	310-311
-	O	311-312
-	O	311-312
>	O	314-315
T	O	316-317
transition	O	318-328
at	O	329-331
base	O	332-336
-	O	336-337
pair	O	337-341
1158	O	342-346
of	O	347-349
the	O	350-353
GALT	O	354-358
gene	O	359-363
that	O	364-368
results	O	369-376
in	O	377-379
a	O	380-381
serine	O	382-388
-	O	388-389
to	O	389-391
-	O	388-389
leucine	O	392-399
substitution	O	400-412
at	O	413-415
codon	O	416-421
135	O	422-425
(	O	426-427
S135L	O	427-432
)	O	432-433
.	O	433-434

We	O	435-437
developed	O	438-447
a	O	448-449
method	O	450-456
with	O	457-461
which	O	462-467
to	O	468-470
screen	O	471-477
populations	O	478-489
for	O	490-493
its	O	494-497
prevalence	O	498-508
.	O	508-509

We	O	510-512
compared	O	513-521
galactose	O	522-531
-	O	531-532
1	O	532-533
-	O	531-532
phosphate	O	534-543
uridyltransferase	O	544-561
among	O	562-567
erythrocytes	O	568-580
,	O	580-581
leukocytes	O	582-592
,	O	592-593
and	O	594-597
transformed	O	598-609
lymphoblasts	O	610-622
,	O	622-623
as	O	624-626
well	O	627-631
as	O	632-634
total	O	635-640
body	O	641-645
oxidation	O	646-655
of	O	656-658
D	O	659-660
-	O	660-661
(	O	662-663
13C	O	663-666
)	O	666-667
-	O	668-669
galactose	O	669-678
to	O	679-681
13CO2	O	682-687
among	O	688-693
three	O	694-699
genotypes	O	700-709
for	O	710-713
GALT	O	714-718
(	O	719-720
S135L	O	720-725
/	O	725-726
S135L	O	720-725
,	O	731-732
Q188R	O	733-738
/	O	738-739
Q188R	O	733-738
,	O	744-745
and	O	746-749
Normal	O	750-756
/	O	756-757
Normal	O	750-756
)	O	763-764
.	O	764-765

RESULTS	O	766-773
We	O	775-777
found	O	778-783
a	O	784-785
48	O	786-788
%	O	788-789
prevalence	O	790-800
of	O	801-803
the	O	804-807
S135L	O	808-813
mutation	O	814-822
among	O	823-828
17	O	829-831
black	O	832-837
American	O	838-846
patients	O	847-855
with	O	856-860
classic	B	861-868
galactosemia	I	869-881
and	O	882-885
a	O	886-887
1	O	888-889
%	O	889-890
prevalence	O	891-901
in	O	902-904
a	O	905-906
population	O	907-917
of	O	918-920
50	O	921-923
black	O	924-929
Americans	O	930-939
without	O	940-947
galactosemia	B	948-960
.	O	960-961

The	O	962-965
S135L	O	966-971
mutation	O	972-980
was	O	981-984
not	O	985-988
found	O	989-994
in	O	995-997
84	O	998-1000
white	O	1001-1006
patients	O	1007-1015
with	O	1016-1020
G	O	1021-1022
/	O	1022-1023
G	O	1021-1022
galactosemia	B	1025-1037
nor	O	1038-1041
in	O	1042-1044
87	O	1045-1047
white	O	1048-1053
control	O	1054-1061
subjects	O	1062-1070
without	O	1071-1078
galactosemia	B	1079-1091
.	O	1091-1092

We	O	1093-1095
found	O	1096-1101
normal	O	1102-1108
whole	O	1109-1114
body	O	1115-1119
oxidation	O	1120-1129
of	O	1130-1132
D	O	1133-1134
-	O	1134-1135
(	O	1136-1137
13C	O	1137-1140
)	O	1140-1141
-	O	1142-1143
galactose	O	1143-1152
by	O	1153-1155
the	O	1156-1159
patient	O	1160-1167
homozygous	O	1168-1178
for	O	1179-1182
S135L	O	1183-1188
and	O	1189-1192
various	O	1193-1200
degrees	O	1201-1208
of	O	1209-1211
enzyme	O	1212-1218
impairment	O	1219-1229
among	O	1230-1235
different	O	1236-1245
tissues	O	1246-1253
.	O	1253-1254

CONCLUSIONS	O	1255-1266
The	O	1268-1271
S135L	O	1272-1277
mutation	O	1278-1286
in	O	1287-1289
the	O	1290-1293
GALT	O	1294-1298
gene	O	1299-1303
is	O	1304-1306
a	O	1307-1308
prevalent	O	1309-1318
cause	O	1319-1324
of	O	1325-1327
galactosemia	B	1328-1340
among	O	1341-1346
black	O	1347-1352
patients	O	1353-1361
.	O	1361-1362

Because	O	1363-1370
GALT	O	1371-1375
activity	O	1376-1384
varies	O	1385-1391
in	O	1392-1394
different	O	1395-1404
tissues	O	1405-1412
of	O	1413-1415
patients	O	1416-1424
homozygous	O	1425-1435
for	O	1436-1439
S135L	O	1440-1445
,	O	1445-1446
they	O	1447-1451
may	O	1452-1455
have	O	1456-1460
a	O	1461-1462
better	O	1463-1469
clinical	O	1470-1478
outcome	O	1479-1486
than	O	1487-1491
patients	O	1492-1500
who	O	1501-1504
are	O	1505-1508
homozygous	O	1509-1519
for	O	1520-1523
Q188R	O	1524-1529
when	O	1530-1534
both	O	1535-1539
are	O	1540-1543
treated	O	1544-1551
from	O	1552-1556
infancy	O	1557-1564
.	O	1564-1565
.	O	1564-1565

Constitutive	O	0-12
and	O	13-16
regulated	O	17-26
modes	O	27-32
of	O	33-35
splicing	O	36-44
produce	O	45-52
six	O	53-56
major	O	57-62
myotonic	B	63-71
dystrophy	I	72-81
protein	O	82-89
kinase	O	90-96
(	O	97-98
DMPK	O	98-102
)	O	102-103
isoforms	O	104-112
with	O	113-117
distinct	O	118-126
properties	O	127-137
.	O	137-138

Myotonic	B	139-147
dystrophy	I	148-157
(	O	158-159
DM	B	159-161
)	O	161-162
is	O	163-165
the	O	166-169
most	O	170-174
prevalent	O	175-184
inherited	B	185-194
neuromuscular	I	195-208
disease	I	209-216
in	O	217-219
adults	O	220-226
.	O	226-227

The	O	228-231
genetic	B	232-239
defect	I	240-246
is	O	247-249
a	O	250-251
CTG	O	252-255
triplet	O	256-263
repeat	O	264-270
expansion	O	271-280
in	O	281-283
the	O	284-287
3	O	288-289
-	O	289-290
untranslated	O	290-302
region	O	303-309
of	O	310-312
the	O	313-316
myotonic	B	317-325
dystrophy	I	326-335
protein	O	336-343
kinase	O	344-350
(	O	351-352
DMPK	O	352-356
)	O	356-357
gene	O	358-362
,	O	362-363
consisting	O	364-374
of	O	375-377
15	O	378-380
exons	O	381-386
.	O	386-387

Using	O	388-393
a	O	394-395
transgenic	O	396-406
DMPK	O	407-411
-	O	411-412
overexpressor	O	412-425
mouse	O	426-431
model	O	432-437
,	O	437-438
we	O	439-441
demonstrate	O	442-453
here	O	454-458
that	O	459-463
the	O	464-467
endogenous	O	468-478
mouse	O	479-484
DMPK	O	485-489
gene	O	490-494
and	O	495-498
the	O	499-502
human	O	503-508
DMPK	O	509-513
transgene	O	514-523
produce	O	524-531
six	O	532-535
major	O	536-541
alternatively	O	542-555
spliced	O	556-563
mRNAs	O	564-569
which	O	570-575
have	O	576-580
almost	O	581-587
identical	O	588-597
cell	O	598-602
type	O	603-607
-	O	607-608
dependent	O	608-617
distribution	O	618-630
frequencies	O	631-642
and	O	643-646
expression	O	647-657
patterns	O	658-666
.	O	666-667

Use	O	668-671
of	O	672-674
a	O	675-676
cryptic	O	677-684
5	O	685-686
splice	O	687-693
site	O	694-698
in	O	699-701
exon	O	702-706
8	O	707-708
,	O	708-709
which	O	710-715
results	O	716-723
in	O	724-726
absence	O	727-734
or	O	735-737
presence	O	738-746
of	O	747-749
15	O	750-752
nucleotides	O	753-764
specifying	O	765-775
a	O	776-777
VSGGG	O	778-783
peptide	O	784-791
motif	O	792-797
,	O	797-798
and	O	799-802
/	O	802-803
or	O	803-805
use	O	806-809
of	O	810-812
a	O	813-814
cryptic	O	815-822
3	O	823-824
splice	O	825-831
site	O	832-836
in	O	837-839
exon	O	840-844
14	O	845-847
,	O	847-848
which	O	849-854
leads	O	855-860
to	O	861-863
a	O	864-865
frameshift	O	866-876
in	O	877-879
the	O	880-883
mRNA	O	884-888
reading	O	889-896
frame	O	897-902
,	O	902-903
occur	O	904-909
as	O	910-912
independent	O	913-924
stochastic	O	925-935
events	O	936-942
in	O	943-945
all	O	946-949
tissues	O	950-957
examined	O	958-966
.	O	966-967

In	O	968-970
contrast	O	971-979
,	O	979-980
the	O	981-984
excision	O	985-993
of	O	994-996
exons	O	997-1002
13	O	1003-1005
/	O	1005-1006
14	O	1006-1008
that	O	1009-1013
causes	O	1014-1020
a	O	1021-1022
frameshift	O	1023-1033
and	O	1034-1037
creates	O	1038-1045
a	O	1046-1047
C	O	1048-1049
-	O	1049-1050
terminally	O	1050-1060
truncated	O	1061-1070
protein	O	1071-1078
is	O	1079-1081
clearly	O	1082-1089
cell	O	1090-1094
type	O	1095-1099
dependent	O	1100-1109
and	O	1110-1113
occurs	O	1114-1120
predominantly	O	1121-1134
in	O	1135-1137
smooth	O	1138-1144
muscle	O	1145-1151
.	O	1151-1152

We	O	1153-1155
generated	O	1156-1165
all	O	1166-1169
six	O	1170-1173
full	O	1174-1178
-	O	1178-1179
length	O	1179-1185
mouse	O	1186-1191
cDNAs	O	1192-1197
that	O	1198-1202
result	O	1203-1209
from	O	1210-1214
combinations	O	1215-1227
of	O	1228-1230
these	O	1231-1236
three	O	1237-1242
major	O	1243-1248
splicing	O	1249-1257
events	O	1258-1264
and	O	1265-1268
show	O	1269-1273
that	O	1274-1278
their	O	1279-1284
transfection	O	1285-1297
into	O	1298-1302
cells	O	1303-1308
in	O	1309-1311
culture	O	1312-1319
leads	O	1320-1325
to	O	1326-1328
production	O	1329-1339
of	O	1340-1342
four	O	1343-1347
different	O	1348-1357
approximately	O	1358-1371
74	O	1372-1374
kDa	O	1375-1378
full	O	1379-1383
-	O	1383-1384
length	O	1384-1390
(	O	1391-1392
heart	O	1392-1397
-	O	1397-1398
,	O	1398-1399
skeletal	O	1400-1408
muscle	O	1409-1415
-	O	1415-1416
or	O	1417-1419
brain	O	1420-1425
-	O	1425-1426
specific	O	1426-1434
)	O	1434-1435
and	O	1436-1439
two	O	1440-1443
C	O	1444-1445
-	O	1445-1446
terminally	O	1446-1456
truncated	O	1457-1466
approximately	O	1467-1480
68	O	1481-1483
kDa	O	1484-1487
(	O	1488-1489
smooth	O	1489-1495
muscle	O	1496-1502
-	O	1502-1503
specific	O	1503-1511
)	O	1511-1512
isoforms	O	1513-1521
.	O	1521-1522

Information	O	1523-1534
on	O	1535-1537
DMPK	O	1538-1542
mRNA	O	1543-1547
and	O	1548-1551
protein	O	1552-1559
isoform	O	1560-1567
expression	O	1568-1578
patterns	O	1579-1587
will	O	1588-1592
be	O	1593-1595
useful	O	1596-1602
for	O	1603-1606
recognizing	O	1607-1618
differential	O	1619-1631
effects	O	1632-1639
of	O	1640-1642
(	O	1643-1644
CTG	O	1644-1647
)	O	1647-1648
(	O	1649-1650
n	O	1650-1651
)	O	1651-1652
expansion	O	1653-1662
in	O	1663-1665
DM	B	1666-1668
manifestation	O	1669-1682
.	O	1682-1683
.	O	1682-1683

Linkage	O	0-7
analysis	O	8-16
in	O	17-19
a	O	20-21
large	O	22-27
Brazilian	O	28-37
family	O	38-44
with	O	45-49
van	B	50-53
der	I	54-57
Woude	I	58-63
syndrome	I	64-72
suggests	O	73-81
the	O	82-85
existence	O	86-95
of	O	96-98
a	O	99-100
susceptibility	O	101-115
locus	O	116-121
for	O	122-125
cleft	B	126-131
palate	I	132-138
at	O	139-141
17p11	O	142-147
.	O	147-148
2	O	148-149
-	O	149-150
11	O	145-147
.	O	147-148
1	O	142-143
.	O	147-148

van	B	156-159
der	I	160-163
Woude	I	164-169
syndrome	I	170-178
(	O	179-180
VWS	B	180-183
)	O	183-184
,	O	184-185
which	O	186-191
has	O	192-195
been	O	196-200
mapped	O	201-207
to	O	208-210
1q32	O	211-215
-	O	215-216
41	O	216-218
,	O	218-219
is	O	220-222
characterized	O	223-236
by	O	237-239
pits	B	240-244
and	I	245-248
/	I	248-249
or	I	249-251
sinuses	I	252-259
of	I	260-262
the	I	263-266
lower	I	267-272
lip	I	273-276
,	O	276-277
cleft	B	278-283
lip	I	284-287
/	I	287-288
palate	I	288-294
(	O	295-296
CL	B	296-298
/	I	298-299
P	I	299-300
)	O	300-301
,	O	301-302
cleft	B	303-308
palate	I	309-315
(	O	316-317
CP	B	317-319
)	O	319-320
,	O	320-321
bifid	B	322-327
uvula	I	328-333
,	O	333-334
and	O	335-338
hypodontia	B	339-349
(	O	350-351
H	B	351-352
)	O	352-353
.	O	353-354

The	O	355-358
expression	O	359-369
of	O	370-372
VWS	B	373-376
,	O	376-377
which	O	378-383
has	O	384-387
incomplete	O	388-398
penetrance	O	399-409
,	O	409-410
is	O	411-413
highly	O	414-420
variable	O	421-429
.	O	429-430

Both	O	431-435
the	O	436-439
occurrence	O	440-450
of	O	451-453
CL	B	454-456
/	I	456-457
P	I	457-458
and	O	459-462
CP	B	463-465
within	O	466-472
the	O	473-476
same	O	477-481
genealogy	O	482-491
and	O	492-495
a	O	496-497
recurrence	O	498-508
risk	O	509-513
<	O	514-515
40	O	516-518
%	O	518-519
for	O	520-523
CP	B	524-526
among	O	527-532
descendants	O	533-544
with	O	545-549
VWS	B	550-553
have	O	554-558
suggested	O	559-568
that	O	569-573
the	O	574-577
development	O	578-589
of	O	590-592
clefts	B	593-599
in	O	600-602
this	O	603-607
syndrome	O	608-616
is	O	617-619
influenced	O	620-630
by	O	631-633
modifying	O	634-643
genes	O	644-649
at	O	650-652
other	O	653-658
loci	O	659-663
.	O	663-664

To	O	665-667
test	O	668-672
this	O	673-677
hypothesis	O	678-688
,	O	688-689
we	O	690-692
have	O	693-697
conducted	O	698-707
linkage	O	708-715
analysis	O	716-724
in	O	725-727
a	O	728-729
large	O	730-735
Brazilian	O	736-745
kindred	O	746-753
with	O	754-758
VWS	B	759-762
,	O	762-763
considering	O	764-775
as	O	776-778
affected	O	779-787
the	O	788-791
individuals	O	792-803
with	O	804-808
CP	B	809-811
,	O	811-812
regardless	O	813-823
of	O	824-826
whether	O	827-834
it	O	835-837
is	O	838-840
associated	O	841-851
with	O	852-856
other	O	857-862
clinical	O	863-871
signs	O	872-877
of	O	878-880
VWS	B	881-884
.	O	884-885

Our	O	886-889
results	O	890-897
suggest	O	898-905
that	O	906-910
a	O	911-912
gene	O	913-917
at	O	918-920
17p11	O	921-926
.	O	926-927

2	O	928-929
-	O	929-930
11	O	930-932
2	O	933-934
-	O	934-935
11	O	935-937
.	O	937-938
1	O	939-940
,	O	940-941
together	O	942-950
with	O	951-955
the	O	956-959
VWS	B	960-963
gene	O	964-968
at	O	969-971
1p32	O	972-976
-	O	976-977
41	O	977-979
,	O	979-980
enhances	O	981-989
the	O	990-993
probability	O	994-1005
of	O	1006-1008
CP	B	1009-1011
in	O	1012-1014
an	O	1015-1017
individual	O	1018-1028
carrying	O	1029-1037
the	O	1038-1041
two	O	1042-1045
at	O	1046-1048
-	O	1048-1049
risk	O	1049-1053
genes	O	1054-1059
.	O	1059-1060

If	O	1061-1063
this	O	1064-1068
hypothesis	O	1069-1079
is	O	1080-1082
confirmed	O	1083-1092
in	O	1093-1095
other	O	1096-1101
VWS	B	1102-1105
pedigrees	O	1106-1115
,	O	1115-1116
it	O	1117-1119
will	O	1120-1124
represent	O	1125-1134
one	O	1135-1138
of	O	1139-1141
the	O	1142-1145
first	O	1146-1151
examples	O	1152-1160
of	O	1161-1163
a	O	1164-1165
gene	O	1166-1170
,	O	1170-1171
mapped	O	1172-1178
through	O	1179-1186
linkage	O	1187-1194
analysis	O	1195-1203
,	O	1203-1204
which	O	1205-1210
modifies	O	1211-1219
the	O	1220-1223
expression	O	1224-1234
of	O	1235-1237
a	O	1238-1239
major	O	1240-1245
gene	O	1246-1250
.	O	1250-1251

Diverse	O	0-7
point	O	8-13
mutations	O	14-23
in	O	24-26
the	O	27-30
human	O	31-36
glucose	O	37-44
-	O	44-45
6	O	45-46
-	O	44-45
phosphate	O	47-56
dehydrogenase	O	57-70
gene	O	71-75
cause	O	76-81
enzyme	B	82-88
deficiency	I	89-99
and	O	100-103
mild	O	104-108
or	O	109-111
severe	O	112-118
hemolytic	B	119-128
anemia	I	129-135
.	O	135-136

Glucose	B	137-144
-	I	144-145
6	I	145-146
-	I	144-145
phosphate	I	147-156
dehydrogenase	I	157-170
(	I	171-172
G6PD	I	172-176
;	I	176-177
EC	I	178-180
1	I	181-182
.	I	182-183
1	I	184-185
.	I	185-186
1	I	187-188
.	I	188-189
49	I	190-192
)	I	192-193
deficiency	I	194-204
is	O	205-207
a	O	208-209
common	O	210-216
genetic	B	217-224
abnormality	I	225-236
affecting	O	237-246
an	O	247-249
estimated	O	250-259
400	O	260-263
million	O	264-271
people	O	272-278
worldwide	O	279-288
.	O	288-289

Clinical	O	290-298
and	O	299-302
biochemical	O	303-314
analyses	O	315-323
have	O	324-328
identified	O	329-339
many	O	340-344
variants	O	345-353
exhibiting	O	354-364
a	O	365-366
range	O	367-372
of	O	373-375
phenotypes	O	376-386
,	O	386-387
which	O	388-393
have	O	394-398
been	O	399-403
well	O	404-408
characterized	O	409-422
from	O	423-427
the	O	428-431
hematological	O	432-445
point	O	446-451
of	O	452-454
view	O	455-459
.	O	459-460

However	O	461-468
,	O	468-469
until	O	470-475
now	O	476-479
,	O	479-480
their	O	481-486
precise	O	487-494
molecular	O	495-504
basis	O	505-510
has	O	511-514
remained	O	515-523
unknown	O	524-531
.	O	531-532

We	O	533-535
have	O	536-540
cloned	O	541-547
and	O	548-551
sequenced	O	552-561
seven	O	562-567
mutant	O	568-574
G6PD	O	575-579
alleles	O	580-587
.	O	587-588

In	O	589-591
the	O	592-595
nondeficient	O	596-608
polymorphic	O	609-620
African	O	621-628
variant	O	629-636
G6PD	O	637-641
A	O	642-643
we	O	644-646
have	O	647-651
found	O	652-657
a	O	658-659
single	O	660-666
point	O	667-672
mutation	O	673-681
.	O	681-682

The	O	683-686
other	O	687-692
six	O	693-696
mutants	O	697-704
investigated	O	705-717
were	O	718-722
all	O	723-726
associated	O	727-737
with	O	738-742
enzyme	B	743-749
deficiency	I	750-760
.	O	760-761

In	O	762-764
one	O	765-768
of	O	769-771
the	O	772-775
commonest	O	776-785
,	O	785-786
G6PD	O	787-791
Mediterranean	O	792-805
,	O	805-806
which	O	807-812
is	O	813-815
associated	O	816-826
with	O	827-831
favism	B	832-838
among	O	839-844
other	O	845-850
clinical	O	851-859
manifestations	O	860-874
,	O	874-875
a	O	876-877
single	O	878-884
amino	O	885-890
acid	O	891-895
replacement	O	896-907
was	O	908-911
found	O	912-917
(	O	918-919
serine	O	919-925
-	O	925-926
-	O	925-926
-	O	925-926
-	O	925-926
phenylalanine	O	929-942
)	O	942-943
it	O	945-947
must	O	948-952
be	O	953-955
responsible	O	956-967
for	O	968-971
the	O	972-975
decreased	O	976-985
stability	O	986-995
and	O	996-999
the	O	1000-1003
reduced	O	1004-1011
catalytic	O	1012-1021
efficiency	O	1022-1032
of	O	1033-1035
this	O	1036-1040
enzyme	O	1041-1047
.	O	1047-1048

Single	O	1049-1055
point	O	1056-1061
mutations	O	1062-1071
were	O	1072-1076
also	O	1077-1081
found	O	1082-1087
in	O	1088-1090
G6PD	O	1091-1095
Metaponto	O	1096-1105
(	O	1106-1107
Southern	O	1107-1115
Italy	O	1116-1121
)	O	1121-1122
and	O	1123-1126
in	O	1127-1129
G6PD	O	1130-1134
Ilesha	O	1135-1141
(	O	1142-1143
Nigeria	O	1143-1150
)	O	1150-1151
,	O	1151-1152
which	O	1153-1158
are	O	1159-1162
asymptomatic	O	1163-1175
,	O	1175-1176
and	O	1177-1180
in	O	1181-1183
G6PD	O	1184-1188
Chatham	O	1189-1196
,	O	1196-1197
which	O	1198-1203
was	O	1204-1207
observed	O	1208-1216
in	O	1217-1219
an	O	1220-1222
Indian	O	1223-1229
boy	O	1230-1233
with	O	1234-1238
neonatal	B	1239-1247
jaundice	I	1248-1256
.	O	1256-1257

In	O	1258-1260
G6PD	O	1261-1265
"	O	1266-1267
Matera	O	1268-1274
,	O	1274-1275
"	O	1276-1277
which	O	1278-1283
is	O	1284-1286
now	O	1287-1290
known	O	1291-1296
to	O	1297-1299
be	O	1300-1302
the	O	1303-1306
same	O	1307-1311
as	O	1312-1314
G6PD	O	1315-1319
A	O	1320-1321
-	O	1321-1322
,	O	1322-1323
two	O	1324-1327
separate	O	1328-1336
point	O	1337-1342
mutations	O	1343-1352
were	O	1353-1357
found	O	1358-1363
,	O	1363-1364
one	O	1365-1368
of	O	1369-1371
which	O	1372-1377
is	O	1378-1380
the	O	1381-1384
same	O	1385-1389
as	O	1390-1392
in	O	1393-1395
G6PD	O	1396-1400
A	O	1401-1402
.	O	1402-1403
In	O	1404-1406
G6PD	O	1407-1411
Santiago	O	1412-1420
,	O	1420-1421
a	O	1422-1423
de	O	1424-1426
novo	O	1427-1431
mutation	O	1432-1440
(	O	1441-1442
glycine	O	1442-1449
-	O	1449-1450
-	O	1449-1450
-	O	1449-1450
-	O	1449-1450
arginine	O	1453-1461
)	O	1461-1462
is	O	1463-1465
associated	O	1466-1476
with	O	1477-1481
severe	O	1482-1488
chronic	O	1489-1496
hemolytic	B	1497-1506
anemia	I	1507-1513
.	O	1513-1514

The	O	1515-1518
mutations	O	1519-1528
observed	O	1529-1537
show	O	1538-1542
a	O	1543-1544
striking	O	1545-1553
predominance	O	1554-1566
of	O	1567-1569
C	O	1570-1571
-	O	1571-1572
-	O	1571-1572
-	O	1571-1572
-	O	1571-1572
T	O	1575-1576
transitions	O	1577-1588
,	O	1588-1589
with	O	1590-1594
CG	O	1595-1597
doublets	O	1598-1606
involved	O	1607-1615
in	O	1616-1618
four	O	1619-1623
of	O	1624-1626
seven	O	1627-1632
cases	O	1633-1638
.	O	1638-1639

Thus	O	1640-1644
,	O	1644-1645
diverse	O	1646-1653
point	O	1654-1659
mutations	O	1660-1669
may	O	1670-1673
account	O	1674-1681
largely	O	1682-1689
for	O	1690-1693
the	O	1694-1697
phenotypic	O	1698-1708
heterogeneity	O	1709-1722
of	O	1723-1725
G6PD	B	1726-1730
deficiency	I	1731-1741
.	O	1741-1742

Increased	O	0-9
high	O	10-14
-	O	14-15
density	O	15-22
lipoprotein	O	23-34
levels	O	35-41
caused	O	42-48
by	O	49-51
a	O	52-53
common	O	54-60
cholesteryl	O	61-72
-	O	72-73
ester	O	65-70
transfer	O	79-87
protein	O	88-95
gene	O	96-100
mutation	O	101-109
.	O	109-110

BACKGROUND	O	111-121
AND	O	122-125
METHODS	O	126-133
.	O	133-134

The	O	135-138
plasma	O	139-145
cholesteryl	O	146-157
-	O	157-158
ester	O	150-155
transfer	O	164-172
protein	O	173-180
(	O	181-182
CETP	O	182-186
)	O	186-187
catalyzes	O	188-197
the	O	198-201
transfer	O	202-210
of	O	211-213
cholesteryl	O	214-225
esters	O	226-232
from	O	233-237
high	O	238-242
-	O	242-243
density	O	243-250
lipoprotein	O	251-262
(	O	263-264
HDL	O	264-267
)	O	267-268
to	O	269-271
other	O	272-277
lipoproteins	O	278-290
.	O	290-291

We	O	292-294
recently	O	295-303
described	O	304-313
a	O	314-315
Japanese	O	316-324
family	O	325-331
with	O	332-336
increased	O	337-346
HDL	O	347-350
levels	O	351-357
and	O	358-361
CETP	B	362-366
deficiency	I	367-377
due	O	378-381
to	O	382-384
a	O	385-386
splicing	O	387-395
defect	O	396-402
of	O	403-405
the	O	406-409
CETP	O	410-414
gene	O	415-419
.	O	419-420

To	O	421-423
assess	O	424-430
the	O	431-434
frequency	O	435-444
and	O	445-448
phenotype	O	449-458
of	O	459-461
this	O	462-466
condition	O	467-476
,	O	476-477
we	O	478-480
screened	O	481-489
11	O	490-492
additional	O	493-503
families	O	504-512
with	O	513-517
high	O	518-522
HDL	O	523-526
levels	O	527-533
by	O	534-536
means	O	537-542
of	O	543-545
a	O	546-547
radioimmunoassay	O	548-564
for	O	565-568
CETP	O	569-573
and	O	574-577
DNA	O	578-581
analysis	O	582-590
.	O	590-591

RESULTS	O	592-599
.	O	599-600

We	O	601-603
found	O	604-609
the	O	610-613
same	O	614-618
CETP	O	619-623
gene	O	624-628
mutation	O	629-637
in	O	638-640
four	O	641-645
families	O	646-654
from	O	655-659
three	O	660-665
different	O	666-675
regions	O	676-683
of	O	684-686
Japan	O	687-692
.	O	692-693

Analysis	O	694-702
of	O	703-705
restriction	O	706-717
-	O	717-718
fragment	O	718-726
-	O	717-718
length	O	727-733
polymorphisms	O	734-747
of	O	748-750
the	O	751-754
mutant	O	755-761
CETP	O	762-766
allele	O	767-773
showed	O	774-780
that	O	781-785
all	O	786-789
probands	O	790-798
were	O	799-803
homozygous	O	804-814
for	O	815-818
the	O	819-822
identical	O	823-832
haplotype	O	833-842
.	O	842-843

Family	O	844-850
members	O	851-858
homozygous	O	859-869
for	O	870-873
CETP	B	874-878
deficiency	I	879-889
(	O	890-891
n	O	891-892
=	O	893-894
10	O	895-897
)	O	897-898
had	O	899-902
moderate	O	903-911
hypercholesterolemia	B	912-932
(	O	933-934
mean	O	934-938
total	O	939-944
cholesterol	O	945-956
level	O	957-962
[	O	963-964
+	O	964-965
/	O	965-966
-	O	966-967
SD	O	968-970
]	O	970-971
,	O	971-972
7	O	973-974
.	O	974-975
01	O	976-978
+	O	979-980
/	O	980-981
-	O	981-982
0	O	983-984
.	O	984-985
83	O	986-988
mmol	O	989-993
per	O	994-997
liter	O	998-1003
)	O	1003-1004
,	O	1004-1005
markedly	O	1006-1014
increased	O	1015-1024
levels	O	1025-1031
of	O	1032-1034
HDL	O	1035-1038
cholesterol	O	1039-1050
(	O	1051-1052
4	O	1052-1053
.	O	1053-1054

24	O	1055-1057
+	O	1058-1059
/	O	1059-1060
-	O	1060-1061
1	O	1062-1063
.	O	1063-1064
01	O	1065-1067
mmol	O	1068-1072
per	O	1073-1076
liter	O	1077-1082
)	O	1082-1083
and	O	1084-1087
apolipoprotein	O	1088-1102
A	O	1103-1104
-	O	1104-1105
I	O	1105-1106
,	O	1106-1107
and	O	1108-1111
decreased	O	1112-1121
levels	O	1122-1128
of	O	1129-1131
low	O	1132-1135
-	O	1135-1136
density	O	1136-1143
lipoprotein	O	1144-1155
cholesterol	O	1156-1167
(	O	1168-1169
1	O	1169-1170
.	O	1170-1171

99	O	1172-1174
+	O	1175-1176
/	O	1176-1177
-	O	1177-1178
0	O	1179-1180
.	O	1180-1181
80	O	1182-1184
mmol	O	1185-1189
per	O	1190-1193
liter	O	1194-1199
)	O	1199-1200
and	O	1201-1204
apolipoprotein	O	1205-1219
B	O	1220-1221
.	O	1221-1222
Members	O	1223-1230
heterozygous	O	1231-1243
for	O	1244-1247
the	O	1248-1251
deficiency	O	1252-1262
(	O	1263-1264
n	O	1264-1265
=	O	1266-1267
20	O	1268-1270
)	O	1270-1271
,	O	1271-1272
whose	O	1273-1278
CETP	O	1279-1283
levels	O	1284-1290
were	O	1291-1295
in	O	1296-1298
the	O	1299-1302
lower	O	1303-1308
part	O	1309-1313
of	O	1314-1316
the	O	1317-1320
normal	O	1321-1327
range	O	1328-1333
,	O	1333-1334
had	O	1335-1338
moderately	O	1339-1349
increased	O	1350-1359
levels	O	1360-1366
of	O	1367-1369
HDL	O	1370-1373
cholesterol	O	1374-1385
and	O	1386-1389
apolipoprotein	O	1390-1404
A	O	1405-1406
-	O	1406-1407
I	O	1407-1408
and	O	1409-1412
an	O	1413-1415
increased	O	1416-1425
ratio	O	1426-1431
of	O	1432-1434
HDL	O	1435-1438
subclass	O	1439-1447
2	O	1448-1449
to	O	1450-1452
HDL	O	1453-1456
subclass	O	1457-1465
3	O	1466-1467
,	O	1467-1468
as	O	1469-1471
compared	O	1472-1480
with	O	1481-1485
unaffected	O	1486-1496
family	O	1497-1503
members	O	1504-1511
(	O	1512-1513
1	O	1513-1514
.	O	1514-1515
5	O	1516-1517
+	O	1518-1519
/	O	1519-1520
-	O	1520-1521
0	O	1522-1523
.	O	1523-1524
8	O	1525-1526
vs	O	1527-1529
.	O	1529-1530
0	O	1531-1532
.	O	1532-1533
7	O	1534-1535
+	O	1536-1537
/	O	1537-1538
-	O	1538-1539
0	O	1540-1541
.	O	1541-1542
4	O	1543-1544
)	O	1544-1545
.	O	1545-1546

CETP	B	1547-1551
deficiency	I	1552-1562
was	O	1563-1566
not	O	1567-1570
found	O	1571-1576
in	O	1577-1579
six	O	1580-1583
unrelated	O	1584-1593
subjects	O	1594-1602
with	O	1603-1607
elevated	O	1608-1616
HDL	O	1617-1620
cholesterol	O	1621-1632
levels	O	1633-1639
who	O	1640-1643
were	O	1644-1648
from	O	1649-1653
different	O	1654-1663
parts	O	1664-1669
of	O	1670-1672
the	O	1673-1676
United	O	1677-1683
States	O	1684-1690
.	O	1690-1691

CONCLUSIONS	O	1692-1703
.	O	1703-1704

CETP	B	1705-1709
deficiency	I	1710-1720
appears	O	1721-1728
to	O	1729-1731
be	O	1732-1734
a	O	1735-1736
frequent	O	1737-1745
cause	O	1746-1751
of	O	1752-1754
increased	O	1755-1764
HDL	O	1765-1768
levels	O	1769-1775
in	O	1776-1778
the	O	1779-1782
population	O	1783-1793
of	O	1794-1796
Japan	O	1797-1802
,	O	1802-1803
possibly	O	1804-1812
because	O	1813-1820
of	O	1821-1823
a	O	1824-1825
founder	O	1826-1833
effect	O	1834-1840
.	O	1840-1841

The	O	1842-1845
results	O	1846-1853
that	O	1854-1858
we	O	1859-1861
observed	O	1862-1870
in	O	1871-1873
heterozygotes	O	1874-1887
suggest	O	1888-1895
that	O	1896-1900
CETP	O	1901-1905
normally	O	1906-1914
plays	O	1915-1920
a	O	1921-1922
part	O	1923-1927
in	O	1928-1930
the	O	1931-1934
regulation	O	1935-1945
of	O	1946-1948
levels	O	1949-1955
of	O	1956-1958
HDL	O	1959-1962
subclass	O	1963-1971
2	O	1972-1973
.	O	1973-1974
There	O	1975-1980
was	O	1981-1984
no	O	1985-1987
evidence	O	1988-1996
of	O	1997-1999
premature	B	2000-2009
atherosclerosis	I	2010-2025
in	O	2026-2028
the	O	2029-2032
families	O	2033-2041
with	O	2042-2046
CETP	B	2047-2051
deficiency	I	2052-2062
.	O	2062-2063

In	O	2064-2066
fact	O	2067-2071
,	O	2071-2072
the	O	2073-2076
lipoprotein	O	2077-2088
profile	O	2089-2096
of	O	2097-2099
persons	O	2100-2107
with	O	2108-2112
CETP	B	2113-2117
deficiency	I	2118-2128
is	O	2129-2131
potentially	O	2132-2143
antiatherogenic	O	2144-2159
and	O	2160-2163
may	O	2164-2167
be	O	2168-2170
associated	O	2171-2181
with	O	2182-2186
an	O	2187-2189
increased	O	2190-2199
life	O	2200-2204
span	O	2205-2209
.	O	2209-2210

Hereditary	O	0-10
deficiency	B	11-21
of	I	22-24
the	I	25-28
seventh	I	29-36
component	I	37-46
of	I	47-49
complement	I	50-60
and	O	61-64
recurrent	O	65-74
meningococcal	B	75-88
infection	I	89-98
:	O	98-99
investigations	O	100-114
of	O	115-117
an	O	118-120
Irish	O	121-126
family	O	127-133
using	O	134-139
a	O	140-141
novel	O	142-147
haemolytic	O	148-158
screening	O	159-168
assay	O	169-174
for	O	175-178
complement	O	179-189
activity	O	190-198
and	O	199-202
C7	O	203-205
M	O	206-207
/	O	207-208
N	O	208-209
allotyping	O	210-220
.	O	220-221

Terminal	B	222-230
complement	I	231-241
component	I	242-251
deficiency	I	252-262
predisposes	O	263-274
to	O	275-277
meningococcal	B	278-291
infection	I	292-301
and	O	302-305
is	O	306-308
inherited	O	309-318
in	O	319-321
an	O	322-324
autosomal	O	325-334
co	O	335-337
-	O	337-338
dominant	O	338-346
manner	O	347-353
.	O	353-354

An	O	355-357
Irish	O	358-363
family	O	364-370
is	O	371-373
described	O	374-383
,	O	383-384
in	O	385-387
which	O	388-393
2	O	394-395
of	O	396-398
3	O	399-400
brothers	O	401-409
had	O	410-413
recurrent	O	414-423
meningococcal	B	424-437
infection	I	438-447
.	O	447-448

A	O	449-450
novel	O	451-456
screening	O	457-466
assay	O	467-472
was	O	473-476
used	O	477-481
to	O	482-484
investigate	O	485-496
for	O	497-500
terminal	B	501-509
complement	I	510-520
deficiency	I	521-531
and	O	532-535
the	O	536-539
2	O	540-541
affected	O	542-550
brothers	O	551-559
were	O	560-564
found	O	565-570
to	O	571-573
be	O	574-576
completely	B	577-587
deficient	I	588-597
in	I	598-600
the	I	601-604
seventh	I	605-612
component	I	613-622
of	I	623-625
complement	I	626-636
(	O	637-638
C7	O	638-640
)	O	640-641
.	O	641-642

Enzyme	O	643-649
-	O	649-650
linked	O	650-656
immunosorbent	O	657-670
assay	O	671-676
for	O	677-680
C7	O	681-683
revealed	O	684-692
lower	O	693-698
than	O	699-703
normal	O	704-710
levels	O	711-717
in	O	718-720
the	O	721-724
remaining	O	725-734
brother	O	735-742
and	O	743-746
parents	O	747-754
.	O	754-755

C7	O	756-758
M	O	759-760
/	O	760-761
N	O	761-762
protein	O	763-770
polymorphism	O	771-783
allotyping	O	784-794
,	O	794-795
used	O	796-800
to	O	801-803
investigate	O	804-815
the	O	816-819
segregation	O	820-831
of	O	832-834
the	O	835-838
C7	B	839-841
deficiency	I	842-852
genes	O	853-858
,	O	858-859
showed	O	860-866
that	O	867-871
the	O	872-875
apparently	O	876-886
complement	O	887-897
sufficient	O	898-908
brother	O	909-916
was	O	917-920
heterozygous	O	921-933
C7	B	934-936
deficient	I	937-946
and	O	947-950
a	O	951-952
carrier	O	953-960
of	O	961-963
one	O	964-967
of	O	968-970
the	O	971-974
deficiency	O	975-985
genes	O	986-991
.	O	991-992

Complement	O	993-1003
screening	O	1004-1013
should	O	1014-1020
be	O	1021-1023
carried	O	1024-1031
out	O	1032-1035
in	O	1036-1038
any	O	1039-1042
individual	O	1043-1053
suffering	O	1054-1063
recurrent	O	1064-1073
meningococcal	B	1074-1087
infection	I	1088-1097
or	O	1098-1100
infection	O	1101-1110
with	O	1111-1115
an	O	1116-1118
uncommon	O	1119-1127
meningococcal	B	1128-1141
serogroup	O	1142-1151
.	O	1151-1152

Identification	O	1153-1167
of	O	1168-1170
complement	B	1171-1181
deficient	I	1182-1191
patients	O	1192-1200
allows	O	1201-1207
the	O	1208-1211
implementation	O	1212-1226
of	O	1227-1229
strategies	O	1230-1240
to	O	1241-1243
prevent	O	1244-1251
recurrent	O	1252-1261
infection	O	1262-1271
.	O	1271-1272
.	O	1271-1272

Mild	O	0-4
and	O	5-8
severe	O	9-15
muscular	B	16-24
dystrophy	I	25-34
associated	O	35-45
with	O	46-50
deletions	O	51-60
in	O	61-63
Xp21	O	64-68
of	O	69-71
the	O	72-75
human	O	76-81
X	O	82-83
chromosome	O	84-94
.	O	94-95

We	O	96-98
have	O	99-103
analysed	O	104-112
over	O	113-117
300	O	118-121
patients	O	122-130
suffering	O	131-140
from	O	141-145
Duchenne	B	146-154
or	I	155-157
Becker	I	158-164
muscular	I	165-173
dystrophy	I	174-183
(	O	184-185
DMD	B	185-188
or	O	189-191
BMD	B	192-195
)	O	195-196
.	O	196-197

Deletions	O	198-207
have	O	208-212
been	O	213-217
characterised	O	218-231
which	O	232-237
encompass	O	238-247
either	O	248-254
the	O	255-258
pERT87	O	259-265
(	O	266-267
DXS164	O	267-273
)	O	273-274
locus	O	275-280
only	O	281-285
,	O	285-286
the	O	287-290
XJ1	O	291-294
.	O	294-295
1	O	296-297
(	O	298-299
DXS206	O	299-305
)	O	305-306
and	O	307-310
HIP25	O	311-316
loci	O	317-321
only	O	322-326
,	O	326-327
or	O	328-330
all	O	331-334
three	O	335-340
loci	O	341-345
.	O	345-346

These	O	347-352
loci	O	353-357
have	O	358-362
been	O	363-367
shown	O	368-373
to	O	374-376
lie	O	377-380
within	O	381-387
the	O	388-391
DMD	B	392-395
region	O	396-402
covering	O	403-411
several	O	412-419
hundred	O	420-427
kilobases	O	428-437
(	O	438-439
kb	O	439-441
)	O	441-442
of	O	443-445
DNA	O	446-449
.	O	449-450

One	O	451-454
mildly	O	455-461
affected	O	462-470
BMD	B	471-474
patient	O	475-482
possesses	O	483-492
a	O	493-494
deletion	O	495-503
of	O	504-506
at	O	507-509
least	O	510-515
110	O	516-519
kb	O	520-522
including	O	523-532
exons	O	533-538
of	O	539-541
the	O	542-545
DMD	B	546-549
gene	O	550-554
.	O	554-555

Other	O	556-561
patients	O	562-570
with	O	571-575
similar	O	576-583
exon	O	584-588
deletions	O	589-598
,	O	598-599
or	O	600-602
smaller	O	603-610
deletions	O	611-620
,	O	620-621
show	O	622-626
the	O	627-630
more	O	631-635
severe	O	636-642
phenotype	O	643-652
typical	O	653-660
of	O	661-663
DMD	B	664-667
.	O	667-668

We	O	669-671
conclude	O	672-680
from	O	681-685
these	O	686-691
studies	O	692-699
that	O	700-704
the	O	705-708
severity	O	709-717
of	O	718-720
the	O	721-724
clinical	O	725-733
phenotype	O	734-743
cannot	O	744-750
be	O	751-753
explained	O	754-763
on	O	764-766
the	O	767-770
basis	O	771-776
of	O	777-779
the	O	780-783
size	O	784-788
of	O	789-791
the	O	792-795
deletion	O	796-804
.	O	804-805

We	O	806-808
discuss	O	809-816
this	O	817-821
in	O	822-824
the	O	825-828
context	O	829-836
of	O	837-839
candidate	O	840-849
gene	O	850-854
sequences	O	855-864
.	O	864-865

Meiotic	O	0-7
segregation	O	8-19
analysis	O	20-28
of	O	29-31
RB1	O	32-35
alleles	O	36-43
in	O	44-46
retinoblastoma	B	47-61
pedigrees	O	62-71
by	O	72-74
use	O	75-78
of	O	79-81
single	O	82-88
-	O	88-89
sperm	O	89-94
typing	O	95-101
.	O	101-102

In	O	103-105
hereditary	B	106-116
retinoblastoma	I	117-131
,	O	131-132
different	O	133-142
epidemiological	O	143-158
studies	O	159-166
have	O	167-171
indicated	O	172-181
a	O	182-183
preferential	O	184-196
paternal	O	197-205
transmission	O	206-218
of	O	219-221
mutant	O	222-228
retinoblastoma	B	229-243
alleles	O	244-251
to	O	252-254
offspring	O	255-264
,	O	264-265
suggesting	O	266-276
the	O	277-280
occurrence	O	281-291
of	O	292-294
a	O	295-296
meiotic	O	297-304
drive	O	305-310
.	O	310-311

To	O	312-314
investigate	O	315-326
this	O	327-331
mechanism	O	332-341
,	O	341-342
we	O	343-345
analyzed	O	346-354
sperm	O	355-360
samples	O	361-368
from	O	369-373
six	O	374-377
individuals	O	378-389
from	O	390-394
five	O	395-399
unrelated	O	400-409
families	O	410-418
affected	O	419-427
with	O	428-432
hereditary	B	433-443
retinoblastoma	I	444-458
.	O	458-459

Single	O	460-466
-	O	466-467
sperm	O	467-472
typing	O	473-479
techniques	O	480-490
were	O	491-495
performed	O	496-505
for	O	506-509
each	O	510-514
sample	O	515-521
by	O	522-524
study	O	525-530
of	O	531-533
two	O	534-537
informative	O	538-549
short	O	550-555
tandem	O	556-562
repeats	O	563-570
located	O	571-578
either	O	579-585
in	O	586-588
or	O	589-591
close	O	592-597
to	O	598-600
the	O	601-604
retinoblastoma	B	605-619
gene	O	620-624
(	O	625-626
RB1	O	626-629
)	O	629-630
.	O	630-631

The	O	632-635
segregation	O	636-647
probability	O	648-659
of	O	660-662
mutant	O	663-669
RB1	O	670-673
alleles	O	674-681
in	O	682-684
sperm	O	685-690
samples	O	691-698
was	O	699-702
assessed	O	703-711
by	O	712-714
use	O	715-718
of	O	719-721
the	O	722-725
SPERMSEG	O	726-734
program	O	735-742
,	O	742-743
which	O	744-749
includes	O	750-758
experimental	O	759-771
parameters	O	772-782
,	O	782-783
recombination	O	784-797
fractions	O	798-807
between	O	808-815
the	O	816-819
markers	O	820-827
,	O	827-828
and	O	829-832
segregation	O	833-844
parameters	O	845-855
.	O	855-856

A	O	857-858
total	O	859-864
of	O	865-867
2	O	868-869
,	O	869-870
952	O	871-874
single	O	875-881
sperm	O	882-887
from	O	888-892
the	O	893-896
six	O	897-900
donors	O	901-907
were	O	908-912
analyzed	O	913-921
.	O	921-922

We	O	923-925
detected	O	926-934
a	O	935-936
significant	O	937-948
segregation	O	949-960
distortion	O	961-971
in	O	972-974
the	O	975-978
data	O	979-983
as	O	984-986
a	O	987-988
whole	O	989-994
(	O	995-996
P	O	996-997
=	O	998-999
.	O	999-1000
0099	O	1001-1005
)	O	1005-1006
and	O	1007-1010
a	O	1011-1012
significant	O	1013-1024
heterogeneity	O	1025-1038
in	O	1039-1041
the	O	1042-1045
segregation	O	1046-1057
rate	O	1058-1062
across	O	1063-1069
donors	O	1070-1076
(	O	1077-1078
.	O	1078-1079
0092	O	1080-1084
)	O	1084-1085
.	O	1085-1086

Further	O	1087-1094
analysis	O	1095-1103
shows	O	1104-1109
that	O	1110-1114
this	O	1115-1119
result	O	1120-1126
can	O	1127-1130
be	O	1131-1133
explained	O	1134-1143
by	O	1144-1146
segregation	O	1147-1158
distortion	O	1159-1169
in	O	1170-1172
favor	O	1173-1178
of	O	1179-1181
the	O	1182-1185
normal	O	1186-1192
allele	O	1193-1199
in	O	1200-1202
one	O	1203-1206
donor	O	1207-1212
only	O	1213-1217
and	O	1218-1221
that	O	1222-1226
it	O	1227-1229
does	O	1230-1234
not	O	1235-1238
provide	O	1239-1246
evidence	O	1247-1255
of	O	1256-1258
a	O	1259-1260
significant	O	1261-1272
segregation	O	1273-1284
distortion	O	1285-1295
in	O	1296-1298
the	O	1299-1302
other	O	1303-1308
donors	O	1309-1315
.	O	1315-1316

The	O	1317-1320
segregation	O	1321-1332
distortion	O	1333-1343
favoring	O	1344-1352
the	O	1353-1356
mutant	O	1357-1363
RB1	O	1364-1367
allele	O	1368-1374
does	O	1375-1379
not	O	1380-1383
seem	O	1384-1388
to	O	1389-1391
occur	O	1392-1397
during	O	1398-1404
spermatogenesis	O	1405-1420
,	O	1420-1421
and	O	1422-1425
,	O	1425-1426
thus	O	1427-1431
,	O	1431-1432
meiotic	O	1433-1440
drive	O	1441-1446
may	O	1447-1450
result	O	1451-1457
either	O	1458-1464
from	O	1465-1469
various	O	1470-1477
mechanisms	O	1478-1488
,	O	1488-1489
including	O	1490-1499
a	O	1500-1501
fertilization	O	1502-1515
advantage	O	1516-1525
or	O	1526-1528
a	O	1529-1530
better	O	1531-1537
mobility	O	1538-1546
in	O	1547-1549
sperm	O	1550-1555
bearing	O	1556-1563
a	O	1564-1565
mutant	O	1566-1572
RB1	O	1573-1576
gene	O	1577-1581
,	O	1581-1582
or	O	1583-1585
from	O	1586-1590
the	O	1591-1594
existence	O	1595-1604
of	O	1605-1607
a	O	1608-1609
defectively	O	1610-1621
imprinted	O	1622-1631
gene	O	1632-1636
located	O	1637-1644
on	O	1645-1647
the	O	1648-1651
human	O	1652-1657
X	O	1658-1659
chromosome	O	1660-1670
.	O	1670-1671

Functional	O	0-10
differences	O	11-22
of	O	23-25
the	O	26-29
PDS	B	30-33
gene	O	34-38
product	O	39-46
are	O	47-50
associated	O	51-61
with	O	62-66
phenotypic	O	67-77
variation	O	78-87
in	O	88-90
patients	O	91-99
with	O	100-104
Pendred	B	105-112
syndrome	I	113-121
and	O	122-125
non	B	126-129
-	I	129-130
syndromic	I	130-139
hearing	I	140-147
loss	I	148-152
(	O	153-154
DFNB4	B	154-159
)	O	159-160
.	O	160-161

The	O	162-165
PDS	B	166-169
gene	O	170-174
encodes	O	175-182
a	O	183-184
transmembrane	O	185-198
protein	O	199-206
,	O	206-207
known	O	208-213
as	O	214-216
pendrin	O	217-224
,	O	224-225
which	O	226-231
functions	O	232-241
as	O	242-244
a	O	245-246
transporter	O	247-258
of	O	259-261
iodide	O	262-268
and	O	269-272
chloride	O	273-281
.	O	281-282

Mutations	O	283-292
in	O	293-295
this	O	296-300
gene	O	301-305
are	O	306-309
responsible	O	310-321
for	O	322-325
Pendred	B	326-333
syndrome	I	334-342
and	O	343-346
autosomal	B	347-356
recessive	I	357-366
non	I	367-370
-	I	370-371
syndromic	I	371-380
hearing	I	381-388
loss	I	389-393
at	O	394-396
the	O	397-400
DFNB4	B	401-406
locus	O	407-412
on	O	413-415
chromosome	O	416-426
7q31	O	427-431
.	O	431-432

A	O	433-434
screen	O	435-441
of	O	442-444
20	O	445-447
individuals	O	448-459
from	O	460-464
the	O	465-468
midwestern	O	469-479
USA	O	480-483
with	O	484-488
non	B	489-492
-	I	492-493
syndromic	I	493-502
hearing	I	503-510
loss	I	511-515
and	O	516-519
dilated	O	520-527
vestibular	O	528-538
aqueducts	O	539-548
identified	O	549-559
three	O	560-565
people	O	566-572
(	O	573-574
15	O	574-576
%	O	576-577
)	O	577-578
with	O	579-583
PDS	B	584-587
mutations	O	588-597
.	O	597-598

To	O	599-601
determine	O	602-611
whether	O	612-619
PDS	B	620-623
mutations	O	624-633
in	O	634-636
individuals	O	637-648
with	O	649-653
Pendred	B	654-661
syndrome	I	662-670
differ	O	671-677
functionally	O	678-690
from	O	691-695
PDS	B	696-699
mutations	O	700-709
in	O	710-712
individuals	O	713-724
with	O	725-729
non	B	730-733
-	I	733-734
syndromic	I	734-743
hearing	I	744-751
loss	I	752-756
,	O	756-757
we	O	758-760
compared	O	761-769
three	O	770-775
common	O	776-782
Pendred	B	783-790
syndrome	I	791-799
allele	O	800-806
variants	O	807-815
(	O	816-817
L236P	O	817-822
,	O	822-823
T416P	O	824-829
and	O	830-833
E384G	O	834-839
)	O	839-840
,	O	840-841
with	O	842-846
three	O	847-852
PDS	B	853-856
mutations	O	857-866
reported	O	867-875
only	O	876-880
in	O	881-883
individuals	O	884-895
with	O	896-900
non	B	901-904
-	I	904-905
syndromic	I	905-914
hearing	I	915-922
loss	I	923-927
(	O	928-929
V480D	O	929-934
,	O	934-935
V653A	O	936-941
and	O	942-945
I490L	O	946-951
/	O	951-952
G497S	O	952-957
)	O	957-958
.	O	958-959

The	O	960-963
mutations	O	964-973
associated	O	974-984
with	O	985-989
Pendred	B	990-997
syndrome	I	998-1006
have	O	1007-1011
complete	O	1012-1020
loss	O	1021-1025
of	O	1026-1028
pendrin	O	1029-1036
-	O	1036-1037
induced	O	1037-1044
chloride	O	1045-1053
and	O	1054-1057
iodide	O	1058-1064
transport	O	1065-1074
,	O	1074-1075
while	O	1076-1081
alleles	O	1082-1089
unique	O	1090-1096
to	O	1097-1099
people	O	1100-1106
with	O	1107-1111
DFNB4	B	1112-1117
are	O	1118-1121
able	O	1122-1126
to	O	1127-1129
transport	O	1130-1139
both	O	1140-1144
iodide	O	1145-1151
and	O	1152-1155
chloride	O	1156-1164
,	O	1164-1165
albeit	O	1166-1172
at	O	1173-1175
a	O	1176-1177
much	O	1178-1182
lower	O	1183-1188
level	O	1189-1194
than	O	1195-1199
wild	O	1200-1204
-	O	1204-1205
type	O	1205-1209
pendrin	O	1210-1217
.	O	1217-1218

We	O	1219-1221
hypothesize	O	1222-1233
that	O	1234-1238
this	O	1239-1243
residual	O	1244-1252
level	O	1253-1258
of	O	1259-1261
anion	O	1262-1267
transport	O	1268-1277
is	O	1278-1280
sufficient	O	1281-1291
to	O	1292-1294
eliminate	O	1295-1304
or	O	1305-1307
postpone	O	1308-1316
the	O	1317-1320
onset	O	1321-1326
of	O	1327-1329
goiter	B	1330-1336
in	O	1337-1339
individuals	O	1340-1351
with	O	1352-1356
DFNB4	B	1357-1362
.	O	1362-1363

We	O	1364-1366
propose	O	1367-1374
a	O	1375-1376
model	O	1377-1382
for	O	1383-1386
pendrin	O	1387-1394
function	O	1395-1403
in	O	1404-1406
the	O	1407-1410
thyroid	O	1411-1418
in	O	1419-1421
which	O	1422-1427
pendrin	O	1428-1435
transports	O	1436-1446
iodide	O	1447-1453
across	O	1454-1460
the	O	1461-1464
apical	O	1465-1471
membrane	O	1472-1480
of	O	1481-1483
the	O	1484-1487
thyrocyte	O	1488-1497
into	O	1498-1502
the	O	1503-1506
colloid	O	1507-1514
space	O	1515-1520
.	O	1520-1521
.	O	1520-1521

Late	O	0-4
-	O	4-5
onset	O	5-10
metachromatic	B	11-24
leukodystrophy	I	25-39
:	O	39-40
molecular	O	41-50
pathology	O	51-60
in	O	61-63
two	O	64-67
siblings	O	68-76
.	O	76-77

We	O	78-80
report	O	81-87
on	O	88-90
a	O	91-92
new	O	93-96
allele	O	97-103
at	O	104-106
the	O	107-110
arylsulfatase	O	111-124
A	O	125-126
(	O	127-128
ARSA	O	128-132
)	O	132-133
locus	O	134-139
causing	O	140-147
late	O	148-152
-	O	152-153
onset	O	153-158
metachromatic	B	159-172
leukodystrophy	I	173-187
(	O	188-189
MLD	B	189-192
)	O	192-193
.	O	193-194

In	O	195-197
that	O	198-202
allele	O	203-209
arginine84	O	210-220
,	O	220-221
a	O	222-223
residue	O	224-231
that	O	232-236
is	O	237-239
highly	O	240-246
conserved	O	247-256
in	O	257-259
the	O	260-263
arylsulfatase	O	264-277
gene	O	278-282
family	O	283-289
,	O	289-290
is	O	291-293
replaced	O	294-302
by	O	303-305
glutamine	O	306-315
.	O	315-316

In	O	317-319
contrast	O	320-328
to	O	329-331
alleles	O	332-339
that	O	340-344
cause	O	345-350
early	O	351-356
-	O	356-357
onset	O	357-362
MLD	B	363-366
,	O	366-367
the	O	368-371
arginine84	O	372-382
to	O	383-385
glutamine	O	386-395
substitution	O	396-408
is	O	409-411
associated	O	412-422
with	O	423-427
some	O	428-432
residual	O	433-441
ARSA	O	442-446
activity	O	447-455
.	O	455-456

A	O	457-458
comparison	O	459-469
of	O	470-472
genotypes	O	473-482
,	O	482-483
ARSA	O	484-488
activities	O	489-499
,	O	499-500
and	O	501-504
clinical	O	505-513
data	O	514-518
on	O	519-521
4	O	522-523
individuals	O	524-535
carrying	O	536-544
the	O	545-548
allele	O	549-555
of	O	556-558
81	O	559-561
patients	O	562-570
with	O	571-575
MLD	B	576-579
examined	O	580-588
,	O	588-589
further	O	590-597
validates	O	598-607
the	O	608-611
concept	O	612-619
that	O	620-624
different	O	625-634
degrees	O	635-642
of	O	643-645
residual	O	646-654
ARSA	O	655-659
activity	O	660-668
are	O	669-672
the	O	673-676
basis	O	677-682
of	O	683-685
phenotypical	O	686-698
variation	O	699-708
in	O	709-711
MLD	B	712-715
.	O	715-716
.	O	715-716

Defective	O	0-9
CD95	O	10-14
/	O	14-15
APO	O	15-18
-	O	18-19
1	O	19-20
/	O	14-15
Fas	O	21-24
signal	O	25-31
complex	O	32-39
formation	O	40-49
in	O	50-52
the	O	53-56
human	O	57-62
autoimmune	B	63-73
lymphoproliferative	I	74-93
syndrome	I	94-102
,	I	102-103
type	I	104-108
Ia	I	109-111
.	O	111-112

Heterozygous	O	113-125
mutations	O	126-135
in	O	136-138
the	O	139-142
CD95	O	143-147
(	O	148-149
APO	O	149-152
-	O	152-153
1	O	153-154
/	O	154-155
Fas	O	155-158
)	O	158-159
receptor	O	160-168
occur	O	169-174
in	O	175-177
most	O	178-182
individuals	O	183-194
with	O	195-199
autoimmune	B	200-210
lymphoproliferative	I	211-230
syndrome	I	231-239
(	O	240-241
ALPS	B	241-245
)	O	245-246
and	O	247-250
dominantly	O	251-261
interfere	O	262-271
with	O	272-276
apoptosis	O	277-286
by	O	287-289
an	O	290-292
unknown	O	293-300
mechanism	O	301-310
.	O	310-311

We	O	312-314
show	O	315-319
that	O	320-324
local	O	325-330
or	O	331-333
global	O	334-340
alterations	O	341-352
in	O	353-355
the	O	356-359
structure	O	360-369
of	O	370-372
the	O	373-376
cytoplasmic	O	377-388
death	O	389-394
domain	O	395-401
from	O	402-406
nine	O	407-411
independent	O	412-423
ALPS	B	424-428
CD95	O	429-433
death	O	434-439
-	O	439-440
domain	O	440-446
mutations	O	447-456
result	O	457-463
in	O	464-466
a	O	467-468
failure	O	469-476
to	O	477-479
bind	O	480-484
the	O	485-488
FADD	O	489-493
/	O	493-494
MORT1	O	494-499
signaling	O	500-509
protein	O	510-517
.	O	517-518

Despite	O	519-526
heterozygosity	O	527-541
for	O	542-545
the	O	546-549
abnormal	O	550-558
allele	O	559-565
,	O	565-566
lymphocytes	O	567-578
from	O	579-583
ALPS	B	584-588
patients	O	589-597
showed	O	598-604
markedly	O	605-613
decreased	O	614-623
FADD	O	624-628
association	O	629-640
and	O	641-644
a	O	645-646
loss	O	647-651
of	O	652-654
caspase	O	655-662
recruitment	O	663-674
and	O	675-678
activation	O	679-689
after	O	690-695
CD95	O	696-700
crosslinking	O	701-713
.	O	713-714

These	O	715-720
data	O	721-725
suggest	O	726-733
that	O	734-738
intracytoplasmic	O	739-755
CD95	O	756-760
mutations	O	761-770
in	O	771-773
ALPS	B	774-778
impair	O	779-785
apoptosis	O	786-795
chiefly	O	796-803
by	O	804-806
disrupting	O	807-817
death	O	818-823
-	O	823-824
domain	O	824-830
interactions	O	831-843
with	O	844-848
the	O	849-852
signaling	O	853-862
protein	O	863-870
FADD	O	871-875
/	O	875-876
MORT1	O	876-881
.	O	881-882
.	O	881-882

Classical	B	0-9
galactosemia	I	10-22
and	O	23-26
mutations	O	27-36
at	O	37-39
the	O	40-43
galactose	O	44-53
-	O	53-54
1	O	54-55
-	O	53-54
phosphate	O	56-65
uridyl	O	66-72
transferase	O	73-84
(	O	85-86
GALT	O	86-90
)	O	90-91
gene	O	92-96
.	O	96-97

Classical	B	98-107
galactosemia	I	108-120
is	O	121-123
caused	O	124-130
by	O	131-133
a	O	134-135
deficiency	O	136-146
in	O	147-149
activity	O	150-158
of	O	159-161
the	O	162-165
enzyme	O	166-172
galactose	O	173-182
-	O	182-183
1	O	183-184
-	O	182-183
phosphate	O	185-194
uridyl	O	195-201
transferase	O	202-213
(	O	214-215
GALT	O	215-219
)	O	219-220
,	O	220-221
which	O	222-227
,	O	227-228
in	O	229-231
turn	O	232-236
,	O	236-237
is	O	238-240
caused	O	241-247
by	O	248-250
mutations	O	251-260
at	O	261-263
the	O	264-267
GALT	O	268-272
gene	O	273-277
.	O	277-278

The	O	279-282
disorder	O	283-291
exhibits	O	292-300
considerable	O	301-313
allelic	O	314-321
heterogeneity	O	322-335
and	O	336-339
,	O	339-340
at	O	341-343
the	O	344-347
end	O	348-351
of	O	352-354
1998	O	355-359
,	O	359-360
more	O	361-365
than	O	366-370
150	O	371-374
different	O	375-384
base	O	385-389
changes	O	390-397
were	O	398-402
recorded	O	403-411
in	O	412-414
24	O	415-417
different	O	418-427
populations	O	428-439
and	O	440-443
ethnic	O	444-450
groups	O	451-457
in	O	458-460
15	O	461-463
countries	O	464-473
worldwide	O	474-483
.	O	483-484

The	O	485-488
mutations	O	489-498
most	O	499-503
frequently	O	504-514
cited	O	515-520
are	O	521-524
Q188R	O	525-530
,	O	530-531
K285N	O	532-537
,	O	537-538
S135L	O	539-544
,	O	544-545
and	O	546-549
N314D	O	550-555
.	O	555-556

Q188R	O	557-562
is	O	563-565
the	O	566-569
most	O	570-574
common	O	575-581
mutation	O	582-590
in	O	591-593
European	O	594-602
populations	O	603-614
or	O	615-617
in	O	618-620
those	O	621-626
predominantly	O	627-640
of	O	641-643
European	O	644-652
descent	O	653-660
.	O	660-661

Overall	O	662-669
,	O	669-670
it	O	671-673
accounts	O	674-682
for	O	683-686
60	O	687-689
-	O	689-690
70	O	690-692
%	O	692-693
of	O	694-696
mutant	O	697-703
chromosomes	O	704-715
,	O	715-716
but	O	717-720
there	O	721-726
are	O	727-730
significant	O	731-742
differences	O	743-754
in	O	755-757
its	O	758-761
relative	O	762-770
frequency	O	771-780
in	O	781-783
individual	O	784-794
populations	O	795-806
.	O	806-807

Individuals	O	808-819
homoallelic	O	820-831
for	O	832-835
Q188R	O	836-841
tend	O	842-846
to	O	847-849
have	O	850-854
a	O	855-856
severe	O	857-863
phenotype	O	864-873
and	O	874-877
this	O	878-882
is	O	883-885
in	O	886-888
keeping	O	889-896
with	O	897-901
the	O	902-905
virtually	O	906-915
complete	O	916-924
loss	O	925-929
of	O	930-932
enzyme	O	933-939
activity	O	940-948
observed	O	949-957
in	O	958-960
in	O	961-963
vitro	O	964-969
expression	O	970-980
systems	O	981-988
.	O	988-989

Globally	O	990-998
,	O	998-999
K285N	O	1000-1005
is	O	1006-1008
rarer	O	1009-1014
,	O	1014-1015
but	O	1016-1019
in	O	1020-1022
many	O	1023-1027
European	O	1028-1036
populations	O	1037-1048
it	O	1049-1051
can	O	1052-1055
be	O	1056-1058
found	O	1059-1064
on	O	1065-1067
25	O	1068-1070
-	O	1070-1071
40	O	1071-1073
%	O	1073-1074
of	O	1075-1077
mutant	O	1078-1084
chromosomes	O	1085-1096
.	O	1096-1097

It	O	1098-1100
is	O	1101-1103
invariably	O	1104-1114
associated	O	1115-1125
with	O	1126-1130
a	O	1131-1132
severe	O	1133-1139
phenotype	O	1140-1149
.	O	1149-1150

S135L	O	1151-1156
is	O	1157-1159
found	O	1160-1165
almost	O	1166-1172
exclusively	O	1173-1184
in	O	1185-1187
African	O	1188-1195
Americans	O	1196-1205
.	O	1205-1206

In	O	1207-1209
vitro	O	1210-1215
expression	O	1216-1226
results	O	1227-1234
are	O	1235-1238
discrepant	O	1239-1249
,	O	1249-1250
but	O	1251-1254
some	O	1255-1259
individuals	O	1260-1271
carrying	O	1272-1280
S135L	O	1281-1286
appear	O	1287-1293
to	O	1294-1296
exhibit	O	1297-1304
GALT	O	1305-1309
activity	O	1310-1318
in	O	1319-1321
some	O	1322-1326
tissues	O	1327-1334
.	O	1334-1335

Duarte	O	1336-1342
1	O	1343-1344
(	O	1345-1346
or	O	1346-1348
Los	O	1349-1352
Angeles	O	1353-1360
)	O	1360-1361
and	O	1362-1365
Duarte	O	1366-1372
2	O	1373-1374
(	O	1375-1376
or	O	1376-1378
Duarte	O	1379-1385
)	O	1385-1386
variants	O	1387-1395
carry	O	1396-1401
the	O	1402-1405
same	O	1406-1410
amino	O	1411-1416
acid	O	1417-1421
substitution	O	1422-1434
,	O	1434-1435
N314D	O	1436-1441
,	O	1441-1442
even	O	1443-1447
though	O	1448-1454
D1	O	1455-1457
is	O	1458-1460
associated	O	1461-1471
with	O	1472-1476
increased	O	1477-1486
erythrocyte	O	1487-1498
GALT	O	1499-1503
activity	O	1504-1512
and	O	1513-1516
D2	O	1517-1519
with	O	1520-1524
reduced	O	1525-1532
activity	O	1533-1541
.	O	1541-1542

N314D	O	1543-1548
is	O	1549-1551
in	O	1552-1554
linkage	O	1555-1562
disequilibrium	O	1563-1577
with	O	1578-1582
other	O	1583-1588
base	O	1589-1593
changes	O	1594-1601
that	O	1602-1606
differ	O	1607-1613
on	O	1614-1616
the	O	1617-1620
D1	O	1621-1623
and	O	1624-1627
D2	O	1628-1630
alleles	O	1631-1638
.	O	1638-1639

N314D	O	1640-1645
does	O	1646-1650
not	O	1651-1654
impair	O	1655-1661
GALT	O	1662-1666
activity	O	1667-1675
in	O	1676-1678
in	O	1679-1681
vitro	O	1682-1687
expression	O	1688-1698
systems	O	1699-1706
.	O	1706-1707

However	O	1708-1715
,	O	1715-1716
there	O	1717-1722
are	O	1723-1726
differences	O	1727-1738
in	O	1739-1741
the	O	1742-1745
abundance	O	1746-1755
of	O	1756-1758
GALT	O	1759-1763
protein	O	1764-1771
in	O	1772-1774
lymphoblastoid	O	1775-1789
cells	O	1790-1795
lines	O	1796-1801
from	O	1802-1806
D2	O	1807-1809
and	O	1810-1813
D1	O	1814-1816
individuals	O	1817-1828
.	O	1828-1829

It	O	1830-1832
is	O	1833-1835
unclear	O	1836-1843
whether	O	1844-1851
the	O	1852-1855
specific	O	1856-1864
molecular	O	1865-1874
changes	O	1875-1882
that	O	1883-1887
distinguish	O	1888-1899
the	O	1900-1903
D1	O	1904-1906
and	O	1907-1910
D2	O	1911-1913
alleles	O	1914-1921
account	O	1922-1929
for	O	1930-1933
the	O	1934-1937
different	O	1938-1947
activities	O	1948-1958
.	O	1958-1959

The	O	1960-1963
considerable	O	1964-1976
genetic	O	1977-1984
heterogeneity	O	1985-1998
documented	O	1999-2009
to	O	2010-2012
date	O	2013-2017
undoubtedly	O	2018-2029
contributes	O	2030-2041
to	O	2042-2044
the	O	2045-2048
phenotypic	O	2049-2059
heterogeneity	O	2060-2073
that	O	2074-2078
is	O	2079-2081
observed	O	2082-2090
in	O	2091-2093
galactosemia	B	2094-2106
.	O	2106-2107

The	O	2108-2111
additional	O	2112-2122
effects	O	2123-2130
of	O	2131-2133
nonallelic	O	2134-2144
variation	O	2145-2154
and	O	2155-2158
other	O	2159-2164
constitutional	O	2165-2179
factors	O	2180-2187
on	O	2188-2190
phenotypic	O	2191-2201
variability	O	2202-2213
remain	O	2214-2220
to	O	2221-2223
be	O	2224-2226
elucidated	O	2227-2237
.	O	2237-2238
.	O	2237-2238

X	B	0-1
-	I	1-2
linked	I	2-8
retinoschisis	I	9-22
with	O	23-27
point	O	28-33
mutations	O	34-43
in	O	44-46
the	O	47-50
XLRS1	O	51-56
gene	O	57-61
.	O	61-62

BACKGROUND	O	63-73
X	B	75-76
-	I	76-77
linked	I	77-83
retinoschisis	I	84-97
(	O	98-99
XLRS	B	99-103
)	O	103-104
is	O	105-107
a	O	108-109
relatively	O	110-120
rare	O	121-125
vitreoretinal	B	126-139
dystrophy	I	140-149
that	O	150-154
causes	O	155-161
visual	B	162-168
loss	I	169-173
in	O	174-176
young	O	177-182
men	O	183-186
.	O	186-187

Recently	O	188-196
,	O	196-197
a	O	198-199
gene	O	200-204
responsible	O	205-216
for	O	217-220
this	O	221-225
disease	O	226-233
,	O	233-234
designated	O	235-245
XLRS1	O	246-251
,	O	251-252
was	O	253-256
identified	O	257-267
,	O	267-268
and	O	269-272
several	O	273-280
deleterious	O	281-292
gene	O	293-297
mutations	O	298-307
were	O	308-312
reported	O	313-321
.	O	321-322

OBJECTIVE	O	323-332
To	O	334-336
analyze	O	337-344
Japanese	O	345-353
patients	O	354-362
clinically	O	363-373
diagnosed	O	374-383
as	O	384-386
having	O	387-393
XLRS	B	394-398
formutational	O	399-412
changes	O	413-420
in	O	421-423
the	O	424-427
XLRS1	O	428-433
gene	O	434-438
.	O	438-439

METHODS	O	440-447
Ten	O	449-452
patients	O	453-461
with	O	462-466
XLRS	B	467-471
underwent	O	472-481
full	O	482-486
ophthalmologic	O	487-501
examination	O	502-513
,	O	513-514
including	O	515-524
slitlamp	O	525-533
biomicroscopy	O	534-547
and	O	548-551
dilated	O	552-559
funduscopy	O	560-570
.	O	570-571

Genomic	O	572-579
DNA	O	580-583
was	O	584-587
isolated	O	588-596
from	O	597-601
leukocytes	O	602-612
,	O	612-613
and	O	614-617
all	O	618-621
exons	O	622-627
of	O	628-630
the	O	631-634
XLRS1	O	635-640
gene	O	641-645
were	O	646-650
amplified	O	651-660
by	O	661-663
polymerase	O	664-674
chain	O	675-680
reaction	O	681-689
and	O	690-693
analyzed	O	694-702
using	O	703-708
a	O	709-710
direct	O	711-717
sequencing	O	718-728
method	O	729-735
.	O	735-736

RESULTS	O	737-744
Point	O	746-751
mutations	O	752-761
in	O	762-764
the	O	765-768
XLRS1	O	769-774
gene	O	775-779
were	O	780-784
identified	O	785-795
in	O	796-798
all	O	799-802
10	O	803-805
patients	O	806-814
.	O	814-815

The	O	816-819
mutations	O	820-829
were	O	830-834
identical	O	835-844
in	O	845-847
each	O	848-852
of	O	853-855
2	O	856-857
pairs	O	858-863
of	O	864-866
brothers	O	867-875
.	O	875-876

Six	O	877-880
of	O	881-883
the	O	884-887
point	O	888-893
mutations	O	894-903
represented	O	904-915
missense	O	916-924
mutations	O	925-934
,	O	934-935
1	O	936-937
was	O	938-941
a	O	942-943
nonsense	O	944-952
mutation	O	953-961
,	O	961-962
and	O	963-966
1	O	967-968
was	O	969-972
a	O	973-974
frameshift	O	975-985
mutation	O	986-994
.	O	994-995

Five	O	996-1000
of	O	1001-1003
the	O	1004-1007
mutations	O	1008-1017
are	O	1018-1021
newly	O	1022-1027
reported	O	1028-1036
herein	O	1037-1043
.	O	1043-1044

CONCLUSIONS	O	1045-1056
The	O	1058-1061
discovery	O	1062-1071
of	O	1072-1074
new	O	1075-1078
point	O	1079-1084
mutations	O	1085-1094
in	O	1095-1097
this	O	1098-1102
study	O	1103-1108
increases	O	1109-1118
the	O	1119-1122
available	O	1123-1132
information	O	1133-1144
regarding	O	1145-1154
the	O	1155-1158
spectrum	O	1159-1167
of	O	1168-1170
genetic	B	1171-1178
abnormalities	I	1179-1192
and	O	1193-1196
clinical	O	1197-1205
manifestations	O	1206-1220
of	O	1221-1223
XLRS	B	1224-1228
.	O	1228-1229

However	O	1230-1237
,	O	1237-1238
the	O	1239-1242
limited	O	1243-1250
data	O	1251-1255
failed	O	1256-1262
to	O	1263-1265
reveal	O	1266-1272
a	O	1273-1274
correlation	O	1275-1286
between	O	1287-1294
mutation	O	1295-1303
and	O	1304-1307
disease	O	1308-1315
phenotype	O	1316-1325
.	O	1325-1326

CLINICAL	O	1327-1335
RELEVANCE	O	1336-1345
Identification	O	1347-1361
of	O	1362-1364
mutations	O	1365-1374
in	O	1375-1377
the	O	1378-1381
XLRS1	O	1382-1387
gene	O	1388-1392
and	O	1393-1396
expanded	O	1397-1405
information	O	1406-1417
on	O	1418-1420
clinical	O	1421-1429
manifestations	O	1430-1444
will	O	1445-1449
facilitate	O	1450-1460
early	O	1461-1466
diagnosis	O	1467-1476
,	O	1476-1477
appropriate	O	1478-1489
early	O	1490-1495
therapy	O	1496-1503
,	O	1503-1504
and	O	1505-1508
genetic	O	1509-1516
counseling	O	1517-1527
regarding	O	1528-1537
the	O	1538-1541
prognosis	O	1542-1551
of	O	1552-1554
XLRS	B	1555-1559
.	O	1559-1560
.	O	1559-1560

Relationship	O	0-12
among	O	13-18
genotype	O	19-27
,	O	27-28
biochemical	O	29-40
phenotype	O	41-50
,	O	50-51
and	O	52-55
cognitive	O	56-65
performance	O	66-77
in	O	78-80
females	O	81-88
with	O	89-93
phenylalanine	B	94-107
hydroxylase	I	108-119
deficiency	I	120-130
:	O	130-131
report	O	132-138
from	O	139-143
the	O	144-147
Maternal	B	148-156
Phenylketonuria	I	157-172
Collaborative	O	173-186
Study	O	187-192
.	O	192-193

OBJECTIVE	O	194-203
To	O	205-207
examine	O	208-215
the	O	216-219
relationship	O	220-232
of	O	233-235
phenylalanine	O	236-249
hydroxylase	O	250-261
(	O	262-263
PAH	O	263-266
)	O	266-267
genotypes	O	268-277
to	O	278-280
biochemical	O	281-292
phenotype	O	293-302
and	O	303-306
cognitive	O	307-316
development	O	317-328
in	O	329-331
maternal	B	332-340
phenylketonuria	I	341-356
(	O	357-358
PKU	B	358-361
)	O	361-362
.	O	362-363

METHODOLOGY	O	364-375
PAH	O	377-380
gene	O	381-385
mutations	O	386-395
were	O	396-400
examined	O	401-409
in	O	410-412
222	O	413-416
hyperphenylalaninemic	B	417-438
females	O	439-446
enrolled	O	447-455
in	O	456-458
the	O	459-462
Maternal	B	463-471
PKU	I	472-475
Collaborative	O	476-489
Study	O	490-495
(	O	496-497
MPKUCS	O	497-503
)	O	503-504
.	O	504-505

A	O	506-507
total	O	508-513
of	O	514-516
84	O	517-519
different	O	520-529
mutations	O	530-539
were	O	540-544
detected	O	545-553
,	O	553-554
and	O	555-558
complete	O	559-567
genotype	O	568-576
was	O	577-580
obtained	O	581-589
in	O	590-592
199	O	593-596
individuals	O	597-608
.	O	608-609

Based	O	610-615
on	O	616-618
previous	O	619-627
knowledge	O	628-637
about	O	638-643
mutation	O	644-652
-	O	652-653
phenotype	O	653-662
associations	O	663-675
,	O	675-676
78	O	677-679
of	O	680-682
the	O	683-686
mutations	O	687-696
could	O	697-702
be	O	703-705
assigned	O	706-714
to	O	715-717
one	O	718-721
of	O	722-724
four	O	725-729
classes	O	730-737
of	O	738-740
severity	O	741-749
(	O	750-751
severe	O	751-757
PKU	B	758-761
,	O	761-762
moderate	O	763-771
PKU	B	772-775
,	O	775-776
mild	O	777-781
PKU	B	782-785
,	O	785-786
and	O	787-790
mild	B	791-795
hyperphenylalaninemia	I	796-817
[	O	818-819
MHP	B	819-822
]	O	822-823
)	O	823-824
.	O	824-825

Then	O	826-830
,	O	830-831
189	O	832-835
MPKUCS	O	836-842
subjects	O	843-851
were	O	852-856
grouped	O	857-864
according	O	865-874
to	O	875-877
the	O	878-881
various	O	882-889
combinations	O	890-902
of	O	903-905
mutation	O	906-914
classifications	O	915-930
.	O	930-931

The	O	932-935
sample	O	936-942
sizes	O	943-948
were	O	949-953
large	O	954-959
enough	O	960-966
for	O	967-970
statistical	O	971-982
testing	O	983-990
in	O	991-993
four	O	994-998
groups	O	999-1005
with	O	1006-1010
at	O	1011-1013
least	O	1014-1019
one	O	1020-1023
mutation	O	1024-1032
that	O	1033-1037
completely	O	1038-1048
abolishes	O	1049-1058
enzyme	O	1059-1065
activity	O	1066-1074
.	O	1074-1075

These	O	1076-1081
patients	O	1082-1090
are	O	1091-1094
considered	O	1095-1105
functionally	O	1106-1118
hemizygous	O	1119-1129
.	O	1129-1130

RESULTS	O	1131-1138
The	O	1140-1143
biochemical	O	1144-1155
phenotype	O	1156-1165
predicted	O	1166-1175
from	O	1176-1180
the	O	1181-1184
genotype	O	1185-1193
in	O	1194-1196
functionally	O	1197-1209
hemizygous	O	1210-1220
patients	O	1221-1229
was	O	1230-1233
related	O	1234-1241
significantly	O	1242-1255
to	O	1256-1258
the	O	1259-1262
assigned	O	1263-1271
phenylalanine	O	1272-1285
level	O	1286-1291
.	O	1291-1292

Cognitive	O	1293-1302
performance	O	1303-1314
(	O	1315-1316
IQ	O	1316-1318
)	O	1318-1319
was	O	1320-1323
also	O	1324-1328
significantly	O	1329-1342
related	O	1343-1350
to	O	1351-1353
genotype	O	1354-1362
.	O	1362-1363

The	O	1364-1367
IQ	O	1368-1370
of	O	1371-1373
PAH	B	1374-1377
-	I	1377-1378
deficient	I	1378-1387
mothers	O	1388-1395
with	O	1396-1400
a	O	1401-1402
severe	O	1403-1409
PKU	B	1410-1413
mutation	O	1414-1422
in	O	1423-1425
combination	O	1426-1437
with	O	1438-1442
a	O	1443-1444
MHP	B	1445-1448
mutation	O	1449-1457
or	O	1458-1460
a	O	1461-1462
mild	O	1463-1467
PKU	B	1468-1471
mutation	O	1472-1480
was	O	1481-1484
99	O	1485-1487
and	O	1488-1491
96	O	1492-1494
,	O	1494-1495
respectively	O	1496-1508
,	O	1508-1509
whereas	O	1510-1517
the	O	1518-1521
IQ	O	1522-1524
of	O	1525-1527
PKU	B	1528-1531
mothers	O	1532-1539
with	O	1540-1544
two	O	1545-1548
severe	O	1549-1555
PKU	B	1556-1559
mutations	O	1560-1569
or	O	1570-1572
with	O	1573-1577
one	O	1578-1581
severe	O	1582-1588
and	O	1589-1592
one	O	1593-1596
moderate	O	1597-1605
PKU	B	1606-1609
mutation	O	1610-1618
was	O	1619-1622
83	O	1623-1625
and	O	1626-1629
84	O	1630-1632
,	O	1632-1633
respectively	O	1634-1646
.	O	1646-1647

Of	O	1648-1650
the	O	1651-1654
patients	O	1655-1663
with	O	1664-1668
PKU	B	1669-1672
,	O	1672-1673
92	O	1674-1676
%	O	1676-1677
had	O	1678-1681
been	O	1682-1686
treated	O	1687-1694
during	O	1695-1701
childhood	O	1702-1711
.	O	1711-1712

Those	O	1713-1718
who	O	1719-1722
were	O	1723-1727
untreated	O	1728-1737
or	O	1738-1740
treated	O	1741-1748
late	O	1749-1753
had	O	1754-1757
lower	O	1758-1763
than	O	1764-1768
average	O	1769-1776
IQ	O	1777-1779
scores	O	1780-1786
for	O	1787-1790
their	O	1791-1796
group	O	1797-1802
of	O	1803-1805
mutation	O	1806-1814
combinations	O	1815-1827
.	O	1827-1828

Females	O	1829-1836
with	O	1837-1841
moderate	O	1842-1850
or	O	1851-1853
mild	O	1854-1858
PKU	B	1859-1862
who	O	1863-1866
were	O	1867-1871
treated	O	1872-1879
early	O	1880-1885
and	O	1886-1889
treated	O	1890-1897
for	O	1898-1901
>	O	1902-1903
6	O	1904-1905
years	O	1906-1911
showed	O	1912-1918
IQ	O	1919-1921
scores	O	1922-1928
10	O	1929-1931
points	O	1932-1938
above	O	1939-1944
average	O	1945-1952
for	O	1953-1956
their	O	1957-1962
group	O	1963-1968
.	O	1968-1969

CONCLUSIONS	O	1970-1981
The	O	1983-1986
reproductive	O	1987-1999
outcome	O	2000-2007
in	O	2008-2010
maternal	B	2011-2019
phenylketonuria	I	2020-2035
is	O	2036-2038
dependent	O	2039-2048
on	O	2049-2051
prenatal	O	2052-2060
metabolic	O	2061-2070
control	O	2071-2078
and	O	2079-2082
postnatal	O	2083-2092
environmental	O	2093-2106
circumstances	O	2107-2120
.	O	2120-2121

Both	O	2122-2126
factors	O	2127-2134
depend	O	2135-2141
on	O	2142-2144
the	O	2145-2148
intellectual	O	2149-2161
resources	O	2162-2171
of	O	2172-2174
the	O	2175-2178
mother	O	2179-2185
with	O	2186-2190
PKU	B	2191-2194
.	O	2194-2195

The	O	2196-2199
significant	O	2200-2211
relationship	O	2212-2224
among	O	2225-2230
genotype	O	2231-2239
,	O	2239-2240
biochemical	O	2241-2252
phenotype	O	2253-2262
,	O	2262-2263
and	O	2264-2267
cognitive	O	2268-2277
performance	O	2278-2289
observed	O	2290-2298
in	O	2299-2301
the	O	2302-2305
present	O	2306-2313
study	O	2314-2319
is	O	2320-2322
of	O	2323-2325
importance	O	2326-2336
for	O	2337-2340
the	O	2341-2344
development	O	2345-2356
of	O	2357-2359
an	O	2360-2362
optimal	O	2363-2370
strategy	O	2371-2379
for	O	2380-2383
future	O	2384-2390
treatment	O	2391-2400
of	O	2401-2403
females	O	2404-2411
with	O	2412-2416
PKU	B	2417-2420
who	O	2421-2424
plan	O	2425-2429
pregnancy	O	2430-2439
.	O	2439-2440
.	O	2439-2440

Uncoupling	O	0-10
of	O	11-13
hypomyelination	B	14-29
and	O	30-33
glial	B	34-39
cell	I	40-44
death	I	45-50
by	O	51-53
a	O	54-55
mutation	O	56-64
in	O	65-67
the	O	68-71
proteolipid	O	72-83
protein	O	84-91
gene	O	92-96
.	O	96-97

Proteolipid	O	98-109
protein	O	110-117
(	O	118-119
PLP	O	119-122
;	O	122-123
M	O	124-125
(	O	126-127
r	O	127-128
)	O	128-129
30	O	130-132
,	O	132-133
000	O	134-137
)	O	137-138
is	O	139-141
a	O	142-143
highly	O	144-150
conserved	O	151-160
major	O	161-166
polytopic	O	167-176
membrane	O	177-185
protein	O	186-193
in	O	194-196
myelin	O	197-203
but	O	204-207
its	O	208-211
cellular	O	212-220
function	O	221-229
remains	O	230-237
obscure	O	238-245
.	O	245-246

Neurological	O	247-259
mutant	O	260-266
mice	O	267-271
can	O	272-275
often	O	276-281
provide	O	282-289
model	O	290-295
systems	O	296-303
for	O	304-307
human	O	308-313
genetic	B	314-321
disorders	I	322-331
.	O	332-333

Mutations	O	334-343
of	O	344-346
the	O	347-350
X	O	351-352
-	O	352-353
chromosome	O	353-363
-	O	352-353
linked	O	364-370
PLP	O	371-374
gene	O	375-379
are	O	380-383
lethal	O	384-390
,	O	390-391
identified	O	392-402
first	O	403-408
in	O	409-411
the	O	412-415
jimpy	O	416-421
mouse	O	422-427
and	O	428-431
subsequently	O	432-444
in	O	445-447
patients	O	448-456
with	O	457-461
Pelizaeus	B	462-471
-	I	471-472
Merzbacher	I	472-482
disease	I	483-490
.	O	490-491

The	O	492-495
unexplained	O	496-507
phenotype	O	508-517
of	O	518-520
these	O	521-526
mutations	O	527-536
includes	O	537-545
degeneration	B	546-558
and	I	559-562
premature	I	563-572
cell	I	573-577
death	I	578-583
of	I	584-586
oligodendrocytes	I	587-603
with	O	604-608
associated	O	609-619
hypomyelination	B	620-635
.	O	635-636

Here	O	637-641
we	O	642-644
show	O	645-649
that	O	650-654
a	O	655-656
new	O	657-660
mouse	O	661-666
mutant	O	667-673
rumpshaker	O	674-684
is	O	685-687
defined	O	688-695
by	O	696-698
the	O	699-702
amino	O	703-708
-	O	708-709
acid	O	709-713
substitution	O	714-726
Ile	O	727-730
-	O	730-731
to	O	731-733
-	O	730-731
Thr	O	734-737
at	O	738-740
residue	O	741-748
186	O	749-752
in	O	753-755
a	O	756-757
membrane	O	758-766
-	O	766-767
embedded	O	767-775
domain	O	776-782
of	O	783-785
PLP	O	786-789
.	O	789-790

Surprisingly	O	791-803
,	O	803-804
rumpshaker	O	805-815
mice	O	816-820
,	O	820-821
although	O	822-830
myelin	B	831-837
-	I	837-838
deficient	I	838-847
,	O	847-848
have	O	849-853
normal	O	854-860
longevity	O	861-870
and	O	871-874
a	O	875-876
full	O	877-881
complement	O	882-892
of	O	893-895
morphologically	O	896-911
normal	O	912-918
oligodendrocytes	O	919-935
.	O	935-936

Hypomyelination	B	937-952
can	O	953-956
thus	O	957-961
be	O	962-964
genetically	O	965-976
separated	O	977-986
from	O	987-991
the	O	992-995
PLP	O	996-999
-	O	999-1000
dependent	O	1000-1009
oligodendrocyte	B	1010-1025
degeneration	I	1026-1038
.	O	1038-1039

We	O	1040-1042
suggest	O	1043-1050
that	O	1051-1055
PLP	O	1056-1059
has	O	1060-1063
a	O	1064-1065
vital	O	1066-1071
function	O	1072-1080
in	O	1081-1083
glial	O	1084-1089
cell	O	1090-1094
development	O	1095-1106
,	O	1106-1107
distinct	O	1108-1116
from	O	1117-1121
its	O	1122-1125
later	O	1126-1131
role	O	1132-1136
in	O	1137-1139
myelin	O	1140-1146
assembly	O	1147-1155
,	O	1155-1156
and	O	1157-1160
that	O	1161-1165
this	O	1166-1170
dichotomy	O	1171-1180
of	O	1181-1183
action	O	1184-1190
may	O	1191-1194
explain	O	1195-1202
the	O	1203-1206
clinical	O	1207-1215
spectrum	O	1216-1224
of	O	1225-1227
Pelizaeus	B	1228-1237
-	I	1237-1238
Merzbacher	I	1238-1248
disease	I	1249-1256
.	O	1256-1257
.	O	1256-1257

Mutational	O	0-10
analysis	O	11-19
of	O	20-22
the	O	23-26
HGO	O	27-30
gene	O	31-35
in	O	36-38
Finnish	O	39-46
alkaptonuria	B	47-59
patients	O	60-68
.	O	68-69

Alkaptonuria	B	70-82
(	O	83-84
AKU	B	84-87
)	O	87-88
,	O	88-89
the	O	90-93
prototypic	O	94-104
inborn	B	105-111
error	I	112-117
of	I	118-120
metabolism	I	121-131
,	O	131-132
has	O	133-136
recently	O	137-145
been	O	146-150
shown	O	151-156
to	O	157-159
be	O	160-162
caused	O	163-169
by	O	170-172
loss	O	173-177
of	O	178-180
function	O	181-189
mutations	O	190-199
in	O	200-202
the	O	203-206
homogentisate	O	207-220
-	O	220-221
1	O	221-222
,	O	222-223
2	O	224-225
-	O	225-226
dioxygenase	O	226-237
gene	O	238-242
(	O	243-244
HGO	O	244-247
)	O	247-248
.	O	248-249

So	O	250-252
far	O	253-256
17	O	257-259
mutations	O	260-269
have	O	270-274
been	O	275-279
characterised	O	280-293
in	O	294-296
AKU	B	297-300
patients	O	301-309
of	O	310-312
different	O	313-322
ethnic	O	323-329
origin	O	330-336
.	O	336-337

We	O	338-340
describe	O	341-349
three	O	350-355
novel	O	356-361
mutations	O	362-371
(	O	372-373
R58fs	O	373-378
,	O	378-379
R330S	O	380-385
,	O	385-386
and	O	387-390
H371R	O	391-396
)	O	396-397
and	O	398-401
one	O	402-405
common	O	406-412
AKU	B	413-416
mutation	O	417-425
(	O	426-427
M368V	O	427-432
)	O	432-433
,	O	433-434
detected	O	435-443
by	O	444-446
mutational	O	447-457
and	O	458-461
polymorphism	O	462-474
analysis	O	475-483
of	O	484-486
the	O	487-490
HGO	O	491-494
gene	O	495-499
in	O	500-502
five	O	503-507
Finnish	O	508-515
AKU	B	516-519
pedigrees	O	520-529
.	O	529-530

The	O	531-534
three	O	535-540
novel	O	541-546
AKU	B	547-550
mutations	O	551-560
are	O	561-564
most	O	565-569
likely	O	570-576
specific	O	577-585
for	O	586-589
the	O	590-593
Finnish	O	594-601
population	O	602-612
and	O	613-616
have	O	617-621
originated	O	622-632
recently	O	633-641
.	O	641-642
.	O	641-642

Putative	O	0-8
X	B	9-10
-	I	10-11
linked	I	11-17
adrenoleukodystrophy	I	18-38
gene	O	39-43
shares	O	44-50
unexpected	O	51-61
homology	O	62-70
with	O	71-75
ABC	O	76-79
transporters	O	80-92
.	O	92-93

Adrenoleukodystrophy	B	94-114
(	O	115-116
ALD	B	116-119
)	O	119-120
is	O	121-123
an	O	124-126
X	B	127-128
-	I	128-129
linked	I	129-135
disease	I	136-143
affecting	O	144-153
1	O	154-155
/	O	155-156
20	O	156-158
,	O	158-159
000	O	160-163
males	O	164-169
either	O	170-176
as	O	177-179
cerebral	B	180-188
ALD	I	189-192
in	O	193-195
childhood	O	196-205
or	O	206-208
as	O	209-211
adrenomyeloneuropathy	B	212-233
(	O	234-235
AMN	B	235-238
)	O	238-239
in	O	240-242
adults	O	243-249
.	O	249-250

Childhood	O	251-260
ALD	B	261-264
is	O	265-267
the	O	268-271
more	O	272-276
severe	O	277-283
form	O	284-288
,	O	288-289
with	O	290-294
onset	O	295-300
of	O	301-303
neurological	O	304-316
symptoms	O	317-325
between	O	326-333
5	O	334-335
-	O	335-336
12	O	336-338
years	O	339-344
of	O	345-347
age	O	348-351
.	O	351-352

Central	B	353-360
nervous	I	361-368
system	I	369-375
demyelination	I	376-389
progresses	O	390-400
rapidly	O	401-408
and	O	409-412
death	O	413-418
occurs	O	419-425
within	O	426-432
a	O	433-434
few	O	435-438
years	O	439-444
.	O	444-445

AMN	B	446-449
is	O	450-452
a	O	453-454
milder	O	455-461
form	O	462-466
of	O	467-469
the	O	470-473
disease	O	474-481
with	O	482-486
onset	O	487-492
at	O	493-495
15	O	496-498
-	O	498-499
30	O	499-501
years	O	502-507
of	O	508-510
age	O	511-514
and	O	515-518
a	O	519-520
more	O	521-525
progressive	O	526-537
course	O	538-544
.	O	544-545

Adrenal	B	546-553
insufficiency	I	554-567
(	O	568-569
Addisons	B	569-577
disease	I	578-585
)	O	585-586
may	O	587-590
remain	O	591-597
the	O	598-601
only	O	602-606
clinical	O	607-615
manifestation	O	616-629
of	O	630-632
ALD	B	633-636
.	O	636-637

The	O	638-641
principal	O	642-651
biochemical	O	652-663
abnormality	O	664-675
of	O	676-678
ALD	B	679-682
is	O	683-685
the	O	686-689
accumulation	O	690-702
of	O	703-705
very	O	706-710
-	O	710-711
long	O	711-715
-	O	710-711
chain	O	716-721
fatty	O	722-727
acids	O	728-733
(	O	734-735
VLCFA	O	735-740
)	O	740-741
because	O	742-749
of	O	750-752
impaired	O	753-761
beta	O	762-766
-	O	766-767
oxidation	O	767-776
in	O	777-779
peroxisomes	O	780-791
.	O	791-792

The	O	793-796
normal	O	797-803
oxidation	O	804-813
of	O	814-816
VLCFA	O	817-822
-	O	822-823
CoA	O	823-826
in	O	827-829
patients	O	830-838
fibroblasts	O	839-850
suggested	O	851-860
that	O	861-865
the	O	866-869
gene	O	870-874
coding	O	875-881
for	O	882-885
the	O	886-889
VLCFA	O	890-895
-	O	895-896
CoA	O	896-899
synthetase	O	900-910
could	O	911-916
be	O	917-919
a	O	920-921
candidate	O	922-931
gene	O	932-936
for	O	937-940
ALD	B	941-944
.	O	944-945

Here	O	946-950
we	O	951-953
use	O	954-957
positional	O	958-968
cloning	O	969-976
to	O	977-979
identify	O	980-988
a	O	989-990
gene	O	991-995
partially	O	996-1005
deleted	O	1006-1013
in	O	1014-1016
6	O	1017-1018
of	O	1019-1021
85	O	1022-1024
independent	O	1025-1036
patients	O	1037-1045
with	O	1046-1050
ALD	B	1051-1054
.	O	1054-1055

In	O	1056-1058
familial	O	1059-1067
cases	O	1068-1073
,	O	1073-1074
the	O	1075-1078
deletions	O	1079-1088
segregated	O	1089-1099
with	O	1100-1104
the	O	1105-1108
disease	O	1109-1116
.	O	1116-1117

An	O	1118-1120
identical	O	1121-1130
deletion	O	1131-1139
was	O	1140-1143
detected	O	1144-1152
in	O	1153-1155
two	O	1156-1159
brothers	O	1160-1168
presenting	O	1169-1179
with	O	1180-1184
different	O	1185-1194
clinical	O	1195-1203
ALD	B	1204-1207
phenotypes	O	1208-1218
.	O	1218-1219

Candidate	O	1220-1229
exons	O	1230-1235
were	O	1236-1240
identified	O	1241-1251
by	O	1252-1254
computer	O	1255-1263
analysis	O	1264-1272
of	O	1273-1275
genomic	O	1276-1283
sequences	O	1284-1293
and	O	1294-1297
used	O	1298-1302
to	O	1303-1305
isolate	O	1306-1313
complementary	O	1314-1327
DNAs	O	1328-1332
by	O	1333-1335
exon	O	1336-1340
connection	O	1341-1351
and	O	1352-1355
screening	O	1356-1365
of	O	1366-1368
cDNA	O	1369-1373
libraries	O	1374-1383
.	O	1383-1384

The	O	1385-1388
deduced	O	1389-1396
protein	O	1397-1404
sequence	O	1405-1413
shows	O	1414-1419
significant	O	1420-1431
sequence	O	1432-1440
identity	O	1441-1449
to	O	1450-1452
a	O	1453-1454
peroxisomal	O	1455-1466
membrane	O	1467-1475
protein	O	1476-1483
of	O	1484-1486
M	O	1487-1488
(	O	1489-1490
r	O	1490-1491
)	O	1491-1492
70K	O	1493-1496
that	O	1497-1501
is	O	1502-1504
involved	O	1505-1513
in	O	1514-1516
peroxisome	O	1517-1527
biogenesis	O	1528-1538
and	O	1539-1542
belongs	O	1543-1550
to	O	1551-1553
the	O	1554-1557
ATP	O	1558-1561
-	O	1561-1562
binding	O	1562-1569
cassette	O	1570-1578
superfamily	O	1579-1590
of	O	1591-1593
transporters	O	1594-1606
.	O	1606-1607
.	O	1606-1607

Cardiac	O	0-7
Na	O	8-10
(	O	10-11
+	O	11-12
)	O	12-13
channel	O	14-21
dysfunction	O	22-33
in	O	34-36
Brugada	B	37-44
syndrome	I	45-53
is	O	54-56
aggravated	O	57-67
by	O	68-70
beta	O	71-75
(	O	75-76
1	O	76-77
)	O	77-78
-	O	78-79
subunit	O	79-86
.	O	86-87

BACKGROUND	O	88-98
Mutations	O	100-109
in	O	110-112
the	O	113-116
gene	O	117-121
encoding	O	122-130
the	O	131-134
human	O	135-140
cardiac	O	141-148
Na	O	149-151
(	O	152-153
+	O	153-154
)	O	154-155
channel	O	156-163
alpha	O	164-169
-	O	169-170
subunit	O	170-177
(	O	178-179
hH1	O	179-182
)	O	182-183
are	O	184-187
responsible	O	188-199
for	O	200-203
chromosome	O	204-214
3	O	215-216
-	O	216-217
linked	O	217-223
congenital	B	224-234
long	I	235-239
-	I	239-240
QT	I	240-242
syndrome	I	243-251
(	O	252-253
LQT3	B	253-257
)	O	257-258
and	O	259-262
idiopathic	B	263-273
ventricular	I	274-285
fibrillation	I	286-298
(	O	299-300
IVF	B	300-303
)	O	303-304
.	O	304-305

An	O	306-308
auxiliary	O	309-318
beta	O	319-323
(	O	324-325
1	O	325-326
)	O	326-327
-	O	328-329
subunit	O	329-336
,	O	336-337
widely	O	338-344
expressed	O	345-354
in	O	355-357
excitable	O	358-367
tissues	O	368-375
,	O	375-376
shifts	O	377-383
the	O	384-387
voltage	O	388-395
dependence	O	396-406
of	O	407-409
steady	O	410-416
-	O	416-417
state	O	417-422
inactivation	O	423-435
toward	O	436-442
more	O	443-447
negative	O	448-456
potentials	O	457-467
and	O	468-471
restores	O	472-480
normal	O	481-487
gating	O	488-494
kinetics	O	495-503
of	O	504-506
brain	O	507-512
and	O	513-516
skeletal	O	517-525
muscle	O	526-532
Na	O	533-535
(	O	536-537
+	O	537-538
)	O	538-539
channels	O	540-548
expressed	O	549-558
in	O	559-561
Xenopus	O	562-569
oocytes	O	570-577
but	O	578-581
has	O	582-585
little	O	586-592
if	O	593-595
any	O	596-599
functional	O	600-610
effect	O	611-617
on	O	618-620
the	O	621-624
cardiac	O	625-632
isoform	O	633-640
.	O	640-641

Here	O	642-646
,	O	646-647
we	O	648-650
characterize	O	651-663
the	O	664-667
altered	O	668-675
effects	O	676-683
of	O	684-686
a	O	687-688
human	O	689-694
beta	O	695-699
(	O	700-701
1	O	701-702
)	O	702-703
-	O	704-705
subunit	O	705-712
(	O	713-714
hbeta	O	714-719
(	O	720-721
1	O	721-722
)	O	722-723
)	O	722-723
on	O	725-727
the	O	728-731
heterologously	O	732-746
expressed	O	747-756
hH1	O	757-760
mutation	O	761-769
(	O	770-771
T1620M	O	771-777
)	O	777-778
previously	O	779-789
associated	O	790-800
with	O	801-805
IVF	B	806-809
.	O	809-810

METHODS	O	811-818
AND	O	819-822
RESULTS	O	823-830
When	O	832-836
expressed	O	837-846
alone	O	847-852
in	O	853-855
Xenopus	O	856-863
oocytes	O	864-871
,	O	871-872
T1620M	O	873-879
exhibited	O	880-889
no	O	890-892
persistent	O	893-903
currents	O	904-912
,	O	912-913
in	O	914-916
contrast	O	917-925
to	O	926-928
the	O	929-932
LQT3	B	933-937
mutant	O	938-944
channels	O	945-953
,	O	953-954
but	O	955-958
the	O	959-962
midpoint	O	963-971
of	O	972-974
steady	O	975-981
-	O	981-982
state	O	982-987
inactivation	O	988-1000
(	O	1001-1002
V	O	1002-1003
(	O	1004-1005
1	O	1005-1006
/	O	1006-1007
2	O	1007-1008
)	O	1008-1009
)	O	1008-1009
was	O	1011-1014
significantly	O	1015-1028
shifted	O	1029-1036
toward	O	1037-1043
more	O	1044-1048
positive	O	1049-1057
potentials	O	1058-1068
than	O	1069-1073
for	O	1074-1077
wild	O	1078-1082
-	O	1082-1083
type	O	1083-1087
hH1	O	1088-1091
.	O	1091-1092

Coexpression	O	1093-1105
of	O	1106-1108
hbeta	O	1109-1114
(	O	1115-1116
1	O	1116-1117
)	O	1117-1118
did	O	1119-1122
not	O	1123-1126
significantly	O	1127-1140
alter	O	1141-1146
current	O	1147-1154
decay	O	1155-1160
or	O	1161-1163
recovery	O	1164-1172
from	O	1173-1177
inactivation	O	1178-1190
of	O	1191-1193
wild	O	1194-1198
-	O	1198-1199
type	O	1199-1203
hH1	O	1204-1207
;	O	1207-1208
however	O	1209-1216
,	O	1216-1217
it	O	1218-1220
further	O	1221-1228
shifted	O	1229-1236
the	O	1237-1240
V	O	1241-1242
(	O	1243-1244
1	O	1244-1245
/	O	1245-1246
2	O	1246-1247
)	O	1247-1248
and	O	1249-1252
accelerated	O	1253-1264
the	O	1265-1268
recovery	O	1269-1277
from	O	1278-1282
inactivation	O	1283-1295
of	O	1296-1298
T1620M	O	1299-1305
.	O	1305-1306

Oocyte	O	1307-1313
macropatch	O	1314-1324
analysis	O	1325-1333
revealed	O	1334-1342
that	O	1343-1347
the	O	1348-1351
activation	O	1352-1362
kinetics	O	1363-1371
of	O	1372-1374
T1620M	O	1375-1381
were	O	1382-1386
normal	O	1387-1393
.	O	1393-1394

CONCLUSIONS	O	1395-1406
It	O	1408-1410
is	O	1411-1413
suggested	O	1414-1423
that	O	1424-1428
coexpression	O	1429-1441
of	O	1442-1444
hbeta	O	1445-1450
(	O	1451-1452
1	O	1452-1453
)	O	1453-1454
exposes	O	1455-1462
a	O	1463-1464
more	O	1465-1469
severe	O	1470-1476
functional	O	1477-1487
defect	O	1488-1494
that	O	1495-1499
results	O	1500-1507
in	O	1508-1510
a	O	1511-1512
greater	O	1513-1520
overlap	O	1521-1528
in	O	1529-1531
the	O	1532-1535
relationship	O	1536-1548
between	O	1549-1556
channel	O	1557-1564
inactivation	O	1565-1577
and	O	1578-1581
activation	O	1582-1592
(	O	1593-1594
window	O	1594-1600
current	O	1601-1608
)	O	1608-1609
in	O	1610-1612
T1620M	O	1613-1619
,	O	1619-1620
which	O	1621-1626
is	O	1627-1629
proposed	O	1630-1638
to	O	1639-1641
be	O	1642-1644
a	O	1645-1646
potential	O	1647-1656
pathophysiological	O	1657-1675
mechanism	O	1676-1685
of	O	1686-1688
IVF	B	1689-1692
in	O	1693-1695
vivo	O	1696-1700
.	O	1700-1701

One	O	1702-1705
possible	O	1706-1714
explanation	O	1715-1726
for	O	1727-1730
our	O	1731-1734
finding	O	1735-1742
is	O	1743-1745
an	O	1746-1748
altered	O	1749-1756
alpha	O	1757-1762
-	O	1762-1763
/	O	1763-1764
beta	O	1764-1768
(	O	1769-1770
1	O	1770-1771
)	O	1771-1772
-	O	1773-1774
subunit	O	1774-1781
association	O	1782-1793
in	O	1794-1796
the	O	1797-1800
mutant	O	1801-1807
.	O	1807-1808
.	O	1807-1808

Autosomal	B	0-9
recessive	I	10-19
familial	I	20-28
neurohypophyseal	I	29-45
diabetes	I	46-54
insipidus	I	55-64
with	O	65-69
continued	O	70-79
secretion	O	80-89
of	O	90-92
mutant	O	93-99
weakly	O	100-106
active	O	107-113
vasopressin	O	114-125
.	O	125-126

Familial	B	127-135
neurohypophyseal	I	136-152
diabetes	I	153-161
insipidus	I	162-171
is	O	172-174
an	O	175-177
autosomal	B	178-187
dominant	I	188-196
disorder	I	197-205
characterized	O	206-219
by	O	220-222
post	O	223-227
-	O	227-228
natal	O	228-233
development	O	234-245
of	O	246-248
arginine	B	249-257
vasopressin	I	258-269
(	I	270-271
AVP	I	271-274
)	I	274-275
deficiency	I	276-286
due	O	287-290
to	O	291-293
mutations	O	294-303
in	O	304-306
the	O	307-310
AVP	O	311-314
gene	O	315-319
.	O	319-320

All	O	321-324
published	O	325-334
mutations	O	335-344
affect	O	345-351
the	O	352-355
signal	O	356-362
peptide	O	363-370
or	O	371-373
the	O	374-377
neurophysin	O	378-389
-	O	389-390
II	O	390-392
carrier	O	393-400
protein	O	401-408
and	O	409-412
are	O	413-416
presumed	O	417-425
to	O	426-428
interfere	O	429-438
with	O	439-443
processing	O	444-454
of	O	455-457
the	O	458-461
preprohormone	O	462-475
,	O	475-476
leading	O	477-484
to	O	485-487
neuronal	B	488-496
damage	I	497-503
.	O	503-504

We	O	505-507
studied	O	508-515
an	O	516-518
unusual	O	519-526
Palestinian	O	527-538
family	O	539-545
consisting	O	546-556
of	O	557-559
asymptomatic	O	560-572
first	O	573-578
cousin	O	579-585
parents	O	586-593
and	O	594-597
three	O	598-603
children	O	604-612
affected	O	613-621
with	O	622-626
neurohypophyseal	B	627-643
diabetes	I	644-652
insipidus	I	653-662
,	O	662-663
suggesting	O	664-674
autosomal	O	675-684
recessive	O	685-694
inheritance	O	695-706
.	O	706-707

All	O	708-711
three	O	712-717
affected	O	718-726
children	O	727-735
were	O	736-740
homozygous	O	741-751
and	O	752-755
the	O	756-759
parents	O	760-767
heterozygous	O	768-780
for	O	781-784
a	O	785-786
single	O	787-793
novel	O	794-799
mutation	O	800-808
(	O	809-810
C301	O	810-814
-	O	814-815
>	O	816-817
T	O	818-819
)	O	819-820
in	O	821-823
exon	O	824-828
1	O	829-830
,	O	830-831
replacing	O	832-841
Pro7	O	842-846
of	O	847-849
mature	O	850-856
AVP	O	857-860
with	O	861-865
Leu	O	866-869
(	O	870-871
Leu	O	871-874
-	O	874-875
AVP	O	875-878
)	O	878-879
.	O	879-880

Leu	O	881-884
-	O	884-885
AVP	O	885-888
was	O	889-892
a	O	893-894
weak	O	895-899
agonist	O	900-907
with	O	908-912
approximately	O	913-926
30	O	927-929
-	O	929-930
fold	O	930-934
reduced	O	935-942
binding	O	943-950
to	O	951-953
the	O	954-957
human	O	958-963
V2	O	964-966
receptor	O	967-975
.	O	975-976

Measured	O	977-985
by	O	986-988
radioimmunoassay	O	989-1005
with	O	1006-1010
a	O	1011-1012
synthetic	O	1013-1022
Leu	O	1023-1026
-	O	1026-1027
AVP	O	1027-1030
standard	O	1031-1039
,	O	1039-1040
serum	O	1041-1046
Leu	O	1047-1050
-	O	1050-1051
AVP	O	1051-1054
levels	O	1055-1061
were	O	1062-1066
elevated	O	1067-1075
in	O	1076-1078
all	O	1079-1082
three	O	1083-1088
children	O	1089-1097
and	O	1098-1101
further	O	1102-1109
increased	O	1110-1119
during	O	1120-1126
water	O	1127-1132
deprivation	O	1133-1144
to	O	1145-1147
as	O	1148-1150
high	O	1151-1155
as	O	1156-1158
30	O	1159-1161
times	O	1162-1167
normal	O	1168-1174
.	O	1174-1175

The	O	1176-1179
youngest	O	1180-1188
child	O	1189-1194
(	O	1195-1196
2	O	1196-1197
years	O	1198-1203
old	O	1204-1207
)	O	1207-1208
was	O	1209-1212
only	O	1213-1217
mildly	O	1218-1224
affected	O	1225-1233
but	O	1234-1237
had	O	1238-1241
Leu	O	1242-1245
-	O	1245-1246
AVP	O	1246-1249
levels	O	1250-1256
similar	O	1257-1264
to	O	1265-1267
her	O	1268-1271
severely	O	1272-1280
affected	O	1281-1289
8	O	1290-1291
-	O	1291-1292
year	O	1292-1296
-	O	1291-1292
old	O	1297-1300
brother	O	1301-1308
,	O	1308-1309
suggesting	O	1310-1320
that	O	1321-1325
unknown	O	1326-1333
mechanisms	O	1334-1344
may	O	1345-1348
partially	O	1349-1358
compensate	O	1359-1369
for	O	1370-1373
a	O	1374-1375
deficiency	B	1376-1386
of	I	1387-1389
active	I	1390-1396
AVP	I	1397-1400
in	O	1401-1403
very	O	1404-1408
young	O	1409-1414
children	O	1415-1423
.	O	1423-1424
.	O	1423-1424

Autosomal	O	0-9
dominant	O	10-18
aniridia	B	19-27
linked	O	28-34
to	O	35-37
the	O	38-41
chromosome	O	42-52
11p13	O	53-58
markers	O	59-66
catalase	O	67-75
and	O	76-79
D11S151	O	80-87
in	O	88-90
a	O	91-92
large	O	93-98
Dutch	O	99-104
family	O	105-111
.	O	111-112

In	O	113-115
a	O	116-117
large	O	118-123
pedigree	O	124-132
with	O	133-137
autosomal	O	138-147
dominant	O	148-156
aniridia	B	157-165
,	O	165-166
we	O	167-169
found	O	170-175
close	O	176-181
linkage	O	182-189
between	O	190-197
the	O	198-201
aniridia	B	202-210
locus	O	211-216
AN2	O	217-220
and	O	221-224
the	O	225-228
markers	O	229-236
catalase	O	237-245
(	O	246-247
CAT	O	247-250
)	O	250-251
(	O	252-253
zeta	O	253-257
=	O	258-259
7	O	260-261
.	O	261-262
27	O	263-265
at	O	266-268
theta	O	269-274
=	O	275-276
0	O	277-278
.	O	278-279
00	O	280-282
)	O	282-283
and	O	284-287
D11S151	O	288-295
(	O	296-297
zeta	O	297-301
=	O	302-303
3	O	304-305
.	O	305-306
86	O	307-309
at	O	310-312
theta	O	313-318
=	O	319-320
0	O	321-322
.	O	322-323
10	O	324-326
)	O	326-327
flanking	O	328-336
the	O	337-340
AN2	O	341-344
locus	O	345-350
on	O	351-353
11p13	O	354-359
.	O	359-360

Positive	O	361-369
lod	O	370-373
scores	O	374-380
were	O	381-385
also	O	386-390
obtained	O	391-399
for	O	400-403
the	O	404-407
11p13	O	408-413
-	O	413-414
-	O	413-414
-	O	413-414
-	O	413-414
11p14	O	417-422
markers	O	423-430
D11S16	O	431-437
and	O	438-441
FSHB	O	442-446
with	O	447-451
the	O	452-455
linkage	O	456-463
group	O	464-469
CAT	O	470-473
/	O	473-474
AN2	O	474-477
/	O	473-474
D11S151	O	478-485
.	O	485-486

We	O	487-489
conclude	O	490-498
that	O	499-503
the	O	504-507
autosomal	O	508-517
dominant	O	518-526
aniridia	B	527-535
in	O	536-538
this	O	539-543
family	O	544-550
is	O	551-553
due	O	554-557
to	O	558-560
a	O	561-562
mutation	O	563-571
at	O	572-574
the	O	575-578
AN2	O	579-582
locus	O	583-588
on	O	589-591
11p13	O	592-597
.	O	597-598

We	O	599-601
have	O	602-606
excluded	O	607-615
linkage	O	616-623
(	O	624-625
zeta	O	625-629
less	O	630-634
than	O	635-639
-	O	640-641
2	O	641-642
at	O	643-645
theta	O	646-651
less	O	652-656
than	O	657-661
0	O	662-663
.	O	663-664
18	O	665-667
)	O	667-668
between	O	669-676
the	O	677-680
aniridia	B	681-689
and	O	690-693
the	O	694-697
chromosome	O	698-708
2p25	O	709-713
marker	O	714-720
D2S1	O	721-725
(	O	726-727
linked	O	727-733
to	O	734-736
ACP1	O	737-741
)	O	741-742
.	O	742-743

Knobloch	B	0-8
syndrome	I	9-17
involving	O	18-27
midline	B	28-35
scalp	I	36-41
defect	I	42-48
of	I	49-51
the	I	52-55
frontal	I	56-63
region	I	64-70
.	O	70-71

We	O	72-74
report	O	75-81
on	O	82-84
a	O	85-86
4	O	87-88
-	O	88-89
year	O	89-93
-	O	88-89
old	O	94-97
boy	O	98-101
with	O	102-106
Knobloch	B	107-115
syndrome	I	116-124
.	O	124-125

He	O	126-128
has	O	129-132
vitreoretinal	B	133-146
degeneration	I	147-159
,	O	159-160
high	B	161-165
myopia	I	166-172
,	O	172-173
cataract	B	174-182
,	O	182-183
telecanthus	B	184-195
,	O	195-196
hypertelorism	B	197-210
,	O	210-211
and	O	212-215
a	O	216-217
high	B	218-222
-	I	222-223
arched	I	223-229
palate	I	230-236
.	O	236-237

He	O	238-240
also	O	241-245
has	O	246-249
a	O	250-251
defect	B	252-258
of	I	259-261
the	I	262-265
anterior	I	266-274
midline	I	275-282
scalp	I	283-288
with	O	289-293
involvement	O	294-305
of	O	306-308
the	O	309-312
frontal	O	313-320
bone	O	321-325
as	O	326-328
documented	O	329-339
by	O	340-342
a	O	343-344
computed	O	345-353
tomography	O	354-364
(	O	365-366
CT	O	366-368
)	O	368-369
scan	O	370-374
.	O	374-375

The	O	376-379
brain	O	380-385
was	O	386-389
normal	O	390-396
on	O	397-399
CT	O	400-402
scan	O	403-407
and	O	408-411
magnetic	O	412-420
resonance	O	421-430
imaging	O	431-438
.	O	438-439

We	O	440-442
present	O	443-450
a	O	451-452
review	O	453-459
of	O	460-462
the	O	463-466
23	O	467-469
published	O	470-479
cases	O	480-485
with	O	486-490
this	O	491-495
syndrome	O	496-504
.	O	504-505

Our	O	506-509
patient	O	510-517
illustrates	O	518-529
the	O	530-533
importance	O	534-544
of	O	545-547
investigating	O	548-561
for	O	562-565
underlying	O	566-576
ocular	O	577-583
and	O	584-587
central	O	588-595
nervous	O	596-603
system	O	604-610
pathology	O	611-620
whenever	O	621-629
midline	B	630-637
scalp	I	638-643
defects	I	644-651
are	O	652-655
present	O	656-663
.	O	663-664
.	O	663-664

Pendred	B	0-7
syndrome	I	8-16
:	O	16-17
phenotypic	O	18-28
variability	O	29-40
in	O	41-43
two	O	44-47
families	O	48-56
carrying	O	57-65
the	O	66-69
same	O	70-74
PDS	B	75-78
missense	O	79-87
mutation	O	88-96
.	O	96-97

Pendred	B	98-105
syndrome	I	106-114
comprises	O	115-124
congenital	B	125-135
sensorineural	I	136-149
hearing	I	150-157
loss	I	158-162
,	O	162-163
thyroid	B	164-171
goiter	I	172-178
,	O	178-179
and	O	180-183
positive	O	184-192
perchlorate	O	193-204
discharge	O	205-214
test	O	215-219
.	O	219-220

Recently	O	221-229
,	O	229-230
this	O	231-235
autosomal	B	236-245
recessive	I	246-255
disorder	I	256-264
was	O	265-268
shown	O	269-274
to	O	275-277
be	O	278-280
caused	O	281-287
by	O	288-290
mutations	O	291-300
in	O	301-303
the	O	304-307
PDS	B	308-311
gene	O	312-316
,	O	316-317
which	O	318-323
encodes	O	324-331
an	O	332-334
anion	O	335-340
transporter	O	341-352
called	O	353-359
pendrin	O	360-367
.	O	367-368

Molecular	O	369-378
analysis	O	379-387
of	O	388-390
the	O	391-394
PDS	B	395-398
gene	O	399-403
was	O	404-407
performed	O	408-417
in	O	418-420
two	O	421-424
consanguineous	O	425-439
large	O	440-445
families	O	446-454
from	O	455-459
Southern	O	460-468
Tunisia	O	469-476
comprising	O	477-487
a	O	488-489
total	O	490-495
of	O	496-498
23	O	499-501
individuals	O	502-513
affected	O	514-522
with	O	523-527
profound	O	528-536
congenital	B	537-547
deafness	I	548-556
;	O	556-557
the	O	558-561
same	O	562-566
missense	O	567-575
mutation	O	576-584
,	O	584-585
L445W	O	586-591
,	O	591-592
was	O	593-596
identified	O	597-607
in	O	608-610
all	O	611-614
affected	O	615-623
individuals	O	624-635
.	O	635-636

A	O	637-638
widened	B	639-646
vestibular	I	647-657
aqueduct	I	658-666
was	O	667-670
found	O	671-676
in	O	677-679
all	O	680-683
patients	O	684-692
who	O	693-696
underwent	O	697-706
computed	O	707-715
tomography	O	716-726
(	O	727-728
CT	O	728-730
)	O	730-731
scan	O	732-736
exploration	O	737-748
of	O	749-751
the	O	752-755
inner	O	756-761
ear	O	762-765
.	O	765-766

In	O	767-769
contrast	O	770-778
,	O	778-779
goiter	B	780-786
was	O	787-790
present	O	791-798
in	O	799-801
only	O	802-806
11	O	807-809
affected	O	810-818
individuals	O	819-830
,	O	830-831
who	O	832-835
interestingly	O	836-849
had	O	850-853
a	O	854-855
normal	O	856-862
result	O	863-869
of	O	870-872
the	O	873-876
perchlorate	O	877-888
discharge	O	889-898
test	O	899-903
whenever	O	904-912
performed	O	913-922
.	O	922-923

The	O	924-927
present	O	928-935
results	O	936-943
question	O	944-952
the	O	953-956
sensitivity	O	957-968
of	O	969-971
the	O	972-975
perchlorate	O	976-987
test	O	988-992
for	O	993-996
the	O	997-1000
diagnosis	O	1001-1010
of	O	1011-1013
Pendred	B	1014-1021
syndrome	I	1022-1030
and	O	1031-1034
support	O	1035-1042
the	O	1043-1046
use	O	1047-1050
of	O	1051-1053
a	O	1054-1055
molecular	O	1056-1065
analysis	O	1066-1074
of	O	1075-1077
the	O	1078-1081
PDS	B	1082-1085
gene	O	1086-1090
in	O	1091-1093
the	O	1094-1097
assessment	O	1098-1108
of	O	1109-1111
individuals	O	1112-1123
with	O	1124-1128
severe	O	1129-1135
to	O	1136-1138
profound	O	1139-1147
congenital	B	1148-1158
hearing	I	1159-1166
loss	I	1167-1171
associated	O	1172-1182
with	O	1183-1187
inner	B	1188-1193
ear	I	1194-1197
morphological	I	1198-1211
anomaly	I	1212-1219
even	O	1220-1224
in	O	1225-1227
the	O	1228-1231
absence	O	1232-1239
of	O	1240-1242
a	O	1243-1244
thyroid	B	1245-1252
goiter	I	1253-1259
.	O	1259-1260
.	O	1259-1260

The	O	0-3
type	O	4-8
of	O	9-11
somatic	O	12-19
mutation	O	20-28
at	O	29-31
APC	O	32-35
in	O	36-38
familial	B	39-47
adenomatous	I	48-59
polyposis	I	60-69
is	O	70-72
determined	O	73-83
by	O	84-86
the	O	87-90
site	O	91-95
of	O	96-98
the	O	99-102
germline	O	103-111
mutation	O	112-120
:	O	120-121
a	O	122-123
new	O	124-127
facet	O	128-133
to	O	134-136
Knudson	O	137-144
'	O	144-145
s	O	141-142
'	O	147-148
two	O	148-151
-	O	151-152
hit	O	152-155
'	O	147-148
hypothesis	O	157-167
.	O	167-168

APC	O	169-172
is	O	173-175
often	O	176-181
cited	O	182-187
as	O	188-190
a	O	191-192
prime	O	193-198
example	O	199-206
of	O	207-209
a	O	210-211
tumor	B	212-217
suppressor	O	218-228
gene	O	229-233
.	O	233-234

Truncating	O	235-245
germline	O	246-254
and	O	255-258
somatic	O	259-266
mutations	O	267-276
(	O	277-278
or	O	278-280
,	O	280-281
infrequently	O	282-294
,	O	294-295
allelic	O	296-303
loss	O	304-308
)	O	308-309
occur	O	310-315
in	O	316-318
tumors	B	319-325
in	O	326-328
FAP	B	329-332
(	O	333-334
familial	B	334-342
adenomatous	I	343-354
polyposis	I	355-364
)	O	364-365
.	O	365-366

Most	O	367-371
sporadic	B	372-380
colorectal	I	381-391
cancers	I	392-399
also	O	400-404
have	O	405-409
two	O	410-413
APC	B	414-417
mutations	O	418-427
.	O	427-428

Clues	O	429-434
from	O	435-439
attenuated	B	440-450
polyposis	I	451-460
,	O	460-461
missense	O	462-470
germline	O	471-479
variants	O	480-488
with	O	489-493
mild	O	494-498
disease	O	499-506
and	O	507-510
the	O	511-514
somatic	O	515-522
mutation	O	523-531
cluster	O	532-539
region	O	540-546
(	O	547-548
codons	O	548-554
1	O	555-556
,	O	556-557
250	O	558-561
-	O	561-562
1	O	562-563
,	O	563-564
450	O	565-568
)	O	568-569
indicate	O	570-578
,	O	578-579
however	O	580-587
,	O	587-588
that	O	589-593
APC	B	594-597
mutations	O	598-607
might	O	608-613
not	O	614-617
result	O	618-624
in	O	625-627
simple	O	628-634
loss	O	635-639
of	O	640-642
protein	O	643-650
function	O	651-659
.	O	659-660

We	O	661-663
have	O	664-668
found	O	669-674
that	O	675-679
FAP	B	680-683
patients	O	684-692
with	O	693-697
germline	O	698-706
APC	B	707-710
mutations	O	711-720
within	O	721-727
a	O	728-729
small	O	730-735
region	O	736-742
(	O	743-744
codons	O	744-750
1	O	751-752
,	O	752-753
194	O	754-757
-	O	757-758
1	O	754-755
,	O	759-760
392	O	761-764
at	O	765-767
most	O	768-772
)	O	772-773
mainly	O	774-780
show	O	781-785
allelic	O	786-793
loss	O	794-798
in	O	799-801
their	O	802-807
colorectal	B	808-818
adenomas	I	819-827
,	O	827-828
in	O	829-831
contrast	O	832-840
to	O	841-843
other	O	844-849
FAP	B	850-853
patients	O	854-862
,	O	862-863
whose	O	864-869
second	O	870-876
hits	O	877-881
tend	O	882-886
to	O	887-889
occur	O	890-895
by	O	896-898
truncating	O	899-909
mutations	O	910-919
in	O	920-922
the	O	923-926
mutation	O	927-935
cluster	O	936-943
region	O	944-950
.	O	950-951

Our	O	952-955
results	O	956-963
indicate	O	964-972
that	O	973-977
different	O	978-987
APC	B	988-991
mutations	O	992-1001
provide	O	1002-1009
cells	O	1010-1015
with	O	1016-1020
different	O	1021-1030
selective	O	1031-1040
advantages	O	1041-1051
,	O	1051-1052
with	O	1053-1057
mutations	O	1058-1067
close	O	1068-1073
to	O	1074-1076
codon	O	1077-1082
1	O	1083-1084
,	O	1084-1085
300	O	1086-1089
providing	O	1090-1099
the	O	1100-1103
greatest	O	1104-1112
advantage	O	1113-1122
.	O	1122-1123

Allelic	O	1124-1131
loss	O	1132-1136
is	O	1137-1139
selected	O	1140-1148
strongly	O	1149-1157
in	O	1158-1160
cells	O	1161-1166
with	O	1167-1171
one	O	1172-1175
mutation	O	1176-1184
near	O	1185-1189
codon	O	1190-1195
1	O	1196-1197
,	O	1197-1198
300	O	1199-1202
.	O	1202-1203

A	O	1204-1205
different	O	1206-1215
germline	O	1216-1224
-	O	1224-1225
somatic	O	1225-1232
APC	B	1233-1236
mutation	O	1237-1245
association	O	1246-1257
exists	O	1258-1264
in	O	1265-1267
FAP	B	1268-1271
desmoids	I	1272-1280
.	O	1280-1281

APC	O	1282-1285
is	O	1286-1288
not	O	1289-1292
,	O	1292-1293
therefore	O	1294-1303
,	O	1303-1304
a	O	1305-1306
classical	O	1307-1316
tumor	B	1317-1322
suppressor	O	1323-1333
.	O	1333-1334

Our	O	1335-1338
findings	O	1339-1347
also	O	1348-1352
indicate	O	1353-1361
a	O	1362-1363
new	O	1364-1367
mechanism	O	1368-1377
for	O	1378-1381
disease	O	1382-1389
severity	O	1390-1398
if	O	1400-1402
a	O	1403-1404
broader	O	1405-1412
spectrum	O	1413-1421
of	O	1422-1424
mutations	O	1425-1434
is	O	1435-1437
selected	O	1438-1446
in	O	1447-1449
tumors	B	1450-1456
,	O	1456-1457
the	O	1458-1461
somatic	O	1462-1469
mutation	O	1470-1478
rate	O	1479-1483
is	O	1484-1486
effectively	O	1487-1498
higher	O	1499-1505
and	O	1506-1509
more	O	1510-1514
tumors	B	1515-1521
grow	O	1522-1526
.	O	1526-1527
.	O	1526-1527

Purification	O	0-12
of	O	13-15
human	O	16-21
very	O	22-26
-	O	26-27
long	O	27-31
-	O	26-27
chain	O	32-37
acyl	O	38-42
-	O	42-43
coenzyme	O	43-51
A	O	52-53
dehydrogenase	O	54-67
and	O	68-71
characterization	O	72-88
of	O	89-91
its	O	92-95
deficiency	O	96-106
in	O	107-109
seven	O	110-115
patients	O	116-124
.	O	124-125

Mitochondrial	O	126-139
very	O	140-144
-	O	144-145
long	O	145-149
-	O	144-145
chain	O	150-155
acyl	O	156-160
-	O	160-161
coenzyme	O	161-169
A	O	170-171
dehydrogenase	O	172-185
(	O	186-187
VLCAD	O	187-192
)	O	192-193
was	O	194-197
purified	O	198-206
from	O	207-211
human	O	212-217
liver	O	218-223
.	O	223-224

The	O	225-228
molecular	O	229-238
masses	O	239-245
of	O	246-248
the	O	249-252
native	O	253-259
enzyme	O	260-266
and	O	267-270
the	O	271-274
subunit	O	275-282
were	O	283-287
estimated	O	288-297
to	O	298-300
be	O	301-303
154	O	304-307
and	O	308-311
70	O	312-314
kD	O	315-317
,	O	317-318
respectively	O	319-331
.	O	331-332

The	O	333-336
enzyme	O	337-343
was	O	344-347
found	O	348-353
to	O	354-356
catalyze	O	357-365
the	O	366-369
major	O	370-375
part	O	376-380
of	O	381-383
mitochondrial	O	384-397
palmitoylcoenzyme	O	398-415
A	O	416-417
dehydrogenation	O	418-433
in	O	434-436
liver	O	437-442
,	O	442-443
heart	O	444-449
,	O	449-450
skeletal	O	451-459
muscle	O	460-466
,	O	466-467
and	O	468-471
skin	O	472-476
fibroblasts	O	477-488
(	O	489-490
89	O	490-492
-	O	492-493
97	O	493-495
,	O	495-496
86	O	497-499
-	O	499-500
99	O	500-502
,	O	502-503
96	O	504-506
-	O	506-507
99	O	507-509
,	O	509-510
and	O	511-514
78	O	515-517
-	O	517-518
87	O	518-520
%	O	520-521
,	O	521-522
respectively	O	523-535
)	O	535-536
.	O	536-537

Skin	O	538-542
fibroblasts	O	543-554
from	O	555-559
26	O	560-562
patients	O	563-571
suspected	O	572-581
of	O	582-584
having	O	585-591
a	O	592-593
disorder	O	594-602
of	O	603-605
mitochondrial	O	606-619
beta	O	620-624
-	O	624-625
oxidation	O	625-634
were	O	635-639
analyzed	O	640-648
for	O	649-652
VLCAD	O	653-658
protein	O	659-666
using	O	667-672
immunoblotting	O	673-687
,	O	687-688
and	O	689-692
7	O	693-694
of	O	695-697
them	O	698-702
contained	O	703-712
undetectable	O	713-725
or	O	726-728
trace	O	729-734
levels	O	735-741
of	O	742-744
the	O	745-748
enzyme	O	749-755
.	O	755-756

The	O	757-760
seven	O	761-766
deficient	O	767-776
fibroblast	O	777-787
lines	O	788-793
were	O	794-798
characterized	O	799-812
by	O	813-815
measuring	O	816-825
acyl	O	826-830
-	O	830-831
coenzyme	O	831-839
A	O	840-841
dehydrogenation	O	842-857
activities	O	858-868
,	O	868-869
overall	O	870-877
palmitic	O	878-886
acid	O	887-891
oxidation	O	892-901
,	O	901-902
and	O	903-906
VLCAD	O	907-912
protein	O	913-920
synthesis	O	921-930
using	O	931-936
pulse	O	937-942
-	O	942-943
chase	O	943-948
,	O	948-949
further	O	950-957
confirming	O	958-968
the	O	969-972
diagnosis	O	973-982
of	O	983-985
VLCAD	B	986-991
deficiency	I	992-1002
.	O	1002-1003

These	O	1004-1009
results	O	1010-1017
suggested	O	1018-1027
the	O	1028-1031
heterogenous	O	1032-1044
nature	O	1045-1051
of	O	1052-1054
the	O	1055-1058
mutations	O	1059-1068
causing	O	1069-1076
the	O	1077-1080
deficiency	O	1081-1091
in	O	1092-1094
the	O	1095-1098
seven	O	1099-1104
patients	O	1105-1113
.	O	1113-1114

Clinically	O	1115-1125
,	O	1125-1126
all	O	1127-1130
patients	O	1131-1139
with	O	1140-1144
VLCAD	B	1145-1150
deficiency	I	1151-1161
exhibited	O	1162-1171
cardiac	B	1172-1179
disease	I	1180-1187
.	O	1187-1188

At	O	1189-1191
least	O	1192-1197
four	O	1198-1202
of	O	1203-1205
them	O	1206-1210
presented	O	1211-1220
with	O	1221-1225
hypertrophic	B	1226-1238
cardiomyopathy	I	1239-1253
.	O	1253-1254

This	O	1255-1259
frequency	O	1260-1269
(	O	1270-1271
>	O	1271-1272
57	O	1273-1275
%	O	1275-1276
)	O	1276-1277
was	O	1278-1281
much	O	1282-1286
higher	O	1287-1293
than	O	1294-1298
that	O	1299-1303
observed	O	1304-1312
in	O	1313-1315
patients	O	1316-1324
with	O	1325-1329
other	O	1330-1335
disorders	O	1336-1345
of	O	1346-1348
mitochondrial	O	1349-1362
long	O	1363-1367
-	O	1367-1368
chain	O	1368-1373
fatty	O	1374-1379
acid	O	1380-1384
oxidation	O	1385-1394
that	O	1395-1399
may	O	1400-1403
be	O	1404-1406
accompanied	O	1407-1418
by	O	1419-1421
cardiac	B	1422-1429
disease	I	1430-1437
in	O	1438-1440
infants	O	1441-1448
.	O	1448-1449
.	O	1448-1449

A	O	0-1
germ	O	2-6
line	O	7-11
mutation	O	12-20
within	O	21-27
the	O	28-31
coding	O	32-38
sequence	O	39-47
for	O	48-51
the	O	52-55
putative	O	56-64
5	O	65-66
-	O	66-67
phosphoribosyl	O	67-81
-	O	66-67
1	O	82-83
-	O	66-67
pyrophosphate	O	84-97
binding	O	98-105
site	O	106-110
of	O	111-113
hypoxanthine	O	114-126
-	O	126-127
guanine	O	127-134
phosphoribosyltransferase	O	135-160
(	O	161-162
HPRT	O	162-166
)	O	166-167
in	O	168-170
a	O	171-172
Lesch	B	173-178
-	I	178-179
Nyhan	I	179-184
patient	O	185-192
:	O	192-193
missense	O	194-202
mutations	O	203-212
within	O	213-219
a	O	220-221
functionally	O	222-234
important	O	235-244
region	O	245-251
probably	O	252-260
cause	O	261-266
disease	O	267-274
.	O	274-275

Lesch	B	276-281
-	I	281-282
Nyhan	I	282-287
syndrome	I	288-296
caused	O	297-303
by	O	304-306
a	O	307-308
complete	B	309-317
deficiency	I	318-328
of	I	329-331
hypoxanthine	I	332-344
guanine	I	345-352
phosphoribosyltransferase	I	353-378
(	O	379-380
HPRT	O	380-384
)	O	384-385
is	O	386-388
the	O	389-392
result	O	393-399
of	O	400-402
a	O	403-404
heterogeneous	O	405-418
group	O	419-424
of	O	425-427
germ	O	428-432
line	O	433-437
mutations	O	438-447
.	O	447-448

Identification	O	449-463
of	O	464-466
each	O	467-471
mutant	O	472-478
gene	O	479-483
provides	O	484-492
valuable	O	493-501
information	O	502-513
as	O	514-516
to	O	517-519
the	O	520-523
type	O	524-528
of	O	529-531
mutation	O	532-540
that	O	541-545
occurs	O	546-552
spontaneously	O	553-566
.	O	566-567

We	O	568-570
report	O	571-577
here	O	578-582
a	O	583-584
newly	O	585-590
identified	O	591-601
HPRT	O	602-606
mutation	O	607-615
in	O	616-618
a	O	619-620
Japanese	O	621-629
patient	O	630-637
with	O	638-642
Lesch	B	643-648
-	I	648-649
Nyhan	I	649-654
syndrome	I	655-663
.	O	663-664

This	O	665-669
gene	O	670-674
,	O	674-675
designated	O	676-686
HPRT	O	687-691
Tokyo	O	692-697
,	O	697-698
had	O	699-702
a	O	703-704
single	O	705-711
nucleotide	O	712-722
change	O	723-729
from	O	730-734
G	O	735-736
to	O	737-739
A	O	740-741
,	O	741-742
as	O	743-745
identified	O	746-756
by	O	757-759
sequencing	O	760-770
cDNA	O	771-775
amplified	O	776-785
by	O	786-788
the	O	789-792
polymerase	O	793-803
chain	O	804-809
reaction	O	810-818
.	O	818-819

Allele	O	820-826
specific	O	827-835
oligonucleotide	O	836-851
hybridization	O	852-865
analysis	O	866-874
using	O	875-880
amplified	O	881-890
genomic	O	891-898
DNA	O	899-902
showed	O	903-909
that	O	910-914
the	O	915-918
mutant	O	919-925
gene	O	926-930
was	O	931-934
transmitted	O	935-946
from	O	947-951
the	O	952-955
maternal	O	956-964
germ	O	965-969
line	O	970-974
.	O	974-975

This	O	976-980
mutation	O	981-989
would	O	990-995
lead	O	996-1000
to	O	1001-1003
an	O	1004-1006
amino	O	1007-1012
acid	O	1013-1017
substitution	O	1018-1030
of	O	1031-1033
Asp	O	1034-1037
for	O	1038-1041
Gly	O	1042-1045
at	O	1046-1048
the	O	1049-1052
amino	O	1053-1058
acid	O	1059-1063
position	O	1064-1072
140	O	1073-1076
located	O	1077-1084
within	O	1085-1091
the	O	1092-1095
putative	O	1096-1104
5	O	1105-1106
-	O	1106-1107
phosphoribosyl	O	1107-1121
-	O	1106-1107
1	O	1122-1123
-	O	1106-1107
pyrophosphate	O	1124-1137
(	O	1138-1139
PRPP	O	1139-1143
)	O	1143-1144
binding	O	1145-1152
region	O	1153-1159
.	O	1159-1160

Missense	O	1161-1169
mutations	O	1170-1179
in	O	1180-1182
human	O	1183-1188
HPRT	B	1189-1193
deficient	I	1194-1203
patients	O	1204-1212
thus	O	1213-1217
far	O	1218-1221
reported	O	1222-1230
tend	O	1231-1235
to	O	1236-1238
accumulate	O	1239-1249
in	O	1250-1252
this	O	1253-1257
functionally	O	1258-1270
active	O	1271-1277
region	O	1278-1284
.	O	1284-1285

However	O	1286-1293
,	O	1293-1294
a	O	1295-1296
comparison	O	1297-1307
of	O	1308-1310
the	O	1311-1314
data	O	1315-1319
suggested	O	1320-1329
that	O	1330-1334
both	O	1335-1339
missense	O	1340-1348
and	O	1349-1352
synonymous	O	1353-1363
mutations	O	1364-1373
can	O	1374-1377
occur	O	1378-1383
at	O	1384-1386
any	O	1387-1390
coding	O	1391-1397
sequence	O	1398-1406
of	O	1407-1409
the	O	1410-1413
human	O	1414-1419
germ	O	1420-1424
line	O	1425-1429
HPRT	O	1430-1434
gene	O	1435-1439
,	O	1439-1440
but	O	1441-1444
that	O	1445-1449
a	O	1450-1451
limited	O	1452-1459
percentage	O	1460-1470
of	O	1471-1473
all	O	1474-1477
the	O	1478-1481
missense	O	1482-1490
mutations	O	1491-1500
cause	O	1501-1506
disease	O	1507-1514
.	O	1514-1515

The	O	1516-1519
probability	O	1520-1531
that	O	1532-1536
a	O	1537-1538
mutation	O	1539-1547
will	O	1548-1552
cause	O	1553-1558
disease	O	1559-1566
tends	O	1567-1572
to	O	1573-1575
be	O	1576-1578
higher	O	1579-1585
when	O	1586-1590
the	O	1591-1594
missense	O	1595-1603
mutation	O	1604-1612
is	O	1613-1615
within	O	1616-1622
a	O	1623-1624
functionally	O	1625-1637
important	O	1638-1647
sequence	O	1648-1656
.	O	1656-1657
.	O	1656-1657

In	O	0-2
vitro	O	3-8
and	O	9-12
in	O	13-15
vivo	O	16-20
correlations	O	21-33
for	O	34-37
I65T	O	38-42
and	O	43-46
M1V	O	47-50
mutations	O	51-60
at	O	61-63
the	O	64-67
phenylalanine	O	68-81
hydroxylase	O	82-93
locus	O	94-99
.	O	99-100

Mutations	O	101-110
at	O	111-113
the	O	114-117
phenylalanine	O	118-131
hydroxylase	O	132-143
(	O	144-145
PAH	O	145-148
)	O	148-149
locus	O	150-155
are	O	156-159
the	O	160-163
major	O	164-169
cause	O	170-175
of	O	176-178
hyperphenylalaninemia	B	179-200
.	O	200-201

We	O	202-204
have	O	205-209
previously	O	210-220
described	O	221-230
four	O	231-235
mutations	O	236-245
(	O	246-247
M1V	O	247-250
,	O	250-251
IVS12nt1	O	252-260
,	O	260-261
R408W	O	262-267
,	O	267-268
and	O	269-272
S349P	O	273-278
)	O	278-279
at	O	280-282
the	O	283-286
PAH	O	287-290
locus	O	291-296
in	O	297-299
French	O	300-306
Canadians	O	307-316
with	O	317-321
ancestry	O	322-330
in	O	331-333
eastern	O	334-341
Quebec	O	342-348
.	O	348-349

Here	O	350-354
we	O	355-357
report	O	358-364
(	O	365-366
1	O	366-367
)	O	367-368
identification	O	369-383
of	O	384-386
another	O	387-394
mutation	O	395-403
,	O	403-404
on	O	405-407
a	O	408-409
haplotype	O	410-419
9	O	420-421
chromosome	O	422-432
,	O	432-433
which	O	434-439
converts	O	440-448
codon	O	449-454
65	O	455-457
from	O	458-462
isoleucine	O	463-473
(	O	474-475
ATT	O	475-478
)	O	478-479
to	O	480-482
threonine	O	483-492
(	O	493-494
ACT	O	494-497
)	O	497-498
,	O	498-499
(	O	500-501
2	O	501-502
)	O	502-503
expression	O	504-514
analysis	O	515-523
of	O	524-526
the	O	527-530
I65T	O	531-535
mutation	O	536-544
in	O	545-547
COS	O	548-551
cells	O	552-557
demonstrating	O	558-571
75	O	572-574
%	O	574-575
loss	O	576-580
of	O	581-583
both	O	584-588
immunoreactive	O	589-603
protein	O	604-611
and	O	612-615
enzyme	O	616-622
activity	O	623-631
,	O	631-632
and	O	633-636
(	O	637-638
3	O	638-639
)	O	639-640
expression	O	641-651
analysis	O	652-660
of	O	661-663
the	O	664-667
most	O	668-672
prevalent	O	673-682
PKU	B	683-686
allele	O	687-693
(	O	694-695
M1V	O	695-698
)	O	698-699
in	O	700-702
eastern	O	703-710
Quebec	O	711-717
,	O	717-718
showing	O	719-726
nondetectable	O	727-740
levels	O	741-747
of	O	748-750
PAH	O	751-754
protein	O	755-762
and	O	763-766
activity	O	767-775
,	O	775-776
a	O	777-778
finding	O	779-786
compatible	O	787-797
with	O	798-802
a	O	803-804
mutation	O	805-813
in	O	814-816
the	O	817-820
translation	O	821-832
initiation	O	833-843
codon	O	844-849
.	O	849-850

Homozygosity	O	851-863
for	O	864-867
M1V	O	868-871
and	O	872-875
codominant	O	876-886
inheritance	O	887-898
of	O	899-901
I65T	O	902-906
/	O	906-907
R408W	O	907-912
were	O	913-917
both	O	918-922
associated	O	923-933
with	O	934-938
classical	B	939-948
phenylketonuria	I	949-964
.	O	964-965
.	O	964-965

Experimental	O	0-12
hemochromatosis	B	13-28
due	O	29-32
to	O	33-35
MHC	O	36-39
class	O	40-45
I	O	46-47
HFE	B	48-51
deficiency	I	52-62
:	O	62-63
immune	O	64-70
status	O	71-77
and	O	78-81
iron	O	82-86
metabolism	O	87-97
.	O	97-98

The	O	99-102
puzzling	O	103-111
linkage	O	112-119
between	O	120-127
genetic	O	128-135
hemochromatosis	B	136-151
and	O	152-155
histocompatibility	O	156-174
loci	O	175-179
became	O	180-186
even	O	187-191
more	O	192-196
so	O	197-199
when	O	200-204
the	O	205-208
gene	O	209-213
involved	O	214-222
,	O	222-223
HFE	O	224-227
,	O	227-228
was	O	229-232
identified	O	233-243
.	O	243-244

Indeed	O	245-251
,	O	251-252
within	O	253-259
the	O	260-263
well	O	264-268
defined	O	269-276
,	O	276-277
mainly	O	278-284
peptide	O	285-292
-	O	292-293
binding	O	293-300
,	O	300-301
MHC	O	302-305
class	O	306-311
I	O	312-313
family	O	314-320
of	O	321-323
molecules	O	324-333
,	O	333-334
HFE	O	335-338
seems	O	339-344
to	O	345-347
perform	O	348-355
an	O	356-358
unusual	O	359-366
yet	O	367-370
essential	O	371-380
function	O	381-389
.	O	389-390

As	O	391-393
yet	O	394-397
,	O	397-398
our	O	399-402
understanding	O	403-416
of	O	417-419
HFE	O	420-423
function	O	424-432
in	O	433-435
iron	O	436-440
homeostasis	O	441-452
is	O	453-455
only	O	456-460
partial	O	461-468
;	O	468-469
an	O	470-472
even	O	473-477
more	O	478-482
open	O	483-487
question	O	488-496
is	O	497-499
its	O	500-503
possible	O	504-512
role	O	513-517
in	O	518-520
the	O	521-524
immune	O	525-531
system	O	532-538
.	O	538-539

To	O	540-542
advance	O	543-550
on	O	551-553
both	O	554-558
of	O	559-561
these	O	562-567
avenues	O	568-575
,	O	575-576
we	O	577-579
report	O	580-586
the	O	587-590
deletion	O	591-599
of	O	600-602
HFE	O	603-606
alpha1	O	607-613
and	O	614-617
alpha2	O	618-624
putative	O	625-633
ligand	O	634-640
binding	O	641-648
domains	O	649-656
in	O	657-659
vivo	O	660-664
.	O	664-665

HFE	B	666-669
-	I	669-670
deficient	I	670-679
animals	O	680-687
were	O	688-692
analyzed	O	693-701
for	O	702-705
a	O	706-707
comprehensive	O	708-721
set	O	722-725
of	O	726-728
metabolic	O	729-738
and	O	739-742
immune	O	743-749
parameters	O	750-760
.	O	760-761

Faithfully	O	762-772
mimicking	O	773-782
human	O	783-788
hemochromatosis	B	789-804
,	O	804-805
mice	O	806-810
homozygous	O	811-821
for	O	822-825
this	O	826-830
deletion	O	831-839
develop	O	840-847
iron	O	848-852
overload	O	853-861
,	O	861-862
characterized	O	863-876
by	O	877-879
a	O	880-881
higher	O	882-888
plasma	O	889-895
iron	O	896-900
content	O	901-908
and	O	909-912
a	O	913-914
raised	O	915-921
transferrin	O	922-933
saturation	O	934-944
as	O	945-947
well	O	948-952
as	O	953-955
an	O	956-958
elevated	O	959-967
hepatic	O	968-975
iron	O	976-980
load	O	981-985
.	O	985-986

The	O	987-990
primary	O	991-998
defect	O	999-1005
could	O	1006-1011
,	O	1011-1012
indeed	O	1013-1019
,	O	1019-1020
be	O	1021-1023
traced	O	1024-1030
to	O	1031-1033
an	O	1034-1036
augmented	O	1037-1046
duodenal	O	1047-1055
iron	O	1056-1060
absorption	O	1061-1071
.	O	1071-1072

In	O	1073-1075
parallel	O	1076-1084
,	O	1084-1085
measurement	O	1086-1097
of	O	1098-1100
the	O	1101-1104
gut	O	1105-1108
mucosal	O	1109-1116
iron	O	1117-1121
content	O	1122-1129
as	O	1130-1132
well	O	1133-1137
as	O	1138-1140
iron	O	1141-1145
regulatory	O	1146-1156
proteins	O	1157-1165
allows	O	1166-1172
a	O	1173-1174
more	O	1175-1179
informed	O	1180-1188
evaluation	O	1189-1199
of	O	1200-1202
various	O	1203-1210
hypotheses	O	1211-1221
regarding	O	1222-1231
the	O	1232-1235
precise	O	1236-1243
role	O	1244-1248
of	O	1249-1251
HFE	O	1252-1255
in	O	1256-1258
iron	O	1259-1263
homeostasis	O	1264-1275
.	O	1275-1276

Finally	O	1277-1284
,	O	1284-1285
an	O	1286-1288
extensive	O	1289-1298
phenotyping	O	1299-1310
of	O	1311-1313
primary	O	1314-1321
and	O	1322-1325
secondary	O	1326-1335
lymphoid	O	1336-1344
organs	O	1345-1351
including	O	1352-1361
the	O	1362-1365
gut	O	1366-1369
provides	O	1370-1378
no	O	1379-1381
compelling	O	1382-1392
evidence	O	1393-1401
for	O	1402-1405
an	O	1406-1408
obvious	O	1409-1416
immune	O	1417-1423
-	O	1423-1424
linked	O	1424-1430
function	O	1431-1439
for	O	1440-1443
HFE	O	1444-1447
.	O	1447-1448
.	O	1447-1448

[	O	0-1
Genetic	O	1-8
heterogeneity	O	9-22
of	O	23-25
G6PD	B	26-30
deficiency	I	31-41
:	O	41-42
mutant	O	43-49
alleles	O	50-57
of	O	58-60
G6PD	O	61-65
in	O	66-68
the	O	69-72
Shekii	O	73-79
district	O	80-88
of	O	89-91
Azerbaijan	O	92-102
]	O	102-103
Examination	O	104-115
on	O	116-118
G6PD	B	119-123
deficiency	I	124-134
in	O	135-137
349	O	138-141
patients	O	142-150
of	O	151-153
Shekii	O	154-160
district	O	161-169
hospital	O	170-178
(	O	179-180
Azerbaijan	O	180-190
)	O	190-191
revealed	O	192-200
16	O	201-203
hemi	O	204-208
-	O	208-209
,	O	209-210
4	O	211-212
homo	O	213-217
-	O	217-218
and	O	219-222
9	O	223-224
heterozygotic	O	225-238
carriers	O	239-247
of	O	248-250
the	O	251-254
defect	O	255-261
.	O	261-262

Gd	O	263-265
-	O	265-266
frequency	O	267-276
,	O	276-277
calculated	O	278-288
from	O	289-293
the	O	294-297
data	O	298-302
obtained	O	303-311
(	O	312-313
7	O	313-314
.	O	314-315

7	O	316-317
%	O	317-318
)	O	318-319
,	O	319-320
may	O	321-324
be	O	325-327
compared	O	328-336
to	O	337-339
neighbouring	O	340-352
regions	O	353-360
frequencies	O	361-372
(	O	373-374
6	O	374-375
-	O	375-376
30	O	376-378
%	O	378-379
)	O	379-380
.	O	380-381

Carriers	O	382-390
of	O	391-393
G6PD	B	394-398
deficiency	I	399-409
are	O	410-413
residents	O	414-423
of	O	424-426
11	O	427-429
villages	O	430-438
located	O	439-446
in	O	447-449
Alasani	O	450-457
-	O	457-458
Aphtalan	O	458-466
valley	O	467-473
,	O	473-474
highly	O	475-481
endemic	O	482-489
with	O	490-494
malaria	B	495-502
in	O	503-505
the	O	506-509
past	O	510-514
;	O	514-515
nearly	O	516-522
all	O	523-526
marriages	O	527-536
are	O	537-540
endogamic	O	541-550
.	O	550-551

Physico	O	552-559
-	O	559-560
chemical	O	560-568
and	O	569-572
kinetic	O	573-580
study	O	581-586
of	O	587-589
10	O	590-592
mutant	O	593-599
forms	O	600-605
of	O	606-608
G6PD	O	609-613
,	O	613-614
according	O	615-624
to	O	625-627
WHO	O	628-631
program	O	632-639
,	O	639-640
led	O	641-644
to	O	645-647
identification	O	648-662
of	O	663-665
5	O	666-667
variants	O	668-676
of	O	677-679
the	O	680-683
II	O	684-686
class	O	687-692
(	O	693-694
Shekii	O	694-700
,	O	700-701
Bideiz	O	702-708
,	O	708-709
Shirin	O	710-716
-	O	716-717
Bulakh	O	717-723
,	O	723-724
Okhut	O	725-730
I	O	731-732
and	O	733-736
Zakataly	O	737-745
)	O	745-746
and	O	747-750
2	O	751-752
variants	O	753-761
of	O	762-764
the	O	765-768
III	O	769-772
class	O	773-778
(	O	779-780
Okhut	O	780-785
II	O	786-788
and	O	789-792
Martinique	O	793-803
-	O	803-804
like	O	804-808
)	O	808-809
.	O	809-810

Resemblance	O	811-822
of	O	823-825
the	O	826-829
majority	O	830-838
of	O	839-841
variants	O	842-850
in	O	851-853
electrophoretic	O	854-869
mobility	O	870-878
and	O	879-882
the	O	883-886
level	O	887-892
of	O	893-895
erythrocyte	O	896-907
enzyme	O	908-914
activity	O	915-923
permit	O	924-930
to	O	931-933
suggest	O	934-941
the	O	942-945
existence	O	946-955
of	O	956-958
a	O	959-960
common	O	961-967
parental	O	968-976
mutant	O	977-983
G6PD	O	984-988
allele	O	989-995
distributed	O	996-1007
in	O	1008-1010
this	O	1011-1015
area	O	1016-1020
.	O	1020-1021

[	O	0-1
Gd	O	1-3
-	O	3-4
allele	O	5-11
distribution	O	12-24
patterns	O	25-33
in	O	34-36
Azerbaijan	O	37-47
.	O	47-48

III	O	49-52
.	O	52-53

The	O	54-57
identification	O	58-72
of	O	73-75
mutant	O	76-82
forms	O	83-88
of	O	89-91
glucose	O	92-99
-	O	99-100
6	O	100-101
-	O	99-100
phosphate	O	102-111
dehydrogenase	O	112-125
]	O	125-126
In	O	127-129
28	O	130-132
families	O	133-141
with	O	142-146
G6PD	B	147-151
deficiency	I	152-162
living	O	163-169
in	O	170-172
3	O	173-174
settlements	O	175-186
of	O	187-189
Shekii	O	190-196
district	O	197-205
of	O	206-208
Azerbaijan	O	209-219
11	O	220-222
G6PD	O	223-227
variants	O	228-236
of	O	237-239
II	O	240-242
and	O	243-246
III	O	247-250
classes	O	251-258
differing	O	259-268
by	O	269-271
kinetic	O	272-279
properties	O	280-290
were	O	291-295
identified	O	296-306
according	O	307-316
WHO	O	317-320
program	O	321-328
.	O	328-329

9	O	330-331
of	O	332-334
them	O	335-339
are	O	340-343
characterized	O	344-357
with	O	358-362
the	O	363-366
same	O	367-371
electrophoretic	O	372-387
mobility	O	388-396
.	O	396-397

Comparison	O	398-408
of	O	409-411
G6PD	O	412-416
spectra	O	417-424
in	O	425-427
two	O	428-431
subpopulations	O	432-446
and	O	447-450
in	O	451-453
a	O	454-455
mixed	O	456-461
group	O	462-467
permits	O	468-475
to	O	476-478
make	O	479-483
a	O	484-485
conclusion	O	486-496
about	O	497-502
existence	O	503-512
of	O	513-515
common	O	516-522
and	O	523-526
rare	O	527-531
G6PD	O	532-536
alleles	O	537-544
in	O	545-547
examined	O	548-556
population	O	557-567
.	O	567-568

They	O	569-573
distribute	O	574-584
by	O	585-587
gene	O	588-592
drift	O	593-598
supported	O	599-608
by	O	609-611
natural	O	612-619
selection	O	620-629
.	O	629-630

Among	O	631-636
7	O	637-638
samples	O	639-646
of	O	647-649
G6PD	O	650-654
with	O	655-659
normal	O	660-666
and	O	667-670
increased	O	671-680
activity	O	681-689
two	O	690-693
new	O	694-697
variants	O	698-706
of	O	707-709
IV	O	710-712
class	O	713-718
-	O	719-720
-	O	719-720
Nukha	O	722-727
and	O	728-731
Bash	O	732-736
-	O	736-737
Kungut	O	737-743
-	O	744-745
-	O	744-745
were	O	747-751
found	O	752-757
.	O	757-758
.	O	757-758

Determination	O	0-13
of	O	14-16
carrier	O	17-24
status	O	25-31
for	O	32-35
the	O	36-39
Wiskott	B	40-47
-	I	47-48
Aldrich	I	48-55
syndrome	I	56-64
by	O	65-67
flow	O	68-72
cytometric	O	73-83
analysis	O	84-92
of	O	93-95
Wiskott	B	96-103
-	I	103-104
Aldrich	I	104-111
syndrome	I	112-120
protein	O	121-128
expression	O	129-139
in	O	140-142
peripheral	O	143-153
blood	O	154-159
mononuclear	O	160-171
cells	O	172-177
.	O	177-178

The	O	179-182
Wiskott	B	183-190
-	I	190-191
Aldrich	I	191-198
syndrome	I	199-207
(	O	208-209
WAS	B	209-212
)	O	212-213
is	O	214-216
caused	O	217-223
by	O	224-226
defects	O	227-234
in	O	235-237
the	O	238-241
WAS	B	242-245
protein	O	246-253
(	O	254-255
WASP	O	255-259
)	O	259-260
gene	O	261-265
on	O	266-268
the	O	269-272
X	O	273-274
chromosome	O	275-285
.	O	285-286

Previous	O	287-295
study	O	296-301
disclosed	O	302-311
that	O	312-316
flow	O	317-321
cytometric	O	322-332
analysis	O	333-341
of	O	342-344
intracellular	O	345-358
WASP	O	359-363
expression	O	364-374
(	O	375-376
FCM	O	376-379
-	O	379-380
WASP	O	380-384
analysis	O	385-393
)	O	393-394
in	O	395-397
lymphocytes	O	398-409
was	O	410-413
useful	O	414-420
for	O	421-424
the	O	425-428
diagnosis	O	429-438
of	O	439-441
WAS	B	442-445
patients	O	446-454
.	O	454-455

Lymphocytes	O	456-467
from	O	468-472
all	O	473-476
WAS	B	477-480
patients	O	481-489
showed	O	490-496
WASPdim	O	497-504
instead	O	505-512
of	O	513-515
WASPbright	O	516-526
.	O	526-527

Here	O	528-532
we	O	533-535
report	O	536-542
that	O	543-547
FCM	O	548-551
-	O	551-552
WASP	O	552-556
analysis	O	557-565
in	O	566-568
monocytes	O	569-578
could	O	579-584
be	O	585-587
a	O	588-589
useful	O	590-596
tool	O	597-601
for	O	602-605
the	O	606-609
WAS	B	610-613
carrier	O	614-621
diagnosis	O	622-631
.	O	631-632

Monocytes	O	633-642
from	O	643-647
all	O	648-651
nine	O	652-656
WAS	B	657-660
carriers	O	661-669
showed	O	670-676
varied	O	677-683
population	O	684-694
of	O	695-697
WASPdim	O	698-705
together	O	706-714
with	O	715-719
WASPbright	O	720-730
.	O	730-731

None	O	732-736
of	O	737-739
control	O	740-747
individuals	O	748-759
possessed	O	760-769
the	O	770-773
WASPdim	O	774-781
population	O	782-792
.	O	792-793

In	O	794-796
contrast	O	797-805
,	O	805-806
lymphocytes	O	807-818
from	O	819-823
all	O	824-827
the	O	828-831
carriers	O	832-840
except	O	841-847
two	O	848-851
lacked	O	852-858
the	O	859-862
WASPdim	O	863-870
population	O	871-881
.	O	881-882

The	O	883-886
difference	O	887-897
of	O	898-900
the	O	901-904
WASPdim	O	905-912
population	O	913-923
in	O	924-926
monocytes	O	927-936
and	O	937-940
lymphocytes	O	941-952
observed	O	953-961
in	O	962-964
WAS	B	965-968
carriers	O	969-977
suggests	O	978-986
that	O	987-991
WASP	O	992-996
plays	O	997-1002
a	O	1003-1004
more	O	1005-1009
critical	O	1010-1018
role	O	1019-1023
in	O	1024-1026
the	O	1027-1030
development	O	1031-1042
of	O	1043-1045
lymphocytes	O	1046-1057
than	O	1058-1062
in	O	1063-1065
that	O	1066-1070
of	O	1071-1073
monocytes	O	1074-1083
.	O	1083-1084

The	O	1085-1088
present	O	1089-1096
studies	O	1097-1104
suggest	O	1105-1112
that	O	1113-1117
a	O	1118-1119
skewed	O	1120-1126
X	O	1127-1128
-	O	1128-1129
chromosomal	O	1129-1140
inactivation	O	1141-1153
pattern	O	1154-1161
observed	O	1162-1170
in	O	1171-1173
WAS	B	1174-1177
carrier	O	1178-1185
peripheral	O	1186-1196
blood	O	1197-1202
cells	O	1203-1208
is	O	1209-1211
not	O	1212-1215
fixed	O	1216-1221
at	O	1222-1224
the	O	1225-1228
hemopoietic	O	1229-1240
stem	O	1241-1245
cell	O	1246-1250
level	O	1251-1256
but	O	1257-1260
progresses	O	1261-1271
after	O	1272-1277
the	O	1278-1281
lineage	O	1282-1289
commitment	O	1290-1300
.	O	1300-1301
.	O	1300-1301

Linkage	O	0-7
of	O	8-10
DNA	O	11-14
markers	O	15-22
at	O	23-25
Xq28	O	26-30
to	O	31-33
adrenoleukodystrophy	B	34-54
and	O	55-58
adrenomyeloneuropathy	B	59-80
present	O	81-88
within	O	89-95
the	O	96-99
same	O	100-104
family	O	105-111
.	O	111-112

We	O	113-115
present	O	116-123
a	O	124-125
large	O	126-131
kindred	O	132-139
that	O	140-144
contained	O	145-154
patients	O	155-163
with	O	164-168
either	O	169-175
adrenoleukodystrophy	B	176-196
(	O	197-198
ALD	B	198-201
)	O	201-202
or	O	203-205
adrenomyeloneuropathy	B	206-227
(	O	228-229
AMN	B	229-232
)	O	232-233
.	O	233-234

The	O	235-238
pedigree	O	239-247
clearly	O	248-255
supported	O	256-265
the	O	266-269
X	O	270-271
-	O	271-272
linked	O	272-278
mode	O	279-283
of	O	284-286
inheritance	O	287-298
of	O	299-301
the	O	302-305
nonneonatal	O	306-317
form	O	318-322
of	O	323-325
ALD	B	326-329
/	O	329-330
AMN	B	330-333
.	O	333-334

Analysis	O	335-343
with	O	344-348
DNA	O	349-352
markers	O	353-360
at	O	361-363
Xq28	O	364-368
suggested	O	369-378
segregation	O	379-390
of	O	391-393
both	O	394-398
ALD	B	399-402
and	O	403-406
AMN	B	407-410
with	O	411-415
an	O	416-418
identical	O	419-428
haplotype	O	429-438
.	O	438-439

This	O	440-444
indicated	O	445-454
that	O	455-459
nonneonatal	O	460-471
ALD	B	472-475
and	O	476-479
AMN	B	480-483
are	O	484-487
caused	O	488-494
by	O	495-497
a	O	498-499
mutation	O	500-508
in	O	509-511
the	O	512-515
same	O	516-520
gene	O	521-525
at	O	526-528
Xq28	O	529-533
.	O	533-534

It	O	535-537
showed	O	538-544
,	O	544-545
furthermore	O	546-557
,	O	557-558
that	O	559-563
phenotypic	O	564-574
differences	O	575-586
between	O	587-594
ALD	B	595-598
and	O	599-602
AMN	B	603-606
are	O	607-610
not	O	611-614
necessarily	O	615-626
the	O	627-630
consequence	O	631-642
of	O	643-645
allelic	O	646-653
heterogeneity	O	654-667
due	O	668-671
to	O	672-674
different	O	675-684
mutations	O	685-694
within	O	695-701
the	O	702-705
same	O	706-710
gene	O	711-715
.	O	715-716

The	O	717-720
maximal	O	721-728
lod	O	729-732
score	O	733-738
for	O	739-742
linkage	O	743-750
of	O	751-753
the	O	754-757
ALD	B	758-761
/	O	761-762
AMN	B	762-765
gene	O	766-770
and	O	771-774
the	O	775-778
multiallelic	O	779-791
anonymous	O	792-801
DNA	O	802-805
marker	O	806-812
at	O	813-815
DXS52	O	816-821
was	O	822-825
3	O	826-827
.	O	827-828
0	O	829-830
at	O	831-833
a	O	834-835
recombination	O	836-849
fraction	O	850-858
of	O	859-861
0	O	862-863
.	O	863-864
00	O	865-867
.	O	867-868

This	O	869-873
made	O	874-878
a	O	879-880
prenatal	O	881-889
or	O	890-892
presymptomatic	O	893-907
diagnosis	O	908-917
and	O	918-921
heterozygote	O	922-934
detection	O	935-944
by	O	945-947
DNA	O	948-951
analysis	O	952-960
with	O	961-965
this	O	966-970
marker	O	971-977
reliable	O	978-986
.	O	986-987

Further	O	0-7
investigation	O	8-21
of	O	22-24
the	O	25-28
HEXA	O	29-33
gene	O	34-38
intron	O	39-45
9	O	46-47
donor	O	48-53
splice	O	54-60
site	O	61-65
mutation	O	66-74
frequently	O	75-85
found	O	86-91
in	O	92-94
non	O	95-98
-	O	98-99
Jewish	O	99-105
Tay	B	106-109
-	I	109-110
Sachs	I	110-115
disease	I	116-123
patients	O	124-132
from	O	133-137
the	O	138-141
British	O	142-149
Isles	O	150-155
.	O	155-156

In	O	157-159
a	O	160-161
previous	O	162-170
study	O	171-176
we	O	177-179
found	O	180-185
that	O	186-190
a	O	191-192
Tay	B	193-196
-	I	196-197
Sachs	I	197-202
disease	I	203-210
(	O	211-212
TSD	B	212-215
)	O	215-216
causing	O	217-224
mutation	O	225-233
in	O	234-236
the	O	237-240
intron	O	241-247
9	O	248-249
donor	O	250-255
splice	O	256-262
site	O	263-267
of	O	268-270
the	O	271-274
HEXA	O	275-279
gene	O	280-284
occurs	O	285-291
at	O	292-294
high	O	295-299
frequency	O	300-309
in	O	310-312
non	O	313-316
-	O	316-317
Jewish	O	317-323
patients	O	324-332
and	O	333-336
carriers	O	337-345
from	O	346-350
the	O	351-354
British	O	355-362
Isles	O	363-368
.	O	368-369

It	O	370-372
was	O	373-376
found	O	377-382
more	O	383-387
frequently	O	388-398
in	O	399-401
subjects	O	402-410
of	O	411-413
Irish	O	414-419
,	O	419-420
Scottish	O	421-429
,	O	429-430
and	O	431-434
Welsh	O	435-440
origin	O	441-447
compared	O	448-456
with	O	457-461
English	O	462-469
origin	O	470-476
(	O	477-478
63	O	478-480
%	O	480-481
and	O	482-485
31	O	486-488
%	O	488-489
respectively	O	490-502
)	O	502-503
.	O	503-504

We	O	505-507
have	O	508-512
now	O	513-516
tested	O	517-523
,	O	523-524
in	O	525-527
a	O	528-529
blind	O	530-535
study	O	536-541
,	O	541-542
26	O	543-545
American	O	546-554
TSD	B	555-558
carriers	O	559-567
and	O	568-571
28	O	572-574
non	O	575-578
-	O	578-579
carriers	O	579-587
who	O	588-591
have	O	592-596
British	O	597-604
ancestry	O	605-613
for	O	614-617
the	O	618-621
intron	O	622-628
9	O	629-630
splice	O	631-637
site	O	638-642
mutation	O	643-651
.	O	651-652

Six	O	653-656
of	O	657-659
the	O	660-663
carriers	O	664-672
and	O	673-676
none	O	677-681
of	O	682-684
the	O	685-688
controls	O	689-697
were	O	698-702
positive	O	703-711
for	O	712-715
the	O	716-719
mutation	O	720-728
.	O	728-729

All	O	730-733
six	O	734-737
had	O	738-741
Irish	O	742-747
ancestry	O	748-756
,	O	756-757
compared	O	758-766
with	O	767-771
nine	O	772-776
of	O	777-779
the	O	780-783
20	O	784-786
other	O	787-792
(	O	793-794
intron	O	794-800
9	O	801-802
mutation	O	803-811
negative	O	812-820
)	O	820-821
TSD	B	822-825
carriers	O	826-834
(	O	835-836
p	O	836-837
<	O	838-839
0	O	840-841
.	O	841-842
05	O	843-845
)	O	845-846
.	O	846-847

These	O	848-853
results	O	854-861
confirm	O	862-869
the	O	870-873
previously	O	874-884
found	O	885-890
high	O	891-895
frequency	O	896-905
of	O	906-908
the	O	909-912
intron	O	913-919
9	O	920-921
mutation	O	922-930
in	O	931-933
non	O	934-937
-	O	937-938
Jewish	O	938-944
TSD	B	945-948
families	O	949-957
of	O	958-960
British	O	961-968
Isles	O	969-974
,	O	974-975
particularly	O	976-988
Irish	O	989-994
,	O	994-995
origin	O	996-1002
,	O	1002-1003
and	O	1004-1007
reinforce	O	1008-1017
the	O	1018-1021
need	O	1022-1026
to	O	1027-1029
screen	O	1030-1036
such	O	1037-1041
families	O	1042-1050
for	O	1051-1054
this	O	1055-1059
mutation	O	1060-1068
.	O	1068-1069

The	O	0-3
murine	O	4-10
homologues	O	11-21
of	O	22-24
the	O	25-28
Huntington	B	29-39
disease	I	40-47
gene	O	48-52
(	O	53-54
Hdh	O	54-57
)	O	57-58
and	O	59-62
the	O	63-66
alpha	O	67-72
-	O	72-73
adducin	O	73-80
gene	O	81-85
(	O	86-87
Add1	O	87-91
)	O	91-92
map	O	93-96
to	O	97-99
mouse	O	100-105
chromosome	O	106-116
5	O	117-118
within	O	119-125
a	O	126-127
region	O	128-134
of	O	135-137
conserved	O	138-147
synteny	O	148-155
with	O	156-160
human	O	161-166
chromosome	O	167-177
4p16	O	178-182
.	O	182-183
3	O	183-184
.	O	182-183

Huntington	B	186-196
disease	I	197-204
(	O	205-206
HD	B	206-208
)	O	208-209
is	O	210-212
a	O	213-214
severe	O	215-221
autosomal	B	222-231
dominant	I	232-240
neurodegenerative	I	241-258
disorder	I	259-267
associated	O	268-278
with	O	279-283
a	O	284-285
novel	O	286-291
gene	O	292-296
(	O	297-298
IT15	O	298-302
)	O	302-303
.	O	303-304

Recently	O	305-313
,	O	313-314
we	O	315-317
reported	O	318-326
the	O	327-330
cloning	O	331-338
of	O	339-341
Hdh	O	342-345
,	O	345-346
the	O	347-350
murine	O	351-357
homologue	O	358-367
of	O	368-370
IT15	O	371-375
.	O	375-376

Here	O	377-381
,	O	381-382
using	O	383-388
an	O	389-391
interspecific	O	392-405
backcross	O	406-415
,	O	415-416
we	O	417-419
have	O	420-424
mapped	O	425-431
both	O	432-436
Hdh	O	437-440
and	O	441-444
the	O	445-448
mouse	O	449-454
homologue	O	455-464
of	O	465-467
human	O	468-473
alpha	O	474-479
-	O	479-480
adducin	O	480-487
(	O	488-489
Add1	O	489-493
)	O	493-494
,	O	494-495
a	O	496-497
membrane	O	498-506
-	O	506-507
associated	O	507-517
cytoskeletal	O	518-530
protein	O	531-538
gene	O	539-543
.	O	543-544

Both	O	545-549
of	O	550-552
these	O	553-558
genes	O	559-564
map	O	565-568
in	O	569-571
the	O	572-575
same	O	576-580
position	O	581-589
on	O	590-592
mouse	O	593-598
chromosome	O	599-609
5	O	610-611
in	O	612-614
a	O	615-616
region	O	617-623
associated	O	624-634
with	O	635-639
ancestral	O	640-649
chromosomal	O	650-661
rearrangements	O	662-676
and	O	677-680
show	O	681-685
no	O	686-688
recombination	O	689-702
with	O	703-707
D5H4S43	O	708-715
,	O	715-716
D5H4S115	O	717-725
,	O	725-726
and	O	727-730
D5H4S62	O	731-738
,	O	738-739
the	O	740-743
murine	O	744-750
homologues	O	751-761
of	O	762-764
D4S43	O	765-770
,	O	770-771
D4S115	O	772-778
,	O	778-779
and	O	780-783
D4S62	O	784-789
,	O	789-790
respectively	O	791-803
.	O	803-804

Further	O	805-812
mapping	O	813-820
studies	O	821-828
of	O	829-831
humans	O	832-838
,	O	838-839
mice	O	840-844
,	O	844-845
and	O	846-849
other	O	850-855
mammalian	O	856-865
species	O	866-873
should	O	874-880
reveal	O	881-887
the	O	888-891
nature	O	892-898
of	O	899-901
the	O	902-905
rearrangements	O	906-920
affecting	O	921-930
this	O	931-935
chromosomal	O	936-947
segment	O	948-955
during	O	956-962
mammalian	O	963-972
evolution	O	973-982
.	O	982-983
.	O	982-983

Linkage	O	0-7
analysis	O	8-16
of	O	17-19
the	O	20-23
apolipoprotein	O	24-38
C2	O	39-41
gene	O	42-46
and	O	47-50
myotonic	B	51-59
dystrophy	I	60-69
on	O	70-72
human	O	73-78
chromosome	O	79-89
19	O	90-92
reveals	O	93-100
linkage	O	101-108
disequilibrium	O	109-123
in	O	124-126
a	O	127-128
French	O	129-135
-	O	135-136
Canadian	O	136-144
population	O	145-155
.	O	155-156

The	O	157-160
gene	O	161-165
for	O	166-169
human	O	170-175
apolipoprotein	O	176-190
C2	O	191-193
(	O	194-195
APOC2	O	195-200
)	O	200-201
,	O	201-202
situated	O	203-211
on	O	212-214
the	O	215-218
proximal	O	219-227
long	O	228-232
arm	O	233-236
of	O	237-239
chromosome	O	240-250
19	O	251-253
,	O	253-254
is	O	255-257
closely	O	258-265
linked	O	266-272
to	O	273-275
the	O	276-279
gene	O	280-284
for	O	285-288
the	O	289-292
most	O	293-297
common	O	298-304
form	O	305-309
of	O	310-312
adult	O	313-318
muscular	B	319-327
dystrophy	I	328-337
,	O	337-338
myotonic	B	339-347
dystrophy	I	348-357
(	O	358-359
DM	B	359-361
)	O	361-362
.	O	362-363

Six	O	364-367
APOC2	O	368-373
RFLPs	O	374-379
(	O	380-381
TaqI	O	381-385
,	O	385-386
BglI	O	387-391
,	O	391-392
BanI	O	393-397
,	O	397-398
BamHI	O	399-404
,	O	404-405
NcoI	O	406-410
,	O	410-411
and	O	412-415
AvaII	O	416-421
)	O	421-422
have	O	423-427
been	O	428-432
identified	O	433-443
to	O	444-446
date	O	447-451
.	O	451-452

We	O	453-455
have	O	456-460
conducted	O	461-470
a	O	471-472
comprehensive	O	473-486
DM	B	487-489
linkage	O	490-497
study	O	498-503
utilizing	O	504-513
all	O	514-517
six	O	518-521
RFLPs	O	522-527
and	O	528-531
involving	O	532-541
50	O	542-544
families	O	545-553
and	O	554-557
372	O	558-561
individuals	O	562-573
.	O	573-574

The	O	575-578
most	O	579-583
informative	O	584-595
RFLPs	O	596-601
are	O	602-605
,	O	605-606
in	O	607-609
descending	O	610-620
order	O	621-626
,	O	626-627
NcoI	O	628-632
(	O	633-634
lod	O	634-637
=	O	638-639
6	O	640-641
.	O	641-642

64	O	643-645
,	O	645-646
theta	O	647-652
=	O	653-654
0	O	655-656
.	O	656-657
05	O	658-660
)	O	660-661
,	O	661-662
BglI	O	663-667
(	O	668-669
lod	O	669-672
=	O	673-674
6	O	675-676
.	O	676-677

12	O	678-680
,	O	680-681
theta	O	682-687
=	O	688-689
0	O	690-691
.	O	691-692
05	O	693-695
)	O	695-696
,	O	696-697
AvaII	O	698-703
(	O	704-705
lod	O	705-708
=	O	709-710
6	O	711-712
.	O	712-713

02	O	714-716
,	O	716-717
theta	O	718-723
=	O	724-725
0	O	726-727
.	O	727-728
03	O	729-731
)	O	731-732
,	O	732-733
BanI	O	734-738
(	O	739-740
lod	O	740-743
=	O	744-745
5	O	746-747
.	O	747-748
76	O	749-751
,	O	751-752
theta	O	753-758
=	O	759-760
0	O	761-762
.	O	762-763
04	O	764-766
)	O	766-767
,	O	767-768
TaqI	O	769-773
(	O	774-775
lod	O	775-778
=	O	779-780
4	O	781-782
.	O	782-783
29	O	784-786
,	O	786-787
theta	O	788-793
=	O	794-795
0	O	796-797
.	O	797-798
06	O	799-801
)	O	801-802
,	O	802-803
and	O	804-807
BamHI	O	808-813
(	O	814-815
lod	O	815-818
=	O	819-820
1	O	821-822
.	O	822-823

75	O	824-826
,	O	826-827
theta	O	828-833
=	O	834-835
0	O	836-837
.	O	837-838
01	O	839-841
)	O	841-842
.	O	842-843

A	O	844-845
substantial	O	846-857
increase	O	858-866
in	O	867-869
the	O	870-873
lod	O	874-877
scores	O	878-884
over	O	885-889
those	O	890-895
seen	O	896-900
with	O	901-905
the	O	906-909
individual	O	910-920
RFLPs	O	921-926
was	O	927-930
obtained	O	931-939
when	O	940-944
the	O	945-948
linkage	O	949-956
of	O	957-959
the	O	960-963
entire	O	964-970
APOC2	O	971-976
haplotype	O	977-986
(	O	987-988
composed	O	988-996
of	O	997-999
the	O	1000-1003
six	O	1004-1007
RFLPs	O	1008-1013
)	O	1013-1014
was	O	1015-1018
studied	O	1019-1026
(	O	1027-1028
lod	O	1028-1031
=	O	1032-1033
17	O	1034-1036
.	O	1036-1037

87	O	1038-1040
,	O	1040-1041
theta	O	1042-1047
=	O	1048-1049
0	O	1050-1051
.	O	1051-1052
04	O	1053-1055
)	O	1055-1056
.	O	1056-1057

We	O	1058-1060
have	O	1061-1065
observed	O	1066-1074
significant	O	1075-1086
inter	O	1087-1092
-	O	1092-1093
APOC2	O	1093-1098
RFLP	O	1099-1103
linkage	O	1104-1111
disequilibrium	O	1112-1126
.	O	1126-1127

Consequently	O	1128-1140
,	O	1140-1141
the	O	1142-1145
three	O	1146-1151
most	O	1152-1156
informative	O	1157-1168
RFLPs	O	1169-1174
have	O	1175-1179
been	O	1180-1184
found	O	1185-1190
to	O	1191-1193
be	O	1194-1196
BanI	O	1197-1201
,	O	1201-1202
TaqI	O	1203-1207
,	O	1207-1208
and	O	1209-1212
either	O	1213-1219
BglI	O	1220-1224
,	O	1224-1225
AvaII	O	1226-1231
,	O	1231-1232
or	O	1233-1235
NcoI	O	1236-1240
polymorphisms	O	1241-1254
.	O	1254-1255

We	O	1256-1258
also	O	1259-1263
demonstrate	O	1264-1275
linkage	O	1276-1283
disequilibrium	O	1284-1298
between	O	1299-1306
DM	O	1307-1309
and	O	1310-1313
APOC2	O	1314-1319
in	O	1320-1322
our	O	1323-1326
French	O	1327-1333
-	O	1333-1334
Canadian	O	1334-1342
population	O	1343-1353
(	O	1354-1355
standardized	O	1355-1367
disequilibrium	O	1368-1382
constant	O	1383-1391
phi	O	1392-1395
=	O	1396-1397
.	O	1397-1398
22	O	1399-1401
,	O	1401-1402
chi	O	1403-1406
2	O	1407-1408
=	O	1409-1410
5	O	1411-1412
.	O	1412-1413
12	O	1414-1416
,	O	1416-1417
df	O	1418-1420
=	O	1421-1422
1	O	1423-1424
,	O	1424-1425
P	O	1426-1427
less	O	1428-1432
than	O	1433-1437
0	O	1438-1439
.	O	1439-1440
04	O	1441-1443
)	O	1443-1444
.	O	1444-1445

This	O	1446-1450
represents	O	1451-1461
the	O	1462-1465
first	O	1466-1471
evidence	O	1472-1480
of	O	1481-1483
linkage	O	1484-1491
disequilibrium	O	1492-1506
between	O	1507-1514
APOC2	O	1515-1520
and	O	1521-1524
the	O	1525-1528
DM	B	1529-1531
locus	O	1532-1537
.	O	1537-1538

A	O	0-1
retrospective	O	2-15
anonymous	O	16-25
pilot	O	26-31
study	O	32-37
in	O	38-40
screening	O	41-50
newborns	O	51-59
for	O	60-63
HFE	O	64-67
mutations	O	68-77
in	O	78-80
Scandinavian	O	81-93
populations	O	94-105
.	O	105-106

We	O	107-109
have	O	110-114
retrospectively	O	115-130
analyzed	O	131-139
837	O	140-143
random	O	144-150
anonymized	O	151-161
dried	O	162-167
blood	O	168-173
spot	O	174-178
(	O	179-180
DBS	O	180-183
)	O	183-184
samples	O	185-192
from	O	193-197
neonatal	O	198-206
screening	O	207-216
programs	O	217-225
in	O	226-228
Scandinavia	O	229-240
for	O	241-244
mutations	O	245-254
in	O	255-257
HFE	O	258-261
,	O	261-262
the	O	263-266
candidate	O	267-276
gene	O	277-281
for	O	282-285
hemochromatosis	B	286-301
.	O	301-302

We	O	303-305
have	O	306-310
found	O	311-316
C282Y	O	317-322
allele	O	323-329
frequencies	O	330-341
of	O	342-344
2	O	345-346
.	O	346-347
3	O	348-349
%	O	349-350
(	O	351-352
+	O	352-353
2	O	354-355
.	O	355-356
0	O	357-358
%	O	358-359
)	O	359-360
(	O	361-362
-	O	362-363
1	O	363-364
.	O	364-365

3	O	366-367
%	O	367-368
)	O	368-369
in	O	370-372
Greenland	O	373-382
,	O	382-383
4	O	384-385
.	O	385-386
5	O	387-388
%	O	388-389
+	O	390-391
/	O	391-392
-	O	392-393
1	O	393-394
.	O	394-395

9	O	396-397
%	O	397-398
in	O	399-401
Iceland	O	402-409
,	O	409-410
5	O	411-412
.	O	412-413
1	O	414-415
%	O	415-416
+	O	417-418
/	O	418-419
-	O	419-420
2	O	420-421
.	O	421-422

3	O	423-424
%	O	424-425
in	O	426-428
the	O	429-432
Faeroe	O	433-439
Islands	O	440-447
,	O	447-448
and	O	449-452
8	O	453-454
.	O	454-455
2	O	456-457
%	O	457-458
+	O	459-460
/	O	460-461
-	O	461-462
2	O	462-463
.	O	463-464

7	O	465-466
%	O	466-467
in	O	468-470
Denmark	O	471-478
.	O	478-479

The	O	480-483
high	O	484-488
prevalence	O	489-499
of	O	500-502
HFE	O	503-506
mutations	O	507-516
in	O	517-519
Denmark	O	520-527
suggests	O	528-536
that	O	537-541
population	O	542-552
screening	O	553-562
for	O	563-566
the	O	567-570
C282Y	O	571-576
mutation	O	577-585
could	O	586-591
be	O	592-594
highly	O	595-601
advantageous	O	602-614
in	O	615-617
terms	O	618-623
of	O	624-626
preventive	O	627-637
health	O	638-644
care	O	645-649
.	O	649-650

Long	O	651-655
-	O	655-656
term	O	656-660
follow	O	661-667
-	O	667-668
up	O	668-670
evaluation	O	671-681
of	O	682-684
C282Y	O	685-690
homozygotes	O	691-702
and	O	703-706
H63D	O	707-711
/	O	711-712
C282Y	O	712-717
compound	O	718-726
heterozygotes	O	727-740
will	O	741-745
give	O	746-750
an	O	751-753
indication	O	754-764
of	O	765-767
the	O	768-771
penetrance	O	772-782
of	O	783-785
the	O	786-789
mutations	O	790-799
.	O	799-800

Hereditary	O	0-10
TP53	O	11-15
codon	O	16-21
292	O	22-25
and	O	26-29
somatic	O	30-37
P16INK4A	O	38-46
codon	O	47-52
94	O	53-55
mutations	O	56-65
in	O	66-68
a	O	69-70
Li	B	71-73
-	I	73-74
Fraumeni	I	74-82
syndrome	I	83-91
family	O	92-98
.	O	98-99

Li	B	100-102
-	I	102-103
Fraumeni	I	103-111
syndrome	I	112-120
is	O	121-123
an	O	124-126
autosomal	B	127-136
dominant	I	137-145
disorder	I	146-154
that	O	155-159
is	O	160-162
characterized	O	163-176
by	O	177-179
various	O	180-187
types	O	188-193
of	O	194-196
cancer	B	197-203
in	O	204-206
childhood	O	207-216
and	O	217-220
adult	O	221-226
cases	O	227-232
.	O	232-233

Although	O	234-242
hereditary	O	243-253
TP53	O	254-258
mutation	O	259-267
is	O	268-270
very	O	271-275
rare	O	276-280
in	O	281-283
different	O	284-293
human	O	294-299
cancers	B	300-307
,	O	307-308
it	O	309-311
has	O	312-315
been	O	316-320
frequently	O	321-331
reported	O	332-340
in	O	341-343
Li	B	344-346
-	I	346-347
Fraumeni	I	347-355
syndrome	I	356-364
.	O	364-365

On	O	366-368
the	O	369-372
other	O	373-378
hand	O	379-383
,	O	383-384
hereditary	O	385-395
mutations	O	396-405
of	O	406-408
TP57KIP2	O	409-417
,	O	417-418
P15INK4B	O	419-427
,	O	427-428
and	O	429-432
P16INK4A	O	433-441
,	O	441-442
which	O	443-448
affect	O	449-455
the	O	456-459
cell	O	460-464
cycle	O	465-470
similar	O	471-478
to	O	479-481
TP53	O	482-486
,	O	486-487
were	O	488-492
observed	O	493-501
in	O	502-504
some	O	505-509
types	O	510-515
of	O	516-518
cancer	B	519-525
.	O	525-526

In	O	527-529
a	O	530-531
Turkish	O	532-539
family	O	540-546
with	O	547-551
the	O	552-555
diagnosis	O	556-565
of	O	566-568
Li	B	569-571
-	I	571-572
Fraumeni	I	572-580
syndrome	I	581-589
,	O	589-590
we	O	591-593
analyzed	O	594-602
the	O	603-606
mutation	O	607-615
pattern	O	616-623
of	O	624-626
TP53	O	627-631
,	O	631-632
P57KIP2	O	633-640
,	O	640-641
P15INK4B	O	642-650
,	O	650-651
and	O	652-655
P16INK4A	O	656-664
in	O	665-667
the	O	668-671
peripheral	O	672-682
blood	O	683-688
,	O	688-689
and	O	690-693
loss	O	694-698
of	O	699-701
heterozygosity	O	702-716
(	O	717-718
homo	O	718-722
/	O	722-723
hemizygous	O	723-733
deletion	O	734-742
)	O	742-743
pattern	O	744-751
of	O	752-754
TP53	O	755-759
and	O	760-763
P15INK4B	O	764-772
/	O	772-773
P16INK4A	O	773-781
in	O	782-784
two	O	785-788
tumor	B	789-794
tissues	O	795-802
.	O	802-803

The	O	804-807
propositus	O	808-818
had	O	819-822
a	O	823-824
seminoma	B	825-833
,	O	833-834
his	O	835-838
daughter	O	839-847
a	O	848-849
medulloblastoma	B	850-865
,	O	865-866
and	O	867-870
one	O	871-874
of	O	875-877
his	O	878-881
healthy	O	882-889
cousins	O	890-897
,	O	897-898
a	O	899-900
TP53	O	901-905
codon	O	906-911
292	O	912-915
missense	O	916-924
point	O	925-930
mutation	O	931-939
(	O	940-941
AAA	O	941-944
-	O	944-945
-	O	944-945
>	O	947-948
ATA	O	949-952
;	O	952-953
Lys	O	954-957
-	O	957-958
-	O	957-958
>	O	960-961
Ile	O	962-965
)	O	965-966
in	O	967-969
the	O	970-973
peripheral	O	974-984
blood	O	985-990
cells	O	991-996
.	O	996-997

Tumor	O	998-1003
tissue	O	1004-1010
obtained	O	1011-1019
from	O	1020-1024
the	O	1025-1028
propositus	O	1029-1039
with	O	1040-1044
the	O	1045-1048
seminoma	B	1049-1057
revealed	O	1058-1066
loss	O	1067-1071
of	O	1072-1074
heterozygosity	O	1075-1089
in	O	1090-1092
the	O	1093-1096
TP53	O	1097-1101
gene	O	1102-1106
.	O	1106-1107

In	O	1108-1110
the	O	1111-1114
analyses	O	1115-1123
of	O	1124-1126
tumor	B	1127-1132
tissues	O	1133-1140
from	O	1141-1145
the	O	1146-1149
propositus	O	1150-1160
and	O	1161-1164
his	O	1165-1168
daughter	O	1169-1177
,	O	1177-1178
a	O	1179-1180
P16INK4A	O	1181-1189
codon	O	1190-1195
94	O	1196-1198
missense	O	1199-1207
point	O	1208-1213
mutation	O	1214-1222
(	O	1223-1224
GCG	O	1224-1227
-	O	1227-1228
-	O	1227-1228
>	O	1230-1231
GAG	O	1232-1235
;	O	1235-1236
Ala	O	1237-1240
-	O	1240-1241
-	O	1240-1241
>	O	1243-1244
Glu	O	1245-1248
)	O	1248-1249
was	O	1250-1253
observed	O	1254-1262
with	O	1263-1267
the	O	1268-1271
hereditary	O	1272-1282
TP53	O	1283-1287
mutation	O	1288-1296
.	O	1296-1297

P16INK4A	O	1298-1306
codon	O	1307-1312
94	O	1313-1315
mutation	O	1316-1324
observed	O	1325-1333
in	O	1334-1336
our	O	1337-1340
family	O	1341-1347
is	O	1348-1350
a	O	1351-1352
novel	O	1353-1358
mutation	O	1359-1367
in	O	1368-1370
Li	B	1371-1373
-	I	1373-1374
Fraumeni	I	1374-1382
syndrome	I	1383-1391
.	O	1391-1392

No	O	1393-1395
other	O	1396-1401
gene	O	1402-1406
alteration	O	1407-1417
in	O	1418-1420
TP53	O	1421-1425
,	O	1425-1426
P57KIP2	O	1427-1434
,	O	1434-1435
P15INK4B	O	1436-1444
,	O	1444-1445
and	O	1446-1449
P16INK4A	O	1450-1458
was	O	1459-1462
observed	O	1463-1471
.	O	1471-1472

Existence	O	1473-1482
of	O	1483-1485
the	O	1486-1489
P16INK4A	O	1490-1498
mutation	O	1499-1507
and	O	1508-1511
the	O	1512-1515
hereditary	O	1516-1526
TP53	O	1527-1531
mutation	O	1532-1540
with	O	1541-1545
or	O	1546-1548
without	O	1549-1556
loss	O	1557-1561
of	O	1562-1564
heterozygosity	O	1565-1579
in	O	1580-1582
the	O	1583-1586
TP53	O	1587-1591
gene	O	1592-1596
(	O	1597-1598
seminoma	B	1598-1606
/	O	1606-1607
medulloblastoma	B	1607-1622
)	O	1622-1623
may	O	1624-1627
be	O	1628-1630
evidence	O	1631-1639
for	O	1640-1643
a	O	1644-1645
common	O	1646-1652
mechanism	O	1653-1662
involved	O	1663-1671
in	O	1672-1674
tumorogenesis	B	1675-1688
.	O	1688-1689

The	O	1690-1693
gene	O	1694-1698
alterations	O	1699-1710
in	O	1711-1713
TP53	O	1714-1718
and	O	1719-1722
P16INK4A	O	1723-1731
genes	O	1732-1737
may	O	1738-1741
be	O	1742-1744
used	O	1745-1749
as	O	1750-1752
tumor	B	1753-1758
markers	O	1759-1766
in	O	1767-1769
our	O	1770-1773
family	O	1774-1780
.	O	1780-1781
.	O	1780-1781

An	O	0-2
amino	O	3-8
-	O	8-9
acid	O	9-13
substitution	O	14-26
involved	O	27-35
in	O	36-38
phenylketonuria	B	39-54
is	O	55-57
in	O	58-60
linkage	O	61-68
disequilibrium	O	69-83
with	O	84-88
DNA	O	89-92
haplotype	O	93-102
2	O	103-104
.	O	104-105
Phenylketonuria	B	106-121
(	O	122-123
PKU	B	123-126
)	O	126-127
is	O	128-130
an	O	131-133
autosomal	B	134-143
recessive	I	144-153
human	I	154-159
genetic	I	160-167
disorder	I	168-176
caused	O	177-183
by	O	184-186
a	O	187-188
deficiency	B	189-199
of	I	200-202
hepatic	I	203-210
phenylalanine	I	211-224
hydroxylase	I	225-236
(	O	237-238
PAH	O	238-241
,	O	241-242
phenylalanine	O	243-256
4	O	257-258
-	O	258-259
monooxygenase	O	259-272
,	O	272-273
EC	O	274-276
1	O	277-278
.	O	278-279
14	O	280-282
.	O	282-283
16	O	284-286
.	O	286-287
1	O	288-289
)	O	289-290
.	O	290-291

PKU	B	292-295
is	O	296-298
a	O	299-300
common	O	301-307
inborn	B	308-314
error	I	315-320
of	I	321-323
amino	I	324-329
-	I	329-330
acid	I	330-334
metabolism	I	335-345
in	O	346-348
caucasian	O	349-358
populations	O	359-370
and	O	371-374
approximately	O	375-388
1	O	389-390
in	O	391-393
50	O	394-396
individuals	O	397-408
are	O	409-412
carriers	O	413-421
of	O	422-424
a	O	425-426
PKU	B	427-430
allele	O	431-437
.	O	437-438

To	O	439-441
define	O	442-448
the	O	449-452
molecular	O	453-462
basis	O	463-468
of	O	469-471
PKU	B	472-475
,	O	475-476
we	O	477-479
characterized	O	480-493
twelve	O	494-500
restriction	O	501-512
fragment	O	513-521
-	O	521-522
length	O	522-528
polymorphism	O	529-541
(	O	542-543
RFLP	O	543-547
)	O	547-548
haplotypes	O	549-559
of	O	560-562
the	O	563-566
PAH	O	567-570
locus	O	571-576
in	O	577-579
the	O	580-583
northern	O	584-592
European	O	593-601
population	O	602-612
and	O	613-616
observed	O	617-625
that	O	626-630
90	O	631-633
%	O	633-634
of	O	635-637
the	O	638-641
PKU	B	642-645
alleles	O	646-653
in	O	654-656
this	O	657-661
population	O	662-672
are	O	673-676
confined	O	677-685
to	O	686-688
four	O	689-693
common	O	694-700
RFLP	O	701-705
haplotypes	O	706-716
.	O	716-717

We	O	718-720
have	O	721-725
recently	O	726-734
reported	O	735-743
a	O	744-745
splicing	O	746-754
mutation	O	755-763
in	O	764-766
the	O	767-770
PAH	O	771-774
gene	O	775-779
that	O	780-784
is	O	785-787
associated	O	788-798
with	O	799-803
RFLP	O	804-808
haplotype	O	809-818
3	O	819-820
which	O	821-826
is	O	827-829
present	O	830-837
at	O	838-840
about	O	841-846
40	O	847-849
%	O	849-850
of	O	851-853
mutant	O	854-860
alleles	O	861-868
.	O	868-869

We	O	870-872
now	O	873-876
report	O	877-883
the	O	884-887
molecular	B	888-897
lesion	I	898-904
associated	O	905-915
with	O	916-920
the	O	921-924
RFLP	O	925-929
haplotype	O	930-939
2	O	940-941
mutant	O	942-948
allele	O	949-955
.	O	955-956

This	O	957-961
defect	O	962-968
is	O	969-971
caused	O	972-978
by	O	979-981
a	O	982-983
C	O	984-985
-	O	985-986
to	O	986-988
-	O	985-986
T	O	989-990
transition	O	991-1001
in	O	1002-1004
exon	O	1005-1009
12	O	1010-1012
resulting	O	1013-1022
in	O	1023-1025
an	O	1026-1028
amino	O	1029-1034
-	O	1034-1035
acid	O	1035-1039
substitution	O	1040-1052
(	O	1053-1054
Arg	O	1054-1057
to	O	1058-1060
Trp	O	1061-1064
)	O	1064-1065
at	O	1066-1068
residue	O	1069-1076
408	O	1077-1080
of	O	1081-1083
PAH	O	1084-1087
.	O	1087-1088

Direct	O	1089-1095
hybridization	O	1096-1109
analysis	O	1110-1118
of	O	1119-1121
the	O	1122-1125
point	O	1126-1131
mutation	O	1132-1140
using	O	1141-1146
a	O	1147-1148
specific	O	1149-1157
oligonucleotide	O	1158-1173
probe	O	1174-1179
demonstrated	O	1180-1192
that	O	1193-1197
this	O	1198-1202
mutation	O	1203-1211
is	O	1212-1214
also	O	1215-1219
in	O	1220-1222
linkage	O	1223-1230
disequilibrium	O	1231-1245
with	O	1246-1250
RFLP	O	1251-1255
haplotype	O	1256-1265
2	O	1266-1267
alleles	O	1268-1275
that	O	1276-1280
make	O	1281-1285
up	O	1286-1288
about	O	1289-1294
20	O	1295-1297
%	O	1297-1298
of	O	1299-1301
mutant	O	1302-1308
PAH	O	1309-1312
genes	O	1313-1318

The	O	0-3
effects	O	4-11
of	O	12-14
dystrophin	O	15-25
gene	O	26-30
mutations	O	31-40
on	O	41-43
the	O	44-47
ERG	O	48-51
in	O	52-54
mice	O	55-59
and	O	60-63
humans	O	64-70
.	O	70-71

PURPOSE	O	72-79
.	O	79-80

The	O	81-84
authors	O	85-92
earlier	O	93-100
findings	O	101-109
of	O	110-112
a	O	113-114
negative	O	115-123
electroretinogram	O	124-141
(	O	142-143
ERG	O	143-146
)	O	146-147
in	O	148-150
a	O	151-152
boy	O	153-156
with	O	157-161
Duchenne	B	162-170
muscular	I	171-179
dystrophy	I	180-189
(	O	190-191
DMD	B	191-194
)	O	194-195
led	O	196-199
them	O	200-204
to	O	205-207
investigate	O	208-219
dystrophin	O	220-230
gene	O	231-235
deletions	O	236-245
and	O	246-249
ERGs	O	250-254
in	O	255-257
five	O	258-262
boys	O	263-267
with	O	268-272
DMD	B	273-276
.	O	276-277

The	O	278-281
authors	O	282-289
wanted	O	290-296
to	O	297-299
determined	O	300-310
whether	O	311-318
there	O	319-324
were	O	325-329
similar	O	330-337
ERG	O	338-341
findings	O	342-350
in	O	351-353
an	O	354-356
animal	O	357-363
model	O	364-369
for	O	370-373
DMD	B	374-377
,	O	377-378
the	O	379-382
mdx	O	383-386
mouse	O	387-392
.	O	392-393

METHODS	O	394-401
.	O	401-402

Ganzfeld	O	403-411
ERGs	O	412-416
were	O	417-421
recorded	O	422-430
in	O	431-433
five	O	434-438
boys	O	439-443
with	O	444-448
DMD	B	449-452
after	O	453-458
a	O	459-460
complete	O	461-469
ophthalmic	O	470-480
examination	O	481-492
.	O	492-493

The	O	494-497
dystrophin	O	498-508
gene	O	509-513
was	O	514-517
analyzed	O	518-526
by	O	527-529
Southern	O	530-538
blot	O	539-543
hybridization	O	544-557
.	O	557-558

ERGs	O	559-563
were	O	564-568
recorded	O	569-577
in	O	578-580
anesthetized	O	581-593
mdx	O	594-597
and	O	598-601
control	O	602-609
mice	O	610-614
with	O	615-619
a	O	620-621
modified	O	622-630
Grass	O	631-636
photostimulator	O	637-652
(	O	653-654
Grass	O	654-659
Instrument	O	660-670
Company	O	671-678
,	O	678-679
Quincy	O	680-686
,	O	686-687
MA	O	688-690
)	O	690-691
.	O	691-692

RESULTS	O	693-700
.	O	700-701

Ophthalmic	O	702-712
examinations	O	713-725
in	O	726-728
all	O	729-732
five	O	733-737
boys	O	738-742
had	O	743-746
normal	O	747-753
findings	O	754-762
,	O	762-763
yet	O	764-767
an	O	768-770
abnormal	O	771-779
negative	O	780-788
ERG	O	789-792
was	O	793-796
recorded	O	797-805
for	O	806-809
each	O	810-814
subject	O	815-822
.	O	822-823

The	O	824-827
subjects	O	828-836
gene	O	837-841
deletions	O	842-851
were	O	852-856
variable	O	857-865
,	O	865-866
ranging	O	867-874
from	O	875-879
large	O	880-885
deletions	O	886-895
to	O	896-898
no	O	899-901
detectable	O	902-912
deletions	O	913-922
.	O	922-923

The	O	924-927
ERGs	O	928-932
of	O	933-935
the	O	936-939
mdx	O	940-943
mice	O	944-948
were	O	949-953
normal	O	954-960
and	O	961-964
did	O	965-968
not	O	969-972
differ	O	973-979
significantly	O	980-993
from	O	994-998
those	O	999-1004
of	O	1005-1007
the	O	1008-1011
control	O	1012-1019
mice	O	1020-1024
.	O	1024-1025

CONCLUSIONS	O	1026-1037
.	O	1037-1038

The	O	1039-1042
authors	O	1043-1050
believe	O	1051-1058
the	O	1059-1062
unique	O	1063-1069
ERG	O	1070-1073
recorded	O	1074-1082
for	O	1083-1086
the	O	1087-1090
human	O	1091-1096
subjects	O	1097-1105
is	O	1106-1108
a	O	1109-1110
manifestation	O	1111-1124
of	O	1125-1127
DMD	B	1128-1131
associated	O	1132-1142
with	O	1143-1147
defects	O	1148-1155
at	O	1156-1158
the	O	1159-1162
dystrophin	O	1163-1173
gene	O	1174-1178
locus	O	1179-1184
and	O	1185-1188
represents	O	1189-1199
a	O	1200-1201
new	O	1202-1205
clinical	O	1206-1214
entity	O	1215-1221
.	O	1221-1222

The	O	1223-1226
ERG	O	1227-1230
of	O	1231-1233
the	O	1234-1237
mdx	O	1238-1241
mouse	O	1242-1247
may	O	1248-1251
be	O	1252-1254
spared	O	1255-1261
for	O	1262-1265
several	O	1266-1273
reasons	O	1274-1281
,	O	1281-1282
including	O	1283-1292
milder	O	1293-1299
effects	O	1300-1307
of	O	1308-1310
the	O	1311-1314
mouse	O	1315-1320
gene	O	1321-1325
defect	O	1326-1332
,	O	1332-1333
differences	O	1334-1345
in	O	1346-1348
muscle	O	1349-1355
and	O	1356-1359
retinal	O	1360-1367
gene	O	1368-1372
product	O	1373-1380
,	O	1380-1381
or	O	1382-1384
species	O	1385-1392
differences	O	1393-1404
in	O	1405-1407
the	O	1408-1411
biochemical	O	1412-1423
role	O	1424-1428
of	O	1429-1431
dystrophin	O	1432-1442
.	O	1442-1443

The	O	1444-1447
ERG	O	1448-1451
shows	O	1452-1457
promise	O	1458-1465
of	O	1466-1468
becoming	O	1469-1477
a	O	1478-1479
noninvasive	O	1480-1491
diagnostic	O	1492-1502
tool	O	1503-1507
for	O	1508-1511
DMD	B	1512-1515
and	O	1516-1519
its	O	1520-1523
milder	O	1524-1530
allelic	O	1531-1538
forms	O	1539-1544
.	O	1544-1545
.	O	1544-1545

Eight	O	0-5
novel	O	6-11
inactivating	O	12-24
germ	O	25-29
line	O	30-34
mutations	O	35-44
at	O	45-47
the	O	48-51
APC	B	52-55
gene	O	56-60
identified	O	61-71
by	O	72-74
denaturing	O	75-85
gradient	O	86-94
gel	O	95-98
electrophoresis	O	99-114
.	O	114-115

Familial	B	116-124
adenomatous	I	125-136
polyposis	I	137-146
(	O	147-148
FAP	B	148-151
)	O	151-152
is	O	153-155
a	O	156-157
dominantly	O	158-168
inherited	O	169-178
condition	O	179-188
predisposing	O	189-201
to	O	202-204
colorectal	B	205-215
cancer	I	216-222
.	O	222-223

The	O	224-227
recent	O	228-234
isolation	O	235-244
of	O	245-247
the	O	248-251
responsible	O	252-263
gene	O	264-268
(	O	269-270
adenomatous	B	270-281
polyposis	I	282-291
coli	I	292-296
or	O	297-299
APC	B	300-303
)	O	303-304
has	O	305-308
facilitated	O	309-320
the	O	321-324
search	O	325-331
for	O	332-335
germ	O	336-340
line	O	341-345
mutations	O	346-355
in	O	356-358
affected	O	359-367
individuals	O	368-379
.	O	379-380

Previous	O	381-389
authors	O	390-397
have	O	398-402
used	O	403-407
the	O	408-411
RNase	O	412-417
protection	O	418-428
assay	O	429-434
and	O	435-438
the	O	439-442
single	O	443-449
-	O	449-450
strand	O	450-456
conformation	O	457-469
polymorphisms	O	470-483
procedure	O	484-493
to	O	494-496
screen	O	497-503
for	O	504-507
mutations	O	508-517
.	O	517-518

In	O	519-521
this	O	522-526
study	O	527-532
we	O	533-535
used	O	536-540
denaturing	O	541-551
gradient	O	552-560
gel	O	561-564
electrophoresis	O	565-580
(	O	581-582
DGGE	O	582-586
)	O	586-587
.	O	587-588

DGGE	O	589-593
analysis	O	594-602
of	O	603-605
10	O	606-608
APC	B	609-612
exons	O	613-618
(	O	619-620
4	O	620-621
,	O	621-622
5	O	623-624
,	O	624-625
7	O	626-627
,	O	627-628
8	O	629-630
,	O	630-631
9	O	632-633
,	O	633-634
10	O	635-637
,	O	637-638
12	O	639-641
,	O	641-642
13	O	643-645
,	O	645-646
14	O	647-649
,	O	649-650
and	O	651-654
part	O	655-659
of	O	660-662
15	O	663-665
)	O	665-666
in	O	667-669
33	O	670-672
unrelated	O	673-682
Dutch	O	683-688
FAP	B	689-692
patients	O	693-701
has	O	702-705
led	O	706-709
to	O	710-712
the	O	713-716
identification	O	717-731
of	O	732-734
eight	O	735-740
novel	O	741-746
germ	O	747-751
line	O	752-756
mutations	O	757-766
resulting	O	767-776
in	O	777-779
stop	O	780-784
codons	O	785-791
or	O	792-794
frameshifts	O	795-806
.	O	806-807

The	O	808-811
results	O	812-819
reported	O	820-828
here	O	829-833
indicate	O	834-842
that	O	843-847
(	O	848-849
1	O	849-850
)	O	850-851
familial	B	852-860
adenomatous	I	861-872
polyposis	I	873-882
is	O	883-885
caused	O	886-892
by	O	893-895
an	O	896-898
extremely	O	899-908
heterogeneous	O	909-922
spectrum	O	923-931
of	O	932-934
point	O	935-940
mutations	O	941-950
;	O	950-951
(	O	952-953
2	O	953-954
)	O	954-955
all	O	956-959
the	O	960-963
mutations	O	964-973
found	O	974-979
in	O	980-982
this	O	983-987
study	O	988-993
are	O	994-997
chain	O	998-1003
terminating	O	1004-1015
;	O	1015-1016
and	O	1017-1020
(	O	1021-1022
3	O	1022-1023
)	O	1023-1024
DGGE	O	1025-1029
represents	O	1030-1040
a	O	1041-1042
rapid	O	1043-1048
and	O	1049-1052
sensitive	O	1053-1062
technique	O	1063-1072
for	O	1073-1076
the	O	1077-1080
detection	O	1081-1090
of	O	1091-1093
mutations	O	1094-1103
in	O	1104-1106
the	O	1107-1110
unusually	O	1111-1120
large	O	1121-1126
APC	B	1127-1130
gene	O	1131-1135
.	O	1135-1136

An	O	1137-1139
extension	O	1140-1149
of	O	1150-1152
the	O	1153-1156
DGGE	O	1157-1161
analysis	O	1162-1170
to	O	1171-1173
the	O	1174-1177
entire	O	1178-1184
coding	O	1185-1191
region	O	1192-1198
in	O	1199-1201
a	O	1202-1203
sufficient	O	1204-1214
number	O	1215-1221
of	O	1222-1224
clinically	O	1225-1235
well	O	1236-1240
-	O	1240-1241
characterized	O	1241-1254
,	O	1254-1255
unrelated	O	1256-1265
patients	O	1266-1274
will	O	1275-1279
facilitate	O	1280-1290
the	O	1291-1294
establishment	O	1295-1308
of	O	1309-1311
genotype	O	1312-1320
-	O	1320-1321
phenotype	O	1321-1330
correlations	O	1331-1343
.	O	1343-1344

On	O	1345-1347
the	O	1348-1351
other	O	1352-1357
hand	O	1358-1362
,	O	1362-1363
the	O	1364-1367
occurrence	O	1368-1378
of	O	1379-1381
an	O	1382-1384
extremely	O	1385-1394
heterogeneous	O	1395-1408
spectrum	O	1409-1417
of	O	1418-1420
mutations	O	1421-1430
spread	O	1431-1437
throughout	O	1438-1448
the	O	1449-1452
entire	O	1453-1459
length	O	1460-1466
of	O	1467-1469
the	O	1470-1473
large	O	1474-1479
APC	B	1480-1483
gene	O	1484-1488
among	O	1489-1494
the	O	1495-1498
FAP	B	1499-1502
patients	O	1503-1511
indicates	O	1512-1521
that	O	1522-1526
this	O	1527-1531
approach	O	1532-1540
may	O	1541-1544
not	O	1545-1548
be	O	1549-1551
useful	O	1552-1558
as	O	1559-1561
a	O	1562-1563
rapid	O	1564-1569
presymptomatic	O	1570-1584
diagnostic	O	1585-1595
procedure	O	1596-1605
in	O	1606-1608
a	O	1609-1610
routine	O	1611-1618
laboratory	O	1619-1629
.	O	1629-1630

Nevertheless	O	1631-1643
,	O	1643-1644
the	O	1645-1648
above	O	1649-1654
DGGE	O	1655-1659
approach	O	1660-1668
has	O	1669-1672
incidentally	O	1673-1685
led	O	1686-1689
to	O	1690-1692
the	O	1693-1696
identification	O	1697-1711
of	O	1712-1714
a	O	1715-1716
common	O	1717-1723
polymorphism	O	1724-1736
in	O	1737-1739
exon	O	1740-1744
13	O	1745-1747
.	O	1747-1748

Such	O	1749-1753
intragenic	O	1754-1764
polymorphisms	O	1765-1778
offer	O	1779-1784
a	O	1785-1786
practical	O	1787-1796
approach	O	1797-1805
to	O	1806-1808
a	O	1809-1810
more	O	1811-1815
rapid	O	1816-1821
procedure	O	1822-1831
for	O	1832-1835
presymptomatic	O	1836-1850
diagnosis	O	1851-1860
of	O	1861-1863
FAP	B	1864-1867
by	O	1868-1870
linkage	O	1871-1878
analysis	O	1879-1887
in	O	1888-1890
informative	O	1891-1902
families	O	1903-1911
.	O	1911-1912
.	O	1911-1912

Novel	O	0-5
mutations	O	6-15
in	O	16-18
XLRS1	O	19-24
causing	O	25-32
retinoschisis	B	33-46
,	O	46-47
including	O	48-57
first	O	58-63
evidence	O	64-72
of	O	73-75
putative	O	76-84
leader	O	85-91
sequence	O	92-100
change	O	101-107
.	O	107-108

Juvenile	B	109-117
retinoschisis	I	118-131
is	O	132-134
an	O	135-137
X	B	138-139
-	I	139-140
linked	I	140-146
recessive	I	147-156
disease	I	157-164
caused	O	165-171
by	O	172-174
mutations	O	175-184
in	O	185-187
the	O	188-191
XLRS1	O	192-197
gene	O	198-202
.	O	202-203

We	O	204-206
screened	O	207-215
31	O	216-218
new	O	219-222
unrelated	O	223-232
patients	O	233-241
and	O	242-245
families	O	246-254
for	O	255-258
XLRS1	O	259-264
mutations	O	265-274
in	O	275-277
addition	O	278-286
to	O	287-289
previously	O	290-300
reported	O	301-309
mutations	O	310-319
for	O	320-323
60	O	324-326
of	O	327-329
our	O	330-333
families	O	334-342
(	O	343-344
Retinoschisis	B	344-357
Consortium	O	358-368
,	O	368-369
Hum	O	370-373
Mol	O	374-377
Genet	O	378-383
1998	O	384-388
;	O	388-389
7	O	390-391
1185	O	393-397
-	O	397-398
1192	O	398-402
)	O	402-403
.	O	403-404

Twenty	O	405-411
-	O	411-412
three	O	412-417
different	O	418-427
mutations	O	428-437
including	O	438-447
12	O	448-450
novel	O	451-456
ones	O	457-461
were	O	462-466
identified	O	467-477
in	O	478-480
28	O	481-483
patients	O	484-492
.	O	492-493

Mutations	O	494-503
identified	O	504-514
in	O	515-517
this	O	518-522
study	O	523-528
include	O	529-536
19	O	537-539
missense	O	540-548
mutations	O	549-558
,	O	558-559
two	O	560-563
nonsense	O	564-572
mutations	O	573-582
,	O	582-583
one	O	584-587
intragenic	O	588-598
deletion	O	599-607
,	O	607-608
four	O	609-613
microdeletions	O	614-628
,	O	628-629
one	O	630-633
insertion	O	634-643
,	O	643-644
and	O	645-648
one	O	649-652
intronic	O	653-661
sequence	O	662-670
substitution	O	671-683
that	O	684-688
is	O	689-691
likely	O	692-698
to	O	699-701
result	O	702-708
in	O	709-711
a	O	712-713
splice	O	714-720
site	O	721-725
defect	O	726-732
.	O	732-733

Two	O	734-737
novel	O	738-743
mutations	O	744-753
,	O	753-754
c	O	755-756
.	O	756-757
38T	O	758-761
-	O	761-762
-	O	761-762
>	O	764-765
C	O	766-767
(	O	768-769
L13P	O	769-773
)	O	773-774
and	O	775-778
c	O	779-780
.	O	780-781
667T	O	782-786
-	O	786-787
-	O	786-787
>	O	789-790
C	O	791-792
(	O	793-794
C223R	O	794-799
)	O	799-800
,	O	800-801
respectively	O	802-814
,	O	814-815
present	O	816-823
the	O	824-827
first	O	828-833
genetic	O	834-841
evidence	O	842-850
for	O	851-854
the	O	855-858
functional	O	859-869
significance	O	870-882
of	O	883-885
the	O	886-889
putative	O	890-898
leader	O	899-905
peptide	O	906-913
sequence	O	914-922
and	O	923-926
for	O	927-930
the	O	931-934
functional	O	935-945
significance	O	946-958
at	O	959-961
the	O	962-965
carboxyl	O	966-974
terminal	O	975-983
of	O	984-986
the	O	987-990
XLRS1	O	991-996
protein	O	997-1004
beyond	O	1005-1011
the	O	1012-1015
discoidin	O	1016-1025
domain	O	1026-1032
.	O	1032-1033

Mutations	O	1034-1043
in	O	1044-1046
25	O	1047-1049
of	O	1050-1052
the	O	1053-1056
families	O	1057-1065
were	O	1066-1070
localized	O	1071-1080
to	O	1081-1083
exons	O	1084-1089
4	O	1090-1091
-	O	1091-1092
6	O	1092-1093
,	O	1093-1094
emphasizing	O	1095-1106
the	O	1107-1110
critical	O	1111-1119
functional	O	1120-1130
significance	O	1131-1143
of	O	1144-1146
the	O	1147-1150
discoidin	O	1151-1160
domain	O	1161-1167
of	O	1168-1170
the	O	1171-1174
XLRS1	O	1175-1180
protein	O	1181-1188

Clinical	O	0-8
use	O	9-12
of	O	13-15
DNA	O	16-19
markers	O	20-27
linked	O	28-34
to	O	35-37
the	O	38-41
gene	O	42-46
for	O	47-50
Duchenne	B	51-59
muscular	I	60-68
dystrophy	I	69-78
.	O	78-79

Seventy	O	80-87
families	O	88-96
with	O	97-101
Duchenne	B	102-110
muscular	I	111-119
dystrophy	I	120-129
(	O	130-131
DMD	B	131-134
)	O	134-135
known	O	136-141
to	O	142-144
the	O	145-148
Institute	O	149-158
of	O	159-161
Child	O	162-167
Health	O	168-174
fall	O	175-179
into	O	180-184
three	O	185-190
categories	O	191-201
with	O	202-206
respect	O	207-214
to	O	215-217
potential	O	218-227
linkage	O	228-235
analysis	O	236-244
with	O	245-249
the	O	250-253
X	O	254-255
chromosome	O	256-266
DNA	O	267-270
markers	O	271-278
RC8	O	279-282
and	O	283-286
L1	O	287-289
.	O	289-290

28	O	291-293
that	O	294-298
bridge	O	299-305
the	O	306-309
DMD	B	310-313
gene	O	314-318
.	O	318-319

Families	O	320-328
in	O	329-331
which	O	332-337
there	O	338-343
is	O	344-346
at	O	347-349
least	O	350-355
one	O	356-359
obligatory	O	360-370
female	O	371-377
heterozygote	O	378-390
(	O	391-392
n	O	392-393
=	O	394-395
13	O	396-398
)	O	398-399
.	O	399-400

Here	O	401-405
prediction	O	406-416
and	O	417-420
exclusion	O	421-430
of	O	431-433
DMD	B	434-437
gene	O	438-442
transmission	O	443-455
may	O	456-459
be	O	460-462
possible	O	463-471
,	O	471-472
the	O	473-476
accuracy	O	477-485
being	O	486-491
dependent	O	492-501
on	O	502-504
the	O	505-508
closeness	O	509-518
of	O	519-521
the	O	522-525
linkage	O	526-533
of	O	534-536
the	O	537-540
DNA	O	541-544
marker	O	545-551
(	O	552-553
s	O	553-554
)	O	554-555
to	O	556-558
the	O	559-562
DMD	B	563-566
gene	O	567-571
;	O	571-572
an	O	573-575
illustrative	O	576-588
case	O	589-593
is	O	594-596
reported	O	597-605
.	O	605-606

Families	O	607-615
in	O	616-618
which	O	619-624
there	O	625-630
is	O	631-633
a	O	634-635
single	O	636-642
affected	O	643-651
boy	O	652-655
,	O	655-656
who	O	657-660
also	O	661-665
has	O	666-669
one	O	670-673
or	O	674-676
more	O	677-681
healthy	O	682-689
brothers	O	690-698
(	O	699-700
n	O	700-701
=	O	702-703
26	O	704-706
)	O	706-707
.	O	707-708

Given	O	709-714
an	O	715-717
informative	O	718-729
restriction	O	730-741
fragment	O	742-750
length	O	751-757
polymorphism	O	758-770
(	O	771-772
RFLP	O	772-776
)	O	776-777
,	O	777-778
the	O	779-782
probability	O	783-794
that	O	795-799
the	O	800-803
boy	O	804-807
represents	O	808-818
a	O	819-820
new	O	821-824
mutation	O	825-833
can	O	834-837
be	O	838-840
reassessed	O	841-851
;	O	851-852
it	O	853-855
is	O	856-858
also	O	859-863
possible	O	864-872
to	O	873-875
exclude	O	876-883
the	O	884-887
DMD	B	888-891
gene	O	892-896
in	O	897-899
a	O	900-901
sister	O	902-908
.	O	908-909

Families	O	910-918
with	O	919-923
a	O	924-925
single	O	926-932
affected	O	933-941
boy	O	942-945
with	O	946-950
no	O	951-953
brother	O	954-961
(	O	962-963
n	O	963-964
=	O	965-966
30	O	967-969
)	O	969-970
.	O	970-971

Here	O	972-976
exclusion	O	977-986
of	O	987-989
the	O	990-993
DMD	B	994-997
gene	O	998-1002
in	O	1003-1005
a	O	1006-1007
sister	O	1008-1014
may	O	1015-1018
be	O	1019-1021
possible	O	1022-1030
.	O	1030-1031

Only	O	1032-1036
in	O	1037-1039
one	O	1040-1043
family	O	1044-1050
was	O	1051-1054
there	O	1055-1060
no	O	1061-1063
possibility	O	1064-1075
of	O	1076-1078
useful	O	1079-1085
linkage	O	1086-1093
analysis	O	1094-1102
.	O	1102-1103

The	O	1104-1107
linkage	O	1108-1115
analysis	O	1116-1124
required	O	1125-1133
is	O	1134-1136
described	O	1137-1146
,	O	1146-1147
and	O	1148-1151
the	O	1152-1155
need	O	1156-1160
to	O	1161-1163
check	O	1164-1169
DMD	B	1170-1173
families	O	1174-1182
for	O	1183-1186
informative	O	1187-1198
RFLPs	O	1199-1204
is	O	1205-1207
stressed	O	1208-1216
.	O	1216-1217

Molecular	O	0-9
characterization	O	10-26
of	O	27-29
glucose	B	30-37
-	I	37-38
6	I	38-39
-	I	37-38
phosphate	I	40-49
dehydrogenase	I	50-63
(	I	64-65
G6PD	I	65-69
)	I	69-70
deficiency	I	71-81
in	O	82-84
patients	O	85-93
of	O	94-96
Chinese	O	97-104
descent	O	105-112
and	O	113-116
identification	O	117-131
of	O	132-134
new	O	135-138
base	O	139-143
substitutions	O	144-157
in	O	158-160
the	O	161-164
human	O	165-170
G6PD	O	171-175
gene	O	176-180
.	O	180-181

The	O	182-185
underlying	O	186-196
DNA	O	197-200
changes	O	201-208
associated	O	209-219
with	O	220-224
glucose	B	225-232
-	I	232-233
6	I	233-234
-	I	232-233
phosphate	I	235-244
dehydrogenase	I	245-258
(	I	259-260
G6PD	I	260-264
)	I	264-265
-	I	266-267
deficient	I	267-276
Asians	O	277-283
have	O	284-288
not	O	289-292
been	O	293-297
extensively	O	298-309
investigated	O	310-322
.	O	322-323

To	O	324-326
fill	O	327-331
this	O	332-336
gap	O	337-340
,	O	340-341
we	O	342-344
sequenced	O	345-354
the	O	355-358
G6PD	O	359-363
gene	O	364-368
of	O	369-371
43	O	372-374
G6PD	B	375-379
-	I	379-380
deficient	I	380-389
Chinese	O	390-397
whose	O	398-403
G6PD	O	404-408
was	O	409-412
well	O	413-417
characterized	O	418-431
biochemically	O	432-445
.	O	445-446

DNA	O	447-450
samples	O	451-458
were	O	459-463
obtained	O	464-472
from	O	473-477
peripheral	O	478-488
blood	O	489-494
of	O	495-497
these	O	498-503
individuals	O	504-515
for	O	516-519
sequencing	O	520-530
using	O	531-536
a	O	537-538
direct	O	539-545
polymerase	O	546-556
chain	O	557-562
reaction	O	563-571
(	O	572-573
PCR	O	573-576
)	O	576-577
sequencing	O	578-588
procedure	O	589-598
.	O	598-599

From	O	600-604
these	O	605-610
43	O	611-613
samples	O	614-621
,	O	621-622
we	O	623-625
have	O	626-630
identified	O	631-641
five	O	642-646
different	O	647-656
types	O	657-662
of	O	663-665
nucleotide	O	666-676
substitutions	O	677-690
in	O	691-693
the	O	694-697
G6PD	O	698-702
gene	O	703-707
at	O	709-711
cDNA	O	712-716
1388	O	717-721
from	O	722-726
G	O	727-728
to	O	729-731
A	O	732-733
(	O	734-735
Arg	O	735-738
to	O	739-741
His	O	742-745
)	O	745-746
;	O	746-747
at	O	748-750
cDNA	O	751-755
1376	O	756-760
from	O	761-765
G	O	766-767
to	O	768-770
T	O	771-772
(	O	773-774
Arg	O	774-777
to	O	778-780
Leu	O	781-784
)	O	784-785
;	O	785-786
at	O	787-789
cDNA	O	790-794
1024	O	795-799
from	O	800-804
C	O	805-806
to	O	807-809
T	O	810-811
(	O	812-813
Leu	O	813-816
to	O	817-819
Phe	O	820-823
)	O	823-824
;	O	824-825
at	O	826-828
cDNA	O	829-833
392	O	834-837
from	O	838-842
G	O	843-844
to	O	845-847
T	O	848-849
(	O	850-851
Gly	O	851-854
to	O	855-857
Val	O	858-861
)	O	861-862
;	O	862-863
at	O	864-866
cDNA	O	867-871
95	O	872-874
from	O	875-879
A	O	880-881
to	O	882-884
G	O	885-886
(	O	887-888
His	O	888-891
to	O	892-894
Arg	O	895-898
)	O	898-899
.	O	899-900

These	O	901-906
five	O	907-911
nucleotide	O	912-922
substitutions	O	923-936
account	O	937-944
for	O	945-948
over	O	949-953
83	O	954-956
%	O	956-957
of	O	958-960
our	O	961-964
43	O	965-967
G6PD	B	968-972
-	I	972-973
deficient	I	973-982
samples	O	983-990
and	O	991-994
these	O	995-1000
substitutions	O	1001-1014
have	O	1015-1019
not	O	1020-1023
been	O	1024-1028
reported	O	1029-1037
in	O	1038-1040
non	O	1041-1044
-	O	1044-1045
Asians	O	1045-1051
.	O	1051-1052

The	O	1053-1056
substitutions	O	1057-1070
found	O	1071-1076
at	O	1077-1079
cDNA	O	1080-1084
392	O	1085-1088
and	O	1089-1092
cDNA	O	1093-1097
1024	O	1098-1102
are	O	1103-1106
new	O	1107-1110
findings	O	1111-1119
.	O	1119-1120

The	O	1121-1124
substitutions	O	1125-1138
at	O	1139-1141
cDNA	O	1142-1146
1376	O	1147-1151
and	O	1152-1155
1388	O	1156-1160
account	O	1161-1168
for	O	1169-1172
over	O	1173-1177
50	O	1178-1180
%	O	1180-1181
of	O	1182-1184
the	O	1185-1188
43	O	1189-1191
samples	O	1192-1199
examined	O	1200-1208
indicating	O	1209-1219
a	O	1220-1221
high	O	1222-1226
prevalence	O	1227-1237
of	O	1238-1240
these	O	1241-1246
two	O	1247-1250
alleles	O	1251-1258
among	O	1259-1264
G6PD	B	1265-1269
-	I	1269-1270
deficient	I	1270-1279
Chinese	O	1280-1287
.	O	1287-1288

Our	O	1289-1292
findings	O	1293-1301
add	O	1302-1305
support	O	1306-1313
to	O	1314-1316
the	O	1317-1320
notion	O	1321-1327
that	O	1328-1332
diverse	O	1333-1340
point	O	1341-1346
mutations	O	1347-1356
may	O	1357-1360
account	O	1361-1368
largely	O	1369-1376
for	O	1377-1380
much	O	1381-1385
of	O	1386-1388
the	O	1389-1392
phenotypic	O	1393-1403
heterogeneity	O	1404-1417
of	O	1418-1420
G6PD	B	1421-1425
deficiency	I	1426-1436
.	O	1436-1437
.	O	1436-1437

Norrie	B	0-6
disease	I	7-14
gene	O	15-19
:	O	19-20
characterization	O	21-37
of	O	38-40
deletions	O	41-50
and	O	51-54
possible	O	55-63
function	O	64-72
.	O	72-73

Positional	O	74-84
cloning	O	85-92
experiments	O	93-104
have	O	105-109
resulted	O	110-118
recently	O	119-127
in	O	128-130
the	O	131-134
isolation	O	135-144
of	O	145-147
a	O	148-149
candidate	O	150-159
gene	O	160-164
for	O	165-168
Norrie	B	169-175
disease	I	176-183
(	O	184-185
pseudoglioma	B	185-197
;	O	197-198
NDP	B	199-202
)	O	202-203
,	O	203-204
a	O	205-206
severe	O	207-213
X	B	214-215
-	I	215-216
linked	I	216-222
neurodevelopmental	I	223-241
disorder	I	242-250
.	O	250-251

Here	O	252-256
we	O	257-259
report	O	260-266
the	O	267-270
isolation	O	271-280
and	O	281-284
analysis	O	285-293
of	O	294-296
human	O	297-302
genomic	O	303-310
DNA	O	311-314
clones	O	315-321
encompassing	O	322-334
the	O	335-338
NDP	B	339-342
gene	O	343-347
.	O	347-348

The	O	349-352
gene	O	353-357
spans	O	358-363
28	O	364-366
kb	O	367-369
and	O	370-373
consists	O	374-382
of	O	383-385
3	O	386-387
exons	O	388-393
,	O	393-394
the	O	395-398
first	O	399-404
of	O	405-407
which	O	408-413
is	O	414-416
entirely	O	417-425
contained	O	426-435
within	O	436-442
the	O	443-446
5	O	447-448
untranslated	O	449-461
region	O	462-468
.	O	468-469

Detailed	O	470-478
analysis	O	479-487
of	O	488-490
genomic	O	491-498
deletions	O	499-508
in	O	509-511
Norrie	B	512-518
patients	O	519-527
shows	O	528-533
that	O	534-538
they	O	539-543
are	O	544-547
heterogeneous	O	548-561
,	O	561-562
both	O	563-567
in	O	568-570
size	O	571-575
and	O	576-579
in	O	580-582
position	O	583-591
.	O	591-592

By	O	593-595
PCR	O	596-599
analysis	O	600-608
,	O	608-609
we	O	610-612
found	O	613-618
that	O	619-623
expression	O	624-634
of	O	635-637
the	O	638-641
NDP	B	642-645
gene	O	646-650
was	O	651-654
not	O	655-658
confined	O	659-667
to	O	668-670
the	O	671-674
eye	O	675-678
or	O	679-681
to	O	682-684
the	O	685-688
brain	O	689-694
.	O	694-695

An	O	696-698
extensive	O	699-708
DNA	O	709-712
and	O	713-716
protein	O	717-724
sequence	O	725-733
comparison	O	734-744
between	O	745-752
the	O	753-756
human	O	757-762
NDP	B	763-766
gene	O	767-771
and	O	772-775
related	O	776-783
genes	O	784-789
from	O	790-794
the	O	795-798
database	O	799-807
revealed	O	808-816
homology	O	817-825
with	O	826-830
cysteine	O	831-839
-	O	839-840
rich	O	840-844
protein	O	845-852
-	O	852-853
binding	O	853-860
domains	O	861-868
of	O	869-871
immediate	O	872-881
-	O	881-882
-	O	881-882
early	O	883-888
genes	O	889-894
implicated	O	895-905
in	O	906-908
the	O	909-912
regulation	O	913-923
of	O	924-926
cell	O	927-931
proliferation	O	932-945
.	O	945-946

We	O	947-949
propose	O	950-957
that	O	958-962
NDP	O	963-966
is	O	967-969
a	O	970-971
molecule	O	972-980
related	O	981-988
in	O	989-991
function	O	992-1000
to	O	1001-1003
these	O	1004-1009
genes	O	1010-1015
and	O	1016-1019
may	O	1020-1023
be	O	1024-1026
involved	O	1027-1035
in	O	1036-1038
a	O	1039-1040
pathway	O	1041-1048
that	O	1049-1053
regulates	O	1054-1063
neural	O	1064-1070
cell	O	1071-1075
differentiation	O	1076-1091
and	O	1092-1095
proliferation	O	1096-1109
.	O	1109-1110
.	O	1109-1110

Prenatal	O	0-8
diagnosis	O	9-18
of	O	19-21
Wolman	B	22-28
disease	I	29-36
.	O	36-37

Two	O	38-41
pregnancies	O	42-53
at	O	54-56
risk	O	57-61
for	O	62-65
Wolman	B	66-72
disease	I	73-80
were	O	81-85
monitored	O	86-95
by	O	96-98
assay	O	99-104
and	O	105-108
electrophoresis	O	109-124
of	O	125-127
acid	O	128-132
lipase	O	133-139
in	O	140-142
cultured	O	143-151
amniotic	O	152-160
-	O	160-161
fluid	O	161-166
cells	O	167-172
.	O	172-173

Cells	O	174-179
from	O	180-184
patient	O	185-192
1	O	193-194
had	O	195-198
5	O	199-200
%	O	200-201
of	O	202-204
control	O	205-212
levels	O	213-219
of	O	220-222
acid	O	223-227
lipase	O	228-234
,	O	234-235
using	O	236-241
14C	O	242-245
-	O	245-246
triolein	O	246-254
as	O	255-257
substrate	O	258-267
;	O	267-268
however	O	269-276
,	O	276-277
when	O	278-282
artificial	O	283-293
substrates	O	294-304
(	O	305-306
esters	O	306-312
of	O	313-315
4	O	316-317
-	O	317-318
methylumbelliferone	O	318-337
and	O	338-341
p	O	342-343
-	O	343-344
nitrophenol	O	344-355
)	O	355-356
were	O	357-361
used	O	362-366
to	O	367-369
measure	O	370-377
acid	O	378-382
lipase	O	383-389
,	O	389-390
these	O	391-396
cells	O	397-402
had	O	403-406
30	O	407-409
%	O	409-410
of	O	411-413
control	O	414-421
levels	O	422-428
.	O	428-429

Electrophoresis	O	430-445
of	O	446-448
cell	O	449-453
extracts	O	454-462
revealed	O	463-471
the	O	472-475
absence	O	476-483
of	O	484-486
the	O	487-490
A	O	491-492
form	O	493-497
of	O	498-500
acid	O	501-505
lipase	O	506-512
,	O	512-513
consistent	O	514-524
with	O	525-529
the	O	530-533
diagnosis	O	534-543
of	O	544-546
Wolman	B	547-553
disease	I	554-561
.	O	561-562

Analysis	O	563-571
of	O	572-574
fetal	O	575-580
tissues	O	581-588
following	O	589-598
prostaglandin	O	599-612
termination	O	613-624
of	O	625-627
this	O	628-632
pregnancy	O	633-642
confirmed	O	643-652
the	O	653-656
diagnosis	O	657-666
.	O	666-667

Assay	O	668-673
of	O	674-676
fetal	O	677-682
-	O	682-683
skin	O	683-687
fibroblasts	O	688-699
with	O	700-704
14C	O	705-708
-	O	708-709
triolein	O	709-717
,	O	717-718
as	O	719-721
well	O	722-726
as	O	727-729
with	O	730-734
artificial	O	735-745
substrates	O	746-756
,	O	756-757
showed	O	758-764
marked	O	765-771
deficiency	O	772-782
of	O	783-785
acid	O	786-790
lipase	O	791-797
activity	O	798-806
.	O	806-807

Electrophoresis	O	808-823
of	O	824-826
fetal	O	827-832
-	O	832-833
tissue	O	833-839
extracts	O	840-848
also	O	849-853
demonstrated	O	854-866
the	O	867-870
absence	O	871-878
of	O	879-881
the	O	882-885
A	O	886-887
form	O	888-892
of	O	893-895
acid	O	896-900
lipase	O	901-907
.	O	907-908

Amniotic	O	909-917
-	O	917-918
fluid	O	918-923
cells	O	924-929
from	O	930-934
patient	O	935-942
2	O	943-944
showed	O	945-951
normal	O	952-958
levels	O	959-965
of	O	966-968
acid	O	969-973
lipase	O	974-980
with	O	981-985
all	O	986-989
substrates	O	990-1000
tested	O	1001-1007
;	O	1007-1008
the	O	1009-1012
electrophoretic	O	1013-1028
pattern	O	1029-1036
of	O	1037-1039
acid	O	1040-1044
lipase	O	1045-1051
was	O	1052-1055
normal	O	1056-1062
.	O	1062-1063

The	O	1064-1067
results	O	1068-1075
suggest	O	1076-1083
that	O	1084-1088
the	O	1089-1092
prenatal	O	1093-1101
diagnosis	O	1102-1111
of	O	1112-1114
Wolman	B	1115-1121
disease	I	1122-1129
be	O	1130-1132
made	O	1133-1137
using	O	1138-1143
the	O	1144-1147
radioassay	O	1148-1158
of	O	1159-1161
acid	O	1162-1166
lipase	O	1167-1173
and	O	1174-1177
/	O	1177-1178
or	O	1178-1180
electrophoresis	O	1181-1196
.	O	1196-1197
.	O	1196-1197

Somatic	O	0-7
mutations	O	8-17
in	O	18-20
the	O	21-24
BRCA1	O	25-30
gene	O	31-35
in	O	36-38
sporadic	B	39-47
ovarian	I	48-55
tumours	I	56-63
.	O	63-64

The	O	65-68
BRCA1	O	69-74
gene	O	75-79
on	O	80-82
chromosome	O	83-93
17q21	O	94-99
is	O	100-102
responsible	O	103-114
for	O	115-118
an	O	119-121
autosomal	B	122-131
dominant	I	132-140
syndrome	I	141-149
of	O	150-152
increased	O	153-162
susceptibility	O	163-177
to	O	178-180
breast	B	181-187
and	I	188-191
ovarian	I	192-199
cancer	I	200-206
but	O	207-210
no	O	211-213
somatic	O	214-221
mutations	O	222-231
in	O	232-234
tumours	B	235-242
have	O	243-247
yet	O	248-251
been	O	252-256
described	O	257-266
.	O	266-267

To	O	268-270
study	O	271-276
the	O	277-280
potential	O	281-290
role	O	291-295
of	O	296-298
BRCA1	O	299-304
in	O	305-307
sporadic	O	308-316
carcinogenesis	O	317-331
,	O	331-332
we	O	333-335
analysed	O	336-344
the	O	345-348
genomic	O	349-356
DNA	O	357-360
of	O	361-363
tumour	B	364-370
and	O	371-374
normal	O	375-381
fractions	O	382-391
of	O	392-394
47	O	395-397
ovarian	B	398-405
cancers	I	406-413
for	O	414-417
mutations	O	418-427
in	O	428-430
BRCA1	O	431-436
using	O	437-442
the	O	443-446
single	O	447-453
-	O	453-454
strand	O	454-460
conformation	O	461-473
polymorphism	O	474-486
technique	O	487-496
.	O	496-497

We	O	498-500
now	O	501-504
describe	O	505-513
somatic	O	514-521
mutations	O	522-531
in	O	532-534
the	O	535-538
DNA	O	539-542
of	O	543-545
four	O	546-550
tumours	B	551-558
which	O	559-564
also	O	565-569
had	O	570-573
loss	O	574-578
of	O	579-581
heterozygosity	O	582-596
(	O	597-598
LOH	O	598-601
)	O	601-602
at	O	603-605
a	O	606-607
BRCA1	O	608-613
intragenic	O	614-624
marker	O	625-631
.	O	631-632

Our	O	633-636
data	O	637-641
support	O	642-649
a	O	650-651
tumour	B	652-658
suppressor	O	659-669
mechanism	O	670-679
for	O	680-683
BRCA1	O	684-689
;	O	689-690
somatic	O	691-698
mutations	O	699-708
and	O	709-712
LOH	O	713-716
may	O	717-720
result	O	721-727
in	O	728-730
inactivation	O	731-743
of	O	744-746
BRCA1	O	747-752
in	O	753-755
at	O	756-758
least	O	759-764
a	O	765-766
small	O	767-772
number	O	773-779
of	O	780-782
ovarian	B	783-790
cancers	I	791-798
.	O	798-799
.	O	798-799

Skewed	O	0-6
X	O	7-8
inactivation	O	9-21
in	O	22-24
a	O	25-26
female	O	27-33
MZ	O	34-36
twin	O	37-41
results	O	42-49
in	O	50-52
Duchenne	B	53-61
muscular	I	62-70
dystrophy	I	71-80
.	O	80-81

One	O	82-85
of	O	86-88
female	O	89-95
MZ	O	96-98
twins	O	99-104
presented	O	105-114
with	O	115-119
muscular	B	120-128
dystrophy	I	129-138
.	O	138-139

Physical	O	140-148
examination	O	149-160
,	O	160-161
creatine	O	162-170
phosphokinase	O	171-184
levels	O	185-191
,	O	191-192
and	O	193-196
muscle	O	197-203
biopsy	O	204-210
were	O	211-215
consistent	O	216-226
with	O	227-231
Duchenne	B	232-240
muscular	I	241-249
dystrophy	I	250-259
(	O	260-261
DMD	B	261-264
)	O	264-265
.	O	265-266

However	O	267-274
,	O	274-275
because	O	276-283
of	O	284-286
her	O	287-290
sex	O	291-294
she	O	295-298
was	O	299-302
diagnosed	O	303-312
as	O	313-315
having	O	316-322
limb	B	323-327
-	I	327-328
girdle	I	328-334
muscular	I	335-343
dystrophy	I	344-353
.	O	353-354

With	O	355-359
cDNA	O	360-364
probes	O	365-371
to	O	372-374
the	O	375-378
DMD	B	379-382
gene	O	383-387
,	O	387-388
a	O	389-390
gene	O	391-395
deletion	O	396-404
was	O	405-408
detected	O	409-417
in	O	418-420
the	O	421-424
twins	O	425-430
and	O	431-434
their	O	435-440
mother	O	441-447
.	O	447-448

The	O	449-452
de	O	453-455
novo	O	456-460
mutation	O	461-469
which	O	470-475
arose	O	476-481
in	O	482-484
the	O	485-488
mother	O	489-495
was	O	496-499
shown	O	500-505
by	O	506-508
novel	O	509-514
junction	O	515-523
fragments	O	524-533
generated	O	534-543
by	O	544-546
HindIII	O	547-554
,	O	554-555
PstI	O	556-560
,	O	560-561
or	O	562-564
TaqI	O	565-569
when	O	570-574
probed	O	575-581
with	O	582-586
cDNA8	O	587-592
.	O	592-593

Additional	O	594-604
evidence	O	605-613
of	O	614-616
a	O	617-618
large	O	619-624
gene	O	625-629
deletion	O	630-638
was	O	639-642
given	O	643-648
by	O	649-651
novel	O	652-657
SfiI	O	658-662
junction	O	663-671
fragments	O	672-681
detected	O	682-690
by	O	691-693
probes	O	694-700
p20	O	701-704
,	O	704-705
J	O	706-707
-	O	707-708
Bir	O	708-711
,	O	711-712
and	O	713-716
J	O	717-718
-	O	718-719
66	O	719-721
on	O	722-724
pulsed	O	725-731
-	O	731-732
field	O	732-737
gel	O	738-741
electrophoresis	O	742-757
(	O	758-759
PFGE	O	759-763
)	O	763-764
.	O	764-765

Immunoblot	O	766-776
analysis	O	777-785
of	O	786-788
muscle	O	789-795
from	O	796-800
the	O	801-804
affected	O	805-813
twin	O	814-818
showed	O	819-825
dystrophin	O	826-836
of	O	837-839
normal	O	840-846
size	O	847-851
but	O	852-855
of	O	856-858
reduced	O	859-866
amount	O	867-873
.	O	873-874

Immunofluorescent	O	875-892
visualization	O	893-906
of	O	907-909
dystrophin	O	910-920
revealed	O	921-929
foci	O	930-934
of	O	935-937
dystrophin	O	938-948
-	O	948-949
positive	O	949-957
fibers	O	958-964
adjacent	O	965-973
to	O	974-976
foci	O	977-981
of	O	982-984
dystrophin	O	985-995
-	O	995-996
negative	O	996-1004
fibers	O	1005-1011
.	O	1011-1012

These	O	1013-1018
data	O	1019-1023
indicate	O	1024-1032
that	O	1033-1037
the	O	1038-1041
affected	O	1042-1050
twin	O	1051-1055
is	O	1056-1058
a	O	1059-1060
manifesting	O	1061-1072
carrier	O	1073-1080
of	O	1081-1083
an	O	1084-1086
abnormal	O	1087-1095
DMD	B	1096-1099
gene	O	1100-1104
,	O	1104-1105
her	O	1106-1109
myopathy	B	1110-1118
being	O	1119-1124
a	O	1125-1126
direct	O	1127-1133
result	O	1134-1140
of	O	1141-1143
underexpression	O	1144-1159
of	O	1160-1162
dystrophin	O	1163-1173
.	O	1173-1174

Cytogenetic	O	1175-1186
analysis	O	1187-1195
revealed	O	1196-1204
normal	O	1205-1211
karyotypes	O	1212-1222
,	O	1222-1223
eliminating	O	1224-1235
the	O	1236-1239
possibility	O	1240-1251
of	O	1252-1254
a	O	1255-1256
translocation	O	1257-1270
affecting	O	1271-1280
DMD	B	1281-1284
gene	O	1285-1289
function	O	1290-1298
.	O	1298-1299

Both	O	1300-1304
linkage	O	1305-1312
analysis	O	1313-1321
and	O	1322-1325
DNA	O	1326-1329
fingerprint	O	1330-1341
analysis	O	1342-1350
revealed	O	1351-1359
that	O	1360-1364
each	O	1365-1369
twin	O	1370-1374
has	O	1375-1378
two	O	1379-1382
different	O	1383-1392
X	O	1393-1394
chromosomes	O	1395-1406
,	O	1406-1407
eliminating	O	1408-1419
the	O	1420-1423
possibility	O	1424-1435
of	O	1436-1438
uniparental	B	1439-1450
disomy	I	1451-1457
as	O	1458-1460
a	O	1461-1462
mechanism	O	1463-1472
for	O	1473-1476
DMD	B	1477-1480
expression	O	1481-1491
.	O	1491-1492

On	O	1493-1495
the	O	1496-1499
basis	O	1500-1505
of	O	1506-1508
methylation	O	1509-1520
differences	O	1521-1532
of	O	1533-1535
the	O	1536-1539
paternal	O	1540-1548
and	O	1549-1552
maternal	O	1553-1561
X	O	1562-1563
chromosomes	O	1564-1575
in	O	1576-1578
these	O	1579-1584
MZ	O	1585-1587
twins	O	1588-1593
,	O	1593-1594
we	O	1595-1597
propose	O	1598-1605
uneven	O	1606-1612
lyonization	O	1613-1624
(	O	1625-1626
X	O	1626-1627
chromosome	O	1628-1638
inactivation	O	1639-1651
)	O	1651-1652
as	O	1653-1655
the	O	1656-1659
underlying	O	1660-1670
mechanism	O	1671-1680
for	O	1681-1684
disease	O	1685-1692
expression	O	1693-1703
in	O	1704-1706
the	O	1707-1710
affected	O	1711-1719
female	O	1720-1726
.	O	1726-1727
.	O	1726-1727

Coincident	O	0-10
Kaposi	B	11-17
sarcoma	I	18-25
and	O	26-29
T	B	30-31
-	I	31-32
cell	I	32-36
lymphoma	I	37-45
in	O	46-48
a	O	49-50
patient	O	51-58
with	O	59-63
the	O	64-67
Wiskott	B	68-75
-	I	75-76
Aldrich	I	76-83
syndrome	I	84-92
.	O	92-93

A	O	94-95
24	O	96-98
year	O	99-103
old	O	104-107
male	O	108-112
with	O	113-117
a	O	118-119
history	O	120-127
of	O	128-130
eczema	B	131-137
,	O	137-138
recurrent	O	139-148
mild	O	149-153
infections	O	154-164
,	O	164-165
and	O	166-169
thrombocytopenia	B	170-186
consistent	O	187-197
with	O	198-202
the	O	203-206
Wiskott	B	207-214
-	I	214-215
Aldrich	I	215-222
syndrome	I	223-231
(	O	232-233
WAS	B	233-236
)	O	236-237
presented	O	238-247
with	O	248-252
a	O	253-254
mediastinal	O	255-266
mass	O	267-271
,	O	271-272
generalized	O	273-284
lymphadenopathy	B	285-300
,	O	300-301
splenomegaly	B	302-314
,	O	314-315
and	O	316-319
severe	O	320-326
thrombocytopenia	B	327-343
.	O	343-344

Studies	O	345-352
of	O	353-355
immune	O	356-362
function	O	363-371
including	O	372-381
immunoglobulin	O	382-396
levels	O	397-403
and	O	404-407
T	O	408-409
-	O	409-410
cell	O	410-414
subsets	O	415-422
were	O	423-427
normal	O	428-434
.	O	434-435

Furthermore	O	436-447
,	O	447-448
his	O	449-452
T	O	453-454
lymphocytes	O	455-466
proliferated	O	467-479
normally	O	480-488
in	O	489-491
response	O	492-500
to	O	501-503
phytohemagglutinin	O	504-522
,	O	522-523
concanavalin	O	524-536
A	O	537-538
,	O	538-539
and	O	540-543
the	O	544-547
combination	O	548-559
of	O	560-562
neuraminidase	O	563-576
/	O	576-577
galactose	O	577-586
oxidase	O	587-594
.	O	594-595

However	O	596-603
,	O	603-604
their	O	605-610
proliferative	O	611-624
responses	O	625-634
to	O	635-637
anti	O	638-642
-	O	642-643
CD43	O	643-647
antibody	O	648-656
and	O	657-660
periodate	O	661-670
were	O	671-675
diminished	O	676-686
,	O	686-687
consistent	O	688-698
with	O	699-703
the	O	704-707
clinical	O	708-716
diagnosis	O	717-726
of	O	727-729
WAS	B	730-733
.	O	733-734

An	O	735-737
initial	O	738-745
inguinal	O	746-754
lymph	O	755-760
node	O	761-765
biopsy	O	766-772
surprisingly	O	773-785
revealed	O	786-794
Kaposi	B	795-801
sarcoma	I	802-809
.	O	809-810

However	O	811-818
,	O	818-819
following	O	820-829
splenectomy	O	830-841
to	O	842-844
increase	O	845-853
the	O	854-857
platelet	O	858-866
count	O	867-872
,	O	872-873
biopsy	O	874-880
of	O	881-883
the	O	884-887
mediastinal	O	888-899
mass	O	900-904
revealed	O	905-913
T	B	914-915
-	I	915-916
cell	I	916-920
large	I	921-926
cell	I	927-931
lymphoma	I	932-940
.	O	940-941

Studies	O	942-949
of	O	950-952
biopsied	O	953-961
tissue	O	962-968
for	O	969-972
the	O	973-976
presence	O	977-985
of	O	986-988
Epstein	B	989-996
-	I	996-997
Barr	I	997-1001
virus	I	1002-1007
and	O	1008-1011
cytomegalovirus	B	1012-1027
were	O	1028-1032
negative	O	1033-1041
,	O	1041-1042
as	O	1043-1045
were	O	1046-1050
studies	O	1051-1058
of	O	1059-1061
blood	O	1062-1067
,	O	1067-1068
including	O	1069-1078
the	O	1079-1082
polymerase	O	1083-1093
chain	O	1094-1099
reaction	O	1100-1108
,	O	1108-1109
for	O	1110-1113
the	O	1114-1117
presence	O	1118-1126
of	O	1127-1129
the	O	1130-1133
human	B	1134-1139
immunodeficiency	I	1140-1156
virus	I	1157-1162
(	O	1163-1164
HIV	B	1164-1167
)	O	1167-1168
.	O	1168-1169

This	O	1170-1174
is	O	1175-1177
the	O	1178-1181
first	O	1182-1187
report	O	1188-1194
of	O	1195-1197
Kaposi	B	1198-1204
sarcoma	I	1205-1212
arising	O	1213-1220
in	O	1221-1223
a	O	1224-1225
patient	O	1226-1233
with	O	1234-1238
a	O	1239-1240
congenital	B	1241-1251
immunodeficiency	I	1252-1268
syndrome	I	1269-1277
.	O	1277-1278

Although	O	1279-1287
Kaposi	B	1288-1294
sarcoma	I	1295-1302
can	O	1303-1306
arise	O	1307-1312
in	O	1313-1315
the	O	1316-1319
face	O	1320-1324
of	O	1325-1327
the	O	1328-1331
severe	O	1332-1338
immunosuppression	O	1339-1356
that	O	1357-1361
follows	O	1362-1369
allograft	O	1370-1379
transplantation	O	1380-1395
and	O	1396-1399
in	O	1400-1402
patients	O	1403-1411
infected	O	1412-1420
with	O	1421-1425
HIV	B	1426-1429
,	O	1429-1430
we	O	1431-1433
postulate	O	1434-1443
that	O	1444-1448
longevity	O	1449-1458
in	O	1459-1461
the	O	1462-1465
face	O	1466-1470
of	O	1471-1473
mild	O	1474-1478
immunosuppression	O	1479-1496
was	O	1497-1500
the	O	1501-1504
major	O	1505-1510
factor	O	1511-1517
in	O	1518-1520
the	O	1521-1524
development	O	1525-1536
of	O	1537-1539
Kaposi	B	1540-1546
sarcoma	I	1547-1554
in	O	1555-1557
this	O	1558-1562
patient	O	1563-1570
.	O	1570-1571
.	O	1570-1571

Treatment	O	0-9
of	O	10-12
cerebrotendinous	B	13-29
xanthomatosis	I	30-43
:	O	43-44
effects	O	45-52
of	O	53-55
chenodeoxycholic	O	56-72
acid	O	73-77
,	O	77-78
pravastatin	O	79-90
,	O	90-91
and	O	92-95
combined	O	96-104
use	O	105-108
.	O	108-109

Treatments	O	110-120
by	O	121-123
oral	O	124-128
administration	O	129-143
of	O	144-146
chenodeoxycholic	O	147-163
acid	O	164-168
(	O	169-170
CDCA	O	170-174
)	O	174-175
alone	O	176-181
,	O	181-182
3	O	183-184
-	O	184-185
hydroxy	O	185-192
-	O	184-185
3	O	183-184
-	O	184-185
methylglutaryl	O	195-209
(	O	210-211
HMG	O	211-214
)	O	214-215
CoA	O	216-219
reductase	O	220-229
inhibitor	O	230-239
(	O	240-241
pravastatin	O	241-252
)	O	252-253
alone	O	254-259
,	O	259-260
and	O	261-264
combination	O	265-276
of	O	277-279
the	O	280-283
two	O	284-287
drugs	O	288-293
were	O	294-298
attempted	O	299-308
for	O	309-312
7	O	313-314
patients	O	315-323
with	O	324-328
cerebrotendinous	B	329-345
xanthomatosis	I	346-359
(	O	360-361
CTX	B	361-364
)	O	364-365
.	O	365-366

CDCA	O	367-371
treatment	O	372-381
at	O	382-384
a	O	385-386
dose	O	387-391
of	O	392-394
300	O	395-398
mg	O	399-401
/	O	401-402
day	O	402-405
reduced	O	406-413
serum	O	414-419
cholestanol	O	420-431
(	O	432-433
67	O	433-435
.	O	435-436

3	O	437-438
%	O	438-439
reduction	O	440-449
)	O	449-450
,	O	450-451
lathosterol	O	452-463
(	O	464-465
50	O	465-467
.	O	467-468

8	O	469-470
%	O	470-471
)	O	471-472
,	O	472-473
campesterol	O	474-485
(	O	486-487
61	O	487-489
.	O	489-490

7	O	491-492
%	O	492-493
)	O	493-494
and	O	495-498
sitosterol	O	499-509
(	O	510-511
12	O	511-513
.	O	513-514

7	O	515-516
%	O	516-517
)	O	517-518
.	O	518-519

However	O	520-527
,	O	527-528
the	O	529-532
sera	O	533-537
of	O	538-540
the	O	541-544
patients	O	545-553
changed	O	554-561
to	O	562-564
be	O	565-567
"	O	568-569
atherogenic	O	570-581
"	O	582-583
;	O	583-584
total	O	585-590
cholesterol	O	591-602
,	O	602-603
triglyceride	O	604-616
and	O	617-620
low	O	621-624
-	O	624-625
density	O	625-632
lipoprotein	O	633-644
(	O	645-646
LDL	O	646-649
)	O	649-650
-	O	651-652
cholesterol	O	652-663
were	O	664-668
increased	O	669-678
,	O	678-679
while	O	680-685
high	O	686-690
-	O	690-691
density	O	691-698
lipoprotein	O	699-710
(	O	711-712
HDL	O	712-715
)	O	715-716
-	O	717-718
cholesterol	O	718-729
was	O	730-733
decreased	O	734-743
.	O	743-744

Contrarily	O	745-755
,	O	755-756
pravastatin	O	757-768
at	O	769-771
a	O	772-773
dose	O	774-778
of	O	779-781
10	O	782-784
mg	O	785-787
/	O	787-788
day	O	788-791
improved	O	792-800
the	O	801-804
sera	O	805-809
of	O	810-812
the	O	813-816
patients	O	817-825
to	O	826-828
be	O	829-831
markedly	O	832-840
"	O	841-842
anti	O	843-847
-	O	847-848
atherogenic	O	848-859
"	O	860-861
,	O	861-862
but	O	863-866
the	O	867-870
reductions	O	871-881
of	O	882-884
cholestanol	O	885-896
(	O	897-898
30	O	898-900
.	O	900-901

4	O	902-903
%	O	903-904
)	O	904-905
,	O	905-906
lathosterol	O	907-918
(	O	919-920
44	O	920-922
.	O	922-923

0	O	924-925
%	O	925-926
)	O	926-927
,	O	927-928
campesterol	O	929-940
(	O	941-942
22	O	942-944
.	O	944-945

9	O	946-947
%	O	947-948
)	O	948-949
and	O	950-953
sitosterol	O	954-964
(	O	965-966
9	O	966-967
.	O	967-968

6	O	969-970
%	O	970-971
)	O	971-972
were	O	973-977
inadequate	O	978-988
.	O	988-989

Combined	O	990-998
treatment	O	999-1008
with	O	1009-1013
CDCA	O	1014-1018
and	O	1019-1022
pravastatin	O	1023-1034
showed	O	1035-1041
good	O	1042-1046
overlapping	O	1047-1058
of	O	1059-1061
the	O	1062-1065
effects	O	1066-1073
of	O	1074-1076
each	O	1077-1081
drug	O	1082-1086
alone	O	1087-1092
.	O	1092-1093

The	O	1094-1097
sera	O	1098-1102
of	O	1103-1105
the	O	1106-1109
patients	O	1110-1118
were	O	1119-1123
apparently	O	1124-1134
more	O	1135-1139
"	O	1140-1141
anti	O	1142-1146
-	O	1146-1147
atherogenic	O	1147-1158
"	O	1159-1160
than	O	1161-1165
those	O	1166-1171
after	O	1172-1177
CDCA	O	1178-1182
treatment	O	1183-1192
.	O	1192-1193

Serum	O	1194-1199
cholestanol	O	1200-1211
concentration	O	1212-1225
was	O	1226-1229
still	O	1230-1235
2	O	1236-1237
.	O	1237-1238
7	O	1239-1240
times	O	1241-1246
higher	O	1247-1253
than	O	1254-1258
in	O	1259-1261
controls	O	1262-1270
,	O	1270-1271
but	O	1272-1275
the	O	1276-1279
serum	O	1280-1285
lathosterol	O	1286-1297
level	O	1298-1303
was	O	1304-1307
within	O	1308-1314
the	O	1315-1318
normal	O	1319-1325
range	O	1326-1331
,	O	1331-1332
indicating	O	1333-1343
that	O	1344-1348
the	O	1349-1352
enhancement	O	1353-1364
of	O	1365-1367
overall	O	1368-1375
cholesterol	O	1376-1387
synthesis	O	1388-1397
in	O	1398-1400
the	O	1401-1404
patients	O	1405-1413
was	O	1414-1417
sufficiently	O	1418-1430
suppressed	O	1431-1441
.	O	1441-1442

Plant	O	1443-1448
sterol	O	1449-1455
levels	O	1456-1462
were	O	1463-1467
also	O	1468-1472
within	O	1473-1479
the	O	1480-1483
normal	O	1484-1490
range	O	1491-1496
.	O	1496-1497

The	O	1498-1501
combination	O	1502-1513
of	O	1514-1516
CDCA	O	1517-1521
and	O	1522-1525
pravastatin	O	1526-1537
was	O	1538-1541
a	O	1542-1543
good	O	1544-1548
treatment	O	1549-1558
for	O	1559-1562
CTX	B	1563-1566
,	O	1566-1567
based	O	1568-1573
on	O	1574-1576
the	O	1577-1580
improvement	O	1581-1592
of	O	1593-1595
serum	O	1596-1601
lipoprotein	O	1602-1613
metabolism	O	1614-1624
,	O	1624-1625
the	O	1626-1629
suppression	O	1630-1641
of	O	1642-1644
cholesterol	O	1645-1656
synthesis	O	1657-1666
,	O	1666-1667
and	O	1668-1671
reductions	O	1672-1682
of	O	1683-1685
cholestanol	O	1686-1697
and	O	1698-1701
plant	O	1702-1707
sterol	O	1708-1714
levels	O	1715-1721
.	O	1721-1722

In	O	1723-1725
all	O	1726-1729
of	O	1730-1732
7	O	1733-1734
patients	O	1735-1743
,	O	1743-1744
the	O	1745-1748
progression	O	1749-1760
of	O	1761-1763
disease	O	1764-1771
was	O	1772-1775
arrested	O	1776-1784
,	O	1784-1785
but	O	1786-1789
dramatic	O	1790-1798
effects	O	1799-1806
on	O	1807-1809
clinical	O	1810-1818
manifestations	O	1819-1833
,	O	1833-1834
xanthoma	B	1835-1843
,	O	1843-1844
and	O	1845-1848
electrophysiological	O	1849-1869
findings	O	1870-1878
could	O	1879-1884
not	O	1885-1888
be	O	1889-1891
found	O	1892-1897
after	O	1898-1903
the	O	1904-1907
treatment	O	1908-1917
of	O	1918-1920
these	O	1921-1926
drugs	O	1927-1932

Combined	B	0-8
genetic	I	9-16
deficiency	I	17-27
of	I	28-30
C6	I	31-33
and	I	34-37
C7	I	38-40
in	O	41-43
man	O	44-47
.	O	47-48

By	O	49-51
routine	O	52-59
screening	O	60-69
of	O	70-72
sera	O	73-77
,	O	77-78
a	O	79-80
subject	O	81-88
was	O	89-92
discovered	O	93-103
who	O	104-107
showed	O	108-114
a	O	115-116
sub	B	117-120
-	I	120-121
total	I	121-126
deficiency	I	127-137
of	I	138-140
C6	I	141-143
and	I	144-147
C7	I	148-150
.	O	150-151

No	O	152-154
clinical	O	155-163
disease	O	164-171
was	O	172-175
associated	O	176-186
with	O	187-191
this	O	192-196
deficiency	O	197-207
which	O	208-213
was	O	214-217
transmitted	O	218-229
through	O	230-237
the	O	238-241
subjects	O	242-250
family	O	251-257
as	O	258-260
a	O	261-262
single	O	263-269
genetic	O	270-277
characteristic	O	278-292
,	O	292-293
the	O	294-297
C6	B	298-300
deficiency	I	301-311
being	O	312-317
associated	O	318-328
with	O	329-333
a	O	334-335
silent	O	336-342
allele	O	343-349
at	O	350-352
the	O	353-356
structural	O	357-367
locus	O	368-373
.	O	373-374

The	O	375-378
propositus	O	379-389
was	O	390-393
found	O	394-399
to	O	400-402
have	O	403-407
low	O	408-411
quantities	O	412-422
of	O	423-425
an	O	426-428
abnormal	O	429-437
C6	O	438-440
which	O	441-446
was	O	447-450
both	O	451-455
antigenically	O	456-469
deficient	O	470-479
and	O	480-483
smaller	O	484-491
in	O	492-494
size	O	495-499
than	O	500-504
normal	O	505-511
C6	O	512-514
(	O	515-516
110	O	516-519
,	O	519-520
000	O	521-524
daltons	O	525-532
compared	O	533-541
with	O	542-546
140	O	547-550
,	O	550-551
000	O	552-555
daltons	O	556-563
)	O	563-564
and	O	565-568
small	O	569-574
quantities	O	575-585
of	O	586-588
apparently	O	589-599
normal	O	600-606
C7	O	607-609
.	O	609-610

It	O	611-613
is	O	614-616
concluded	O	617-626
that	O	627-631
the	O	632-635
most	O	636-640
likely	O	641-647
explanation	O	648-659
for	O	660-663
this	O	664-668
defect	O	669-675
is	O	676-678
that	O	679-683
the	O	684-687
subject	O	688-695
has	O	696-699
a	O	700-701
structural	O	702-712
mutation	O	713-721
in	O	722-724
his	O	725-728
C6	O	729-731
gene	O	732-736
which	O	737-742
produces	O	743-751
hyopsynthesis	O	752-765
not	O	766-769
only	O	770-774
of	O	775-777
C6	O	778-780
but	O	781-784
also	O	785-789
of	O	790-792
the	O	793-796
closely	O	797-804
linked	O	805-811
gene	O	812-816
for	O	817-820
C7	O	821-823
.	O	823-824

These	O	825-830
findings	O	831-839
suggest	O	840-847
the	O	848-851
possibility	O	852-863
that	O	864-868
C6	O	869-871
and	O	872-875
C7	O	876-878
may	O	879-882
function	O	883-891
as	O	892-894
a	O	895-896
single	O	897-903
genetic	O	904-911
unit	O	912-916
and	O	917-920
that	O	921-925
the	O	926-929
primary	O	930-937
transcript	O	938-948
copied	O	949-955
from	O	956-960
the	O	961-964
genome	O	965-971
includes	O	972-980
information	O	981-992
for	O	993-996
both	O	997-1001
proteins	O	1002-1010
.	O	1010-1011
.	O	1010-1011

Partial	O	0-7
deletion	O	8-16
8q	O	17-19
without	O	20-27
Langer	B	28-34
-	I	34-35
Giedion	I	35-42
syndrome	I	43-51
:	O	51-52
a	O	53-54
recognisable	O	55-67
syndrome	O	68-76
.	O	76-77

We	O	78-80
report	O	81-87
two	O	88-91
de	O	92-94
novo	O	95-99
cases	O	100-105
of	O	106-108
del	O	109-112
(	O	113-114
8	O	114-115
)	O	115-116
(	O	117-118
pter	O	118-122
-	O	122-123
-	O	122-123
-	O	122-123
-	O	122-123
q24	O	126-129
.	O	129-130

1	O	131-132
)	O	133-134
with	O	135-139
breakpoints	O	140-151
involving	O	152-161
the	O	162-165
distal	O	166-172
part	O	173-177
of	O	178-180
band	O	181-185
8q24	O	186-190
.	O	190-191
1	O	192-193
1	O	194-195
.	O	195-196

The	O	197-200
clinical	O	201-209
features	O	210-218
were	O	219-223
similar	O	224-231
and	O	232-235
there	O	236-241
were	O	242-246
no	O	247-249
obvious	O	250-257
stigmata	O	258-266
of	O	267-269
Langer	B	270-276
-	I	276-277
Giedion	I	277-284
syndrome	I	285-293
(	O	294-295
LGS	B	295-298
)	O	298-299
.	O	299-300

There	O	301-306
are	O	307-310
three	O	311-316
other	O	317-322
cases	O	323-328
reported	O	329-337
with	O	338-342
a	O	343-344
deletion	O	345-353
of	O	354-356
chromosome	O	357-367
8	O	368-369
at	O	370-372
approximately	O	373-386
the	O	387-390
same	O	391-395
breakpoint	O	396-406
,	O	406-407
one	O	408-411
without	O	412-419
LGS	B	420-423
and	O	424-427
some	O	428-432
similarities	O	433-445
to	O	446-448
our	O	449-452
cases	O	453-458
,	O	458-459
the	O	460-463
other	O	464-469
two	O	470-473
with	O	474-478
LGS	B	479-482
.	O	482-483

Our	O	484-487
findings	O	488-496
would	O	497-502
support	O	503-510
the	O	511-514
observation	O	515-526
that	O	527-531
the	O	532-535
critical	O	536-544
segment	O	545-552
for	O	553-556
the	O	557-560
assignment	O	561-571
of	O	572-574
LGS	B	575-578
is	O	579-581
proximal	O	582-590
to	O	591-593
or	O	594-596
involves	O	597-605
the	O	606-609
proximal	O	610-618
part	O	619-623
of	O	624-626
8q24	O	627-631
.	O	631-632
1	O	633-634
,	O	634-635
but	O	636-639
a	O	640-641
review	O	642-648
of	O	649-651
published	O	652-661
reports	O	662-669
suggests	O	670-678
that	O	679-683
the	O	684-687
aetiology	O	688-697
of	O	698-700
LGS	B	701-704
may	O	705-708
be	O	709-711
a	O	712-713
more	O	714-718
complex	O	719-726
issue	O	727-732

Iron	O	0-4
-	O	4-5
dependent	O	5-14
self	O	15-19
-	O	19-20
assembly	O	20-28
of	O	29-31
recombinant	O	32-43
yeast	O	44-49
frataxin	O	50-58
:	O	58-59
implications	O	60-72
for	O	73-76
Friedreich	B	77-87
ataxia	I	88-94
.	O	94-95

Frataxin	B	96-104
deficiency	I	105-115
is	O	116-118
the	O	119-122
primary	O	123-130
cause	O	131-136
of	O	137-139
Friedreich	B	140-150
ataxia	I	151-157
(	O	158-159
FRDA	B	159-163
)	O	163-164
,	O	164-165
an	O	166-168
autosomal	B	169-178
recessive	I	179-188
cardiodegenerative	I	189-207
and	I	208-211
neurodegenerative	I	212-229
disease	I	230-237
.	O	237-238

Frataxin	O	239-247
is	O	248-250
a	O	251-252
nuclear	O	253-260
-	O	260-261
encoded	O	261-268
mitochondrial	O	269-282
protein	O	283-290
that	O	291-295
is	O	296-298
widely	O	299-305
conserved	O	306-315
among	O	316-321
eukaryotes	O	322-332
.	O	332-333

Genetic	O	334-341
inactivation	O	342-354
of	O	355-357
the	O	358-361
yeast	O	362-367
frataxin	O	368-376
homologue	O	377-386
(	O	387-388
Yfh1p	O	388-393
)	O	393-394
results	O	395-402
in	O	403-405
mitochondrial	B	406-419
iron	I	420-424
accumulation	I	425-437
and	O	438-441
hypersensitivity	B	442-458
to	I	459-461
oxidative	I	462-471
stress	I	472-478
.	O	478-479

Increased	O	480-489
iron	O	490-494
deposition	O	495-505
and	O	506-509
evidence	O	510-518
of	O	519-521
oxidative	O	522-531
damage	O	532-538
have	O	539-543
also	O	544-548
been	O	549-553
observed	O	554-562
in	O	563-565
cardiac	O	566-573
tissue	O	574-580
and	O	581-584
cultured	O	585-593
fibroblasts	O	594-605
from	O	606-610
patients	O	611-619
with	O	620-624
FRDA	B	625-629
.	O	629-630

These	O	631-636
findings	O	637-645
indicate	O	646-654
that	O	655-659
frataxin	O	660-668
is	O	669-671
essential	O	672-681
for	O	682-685
mitochondrial	O	686-699
iron	O	700-704
homeostasis	O	705-716
and	O	717-720
protection	O	721-731
from	O	732-736
iron	O	737-741
-	O	741-742
induced	O	742-749
formation	O	750-759
of	O	760-762
free	O	763-767
radicals	O	768-776
.	O	776-777

The	O	778-781
functional	O	782-792
mechanism	O	793-802
of	O	803-805
frataxin	O	806-814
,	O	814-815
however	O	816-823
,	O	823-824
is	O	825-827
still	O	828-833
unknown	O	834-841
.	O	841-842

We	O	843-845
have	O	846-850
expressed	O	851-860
the	O	861-864
mature	O	865-871
form	O	872-876
of	O	877-879
Yfh1p	O	880-885
(	O	886-887
mYfh1p	O	887-893
)	O	893-894
in	O	895-897
Escherichia	O	898-909
coli	O	910-914
and	O	915-918
have	O	919-923
analyzed	O	924-932
its	O	933-936
function	O	937-945
in	O	946-948
vitro	O	949-954
.	O	954-955

Isolated	O	956-964
mYfh1p	O	965-971
is	O	972-974
a	O	975-976
soluble	O	977-984
monomer	O	985-992
(	O	993-994
13	O	994-996
,	O	996-997
783	O	998-1001
Da	O	1002-1004
)	O	1004-1005
that	O	1006-1010
contains	O	1011-1019
no	O	1020-1022
iron	O	1023-1027
and	O	1028-1031
shows	O	1032-1037
no	O	1038-1040
significant	O	1041-1052
tendency	O	1053-1061
to	O	1062-1064
self	O	1065-1069
-	O	1069-1070
associate	O	1070-1079
.	O	1079-1080

Aerobic	O	1081-1088
addition	O	1089-1097
of	O	1098-1100
ferrous	O	1101-1108
iron	O	1109-1113
to	O	1114-1116
mYfh1p	O	1117-1123
results	O	1124-1131
in	O	1132-1134
assembly	O	1135-1143
of	O	1144-1146
regular	O	1147-1154
spherical	O	1155-1164
multimers	O	1165-1174
with	O	1175-1179
a	O	1180-1181
molecular	O	1182-1191
mass	O	1192-1196
of	O	1197-1199
approximately	O	1200-1213
1	O	1214-1215
.	O	1215-1216
1	O	1217-1218
MDa	O	1219-1222
(	O	1223-1224
megadaltons	O	1224-1235
)	O	1235-1236
and	O	1237-1240
a	O	1241-1242
diameter	O	1243-1251
of	O	1252-1254
13	O	1255-1257
+	O	1258-1259
/	O	1259-1260
-	O	1260-1261
2	O	1261-1262
nm	O	1263-1265
.	O	1265-1266

Each	O	1267-1271
multimer	O	1272-1280
consists	O	1281-1289
of	O	1290-1292
approximately	O	1293-1306
60	O	1307-1309
subunits	O	1310-1318
and	O	1319-1322
can	O	1323-1326
sequester	O	1327-1336
>	O	1337-1338
3	O	1339-1340
,	O	1340-1341
000	O	1342-1345
atoms	O	1346-1351
of	O	1352-1354
iron	O	1355-1359
.	O	1359-1360

Titration	O	1361-1370
of	O	1371-1373
mYfh1p	O	1374-1380
with	O	1381-1385
increasing	O	1386-1396
iron	O	1397-1401
concentrations	O	1402-1416
supports	O	1417-1425
a	O	1426-1427
stepwise	O	1428-1436
mechanism	O	1437-1446
of	O	1447-1449
multimer	O	1450-1458
assembly	O	1459-1467
.	O	1467-1468

Sequential	O	1469-1479
addition	O	1480-1488
of	O	1489-1491
an	O	1492-1494
iron	O	1495-1499
chelator	O	1500-1508
and	O	1509-1512
a	O	1513-1514
reducing	O	1515-1523
agent	O	1524-1529
results	O	1530-1537
in	O	1538-1540
quantitative	O	1541-1553
iron	O	1554-1558
release	O	1559-1566
with	O	1567-1571
concomitant	O	1572-1583
disassembly	O	1584-1595
of	O	1596-1598
the	O	1599-1602
multimer	O	1603-1611
,	O	1611-1612
indicating	O	1613-1623
that	O	1624-1628
mYfh1p	O	1629-1635
sequesters	O	1636-1646
iron	O	1647-1651
in	O	1652-1654
an	O	1655-1657
available	O	1658-1667
form	O	1668-1672
.	O	1672-1673

In	O	1674-1676
yeast	O	1677-1682
mitochondria	O	1683-1695
,	O	1695-1696
native	O	1697-1703
mYfh1p	O	1704-1710
exists	O	1711-1717
as	O	1718-1720
monomer	O	1721-1728
and	O	1729-1732
a	O	1733-1734
higher	O	1735-1741
-	O	1741-1742
order	O	1742-1747
species	O	1748-1755
with	O	1756-1760
a	O	1761-1762
molecular	O	1763-1772
weight	O	1773-1779
>	O	1780-1781
600	O	1782-1785
,	O	1785-1786
000	O	1787-1790
.	O	1790-1791

After	O	1792-1797
addition	O	1798-1806
of	O	1807-1809
(	O	1810-1811
55	O	1811-1813
)	O	1813-1814
Fe	O	1815-1817
to	O	1818-1820
the	O	1821-1824
medium	O	1825-1831
,	O	1831-1832
immunoprecipitates	O	1833-1851
of	O	1852-1854
this	O	1855-1859
species	O	1860-1867
contain	O	1868-1875
>	O	1876-1877
16	O	1878-1880
atoms	O	1881-1886
of	O	1887-1889
(	O	1890-1891
55	O	1891-1893
)	O	1893-1894
Fe	O	1895-1897
per	O	1898-1901
molecule	O	1902-1910
of	O	1911-1913
mYfh1p	O	1914-1920
.	O	1920-1921

We	O	1922-1924
propose	O	1925-1932
that	O	1933-1937
iron	O	1938-1942
-	O	1942-1943
dependent	O	1943-1952
self	O	1953-1957
-	O	1957-1958
assembly	O	1958-1966
of	O	1967-1969
recombinant	O	1970-1981
mYfh1p	O	1982-1988
reflects	O	1989-1997
a	O	1998-1999
physiological	O	2000-2013
role	O	2014-2018
for	O	2019-2022
frataxin	O	2023-2031
in	O	2032-2034
mitochondrial	O	2035-2048
iron	O	2049-2053
sequestration	O	2054-2067
and	O	2068-2071
bioavailability	O	2072-2087
.	O	2087-2088
.	O	2087-2088

Human	O	0-5
mutations	O	6-15
in	O	16-18
glucose	O	19-26
6	O	27-28
-	O	28-29
phosphate	O	29-38
dehydrogenase	O	39-52
reflect	O	53-60
evolutionary	O	61-73
history	O	74-81
.	O	81-82

Glucose	O	83-90
6	O	91-92
-	O	92-93
phosphate	O	93-102
dehydrogenase	O	103-116
(	O	117-118
G6PD	O	118-122
)	O	122-123
is	O	124-126
a	O	127-128
cytosolic	O	129-138
enzyme	O	139-145
encoded	O	146-153
by	O	154-156
a	O	157-158
housekeeping	O	159-171
X	O	172-173
-	O	173-174
linked	O	174-180
gene	O	181-185
whose	O	186-191
main	O	192-196
function	O	197-205
is	O	206-208
to	O	209-211
produce	O	212-219
NADPH	O	220-225
,	O	225-226
a	O	227-228
key	O	229-232
electron	O	233-241
donor	O	242-247
in	O	248-250
the	O	251-254
defense	O	255-262
against	O	263-270
oxidizing	O	271-280
agents	O	281-287
and	O	288-291
in	O	292-294
reductive	O	295-304
biosynthetic	O	305-317
reactions	O	318-327
.	O	327-328

Inherited	O	329-338
G6PD	B	339-343
deficiency	I	344-354
is	O	355-357
associated	O	358-368
with	O	369-373
either	O	374-380
episodic	B	381-389
hemolytic	I	390-399
anemia	I	400-406
(	O	407-408
triggered	O	408-417
by	O	418-420
fava	O	421-425
beans	O	426-431
or	O	432-434
other	O	435-440
agents	O	441-447
)	O	447-448
or	O	449-451
life	B	452-456
-	I	456-457
long	I	457-461
hemolytic	I	462-471
anemia	I	472-478
.	O	478-479

We	O	480-482
show	O	483-487
here	O	488-492
that	O	493-497
an	O	498-500
evolutionary	O	501-513
analysis	O	514-522
is	O	523-525
a	O	526-527
key	O	528-531
to	O	532-534
understanding	O	535-548
the	O	549-552
biology	O	553-560
of	O	561-563
a	O	564-565
housekeeping	O	566-578
gene	O	579-583
.	O	583-584

From	O	585-589
the	O	590-593
alignment	O	594-603
of	O	604-606
the	O	607-610
amino	O	611-616
acid	O	617-621
(	O	622-623
aa	O	623-625
)	O	625-626
sequence	O	627-635
of	O	636-638
52	O	639-641
glucose	O	642-649
6	O	650-651
-	O	651-652
phosphate	O	652-661
dehydrogenase	O	662-675
(	O	676-677
G6PD	O	677-681
)	O	681-682
species	O	683-690
from	O	691-695
42	O	696-698
different	O	699-708
organisms	O	709-718
,	O	718-719
we	O	720-722
found	O	723-728
a	O	729-730
striking	O	731-739
correlation	O	740-751
between	O	752-759
the	O	760-763
aa	O	764-766
replacements	O	767-779
that	O	780-784
cause	O	785-790
G6PD	B	791-795
deficiency	I	796-806
in	O	807-809
humans	O	810-816
and	O	817-820
the	O	821-824
sequence	O	825-833
conservation	O	834-846
of	O	847-849
G6PD	O	850-854
two	O	856-859
-	O	859-860
thirds	O	860-866
of	O	867-869
such	O	870-874
replacements	O	875-887
are	O	888-891
in	O	892-894
highly	O	895-901
and	O	902-905
moderately	O	906-916
conserved	O	917-926
(	O	927-928
50	O	928-930
-	O	930-931
99	O	931-933
%	O	933-934
)	O	934-935
aa	O	936-938
;	O	938-939
relatively	O	940-950
few	O	951-954
are	O	955-958
in	O	959-961
fully	O	962-967
conserved	O	968-977
aa	O	978-980
(	O	981-982
where	O	982-987
they	O	988-992
might	O	993-998
be	O	999-1001
lethal	O	1002-1008
)	O	1008-1009
or	O	1010-1012
in	O	1013-1015
poorly	O	1016-1022
conserved	O	1023-1032
aa	O	1033-1035
,	O	1035-1036
where	O	1037-1042
presumably	O	1043-1053
they	O	1054-1058
simply	O	1059-1065
would	O	1066-1071
not	O	1072-1075
cause	O	1076-1081
G6PD	B	1082-1086
deficiency	I	1087-1097
.	O	1097-1098

This	O	1099-1103
is	O	1104-1106
consistent	O	1107-1117
with	O	1118-1122
the	O	1123-1126
notion	O	1127-1133
that	O	1134-1138
all	O	1139-1142
human	O	1143-1148
mutants	O	1149-1156
have	O	1157-1161
residual	O	1162-1170
enzyme	O	1171-1177
activity	O	1178-1186
and	O	1187-1190
that	O	1191-1195
null	O	1196-1200
mutations	O	1201-1210
are	O	1211-1214
lethal	O	1215-1221
at	O	1222-1224
some	O	1225-1229
stage	O	1230-1235
of	O	1236-1238
development	O	1239-1250
.	O	1250-1251

Comparing	O	1252-1261
the	O	1262-1265
distribution	O	1266-1278
of	O	1279-1281
mutations	O	1282-1291
in	O	1292-1294
a	O	1295-1296
human	O	1297-1302
housekeeping	O	1303-1315
gene	O	1316-1320
with	O	1321-1325
evolutionary	O	1326-1338
conservation	O	1339-1351
is	O	1352-1354
a	O	1355-1356
useful	O	1357-1363
tool	O	1364-1368
for	O	1369-1372
pinpointing	O	1373-1384
amino	O	1385-1390
acid	O	1391-1395
residues	O	1396-1404
important	O	1405-1414
for	O	1415-1418
the	O	1419-1422
stability	O	1423-1432
or	O	1433-1435
the	O	1436-1439
function	O	1440-1448
of	O	1449-1451
the	O	1452-1455
corresponding	O	1456-1469
protein	O	1470-1477
.	O	1477-1478

In	O	1479-1481
view	O	1482-1486
of	O	1487-1489
the	O	1490-1493
current	O	1494-1501
explosive	O	1502-1511
increase	O	1512-1520
in	O	1521-1523
full	O	1524-1528
genome	O	1529-1535
sequencing	O	1536-1546
projects	O	1547-1555
,	O	1555-1556
this	O	1557-1561
tool	O	1562-1566
will	O	1567-1571
become	O	1572-1578
rapidly	O	1579-1586
available	O	1587-1596
for	O	1597-1600
numerous	O	1601-1609
other	O	1610-1615
genes	O	1616-1621
.	O	1621-1622
.	O	1621-1622

Regionally	O	0-10
clustered	O	11-20
APC	B	21-24
mutations	O	25-34
are	O	35-38
associated	O	39-49
with	O	50-54
a	O	55-56
severe	O	57-63
phenotype	O	64-73
and	O	74-77
occur	O	78-83
at	O	84-86
a	O	87-88
high	O	89-93
frequency	O	94-103
in	O	104-106
new	O	107-110
mutation	O	111-119
cases	O	120-125
of	O	126-128
adenomatous	B	129-140
polyposis	I	141-150
coli	I	151-155
.	O	155-156

Germline	O	157-165
mutation	O	166-174
in	O	175-177
APC	O	178-181
at	O	182-184
5q21	O	185-189
-	O	189-190
22	O	190-192
results	O	193-200
in	O	201-203
the	O	204-207
dominantly	O	208-218
inherited	O	219-228
syndrome	O	229-237
adenomatous	B	238-249
polyposis	I	250-259
coli	I	260-264
(	O	265-266
APC	B	266-269
)	O	269-270
.	O	270-271

Somatic	O	272-279
mutation	O	280-288
in	O	289-291
this	O	292-296
gene	O	297-301
is	O	302-304
an	O	305-307
early	O	308-313
event	O	314-319
in	O	320-322
colorectal	O	323-333
tumourigenesis	O	334-348
.	O	348-349

Both	O	350-354
types	O	355-360
of	O	361-363
mutation	O	364-372
are	O	373-376
concentrated	O	377-389
in	O	390-392
the	O	393-396
5	O	397-398
half	O	399-403
of	O	404-406
exon	O	407-411
15	O	412-414
.	O	414-415

We	O	416-418
have	O	419-423
used	O	424-428
single	O	429-435
strand	O	436-442
conformational	O	443-457
polymorphism	O	458-470
(	O	471-472
SSCP	O	472-476
)	O	476-477
and	O	478-481
heteroduplex	O	482-494
analysis	O	495-503
to	O	504-506
screen	O	507-513
for	O	514-517
variants	O	518-526
in	O	527-529
this	O	530-534
region	O	535-541
of	O	542-544
the	O	545-548
gene	O	549-553
in	O	554-556
a	O	557-558
total	O	559-564
of	O	565-567
45	O	568-570
affected	O	571-579
but	O	580-583
unrelated	O	584-593
individuals	O	594-605
.	O	605-606

Eighteen	O	607-615
patients	O	616-624
had	O	625-628
no	O	629-631
family	O	632-638
history	O	639-646
of	O	647-649
the	O	650-653
disease	O	654-661
;	O	661-662
of	O	663-665
these	O	666-671
11	O	672-674
were	O	675-679
classified	O	680-690
as	O	691-693
having	O	694-700
a	O	701-702
severe	O	703-709
phenotype	O	710-719
,	O	719-720
based	O	721-726
on	O	727-729
an	O	730-732
early	O	733-738
age	O	739-742
at	O	743-745
presentation	O	746-758
or	O	759-761
cancer	B	762-768
development	O	769-780
.	O	780-781

This	O	782-786
compared	O	787-795
with	O	796-800
6	O	801-802
of	O	803-805
27	O	806-808
familial	O	809-817
cases	O	818-823
.	O	823-824

A	O	825-826
5	O	827-828
bp	O	829-831
deletion	O	832-840
at	O	841-843
codon	O	844-849
1309	O	850-854
reported	O	855-863
to	O	864-866
occur	O	867-872
in	O	873-875
10	O	876-878
-	O	878-879
15	O	879-881
%	O	881-882
of	O	883-885
unselected	O	886-896
APC	B	897-900
patients	O	901-909
worldwide	O	910-919
,	O	919-920
was	O	921-924
found	O	925-930
in	O	931-933
5	O	934-935
of	O	936-938
the	O	939-942
18	O	943-945
new	O	946-949
mutation	O	950-958
cases	O	959-964
and	O	965-968
4	O	969-970
of	O	971-973
the	O	974-977
27	O	978-980
familial	O	981-989
cases	O	990-995
all	O	997-1000
nine	O	1001-1005
were	O	1006-1010
classed	O	1011-1018
as	O	1019-1021
severe	O	1022-1028
.	O	1028-1029

A	O	1030-1031
further	O	1032-1039
3	O	1040-1041
new	O	1042-1045
mutations	O	1046-1055
and	O	1056-1059
1	O	1060-1061
familial	O	1062-1070
mutation	O	1071-1079
were	O	1080-1084
located	O	1085-1092
downstream	O	1093-1103
from	O	1104-1108
codon	O	1109-1114
1309	O	1115-1119
,	O	1119-1120
these	O	1121-1126
individuals	O	1127-1138
similarly	O	1139-1148
being	O	1149-1154
classed	O	1155-1162
as	O	1163-1165
phenotypically	O	1166-1180
severe	O	1181-1187
.	O	1187-1188

In	O	1189-1191
contrast	O	1192-1200
all	O	1201-1204
of	O	1205-1207
the	O	1208-1211
APC	B	1212-1215
mutations	O	1216-1225
detected	O	1226-1234
in	O	1235-1237
affected	O	1238-1246
individuals	O	1247-1258
with	O	1259-1263
an	O	1264-1266
average	O	1267-1274
phenotype	O	1275-1284
were	O	1285-1289
located	O	1290-1297
prior	O	1298-1303
to	O	1304-1306
codon	O	1307-1312
1309	O	1313-1317
.	O	1317-1318

The	O	1319-1322
frequent	O	1323-1331
association	O	1332-1343
of	O	1344-1346
a	O	1347-1348
severe	O	1349-1355
phenotype	O	1356-1365
with	O	1366-1370
fresh	O	1371-1376
mutation	O	1377-1385
may	O	1386-1389
explain	O	1390-1397
the	O	1398-1401
apparent	O	1402-1410
conflict	O	1411-1419
of	O	1420-1422
a	O	1423-1424
high	O	1425-1429
mutation	O	1430-1438
rate	O	1439-1443
(	O	1444-1445
20	O	1445-1447
-	O	1447-1448
30	O	1448-1450
%	O	1450-1451
)	O	1451-1452
in	O	1453-1455
a	O	1456-1457
condition	O	1458-1467
,	O	1467-1468
which	O	1469-1474
on	O	1475-1477
average	O	1478-1485
,	O	1485-1486
is	O	1487-1489
lethal	O	1490-1496
at	O	1497-1499
a	O	1500-1501
post	O	1502-1506
-	O	1506-1507
reproductive	O	1507-1519
age	O	1520-1523
.	O	1523-1524
.	O	1523-1524

Analysis	O	0-8
of	O	9-11
alkaptonuria	B	12-24
(	O	25-26
AKU	B	26-29
)	O	29-30
mutations	O	31-40
and	O	41-44
polymorphisms	O	45-58
reveals	O	59-66
that	O	67-71
the	O	72-75
CCC	O	76-79
sequence	O	80-88
motif	O	89-94
is	O	95-97
a	O	98-99
mutational	O	100-110
hot	O	111-114
spot	O	115-119
in	O	120-122
the	O	123-126
homogentisate	O	127-140
1	O	141-142
,	O	142-143
2	O	143-144
dioxygenase	O	145-156
gene	O	157-161
(	O	162-163
HGO	O	163-166
)	O	166-167
.	O	167-168

We	O	169-171
recently	O	172-180
showed	O	181-187
that	O	188-192
alkaptonuria	B	193-205
(	O	206-207
AKU	B	207-210
)	O	210-211
is	O	212-214
caused	O	215-221
by	O	222-224
loss	O	225-229
-	O	229-230
of	O	230-232
-	O	229-230
function	O	233-241
mutations	O	242-251
in	O	252-254
the	O	255-258
homogentisate	O	259-272
1	O	273-274
,	O	274-275
2	O	276-277
dioxygenase	O	278-289
gene	O	290-294
(	O	295-296
HGO	O	296-299
)	O	299-300
.	O	300-301

Herein	O	302-308
we	O	309-311
describe	O	312-320
haplotype	O	321-330
and	O	331-334
mutational	O	335-345
analyses	O	346-354
of	O	355-357
HGO	O	358-361
in	O	362-364
seven	O	365-370
new	O	371-374
AKU	B	375-378
pedigrees	O	379-388
.	O	388-389

These	O	390-395
analyses	O	396-404
identified	O	405-415
two	O	416-419
novel	O	420-425
single	O	426-432
-	O	432-433
nucleotide	O	433-443
polymorphisms	O	444-457
(	O	458-459
INV4	O	459-463
+	O	464-465
31A	O	466-469
-	O	469-470
-	O	469-470
>	O	472-473
G	O	474-475
and	O	476-479
INV11	O	480-485
+	O	486-487
18A	O	488-491
-	O	491-492
-	O	491-492
>	O	494-495
G	O	496-497
)	O	497-498
and	O	499-502
six	O	503-506
novel	O	507-512
AKU	B	513-516
mutations	O	517-526
(	O	527-528
INV1	O	528-532
-	O	532-533
1G	O	533-535
-	O	532-533
-	O	532-533
>	O	538-539
A	O	540-541
,	O	541-542
W60G	O	543-547
,	O	547-548
Y62C	O	549-553
,	O	553-554
A122D	O	555-560
,	O	560-561
P230T	O	562-567
,	O	567-568
and	O	569-572
D291E	O	573-578
)	O	578-579
,	O	579-580
which	O	581-586
further	O	587-594
illustrates	O	595-606
the	O	607-610
remarkable	O	611-621
allelic	O	622-629
heterogeneity	O	630-643
found	O	644-649
in	O	650-652
AKU	B	653-656
.	O	656-657

Reexamination	O	658-671
of	O	672-674
all	O	675-678
29	O	679-681
mutations	O	682-691
and	O	692-695
polymorphisms	O	696-709
thus	O	710-714
far	O	715-718
described	O	719-728
in	O	729-731
HGO	O	732-735
shows	O	736-741
that	O	742-746
these	O	747-752
nucleotide	O	753-763
changes	O	764-771
are	O	772-775
not	O	776-779
randomly	O	780-788
distributed	O	789-800
;	O	800-801
the	O	802-805
CCC	O	806-809
sequence	O	810-818
motif	O	819-824
and	O	825-828
its	O	829-832
inverted	O	833-841
complement	O	842-852
,	O	852-853
GGG	O	854-857
,	O	857-858
are	O	859-862
preferentially	O	863-877
mutated	O	878-885
.	O	885-886

These	O	887-892
analyses	O	893-901
also	O	902-906
demonstrated	O	907-919
that	O	920-924
the	O	925-928
nucleotide	O	929-939
substitutions	O	940-953
in	O	954-956
HGO	O	957-960
do	O	961-963
not	O	964-967
involve	O	968-975
CpG	O	976-979
dinucleotides	O	980-993
,	O	993-994
which	O	995-1000
illustrates	O	1001-1012
important	O	1013-1022
differences	O	1023-1034
between	O	1035-1042
HGO	O	1043-1046
and	O	1047-1050
other	O	1051-1056
genes	O	1057-1062
for	O	1063-1066
the	O	1067-1070
occurrence	O	1071-1081
of	O	1082-1084
mutation	O	1085-1093
at	O	1094-1096
specific	O	1097-1105
short	O	1106-1111
-	O	1111-1112
sequence	O	1112-1120
motifs	O	1121-1127
.	O	1127-1128

Because	O	1129-1136
the	O	1137-1140
CCC	O	1141-1144
sequence	O	1145-1153
motifs	O	1154-1160
comprise	O	1161-1169
a	O	1170-1171
significant	O	1172-1183
proportion	O	1184-1194
(	O	1195-1196
34	O	1196-1198
.	O	1198-1199

5	O	1200-1201
%	O	1201-1202
)	O	1202-1203
of	O	1204-1206
all	O	1207-1210
mutated	O	1211-1218
bases	O	1219-1224
that	O	1225-1229
have	O	1230-1234
been	O	1235-1239
observed	O	1240-1248
in	O	1249-1251
HGO	O	1252-1255
,	O	1255-1256
we	O	1257-1259
conclude	O	1260-1268
that	O	1269-1273
the	O	1274-1277
CCC	O	1278-1281
triplet	O	1282-1289
is	O	1290-1292
a	O	1293-1294
mutational	O	1295-1305
hot	O	1306-1309
spot	O	1310-1314
in	O	1315-1317
HGO	O	1318-1321
.	O	1321-1322

Further	O	0-7
evidence	O	8-16
for	O	17-20
heterogeneity	O	21-34
of	O	35-37
glucose	B	38-45
-	I	45-46
6	I	46-47
-	I	45-46
phosphate	I	48-57
dehydrogenase	I	58-71
deficiency	I	72-82
in	O	83-85
Papua	O	86-91
New	O	92-95
Guinea	O	96-102
.	O	102-103

Four	O	104-108
new	O	109-112
G6PD	O	113-117
variants	O	118-126
have	O	127-131
been	O	132-136
characterized	O	137-150
in	O	151-153
individuals	O	154-165
from	O	166-170
Papua	O	171-176
New	O	177-180
Guinea	O	181-187
.	O	187-188

This	O	189-193
study	O	194-199
demonstrates	O	200-212
that	O	213-217
the	O	218-221
previously	O	222-232
reported	O	233-241
Markham	O	242-249
variant	O	250-257
and	O	258-261
the	O	262-265
newly	O	266-271
characterized	O	272-285
Salata	O	286-292
variant	O	293-300
may	O	301-304
be	O	305-307
widely	O	308-314
distributed	O	315-326
in	O	327-329
Papua	O	330-335
New	O	336-339
Guinea	O	340-346
.	O	346-347

Th	O	348-350
data	O	351-355
presented	O	356-365
here	O	366-370
together	O	371-379
with	O	380-384
those	O	385-390
of	O	391-393
previously	O	394-404
published	O	405-414
studies	O	415-422
demonstrate	O	423-434
a	O	435-436
degree	O	437-443
of	O	444-446
heterogeneity	O	447-460
of	O	461-463
G6PD	B	464-468
deficiency	I	469-479
that	O	480-484
is	O	485-487
much	O	488-492
higher	O	493-499
than	O	500-504
that	O	505-509
in	O	510-512
other	O	513-518
regions	O	519-526
of	O	527-529
the	O	530-533
world	O	534-539
where	O	540-545
G6PD	B	546-550
deficiency	I	551-561
is	O	562-564
common	O	565-571
.	O	571-572
.	O	571-572

Overgrowth	B	0-10
of	I	11-13
oral	I	14-18
mucosa	I	19-25
and	I	26-29
facial	I	30-36
skin	I	37-41
,	O	41-42
a	O	43-44
novel	O	45-50
feature	O	51-58
of	O	59-61
aspartylglucosaminuria	B	62-84
.	O	84-85

Aspartylglucosaminuria	B	86-108
(	O	109-110
AGU	B	110-113
)	O	113-114
is	O	115-117
a	O	118-119
lysosomal	B	120-129
storage	I	130-137
disorder	I	138-146
caused	O	147-153
by	O	154-156
deficiency	B	157-167
of	I	168-170
aspartylglucosaminidase	I	171-194
(	O	195-196
AGA	O	196-199
)	O	199-200
.	O	200-201

The	O	202-205
main	O	206-210
symptom	O	211-218
is	O	219-221
progressive	O	222-233
mental	B	234-240
retardation	I	241-252
.	O	252-253

A	O	254-255
spectrum	O	256-264
of	O	265-267
different	O	268-277
mutations	O	278-287
has	O	288-291
been	O	292-296
reported	O	297-305
in	O	306-308
this	O	309-313
disease	O	314-321
,	O	321-322
one	O	323-326
missense	O	327-335
mutation	O	336-344
(	O	345-346
Cys163Ser	O	346-355
)	O	355-356
being	O	357-362
responsible	O	363-374
for	O	375-378
the	O	379-382
majority	O	383-391
of	O	392-394
Finnish	O	395-402
cases	O	403-408
.	O	408-409

We	O	410-412
were	O	413-417
able	O	418-422
to	O	423-425
examine	O	426-433
66	O	434-436
Finnish	O	437-444
AGU	B	445-448
patients	O	449-457
for	O	458-461
changes	O	462-469
in	O	470-472
the	O	473-476
oral	O	477-481
mucosa	O	482-488
and	O	489-492
44	O	493-495
of	O	496-498
these	O	499-504
for	O	505-508
changes	O	509-516
in	O	517-519
facial	O	520-526
skin	O	527-531
.	O	531-532

Biopsy	O	533-539
specimens	O	540-549
of	O	550-552
16	O	553-555
oral	O	556-560
lesions	O	561-568
,	O	568-569
12	O	570-572
of	O	573-575
them	O	576-580
associated	O	581-591
with	O	592-596
the	O	597-600
teeth	O	601-606
,	O	606-607
plus	O	608-612
two	O	613-616
facial	B	617-623
lesions	I	624-631
were	O	632-636
studied	O	637-644
histologically	O	645-659
.	O	659-660

Immunohistochemical	O	661-680
staining	O	681-689
for	O	690-693
AGA	O	694-697
was	O	698-701
performed	O	702-711
on	O	712-714
15	O	715-717
oral	O	718-722
specimens	O	723-732
.	O	732-733

Skin	O	734-738
was	O	739-742
seborrhoeic	O	743-754
in	O	755-757
adolescent	O	758-768
and	O	769-772
adult	O	773-778
patients	O	779-787
,	O	787-788
with	O	789-793
erythema	B	794-802
of	I	803-805
the	I	806-809
facial	I	810-816
skin	I	817-821
already	O	822-829
common	O	830-836
in	O	837-839
childhood	O	840-849
.	O	849-850

Of	O	851-853
44	O	854-856
patients	O	857-865
,	O	865-866
nine	O	867-871
(	O	872-873
20	O	873-875
%	O	875-876
)	O	876-877
had	O	878-881
facial	B	882-888
angiofibromas	I	889-902
,	O	902-903
tumours	B	904-911
primarily	O	912-921
occurring	O	922-931
in	O	932-934
association	O	935-946
with	O	947-951
tuberous	B	952-960
sclerosis	I	961-970
.	O	970-971

Oedemic	B	972-979
buccal	I	980-986
mucosa	I	987-993
(	O	994-995
leucoedema	B	995-1005
)	O	1005-1006
and	O	1007-1010
gingival	B	1011-1019
overgrowths	I	1020-1031
were	O	1032-1036
more	O	1037-1041
frequent	O	1042-1050
in	O	1051-1053
AGU	B	1054-1057
patients	O	1058-1066
than	O	1067-1071
in	O	1072-1074
controls	O	1075-1083
(	O	1084-1085
p	O	1085-1086
<	O	1087-1088
0	O	1089-1090
.	O	1090-1091
001	O	1092-1095
)	O	1095-1096
.	O	1096-1097

Of	O	1098-1100
16	O	1101-1103
oral	B	1104-1108
mucosal	I	1109-1116
lesions	I	1117-1124
studied	O	1125-1132
histologically	O	1133-1147
,	O	1147-1148
15	O	1149-1151
represented	O	1152-1163
fibroepithelial	B	1164-1179
or	I	1180-1182
epithelial	I	1183-1193
hyperplasias	I	1194-1206
and	O	1207-1210
were	O	1211-1215
reactive	O	1216-1224
in	O	1225-1227
nature	O	1228-1234
.	O	1234-1235

Cytoplasmic	O	1236-1247
vacuolisation	O	1248-1261
was	O	1262-1265
evident	O	1266-1273
in	O	1274-1276
four	O	1277-1281
.	O	1281-1282

Immunohistochemically	O	1283-1304
,	O	1304-1305
expression	O	1306-1316
of	O	1317-1319
AGA	O	1320-1323
in	O	1324-1326
AGU	B	1327-1330
patients	O	1331-1339
mucosal	B	1340-1347
lesions	I	1348-1355
did	O	1356-1359
not	O	1360-1363
differ	O	1364-1370
from	O	1371-1375
that	O	1376-1380
seen	O	1381-1385
in	O	1386-1388
corresponding	O	1389-1402
lesions	O	1403-1410
of	O	1411-1413
normal	O	1414-1420
subjects	O	1421-1429
.	O	1429-1430

Thus	O	1431-1435
,	O	1435-1436
the	O	1437-1440
high	O	1441-1445
frequency	O	1446-1455
of	O	1456-1458
mucosal	B	1459-1466
overgrowth	I	1467-1477
in	O	1478-1480
AGU	B	1481-1484
patients	O	1485-1493
does	O	1494-1498
not	O	1499-1502
appear	O	1503-1509
to	O	1510-1512
be	O	1513-1515
directly	O	1516-1524
associated	O	1525-1535
with	O	1536-1540
lysosomal	O	1541-1550
storage	O	1551-1558
or	O	1559-1561
with	O	1562-1566
alterations	O	1567-1578
in	O	1579-1581
the	O	1582-1585
level	O	1586-1591
of	O	1592-1594
AGA	O	1595-1598
expression	O	1599-1609
.	O	1609-1610

Molecular	O	0-9
characterization	O	10-26
of	O	27-29
galactosemia	B	30-42
(	O	43-44
type	O	44-48
1	O	49-50
)	O	50-51
mutations	O	52-61
in	O	62-64
Japanese	O	65-73
.	O	73-74

We	O	75-77
characterized	O	78-91
two	O	92-95
novel	O	96-101
mutations	O	102-111
of	O	112-114
the	O	115-118
galactose	O	119-128
-	O	128-129
1	O	129-130
-	O	128-129
phosphate	O	131-140
uridyltransferase	O	141-158
(	O	159-160
GALT	O	160-164
)	O	164-165
gene	O	166-170
in	O	171-173
two	O	174-177
Japanese	O	178-186
patients	O	187-195
with	O	196-200
GALT	B	201-205
deficiency	I	206-216
and	O	217-220
identified	O	221-231
N314D	O	232-237
and	O	238-241
R333W	O	242-247
mutations	O	248-257
,	O	257-258
previously	O	259-269
found	O	270-275
in	O	276-278
Caucasians	O	279-289
.	O	289-290

One	O	291-294
novel	O	295-300
missense	O	301-309
mutation	O	310-318
was	O	319-322
an	O	323-325
G	O	326-327
-	O	327-328
to	O	328-330
-	O	327-328
A	O	331-332
transition	O	333-343
in	O	344-346
exon	O	347-351
8	O	352-353
,	O	353-354
resulting	O	355-364
in	O	365-367
the	O	368-371
substitution	O	372-384
of	O	385-387
arginine	O	388-396
by	O	397-399
histidine	O	400-409
at	O	410-412
the	O	413-416
codon	O	417-422
231	O	423-426
(	O	427-428
R231H	O	428-433
)	O	433-434
.	O	434-435

GALT	O	436-440
activity	O	441-449
of	O	450-452
the	O	453-456
R231H	O	457-462
mutant	O	463-469
construct	O	470-479
was	O	480-483
reduced	O	484-491
to	O	492-494
15	O	495-497
%	O	497-498
of	O	499-501
normal	O	502-508
controls	O	509-517
in	O	518-520
a	O	521-522
COS	O	523-526
cell	O	527-531
expression	O	532-542
system	O	543-549
.	O	549-550

The	O	551-554
other	O	555-560
was	O	561-564
a	O	565-566
splicing	O	567-575
mutation	O	576-584
,	O	584-585
an	O	586-588
A	O	589-590
-	O	590-591
to	O	591-593
-	O	590-591
G	O	594-595
transition	O	596-606
at	O	607-609
the	O	610-613
38th	O	614-618
nucleotide	O	619-629
in	O	630-632
exon	O	633-637
3	O	638-639
(	O	640-641
318A	O	641-645
-	O	645-646
-	O	645-646
>	O	648-649
G	O	650-651
)	O	651-652
,	O	652-653
resulting	O	654-663
in	O	664-666
a	O	667-668
38	O	669-671
-	O	671-672
bp	O	672-674
deletion	O	675-683
in	O	684-686
the	O	687-690
GALT	O	691-695
cDNA	O	696-700
by	O	701-703
activating	O	704-714
a	O	715-716
cryptic	O	717-724
splice	O	725-731
acceptor	O	732-740
site	O	741-745
.	O	745-746

In	O	747-749
seven	O	750-755
Japanese	O	756-764
families	O	765-773
(	O	774-775
14	O	775-777
alleles	O	778-785
for	O	786-789
classic	O	790-797
form	O	798-802
and	O	803-806
one	O	807-810
allele	O	811-817
for	O	818-821
Duarte	O	822-828
variant	O	829-836
)	O	836-837
with	O	838-842
GALT	B	843-847
deficiency	I	848-858
,	O	858-859
the	O	860-863
R231H	O	864-869
and	O	870-873
318A	O	874-878
-	O	878-879
-	O	878-879
>	O	881-882
G	O	883-884
mutations	O	885-894
were	O	895-899
found	O	900-905
only	O	906-910
on	O	911-913
both	O	914-918
alleles	O	919-926
of	O	927-929
the	O	930-933
proband	O	934-941
.	O	941-942

The	O	943-946
N314D	O	947-952
and	O	953-956
R333W	O	957-962
mutations	O	963-972
were	O	973-977
found	O	978-983
on	O	984-986
one	O	987-990
allele	O	991-997
each	O	998-1002
.	O	1002-1003

The	O	1004-1007
Q188R	O	1008-1013
was	O	1014-1017
prevalent	O	1018-1027
in	O	1028-1030
the	O	1031-1034
United	O	1035-1041
States	O	1042-1048
but	O	1049-1052
not	O	1053-1056
in	O	1057-1059
Japanese	O	1060-1068
patients	O	1069-1077
.	O	1077-1078

The	O	1079-1082
N314D	O	1083-1088
mutation	O	1089-1097
was	O	1098-1101
associated	O	1102-1112
with	O	1113-1117
the	O	1118-1121
Duarte	O	1122-1128
variant	O	1129-1136
in	O	1137-1139
Japanese	O	1140-1148
persons	O	1149-1156
,	O	1156-1157
as	O	1158-1160
well	O	1161-1165
as	O	1166-1168
in	O	1169-1171
the	O	1172-1175
United	O	1176-1182
States	O	1183-1189
.	O	1189-1190

We	O	1191-1193
speculate	O	1194-1203
that	O	1204-1208
classic	B	1209-1216
galactosemia	I	1217-1229
mutations	O	1230-1239
appear	O	1240-1246
to	O	1247-1249
differ	O	1250-1256
between	O	1257-1264
Japanese	O	1265-1273
and	O	1274-1277
Caucasian	O	1278-1287
patients	O	1288-1296
.	O	1296-1297

Our	O	1298-1301
limited	O	1302-1309
data	O	1310-1314
set	O	1315-1318
on	O	1319-1321
galactosemia	B	1322-1334
mutations	O	1335-1344
in	O	1345-1347
Japanese	O	1348-1356
suggests	O	1357-1365
that	O	1366-1370
the	O	1371-1374
N314D	O	1375-1380
GALT	O	1381-1385
mutation	O	1386-1394
encoding	O	1395-1403
the	O	1404-1407
Duarte	O	1408-1414
variant	O	1415-1422
arose	O	1423-1428
before	O	1429-1435
Asian	O	1436-1441
and	O	1442-1445
Caucasian	O	1446-1455
people	O	1456-1462
diverged	O	1463-1471
and	O	1472-1475
that	O	1476-1480
classic	B	1481-1488
galactosemia	I	1489-1501
mutations	O	1502-1511
arose	O	1512-1517
and	O	1518-1521
/	O	1521-1522
or	O	1522-1524
accumulated	O	1525-1536
after	O	1537-1542
the	O	1543-1546
divergence	O	1547-1557
of	O	1558-1560
Asian	O	1561-1566
and	O	1567-1570
Caucasian	O	1571-1580
populations	O	1581-1592
.	O	1592-1593
.	O	1592-1593

Linkage	O	0-7
disequilibrium	O	8-22
mapping	O	23-30
in	O	31-33
isolated	O	34-42
founder	O	43-50
populations	O	51-62
:	O	62-63
diastrophic	B	64-75
dysplasia	I	76-85
in	O	86-88
Finland	O	89-96
.	O	96-97

Linkage	O	98-105
disequilibrium	O	106-120
mapping	O	121-128
in	O	129-131
isolated	O	132-140
populations	O	141-152
provides	O	153-161
a	O	162-163
powerful	O	164-172
tool	O	173-177
for	O	178-181
fine	O	182-186
structure	O	187-196
localization	O	197-209
of	O	210-212
disease	O	213-220
genes	O	221-226
.	O	226-227

Here	O	228-232
,	O	232-233
Luria	O	234-239
and	O	240-243
Delbrucks	O	244-253
classical	O	254-263
methods	O	264-271
for	O	272-275
analysing	O	276-285
bacterial	O	286-295
cultures	O	296-304
are	O	305-308
adapted	O	309-316
to	O	317-319
the	O	320-323
study	O	324-329
of	O	330-332
human	O	333-338
isolated	O	339-347
founder	O	348-355
populations	O	356-367
in	O	368-370
order	O	371-376
to	O	377-379
estimate	O	380-388
(	O	389-390
i	O	390-391
)	O	391-392
the	O	393-396
recombination	O	397-410
fraction	O	411-419
between	O	420-427
a	O	428-429
disease	O	430-437
locus	O	438-443
and	O	444-447
a	O	448-449
marker	O	450-456
;	O	456-457
(	O	458-459
ii	O	459-461
)	O	461-462
the	O	463-466
expected	O	467-475
degree	O	476-482
of	O	483-485
allelic	O	486-493
homogeneity	O	494-505
in	O	506-508
a	O	509-510
population	O	511-521
;	O	521-522
and	O	523-526
(	O	527-528
iii	O	528-531
)	O	531-532
the	O	533-536
mutation	O	537-545
rate	O	546-550
of	O	551-553
marker	O	554-560
loci	O	561-565
.	O	565-566

Using	O	567-572
these	O	573-578
methods	O	579-586
,	O	586-587
we	O	588-590
report	O	591-597
striking	O	598-606
linkage	O	607-614
disequilibrium	O	615-629
for	O	630-633
diastrophic	B	634-645
dysplasia	I	646-655
(	O	656-657
DTD	B	657-660
)	O	660-661
in	O	662-664
Finland	O	665-672
indicating	O	673-683
that	O	684-688
the	O	689-692
DTD	B	693-696
gene	O	697-701
should	O	702-708
lie	O	709-712
within	O	713-719
0	O	720-721
.	O	721-722
06	O	723-725
centimorgans	O	726-738
(	O	739-740
or	O	740-742
about	O	743-748
60	O	749-751
kilobases	O	752-761
)	O	761-762
of	O	763-765
the	O	766-769
CSF1R	O	770-775
gene	O	776-780
.	O	780-781

Predictions	O	782-793
about	O	794-799
allelic	O	800-807
homogeneity	O	808-819
in	O	820-822
Finland	O	823-830
and	O	831-834
mutation	O	835-843
rates	O	844-849
in	O	850-852
simple	O	853-859
sequence	O	860-868
repeats	O	869-876
are	O	877-880
confirmed	O	881-890
by	O	891-893
independent	O	894-905
observations	O	906-918
.	O	918-919

Mutations	O	0-9
in	O	10-12
TNFRSF11A	O	13-22
,	O	22-23
affecting	O	24-33
the	O	34-37
signal	O	38-44
peptide	O	45-52
of	O	53-55
RANK	O	56-60
,	O	60-61
cause	O	62-67
familial	B	68-76
expansile	I	77-86
osteolysis	I	87-97
.	O	97-98

Familial	B	99-107
expansile	I	108-117
osteolysis	I	118-128
(	O	129-130
FEO	B	130-133
,	O	133-134
MIM	O	135-138
174810	O	139-145
)	O	145-146
is	O	147-149
a	O	150-151
rare	O	152-156
,	O	156-157
autosomal	B	158-167
dominant	I	168-176
bone	I	177-181
disorder	I	182-190
characterized	O	191-204
by	O	205-207
focal	O	208-213
areas	O	214-219
of	O	220-222
increased	B	223-232
bone	I	233-237
remodelling	I	238-249
.	O	249-250

The	O	251-254
osteolytic	B	255-265
lesions	I	266-273
,	O	273-274
which	O	275-280
develop	O	281-288
usually	O	289-296
in	O	297-299
the	O	300-303
long	O	304-308
bones	O	309-314
during	O	315-321
early	O	322-327
adulthood	O	328-337
,	O	337-338
show	O	339-343
increased	O	344-353
osteoblast	O	354-364
and	O	365-368
osteoclast	O	369-379
activity	O	380-388
.	O	388-389

Our	O	390-393
previous	O	394-402
linkage	O	403-410
studies	O	411-418
mapped	O	419-425
the	O	426-429
gene	O	430-434
responsible	O	435-446
for	O	447-450
FEO	B	451-454
to	O	455-457
an	O	458-460
interval	O	461-469
of	O	470-472
less	O	473-477
than	O	478-482
5	O	483-484
cM	O	485-487
between	O	488-495
D18S64	O	496-502
and	O	503-506
D18S51	O	507-513
on	O	514-516
chromosome	O	517-527
18q21	O	528-533
.	O	533-534

2	O	535-536
-	O	536-537
21	O	537-539
2	O	540-541
-	O	541-542
21	O	542-544
.	O	544-545

3	O	546-547
in	O	548-550
a	O	551-552
large	O	553-558
Northern	O	559-567
Irish	O	568-573
family	O	574-580
.	O	580-581

The	O	582-585
gene	O	586-590
encoding	O	591-599
receptor	O	600-608
activator	O	609-618
of	O	619-621
nuclear	O	622-629
factor	O	630-636
-	O	636-637
kappa	O	637-642
B	O	643-644
(	O	645-646
RANK	O	646-650
;	O	650-651
ref	O	652-655
.	O	655-656
5	O	657-658
)	O	658-659
,	O	659-660
TNFRSF11A	O	661-670
,	O	670-671
maps	O	672-676
to	O	677-679
this	O	680-684
region	O	685-691
.	O	691-692

RANK	O	693-697
is	O	698-700
essential	O	701-710
in	O	711-713
osteoclast	O	714-724
formation	O	725-734
.	O	734-735

We	O	736-738
identified	O	739-749
two	O	750-753
heterozygous	O	754-766
insertion	O	767-776
mutations	O	777-786
in	O	787-789
exon	O	790-794
1	O	795-796
of	O	797-799
TNFRSF11A	O	800-809
in	O	810-812
affected	O	813-821
members	O	822-829
of	O	830-832
four	O	833-837
families	O	838-846
with	O	847-851
FEO	B	852-855
or	O	856-858
familial	B	859-867
Paget	I	868-873
disease	I	874-881
of	I	882-884
bone	I	885-889
(	O	890-891
PDB	B	891-894
)	O	894-895
.	O	895-896

One	O	897-900
was	O	901-904
a	O	905-906
duplication	O	907-918
of	O	919-921
18	O	922-924
bases	O	925-930
and	O	931-934
the	O	935-938
other	O	939-944
a	O	945-946
duplication	O	947-958
of	O	959-961
27	O	962-964
bases	O	965-970
,	O	970-971
both	O	972-976
of	O	977-979
which	O	980-985
affected	O	986-994
the	O	995-998
signal	O	999-1005
peptide	O	1006-1013
region	O	1014-1020
of	O	1021-1023
the	O	1024-1027
RANK	O	1028-1032
molecule	O	1033-1041
.	O	1041-1042

Expression	O	1043-1053
of	O	1054-1056
recombinant	O	1057-1068
forms	O	1069-1074
of	O	1075-1077
the	O	1078-1081
mutant	O	1082-1088
RANK	O	1089-1093
proteins	O	1094-1102
revealed	O	1103-1111
perturbations	O	1112-1125
in	O	1126-1128
expression	O	1129-1139
levels	O	1140-1146
and	O	1147-1150
lack	O	1151-1155
of	O	1156-1158
normal	O	1159-1165
cleavage	O	1166-1174
of	O	1175-1177
the	O	1178-1181
signal	O	1182-1188
peptide	O	1189-1196
.	O	1196-1197

Both	O	1198-1202
mutations	O	1203-1212
caused	O	1213-1219
an	O	1220-1222
increase	O	1223-1231
in	O	1232-1234
RANK	O	1235-1239
-	O	1239-1240
mediated	O	1240-1248
nuclear	O	1249-1256
factor	O	1257-1263
-	O	1263-1264
kappaB	O	1264-1270
(	O	1271-1272
NF	O	1272-1274
-	O	1274-1275
kappaB	O	1275-1281
)	O	1281-1282
signalling	O	1283-1293
in	O	1294-1296
vitro	O	1297-1302
,	O	1302-1303
consistent	O	1304-1314
with	O	1315-1319
the	O	1320-1323
presence	O	1324-1332
of	O	1333-1335
an	O	1336-1338
activating	O	1339-1349
mutation	O	1350-1358
.	O	1358-1359

Adrenoleukodystrophy	O	0-20
-	O	20-21
related	O	21-28
protein	O	29-36
can	O	37-40
compensate	O	41-51
functionally	O	52-64
for	O	65-68
adrenoleukodystrophy	B	69-89
protein	I	90-97
deficiency	I	98-108
(	O	109-110
X	B	110-111
-	I	111-112
ALD	I	112-115
)	O	115-116
:	O	116-117
implications	O	118-130
for	O	131-134
therapy	O	135-142
.	O	142-143

Inherited	B	144-153
defects	I	154-161
in	O	162-164
the	O	165-168
peroxisomal	O	169-180
ATP	O	181-184
-	O	184-185
binding	O	185-192
cassette	O	193-201
(	O	202-203
ABC	O	203-206
)	O	206-207
transporter	O	208-219
adrenoleukodystrophy	B	220-240
protein	O	241-248
(	O	249-250
ALDP	O	250-254
)	O	254-255
lead	O	256-260
to	O	261-263
the	O	264-267
lethal	O	268-274
peroxisomal	B	275-286
disorder	I	287-295
X	B	296-297
-	I	297-298
linked	I	298-304
adrenoleukodystrophy	I	305-325
(	O	326-327
X	B	327-328
-	I	328-329
ALD	I	329-332
)	O	332-333
,	O	333-334
for	O	335-338
which	O	339-344
no	O	345-347
efficient	O	348-357
treatment	O	358-367
has	O	368-371
been	O	372-376
established	O	377-388
so	O	389-391
far	O	392-395
.	O	395-396

Three	O	397-402
other	O	403-408
peroxisomal	O	409-420
ABC	O	421-424
transporters	O	425-437
currently	O	438-447
are	O	448-451
known	O	452-457
adrenoleukodystrophy	O	459-479
-	O	479-480
related	O	480-487
protein	O	488-495
(	O	496-497
ALDRP	O	497-502
)	O	502-503
,	O	503-504
70	O	505-507
kDa	O	508-511
peroxisomal	O	512-523
membrane	O	524-532
protein	O	533-540
(	O	541-542
PMP70	O	542-547
)	O	547-548
and	O	549-552
PMP70	O	553-558
-	O	558-559
related	O	560-567
protein	O	568-575
.	O	575-576

By	O	577-579
using	O	580-585
transient	O	586-595
and	O	596-599
stable	O	600-606
overexpression	O	607-621
of	O	622-624
human	O	625-630
cDNAs	O	631-636
encoding	O	637-645
ALDP	O	646-650
and	O	651-654
its	O	655-658
closest	O	659-666
relative	O	667-675
ALDRP	O	676-681
,	O	681-682
we	O	683-685
could	O	686-691
restore	O	692-699
the	O	700-703
impaired	O	704-712
peroxisomal	O	713-724
beta	O	725-729
-	O	729-730
oxidation	O	730-739
in	O	740-742
fibroblasts	O	743-754
of	O	755-757
X	B	758-759
-	I	759-760
ALD	I	760-763
patients	O	764-772
.	O	772-773

The	O	774-777
pathognomonic	O	778-791
accumulation	O	792-804
of	O	805-807
very	O	808-812
long	O	813-817
chain	O	818-823
fatty	O	824-829
acids	O	830-835
could	O	836-841
also	O	842-846
be	O	847-849
prevented	O	850-859
by	O	860-862
overexpression	O	863-877
of	O	878-880
ALDRP	O	881-886
in	O	887-889
immortalized	O	890-902
X	O	903-904
-	O	904-905
ALD	O	905-908
cells	O	909-914
.	O	914-915

Immunofluorescence	O	916-934
analysis	O	935-943
demonstrated	O	944-956
that	O	957-961
the	O	962-965
functional	O	966-976
replacement	O	977-988
of	O	989-991
ALDP	O	992-996
by	O	997-999
ALDRP	O	1000-1005
was	O	1006-1009
not	O	1010-1013
due	O	1014-1017
to	O	1018-1020
stabilization	O	1021-1034
of	O	1035-1037
the	O	1038-1041
mutated	O	1042-1049
ALDP	O	1050-1054
itself	O	1055-1061
.	O	1061-1062

Moreover	O	1063-1071
,	O	1071-1072
we	O	1073-1075
were	O	1076-1080
able	O	1081-1085
to	O	1086-1088
restore	O	1089-1096
the	O	1097-1100
peroxisomal	O	1101-1112
beta	O	1113-1117
-	O	1117-1118
oxidation	O	1118-1127
defect	O	1128-1134
in	O	1135-1137
the	O	1138-1141
liver	O	1142-1147
of	O	1148-1150
ALDP	O	1151-1155
-	O	1155-1156
deficient	O	1156-1165
mice	O	1166-1170
by	O	1171-1173
stimulation	O	1174-1185
of	O	1186-1188
ALDRP	O	1189-1194
and	O	1195-1198
PMP70	O	1199-1204
gene	O	1205-1209
expression	O	1210-1220
through	O	1221-1228
a	O	1229-1230
dietary	O	1231-1238
treatment	O	1239-1248
with	O	1249-1253
the	O	1254-1257
peroxisome	O	1258-1268
proliferator	O	1269-1281
fenofibrate	O	1282-1293
.	O	1293-1294

These	O	1295-1300
results	O	1301-1308
suggest	O	1309-1316
that	O	1317-1321
a	O	1322-1323
correction	O	1324-1334
of	O	1335-1337
the	O	1338-1341
biochemical	O	1342-1353
defect	O	1354-1360
in	O	1361-1363
X	B	1364-1365
-	I	1365-1366
ALD	I	1366-1369
could	O	1370-1375
be	O	1376-1378
possible	O	1379-1387
by	O	1388-1390
drug	O	1391-1395
-	O	1395-1396
induced	O	1396-1403
overexpression	O	1404-1418
or	O	1419-1421
ectopic	O	1422-1429
expression	O	1430-1440
of	O	1441-1443
ALDRP	O	1444-1449
.	O	1449-1450
.	O	1449-1450

The	O	0-3
normal	O	4-10
Huntington	B	11-21
disease	I	22-29
(	O	30-31
HD	B	31-33
)	O	33-34
allele	O	35-41
,	O	41-42
or	O	43-45
a	O	46-47
closely	O	48-55
linked	O	56-62
gene	O	63-67
,	O	67-68
influences	O	69-79
age	O	80-83
at	O	84-86
onset	O	87-92
of	O	93-95
HD	B	96-98
.	O	98-99

We	O	100-102
evaluated	O	103-112
the	O	113-116
hypothesis	O	117-127
that	O	128-132
Huntington	B	133-143
disease	I	144-151
(	O	152-153
HD	B	153-155
)	O	155-156
is	O	157-159
influenced	O	160-170
by	O	171-173
the	O	174-177
normal	O	178-184
HD	B	185-187
allele	O	188-194
by	O	195-197
comparing	O	198-207
transmission	O	208-220
patterns	O	221-229
of	O	230-232
genetically	O	233-244
linked	O	245-251
markers	O	252-259
at	O	260-262
the	O	263-266
D4S10	O	267-272
locus	O	273-278
in	O	279-281
the	O	282-285
normal	O	286-292
parent	O	293-299
against	O	300-307
age	O	308-311
at	O	312-314
onset	O	315-320
in	O	321-323
the	O	324-327
affected	O	328-336
offspring	O	337-346
.	O	346-347

Analysis	O	348-356
of	O	357-359
information	O	360-371
from	O	372-376
21	O	377-379
sibships	O	380-388
in	O	389-391
14	O	392-394
kindreds	O	395-403
showed	O	404-410
a	O	411-412
significant	O	413-424
tendency	O	425-433
for	O	434-437
sibs	O	438-442
who	O	443-446
have	O	447-451
similar	O	452-459
onset	O	460-465
ages	O	466-470
to	O	471-473
share	O	474-479
the	O	480-483
same	O	484-488
D4S10	O	489-494
allele	O	495-501
from	O	502-506
the	O	507-510
normal	O	511-517
parent	O	518-524
.	O	524-525

Affected	O	526-534
sibs	O	535-539
who	O	540-543
inherited	O	544-553
different	O	554-563
D4S10	O	564-569
alleles	O	570-577
from	O	578-582
the	O	583-586
normal	O	587-593
parent	O	594-600
tended	O	601-607
to	O	608-610
have	O	611-615
more	O	616-620
variable	O	621-629
ages	O	630-634
at	O	635-637
onset	O	638-643
.	O	643-644

These	O	645-650
findings	O	651-659
suggest	O	660-667
that	O	668-672
the	O	673-676
expression	O	677-687
of	O	688-690
HD	B	691-693
is	O	694-696
modulated	O	697-706
by	O	707-709
the	O	710-713
normal	O	714-720
HD	B	721-723
allele	O	724-730
or	O	731-733
by	O	734-736
a	O	737-738
closely	O	739-746
linked	O	747-753
locus	O	754-759
.	O	759-760
.	O	759-760

Synergistic	O	0-11
effect	O	12-18
of	O	19-21
histone	O	22-29
hyperacetylation	O	30-46
and	O	47-50
DNA	O	51-54
demethylation	O	55-68
in	O	69-71
the	O	72-75
reactivation	O	76-88
of	O	89-91
the	O	92-95
FMR1	O	96-100
gene	O	101-105
.	O	105-106

Most	O	107-111
fragile	B	112-119
X	I	120-121
syndrome	I	122-130
patients	O	131-139
have	O	140-144
expansion	O	145-154
of	O	155-157
a	O	158-159
(	O	160-161
CGG	O	161-164
)	O	164-165
(	O	166-167
n	O	167-168
)	O	168-169
sequence	O	170-178
with	O	179-183
>	O	184-185
200	O	186-189
repeats	O	190-197
(	O	198-199
full	O	199-203
mutation	O	204-212
)	O	212-213
in	O	214-216
the	O	217-220
FMR1	O	221-225
gene	O	226-230
responsible	O	231-242
for	O	243-246
this	O	247-251
condition	O	252-261
.	O	261-262

Hypermethylation	O	263-279
of	O	280-282
the	O	283-286
expanded	O	287-295
repeat	O	296-302
and	O	303-306
of	O	307-309
the	O	310-313
FMR1	O	314-318
promoter	O	319-327
is	O	328-330
almost	O	331-337
always	O	338-344
present	O	345-352
and	O	353-356
apparently	O	357-367
suppresses	O	368-378
transcription	O	379-392
,	O	392-393
resulting	O	394-403
in	O	404-406
absence	O	407-414
of	O	415-417
the	O	418-421
FMR1	O	422-426
protein	O	427-434
.	O	434-435

We	O	436-438
recently	O	439-447
showed	O	448-454
that	O	455-459
transcriptional	O	460-475
reactivation	O	476-488
of	O	489-491
FMR1	O	492-496
full	O	497-501
mutations	O	502-511
can	O	512-515
be	O	516-518
achieved	O	519-527
by	O	528-530
inducing	O	531-539
DNA	O	540-543
demethylation	O	544-557
with	O	558-562
5	O	563-564
-	O	564-565
azadeoxycytidine	O	565-581
(	O	582-583
5	O	583-584
-	O	584-585
azadC	O	585-590
)	O	590-591
.	O	591-592

The	O	593-596
level	O	597-602
of	O	603-605
histone	O	606-613
acetylation	O	614-625
is	O	626-628
another	O	629-636
important	O	637-646
factor	O	647-653
in	O	654-656
regulating	O	657-667
gene	O	668-672
expression	O	673-683
;	O	683-684
therefore	O	685-694
,	O	694-695
we	O	696-698
treated	O	699-706
lymphoblastoid	O	707-721
cell	O	722-726
lines	O	727-732
of	O	733-735
non	O	736-739
-	O	739-740
mosaic	O	740-746
full	O	747-751
mutation	O	752-760
patients	O	761-769
with	O	770-774
three	O	775-780
drugs	O	781-786
capable	O	787-794
of	O	795-797
inducing	O	798-806
histone	O	807-814
hyperacetylation	O	815-831
.	O	831-832

We	O	833-835
observed	O	836-844
a	O	845-846
consistent	O	847-857
,	O	857-858
although	O	859-867
modest	O	868-874
,	O	874-875
reactivation	O	876-888
of	O	889-891
the	O	892-895
FMR1	O	896-900
gene	O	901-905
with	O	906-910
4	O	911-912
-	O	912-913
phenylbutyrate	O	913-927
,	O	927-928
sodium	O	929-935
butyrate	O	936-944
and	O	945-948
trichostatin	O	949-961
A	O	962-963
,	O	963-964
as	O	965-967
shown	O	968-973
by	O	974-976
RT	O	977-979
-	O	979-980
PCR	O	980-983
.	O	983-984

However	O	985-992
,	O	992-993
we	O	994-996
report	O	997-1003
that	O	1004-1008
combining	O	1009-1018
these	O	1019-1024
drugs	O	1025-1030
with	O	1031-1035
5	O	1036-1037
-	O	1037-1038
azadC	O	1038-1043
results	O	1044-1051
in	O	1052-1054
a	O	1055-1056
2	O	1057-1058
-	O	1058-1059
to	O	1060-1062
5	O	1063-1064
-	O	1064-1065
fold	O	1065-1069
increase	O	1070-1078
in	O	1079-1081
FMR1	O	1082-1086
mRNA	O	1087-1091
levels	O	1092-1098
obtained	O	1099-1107
with	O	1108-1112
5	O	1113-1114
-	O	1114-1115
azadC	O	1115-1120
alone	O	1121-1126
,	O	1126-1127
thus	O	1128-1132
showing	O	1133-1140
a	O	1141-1142
marked	O	1143-1149
synergistic	O	1150-1161
effect	O	1162-1168
of	O	1169-1171
histone	O	1172-1179
hyperacetylation	O	1180-1196
and	O	1197-1200
DNA	O	1201-1204
demethylation	O	1205-1218
in	O	1219-1221
the	O	1222-1225
reactivation	O	1226-1238
of	O	1239-1241
FMR1	O	1242-1246
full	O	1247-1251
mutations	O	1252-1261
.	O	1261-1262
.	O	1261-1262

Genetic	O	0-7
heterogeneity	O	8-21
in	O	22-24
X	B	25-26
-	I	26-27
linked	I	27-33
amelogenesis	I	34-46
imperfecta	I	47-57
.	O	57-58

The	O	59-62
AMELX	O	63-68
gene	O	69-73
located	O	74-81
at	O	82-84
Xp22	O	85-89
.	O	89-90
1	O	91-92
-	O	92-93
p22	O	93-96
.	O	96-97

3	O	98-99
encodes	O	100-107
for	O	108-111
the	O	112-115
enamel	O	116-122
protein	O	123-130
amelogenin	O	131-141
and	O	142-145
has	O	146-149
been	O	150-154
implicated	O	155-165
as	O	166-168
the	O	169-172
gene	O	173-177
responsible	O	178-189
for	O	190-193
the	O	194-197
inherited	B	198-207
dental	I	208-214
abnormality	I	215-226
X	B	227-228
-	I	228-229
linked	I	229-235
amelogenesis	I	236-248
imperfecta	I	249-259
(	O	260-261
XAI	B	261-264
)	O	264-265
.	O	265-266

Three	O	267-272
families	O	273-281
with	O	282-286
XAI	B	287-290
have	O	291-295
been	O	296-300
investigated	O	301-313
using	O	314-319
polymorphic	O	320-331
DNA	O	332-335
markers	O	336-343
flanking	O	344-352
the	O	353-356
position	O	357-365
of	O	366-368
AMELX	O	369-374
.	O	374-375

Using	O	376-381
two	O	382-385
-	O	385-386
point	O	386-391
linkage	O	392-399
analysis	O	400-408
,	O	408-409
linkage	O	410-417
was	O	418-421
established	O	422-433
between	O	434-441
XAI	B	442-445
and	O	446-449
several	O	450-457
of	O	458-460
these	O	461-466
markers	O	467-474
in	O	475-477
two	O	478-481
families	O	482-490
,	O	490-491
with	O	492-496
a	O	497-498
combined	O	499-507
lod	O	508-511
score	O	512-517
of	O	518-520
6	O	521-522
.	O	522-523
05	O	524-526
for	O	527-530
DXS16	O	531-536
at	O	537-539
theta	O	540-545
=	O	546-547
0	O	548-549
.	O	549-550
04	O	551-553
04	O	554-556
.	O	556-557

This	O	558-562
supports	O	563-571
the	O	572-575
involvement	O	576-587
of	O	588-590
AMELX	O	591-596
,	O	596-597
located	O	598-605
close	O	606-611
to	O	612-614
DXS16	O	615-620
,	O	620-621
in	O	622-624
the	O	625-628
XAI	B	629-632
disease	I	633-640
process	O	641-648
(	O	649-650
AIH1	O	650-654
)	O	654-655
in	O	656-658
those	O	659-664
families	O	665-673
.	O	673-674

Using	O	675-680
multipoint	O	681-691
linkage	O	692-699
analysis	O	700-708
,	O	708-709
the	O	710-713
combined	O	714-722
maximum	O	723-730
lod	O	731-734
score	O	735-740
for	O	741-744
these	O	745-750
two	O	751-754
families	O	755-763
was	O	764-767
7	O	768-769
.	O	769-770
30	O	771-773
for	O	774-777
a	O	778-779
location	O	780-788
of	O	789-791
AIH1	O	792-796
at	O	797-799
2	O	800-801
cM	O	802-804
distal	O	805-811
to	O	812-814
DXS16	O	815-820
.	O	820-821

The	O	822-825
support	O	826-833
interval	O	834-842
around	O	843-849
this	O	850-854
location	O	855-863
extended	O	864-872
about	O	873-878
8	O	879-880
cM	O	881-883
proximal	O	884-892
to	O	893-895
DXS92	O	896-901
,	O	901-902
and	O	903-906
the	O	907-910
AIH1	O	911-915
location	O	916-924
could	O	925-930
not	O	931-934
be	O	935-937
precisely	O	938-947
defined	O	948-955
by	O	956-958
multipoint	O	959-969
mapping	O	970-977
.	O	977-978

Study	O	979-984
of	O	985-987
recombination	O	988-1001
events	O	1002-1008
indicated	O	1009-1018
that	O	1019-1023
AIH1	O	1024-1028
lies	O	1029-1033
in	O	1034-1036
the	O	1037-1040
interval	O	1041-1049
between	O	1050-1057
DXS143	O	1058-1064
and	O	1065-1068
DXS85	O	1069-1074
.	O	1074-1075

There	O	1076-1081
was	O	1082-1085
significant	O	1086-1097
evidence	O	1098-1106
against	O	1107-1114
linkage	O	1115-1122
to	O	1123-1125
this	O	1126-1130
region	O	1131-1137
in	O	1138-1140
the	O	1141-1144
third	O	1145-1150
family	O	1151-1157
,	O	1157-1158
indicating	O	1159-1169
locus	O	1170-1175
heterogeneity	O	1176-1189
in	O	1190-1192
XAI	B	1193-1196
.	O	1196-1197

Further	O	1198-1205
analysis	O	1206-1214
with	O	1215-1219
markers	O	1220-1227
on	O	1228-1230
the	O	1231-1234
long	O	1235-1239
arm	O	1240-1243
of	O	1244-1246
the	O	1247-1250
X	O	1251-1252
chromosome	O	1253-1263
showed	O	1264-1270
evidence	O	1271-1279
of	O	1280-1282
linkage	O	1283-1290
to	O	1291-1293
DXS144E	O	1294-1301
and	O	1302-1305
F9	O	1306-1308
with	O	1309-1313
no	O	1314-1316
recombination	O	1317-1330
with	O	1331-1335
either	O	1336-1342
of	O	1343-1345
these	O	1346-1351
markers	O	1352-1359
.	O	1359-1360

Two	O	1361-1364
-	O	1364-1365
point	O	1365-1370
analysis	O	1371-1379
gave	O	1380-1384
a	O	1385-1386
peak	O	1387-1391
lod	O	1392-1395
score	O	1396-1401
at	O	1402-1404
DXS144E	O	1405-1412
with	O	1413-1417
a	O	1418-1419
maximum	O	1420-1427
lod	O	1428-1431
score	O	1432-1437
of	O	1438-1440
2	O	1441-1442
.	O	1442-1443
83	O	1444-1446
at	O	1447-1449
theta	O	1450-1455
=	O	1456-1457
0	O	1458-1459
,	O	1459-1460
with	O	1461-1465
a	O	1466-1467
peak	O	1468-1472
lod	O	1473-1476
score	O	1477-1482
in	O	1483-1485
multipoint	O	1486-1496
linkage	O	1497-1504
analysis	O	1505-1513
of	O	1514-1516
2	O	1517-1518
.	O	1518-1519
84	O	1520-1522
at	O	1523-1525
theta	O	1526-1531
=	O	1532-1533
0	O	1534-1535
.	O	1535-1536

The	O	1537-1540
support	O	1541-1548
interval	O	1549-1557
extended	O	1558-1566
9	O	1567-1568
cM	O	1569-1571
proximal	O	1572-1580
to	O	1581-1583
DXS144E	O	1584-1591
and	O	1592-1595
14	O	1596-1598
cM	O	1599-1601
distal	O	1602-1608
to	O	1609-1611
F9	O	1612-1614
.	O	1614-1615
(	O	1616-1617
ABSTRACT	O	1617-1625
TRUNCATED	O	1626-1635
AT	O	1636-1638
250	O	1639-1642
WORDS	O	1643-1648
)	O	1648-1649
.	O	1649-1650

Anonymous	O	0-9
marker	O	10-16
loci	O	17-21
within	O	22-28
400	O	29-32
kb	O	33-35
of	O	36-38
HLA	O	39-42
-	O	42-43
A	O	41-42
generate	O	45-53
haplotypes	O	54-64
in	O	65-67
linkage	O	68-75
disequilibrium	O	76-90
with	O	91-95
the	O	96-99
hemochromatosis	B	100-115
gene	O	116-120
(	O	121-122
HFE	O	122-125
)	O	125-126
The	O	127-130
hemochromatosis	B	131-146
gene	O	147-151
(	O	152-153
HFE	O	153-156
)	O	156-157
maps	O	158-162
to	O	163-165
6p21	O	166-170
.	O	170-171
3	O	172-173
and	O	174-177
is	O	178-180
less	O	181-185
than	O	186-190
1	O	191-192
cM	O	193-195
from	O	196-200
the	O	201-204
HLA	O	205-208
class	O	209-214
I	O	215-216
genes	O	217-222
;	O	222-223
however	O	224-231
,	O	231-232
the	O	233-236
precise	O	237-244
physical	O	245-253
location	O	254-262
of	O	263-265
the	O	266-269
gene	O	270-274
has	O	275-278
remained	O	279-287
elusive	O	288-295
and	O	296-299
controversial	O	300-313
.	O	313-314

The	O	315-318
unambiguous	O	319-330
identification	O	331-345
of	O	346-348
a	O	349-350
crossover	O	351-360
event	O	361-366
within	O	367-373
hemochromatosis	B	374-389
families	O	390-398
is	O	399-401
very	O	402-406
difficult	O	407-416
;	O	416-417
it	O	418-420
is	O	421-423
particularly	O	424-436
hampered	O	437-445
by	O	446-448
the	O	449-452
variability	O	453-464
of	O	465-467
the	O	468-471
phenotypic	O	472-482
expression	O	483-493
as	O	494-496
well	O	497-501
as	O	502-504
by	O	505-507
the	O	508-511
sex	O	512-515
-	O	515-516
and	O	517-520
age	O	521-524
-	O	524-525
related	O	525-532
penetrance	O	533-543
of	O	544-546
the	O	547-550
disease	O	551-558
.	O	558-559

For	O	560-563
these	O	564-569
practical	O	570-579
considerations	O	580-594
,	O	594-595
traditional	O	596-607
linkage	O	608-615
analysis	O	616-624
could	O	625-630
prove	O	631-636
of	O	637-639
limited	O	640-647
value	O	648-653
in	O	654-656
further	O	657-664
refining	O	665-673
the	O	674-677
extrapolated	O	678-690
physical	O	691-699
position	O	700-708
of	O	709-711
HFE	O	712-715
.	O	715-716

We	O	717-719
therefore	O	720-729
embarked	O	730-738
upon	O	739-743
a	O	744-745
linkage	O	746-753
-	O	753-754
disequilibrium	O	754-768
analysis	O	769-777
of	O	778-780
HFE	O	781-784
and	O	785-788
normal	O	789-795
chromosomes	O	796-807
from	O	808-812
the	O	813-816
Brittany	O	817-825
population	O	826-836
.	O	836-837

In	O	838-840
the	O	841-844
present	O	845-852
report	O	853-859
,	O	859-860
66	O	861-863
hemochromatosis	B	864-879
families	O	880-888
yielding	O	889-897
151	O	898-901
hemochromatosis	B	902-917
chromosomes	O	918-929
and	O	930-933
182	O	934-937
normal	O	938-944
chromosomes	O	945-956
were	O	957-961
RFLP	O	962-966
-	O	966-967
typed	O	967-972
with	O	973-977
a	O	978-979
battery	O	980-987
of	O	988-990
probes	O	991-997
,	O	997-998
including	O	999-1008
two	O	1009-1012
newly	O	1013-1018
derived	O	1019-1026
polymorphic	O	1027-1038
markers	O	1039-1046
from	O	1047-1051
the	O	1052-1055
6	O	1056-1057
.	O	1057-1058
7	O	1059-1060
and	O	1061-1064
HLA	O	1065-1068
-	O	1068-1069
F	O	1069-1070
loci	O	1071-1075
located	O	1076-1083
150	O	1084-1087
and	O	1088-1091
250	O	1092-1095
kb	O	1096-1098
telomeric	O	1099-1108
to	O	1109-1111
HLA	O	1112-1115
-	O	1115-1116
A	O	1114-1115
,	O	1117-1118
respectively	O	1119-1131
.	O	1131-1132

The	O	1133-1136
results	O	1137-1144
suggest	O	1145-1152
a	O	1153-1154
strong	O	1155-1161
peak	O	1162-1166
of	O	1167-1169
existing	O	1170-1178
linkage	O	1179-1186
disequilibrium	O	1187-1201
focused	O	1202-1209
within	O	1210-1216
the	O	1217-1220
i82	O	1221-1224
-	O	1224-1225
to	O	1225-1227
-	O	1224-1225
6	O	1228-1229
.	O	1229-1230

7	O	1231-1232
interval	O	1233-1241
(	O	1242-1243
approximately	O	1243-1256
250	O	1257-1260
kb	O	1261-1263
)	O	1263-1264
.	O	1264-1265

The	O	1266-1269
zone	O	1270-1274
of	O	1275-1277
linkage	O	1278-1285
disequilibrium	O	1286-1300
is	O	1301-1303
flanked	O	1304-1311
by	O	1312-1314
the	O	1315-1318
i97	O	1319-1322
locus	O	1323-1328
,	O	1328-1329
positioned	O	1330-1340
30	O	1341-1343
kb	O	1344-1346
proximal	O	1347-1355
to	O	1356-1358
i82	O	1359-1362
,	O	1362-1363
and	O	1364-1367
the	O	1368-1371
HLA	O	1372-1375
-	O	1375-1376
F	O	1376-1377
gene	O	1378-1382
,	O	1382-1383
found	O	1384-1389
250	O	1390-1393
kb	O	1394-1396
distal	O	1397-1403
to	O	1404-1406
HLA	O	1407-1410
-	O	1410-1411
A	O	1409-1410
,	O	1412-1413
markers	O	1414-1421
of	O	1422-1424
which	O	1425-1430
display	O	1431-1438
no	O	1439-1441
significant	O	1442-1453
association	O	1454-1465
with	O	1466-1470
HFE	O	1471-1474
.	O	1474-1475

These	O	1476-1481
data	O	1482-1486
support	O	1487-1494
the	O	1495-1498
possibility	O	1499-1510
that	O	1511-1515
HFE	O	1516-1519
resides	O	1520-1527
within	O	1528-1534
the	O	1535-1538
400	O	1539-1542
-	O	1542-1543
kb	O	1543-1545
expanse	O	1546-1553
of	O	1554-1556
DNA	O	1557-1560
between	O	1561-1568
i97	O	1569-1572
and	O	1573-1576
HLA	O	1577-1580
-	O	1580-1581
F	O	1581-1582
.	O	1582-1583

Alternatively	O	1584-1597
,	O	1597-1598
the	O	1599-1602
very	O	1603-1607
tight	O	1608-1613
association	O	1614-1625
of	O	1626-1628
HLA	O	1629-1632
-	O	1632-1633
A3	O	1633-1635
and	O	1636-1639
allele	O	1640-1646
1	O	1647-1648
of	O	1649-1651
the	O	1652-1655
6	O	1656-1657
.	O	1657-1658
7	O	1659-1660
locus	O	1661-1666
,	O	1666-1667
both	O	1668-1672
of	O	1673-1675
which	O	1676-1681
are	O	1682-1685
comprised	O	1686-1695
by	O	1696-1698
the	O	1699-1702
major	O	1703-1708
ancestral	O	1709-1718
or	O	1719-1721
founder	O	1722-1729
HFE	O	1730-1733
haplotype	O	1734-1743
in	O	1744-1746
Brittany	O	1747-1755
,	O	1755-1756
supports	O	1757-1765
the	O	1766-1769
possibility	O	1770-1781
that	O	1782-1786
the	O	1787-1790
disease	O	1791-1798
gene	O	1799-1803
may	O	1804-1807
reside	O	1808-1814
immediately	O	1815-1826
telomeric	O	1827-1836
to	O	1837-1839
the	O	1840-1843
6	O	1844-1845
.	O	1845-1846
7	O	1847-1848
locus	O	1849-1854
within	O	1855-1861
the	O	1862-1865
linkage	O	1866-1873
-	O	1873-1874
disequilibrium	O	1874-1888
zone	O	1889-1893
.	O	1893-1894

Additionally	O	1895-1907
,	O	1907-1908
hemochromatosis	B	1909-1924
haplotypes	O	1925-1935
possessing	O	1936-1946
HLA	O	1947-1950
-	O	1950-1951
A11	O	1951-1954
and	O	1955-1958
the	O	1959-1962
low	O	1963-1966
-	O	1966-1967
frequency	O	1967-1976
HLA	O	1977-1980
-	O	1980-1981
F	O	1981-1982
polymorphism	O	1983-1995
(	O	1996-1997
allele	O	1997-2003
2	O	2004-2005
)	O	2005-2006
are	O	2007-2010
supportive	O	2011-2021
of	O	2022-2024
a	O	2025-2026
separate	O	2027-2035
founder	O	2036-2043
chromosome	O	2044-2054
containing	O	2055-2065
a	O	2066-2067
second	O	2068-2074
,	O	2074-2075
independently	O	2076-2089
arising	O	2090-2097
mutant	O	2098-2104
allele	O	2105-2111
.	O	2111-2112

Overall	O	2113-2120
,	O	2120-2121
the	O	2122-2125
establishment	O	2126-2139
of	O	2140-2142
a	O	2143-2144
likely	O	2145-2151
"	O	2152-2153
hemochromatosis	B	2154-2169
critical	O	2170-2178
region	O	2179-2185
"	O	2186-2187
centromeric	O	2188-2199
boundary	O	2200-2208
and	O	2209-2212
the	O	2213-2216
identification	O	2217-2231
of	O	2232-2234
a	O	2235-2236
linkage	O	2237-2244
-	O	2244-2245
disequilibrium	O	2245-2259
zone	O	2260-2264
both	O	2265-2269
significantly	O	2270-2283
contribute	O	2284-2294
to	O	2295-2297
a	O	2298-2299
reduction	O	2300-2309
in	O	2310-2312
the	O	2313-2316
amount	O	2317-2323
of	O	2324-2326
DNA	O	2327-2330
required	O	2331-2339
to	O	2340-2342
be	O	2343-2345
searched	O	2346-2354
for	O	2355-2358
novel	O	2359-2364
coding	O	2365-2371
sequences	O	2372-2381
constituting	O	2382-2394
the	O	2395-2398
HFE	B	2399-2402
defect	I	2403-2409

Natural	O	0-7
selection	O	8-17
of	O	18-20
hemi	O	21-25
-	O	25-26
and	O	27-30
heterozygotes	O	31-44
for	O	45-48
G6PD	B	49-53
deficiency	I	54-64
in	O	65-67
Africa	O	68-74
by	O	75-77
resistance	O	78-88
to	O	89-91
severe	O	92-98
malaria	B	99-106
.	O	106-107

Glucose	B	108-115
-	I	115-116
6	I	116-117
-	I	115-116
phosphate	I	118-127
dehydrogenase	I	128-141
(	I	142-143
G6PD	I	143-147
)	I	147-148
deficiency	I	149-159
,	O	159-160
the	O	161-164
most	O	165-169
common	O	170-176
enzymopathy	B	177-188
of	O	189-191
humans	O	192-198
,	O	198-199
affects	O	200-207
over	O	208-212
400	O	213-216
million	O	217-224
people	O	225-231
.	O	231-232

The	O	233-236
geographical	O	237-249
correlation	O	250-261
of	O	262-264
its	O	265-268
distribution	O	269-281
with	O	282-286
the	O	287-290
historical	O	291-301
endemicity	O	302-312
of	O	313-315
malaria	B	316-323
suggests	O	324-332
that	O	333-337
this	O	338-342
disorder	O	343-351
has	O	352-355
risen	O	356-361
in	O	362-364
frequency	O	365-374
through	O	375-382
natural	O	383-390
selection	O	391-400
by	O	401-403
malaria	B	404-411
.	O	411-412

However	O	413-420
,	O	420-421
attempts	O	422-430
to	O	431-433
confirm	O	434-441
that	O	442-446
G6PD	B	447-451
deficiency	I	452-462
is	O	463-465
protective	O	466-476
in	O	477-479
case	O	480-484
-	O	484-485
control	O	485-492
studies	O	493-500
of	O	501-503
malaria	B	504-511
have	O	512-516
yielded	O	517-524
conflicting	O	525-536
results	O	537-544
.	O	544-545

Hence	O	546-551
,	O	551-552
for	O	553-556
this	O	557-561
X	B	562-563
-	I	563-564
linked	I	564-570
disorder	I	571-579
,	O	579-580
it	O	581-583
is	O	584-586
unclear	O	587-594
whether	O	595-602
both	O	603-607
male	O	608-612
hemizygotes	O	613-624
and	O	625-628
female	O	629-635
heterozygotes	O	636-649
are	O	650-653
protected	O	654-663
or	O	664-666
,	O	666-667
as	O	668-670
frequently	O	671-681
suggested	O	682-691
,	O	691-692
only	O	693-697
females	O	698-705
.	O	705-706

Furthermore	O	707-718
,	O	718-719
how	O	720-723
much	O	724-728
protection	O	729-739
may	O	740-743
be	O	744-746
afforded	O	747-755
is	O	756-758
unknown	O	759-766
.	O	766-767

Here	O	768-772
we	O	773-775
report	O	776-782
that	O	783-787
,	O	787-788
in	O	789-791
two	O	792-795
large	O	796-801
case	O	802-806
-	O	806-807
control	O	807-814
studies	O	815-822
of	O	823-825
over	O	826-830
2	O	831-832
,	O	832-833
000	O	834-837
African	O	838-845
children	O	846-854
,	O	854-855
the	O	856-859
common	O	860-866
African	O	867-874
form	O	875-879
of	O	880-882
G6PD	B	883-887
deficiency	I	888-898
(	O	899-900
G6PD	B	900-904
A	I	905-906
-	I	906-907
)	O	907-908
is	O	909-911
associated	O	912-922
with	O	923-927
a	O	928-929
46	O	930-932
-	O	932-933
58	O	933-935
%	O	935-936
reduction	O	937-946
in	O	947-949
risk	O	950-954
of	O	955-957
severe	O	958-964
malaria	B	965-972
for	O	973-976
both	O	977-981
female	O	982-988
heterozygotes	O	989-1002
and	O	1003-1006
male	O	1007-1011
hemizygotes	O	1012-1023
.	O	1023-1024

A	O	1025-1026
mathematical	O	1027-1039
model	O	1040-1045
incorporating	O	1046-1059
the	O	1060-1063
measured	O	1064-1072
selective	O	1073-1082
advantage	O	1083-1092
against	O	1093-1100
malaria	B	1101-1108
suggests	O	1109-1117
that	O	1118-1122
a	O	1123-1124
counterbalancing	O	1125-1141
selective	O	1142-1151
disadvantage	O	1152-1164
,	O	1164-1165
associated	O	1166-1176
with	O	1177-1181
this	O	1182-1186
enzyme	B	1187-1193
deficiency	I	1194-1204
,	O	1204-1205
has	O	1206-1209
retarded	O	1210-1218
its	O	1219-1222
rise	O	1223-1227
in	O	1228-1230
frequency	O	1231-1240
in	O	1241-1243
malaria	B	1244-1251
-	O	1251-1252
endemic	O	1252-1259
regions	O	1260-1267
.	O	1267-1268

Although	O	1269-1277
G6PD	B	1278-1282
deficiency	I	1283-1293
is	O	1294-1296
now	O	1297-1300
regarded	O	1301-1309
as	O	1310-1312
a	O	1313-1314
generally	O	1315-1324
benign	O	1325-1331
disorder	O	1332-1340
,	O	1340-1341
in	O	1342-1344
earlier	O	1345-1352
environmental	O	1353-1366
conditions	O	1367-1377
it	O	1378-1380
could	O	1381-1386
have	O	1387-1391
been	O	1392-1396
significantly	O	1397-1410
disadvantageous	O	1411-1426
.	O	1426-1427
.	O	1426-1427

Prader	B	0-6
-	I	6-7
Willi	I	7-12
syndrome	I	13-21
and	O	22-25
chromosome	O	26-36
15	O	37-39
.	O	39-40

A	O	41-42
clinical	O	43-51
discussion	O	52-62
of	O	63-65
20	O	66-68
cases	O	69-74
.	O	74-75

A	O	76-77
chromosome	B	78-88
15	I	89-91
anomaly	I	92-99
was	O	100-103
observed	O	104-112
in	O	113-115
12	O	116-118
of	O	119-121
20	O	122-124
patients	O	125-133
,	O	133-134
17	O	135-137
of	O	138-140
whom	O	141-145
were	O	146-150
clinically	O	151-161
suspected	O	162-171
of	O	172-174
having	O	175-181
Prader	B	182-188
-	I	188-189
Willi	I	189-194
syndrome	I	195-203
(	O	204-205
PWS	B	205-208
)	O	208-209
.	O	209-210

The	O	211-214
clinical	O	215-223
features	O	224-232
of	O	233-235
eight	O	236-241
cases	O	242-247
with	O	248-252
15q11	O	253-258
-	O	258-259
12	O	259-261
deletion	O	262-270
were	O	271-275
very	O	276-280
similar	O	281-288
to	O	289-291
those	O	292-297
originally	O	298-308
described	O	309-318
in	O	319-321
PWS	B	322-325
.	O	325-326

On	O	327-329
the	O	330-333
other	O	334-339
hand	O	340-344
,	O	344-345
the	O	346-349
group	O	350-355
of	O	356-358
normal	O	359-365
karyotype	O	366-375
patients	O	376-384
is	O	385-387
heterogeneous	O	388-401
,	O	401-402
and	O	403-406
their	O	407-412
features	O	413-421
do	O	422-424
not	O	425-428
strictly	O	429-437
correspond	O	438-448
to	O	449-451
the	O	452-455
clinical	O	456-464
definition	O	465-475
of	O	476-478
PWS	B	479-482
.	O	482-483

However	O	484-491
,	O	491-492
the	O	493-496
hypothesis	O	497-507
that	O	508-512
PWS	B	513-516
is	O	517-519
associated	O	520-530
with	O	531-535
deletion	O	536-544
of	O	545-547
15q11	O	548-553
-	O	553-554
12	O	554-556
can	O	557-560
neither	O	561-568
explain	O	569-576
the	O	577-580
apparently	O	581-591
balanced	O	592-600
translocations	O	601-615
of	O	616-618
chromosome	O	619-629
15	O	630-632
nor	O	633-636
account	O	637-644
for	O	645-648
the	O	649-652
small	O	653-658
supernumerary	O	659-672
metacentric	O	673-684
chromosomes	O	685-696
corresponding	O	697-710
to	O	711-713
an	O	714-716
isochromosome	O	717-730
15	O	731-733
for	O	734-737
band	O	738-742
15q11	O	743-748
observed	O	749-757
in	O	758-760
some	O	761-765
cases	O	766-771
.	O	771-772
.	O	771-772

Molecular	O	0-9
basis	O	10-15
of	O	16-18
phenylketonuria	B	19-34
and	O	35-38
related	O	39-46
hyperphenylalaninemias	B	47-69
:	O	69-70
mutations	O	71-80
and	O	81-84
polymorphisms	O	85-98
in	O	99-101
the	O	102-105
human	O	106-111
phenylalanine	O	112-125
hydroxylase	O	126-137
gene	O	138-142
.	O	142-143

Mutations	O	144-153
in	O	154-156
the	O	157-160
human	O	161-166
phenylalanine	O	167-180
hydroxylase	O	181-192
gene	O	193-197
producing	O	198-207
phenylketonuria	B	208-223
or	O	224-226
hyperphenylalaninemia	B	227-248
have	O	249-253
now	O	254-257
been	O	258-262
identified	O	263-273
in	O	274-276
many	O	277-281
patients	O	282-290
from	O	291-295
various	O	296-303
ethnic	O	304-310
groups	O	311-317
.	O	317-318

These	O	319-324
mutations	O	325-334
all	O	335-338
exhibit	O	339-346
a	O	347-348
high	O	349-353
degree	O	354-360
of	O	361-363
association	O	364-375
with	O	376-380
specific	O	381-389
restriction	O	390-401
fragment	O	402-410
-	O	410-411
length	O	411-417
polymorphism	O	418-430
haplotypes	O	431-441
at	O	442-444
the	O	445-448
PAH	O	449-452
locus	O	453-458
.	O	458-459

About	O	460-465
50	O	466-468
of	O	469-471
these	O	472-477
mutations	O	478-487
are	O	488-491
single	O	492-498
-	O	498-499
base	O	499-503
substitutions	O	504-517
,	O	517-518
including	O	519-528
six	O	529-532
nonsense	O	533-541
mutations	O	542-551
and	O	552-555
eight	O	556-561
splicing	O	562-570
mutations	O	571-580
,	O	580-581
with	O	582-586
the	O	587-590
remainder	O	591-600
being	O	601-606
missense	O	607-615
mutations	O	616-625
.	O	625-626

One	O	627-630
splicing	O	631-639
mutation	O	640-648
results	O	649-656
in	O	657-659
a	O	660-661
3	O	662-663
amino	O	664-669
acid	O	670-674
in	O	675-677
-	O	677-678
frame	O	678-683
insertion	O	684-693
.	O	693-694

Two	O	695-698
or	O	699-701
3	O	702-703
large	O	704-709
deletions	O	710-719
,	O	719-720
2	O	721-722
single	O	723-729
codon	O	730-735
deletions	O	736-745
,	O	745-746
and	O	747-750
2	O	751-752
single	O	753-759
base	O	760-764
deletions	O	765-774
have	O	775-779
been	O	780-784
found	O	785-790
.	O	790-791

Twelve	O	792-798
of	O	799-801
the	O	802-805
missense	O	806-814
mutations	O	815-824
apparently	O	825-835
result	O	836-842
from	O	843-847
the	O	848-851
methylation	O	852-863
and	O	864-867
subsequent	O	868-878
deamination	O	879-890
of	O	891-893
highly	O	894-900
mutagenic	O	901-910
CpG	O	911-914
dinucleotides	O	915-928
.	O	928-929

Recurrent	O	930-939
mutation	O	940-948
has	O	949-952
been	O	953-957
observed	O	958-966
at	O	967-969
several	O	970-977
of	O	978-980
these	O	981-986
sites	O	987-992
,	O	992-993
producing	O	994-1003
associations	O	1004-1016
with	O	1017-1021
different	O	1022-1031
haplotypes	O	1032-1042
in	O	1043-1045
different	O	1046-1055
populations	O	1056-1067
.	O	1067-1068

About	O	1069-1074
half	O	1075-1079
of	O	1080-1082
all	O	1083-1086
missense	O	1087-1095
mutations	O	1096-1105
have	O	1106-1110
been	O	1111-1115
examined	O	1116-1124
by	O	1125-1127
in	O	1128-1130
vitro	O	1131-1136
expression	O	1137-1147
analysis	O	1148-1156
,	O	1156-1157
and	O	1158-1161
a	O	1162-1163
significant	O	1164-1175
correlation	O	1176-1187
has	O	1188-1191
been	O	1192-1196
observed	O	1197-1205
between	O	1206-1213
residual	O	1214-1222
PAH	O	1223-1226
activity	O	1227-1235
and	O	1236-1239
disease	O	1240-1247
phenotype	O	1248-1257
.	O	1257-1258

Since	O	1259-1264
continuing	O	1265-1275
advances	O	1276-1284
in	O	1285-1287
molecular	O	1288-1297
methodologies	O	1298-1311
have	O	1312-1316
dramatically	O	1317-1329
accelerated	O	1330-1341
the	O	1342-1345
rate	O	1346-1350
in	O	1351-1353
which	O	1354-1359
new	O	1360-1363
mutations	O	1364-1373
are	O	1374-1377
being	O	1378-1383
identified	O	1384-1394
and	O	1395-1398
characterized	O	1399-1412
,	O	1412-1413
this	O	1414-1418
register	O	1419-1427
of	O	1428-1430
mutations	O	1431-1440
will	O	1441-1445
be	O	1446-1448
updated	O	1449-1456
periodically	O	1457-1469
.	O	1469-1470
.	O	1469-1470

The	O	0-3
intron	O	4-10
7	O	11-12
donor	O	13-18
splice	O	19-25
site	O	26-30
transition	O	31-41
:	O	41-42
a	O	43-44
second	O	45-51
Tay	B	52-55
-	I	55-56
Sachs	I	56-61
disease	I	62-69
mutation	O	70-78
in	O	79-81
French	O	82-88
Canada	O	89-95
.	O	95-96

Mutations	O	97-106
at	O	107-109
the	O	110-113
hexosaminidase	O	114-128
A	O	129-130
(	O	131-132
HEXA	O	132-136
)	O	136-137
gene	O	138-142
which	O	143-148
cause	O	149-154
Tay	B	155-158
-	I	158-159
Sachs	I	159-164
disease	I	165-172
(	O	173-174
TSD	B	174-177
)	O	177-178
have	O	179-183
elevated	O	184-192
frequency	O	193-202
in	O	203-205
the	O	206-209
Ashkenazi	O	210-219
Jewish	O	220-226
and	O	227-230
French	O	231-237
-	O	237-238
Canadian	O	238-246
populations	O	247-258
.	O	258-259

We	O	260-262
report	O	263-269
a	O	270-271
novel	O	272-277
TSD	B	278-281
allele	O	282-288
in	O	289-291
the	O	292-295
French	O	296-302
-	O	302-303
Canadian	O	303-311
population	O	312-322
associated	O	323-333
with	O	334-338
the	O	339-342
infantile	O	343-352
form	O	353-357
of	O	358-360
the	O	361-364
disease	O	365-372
.	O	372-373

The	O	374-377
mutation	O	378-386
,	O	386-387
a	O	388-389
G	O	390-391
-	O	391-392
-	O	391-392
>	O	394-395
A	O	396-397
transition	O	398-408
at	O	409-411
the	O	412-415
+	O	416-417
1	O	418-419
position	O	420-428
of	O	429-431
intron	O	432-438
7	O	439-440
,	O	440-441
abolishes	O	442-451
the	O	452-455
donor	O	456-461
splice	O	462-468
site	O	469-473
.	O	473-474

Cultured	O	475-483
human	O	484-489
fibroblasts	O	490-501
from	O	502-506
a	O	507-508
compound	O	509-517
heterozygote	O	518-530
for	O	531-534
this	O	535-539
transition	O	540-550
(	O	551-552
and	O	552-555
for	O	556-559
a	O	560-561
deletion	O	562-570
mutation	O	571-579
)	O	579-580
produce	O	581-588
no	O	589-591
detectable	O	592-602
HEXA	O	603-607
mRNA	O	608-612
.	O	612-613

The	O	614-617
intron	O	618-624
7	O	625-626
+	O	627-628
1	O	629-630
mutation	O	631-639
occurs	O	640-646
in	O	647-649
the	O	650-653
base	O	654-658
adjacent	O	659-667
to	O	668-670
the	O	671-674
site	O	675-679
of	O	680-682
the	O	683-686
adult	O	687-692
-	O	692-693
onset	O	693-698
TSD	B	699-702
mutation	O	703-711
(	O	712-713
G805A	O	713-718
)	O	718-719
.	O	719-720

In	O	721-723
both	O	724-728
mutations	O	729-738
a	O	739-740
restriction	O	741-752
site	O	753-757
for	O	758-761
the	O	762-765
endonuclease	O	766-778
EcoRII	O	779-785
is	O	786-788
abolished	O	789-798
.	O	798-799

Unambiguous	O	800-811
diagnosis	O	812-821
,	O	821-822
therefore	O	823-832
,	O	832-833
requires	O	834-842
allele	O	843-849
-	O	849-850
specific	O	850-858
oligonucleotide	O	859-874
hybridization	O	875-888
to	O	889-891
distinguish	O	892-903
between	O	904-911
these	O	912-917
two	O	918-921
mutant	O	922-928
alleles	O	929-936
.	O	936-937

The	O	938-941
intron	O	942-948
7	O	949-950
+	O	951-952
1	O	953-954
mutation	O	955-963
has	O	964-967
been	O	968-972
detected	O	973-981
in	O	982-984
three	O	985-990
unrelated	O	991-1000
families	O	1001-1009
.	O	1009-1010

Obligate	O	1011-1019
heterozygotes	O	1020-1033
for	O	1034-1037
the	O	1038-1041
intron	O	1042-1048
7	O	1049-1050
+	O	1051-1052
1	O	1053-1054
mutation	O	1055-1063
were	O	1064-1068
born	O	1069-1073
in	O	1074-1076
the	O	1077-1080
Saguenay	O	1081-1089
-	O	1089-1090
Lac	O	1090-1093
-	O	1089-1090
St	O	1094-1096
-	O	1089-1090
Jean	O	1097-1101
region	O	1102-1108
of	O	1109-1111
Quebec	O	1112-1118
.	O	1118-1119

The	O	1120-1123
most	O	1124-1128
recent	O	1129-1135
ancestors	O	1136-1145
common	O	1146-1152
to	O	1153-1155
obligate	O	1156-1164
carriers	O	1165-1173
of	O	1174-1176
this	O	1177-1181
mutation	O	1182-1190
were	O	1191-1195
from	O	1196-1200
the	O	1201-1204
Charlevoix	O	1205-1215
region	O	1216-1222
of	O	1223-1225
the	O	1226-1229
province	O	1230-1238
of	O	1239-1241
Quebec	O	1242-1248
.	O	1248-1249

This	O	1250-1254
mutation	O	1255-1263
thus	O	1264-1268
has	O	1269-1272
a	O	1273-1274
different	O	1275-1284
geographic	O	1285-1295
centre	O	1296-1302
of	O	1303-1305
diffusion	O	1306-1315
and	O	1316-1319
is	O	1320-1322
probably	O	1323-1331
less	O	1332-1336
common	O	1337-1343
than	O	1344-1348
the	O	1349-1352
exon	O	1353-1357
1	O	1358-1359
deletion	O	1360-1368
TSD	B	1369-1372
mutation	O	1373-1381
in	O	1382-1384
French	O	1385-1391
Canadians	O	1392-1401
.	O	1401-1402

Neither	O	1403-1410
mutation	O	1411-1419
has	O	1420-1423
been	O	1424-1428
detected	O	1429-1437
in	O	1438-1440
France	O	1441-1447
,	O	1447-1448
the	O	1449-1452
ancestral	O	1453-1462
homeland	O	1463-1471
of	O	1472-1474
French	O	1475-1481
Canada	O	1482-1488
.	O	1488-1489
.	O	1488-1489

Recessively	O	0-11
inherited	O	12-21
multiple	B	22-30
epiphyseal	I	31-41
dysplasia	I	42-51
with	O	52-56
normal	O	57-63
stature	O	64-71
,	O	71-72
club	B	73-77
foot	I	78-82
,	O	82-83
and	O	84-87
double	B	88-94
layered	I	95-102
patella	I	103-110
caused	O	111-117
by	O	118-120
a	O	121-122
DTDST	O	123-128
mutation	O	129-137
.	O	137-138

We	O	139-141
have	O	142-146
observed	O	147-155
over	O	156-160
25	O	161-163
different	O	164-173
mutations	O	174-183
in	O	184-186
the	O	187-190
diastrophic	B	191-202
dysplasia	I	203-212
sulphate	O	213-221
transporter	O	222-233
gene	O	234-238
(	O	239-240
DTDST	O	240-245
)	O	245-246
in	O	247-249
association	O	250-261
with	O	262-266
the	O	267-270
recessive	B	271-280
disorders	I	281-290
achondrogenesis	B	291-306
1B	I	307-309
,	O	309-310
atelosteogenesis	B	311-327
2	I	328-329
,	O	329-330
and	O	331-334
diastrophic	B	335-346
dysplasia	I	347-356
.	O	356-357

The	O	358-361
c862t	O	362-367
(	O	368-369
R279W	O	369-374
)	O	374-375
transition	O	376-386
is	O	387-389
the	O	390-393
most	O	394-398
common	O	399-405
mutation	O	406-414
in	O	415-417
non	O	418-421
-	O	421-422
Finnish	O	422-429
patients	O	430-438
,	O	438-439
but	O	440-443
in	O	444-446
these	O	447-452
disorders	O	453-462
it	O	463-465
is	O	466-468
usually	O	469-476
combined	O	477-485
with	O	486-490
other	O	491-496
DTDST	O	497-502
mutations	O	503-512
.	O	512-513

We	O	514-516
had	O	517-520
not	O	521-524
seen	O	525-529
a	O	530-531
case	O	532-536
of	O	537-539
homozygosity	O	540-552
for	O	553-556
c862t	O	557-562
(	O	563-564
R279W	O	564-569
)	O	569-570
until	O	571-576
we	O	577-579
analysed	O	580-588
DNA	O	589-592
from	O	593-597
a	O	598-599
36	O	600-602
year	O	603-607
old	O	608-611
male	O	612-616
with	O	617-621
tall	O	622-626
-	O	626-627
normal	O	627-633
stature	O	634-641
(	O	642-643
180	O	643-646
cm	O	647-649
)	O	649-650
who	O	651-654
asked	O	655-660
for	O	661-664
genetic	O	665-672
counselling	O	673-684
for	O	685-688
suspected	O	689-698
multiple	B	699-707
epiphyseal	I	708-718
dysplasia	I	719-728
.	O	728-729

He	O	730-732
was	O	733-736
treated	O	737-744
for	O	745-748
club	B	749-753
foot	I	754-758
and	O	759-762
hip	B	763-766
dysplasia	I	767-776
at	O	777-779
birth	O	780-785
.	O	785-786

Skeletal	O	787-795
changes	O	796-803
consistent	O	804-814
with	O	815-819
multiple	B	820-828
epiphyseal	I	829-839
dysplasia	I	840-849
,	O	849-850
with	O	851-855
the	O	856-859
peculiar	O	860-868
finding	O	869-876
of	O	877-879
a	O	880-881
double	B	882-888
layered	I	889-896
patella	I	897-904
,	O	904-905
were	O	906-910
recognised	O	911-921
during	O	922-928
childhood	O	929-938
.	O	938-939

Cleft	B	940-945
palate	I	946-952
,	O	952-953
swelling	B	954-962
of	I	963-965
the	I	966-969
ear	I	970-973
pinna	I	974-979
,	O	979-980
and	O	981-984
hitch	B	985-990
hiker	I	991-996
thumb	I	997-1002
were	O	1003-1007
absent	O	1008-1014
.	O	1014-1015

He	O	1016-1018
was	O	1019-1022
found	O	1023-1028
to	O	1029-1031
be	O	1032-1034
homozygous	O	1035-1045
,	O	1045-1046
and	O	1047-1050
both	O	1051-1055
healthy	O	1056-1063
parents	O	1064-1071
heterozygous	O	1072-1084
,	O	1084-1085
for	O	1086-1089
the	O	1090-1093
R279W	O	1094-1099
mutation	O	1100-1108
in	O	1109-1111
DTDST	O	1112-1117
,	O	1117-1118
and	O	1119-1122
his	O	1123-1126
fibroblasts	O	1127-1138
showed	O	1139-1145
a	O	1146-1147
sulphate	O	1148-1156
incorporation	O	1157-1170
defect	O	1171-1177
typical	O	1178-1185
of	O	1186-1188
DTDST	B	1189-1194
disorders	I	1195-1204
.	O	1204-1205

Counselling	O	1206-1217
was	O	1218-1221
given	O	1222-1227
for	O	1228-1231
a	O	1232-1233
recessive	B	1234-1243
disorder	I	1244-1252
,	O	1252-1253
thereby	O	1254-1261
considerably	O	1262-1274
reducing	O	1275-1283
the	O	1284-1287
probability	O	1288-1299
of	O	1300-1302
affected	O	1303-1311
offspring	O	1312-1321
.	O	1321-1322

Multiple	B	1323-1331
epiphyseal	I	1332-1342
dysplasia	I	1343-1352
is	O	1353-1355
more	O	1356-1360
frequently	O	1361-1371
caused	O	1372-1378
by	O	1379-1381
dominant	O	1382-1390
mutations	O	1391-1400
in	O	1401-1403
the	O	1404-1407
COMP	O	1408-1412
(	O	1413-1414
EDM1	B	1414-1418
,	O	1418-1419
McKusick	O	1420-1428
132400	O	1429-1435
)	O	1435-1436
and	O	1437-1440
COL9A2	O	1441-1447
genes	O	1448-1453
(	O	1454-1455
EDM2	B	1455-1459
,	O	1459-1460
McKusick	O	1461-1469
600204	O	1470-1476
)	O	1476-1477
.	O	1477-1478

A	O	1479-1480
few	O	1481-1484
other	O	1485-1490
patients	O	1491-1499
and	O	1500-1503
families	O	1504-1512
with	O	1513-1517
features	O	1518-1526
similar	O	1527-1534
to	O	1535-1537
our	O	1538-1541
proband	O	1542-1549
have	O	1550-1554
been	O	1555-1559
described	O	1560-1569
previously	O	1570-1580
and	O	1581-1584
considered	O	1585-1595
to	O	1596-1598
have	O	1599-1603
autosomal	O	1604-1613
recessive	O	1614-1623
MED	B	1624-1627
(	O	1628-1629
EDM4	B	1629-1633
,	O	1633-1634
McKusick	O	1635-1643
226900	O	1644-1650
)	O	1650-1651
.	O	1651-1652

This	O	1653-1657
observation	O	1658-1669
confirms	O	1670-1678
the	O	1679-1682
existence	O	1683-1692
of	O	1693-1695
this	O	1696-1700
entity	O	1701-1707
and	O	1708-1711
assigns	O	1712-1719
it	O	1720-1722
to	O	1723-1725
the	O	1726-1729
phenotypic	O	1730-1740
spectrum	O	1741-1749
associated	O	1750-1760
with	O	1761-1765
mutations	O	1766-1775
at	O	1776-1778
the	O	1779-1782
DTDST	O	1783-1788
locus	O	1789-1794
.	O	1794-1795
.	O	1794-1795

Myotonic	B	0-8
dystrophy	I	9-18
:	O	18-19
size	O	20-24
-	O	24-25
and	O	26-29
sex	O	30-33
-	O	33-34
dependent	O	34-43
dynamics	O	44-52
of	O	53-55
CTG	O	56-59
meiotic	O	60-67
instability	O	68-79
,	O	79-80
and	O	81-84
somatic	O	85-92
mosaicism	O	93-102
.	O	102-103

Myotonic	B	104-112
dystrophy	I	113-122
(	O	123-124
DM	B	124-126
)	O	126-127
is	O	128-130
a	O	131-132
progressive	O	133-144
neuromuscular	B	145-158
disorder	I	159-167
which	O	168-173
results	O	174-181
from	O	182-186
elongations	O	187-198
of	O	199-201
an	O	202-204
unstable	O	205-213
(	O	214-215
CTG	O	215-218
)	O	218-219
n	O	220-221
repeat	O	222-228
,	O	228-229
located	O	230-237
in	O	238-240
the	O	241-244
3	O	245-246
untranslated	O	247-259
region	O	260-266
of	O	267-269
the	O	270-273
DM	B	274-276
gene	O	277-281
.	O	281-282

A	O	283-284
correlation	O	285-296
has	O	297-300
been	O	301-305
demonstrated	O	306-318
between	O	319-326
the	O	327-330
increase	O	331-339
in	O	340-342
the	O	343-346
repeat	O	347-353
number	O	354-360
of	O	361-363
this	O	364-368
sequence	O	369-377
and	O	378-381
the	O	382-385
severity	O	386-394
of	O	395-397
the	O	398-401
disease	O	402-409
.	O	409-410

However	O	411-418
,	O	418-419
the	O	420-423
clinical	O	424-432
status	O	433-439
of	O	440-442
patients	O	443-451
cannot	O	452-458
be	O	459-461
unambiguously	O	462-475
ascertained	O	476-487
solely	O	488-494
on	O	495-497
the	O	498-501
basis	O	502-507
of	O	508-510
the	O	511-514
number	O	515-521
of	O	522-524
CTG	O	525-528
repeats	O	529-536
.	O	536-537

Moreover	O	538-546
,	O	546-547
the	O	548-551
exclusive	O	552-561
maternal	O	562-570
inheritance	O	571-582
of	O	583-585
the	O	586-589
congenital	O	590-600
form	O	601-605
remains	O	606-613
unexplained	O	614-625
.	O	625-626

Our	O	627-630
observation	O	631-642
of	O	643-645
differently	O	646-657
sized	O	658-663
repeats	O	664-671
in	O	672-674
various	O	675-682
DM	B	683-685
tissues	O	686-693
from	O	694-698
the	O	699-702
same	O	703-707
individual	O	708-718
may	O	719-722
explain	O	723-730
why	O	731-734
the	O	735-738
size	O	739-743
of	O	744-746
the	O	747-750
mutation	O	751-759
observed	O	760-768
in	O	769-771
lymphocytes	O	772-783
does	O	784-788
not	O	789-792
necessarily	O	793-804
correlate	O	805-814
with	O	815-819
the	O	820-823
severity	O	824-832
and	O	833-836
nature	O	837-843
of	O	844-846
symptoms	O	847-855
.	O	855-856

Through	O	857-864
a	O	865-866
molecular	O	867-876
and	O	877-880
genetic	O	881-888
study	O	889-894
of	O	895-897
142	O	898-901
families	O	902-910
including	O	911-920
418	O	921-924
DM	B	925-927
patients	O	928-936
,	O	936-937
we	O	938-940
have	O	941-945
investigated	O	946-958
the	O	959-962
dynamics	O	963-971
of	O	972-974
the	O	975-978
CTG	O	979-982
repeat	O	983-989
meiotic	O	990-997
instability	O	998-1009
.	O	1009-1010

A	O	1011-1012
positive	O	1013-1021
correlation	O	1022-1033
between	O	1034-1041
the	O	1042-1045
size	O	1046-1050
of	O	1051-1053
the	O	1054-1057
repeat	O	1058-1064
and	O	1065-1068
the	O	1069-1072
intergenerational	O	1073-1090
enlargement	O	1091-1102
was	O	1103-1106
observed	O	1107-1115
similarly	O	1116-1125
through	O	1126-1133
male	O	1134-1138
and	O	1139-1142
female	O	1143-1149
meioses	O	1150-1157
for	O	1158-1161
<	O	1162-1163
or	O	1164-1166
=	O	1167-1168
0	O	1169-1170
.	O	1170-1171
5	O	1172-1173
-	O	1173-1174
kb	O	1174-1176
CTG	O	1177-1180
sequences	O	1181-1190
.	O	1190-1191

Beyond	O	1192-1198
0	O	1199-1200
.	O	1200-1201
5	O	1202-1203
kb	O	1204-1206
,	O	1206-1207
the	O	1208-1211
intergenerational	O	1212-1229
variation	O	1230-1239
was	O	1240-1243
more	O	1244-1248
important	O	1249-1258
through	O	1259-1266
female	O	1267-1273
meioses	O	1274-1281
,	O	1281-1282
whereas	O	1283-1290
a	O	1291-1292
tendency	O	1293-1301
to	O	1302-1304
compression	O	1305-1316
was	O	1317-1320
observed	O	1321-1329
almost	O	1330-1336
exclusively	O	1337-1348
in	O	1349-1351
male	O	1352-1356
meioses	O	1357-1364
,	O	1364-1365
for	O	1366-1369
>	O	1370-1371
or	O	1372-1374
=	O	1375-1376
1	O	1377-1378
.	O	1378-1379

5	O	1380-1381
-	O	1381-1382
kb	O	1382-1384
fragments	O	1385-1394
.	O	1394-1395

This	O	1396-1400
implies	O	1401-1408
a	O	1409-1410
size	O	1411-1415
-	O	1415-1416
and	O	1417-1420
sex	O	1421-1424
-	O	1424-1425
dependent	O	1425-1434
meiotic	O	1435-1442
instability	O	1443-1454
.	O	1454-1455

Moreover	O	1456-1464
,	O	1464-1465
segregation	O	1466-1477
analysis	O	1478-1486
supports	O	1487-1495
the	O	1496-1499
hypothesis	O	1500-1510
of	O	1511-1513
a	O	1514-1515
maternal	O	1516-1524
as	O	1525-1527
well	O	1528-1532
as	O	1533-1535
a	O	1536-1537
familial	O	1538-1546
predisposition	O	1547-1561
for	O	1562-1565
the	O	1566-1569
occurrence	O	1570-1580
of	O	1581-1583
the	O	1584-1587
congenital	O	1588-1598
form	O	1599-1603
.	O	1603-1604

Finally	O	1605-1612
,	O	1612-1613
this	O	1614-1618
analysis	O	1619-1627
reveals	O	1628-1635
a	O	1636-1637
significant	O	1638-1649
excess	O	1650-1656
of	O	1657-1659
transmitting	O	1660-1672
grandfathers	O	1673-1685
partially	O	1686-1695
accounted	O	1696-1705
for	O	1706-1709
by	O	1710-1712
increased	O	1713-1722
fertility	O	1723-1732
in	O	1733-1735
affected	O	1736-1744
males	O	1745-1750

Fatal	O	0-5
pyoderma	B	6-14
gangrenosum	I	15-26
in	O	27-29
association	O	30-41
with	O	42-46
C7	B	47-49
deficiency	I	50-60
.	O	60-61

Although	O	62-70
pyoderma	B	71-79
gangrenosum	I	80-91
(	O	92-93
PG	B	93-95
)	O	95-96
is	O	97-99
often	O	100-105
associated	O	106-116
with	O	117-121
systemic	B	122-130
diseases	I	131-139
,	O	139-140
it	O	141-143
has	O	144-147
not	O	148-151
been	O	152-156
reported	O	157-165
in	O	166-168
association	O	169-180
with	O	181-185
congenital	B	186-196
complement	I	197-207
deficiencies	I	208-220
.	O	220-221

We	O	222-224
describe	O	225-233
an	O	234-236
aggressive	O	237-247
and	O	248-251
ultimately	O	252-262
fatal	O	263-268
case	O	269-273
of	O	274-276
PG	B	277-279
in	O	280-282
a	O	283-284
patient	O	285-292
with	O	293-297
a	O	298-299
congenital	O	300-310
C7	B	311-313
deficiency	I	314-324
.	O	324-325

Deficiencies	B	326-338
of	I	339-341
C7	I	342-344
can	O	345-348
be	O	349-351
associated	O	352-362
with	O	363-367
decreased	O	368-377
neutrophil	O	378-388
chemotaxis	O	389-399
,	O	399-400
phagocytosis	O	401-413
,	O	413-414
and	O	415-418
opsonization	O	419-431
,	O	431-432
similar	O	433-440
to	O	441-443
the	O	444-447
immunologic	B	448-459
abnormalities	I	460-473
described	O	474-483
in	O	484-486
patients	O	487-495
with	O	496-500
PG	B	501-503
.	O	503-504

Our	O	505-508
patients	O	509-517
decreased	O	518-527
complement	O	528-538
level	O	539-544
,	O	544-545
if	O	546-548
not	O	549-552
directly	O	553-561
related	O	562-569
to	O	570-572
the	O	573-576
development	O	577-588
of	O	589-591
PG	B	592-594
,	O	594-595
may	O	596-599
have	O	600-604
contributed	O	605-616
to	O	617-619
the	O	620-623
aggressive	O	624-634
nature	O	635-641
of	O	642-644
her	O	645-648
disease	O	649-656
.	O	656-657
.	O	656-657

Emerin	B	0-6
deficiency	I	7-17
at	O	18-20
the	O	21-24
nuclear	O	25-32
membrane	O	33-41
in	O	42-44
patients	O	45-53
with	O	54-58
Emery	B	59-64
-	I	64-65
Dreifuss	I	65-73
muscular	I	74-82
dystrophy	I	83-92
.	O	92-93

Mutations	O	94-103
in	O	104-106
the	O	107-110
STA	O	111-114
gene	O	115-119
at	O	120-122
the	O	123-126
Xq28	O	127-131
locus	O	132-137
have	O	138-142
been	O	143-147
found	O	148-153
in	O	154-156
patients	O	157-165
with	O	166-170
X	B	171-172
-	I	172-173
linked	I	173-179
Emery	I	180-185
-	I	185-186
Dreifuss	I	186-194
muscular	I	195-203
dystrophy	I	204-213
(	O	214-215
EDMD	B	215-219
)	O	219-220
.	O	220-221

This	O	222-226
gene	O	227-231
encodes	O	232-239
a	O	240-241
hitherto	O	242-250
unknown	O	251-258
protein	O	259-266
named	O	267-272
emerin	O	273-279
.	O	279-280

To	O	281-283
elucidate	O	284-293
the	O	294-297
subcellular	O	298-309
localization	O	310-322
of	O	323-325
emerin	O	326-332
,	O	332-333
we	O	334-336
raised	O	337-343
two	O	344-347
antisera	O	348-356
against	O	357-364
synthetic	O	365-374
peptide	O	375-382
fragments	O	383-392
predicted	O	393-402
from	O	403-407
emerin	O	408-414
cDNA	O	415-419
.	O	419-420

Using	O	421-426
both	O	427-431
antisera	O	432-440
,	O	440-441
we	O	442-444
found	O	445-450
positive	O	451-459
nuclear	O	460-467
membrane	O	468-476
staining	O	477-485
in	O	486-488
skeletal	O	489-497
,	O	497-498
cardiac	O	499-506
and	O	507-510
smooth	O	511-517
muscles	O	518-525
in	O	526-528
the	O	529-532
normal	O	533-539
controls	O	540-548
and	O	549-552
in	O	553-555
patients	O	556-564
with	O	565-569
neuromuscular	B	570-583
diseases	I	584-592
other	O	593-598
than	O	599-603
EDMD	B	604-608
.	O	608-609

In	O	610-612
contrast	O	613-621
,	O	621-622
a	O	623-624
deficiency	O	625-635
in	O	636-638
immunofluorescent	O	639-656
staining	O	657-665
of	O	666-668
skeletal	O	669-677
and	O	678-681
cardiac	O	682-689
muscle	O	690-696
from	O	697-701
EDMD	B	702-706
patients	O	707-715
was	O	716-719
observed	O	720-728
.	O	728-729

A	O	730-731
34	O	732-734
kD	O	735-737
protein	O	738-745
is	O	746-748
immunoreactive	O	749-763
with	O	764-768
the	O	769-772
antisera	O	773-781
-	O	781-782
-	O	781-782
the	O	783-786
protein	O	787-794
is	O	795-797
equivalent	O	798-808
to	O	809-811
that	O	812-816
predicted	O	817-826
for	O	827-830
emerin	O	831-837
.	O	837-838

Together	O	839-847
,	O	847-848
our	O	849-852
findings	O	853-861
suggest	O	862-869
the	O	870-873
specific	O	874-882
deficiency	B	883-893
of	I	894-896
emerin	I	897-903
in	O	904-906
the	O	907-910
nuclear	O	911-918
membrane	O	919-927
of	O	928-930
muscle	O	931-937
cells	O	938-943
in	O	944-946
patients	O	947-955
with	O	956-960
EDMD	B	961-965
.	O	965-966
.	O	965-966

A	O	0-1
p16INK4a	O	2-10
-	O	10-11
insensitive	O	11-22
CDK4	O	23-27
mutant	O	28-34
targeted	O	35-43
by	O	44-46
cytolytic	O	47-56
T	O	57-58
lymphocytes	O	59-70
in	O	71-73
a	O	74-75
human	O	76-81
melanoma	B	82-90
.	O	90-91

A	O	92-93
mutated	O	94-101
cyclin	O	102-108
-	O	108-109
dependent	O	109-118
kinase	O	119-125
4	O	126-127
(	O	128-129
CDK4	O	129-133
)	O	133-134
was	O	135-138
identified	O	139-149
as	O	150-152
a	O	153-154
tumor	B	155-160
-	O	160-161
specific	O	161-169
antigen	O	170-177
recognized	O	178-188
by	O	189-191
HLA	O	192-195
-	O	195-196
A2	O	196-198
.	O	198-199

1	O	200-201
-	O	201-202
restricted	O	202-212
autologous	O	213-223
cytolytic	O	224-233
T	O	234-235
lymphocytes	O	236-247
(	O	248-249
CTLs	O	249-253
)	O	253-254
in	O	255-257
a	O	258-259
human	O	260-265
melanoma	B	266-274
.	O	274-275

The	O	276-279
mutated	O	280-287
CDK4	O	288-292
allele	O	293-299
was	O	300-303
present	O	304-311
in	O	312-314
autologous	O	315-325
cultured	O	326-334
melanoma	B	335-343
cells	O	344-349
and	O	350-353
metastasis	O	354-364
tissue	O	365-371
,	O	371-372
but	O	373-376
not	O	377-380
in	O	381-383
the	O	384-387
patients	O	388-396
lymphocytes	O	397-408
.	O	408-409

The	O	410-413
mutation	O	414-422
,	O	422-423
an	O	424-426
arginine	O	427-435
-	O	435-436
to	O	436-438
-	O	435-436
cysteine	O	439-447
exchange	O	448-456
at	O	457-459
residue	O	460-467
24	O	468-470
,	O	470-471
was	O	472-475
part	O	476-480
of	O	481-483
the	O	484-487
CDK4	O	488-492
peptide	O	493-500
recognized	O	501-511
by	O	512-514
CTLs	O	515-519
and	O	520-523
prevented	O	524-533
binding	O	534-541
of	O	542-544
the	O	545-548
CDK4	O	549-553
inhibitor	O	554-563
p16INK4a	O	564-572
,	O	572-573
but	O	574-577
not	O	578-581
of	O	582-584
p21	O	585-588
or	O	589-591
of	O	592-594
p27KIP1	O	595-602
.	O	602-603

The	O	604-607
same	O	608-612
mutation	O	613-621
was	O	622-625
found	O	626-631
in	O	632-634
one	O	635-638
additional	O	639-649
melanoma	B	650-658
among	O	659-664
28	O	665-667
melanomas	B	668-677
analyzed	O	678-686
.	O	686-687

These	O	688-693
results	O	694-701
suggest	O	702-709
that	O	710-714
mutation	O	715-723
of	O	724-726
CDK4	O	727-731
can	O	732-735
create	O	736-742
a	O	743-744
tumor	B	745-750
-	O	750-751
specific	O	751-759
antigen	O	760-767
and	O	768-771
can	O	772-775
disrupt	O	776-783
the	O	784-787
cell	O	788-792
-	O	792-793
cycle	O	793-798
regulation	O	799-809
exerted	O	810-817
by	O	818-820
the	O	821-824
tumor	B	825-830
suppressor	O	831-841
p16INK4a	O	842-850
.	O	850-851
.	O	850-851

Molecular	O	0-9
analysis	O	10-18
in	O	19-21
familial	B	22-30
neurohypophyseal	I	31-47
diabetes	I	48-56
insipidus	I	57-66
:	O	66-67
early	O	68-73
diagnosis	O	74-83
of	O	84-86
an	O	87-89
asymptomatic	O	90-102
carrier	O	103-110
.	O	110-111

Familial	B	112-120
neurohypophyseal	I	121-137
diabetes	I	138-146
insipidus	I	147-156
(	O	157-158
FNDI	B	158-162
)	O	162-163
is	O	164-166
an	O	167-169
inherited	O	170-179
deficiency	B	180-190
of	I	191-193
the	I	194-197
hormone	I	198-205
arginine	I	206-214
vasopressin	I	215-226
(	O	227-228
AVP	O	228-231
)	O	231-232
and	O	233-236
is	O	237-239
transmitted	O	240-251
as	O	252-254
an	O	255-257
autosomal	O	258-267
dominant	O	268-276
trait	O	277-282
.	O	282-283

In	O	284-286
the	O	287-290
present	O	291-298
study	O	299-304
we	O	305-307
have	O	308-312
analyzed	O	313-321
the	O	322-325
AVP	O	326-329
-	O	329-330
neurophysin	O	330-341
II	O	342-344
(	O	345-346
AVP	O	346-349
-	O	349-350
NPII	O	350-354
)	O	354-355
gene	O	356-360
in	O	361-363
a	O	364-365
Spanish	O	366-373
kindred	O	374-381
.	O	381-382

Studies	O	383-390
were	O	391-395
performed	O	396-405
on	O	406-408
seven	O	409-414
members	O	415-422
(	O	423-424
four	O	424-428
clinically	O	429-439
affected	O	440-448
)	O	448-449
of	O	450-452
the	O	453-456
family	O	457-463
.	O	463-464

Patients	O	465-473
were	O	474-478
diagnosed	O	479-488
at	O	489-491
the	O	492-495
Hospital	O	496-504
Universitario	O	505-518
Gregorio	O	519-527
Maranon	O	528-535
(	O	536-537
Madrid	O	537-543
,	O	543-544
Spain	O	545-550
)	O	550-551
.	O	551-552

The	O	553-556
entire	O	557-563
coding	O	564-570
region	O	571-577
of	O	578-580
the	O	581-584
AVP	O	585-588
-	O	588-589
NPII	O	589-593
gene	O	594-598
of	O	599-601
all	O	602-605
family	O	606-612
members	O	613-620
was	O	621-624
amplified	O	625-634
by	O	635-637
PCR	O	638-641
and	O	642-645
sequenced	O	646-655
.	O	655-656

All	O	657-660
affected	O	661-669
individuals	O	670-681
presented	O	682-691
a	O	692-693
missense	O	694-702
mutation	O	703-711
(	O	712-713
G1757	O	713-718
-	O	718-719
-	O	718-719
>	O	721-722
A	O	723-724
)	O	724-725
that	O	726-730
replaces	O	731-739
glycine	O	740-747
at	O	748-750
position	O	751-759
23	O	760-762
with	O	763-767
arginine	O	768-776
within	O	777-783
the	O	784-787
NPII	O	788-792
domain	O	793-799
.	O	799-800

The	O	801-804
substitution	O	805-817
was	O	818-821
confirmed	O	822-831
by	O	832-834
restriction	O	835-846
endonuclease	O	847-859
analysis	O	860-868
and	O	869-872
was	O	873-876
present	O	877-884
in	O	885-887
heterozygosis	O	888-901
.	O	901-902

Additionally	O	903-915
,	O	915-916
one	O	917-920
of	O	921-923
the	O	924-927
asymptomatic	O	928-940
relatives	O	941-950
(	O	951-952
a	O	952-953
girl	O	954-958
8	O	959-960
months	O	961-967
old	O	968-971
at	O	972-974
the	O	975-978
time	O	979-983
of	O	984-986
study	O	987-992
)	O	992-993
was	O	994-997
identified	O	998-1008
as	O	1009-1011
carrier	O	1012-1019
of	O	1020-1022
the	O	1023-1026
same	O	1027-1031
mutation	O	1032-1040
and	O	1041-1044
developed	O	1045-1054
the	O	1055-1058
disease	O	1059-1066
3	O	1067-1068
months	O	1069-1075
later	O	1076-1081
.	O	1081-1082

The	O	1083-1086
alteration	O	1087-1097
found	O	1098-1103
in	O	1104-1106
the	O	1107-1110
second	O	1111-1117
exon	O	1118-1122
of	O	1123-1125
the	O	1126-1129
gene	O	1130-1134
in	O	1135-1137
this	O	1138-1142
family	O	1143-1149
seems	O	1150-1155
to	O	1156-1158
be	O	1159-1161
responsible	O	1162-1173
for	O	1174-1177
the	O	1178-1181
disease	O	1182-1189
,	O	1189-1190
as	O	1191-1193
all	O	1194-1197
individuals	O	1198-1209
harboring	O	1210-1219
the	O	1220-1223
mutation	O	1224-1232
had	O	1233-1236
been	O	1237-1241
previously	O	1242-1252
diagnosed	O	1253-1262
or	O	1263-1265
have	O	1266-1270
eventually	O	1271-1281
developed	O	1282-1291
FNDI	B	1292-1296
.	O	1296-1297

Identification	O	1298-1312
of	O	1313-1315
the	O	1316-1319
molecular	O	1320-1329
defect	O	1330-1336
underlying	O	1337-1347
FNDI	B	1348-1352
in	O	1353-1355
affected	O	1356-1364
families	O	1365-1373
is	O	1374-1376
a	O	1377-1378
powerful	O	1379-1387
tool	O	1388-1392
for	O	1393-1396
early	O	1397-1402
asymptomatic	O	1403-1415
diagnosis	O	1416-1425
in	O	1426-1428
infants	O	1429-1436
.	O	1436-1437
.	O	1436-1437

Sialophorin	O	0-11
,	O	11-12
a	O	13-14
surface	O	15-22
sialoglycoprotein	O	23-40
defective	O	41-50
in	O	51-53
the	O	54-57
Wiskott	B	58-65
-	I	65-66
Aldrich	I	66-73
syndrome	I	74-82
,	O	82-83
is	O	84-86
involved	O	87-95
in	O	96-98
human	O	99-104
T	O	105-106
lymphocyte	O	107-117
proliferation	O	118-131
.	O	131-132

The	O	133-136
mAb	O	137-140
L10	O	141-144
was	O	145-148
used	O	149-153
to	O	154-156
determine	O	157-166
the	O	167-170
distribution	O	171-183
and	O	184-187
the	O	188-191
function	O	192-200
of	O	201-203
sialophorin	O	204-215
,	O	215-216
the	O	217-220
heavily	O	221-228
glycosylated	O	229-241
surface	O	242-249
molecule	O	250-258
that	O	259-263
is	O	264-266
deficient	O	267-276
/	O	276-277
defective	O	277-286
in	O	287-289
lymphocytes	O	290-301
of	O	302-304
patients	O	305-313
with	O	314-318
the	O	319-322
X	B	323-324
-	I	324-325
linked	I	325-331
immunodeficiency	I	332-348
Wiskott	I	349-356
-	I	356-357
Aldrich	I	357-364
syndrome	I	365-373
.	O	373-374

Dual	O	375-379
-	O	379-380
parameter	O	380-389
FACS	O	390-394
analysis	O	395-403
indicated	O	404-413
that	O	414-418
sialophorin	O	419-430
is	O	431-433
expressed	O	434-443
on	O	444-446
CD4	O	447-450
+	O	451-452
and	O	453-456
CD8	O	457-460
+	O	461-462
lymphocytes	O	463-474
,	O	474-475
on	O	476-478
a	O	479-480
subpopulation	O	481-494
of	O	495-497
peripheral	O	498-508
blood	O	509-514
B	O	515-516
lymphocytes	O	517-528
,	O	528-529
on	O	530-532
all	O	533-536
thymocytes	O	537-547
,	O	547-548
and	O	549-552
on	O	553-555
a	O	556-557
subpopulation	O	558-571
of	O	572-574
bone	O	575-579
marrow	O	580-586
cells	O	587-592
.	O	592-593

Functional	O	594-604
studies	O	605-612
demonstrated	O	613-625
that	O	626-630
L10	O	631-634
mAb	O	635-638
stimulates	O	639-649
the	O	650-653
proliferation	O	654-667
of	O	668-670
peripheral	O	671-681
blood	O	682-687
T	O	688-689
lymphocytes	O	690-701
as	O	702-704
measured	O	705-713
by	O	714-716
stimulation	O	717-728
of	O	729-731
[	O	732-733
3H	O	733-735
]	O	735-736
thymidine	O	737-746
incorporation	O	747-760
.	O	760-761

The	O	762-765
time	O	766-770
course	O	771-777
and	O	778-781
magnitude	O	782-791
of	O	792-794
increased	O	795-804
[	O	805-806
3H	O	806-808
]	O	808-809
thymidine	O	810-819
incorporation	O	820-833
by	O	834-836
T	O	837-838
lymphocytes	O	839-850
in	O	851-853
response	O	854-862
to	O	863-865
L10	O	866-869
mAb	O	870-873
paralleled	O	874-884
that	O	885-889
induced	O	890-897
by	O	898-900
anti	O	901-905
-	O	905-906
CD3	O	906-909
mAb	O	910-913
.	O	913-914

Effective	O	915-924
stimulation	O	925-936
was	O	937-940
dependent	O	941-950
on	O	951-953
the	O	954-957
presence	O	958-966
of	O	967-969
monocytes	O	970-979
and	O	980-983
the	O	984-987
Fc	O	988-990
portion	O	991-998
of	O	999-1001
L10	O	1002-1005
mAb	O	1006-1009
.	O	1009-1010

Stimulation	O	1011-1022
of	O	1023-1025
lymphocytes	O	1026-1037
by	O	1038-1040
L10	O	1041-1044
,	O	1044-1045
like	O	1046-1050
stimulation	O	1051-1062
by	O	1063-1065
anti	O	1066-1070
-	O	1070-1071
CD3	O	1071-1074
mAb	O	1075-1078
,	O	1078-1079
involves	O	1080-1088
increased	O	1089-1098
expression	O	1099-1109
of	O	1110-1112
4F2	O	1113-1116
,	O	1116-1117
HLA	O	1118-1121
-	O	1121-1122
DR	O	1122-1124
,	O	1124-1125
and	O	1126-1129
IL	O	1130-1132
-	O	1132-1133
2	O	1133-1134
-	O	1132-1133
R	O	1135-1136
.	O	1136-1137

These	O	1138-1143
observations	O	1144-1156
suggest	O	1157-1164
that	O	1165-1169
sialophorin	O	1170-1181
functions	O	1182-1191
in	O	1192-1194
T	O	1195-1196
cell	O	1197-1201
activation	O	1202-1212
.	O	1212-1213
.	O	1212-1213

Characterization	O	0-16
of	O	17-19
the	O	20-23
rat	O	24-27
spinocerebellar	O	28-43
ataxia	O	44-50
type	O	51-55
3	O	56-57
gene	O	58-62
.	O	62-63

Machado	B	64-71
-	I	71-72
Joseph	I	72-78
disease	I	79-86
(	O	87-88
MJD	B	88-91
)	O	91-92
belongs	O	93-100
to	O	101-103
a	O	104-105
group	O	106-111
of	O	112-114
clinically	O	115-125
and	O	126-129
genetically	O	130-141
heterogeneous	O	142-155
neurodegenerative	B	156-173
disorders	I	174-183
characterized	O	184-197
by	O	198-200
progressive	B	201-212
cerebellar	I	213-223
ataxia	I	224-230
.	O	230-231

The	O	232-235
disease	O	236-243
-	O	243-244
causing	O	244-251
mutation	O	252-260
has	O	261-264
recently	O	265-273
been	O	274-278
identified	O	279-289
as	O	290-292
an	O	293-295
unstable	O	296-304
and	O	305-308
expanded	O	309-317
(	O	318-319
CAG	O	319-322
)	O	322-323
n	O	324-325
trinucleotide	O	326-339
repeat	O	340-346
in	O	347-349
a	O	350-351
novel	O	352-357
gene	O	358-362
of	O	363-365
unknown	O	366-373
function	O	374-382
.	O	382-383

In	O	384-386
Caucasians	O	387-397
,	O	397-398
repeat	O	399-405
expansions	O	406-416
in	O	417-419
the	O	420-423
MJD1	O	424-428
gene	O	429-433
have	O	434-438
also	O	439-443
been	O	444-448
found	O	449-454
in	O	455-457
patients	O	458-466
with	O	467-471
the	O	472-475
clinically	O	476-486
distinct	O	487-495
autosomal	O	496-505
dominant	O	506-514
spinocerebellar	B	515-530
ataxia	I	531-537
type	I	538-542
3	I	543-544
(	O	545-546
SCA3	B	546-550
)	O	550-551
.	O	551-552

In	O	553-555
order	O	556-561
to	O	562-564
gain	O	565-569
insight	O	570-577
into	O	578-582
the	O	583-586
biology	O	587-594
of	O	595-597
the	O	598-601
MJD1	O	602-606
/	O	606-607
SCA3	O	607-611
gene	O	612-616
we	O	617-619
cloned	O	620-626
the	O	627-630
rat	O	631-634
homologue	O	635-644
and	O	645-648
studied	O	649-656
its	O	657-660
expression	O	661-671
.	O	671-672

The	O	673-676
rat	O	677-680
and	O	681-684
human	O	685-690
ataxin	O	691-697
-	O	697-698
3	O	698-699
genes	O	700-705
are	O	706-709
highly	O	710-716
homologous	O	717-727
with	O	728-732
an	O	733-735
overall	O	736-743
sequence	O	744-752
identity	O	753-761
of	O	762-764
approximately	O	765-778
88	O	779-781
%	O	781-782
.	O	782-783

However	O	784-791
,	O	791-792
the	O	793-796
C	O	797-798
-	O	798-799
terminal	O	799-807
end	O	808-811
of	O	812-814
the	O	815-818
putative	O	819-827
protein	O	828-835
differs	O	836-843
strongly	O	844-852
from	O	853-857
the	O	858-861
published	O	862-871
human	O	872-877
sequence	O	878-886
.	O	886-887

The	O	888-891
(	O	892-893
CAG	O	893-896
)	O	896-897
n	O	898-899
block	O	900-905
in	O	906-908
the	O	909-912
rat	O	913-916
cDNA	O	917-921
consists	O	922-930
of	O	931-933
just	O	934-938
three	O	939-944
interrupted	O	945-956
units	O	957-962
suggesting	O	963-973
that	O	974-978
a	O	979-980
long	O	981-985
polyglutamine	O	986-999
stretch	O	1000-1007
is	O	1008-1010
not	O	1011-1014
essential	O	1015-1024
for	O	1025-1028
the	O	1029-1032
normal	O	1033-1039
function	O	1040-1048
of	O	1049-1051
the	O	1052-1055
ataxin	O	1056-1062
-	O	1062-1063
3	O	1063-1064
protein	O	1065-1072
in	O	1073-1075
rodents	O	1076-1083
.	O	1083-1084

The	O	1085-1088
expression	O	1089-1099
pattern	O	1100-1107
of	O	1108-1110
the	O	1111-1114
SCA3	O	1115-1119
gene	O	1120-1124
in	O	1125-1127
various	O	1128-1135
rat	O	1136-1139
and	O	1140-1143
human	O	1144-1149
tissues	O	1150-1157
was	O	1158-1161
investigated	O	1162-1174
by	O	1175-1177
Northern	O	1178-1186
blot	O	1187-1191
analyses	O	1192-1200
.	O	1200-1201

The	O	1202-1205
mature	O	1206-1212
transcript	O	1213-1223
is	O	1224-1226
approximately	O	1227-1240
6	O	1241-1242
kb	O	1243-1245
in	O	1246-1248
length	O	1249-1255
.	O	1255-1256

In	O	1257-1259
rat	O	1260-1263
testis	O	1264-1270
,	O	1270-1271
a	O	1272-1273
smaller	O	1274-1281
transcript	O	1282-1292
of	O	1293-1295
1	O	1296-1297
.	O	1297-1298
3	O	1299-1300
kb	O	1301-1303
was	O	1304-1307
identified	O	1308-1318
.	O	1318-1319

Transcription	O	1320-1333
of	O	1334-1336
rsca3	O	1337-1342
was	O	1343-1346
detected	O	1347-1355
in	O	1356-1358
most	O	1359-1363
rat	O	1364-1367
tissues	O	1368-1375
including	O	1376-1385
brain	O	1386-1391
.	O	1391-1392

Analyzing	O	1393-1402
the	O	1403-1406
expression	O	1407-1417
level	O	1418-1423
of	O	1424-1426
the	O	1427-1430
SCA3	O	1431-1435
gene	O	1436-1440
in	O	1441-1443
several	O	1444-1451
human	O	1452-1457
brain	O	1458-1463
sections	O	1464-1472
revealed	O	1473-1481
no	O	1482-1484
significant	O	1485-1496
higher	O	1497-1503
mRNA	O	1504-1508
level	O	1509-1514
in	O	1515-1517
regions	O	1518-1525
predominantly	O	1526-1539
affected	O	1540-1548
in	O	1549-1551
MJD	B	1552-1555
.	O	1555-1556

Thus	O	1557-1561
additional	O	1562-1572
molecules	O	1573-1582
and	O	1583-1586
/	O	1586-1587
or	O	1587-1589
regulatory	O	1590-1600
events	O	1601-1607
are	O	1608-1611
necessary	O	1612-1621
to	O	1622-1624
explain	O	1625-1632
the	O	1633-1636
exclusive	O	1637-1646
degeneration	B	1647-1659
of	I	1660-1662
certain	I	1663-1670
brain	I	1671-1676
areas	I	1677-1682
.	O	1682-1683

The	O	0-3
alveolar	B	4-12
rhabdomyosarcoma	I	13-29
PAX3	O	30-34
/	O	34-35
FKHR	O	35-39
fusion	O	40-46
protein	O	47-54
is	O	55-57
a	O	58-59
transcriptional	O	60-75
activator	O	76-85
.	O	85-86

Chimeric	O	87-95
transcription	O	96-109
factors	O	110-117
,	O	117-118
created	O	119-126
by	O	127-129
gene	O	130-134
fusions	O	135-142
as	O	143-145
the	O	146-149
result	O	150-156
of	O	157-159
chromosomal	O	160-171
translocations	O	172-186
,	O	186-187
have	O	188-192
been	O	193-197
implicated	O	198-208
in	O	209-211
the	O	212-215
pathogenesis	O	216-228
of	O	229-231
several	O	232-239
pathologically	O	240-254
disparate	O	255-264
solid	B	265-270
tumors	I	271-277
.	O	277-278

The	O	279-282
PAX3	O	283-287
/	O	287-288
FKHR	O	288-292
fusion	O	293-299
gene	O	300-304
,	O	304-305
formed	O	306-312
by	O	313-315
a	O	316-317
t	O	318-319
(	O	320-321
2	O	321-322
;	O	322-323
13	O	324-326
)	O	326-327
(	O	328-329
q35	O	329-332
;	O	332-333
q14	O	334-337
)	O	337-338
in	O	339-341
alveolar	B	342-350
rhabdomyosarcoma	I	351-367
,	O	367-368
encodes	O	369-376
a	O	377-378
hybrid	O	379-385
protein	O	386-393
that	O	394-398
contains	O	399-407
both	O	408-412
PAX3	O	413-417
DNA	O	418-421
binding	O	422-429
domains	O	430-437
,	O	437-438
the	O	439-442
paired	O	443-449
box	O	450-453
and	O	454-457
homeodomain	O	458-469
,	O	469-470
linked	O	471-477
to	O	478-480
the	O	481-484
bisected	O	485-493
DNA	O	494-497
binding	O	498-505
domain	O	506-512
of	O	513-515
FKHR	O	516-520
,	O	520-521
a	O	522-523
member	O	524-530
of	O	531-533
the	O	534-537
forkhead	O	538-546
family	O	547-553
of	O	554-556
transcription	O	557-570
factors	O	571-578
.	O	578-579

Here	O	580-584
we	O	585-587
report	O	588-594
that	O	595-599
PAX3	O	600-604
and	O	605-608
PAX3	O	609-613
/	O	613-614
FKHR	O	614-618
display	O	619-626
similar	O	627-634
,	O	634-635
but	O	636-639
not	O	640-643
identical	O	644-653
transactivation	O	654-669
activities	O	670-680
when	O	681-685
tested	O	686-692
with	O	693-697
model	O	698-703
Pax	O	704-707
recognition	O	708-719
sequences	O	720-729
.	O	729-730

No	O	731-733
functional	O	734-744
role	O	745-749
could	O	750-755
be	O	756-758
ascribed	O	759-767
solely	O	768-774
to	O	775-777
the	O	778-781
residual	O	782-790
FKHR	O	791-795
binding	O	796-803
domain	O	804-810
present	O	811-818
in	O	819-821
the	O	822-825
fusion	O	826-832
protein	O	833-840
,	O	840-841
but	O	842-845
FKHR	O	846-850
was	O	851-854
found	O	855-860
to	O	861-863
contribute	O	864-874
a	O	875-876
strong	O	877-883
carboxyl	O	884-892
terminal	O	893-901
activation	O	902-912
domain	O	913-919
replacing	O	920-929
the	O	930-933
one	O	934-937
located	O	938-945
in	O	946-948
the	O	949-952
unrearranged	O	953-965
PAX3	O	966-970
gene	O	971-975
.	O	975-976

We	O	977-979
show	O	980-984
that	O	985-989
the	O	990-993
native	O	994-1000
PAX3	O	1001-1005
/	O	1005-1006
FKHR	O	1006-1010
protein	O	1011-1018
present	O	1019-1026
in	O	1027-1029
tumor	B	1030-1035
cells	O	1036-1041
with	O	1042-1046
this	O	1047-1051
translocation	O	1052-1065
has	O	1066-1069
transcriptional	O	1070-1085
characteristics	O	1086-1101
similar	O	1102-1109
to	O	1110-1112
the	O	1113-1116
in	O	1117-1119
vitro	O	1120-1125
expressed	O	1126-1135
protein	O	1136-1143
.	O	1143-1144

The	O	1145-1148
ability	O	1149-1156
of	O	1157-1159
the	O	1160-1163
PAX3	O	1164-1168
/	O	1168-1169
FKHR	O	1169-1173
hybrid	O	1174-1180
protein	O	1181-1188
to	O	1189-1191
bind	O	1192-1196
DNA	O	1197-1200
in	O	1201-1203
a	O	1204-1205
sequence	O	1206-1214
specific	O	1215-1223
manner	O	1224-1230
and	O	1231-1234
to	O	1235-1237
transactivate	O	1238-1251
the	O	1252-1255
expression	O	1256-1266
of	O	1267-1269
artificial	O	1270-1280
reporter	O	1281-1289
genes	O	1290-1295
suggests	O	1296-1304
that	O	1305-1309
its	O	1310-1313
aberrant	O	1314-1322
expression	O	1323-1333
could	O	1334-1339
subvert	O	1340-1347
the	O	1348-1351
transcriptional	O	1352-1367
programs	O	1368-1376
that	O	1377-1381
normally	O	1382-1390
control	O	1391-1398
the	O	1399-1402
growth	O	1403-1409
,	O	1409-1410
differentiation	O	1411-1426
,	O	1426-1427
and	O	1428-1431
survival	O	1432-1440
of	O	1441-1443
primitive	O	1444-1453
myogenic	O	1454-1462
precursors	O	1463-1473
in	O	1474-1476
vivo	O	1477-1481
.	O	1481-1482
.	O	1481-1482

Myotonia	B	0-8
levior	I	9-15
is	O	16-18
a	O	19-20
chloride	B	21-29
channel	I	30-37
disorder	I	38-46
.	O	46-47

The	O	48-51
group	O	52-57
of	O	58-60
dominant	B	61-69
non	I	70-73
-	I	73-74
dystrophic	I	74-84
myotonias	I	85-94
,	O	94-95
comprising	O	96-106
disorders	O	107-116
characterized	O	117-130
by	O	131-133
clinically	O	134-144
similar	O	145-152
forms	O	153-158
of	O	159-161
myogenic	O	162-170
muscle	O	171-177
stiffness	O	178-187
,	O	187-188
is	O	189-191
genetically	O	192-203
inhomogeneous	O	204-217
.	O	217-218

Dominant	B	219-227
myotonia	I	228-236
congenita	I	237-246
(	O	247-248
Thomsens	B	248-256
disease	I	257-264
)	O	264-265
is	O	266-268
linked	O	269-275
to	O	276-278
CLCN1	O	279-284
,	O	284-285
the	O	286-289
gene	O	290-294
encoding	O	295-303
the	O	304-307
major	O	308-313
muscle	O	314-320
chloride	O	321-329
channel	O	330-337
,	O	337-338
localized	O	339-348
on	O	349-351
chromosome	O	352-362
7q35	O	363-367
.	O	367-368

In	O	369-371
contrast	O	372-380
,	O	380-381
dominant	B	382-390
myotonias	I	391-400
sensitive	O	401-410
to	O	411-413
potassium	O	414-423
are	O	424-427
caused	O	428-434
by	O	435-437
point	O	438-443
mutations	O	444-453
in	O	454-456
SCN4A	O	457-462
on	O	463-465
chromosome	O	466-476
17q	O	477-480
,	O	480-481
the	O	482-485
gene	O	486-490
for	O	491-494
the	O	495-498
alpha	O	499-504
subunit	O	505-512
of	O	513-515
the	O	516-519
adult	O	520-525
skeletal	O	526-534
muscle	O	535-541
sodium	O	542-548
channel	O	549-556
.	O	556-557

No	O	558-560
linkage	O	561-568
or	O	569-571
molecular	O	572-581
genetic	O	582-589
data	O	590-594
are	O	595-598
as	O	599-601
yet	O	602-605
available	O	606-615
on	O	616-618
myotonia	B	619-627
levior	I	628-634
characterized	O	635-648
by	O	649-651
milder	O	652-658
symptoms	O	659-667
and	O	668-671
later	O	672-677
onset	O	678-683
of	O	684-686
myotonia	B	687-695
than	O	696-700
in	O	701-703
Thomsens	B	704-712
disease	I	713-720
,	O	720-721
and	O	722-725
absence	O	726-733
of	O	734-736
muscle	B	737-743
hypertrophy	I	744-755
.	O	755-756

We	O	757-759
report	O	760-766
a	O	767-768
CLCN1	O	769-774
Gln	O	775-778
-	O	778-779
552	O	779-782
-	O	778-779
Arg	O	783-786
substitution	O	787-799
for	O	800-803
a	O	804-805
family	O	806-812
with	O	813-817
dominant	O	818-826
inheritance	O	827-838
previously	O	839-849
diagnosed	O	850-859
to	O	860-862
have	O	863-867
myotonia	B	868-876
levior	I	877-883
.	O	883-884

Thus	O	885-889
,	O	889-890
this	O	891-895
disorder	O	896-904
appears	O	905-912
as	O	913-915
a	O	916-917
variant	O	918-925
of	O	926-928
Thomsens	B	929-937
disease	I	938-945
due	O	946-949
to	O	950-952
mutations	O	953-962
leading	O	963-970
to	O	971-973
low	O	974-977
clinical	O	978-986
expressivity	O	987-999
.	O	999-1000

In	O	1001-1003
addition	O	1004-1012
,	O	1012-1013
we	O	1014-1016
report	O	1017-1023
a	O	1024-1025
novel	O	1026-1031
Ile	O	1032-1035
-	O	1035-1036
290	O	1036-1039
-	O	1035-1036
Met	O	1040-1043
CLCN1	O	1044-1049
mutation	O	1050-1058
for	O	1059-1062
a	O	1063-1064
typical	O	1065-1072
Thomsen	O	1073-1080
pedigree	O	1081-1089
.	O	1089-1090

In	O	1091-1093
another	O	1094-1101
family	O	1102-1108
previously	O	1109-1119
diagnosed	O	1120-1129
as	O	1130-1132
having	O	1133-1139
Thomsens	B	1140-1148
disease	I	1149-1156
,	O	1156-1157
we	O	1158-1160
unexpectedly	O	1161-1173
found	O	1174-1179
a	O	1180-1181
CLCN1	O	1182-1187
14	O	1188-1190
bp	O	1191-1193
deletion	O	1194-1202
known	O	1203-1208
to	O	1209-1211
cause	O	1212-1217
recessive	B	1218-1227
myotonia	I	1228-1236
,	O	1236-1237
and	O	1238-1241
a	O	1242-1243
rare	O	1244-1248
Trp	O	1249-1252
-	O	1252-1253
118	O	1253-1256
-	O	1252-1253
Gly	O	1257-1260
polymorphism	O	1261-1273
.	O	1273-1274
.	O	1273-1274

Markedly	O	0-8
accelerated	O	9-20
catabolism	O	21-31
of	O	32-34
apolipoprotein	O	35-49
A	O	50-51
-	O	51-52
II	O	52-54
(	O	55-56
ApoA	O	56-60
-	O	60-61
II	O	61-63
)	O	63-64
and	O	65-68
high	O	69-73
density	O	74-81
lipoproteins	O	82-94
containing	O	95-105
ApoA	O	106-110
-	O	110-111
II	O	111-113
in	O	114-116
classic	O	117-124
lecithin	O	125-133
:	O	133-134
cholesterol	B	135-146
acyltransferase	I	147-162
deficiency	I	163-173
and	O	174-177
fish	B	178-182
-	I	182-183
eye	I	183-186
disease	I	187-194
.	O	194-195

Classic	B	196-203
(	I	204-205
complete	I	205-213
)	I	213-214
lecithin	I	215-223
cholesterol	I	225-236
acyltransferase	I	237-252
(	I	253-254
LCAT	I	254-258
)	I	258-259
deficiency	I	260-270
and	O	271-274
Fish	B	275-279
-	I	279-280
eye	I	280-283
disease	I	284-291
(	O	292-293
partial	B	293-300
LCAT	I	301-305
deficiency	I	306-316
)	O	316-317
are	O	318-321
genetic	O	322-329
syndromes	O	330-339
associated	O	340-350
with	O	351-355
markedly	O	356-364
decreased	O	365-374
plasma	O	375-381
levels	O	382-388
of	O	389-391
high	O	392-396
density	O	397-404
lipoprotein	O	405-416
(	O	417-418
HDL	O	418-421
)	O	421-422
cholesterol	O	423-434
but	O	435-438
not	O	439-442
with	O	443-447
an	O	448-450
increased	O	451-460
risk	O	461-465
of	O	466-468
atherosclerotic	B	469-484
cardiovascular	I	485-499
disease	I	500-507
.	O	507-508

We	O	509-511
investigated	O	512-524
the	O	525-528
metabolism	O	529-539
of	O	540-542
the	O	543-546
HDL	O	547-550
apolipoproteins	O	551-566
(	O	567-568
apo	O	568-571
)	O	571-572
apoA	O	573-577
-	O	577-578
I	O	578-579
and	O	580-583
apoA	O	584-588
-	O	588-589
II	O	589-591
in	O	592-594
a	O	595-596
total	O	597-602
of	O	603-605
five	O	606-610
patients	O	611-619
with	O	620-624
LCAT	B	625-629
deficiency	I	630-640
,	O	640-641
one	O	642-645
with	O	646-650
classic	B	651-658
LCAT	I	659-663
deficiency	I	664-674
and	O	675-678
four	O	679-683
with	O	684-688
Fish	B	689-693
-	I	693-694
eye	I	694-697
disease	I	698-705
.	O	705-706

Plasma	O	707-713
levels	O	714-720
of	O	721-723
apoA	O	724-728
-	O	728-729
II	O	729-731
were	O	732-736
decreased	O	737-746
to	O	747-749
a	O	750-751
proportionately	O	752-767
greater	O	768-775
extent	O	776-782
(	O	783-784
23	O	784-786
%	O	786-787
of	O	788-790
normal	O	791-797
)	O	797-798
than	O	799-803
apoA	O	804-808
-	O	808-809
I	O	809-810
(	O	811-812
30	O	812-814
%	O	814-815
of	O	816-818
normal	O	819-825
)	O	825-826
.	O	826-827

In	O	828-830
addition	O	831-839
,	O	839-840
plasma	O	841-847
concentrations	O	848-862
of	O	863-865
HDL	O	866-869
particles	O	870-879
containing	O	880-890
both	O	891-895
apoA	O	896-900
-	O	900-901
I	O	901-902
and	O	903-906
apoA	O	907-911
-	O	911-912
II	O	912-914
(	O	915-916
LpA	O	916-919
-	O	919-920
I	O	920-921
A	O	923-924
-	O	924-925
II	O	925-927
)	O	927-928
were	O	929-933
much	O	934-938
lower	O	939-944
(	O	945-946
18	O	946-948
%	O	948-949
of	O	950-952
normal	O	953-959
)	O	959-960
than	O	961-965
those	O	966-971
of	O	972-974
particles	O	975-984
containing	O	985-995
only	O	996-1000
apoA	O	1001-1005
-	O	1005-1006
I	O	1006-1007
(	O	1008-1009
LpA	O	1009-1012
-	O	1012-1013
I	O	1013-1014
)	O	1014-1015
(	O	1016-1017
51	O	1017-1019
%	O	1019-1020
of	O	1021-1023
normal	O	1024-1030
)	O	1030-1031
.	O	1031-1032

The	O	1033-1036
metabolic	O	1037-1046
basis	O	1047-1052
for	O	1053-1056
the	O	1057-1060
low	O	1061-1064
levels	O	1065-1071
of	O	1072-1074
apoA	O	1075-1079
-	O	1079-1080
II	O	1080-1082
and	O	1083-1086
LpA	O	1087-1090
-	O	1090-1091
I	O	1091-1092
A	O	1094-1095
-	O	1095-1096
II	O	1096-1098
was	O	1099-1102
investigated	O	1103-1115
in	O	1116-1118
all	O	1119-1122
five	O	1123-1127
patients	O	1128-1136
using	O	1137-1142
both	O	1143-1147
exogenous	O	1148-1157
radiotracer	O	1158-1169
and	O	1170-1173
endogenous	O	1174-1184
stable	O	1185-1191
isotope	O	1192-1199
labeling	O	1200-1208
techniques	O	1209-1219
.	O	1219-1220

The	O	1221-1224
mean	O	1225-1229
plasma	O	1230-1236
residence	O	1237-1246
time	O	1247-1251
of	O	1252-1254
apoA	O	1255-1259
-	O	1259-1260
I	O	1260-1261
was	O	1262-1265
decreased	O	1266-1275
at	O	1276-1278
2	O	1279-1280
.	O	1280-1281
08	O	1282-1284
+	O	1285-1286
/	O	1286-1287
-	O	1287-1288
0	O	1289-1290
.	O	1290-1291
27	O	1292-1294
d	O	1295-1296
(	O	1297-1298
controls	O	1298-1306
4	O	1307-1308
.	O	1308-1309
74	O	1310-1312
+	O	1313-1314
/	O	1314-1315
-	O	1315-1316
0	O	1317-1318
.	O	1318-1319
65	O	1320-1322
days	O	1323-1327
)	O	1327-1328
;	O	1328-1329
however	O	1330-1337
,	O	1337-1338
the	O	1339-1342
residence	O	1343-1352
time	O	1353-1357
of	O	1358-1360
apoA	O	1361-1365
-	O	1365-1366
II	O	1366-1368
was	O	1369-1372
even	O	1373-1377
shorter	O	1378-1385
at	O	1386-1388
1	O	1389-1390
.	O	1390-1391
66	O	1392-1394
+	O	1395-1396
/	O	1396-1397
-	O	1397-1398
0	O	1399-1400
.	O	1400-1401
24	O	1402-1404
d	O	1405-1406
(	O	1407-1408
controls	O	1408-1416
5	O	1417-1418
.	O	1418-1419
25	O	1420-1422
+	O	1423-1424
/	O	1424-1425
-	O	1425-1426
0	O	1427-1428
.	O	1428-1429
61	O	1430-1432
d	O	1433-1434
)	O	1434-1435
.	O	1435-1436

In	O	1437-1439
addition	O	1440-1448
,	O	1448-1449
the	O	1450-1453
catabolism	O	1454-1464
of	O	1465-1467
apoA	O	1468-1472
-	O	1472-1473
I	O	1473-1474
in	O	1475-1477
LpA	O	1478-1481
-	O	1481-1482
I	O	1482-1483
A	O	1485-1486
-	O	1486-1487
II	O	1487-1489
was	O	1490-1493
substantially	O	1494-1507
faster	O	1508-1514
than	O	1515-1519
that	O	1520-1524
of	O	1525-1527
apoA	O	1528-1532
-	O	1532-1533
I	O	1533-1534
in	O	1535-1537
LpA	O	1538-1541
-	O	1541-1542
I	O	1542-1543
.	O	1543-1544

In	O	1545-1547
summary	O	1548-1555
,	O	1555-1556
genetic	O	1557-1564
syndromes	O	1565-1574
of	O	1575-1577
either	O	1578-1584
complete	B	1585-1593
or	I	1594-1596
partial	I	1597-1604
LCAT	I	1605-1609
deficiency	I	1610-1620
result	O	1621-1627
in	O	1628-1630
low	O	1631-1634
levels	O	1635-1641
of	O	1642-1644
HDL	O	1645-1648
through	O	1649-1656
preferential	O	1657-1669
hypercatabolism	O	1670-1685
of	O	1686-1688
apoA	O	1689-1693
-	O	1693-1694
II	O	1694-1696
and	O	1697-1700
HDL	O	1701-1704
particles	O	1705-1714
containing	O	1715-1725
apoA	O	1726-1730
-	O	1730-1731
II	O	1731-1733
.	O	1733-1734

Because	O	1735-1742
LpA	O	1743-1746
-	O	1746-1747
I	O	1747-1748
has	O	1749-1752
been	O	1753-1757
proposed	O	1758-1766
to	O	1767-1769
be	O	1770-1772
more	O	1773-1777
protective	O	1778-1788
than	O	1789-1793
LpA	O	1794-1797
-	O	1797-1798
I	O	1798-1799
A	O	1801-1802
-	O	1802-1803
II	O	1803-1805
against	O	1806-1813
atherosclerosis	B	1814-1829
,	O	1829-1830
this	O	1831-1835
selective	O	1836-1845
effect	O	1846-1852
on	O	1853-1855
the	O	1856-1859
metabolism	O	1860-1870
of	O	1871-1873
LpA	O	1874-1877
-	O	1877-1878
I	O	1878-1879
A	O	1881-1882
-	O	1882-1883
II	O	1883-1885
may	O	1886-1889
provide	O	1890-1897
a	O	1898-1899
potential	O	1900-1909
explanation	O	1910-1921
why	O	1922-1925
patients	O	1926-1934
with	O	1935-1939
classic	B	1940-1947
LCAT	I	1948-1952
deficiency	I	1953-1963
and	O	1964-1967
Fish	B	1968-1972
-	I	1972-1973
eye	I	1973-1976
disease	I	1977-1984
are	O	1985-1988
not	O	1989-1992
at	O	1993-1995
increased	O	1996-2005
risk	O	2006-2010
for	O	2011-2014
premature	O	2015-2024
atherosclerosis	B	2025-2040
despite	O	2041-2048
markedly	O	2049-2057
decreased	O	2058-2067
levels	O	2068-2074
of	O	2075-2077
HDL	O	2078-2081
cholesterol	O	2082-2093
and	O	2094-2097
apoA	O	2098-2102
-	O	2102-2103
I	O	2103-2104

The	O	0-3
identical	O	4-13
5	O	14-15
'	O	15-16
splice	O	17-23
-	O	23-24
site	O	24-28
acceptor	O	29-37
mutation	O	38-46
in	O	47-49
five	O	50-54
attenuated	B	55-65
APC	I	66-69
families	O	70-78
from	O	79-83
Newfoundland	O	84-96
demonstrates	O	97-109
a	O	110-111
founder	O	112-119
effect	O	120-126
.	O	126-127

Inherited	O	128-137
mutations	O	138-147
of	O	148-150
the	O	151-154
APC	B	155-158
gene	O	159-163
predispose	O	164-174
carriers	O	175-183
to	O	184-186
multiple	O	187-195
adenomatous	B	196-207
polyps	I	208-214
of	I	215-217
the	I	218-221
colon	I	222-227
and	I	228-231
rectum	I	232-238
and	O	239-242
to	O	243-245
colorectal	B	246-256
cancer	I	257-263
.	O	263-264

Mutations	O	265-274
located	O	275-282
at	O	283-285
the	O	286-289
extreme	O	290-297
5	O	298-299
end	O	300-303
of	O	304-306
the	O	307-310
APC	B	311-314
gene	O	315-319
,	O	319-320
however	O	321-328
,	O	328-329
are	O	330-333
associated	O	334-344
with	O	345-349
a	O	350-351
less	O	352-356
severe	O	357-363
disease	O	364-371
known	O	372-377
as	O	378-380
attenuated	B	381-391
adenomatous	I	392-403
polyposis	I	404-413
coli	I	414-418
(	O	419-420
AAPC	B	420-424
)	O	424-425
.	O	425-426

Many	O	427-431
individuals	O	432-443
with	O	444-448
AAPC	B	449-453
develop	O	454-461
relatively	O	462-472
few	O	473-476
colorectal	B	477-487
polyps	I	488-494
but	O	495-498
are	O	499-502
still	O	503-508
at	O	509-511
high	O	512-516
risk	O	517-521
for	O	522-525
colorectal	B	526-536
cancer	I	537-543
.	O	543-544

We	O	545-547
report	O	548-554
here	O	555-559
the	O	560-563
identification	O	564-578
of	O	579-581
a	O	582-583
5	O	584-585
APC	B	586-589
germline	O	590-598
mutation	O	599-607
in	O	608-610
five	O	611-615
separately	O	616-626
ascertained	O	627-638
AAPC	B	639-643
families	O	644-652
from	O	653-657
Newfoundland	O	658-670
,	O	670-671
Canada	O	672-678
.	O	678-679

This	O	680-684
disease	O	685-692
-	O	692-693
causing	O	693-700
mutation	O	701-709
is	O	710-712
a	O	713-714
single	O	715-721
basepair	O	722-730
change	O	731-737
(	O	738-739
G	O	739-740
to	O	741-743
A	O	744-745
)	O	745-746
in	O	747-749
the	O	750-753
splice	O	754-760
-	O	760-761
acceptor	O	761-769
region	O	770-776
of	O	777-779
APC	B	780-783
intron	O	784-790
3	O	791-792
that	O	793-797
creates	O	798-805
a	O	806-807
mutant	O	808-814
RNA	O	815-818
without	O	819-826
exon	O	827-831
4	O	832-833
of	O	834-836
APC	O	837-840
.	O	840-841

The	O	842-845
observation	O	846-857
of	O	858-860
the	O	861-864
same	O	865-869
APC	B	870-873
mutation	O	874-882
in	O	883-885
five	O	886-890
families	O	891-899
from	O	900-904
the	O	905-908
same	O	909-913
geographic	O	914-924
area	O	925-929
demonstrates	O	930-942
a	O	943-944
founder	O	945-952
effect	O	953-959
.	O	959-960

Furthermore	O	961-972
,	O	972-973
the	O	974-977
identification	O	978-992
of	O	993-995
this	O	996-1000
germline	O	1001-1009
mutation	O	1010-1018
strengthens	O	1019-1030
the	O	1031-1034
correlation	O	1035-1046
between	O	1047-1054
the	O	1055-1058
5	O	1059-1060
location	O	1061-1069
of	O	1070-1072
an	O	1073-1075
APC	B	1076-1079
disease	O	1080-1087
-	O	1087-1088
causing	O	1088-1095
mutation	O	1096-1104
and	O	1105-1108
the	O	1109-1112
attenuated	B	1113-1123
polyposis	I	1124-1133
phenotype	O	1134-1143
.	O	1143-1144
.	O	1143-1144

Linkage	O	0-7
of	O	8-10
aspartylglucosaminuria	B	11-33
(	O	34-35
AGU	B	35-38
)	O	38-39
to	O	40-42
marker	O	43-49
loci	O	50-54
on	O	55-57
the	O	58-61
long	O	62-66
arm	O	67-70
of	O	71-73
chromosome	O	74-84
4	O	85-86
.	O	86-87
Aspartylglucosaminuria	B	88-110
(	O	111-112
AGU	B	112-115
)	O	115-116
is	O	117-119
caused	O	120-126
by	O	127-129
deficient	O	130-139
activity	O	140-148
of	O	149-151
the	O	152-155
enzyme	O	156-162
aspartylglucosaminidase	O	163-186
(	O	187-188
AGA	O	188-191
)	O	191-192
.	O	192-193

The	O	194-197
structural	O	198-208
gene	O	209-213
for	O	214-217
AGA	O	218-221
has	O	222-225
been	O	226-230
assigned	O	231-239
to	O	240-242
the	O	243-246
region	O	247-253
4q21	O	254-258
-	O	258-259
qter	O	259-263
of	O	264-266
chromosome	O	267-277
4	O	278-279
.	O	279-280

We	O	281-283
have	O	284-288
studied	O	289-296
the	O	297-300
map	O	301-304
position	O	305-313
of	O	314-316
the	O	317-320
AGU	O	321-324
locus	O	325-330
in	O	331-333
relation	O	334-342
to	O	343-345
other	O	346-351
marker	O	352-358
loci	O	359-363
on	O	364-366
the	O	367-370
long	O	371-375
arm	O	376-379
of	O	380-382
chromosome	O	383-393
4	O	394-395
using	O	396-401
linkage	O	402-409
analyses	O	410-418
.	O	418-419

Restriction	O	420-431
fragment	O	432-440
length	O	441-447
polymorphism	O	448-460
alleles	O	461-468
for	O	469-472
the	O	473-476
ADH2	O	477-481
,	O	481-482
ADH3	O	483-487
,	O	487-488
EGF	O	489-492
,	O	492-493
FG	O	494-496
alpha	O	497-502
and	O	503-506
FG	O	507-509
beta	O	510-514
loci	O	515-519
and	O	520-523
blood	O	524-529
group	O	530-535
antigens	O	536-544
for	O	545-548
the	O	549-552
MNS	O	553-556
locus	O	557-562
were	O	563-567
determined	O	568-578
in	O	579-581
a	O	582-583
panel	O	584-589
of	O	590-592
12	O	593-595
Finnish	O	596-603
AGU	B	604-607
families	O	608-616
.	O	616-617

The	O	618-621
heterozygous	O	622-634
family	O	635-641
members	O	642-649
were	O	650-654
identified	O	655-665
by	O	666-668
reduced	O	669-676
activity	O	677-685
of	O	686-688
AGA	O	689-692
in	O	693-695
lymphocytes	O	696-707
.	O	707-708

Linkage	O	709-716
studies	O	717-724
were	O	725-729
performed	O	730-739
using	O	740-745
both	O	746-750
pairwise	O	751-759
and	O	760-763
multipoint	O	764-774
analyses	O	775-783
.	O	783-784

Loose	O	785-790
linkage	O	791-798
of	O	799-801
the	O	802-805
AGU	B	806-809
locus	O	810-815
to	O	816-818
the	O	819-822
FG	O	823-825
and	O	826-829
MNS	O	830-833
loci	O	834-838
was	O	839-842
observed	O	843-851
(	O	852-853
z	O	853-854
=	O	855-856
1	O	857-858
.	O	858-859

16	O	860-862
,	O	862-863
z	O	864-865
=	O	866-867
1	O	868-869
.	O	869-870

39	O	871-873
,	O	873-874
respectively	O	875-887
)	O	887-888
.	O	888-889

Multipoint	O	890-900
analysis	O	901-909
to	O	910-912
the	O	913-916
fixed	O	917-922
map	O	923-926
[	O	927-928
ADH	O	928-931
-	O	931-932
(	O	933-934
0	O	934-935
.	O	935-936
03	O	937-939
)	O	939-940
-	O	941-942
EGF	O	942-945
-	O	941-942
(	O	947-948
0	O	948-949
.	O	949-950
35	O	951-953
)	O	953-954
-	O	955-956
FG	O	956-958
-	O	955-956
(	O	960-961
0	O	961-962
.	O	962-963
11	O	964-966
)	O	966-967
-	O	968-969
MNS	O	969-972
]	O	972-973
suggests	O	974-982
that	O	983-987
the	O	988-991
location	O	992-1000
of	O	1001-1003
the	O	1004-1007
AGU	O	1008-1011
locus	O	1012-1017
is	O	1018-1020
0	O	1021-1022
.	O	1022-1023
05	O	1024-1026
-	O	1026-1027
0	O	1024-1025
.	O	1028-1029

30	O	1030-1032
recombination	O	1033-1046
units	O	1047-1052
distal	O	1053-1059
to	O	1060-1062
MNS	O	1063-1066
(	O	1067-1068
z	O	1068-1069
=	O	1070-1071
3	O	1072-1073
.	O	1073-1074
03	O	1075-1077
)	O	1077-1078
.	O	1078-1079

The	O	1080-1083
order	O	1084-1089
cen	O	1090-1093
-	O	1093-1094
ADH	O	1094-1097
-	O	1093-1094
EGF	O	1098-1101
-	O	1093-1094
FG	O	1102-1104
-	O	1093-1094
MNS	O	1105-1108
-	O	1093-1094
AGU	O	1109-1112
is	O	1113-1115
35	O	1116-1118
times	O	1119-1124
more	O	1125-1129
likely	O	1130-1136
than	O	1137-1141
the	O	1142-1145
next	O	1146-1150
best	O	1151-1155
order	O	1156-1161
cen	O	1162-1165
-	O	1165-1166
ADH	O	1166-1169
-	O	1165-1166
EGF	O	1170-1173
-	O	1165-1166
AGU	O	1174-1177
-	O	1165-1166
FG	O	1178-1180
-	O	1165-1166
MNS	O	1181-1184
.	O	1184-1185

Linkage	O	0-7
analysis	O	8-16
in	O	17-19
X	B	20-21
-	I	21-22
linked	I	22-28
adrenoleukodystrophy	I	29-49
and	O	50-53
application	O	54-65
in	O	66-68
post	O	69-73
-	O	73-74
and	O	75-78
prenatal	O	79-87
diagnosis	O	88-97
.	O	97-98

We	O	99-101
have	O	102-106
performed	O	107-116
linkage	O	117-124
analysis	O	125-133
with	O	134-138
the	O	139-142
DNA	O	143-146
markers	O	147-154
DXS52	O	155-160
and	O	161-164
the	O	165-168
clotting	O	169-177
factor	O	178-184
VIII	O	185-189
gene	O	190-194
(	O	195-196
F8C	O	196-199
)	O	199-200
,	O	200-201
in	O	202-204
several	O	205-212
large	O	213-218
families	O	219-227
with	O	228-232
X	B	233-234
-	I	234-235
linked	I	235-241
adrenoleukodystrophy	I	242-262
(	O	263-264
ALD	B	264-267
)	O	267-268
.	O	268-269

The	O	270-273
tight	O	274-279
linkage	O	280-287
to	O	288-290
DXS52	O	291-296
could	O	297-302
be	O	303-305
extended	O	306-314
giving	O	315-321
a	O	322-323
maximal	O	324-331
LOD	O	332-335
score	O	336-341
of	O	342-344
22	O	345-347
.	O	347-348
5	O	349-350
at	O	351-353
1	O	354-355
cM	O	356-358
.	O	358-359

F8C	O	360-363
was	O	364-367
also	O	368-372
tightly	O	373-380
linked	O	381-387
to	O	388-390
ALD	B	391-394
with	O	395-399
a	O	400-401
maximal	O	402-409
LOD	O	410-413
score	O	414-419
of	O	420-422
7	O	423-424
.	O	424-425
8	O	426-427
without	O	428-435
recombination	O	436-449
.	O	449-450

Multipoint	O	451-461
linkage	O	462-469
analysis	O	470-478
with	O	479-483
the	O	484-487
markers	O	488-495
DXS304	O	496-502
,	O	502-503
DXS52	O	504-509
,	O	509-510
and	O	511-514
F8C	O	515-518
indicated	O	519-528
that	O	529-533
both	O	534-538
the	O	539-542
gene	O	543-547
for	O	548-551
ALD	B	552-555
and	O	556-559
for	O	560-563
F8C	O	564-567
are	O	568-571
distal	O	572-578
to	O	579-581
DXS52	O	582-587
.	O	587-588

In	O	589-591
four	O	592-596
patients	O	597-605
with	O	606-610
ALD	B	611-614
,	O	614-615
no	O	616-618
major	O	619-624
structural	O	625-635
rearrangement	O	636-649
in	O	650-652
the	O	653-656
Xqter	O	657-662
region	O	663-669
was	O	670-673
observed	O	674-682
;	O	682-683
in	O	684-686
particular	O	687-697
,	O	697-698
there	O	699-704
were	O	705-709
no	O	710-712
abnormalities	B	713-726
in	I	727-729
the	I	730-733
vision	I	734-740
blindness	I	741-750
genes	I	751-756
.	O	756-757

DNA	O	758-761
analysis	O	762-770
appeared	O	771-779
to	O	780-782
be	O	783-785
of	O	786-788
use	O	789-792
in	O	793-795
determination	O	796-809
of	O	810-812
the	O	813-816
carrier	O	817-824
status	O	825-831
of	O	832-834
females	O	835-842
at	O	843-845
risk	O	846-850
,	O	850-851
for	O	852-855
the	O	856-859
determination	O	860-873
of	O	874-876
the	O	877-880
origin	O	881-887
of	O	888-890
the	O	891-894
mutation	O	895-903
in	O	904-906
a	O	907-908
particular	O	909-919
family	O	920-926
,	O	926-927
and	O	928-931
for	O	932-935
prenatal	O	936-944
diagnosis	O	945-954
.	O	954-955

Multicentric	O	0-12
origin	O	13-19
of	O	20-22
hemochromatosis	B	23-38
gene	O	39-43
(	O	44-45
HFE	O	45-48
)	O	48-49
mutations	O	50-59
.	O	59-60

Genetic	B	61-68
hemochromatosis	I	69-84
(	O	85-86
GH	B	86-88
)	O	88-89
is	O	90-92
believed	O	93-101
to	O	102-104
be	O	105-107
a	O	108-109
disease	O	110-117
restricted	O	118-128
to	O	129-131
those	O	132-137
of	O	138-140
European	O	141-149
ancestry	O	150-158
.	O	158-159

In	O	160-162
northwestern	O	163-175
Europe	O	176-182
,	O	182-183
>	O	184-185
80	O	186-188
%	O	188-189
of	O	190-192
GH	B	193-195
patients	O	196-204
are	O	205-208
homozygous	O	209-219
for	O	220-223
one	O	224-227
mutation	O	228-236
,	O	236-237
the	O	238-241
substitution	O	242-254
of	O	255-257
tyrosine	O	258-266
for	O	267-270
cysteine	O	271-279
at	O	280-282
position	O	283-291
282	O	292-295
(	O	296-297
C282Y	O	297-302
)	O	302-303
in	O	304-306
the	O	307-310
unprocessed	O	311-322
protein	O	323-330
.	O	330-331

In	O	332-334
a	O	335-336
proportion	O	337-347
of	O	348-350
GH	B	351-353
patients	O	354-362
,	O	362-363
two	O	364-367
mutations	O	368-377
are	O	378-381
present	O	382-389
,	O	389-390
C282Y	O	391-396
and	O	397-400
H63D	O	401-405
.	O	405-406

The	O	407-410
clinical	O	411-419
significance	O	420-432
of	O	433-435
this	O	436-440
second	O	441-447
mutation	O	448-456
is	O	457-459
such	O	460-464
that	O	465-469
it	O	470-472
appears	O	473-480
to	O	481-483
predispose	O	484-494
1	O	495-496
%	O	496-497
-	O	498-499
2	O	499-500
%	O	500-501
of	O	502-504
compound	O	505-513
heterozygotes	O	514-527
to	O	528-530
expression	O	531-541
of	O	542-544
the	O	545-548
disease	O	549-556
.	O	556-557

The	O	558-561
distribution	O	562-574
of	O	575-577
the	O	578-581
two	O	582-585
mutations	O	586-595
differ	O	596-602
,	O	602-603
C282Y	O	604-609
being	O	610-615
limited	O	616-623
to	O	624-626
those	O	627-632
of	O	633-635
northwestern	O	636-648
European	O	649-657
ancestry	O	658-666
and	O	667-670
H63D	O	671-675
being	O	676-681
found	O	682-687
at	O	688-690
allele	O	691-697
frequencies	O	698-709
>	O	710-711
5	O	712-713
%	O	713-714
,	O	714-715
in	O	716-718
Europe	O	719-725
,	O	725-726
in	O	727-729
countries	O	730-739
bordering	O	740-749
the	O	750-753
Mediterranean	O	754-767
,	O	767-768
in	O	769-771
the	O	772-775
Middle	O	776-782
East	O	783-787
,	O	787-788
and	O	789-792
in	O	793-795
the	O	796-799
Indian	O	800-806
subcontinent	O	807-819
.	O	819-820

The	O	821-824
C282Y	O	825-830
mutation	O	831-839
occurs	O	840-846
on	O	847-849
a	O	850-851
haplotype	O	852-861
that	O	862-866
extends	O	867-874
<	O	875-876
/	O	876-877
=	O	877-878
6	O	879-880
Mb	O	881-883
,	O	883-884
suggesting	O	885-895
that	O	896-900
this	O	901-905
mutation	O	906-914
has	O	915-918
arisen	O	919-925
during	O	926-932
the	O	933-936
past	O	937-941
2	O	942-943
,	O	943-944
000	O	945-948
years	O	949-954
.	O	954-955

The	O	956-959
H63D	O	960-964
mutation	O	965-973
is	O	974-976
older	O	977-982
and	O	983-986
does	O	987-991
not	O	992-995
occur	O	996-1001
on	O	1002-1004
such	O	1005-1009
a	O	1010-1011
large	O	1012-1017
extended	O	1018-1026
haplotype	O	1027-1036
,	O	1036-1037
the	O	1038-1041
haplotype	O	1042-1051
in	O	1052-1054
this	O	1055-1059
case	O	1060-1064
extending	O	1065-1074
<	O	1075-1076
/	O	1076-1077
=	O	1077-1078
700	O	1079-1082
kb	O	1083-1085
.	O	1085-1086

Here	O	1087-1091
we	O	1092-1094
report	O	1095-1101
the	O	1102-1105
finding	O	1106-1113
of	O	1114-1116
the	O	1117-1120
H63D	O	1121-1125
and	O	1126-1129
C282Y	O	1130-1135
mutations	O	1136-1145
on	O	1146-1148
new	O	1149-1152
haplotypes	O	1153-1163
.	O	1163-1164

In	O	1165-1167
Sri	O	1168-1171
Lanka	O	1172-1177
we	O	1178-1180
have	O	1181-1185
found	O	1186-1191
H63D	O	1192-1196
on	O	1197-1199
three	O	1200-1205
new	O	1206-1209
haplotypes	O	1210-1220
and	O	1221-1224
have	O	1225-1229
found	O	1230-1235
C282Y	O	1236-1241
on	O	1242-1244
one	O	1245-1248
new	O	1249-1252
haplotype	O	1253-1262
,	O	1262-1263
demonstrating	O	1264-1277
that	O	1278-1282
these	O	1283-1288
mutations	O	1289-1298
have	O	1299-1303
arisen	O	1304-1310
independently	O	1311-1324
on	O	1325-1327
this	O	1328-1332
island	O	1333-1339
.	O	1339-1340

These	O	1341-1346
results	O	1347-1354
suggest	O	1355-1362
that	O	1363-1367
the	O	1368-1371
HFE	O	1372-1375
gene	O	1376-1380
has	O	1381-1384
been	O	1385-1389
the	O	1390-1393
subject	O	1394-1401
of	O	1402-1404
selection	O	1405-1414
pressure	O	1415-1423
.	O	1423-1424

These	O	1425-1430
selection	O	1431-1440
pressures	O	1441-1450
could	O	1451-1456
be	O	1457-1459
due	O	1460-1463
to	O	1464-1466
infectious	B	1467-1477
diseases	I	1478-1486
,	O	1486-1487
environmental	O	1488-1501
conditions	O	1502-1512
,	O	1512-1513
or	O	1515-1517
other	O	1518-1523
genetic	B	1524-1531
disorders	I	1532-1541
such	O	1542-1546
as	O	1547-1549
anemia	B	1550-1556
.	O	1556-1557

Identification	O	0-14
and	O	15-18
localization	O	19-31
of	O	32-34
mutations	O	35-44
at	O	45-47
the	O	48-51
Lesch	B	52-57
-	I	57-58
Nyhan	I	58-63
locus	O	64-69
by	O	70-72
ribonuclease	O	73-85
A	O	86-87
cleavage	O	88-96
.	O	96-97

Many	O	98-102
mutations	O	103-112
leading	O	113-120
to	O	121-123
human	O	124-129
disease	O	130-137
are	O	138-141
the	O	142-145
result	O	146-152
of	O	153-155
single	O	156-162
DNA	O	163-166
base	O	167-171
pair	O	172-176
changes	O	177-184
that	O	185-189
cannot	O	190-196
be	O	197-199
identified	O	200-210
by	O	211-213
Southern	O	214-222
analysis	O	223-231
.	O	231-232

This	O	233-237
has	O	238-241
prompted	O	242-250
the	O	251-254
development	O	255-266
of	O	267-269
alternative	O	270-281
assays	O	282-288
for	O	289-292
point	O	293-298
mutation	O	299-307
detection	O	308-317
.	O	317-318

The	O	319-322
recently	O	323-331
described	O	332-341
ribonuclease	O	342-354
A	O	355-356
cleavage	O	357-365
procedure	O	366-375
,	O	375-376
with	O	377-381
a	O	382-383
polyuridylic	O	384-396
acid	O	397-401
-	O	401-402
paper	O	402-407
affinity	O	408-416
chromatography	O	417-431
step	O	432-436
,	O	436-437
has	O	438-441
been	O	442-446
used	O	447-451
to	O	452-454
identify	O	455-463
the	O	464-467
mutational	O	468-478
lesions	O	479-486
in	O	487-489
the	O	490-493
hypoxanthine	O	494-506
phosphoribosyltransferase	O	507-532
(	O	533-534
HPRT	O	534-538
)	O	538-539
messenger	O	540-549
RNAs	O	550-554
of	O	555-557
patients	O	558-566
with	O	567-571
Lesch	B	572-577
-	I	577-578
Nyhan	I	578-583
syndrome	I	584-592
.	O	592-593

Distinctive	O	594-605
ribonuclease	O	606-618
A	O	619-620
cleavage	O	621-629
patterns	O	630-638
were	O	639-643
identified	O	644-654
in	O	655-657
messenger	O	658-667
RNA	O	668-671
from	O	672-676
5	O	677-678
of	O	679-681
14	O	682-684
Lesch	B	685-690
-	I	690-691
Nyhan	I	691-696
patients	O	697-705
who	O	706-709
were	O	710-714
chosen	O	715-721
because	O	722-729
no	O	730-732
HPRT	O	733-737
Southern	O	738-746
or	O	747-749
Northern	O	750-758
blotting	O	759-767
pattern	O	768-775
changes	O	776-783
had	O	784-787
been	O	788-792
found	O	793-798
.	O	798-799

This	O	800-804
approach	O	805-813
now	O	814-817
allows	O	818-824
HPRT	O	825-829
mutation	O	830-838
detection	O	839-848
in	O	849-851
50	O	852-854
percent	O	855-862
of	O	863-865
the	O	866-869
cases	O	870-875
of	O	876-878
Lesch	B	879-884
-	I	884-885
Nyhan	I	885-890
syndrome	I	891-899
.	O	899-900

The	O	901-904
polyuridylic	O	905-917
acid	O	918-922
-	O	922-923
paper	O	923-928
affinity	O	929-937
procedure	O	938-947
provides	O	948-956
a	O	957-958
general	O	959-966
method	O	967-973
for	O	974-977
analysis	O	978-986
of	O	987-989
low	O	990-993
abundance	O	994-1003
messenger	O	1004-1013
RNAs	O	1014-1018
.	O	1018-1019
.	O	1018-1019

MEFV	O	0-4
-	O	4-5
Gene	O	5-9
analysis	O	10-18
in	O	19-21
armenian	O	22-30
patients	O	31-39
with	O	40-44
Familial	B	45-53
Mediterranean	I	54-67
fever	I	68-73
:	O	73-74
diagnostic	O	75-85
value	O	86-91
and	O	92-95
unfavorable	O	96-107
renal	O	108-113
prognosis	O	114-123
of	O	124-126
the	O	127-130
M694V	O	131-136
homozygous	O	137-147
genotype	O	148-156
-	O	156-157
genetic	O	157-164
and	O	165-168
therapeutic	O	169-180
implications	O	181-193
.	O	193-194

Familial	B	195-203
Mediterranean	I	204-217
fever	I	218-223
(	O	224-225
FMF	B	225-228
)	O	228-229
is	O	230-232
a	O	233-234
recessively	B	235-246
inherited	I	247-256
disorder	I	257-265
that	O	266-270
is	O	271-273
common	O	274-280
in	O	281-283
patients	O	284-292
of	O	293-295
Armenian	O	296-304
ancestry	O	305-313
.	O	313-314

To	O	315-317
date	O	318-322
,	O	322-323
its	O	324-327
diagnosis	O	328-337
,	O	337-338
which	O	339-344
can	O	345-348
be	O	349-351
made	O	352-356
only	O	357-361
retrospectively	O	362-377
,	O	377-378
is	O	379-381
one	O	382-385
of	O	386-388
exclusion	O	389-398
,	O	398-399
based	O	400-405
entirely	O	406-414
on	O	415-417
nonspecific	O	418-429
clinical	O	430-438
signs	O	439-444
that	O	445-449
result	O	450-456
from	O	457-461
serosal	B	462-469
inflammation	I	470-482
and	O	483-486
that	O	487-491
may	O	492-495
lead	O	496-500
to	O	501-503
unnecessary	O	504-515
surgery	O	516-523
.	O	523-524

Renal	B	525-530
amyloidosis	I	531-542
,	O	542-543
prevented	O	544-553
by	O	554-556
colchicine	O	557-567
,	O	567-568
is	O	569-571
the	O	572-575
most	O	576-580
severe	O	581-587
complication	O	588-600
of	O	601-603
FMF	B	604-607
,	O	607-608
a	O	609-610
disorder	O	611-619
associated	O	620-630
with	O	631-635
mutations	O	636-645
in	O	646-648
the	O	649-652
MEFV	O	653-657
gene	O	658-662
.	O	662-663

To	O	664-666
evaluate	O	667-675
the	O	676-679
diagnostic	O	680-690
and	O	691-694
prognostic	O	695-705
value	O	706-711
of	O	712-714
MEFV	O	715-719
-	O	719-720
gene	O	720-724
analysis	O	725-733
,	O	733-734
we	O	735-737
investigated	O	738-750
90	O	751-753
Armenian	O	754-762
FMF	B	763-766
patients	O	767-775
from	O	776-780
77	O	781-783
unrelated	O	784-793
families	O	794-802
that	O	803-807
were	O	808-812
not	O	813-816
selected	O	817-825
through	O	826-833
genetic	O	834-841
-	O	841-842
linkage	O	842-849
analysis	O	850-858
.	O	858-859

Eight	O	860-865
mutations	O	866-875
,	O	875-876
one	O	877-880
of	O	881-883
which	O	884-889
(	O	890-891
R408Q	O	891-896
)	O	896-897
is	O	898-900
new	O	901-904
,	O	904-905
were	O	906-910
found	O	911-916
to	O	917-919
account	O	920-927
for	O	928-931
93	O	932-934
%	O	934-935
of	O	936-938
the	O	939-942
163	O	943-946
independent	O	947-958
FMF	B	959-962
alleles	O	963-970
,	O	970-971
with	O	972-976
both	O	977-981
FMF	B	982-985
alleles	O	986-993
identified	O	994-1004
in	O	1005-1007
89	O	1008-1010
%	O	1010-1011
of	O	1012-1014
the	O	1015-1018
patients	O	1019-1027
.	O	1027-1028

In	O	1029-1031
several	O	1032-1039
instances	O	1040-1049
,	O	1049-1050
family	O	1051-1057
studies	O	1058-1065
provided	O	1066-1074
molecular	O	1075-1084
evidence	O	1085-1093
for	O	1094-1097
pseudodominant	O	1098-1112
transmission	O	1113-1125
and	O	1126-1129
incomplete	O	1130-1140
penetrance	O	1141-1151
of	O	1152-1154
the	O	1155-1158
disease	O	1159-1166
phenotype	O	1167-1176
.	O	1176-1177

The	O	1178-1181
M694V	O	1182-1187
homozygous	O	1188-1198
genotype	O	1199-1207
was	O	1208-1211
found	O	1212-1217
to	O	1218-1220
be	O	1221-1223
associated	O	1224-1234
with	O	1235-1239
a	O	1240-1241
higher	O	1242-1248
prevalence	O	1249-1259
of	O	1260-1262
renal	B	1263-1268
amyloidosis	I	1269-1280
and	O	1281-1284
arthritis	B	1285-1294
,	O	1294-1295
compared	O	1296-1304
with	O	1305-1309
other	O	1310-1315
genotypes	O	1316-1325
(	O	1326-1327
P	O	1327-1328
=	O	1329-1330
.	O	1330-1331
0002	O	1332-1336
and	O	1337-1340
P	O	1341-1342
=	O	1343-1344
.	O	1344-1345
006	O	1346-1349
,	O	1349-1350
respectively	O	1351-1363
)	O	1363-1364
.	O	1364-1365

The	O	1366-1369
demonstration	O	1370-1383
of	O	1384-1386
both	O	1387-1391
the	O	1392-1395
diagnostic	O	1396-1406
and	O	1407-1410
prognostic	O	1411-1421
value	O	1422-1427
of	O	1428-1430
MEFV	O	1431-1435
analysis	O	1436-1444
and	O	1445-1448
particular	O	1449-1459
modes	O	1460-1465
of	O	1466-1468
inheritance	O	1469-1480
should	O	1481-1487
lead	O	1488-1492
to	O	1493-1495
new	O	1496-1499
ways	O	1500-1504
for	O	1505-1508
management	O	1509-1519
of	O	1520-1522
FMF	O	1523-1526
-	O	1526-1527
including	O	1527-1536
genetic	O	1537-1544
counseling	O	1545-1555
and	O	1556-1559
therapeutic	O	1560-1571
decisions	O	1572-1581
in	O	1582-1584
affected	O	1585-1593
families	O	1594-1602
.	O	1602-1603

Identification	O	0-14
and	O	15-18
localization	O	19-31
of	O	32-34
huntingtin	O	35-45
in	O	46-48
brain	O	49-54
and	O	55-58
human	O	59-64
lymphoblastoid	O	65-79
cell	O	80-84
lines	O	85-90
with	O	91-95
anti	O	96-100
-	O	100-101
fusion	O	101-107
protein	O	108-115
antibodies	O	116-126
.	O	126-127

The	O	128-131
Huntington	B	132-142
disease	I	143-150
(	O	151-152
HD	B	152-154
)	O	154-155
phenotype	O	156-165
is	O	166-168
associated	O	169-179
with	O	180-184
expansion	O	185-194
of	O	195-197
a	O	198-199
trinucleotide	O	200-213
repeat	O	214-220
in	O	221-223
the	O	224-227
IT15	O	228-232
gene	O	233-237
,	O	237-238
which	O	239-244
is	O	245-247
predicted	O	248-257
to	O	258-260
encode	O	261-267
a	O	268-269
348	O	270-273
-	O	273-274
kDa	O	274-277
protein	O	278-285
named	O	286-291
huntington	O	292-302
.	O	302-303

We	O	304-306
used	O	307-311
polyclonal	O	312-322
and	O	323-326
monoclonal	O	327-337
anti	O	338-342
-	O	342-343
fusion	O	343-349
protein	O	350-357
antibodies	O	358-368
to	O	369-371
identify	O	372-380
native	O	381-387
huntingtin	O	388-398
in	O	399-401
rat	O	402-405
,	O	405-406
monkey	O	407-413
,	O	413-414
and	O	415-418
human	O	419-424
.	O	424-425

Western	O	426-433
blots	O	434-439
revealed	O	440-448
a	O	449-450
protein	O	451-458
with	O	459-463
the	O	464-467
expected	O	468-476
molecular	O	477-486
weight	O	487-493
which	O	494-499
is	O	500-502
present	O	503-510
in	O	511-513
the	O	514-517
soluble	O	518-525
fraction	O	526-534
of	O	535-537
rat	O	538-541
and	O	542-545
monkey	O	546-552
brain	O	553-558
tissues	O	559-566
and	O	567-570
lymphoblastoid	O	571-585
cells	O	586-591
from	O	592-596
control	O	597-604
cases	O	605-610
.	O	610-611

In	O	612-614
lymphoblastoid	O	615-629
cell	O	630-634
lines	O	635-640
from	O	641-645
juvenile	O	646-654
-	O	654-655
onset	O	655-660
heterozygote	O	661-673
HD	B	674-676
cases	O	677-682
,	O	682-683
both	O	684-688
normal	O	689-695
and	O	696-699
mutant	O	700-706
huntingtin	O	707-717
are	O	718-721
expressed	O	722-731
,	O	731-732
and	O	733-736
increasing	O	737-747
repeat	O	748-754
expansion	O	755-764
leads	O	765-770
to	O	771-773
lower	O	774-779
levels	O	780-786
of	O	787-789
the	O	790-793
mutant	O	794-800
protein	O	801-808
.	O	808-809

Immunocytochemistry	O	810-829
indicates	O	830-839
that	O	840-844
huntingtin	O	845-855
is	O	856-858
located	O	859-866
in	O	867-869
neurons	O	870-877
throughout	O	878-888
the	O	889-892
brain	O	893-898
,	O	898-899
with	O	900-904
the	O	905-908
highest	O	909-916
levels	O	917-923
evident	O	924-931
in	O	932-934
larger	O	935-941
neurons	O	942-949
.	O	949-950

In	O	951-953
the	O	954-957
human	O	958-963
striatum	O	964-972
,	O	972-973
huntingtin	O	974-984
is	O	985-987
enriched	O	988-996
in	O	997-999
a	O	1000-1001
patch	O	1002-1007
-	O	1007-1008
like	O	1008-1012
distribution	O	1013-1025
,	O	1025-1026
potentially	O	1027-1038
corresponding	O	1039-1052
to	O	1053-1055
the	O	1056-1059
first	O	1060-1065
areas	O	1066-1071
affected	O	1072-1080
in	O	1081-1083
HD	B	1084-1086
.	O	1086-1087

Subcellular	O	1088-1099
localization	O	1100-1112
of	O	1113-1115
huntingtin	O	1116-1126
is	O	1127-1129
consistent	O	1130-1140
with	O	1141-1145
a	O	1146-1147
cytosolic	O	1148-1157
protein	O	1158-1165
primarily	O	1166-1175
found	O	1176-1181
in	O	1182-1184
somatodendritic	O	1185-1200
regions	O	1201-1208
.	O	1208-1209

Huntingtin	O	1210-1220
appears	O	1221-1228
to	O	1229-1231
particularly	O	1232-1244
associate	O	1245-1254
with	O	1255-1259
microtubules	O	1260-1272
,	O	1272-1273
although	O	1274-1282
some	O	1283-1287
is	O	1288-1290
also	O	1291-1295
associated	O	1296-1306
with	O	1307-1311
synaptic	O	1312-1320
vesicles	O	1321-1329
.	O	1329-1330

On	O	1331-1333
the	O	1334-1337
basis	O	1338-1343
of	O	1344-1346
the	O	1347-1350
localization	O	1351-1363
of	O	1364-1366
huntingtin	O	1367-1377
in	O	1378-1380
association	O	1381-1392
with	O	1393-1397
microtubules	O	1398-1410
,	O	1410-1411
we	O	1412-1414
speculate	O	1415-1424
that	O	1425-1429
the	O	1430-1433
mutation	O	1434-1442
impairs	O	1443-1450
the	O	1451-1454
cytoskeletal	O	1455-1467
anchoring	O	1468-1477
or	O	1478-1480
transport	O	1481-1490
of	O	1491-1493
mitochondria	O	1494-1506
,	O	1506-1507
vesicles	O	1508-1516
,	O	1516-1517
or	O	1518-1520
other	O	1521-1526
organelles	O	1527-1537
or	O	1538-1540
molecules	O	1541-1550
.	O	1550-1551
.	O	1550-1551

Correlation	O	0-11
between	O	12-19
the	O	20-23
location	O	24-32
of	O	33-35
germ	O	36-40
-	O	40-41
line	O	41-45
mutations	O	46-55
in	O	56-58
the	O	59-62
APC	B	63-66
gene	O	67-71
and	O	72-75
the	O	76-79
number	O	80-86
of	O	87-89
colorectal	B	90-100
polyps	I	101-107
in	O	108-110
familial	B	111-119
adenomatous	I	120-131
polyposis	I	132-141
patients	O	142-150
.	O	150-151

Recently	O	152-160
we	O	161-163
have	O	164-168
isolated	O	169-177
the	O	178-181
adenomatous	B	182-193
polyposis	I	194-203
coli	I	204-208
(	O	209-210
APC	B	210-213
)	O	213-214
gene	O	215-219
which	O	220-225
causes	O	226-232
familial	B	233-241
adenomatous	I	242-253
polyposis	I	254-263
(	O	264-265
FAP	B	265-268
)	O	268-269
,	O	269-270
and	O	271-274
its	O	275-278
germ	O	279-283
-	O	283-284
line	O	284-288
mutations	O	289-298
in	O	299-301
a	O	302-303
substantial	O	304-315
number	O	316-322
of	O	323-325
FAP	B	326-329
patients	O	330-338
have	O	339-343
been	O	344-348
identified	O	349-359
.	O	359-360

On	O	361-363
the	O	364-367
basis	O	368-373
of	O	374-376
this	O	377-381
information	O	382-393
,	O	393-394
we	O	395-397
compared	O	398-406
the	O	407-410
location	O	411-419
of	O	420-422
germ	O	423-427
-	O	427-428
line	O	428-432
mutations	O	433-442
in	O	443-445
the	O	446-449
APC	B	450-453
gene	O	454-458
in	O	459-461
22	O	462-464
unrelated	O	465-474
patients	O	475-483
(	O	484-485
12	O	485-487
of	O	488-490
whom	O	491-495
have	O	496-500
been	O	501-505
reported	O	506-514
previously	O	515-525
)	O	525-526
with	O	527-531
the	O	532-535
number	O	536-542
of	O	543-545
colorectal	B	546-556
polyps	I	557-563
developed	O	564-573
in	O	574-576
FAP	B	577-580
patients	O	581-589
;	O	589-590
17	O	591-593
were	O	594-598
sparse	O	599-605
types	O	606-611
and	O	612-615
five	O	616-620
were	O	621-625
profuse	O	626-633
types	O	634-639
.	O	639-640

All	O	641-644
but	O	645-648
one	O	649-652
of	O	653-655
the	O	656-659
mutations	O	660-669
were	O	670-674
considered	O	675-685
to	O	686-688
cause	O	689-694
truncation	O	695-705
of	O	706-708
the	O	709-712
gene	O	713-717
product	O	718-725
by	O	726-728
frame	O	729-734
-	O	734-735
shift	O	735-740
due	O	741-744
to	O	745-747
deletion	O	748-756
(	O	757-758
14	O	758-760
cases	O	761-766
)	O	766-767
or	O	768-770
nonsense	O	771-779
mutation	O	780-788
(	O	789-790
seven	O	790-795
cases	O	796-801
)	O	801-802
.	O	802-803

The	O	804-807
location	O	808-816
of	O	817-819
the	O	820-823
germ	O	824-828
-	O	828-829
line	O	829-833
mutations	O	834-843
seems	O	844-849
to	O	850-852
correlate	O	853-862
with	O	863-867
the	O	868-871
two	O	872-875
clinical	O	876-884
types	O	885-890
;	O	890-891
germ	O	892-896
-	O	896-897
line	O	897-901
mutations	O	902-911
in	O	912-914
five	O	915-919
FAP	B	920-923
patients	O	924-932
with	O	933-937
profuse	O	938-945
polyps	B	946-952
were	O	953-957
observed	O	958-966
between	O	967-974
codon	O	975-980
1250	O	981-985
and	O	986-989
codon	O	990-995
1464	O	996-1000
,	O	1000-1001
whereas	O	1002-1009
mutations	O	1010-1019
in	O	1020-1022
17	O	1023-1025
FAP	B	1026-1029
patients	O	1030-1038
with	O	1039-1043
fewer	O	1044-1049
polyps	B	1050-1056
were	O	1057-1061
observed	O	1062-1070
in	O	1071-1073
the	O	1074-1077
other	O	1078-1083
regions	O	1084-1091
of	O	1092-1094
the	O	1095-1098
APC	B	1099-1102
gene	O	1103-1107
.	O	1107-1108

The	O	1109-1112
result	O	1113-1119
suggests	O	1120-1128
that	O	1129-1133
the	O	1134-1137
number	O	1138-1144
of	O	1145-1147
colorectal	B	1148-1158
polyps	I	1159-1165
in	O	1166-1168
FAP	B	1169-1172
patients	O	1173-1181
may	O	1182-1185
be	O	1186-1188
associated	O	1189-1199
with	O	1200-1204
a	O	1205-1206
difference	O	1207-1217
in	O	1218-1220
the	O	1221-1224
stability	O	1225-1234
or	O	1235-1237
biological	O	1238-1248
function	O	1249-1257
of	O	1258-1260
the	O	1261-1264
truncated	O	1265-1274
APC	B	1275-1278
protein	O	1279-1286
.	O	1286-1287
.	O	1286-1287

Duchenne	B	0-8
/	I	8-9
Becker	I	9-15
muscular	I	16-24
dystrophy	I	25-34
:	O	34-35
correlation	O	36-47
of	O	48-50
phenotype	O	51-60
by	O	61-63
electroretinography	O	64-83
with	O	84-88
sites	O	89-94
of	O	95-97
dystrophin	O	98-108
mutations	O	109-118
.	O	118-119

The	O	120-123
dark	O	124-128
-	O	128-129
adapted	O	129-136
electroretinogram	O	137-154
(	O	155-156
ERG	O	156-159
)	O	159-160
of	O	161-163
patients	O	164-172
with	O	173-177
Duchenne	B	178-186
and	I	187-190
Becker	I	191-197
muscular	I	198-206
dystrophy	I	207-216
(	O	217-218
DMD	B	218-221
/	O	221-222
BMD	B	222-225
)	O	225-226
shows	O	227-232
a	O	233-234
marked	O	235-241
reduction	O	242-251
in	O	252-254
b	O	255-256
-	O	256-257
wave	O	257-261
amplitude	O	262-271
.	O	271-272

Genotype	O	273-281
-	O	281-282
phenotype	O	282-291
studies	O	292-299
of	O	300-302
mouse	O	303-308
models	O	309-315
for	O	316-319
DMD	B	320-323
show	O	324-328
position	O	329-337
-	O	337-338
specific	O	338-346
effects	O	347-354
of	O	355-357
the	O	358-361
mutations	O	362-371
upon	O	372-376
the	O	377-380
phenotype	O	381-390
mice	O	392-396
with	O	397-401
5	O	402-403
defects	O	404-411
of	O	412-414
dystrophin	O	415-425
have	O	426-430
normal	O	431-437
ERGs	O	438-442
,	O	442-443
those	O	444-449
with	O	450-454
defects	O	455-462
in	O	463-465
the	O	466-469
central	O	470-477
region	O	478-484
have	O	485-489
a	O	490-491
normal	O	492-498
b	O	499-500
-	O	500-501
wave	O	501-505
amplitude	O	506-515
associated	O	516-526
with	O	527-531
prolonged	O	532-541
implicit	O	542-550
times	O	551-556
for	O	557-560
both	O	561-565
the	O	566-569
b	O	570-571
-	O	571-572
wave	O	572-576
and	O	577-580
oscillatory	O	581-592
potentials	O	593-603
,	O	603-604
and	O	605-608
mice	O	609-613
with	O	614-618
3	O	619-620
defects	O	621-628
have	O	629-633
a	O	634-635
phenotype	O	636-645
similar	O	646-653
to	O	654-656
that	O	657-661
seen	O	662-666
in	O	667-669
DMD	B	671-674
/	O	674-675
BMD	B	675-678
patients	O	679-687
.	O	687-688

The	O	689-692
mouse	O	693-698
studies	O	699-706
suggest	O	707-714
a	O	715-716
key	O	717-720
role	O	721-725
for	O	726-729
the	O	730-733
carboxyl	O	734-742
terminal	O	743-751
dystrophin	O	752-762
isoform	O	763-770
,	O	770-771
Dp260	O	772-777
,	O	777-778
in	O	779-781
retinal	O	782-789
electrophysiology	O	790-807
.	O	807-808

We	O	809-811
have	O	812-816
undertaken	O	817-827
a	O	828-829
systematic	O	830-840
evaluation	O	841-851
of	O	852-854
DMD	B	855-858
/	O	858-859
BMD	B	859-862
patients	O	863-871
through	O	872-879
clinical	O	880-888
examination	O	889-900
and	O	901-904
review	O	905-911
of	O	912-914
the	O	915-918
literature	O	919-929
in	O	930-932
order	O	933-938
to	O	939-941
determine	O	942-951
whether	O	952-959
the	O	960-963
position	O	964-972
-	O	972-973
specific	O	973-981
effects	O	982-989
of	O	990-992
mutations	O	993-1002
noted	O	1003-1008
in	O	1009-1011
the	O	1012-1015
mouse	O	1016-1021
are	O	1022-1025
present	O	1026-1033
in	O	1034-1036
man	O	1037-1040
.	O	1040-1041

We	O	1042-1044
have	O	1045-1049
found	O	1050-1055
that	O	1056-1060
,	O	1060-1061
in	O	1062-1064
man	O	1065-1068
,	O	1068-1069
a	O	1070-1071
wider	O	1072-1077
variation	O	1078-1087
of	O	1088-1090
DMD	B	1091-1094
defects	I	1095-1102
correlate	O	1103-1112
with	O	1113-1117
reductions	O	1118-1128
in	O	1129-1131
the	O	1132-1135
b	O	1136-1137
-	O	1137-1138
wave	O	1138-1142
amplitude	O	1143-1152
.	O	1152-1153

Individuals	O	1154-1165
with	O	1166-1170
normal	O	1171-1177
ERGs	O	1178-1182
have	O	1183-1187
mutations	O	1188-1197
predominantly	O	1198-1211
located	O	1212-1219
5	O	1220-1221
of	O	1222-1224
the	O	1225-1228
transcript	O	1229-1239
initiation	O	1240-1250
site	O	1251-1255
of	O	1256-1258
Dp260	O	1259-1264
.	O	1264-1265

Our	O	1266-1269
results	O	1270-1277
suggest	O	1278-1285
that	O	1286-1290
the	O	1291-1294
most	O	1295-1299
important	O	1300-1309
determinant	O	1310-1321
in	O	1322-1324
the	O	1325-1328
ERG	O	1329-1332
b	O	1333-1334
-	O	1334-1335
wave	O	1335-1339
phenotype	O	1340-1349
is	O	1350-1352
the	O	1353-1356
mutation	O	1357-1365
position	O	1366-1374
,	O	1374-1375
rather	O	1376-1382
than	O	1383-1387
muscle	B	1388-1394
disease	I	1395-1402
severity	O	1403-1411
.	O	1411-1412

Forty	O	1413-1418
-	O	1418-1419
six	O	1419-1422
per	O	1423-1426
cent	O	1427-1431
of	O	1432-1434
patients	O	1435-1443
with	O	1444-1448
mutations	O	1449-1458
5	O	1459-1460
of	O	1461-1463
the	O	1464-1467
Dp260	O	1468-1473
transcript	O	1474-1484
start	O	1485-1490
site	O	1491-1495
have	O	1496-1500
abnormal	O	1501-1509
ERGs	O	1510-1514
,	O	1514-1515
as	O	1516-1518
opposed	O	1519-1526
to	O	1527-1529
94	O	1530-1532
%	O	1532-1533
with	O	1534-1538
more	O	1539-1543
distal	O	1544-1550
mutations	O	1551-1560
.	O	1560-1561

The	O	1562-1565
human	O	1566-1571
genotype	O	1572-1580
-	O	1580-1581
phenotype	O	1581-1590
correlations	O	1591-1603
are	O	1604-1607
consistent	O	1608-1618
with	O	1619-1623
a	O	1624-1625
role	O	1626-1630
for	O	1631-1634
Dp260	O	1635-1640
in	O	1641-1643
normal	O	1644-1650
retinal	O	1651-1658
electrophysiology	O	1659-1676
and	O	1677-1680
may	O	1681-1684
also	O	1685-1689
reflect	O	1690-1697
the	O	1698-1701
expression	O	1702-1712
of	O	1713-1715
other	O	1716-1721
C	O	1722-1723
-	O	1723-1724
terminal	O	1724-1732
dystrophin	O	1733-1743
isoforms	O	1744-1752
and	O	1753-1756
their	O	1757-1762
contributions	O	1763-1776
to	O	1777-1779
retinal	O	1780-1787
signal	O	1788-1794
transmission	O	1795-1807
.	O	1807-1808
.	O	1807-1808

Molecular	O	0-9
characterization	O	10-26
of	O	27-29
two	O	30-33
galactosemia	B	34-46
mutations	O	47-56
and	O	57-60
one	O	61-64
polymorphism	O	65-77
:	O	77-78
implications	O	79-91
for	O	92-95
structure	O	96-105
-	O	105-106
function	O	106-114
analysis	O	115-123
of	O	124-126
human	O	127-132
galactose	O	133-142
-	O	142-143
1	O	143-144
-	O	142-143
phosphate	O	145-154
uridyltransferase	O	155-172
.	O	172-173

We	O	174-176
report	O	177-183
here	O	184-188
the	O	189-192
molecular	O	193-202
characterization	O	203-219
of	O	220-222
two	O	223-226
galactosemia	B	227-239
mutations	O	240-249
,	O	249-250
L74P	O	251-255
and	O	256-259
F171S	O	260-265
,	O	265-266
and	O	267-270
one	O	271-274
polymorphism	O	275-287
,	O	287-288
S135L	O	289-294
,	O	294-295
in	O	296-298
human	O	299-304
galactose	O	305-314
-	O	314-315
1	O	315-316
-	O	314-315
phosphate	O	317-326
uridyltransferase	O	327-344
(	O	345-346
GALT	O	346-350
)	O	350-351
.	O	351-352

Both	O	353-357
galactosemia	B	358-370
mutations	O	371-380
result	O	381-387
in	O	388-390
reduced	O	391-398
enzymatic	O	399-408
activity	O	409-417
when	O	418-422
reconstructed	O	423-436
in	O	437-439
the	O	440-443
cDNA	O	444-448
and	O	449-452
overexpressed	O	453-466
.	O	466-467

The	O	468-471
polymorphism	O	472-484
,	O	484-485
in	O	486-488
contrast	O	489-497
,	O	497-498
has	O	499-502
near	O	503-507
normal	O	508-514
activity	O	515-523
.	O	523-524

Both	O	525-529
mutations	O	530-539
affect	O	540-546
evolutionarily	O	547-561
conserved	O	562-571
residues	O	572-580
,	O	580-581
suggesting	O	582-592
that	O	593-597
they	O	598-602
are	O	603-606
functionally	O	607-619
important	O	620-629
,	O	629-630
while	O	631-636
the	O	637-640
polymorphism	O	641-653
occurs	O	654-660
in	O	661-663
a	O	664-665
nonconserved	O	666-678
domain	O	679-685
which	O	686-691
is	O	692-694
presumably	O	695-705
not	O	706-709
critical	O	710-718
for	O	719-722
enzymatic	O	723-732
function	O	733-741
.	O	741-742

The	O	743-746
F171S	O	747-752
mutation	O	753-761
is	O	762-764
close	O	765-770
to	O	771-773
the	O	774-777
putative	O	778-786
active	O	787-793
-	O	793-794
site	O	794-798
nucleophile	O	799-810
.	O	810-811

Our	O	812-815
data	O	816-820
further	O	821-828
support	O	829-836
the	O	837-840
notion	O	841-847
of	O	848-850
molecular	O	851-860
heterogeneity	O	861-874
of	O	875-877
galactosemia	B	878-890
and	O	891-894
suggest	O	895-902
that	O	903-907
galactosemia	B	908-920
mutations	O	921-930
and	O	931-934
GALT	O	935-939
polymorphisms	O	940-953
may	O	954-957
be	O	958-960
useful	O	961-967
tools	O	968-973
in	O	974-976
highlighting	O	977-989
different	O	990-999
functional	O	1000-1010
domains	O	1011-1018
in	O	1019-1021
human	O	1022-1027
GALT	O	1028-1032
.	O	1032-1033
.	O	1032-1033

Gaucher	B	0-7
disease	I	8-15
:	O	15-16
the	O	17-20
origins	O	21-28
of	O	29-31
the	O	32-35
Ashkenazi	O	36-45
Jewish	O	46-52
N370S	O	53-58
and	O	59-62
84GG	O	63-67
acid	O	68-72
beta	O	73-77
-	O	77-78
glucosidase	O	78-89
mutations	O	90-99
.	O	99-100

Type	O	101-105
1	O	106-107
Gaucher	B	108-115
disease	I	116-123
(	O	124-125
GD	B	125-127
)	O	127-128
,	O	128-129
a	O	130-131
non	O	132-135
-	O	135-136
neuronopathic	O	136-149
lysosomal	B	150-159
storage	I	160-167
disorder	I	168-176
,	O	176-177
results	O	178-185
from	O	186-190
the	O	191-194
deficient	O	195-204
activity	O	205-213
of	O	214-216
acid	O	217-221
beta	O	222-226
-	O	226-227
glucosidase	O	227-238
(	O	239-240
GBA	O	240-243
)	O	243-244
.	O	244-245

Type	O	246-250
1	O	251-252
disease	O	253-260
is	O	261-263
panethnic	O	264-273
but	O	274-277
is	O	278-280
more	O	281-285
prevalent	O	286-295
in	O	296-298
individuals	O	299-310
of	O	311-313
Ashkenazi	O	314-323
Jewish	O	324-330
(	O	331-332
AJ	O	332-334
)	O	334-335
descent	O	336-343
.	O	343-344

Of	O	345-347
the	O	348-351
causative	O	352-361
GBA	O	362-365
mutations	O	366-375
,	O	375-376
N370S	O	377-382
is	O	383-385
particularly	O	386-398
frequent	O	399-407
in	O	408-410
the	O	411-414
AJ	O	415-417
population	O	418-428
,	O	428-429
(	O	430-431
q	O	431-432
approximately	O	433-446
.	O	446-447

03	O	448-450
)	O	450-451
,	O	451-452
whereas	O	453-460
the	O	461-464
84GG	O	465-469
insertion	O	470-479
(	O	480-481
q	O	481-482
approximately	O	483-496
.	O	496-497

003	O	498-501
)	O	501-502
occurs	O	503-509
exclusively	O	510-521
in	O	522-524
the	O	525-528
Ashkenazim	O	529-539
.	O	539-540

To	O	541-543
investigate	O	544-555
the	O	556-559
genetic	O	560-567
history	O	568-575
of	O	576-578
these	O	579-584
mutations	O	585-594
in	O	595-597
the	O	598-601
AJ	O	602-604
population	O	605-615
,	O	615-616
short	O	617-622
tandem	O	623-629
repeat	O	630-636
(	O	637-638
STR	O	638-641
)	O	641-642
markers	O	643-650
were	O	651-655
used	O	656-660
to	O	661-663
map	O	664-667
a	O	668-669
9	O	670-671
.	O	671-672
3	O	673-674
-	O	674-675
cM	O	675-677
region	O	678-684
containing	O	685-695
the	O	696-699
GBA	O	700-703
locus	O	704-709
and	O	710-713
to	O	714-716
genotype	O	717-725
261	O	726-729
AJ	O	730-732
N370S	O	733-738
chromosomes	O	739-750
,	O	750-751
60	O	752-754
European	O	755-763
non	O	764-767
-	O	767-768
Jewish	O	768-774
N370S	O	775-780
chromosomes	O	781-792
,	O	792-793
and	O	794-797
62	O	798-800
AJ	O	801-803
84GG	O	804-808
chromosomes	O	809-820
.	O	820-821

A	O	822-823
highly	O	824-830
conserved	O	831-840
haplotype	O	841-850
at	O	851-853
four	O	854-858
markers	O	859-866
flanking	O	867-875
GBA	O	876-879
(	O	880-881
PKLR	O	881-885
,	O	885-886
D1S1595	O	887-894
,	O	894-895
D1S2721	O	896-903
,	O	903-904
and	O	905-908
D1S2777	O	909-916
)	O	916-917
was	O	918-921
observed	O	922-930
on	O	931-933
both	O	934-938
the	O	939-942
AJ	O	943-945
chromosomes	O	946-957
and	O	958-961
the	O	962-965
non	O	966-969
-	O	969-970
Jewish	O	970-976
N370S	O	977-982
chromosomes	O	983-994
,	O	994-995
suggesting	O	996-1006
the	O	1007-1010
occurrence	O	1011-1021
of	O	1022-1024
a	O	1025-1026
founder	O	1027-1034
common	O	1035-1041
to	O	1042-1044
both	O	1045-1049
populations	O	1050-1061
.	O	1061-1062

Of	O	1063-1065
note	O	1066-1070
,	O	1070-1071
the	O	1072-1075
presence	O	1076-1084
of	O	1085-1087
different	O	1088-1097
divergent	O	1098-1107
haplotypes	O	1108-1118
suggested	O	1119-1128
the	O	1129-1132
occurrence	O	1133-1143
of	O	1144-1146
de	O	1147-1149
novo	O	1150-1154
,	O	1154-1155
recurrent	O	1156-1165
N370S	O	1166-1171
mutations	O	1172-1181
.	O	1181-1182

In	O	1183-1185
contrast	O	1186-1194
,	O	1194-1195
a	O	1196-1197
different	O	1198-1207
conserved	O	1208-1217
haplotype	O	1218-1227
at	O	1228-1230
these	O	1231-1236
markers	O	1237-1244
was	O	1245-1248
identified	O	1249-1259
on	O	1260-1262
the	O	1263-1266
84GG	O	1267-1271
chromosomes	O	1272-1283
,	O	1283-1284
which	O	1285-1290
was	O	1291-1294
unique	O	1295-1301
to	O	1302-1304
the	O	1305-1308
AJ	O	1309-1311
population	O	1312-1322
.	O	1322-1323

On	O	1324-1326
the	O	1327-1330
basis	O	1331-1336
of	O	1337-1339
the	O	1340-1343
linkage	O	1344-1351
disequilibrium	O	1352-1366
(	O	1367-1368
LD	O	1368-1370
)	O	1370-1371
delta	O	1372-1377
values	O	1378-1384
,	O	1384-1385
the	O	1386-1389
non	O	1390-1393
-	O	1393-1394
Jewish	O	1394-1400
European	O	1401-1409
N370S	O	1410-1415
chromosomes	O	1416-1427
had	O	1428-1431
greater	O	1432-1439
haplotype	O	1440-1449
diversity	O	1450-1459
and	O	1460-1463
less	O	1464-1468
LD	O	1469-1471
at	O	1472-1474
the	O	1475-1478
markers	O	1479-1486
flanking	O	1487-1495
the	O	1496-1499
conserved	O	1500-1509
haplotype	O	1510-1519
than	O	1520-1524
did	O	1525-1528
the	O	1529-1532
AJ	O	1533-1535
N370S	O	1536-1541
chromosomes	O	1542-1553
.	O	1553-1554

This	O	1555-1559
finding	O	1560-1567
is	O	1568-1570
consistent	O	1571-1581
with	O	1582-1586
the	O	1587-1590
presence	O	1591-1599
of	O	1600-1602
the	O	1603-1606
N370S	O	1607-1612
mutation	O	1613-1621
in	O	1622-1624
the	O	1625-1628
non	O	1629-1632
-	O	1632-1633
Jewish	O	1633-1639
European	O	1640-1648
population	O	1649-1659
prior	O	1660-1665
to	O	1666-1668
the	O	1669-1672
founding	O	1673-1681
of	O	1682-1684
the	O	1685-1688
AJ	O	1689-1691
population	O	1692-1702
.	O	1702-1703

Coalescence	O	1704-1715
analyses	O	1716-1724
for	O	1725-1728
the	O	1729-1732
N370S	O	1733-1738
and	O	1739-1742
84GG	O	1743-1747
mutations	O	1748-1757
estimated	O	1758-1767
similar	O	1768-1775
coalescence	O	1776-1787
times	O	1788-1793
,	O	1793-1794
of	O	1795-1797
48	O	1798-1800
and	O	1801-1804
55	O	1805-1807
.	O	1807-1808
5	O	1805-1806
generations	O	1810-1821
ago	O	1822-1825
,	O	1825-1826
respectively	O	1827-1839
.	O	1839-1840

The	O	1841-1844
results	O	1845-1852
of	O	1853-1855
these	O	1856-1861
studies	O	1862-1869
are	O	1870-1873
consistent	O	1874-1884
with	O	1885-1889
a	O	1890-1891
significant	O	1892-1903
bottleneck	O	1904-1914
occurring	O	1915-1924
in	O	1925-1927
the	O	1928-1931
AJ	O	1932-1934
population	O	1935-1945
during	O	1946-1952
the	O	1953-1956
first	O	1957-1962
millennium	O	1963-1973
,	O	1973-1974
when	O	1975-1979
the	O	1980-1983
population	O	1984-1994
became	O	1995-2001
established	O	2002-2013
in	O	2014-2016
Europe	O	2017-2023
.	O	2023-2024

Investigation	O	0-13
of	O	14-16
thermoregulatory	O	17-33
characteristics	O	34-49
in	O	50-52
patients	O	53-61
with	O	62-66
Prader	B	67-73
-	I	73-74
Willi	I	74-79
syndrome	I	80-88
.	O	88-89

A	O	90-91
survey	O	92-98
instrument	O	99-109
is	O	110-112
used	O	113-117
to	O	118-120
assess	O	121-127
temperature	O	128-139
regulation	O	140-150
characteristics	O	151-166
in	O	167-169
children	O	170-178
with	O	179-183
Prader	B	184-190
-	I	190-191
Willi	I	191-196
syndrome	I	197-205
(	O	206-207
PWS	B	207-210
)	O	210-211
compared	O	212-220
to	O	221-223
3	O	224-225
control	O	226-233
groups	O	234-240
sibs	O	242-246
of	O	247-249
PWS	B	250-253
patients	O	254-262
(	O	263-264
SIB	O	264-267
)	O	267-268
,	O	268-269
neurodevelopmentally	B	270-290
handicapped	I	291-302
children	O	303-311
(	O	312-313
ND	O	313-315
)	O	315-316
,	O	316-317
and	O	318-321
age	O	322-325
and	O	326-329
gender	O	330-336
matched	O	337-344
well	O	345-349
children	O	350-358
(	O	359-360
WC	O	360-362
)	O	362-363
.	O	363-364

Significant	O	365-376
differences	O	377-388
were	O	389-393
found	O	394-399
between	O	400-407
PWS	B	408-411
patients	O	412-420
,	O	420-421
SIB	O	422-425
controls	O	426-434
,	O	434-435
and	O	436-439
WC	O	440-442
controls	O	443-451
in	O	452-454
the	O	455-458
prevalence	O	459-469
of	O	470-472
febrile	O	473-480
convulsions	O	481-492
,	O	492-493
fever	O	494-499
-	O	499-500
associated	O	500-510
symptoms	O	511-519
,	O	519-520
and	O	521-524
temperature	O	525-536
less	O	537-541
than	O	542-546
94	O	547-549
degrees	O	550-557
F	O	558-559
.	O	559-560
No	O	561-563
differences	O	564-575
were	O	576-580
noted	O	581-586
in	O	587-589
any	O	590-593
variable	O	594-602
between	O	603-610
the	O	611-614
PWS	B	615-618
patients	O	619-627
and	O	628-631
the	O	632-635
ND	O	636-638
controls	O	639-647
,	O	647-648
suggesting	O	649-659
that	O	660-664
these	O	665-670
abnormalities	O	671-684
are	O	685-688
not	O	689-692
unique	O	693-699
to	O	700-702
PWS	B	703-706
,	O	706-707
but	O	708-711
can	O	712-715
occur	O	716-721
in	O	722-724
any	O	725-728
neurodevelopmentally	B	729-749
handicapped	I	750-761
individual	O	762-772
,	O	772-773
further	O	774-781
suggesting	O	782-792
these	O	793-798
do	O	799-801
not	O	802-805
necessarily	O	806-817
reflect	O	818-825
syndrome	O	826-834
-	O	834-835
specific	O	835-843
hypothalamic	B	844-856
abnormalities	I	857-870
.	O	870-871
.	O	870-871

Abnormal	O	0-8
high	O	9-13
density	O	14-21
lipoproteins	O	22-34
in	O	35-37
cerebrotendinous	B	38-54
xanthomatosis	I	55-68
.	O	68-69

The	O	70-73
plasma	O	74-80
lipoprotein	O	81-92
profiles	O	93-101
and	O	102-105
high	O	106-110
density	O	111-118
lipoproteins	O	119-131
(	O	132-133
HDL	O	133-136
)	O	136-137
were	O	138-142
characterized	O	143-156
in	O	157-159
patients	O	160-168
with	O	169-173
the	O	174-177
genetic	B	178-185
disease	I	186-193
cerebrotendinous	B	194-210
xanthomatosis	I	211-224
(	O	225-226
CTX	B	226-229
)	O	229-230
.	O	230-231

Abnormalities	B	232-245
in	I	246-248
the	I	249-252
HDL	I	253-256
may	O	257-260
contribute	O	261-271
to	O	272-274
their	O	275-280
increased	O	281-290
atherogenesis	O	291-304
and	O	305-308
excessive	O	309-318
deposits	O	319-327
of	O	328-330
tissue	O	331-337
sterols	O	338-345
in	O	346-348
the	O	349-352
presence	O	353-361
of	O	362-364
low	O	365-368
or	O	369-371
low	O	372-375
-	O	375-376
normal	O	376-382
concentrations	O	383-397
of	O	398-400
plasma	O	401-407
cholesterol	O	408-419
(	O	420-421
165	O	421-424
+	O	425-426
/	O	426-427
-	O	427-428
25	O	429-431
mg	O	432-434
/	O	434-435
dl	O	435-437
)	O	437-438
and	O	439-442
low	O	443-446
density	O	447-454
lipoproteins	O	455-467
(	O	468-469
LDL	O	469-472
)	O	472-473
.	O	473-474

The	O	475-478
mean	O	479-483
HDL	O	484-487
-	O	487-488
cholesterol	O	488-499
concentration	O	500-513
in	O	514-516
the	O	517-520
CTX	B	521-524
plasmas	O	525-532
was	O	533-536
14	O	537-539
.	O	539-540
5	O	541-542
+	O	543-544
/	O	544-545
-	O	545-546
3	O	547-548
.	O	548-549
2	O	550-551
mg	O	552-554
/	O	554-555
dl	O	555-557
,	O	557-558
about	O	559-564
one	O	565-568
-	O	568-569
third	O	569-574
the	O	575-578
normal	O	579-585
value	O	586-591
.	O	591-592

The	O	593-596
low	O	597-600
HDL	O	601-604
-	O	604-605
cholesterol	O	605-616
reflects	O	617-625
a	O	626-627
low	O	628-631
concentration	O	632-645
and	O	646-649
an	O	650-652
abnormal	O	653-661
lipid	O	662-667
composition	O	668-679
of	O	680-682
the	O	683-686
plasma	O	687-693
HDL	O	694-697
.	O	697-698

Relative	O	699-707
to	O	708-710
normal	O	711-717
HDL	O	718-721
,	O	721-722
the	O	723-726
cholesteryl	O	727-738
esters	O	739-745
are	O	746-749
low	O	750-753
,	O	753-754
free	O	755-759
cholesterol	O	760-771
and	O	772-775
phospholipids	O	776-789
essentially	O	790-801
normal	O	802-808
,	O	808-809
and	O	810-813
triglycerides	O	814-827
increased	O	828-837
.	O	837-838

The	O	839-842
ratio	O	843-848
of	O	849-851
apoprotein	O	852-862
(	O	863-864
apo	O	864-867
)	O	867-868
to	O	869-871
total	O	872-877
cholesterol	O	878-889
in	O	890-892
the	O	893-896
HDL	O	897-900
of	O	901-903
CTX	B	904-907
was	O	908-911
two	O	912-915
to	O	916-918
three	O	919-924
times	O	925-930
greater	O	931-938
than	O	939-943
normal	O	944-950
.	O	950-951

In	O	952-954
the	O	955-958
CTX	B	959-962
HDL	O	963-966
,	O	966-967
the	O	968-971
ratio	O	972-977
of	O	978-980
apoAI	O	981-986
to	O	987-989
apoAII	O	990-996
was	O	997-1000
high	O	1001-1005
,	O	1005-1006
the	O	1007-1010
proportion	O	1011-1021
of	O	1022-1024
apoC	O	1025-1029
low	O	1030-1033
,	O	1033-1034
and	O	1035-1038
a	O	1039-1040
normally	O	1041-1049
minor	O	1050-1055
form	O	1056-1060
of	O	1061-1063
apoAI	O	1064-1069
increased	O	1070-1079
relative	O	1080-1088
to	O	1089-1091
other	O	1092-1097
forms	O	1098-1103
.	O	1103-1104

The	O	1105-1108
HDL	O	1109-1112
in	O	1113-1115
electron	O	1116-1124
micrographs	O	1125-1136
appeared	O	1137-1145
normal	O	1146-1152
morphologically	O	1153-1168
and	O	1169-1172
in	O	1173-1175
particle	O	1176-1184
size	O	1185-1189
.	O	1189-1190

The	O	1191-1194
abnormalities	O	1195-1208
in	O	1209-1211
lipoprotein	O	1212-1223
distribution	O	1224-1236
profile	O	1237-1244
and	O	1245-1248
composition	O	1249-1260
of	O	1261-1263
the	O	1264-1267
plasma	O	1268-1274
HDL	O	1275-1278
result	O	1279-1285
from	O	1286-1290
metabolic	O	1291-1300
defects	O	1301-1308
that	O	1309-1313
are	O	1314-1317
not	O	1318-1321
understood	O	1322-1332
but	O	1333-1336
may	O	1337-1340
be	O	1341-1343
linked	O	1344-1350
to	O	1351-1353
the	O	1354-1357
genetic	B	1358-1365
defect	I	1366-1372
in	O	1373-1375
bile	O	1376-1380
acid	O	1381-1385
synthesis	O	1386-1395
in	O	1396-1398
CTX	B	1399-1402
.	O	1402-1403

As	O	1404-1406
a	O	1407-1408
consequence	O	1409-1420
,	O	1420-1421
it	O	1422-1424
is	O	1425-1427
probable	O	1428-1436
that	O	1437-1441
the	O	1442-1445
normal	O	1446-1452
functions	O	1453-1462
of	O	1463-1465
the	O	1466-1469
HDL	O	1470-1473
,	O	1473-1474
possibly	O	1475-1483
including	O	1484-1493
modulation	O	1494-1504
of	O	1505-1507
LDL	O	1508-1511
-	O	1511-1512
cholesterol	O	1512-1523
uptake	O	1524-1530
and	O	1531-1534
the	O	1535-1538
removal	O	1539-1546
of	O	1547-1549
excess	O	1550-1556
cholesterol	O	1557-1568
from	O	1569-1573
peripheral	O	1574-1584
tissues	O	1585-1592
,	O	1592-1593
are	O	1594-1597
perturbed	O	1598-1607
significantly	O	1608-1621
in	O	1622-1624
this	O	1625-1629
disease	O	1630-1637
.	O	1637-1638

Splicing	O	0-8
defects	O	9-16
in	O	17-19
the	O	20-23
ataxia	B	24-30
-	I	30-31
telangiectasia	I	31-45
gene	O	46-50
,	O	50-51
ATM	O	52-55
:	O	55-56
underlying	O	57-67
mutations	O	68-77
and	O	78-81
consequences	O	82-94
.	O	94-95

Mutations	O	96-105
resulting	O	106-115
in	O	116-118
defective	O	119-128
splicing	O	129-137
constitute	O	138-148
a	O	149-150
significant	O	151-162
proportion	O	163-173
(	O	174-175
30	O	175-177
/	O	177-178
62	O	178-180
[	O	181-182
48	O	182-184
%	O	184-185
]	O	185-186
)	O	186-187
of	O	188-190
a	O	191-192
new	O	193-196
series	O	197-203
of	O	204-206
mutations	O	207-216
in	O	217-219
the	O	220-223
ATM	O	224-227
gene	O	228-232
in	O	233-235
patients	O	236-244
with	O	245-249
ataxia	B	250-256
-	I	256-257
telangiectasia	I	257-271
(	O	272-273
AT	B	273-275
)	O	275-276
that	O	277-281
were	O	282-286
detected	O	287-295
by	O	296-298
the	O	299-302
protein	O	303-310
-	O	310-311
truncation	O	311-321
assay	O	322-327
followed	O	328-336
by	O	337-339
sequence	O	340-348
analysis	O	349-357
of	O	358-360
genomic	O	361-368
DNA	O	369-372
.	O	372-373

Fewer	O	374-379
than	O	380-384
half	O	385-389
of	O	390-392
the	O	393-396
splicing	O	397-405
mutations	O	406-415
involved	O	416-424
the	O	425-428
canonical	O	429-438
AG	O	439-441
splice	O	442-448
-	O	448-449
acceptor	O	449-457
site	O	458-462
or	O	463-465
GT	O	466-468
splice	O	469-475
-	O	475-476
donor	O	476-481
site	O	482-486
.	O	486-487

A	O	488-489
higher	O	490-496
percentage	O	497-507
of	O	508-510
mutations	O	511-520
occurred	O	521-529
at	O	530-532
less	O	533-537
stringently	O	538-549
conserved	O	550-559
sites	O	560-565
,	O	565-566
including	O	567-576
silent	O	577-583
mutations	O	584-593
of	O	594-596
the	O	597-600
last	O	601-605
nucleotide	O	606-616
of	O	617-619
exons	O	620-625
,	O	625-626
mutations	O	627-636
in	O	637-639
nucleotides	O	640-651
other	O	652-657
than	O	658-662
the	O	663-666
conserved	O	667-676
AG	O	677-679
and	O	680-683
GT	O	684-686
in	O	687-689
the	O	690-693
consensus	O	694-703
splice	O	704-710
sites	O	711-716
,	O	716-717
and	O	718-721
creation	O	722-730
of	O	731-733
splice	O	734-740
-	O	740-741
acceptor	O	741-749
or	O	750-752
splice	O	753-759
-	O	759-760
donor	O	760-765
sites	O	766-771
in	O	772-774
either	O	775-781
introns	O	782-789
or	O	790-792
exons	O	793-798
.	O	798-799

These	O	800-805
splicing	O	806-814
mutations	O	815-824
led	O	825-828
to	O	829-831
a	O	832-833
variety	O	834-841
of	O	842-844
consequences	O	845-857
,	O	857-858
including	O	859-868
exon	O	869-873
skipping	O	874-882
and	O	883-886
,	O	886-887
to	O	888-890
a	O	891-892
lesser	O	893-899
degree	O	900-906
,	O	906-907
intron	O	908-914
retention	O	915-924
,	O	924-925
activation	O	926-936
of	O	937-939
cryptic	O	940-947
splice	O	948-954
sites	O	955-960
,	O	960-961
or	O	962-964
creation	O	965-973
of	O	974-976
new	O	977-980
splice	O	981-987
sites	O	988-993
.	O	993-994

In	O	995-997
addition	O	998-1006
,	O	1006-1007
5	O	1008-1009
of	O	1010-1012
12	O	1013-1015
nonsense	O	1016-1024
mutations	O	1025-1034
and	O	1035-1038
1	O	1039-1040
missense	O	1041-1049
mutation	O	1050-1058
were	O	1059-1063
associated	O	1064-1074
with	O	1075-1079
deletion	O	1080-1088
in	O	1089-1091
the	O	1092-1095
cDNA	O	1096-1100
of	O	1101-1103
the	O	1104-1107
exons	O	1108-1113
in	O	1114-1116
which	O	1117-1122
the	O	1123-1126
mutations	O	1127-1136
occurred	O	1137-1145
.	O	1145-1146

No	O	1147-1149
ATM	O	1150-1153
protein	O	1154-1161
was	O	1162-1165
detected	O	1166-1174
by	O	1175-1177
western	O	1178-1185
blotting	O	1186-1194
in	O	1195-1197
any	O	1198-1201
AT	B	1202-1204
cell	O	1205-1209
line	O	1210-1214
in	O	1215-1217
which	O	1218-1223
splicing	O	1224-1232
mutations	O	1233-1242
were	O	1243-1247
identified	O	1248-1258
.	O	1258-1259

Several	O	1260-1267
cases	O	1268-1273
of	O	1274-1276
exon	O	1277-1281
skipping	O	1282-1290
in	O	1291-1293
both	O	1294-1298
normal	O	1299-1305
controls	O	1306-1314
and	O	1315-1318
patients	O	1319-1327
for	O	1328-1331
whom	O	1332-1336
no	O	1337-1339
underlying	O	1340-1350
defect	O	1351-1357
could	O	1358-1363
be	O	1364-1366
found	O	1367-1372
in	O	1373-1375
genomic	O	1376-1383
DNA	O	1384-1387
were	O	1388-1392
also	O	1393-1397
observed	O	1398-1406
,	O	1406-1407
suggesting	O	1408-1418
caution	O	1419-1426
in	O	1427-1429
the	O	1430-1433
interpretation	O	1434-1448
of	O	1449-1451
exon	O	1452-1456
deletions	O	1457-1466
observed	O	1467-1475
in	O	1476-1478
ATM	O	1479-1482
cDNA	O	1483-1487
when	O	1488-1492
there	O	1493-1498
is	O	1499-1501
no	O	1502-1504
accompanying	O	1505-1517
identification	O	1518-1532
of	O	1533-1535
genomic	O	1536-1543
mutations	O	1544-1553
.	O	1553-1554
.	O	1553-1554

Mutations	O	0-9
of	O	10-12
the	O	13-16
cathepsin	O	17-26
C	O	27-28
gene	O	29-33
are	O	34-37
responsible	O	38-49
for	O	50-53
Papillon	B	54-62
-	I	62-63
Lefevre	I	63-70
syndrome	I	71-79
.	O	79-80

Papillon	B	81-89
-	I	89-90
Lefevre	I	90-97
syndrome	I	98-106
(	O	107-108
PLS	B	108-111
)	O	111-112
is	O	113-115
an	O	116-118
autosomal	B	119-128
recessive	I	129-138
disorder	I	139-147
characterised	O	148-161
by	O	162-164
palmoplantar	B	165-177
hyperkeratosis	I	178-192
and	O	193-196
severe	O	197-203
early	O	204-209
onset	O	210-215
periodontitis	B	216-229
that	O	230-234
results	O	235-242
in	O	243-245
the	O	246-249
premature	O	250-259
loss	O	260-264
of	O	265-267
the	O	268-271
primary	O	272-279
and	O	280-283
secondary	O	284-293
dentitions	O	294-304
.	O	304-305

A	O	306-307
major	O	308-313
gene	O	314-318
locus	O	319-324
for	O	325-328
PLS	B	329-332
has	O	333-336
been	O	337-341
mapped	O	342-348
to	O	349-351
a	O	352-353
2	O	354-355
.	O	355-356
8	O	357-358
cM	O	359-361
interval	O	362-370
on	O	371-373
chromosome	O	374-384
11q14	O	385-390
.	O	390-391

Correlation	O	392-403
of	O	404-406
physical	O	407-415
and	O	416-419
genetic	O	420-427
maps	O	428-432
of	O	433-435
this	O	436-440
interval	O	441-449
indicate	O	450-458
it	O	459-461
includes	O	462-470
at	O	471-473
least	O	474-479
40	O	480-482
ESTs	O	483-487
and	O	488-491
six	O	492-495
known	O	496-501
genes	O	502-507
including	O	508-517
the	O	518-521
lysosomal	O	522-531
protease	O	532-540
cathepsin	O	541-550
C	O	551-552
gene	O	553-557
(	O	558-559
CTSC	O	559-563
)	O	563-564
.	O	564-565

The	O	566-569
CTSC	O	570-574
message	O	575-582
is	O	583-585
expressed	O	586-595
at	O	596-598
high	O	599-603
levels	O	604-610
in	O	611-613
a	O	614-615
variety	O	616-623
of	O	624-626
immune	O	627-633
cells	O	634-639
including	O	640-649
polymorphonuclear	O	650-667
leucocytes	O	668-678
,	O	678-679
macrophages	O	680-691
,	O	691-692
and	O	693-696
their	O	697-702
precursors	O	703-713
.	O	713-714

By	O	715-717
RT	O	718-720
-	O	720-721
PCR	O	721-724
,	O	724-725
we	O	726-728
found	O	729-734
CTSC	O	735-739
is	O	740-742
also	O	743-747
expressed	O	748-757
in	O	758-760
epithelial	O	761-771
regions	O	772-779
commonly	O	780-788
affected	O	789-797
by	O	798-800
PLS	B	801-804
,	O	804-805
including	O	806-815
the	O	816-819
palms	O	820-825
,	O	825-826
soles	O	827-832
,	O	832-833
knees	O	834-839
,	O	839-840
and	O	841-844
oral	O	845-849
keratinised	O	850-861
gingiva	O	862-869
.	O	869-870

The	O	871-874
4	O	875-876
.	O	876-877
7	O	878-879
kb	O	880-882
CTSC	O	883-887
gene	O	888-892
consists	O	893-901
of	O	902-904
two	O	905-908
exons	O	909-914
.	O	914-915

Sequence	O	916-924
analysis	O	925-933
of	O	934-936
CTSC	O	937-941
from	O	942-946
subjects	O	947-955
affected	O	956-964
with	O	965-969
PLS	B	970-973
from	O	974-978
five	O	979-983
consanguineous	O	984-998
Turkish	O	999-1006
families	O	1007-1015
identified	O	1016-1026
four	O	1027-1031
different	O	1032-1041
mutations	O	1042-1051
.	O	1051-1052

An	O	1053-1055
exon	O	1056-1060
1	O	1061-1062
nonsense	O	1063-1071
mutation	O	1072-1080
(	O	1081-1082
856C	O	1082-1086
-	O	1086-1087
-	O	1086-1087
>	O	1089-1090
T	O	1091-1092
)	O	1092-1093
introduces	O	1094-1104
a	O	1105-1106
premature	O	1107-1116
stop	O	1117-1121
codon	O	1122-1127
at	O	1128-1130
amino	O	1131-1136
acid	O	1137-1141
286	O	1142-1145
.	O	1145-1146

Three	O	1147-1152
exon	O	1153-1157
2	O	1158-1159
mutations	O	1160-1169
were	O	1170-1174
identified	O	1175-1185
,	O	1185-1186
including	O	1187-1196
a	O	1197-1198
single	O	1199-1205
nucleotide	O	1206-1216
deletion	O	1217-1225
(	O	1226-1227
2692delA	O	1227-1235
)	O	1235-1236
of	O	1237-1239
codon	O	1240-1245
349	O	1246-1249
introducing	O	1250-1261
a	O	1262-1263
frameshift	O	1264-1274
and	O	1275-1278
premature	O	1279-1288
termination	O	1289-1300
codon	O	1301-1306
,	O	1306-1307
a	O	1308-1309
2	O	1310-1311
bp	O	1312-1314
deletion	O	1315-1323
(	O	1324-1325
2673	O	1325-1329
-	O	1329-1330
2674delCT	O	1330-1339
)	O	1339-1340
that	O	1341-1345
results	O	1346-1353
in	O	1354-1356
introduction	O	1357-1369
of	O	1370-1372
a	O	1373-1374
stop	O	1375-1379
codon	O	1380-1385
at	O	1386-1388
amino	O	1389-1394
acid	O	1395-1399
343	O	1400-1403
,	O	1403-1404
and	O	1405-1408
a	O	1409-1410
G	O	1411-1412
-	O	1412-1413
-	O	1412-1413
>	O	1415-1416
A	O	1417-1418
substitution	O	1419-1431
in	O	1432-1434
codon	O	1435-1440
429	O	1441-1444
(	O	1445-1446
2931G	O	1446-1451
-	O	1451-1452
-	O	1451-1452
>	O	1454-1455
A	O	1456-1457
)	O	1457-1458
introducing	O	1459-1470
a	O	1471-1472
premature	O	1473-1482
termination	O	1483-1494
codon	O	1495-1500
.	O	1500-1501

All	O	1502-1505
PLS	B	1506-1509
patients	O	1510-1518
were	O	1519-1523
homozygous	O	1524-1534
for	O	1535-1538
cathepsin	O	1539-1548
C	O	1549-1550
mutations	O	1551-1560
inherited	O	1561-1570
from	O	1571-1575
a	O	1576-1577
common	O	1578-1584
ancestor	O	1585-1593
.	O	1593-1594

Parents	O	1595-1602
and	O	1603-1606
sibs	O	1607-1611
heterozygous	O	1612-1624
for	O	1625-1628
cathepsin	O	1629-1638
C	O	1639-1640
mutations	O	1641-1650
do	O	1651-1653
not	O	1654-1657
show	O	1658-1662
either	O	1663-1669
the	O	1670-1673
palmoplantar	B	1674-1686
hyperkeratosis	I	1687-1701
or	O	1702-1704
severe	O	1705-1711
early	O	1712-1717
onset	O	1718-1723
periodontitis	B	1724-1737
characteristic	O	1738-1752
of	O	1753-1755
PLS	B	1756-1759
.	O	1759-1760

A	O	1761-1762
more	O	1763-1767
complete	O	1768-1776
understanding	O	1777-1790
of	O	1791-1793
the	O	1794-1797
functional	O	1798-1808
physiology	O	1809-1819
of	O	1820-1822
cathepsin	O	1823-1832
C	O	1833-1834
carries	O	1835-1842
significant	O	1843-1854
implications	O	1855-1867
for	O	1868-1871
understanding	O	1872-1885
normal	O	1886-1892
and	O	1893-1896
abnormal	O	1897-1905
skin	O	1906-1910
development	O	1911-1922
and	O	1923-1926
periodontal	B	1927-1938
disease	I	1939-1946
susceptibility	O	1947-1961

Identification	O	0-14
of	O	15-17
a	O	18-19
single	O	20-26
nucleotide	O	27-37
change	O	38-44
in	O	45-47
the	O	48-51
hypoxanthine	O	52-64
-	O	64-65
guanine	O	65-72
phosphoribosyltransferase	O	73-98
gene	O	99-103
(	O	104-105
HPRTYale	O	105-113
)	O	113-114
responsible	O	115-126
for	O	127-130
Lesch	B	131-136
-	I	136-137
Nyhan	I	137-142
syndrome	I	143-151
.	O	151-152

Complete	O	153-161
deficiency	B	162-172
of	I	173-175
hypoxanthine	I	176-188
-	I	188-189
guanine	I	189-196
phosphoribosyltransferase	I	197-222
(	O	223-224
HPRT	O	224-228
)	O	228-229
causes	O	230-236
the	O	237-240
Lesch	B	241-246
-	I	246-247
Nyhan	I	247-252
syndrome	I	253-261
.	O	261-262

Previous	O	263-271
characterization	O	272-288
of	O	289-291
a	O	292-293
mutant	O	294-300
form	O	301-305
of	O	306-308
HPRT	O	309-313
,	O	313-314
HPRTYale	O	315-323
,	O	323-324
from	O	325-329
a	O	330-331
subject	O	332-339
with	O	340-344
the	O	345-348
Lesch	B	349-354
-	I	354-355
Nyhan	I	355-360
syndrome	I	361-369
revealed	O	370-378
normal	O	379-385
mRNA	O	386-390
and	O	391-394
protein	O	395-402
concentrations	O	403-417
,	O	417-418
no	O	419-421
residual	O	422-430
catalytic	O	431-440
activity	O	441-449
,	O	449-450
and	O	451-454
cathodal	O	455-463
migration	O	464-473
upon	O	474-478
PAGE	O	479-483
.	O	483-484

We	O	485-487
have	O	488-492
cloned	O	493-499
and	O	500-503
sequenced	O	504-513
HPRTYale	O	514-522
cDNA	O	523-527
.	O	527-528

The	O	529-532
nucleotide	O	533-543
sequence	O	544-552
of	O	553-555
full	O	556-560
-	O	560-561
length	O	561-567
HPRTYale	O	568-576
cDNA	O	577-581
revealed	O	582-590
a	O	591-592
single	O	593-599
nucleotide	O	600-610
substitution	O	611-623
compared	O	624-632
with	O	633-637
normal	O	638-644
HPRT	O	645-649
cDNA	O	650-654
G	O	656-657
-	O	657-658
-	O	657-658
-	O	657-658
-	O	657-658
C	O	661-662
at	O	663-665
nucleotide	O	666-676
position	O	677-685
211	O	686-689
.	O	689-690

This	O	691-695
transversion	O	696-708
predicts	O	709-717
substitution	O	718-730
of	O	731-733
arginine	O	734-742
for	O	743-746
glycine	O	747-754
at	O	755-757
amino	O	758-763
acid	O	764-768
position	O	769-777
71	O	778-780
,	O	780-781
explaining	O	782-792
the	O	793-796
cathodal	O	797-805
migration	O	806-815
of	O	816-818
HPRTYale	O	819-827
.	O	827-828

Chou	O	829-833
-	O	833-834
Fasman	O	834-840
secondary	O	841-850
structure	O	851-860
analysis	O	861-869
predicts	O	870-878
a	O	879-880
change	O	881-887
in	O	888-890
the	O	891-894
probability	O	895-906
of	O	907-909
beta	O	910-914
-	O	914-915
turn	O	915-919
formation	O	920-929
in	O	930-932
the	O	933-936
region	O	937-943
containing	O	944-954
the	O	955-958
mutation	O	959-967
.	O	967-968

Inclusion	O	969-978
of	O	979-981
the	O	982-985
bulky	O	986-991
arginine	O	992-1000
side	O	1001-1005
chain	O	1006-1011
in	O	1012-1014
place	O	1015-1020
of	O	1021-1023
glycine	O	1024-1031
probably	O	1032-1040
disrupts	O	1041-1049
protein	O	1050-1057
folding	O	1058-1065
as	O	1066-1068
well	O	1069-1073
.	O	1073-1074

Cloning	O	1075-1082
mutant	O	1083-1089
forms	O	1090-1095
of	O	1096-1098
cDNA	O	1099-1103
allows	O	1104-1110
identification	O	1111-1125
of	O	1126-1128
specific	O	1129-1137
mutations	O	1138-1147
,	O	1147-1148
provides	O	1149-1157
insight	O	1158-1165
into	O	1166-1170
mutational	O	1171-1181
mechanisms	O	1182-1192
,	O	1192-1193
and	O	1194-1197
facilitates	O	1198-1209
structure	O	1210-1219
-	O	1219-1220
function	O	1220-1228
analysis	O	1229-1237
of	O	1238-1240
mutant	O	1241-1247
proteins	O	1248-1256
.	O	1256-1257
.	O	1256-1257

Molecular	O	0-9
detection	O	10-19
of	O	20-22
chromosomal	O	23-34
translocations	O	35-49
that	O	50-54
disrupt	O	55-62
the	O	63-66
putative	O	67-75
retinoblastoma	B	76-90
susceptibility	O	91-105
locus	O	106-111
.	O	111-112

A	O	113-114
candidate	O	115-124
DNA	O	125-128
sequence	O	129-137
with	O	138-142
many	O	143-147
of	O	148-150
the	O	151-154
properties	O	155-165
predicted	O	166-175
for	O	176-179
the	O	180-183
retinoblastoma	B	184-198
susceptibility	O	199-213
(	O	214-215
RB1	O	215-218
)	O	218-219
locus	O	220-225
has	O	226-229
been	O	230-234
cloned	O	235-241
(	O	242-243
S	O	243-244
.	O	244-245

H	O	246-247
.	O	247-248
Friend	O	249-255
,	O	255-256
R	O	257-258
.	O	258-259
Bernards	O	260-268
,	O	268-269
S	O	270-271
.	O	271-272
Rogelj	O	273-279
,	O	279-280
R	O	281-282
.	O	282-283
A	O	284-285
.	O	285-286
Weinberg	O	287-295
,	O	295-296
J	O	297-298
.	O	298-299
M	O	300-301
.	O	301-302
Rapaport	O	303-311
,	O	311-312
D	O	313-314
.	O	314-315
M	O	316-317
.	O	317-318
Albert	O	319-325
,	O	325-326
and	O	327-330
T	O	331-332
.	O	332-333
P	O	334-335
.	O	335-336
Dryja	O	337-342
,	O	342-343
Nature	O	344-350
[	O	351-352
London	O	352-358
]	O	358-359
323	O	360-363
643	O	365-368
-	O	368-369
645	O	369-372
,	O	372-373
1986	O	374-378
)	O	378-379
.	O	379-380

The	O	381-384
large	O	385-390
size	O	391-395
of	O	396-398
this	O	399-403
gene	O	404-408
(	O	409-410
ca	O	410-412
.	O	412-413

200	O	414-417
kilobases	O	418-427
[	O	428-429
kb	O	429-431
]	O	431-432
)	O	432-433
and	O	434-437
its	O	438-441
multiple	O	442-450
dispersed	O	451-460
exons	O	461-466
(	O	467-468
Wiggs	O	468-473
et	O	474-476
al	O	477-479
.	O	479-480
,	O	480-481
N	O	482-483
.	O	483-484
Engl	O	485-489
.	O	489-490

J	O	491-492
.	O	492-493
Med	O	494-497
.	O	497-498

318	O	499-502
151	O	504-507
-	O	507-508
157	O	508-511
,	O	511-512
1988	O	513-517
)	O	517-518
complicate	O	519-529
molecular	O	530-539
screening	O	540-549
strategies	O	550-560
important	O	561-570
in	O	571-573
prenatal	O	574-582
and	O	583-586
presymptomatic	O	587-601
diagnosis	O	602-611
and	O	612-615
in	O	616-618
carrier	O	619-626
detection	O	627-636
.	O	636-637

Here	O	638-642
we	O	643-645
used	O	646-650
field	O	651-656
inversion	O	657-666
gel	O	667-670
electrophoresis	O	671-686
(	O	687-688
FIGE	O	688-692
)	O	692-693
to	O	694-696
construct	O	697-706
a	O	707-708
restriction	O	709-720
map	O	721-724
of	O	725-727
approximately	O	728-741
1	O	742-743
,	O	743-744
000	O	745-748
kb	O	749-751
of	O	752-754
DNA	O	755-758
surrounding	O	759-770
the	O	771-774
RB1	O	775-778
locus	O	779-784
and	O	785-788
to	O	789-791
detect	O	792-798
the	O	799-802
translocation	O	803-816
breakpoints	O	817-828
in	O	829-831
three	O	832-837
retinoblastoma	B	838-852
patients	O	853-861
.	O	861-862

DNA	O	863-866
probes	O	867-873
from	O	874-878
either	O	879-885
the	O	886-889
5	O	890-891
or	O	892-894
3	O	895-896
end	O	897-900
of	O	901-903
the	O	904-907
gene	O	908-912
were	O	913-917
used	O	918-922
to	O	923-925
detect	O	926-932
a	O	933-934
250	O	935-938
-	O	938-939
kb	O	939-941
EagI	O	942-946
restriction	O	947-958
fragment	O	959-967
in	O	968-970
DNA	O	971-974
from	O	975-979
unaffected	O	980-990
individuals	O	991-1002
.	O	1002-1003

Both	O	1004-1008
probes	O	1009-1015
identified	O	1016-1026
an	O	1027-1029
additional	O	1030-1040
hybridizing	O	1041-1052
fragment	O	1053-1061
in	O	1062-1064
the	O	1065-1068
DNA	O	1069-1072
from	O	1073-1077
each	O	1078-1082
patient	O	1083-1090
,	O	1090-1091
permitting	O	1092-1102
the	O	1103-1106
breakpoints	O	1107-1118
in	O	1119-1121
all	O	1122-1125
three	O	1126-1131
to	O	1132-1134
be	O	1135-1137
mapped	O	1138-1144
within	O	1145-1151
the	O	1152-1155
cloned	O	1156-1162
RB1	O	1163-1166
gene	O	1167-1171
.	O	1171-1172

Analysis	O	1173-1181
of	O	1182-1184
the	O	1185-1188
breakpoint	O	1189-1199
in	O	1200-1202
one	O	1203-1206
translocation	O	1207-1220
cell	O	1221-1225
line	O	1226-1230
allowed	O	1231-1238
the	O	1239-1242
RB1	O	1243-1246
gene	O	1247-1251
to	O	1252-1254
be	O	1255-1257
oriented	O	1258-1266
with	O	1267-1271
its	O	1272-1275
5	O	1276-1277
end	O	1278-1281
toward	O	1282-1288
the	O	1289-1292
centromere	O	1293-1303
.	O	1303-1304

The	O	1305-1308
5	O	1309-1310
end	O	1311-1314
of	O	1315-1317
the	O	1318-1321
gene	O	1322-1326
also	O	1327-1331
appeared	O	1332-1340
to	O	1341-1343
be	O	1344-1346
associated	O	1347-1357
with	O	1358-1362
a	O	1363-1364
clustering	O	1365-1375
of	O	1376-1378
sites	O	1379-1384
for	O	1385-1388
several	O	1389-1396
infrequently	O	1397-1409
cleaving	O	1410-1418
restriction	O	1419-1430
enzymes	O	1431-1438
,	O	1438-1439
indicating	O	1440-1450
the	O	1451-1454
presence	O	1455-1463
of	O	1464-1466
an	O	1467-1469
HpaII	O	1470-1475
tiny	O	1476-1480
fragment	O	1481-1489
island	O	1490-1496
.	O	1496-1497

The	O	1498-1501
detection	O	1502-1511
and	O	1512-1515
mapping	O	1516-1523
of	O	1524-1526
the	O	1527-1530
translocation	O	1531-1544
breakpoints	O	1545-1556
of	O	1557-1559
all	O	1560-1563
three	O	1564-1569
retinoblastoma	B	1570-1584
patients	O	1585-1593
to	O	1594-1596
within	O	1597-1603
the	O	1604-1607
putative	O	1608-1616
RB1	O	1617-1620
gene	O	1621-1625
substantiated	O	1626-1639
the	O	1640-1643
authenticity	O	1644-1656
of	O	1657-1659
this	O	1660-1664
candidate	O	1665-1674
sequence	O	1675-1683
and	O	1684-1687
demonstrated	O	1688-1700
the	O	1701-1704
utility	O	1705-1712
of	O	1713-1715
FIGE	O	1716-1720
in	O	1721-1723
detecting	O	1724-1733
chromosomal	O	1734-1745
rearrangements	O	1746-1760
affecting	O	1761-1770
this	O	1771-1775
locus	O	1776-1781
.	O	1781-1782

Constitutional	O	0-14
mutations	O	15-24
in	O	25-27
the	O	28-31
WT1	O	32-35
gene	O	36-40
in	O	41-43
patients	O	44-52
with	O	53-57
Denys	B	58-63
-	I	63-64
Drash	I	64-69
syndrome	I	70-78
.	O	78-79

The	O	80-83
Denys	B	84-89
-	I	89-90
Drash	I	90-95
syndrome	I	96-104
is	O	105-107
characterised	O	108-121
by	O	122-124
a	O	125-126
typical	O	127-134
nephropathy	B	135-146
,	O	146-147
genital	B	148-155
abnormalities	I	156-169
and	O	170-173
also	O	174-178
predisposes	O	179-190
to	O	191-193
the	O	194-197
development	O	198-209
of	O	210-212
Wilms	B	213-218
tumor	I	219-224
.	O	224-225

These	O	226-231
patients	O	232-240
eventually	O	241-251
go	O	252-254
into	O	255-259
end	O	260-263
stage	O	264-269
renal	B	270-275
failure	I	276-283
.	O	283-284

A	O	285-286
candidate	O	287-296
Wilms	B	297-302
tumor	I	303-308
gene	O	309-313
,	O	313-314
WT1	O	315-318
,	O	318-319
from	O	320-324
the	O	325-328
11p13	O	329-334
chromosome	O	335-345
region	O	346-352
has	O	353-356
recently	O	357-365
been	O	366-370
cloned	O	371-377
.	O	377-378

We	O	379-381
have	O	382-386
analysed	O	387-395
the	O	396-399
DNA	O	400-403
sequence	O	404-412
in	O	413-415
constitutional	O	416-430
cells	O	431-436
from	O	437-441
eight	O	442-447
patients	O	448-456
and	O	457-460
have	O	461-465
shown	O	466-471
heterozygous	O	472-484
mutations	O	485-494
in	O	495-497
six	O	498-501
of	O	502-504
them	O	505-509
.	O	509-510

Four	O	511-515
of	O	516-518
the	O	519-522
mutations	O	523-532
were	O	533-537
in	O	538-540
exon	O	541-545
9	O	546-547
,	O	547-548
all	O	549-552
resulting	O	553-562
in	O	563-565
missense	O	566-574
mutations	O	575-584
.	O	584-585

Three	O	586-591
were	O	592-596
at	O	597-599
nucleotide	O	600-610
position	O	611-619
1180	O	620-624
resulting	O	625-634
in	O	635-637
an	O	638-640
arg	O	641-644
>	O	645-646
trp	O	647-650
amino	O	651-656
acid	O	657-661
change	O	662-668
.	O	668-669

The	O	670-673
other	O	674-679
was	O	680-683
at	O	684-686
position	O	687-695
1186	O	696-700
converting	O	701-711
an	O	712-714
asp	O	715-718
>	O	719-720
asn	O	721-724
in	O	725-727
the	O	728-731
predicted	O	732-741
resultant	O	742-751
protein	O	752-759
.	O	759-760

One	O	761-764
patient	O	765-772
had	O	773-776
a	O	777-778
missense	O	779-787
mutation	O	788-796
in	O	797-799
exon	O	800-804
8	O	805-806
,	O	806-807
converting	O	808-818
an	O	819-821
arg	O	822-825
>	O	826-827
his	O	828-831
.	O	831-832

A	O	833-834
single	O	835-841
base	O	842-846
pair	O	847-851
insertion	O	852-861
at	O	862-864
nucleotide	O	865-875
position	O	876-884
821	O	885-888
in	O	889-891
exon	O	892-896
6	O	897-898
resulted	O	899-907
in	O	908-910
the	O	911-914
generation	O	915-925
of	O	926-928
a	O	929-930
premature	O	931-940
stop	O	941-945
codon	O	946-951
in	O	952-954
the	O	955-958
last	O	959-963
patient	O	964-971
.	O	971-972

We	O	973-975
were	O	976-980
unable	O	981-987
to	O	988-990
find	O	991-995
a	O	996-997
mutation	O	998-1006
in	O	1007-1009
one	O	1010-1013
patient	O	1014-1021
despite	O	1022-1029
complete	O	1030-1038
sequencing	O	1039-1049
of	O	1050-1052
the	O	1053-1056
genomic	O	1057-1064
sequence	O	1065-1073
of	O	1074-1076
the	O	1077-1080
gene	O	1081-1085
.	O	1085-1086

The	O	1087-1090
last	O	1091-1095
patient	O	1096-1103
carried	O	1104-1111
a	O	1112-1113
constitutional	O	1114-1128
deletion	O	1129-1137
of	O	1138-1140
the	O	1141-1144
11p13	O	1145-1150
region	O	1151-1157
and	O	1158-1161
no	O	1162-1164
additional	O	1165-1175
mutation	O	1176-1184
was	O	1185-1188
found	O	1189-1194
.	O	1194-1195

There	O	1196-1201
was	O	1202-1205
no	O	1206-1208
obvious	O	1209-1216
correlation	O	1217-1228
between	O	1229-1236
the	O	1237-1240
type	O	1241-1245
of	O	1246-1248
mutation	O	1249-1257
and	O	1258-1261
phenotypic	O	1262-1272
expression	O	1273-1283
.	O	1283-1284

These	O	1285-1290
results	O	1291-1298
further	O	1299-1306
demonstrate	O	1307-1318
that	O	1319-1323
the	O	1324-1327
WT1	O	1328-1331
gene	O	1332-1336
is	O	1337-1339
important	O	1340-1349
in	O	1350-1352
both	O	1353-1357
the	O	1358-1361
development	O	1362-1373
of	O	1374-1376
the	O	1377-1380
kidney	O	1381-1387
and	O	1388-1391
the	O	1392-1395
genito	O	1396-1402
-	O	1402-1403
urinary	O	1403-1410
system	O	1411-1417
.	O	1417-1418
.	O	1417-1418

Four	O	0-4
novel	O	5-10
PEPD	O	11-15
alleles	O	16-23
causing	O	24-31
prolidase	B	32-41
deficiency	I	42-52
.	O	52-53

Mutations	O	54-63
at	O	64-66
the	O	67-70
PEPD	O	71-75
locus	O	76-81
cause	O	82-87
prolidase	B	88-97
deficiency	I	98-108
(	O	109-110
McKusick	O	110-118
170100	O	119-125
)	O	125-126
,	O	126-127
a	O	128-129
rare	O	130-134
autosomal	B	135-144
recessive	I	145-154
disorder	I	155-163
characterized	O	164-177
by	O	178-180
iminodipeptiduria	B	181-198
,	O	198-199
skin	B	200-204
ulcers	I	205-211
,	O	211-212
mental	B	213-219
retardation	I	220-231
,	O	231-232
and	O	233-236
recurrent	O	237-246
infections	O	247-257
.	O	257-258

Four	O	259-263
PEPD	O	264-268
mutations	O	269-278
from	O	279-283
five	O	284-288
severely	O	289-297
affected	O	298-306
individuals	O	307-318
were	O	319-323
characterized	O	324-337
by	O	338-340
analysis	O	341-349
of	O	350-352
reverse	O	353-360
-	O	360-361
transcribed	O	361-372
,	O	372-373
PCR	O	374-377
-	O	377-378
amplified	O	378-387
(	O	388-389
RT	O	389-391
-	O	391-392
PCR	O	392-395
)	O	395-396
cDNA	O	397-401
.	O	401-402

We	O	403-405
used	O	406-410
SSCP	O	411-415
analysis	O	416-424
on	O	425-427
four	O	428-432
overlapping	O	433-444
cDNA	O	445-449
fragments	O	450-459
covering	O	460-468
the	O	469-472
entire	O	473-479
coding	O	480-486
region	O	487-493
of	O	494-496
the	O	497-500
PEPD	O	501-505
gene	O	506-510
and	O	511-514
detected	O	515-523
abnormal	O	524-532
SSCP	O	533-537
bands	O	538-543
for	O	544-547
the	O	548-551
fragment	O	552-560
spanning	O	561-569
all	O	570-573
or	O	574-576
part	O	577-581
of	O	582-584
exons	O	585-590
13	O	591-593
-	O	593-594
15	O	594-596
in	O	597-599
three	O	600-605
of	O	606-608
the	O	609-612
probands	O	613-621
.	O	621-622

Direct	O	623-629
sequencing	O	630-640
of	O	641-643
the	O	644-647
mutant	O	648-654
cDNAs	O	655-660
showed	O	661-667
a	O	668-669
G	O	670-671
-	O	671-672
-	O	671-672
>	O	674-675
A	O	676-677
,	O	677-678
1342	O	679-683
substitution	O	684-696
(	O	697-698
G448R	O	698-703
)	O	703-704
in	O	705-707
two	O	708-711
patients	O	712-720
and	O	721-724
a	O	725-726
3	O	727-728
-	O	728-729
bp	O	729-731
deletion	O	732-740
(	O	741-742
delta	O	742-747
E452	O	748-752
or	O	753-755
delta	O	756-761
E453	O	762-766
)	O	766-767
in	O	768-770
another	O	771-778
.	O	778-779

In	O	780-782
the	O	783-786
other	O	787-792
two	O	793-796
probands	O	797-805
the	O	806-809
amplified	O	810-819
products	O	820-828
were	O	829-833
of	O	834-836
reduced	O	837-844
size	O	845-849
.	O	849-850

Direct	O	851-857
sequencing	O	858-868
of	O	869-871
these	O	872-877
mutant	O	878-884
cDNAs	O	885-890
revealed	O	891-899
a	O	900-901
deletion	O	902-910
of	O	911-913
exon	O	914-918
5	O	919-920
in	O	921-923
one	O	924-927
patient	O	928-935
and	O	936-939
of	O	940-942
exon	O	943-947
7	O	948-949
in	O	950-952
the	O	953-956
other	O	957-962
.	O	962-963

Intronic	O	964-972
sequences	O	973-982
flanking	O	983-991
exons	O	992-997
5	O	998-999
and	O	1000-1003
7	O	1004-1005
were	O	1006-1010
identified	O	1011-1021
using	O	1022-1027
inverse	O	1028-1035
PCR	O	1036-1039
followed	O	1040-1048
by	O	1049-1051
direct	O	1052-1058
sequencing	O	1059-1069
.	O	1069-1070

Conventional	O	1071-1083
PCR	O	1084-1087
and	O	1088-1091
direct	O	1092-1098
sequencing	O	1099-1109
then	O	1110-1114
established	O	1115-1126
the	O	1127-1130
intron	O	1131-1137
-	O	1137-1138
exon	O	1138-1142
borders	O	1143-1150
of	O	1151-1153
the	O	1154-1157
mutant	O	1158-1164
genomic	O	1165-1172
DNA	O	1173-1176
revealing	O	1177-1186
two	O	1187-1190
splice	O	1191-1197
acceptor	O	1198-1206
mutations	O	1207-1216
a	O	1218-1219
G	O	1220-1221
-	O	1221-1222
-	O	1221-1222
>	O	1224-1225
C	O	1226-1227
substitution	O	1228-1240
at	O	1241-1243
position	O	1244-1252
-	O	1253-1254
1	O	1254-1255
of	O	1256-1258
intron	O	1259-1265
4	O	1266-1267
and	O	1268-1271
an	O	1272-1274
A	O	1275-1276
-	O	1276-1277
-	O	1276-1277
>	O	1279-1280
G	O	1281-1282
substitution	O	1283-1295
at	O	1296-1298
position	O	1299-1307
-	O	1308-1309
2	O	1309-1310
of	O	1311-1313
intron	O	1314-1320
6	O	1321-1322
.	O	1322-1323

Our	O	1324-1327
results	O	1328-1335
indicate	O	1336-1344
that	O	1345-1349
the	O	1350-1353
severe	O	1354-1360
form	O	1361-1365
of	O	1366-1368
prolidase	B	1369-1378
deficiency	I	1379-1389
is	O	1390-1392
caused	O	1393-1399
by	O	1400-1402
multiple	O	1403-1411
PEPD	O	1412-1416
alleles	O	1417-1424
.	O	1424-1425

In	O	1426-1428
this	O	1429-1433
report	O	1434-1440
we	O	1441-1443
attempt	O	1444-1451
to	O	1452-1454
begin	O	1455-1460
the	O	1461-1464
process	O	1465-1472
of	O	1473-1475
describing	O	1476-1486
these	O	1487-1492
alleles	O	1493-1500
and	O	1501-1504
cataloging	O	1505-1515
their	O	1516-1521
phenotypic	O	1522-1532
expression	O	1533-1543
.	O	1543-1544
.	O	1543-1544

Translocation	O	0-13
t	O	14-15
(	O	15-16
5	O	16-17
;	O	17-18
11	O	18-20
)	O	20-21
(	O	15-16
q13	O	22-25
.	O	25-26
1	O	18-19
;	O	17-18
p13	O	28-31
)	O	20-21

associated	O	33-43
with	O	44-48
familial	O	49-57
isolated	B	58-66
aniridia	I	67-75
.	O	75-76

A	O	77-78
father	O	79-85
and	O	86-89
daughter	O	90-98
with	O	99-103
isolated	B	104-112
aniridia	I	113-121
were	O	122-126
observed	O	127-135
to	O	136-138
have	O	139-143
an	O	144-146
apparently	O	147-157
balanced	O	158-166
,	O	166-167
reciprocal	O	168-178
translocation	O	179-192
involving	O	193-202
chromosomes	O	203-214
5	O	215-216
and	O	217-220
11	O	221-223
[	O	224-225
t	O	225-226
(	O	227-228
5	O	228-229
;	O	229-230
11	O	231-233
)	O	233-234
(	O	235-236
q13	O	236-239
.	O	239-240

1	O	241-242
;	O	242-243
p13	O	244-247
)	O	247-248
]	O	248-249
.	O	249-250

No	O	251-253
other	O	254-259
clinical	O	260-268
characteristics	O	269-284
often	O	285-290
associated	O	291-301
with	O	302-306
the	O	307-310
deletion	O	311-319
of	O	320-322
11p13	O	323-328
were	O	329-333
observed	O	334-342
in	O	343-345
this	O	346-350
family	O	351-357
.	O	357-358

This	O	359-363
finding	O	364-371
,	O	371-372
in	O	373-375
association	O	376-387
with	O	388-392
3	O	393-394
other	O	395-400
instances	O	401-410
of	O	411-413
single	O	414-420
breaks	O	421-427
at	O	428-430
11p13	O	431-436
and	O	437-440
aniridia	B	441-449
,	O	449-450
supports	O	451-459
the	O	460-463
assignment	O	464-474
of	O	475-477
AN2	O	478-481
to	O	482-484
11p13	O	485-490
.	O	490-491

Genotype	O	0-8
-	O	8-9
phenotype	O	9-18
analysis	O	19-27
in	O	28-30
X	B	31-32
-	I	32-33
linked	I	33-39
Emery	I	40-45
-	I	45-46
Dreifuss	I	46-54
muscular	I	55-63
dystrophy	I	64-73
and	O	74-77
identification	O	78-92
of	O	93-95
a	O	96-97
missense	O	98-106
mutation	O	107-115
associated	O	116-126
with	O	127-131
a	O	132-133
milder	O	134-140
phenotype	O	141-150
.	O	150-151

Direct	O	152-158
sequencing	O	159-169
of	O	170-172
the	O	173-176
emerin	O	177-183
gene	O	184-188
in	O	189-191
22	O	192-194
families	O	195-203
with	O	204-208
Emery	B	209-214
-	I	214-215
Dreifuss	I	215-223
muscular	I	224-232
dystrophy	I	233-242
(	O	243-244
EMD	B	244-247
)	O	247-248
revealed	O	249-257
mutations	O	258-267
in	O	268-270
21	O	271-273
(	O	274-275
95	O	275-277
%	O	277-278
)	O	278-279
,	O	279-280
confirming	O	281-291
that	O	292-296
emerin	O	297-303
mutations	O	304-313
can	O	314-317
be	O	318-320
identified	O	321-331
in	O	332-334
the	O	335-338
majority	O	339-347
of	O	348-350
families	O	351-359
with	O	360-364
X	B	365-366
-	I	366-367
linked	I	367-373
EMD	I	374-377
.	O	377-378

Most	O	379-383
emerin	O	384-390
mutations	O	391-400
result	O	401-407
in	O	408-410
absence	O	411-418
of	O	419-421
the	O	422-425
protein	O	426-433
.	O	433-434

In	O	435-437
this	O	438-442
study	O	443-448
three	O	449-454
mutations	O	455-464
(	O	465-466
a	O	466-467
missense	O	468-476
mutation	O	477-485
Pro183Thr	O	486-495
and	O	496-499
two	O	500-503
in	O	504-506
-	O	506-507
frame	O	507-512
deletions	O	513-522
removing	O	523-531
residues	O	532-540
95	O	541-543
-	O	543-544
99	O	544-546
and	O	547-550
236	O	551-554
-	O	554-555
241	O	555-558
,	O	558-559
respectively	O	560-572
)	O	572-573
were	O	574-578
unusual	O	579-586
in	O	587-589
being	O	590-595
associated	O	596-606
with	O	607-611
expression	O	612-622
of	O	623-625
mutant	O	626-632
protein	O	633-640
.	O	640-641

The	O	642-645
phenotype	O	646-655
in	O	656-658
these	O	659-664
families	O	665-673
was	O	674-677
compared	O	678-686
in	O	687-689
detail	O	690-696
with	O	697-701
the	O	702-705
clinical	O	706-714
features	O	715-723
in	O	724-726
cases	O	727-732
with	O	733-737
typical	O	738-745
null	O	746-750
mutations	O	751-760
.	O	760-761

For	O	762-765
the	O	766-769
in	O	770-772
-	O	772-773
frame	O	773-778
deletions	O	779-788
there	O	789-794
were	O	795-799
no	O	800-802
significant	O	803-814
differences	O	815-826
.	O	826-827

In	O	828-830
the	O	831-834
family	O	835-841
with	O	842-846
the	O	847-850
missense	O	851-859
mutation	O	860-868
the	O	869-872
phenotype	O	873-882
was	O	883-886
milder	O	887-893
.	O	893-894

Age	O	895-898
at	O	899-901
onset	O	902-907
was	O	908-911
later	O	912-917
for	O	918-921
first	O	922-927
symptoms	O	928-936
and	O	937-940
for	O	941-944
development	O	945-956
of	O	957-959
ankle	B	960-965
contractures	I	966-978
and	O	979-982
muscle	B	983-989
weakness	I	990-998
.	O	998-999

These	O	1000-1005
findings	O	1006-1014
have	O	1015-1019
diagnostic	O	1020-1030
implications	O	1031-1043
as	O	1044-1046
well	O	1047-1051
as	O	1052-1054
pointing	O	1055-1063
to	O	1064-1066
functionally	O	1067-1079
important	O	1080-1089
regions	O	1090-1097
of	O	1098-1100
the	O	1101-1104
emerin	O	1105-1111
protein	O	1112-1119
.	O	1119-1120
.	O	1119-1120

Asef	O	0-4
,	O	4-5
a	O	6-7
link	O	8-12
between	O	13-20
the	O	21-24
tumor	B	25-30
suppressor	O	31-41
APC	O	42-45
and	O	46-49
G	O	50-51
-	O	51-52
protein	O	52-59
signaling	O	60-69
.	O	69-70

The	O	71-74
adenomatous	B	75-86
polyposis	I	87-96
coli	I	97-101
gene	O	102-106
(	O	107-108
APC	O	108-111
)	O	111-112
is	O	113-115
mutated	O	116-123
in	O	124-126
familial	B	127-135
adenomatous	I	136-147
polyposis	I	148-157
and	O	158-161
in	O	162-164
sporadic	O	165-173
colorectal	B	174-184
tumors	I	185-191
.	O	191-192

Here	O	193-197
the	O	198-201
APC	B	202-205
gene	O	206-210
product	O	211-218
is	O	219-221
shown	O	222-227
to	O	228-230
bind	O	231-235
through	O	236-243
its	O	244-247
armadillo	O	248-257
repeat	O	258-264
domain	O	265-271
to	O	272-274
a	O	275-276
Rac	O	277-280
-	O	280-281
specific	O	281-289
guanine	O	290-297
nucleotide	O	298-308
exchange	O	309-317
factor	O	318-324
(	O	325-326
GEF	O	326-329
)	O	329-330
,	O	330-331
termed	O	332-338
Asef	O	339-343
.	O	343-344

Endogenous	O	345-355
APC	O	356-359
colocalized	O	360-371
with	O	372-376
Asef	O	377-381
in	O	382-384
mouse	O	385-390
colon	O	391-396
epithelial	O	397-407
cells	O	408-413
and	O	414-417
neuronal	O	418-426
cells	O	427-432
.	O	432-433

Furthermore	O	434-445
,	O	445-446
APC	O	447-450
enhanced	O	451-459
the	O	460-463
GEF	O	464-467
activity	O	468-476
of	O	477-479
Asef	O	480-484
and	O	485-488
stimulated	O	489-499
Asef	O	500-504
-	O	504-505
mediated	O	505-513
cell	O	514-518
flattening	O	519-529
,	O	529-530
membrane	O	531-539
ruffling	O	540-548
,	O	548-549
and	O	550-553
lamellipodia	O	554-566
formation	O	567-576
in	O	577-579
MDCK	O	580-584
cells	O	585-590
.	O	590-591

These	O	592-597
results	O	598-605
suggest	O	606-613
that	O	614-618
the	O	619-622
APC	O	623-626
-	O	626-627
Asef	O	627-631
complex	O	632-639
may	O	640-643
regulate	O	644-652
the	O	653-656
actin	O	657-662
cytoskeletal	O	663-675
network	O	676-683
,	O	683-684
cell	O	685-689
morphology	O	690-700
and	O	701-704
migration	O	705-714
,	O	714-715
and	O	716-719
neuronal	O	720-728
function	O	729-737
.	O	737-738
.	O	737-738

Localization	O	0-12
of	O	13-15
the	O	16-19
region	O	20-26
homologous	O	27-37
to	O	38-40
the	O	41-44
Duchenne	B	45-53
muscular	I	54-62
dystrophy	I	63-72
locus	O	73-78
on	O	79-81
the	O	82-85
mouse	O	86-91
X	O	92-93
chromosome	O	94-104
.	O	104-105

Recent	O	106-112
progress	O	113-121
has	O	122-125
resulted	O	126-134
in	O	135-137
part	O	138-142
of	O	143-145
the	O	146-149
gene	O	150-154
mutated	O	155-162
in	O	163-165
Duchenne	B	166-174
and	I	175-178
the	I	179-182
milder	I	183-189
Becker	I	190-196
muscular	I	197-205
dystrophies	I	206-217
being	O	218-223
cloned	O	224-230
and	O	231-234
has	O	235-238
suggested	O	239-248
that	O	249-253
the	O	254-257
gene	O	258-262
itself	O	263-269
extends	O	270-277
over	O	278-282
1	O	283-284
,	O	284-285
000	O	286-289
to	O	290-292
2	O	293-294
,	O	294-295
000	O	296-299
kilobases	O	300-309
(	O	310-311
kb	O	311-313
)	O	313-314
.	O	314-315

To	O	316-318
study	O	319-324
how	O	325-328
mutations	O	329-338
in	O	339-341
this	O	342-346
gene	O	347-351
affect	O	352-358
muscle	O	359-365
development	O	366-377
and	O	378-381
integrity	O	382-391
,	O	391-392
it	O	393-395
would	O	396-401
be	O	402-404
of	O	405-407
interest	O	408-416
to	O	417-419
have	O	420-424
available	O	425-434
a	O	435-436
mouse	O	437-442
model	O	443-448
of	O	449-451
the	O	452-455
human	O	456-461
disease	O	462-469
.	O	469-470

The	O	471-474
mouse	O	475-480
mdx	O	481-484
mutation	O	485-493
affects	O	494-501
muscle	O	502-508
and	O	509-512
confers	O	513-520
a	O	521-522
mild	O	523-527
dystrophic	B	528-538
syndrome	I	539-547
,	O	547-548
but	O	549-552
it	O	553-555
is	O	556-558
not	O	559-562
clear	O	563-568
whether	O	569-576
this	O	577-581
mutation	O	582-590
is	O	591-593
equivalent	O	594-604
to	O	605-607
Duchenne	B	608-616
/	I	616-617
Becker	I	617-623
muscular	I	624-632
dystrophy	I	633-642
in	O	643-645
man	O	646-649
.	O	649-650

Here	O	651-655
we	O	656-658
describe	O	659-667
the	O	668-671
use	O	672-675
of	O	676-678
two	O	679-682
sequences	O	683-692
from	O	693-697
the	O	698-701
human	O	702-707
Duchenne	B	708-716
muscular	I	717-725
dystrophy	I	726-735
(	O	736-737
DMD	B	737-740
)	O	740-741
gene	O	742-746
that	O	747-751
cross	O	752-757
-	O	757-758
hybridize	O	758-767
to	O	768-770
mouse	O	771-776
X	O	777-778
-	O	778-779
linked	O	779-785
sequences	O	786-795
to	O	796-798
localize	O	799-807
the	O	808-811
gene	O	812-816
homologous	O	817-827
to	O	828-830
DMD	B	831-834
in	O	835-837
the	O	838-841
mouse	O	842-847
.	O	847-848

Both	O	849-853
sequences	O	854-863
map	O	864-867
to	O	868-870
the	O	871-874
region	O	875-881
of	O	882-884
10	O	885-887
centimorgan	O	888-899
lying	O	900-905
between	O	906-913
the	O	914-917
Tabby	O	918-923
(	O	924-925
Ta	O	925-927
)	O	927-928
and	O	929-932
St14	O	933-937
-	O	937-938
1	O	935-936
(	O	940-941
DxPas8	O	941-947
)	O	947-948
loci	O	949-953
,	O	953-954
close	O	955-960
to	O	961-963
the	O	964-967
phosphorylase	O	968-981
b	O	982-983
kinase	O	984-990
locus	O	991-996
(	O	997-998
Phk	O	998-1001
)	O	1001-1002
.	O	1002-1003

By	O	1004-1006
analogy	O	1007-1014
with	O	1015-1019
the	O	1020-1023
human	O	1024-1029
X	O	1030-1031
-	O	1031-1032
chromosome	O	1032-1042
,	O	1042-1043
we	O	1044-1046
conclude	O	1047-1055
that	O	1056-1060
the	O	1061-1064
region	O	1065-1071
in	O	1072-1074
the	O	1075-1078
mouse	O	1079-1084
around	O	1085-1091
the	O	1092-1095
G6pd	O	1096-1100
and	O	1101-1104
St14	O	1105-1109
-	O	1109-1110
1	O	1107-1108
loci	O	1112-1116
may	O	1117-1120
contain	O	1121-1128
two	O	1129-1132
genes	O	1133-1138
corresponding	O	1139-1152
to	O	1153-1155
distinct	O	1156-1164
human	O	1165-1170
myopathies	B	1171-1181
Emery	B	1183-1188
Dreifuss	I	1189-1197
muscular	I	1198-1206
dystrophy	I	1207-1216
which	O	1217-1222
is	O	1223-1225
known	O	1226-1231
to	O	1232-1234
be	O	1235-1237
closely	O	1238-1245
linked	O	1246-1252
to	O	1253-1255
St14	O	1256-1260
-	O	1260-1261
1	O	1258-1259
in	O	1263-1265
man	O	1266-1269
and	O	1270-1273
the	O	1274-1277
DMD	B	1278-1281
homologue	O	1282-1291
described	O	1292-1301
here	O	1302-1306
.	O	1306-1307
.	O	1306-1307

Molecular	O	0-9
basis	O	10-15
of	O	16-18
hexosaminidase	B	19-33
A	I	34-35
deficiency	I	36-46
and	O	47-50
pseudodeficiency	O	51-67
in	O	68-70
the	O	71-74
Berks	O	75-80
County	O	81-87
Pennsylvania	O	88-100
Dutch	O	101-106
.	O	106-107

Following	O	108-117
the	O	118-121
birth	O	122-127
of	O	128-130
two	O	131-134
infants	O	135-142
with	O	143-147
Tay	B	148-151
-	I	151-152
Sachs	I	152-157
disease	I	158-165
(	O	166-167
TSD	B	167-170
)	O	170-171
,	O	171-172
a	O	173-174
non	O	175-178
-	O	178-179
Jewish	O	179-185
,	O	185-186
Pennsylvania	O	187-199
Dutch	O	200-205
kindred	O	206-213
was	O	214-217
screened	O	218-226
for	O	227-230
TSD	B	231-234
carriers	O	235-243
using	O	244-249
the	O	250-253
biochemical	O	254-265
assay	O	266-271
.	O	271-272

A	O	273-274
high	O	275-279
frequency	O	280-289
of	O	290-292
individuals	O	293-304
who	O	305-308
appeared	O	309-317
to	O	318-320
be	O	321-323
TSD	B	324-327
heterozygotes	O	328-341
was	O	342-345
detected	O	346-354
(	O	355-356
Kelly	O	356-361
et	O	362-364
al	O	365-367
.	O	367-368
,	O	368-369
1975	O	370-374
)	O	374-375
.	O	375-376

Clinical	O	377-385
and	O	386-389
biochemical	O	390-401
evidence	O	402-410
suggested	O	411-420
that	O	421-425
the	O	426-429
increased	O	430-439
carrier	O	440-447
frequency	O	448-457
was	O	458-461
due	O	462-465
to	O	466-468
at	O	469-471
least	O	472-477
two	O	478-481
altered	O	482-489
alleles	O	490-497
for	O	498-501
the	O	502-505
hexosaminidase	O	506-520
A	O	521-522
alpha	O	523-528
-	O	528-529
subunit	O	529-536
.	O	536-537

We	O	538-540
now	O	541-544
report	O	545-551
two	O	552-555
mutant	O	556-562
alleles	O	563-570
in	O	571-573
this	O	574-578
Pennsylvania	O	579-591
Dutch	O	592-597
kindred	O	598-605
,	O	605-606
and	O	607-610
one	O	611-614
polymorphism	O	615-627
.	O	627-628

One	O	629-632
allele	O	633-639
,	O	639-640
reported	O	641-649
originally	O	650-660
in	O	661-663
a	O	664-665
French	O	666-672
TSD	B	673-676
patient	O	677-684
(	O	685-686
Akli	O	686-690
et	O	691-693
al	O	694-696
.	O	696-697
,	O	697-698
1991	O	699-703
)	O	703-704
,	O	704-705
is	O	706-708
a	O	709-710
GT	O	711-713
-	O	713-714
-	O	713-714
>	O	716-717
AT	O	718-720
transition	O	721-731
at	O	732-734
the	O	735-738
donor	O	739-744
splice	O	745-751
-	O	751-752
site	O	752-756
of	O	757-759
intron	O	760-766
9	O	767-768
.	O	768-769

The	O	770-773
second	O	774-780
,	O	780-781
a	O	782-783
C	O	784-785
-	O	785-786
-	O	785-786
>	O	788-789
T	O	790-791
transition	O	792-802
at	O	803-805
nucleotide	O	806-816
739	O	817-820
(	O	821-822
Arg247Trp	O	822-831
)	O	831-832
,	O	832-833
has	O	834-837
been	O	838-842
shown	O	843-848
by	O	849-851
Triggs	O	852-858
-	O	858-859
Raine	O	859-864
et	O	865-867
al	O	868-870
.	O	870-871
(	O	872-873
1992	O	873-877
)	O	877-878
to	O	879-881
be	O	882-884
a	O	885-886
clinically	O	887-897
benign	O	898-904
"	O	905-906
pseudodeficient	O	907-922
"	O	923-924
allele	O	925-931
associated	O	932-942
with	O	943-947
reduced	O	948-955
enzyme	O	956-962
activity	O	963-971
against	O	972-979
artificial	O	980-990
substrate	O	991-1000
.	O	1000-1001

Finally	O	1002-1009
,	O	1009-1010
a	O	1011-1012
polymorphism	O	1013-1025
[	O	1026-1027
G	O	1027-1028
-	O	1028-1029
-	O	1028-1029
>	O	1031-1032
A	O	1033-1034
(	O	1035-1036
759	O	1036-1039
)	O	1039-1040
]	O	1040-1041
,	O	1041-1042
which	O	1043-1048
leaves	O	1049-1055
valine	O	1056-1062
at	O	1063-1065
codon	O	1066-1071
253	O	1072-1075
unchanged	O	1076-1085
,	O	1085-1086
is	O	1087-1089
described	O	1090-1099
.	O	1100-1101

Gene	O	0-4
transfer	O	5-13
and	O	14-17
expression	O	18-28
of	O	29-31
human	O	32-37
phenylalanine	O	38-51
hydroxylase	O	52-63
.	O	63-64

Phenylketonuria	B	65-80
(	O	81-82
PKU	B	82-85
)	O	85-86
is	O	87-89
caused	O	90-96
by	O	97-99
a	O	100-101
genetic	O	102-109
deficiency	B	110-120
of	I	121-123
the	I	124-127
enzyme	I	128-134
phenylalanine	I	135-148
hydroxylase	I	149-160
(	O	161-162
PAH	O	162-165
)	O	165-166
.	O	166-167

A	O	168-169
full	O	170-174
-	O	174-175
length	O	175-181
complementary	O	182-195
DNA	O	196-199
clone	O	200-205
of	O	206-208
human	O	209-214
PAH	O	215-218
was	O	219-222
inserted	O	223-231
into	O	232-236
a	O	237-238
eukaryotic	O	239-249
expression	O	250-260
vector	O	261-267
and	O	268-271
transferred	O	272-283
into	O	284-288
mouse	O	289-294
NIH3T3	O	295-301
cells	O	302-307
which	O	308-313
do	O	314-316
not	O	317-320
normally	O	321-329
express	O	330-337
PAH	O	338-341
.	O	341-342

The	O	343-346
transformed	O	347-358
mouse	O	359-364
cells	O	365-370
expressed	O	371-380
PAH	O	381-384
messenger	O	385-394
RNA	O	395-398
,	O	398-399
immunoreactive	O	400-414
protein	O	415-422
,	O	422-423
and	O	424-427
enzymatic	O	428-437
activity	O	438-446
that	O	447-451
are	O	452-455
characteristic	O	456-470
of	O	471-473
the	O	474-477
normal	O	478-484
human	O	485-490
liver	O	491-496
products	O	497-505
,	O	505-506
demonstrating	O	507-520
that	O	521-525
a	O	526-527
single	O	528-534
gene	O	535-539
contains	O	540-548
all	O	549-552
of	O	553-555
the	O	556-559
necessary	O	560-569
genetic	O	570-577
information	O	578-589
to	O	590-592
code	O	593-597
for	O	598-601
functional	O	602-612
PAH	O	613-616
.	O	616-617

These	O	618-623
results	O	624-631
support	O	632-639
the	O	640-643
use	O	644-647
of	O	648-650
the	O	651-654
human	O	655-660
PAH	O	661-664
probe	O	665-670
in	O	671-673
prenatal	O	674-682
diagnosis	O	683-692
and	O	693-696
detection	O	697-706
of	O	707-709
carriers	O	710-718
,	O	718-719
to	O	720-722
provide	O	723-730
new	O	731-734
opportunities	O	735-748
for	O	749-752
the	O	753-756
biochemical	O	757-768
characterization	O	769-785
of	O	786-788
normal	O	789-795
and	O	796-799
mutant	O	800-806
enzymes	O	807-814
,	O	814-815
and	O	816-819
in	O	820-822
the	O	823-826
investigation	O	827-840
of	O	841-843
alternative	O	844-855
genetic	O	856-863
therapies	O	864-873
for	O	874-877
PKU	B	878-881
.	O	881-882
.	O	881-882

Macular	B	0-7
dystrophy	I	8-17
associated	O	18-28
with	O	29-33
mutations	O	34-43
at	O	44-46
codon	O	47-52
172	O	53-56
in	O	57-59
the	O	60-63
human	O	64-69
retinal	B	70-77
degeneration	I	78-90
slow	O	91-95
gene	O	96-100
.	O	100-101

BACKGROUND	O	102-112
Recently	O	114-122
,	O	122-123
mutations	O	124-133
in	O	134-136
the	O	137-140
retinal	B	141-148
degeneration	I	149-161
slow	O	162-166
(	O	167-168
rds	O	168-171
)	O	171-172
gene	O	173-177
which	O	178-183
codes	O	184-189
for	O	190-193
peripherin	O	194-204
-	O	204-205
rds	O	205-208
have	O	209-213
been	O	214-218
implicated	O	219-229
as	O	230-232
a	O	233-234
cause	O	235-240
of	O	241-243
autosomal	B	244-253
dominant	I	254-262
retinitis	I	263-272
pigmentosa	I	273-283
.	O	283-284

Because	O	285-292
this	O	293-297
gene	O	298-302
is	O	303-305
expressed	O	306-315
in	O	316-318
both	O	319-323
rods	O	324-328
and	O	329-332
cones	O	333-338
,	O	338-339
mutations	O	340-349
in	O	350-352
the	O	353-356
rds	O	357-360
gene	O	361-365
might	O	366-371
be	O	372-374
expected	O	375-383
to	O	384-386
cause	O	387-392
degeneration	O	393-405
affecting	O	406-415
either	O	416-422
the	O	423-426
scotopic	O	427-435
or	O	436-438
photopic	O	439-447
systems	O	448-455
.	O	455-456

Mutations	O	457-466
at	O	467-469
codon	O	470-475
172	O	476-479
of	O	480-482
the	O	483-486
rds	O	487-490
gene	O	491-495
have	O	496-500
been	O	501-505
identified	O	506-516
in	O	517-519
three	O	520-525
families	O	526-534
with	O	535-539
autosomal	O	540-549
dominantly	O	550-560
inherited	O	561-570
,	O	570-571
progressive	O	572-583
macular	B	584-591
dystrophy	I	592-601
.	O	601-602

METHODS	O	603-610
Affected	O	612-620
individuals	O	621-632
underwent	O	633-642
ophthalmic	O	643-653
examination	O	654-665
,	O	665-666
scotopic	O	667-675
perimetry	O	676-685
,	O	685-686
dark	O	687-691
adaptometry	O	692-703
,	O	703-704
measurement	O	705-716
of	O	717-719
color	O	720-725
-	O	725-726
contrast	O	726-734
sensitivity	O	735-746
,	O	746-747
and	O	748-751
electroretinography	O	752-771
to	O	772-774
characterize	O	775-787
the	O	788-791
photoreceptor	O	792-805
dysfunction	O	806-817
.	O	817-818

RESULTS	O	819-826
In	O	828-830
all	O	831-834
but	O	835-838
one	O	839-842
affected	O	843-851
member	O	852-858
,	O	858-859
symptoms	O	860-868
of	O	869-871
progressive	O	872-883
central	O	884-891
visual	B	892-898
loss	I	899-903
developed	O	904-913
in	O	914-916
the	O	917-920
third	O	921-926
or	O	927-929
fourth	O	930-936
decade	O	937-943
of	O	944-946
life	O	947-951
accompanied	O	952-963
by	O	964-966
central	B	967-974
scotoma	I	975-982
and	O	983-986
well	O	987-991
-	O	991-992
demarcated	O	992-1002
atrophy	B	1003-1010
of	I	1011-1013
the	I	1014-1017
retinal	I	1018-1025
pigment	I	1026-1033
epithelium	I	1034-1044
and	O	1045-1048
choriocapillaris	B	1049-1065
of	I	1066-1068
the	I	1069-1072
macula	I	1073-1079
.	O	1079-1080

In	O	1081-1083
general	O	1084-1091
,	O	1091-1092
cone	O	1093-1097
and	O	1098-1101
rod	O	1102-1105
thresholds	O	1106-1116
were	O	1117-1121
elevated	O	1122-1130
,	O	1130-1131
and	O	1132-1135
color	O	1136-1141
-	O	1141-1142
contrast	O	1142-1150
sensitivity	O	1151-1162
was	O	1163-1166
absent	O	1167-1173
in	O	1174-1176
the	O	1177-1180
central	O	1181-1188
visual	O	1189-1195
field	O	1196-1201
.	O	1201-1202

Peripherally	O	1203-1215
,	O	1215-1216
the	O	1217-1220
scotopic	O	1221-1229
sensitivities	O	1230-1243
were	O	1244-1248
normal	O	1249-1255
,	O	1255-1256
as	O	1257-1259
was	O	1260-1263
the	O	1264-1267
recovery	O	1268-1276
from	O	1277-1281
bleach	O	1282-1288
.	O	1288-1289

Cone	O	1290-1294
electroretinograms	O	1295-1313
were	O	1314-1318
diminished	O	1319-1329
in	O	1330-1332
amplitude	O	1333-1342
,	O	1342-1343
and	O	1344-1347
delayed	O	1348-1355
in	O	1356-1358
all	O	1359-1362
affected	O	1363-1371
adults	O	1372-1378
except	O	1379-1385
one	O	1386-1389
.	O	1389-1390

Rod	O	1391-1394
electroretinograms	O	1395-1413
were	O	1414-1418
normal	O	1419-1425
or	O	1426-1428
near	O	1429-1433
normal	O	1434-1440
in	O	1441-1443
amplitude	O	1444-1453
,	O	1453-1454
and	O	1455-1458
had	O	1459-1462
normal	O	1463-1469
implicit	O	1470-1478
times	O	1479-1484
.	O	1484-1485

Affected	O	1486-1494
asymptomatic	O	1495-1507
children	O	1508-1516
had	O	1517-1520
macular	O	1521-1528
changes	O	1529-1536
,	O	1536-1537
abnormal	O	1538-1546
color	O	1547-1552
-	O	1552-1553
contrast	O	1553-1561
sensitivity	O	1562-1573
,	O	1573-1574
and	O	1575-1578
reduced	O	1579-1586
pattern	O	1587-1594
and	O	1595-1598
cone	O	1599-1603
electroretinograms	O	1604-1622
.	O	1622-1623

CONCLUSION	O	1624-1634
These	O	1636-1641
results	O	1642-1649
indicate	O	1650-1658
that	O	1659-1663
mutations	O	1664-1673
in	O	1674-1676
the	O	1677-1680
rds	O	1681-1684
gene	O	1685-1689
can	O	1690-1693
be	O	1694-1696
expressed	O	1697-1706
as	O	1707-1709
a	O	1710-1711
macular	B	1712-1719
dystrophy	I	1720-1729
,	O	1729-1730
with	O	1731-1735
evidence	O	1736-1744
of	O	1745-1747
primary	O	1748-1755
cone	B	1756-1760
dysfunction	I	1761-1772
and	O	1773-1776
preservation	O	1777-1789
of	O	1790-1792
peripheral	O	1793-1803
rod	O	1804-1807
function	O	1808-1816
.	O	1816-1817
.	O	1816-1817

Glucose	O	0-7
6	O	8-9
-	O	9-10
phosphate	O	10-19
dehydrogenase	O	20-33
variants	O	34-42
:	O	42-43
Gd	O	44-46
(	O	47-48
+	O	48-49
)	O	49-50
Alexandra	O	51-60
associated	O	61-71
with	O	72-76
neonatal	B	77-85
jaundice	I	86-94
and	O	95-98
Gd	O	99-101
(	O	102-103
-	O	103-104
)	O	104-105
Camperdown	O	106-116
in	O	117-119
a	O	120-121
young	O	122-127
man	O	128-131
with	O	132-136
lamellar	B	137-145
cataracts	I	146-155
.	O	155-156

Two	O	157-160
male	O	161-165
subjects	O	166-174
are	O	175-178
described	O	179-188
,	O	188-189
with	O	190-194
unusual	O	195-202
clinical	O	203-211
presentations	O	212-225
and	O	226-229
with	O	230-234
hitherto	O	235-243
undescribed	O	244-255
G6PD	O	256-260
variants	O	261-269
.	O	269-270

The	O	271-274
first	O	275-280
,	O	280-281
of	O	282-284
Italian	O	285-292
extraction	O	293-303
,	O	303-304
suffered	O	305-313
from	O	314-318
severe	O	319-325
neonatal	B	326-334
jaundice	I	335-343
following	O	344-353
maternal	O	354-362
ingestion	O	363-372
of	O	373-375
fresh	O	376-381
broad	O	382-387
beans	O	388-393
(	O	394-395
Vicia	O	395-400
fava	O	401-405
)	O	405-406
both	O	407-411
prenatally	O	412-422
and	O	423-426
postnatally	O	427-438
the	O	440-443
expression	O	444-454
of	O	455-457
the	O	458-461
enzymatic	O	462-471
defect	O	472-478
was	O	479-482
much	O	483-487
more	O	488-492
severe	O	493-499
in	O	500-502
the	O	503-506
neonatal	O	507-515
period	O	516-522
than	O	523-527
on	O	528-530
retesting	O	531-540
in	O	541-543
adolescence	O	544-555
,	O	555-556
when	O	557-561
biochemical	O	562-573
characterization	O	574-590
showed	O	591-597
unique	O	598-604
features	O	605-613
which	O	614-619
justify	O	620-627
designation	O	628-639
as	O	640-642
a	O	643-644
new	O	645-648
variant	O	649-656
Gd	O	657-659
(	O	660-661
+	O	661-662
)	O	662-663
Alexandra	O	664-673
.	O	673-674

The	O	675-678
second	O	679-685
patient	O	686-693
,	O	693-694
a	O	695-696
boy	O	697-700
of	O	701-703
Maltese	O	704-711
extraction	O	712-722
who	O	723-726
was	O	727-730
found	O	731-736
to	O	737-739
have	O	740-744
bilateral	B	745-754
lamellar	I	755-763
cataracts	I	764-773
at	O	774-776
the	O	777-780
age	O	781-784
of	O	785-787
4	O	788-789
years	O	790-795
,	O	795-796
was	O	797-800
identified	O	801-811
as	O	812-814
G6PD	B	815-819
deficient	I	820-829
only	O	830-834
as	O	835-837
a	O	838-839
result	O	840-846
of	O	847-849
a	O	850-851
survey	O	852-858
of	O	859-861
children	O	862-870
of	O	871-873
Mediterranean	O	874-887
origin	O	888-894
with	O	895-899
unexplained	O	900-911
cataract	B	912-920
formation	O	921-930
;	O	930-931
he	O	932-934
has	O	935-938
approximately	O	939-952
15	O	953-955
%	O	955-956
of	O	957-959
normal	O	960-966
enzyme	O	967-973
activity	O	974-982
,	O	982-983
with	O	984-988
another	O	989-996
unique	O	997-1003
combination	O	1004-1015
of	O	1016-1018
biochemical	O	1019-1030
characteristics	O	1031-1046
which	O	1047-1052
has	O	1053-1056
led	O	1057-1060
to	O	1061-1063
its	O	1064-1067
designation	O	1068-1079
as	O	1080-1082
Gd	O	1083-1085
(	O	1086-1087
-	O	1087-1088
)	O	1088-1089
Camperdown	O	1090-1100
.	O	1100-1101

Although	O	1102-1110
this	O	1111-1115
association	O	1116-1127
may	O	1128-1131
be	O	1132-1134
coincidental	O	1135-1147
,	O	1147-1148
it	O	1149-1151
prompts	O	1152-1159
further	O	1160-1167
attention	O	1168-1177
to	O	1178-1180
the	O	1181-1184
possibility	O	1185-1196
that	O	1197-1201
under	O	1202-1207
certain	O	1208-1215
circumstances	O	1216-1229
G6PD	B	1230-1234
deficiency	I	1235-1245
may	O	1246-1249
favor	O	1250-1255
cataract	B	1256-1264
formation	O	1265-1274
.	O	1274-1275

The	O	1276-1279
two	O	1280-1283
cases	O	1284-1289
illustrate	O	1290-1300
the	O	1301-1304
value	O	1305-1310
of	O	1311-1313
characterization	O	1314-1330
of	O	1331-1333
the	O	1334-1337
mutant	O	1338-1344
enzyme	O	1345-1351
whenever	O	1352-1360
unexpected	O	1361-1371
clinical	O	1372-1380
or	O	1381-1383
laboratory	O	1384-1394
results	O	1395-1402
are	O	1403-1406
obtained	O	1407-1415
.	O	1415-1416
.	O	1415-1416

DNA	O	0-3
restriction	O	4-15
fragments	O	16-25
associated	O	26-36
with	O	37-41
alpha	O	42-47
1	O	48-49
-	O	49-50
antitrypsin	O	50-61
indicate	O	62-70
a	O	71-72
single	O	73-79
origin	O	80-86
for	O	87-90
deficiency	O	91-101
allele	O	102-108
PI	O	109-111
Z	O	112-113
.	O	113-114

The	O	115-118
alpha	O	119-124
1	O	125-126
-	O	126-127
protease	O	127-135
inhibitor	O	136-145
,	O	145-146
or	O	147-149
alpha	O	150-155
-	O	155-156
antitrypsin	O	156-167
(	O	168-169
AAT	O	169-172
)	O	172-173
,	O	173-174
a	O	175-176
major	O	177-182
plasma	O	183-189
inhibitor	O	190-199
of	O	200-202
leukocyte	O	203-212
elastase	O	213-221
and	O	222-225
bacterial	O	226-235
proteases	O	236-245
,	O	245-246
is	O	247-249
encoded	O	250-257
at	O	258-260
the	O	261-264
PI	O	265-267
locus	O	268-273
on	O	274-276
chromosome	O	277-287
14	O	288-290
(	O	291-292
14q24	O	292-297
.	O	297-298

3	O	299-300
-	O	300-301
q32	O	301-304
.	O	304-305

1	O	306-307
)	O	307-308
.	O	308-309

A	O	310-311
deficiency	B	312-322
of	I	323-325
AAT	I	326-329
in	O	330-332
individuals	O	333-344
homozygous	O	345-355
for	O	356-359
the	O	360-363
PI	O	364-366
Z	O	367-368
allele	O	369-375
occurs	O	376-382
in	O	383-385
about	O	386-391
1	O	392-393
in	O	394-396
2	O	397-398
,	O	398-399
000	O	400-403
-	O	403-404
8	O	404-405
,	O	405-406
000	O	407-410
caucasians	O	411-421
and	O	422-425
is	O	426-428
associated	O	429-439
with	O	440-444
an	O	445-447
increased	O	448-457
risk	O	458-462
of	O	463-465
early	O	466-471
adult	O	472-477
onset	O	478-483
emphysema	B	484-493
and	O	494-497
liver	B	498-503
disease	I	504-511
in	O	512-514
childhood	O	515-524
.	O	524-525

We	O	526-528
have	O	529-533
now	O	534-537
used	O	538-542
DNA	O	543-546
polymorphisms	O	547-560
associated	O	561-571
with	O	572-576
the	O	577-580
AAT	O	581-584
gene	O	585-589
to	O	590-592
investigate	O	593-604
the	O	605-608
origin	O	609-615
of	O	616-618
the	O	619-622
PI	O	623-625
Z	O	626-627
allele	O	628-634
.	O	634-635

Using	O	636-641
two	O	642-645
genomic	O	646-653
probes	O	654-660
extending	O	661-670
into	O	671-675
the	O	676-679
5	O	680-681
and	O	682-685
3	O	686-687
flanking	O	688-696
regions	O	697-704
,	O	704-705
respectively	O	706-718
,	O	718-719
we	O	720-722
have	O	723-727
identified	O	728-738
eight	O	739-744
polymorphic	O	745-756
restriction	O	757-768
sites	O	769-774
.	O	774-775

Extensive	O	776-785
linkage	O	786-793
disequilibrium	O	794-808
occurs	O	809-815
throughout	O	816-826
the	O	827-830
probed	O	831-837
region	O	838-844
with	O	845-849
the	O	850-853
PI	O	854-856
Z	O	857-858
allele	O	859-865
,	O	865-866
but	O	867-870
not	O	871-874
with	O	875-879
normal	O	880-886
PI	O	887-889
M	O	890-891
alleles	O	892-899
.	O	899-900

The	O	901-904
Z	O	905-906
allele	O	907-913
occurs	O	914-920
mainly	O	921-927
with	O	928-932
one	O	933-936
haplotype	O	937-946
,	O	946-947
indicating	O	948-958
a	O	959-960
single	O	961-967
,	O	967-968
relatively	O	969-979
recent	O	980-986
,	O	986-987
origin	O	988-994
in	O	995-997
caucasians	O	998-1008

Myotonic	B	0-8
dystrophy	I	9-18
in	O	19-21
transgenic	O	22-32
mice	O	33-37
expressing	O	38-48
an	O	49-51
expanded	O	52-60
CUG	O	61-64
repeat	O	65-71
.	O	71-72

Myotonic	B	73-81
dystrophy	I	82-91
(	O	92-93
DM	B	93-95
)	O	95-96
,	O	96-97
the	O	98-101
most	O	102-106
common	O	107-113
form	O	114-118
of	O	119-121
muscular	B	122-130
dystrophy	I	131-140
in	O	141-143
adult	O	144-149
humans	O	150-156
,	O	156-157
results	O	158-165
from	O	166-170
expansion	O	171-180
of	O	181-183
a	O	184-185
CTG	O	186-189
repeat	O	190-196
in	O	197-199
the	O	200-203
3	O	204-205
untranslated	O	206-218
region	O	219-225
of	O	226-228
the	O	229-232
DMPK	O	233-237
gene	O	238-242
.	O	242-243

The	O	244-247
mutant	O	248-254
DMPK	O	255-259
messenger	O	260-269
RNA	O	270-273
(	O	274-275
mRNA	O	275-279
)	O	279-280
contains	O	281-289
an	O	290-292
expanded	O	293-301
CUG	O	302-305
repeat	O	306-312
and	O	313-316
is	O	317-319
retained	O	320-328
in	O	329-331
the	O	332-335
nucleus	O	336-343
.	O	343-344

We	O	345-347
have	O	348-352
expressed	O	353-362
an	O	363-365
untranslated	O	366-378
CUG	O	379-382
repeat	O	383-389
in	O	390-392
an	O	393-395
unrelated	O	396-405
mRNA	O	406-410
in	O	411-413
transgenic	O	414-424
mice	O	425-429
.	O	429-430

Mice	O	431-435
that	O	436-440
expressed	O	441-450
expanded	O	451-459
CUG	O	460-463
repeats	O	464-471
developed	O	472-481
myotonia	B	482-490
and	O	491-494
myopathy	B	495-503
,	O	503-504
whereas	O	505-512
mice	O	513-517
expressing	O	518-528
a	O	529-530
nonexpanded	O	531-542
repeat	O	543-549
did	O	550-553
not	O	554-557
.	O	557-558

Thus	O	559-563
,	O	563-564
transcripts	O	565-576
with	O	577-581
expanded	O	582-590
CUG	O	591-594
repeats	O	595-602
are	O	603-606
sufficient	O	607-617
to	O	618-620
generate	O	621-629
a	O	630-631
DM	B	632-634
phenotype	O	635-644
.	O	644-645

This	O	646-650
result	O	651-657
supports	O	658-666
a	O	667-668
role	O	669-673
for	O	674-677
RNA	O	678-681
gain	O	682-686
of	O	687-689
function	O	690-698
in	O	699-701
disease	O	702-709
pathogenesis	O	710-722
.	O	722-723
.	O	722-723

Submicroscopic	O	0-14
deletion	O	15-23
in	O	24-26
cousins	O	27-34
with	O	35-39
Prader	B	40-46
-	I	46-47
Willi	I	47-52
syndrome	I	53-61
causes	O	62-68
a	O	69-70
grandmatrilineal	O	71-87
inheritance	O	88-99
pattern	O	100-107
:	O	107-108
effects	O	109-116
of	O	117-119
imprinting	O	120-130
.	O	130-131

The	O	132-135
Prader	B	136-142
-	I	142-143
Willi	I	143-148
syndrome	I	149-157
(	O	158-159
PWS	B	159-162
)	O	162-163
critical	O	164-172
region	O	173-179
on	O	180-182
15q11	O	183-188
-	O	188-189
q13	O	189-192
is	O	193-195
subject	O	196-203
to	O	204-206
imprinting	O	207-217
.	O	217-218

PWS	B	219-222
becomes	O	223-230
apparent	O	231-239
when	O	240-244
genes	O	245-250
on	O	251-253
the	O	254-257
paternally	O	258-268
inherited	O	269-278
chromosome	O	279-289
are	O	290-293
not	O	294-297
expressed	O	298-307
.	O	307-308

Familial	B	309-317
PWS	I	318-321
is	O	322-324
rare	O	325-329
.	O	329-330

We	O	331-333
report	O	334-340
on	O	341-343
a	O	344-345
family	O	346-352
in	O	353-355
which	O	356-361
a	O	362-363
male	O	364-368
and	O	369-372
a	O	373-374
female	O	375-381
paternal	O	382-390
first	O	391-396
cousin	O	397-403
both	O	404-408
have	O	409-413
PWS	B	414-417
with	O	418-422
cytogenetically	O	423-438
normal	O	439-445
karyotypes	O	446-456
.	O	456-457

Fluorescence	O	458-470
in	O	471-473
situ	O	474-478
hybridization	O	479-492
(	O	493-494
FISH	O	494-498
)	O	498-499
analysis	O	500-508
shows	O	509-514
a	O	515-516
submicroscopic	O	517-531
deletion	O	532-540
of	O	541-543
SNRPN	O	544-549
,	O	549-550
but	O	551-554
not	O	555-558
the	O	559-562
closely	O	563-570
associated	O	571-581
loci	O	582-586
D15S10	O	587-593
,	O	593-594
D15S11	O	595-601
,	O	601-602
D15S63	O	603-609
,	O	609-610
and	O	611-614
GABRB3	O	615-621
.	O	621-622

The	O	623-626
cousins	O	627-634
fathers	O	635-642
and	O	643-646
two	O	647-650
paternal	O	651-659
aunts	O	660-665
have	O	666-670
the	O	671-674
same	O	675-679
deletion	O	680-688
and	O	689-692
are	O	693-696
clinically	O	697-707
normal	O	708-714
.	O	714-715

The	O	716-719
grandmother	O	720-731
of	O	732-734
the	O	735-738
cousins	O	739-746
is	O	747-749
deceased	O	750-758
and	O	759-762
not	O	763-766
available	O	767-776
for	O	777-780
study	O	781-786
,	O	786-787
and	O	788-791
their	O	792-797
grandfather	O	798-809
is	O	810-812
not	O	813-816
deleted	O	817-824
for	O	825-828
SNRPN	O	829-834
.	O	834-835

DNA	O	836-839
methylation	O	840-851
analysis	O	852-860
of	O	861-863
D15S63	O	864-870
is	O	871-873
consistent	O	874-884
with	O	885-889
an	O	890-892
abnormality	O	893-904
of	O	905-907
the	O	908-911
imprinting	O	912-922
center	O	923-929
associated	O	930-940
with	O	941-945
PWS	B	946-949
.	O	949-950

"	O	951-952
Grandmatrilineal	O	953-969
"	O	970-971
inheritance	O	972-983
occurs	O	984-990
when	O	991-995
a	O	996-997
woman	O	998-1003
with	O	1004-1008
deletion	O	1009-1017
of	O	1018-1020
an	O	1021-1023
imprinted	O	1024-1033
,	O	1033-1034
paternally	O	1035-1045
expressed	O	1046-1055
gene	O	1056-1060
is	O	1061-1063
at	O	1064-1066
risk	O	1067-1071
of	O	1072-1074
having	O	1075-1081
affected	O	1082-1090
grandchildren	O	1091-1104
through	O	1105-1112
her	O	1113-1116
sons	O	1117-1121
.	O	1121-1122

In	O	1123-1125
this	O	1126-1130
case	O	1131-1135
,	O	1135-1136
PWS	B	1137-1140
does	O	1141-1145
not	O	1146-1149
become	O	1150-1156
evident	O	1157-1164
as	O	1165-1167
long	O	1168-1172
as	O	1173-1175
the	O	1176-1179
deletion	O	1180-1188
is	O	1189-1191
passed	O	1192-1198
through	O	1199-1206
the	O	1207-1210
matrilineal	O	1211-1222
line	O	1223-1227
.	O	1227-1228

This	O	1229-1233
represents	O	1234-1244
a	O	1245-1246
unique	O	1247-1253
inheritance	O	1254-1265
pattern	O	1266-1273
due	O	1274-1277
to	O	1278-1280
imprinting	O	1281-1291
.	O	1291-1292
.	O	1291-1292

Expression	O	0-10
and	O	11-14
imprinting	O	15-25
of	O	26-28
MAGEL2	O	29-35
suggest	O	36-43
a	O	44-45
role	O	46-50
in	O	51-53
Prader	B	54-60
-	I	60-61
willi	I	61-66
syndrome	I	67-75
and	O	76-79
the	O	80-83
homologous	O	84-94
murine	O	95-101
imprinting	O	102-112
phenotype	O	113-122
.	O	122-123

Prader	B	124-130
-	I	130-131
Willi	I	131-136
syndrome	I	137-145
(	O	146-147
PWS	B	147-150
)	O	150-151
is	O	152-154
caused	O	155-161
by	O	162-164
the	O	165-168
loss	O	169-173
of	O	174-176
expression	O	177-187
of	O	188-190
imprinted	O	191-200
genes	O	201-206
in	O	207-209
chromosome	O	210-220
15q11	O	221-226
-	O	226-227
q13	O	227-230
.	O	230-231

Affected	O	232-240
individuals	O	241-252
exhibit	O	253-260
neonatal	B	261-269
hypotonia	I	270-279
,	O	279-280
developmental	B	281-294
delay	I	295-300
and	O	301-304
childhood	B	305-314
-	I	314-315
onset	I	315-320
obesity	I	321-328
.	O	328-329

Necdin	O	330-336
,	O	336-337
a	O	338-339
protein	O	340-347
implicated	O	348-358
in	O	359-361
the	O	362-365
terminal	O	366-374
differentiation	O	375-390
of	O	391-393
neurons	O	394-401
,	O	401-402
is	O	403-405
the	O	406-409
only	O	410-414
PWS	B	415-418
candidate	O	419-428
gene	O	429-433
to	O	434-436
reduce	O	437-443
viability	O	444-453
when	O	454-458
disrupted	O	459-468
in	O	469-471
a	O	472-473
mouse	O	474-479
model	O	480-485
.	O	485-486

In	O	487-489
this	O	490-494
study	O	495-500
,	O	500-501
we	O	502-504
have	O	505-509
characterized	O	510-523
MAGEL2	O	524-530
(	O	531-532
also	O	532-536
known	O	537-542
as	O	543-545
NDNL1	O	546-551
)	O	551-552
,	O	552-553
a	O	554-555
gene	O	556-560
with	O	561-565
51	O	566-568
%	O	568-569
amino	O	570-575
acid	O	576-580
sequence	O	581-589
similarity	O	590-600
to	O	601-603
necdin	O	604-610
and	O	611-614
located	O	615-622
41	O	623-625
kb	O	626-628
distal	O	629-635
to	O	636-638
NDN	O	639-642
in	O	643-645
the	O	646-649
PWS	B	650-653
deletion	O	654-662
region	O	663-669
.	O	669-670

MAGEL2	O	671-677
is	O	678-680
expressed	O	681-690
predominantly	O	691-704
in	O	705-707
brain	O	708-713
,	O	713-714
the	O	715-718
primary	O	719-726
tissue	O	727-733
affected	O	734-742
in	O	743-745
PWS	B	746-749
and	O	750-753
in	O	754-756
several	O	757-764
fetal	O	765-770
tissues	O	771-778
as	O	779-781
shown	O	782-787
by	O	788-790
northern	O	791-799
blot	O	800-804
analysis	O	805-813
.	O	813-814

MAGEL2	O	815-821
is	O	822-824
imprinted	O	825-834
with	O	835-839
monoallelic	O	840-851
expression	O	852-862
in	O	863-865
control	O	866-873
brain	O	874-879
,	O	879-880
and	O	881-884
paternal	O	885-893
-	O	893-894
only	O	894-898
expression	O	899-909
in	O	910-912
the	O	913-916
central	O	917-924
nervous	O	925-932
system	O	933-939
as	O	940-942
demonstrated	O	943-955
by	O	956-958
its	O	959-962
lack	O	963-967
of	O	968-970
expression	O	971-981
in	O	982-984
brain	O	985-990
from	O	991-995
a	O	996-997
PWS	B	998-1001
-	O	1001-1002
affected	O	1002-1010
individual	O	1011-1021
.	O	1021-1022

The	O	1023-1026
orthologous	O	1027-1038
mouse	O	1039-1044
gene	O	1045-1049
(	O	1050-1051
Magel2	O	1051-1057
)	O	1057-1058
is	O	1059-1061
located	O	1062-1069
within	O	1070-1076
150	O	1077-1080
kb	O	1081-1083
of	O	1084-1086
NDN	O	1087-1090
,	O	1091-1092
is	O	1093-1095
imprinted	O	1096-1105
with	O	1106-1110
paternal	O	1111-1119
-	O	1119-1120
only	O	1120-1124
expression	O	1125-1135
and	O	1136-1139
is	O	1140-1142
expressed	O	1143-1152
predominantly	O	1153-1166
in	O	1167-1169
late	O	1170-1174
developmental	O	1175-1188
stages	O	1189-1195
and	O	1196-1199
adult	O	1200-1205
brain	O	1206-1211
as	O	1212-1214
shown	O	1215-1220
by	O	1221-1223
northern	O	1224-1232
blotting	O	1233-1241
,	O	1241-1242
RT	O	1243-1245
-	O	1245-1246
PCR	O	1246-1249
and	O	1250-1253
whole	O	1254-1259
-	O	1259-1260
mount	O	1260-1265
RNA	O	1266-1269
in	O	1270-1272
situ	O	1273-1277
hybridization	O	1278-1291
.	O	1291-1292

Magel2	O	1293-1299
distribution	O	1300-1312
partially	O	1313-1322
overlaps	O	1323-1331
that	O	1332-1336
of	O	1337-1339
NDN	O	1340-1343
,	O	1344-1345
with	O	1346-1350
strong	O	1351-1357
expression	O	1358-1368
being	O	1369-1374
detected	O	1375-1383
in	O	1384-1386
the	O	1387-1390
central	O	1391-1398
nervous	O	1399-1406
system	O	1407-1413
in	O	1414-1416
mid	O	1417-1420
-	O	1420-1421
gestation	O	1421-1430
mouse	O	1431-1436
embryos	O	1437-1444
by	O	1445-1447
in	O	1448-1450
situ	O	1451-1455
hybridization	O	1456-1469
.	O	1469-1470

We	O	1471-1473
hypothesize	O	1474-1485
that	O	1486-1490
,	O	1490-1491
although	O	1492-1500
loss	O	1501-1505
of	O	1506-1508
necdin	O	1509-1515
expression	O	1516-1526
may	O	1527-1530
be	O	1531-1533
important	O	1534-1543
in	O	1544-1546
the	O	1547-1550
neonatal	O	1551-1559
presentation	O	1560-1572
of	O	1573-1575
PWS	B	1576-1579
,	O	1579-1580
loss	O	1581-1585
of	O	1586-1588
MAGEL2	O	1589-1595
may	O	1596-1599
be	O	1600-1602
critical	O	1603-1611
to	O	1612-1614
abnormalities	B	1615-1628
in	I	1629-1631
brain	I	1632-1637
development	I	1638-1649
and	O	1650-1653
dysmorphic	B	1654-1664
features	I	1665-1673
in	O	1674-1676
individuals	O	1677-1688
with	O	1689-1693
PWS	B	1694-1697
.	O	1697-1698
.	O	1697-1698

A	O	0-1
single	O	2-8
origin	O	9-15
of	O	16-18
phenylketonuria	B	19-34
in	O	35-37
Yemenite	O	38-46
Jews	O	47-51
.	O	51-52

Phenylketonuria	B	53-68
(	O	69-70
PKU	B	70-73
)	O	73-74
is	O	75-77
a	O	78-79
metabolic	B	80-89
disease	I	90-97
caused	O	98-104
by	O	105-107
recessive	O	108-117
mutations	O	118-127
of	O	128-130
the	O	131-134
gene	O	135-139
encoding	O	140-148
the	O	149-152
hepatic	O	153-160
enzyme	O	161-167
phenylalanine	O	168-181
hydroxylase	O	182-193
(	O	194-195
PAH	O	195-198
)	O	198-199
.	O	199-200

The	O	201-204
incidence	O	205-214
of	O	215-217
PKU	B	218-221
varies	O	222-228
widely	O	229-235
across	O	236-242
different	O	243-252
geographic	O	253-263
areas	O	264-269
,	O	269-270
and	O	271-274
is	O	275-277
highest	O	278-285
(	O	286-287
about	O	287-292
1	O	293-294
in	O	295-297
5	O	298-299
,	O	299-300
000	O	301-304
live	O	305-309
births	O	310-316
)	O	316-317
in	O	318-320
Ireland	O	321-328
and	O	329-332
western	O	333-340
Scotland	O	341-349
,	O	349-350
and	O	351-354
among	O	355-360
Yemenite	O	361-369
Jews	O	370-374
.	O	374-375

A	O	376-377
limited	O	378-385
number	O	386-392
of	O	393-395
point	O	396-401
mutations	O	402-411
account	O	412-419
for	O	420-423
most	O	424-428
of	O	429-431
the	O	432-435
PKU	B	436-439
cases	O	440-445
in	O	446-448
the	O	449-452
European	O	453-461
population	O	462-472
.	O	472-473

Here	O	474-478
we	O	479-481
report	O	482-488
that	O	489-493
a	O	494-495
single	O	496-502
molecular	O	503-512
defect	O	513-519
-	O	519-520
-	O	519-520
a	O	521-522
deletion	O	523-531
spanning	O	532-540
the	O	541-544
third	O	545-550
exon	O	551-555
of	O	556-558
the	O	559-562
PAH	O	563-566
gene	O	567-571
-	O	571-572
-	O	571-572
is	O	573-575
responsible	O	576-587
for	O	588-591
all	O	592-595
the	O	596-599
PKU	B	600-603
cases	O	604-609
among	O	610-615
the	O	616-619
Yemenite	O	620-628
Jews	O	629-633
.	O	633-634

Examination	O	635-646
of	O	647-649
a	O	650-651
random	O	652-658
sample	O	659-665
of	O	666-668
Yemenite	O	669-677
Jews	O	678-682
using	O	683-688
a	O	689-690
molecular	O	691-700
probe	O	701-706
that	O	707-711
detects	O	712-719
the	O	720-723
carriers	O	724-732
of	O	733-735
this	O	736-740
deletion	O	741-749
indicated	O	750-759
a	O	760-761
high	O	762-766
frequency	O	767-776
of	O	777-779
the	O	780-783
defective	O	784-793
gene	O	794-798
in	O	799-801
this	O	802-806
community	O	807-816
.	O	816-817

Although	O	818-826
the	O	827-830
deleted	O	831-838
PAH	O	839-842
gene	O	843-847
was	O	848-851
traced	O	852-858
to	O	859-861
25	O	862-864
different	O	865-874
locations	O	875-884
throughout	O	885-895
Yemen	O	896-901
,	O	901-902
family	O	903-909
histories	O	910-919
and	O	920-923
official	O	924-932
documents	O	933-942
of	O	943-945
the	O	946-949
Yemenite	O	950-958
Jewish	O	959-965
community	O	966-975
showed	O	976-982
that	O	983-987
the	O	988-991
common	O	992-998
ancestor	O	999-1007
of	O	1008-1010
all	O	1011-1014
the	O	1015-1018
carriers	O	1019-1027
of	O	1028-1030
this	O	1031-1035
genetic	B	1036-1043
defect	I	1044-1050
lived	O	1051-1056
in	O	1057-1059
Sana	O	1060-1064
,	O	1064-1065
the	O	1066-1069
capital	O	1070-1077
of	O	1078-1080
Yemen	O	1081-1086
,	O	1086-1087
before	O	1088-1094
the	O	1095-1098
eighteenth	O	1099-1109
century	O	1110-1117
.	O	1117-1118
.	O	1117-1118

High	O	0-4
resolution	O	5-15
genetic	O	16-23
analysis	O	24-32
suggests	O	33-41
one	O	42-45
ancestral	O	46-55
predisposing	O	56-68
haplotype	O	69-78
for	O	79-82
the	O	83-86
origin	O	87-93
of	O	94-96
the	O	97-100
myotonic	B	101-109
dystrophy	I	110-119
mutation	O	120-128
.	O	128-129

The	O	130-133
mutation	O	134-142
causing	O	143-150
myotonic	B	151-159
dystrophy	I	160-169
(	O	170-171
DM	B	171-173
)	O	173-174
has	O	175-178
been	O	179-183
identified	O	184-194
as	O	195-197
an	O	198-200
amplification	O	201-214
of	O	215-217
an	O	218-220
unstable	O	221-229
trinucleotide	O	230-243
(	O	244-245
CTG	O	245-248
)	O	248-249
n	O	250-251
repeat	O	252-258
in	O	259-261
over	O	262-266
99	O	267-269
%	O	269-270
of	O	271-273
the	O	274-277
global	O	278-284
DM	B	285-287
population	O	288-298
.	O	298-299

It	O	300-302
is	O	303-305
in	O	306-308
complete	O	309-317
linkage	O	318-325
disequilibrium	O	326-340
with	O	341-345
an	O	346-348
Alu	O	349-352
element	O	353-360
polymorphism	O	361-373
within	O	374-380
the	O	381-384
DM	B	385-387
kinase	O	388-394
gene	O	395-399
,	O	399-400
suggesting	O	401-411
that	O	412-416
DM	B	417-419
is	O	420-422
a	O	423-424
consequence	O	425-436
of	O	437-439
one	O	440-443
or	O	444-446
few	O	447-450
ancestral	O	451-460
mutations	O	461-470
.	O	470-471

A	O	472-473
recent	O	474-480
analysis	O	481-489
utilizing	O	490-499
this	O	500-504
polymorphism	O	505-517
as	O	518-520
well	O	521-525
as	O	526-528
a	O	529-530
flanking	O	531-539
dinucleotide	O	540-552
marker	O	553-559
,	O	559-560
suggested	O	561-570
that	O	571-575
similar	O	576-583
to	O	584-586
Fragile	B	587-594
X	I	595-596
syndrome	I	597-605
,	O	605-606
DM	B	607-609
exhibited	O	610-619
a	O	620-621
founder	O	622-629
effect	O	630-636
(	O	637-638
Imbert	O	638-644
et	O	645-647
al	O	648-650
.	O	650-651
,	O	651-652
1993	O	653-657
Nature	O	658-664
Genet	O	665-670
.	O	670-671

4	O	672-673
,	O	673-674
72	O	675-677
-	O	677-678
76	O	678-680
)	O	680-681
.	O	681-682

In	O	683-685
contrast	O	686-694
,	O	694-695
the	O	696-699
low	O	700-703
reproductive	O	704-716
fitness	O	717-724
of	O	725-727
individuals	O	728-739
with	O	740-744
congenital	O	745-755
DM	B	756-758
(	O	759-760
the	O	760-763
endpoint	O	764-772
of	O	773-775
genetic	O	776-783
anticipation	O	784-796
in	O	797-799
myotonic	B	800-808
dystrophy	I	809-818
)	O	818-819
suggests	O	820-828
a	O	829-830
higher	O	831-837
rate	O	838-842
of	O	843-845
new	O	846-849
mutations	O	850-859
.	O	859-860

We	O	861-863
present	O	864-871
a	O	872-873
high	O	874-878
resolution	O	879-889
genetic	O	890-897
analysis	O	898-906
of	O	907-909
the	O	910-913
DM	B	914-916
locus	O	917-922
using	O	923-928
PCR	O	929-932
based	O	933-938
assays	O	939-945
of	O	946-948
nine	O	949-953
polymorphisms	O	954-967
,	O	967-968
spanning	O	969-977
a	O	978-979
physical	O	980-988
distance	O	989-997
of	O	998-1000
30	O	1001-1003
kb	O	1004-1006
,	O	1006-1007
within	O	1008-1014
and	O	1015-1018
immediately	O	1019-1030
flanking	O	1031-1039
the	O	1040-1043
DM	B	1044-1046
kinase	O	1047-1053
gene	O	1054-1058
.	O	1058-1059

The	O	1060-1063
persistent	O	1064-1074
complete	O	1075-1083
allelic	O	1084-1091
association	O	1092-1103
of	O	1104-1106
the	O	1107-1110
DM	B	1111-1113
mutation	O	1114-1122
with	O	1123-1127
all	O	1128-1131
these	O	1132-1137
polymorphisms	O	1138-1151
provides	O	1152-1160
further	O	1161-1168
support	O	1169-1176
to	O	1177-1179
previous	O	1180-1188
observations	O	1189-1201
and	O	1202-1205
suggests	O	1206-1214
more	O	1215-1219
strongly	O	1220-1228
that	O	1229-1233
the	O	1234-1237
DM	B	1238-1240
mutation	O	1241-1249
occurred	O	1250-1258
on	O	1259-1261
the	O	1262-1265
background	O	1266-1276
of	O	1277-1279
a	O	1280-1281
particular	O	1282-1292
haplotype	O	1293-1302
in	O	1303-1305
which	O	1306-1311
the	O	1312-1315
(	O	1316-1317
CTG	O	1317-1320
)	O	1320-1321
n	O	1322-1323
repeat	O	1324-1330
became	O	1331-1337
inherently	O	1338-1348
unstable	O	1349-1357
and	O	1358-1361
therefore	O	1362-1371
predisposed	O	1372-1383
to	O	1384-1386
amplification	O	1387-1400
.	O	1400-1401

Identification	O	0-14
and	O	15-18
rapid	O	19-24
detection	O	25-34
of	O	35-37
three	O	38-43
Tay	B	44-47
-	I	47-48
Sachs	I	48-53
mutations	O	54-63
in	O	64-66
the	O	67-70
Moroccan	O	71-79
Jewish	O	80-86
population	O	87-97
.	O	97-98

Infantile	O	99-108
Tay	B	109-112
-	I	112-113
Sachs	I	113-118
disease	I	119-126
(	O	127-128
TSD	B	128-131
)	O	131-132
is	O	133-135
caused	O	136-142
by	O	143-145
mutations	O	146-155
in	O	156-158
the	O	159-162
HEXA	O	163-167
gene	O	168-172
that	O	173-177
result	O	178-184
in	O	185-187
the	O	188-191
complete	O	192-200
absence	O	201-208
of	O	209-211
beta	O	212-216
-	O	216-217
hexosaminidase	O	217-231
A	O	232-233
activity	O	234-242
.	O	242-243

It	O	244-246
is	O	247-249
well	O	250-254
known	O	255-260
that	O	261-265
an	O	266-268
elevated	O	269-277
frequency	O	278-287
of	O	288-290
TSD	B	291-294
mutations	O	295-304
exists	O	305-311
among	O	312-317
Ashkenazi	O	318-327
Jews	O	328-332
.	O	332-333

More	O	334-338
recently	O	339-347
it	O	348-350
has	O	351-354
become	O	355-361
apparent	O	362-370
that	O	371-375
elevated	O	376-384
carrier	O	385-392
frequencies	O	393-404
for	O	405-408
TSD	B	409-412
also	O	413-417
occur	O	418-423
in	O	424-426
several	O	427-434
other	O	435-440
ethnic	O	441-447
groups	O	448-454
,	O	454-455
including	O	456-465
Moroccan	O	466-474
Jews	O	475-479
,	O	479-480
a	O	481-482
subgroup	O	483-491
of	O	492-494
Sephardic	O	495-504
Jews	O	505-509
.	O	509-510

Elsewhere	O	511-520
we	O	521-523
reported	O	524-532
an	O	533-535
in	O	536-538
-	O	538-539
frame	O	539-544
deletion	O	545-553
of	O	554-556
one	O	557-560
of	O	561-563
the	O	564-567
two	O	568-571
adjacent	O	572-580
phenylalanine	O	581-594
codons	O	595-601
at	O	602-604
position	O	605-613
304	O	614-617
or	O	618-620
305	O	621-624
(	O	625-626
delta	O	626-631
F304	O	632-636
/	O	636-637
305	O	637-640
)	O	640-641
in	O	642-644
one	O	645-648
HEXA	O	649-653
allele	O	654-660
of	O	661-663
a	O	664-665
Moroccan	O	666-674
Jewish	O	675-681
TSD	B	682-685
patient	O	686-693
and	O	694-697
in	O	698-700
three	O	701-706
obligate	O	707-715
carriers	O	716-724
from	O	725-729
six	O	730-733
unrelated	O	734-743
Moroccan	O	744-752
Jewish	O	753-759
families	O	760-768
.	O	768-769

We	O	770-772
have	O	773-777
now	O	778-781
identified	O	782-792
two	O	793-796
additional	O	797-807
mutations	O	808-817
within	O	818-824
exon	O	825-829
5	O	830-831
of	O	832-834
the	O	835-838
HEXA	O	839-843
gene	O	844-848
that	O	849-853
account	O	854-861
for	O	862-865
the	O	866-869
remaining	O	870-879
TSD	B	880-883
alleles	O	884-891
in	O	892-894
the	O	895-898
patient	O	899-906
and	O	907-910
carriers	O	911-919
.	O	919-920

One	O	921-924
of	O	925-927
the	O	928-931
mutations	O	932-941
is	O	942-944
a	O	945-946
novel	O	947-952
C	O	953-954
-	O	954-955
to	O	955-957
-	O	954-955
G	O	958-959
transversion	O	960-972
,	O	972-973
resulting	O	974-983
in	O	984-986
a	O	987-988
replacement	O	989-1000
of	O	1001-1003
Tyr180	O	1004-1010
by	O	1011-1013
a	O	1014-1015
stop	O	1016-1020
codon	O	1021-1026
.	O	1026-1027

The	O	1028-1031
other	O	1032-1037
mutation	O	1038-1046
is	O	1047-1049
a	O	1050-1051
G	O	1052-1053
-	O	1053-1054
to	O	1054-1056
-	O	1053-1054
A	O	1057-1058
transition	O	1059-1069
resulting	O	1070-1079
in	O	1080-1082
an	O	1083-1085
Arg170	O	1086-1092
-	O	1092-1093
to	O	1093-1095
-	O	1092-1093
Gln	O	1096-1099
substitution	O	1100-1112
.	O	1112-1113

This	O	1114-1118
mutation	O	1119-1127
is	O	1128-1130
at	O	1131-1133
a	O	1134-1135
CpG	O	1136-1139
site	O	1140-1144
in	O	1145-1147
a	O	1148-1149
Japanese	O	1150-1158
infant	O	1159-1165
with	O	1166-1170
Tay	B	1171-1174
-	I	1174-1175
Sachs	I	1175-1180
disease	I	1181-1188
and	O	1189-1192
was	O	1193-1196
described	O	1197-1206
elsewhere	O	1207-1216
.	O	1216-1217

Analysis	O	1218-1226
of	O	1227-1229
nine	O	1230-1234
obligate	O	1235-1243
carriers	O	1244-1252
from	O	1253-1257
seven	O	1258-1263
unrelated	O	1264-1273
families	O	1274-1282
showed	O	1283-1289
that	O	1290-1294
four	O	1295-1299
harbor	O	1300-1306
the	O	1307-1310
delta	O	1311-1316
F304	O	1317-1321
/	O	1321-1322
305	O	1322-1325
mutation	O	1326-1334
,	O	1334-1335
two	O	1336-1339
the	O	1340-1343
Arg170	O	1344-1350
-	O	1350-1351
-	O	1350-1351
-	O	1350-1351
-	O	1350-1351
Gln	O	1354-1357
mutation	O	1358-1366
,	O	1366-1367
and	O	1368-1371
one	O	1372-1375
the	O	1376-1379
Tyr180	O	1380-1386
-	O	1386-1387
-	O	1386-1387
-	O	1386-1387
-	O	1386-1387
Stop	O	1390-1394
mutation	O	1395-1403
.	O	1403-1404

We	O	1405-1407
also	O	1408-1412
have	O	1413-1417
developed	O	1418-1427
rapid	O	1428-1433
,	O	1433-1434
nonradioactive	O	1435-1449
assays	O	1450-1456
for	O	1457-1460
the	O	1461-1464
detection	O	1465-1474
of	O	1475-1477
each	O	1478-1482
mutation	O	1483-1491
,	O	1491-1492
which	O	1493-1498
should	O	1499-1505
be	O	1506-1508
helpful	O	1509-1516
for	O	1517-1520
carrier	O	1521-1528
screening	O	1529-1538
.	O	1538-1539
.	O	1538-1539

Mapping	O	0-7
of	O	8-10
the	O	11-14
mouse	O	15-20
homologue	O	21-30
of	O	31-33
the	O	34-37
Wilson	B	38-44
disease	I	45-52
gene	O	53-57
to	O	58-60
mouse	O	61-66
chromosome	O	67-77
8	O	78-79
.	O	79-80

ATP7B	O	81-86
,	O	86-87
the	O	88-91
gene	O	92-96
altered	O	97-104
in	O	105-107
Wilson	B	108-114
disease	I	115-122
(	O	123-124
WD	B	124-126
)	O	126-127
patients	O	128-136
,	O	136-137
lies	O	138-142
in	O	143-145
a	O	146-147
block	O	148-153
of	O	154-156
homology	O	157-165
shared	O	166-172
between	O	173-180
human	O	181-186
chromosome	O	187-197
13q14	O	198-203
and	O	204-207
the	O	208-211
central	O	212-219
region	O	220-226
of	O	227-229
mouse	O	230-235
chromosome	O	236-246
14	O	247-249
.	O	249-250

However	O	251-258
,	O	258-259
we	O	260-262
have	O	263-267
mapped	O	268-274
the	O	275-278
murine	O	279-285
homologue	O	286-295
of	O	296-298
ATP7B	O	299-304
(	O	305-306
Atp7b	O	306-311
)	O	311-312
to	O	313-315
mouse	O	316-321
chromosome	O	322-332
8	O	333-334
by	O	335-337
somatic	O	338-345
cell	O	346-350
hybrid	O	351-357
analysis	O	358-366
.	O	366-367

Analysis	O	368-376
of	O	377-379
80	O	380-382
interspecific	O	383-396
backcross	O	397-406
offspring	O	407-416
was	O	417-420
used	O	421-425
to	O	426-428
position	O	429-437
Atp7b	O	438-443
close	O	444-449
to	O	450-452
D8Mit3	O	453-459
and	O	460-463
another	O	464-471
ATPase	O	472-478
locus	O	479-484
,	O	484-485
Atp4b	O	486-491
,	O	491-492
on	O	493-495
mouse	O	496-501
chromosome	O	502-512
8	O	513-514
.	O	514-515

ATP4B	O	516-521
lies	O	522-526
in	O	527-529
13q34	O	530-535
and	O	536-539
is	O	540-542
separated	O	543-552
from	O	553-557
ATP7B	O	558-563
by	O	564-566
several	O	567-574
loci	O	575-579
whose	O	580-585
mouse	O	586-591
homologues	O	592-602
map	O	603-606
to	O	607-609
mouse	O	610-615
chromosome	O	616-626
14	O	627-629
.	O	629-630

The	O	631-634
assignment	O	635-645
of	O	646-648
Atp7b	O	649-654
to	O	655-657
mouse	O	658-663
chromosome	O	664-674
8	O	675-676
identifies	O	677-687
a	O	688-689
previously	O	690-700
unrecognized	O	701-713
region	O	714-720
of	O	721-723
homology	O	724-732
between	O	733-740
this	O	741-745
chromosome	O	746-756
and	O	757-760
human	O	761-766
chromosome	O	767-777
13	O	778-780
.	O	780-781

This	O	782-786
assignment	O	787-797
suggests	O	798-806
a	O	807-808
possible	O	809-817
location	O	818-826
for	O	827-830
the	O	831-834
toxic	O	835-840
milk	O	841-845
mutation	O	846-854
in	O	855-857
the	O	858-861
mouse	O	862-867
,	O	867-868
which	O	869-874
has	O	875-878
been	O	879-883
proposed	O	884-892
as	O	893-895
a	O	896-897
homologue	O	898-907
of	O	908-910
WD	B	911-913
.	O	913-914
.	O	913-914

Characteristics	O	0-15
of	O	16-18
intergenerational	O	19-36
contractions	O	37-49
of	O	50-52
the	O	53-56
CTG	O	57-60
repeat	O	61-67
in	O	68-70
myotonic	B	71-79
dystrophy	I	80-89
.	O	89-90

In	O	91-93
myotonic	B	94-102
dystrophy	I	103-112
(	O	113-114
DM	B	114-116
)	O	116-117
,	O	117-118
the	O	119-122
size	O	123-127
of	O	128-130
a	O	131-132
CTG	O	133-136
repeat	O	137-143
in	O	144-146
the	O	147-150
DM	B	151-153
kinase	O	154-160
gene	O	161-165
generally	O	166-175
increases	O	176-185
in	O	186-188
successive	O	189-199
generations	O	200-211
with	O	212-216
clinical	O	217-225
evidence	O	226-234
of	O	235-237
anticipation	O	238-250
.	O	250-251

However	O	252-259
,	O	259-260
there	O	261-266
have	O	267-271
also	O	272-276
been	O	277-281
cases	O	282-287
with	O	288-292
an	O	293-295
intergenerational	O	296-313
contraction	O	314-325
of	O	326-328
the	O	329-332
repeat	O	333-339
.	O	339-340

We	O	341-343
examined	O	344-352
1	O	353-354
,	O	354-355
489	O	356-359
DM	B	360-362
parent	O	363-369
-	O	369-370
offspring	O	370-379
pairs	O	380-385
,	O	385-386
of	O	387-389
which	O	390-395
95	O	396-398
(	O	399-400
6	O	400-401
.	O	401-402

4	O	403-404
%	O	404-405
)	O	405-406
showed	O	407-413
such	O	414-418
contractions	O	419-431
in	O	432-434
peripheral	O	435-445
blood	O	446-451
leukocytes	O	452-462
(	O	463-464
PBL	O	464-467
)	O	467-468
.	O	468-469

In	O	470-472
56	O	473-475
of	O	476-478
the	O	479-482
95	O	483-485
pairs	O	486-491
,	O	491-492
clinical	O	493-501
data	O	502-506
allowed	O	507-514
an	O	515-517
analysis	O	518-526
of	O	527-529
their	O	530-535
anticipation	O	536-548
status	O	549-555
.	O	555-556

It	O	557-559
is	O	560-562
surprising	O	563-573
that	O	574-578
anticipation	O	579-591
occurred	O	592-600
in	O	601-603
27	O	604-606
(	O	607-608
48	O	608-610
%	O	610-611
)	O	611-612
of	O	613-615
these	O	616-621
56	O	622-624
pairs	O	625-630
,	O	630-631
while	O	632-637
none	O	638-642
clearly	O	643-650
showed	O	651-657
a	O	658-659
later	O	660-665
onset	O	666-671
of	O	672-674
DM	B	675-677
in	O	678-680
the	O	681-684
symptomatic	O	685-696
offspring	O	697-706
.	O	706-707

The	O	708-711
contraction	O	712-723
occurred	O	724-732
in	O	733-735
76	O	736-738
(	O	739-740
10	O	740-742
%	O	742-743
)	O	743-744
of	O	745-747
753	O	748-751
paternal	O	752-760
transmissions	O	761-774
and	O	775-778
in	O	779-781
19	O	782-784
(	O	785-786
3	O	786-787
%	O	787-788
)	O	788-789
of	O	790-792
736	O	793-796
maternal	O	797-805
transmissions	O	806-819
.	O	819-820

Anticipation	O	821-833
was	O	834-837
observed	O	838-846
more	O	847-851
frequently	O	852-862
in	O	863-865
maternal	O	866-874
(	O	875-876
85	O	876-878
%	O	878-879
)	O	879-880
than	O	881-885
in	O	886-888
paternal	O	889-897
(	O	898-899
37	O	899-901
%	O	901-902
)	O	902-903
transmissions	O	904-917
(	O	918-919
P	O	919-920
<	O	921-922
.	O	922-923
001	O	924-927
)	O	927-928
.	O	928-929

The	O	930-933
parental	O	934-942
repeat	O	943-949
size	O	950-954
correlated	O	955-965
with	O	966-970
the	O	971-974
size	O	975-979
of	O	980-982
intergenerational	O	983-1000
contraction	O	1001-1012
(	O	1013-1014
r2	O	1014-1016
=	O	1017-1018
.	O	1018-1019
50	O	1020-1022
,	O	1022-1023
P	O	1024-1025
<	O	1026-1027
<	O	1028-1029
.	O	1029-1030
001	O	1031-1034
)	O	1034-1035
,	O	1035-1036
and	O	1037-1040
the	O	1041-1044
slope	O	1045-1050
of	O	1051-1053
linear	O	1054-1060
regression	O	1061-1071
was	O	1072-1075
steeper	O	1076-1083
in	O	1084-1086
paternal	O	1087-1095
(	O	1096-1097
-	O	1097-1098
.	O	1098-1099

62	O	1100-1102
)	O	1102-1103
than	O	1104-1108
in	O	1109-1111
maternal	O	1112-1120
(	O	1121-1122
-	O	1122-1123
.	O	1123-1124

30	O	1125-1127
)	O	1127-1128
transmissions	O	1129-1142
(	O	1143-1144
P	O	1144-1145
<	O	1146-1147
<	O	1148-1149
.	O	1149-1150
001	O	1151-1154
)	O	1154-1155
.	O	1155-1156

Sixteen	O	1157-1164
DM	B	1165-1167
parents	O	1168-1175
had	O	1176-1179
multiple	O	1180-1188
DM	B	1189-1191
offspring	O	1192-1201
with	O	1202-1206
the	O	1207-1210
CTG	O	1211-1214
repeat	O	1215-1221
contractions	O	1222-1234
.	O	1234-1235

This	O	1236-1240
frequency	O	1241-1250
was	O	1251-1254
higher	O	1255-1261
than	O	1262-1266
the	O	1267-1270
frequency	O	1271-1280
expected	O	1281-1289
from	O	1290-1294
the	O	1295-1298
probability	O	1299-1310
of	O	1311-1313
the	O	1314-1317
repeat	O	1318-1324
contractions	O	1325-1337
(	O	1338-1339
6	O	1339-1340
.	O	1340-1341

4	O	1342-1343
%	O	1343-1344
)	O	1344-1345
and	O	1346-1349
the	O	1350-1353
size	O	1354-1358
of	O	1359-1361
DM	B	1362-1364
sib	O	1365-1368
population	O	1369-1379
(	O	1380-1381
1	O	1381-1382
.	O	1382-1383

54	O	1384-1386
DM	B	1387-1389
offspring	O	1390-1399
per	O	1400-1403
DM	B	1404-1406
parent	O	1407-1413
,	O	1413-1414
in	O	1415-1417
968	O	1418-1421
DM	B	1422-1424
parents	O	1425-1432
)	O	1432-1433
.	O	1433-1434

We	O	1435-1437
conclude	O	1438-1446
that	O	1447-1451
(	O	1452-1453
1	O	1453-1454
)	O	1454-1455
intergenerational	O	1456-1473
contractions	O	1474-1486
of	O	1487-1489
the	O	1490-1493
CTG	O	1494-1497
repeat	O	1498-1504
in	O	1505-1507
leukocyte	O	1508-1517
DNA	O	1518-1521
frequently	O	1522-1532
accompanies	O	1533-1544
apparent	O	1545-1553
anticipation	O	1554-1566
,	O	1566-1567
especially	O	1568-1578
when	O	1579-1583
DM	B	1584-1586
is	O	1587-1589
maternally	O	1590-1600
transmitted	O	1601-1612
,	O	1612-1613
and	O	1614-1617
(	O	1618-1619
2	O	1619-1620
)	O	1620-1621
the	O	1622-1625
paternal	O	1626-1634
origin	O	1635-1641
of	O	1642-1644
the	O	1645-1648
repeat	O	1649-1655
and	O	1656-1659
the	O	1660-1663
presence	O	1664-1672
of	O	1673-1675
the	O	1676-1679
repeat	O	1680-1686
contraction	O	1687-1698
in	O	1699-1701
a	O	1702-1703
sibling	O	1704-1711
increase	O	1712-1720
the	O	1721-1724
probability	O	1725-1736
of	O	1737-1739
the	O	1740-1743
CTG	O	1744-1747
repeat	O	1748-1754
contraction	O	1755-1766

Splice	O	0-6
-	O	6-7
site	O	7-11
mutation	O	12-20
in	O	21-23
the	O	24-27
PDS	B	28-31
gene	O	32-36
may	O	37-40
result	O	41-47
in	O	48-50
intrafamilial	O	51-64
variability	O	65-76
for	O	77-80
deafness	B	81-89
in	O	90-92
Pendred	B	93-100
syndrome	I	101-109
.	O	109-110

Pendred	B	111-118
syndrome	I	119-127
is	O	128-130
a	O	131-132
recessive	B	133-142
inherited	I	143-152
disorder	I	153-161
that	O	162-166
consists	O	167-175
of	O	176-178
developmental	B	179-192
abnormalities	I	193-206
of	I	207-209
the	I	210-213
cochlea	I	214-221
,	O	221-222
sensorineural	B	223-236
hearing	I	237-244
loss	I	245-249
,	O	249-250
and	O	251-254
diffuse	B	255-262
thyroid	I	263-270
enlargement	I	271-282
(	O	283-284
goiter	B	284-290
)	O	290-291
.	O	291-292

This	O	293-297
disorder	O	298-306
may	O	307-310
account	O	311-318
for	O	319-322
up	O	323-325
to	O	326-328
10	O	329-331
%	O	331-332
of	O	333-335
cases	O	336-341
of	O	342-344
hereditary	B	345-355
deafness	I	356-364
.	O	364-365

The	O	366-369
disease	O	370-377
gene	O	378-382
(	O	383-384
PDS	B	384-387
)	O	387-388
has	O	389-392
been	O	393-397
mapped	O	398-404
to	O	405-407
chromosome	O	408-418
7q22	O	419-423
-	O	423-424
q31	O	424-427
,	O	427-428
and	O	429-432
encodes	O	433-440
a	O	441-442
chloride	O	443-451
-	O	451-452
iodide	O	452-458
transport	O	459-468
protein	O	469-476
.	O	476-477

We	O	478-480
performed	O	481-490
mutation	O	491-499
analysis	O	500-508
of	O	509-511
individual	O	512-522
exons	O	523-528
of	O	529-531
the	O	532-535
PDS	B	536-539
gene	O	540-544
in	O	545-547
one	O	548-551
Spanish	O	552-559
family	O	560-566
that	O	567-571
shows	O	572-577
intrafamilial	O	578-591
variability	O	592-603
of	O	604-606
the	O	607-610
deafness	B	611-619
phenotype	O	620-629
(	O	630-631
two	O	631-634
patients	O	635-643
with	O	644-648
profound	O	649-657
and	O	658-661
one	O	662-665
with	O	666-670
moderate	O	671-679
-	O	679-680
severe	O	680-686
deafness	B	687-695
)	O	695-696
.	O	696-697

We	O	698-700
identified	O	701-711
a	O	712-713
new	O	714-717
splice	O	718-724
-	O	724-725
site	O	725-729
mutation	O	730-738
affecting	O	739-748
intron	O	749-755
4	O	756-757
of	O	758-760
the	O	761-764
PDS	B	765-768
gene	O	769-773
,	O	773-774
at	O	775-777
nucleotide	O	778-788
position	O	789-797
639	O	798-801
+	O	802-803
7	O	804-805
.	O	805-806
RNA	O	807-810
analysis	O	811-819
from	O	820-824
lymphocytes	O	825-836
of	O	837-839
the	O	840-843
affected	O	844-852
patients	O	853-861
showed	O	862-868
that	O	869-873
mutation	O	874-882
639	O	883-886
+	O	887-888
7A	O	889-891
-	O	891-892
-	O	891-892
>	O	894-895
G	O	896-897
generates	O	898-907
a	O	908-909
new	O	910-913
donor	O	914-919
splice	O	920-926
site	O	927-931
,	O	931-932
leading	O	933-940
to	O	941-943
an	O	944-946
mRNA	O	947-951
with	O	952-956
an	O	957-959
insertion	O	960-969
of	O	970-972
six	O	973-976
nucleotides	O	977-988
from	O	989-993
intron	O	994-1000
4	O	1001-1002
of	O	1003-1005
PDS	O	1006-1009
.	O	1009-1010

Since	O	1011-1016
the	O	1017-1020
newly	O	1021-1026
created	O	1027-1034
donor	O	1035-1040
splice	O	1041-1047
site	O	1048-1052
is	O	1053-1055
likely	O	1056-1062
to	O	1063-1065
compete	O	1066-1073
with	O	1074-1078
the	O	1079-1082
normal	O	1083-1089
one	O	1090-1093
,	O	1093-1094
variations	O	1095-1105
of	O	1106-1108
the	O	1109-1112
levels	O	1113-1119
of	O	1120-1122
normal	O	1123-1129
and	O	1130-1133
aberrant	O	1134-1142
transcripts	O	1143-1154
of	O	1155-1157
the	O	1158-1161
PDS	B	1162-1165
gene	O	1166-1170
in	O	1171-1173
the	O	1174-1177
cochlea	O	1178-1185
may	O	1186-1189
explain	O	1190-1197
the	O	1198-1201
variability	O	1202-1213
in	O	1214-1216
the	O	1217-1220
deafness	B	1221-1229
presentation	O	1230-1242
.	O	1242-1243
.	O	1242-1243

Heterozygous	O	0-12
loss	O	13-17
of	O	18-20
Six5	O	21-25
in	O	26-28
mice	O	29-33
is	O	34-36
sufficient	O	37-47
to	O	48-50
cause	O	51-56
ocular	O	57-63
cataracts	B	64-73
.	O	73-74

Myotonic	B	75-83
dystrophy	I	84-93
(	O	94-95
DM	B	95-97
)	O	97-98
is	O	99-101
an	O	102-104
autosomal	B	105-114
dominant	I	115-123
disorder	O	124-132
characterized	O	133-146
by	O	147-149
skeletal	O	150-158
muscle	B	159-165
wasting	I	166-173
,	O	173-174
myotonia	B	175-183
,	O	183-184
cardiac	B	185-192
arrhythmia	I	193-203
,	O	203-204
hyperinsulinaemia	B	205-222
,	O	222-223
mental	B	224-230
retardation	I	231-242
and	O	243-246
ocular	O	247-253
cataracts	B	254-263
.	O	263-264

The	O	265-268
genetic	B	269-276
defect	I	277-283
in	O	284-286
DM	B	287-289
is	O	290-292
a	O	293-294
CTG	O	295-298
repeat	O	299-305
expansion	O	306-315
located	O	316-323
in	O	324-326
the	O	327-330
3	O	331-332
untranslated	O	333-345
region	O	346-352
of	O	353-355
DMPK	O	356-360
and	O	361-364
5	O	365-366
of	O	367-369
a	O	370-371
homeodomain	O	372-383
-	O	383-384
encoding	O	384-392
gene	O	393-397
,	O	397-398
SIX5	O	399-403
(	O	404-405
formerly	O	405-413
DMAHP	O	414-419
;	O	419-420
refs	O	421-425
2	O	426-427
-	O	427-428
5	O	428-429
)	O	429-430
.	O	430-431

There	O	432-437
are	O	438-441
three	O	442-447
mechanisms	O	448-458
by	O	459-461
which	O	462-467
CTG	O	468-471
expansion	O	472-481
can	O	482-485
result	O	486-492
in	O	493-495
DM	B	496-498
.	O	498-499

First	O	500-505
,	O	505-506
repeat	O	507-513
expansion	O	514-523
may	O	524-527
alter	O	528-533
the	O	534-537
processing	O	538-548
or	O	549-551
transport	O	552-561
of	O	562-564
the	O	565-568
mutant	O	569-575
DMPK	O	576-580
mRNA	O	581-585
and	O	586-589
consequently	O	590-602
reduce	O	603-609
DMPK	O	610-614
levels	O	615-621
.	O	621-622

Second	O	623-629
,	O	629-630
CTG	O	631-634
expansion	O	635-644
may	O	645-648
establish	O	649-658
a	O	659-660
region	O	661-667
of	O	668-670
heterochromatin	O	671-686
3	O	687-688
of	O	689-691
the	O	692-695
repeat	O	696-702
sequence	O	703-711
and	O	712-715
decrease	O	716-724
SIX5	O	725-729
transcription	O	730-743
.	O	743-744

Third	O	745-750
,	O	750-751
toxic	O	752-757
effects	O	758-765
of	O	766-768
the	O	769-772
repeat	O	773-779
expansion	O	780-789
may	O	790-793
be	O	794-796
intrinsic	O	797-806
to	O	807-809
the	O	810-813
repeated	O	814-822
elements	O	823-831
at	O	832-834
the	O	835-838
level	O	839-844
of	O	845-847
DNA	O	848-851
or	O	852-854
RNA	O	855-858
(	O	859-860
refs	O	860-864
10	O	865-867
,	O	867-868
11	O	869-871
)	O	871-872
.	O	872-873

Previous	O	874-882
studies	O	883-890
have	O	891-895
demonstrated	O	896-908
that	O	909-913
a	O	914-915
dose	O	916-920
-	O	920-921
dependent	O	921-930
loss	O	931-935
of	O	936-938
Dm15	O	939-943
(	O	944-945
the	O	945-948
mouse	O	949-954
DMPK	O	955-959
homologue	O	960-969
)	O	969-970
in	O	971-973
mice	O	974-978
produces	O	979-987
a	O	988-989
partial	O	990-997
DM	B	998-1000
phenotype	O	1001-1010
characterized	O	1011-1024
by	O	1025-1027
decreased	O	1028-1037
development	O	1038-1049
of	O	1050-1052
skeletal	O	1053-1061
muscle	O	1062-1068
force	O	1069-1074
and	O	1075-1078
cardiac	B	1079-1086
conduction	I	1087-1097
disorders	I	1098-1107
.	O	1107-1108

To	O	1109-1111
test	O	1112-1116
the	O	1117-1120
role	O	1121-1125
of	O	1126-1128
Six5	O	1129-1133
loss	O	1134-1138
in	O	1139-1141
DM	B	1142-1144
,	O	1144-1145
we	O	1146-1148
have	O	1149-1153
analysed	O	1154-1162
a	O	1163-1164
strain	O	1165-1171
of	O	1172-1174
mice	O	1175-1179
in	O	1180-1182
which	O	1183-1188
Six5	O	1189-1193
was	O	1194-1197
deleted	O	1198-1205
.	O	1205-1206

Our	O	1207-1210
results	O	1211-1218
demonstrate	O	1219-1230
that	O	1231-1235
the	O	1236-1239
rate	O	1240-1244
and	O	1245-1248
severity	O	1249-1257
of	O	1258-1260
cataract	B	1261-1269
formation	O	1270-1279
is	O	1280-1282
inversely	O	1283-1292
related	O	1293-1300
to	O	1301-1303
Six5	O	1304-1308
dosage	O	1309-1315
and	O	1316-1319
is	O	1320-1322
temporally	O	1323-1333
progressive	O	1334-1345
.	O	1345-1346

Six5	O	1347-1351
+	O	1352-1353
/	O	1353-1354
-	O	1354-1355
and	O	1356-1359
Six5	O	1360-1364
-	O	1364-1365
/	O	1365-1366
-	O	1364-1365
mice	O	1368-1372
show	O	1373-1377
increased	O	1378-1387
steady	O	1388-1394
-	O	1394-1395
state	O	1395-1400
levels	O	1401-1407
of	O	1408-1410
the	O	1411-1414
Na	O	1415-1417
+	O	1418-1419
/	O	1419-1420
K	O	1420-1421
+	O	1422-1423
-	O	1424-1425
ATPase	O	1425-1431
alpha	O	1432-1437
-	O	1437-1438
1	O	1438-1439
subunit	O	1440-1447
and	O	1448-1451
decreased	O	1452-1461
Dm15	O	1462-1466
mRNA	O	1467-1471
levels	O	1472-1478
.	O	1478-1479

Thus	O	1480-1484
,	O	1484-1485
altered	O	1486-1493
ion	O	1494-1497
homeostasis	O	1498-1509
within	O	1510-1516
the	O	1517-1520
lens	O	1521-1525
may	O	1526-1529
contribute	O	1530-1540
to	O	1541-1543
cataract	B	1544-1552
formation	O	1553-1562
.	O	1562-1563

As	O	1564-1566
ocular	O	1567-1573
cataracts	B	1574-1583
are	O	1584-1587
a	O	1588-1589
characteristic	O	1590-1604
feature	O	1605-1612
of	O	1613-1615
DM	B	1616-1618
,	O	1618-1619
these	O	1620-1625
results	O	1626-1633
demonstrate	O	1634-1645
that	O	1646-1650
decreased	O	1651-1660
SIX5	O	1661-1665
transcription	O	1666-1679
is	O	1680-1682
important	O	1683-1692
in	O	1693-1695
the	O	1696-1699
aetiology	O	1700-1709
of	O	1710-1712
DM	B	1713-1715
.	O	1715-1716

Our	O	1717-1720
data	O	1721-1725
support	O	1726-1733
the	O	1734-1737
hypothesis	O	1738-1748
that	O	1749-1753
DM	B	1754-1756
is	O	1757-1759
a	O	1760-1761
contiguous	O	1762-1772
gene	O	1773-1777
syndrome	O	1778-1786
associated	O	1787-1797
with	O	1798-1802
the	O	1803-1806
partial	O	1807-1814
loss	O	1815-1819
of	O	1820-1822
both	O	1823-1827
DMPK	O	1828-1832
and	O	1833-1836
SIX5	O	1837-1841
.	O	1841-1842
.	O	1841-1842

Cis	O	0-3
and	O	4-7
trans	O	8-13
effects	O	14-21
of	O	22-24
the	O	25-28
myotonic	B	29-37
dystrophy	I	38-47
(	O	48-49
DM	B	49-51
)	O	51-52
mutation	O	53-61
in	O	62-64
a	O	65-66
cell	O	67-71
culture	O	72-79
model	O	80-85
.	O	85-86

The	O	87-90
mutation	O	91-99
causing	O	100-107
myotonic	B	108-116
dystrophy	I	117-126
(	O	127-128
DM	B	128-130
)	O	130-131
has	O	132-135
been	O	136-140
identified	O	141-151
as	O	152-154
a	O	155-156
CTG	O	157-160
expansion	O	161-170
in	O	171-173
the	O	174-177
3	O	178-179
-	O	179-180
untranslated	O	180-192
region	O	193-199
(	O	200-201
3	O	201-202
-	O	202-203
UTR	O	203-206
)	O	206-207
of	O	208-210
the	O	211-214
DM	B	215-217
protein	O	218-225
kinase	O	226-232
gene	O	233-237
(	O	238-239
DMPK	O	239-243
)	O	243-244
,	O	244-245
but	O	246-249
the	O	250-253
mechanism	O	254-263
(	O	264-265
s	O	265-266
)	O	266-267
of	O	268-270
pathogenesis	O	271-283
remain	O	284-290
unknown	O	291-298
.	O	298-299

Studies	O	300-307
using	O	308-313
DM	B	314-316
patient	O	317-324
materials	O	325-334
have	O	335-339
often	O	340-345
produced	O	346-354
confusing	O	355-364
results	O	365-372
.	O	372-373

Therefore	O	374-383
,	O	383-384
to	O	385-387
study	O	388-393
the	O	394-397
effects	O	398-405
of	O	406-408
the	O	409-412
DM	B	413-415
mutation	O	416-424
in	O	425-427
a	O	428-429
controlled	O	430-440
environment	O	441-452
,	O	452-453
we	O	454-456
have	O	457-461
established	O	462-473
a	O	474-475
cell	O	476-480
culture	O	481-488
model	O	489-494
system	O	495-501
using	O	502-507
C2C12	O	508-513
mouse	O	514-519
myoblasts	O	520-529
.	O	529-530

By	O	531-533
expressing	O	534-544
chimeric	O	545-553
reporter	O	554-562
constructs	O	563-573
containing	O	574-584
a	O	585-586
reporter	O	587-595
gene	O	596-600
fused	O	601-606
to	O	607-609
a	O	610-611
human	O	612-617
DMPK	O	618-622
3	O	623-624
-	O	624-625
UTR	O	625-628
,	O	628-629
we	O	630-632
identified	O	633-643
both	O	644-648
cis	O	649-652
and	O	653-656
trans	O	657-662
effects	O	663-670
that	O	671-675
are	O	676-679
mediated	O	680-688
by	O	689-691
the	O	692-695
DM	B	696-698
mutation	O	699-707
.	O	707-708

Our	O	709-712
data	O	713-717
show	O	718-722
that	O	723-727
a	O	728-729
mutant	O	730-736
DMPK	O	737-741
3	O	742-743
-	O	743-744
UTR	O	744-747
,	O	747-748
with	O	749-753
as	O	754-756
few	O	757-760
as	O	761-763
57	O	764-766
CTGs	O	767-771
,	O	771-772
had	O	773-776
a	O	777-778
negative	O	779-787
cis	O	788-791
effect	O	792-798
on	O	799-801
protein	O	802-809
expression	O	810-820
and	O	821-824
resulted	O	825-833
in	O	834-836
the	O	837-840
aggregation	O	841-852
of	O	853-855
reporter	O	856-864
transcripts	O	865-876
into	O	877-881
discrete	O	882-890
nuclear	O	891-898
foci	O	899-903
.	O	903-904

We	O	905-907
determined	O	908-918
by	O	919-921
deletion	O	922-930
analysis	O	931-939
that	O	940-944
an	O	945-947
expanded	O	948-956
(	O	957-958
CTG	O	958-961
)	O	961-962
(	O	963-964
n	O	964-965
)	O	965-966
tract	O	967-972
alone	O	973-978
was	O	979-982
sufficient	O	983-993
to	O	994-996
mediate	O	997-1004
these	O	1005-1010
cis	O	1011-1014
effects	O	1015-1022
.	O	1022-1023

Furthermore	O	1024-1035
,	O	1035-1036
in	O	1037-1039
contrast	O	1040-1048
to	O	1049-1051
the	O	1052-1055
normal	O	1056-1062
DMPK	O	1063-1067
3	O	1068-1069
-	O	1069-1070
UTR	O	1070-1073
mRNA	O	1074-1078
,	O	1078-1079
a	O	1080-1081
mutant	O	1082-1088
DMPK	O	1089-1093
3	O	1094-1095
-	O	1095-1096
UTR	O	1096-1099
mRNA	O	1100-1104
with	O	1105-1109
(	O	1110-1111
CUG	O	1111-1114
)	O	1114-1115
(	O	1116-1117
200	O	1117-1120
)	O	1120-1121
selectively	O	1122-1133
inhibited	O	1134-1143
myogenic	O	1144-1152
differentiation	O	1153-1168
of	O	1169-1171
C2C12	O	1172-1177
myoblasts	O	1178-1187
.	O	1187-1188

Genetic	O	1189-1196
analysis	O	1197-1205
and	O	1206-1209
the	O	1210-1213
Cre	O	1214-1217
-	O	1217-1218
loxP	O	1219-1223
system	O	1224-1230
were	O	1231-1235
used	O	1236-1240
to	O	1241-1243
clearly	O	1244-1251
demonstrate	O	1252-1263
that	O	1264-1268
the	O	1269-1272
myoblast	O	1273-1281
fusion	O	1282-1288
defect	O	1289-1295
could	O	1296-1301
be	O	1302-1304
rescued	O	1305-1312
by	O	1313-1315
eliminating	O	1316-1327
the	O	1328-1331
expression	O	1332-1342
of	O	1343-1345
the	O	1346-1349
mutant	O	1350-1356
DMPK	O	1357-1361
3	O	1362-1363
-	O	1363-1364
UTR	O	1364-1367
transcript	O	1368-1378
.	O	1378-1379

Characterization	O	1380-1396
of	O	1397-1399
spontaneous	O	1400-1411
deletion	O	1412-1420
events	O	1421-1427
mapped	O	1428-1434
the	O	1435-1438
inhibitory	O	1439-1449
effect	O	1450-1456
to	O	1457-1459
the	O	1460-1463
(	O	1464-1465
CTG	O	1465-1468
)	O	1468-1469
(	O	1470-1471
n	O	1471-1472
)	O	1472-1473
expansion	O	1474-1483
and	O	1484-1487
/	O	1487-1488
or	O	1488-1490
the	O	1491-1494
3	O	1495-1496
end	O	1497-1500
of	O	1501-1503
the	O	1504-1507
DMPK	O	1508-1512
3	O	1513-1514
-	O	1514-1515
UTR	O	1515-1518
.	O	1518-1519

These	O	1520-1525
results	O	1526-1533
provide	O	1534-1541
evidence	O	1542-1550
that	O	1551-1555
the	O	1556-1559
DM	B	1560-1562
mutation	O	1563-1571
acts	O	1572-1576
in	O	1577-1579
cis	O	1580-1583
to	O	1584-1586
reduce	O	1587-1593
protein	O	1594-1601
production	O	1602-1612
(	O	1613-1614
consistent	O	1614-1624
with	O	1625-1629
DMPK	B	1630-1634
haploinsufficiency	I	1635-1653
)	O	1653-1654
and	O	1655-1658
in	O	1659-1661
trans	O	1662-1667
as	O	1668-1670
a	O	1671-1672
riboregulator	O	1673-1686
to	O	1687-1689
inhibit	O	1690-1697
myogenesis	O	1698-1708
.	O	1708-1709
.	O	1708-1709

Intelligence	O	0-12
quotient	O	13-21
profile	O	22-29
in	O	30-32
myotonic	B	33-41
dystrophy	I	42-51
,	O	51-52
intergenerational	O	53-70
deficit	O	71-78
,	O	78-79
and	O	80-83
correlation	O	84-95
with	O	96-100
CTG	O	101-104
amplification	O	105-118
.	O	118-119

An	O	120-122
abbreviated	O	123-134
Wechsler	O	135-143
Adult	O	144-149
Intelligence	O	150-162
Scale	O	163-168
Revised	O	169-176
(	O	177-178
WAIS	O	178-182
-	O	182-183
R	O	183-184
)	O	184-185
was	O	186-189
used	O	190-194
to	O	195-197
assess	O	198-204
verbal	O	205-211
and	O	212-215
arithmetical	O	216-228
cognitive	O	229-238
performance	O	239-250
in	O	251-253
55	O	254-256
subjects	O	257-265
with	O	266-270
myotonic	B	271-279
dystrophy	I	280-289
(	O	290-291
DM	B	291-293
)	O	293-294
,	O	294-295
covering	O	296-304
all	O	305-308
grades	O	309-315
of	O	316-318
disease	O	319-326
severity	O	327-335
,	O	335-336
and	O	337-340
31	O	341-343
controls	O	344-352
at	O	353-355
50	O	356-358
%	O	358-359
risk	O	360-364
of	O	365-367
inheriting	O	368-378
DM	B	379-381
.	O	381-382

Scaled	O	383-389
scores	O	390-396
from	O	397-401
the	O	402-405
assessment	O	406-416
were	O	417-421
converted	O	422-431
into	O	432-436
an	O	437-439
intelligence	O	440-452
quotient	O	453-461
(	O	462-463
IQ	O	463-465
)	O	465-466
estimation	O	467-477
on	O	478-480
each	O	481-485
person	O	486-492
.	O	492-493

Significant	O	494-505
IQ	O	506-508
differences	O	509-520
were	O	521-525
found	O	526-531
between	O	532-539
(	O	541-542
1	O	542-543
)	O	543-544
all	O	545-548
55	O	549-551
DM	B	552-554
subjects	O	555-563
(	O	564-565
mean	O	565-569
90	O	570-572
.	O	572-573
2	O	574-575
,	O	575-576
SD	O	577-579
16	O	580-582
.	O	582-583
1	O	584-585
)	O	585-586
and	O	587-590
31	O	591-593
controls	O	594-602
(	O	603-604
102	O	604-607
.	O	607-608

6	O	609-610
,	O	610-611
SD	O	612-614
9	O	615-616
.	O	616-617
4	O	618-619
)	O	619-620
,	O	620-621
with	O	622-626
no	O	627-629
sex	O	630-633
differences	O	634-645
in	O	646-648
either	O	649-655
group	O	656-661
;	O	661-662
(	O	663-664
2	O	664-665
)	O	665-666
15	O	667-669
affected	O	670-678
parents	O	679-686
(	O	687-688
99	O	688-690
.	O	690-691

3	O	692-693
,	O	693-694
SD	O	695-697
12	O	698-700
.	O	700-701
2	O	702-703
)	O	703-704
and	O	705-708
their	O	709-714
affected	O	715-723
children	O	724-732
(	O	733-734
88	O	734-736
.	O	736-737
1	O	738-739
,	O	739-740
SD	O	741-743
17	O	744-746
.	O	746-747
2	O	748-749
)	O	749-750
,	O	750-751
where	O	752-757
significance	O	758-770
was	O	771-774
dependent	O	775-784
on	O	785-787
parental	O	788-796
sex	O	797-800
being	O	801-806
female	O	807-813
;	O	813-814
and	O	815-818
(	O	819-820
3	O	820-821
)	O	821-822
15	O	823-825
pairs	O	826-831
of	O	832-834
affected	O	835-843
sibs	O	844-848
(	O	849-850
89	O	850-852
.	O	852-853

6	O	854-855
,	O	855-856
SD	O	857-859
13	O	860-862
.	O	862-863
2	O	864-865
)	O	865-866
and	O	867-870
their	O	871-876
normal	O	877-883
sibs	O	884-888
(	O	889-890
100	O	890-893
.	O	893-894

2	O	895-896
,	O	896-897
SD	O	898-900
7	O	901-902
.	O	902-903
6	O	904-905
)	O	905-906
.	O	906-907

IQ	O	908-910
steadily	O	911-919
declined	O	920-928
as	O	929-931
(	O	932-933
1	O	933-934
)	O	934-935
the	O	936-939
age	O	940-943
of	O	944-946
onset	O	947-952
of	O	953-955
signs	O	956-961
and	O	962-965
symptoms	O	966-974
decreased	O	975-984
,	O	984-985
and	O	986-989
(	O	990-991
2	O	991-992
)	O	992-993
the	O	994-997
CTG	O	998-1001
expansion	O	1002-1011
size	O	1012-1016
increased	O	1017-1026
.	O	1026-1027

The	O	1028-1031
correlation	O	1032-1043
appeared	O	1044-1052
to	O	1053-1055
be	O	1056-1058
more	O	1059-1063
linear	O	1064-1070
with	O	1071-1075
age	O	1076-1079
of	O	1080-1082
onset	O	1083-1088
.	O	1088-1089

The	O	1090-1093
correlation	O	1094-1105
of	O	1106-1108
IQ	O	1109-1111
difference	O	1112-1122
and	O	1123-1126
CTG	O	1127-1130
expansion	O	1131-1140
difference	O	1141-1151
in	O	1152-1154
both	O	1155-1159
the	O	1160-1163
DM	B	1164-1166
parent	O	1167-1173
-	O	1173-1174
child	O	1174-1179
pairs	O	1180-1185
and	O	1186-1189
normal	O	1190-1196
sib	O	1197-1200
-	O	1200-1201
affected	O	1201-1209
sib	O	1210-1213
pairs	O	1214-1219
was	O	1220-1223
poor	O	1224-1228
,	O	1228-1229
indicating	O	1230-1240
that	O	1241-1245
CTG	O	1246-1249
expansion	O	1250-1259
is	O	1260-1262
not	O	1263-1266
a	O	1267-1268
reliable	O	1269-1277
predictor	O	1278-1287
of	O	1288-1290
IQ	O	1291-1293
either	O	1294-1300
in	O	1301-1303
individual	O	1304-1314
persons	O	1315-1322
or	O	1323-1325
families	O	1326-1334
.	O	1334-1335

Further	O	1336-1343
analysis	O	1344-1352
of	O	1353-1355
cognitive	O	1356-1365
function	O	1366-1374
in	O	1375-1377
DM	B	1378-1380
is	O	1381-1383
required	O	1384-1392
to	O	1393-1395
clarify	O	1396-1403
specific	O	1404-1412
deficits	O	1413-1421
characteristic	O	1422-1436
of	O	1437-1439
this	O	1440-1444
patient	O	1445-1452
group	O	1453-1458

Complement	B	0-10
factor	I	11-17
2	I	18-19
deficiency	I	20-30
:	O	30-31
a	O	32-33
clinical	O	34-42
and	O	43-46
serological	O	47-58
family	O	59-65
study	O	66-71
.	O	71-72

Inherited	B	73-82
complement	I	83-93
deficiencies	I	94-106
are	O	107-110
associated	O	111-121
with	O	122-126
a	O	127-128
variety	O	129-136
of	O	137-139
connective	O	140-150
tissue	O	151-157
diseases	O	158-166
.	O	166-167

A	O	168-169
family	O	170-176
with	O	177-181
inherited	B	182-191
deficiency	I	192-202
of	I	203-205
complement	I	206-216
factor	I	217-223
2	I	224-225
(	O	226-227
C2	O	227-229
)	O	229-230
is	O	231-233
described	O	234-243
in	O	244-246
which	O	247-252
two	O	253-256
family	O	257-263
members	O	264-271
with	O	272-276
homozygous	O	277-287
C2	B	288-290
deficiency	I	291-301
developed	O	302-311
cutaneous	B	312-321
vasculitis	I	322-332
and	O	333-336
sicca	B	337-342
syndrome	I	343-351
.	O	351-352

The	O	353-356
other	O	357-362
family	O	363-369
members	O	370-377
had	O	378-381
heterozygous	O	382-394
C2	B	395-397
deficiency	I	398-408
and	O	409-412
each	O	413-417
member	O	418-424
had	O	425-428
the	O	429-432
HLA	O	433-436
-	O	436-437
A25	O	437-440
,	O	440-441
B18	O	442-445
,	O	445-446
DR2	O	447-450
(	O	451-452
w15	O	452-455
)	O	455-456
haplotype	O	457-466
.	O	466-467

The	O	468-471
mother	O	472-478
had	O	479-482
seropositive	B	483-495
rheumatoid	I	496-506
arthritis	I	507-516
.	O	516-517

Further	O	518-525
studies	O	526-533
showed	O	534-540
the	O	541-544
presence	O	545-553
of	O	554-556
cryoglobulins	O	557-570
,	O	570-571
antibodies	O	572-582
against	O	583-590
endothelial	O	591-602
cells	O	603-608
,	O	608-609
and	O	610-613
anticardiolipin	O	614-629
antibodies	O	630-640
.	O	640-641
.	O	640-641

Oncogenic	O	0-9
point	O	10-15
mutations	O	16-25
in	O	26-28
exon	O	29-33
20	O	34-36
of	O	37-39
the	O	40-43
RB1	O	44-47
gene	O	48-52
in	O	53-55
families	O	56-64
showing	O	65-72
incomplete	O	73-83
penetrance	O	84-94
and	O	95-98
mild	O	99-103
expression	O	104-114
of	O	115-117
the	O	118-121
retinoblastoma	B	122-136
phenotype	O	137-146
.	O	146-147

The	O	148-151
retinoblastoma	B	152-166
-	O	166-167
predisposition	O	167-181
gene	O	182-186
,	O	186-187
RB1	O	188-191
,	O	191-192
segregates	O	193-203
as	O	204-206
an	O	207-209
autosomal	O	210-219
dominant	O	220-228
trait	O	229-234
with	O	235-239
high	O	240-244
(	O	245-246
90	O	246-248
%	O	248-249
)	O	249-250
penetrance	O	251-261
.	O	261-262

Certain	O	263-270
families	O	271-279
,	O	279-280
however	O	281-288
,	O	288-289
show	O	290-294
an	O	295-297
unusual	O	298-305
low	O	306-309
-	O	309-310
penetrance	O	310-320
phenotype	O	321-330
with	O	331-335
many	O	336-340
individuals	O	341-352
being	O	353-358
unaffected	O	359-369
,	O	369-370
unilaterally	O	371-383
affected	O	384-392
,	O	392-393
or	O	394-396
with	O	397-401
evidence	O	402-410
of	O	411-413
spontaneously	O	414-427
regressed	O	428-437
tumors	B	438-444
.	O	444-445

We	O	446-448
have	O	449-453
used	O	454-458
single	O	459-465
-	O	465-466
strand	O	466-472
conformation	O	473-485
polymorphism	O	486-498
analysis	O	499-507
and	O	508-511
PCR	O	512-515
sequencing	O	516-526
to	O	527-529
study	O	530-535
two	O	536-539
such	O	540-544
families	O	545-553
.	O	553-554

Mutations	O	555-564
were	O	565-569
found	O	570-575
in	O	576-578
exon	O	579-583
20	O	584-586
of	O	587-589
RB1	O	590-593
in	O	594-596
both	O	597-601
cases	O	602-607
.	O	607-608

In	O	609-611
one	O	612-615
family	O	616-622
a	O	623-624
C	O	625-626
-	O	626-627
-	O	626-627
-	O	626-627
-	O	626-627
T	O	630-631
transition	O	632-642
in	O	643-645
codon	O	646-651
661	O	652-655
converts	O	656-664
an	O	665-667
arginine	O	668-676
(	O	677-678
CGG	O	678-681
)	O	681-682
to	O	683-685
a	O	686-687
tryptophan	O	688-698
(	O	699-700
TGG	O	700-703
)	O	703-704
codon	O	705-710
.	O	710-711

In	O	712-714
this	O	715-719
family	O	720-726
,	O	726-727
incomplete	O	728-738
penetrance	O	739-749
and	O	750-753
mild	O	754-758
phenotypic	O	759-769
expression	O	770-780
were	O	781-785
observed	O	786-794
in	O	795-797
virtually	O	798-807
all	O	808-811
patients	O	812-820
,	O	820-821
possibly	O	822-830
indicating	O	831-841
that	O	842-846
single	O	847-853
amino	O	854-859
acid	O	860-864
changes	O	865-872
may	O	873-876
modify	O	877-883
protein	O	884-891
structure	O	892-901
/	O	901-902
function	O	902-910
such	O	911-915
that	O	916-920
tumorigenesis	O	921-934
is	O	935-937
not	O	938-941
inevitable	O	942-952
.	O	952-953

In	O	954-956
the	O	957-960
second	O	961-967
family	O	968-974
the	O	975-978
mutation	O	979-987
in	O	988-990
codon	O	991-996
675	O	997-1000
is	O	1001-1003
a	O	1004-1005
G	O	1006-1007
-	O	1007-1008
-	O	1007-1008
-	O	1007-1008
-	O	1007-1008
T	O	1011-1012
transversion	O	1013-1025
that	O	1026-1030
converts	O	1031-1039
a	O	1040-1041
glutamine	O	1042-1051
(	O	1052-1053
GAA	O	1053-1056
)	O	1056-1057
to	O	1058-1060
a	O	1061-1062
stop	O	1063-1067
(	O	1068-1069
TAA	O	1069-1072
)	O	1072-1073
codon	O	1074-1079
.	O	1079-1080

However	O	1081-1088
,	O	1088-1089
this	O	1090-1094
mutation	O	1095-1103
also	O	1104-1108
occurs	O	1109-1115
near	O	1116-1120
a	O	1121-1122
potential	O	1123-1132
cryptic	O	1133-1140
splice	O	1141-1147
acceptor	O	1148-1156
site	O	1157-1161
,	O	1161-1162
raising	O	1163-1170
the	O	1171-1174
possibility	O	1175-1186
of	O	1187-1189
alternative	O	1190-1201
splicing	O	1202-1210
resulting	O	1211-1220
in	O	1221-1223
a	O	1224-1225
less	O	1226-1230
severely	O	1231-1239
disrupted	O	1240-1249
protein	O	1250-1257
.	O	1257-1258
.	O	1257-1258

Identification	O	0-14
of	O	15-17
a	O	18-19
novel	O	20-25
R21X	O	26-30
mutation	O	31-39
in	O	40-42
the	O	43-46
liver	O	47-52
-	O	52-53
type	O	53-57
arginase	O	58-66
gene	O	67-71
(	O	72-73
ARG1	O	73-77
)	O	77-78
in	O	79-81
four	O	82-86
Portuguese	O	87-97
patients	O	98-106
with	O	107-111
argininemia	B	112-123
.	O	123-124

Argininemia	B	125-136
is	O	137-139
a	O	140-141
rare	O	142-146
autossomal	B	147-157
recessive	I	158-167
disorder	I	168-176
caused	O	177-183
by	O	184-186
deficiency	B	187-197
in	I	198-200
the	I	201-204
cytosolic	I	205-214
liver	I	215-220
-	I	220-221
type	I	221-225
arginase	I	226-234
enzyme	I	235-241
(	O	242-243
L	O	243-244
-	O	244-245
arginine	O	245-253
urea	O	254-258
-	O	258-259
hydrolase	O	259-268
;	O	268-269
E	O	270-271
.	O	271-272
C	O	273-274
.	O	274-275
3	O	276-277
.	O	277-278
5	O	279-280
.	O	280-281
3	O	282-283
.	O	283-284
1	O	285-286
)	O	286-287
.	O	287-288

In	O	289-291
order	O	292-297
to	O	298-300
investigate	O	301-312
the	O	313-316
molecular	O	317-326
basis	O	327-332
for	O	333-336
argininemia	B	337-348
in	O	349-351
four	O	352-356
unrelated	O	357-366
Portuguese	O	367-377
patients	O	378-386
(	O	387-388
two	O	388-391
from	O	392-396
northern	O	397-405
Portugal	O	406-414
and	O	415-418
two	O	419-422
from	O	423-427
Madeira	O	428-435
Island	O	436-442
)	O	442-443
we	O	444-446
performed	O	447-456
a	O	457-458
DNA	O	459-462
sequence	O	463-471
analysis	O	472-480
of	O	481-483
all	O	484-487
the	O	488-491
exons	O	492-497
and	O	498-501
exon	O	502-506
/	O	506-507
intron	O	507-513
boundaries	O	514-524
of	O	525-527
the	O	528-531
liver	O	532-537
-	O	537-538
type	O	538-542
arginase	O	543-551
gene	O	552-556
(	O	557-558
ARG1	O	558-562
)	O	562-563
.	O	563-564

All	O	565-568
patients	O	569-577
were	O	578-582
found	O	583-588
to	O	589-591
be	O	592-594
homozygous	O	595-605
for	O	606-609
a	O	610-611
newly	O	612-617
identified	O	618-628
C	O	629-630
-	O	631-632
>	O	633-634
T	O	635-636
transition	O	637-647
in	O	648-650
codon	O	651-656
21	O	657-659
(	O	660-661
exon	O	661-665
2	O	666-667
)	O	667-668
substituting	O	669-681
arginine	O	682-690
for	O	691-694
a	O	695-696
premature	O	697-706
stop	O	707-711
codon	O	712-717
(	O	718-719
R21X	O	719-723
CGA	O	725-728
to	O	729-731
TGA	O	732-735
)	O	735-736
and	O	737-740
generating	O	741-751
a	O	752-753
NlaIII	O	754-760
restriction	O	761-772
site	O	773-777
.	O	777-778

Restriction	O	779-790
digestion	O	791-800
following	O	801-810
PCR	O	811-814
amplification	O	815-828
of	O	829-831
ARG1	O	832-836
exon	O	837-841
2	O	842-843
confirmed	O	844-853
the	O	854-857
presence	O	858-866
of	O	867-869
the	O	870-873
mutation	O	874-882
.	O	882-883

A	O	0-1
mutation	O	2-10
in	O	11-13
the	O	14-17
pleckstrin	O	18-28
homology	O	29-37
(	O	38-39
PH	O	39-41
)	O	41-42
domain	O	43-49
of	O	50-52
the	O	53-56
FGD1	O	57-61
gene	O	62-66
in	O	67-69
an	O	70-72
Italian	O	73-80
family	O	81-87
with	O	88-92
faciogenital	B	93-105
dysplasia	I	106-115
(	O	116-117
Aarskog	B	117-124
-	I	124-125
Scott	I	125-130
syndrome	I	131-139
)	O	139-140
.	O	140-141

Aarskog	B	142-149
-	I	149-150
Scott	I	150-155
Syndrome	I	156-164
(	O	165-166
AAS	B	166-169
)	O	169-170
is	O	171-173
an	O	174-176
X	B	177-178
-	I	178-179
linked	I	179-185
disorder	I	186-194
characterised	O	195-208
by	O	209-211
short	B	212-217
stature	I	218-225
and	O	226-229
multiple	O	230-238
facial	B	239-245
,	I	245-246
limb	I	247-251
and	I	252-255
genital	I	256-263
abnormalities	I	264-277
.	O	277-278

A	O	279-280
gene	O	281-285
,	O	285-286
FGD1	O	287-291
,	O	291-292
altered	O	293-300
in	O	301-303
a	O	304-305
patient	O	306-313
with	O	314-318
AAS	B	319-322
phenotype	O	323-332
,	O	332-333
has	O	334-337
been	O	338-342
identified	O	343-353
and	O	354-357
found	O	358-363
to	O	364-366
encode	O	367-373
a	O	374-375
protein	O	376-383
with	O	384-388
homology	O	389-397
to	O	398-400
Rho	O	401-404
/	O	404-405
Rac	O	405-408
guanine	O	409-416
nucleotide	O	417-427
exchange	O	428-436
factors	O	437-444
(	O	445-446
Rho	O	446-449
/	O	449-450
Rac	O	450-453
GEF	O	454-457
)	O	457-458
.	O	458-459

However	O	460-467
,	O	467-468
since	O	469-474
this	O	475-479
original	O	480-488
report	O	489-495
on	O	496-498
identification	O	499-513
of	O	514-516
a	O	517-518
mutated	O	519-526
FGD1	O	527-531
gene	O	532-536
in	O	537-539
an	O	540-542
AAS	B	543-546
patient	O	547-554
,	O	554-555
no	O	556-558
additional	O	559-569
mutations	O	570-579
in	O	580-582
the	O	583-586
FGD1	O	587-591
gene	O	592-596
have	O	597-601
been	O	602-606
described	O	607-616
.	O	616-617

We	O	618-620
analysed	O	621-629
13	O	630-632
independent	O	633-644
patients	O	645-653
with	O	654-658
clinical	O	659-667
diagnosis	O	668-677
of	O	678-680
AAS	B	681-684
.	O	684-685

One	O	686-689
patient	O	690-697
presented	O	698-707
a	O	708-709
mutation	O	710-718
that	O	719-723
results	O	724-731
in	O	732-734
a	O	735-736
nucleotide	O	737-747
change	O	748-754
in	O	755-757
exon	O	758-762
10	O	763-765
of	O	766-768
the	O	769-772
FGD1	O	773-777
gene	O	778-782
(	O	783-784
G2559	O	784-789
>	O	790-791
A	O	792-793
)	O	793-794
substituting	O	795-807
a	O	808-809
Gln	O	810-813
for	O	814-817
Arg	O	818-821
in	O	822-824
position	O	825-833
610	O	834-837
.	O	837-838

The	O	839-842
mutation	O	843-851
was	O	852-855
found	O	856-861
to	O	862-864
segregate	O	865-874
with	O	875-879
the	O	880-883
AAS	B	884-887
phenotype	O	888-897
in	O	898-900
affected	O	901-909
males	O	910-915
and	O	916-919
carrier	O	920-927
females	O	928-935
in	O	936-938
the	O	939-942
family	O	943-949
of	O	950-952
this	O	953-957
patient	O	958-965
.	O	965-966

Interestingly	O	967-980
,	O	980-981
Arg	O	982-985
-	O	985-986
610	O	986-989
is	O	990-992
located	O	993-1000
within	O	1001-1007
one	O	1008-1011
of	O	1012-1014
the	O	1015-1018
two	O	1019-1022
pleckstrin	O	1023-1033
homology	O	1034-1042
(	O	1043-1044
PH	O	1044-1046
)	O	1046-1047
domains	O	1048-1055
of	O	1056-1058
the	O	1059-1062
FGD1	O	1063-1067
gene	O	1068-1072
and	O	1073-1076
it	O	1077-1079
corresponds	O	1080-1091
to	O	1092-1094
a	O	1095-1096
highly	O	1097-1103
conserved	O	1104-1113
residue	O	1114-1121
which	O	1122-1127
has	O	1128-1131
been	O	1132-1136
involved	O	1137-1145
in	O	1146-1148
InsP	O	1149-1153
binding	O	1154-1161
in	O	1162-1164
PH	O	1165-1167
domains	O	1168-1175
of	O	1176-1178
other	O	1179-1184
proteins	O	1185-1193
.	O	1193-1194

The	O	1195-1198
same	O	1199-1203
residue	O	1204-1211
is	O	1212-1214
often	O	1215-1220
mutated	O	1221-1228
in	O	1229-1231
the	O	1232-1235
Brutons	O	1236-1243
tyrosine	O	1244-1252
kinase	O	1253-1259
(	O	1260-1261
Btk	O	1261-1264
)	O	1264-1265
gene	O	1266-1270
in	O	1271-1273
patients	O	1274-1282
with	O	1283-1287
an	O	1288-1290
X	B	1291-1292
-	I	1292-1293
linked	I	1293-1299
agammaglobulinemia	I	1300-1318
.	O	1318-1319

The	O	1320-1323
Arg610Gln	O	1324-1333
mutation	O	1334-1342
represents	O	1343-1353
the	O	1354-1357
first	O	1358-1363
case	O	1364-1368
of	O	1369-1371
a	O	1372-1373
mutation	O	1374-1382
in	O	1383-1385
the	O	1386-1389
PH	O	1390-1392
domain	O	1393-1399
of	O	1400-1402
the	O	1403-1406
FGD1	O	1407-1411
gene	O	1412-1416
and	O	1417-1420
additional	O	1421-1431
evidence	O	1432-1440
that	O	1441-1445
mutations	O	1446-1455
in	O	1456-1458
PH	O	1459-1461
domains	O	1462-1469
can	O	1470-1473
be	O	1474-1476
associated	O	1477-1487
to	O	1488-1490
human	O	1491-1496
diseases	O	1497-1505
.	O	1505-1506
.	O	1505-1506

Localization	O	0-12
of	O	13-15
histidase	O	16-25
to	O	26-28
human	O	29-34
chromosome	O	35-45
region	O	46-52
12q22	O	53-58
-	O	58-59
-	O	58-59
-	O	58-59
-	O	58-59
q24	O	62-65
.	O	65-66
1	O	53-54
and	O	68-71
mouse	O	72-77
chromosome	O	78-88
region	O	89-95
10C2	O	96-100
-	O	100-101
-	O	100-101
-	O	100-101
-	O	100-101
D1	O	104-106
.	O	106-107

The	O	108-111
human	O	112-117
gene	O	118-122
for	O	123-126
histidase	O	127-136
(	O	137-138
histidine	O	138-147
ammonia	O	148-155
-	O	155-156
lyase	O	156-161
;	O	161-162
HAL	O	163-166
)	O	166-167
,	O	167-168
the	O	169-172
enzyme	O	173-179
deficient	O	180-189
in	O	190-192
histidinemia	B	193-205
,	O	205-206
was	O	207-210
assigned	O	211-219
to	O	220-222
human	O	223-228
chromosome	O	229-239
12	O	240-242
by	O	243-245
Southern	O	246-254
blot	O	255-259
analysis	O	260-268
of	O	269-271
human	O	272-277
X	O	278-279
mouse	O	280-285
somatic	O	286-293
cell	O	294-298
hybrid	O	299-305
DNA	O	306-309
.	O	309-310

The	O	311-314
gene	O	315-319
was	O	320-323
sublocalized	O	324-336
to	O	337-339
region	O	340-346
12q22	O	347-352
-	O	352-353
-	O	352-353
-	O	352-353
-	O	352-353
q24	O	356-359
.	O	359-360

1	O	361-362
by	O	363-365
in	O	366-368
situ	O	369-373
hybridization	O	374-387
,	O	387-388
using	O	389-394
a	O	395-396
human	O	397-402
histidase	O	403-412
cDNA	O	413-417
.	O	417-418

The	O	419-422
homologous	O	423-433
locus	O	434-439
in	O	440-442
the	O	443-446
mouse	O	447-452
(	O	453-454
Hal	O	454-457
)	O	457-458
was	O	459-462
mapped	O	463-469
to	O	470-472
region	O	473-479
10C2	O	480-484
-	O	484-485
-	O	484-485
-	O	484-485
-	O	484-485
D1	O	488-490
by	O	491-493
in	O	494-496
situ	O	497-501
hybridization	O	502-515
,	O	515-516
using	O	517-522
a	O	523-524
cell	O	525-529
line	O	530-534
from	O	535-539
a	O	540-541
mouse	O	542-547
homozygous	O	548-558
for	O	559-562
a	O	563-564
1	O	565-566
.	O	566-567
10	O	568-570
Robertsonian	O	571-583
translocation	O	584-597
.	O	597-598

These	O	599-604
assignments	O	605-616
extend	O	617-623
the	O	624-627
conserved	O	628-637
syntenic	O	638-646
region	O	647-653
between	O	654-661
human	O	662-667
chromosome	O	668-678
12	O	679-681
and	O	682-685
mouse	O	686-691
chromosome	O	692-702
10	O	703-705
that	O	706-710
includes	O	711-719
the	O	720-723
genes	O	724-729
for	O	730-733
phenylalanine	O	734-747
hydroxylase	O	748-759
,	O	759-760
gamma	O	761-766
interferon	O	767-777
,	O	777-778
peptidase	O	779-788
,	O	788-789
and	O	790-793
citrate	O	794-801
synthase	O	802-810
.	O	810-811

The	O	812-815
localization	O	816-828
of	O	829-831
histidase	O	832-841
to	O	842-844
mouse	O	845-850
chromosome	O	851-861
10	O	862-864
suggests	O	865-873
that	O	874-878
the	O	879-882
histidase	O	883-892
regulatory	O	893-903
locus	O	904-909
(	O	910-911
Hsd	O	911-914
)	O	914-915
and	O	916-919
the	O	920-923
histidinemia	O	924-936
mutation	O	937-945
(	O	946-947
his	O	947-950
)	O	950-951
,	O	951-952
which	O	953-958
are	O	959-962
both	O	963-967
known	O	968-973
to	O	974-976
be	O	977-979
on	O	980-982
chromosome	O	983-993
10	O	994-996
,	O	996-997
may	O	998-1001
be	O	1002-1004
alleles	O	1005-1012
of	O	1013-1015
the	O	1016-1019
histidase	O	1020-1029
structural	O	1030-1040
gene	O	1041-1045
locus	O	1046-1051
.	O	1051-1052

Noninvasive	O	0-11
test	O	12-16
for	O	17-20
fragile	B	21-28
X	I	29-30
syndrome	I	31-39
,	O	39-40
using	O	41-46
hair	O	47-51
root	O	52-56
analysis	O	57-65
.	O	65-66

Identification	O	67-81
of	O	82-84
the	O	85-88
FMR1	O	89-93
gene	O	94-98
and	O	99-102
the	O	103-106
repeat	O	107-113
-	O	113-114
amplification	O	114-127
mechanism	O	128-137
causing	O	138-145
fragile	B	146-153
X	I	154-155
syndrome	I	156-164
led	O	165-168
to	O	169-171
development	O	172-183
of	O	184-186
reliable	O	187-195
DNA	O	196-199
-	O	199-200
based	O	200-205
diagnostic	O	206-216
methods	O	217-224
,	O	224-225
including	O	226-235
Southern	O	236-244
blot	O	245-249
hybridization	O	250-263
and	O	264-267
PCR	O	268-271
.	O	271-272

Both	O	273-277
methods	O	278-285
are	O	286-289
performed	O	290-299
on	O	300-302
DNA	O	303-306
isolated	O	307-315
from	O	316-320
peripheral	O	321-331
blood	O	332-337
cells	O	338-343
and	O	344-347
measure	O	348-355
the	O	356-359
repeat	O	360-366
size	O	367-371
in	O	372-374
FMR1	O	375-379
.	O	379-380

Using	O	381-386
an	O	387-389
immunocytochemical	O	390-408
technique	O	409-418
on	O	419-421
blood	O	422-427
smears	O	428-434
,	O	434-435
we	O	436-438
recently	O	439-447
developed	O	448-457
a	O	458-459
novel	O	460-465
test	O	466-470
for	O	471-474
identification	O	475-489
of	O	490-492
patients	O	493-501
with	O	502-506
fragile	B	507-514
X	I	515-516
syndrome	I	517-525
.	O	525-526

This	O	527-531
method	O	532-538
,	O	538-539
also	O	540-544
called	O	545-551
"	O	552-553
antibody	O	554-562
test	O	563-567
,	O	567-568
"	O	569-570
uses	O	571-575
monoclonal	O	576-586
antibodies	O	587-597
against	O	598-605
the	O	606-609
FMR1	O	610-614
gene	O	615-619
product	O	620-627
(	O	628-629
FMRP	O	629-633
)	O	633-634
and	O	635-638
is	O	639-641
based	O	642-647
on	O	648-650
absence	O	651-658
of	O	659-661
FMRP	O	662-666
in	O	667-669
patients	O	670-678
cells	O	679-684
.	O	684-685

Here	O	686-690
we	O	691-693
describe	O	694-702
a	O	703-704
new	O	705-708
diagnostic	O	709-719
test	O	720-724
to	O	725-727
identify	O	728-736
male	O	737-741
patients	O	742-750
with	O	751-755
fragile	B	756-763
X	I	764-765
syndrome	I	766-774
,	O	774-775
on	O	776-778
the	O	779-782
basis	O	783-788
of	O	789-791
lack	O	792-796
of	O	797-799
FMRP	O	800-804
in	O	805-807
their	O	808-813
hair	O	814-818
roots	O	819-824
.	O	824-825

Expression	O	826-836
of	O	837-839
FMRP	O	840-844
in	O	845-847
hair	O	848-852
roots	O	853-858
was	O	859-862
studied	O	863-870
by	O	871-873
use	O	874-877
of	O	878-880
an	O	881-883
FMRP	O	884-888
-	O	888-889
specific	O	889-897
antibody	O	898-906
test	O	907-911
,	O	911-912
and	O	913-916
the	O	917-920
percentage	O	921-931
of	O	932-934
FMRP	O	935-939
-	O	939-940
expressing	O	940-950
hair	O	951-955
roots	O	956-961
in	O	962-964
controls	O	965-973
and	O	974-977
in	O	978-980
male	O	981-985
fragile	B	986-993
X	I	994-995
patients	O	996-1004
was	O	1005-1008
determined	O	1009-1019
.	O	1019-1020

Control	O	1021-1028
individuals	O	1029-1040
showed	O	1041-1047
clear	O	1048-1053
expression	O	1054-1064
of	O	1065-1067
FMRP	O	1068-1072
in	O	1073-1075
nearly	O	1076-1082
every	O	1083-1088
hair	O	1089-1093
root	O	1094-1098
,	O	1098-1099
whereas	O	1100-1107
male	O	1108-1112
fragile	B	1113-1120
X	I	1121-1122
patients	O	1123-1131
lacked	O	1132-1138
expression	O	1139-1149
of	O	1150-1152
FMRP	O	1153-1157
in	O	1158-1160
almost	O	1161-1167
all	O	1168-1171
their	O	1172-1177
hair	O	1178-1182
roots	O	1183-1188
.	O	1188-1189

Mentally	B	1190-1198
retarded	I	1199-1207
female	O	1208-1214
patients	O	1215-1223
with	O	1224-1228
a	O	1229-1230
full	O	1231-1235
mutation	O	1236-1244
showed	O	1245-1251
FMRP	O	1252-1256
expression	O	1257-1267
in	O	1268-1270
only	O	1271-1275
some	O	1276-1280
of	O	1281-1283
their	O	1284-1289
hair	O	1290-1294
roots	O	1295-1300
(	O	1301-1302
<	O	1302-1303
55	O	1304-1306
%	O	1306-1307
)	O	1307-1308
,	O	1308-1309
and	O	1310-1313
no	O	1314-1316
overlap	O	1317-1324
with	O	1325-1329
normal	O	1330-1336
female	O	1337-1343
controls	O	1344-1352
was	O	1353-1356
observed	O	1357-1365
.	O	1365-1366

The	O	1367-1370
advantages	O	1371-1381
of	O	1382-1384
this	O	1385-1389
test	O	1390-1394
are	O	1395-1398
(	O	1399-1400
1	O	1400-1401
)	O	1401-1402
plucking	O	1403-1411
of	O	1412-1414
hair	O	1415-1419
follicles	O	1420-1429
does	O	1430-1434
no	O	1435-1437
appreciable	O	1438-1449
harm	O	1450-1454
to	O	1455-1457
the	O	1458-1461
mentally	B	1462-1470
retarded	I	1471-1479
patient	O	1480-1487
,	O	1487-1488
(	O	1489-1490
2	O	1490-1491
)	O	1491-1492
hairs	O	1493-1498
can	O	1499-1502
be	O	1503-1505
sent	O	1506-1510
in	O	1511-1513
a	O	1514-1515
simple	O	1516-1522
envelope	O	1523-1531
to	O	1532-1534
a	O	1535-1536
diagnostic	O	1537-1547
center	O	1548-1554
,	O	1554-1555
and	O	1556-1559
(	O	1560-1561
3	O	1561-1562
)	O	1562-1563
the	O	1564-1567
result	O	1568-1574
of	O	1575-1577
the	O	1578-1581
test	O	1582-1586
is	O	1587-1589
available	O	1590-1599
within	O	1600-1606
5	O	1607-1608
h	O	1609-1610
of	O	1611-1613
plucking	O	1614-1622
.	O	1622-1623

In	O	1624-1626
addition	O	1627-1635
,	O	1635-1636
this	O	1637-1641
test	O	1642-1646
enabled	O	1647-1654
us	O	1655-1657
to	O	1658-1660
identify	O	1661-1669
two	O	1670-1673
fragile	B	1674-1681
X	I	1682-1683
patients	O	1684-1692
who	O	1693-1696
did	O	1697-1700
not	O	1701-1704
show	O	1705-1709
the	O	1710-1713
full	O	1714-1718
mutation	O	1719-1727
by	O	1728-1730
analysis	O	1731-1739
of	O	1740-1742
DNA	O	1743-1746
isolated	O	1747-1755
from	O	1756-1760
blood	O	1761-1766
cells	O	1767-1772
.	O	1772-1773
.	O	1772-1773

Pelizaeus	B	0-9
-	I	9-10
Merzbacher	I	10-20
disease	I	21-28
:	O	28-29
detection	O	30-39
of	O	40-42
mutations	O	43-52
Thr181	O	53-59
-	O	59-60
-	O	59-60
-	O	59-60
-	O	59-60
Pro	O	63-66
and	O	67-70
Leu223	O	71-77
-	O	77-78
-	O	77-78
-	O	77-78
-	O	77-78
Pro	O	81-84
in	O	85-87
the	O	88-91
proteolipid	O	92-103
protein	O	104-111
gene	O	112-116
,	O	116-117
and	O	118-121
prenatal	O	122-130
diagnosis	O	131-140
.	O	140-141

A	O	142-143
family	O	144-150
with	O	151-155
an	O	156-158
apparent	O	159-167
history	O	168-175
of	O	176-178
X	O	179-180
-	O	180-181
linked	O	181-187
Pelizaeus	B	188-197
-	I	197-198
Merzbacher	I	198-208
disease	I	209-216
presented	O	217-226
for	O	227-230
genetic	O	231-238
counseling	O	239-249
,	O	249-250
requesting	O	251-261
carrier	O	262-269
detection	O	270-279
and	O	280-283
prenatal	O	284-292
diagnosis	O	293-302
.	O	302-303

RFLP	O	304-308
analysis	O	309-317
using	O	318-323
the	O	324-327
proteolipid	O	328-339
protein	O	340-347
(	O	348-349
PLP	O	349-352
)	O	352-353
gene	O	354-358
probe	O	359-364
was	O	365-368
uninformative	O	369-382
in	O	383-385
this	O	386-390
family	O	391-397
.	O	397-398

A	O	399-400
prenatal	O	401-409
diagnosis	O	410-419
on	O	420-422
a	O	423-424
chorionic	O	425-434
villus	O	435-441
sample	O	442-448
(	O	449-450
CVS	O	450-453
)	O	453-454
was	O	455-458
carried	O	459-466
out	O	467-470
using	O	471-476
single	O	477-483
-	O	483-484
strand	O	484-490
conformation	O	491-503
polymorphism	O	504-516
(	O	517-518
SSCP	O	518-522
)	O	522-523
analysis	O	524-532
of	O	533-535
a	O	536-537
variant	O	538-545
in	O	546-548
exon	O	549-553
4	O	554-555
of	O	556-558
the	O	559-562
PLP	O	563-566
gene	O	567-571
.	O	571-572

The	O	573-576
fetus	O	577-582
was	O	583-586
predicted	O	587-596
to	O	597-599
be	O	600-602
unaffected	O	603-613
.	O	613-614

Sequencing	O	615-625
of	O	626-628
the	O	629-632
exon	O	633-637
from	O	638-642
the	O	643-646
CVS	O	647-650
,	O	650-651
the	O	652-655
predicted	O	656-665
-	O	665-666
carrier	O	666-673
mother	O	674-680
,	O	680-681
and	O	682-685
the	O	686-689
obligate	O	690-698
-	O	698-699
carrier	O	699-706
grandmother	O	707-718
revealed	O	719-727
an	O	728-730
A	O	731-732
-	O	732-733
to	O	733-735
-	O	732-733
C	O	736-737
change	O	738-744
at	O	745-747
nucleotide	O	748-758
541	O	759-762
in	O	763-765
the	O	766-769
two	O	770-773
women	O	774-779
but	O	780-783
not	O	784-787
in	O	788-790
the	O	791-794
fetus	O	795-800
.	O	800-801

As	O	802-804
this	O	805-809
change	O	810-816
results	O	817-824
in	O	825-827
a	O	828-829
Thr	O	830-833
-	O	833-834
to	O	834-836
-	O	833-834
Pro	O	837-840
change	O	841-847
at	O	848-850
amino	O	851-856
acid	O	857-861
181	O	862-865
in	O	866-868
a	O	869-870
region	O	871-877
of	O	878-880
the	O	881-884
gene	O	885-889
predicted	O	890-899
to	O	900-902
be	O	903-905
part	O	906-910
of	O	911-913
a	O	914-915
transmembrane	O	916-929
segment	O	930-937
,	O	937-938
it	O	939-941
was	O	942-945
concluded	O	946-955
that	O	956-960
this	O	961-965
was	O	966-969
the	O	970-973
mutation	O	974-982
causing	O	983-990
the	O	991-994
disease	O	995-1002
in	O	1003-1005
this	O	1006-1010
family	O	1011-1017
.	O	1017-1018

In	O	1019-1021
addition	O	1022-1030
,	O	1030-1031
in	O	1032-1034
a	O	1035-1036
second	O	1037-1043
family	O	1044-1050
,	O	1050-1051
an	O	1052-1054
exon	O	1055-1059
5	O	1060-1061
variant	O	1062-1069
band	O	1070-1074
pattern	O	1075-1082
on	O	1083-1085
SSCP	O	1086-1090
analysis	O	1091-1099
was	O	1100-1103
shown	O	1104-1109
by	O	1110-1112
sequencing	O	1113-1123
to	O	1124-1126
be	O	1127-1129
due	O	1130-1133
to	O	1134-1136
a	O	1137-1138
T	O	1139-1140
-	O	1140-1141
to	O	1141-1143
-	O	1140-1141
C	O	1144-1145
change	O	1146-1152
at	O	1153-1155
nucleotide	O	1156-1166
668	O	1167-1170
.	O	1170-1171

This	O	1172-1176
results	O	1177-1184
in	O	1185-1187
a	O	1188-1189
Leu	O	1190-1193
-	O	1193-1194
to	O	1194-1196
-	O	1193-1194
Pro	O	1197-1200
change	O	1201-1207
in	O	1208-1210
a	O	1211-1212
carrier	O	1213-1220
mother	O	1221-1227
and	O	1228-1231
in	O	1232-1234
her	O	1235-1238
two	O	1239-1242
affected	O	1243-1251
sons	O	1252-1256
.	O	1256-1257

These	O	1258-1263
results	O	1264-1271
provide	O	1272-1279
further	O	1280-1287
examples	O	1288-1296
of	O	1297-1299
mutations	O	1300-1309
in	O	1310-1312
PLP	O	1313-1316
that	O	1317-1321
cause	O	1322-1327
Pelizaeus	B	1328-1337
-	I	1337-1338
Merzbacher	I	1338-1348
disease	I	1349-1356
and	O	1357-1360
illustrate	O	1361-1371
the	O	1372-1375
value	O	1376-1381
of	O	1382-1384
SSCP	O	1385-1389
in	O	1390-1392
genetic	O	1393-1400
analysis	O	1401-1409
.	O	1409-1410
.	O	1409-1410

A	O	0-1
normal	O	2-8
male	O	9-13
with	O	14-18
an	O	19-21
inherited	O	22-31
deletion	O	32-40
of	O	41-43
one	O	44-47
exon	O	48-52
within	O	53-59
the	O	60-63
DMD	B	64-67
gene	O	68-72
.	O	72-73

We	O	74-76
describe	O	77-85
two	O	86-89
brothers	O	90-98
with	O	99-103
identical	O	104-113
inherited	O	114-123
deletions	O	124-133
of	O	134-136
one	O	137-140
single	O	141-147
exon	O	148-152
within	O	153-159
the	O	160-163
middle	O	164-170
of	O	171-173
the	O	174-177
DMD	B	178-181
gene	O	182-186
;	O	186-187
one	O	188-191
brother	O	192-199
has	O	200-203
Becker	B	204-210
muscular	I	211-219
dystrophy	I	220-229
diagnosed	O	230-239
at	O	240-242
11	O	243-245
years	O	246-251
of	O	252-254
age	O	255-258
,	O	258-259
whereas	O	260-267
the	O	268-271
older	O	272-277
brother	O	278-285
is	O	286-288
normal	O	289-295
at	O	296-298
18	O	299-301
.	O	301-302

These	O	303-308
results	O	309-316
have	O	317-321
implications	O	322-334
for	O	335-338
genetic	O	339-346
counselling	O	347-358
and	O	359-362
prenatal	O	363-371
diagnosis	O	372-381
in	O	382-384
families	O	385-393
with	O	394-398
Becker	B	399-405
muscular	I	406-414
dystrophy	I	415-424
.	O	424-425
.	O	424-425

Small	O	0-5
deletions	O	6-15
in	O	16-18
the	O	19-22
type	O	23-27
II	O	28-30
collagen	O	31-39
triple	O	40-46
helix	O	47-52
produce	O	53-60
kniest	B	61-67
dysplasia	I	68-77
.	O	77-78

Kniest	B	79-85
dysplasia	I	86-95
is	O	96-98
a	O	99-100
moderately	O	101-111
severe	O	112-118
type	B	119-123
II	I	124-126
collagenopathy	I	127-141
,	O	141-142
characterized	O	143-156
by	O	157-159
short	O	160-165
trunk	O	166-171
and	O	172-175
limbs	O	176-181
,	O	181-182
kyphoscoliosis	B	183-197
,	O	197-198
midface	B	199-206
hypoplasia	I	207-217
,	O	217-218
severe	O	219-225
myopia	B	226-232
,	O	232-233
and	O	234-237
hearing	B	238-245
loss	I	246-250
.	O	250-251

Mutations	O	252-261
in	O	262-264
the	O	265-268
gene	O	269-273
that	O	274-278
encodes	O	279-286
type	O	287-291
II	O	292-294
collagen	O	295-303
(	O	304-305
COL2A1	O	305-311
)	O	311-312
,	O	312-313
the	O	314-317
predominant	O	318-329
protein	O	330-337
of	O	338-340
cartilage	O	341-350
,	O	350-351
have	O	352-356
been	O	357-361
identified	O	362-372
in	O	373-375
a	O	376-377
number	O	378-384
of	O	385-387
individuals	O	388-399
with	O	400-404
Kniest	B	405-411
dysplasia	I	412-421
.	O	421-422

All	O	423-426
but	O	427-430
two	O	431-434
of	O	435-437
these	O	438-443
previously	O	444-454
described	O	455-464
mutations	O	465-474
cause	O	475-480
in	O	481-483
-	O	483-484
frame	O	484-489
deletions	O	490-499
in	O	500-502
type	O	503-507
II	O	508-510
collagen	O	511-519
,	O	519-520
either	O	521-527
by	O	528-530
small	O	531-536
deletions	O	537-546
in	O	547-549
the	O	550-553
gene	O	554-558
or	O	559-561
splice	O	562-568
site	O	569-573
alterations	O	574-585
.	O	585-586

Furthermore	O	587-598
,	O	598-599
all	O	600-603
but	O	604-607
one	O	608-611
of	O	612-614
these	O	615-620
mutations	O	621-630
is	O	631-633
located	O	634-641
between	O	642-649
exons	O	650-655
12	O	656-658
and	O	659-662
24	O	663-665
in	O	666-668
the	O	669-672
COL2A1	O	673-679
gene	O	680-684
.	O	684-685

We	O	686-688
used	O	689-693
heteroduplex	O	694-706
analysis	O	707-715
to	O	716-718
identify	O	719-727
sequence	O	728-736
anomalies	O	737-746
in	O	747-749
five	O	750-754
individuals	O	755-766
with	O	767-771
Kniest	B	772-778
dysplasia	I	779-788
.	O	788-789

Sequencing	O	790-800
of	O	801-803
the	O	804-807
index	O	808-813
patients	O	814-822
genomic	O	823-830
DNA	O	831-834
identified	O	835-845
four	O	846-850
new	O	851-854
dominant	O	855-863
mutations	O	864-873
in	O	874-876
COL2A1	O	877-883
that	O	884-888
result	O	889-895
in	O	896-898
Kniest	B	899-905
dysplasia	I	906-915
a	O	917-918
21	O	919-921
-	O	921-922
bp	O	922-924
deletion	O	925-933
in	O	934-936
exon	O	937-941
16	O	942-944
,	O	944-945
an	O	946-948
18	O	949-951
-	O	951-952
bp	O	952-954
deletion	O	955-963
in	O	964-966
exon	O	967-971
19	O	972-974
,	O	974-975
and	O	976-979
4	O	980-981
-	O	981-982
bp	O	982-984
deletions	O	985-994
in	O	995-997
the	O	998-1001
splice	O	1002-1008
donor	O	1009-1014
sites	O	1015-1020
of	O	1021-1023
introns	O	1024-1031
14	O	1032-1034
and	O	1035-1038
20	O	1039-1041
.	O	1041-1042

A	O	1043-1044
previously	O	1045-1055
described	O	1056-1065
28	O	1066-1068
-	O	1068-1069
bp	O	1069-1071
deletion	O	1072-1080
at	O	1081-1083
the	O	1084-1087
COL2A1	O	1088-1094
exon	O	1095-1099
12	O	1100-1102
-	O	1102-1103
intron	O	1103-1109
12	O	1110-1112
junction	O	1113-1121
,	O	1121-1122
deleting	O	1123-1131
the	O	1132-1135
splice	O	1136-1142
donor	O	1143-1148
site	O	1149-1153
,	O	1153-1154
was	O	1155-1158
identified	O	1159-1169
in	O	1170-1172
the	O	1173-1176
fifth	O	1177-1182
case	O	1183-1187
.	O	1187-1188

The	O	1189-1192
latter	O	1193-1199
three	O	1200-1205
mutations	O	1206-1215
are	O	1216-1219
predicted	O	1220-1229
to	O	1230-1232
result	O	1233-1239
in	O	1240-1242
exon	O	1243-1247
skipping	O	1248-1256
in	O	1257-1259
the	O	1260-1263
mRNA	O	1264-1268
encoded	O	1269-1276
from	O	1277-1281
the	O	1282-1285
mutant	O	1286-1292
allele	O	1293-1299
.	O	1299-1300

These	O	1301-1306
data	O	1307-1311
suggest	O	1312-1319
that	O	1320-1324
Kniest	B	1325-1331
dysplasia	I	1332-1341
results	O	1342-1349
from	O	1350-1354
shorter	O	1355-1362
type	O	1363-1367
II	O	1368-1370
collagen	O	1371-1379
monomers	O	1380-1388
,	O	1388-1389
and	O	1390-1393
support	O	1394-1401
the	O	1402-1405
hypothesis	O	1406-1416
that	O	1417-1421
alteration	O	1422-1432
of	O	1433-1435
a	O	1436-1437
specific	O	1438-1446
COL2A1	O	1447-1453
domain	O	1454-1460
,	O	1460-1461
which	O	1462-1467
may	O	1468-1471
span	O	1472-1476
from	O	1477-1481
exons	O	1482-1487
12	O	1488-1490
to	O	1491-1493
24	O	1494-1496
,	O	1496-1497
leads	O	1498-1503
to	O	1504-1506
the	O	1507-1510
Kniest	B	1511-1517
dysplasia	I	1518-1527
phenotype	O	1528-1537
.	O	1537-1538
.	O	1537-1538

Adenomatous	B	0-11
polyposis	I	12-21
coli	I	22-26
and	O	27-30
a	O	31-32
cytogenetic	O	33-44
deletion	O	45-53
of	O	54-56
chromosome	O	57-67
5	O	68-69
resulting	O	70-79
from	O	80-84
a	O	85-86
maternal	O	87-95
intrachromosomal	O	96-112
insertion	O	113-122
.	O	122-123

We	O	124-126
present	O	127-134
the	O	135-138
clinical	O	139-147
and	O	148-151
laboratory	O	152-162
findings	O	163-171
in	O	172-174
an	O	175-177
institutionalised	O	178-195
adult	O	196-201
patient	O	202-209
originally	O	210-220
referred	O	221-229
for	O	230-233
autism	B	234-240
.	O	240-241

A	O	242-243
high	O	244-248
risk	O	249-253
of	O	254-256
colorectal	B	257-267
cancer	I	268-274
was	O	275-278
predicted	O	279-288
when	O	289-293
an	O	294-296
interstitial	O	297-309
deletion	O	310-318
of	O	319-321
the	O	322-325
long	O	326-330
arm	O	331-334
of	O	335-337
chromosome	O	338-348
5	O	349-350
,	O	350-351
del	O	352-355
(	O	356-357
5	O	357-358
)	O	358-359
(	O	360-361
q15q22	O	361-367
.	O	367-368

3	O	369-370
)	O	370-371
,	O	371-372
was	O	373-376
detected	O	377-385
in	O	386-388
her	O	389-392
lymphocytes	O	393-404
and	O	405-408
deletion	O	409-417
of	O	418-420
the	O	421-424
MCC	O	425-428
and	O	429-432
APC	B	433-436
genes	O	437-442
confirmed	O	443-452
by	O	453-455
molecular	O	456-465
analysis	O	466-474
.	O	474-475

Adenomatous	B	476-487
polyposis	I	488-497
coli	I	498-502
and	O	503-506
carcinoma	B	507-516
of	I	517-519
the	I	520-523
rectum	I	524-530
were	O	531-535
subsequently	O	536-548
diagnosed	O	549-558
in	O	559-561
the	O	562-565
patient	O	566-573
.	O	573-574

She	O	575-578
was	O	579-582
profoundly	O	583-593
mentally	B	594-602
retarded	I	603-611
,	O	611-612
autistic	B	613-621
,	O	621-622
and	O	623-626
had	O	627-630
minor	O	631-636
dysmorphic	B	637-647
features	I	648-656
consistent	O	657-667
with	O	668-672
those	O	673-678
of	O	679-681
previous	O	682-690
patients	O	691-699
with	O	700-704
similar	O	705-712
deletions	O	713-722
.	O	722-723

The	O	724-727
deletion	O	728-736
arose	O	737-742
as	O	743-745
a	O	746-747
result	O	748-754
of	O	755-757
recombination	O	758-771
within	O	772-778
the	O	779-782
small	O	783-788
insertion	O	789-798
loop	O	799-803
formed	O	804-810
at	O	811-813
meiosis	O	814-821
by	O	822-824
the	O	825-828
direct	O	829-835
insertion	O	836-845
(	O	846-847
dir	O	847-850
ins	O	851-854
(	O	855-856
5	O	856-857
)	O	857-858
(	O	859-860
q22	O	860-863
.	O	863-864

3q14	O	865-869
.	O	869-870

2q15	O	871-875
)	O	875-876
)	O	875-876
found	O	878-883
in	O	884-886
the	O	887-890
patients	O	891-899
mother	O	900-906
.	O	906-907

This	O	908-912
family	O	913-919
further	O	920-927
confirms	O	928-936
the	O	937-940
cytogenetic	O	941-952
mapping	O	953-960
of	O	961-963
both	O	964-968
MCC	O	969-972
and	O	973-976
APC	B	977-980
genes	O	981-986
to	O	987-989
5q22	O	990-994
and	O	995-998
comparison	O	999-1009
with	O	1010-1014
other	O	1015-1020
recent	O	1021-1027
cases	O	1028-1033
suggests	O	1034-1042
that	O	1043-1047
both	O	1048-1052
genes	O	1053-1058
and	O	1059-1062
their	O	1063-1068
closely	O	1069-1076
linked	O	1077-1083
markers	O	1084-1091
lie	O	1092-1095
within	O	1096-1102
the	O	1103-1106
5q22	O	1107-1111
.	O	1111-1112
1	O	1113-1114
subband	O	1115-1122

Somatic	O	0-7
mutations	O	8-17
of	O	18-20
the	O	21-24
APC	B	25-28
gene	O	29-33
in	O	34-36
colorectal	B	37-47
tumors	I	48-54
:	O	54-55
mutation	O	56-64
cluster	O	65-72
region	O	73-79
in	O	80-82
the	O	83-86
APC	B	87-90
gene	O	91-95
.	O	95-96

We	O	97-99
examined	O	100-108
somatic	O	109-116
mutations	O	117-126
of	O	127-129
the	O	130-133
adenomatous	B	134-145
polyposis	I	146-155
coli	I	156-160
(	O	161-162
APC	B	162-165
)	O	165-166
gene	O	167-171
in	O	172-174
63	O	175-177
colorectal	B	178-188
tumors	I	189-195
(	O	196-197
16	O	197-199
adenomas	B	200-208
and	O	209-212
47	O	213-215
carcinomas	B	216-226
)	O	226-227
developed	O	228-237
in	O	238-240
familial	B	241-249
adenomatous	I	250-261
polyposis	I	262-271
(	O	272-273
FAP	B	273-276
)	O	276-277
and	O	278-281
non	O	282-285
-	O	285-286
FAP	O	286-289
patients	O	290-298
.	O	298-299

In	O	300-302
addition	O	303-311
to	O	312-314
loss	O	315-319
of	O	320-322
heterozygosity	O	323-337
(	O	338-339
LOH	O	339-342
)	O	342-343
at	O	344-346
the	O	347-350
APC	B	351-354
locus	O	355-360
in	O	361-363
30	O	364-366
tumors	B	367-373
,	O	373-374
43	O	375-377
other	O	378-383
somatic	O	384-391
mutations	O	392-401
were	O	402-406
detected	O	407-415
.	O	415-416

Twenty	O	417-423
-	O	423-424
one	O	424-427
of	O	428-430
them	O	431-435
were	O	436-440
point	O	441-446
mutations	O	447-456
;	O	456-457
16	O	458-460
nonsense	O	461-469
and	O	470-473
two	O	474-477
missense	O	478-486
mutations	O	487-496
,	O	496-497
and	O	498-501
three	O	502-507
occurred	O	508-516
in	O	517-519
introns	O	520-527
at	O	528-530
the	O	531-534
splicing	O	535-543
site	O	544-548
.	O	548-549

Twenty	O	550-556
-	O	556-557
two	O	557-560
tumors	B	561-567
had	O	568-571
frameshift	O	572-582
mutations	O	583-592
due	O	593-596
to	O	597-599
deletion	O	600-608
or	O	609-611
insertion	O	612-621
;	O	621-622
nineteen	O	623-631
of	O	632-634
them	O	635-639
were	O	640-644
deletions	O	645-654
of	O	655-657
one	O	658-661
to	O	662-664
31	O	665-667
bp	O	668-670
and	O	671-674
three	O	675-680
were	O	681-685
a	O	686-687
1	O	688-689
-	O	689-690
bp	O	690-692
insertion	O	693-702
.	O	702-703

One	O	704-707
tumor	B	708-713
had	O	714-717
a	O	718-719
1	O	720-721
-	O	721-722
bp	O	722-724
deletion	O	725-733
in	O	734-736
an	O	737-739
intron	O	740-746
near	O	747-751
the	O	752-755
splicing	O	756-764
site	O	765-769
.	O	769-770

Hence	O	771-776
,	O	776-777
41	O	778-780
(	O	781-782
95	O	782-784
%	O	784-785
)	O	785-786
of	O	787-789
43	O	790-792
mutations	O	793-802
resulted	O	803-811
in	O	812-814
truncation	O	815-825
of	O	826-828
the	O	829-832
APC	B	833-836
protein	O	837-844
.	O	844-845

Over	O	846-850
60	O	851-853
%	O	853-854
of	O	855-857
the	O	858-861
somatic	O	862-869
mutations	O	870-879
in	O	880-882
the	O	883-886
APC	B	887-890
gene	O	891-895
were	O	896-900
clustered	O	901-910
within	O	911-917
a	O	918-919
small	O	920-925
region	O	926-932
of	O	933-935
exon	O	936-940
15	O	941-943
,	O	943-944
designated	O	945-955
as	O	956-958
MCR	O	959-962
(	O	963-964
mutation	O	964-972
cluster	O	973-980
region	O	981-987
)	O	987-988
,	O	988-989
which	O	990-995
accounted	O	996-1005
for	O	1006-1009
less	O	1010-1014
than	O	1015-1019
10	O	1020-1022
%	O	1022-1023
of	O	1024-1026
the	O	1027-1030
coding	O	1031-1037
region	O	1038-1044
.	O	1044-1045

Combining	O	1046-1055
these	O	1056-1061
data	O	1062-1066
and	O	1067-1070
the	O	1071-1074
results	O	1075-1082
of	O	1083-1085
LOH	O	1086-1089
,	O	1089-1090
more	O	1091-1095
than	O	1096-1100
80	O	1101-1103
%	O	1103-1104
of	O	1105-1107
tumors	B	1108-1114
(	O	1115-1116
14	O	1116-1118
adenomas	B	1119-1127
and	O	1128-1131
39	O	1132-1134
carcinomas	B	1135-1145
)	O	1145-1146
had	O	1147-1150
at	O	1151-1153
least	O	1154-1159
one	O	1160-1163
mutation	O	1164-1172
in	O	1173-1175
the	O	1176-1179
APC	B	1180-1183
gene	O	1184-1188
,	O	1188-1189
of	O	1190-1192
which	O	1193-1198
more	O	1199-1203
than	O	1204-1208
60	O	1209-1211
%	O	1211-1212
(	O	1213-1214
9	O	1214-1215
adenomas	B	1216-1224
and	O	1225-1228
23	O	1229-1231
carcinomas	B	1232-1242
)	O	1242-1243
had	O	1244-1247
two	O	1248-1251
mutations	O	1252-1261
.	O	1261-1262

These	O	1263-1268
results	O	1269-1276
strongly	O	1277-1285
suggest	O	1286-1293
that	O	1294-1298
somatic	O	1299-1306
mutations	O	1307-1316
of	O	1317-1319
the	O	1320-1323
APC	B	1324-1327
gene	O	1328-1332
are	O	1333-1336
associated	O	1337-1347
with	O	1348-1352
development	O	1353-1364
of	O	1365-1367
a	O	1368-1369
great	O	1370-1375
majority	O	1376-1384
of	O	1385-1387
colorectal	B	1388-1398
tumors	I	1399-1405
.	O	1405-1406
.	O	1405-1406

Identification	O	0-14
of	O	15-17
an	O	18-20
altered	O	21-28
splice	O	29-35
site	O	36-40
in	O	41-43
Ashkenazi	O	44-53
Tay	B	54-57
-	I	57-58
Sachs	I	58-63
disease	I	64-71
.	O	71-72

Tay	B	73-76
-	I	76-77
Sachs	I	77-82
disease	I	83-90
is	O	91-93
an	O	94-96
autosomal	B	97-106
recessive	I	107-116
genetic	I	117-124
disorder	I	125-133
resulting	O	134-143
from	O	144-148
mutation	O	149-157
of	O	158-160
the	O	161-164
HEXA	O	165-169
gene	O	170-174
encoding	O	175-183
the	O	184-187
alpha	O	188-193
-	O	193-194
subunit	O	194-201
of	O	202-204
the	O	205-208
lysosomal	O	209-218
enzyme	O	219-225
,	O	225-226
beta	O	227-231
-	O	231-232
N	O	232-233
-	O	231-232
acetylhexosaminidase	O	234-254
A	O	255-256
(	O	257-258
ref	O	258-261
.	O	261-262
1	O	263-264
)	O	264-265
.	O	265-266

A	O	267-268
relatively	O	269-279
high	O	280-284
frequency	O	285-294
of	O	295-297
carriers	O	298-306
(	O	307-308
1	O	308-309
/	O	309-310
27	O	310-312
)	O	312-313
of	O	314-316
a	O	317-318
lethal	O	319-325
,	O	325-326
infantile	O	327-336
form	O	337-341
of	O	342-344
the	O	345-348
disease	O	349-356
is	O	357-359
found	O	360-365
in	O	366-368
the	O	369-372
Ashkenazi	O	373-382
Jewish	O	383-389
population	O	390-400
,	O	400-401
but	O	402-405
it	O	406-408
is	O	409-411
not	O	412-415
yet	O	416-419
evident	O	420-427
whether	O	428-435
this	O	436-440
has	O	441-444
resulted	O	445-453
from	O	454-458
a	O	459-460
founder	O	461-468
effect	O	469-475
and	O	476-479
random	O	480-486
genetic	O	487-494
drift	O	495-500
or	O	501-503
from	O	504-508
a	O	509-510
selective	O	511-520
advantage	O	521-530
of	O	531-533
heterozygotes	O	534-547
.	O	547-548

We	O	549-551
have	O	552-556
identified	O	557-567
a	O	568-569
single	O	570-576
-	O	576-577
base	O	577-581
mutation	O	582-590
in	O	591-593
a	O	594-595
cloned	O	596-602
fragment	O	603-611
of	O	612-614
the	O	615-618
HEXA	O	619-623
gene	O	624-628
from	O	629-633
an	O	634-636
Ashkenazi	O	637-646
Jewish	O	647-653
patient	O	654-661
.	O	661-662

This	O	663-667
change	O	668-674
,	O	674-675
the	O	676-679
substitution	O	680-692
of	O	693-695
a	O	696-697
C	O	698-699
for	O	700-703
G	O	704-705
in	O	706-708
the	O	709-712
first	O	713-718
nucleotide	O	719-729
of	O	730-732
intron	O	733-739
12	O	740-742
is	O	743-745
expected	O	746-754
to	O	755-757
result	O	758-764
in	O	765-767
defective	O	768-777
splicing	O	778-786
of	O	787-789
the	O	790-793
messenger	O	794-803
RNA	O	804-807
.	O	807-808

A	O	809-810
test	O	811-815
for	O	816-819
the	O	820-823
mutant	O	824-830
allele	O	831-837
based	O	838-843
on	O	844-846
amplification	O	847-860
of	O	861-863
DNA	O	864-867
by	O	868-870
the	O	871-874
polymerase	O	875-885
chain	O	886-891
rection	O	892-899
and	O	900-903
cleavage	O	904-912
of	O	913-915
a	O	916-917
DdeI	O	918-922
restriction	O	923-934
site	O	935-939
generated	O	940-949
by	O	950-952
the	O	953-956
mutation	O	957-965
revealed	O	966-974
that	O	975-979
this	O	980-984
case	O	985-989
and	O	990-993
two	O	994-997
other	O	998-1003
cases	O	1004-1009
of	O	1010-1012
the	O	1013-1016
Ashkenazi	O	1017-1026
,	O	1026-1027
infantile	O	1028-1037
form	O	1038-1042
of	O	1043-1045
Tay	B	1046-1049
-	I	1049-1050
Sachs	I	1050-1055
disease	I	1056-1063
are	O	1064-1067
heterozygous	O	1068-1080
for	O	1081-1084
two	O	1085-1088
different	O	1089-1098
mutations	O	1099-1108
.	O	1108-1109

The	O	1110-1113
occurrence	O	1114-1124
of	O	1125-1127
multiple	O	1128-1136
mutant	O	1137-1143
alleles	O	1144-1151
warrants	O	1152-1160
further	O	1161-1168
examination	O	1169-1180
of	O	1181-1183
the	O	1184-1187
selective	O	1188-1197
advantage	O	1198-1207
hypothesis	O	1208-1218
.	O	1218-1219
.	O	1218-1219

Coats	B	0-5
'	I	5-6
disease	I	7-14
of	O	15-17
the	O	18-21
retina	O	22-28
(	O	29-30
unilateral	B	30-40
retinal	I	41-48
telangiectasis	I	49-63
)	O	63-64
caused	O	65-71
by	O	72-74
somatic	O	75-82
mutation	O	83-91
in	O	92-94
the	O	95-98
NDP	O	99-102
gene	O	103-107
:	O	107-108
a	O	109-110
role	O	111-115
for	O	116-119
norrin	O	120-126
in	O	127-129
retinal	O	130-137
angiogenesis	O	138-150
.	O	150-151

Coats	B	152-157
disease	I	158-165
is	O	166-168
characterized	O	169-182
by	O	183-185
abnormal	B	186-194
retinal	I	195-202
vascular	I	203-211
development	I	212-223
(	O	224-225
so	O	225-227
-	O	227-228
called	O	228-234
retinal	B	235-242
telangiectasis	I	243-257
)	O	257-258
which	O	259-264
results	O	265-272
in	O	273-275
massive	O	276-283
intraretinal	B	284-296
and	I	297-300
subretinal	I	301-311
lipid	I	312-317
accumulation	I	318-330
(	O	331-332
exudative	B	332-341
retinal	I	342-349
detachment	I	350-360
)	O	360-361
.	O	361-362

The	O	363-366
classical	O	367-376
form	O	377-381
of	O	382-384
Coats	B	385-390
disease	I	391-398
is	O	399-401
almost	O	402-408
invariably	O	409-419
isolated	O	420-428
,	O	428-429
unilateral	O	430-440
and	O	441-444
seen	O	445-449
in	O	450-452
males	O	453-458
.	O	458-459

A	O	460-461
female	O	462-468
with	O	469-473
a	O	474-475
unilateral	O	476-486
variant	O	487-494
of	O	495-497
Coats	B	498-503
disease	I	504-511
gave	O	512-516
birth	O	517-522
to	O	523-525
a	O	526-527
son	O	528-531
affected	O	532-540
by	O	541-543
Norrie	B	544-550
disease	I	551-558
.	O	558-559

Both	O	560-564
carried	O	565-572
a	O	573-574
missense	O	575-583
mutation	O	584-592
within	O	593-599
the	O	600-603
NDP	O	604-607
gene	O	608-612
on	O	613-615
chromosome	O	616-626
Xp11	O	627-631
.	O	631-632
2	O	633-634
2	O	635-636
.	O	636-637
Subsequently	O	638-650
analysis	O	651-659
of	O	660-662
the	O	663-666
retinas	O	667-674
of	O	675-677
nine	O	678-682
enucleated	O	683-693
eyes	O	694-698
from	O	699-703
males	O	704-709
with	O	710-714
Coats	B	715-720
disease	I	721-728
demonstrated	O	729-741
in	O	742-744
one	O	745-748
a	O	749-750
somatic	O	751-758
mutation	O	759-767
in	O	768-770
the	O	771-774
NDP	O	775-778
gene	O	779-783
which	O	784-789
was	O	790-793
not	O	794-797
present	O	798-805
within	O	806-812
non	O	813-816
-	O	816-817
retinal	O	817-824
tissue	O	825-831
.	O	831-832

We	O	833-835
suggest	O	836-843
that	O	844-848
Coats	B	849-854
telangiectasis	I	855-869
is	O	870-872
secondary	O	873-882
to	O	883-885
somatic	O	886-893
mutation	O	894-902
in	O	903-905
the	O	906-909
NDP	O	910-913
gene	O	914-918
which	O	919-924
results	O	925-932
in	O	933-935
a	O	936-937
deficiency	B	938-948
of	I	949-951
norrin	I	952-958
(	O	959-960
the	O	960-963
protein	O	964-971
product	O	972-979
of	O	980-982
the	O	983-986
NDP	O	987-990
gene	O	991-995
)	O	995-996
within	O	997-1003
the	O	1004-1007
developing	O	1008-1018
retina	O	1019-1025
.	O	1025-1026

This	O	1027-1031
supports	O	1032-1040
recent	O	1041-1047
observations	O	1048-1060
that	O	1061-1065
the	O	1066-1069
protein	O	1070-1077
is	O	1078-1080
critical	O	1081-1089
for	O	1090-1093
normal	O	1094-1100
retinal	O	1101-1108
vasculogenesis	O	1109-1123
.	O	1123-1124

Trisomy	B	0-7
15	I	8-10
with	O	11-15
loss	O	16-20
of	O	21-23
the	O	24-27
paternal	O	28-36
15	O	37-39
as	O	40-42
a	O	43-44
cause	O	45-50
of	O	51-53
Prader	B	54-60
-	I	60-61
Willi	I	61-66
syndrome	I	67-75
due	O	76-79
to	O	80-82
maternal	B	83-91
disomy	I	92-98
.	O	98-99

Uniparental	B	100-111
disomy	I	112-118
has	O	119-122
recently	O	123-131
been	O	132-136
recognized	O	137-147
to	O	148-150
cause	O	151-156
human	O	157-162
disorders	O	163-172
,	O	172-173
including	O	174-183
Prader	B	184-190
-	I	190-191
Willi	I	191-196
syndrome	I	197-205
(	O	206-207
PWS	B	207-210
)	O	210-211
.	O	211-212

We	O	213-215
describe	O	216-224
a	O	225-226
particularly	O	227-239
instructive	O	240-251
case	O	252-256
which	O	257-262
raises	O	263-269
important	O	270-279
issues	O	280-286
concerning	O	287-297
the	O	298-301
mechanisms	O	302-312
producing	O	313-322
uniparental	B	323-334
disomy	I	335-341
and	O	342-345
whose	O	346-351
evaluation	O	352-362
provides	O	363-371
evidence	O	372-380
that	O	381-385
trisomy	O	386-393
may	O	394-397
precede	O	398-405
uniparental	B	406-417
disomy	I	418-424
in	O	425-427
a	O	428-429
fetus	O	430-435
.	O	435-436

Chorionic	O	437-446
villus	O	447-453
sampling	O	454-462
performed	O	463-472
for	O	473-476
advanced	O	477-485
maternal	O	486-494
age	O	495-498
revealed	O	499-507
trisomy	B	508-515
15	I	516-518
in	O	519-521
all	O	522-525
direct	O	526-532
and	O	533-536
cultured	O	537-545
cells	O	546-551
,	O	551-552
though	O	553-559
the	O	560-563
fetus	O	564-569
appeared	O	570-578
normal	O	579-585
.	O	585-586

Chromosome	O	587-597
analysis	O	598-606
of	O	607-609
amniocytes	O	610-620
obtained	O	621-629
at	O	630-632
15	O	633-635
wk	O	636-638
was	O	639-642
normal	O	643-649
in	O	650-652
over	O	653-657
100	O	658-661
cells	O	662-667
studied	O	668-675
.	O	675-676

The	O	677-680
child	O	681-686
was	O	687-690
hypotonic	B	691-700
at	O	701-703
birth	O	704-709
,	O	709-710
and	O	711-714
high	O	715-719
-	O	719-720
resolution	O	720-730
banding	O	731-738
failed	O	739-745
to	O	746-748
reveal	O	749-755
the	O	756-759
deletion	O	760-768
of	O	769-771
15q11	O	772-777
-	O	777-778
13	O	778-780
,	O	780-781
a	O	782-783
deletion	O	784-792
which	O	793-798
is	O	799-801
found	O	802-807
in	O	808-810
50	O	811-813
%	O	813-814
-	O	815-816
70	O	816-818
%	O	818-819
of	O	820-822
patients	O	823-831
with	O	832-836
PWS	B	837-840
.	O	840-841

Over	O	842-846
time	O	847-851
,	O	851-852
typical	O	853-860
features	O	861-869
of	O	870-872
PWS	B	873-876
developed	O	877-886
.	O	886-887

Molecular	O	888-897
genetic	O	898-905
analysis	O	906-914
using	O	915-920
probes	O	921-927
for	O	928-931
chromosome	O	932-942
15	O	943-945
revealed	O	946-954
maternal	O	955-963
disomy	O	964-970
.	O	970-971

Maternal	O	972-980
nondisjunction	O	981-995
with	O	996-1000
fertilization	O	1001-1014
of	O	1015-1017
a	O	1018-1019
disomic	O	1020-1027
egg	O	1028-1031
by	O	1032-1034
a	O	1035-1036
normal	O	1037-1043
sperm	O	1044-1049
,	O	1049-1050
followed	O	1051-1059
by	O	1060-1062
loss	O	1063-1067
of	O	1068-1070
the	O	1071-1074
paternal	O	1075-1083
15	O	1084-1086
,	O	1086-1087
is	O	1088-1090
a	O	1091-1092
likely	O	1093-1099
cause	O	1100-1105
of	O	1106-1108
confined	O	1109-1117
placental	O	1118-1127
mosaicism	O	1128-1137
and	O	1138-1141
uniparental	B	1142-1153
disomy	I	1154-1160
in	O	1161-1163
this	O	1164-1168
case	O	1169-1173
of	O	1174-1176
PWS	B	1177-1180
,	O	1180-1181
and	O	1182-1185
advanced	O	1186-1194
maternal	O	1195-1203
age	O	1204-1207
may	O	1208-1211
be	O	1212-1214
a	O	1215-1216
predisposing	O	1217-1229
factor	O	1230-1236
.	O	1236-1237
.	O	1236-1237

Genetic	O	0-7
defect	B	8-14
in	I	15-17
secretion	I	18-27
of	I	28-30
complement	I	31-41
C5	I	42-44
in	O	45-47
mice	O	48-52
.	O	52-53

A	O	54-55
genetic	O	56-63
deficiency	B	64-74
of	I	75-77
the	I	78-81
fifth	I	82-87
(	I	88-89
C5	I	89-91
)	I	91-92
component	I	93-102
of	I	103-105
complement1	I	106-117
-	I	117-118
3	I	118-119
,	O	119-120
a	O	121-122
serum	O	123-128
glycoprotein	O	129-141
of	O	142-144
molecular	O	145-154
weight	O	155-161
(	O	162-163
MW	O	163-165
)	O	165-166
220	O	167-170
,	O	170-171
000	O	172-175
(	O	176-177
ref	O	177-180
.	O	180-181
4	O	182-183
)	O	183-184
,	O	184-185
has	O	186-189
been	O	190-194
found	O	195-200
in	O	201-203
39	O	204-206
%	O	206-207
of	O	208-210
inbred	O	211-217
strains	O	218-225
of	O	226-228
mice3	O	229-234
.	O	234-235

Sera	O	236-240
of	O	241-243
deficient	O	244-253
mice	O	254-258
lack	O	259-263
detectable	O	264-274
C5	O	275-277
activity	O	278-286
and	O	287-290
protein2	O	291-299
,	O	299-300
3	O	301-302
.	O	302-303

In	O	304-306
addition	O	307-315
deficient	O	316-325
mice	O	326-330
produce	O	331-338
antibody	O	339-347
to	O	348-350
mouse	O	351-356
C5	O	357-359
when	O	360-364
injected	O	365-373
with	O	374-378
sera	O	379-383
from	O	384-388
C5	O	389-391
sufficient	O	392-402
(	O	403-404
normal	O	404-410
)	O	410-411
strains	O	412-419
.	O	419-420

Levy	O	421-425
et	O	426-428
al	O	429-431
.	O	431-432
5	O	433-434
showed	O	435-441
that	O	442-446
somatic	O	447-454
cell	O	455-459
hybrids	O	460-467
between	O	468-475
C5	O	476-478
deficient	O	479-488
(	O	489-490
B10	O	490-493
.	O	493-494

D2	O	495-497
/	O	497-498
old	O	498-501
line	O	502-506
)	O	506-507
macrophages	O	508-519
and	O	520-523
either	O	524-530
C5	O	531-533
sufficient	O	534-544
(	O	545-546
B10	O	546-549
.	O	549-550

D2	O	551-553
/	O	553-554
new	O	554-557
line	O	558-562
)	O	562-563
mouse	O	564-569
kidney	O	570-576
or	O	577-579
chicken	O	580-587
erythroblasts	O	588-601
secreted	O	602-610
haemolytically	O	611-625
active	O	626-632
mouse	O	633-638
C5	O	639-641
in	O	642-644
vitro	O	645-650
.	O	650-651

Several	O	652-659
possible	O	660-668
molecular	O	669-678
mechanisms	O	679-689
to	O	690-692
account	O	693-700
for	O	701-704
the	O	705-708
findings	O	709-717
were	O	718-722
considered	O	723-733
,	O	733-734
but	O	735-738
insufficient	O	739-751
direct	O	752-758
data	O	759-763
were	O	764-768
available	O	769-778
to	O	779-781
choose	O	782-788
among	O	789-794
them	O	795-799
.	O	799-800

We	O	801-803
recently	O	804-812
reported	O	813-821
that	O	822-826
mouse	O	827-832
(	O	833-834
CD	O	834-836
.	O	836-837
1	O	838-839
strain	O	840-846
)	O	846-847
peritoneal	O	848-858
cells	O	859-864
in	O	865-867
culture	O	868-875
synthesise	O	876-886
and	O	887-890
secrete	O	891-898
a	O	899-900
single	O	901-907
chain	O	908-913
precursor	O	914-923
,	O	923-924
pro	O	925-928
-	O	928-929
C5	O	929-931
(	O	932-933
MW	O	933-935
approximately	O	936-949
210	O	950-953
,	O	953-954
000	O	955-958
)	O	958-959
,	O	959-960
of	O	961-963
the	O	964-967
two	O	968-971
-	O	971-972
chain	O	972-977
(	O	978-979
alpha	O	979-984
chain	O	985-990
,	O	990-991
125	O	992-995
,	O	995-996
000	O	997-1000
and	O	1001-1004
beta	O	1005-1009
chain	O	1010-1015
83	O	1016-1018
,	O	1018-1019
000	O	1020-1023
MW	O	1024-1026
)	O	1026-1027
C5	O	1028-1030
protein6	O	1031-1039
.	O	1039-1040

Radiolabelled	O	1041-1054
precursor	O	1055-1064
C5	O	1065-1067
was	O	1068-1071
contained	O	1072-1081
within	O	1082-1088
the	O	1089-1092
cells	O	1093-1098
and	O	1099-1102
was	O	1103-1106
secreted	O	1107-1115
into	O	1116-1120
the	O	1121-1124
tissue	O	1125-1131
culture	O	1132-1139
media	O	1140-1145
.	O	1145-1146

Using	O	1147-1152
similar	O	1153-1160
methods	O	1161-1168
,	O	1168-1169
we	O	1170-1172
now	O	1173-1176
find	O	1177-1181
that	O	1182-1186
C5	B	1187-1189
deficiency	I	1190-1200
in	O	1201-1203
each	O	1204-1208
of	O	1209-1211
five	O	1212-1216
different	O	1217-1226
mouse	O	1227-1232
strains	O	1233-1240
(	O	1241-1242
AKR	O	1242-1245
,	O	1245-1246
SWR	O	1247-1250
,	O	1250-1251
DBA	O	1252-1255
/	O	1255-1256
2J8	O	1256-1259
A	O	1260-1261
/	O	1261-1262
HeJ	O	1262-1265
and	O	1266-1269
B10	O	1270-1273
.	O	1273-1274

D2	O	1275-1277
/	O	1277-1278
old	O	1278-1281
line	O	1282-1286
)	O	1286-1287
is	O	1288-1290
due	O	1291-1294
to	O	1295-1297
a	O	1298-1299
failure	O	1300-1307
in	O	1308-1310
secretion	O	1311-1320
of	O	1321-1323
C5	O	1324-1326
protein	O	1327-1334
and	O	1335-1338
not	O	1339-1342
to	O	1343-1345
a	O	1346-1347
failure	O	1348-1355
in	O	1356-1358
biosynthesis	O	1359-1371
of	O	1372-1374
pro	O	1375-1378
-	O	1378-1379
C5	O	1379-1381

WASP	O	0-4
gene	O	5-9
mutations	O	10-19
in	O	20-22
Wiskott	B	23-30
-	I	30-31
Aldrich	I	31-38
syndrome	I	39-47
and	O	48-51
X	B	52-53
-	I	53-54
linked	I	54-60
thrombocytopenia	I	61-77
.	O	77-78

The	O	79-82
WASP	O	83-87
gene	O	88-92
has	O	93-96
been	O	97-101
recently	O	102-110
cloned	O	111-117
from	O	118-122
Xp11	O	123-127
.	O	127-128

23	O	129-131
and	O	132-135
shown	O	136-141
to	O	142-144
be	O	145-147
mutated	O	148-155
in	O	156-158
three	O	159-164
patients	O	165-173
with	O	174-178
the	O	179-182
Wiskott	B	183-190
-	I	190-191
Aldrich	I	191-198
syndrome	I	199-207
(	O	208-209
WAS	B	209-212
)	O	212-213
.	O	213-214

We	O	215-217
have	O	218-222
developed	O	223-232
a	O	233-234
screening	O	235-244
protocol	O	245-253
for	O	254-257
identifying	O	258-269
WASP	O	270-274
gene	O	275-279
alterations	O	280-291
in	O	292-294
genomic	O	295-302
DNA	O	303-306
and	O	307-310
have	O	311-315
identified	O	316-326
a	O	327-328
spectrum	O	329-337
of	O	338-340
novel	O	341-346
mutations	O	347-356
in	O	357-359
12	O	360-362
additional	O	363-373
unrelated	O	374-383
families	O	384-392
.	O	392-393

These	O	394-399
missense	O	400-408
,	O	408-409
nonsense	O	410-418
and	O	419-422
frameshift	O	423-433
mutations	O	434-443
involve	O	444-451
eight	O	452-457
of	O	458-460
the	O	461-464
12	O	465-467
exons	O	468-473
of	O	474-476
the	O	477-480
gene	O	481-485
.	O	485-486

Two	O	487-490
mutations	O	491-500
creating	O	501-509
premature	O	510-519
termination	O	520-531
codons	O	532-538
were	O	539-543
associated	O	544-554
with	O	555-559
lack	O	560-564
of	O	565-567
detectable	O	568-578
mRNA	O	579-583
on	O	584-586
Northern	O	587-595
blots	O	596-601
.	O	601-602

Four	O	603-607
amino	O	608-613
acid	O	614-618
substitutions	O	619-632
,	O	632-633
Leu27Phe	O	634-642
,	O	642-643
Thr48Ile	O	644-652
,	O	652-653
Val75Met	O	654-662
and	O	663-666
Arg477Lys	O	667-676
,	O	676-677
were	O	678-682
found	O	683-688
in	O	689-691
patients	O	692-700
with	O	701-705
congenital	B	706-716
thrombocytopenia	I	717-733
and	O	734-737
no	O	738-740
clinically	O	741-751
evident	O	752-759
immune	O	760-766
defect	O	767-773
indicating	O	774-784
that	O	785-789
the	O	790-793
WASP	O	794-798
gene	O	799-803
is	O	804-806
the	O	807-810
site	O	811-815
for	O	816-819
mutations	O	820-829
in	O	830-832
X	B	833-834
-	I	834-835
linked	I	835-841
thrombocytopenia	I	842-858
as	O	859-861
well	O	862-866
as	O	867-869
in	O	870-872
WAS	B	873-876
.	O	876-877

A	O	878-879
T	O	880-881
-	O	881-882
cell	O	882-886
line	O	887-891
from	O	892-896
a	O	897-898
WAS	B	899-902
patient	O	903-910
contained	O	911-920
two	O	921-924
independent	O	925-936
DNA	O	937-940
alterations	O	941-952
,	O	952-953
a	O	954-955
constitutional	O	956-970
frameshift	O	971-981
mutation	O	982-990
,	O	990-991
also	O	992-996
present	O	997-1004
in	O	1005-1007
peripheral	O	1008-1018
blood	O	1019-1024
leukocytes	O	1025-1035
from	O	1036-1040
the	O	1041-1044
patient	O	1045-1052
,	O	1052-1053
and	O	1054-1057
compensatory	O	1058-1070
splice	O	1071-1077
site	O	1078-1082
mutation	O	1083-1091
unique	O	1092-1098
to	O	1099-1101
the	O	1102-1105
cell	O	1106-1110
line	O	1111-1115
.	O	1115-1116

The	O	1117-1120
distribution	O	1121-1133
of	O	1134-1136
eight	O	1137-1142
missense	O	1143-1151
mutations	O	1152-1161
provides	O	1162-1170
valuable	O	1171-1179
information	O	1180-1191
on	O	1192-1194
amino	O	1195-1200
acids	O	1201-1206
which	O	1207-1212
are	O	1213-1216
essential	O	1217-1226
for	O	1227-1230
normal	O	1231-1237
protein	O	1238-1245
function	O	1246-1254
,	O	1254-1255
and	O	1256-1259
suggests	O	1260-1268
that	O	1269-1273
sites	O	1274-1279
in	O	1280-1282
the	O	1283-1286
first	O	1287-1292
two	O	1293-1296
exons	O	1297-1302
are	O	1303-1306
hot	O	1307-1310
-	O	1310-1311
spots	O	1311-1316
for	O	1317-1320
mutation	O	1321-1329
.	O	1329-1330

Detection	O	0-9
of	O	10-12
a	O	13-14
nonsense	O	15-23
mutation	O	24-32
in	O	33-35
the	O	36-39
dystrophin	O	40-50
gene	O	51-55
by	O	56-58
multiple	O	59-67
SSCP	O	68-72
.	O	72-73

A	O	74-75
combination	O	76-87
of	O	88-90
multiplex	O	91-100
PCR	O	101-104
with	O	105-109
the	O	110-113
single	O	114-120
strand	O	121-127
conformation	O	128-140
polymorphism	O	141-153
(	O	154-155
SSCP	O	155-159
)	O	159-160
technique	O	161-170
was	O	171-174
employed	O	175-183
to	O	184-186
screen	O	187-193
for	O	194-197
point	O	198-203
mutations	O	204-213
in	O	214-216
the	O	217-220
human	O	221-226
dystrophin	O	227-237
gene	O	238-242
.	O	242-243

Co	O	244-246
-	O	246-247
amplification	O	247-260
of	O	261-263
11	O	264-266
exons	O	267-272
from	O	273-277
genomic	O	278-285
DNA	O	286-289
of	O	290-292
Duchenne	B	293-301
and	I	302-305
Becker	I	306-312
muscular	I	313-321
dystrophy	I	322-331
(	O	332-333
DMD	B	333-336
/	O	336-337
BMD	B	337-340
)	O	340-341
patients	O	342-350
with	O	351-355
no	O	356-358
deletion	O	359-367
or	O	368-370
duplication	O	371-382
was	O	383-386
performed	O	387-396
and	O	397-400
the	O	401-404
samples	O	405-412
subjected	O	413-422
to	O	423-425
multiple	O	426-434
SSCP	O	435-439
analysis	O	440-448
.	O	448-449

We	O	450-452
report	O	453-459
the	O	460-463
case	O	464-468
of	O	469-471
a	O	472-473
nonsense	O	474-482
mutation	O	483-491
in	O	492-494
a	O	495-496
Duchenne	B	497-505
patient	O	506-513
identified	O	514-524
by	O	525-527
this	O	528-532
approach	O	533-541
.	O	541-542

The	O	543-546
mutation	O	547-555
introduces	O	556-566
a	O	567-568
termination	O	569-580
codon	O	581-586
within	O	587-593
exon	O	594-598
8	O	599-600
of	O	601-603
the	O	604-607
dystrophin	O	608-618
gene	O	619-623
.	O	623-624

It	O	625-627
is	O	628-630
predicted	O	631-640
to	O	641-643
cause	O	644-649
a	O	650-651
very	O	652-656
premature	O	657-666
translational	O	667-680
termination	O	681-692
accounting	O	693-703
for	O	704-707
the	O	708-711
severe	O	712-718
phenotype	O	719-728
observed	O	729-737
.	O	737-738

The	O	739-742
patient	O	743-750
inherited	O	751-760
this	O	761-765
mutation	O	766-774
from	O	775-779
his	O	780-783
mother	O	784-790
.	O	790-791

In	O	792-794
addition	O	795-803
the	O	804-807
analysis	O	808-816
revealed	O	817-825
5	O	826-827
polymorphisms	O	828-841
useful	O	842-848
for	O	849-852
internal	O	853-861
control	O	862-869
.	O	869-870
.	O	869-870

Molecular	O	0-9
mechanisms	O	10-20
of	O	21-23
oncogenic	O	24-33
mutations	O	34-43
in	O	44-46
tumors	B	47-53
from	O	54-58
patients	O	59-67
with	O	68-72
bilateral	B	73-82
and	I	83-86
unilateral	I	87-97
retinoblastoma	I	98-112
.	O	112-113

The	O	114-117
RB1	O	118-121
gene	O	122-126
from	O	127-131
12	O	132-134
human	O	135-140
retinoblastoma	B	141-155
tumors	I	156-162
has	O	163-166
been	O	167-171
analyzed	O	172-180
exon	O	181-185
-	O	185-186
by	O	186-188
-	O	185-186
exon	O	181-185
with	O	194-198
the	O	199-202
single	O	203-209
-	O	209-210
strand	O	210-216
conformation	O	217-229
polymorphism	O	230-242
technique	O	243-252
.	O	252-253

Mutations	O	254-263
were	O	264-268
found	O	269-274
in	O	275-277
all	O	278-281
tumors	B	282-288
,	O	288-289
and	O	290-293
one	O	294-297
-	O	297-298
third	O	298-303
of	O	304-306
the	O	307-310
tumors	B	311-317
had	O	318-321
independent	O	322-333
mutations	O	334-343
in	O	344-346
both	O	347-351
alleles	O	352-359
neither	O	360-367
of	O	368-370
which	O	371-376
were	O	377-381
found	O	382-387
in	O	388-390
the	O	391-394
germ	O	395-399
line	O	400-404
,	O	404-405
confirming	O	406-416
their	O	417-422
true	O	423-427
sporadic	O	428-436
nature	O	437-443
.	O	443-444

In	O	445-447
the	O	448-451
remaining	O	452-461
two	O	462-465
-	O	465-466
thirds	O	466-472
of	O	473-475
the	O	476-479
tumors	B	480-486
only	O	487-491
one	O	492-495
mutation	O	496-504
was	O	505-508
found	O	509-514
,	O	514-515
consistent	O	516-526
with	O	527-531
the	O	532-535
loss	O	536-540
-	O	540-541
of	O	541-543
-	O	540-541
heterozygosity	O	544-558
theory	O	559-565
of	O	566-568
tumorigenesis	O	569-582
.	O	582-583

Point	O	584-589
mutations	O	590-599
,	O	599-600
the	O	601-604
majority	O	605-613
of	O	614-616
which	O	617-622
were	O	623-627
C	O	628-629
-	O	629-630
-	O	629-630
>	O	632-633
T	O	634-635
transitions	O	636-647
,	O	647-648
were	O	649-653
the	O	654-657
most	O	658-662
common	O	663-669
abnormality	O	670-681
and	O	682-685
usually	O	686-693
resulted	O	694-702
in	O	703-705
the	O	706-709
conversion	O	710-720
of	O	721-723
an	O	724-726
arginine	O	727-735
codon	O	736-741
to	O	742-744
a	O	745-746
stop	O	747-751
codon	O	752-757
.	O	757-758

Small	O	759-764
deletions	O	765-774
were	O	775-779
the	O	780-783
second	O	784-790
most	O	791-795
common	O	796-802
abnormality	O	803-814
and	O	815-818
most	O	819-823
often	O	824-829
created	O	830-837
a	O	838-839
downstream	O	840-850
stop	O	851-855
codon	O	856-861
as	O	862-864
the	O	865-868
result	O	869-875
of	O	876-878
a	O	879-880
reading	O	881-888
frameshift	O	889-899
.	O	899-900

Deletions	O	901-910
and	O	911-914
point	O	915-920
mutations	O	921-930
also	O	931-935
affected	O	936-944
splice	O	945-951
junctions	O	952-961
.	O	961-962

Direct	O	963-969
repeats	O	970-977
were	O	978-982
present	O	983-990
at	O	991-993
the	O	994-997
breakpoint	O	998-1008
junctions	O	1009-1018
in	O	1019-1021
the	O	1022-1025
majority	O	1026-1034
of	O	1035-1037
deletions	O	1038-1047
,	O	1047-1048
supporting	O	1049-1059
a	O	1060-1061
slipped	O	1062-1069
-	O	1069-1070
mispairing	O	1070-1080
mechanism	O	1081-1090
.	O	1090-1091

Point	O	1092-1097
mutations	O	1098-1107
generally	O	1108-1117
produced	O	1118-1126
DNA	O	1127-1130
sequences	O	1131-1140
which	O	1141-1146
resulted	O	1147-1155
in	O	1156-1158
perfect	O	1159-1166
homology	O	1167-1175
with	O	1176-1180
endogenous	O	1181-1191
sequences	O	1192-1201
which	O	1202-1207
lay	O	1208-1211
within	O	1212-1218
14	O	1219-1221
bp	O	1222-1224
.	O	1224-1225
.	O	1224-1225

PAX6	O	0-4
gene	O	5-9
dosage	O	10-16
effect	O	17-23
in	O	24-26
a	O	27-28
family	O	29-35
with	O	36-40
congenital	B	41-51
cataracts	I	52-61
,	O	61-62
aniridia	B	63-71
,	O	71-72
anophthalmia	B	73-85
and	O	86-89
central	B	90-97
nervous	I	98-105
system	I	106-112
defects	I	113-120
.	O	120-121

The	O	122-125
human	O	126-131
eye	O	132-135
malformation	O	136-148
aniridia	B	149-157
results	O	158-165
from	O	166-170
haploinsufficiency	B	171-189
of	I	190-192
PAX6	I	193-197
,	O	197-198
a	O	199-200
paired	O	201-207
box	O	208-211
DNA	O	212-215
-	O	215-216
binding	O	216-223
protein	O	224-231
.	O	231-232

To	O	233-235
study	O	236-241
this	O	242-246
dosage	O	247-253
effect	O	254-260
,	O	260-261
we	O	262-264
characterized	O	265-278
two	O	279-282
PAX6	O	283-287
mutations	O	288-297
in	O	298-300
a	O	301-302
family	O	303-309
segregating	O	310-321
aniridia	B	322-330
and	O	331-334
a	O	335-336
milder	O	337-343
syndrome	O	344-352
consisting	O	353-363
of	O	364-366
congenital	B	367-377
cataracts	I	378-387
and	O	388-391
late	O	392-396
onset	O	397-402
corneal	B	403-410
dystrophy	I	411-420
.	O	420-421

The	O	422-425
nonsense	O	426-434
mutations	O	435-444
,	O	444-445
at	O	446-448
codons	O	449-455
103	O	456-459
and	O	460-463
353	O	464-467
,	O	467-468
truncate	O	469-477
PAX6	O	478-482
within	O	483-489
the	O	490-493
N	O	494-495
-	O	495-496
terminal	O	496-504
paired	O	505-511
and	O	512-515
C	O	516-517
-	O	517-518
terminal	O	518-526
PST	O	527-530
domains	O	531-538
,	O	538-539
respectively	O	540-552
.	O	552-553

The	O	554-557
wild	O	558-562
-	O	562-563
type	O	563-567
PST	O	568-571
domain	O	572-578
activates	O	579-588
transcription	O	589-602
autonomously	O	603-615
and	O	616-619
the	O	620-623
mutant	O	624-630
form	O	631-635
has	O	636-639
partial	O	640-647
activity	O	648-656
.	O	656-657

A	O	658-659
compound	O	660-668
heterozygote	O	669-681
had	O	682-685
severe	O	686-692
craniofacial	B	693-705
and	I	706-709
central	I	710-717
nervous	I	718-725
system	I	726-732
defects	I	733-740
and	O	741-744
no	B	745-747
eyes	I	748-752
.	O	752-753

The	O	754-757
pattern	O	758-765
of	O	766-768
malformations	O	769-782
is	O	783-785
similar	O	786-793
to	O	794-796
that	O	797-801
in	O	802-804
homozygous	O	805-815
Sey	O	816-819
mice	O	820-824
and	O	825-828
suggests	O	829-837
a	O	838-839
critical	O	840-848
role	O	849-853
for	O	854-857
PAX6	O	858-862
in	O	863-865
controlling	O	866-877
the	O	878-881
migration	O	882-891
and	O	892-895
differentiation	O	896-911
of	O	912-914
specific	O	915-923
neuronal	O	924-932
progenitor	O	933-943
cells	O	944-949
in	O	950-952
the	O	953-956
brain	O	957-962
.	O	962-963
.	O	962-963

Hereditary	B	0-10
C7	I	11-13
deficiency	I	14-24
.	O	24-25

Diagnosis	O	26-35
and	O	36-39
HLA	O	40-43
studies	O	44-51
in	O	52-54
a	O	55-56
French	O	57-63
-	O	63-64
Canadian	O	64-72
family	O	73-79
.	O	79-80

The	O	81-84
serum	O	85-90
of	O	91-93
a	O	94-95
44	O	96-98
-	O	98-99
yr	O	99-101
-	O	98-99
old	O	102-105
woman	O	106-111
of	O	112-114
French	O	115-121
-	O	121-122
Canadian	O	122-130
descent	O	131-138
having	O	139-145
a	O	146-147
B	O	148-149
-	O	149-150
27	O	150-152
positive	O	153-161
ankylosing	B	162-172
spondylitis	I	173-184
was	O	185-188
deficient	B	189-198
in	I	199-201
the	I	202-205
seventh	I	206-213
component	I	214-223
of	I	224-226
complement	I	227-237
(	O	238-239
C7	O	239-241
)	O	241-242
as	O	243-245
determined	O	246-256
by	O	257-259
hemolytic	O	260-269
and	O	270-273
immunochemical	O	274-288
methods	O	289-296
.	O	296-297

No	O	298-300
inhibitor	O	301-310
against	O	311-318
C7	O	319-321
was	O	322-325
detected	O	326-334
,	O	334-335
and	O	336-339
the	O	340-343
levels	O	344-350
of	O	351-353
all	O	354-357
other	O	358-363
complement	O	364-374
components	O	375-385
were	O	386-390
normal	O	391-397
.	O	397-398

No	O	399-401
deficiency	O	402-412
in	O	413-415
the	O	416-419
opsonic	O	420-427
activity	O	428-436
of	O	437-439
the	O	440-443
serum	O	444-449
was	O	450-453
found	O	454-459
,	O	459-460
and	O	461-464
the	O	465-468
results	O	469-476
of	O	477-479
basic	O	480-485
coagulation	O	486-497
studies	O	498-505
of	O	506-508
the	O	509-512
plasma	O	513-519
were	O	520-524
normal	O	525-531
.	O	531-532

On	O	533-535
investigation	O	536-549
of	O	550-552
the	O	553-556
patients	O	557-565
family	O	566-572
,	O	572-573
two	O	574-577
sisters	O	578-585
were	O	586-590
found	O	591-596
to	O	597-599
have	O	600-604
the	O	605-608
same	O	609-613
deficiency	O	614-624
but	O	625-628
were	O	629-633
otherwise	O	634-643
in	O	644-646
good	O	647-651
health	O	652-658
.	O	658-659

The	O	660-663
seven	O	664-669
other	O	670-675
siblings	O	676-684
were	O	685-689
heterozygous	O	690-702
for	O	703-706
C7	B	707-709
deficiency	I	710-720
,	O	720-721
while	O	722-727
the	O	728-731
paternal	O	732-740
aunt	O	741-745
had	O	746-749
a	O	750-751
normal	O	752-758
C7	O	759-761
level	O	762-767
.	O	767-768

In	O	769-771
the	O	772-775
third	O	776-781
generation	O	782-792
,	O	792-793
six	O	794-797
children	O	798-806
of	O	807-809
the	O	810-813
three	O	814-819
homozygous	O	820-830
sisters	O	831-838
and	O	839-842
five	O	843-847
children	O	848-856
of	O	857-859
heterozygotes	O	860-873
were	O	874-878
available	O	879-888
for	O	889-892
testing	O	893-900
.	O	900-901

Studies	O	902-909
of	O	910-912
the	O	913-916
HLA	O	917-920
antigens	O	921-929
in	O	930-932
all	O	933-936
the	O	937-940
22	O	941-943
subjects	O	944-952
and	O	953-956
in	O	957-959
three	O	960-965
spouses	O	966-973
indicated	O	974-983
no	O	984-986
close	O	987-992
linkage	O	993-1000
between	O	1001-1008
the	O	1009-1012
CM	B	1013-1015
deficienty	I	1016-1026
and	O	1027-1030
the	O	1031-1034
HLA	O	1035-1038
system	O	1039-1045
.	O	1045-1046

In	O	1047-1049
addition	O	1050-1058
,	O	1058-1059
the	O	1060-1063
simultaneous	O	1064-1076
occurrence	O	1077-1087
of	O	1088-1090
two	O	1091-1094
hereditary	O	1095-1105
complement	B	1106-1116
deficiencies	I	1117-1129
(	I	1130-1131
C2	I	1131-1133
and	I	1134-1137
C7	I	1138-1140
)	I	1140-1141
was	O	1142-1145
discovered	O	1146-1156
in	O	1157-1159
one	O	1160-1163
family	O	1164-1170
of	O	1171-1173
this	O	1174-1178
remarkable	O	1179-1189
kindred	O	1190-1197
.	O	1197-1198
.	O	1197-1198

Alstrom	B	0-7
syndrome	I	8-16
:	O	16-17
further	O	18-25
evidence	O	26-34
for	O	35-38
linkage	O	39-46
to	O	47-49
human	O	50-55
chromosome	O	56-66
2p13	O	67-71
.	O	71-72

Alstrom	B	73-80
syndrome	I	81-89
is	O	90-92
a	O	93-94
rare	O	95-99
autosomal	B	100-109
recessive	I	110-119
disorder	I	120-128
characterized	O	129-142
by	O	143-145
retinal	B	146-153
degeneration	I	154-166
,	O	166-167
sensorineural	B	168-181
hearing	I	182-189
loss	I	190-194
,	O	194-195
early	O	196-201
-	O	201-202
onset	O	202-207
obesity	B	208-215
,	O	215-216
and	O	217-220
non	B	221-224
-	I	224-225
insulin	I	225-232
-	I	224-225
dependent	I	233-242
diabetes	I	243-251
mellitus	I	252-260
.	O	260-261

The	O	262-265
gene	O	266-270
for	O	271-274
Alstrom	B	275-282
syndrome	I	283-291
(	O	292-293
ALMS1	O	293-298
)	O	298-299
has	O	300-303
been	O	304-308
previously	O	309-319
localized	O	320-329
to	O	330-332
human	O	333-338
chromosome	O	339-349
2p13	O	350-354
by	O	355-357
homozygosity	O	358-370
mapping	O	371-378
in	O	379-381
two	O	382-385
distinct	O	386-394
isolated	O	395-403
populations	O	404-415
-	O	416-417
French	O	418-424
Acadian	O	425-432
and	O	433-436
North	O	437-442
African	O	443-450
.	O	450-451

Pair	O	452-456
-	O	456-457
wise	O	457-461
analyses	O	462-470
resulted	O	471-479
in	O	480-482
maximum	O	483-490
lod	O	491-494
(	O	495-496
logarithm	O	496-505
of	O	506-508
the	O	509-512
odds	O	513-517
ratio	O	518-523
)	O	523-524
scores	O	525-531
of	O	532-534
3	O	535-536
.	O	536-537
84	O	538-540
and	O	541-544
2	O	545-546
.	O	546-547
9	O	548-549
,	O	549-550
respectively	O	551-563
.	O	563-564

To	O	565-567
confirm	O	568-575
these	O	576-581
findings	O	582-590
,	O	590-591
a	O	592-593
large	O	594-599
linkage	O	600-607
study	O	608-613
was	O	614-617
performed	O	618-627
in	O	628-630
twelve	O	631-637
additional	O	638-648
families	O	649-657
segregating	O	658-669
for	O	670-673
Alstrom	B	674-681
syndrome	I	682-690
.	O	690-691

A	O	692-693
maximum	O	694-701
two	O	702-705
-	O	705-706
point	O	706-711
lod	O	712-715
score	O	716-721
of	O	722-724
7	O	725-726
.	O	726-727
13	O	728-730
(	O	731-732
theta	O	732-737
=	O	738-739
0	O	740-741
.	O	741-742
00	O	743-745
)	O	745-746
for	O	747-750
marker	O	751-757
D2S2110	O	758-765
and	O	766-769
a	O	770-771
maximum	O	772-779
cumulative	O	780-790
multipoint	O	791-801
lod	O	802-805
score	O	806-811
of	O	812-814
9	O	815-816
.	O	816-817
16	O	818-820
for	O	821-824
marker	O	825-831
D2S2110	O	832-839
were	O	840-844
observed	O	845-853
,	O	853-854
further	O	855-862
supporting	O	863-873
linkage	O	874-881
to	O	882-884
chromosome	O	885-895
2p13	O	896-900
.	O	900-901

No	O	902-904
evidence	O	905-913
of	O	914-916
genetic	O	917-924
heterogeneity	O	925-938
was	O	939-942
observed	O	943-951
in	O	952-954
these	O	955-960
families	O	961-969
.	O	969-970

Meiotic	O	971-978
recombination	O	979-992
events	O	993-999
have	O	1000-1004
localized	O	1005-1014
the	O	1015-1018
critical	O	1019-1027
region	O	1028-1034
containing	O	1035-1045
ALMS1	O	1046-1051
to	O	1052-1054
a	O	1055-1056
6	O	1057-1058
.	O	1058-1059
1	O	1060-1061
-	O	1061-1062
cM	O	1062-1064
interval	O	1065-1073
flanked	O	1074-1081
by	O	1082-1084
markers	O	1085-1092
D2S327	O	1093-1099
and	O	1100-1103
D2S286	O	1104-1110
.	O	1110-1111

A	O	1112-1113
fine	O	1114-1118
resolution	O	1119-1129
radiation	O	1130-1139
hybrid	O	1140-1146
map	O	1147-1150
of	O	1151-1153
31	O	1154-1156
genes	O	1157-1162
and	O	1163-1166
markers	O	1167-1174
has	O	1175-1178
been	O	1179-1183
constructed	O	1184-1195
.	O	1195-1196

Haplotype	O	0-9
and	O	10-13
multipoint	O	14-24
linkage	O	25-32
analysis	O	33-41
in	O	42-44
Finnish	O	45-52
choroideremia	B	53-66
families	O	67-75
.	O	75-76

Multipoint	O	77-87
linkage	O	88-95
analysis	O	96-104
of	O	105-107
choroideremia	B	108-121
(	O	122-123
TCD	B	123-126
)	O	126-127
and	O	128-131
seven	O	132-137
X	O	138-139
chromosomal	O	140-151
restriction	O	152-163
fragment	O	164-172
length	O	173-179
polymorphisms	O	180-193
(	O	194-195
RFLPs	O	195-200
)	O	200-201
was	O	202-205
carried	O	206-213
out	O	214-217
in	O	218-220
18	O	221-223
Finnish	O	224-231
TCD	B	232-235
families	O	236-244
.	O	244-245

The	O	246-249
data	O	250-254
place	O	255-260
TCD	B	261-264
distal	O	265-271
to	O	272-274
PGK	O	275-278
and	O	279-282
DXS72	O	283-288
,	O	288-289
very	O	290-294
close	O	295-300
to	O	301-303
DXYS1	O	304-309
and	O	310-313
DXYS5	O	314-319
(	O	320-321
Zmax	O	321-325
=	O	326-327
24	O	328-330
at	O	331-333
theta	O	334-339
=	O	340-341
0	O	342-343
)	O	343-344
and	O	345-348
proximal	O	349-357
to	O	358-360
DXYS4	O	361-366
and	O	367-370
DXYS12	O	371-377
.	O	377-378

This	O	379-383
agrees	O	384-390
with	O	391-395
the	O	396-399
data	O	400-404
obtained	O	405-413
from	O	414-418
other	O	419-424
linkage	O	425-432
studies	O	433-440
and	O	441-444
from	O	445-449
physical	O	450-458
mapping	O	459-466
.	O	466-467

All	O	468-471
the	O	472-475
TCD	B	476-479
males	O	480-485
and	O	486-489
carrier	O	490-497
females	O	498-505
studied	O	506-513
have	O	514-518
the	O	519-522
same	O	523-527
DXYS1	O	528-533
allele	O	534-540
in	O	541-543
coupling	O	544-552
with	O	553-557
TCD	B	558-561
.	O	561-562

In	O	563-565
Northeastern	O	566-578
Finland	O	579-586
,	O	586-587
66	O	588-590
/	O	590-591
69	O	591-593
chromosomes	O	594-605
carrying	O	606-614
TCD	B	615-618
had	O	619-622
the	O	623-626
same	O	627-631
haplotype	O	632-641
at	O	642-644
loci	O	645-649
DXS72	O	650-655
,	O	655-656
DXYS1	O	657-662
,	O	662-663
DXYS4	O	664-669
,	O	669-670
and	O	671-674
DXYS12	O	675-681
.	O	681-682

The	O	683-686
same	O	687-691
haplotype	O	692-701
is	O	702-704
seen	O	705-709
in	O	710-712
only	O	713-717
15	O	718-720
/	O	720-721
99	O	721-723
chromosomes	O	724-735
not	O	736-739
carrying	O	740-748
TCD	B	749-752
.	O	752-753

Moreover	O	754-762
,	O	762-763
in	O	764-766
71	O	767-769
/	O	769-770
104	O	770-773
non	O	774-777
-	O	777-778
TCD	O	778-781
chromosomes	O	782-793
,	O	793-794
the	O	795-798
haplotype	O	799-808
at	O	809-811
six	O	812-815
marker	O	816-822
loci	O	823-827
is	O	828-830
different	O	831-840
from	O	841-845
those	O	846-851
seen	O	852-856
in	O	857-859
any	O	860-863
of	O	864-866
the	O	867-870
76	O	871-873
TCD	B	874-877
chromosomes	O	878-889
.	O	889-890

This	O	891-895
supports	O	896-904
the	O	905-908
previously	O	909-919
described	O	920-929
hypothesis	O	930-940
that	O	941-945
the	O	946-949
large	O	950-955
Northern	O	956-964
Finnish	O	965-972
choroideremia	B	973-986
pedigrees	O	987-996
,	O	996-997
comprising	O	998-1008
a	O	1009-1010
total	O	1011-1016
of	O	1017-1019
over	O	1020-1024
80	O	1025-1027
living	O	1028-1034
patients	O	1035-1043
representing	O	1044-1056
more	O	1057-1061
than	O	1062-1066
a	O	1067-1068
fifth	O	1069-1074
of	O	1075-1077
all	O	1078-1081
TCD	B	1082-1085
patients	O	1086-1094
described	O	1095-1104
worldwide	O	1105-1114
,	O	1114-1115
carry	O	1116-1121
the	O	1122-1125
same	O	1126-1130
mutation	O	1131-1139
.	O	1139-1140

These	O	1141-1146
linkage	O	1147-1154
and	O	1155-1158
haplotype	O	1159-1168
data	O	1169-1173
provide	O	1174-1181
improved	O	1182-1190
opportunities	O	1191-1204
for	O	1205-1208
prenatal	O	1209-1217
diagnosis	O	1218-1227
based	O	1228-1233
on	O	1234-1236
RFLP	O	1237-1241
studies	O	1242-1249
.	O	1249-1250
.	O	1249-1250

Genetic	O	0-7
heterogeneity	O	8-21
at	O	22-24
the	O	25-28
glucose	O	29-36
-	O	36-37
6	O	37-38
-	O	36-37
phosphate	O	39-48
dehydrogenase	O	49-62
locus	O	63-68
in	O	69-71
southern	O	72-80
Italy	O	81-86
:	O	86-87
a	O	88-89
study	O	90-95
on	O	96-98
a	O	99-100
population	O	101-111
from	O	112-116
the	O	117-120
Matera	O	121-127
district	O	128-136
.	O	136-137

Glucose	O	138-145
-	O	145-146
6	O	146-147
-	O	145-146
phosphate	O	148-157
dehydrogenase	O	158-171
(	O	172-173
G6PD	O	173-177
)	O	177-178
has	O	179-182
been	O	183-187
analyzed	O	188-196
by	O	197-199
gel	O	200-203
electrophoresis	O	204-219
and	O	220-223
by	O	224-226
quantitative	O	227-239
assay	O	240-245
in	O	246-248
an	O	249-251
unselected	O	252-262
sample	O	263-269
of	O	270-272
1524	O	273-277
schoolboys	O	278-288
from	O	289-293
the	O	294-297
province	O	298-306
of	O	307-309
Matera	O	310-316
(	O	317-318
Lucania	O	318-325
)	O	325-326
in	O	327-329
southern	O	330-338
Italy	O	339-344
.	O	344-345

We	O	346-348
have	O	349-353
identified	O	354-364
43	O	365-367
subjects	O	368-376
with	O	377-381
a	O	382-383
G6PD	O	384-388
variant	O	389-396
.	O	396-397

Of	O	398-400
these	O	401-406
,	O	406-407
31	O	408-410
had	O	411-414
severe	O	415-421
G6PD	B	422-426
deficiency	I	427-437
,	O	437-438
nine	O	439-443
had	O	444-447
mild	O	448-452
to	O	453-455
moderate	O	456-464
deficiency	O	465-475
,	O	475-476
and	O	477-480
three	O	481-486
had	O	487-490
a	O	491-492
non	O	493-496
-	O	496-497
deficient	O	497-506
electrophoretic	O	507-522
variant	O	523-530
.	O	530-531

The	O	532-535
overall	O	536-543
rate	O	544-548
of	O	549-551
G6PD	B	552-556
deficiency	I	557-567
was	O	568-571
2	O	572-573
.	O	573-574
6	O	575-576
%	O	576-577
.	O	577-578

The	O	579-582
frequency	O	583-592
of	O	593-595
G6PD	B	596-600
deficiency	I	601-611
,	O	611-612
ranging	O	613-620
from	O	621-625
7	O	626-627
.	O	627-628
2	O	629-630
%	O	630-631
on	O	632-634
the	O	635-638
Ionian	O	639-645
Coast	O	646-651
to	O	652-654
zero	O	655-659
on	O	660-662
the	O	663-666
eastern	O	667-674
side	O	675-679
of	O	680-682
the	O	683-686
Lucanian	O	687-695
Apennines	O	696-705
,	O	705-706
appears	O	707-714
to	O	715-717
be	O	718-720
inversely	O	721-730
related	O	731-738
to	O	739-741
the	O	742-745
distance	O	746-754
of	O	755-757
each	O	758-762
town	O	763-767
examined	O	768-776
from	O	777-781
the	O	782-785
Ionian	O	786-792
Coast	O	793-798
,	O	798-799
suggesting	O	800-810
that	O	811-815
this	O	816-820
geographic	O	821-831
distribution	O	832-844
may	O	845-848
reflect	O	849-856
,	O	856-857
at	O	858-860
least	O	861-866
in	O	867-869
part	O	870-874
,	O	874-875
gene	O	876-880
flow	O	881-885
from	O	886-890
Greek	O	891-896
settlers	O	897-905
.	O	905-906

Biochemical	O	907-918
characterization	O	919-935
has	O	936-939
shown	O	940-945
that	O	946-950
most	O	951-955
of	O	956-958
the	O	959-962
G6PD	B	963-967
deficiency	I	968-978
in	O	979-981
this	O	982-986
population	O	987-997
is	O	998-1000
accounted	O	1001-1010
for	O	1011-1014
by	O	1015-1017
G6PD	O	1018-1022
Mediterranean	O	1023-1036
.	O	1036-1037

In	O	1038-1040
addition	O	1041-1049
,	O	1049-1050
we	O	1051-1053
have	O	1054-1058
found	O	1059-1064
several	O	1065-1072
examples	O	1073-1081
of	O	1082-1084
two	O	1085-1088
other	O	1089-1094
known	O	1095-1100
polymorphic	O	1101-1112
variants	O	1113-1121
(	O	1122-1123
G6PD	O	1123-1127
Cagliari	O	1128-1136
and	O	1137-1140
G6PD	O	1141-1145
A	O	1146-1147
-	O	1147-1148
)	O	1148-1149
;	O	1149-1150
three	O	1151-1156
new	O	1157-1160
polymorphic	O	1161-1172
variants	O	1173-1181
,	O	1181-1182
G6PD	O	1183-1187
Metaponto	O	1188-1197
(	O	1198-1199
class	O	1199-1204
III	O	1205-1208
)	O	1208-1209
,	O	1209-1210
G6PD	O	1211-1215
Montalbano	O	1216-1226
(	O	1227-1228
class	O	1228-1233
III	O	1234-1237
)	O	1237-1238
,	O	1238-1239
and	O	1240-1243
G6PD	O	1244-1248
Pisticci	O	1249-1257
(	O	1258-1259
class	O	1259-1264
IV	O	1265-1267
)	O	1267-1268
;	O	1268-1269
and	O	1270-1273
two	O	1274-1277
sporadic	O	1278-1286
variants	O	1287-1295
,	O	1295-1296
G6PD	O	1297-1301
Tursi	O	1302-1307
(	O	1308-1309
class	O	1309-1314
III	O	1315-1318
)	O	1318-1319
and	O	1320-1323
G6PD	O	1324-1328
Ferrandina	O	1329-1339
(	O	1340-1341
class	O	1341-1346
II	O	1347-1349
)	O	1349-1350
.	O	1350-1351

These	O	1352-1357
data	O	1358-1362
provide	O	1363-1370
further	O	1371-1378
evidence	O	1379-1387
for	O	1388-1391
the	O	1392-1395
marked	O	1396-1402
genetic	O	1403-1410
heterogeneity	O	1411-1424
of	O	1425-1427
G6PD	B	1428-1432
deficiency	I	1433-1443
within	O	1444-1450
a	O	1451-1452
relatively	O	1453-1463
narrow	O	1464-1470
geographic	O	1471-1481
area	O	1482-1486
and	O	1487-1490
they	O	1491-1495
prove	O	1496-1501
the	O	1502-1505
presence	O	1506-1514
in	O	1515-1517
the	O	1518-1521
Italian	O	1522-1529
peninsula	O	1530-1539
of	O	1540-1542
a	O	1543-1544
gene	O	1545-1549
(	O	1550-1551
GdA	O	1551-1554
-	O	1554-1555
)	O	1555-1556
regarded	O	1557-1565
as	O	1566-1568
characteristically	O	1569-1587
African	O	1588-1595
.	O	1595-1596

Defective	O	0-9
CTLA	O	10-14
-	O	14-15
4	O	15-16
cycling	O	17-24
pathway	O	25-32
in	O	33-35
Chediak	B	36-43
-	I	43-44
Higashi	I	44-51
syndrome	I	52-60
:	O	60-61
a	O	62-63
possible	O	64-72
mechanism	O	73-82
for	O	83-86
deregulation	O	87-99
of	O	100-102
T	O	103-104
lymphocyte	O	105-115
activation	O	116-126
.	O	126-127

Cytotoxic	O	128-137
T	O	138-139
lymphocyte	O	140-150
-	O	150-151
associated	O	151-161
antigen	O	162-169
4	O	170-171
(	O	172-173
CTLA	O	173-177
-	O	177-178
4	O	178-179
,	O	179-180
also	O	181-185
known	O	186-191
as	O	192-194
CD152	O	195-200
)	O	200-201
has	O	202-205
been	O	206-210
shown	O	211-216
to	O	217-219
play	O	220-224
a	O	225-226
major	O	227-232
role	O	233-237
in	O	238-240
the	O	241-244
regulation	O	245-255
of	O	256-258
T	O	259-260
cell	O	261-265
activation	O	266-276
.	O	276-277

Its	O	278-281
membrane	O	282-290
expression	O	291-301
is	O	302-304
highly	O	305-311
regulated	O	312-321
by	O	322-324
endocytosis	O	325-336
and	O	337-340
trafficking	O	341-352
through	O	353-360
the	O	361-364
secretory	O	365-374
lysosome	O	375-383
pathway	O	384-391
.	O	391-392

Chediak	B	393-400
-	I	400-401
Higashi	I	401-408
syndrome	I	409-417
(	O	418-419
CHS	B	419-422
)	O	422-423
is	O	424-426
an	O	427-429
inherited	B	430-439
disorder	I	440-448
caused	O	449-455
by	O	456-458
mutations	O	459-468
in	O	469-471
the	O	472-475
lysosomal	O	476-485
trafficking	O	486-497
regulator	O	498-507
gene	O	508-512
,	O	512-513
LYST	O	514-518
.	O	518-519

It	O	520-522
results	O	523-530
in	O	531-533
defective	O	534-543
membrane	O	544-552
targeting	O	553-562
of	O	563-565
the	O	566-569
proteins	O	570-578
present	O	579-586
in	O	587-589
secretory	O	590-599
lysosomes	O	600-609
,	O	609-610
and	O	611-614
it	O	615-617
is	O	618-620
associated	O	621-631
with	O	632-636
a	O	637-638
variety	O	639-646
of	O	647-649
features	O	650-658
,	O	658-659
including	O	660-669
a	O	670-671
lymphoproliferative	B	672-691
syndrome	I	692-700
with	O	701-705
hemophagocytosis	B	706-722
.	O	722-723

The	O	724-727
murine	O	728-734
equivalent	O	735-745
of	O	746-748
CHS	B	749-752
,	O	752-753
beige	O	754-759
mice	O	760-764
,	O	764-765
present	O	766-773
similar	O	774-781
characteristics	O	782-797
but	O	798-801
do	O	802-804
not	O	805-808
develop	O	809-816
the	O	817-820
lymphoproliferative	B	821-840
syndrome	I	841-849
.	O	849-850

We	O	851-853
show	O	854-858
herein	O	859-865
that	O	866-870
CTLA	O	871-875
-	O	875-876
4	O	876-877
is	O	878-880
present	O	881-888
in	O	889-891
enlarged	O	892-900
,	O	900-901
abnormal	O	902-910
vesicles	O	911-919
in	O	920-922
CHS	B	923-926
T	O	927-928
cells	O	929-934
and	O	935-938
is	O	939-941
not	O	942-945
properly	O	946-954
expressed	O	955-964
at	O	965-967
the	O	968-971
cell	O	972-976
surface	O	977-984
after	O	985-990
T	O	991-992
cell	O	993-997
activation	O	998-1008
,	O	1008-1009
whereas	O	1010-1017
its	O	1018-1021
surface	O	1022-1029
expression	O	1030-1040
is	O	1041-1043
not	O	1044-1047
impaired	O	1048-1056
.	O	1056-1057

It	O	1058-1060
is	O	1061-1063
therefore	O	1064-1073
proposed	O	1074-1082
that	O	1083-1087
the	O	1088-1091
defective	O	1092-1101
surface	O	1102-1109
expression	O	1110-1120
of	O	1121-1123
CTLA	O	1124-1128
-	O	1128-1129
4	O	1129-1130
by	O	1131-1133
CHS	B	1134-1137
T	O	1138-1139
cells	O	1140-1145
is	O	1146-1148
involved	O	1149-1157
in	O	1158-1160
the	O	1161-1164
generation	O	1165-1175
of	O	1176-1178
lymphoproliferative	B	1179-1198
disease	I	1199-1206
.	O	1206-1207

This	O	1208-1212
observation	O	1213-1224
may	O	1225-1228
provide	O	1229-1236
insight	O	1237-1244
into	O	1245-1249
the	O	1250-1253
role	O	1254-1258
of	O	1259-1261
CTLA	O	1262-1266
-	O	1266-1267
4	O	1267-1268
in	O	1269-1271
humans	O	1272-1278
.	O	1278-1279
.	O	1278-1279

Beta	O	0-4
-	O	4-5
catenin	O	5-12
accumulation	O	13-25
and	O	26-29
mutation	O	30-38
of	O	39-41
the	O	42-45
CTNNB1	O	46-52
gene	O	53-57
in	O	58-60
hepatoblastoma	B	61-75
.	O	75-76

Hepatoblastoma	B	77-91
is	O	92-94
a	O	95-96
rare	O	97-101
malignant	B	102-111
tumor	I	112-117
of	I	118-120
the	I	121-124
liver	I	125-130
that	O	131-135
occurs	O	136-142
in	O	143-145
children	O	146-154
at	O	155-157
an	O	158-160
average	O	161-168
age	O	169-172
of	O	173-175
2	O	176-177
to	O	178-180
3	O	181-182
years	O	183-188
.	O	188-189

Epidemiologic	O	190-203
studies	O	204-211
have	O	212-216
shown	O	217-222
an	O	223-225
increased	O	226-235
frequency	O	236-245
of	O	246-248
this	O	249-253
tumor	B	254-259
type	O	260-264
in	O	265-267
families	O	268-276
affected	O	277-285
by	O	286-288
adenomatous	B	289-300
polyposis	I	301-310
coli	I	311-315
.	O	315-316

In	O	317-319
addition	O	320-328
to	O	329-331
the	O	332-335
epidemiologic	O	336-349
data	O	350-354
,	O	354-355
molecular	O	356-365
genetic	O	366-373
studies	O	374-381
suggest	O	382-389
that	O	390-394
inactivation	O	395-407
of	O	408-410
the	O	411-414
APC	B	415-418
tumor	I	419-424
suppressor	O	425-435
may	O	436-439
be	O	440-442
involved	O	443-451
in	O	452-454
hepatoblastoma	B	455-469
tumorigenesis	O	470-483
.	O	483-484

A	O	485-486
major	O	487-492
function	O	493-501
of	O	502-504
APC	O	505-508
is	O	509-511
the	O	512-515
downregulation	O	516-530
of	O	531-533
beta	O	534-538
-	O	538-539
catenin	O	539-546
,	O	546-547
a	O	548-549
transcription	O	550-563
-	O	563-564
activating	O	564-574
protein	O	575-582
with	O	583-587
oncogenic	O	588-597
potential	O	598-607
.	O	607-608

In	O	609-611
an	O	612-614
ongoing	O	615-622
immunohistochemical	O	623-642
study	O	643-648
of	O	649-651
beta	O	652-656
-	O	656-657
catenin	O	657-664
expression	O	665-675
in	O	676-678
sporadic	O	679-687
cases	O	688-693
of	O	694-696
tumor	B	697-702
types	O	703-708
that	O	709-713
are	O	714-717
associated	O	718-728
with	O	729-733
adenomatous	B	734-745
polyposis	I	746-755
coli	I	756-760
,	O	760-761
we	O	762-764
observed	O	765-773
increased	O	774-783
beta	O	784-788
-	O	788-789
catenin	O	789-796
levels	O	797-803
in	O	804-806
the	O	807-810
cytoplasm	O	811-820
and	O	821-824
in	O	825-827
the	O	828-831
nuclei	O	832-838
of	O	839-841
three	O	842-847
investigated	O	848-860
hepatoblastomas	B	861-876
.	O	876-877

Sequencing	O	878-888
of	O	889-891
exon	O	892-896
3	O	897-898
of	O	899-901
the	O	902-905
beta	O	906-910
-	O	910-911
catenin	O	911-918
gene	O	919-923
(	O	924-925
CTNNB1	O	925-931
)	O	931-932
revealed	O	933-941
an	O	942-944
activating	O	945-955
mutation	O	956-964
in	O	965-967
one	O	968-971
of	O	972-974
the	O	975-978
tumor	B	979-984
samples	O	985-992
.	O	992-993

Our	O	994-997
data	O	998-1002
indicate	O	1003-1011
for	O	1012-1015
the	O	1016-1019
first	O	1020-1025
time	O	1026-1030
that	O	1031-1035
beta	O	1036-1040
-	O	1040-1041
catenin	O	1041-1048
accumulation	O	1049-1061
may	O	1062-1065
play	O	1066-1070
a	O	1071-1072
role	O	1073-1077
in	O	1078-1080
the	O	1081-1084
development	O	1085-1096
of	O	1097-1099
hepatoblastoma	B	1100-1114
and	O	1115-1118
that	O	1119-1123
activating	O	1124-1134
mutations	O	1135-1144
of	O	1145-1147
the	O	1148-1151
beta	O	1152-1156
-	O	1156-1157
catenin	O	1157-1164
gene	O	1165-1169
may	O	1170-1173
substitute	O	1174-1184
biallelic	O	1185-1194
APC	O	1195-1198
inactivation	O	1199-1211
in	O	1212-1214
this	O	1215-1219
tumor	B	1220-1225
type	O	1226-1230
.	O	1230-1231

Genes	O	1232-1237
Chromosomes	O	1238-1249
Cancer	O	1250-1256
25	O	1257-1259
399	O	1261-1264
-	O	1264-1265
402	O	1265-1268
,	O	1268-1269
1999	O	1270-1274
.	O	1274-1275
.	O	1274-1275

Sequence	O	0-8
of	O	9-11
DNA	O	12-15
flanking	O	16-24
the	O	25-28
exons	O	29-34
of	O	35-37
the	O	38-41
HEXA	O	42-46
gene	O	47-51
,	O	51-52
and	O	53-56
identification	O	57-71
of	O	72-74
mutations	O	75-84
in	O	85-87
Tay	B	88-91
-	I	91-92
Sachs	I	92-97
disease	I	98-105
.	O	105-106

The	O	107-110
rapid	O	111-116
identification	O	117-131
of	O	132-134
mutations	O	135-144
causing	O	145-152
Tay	B	153-156
-	I	156-157
Sachs	I	157-162
disease	I	163-170
requires	O	171-179
the	O	180-183
capacity	O	184-192
to	O	193-195
readily	O	196-203
screen	O	204-210
the	O	211-214
regions	O	215-222
of	O	223-225
the	O	226-229
HEXA	O	230-234
gene	O	235-239
most	O	240-244
likely	O	245-251
to	O	252-254
be	O	255-257
affected	O	258-266
by	O	267-269
mutation	O	270-278
.	O	278-279

We	O	280-282
have	O	283-287
sequenced	O	288-297
the	O	298-301
portions	O	302-310
of	O	311-313
the	O	314-317
introns	O	318-325
flanking	O	326-334
each	O	335-339
of	O	340-342
the	O	343-346
14	O	347-349
HEXA	O	350-354
exons	O	355-360
in	O	361-363
order	O	364-369
to	O	370-372
specify	O	373-380
oligonucleotide	O	381-396
primers	O	397-404
for	O	405-408
the	O	409-412
PCR	O	413-416
-	O	416-417
dependent	O	417-426
amplification	O	427-440
of	O	441-443
each	O	444-448
exon	O	449-453
and	O	454-457
splice	O	458-464
-	O	464-465
junction	O	465-473
sequence	O	474-482
.	O	482-483

The	O	484-487
amplified	O	488-497
products	O	498-506
were	O	507-511
analyzed	O	512-520
,	O	520-521
by	O	522-524
electrophoresis	O	525-540
in	O	541-543
nondenaturing	O	544-557
polyacrylamide	O	558-572
gels	O	573-577
,	O	577-578
for	O	579-582
the	O	583-586
presence	O	587-595
of	O	596-598
either	O	599-605
heteroduplexes	O	606-620
,	O	620-621
derived	O	622-629
from	O	630-634
the	O	635-638
annealing	O	639-648
of	O	649-651
normal	O	652-658
and	O	659-662
mutant	O	663-669
DNA	O	670-673
strands	O	674-681
,	O	681-682
or	O	683-685
single	O	686-692
-	O	692-693
strand	O	693-699
conformational	O	700-714
polymorphisms	O	715-728
(	O	729-730
SSCP	O	730-734
)	O	734-735
,	O	735-736
derived	O	737-744
from	O	745-749
the	O	750-753
renaturation	O	754-766
of	O	767-769
single	O	770-776
-	O	776-777
stranded	O	777-785
DNA	O	786-789
.	O	789-790

Five	O	791-795
novel	O	796-801
mutations	O	802-811
from	O	812-816
Tay	B	817-820
-	I	820-821
Sachs	I	821-826
disease	I	827-834
patients	O	835-843
were	O	844-848
detected	O	849-857
a	O	859-860
5	O	861-862
-	O	862-863
bp	O	863-865
deletion	O	866-874
of	O	875-877
TCTCC	O	878-883
in	O	884-886
IVS	O	887-890
-	O	890-891
9	O	891-892
;	O	892-893
a	O	894-895
2	O	896-897
-	O	897-898
bp	O	898-900
deletion	O	901-909
of	O	910-912
TG	O	913-915
in	O	916-918
exon	O	919-923
5	O	924-925
;	O	925-926
G78	O	927-930
to	O	931-933
A	O	934-935
,	O	935-936
giving	O	937-943
a	O	944-945
stop	O	946-950
codon	O	951-956
in	O	957-959
exon	O	960-964
1	O	965-966
;	O	966-967
G533	O	968-972
to	O	973-975
T	O	976-977
in	O	978-980
exon	O	981-985
5	O	986-987
,	O	987-988
producing	O	989-998
the	O	999-1002
third	O	1003-1008
amino	O	1009-1014
acid	O	1015-1019
substitution	O	1020-1032
detected	O	1033-1041
at	O	1042-1044
this	O	1045-1049
site	O	1050-1054
;	O	1054-1055
and	O	1056-1059
G	O	1060-1061
to	O	1062-1064
C	O	1065-1066
at	O	1067-1069
position	O	1070-1078
1	O	1079-1080
of	O	1081-1083
IVS	O	1084-1087
-	O	1087-1088
2	O	1088-1089
,	O	1089-1090
expected	O	1091-1099
to	O	1100-1102
produce	O	1103-1110
abnormal	O	1111-1119
splicing	O	1120-1128
.	O	1128-1129

In	O	1130-1132
addition	O	1133-1141
,	O	1141-1142
two	O	1143-1146
mutations	O	1147-1156
,	O	1156-1157
(	O	1158-1159
G1496	O	1159-1164
to	O	1165-1167
A	O	1168-1169
in	O	1170-1172
exon	O	1173-1177
13	O	1178-1180
and	O	1181-1184
a	O	1185-1186
4	O	1187-1188
-	O	1188-1189
bp	O	1189-1191
insertion	O	1192-1201
in	O	1202-1204
exon	O	1205-1209
11	O	1210-1212
)	O	1212-1213
that	O	1214-1218
have	O	1219-1223
previously	O	1224-1234
been	O	1235-1239
reported	O	1240-1248
were	O	1249-1253
identified	O	1254-1264
.	O	1264-1265
.	O	1264-1265

In	O	0-2
vivo	O	3-7
modulation	O	8-18
of	O	19-21
Hmgic	O	22-27
reduces	O	28-35
obesity	B	36-43
.	O	43-44

The	O	45-48
HMGI	O	49-53
family	O	54-60
of	O	61-63
proteins	O	64-72
consists	O	73-81
of	O	82-84
three	O	85-90
members	O	91-98
,	O	98-99
HMGIC	O	100-105
,	O	105-106
HMGI	O	107-111
and	O	112-115
HMGI	O	116-120
(	O	121-122
Y	O	122-123
)	O	123-124
,	O	124-125
that	O	126-130
function	O	131-139
as	O	140-142
architectural	O	143-156
factors	O	157-164
and	O	165-168
are	O	169-172
essential	O	173-182
components	O	183-193
of	O	194-196
the	O	197-200
enhancesome	O	201-212
.	O	212-213

HMGIC	O	214-219
is	O	220-222
predominantly	O	223-236
expressed	O	237-246
in	O	247-249
proliferating	O	250-263
,	O	263-264
undifferentiated	O	265-281
mesenchymal	O	282-293
cells	O	294-299
and	O	300-303
is	O	304-306
not	O	307-310
detected	O	311-319
in	O	320-322
adult	O	323-328
tissues	O	329-336
.	O	336-337

It	O	338-340
is	O	341-343
disrupted	O	344-353
and	O	354-357
misexpressed	O	358-370
in	O	371-373
a	O	374-375
number	O	376-382
of	O	383-385
mesenchymal	B	386-397
tumour	I	398-404
cell	O	405-409
types	O	410-415
,	O	415-416
including	O	417-426
fat	B	427-430
-	I	430-431
cell	I	431-435
tumours	I	436-443
(	O	444-445
lipomas	B	445-452
)	O	452-453
.	O	453-454

In	O	455-457
addition	O	458-466
Hmgic	O	467-472
-	O	472-473
/	O	473-474
-	O	472-473
mice	O	476-480
have	O	481-485
a	O	486-487
deficiency	O	488-498
in	O	499-501
fat	O	502-505
tissue	O	506-512
.	O	512-513

To	O	514-516
study	O	517-522
its	O	523-526
role	O	527-531
in	O	532-534
adipogenesis	O	535-547
and	O	548-551
obesity	B	552-559
,	O	559-560
we	O	561-563
examined	O	564-572
Hmgic	O	573-578
expression	O	579-589
in	O	590-592
the	O	593-596
adipose	O	597-604
tissue	O	605-611
of	O	612-614
adult	O	615-620
,	O	620-621
obese	B	622-627
mice	O	628-632
.	O	632-633

Mice	O	634-638
with	O	639-643
a	O	644-645
partial	B	646-653
or	I	654-656
complete	I	657-665
deficiency	I	666-676
of	I	677-679
Hmgic	I	680-685
resisted	O	686-694
diet	O	695-699
-	O	699-700
induced	O	700-707
obesity	B	708-715
.	O	715-716

Disruption	O	717-727
of	O	728-730
Hmgic	O	731-736
caused	O	737-743
a	O	744-745
reduction	O	746-755
in	O	756-758
the	O	759-762
obesity	B	763-770
induced	O	771-778
by	O	779-781
leptin	B	782-788
deficiency	I	789-799
(	O	800-801
Lepob	O	801-806
/	O	806-807
Lepob	O	801-806
)	O	812-813
in	O	814-816
a	O	817-818
gene	O	819-823
-	O	823-824
dose	O	824-828
-	O	823-824
dependent	O	829-838
manner	O	839-845
.	O	845-846

Our	O	847-850
studies	O	851-858
implicate	O	859-868
a	O	869-870
role	O	871-875
for	O	876-879
HMGIC	O	880-885
in	O	886-888
fat	O	889-892
-	O	892-893
cell	O	893-897
proliferation	O	898-911
,	O	911-912
indicating	O	913-923
that	O	924-928
it	O	929-931
may	O	932-935
be	O	936-938
an	O	939-941
adipose	O	942-949
-	O	949-950
specific	O	950-958
target	O	959-965
for	O	966-969
the	O	970-973
treatment	O	974-983
of	O	984-986
obesity	B	987-994
.	O	994-995
.	O	994-995

Prenatal	O	0-8
diagnosis	O	9-18
by	O	19-21
FISH	O	22-26
in	O	27-29
a	O	30-31
family	O	32-38
with	O	39-43
Pelizaeus	B	44-53
-	I	53-54
Merzbacher	I	54-64
disease	I	65-72
caused	O	73-79
by	O	80-82
duplication	O	83-94
of	O	95-97
PLP	O	98-101
gene	O	102-106
.	O	106-107

A	O	108-109
diagnosis	O	110-119
of	O	120-122
Pelizaeus	B	123-132
-	I	132-133
Merzbacher	I	133-143
disease	I	144-151
(	O	152-153
MIM	O	153-156
312080	O	157-163
)	O	163-164
was	O	165-168
made	O	169-173
in	O	174-176
a	O	177-178
young	O	179-184
boy	O	185-188
.	O	188-189

No	O	190-192
mutation	O	193-201
in	O	202-204
the	O	205-208
coding	O	209-215
region	O	216-222
of	O	223-225
the	O	226-229
proteolipid	O	230-241
protein	O	242-249
(	O	250-251
PLP	O	251-254
)	O	254-255
gene	O	256-260
had	O	261-264
been	O	265-269
found	O	270-275
.	O	275-276

The	O	277-280
boys	O	281-285
maternal	O	286-294
aunt	O	295-299
came	O	300-304
for	O	305-308
prenatal	O	309-317
diagnosis	O	318-327
when	O	328-332
16	O	333-335
+	O	336-337
weeks	O	338-343
pregnant	O	344-352
and	O	353-356
carrying	O	357-365
a	O	366-367
male	O	368-372
fetus	O	373-378
.	O	378-379

Samples	O	380-387
were	O	388-392
tested	O	393-399
for	O	400-403
duplication	O	404-415
of	O	416-418
the	O	419-422
PLP	O	423-426
gene	O	427-431
,	O	431-432
by	O	433-435
interphase	O	436-446
FISH	O	447-451
,	O	451-452
in	O	453-455
lymphocyte	O	456-466
preparations	O	467-479
from	O	480-484
the	O	485-488
proband	O	489-496
,	O	496-497
his	O	498-501
aunt	O	502-506
and	O	507-510
an	O	511-513
amniotic	O	514-522
fluid	O	523-528
cell	O	529-533
preparation	O	534-545
from	O	546-550
the	O	551-554
fetus	O	555-560
.	O	560-561

The	O	562-565
proband	O	566-573
was	O	574-577
found	O	578-583
to	O	584-586
carry	O	587-592
the	O	593-596
duplication	O	597-608
,	O	608-609
thus	O	610-614
confirming	O	615-625
the	O	626-629
diagnosis	O	630-639
of	O	640-642
Pelizaeus	B	643-652
Merzbacher	I	653-663
disease	I	664-671
,	O	671-672
but	O	673-676
neither	O	677-684
the	O	685-688
aunt	O	689-693
nor	O	694-697
the	O	698-701
fetus	O	702-707
carried	O	708-715
a	O	716-717
duplication	O	718-729
.	O	729-730
.	O	729-730

Somatic	O	0-7
rearrangement	O	8-21
of	O	22-24
chromosome	O	25-35
14	O	36-38
in	O	39-41
human	O	42-47
lymphocytes	O	48-59
.	O	59-60

Ataxia	B	61-67
-	I	67-68
telangiectasia	I	68-82
is	O	83-85
a	O	86-87
rare	O	88-92
genetic	B	93-100
disorder	I	101-109
associated	O	110-120
with	O	121-125
immune	B	126-132
deficiency	I	133-143
,	O	143-144
chromosome	B	145-155
instability	I	156-167
,	O	167-168
and	O	169-172
a	O	173-174
predisposition	O	175-189
to	O	190-192
lymphoid	B	193-201
malignancy	I	202-212
.	O	212-213

We	O	214-216
have	O	217-221
detected	O	222-230
chromosomally	O	231-244
anomalous	O	245-254
clones	O	255-261
of	O	262-264
lymphocytes	O	265-276
in	O	277-279
eight	O	280-285
patients	O	286-294
with	O	295-299
this	O	300-304
disorder	O	305-313
.	O	313-314

Chromosome	O	315-325
banding	O	326-333
disclosed	O	334-343
that	O	344-348
the	O	349-352
clones	O	353-359
are	O	360-363
consistently	O	364-376
marked	O	377-383
by	O	384-386
structural	O	387-397
rearrangement	O	398-411
of	O	412-414
the	O	415-418
long	O	419-423
arm	O	424-427
(	O	428-429
q	O	429-430
)	O	430-431
of	O	432-434
chromosome	O	435-445
14	O	446-448
.	O	448-449

A	O	450-451
translocation	O	452-465
involving	O	466-475
14q	O	476-479
was	O	480-483
found	O	484-489
in	O	490-492
clones	O	493-499
obtained	O	500-508
from	O	509-513
seven	O	514-519
of	O	520-522
the	O	523-526
eight	O	527-532
patients	O	533-541
whereas	O	542-549
a	O	550-551
ring	O	552-556
14	O	557-559
chromosome	O	560-570
was	O	571-574
found	O	575-580
in	O	581-583
a	O	584-585
clone	O	586-591
obtained	O	592-600
from	O	601-605
the	O	606-609
other	O	610-615
.	O	615-616

These	O	617-622
findings	O	623-631
as	O	632-634
well	O	635-639
as	O	640-642
data	O	643-647
obtained	O	648-656
by	O	657-659
others	O	660-666
for	O	667-670
patients	O	671-679
with	O	680-684
ataxia	B	685-691
-	I	691-692
telangiectasia	I	692-706
suggest	O	707-714
that	O	715-719
structural	O	720-730
rearrangement	O	731-744
of	O	745-747
14q	O	748-751
is	O	752-754
the	O	755-758
initial	O	759-766
chromosomal	O	767-778
change	O	779-785
in	O	786-788
lymphocyte	O	789-799
clones	O	800-806
of	O	807-809
patients	O	810-818
with	O	819-823
this	O	824-828
disorder	O	829-837
.	O	837-838

Chromosomes	O	839-850
of	O	851-853
lymphocytes	O	854-865
from	O	866-870
one	O	871-874
of	O	875-877
the	O	878-881
patients	O	882-890
were	O	891-895
studied	O	896-903
before	O	904-910
and	O	911-914
after	O	915-920
the	O	921-924
onset	O	925-930
of	O	931-933
chronic	B	934-941
lymphocytic	I	942-953
leukemia	I	954-962
.	O	962-963

Before	O	964-970
leukemia	B	971-979
was	O	980-983
diagnosed	O	984-993
,	O	993-994
the	O	995-998
patient	O	999-1006
had	O	1007-1010
a	O	1011-1012
lymphocyte	O	1013-1023
clone	O	1024-1029
with	O	1030-1034
a	O	1035-1036
14q	O	1037-1040
translocation	O	1041-1054
.	O	1054-1055

This	O	1056-1060
clone	O	1061-1066
appears	O	1067-1074
to	O	1075-1077
have	O	1078-1082
given	O	1083-1088
rise	O	1089-1093
to	O	1094-1096
the	O	1097-1100
leukemic	B	1101-1109
cells	O	1110-1115
.	O	1115-1116

We	O	1117-1119
hypothesize	O	1120-1131
that	O	1132-1136
structural	O	1137-1147
rearrangement	O	1148-1161
of	O	1162-1164
14q	O	1165-1168
is	O	1169-1171
directly	O	1172-1180
related	O	1181-1188
to	O	1189-1191
abnormal	O	1192-1200
growth	O	1201-1207
of	O	1208-1210
lymphocytes	O	1211-1222
and	O	1223-1226
that	O	1227-1231
it	O	1232-1234
may	O	1235-1238
be	O	1239-1241
a	O	1242-1243
step	O	1244-1248
toward	O	1249-1255
the	O	1256-1259
development	O	1260-1271
of	O	1272-1274
lymphoid	B	1275-1283
malignancies	I	1284-1296
.	O	1296-1297

Increasing	O	1298-1308
evidence	O	1309-1317
,	O	1317-1318
provided	O	1319-1327
by	O	1328-1330
others	O	1331-1337
,	O	1337-1338
for	O	1339-1342
the	O	1343-1346
nonrandom	O	1347-1356
involvement	O	1357-1368
of	O	1369-1371
14q	O	1372-1375
in	O	1376-1378
African	O	1379-1386
-	O	1386-1387
type	O	1387-1391
Burkitts	B	1392-1400
lymphoma	I	1401-1409
and	O	1410-1413
other	O	1414-1419
lymphoid	B	1420-1428
neoplasms	I	1429-1438
further	O	1439-1446
strengthens	O	1447-1458
this	O	1459-1463
hypothesis	O	1464-1474
.	O	1474-1475
.	O	1474-1475

Two	O	0-3
missense	O	4-12
mutations	O	13-22
causing	O	23-30
mild	O	31-35
hyperphenylalaninemia	B	36-57
associated	O	58-68
with	O	69-73
DNA	O	74-77
haplotype	O	78-87
12	O	88-90
.	O	90-91

The	O	92-95
genetic	B	96-103
defects	I	104-111
responsible	O	112-123
for	O	124-127
most	O	128-132
phenylketonuria	B	133-148
(	O	149-150
PKU	B	150-153
)	O	153-154
and	O	155-158
hyperphenylalaninemia	B	159-180
(	O	181-182
HPA	B	182-185
)	O	185-186
cases	O	187-192
are	O	193-196
located	O	197-204
in	O	205-207
the	O	208-211
phenylalanine	O	212-225
hydroxylase	O	226-237
(	O	238-239
PAH	O	239-242
)	O	242-243
gene	O	244-248
.	O	248-249

Approximately	O	250-263
50	O	264-266
-	O	266-267
60	O	267-269
mutations	O	270-279
have	O	280-284
been	O	285-289
reported	O	290-298
in	O	299-301
Caucasians	O	302-312
and	O	313-316
are	O	317-320
reflected	O	321-330
in	O	331-333
a	O	334-335
wide	O	336-340
range	O	341-346
of	O	347-349
clinical	O	350-358
severities	O	359-369
.	O	369-370

Most	O	371-375
mutations	O	376-385
are	O	386-389
linked	O	390-396
to	O	397-399
specific	O	400-408
haplotypes	O	409-419
,	O	419-420
as	O	421-423
defined	O	424-431
by	O	432-434
eight	O	435-440
polymorphic	O	441-452
restriction	O	453-464
sites	O	465-470
in	O	471-473
the	O	474-477
PAH	O	478-481
gene	O	482-486
.	O	486-487

We	O	488-490
hypothesized	O	491-503
that	O	504-508
there	O	509-514
is	O	515-517
at	O	518-520
least	O	521-526
one	O	527-530
mild	O	531-535
mutation	O	536-544
linked	O	545-551
to	O	552-554
haplotype	O	555-564
12	O	565-567
in	O	568-570
the	O	571-574
Swedish	O	575-582
PKU	B	583-586
/	O	586-587
HPA	B	587-590
population	O	591-601
,	O	601-602
since	O	603-608
7	O	609-610
of	O	611-613
8	O	614-615
patients	O	616-624
carrying	O	625-633
haplotype	O	634-643
12	O	644-646
had	O	647-650
mild	O	651-655
HPA	B	656-659
.	O	659-660

Sequence	O	661-669
analysis	O	670-678
revealed	O	679-687
a	O	688-689
C	O	690-691
-	O	691-692
to	O	692-694
-	O	691-692
G	O	695-696
transversion	O	697-709
at	O	710-712
the	O	713-716
second	O	717-723
base	O	724-728
of	O	729-731
codon	O	732-737
322	O	738-741
,	O	741-742
resulting	O	743-752
in	O	753-755
a	O	756-757
substitution	O	758-770
of	O	771-773
glycine	O	774-781
for	O	782-785
alanine	O	786-793
,	O	793-794
in	O	795-797
four	O	798-802
mutant	O	803-809
haplotype	O	810-819
12	O	820-822
genes	O	823-828
,	O	828-829
and	O	830-833
a	O	834-835
G	O	836-837
-	O	837-838
to	O	838-840
-	O	837-838
A	O	841-842
transition	O	843-853
at	O	854-856
the	O	857-860
second	O	861-867
base	O	868-872
of	O	873-875
codon	O	876-881
408	O	882-885
,	O	885-886
resulting	O	887-896
in	O	897-899
a	O	900-901
substitution	O	902-914
of	O	915-917
glutamine	O	918-927
for	O	928-931
arginine	O	932-940
,	O	940-941
in	O	942-944
another	O	945-952
three	O	953-958
mutant	O	959-965
haplotype	O	966-975
12	O	976-978
genes	O	979-984
.	O	984-985

These	O	986-991
mutations	O	992-1001
segregated	O	1002-1012
with	O	1013-1017
mutant	O	1018-1024
haplotype	O	1025-1034
12	O	1035-1037
alleles	O	1038-1045
in	O	1046-1048
nuclear	O	1049-1056
families	O	1057-1065
but	O	1066-1069
were	O	1070-1074
not	O	1075-1078
present	O	1079-1086
on	O	1087-1089
normal	O	1090-1096
or	O	1097-1099
other	O	1100-1105
mutant	O	1106-1112
alleles	O	1113-1120
.	O	1120-1121

Both	O	1122-1126
mutations	O	1127-1136
were	O	1137-1141
tested	O	1142-1148
in	O	1149-1151
a	O	1152-1153
eukaryotic	O	1154-1164
expression	O	1165-1175
system	O	1176-1182
in	O	1183-1185
which	O	1186-1191
enzyme	O	1192-1198
activities	O	1199-1209
of	O	1210-1212
different	O	1213-1222
mutant	O	1223-1229
PAH	O	1230-1233
enzymes	O	1234-1241
reflect	O	1242-1249
the	O	1250-1253
relative	O	1254-1262
severities	O	1263-1273
of	O	1274-1276
the	O	1277-1280
mutations	O	1281-1290
,	O	1290-1291
although	O	1292-1300
these	O	1301-1306
in	O	1307-1309
vitro	O	1310-1315
activities	O	1316-1326
cannot	O	1327-1333
be	O	1334-1336
translated	O	1337-1347
directly	O	1348-1356
into	O	1357-1361
in	O	1362-1364
vivo	O	1365-1369
hepatic	O	1370-1377
activities	O	1378-1388
.	O	1388-1389

The	O	1390-1393
A322G	O	1394-1399
mutant	O	1400-1406
PAH	O	1407-1410
had	O	1411-1414
about	O	1415-1420
75	O	1421-1423
%	O	1423-1424
and	O	1425-1428
the	O	1429-1432
R408Q	O	1433-1438
mutant	O	1439-1445
PAH	O	1446-1449
about	O	1450-1455
55	O	1456-1458
%	O	1458-1459
of	O	1460-1462
the	O	1463-1466
wild	O	1467-1471
-	O	1471-1472
type	O	1472-1476
PAH	O	1477-1480
enzyme	O	1481-1487
activity	O	1488-1496
.	O	1496-1497

These	O	1498-1503
in	O	1504-1506
vitro	O	1507-1512
activities	O	1513-1523
are	O	1524-1527
the	O	1528-1531
highest	O	1532-1539
reported	O	1540-1548
for	O	1549-1552
mutant	O	1553-1559
PAH	O	1560-1563
enzymes	O	1564-1571
produced	O	1572-1580
in	O	1581-1583
the	O	1584-1587
same	O	1588-1592
expression	O	1593-1603
system	O	1604-1610
.	O	1610-1611

(	O	1612-1613
ABSTRACT	O	1613-1621
TRUNCATED	O	1622-1631
AT	O	1632-1634
250	O	1635-1638
WORDS	O	1639-1644
)	O	1644-1645
.	O	1645-1646

Genomic	O	0-7
organization	O	8-20
of	O	21-23
the	O	24-27
adrenoleukodystrophy	B	28-48
gene	O	49-53
.	O	53-54

Adrenoleukodystrophy	B	55-75
(	O	76-77
ALD	B	77-80
)	O	80-81
,	O	81-82
the	O	83-86
most	O	87-91
frequent	O	92-100
peroxisomal	B	101-112
disorder	I	113-121
,	O	121-122
is	O	123-125
a	O	126-127
severe	O	128-134
neurodegenerative	B	135-152
disease	I	153-160
associated	O	161-171
with	O	172-176
an	O	177-179
impairment	B	180-190
of	I	191-193
very	I	194-198
long	I	199-203
chain	I	204-209
fatty	I	210-215
acids	I	216-221
beta	I	222-226
-	I	226-227
oxidation	I	227-236
.	O	236-237

We	O	238-240
have	O	241-245
recently	O	246-254
identified	O	255-265
by	O	266-268
positional	O	269-279
cloning	O	280-287
the	O	288-291
gene	O	292-296
responsible	O	297-308
for	O	309-312
ALD	B	313-316
,	O	316-317
located	O	318-325
in	O	326-328
Xq28	O	329-333
.	O	333-334

It	O	335-337
encodes	O	338-345
a	O	346-347
new	O	348-351
member	O	352-358
of	O	359-361
the	O	362-365
"	O	366-367
ABC	O	368-371
"	O	372-373
superfamily	O	374-385
of	O	386-388
membrane	O	389-397
-	O	397-398
associated	O	398-408
transporters	O	409-421
that	O	422-426
shows	O	427-432
,	O	432-433
in	O	434-436
particular	O	437-447
,	O	447-448
significant	O	449-460
homology	O	461-469
to	O	470-472
the	O	473-476
70	O	477-479
-	O	479-480
kDa	O	480-483
peroxisomal	O	484-495
membrane	O	496-504
protein	O	505-512
(	O	513-514
PMP70	O	514-519
)	O	519-520
.	O	520-521

We	O	522-524
report	O	525-531
here	O	532-536
a	O	537-538
detailed	O	539-547
characterization	O	548-564
of	O	565-567
the	O	568-571
ALD	B	572-575
gene	O	576-580
structure	O	581-590
.	O	590-591

It	O	592-594
extends	O	595-602
over	O	603-607
21	O	608-610
kb	O	611-613
and	O	614-617
consists	O	618-626
of	O	627-629
10	O	630-632
exons	O	633-638
.	O	638-639

To	O	640-642
facilitate	O	643-653
the	O	654-657
detection	O	658-667
of	O	668-670
mutations	O	671-680
in	O	681-683
ALD	B	684-687
patients	O	688-696
,	O	696-697
we	O	698-700
have	O	701-705
determined	O	706-716
the	O	717-720
intronic	O	721-729
sequences	O	730-739
flanking	O	740-748
the	O	749-752
exons	O	753-758
as	O	759-761
well	O	762-766
as	O	767-769
the	O	770-773
sequence	O	774-782
of	O	783-785
the	O	786-789
3	O	790-791
untranslated	O	792-804
region	O	805-811
and	O	812-815
of	O	816-818
the	O	819-822
immediate	O	823-832
5	O	833-834
promoter	O	835-843
region	O	844-850
.	O	850-851

Sequences	O	852-861
present	O	862-869
in	O	870-872
distal	O	873-879
exons	O	880-885
cross	O	886-891
-	O	891-892
hybridize	O	892-901
strongly	O	902-910
to	O	911-913
additional	O	914-924
sequences	O	925-934
in	O	935-937
the	O	938-941
human	O	942-947
genome	O	948-954
.	O	954-955

The	O	956-959
ALD	B	960-963
gene	O	964-968
has	O	969-972
been	O	973-977
positioned	O	978-988
on	O	989-991
a	O	992-993
pulsed	O	994-1000
-	O	1000-1001
field	O	1001-1006
map	O	1007-1010
between	O	1011-1018
DXS15	O	1019-1024
and	O	1025-1028
the	O	1029-1032
L1CAM	O	1033-1038
gene	O	1039-1043
,	O	1043-1044
about	O	1045-1050
650	O	1051-1054
kb	O	1055-1057
upstream	O	1058-1066
from	O	1067-1071
the	O	1072-1075
color	O	1076-1081
pigment	O	1082-1089
genes	O	1090-1095
.	O	1095-1096

The	O	1097-1100
frequent	O	1101-1109
occurrence	O	1110-1120
of	O	1121-1123
color	O	1124-1129
vision	O	1130-1136
anomalies	O	1137-1146
observed	O	1147-1155
in	O	1156-1158
patients	O	1159-1167
with	O	1168-1172
adrenomyeloneuropathy	B	1173-1194
(	O	1195-1196
the	O	1196-1199
adult	O	1200-1205
onset	O	1206-1211
form	O	1212-1216
of	O	1217-1219
ALD	B	1220-1223
)	O	1223-1224
thus	O	1225-1229
does	O	1230-1234
not	O	1235-1238
represent	O	1239-1248
a	O	1249-1250
contiguous	B	1251-1261
gene	I	1262-1266
syndrome	I	1267-1275
but	O	1276-1279
a	O	1280-1281
secondary	O	1282-1291
manifestation	O	1292-1305
of	O	1306-1308
ALD	B	1309-1312
.	O	1312-1313
.	O	1312-1313

BRCA1	O	0-5
interacts	O	6-15
with	O	16-20
components	O	21-31
of	O	32-34
the	O	35-38
histone	O	39-46
deacetylase	O	47-58
complex	O	59-66
.	O	66-67

Germ	O	68-72
-	O	72-73
line	O	73-77
mutations	O	78-87
in	O	88-90
the	O	91-94
BRCA1	O	95-100
tumor	O	101-106
-	O	106-107
suppressor	O	107-117
gene	O	118-122
are	O	123-126
associated	O	127-137
with	O	138-142
an	O	143-145
increased	O	146-155
susceptibility	O	156-170
to	O	171-173
breast	B	174-180
and	I	181-184
ovarian	I	185-192
cancer	I	193-199
.	O	199-200

BRCA1	O	201-206
contains	O	207-215
a	O	216-217
carboxyl	O	218-226
-	O	226-227
terminal	O	227-235
domain	O	236-242
(	O	243-244
BRCT	O	244-248
)	O	248-249
that	O	250-254
is	O	255-257
shared	O	258-264
with	O	265-269
several	O	270-277
other	O	278-283
proteins	O	284-292
involved	O	293-301
in	O	302-304
maintaining	O	305-316
genome	O	317-323
integrity	O	324-333
.	O	333-334

In	O	335-337
an	O	338-340
effort	O	341-347
to	O	348-350
understand	O	351-361
the	O	362-365
function	O	366-374
of	O	375-377
BRCA1	O	378-383
,	O	383-384
we	O	385-387
sought	O	388-394
to	O	395-397
isolate	O	398-405
proteins	O	406-414
that	O	415-419
interact	O	420-428
with	O	429-433
the	O	434-437
BRCT	O	438-442
domain	O	443-449
.	O	449-450

Purified	O	451-459
BRCT	O	460-464
polypeptide	O	465-476
was	O	477-480
used	O	481-485
as	O	486-488
a	O	489-490
probe	O	491-496
to	O	497-499
screen	O	500-506
a	O	507-508
human	O	509-514
placenta	O	515-523
cDNA	O	524-528
expression	O	529-539
library	O	540-547
by	O	548-550
Far	O	551-554
Western	O	555-562
analysis	O	563-571
.	O	571-572

Here	O	573-577
we	O	578-580
report	O	581-587
that	O	588-592
BRCA1	O	593-598
interacts	O	599-608
in	O	609-611
vivo	O	612-616
and	O	617-620
in	O	621-623
vitro	O	624-629
with	O	630-634
the	O	635-638
Rb	O	639-641
-	O	641-642
binding	O	642-649
proteins	O	650-658
,	O	658-659
RbAp46	O	660-666
and	O	667-670
RbAp48	O	671-677
,	O	677-678
as	O	679-681
well	O	682-686
as	O	687-689
with	O	690-694
Rb	O	695-697
.	O	697-698

Moreover	O	699-707
,	O	707-708
the	O	709-712
BRCT	O	713-717
domain	O	718-724
associates	O	725-735
with	O	736-740
the	O	741-744
histone	O	745-752
deacetylases	O	753-765
HDAC1	O	766-771
and	O	772-775
HDAC2	O	776-781
.	O	781-782

These	O	783-788
results	O	789-796
demonstrate	O	797-808
that	O	809-813
BRCA1	O	814-819
interacts	O	820-829
with	O	830-834
components	O	835-845
of	O	846-848
the	O	849-852
histone	O	853-860
deacetylase	O	861-872
complex	O	873-880
,	O	880-881
and	O	882-885
therefore	O	886-895
may	O	896-899
explain	O	900-907
the	O	908-911
involvement	O	912-923
of	O	924-926
BRCA1	O	927-932
in	O	933-935
multiple	O	936-944
processes	O	945-954
such	O	955-959
as	O	960-962
transcription	O	963-976
,	O	976-977
DNA	O	978-981
repair	O	982-988
,	O	988-989
and	O	990-993
recombination	O	994-1007
.	O	1007-1008
.	O	1007-1008

Deletion	O	0-8
of	O	9-11
the	O	12-15
KIT	O	16-19
and	O	20-23
PDGFRA	O	24-30
genes	O	31-36
in	O	37-39
a	O	40-41
patient	O	42-49
with	O	50-54
piebaldism	B	55-65
.	O	65-66

We	O	67-69
have	O	70-74
previously	O	75-85
shown	O	86-91
that	O	92-96
human	O	97-102
piebaldism	B	103-113
results	O	114-121
from	O	122-126
mutations	O	127-136
of	O	137-139
the	O	140-143
KIT	O	144-147
gene	O	148-152
,	O	152-153
which	O	154-159
encodes	O	160-167
the	O	168-171
receptor	O	172-180
for	O	181-184
the	O	185-188
mast	O	189-193
/	O	193-194
stem	O	194-198
cell	O	199-203
growth	O	204-210
factor	O	211-217
and	O	218-221
is	O	222-224
located	O	225-232
in	O	233-235
chromosome	O	236-246
segment	O	247-254
4q12	O	255-259
.	O	259-260

Using	O	261-266
DNA	O	267-270
of	O	271-273
a	O	274-275
patient	O	276-283
with	O	284-288
piebaldism	B	289-299
,	O	299-300
mental	B	301-307
retardation	I	308-319
,	O	319-320
and	O	321-324
multiple	B	325-333
congenital	I	334-344
anomalies	I	345-354
associated	O	355-365
with	O	366-370
a	O	371-372
46	O	373-375
,	O	375-376
XY	O	377-379
,	O	379-380
del	O	381-384
(	O	385-386
4	O	386-387
)	O	387-388
(	O	389-390
q12q21	O	390-396
.	O	396-397
1	O	398-399
)	O	399-400
karyotype	O	401-410
,	O	410-411
we	O	412-414
carried	O	415-422
out	O	423-426
quantitative	O	427-439
Southern	O	440-448
blot	O	449-453
hybridization	O	454-467
analyses	O	468-476
of	O	477-479
the	O	480-483
KIT	O	484-487
gene	O	488-492
and	O	493-496
the	O	497-500
adjacent	O	501-509
PDGFRA	O	510-516
(	O	517-518
platelet	O	518-526
-	O	526-527
derived	O	527-534
growth	O	535-541
factor	O	542-548
receptor	O	549-557
alpha	O	558-563
subunit	O	564-571
)	O	571-572
genes	O	573-578
.	O	578-579

The	O	580-583
patient	O	584-591
was	O	592-595
hemizygous	O	596-606
for	O	607-610
both	O	611-615
the	O	616-619
KIT	O	620-623
and	O	624-627
PDGFRA	O	628-634
genes	O	635-640
,	O	640-641
indicating	O	642-652
that	O	653-657
both	O	658-662
of	O	663-665
these	O	666-671
genes	O	672-677
are	O	678-681
included	O	682-690
within	O	691-697
the	O	698-701
deleted	O	702-709
region	O	710-716
.	O	716-717

Therefore	O	718-727
,	O	727-728
deletion	O	729-737
of	O	738-740
the	O	741-744
KIT	O	745-748
and	O	749-752
PDGFRA	O	753-759
genes	O	760-765
may	O	766-769
account	O	770-777
for	O	778-781
the	O	782-785
piebald	B	786-793
phenotype	O	794-803
in	O	804-806
this	O	807-811
patient	O	812-819
.	O	819-820

Glucose	O	0-7
-	O	7-8
6	O	8-9
-	O	7-8
phosphate	O	10-19
dehydrogenase	O	20-33
variants	O	34-42
and	O	43-46
their	O	47-52
frequency	O	53-62
in	O	63-65
Guangdong	O	66-75
,	O	75-76
China	O	77-82
.	O	82-83

Erythrocyte	O	84-95
glucose	O	96-103
-	O	103-104
6	O	104-105
-	O	103-104
phosphate	O	106-115
dehydrogenase	O	116-129
(	O	130-131
G6PD	O	131-135
)	O	135-136
was	O	137-140
characterized	O	141-154
in	O	155-157
blood	O	158-163
samples	O	164-171
obtained	O	172-180
from	O	181-185
97	O	186-188
randomly	O	189-197
selected	O	198-206
males	O	207-212
with	O	213-217
enzyme	B	218-224
deficiency	I	225-235
from	O	236-240
various	O	241-248
regions	O	249-256
of	O	257-259
Guangdong	O	260-269
Province	O	270-278
,	O	278-279
China	O	280-285
.	O	285-286

Nine	O	287-291
new	O	292-295
variants	O	296-304
(	O	305-306
Gd	O	306-308
Kaiping	O	309-316
,	O	316-317
Gd	O	318-320
Boluo	O	321-326
,	O	326-327
Gd	O	328-330
Huiyang	O	331-338
,	O	338-339
Gd	O	340-342
Gaomin	O	343-349
,	O	349-350
Gd	O	351-353
Qing	O	354-358
-	O	358-359
Baijiang	O	359-367
,	O	367-368
Gd	O	369-371
Gaozhou	O	372-379
,	O	379-380
Gd	O	381-383
Huazhou	O	384-391
,	O	391-392
Gd	O	393-395
Nanhai	O	396-402
,	O	402-403
and	O	404-407
Gd	O	408-410
Guangzhou	O	411-420
)	O	420-421
were	O	422-426
identified	O	427-437
.	O	437-438

Of	O	439-441
the	O	442-445
31	O	446-448
variants	O	449-457
found	O	458-463
in	O	464-466
this	O	467-471
province	O	472-480
,	O	480-481
Gd	O	482-484
Kaiping	O	485-492
,	O	492-493
Gd	O	494-496
Taiwan	O	497-503
-	O	503-504
Hakka	O	504-509
,	O	509-510
Gd	O	511-513
Haad	O	514-518
Yai	O	519-522
,	O	522-523
Gd	O	524-526
Haad	O	527-531
Yai	O	532-535
-	O	535-536
like	O	536-540
and	O	541-544
Gd	O	545-547
Huiyang	O	548-555
occurred	O	556-564
most	O	565-569
frequently	O	570-580
.	O	580-581

The	O	582-585
frequency	O	586-595
of	O	596-598
each	O	599-603
variant	O	604-611
was	O	612-615
calculated	O	616-626
.	O	626-627

The	O	628-631
results	O	632-639
demonstrated	O	640-652
that	O	653-657
the	O	658-661
genetic	O	662-669
heterogeneity	O	670-683
of	O	684-686
G6PD	B	687-691
deficiency	I	692-702
was	O	703-706
high	O	707-711
in	O	712-714
this	O	715-719
area	O	720-724
.	O	724-725
.	O	724-725

A	O	0-1
common	O	2-8
molecular	O	9-18
basis	O	19-24
for	O	25-28
rearrangement	B	29-42
disorders	I	43-52
on	O	53-55
chromosome	O	56-66
22q11	O	67-72
.	O	72-73

The	O	74-77
chromosome	O	78-88
22q11	O	89-94
region	O	95-101
is	O	102-104
susceptible	O	105-116
to	O	117-119
rearrangements	O	120-134
that	O	135-139
are	O	140-143
associated	O	144-154
with	O	155-159
congenital	B	160-170
anomaly	I	171-178
disorders	I	179-188
and	O	189-192
malignant	B	193-202
tumors	I	203-209
.	O	209-210

Three	O	211-216
congenital	B	217-227
anomaly	I	228-235
disorders	I	236-245
,	O	245-246
cat	B	247-250
-	I	250-251
eye	I	251-254
syndrome	I	255-263
,	O	263-264
der	B	265-268
(	I	269-270
)	I	270-271
syndrome	I	272-280
and	O	281-284
velo	B	285-289
-	I	289-290
cardio	I	290-296
-	I	289-290
facial	I	297-303
syndrome	I	304-312
/	O	312-313
DiGeorge	B	313-321
syndrome	I	322-330
(	O	331-332
VCFS	B	332-336
/	O	336-337
DGS	B	337-340
)	O	340-341
are	O	342-345
associated	O	346-356
with	O	357-361
tetrasomy	O	362-371
,	O	371-372
trisomy	O	373-380
or	O	381-383
monosomy	O	384-392
,	O	392-393
respectively	O	394-406
,	O	406-407
for	O	408-411
part	O	412-416
of	O	417-419
chromosome	O	420-430
22q11	O	431-436
.	O	436-437

VCFS	B	438-442
/	O	442-443
DGS	B	443-446
is	O	447-449
the	O	450-453
most	O	454-458
common	O	459-465
syndrome	O	466-474
associated	O	475-485
with	O	486-490
22q11	O	491-496
rearrangements	O	497-511
.	O	511-512

In	O	513-515
order	O	516-521
to	O	522-524
determine	O	525-534
whether	O	535-542
there	O	543-548
are	O	549-552
particular	O	553-563
regions	O	564-571
on	O	572-574
22q11	O	575-580
that	O	581-585
are	O	586-589
prone	O	590-595
to	O	596-598
rearrangements	O	599-613
,	O	613-614
the	O	615-618
deletion	O	619-627
end	O	628-631
-	O	631-632
points	O	632-638
in	O	639-641
a	O	642-643
large	O	644-649
number	O	650-656
of	O	657-659
VCFS	B	660-664
/	O	664-665
DGS	B	665-668
patients	O	669-677
were	O	678-682
defined	O	683-690
by	O	691-693
haplotype	O	694-703
analysis	O	704-712
.	O	712-713

Most	O	714-718
VCFS	B	719-723
/	O	723-724
DGS	B	724-727
patients	O	728-736
have	O	737-741
a	O	742-743
similar	O	744-751
3	O	752-753
Mb	O	754-756
deletion	O	757-765
,	O	765-766
some	O	767-771
have	O	772-776
a	O	777-778
nested	O	779-785
distal	O	786-792
deletion	O	793-801
breakpoint	O	802-812
resulting	O	813-822
in	O	823-825
a	O	826-827
1	O	828-829
.	O	829-830
5	O	831-832
Mb	O	833-835
deletion	O	836-844
and	O	845-848
a	O	849-850
few	O	851-854
rare	O	855-859
patients	O	860-868
have	O	869-873
unique	O	874-880
deletions	O	881-890
or	O	891-893
translocations	O	894-908
.	O	908-909

The	O	910-913
high	O	914-918
prevalence	O	919-929
of	O	930-932
the	O	933-936
disorder	O	937-945
in	O	946-948
the	O	949-952
population	O	953-963
and	O	964-967
the	O	968-971
fact	O	972-976
that	O	977-981
most	O	982-986
cases	O	987-992
occur	O	993-998
sporadically	O	999-1011
suggest	O	1012-1019
that	O	1020-1024
sequences	O	1025-1034
at	O	1035-1037
or	O	1038-1040
near	O	1041-1045
the	O	1046-1049
breakpoints	O	1050-1061
confer	O	1062-1068
susceptibility	O	1069-1083
to	O	1084-1086
chromosome	O	1087-1097
rearrangements	O	1098-1112
.	O	1112-1113

To	O	1114-1116
investigate	O	1117-1128
this	O	1129-1133
hypothesis	O	1134-1144
,	O	1144-1145
we	O	1146-1148
developed	O	1149-1158
hamster	O	1159-1166
-	O	1166-1167
human	O	1167-1172
somatic	O	1173-1180
hybrid	O	1181-1187
cell	O	1188-1192
lines	O	1193-1198
from	O	1199-1203
VCFS	B	1204-1208
/	O	1208-1209
DGS	B	1209-1212
patients	O	1213-1221
with	O	1222-1226
all	O	1227-1230
three	O	1231-1236
classes	O	1237-1244
of	O	1245-1247
deletions	O	1248-1257
and	O	1258-1261
we	O	1262-1264
now	O	1265-1268
show	O	1269-1273
that	O	1274-1278
the	O	1279-1282
breakpoints	O	1283-1294
occur	O	1295-1300
within	O	1301-1307
similar	O	1308-1315
low	O	1316-1319
copy	O	1320-1324
repeats	O	1325-1332
,	O	1332-1333
termed	O	1334-1340
LCR22s	O	1341-1347
.	O	1347-1348

To	O	1349-1351
support	O	1352-1359
this	O	1360-1364
idea	O	1365-1369
further	O	1370-1377
,	O	1377-1378
we	O	1379-1381
identified	O	1382-1392
a	O	1393-1394
family	O	1395-1401
that	O	1402-1406
carries	O	1407-1414
an	O	1415-1417
interstitial	O	1418-1430
duplication	O	1431-1442
of	O	1443-1445
the	O	1446-1449
same	O	1450-1454
3	O	1455-1456
Mb	O	1457-1459
region	O	1460-1466
that	O	1467-1471
is	O	1472-1474
deleted	O	1475-1482
in	O	1483-1485
VCFS	B	1486-1490
/	O	1490-1491
DGS	B	1491-1494
patients	O	1495-1503
.	O	1503-1504

We	O	1505-1507
present	O	1508-1515
models	O	1516-1522
to	O	1523-1525
explain	O	1526-1533
how	O	1534-1537
the	O	1538-1541
LCR22s	O	1542-1548
can	O	1549-1552
mediate	O	1553-1560
different	O	1561-1570
homologous	O	1571-1581
recombination	O	1582-1595
events	O	1596-1602
,	O	1602-1603
thereby	O	1604-1611
generating	O	1612-1622
a	O	1623-1624
number	O	1625-1631
of	O	1632-1634
rearrangements	O	1635-1649
that	O	1650-1654
are	O	1655-1658
associated	O	1659-1669
with	O	1670-1674
congenital	B	1675-1685
anomaly	I	1686-1693
disorders	I	1694-1703
.	O	1703-1704

We	O	1705-1707
identified	O	1708-1718
five	O	1719-1723
additional	O	1724-1734
copies	O	1735-1741
of	O	1742-1744
the	O	1745-1748
LCR22	O	1749-1754
on	O	1755-1757
22q11	O	1758-1763
that	O	1764-1768
may	O	1769-1772
mediate	O	1773-1780
other	O	1781-1786
rearrangements	O	1787-1801
leading	O	1802-1809
to	O	1810-1812
disease	O	1813-1820
.	O	1820-1821

Typical	O	0-7
and	O	8-11
partial	O	12-19
cat	B	20-23
eye	I	24-27
syndrome	I	28-36
:	O	36-37
identification	O	38-52
of	O	53-55
the	O	56-59
marker	O	60-66
chromosome	O	67-77
by	O	78-80
FISH	O	81-85
.	O	85-86

Three	O	87-92
children	O	93-101
are	O	102-105
reported	O	106-114
with	O	115-119
typical	O	120-127
cat	B	128-131
eye	I	132-135
syndrome	I	136-144
(	O	145-146
CES	B	146-149
)	O	149-150
and	O	151-154
three	O	155-160
more	O	161-165
children	O	166-174
with	O	175-179
partial	O	180-187
CES	B	188-191
because	O	192-199
of	O	200-202
absence	O	203-210
of	O	211-213
coloboma	O	214-222
,	O	222-223
in	O	224-226
which	O	227-232
the	O	233-236
supernumerary	O	237-250
marker	O	251-257
chromosome	O	258-268
was	O	269-272
studied	O	273-280
by	O	281-283
FISH	O	284-288
.	O	288-289

Using	O	290-295
a	O	296-297
genomic	O	298-305
library	O	306-313
,	O	313-314
and	O	315-318
also	O	319-323
a	O	324-325
centromeric	O	326-337
and	O	338-341
particularly	O	342-354
a	O	355-356
cosmid	O	357-363
probe	O	364-369
of	O	370-372
22q11	O	373-378
,	O	378-379
partial	O	380-387
tetrasomy	B	388-397
was	O	398-401
shown	O	402-407
in	O	408-410
all	O	411-414
cases	O	415-420
.	O	420-421
.	O	420-421

An	O	0-2
intrachromosomal	O	3-19
insertion	O	20-29
causing	O	30-37
5q22	O	38-42
deletion	O	43-51
and	O	52-55
familial	B	56-64
adenomatous	I	65-76
polyposis	I	77-86
coli	I	87-91
in	O	92-94
two	O	95-98
generations	O	99-110
.	O	110-111

We	O	112-114
report	O	115-121
familial	B	122-130
adenomatous	I	131-142
polyposis	I	143-152
coli	I	153-157
(	O	158-159
FAPC	B	159-163
)	O	163-164
with	O	165-169
epidermoid	B	170-180
cysts	I	181-186
,	O	186-187
osteomata	B	188-197
,	O	197-198
and	O	199-202
areas	O	203-208
of	O	209-211
congenital	B	212-222
hypertrophy	I	223-234
of	I	235-237
the	I	238-241
retinal	I	242-249
pigment	I	250-257
epithelium	I	258-268
(	O	269-270
CHRPEs	B	270-276
)	O	276-277
in	O	278-280
a	O	281-282
male	O	283-287
patient	O	288-295
and	O	296-299
his	O	300-303
maternal	O	304-312
aunt	O	313-317
,	O	317-318
both	O	319-323
of	O	324-326
whom	O	327-331
suffered	O	332-340
a	O	341-342
mild	O	343-347
to	O	348-350
moderate	O	351-359
degree	O	360-366
of	O	367-369
mental	B	370-376
handicap	I	377-385
.	O	385-386

Both	O	387-391
had	O	392-395
an	O	396-398
interstitial	O	399-411
deletion	O	412-420
of	O	421-423
the	O	424-427
long	O	428-432
arm	O	433-436
of	O	437-439
chromosome	O	440-450
5	O	451-452
(	O	453-454
del	O	454-457
(	O	458-459
5	O	459-460
)	O	460-461
(	O	462-463
q22q23	O	463-469
.	O	469-470

2	O	471-472
)	O	472-473
)	O	472-473
.	O	474-475

Two	O	476-479
other	O	480-485
normal	O	486-492
family	O	493-499
members	O	500-507
had	O	508-511
the	O	512-515
underlying	O	516-526
direct	O	527-533
insertion	O	534-543
of	O	544-546
chromosome	O	547-557
5	O	558-559
(	O	560-561
dir	O	561-564
ins	O	565-568
(	O	569-570
5	O	570-571
)	O	571-572
(	O	573-574
q31	O	574-577
.	O	577-578

3q22q23	O	579-586
3q22q23	O	587-594
.	O	594-595

2	O	596-597
)	O	597-598
)	O	597-598
.	O	599-600

Molecular	O	601-610
genetic	O	611-618
and	O	619-622
fluorescent	O	623-634
hybridisation	O	635-648
studies	O	649-656
have	O	657-661
shown	O	662-667
that	O	668-672
loci	O	673-677
D5S37	O	678-683
and	O	684-687
D5S98	O	688-693
are	O	694-697
outside	O	698-705
the	O	706-709
deletion	O	710-718
whereas	O	719-726
loci	O	727-731
detected	O	732-740
by	O	741-743
probes	O	744-750
EF5	O	751-754
.	O	754-755

44	O	756-758
and	O	759-762
YN5	O	763-766
.	O	766-767

48	O	768-770
are	O	771-774
lost	O	775-779
.	O	779-780

As	O	781-783
expected	O	784-792
,	O	792-793
the	O	794-797
molecular	O	798-807
analyses	O	808-816
indicate	O	817-825
loss	O	826-830
of	O	831-833
one	O	834-837
allele	O	838-844
at	O	845-847
the	O	848-851
MCC	O	852-855
and	O	856-859
APC	B	860-863
loci	O	864-868
.	O	868-869

The	O	870-873
APC	B	874-877
gene	O	878-882
is	O	883-885
located	O	886-893
within	O	894-900
band	O	901-905
5q22	O	906-910
.	O	910-911

Familial	O	912-920
direct	O	921-927
insertions	O	928-938
should	O	939-945
be	O	946-948
considered	O	949-959
as	O	960-962
a	O	963-964
cause	O	965-970
of	O	971-973
recurrent	O	974-983
microdeletion	O	984-997
syndromes	O	998-1007
.	O	1007-1008

Cloning	O	0-7
of	O	8-10
the	O	11-14
Huntington	B	15-25
disease	I	26-33
region	O	34-40
in	O	41-43
yeast	O	44-49
artificial	O	50-60
chromosomes	O	61-72
.	O	72-73

The	O	74-77
gene	O	78-82
responsible	O	83-94
for	O	95-98
Huntington	B	99-109
disease	I	110-117
has	O	118-121
been	O	122-126
localized	O	127-136
to	O	137-139
a	O	140-141
2	O	142-143
.	O	143-144
5	O	145-146
million	O	147-154
base	O	155-159
pair	O	160-164
(	O	165-166
Mb	O	166-168
)	O	168-169
region	O	170-176
between	O	177-184
the	O	185-188
loci	O	189-193
D4S10	O	194-199
and	O	200-203
D4S168	O	204-210
on	O	211-213
the	O	214-217
short	O	218-223
arm	O	224-227
of	O	228-230
chromosome	O	231-241
4	O	242-243
.	O	243-244

As	O	245-247
part	O	248-252
of	O	253-255
a	O	256-257
strategy	O	258-266
to	O	267-269
clone	O	270-275
the	O	276-279
HD	B	280-282
gene	O	283-287
on	O	288-290
the	O	291-294
basis	O	295-300
of	O	301-303
its	O	304-307
chromosomal	O	308-319
location	O	320-328
,	O	328-329
we	O	330-332
isolated	O	333-341
genomic	O	342-349
DNA	O	350-353
from	O	354-358
the	O	359-362
HD	B	363-365
region	O	366-372
as	O	373-375
a	O	376-377
set	O	378-381
of	O	382-384
overlapping	O	385-396
yeast	O	397-402
artificial	O	403-413
chromosome	O	414-424
(	O	425-426
YAC	O	426-429
)	O	429-430
clones	O	431-437
.	O	437-438

Twenty	O	439-445
-	O	445-446
eight	O	446-451
YAC	O	452-455
clones	O	456-462
were	O	463-467
identified	O	468-478
by	O	479-481
screening	O	482-491
human	O	492-497
YAC	O	498-501
libraries	O	502-511
with	O	512-516
twelve	O	517-523
PCR	O	524-527
-	O	527-528
based	O	528-533
sequence	O	534-542
-	O	542-543
tagged	O	543-549
sites	O	550-555
(	O	556-557
STSs	O	557-561
)	O	561-562
from	O	563-567
the	O	568-571
region	O	572-578
.	O	578-579

We	O	580-582
assembled	O	583-592
the	O	593-596
YAC	O	597-600
clones	O	601-607
into	O	608-612
overlapping	O	613-624
sets	O	625-629
by	O	630-632
hybridizing	O	633-644
them	O	645-649
to	O	650-652
a	O	653-654
large	O	655-660
number	O	661-667
of	O	668-670
DNA	O	671-674
probes	O	675-681
from	O	682-686
the	O	687-690
HD	B	691-693
region	O	694-700
,	O	700-701
including	O	702-711
the	O	712-715
STSs	O	716-720
.	O	720-721

In	O	722-724
addition	O	725-733
,	O	733-734
we	O	735-737
isolated	O	738-746
the	O	747-750
ends	O	751-755
of	O	756-758
the	O	759-762
human	O	763-768
DNA	O	769-772
inserts	O	773-780
of	O	781-783
most	O	784-788
of	O	789-791
the	O	792-795
YAC	O	796-799
clones	O	800-806
to	O	807-809
assist	O	810-816
in	O	817-819
the	O	820-823
construction	O	824-836
of	O	837-839
the	O	840-843
contig	O	844-850
.	O	850-851

Although	O	852-860
almost	O	861-867
half	O	868-872
of	O	873-875
the	O	876-879
YACs	O	880-884
appear	O	885-891
to	O	892-894
contain	O	895-902
chimeric	O	903-911
inserts	O	912-919
and	O	920-923
several	O	924-931
contain	O	932-939
internal	O	940-948
deletions	O	949-958
or	O	959-961
other	O	962-967
rearrangements	O	968-982
,	O	982-983
we	O	984-986
were	O	987-991
able	O	992-996
to	O	997-999
obtain	O	1000-1006
over	O	1007-1011
2	O	1012-1013
.	O	1013-1014
2	O	1015-1016
Mb	O	1017-1019
of	O	1020-1022
the	O	1023-1026
HD	B	1027-1029
region	O	1030-1036
in	O	1037-1039
YACs	O	1040-1044
,	O	1044-1045
including	O	1046-1055
one	O	1056-1059
continuous	O	1060-1070
segment	O	1071-1078
of	O	1079-1081
2	O	1082-1083
.	O	1083-1084
0	O	1085-1086
Mb	O	1087-1089
covering	O	1090-1098
the	O	1099-1102
region	O	1103-1109
that	O	1110-1114
most	O	1115-1119
likely	O	1120-1126
contains	O	1127-1135
the	O	1136-1139
HD	B	1140-1142
gene	O	1143-1147
.	O	1147-1148

Ten	O	1149-1152
of	O	1153-1155
the	O	1156-1159
twenty	O	1160-1166
eight	O	1167-1172
YAC	O	1173-1176
clones	O	1177-1183
comprise	O	1184-1192
a	O	1193-1194
minimal	O	1195-1202
set	O	1203-1206
spanning	O	1207-1215
the	O	1216-1219
2	O	1220-1221
.	O	1221-1222
2	O	1223-1224
Mb	O	1225-1227
.	O	1227-1228

These	O	1229-1234
clones	O	1235-1241
provide	O	1242-1249
reagents	O	1250-1258
for	O	1259-1262
the	O	1263-1266
complete	O	1267-1275
characterization	O	1276-1292
of	O	1293-1295
this	O	1296-1300
region	O	1301-1307
of	O	1308-1310
the	O	1311-1314
genome	O	1315-1321
and	O	1322-1325
for	O	1326-1329
the	O	1330-1333
eventual	O	1334-1342
isolation	O	1343-1352
of	O	1353-1355
the	O	1356-1359
HD	B	1360-1362
gene	O	1363-1367
.	O	1367-1368

Three	O	0-5
novel	O	6-11
mutations	O	12-21
in	O	22-24
five	O	25-29
unrelated	O	30-39
subjects	O	40-48
with	O	49-53
hereditary	O	54-64
protein	B	65-72
S	I	73-74
deficiency	I	75-85
type	I	86-90
I	I	91-92
.	O	92-93

A	O	94-95
panel	O	96-101
of	O	102-104
eight	O	105-110
unrelated	O	111-120
subjects	O	121-129
with	O	130-134
inherited	O	135-144
type	B	145-149
I	I	150-151
protein	I	152-159
S	I	160-161
deficiency	I	162-172
was	O	173-176
screened	O	177-185
for	O	186-189
mutations	O	190-199
in	O	200-202
the	O	203-206
PROS1	O	207-212
gene	O	213-217
.	O	217-218

In	O	219-221
five	O	222-226
subjects	O	227-235
an	O	236-238
abnormality	O	239-250
was	O	251-254
found	O	255-260
but	O	261-264
mutations	O	265-274
were	O	275-279
not	O	280-283
detected	O	284-292
in	O	293-295
the	O	296-299
remaining	O	300-309
three	O	310-315
subjects	O	316-324
.	O	324-325

Two	O	326-329
subjects	O	330-338
shared	O	339-345
a	O	346-347
G	O	348-349
-	O	349-350
-	O	349-350
>	O	352-353
A	O	354-355
transition	O	356-366
at	O	367-369
position	O	370-378
+	O	379-380
5	O	381-382
of	O	383-385
the	O	386-389
donor	O	390-395
splice	O	396-402
site	O	403-407
consensus	O	408-417
sequence	O	418-426
of	O	427-429
intron	O	430-436
10	O	437-439
.	O	439-440

Also	O	441-445
in	O	446-448
two	O	449-452
subjects	O	453-461
an	O	462-464
A	O	465-466
-	O	466-467
-	O	466-467
>	O	469-470
T	O	471-472
transversion	O	473-485
was	O	486-489
detected	O	490-498
in	O	499-501
the	O	502-505
stopcodon	O	506-515
of	O	516-518
the	O	519-522
PROS1	O	523-528
gene	O	529-533
;	O	533-534
this	O	535-539
transversion	O	540-552
predicts	O	553-561
a	O	562-563
protein	O	564-571
S	O	572-573
molecule	O	574-582
that	O	583-587
is	O	588-590
extended	O	591-599
by	O	600-602
14	O	603-605
amino	O	606-611
acids	O	612-617
.	O	617-618

The	O	619-622
fifth	O	623-628
subject	O	629-636
was	O	637-640
found	O	641-646
to	O	647-649
possess	O	650-657
two	O	658-661
sequence	O	662-670
abnormalities	O	671-684
.	O	684-685

One	O	686-689
allele	O	690-696
carried	O	697-704
a	O	705-706
G	O	707-708
-	O	708-709
-	O	708-709
>	O	711-712
A	O	713-714
transition	O	715-725
near	O	726-730
the	O	731-734
donor	O	735-740
splice	O	741-747
junction	O	748-756
of	O	757-759
intron	O	760-766
2	O	767-768
,	O	768-769
but	O	770-773
this	O	774-778
abnormality	O	779-790
is	O	791-793
probably	O	794-802
neutral	O	803-810
,	O	810-811
since	O	812-817
it	O	818-820
was	O	821-824
inherited	O	825-834
from	O	835-839
the	O	840-843
parent	O	844-850
with	O	851-855
normal	O	856-862
protein	O	863-870
S	O	871-872
antigen	O	873-880
levels	O	881-887
.	O	887-888

In	O	889-891
the	O	892-895
other	O	896-901
allele	O	902-908
a	O	909-910
single	O	911-917
T	O	918-919
insertion	O	920-929
in	O	930-932
codon	O	933-938
-	O	939-940
25	O	940-942
was	O	943-946
found	O	947-952
.	O	952-953

Analysis	O	954-962
of	O	963-965
platelet	O	966-974
RNA	O	975-978
showed	O	979-985
that	O	986-990
only	O	991-995
the	O	996-999
mRNA	O	1000-1004
with	O	1005-1009
the	O	1010-1013
A	O	1014-1015
-	O	1015-1016
-	O	1015-1016
>	O	1018-1019
T	O	1020-1021
mutation	O	1022-1030
in	O	1031-1033
the	O	1034-1037
stopcodon	O	1038-1047
is	O	1048-1050
present	O	1051-1058
in	O	1059-1061
amounts	O	1062-1069
comparable	O	1070-1080
to	O	1081-1083
wildtype	O	1084-1092
RNA	O	1093-1096
.	O	1096-1097

mRNA	O	1098-1102
from	O	1103-1107
the	O	1108-1111
alleles	O	1112-1119
with	O	1120-1124
the	O	1125-1128
other	O	1129-1134
two	O	1135-1138
mutations	O	1139-1148
was	O	1149-1152
either	O	1153-1159
undetectable	O	1160-1172
or	O	1173-1175
present	O	1176-1183
in	O	1184-1186
greatly	O	1187-1194
reduced	O	1195-1202
amounts	O	1203-1210
.	O	1210-1211

The	O	1212-1215
latter	O	1216-1222
indicates	O	1223-1232
that	O	1233-1237
a	O	1238-1239
mRNA	O	1240-1244
based	O	1245-1250
approach	O	1251-1259
is	O	1260-1262
not	O	1263-1266
feasible	O	1267-1275
for	O	1276-1279
the	O	1280-1283
genetic	O	1284-1291
analysis	O	1292-1300
of	O	1301-1303
protein	B	1304-1311
S	I	1312-1313
deficiency	I	1314-1324
type	I	1325-1329
I	I	1330-1331
.	O	1331-1332
.	O	1331-1332

A	O	0-1
potential	O	2-11
animal	O	12-18
model	O	19-24
for	O	25-28
Lesch	B	29-34
-	I	34-35
Nyhan	I	35-40
syndrome	I	41-49
through	O	50-57
introduction	O	58-70
of	O	71-73
HPRT	O	74-78
mutations	O	79-88
into	O	89-93
mice	O	94-98
.	O	98-99

The	O	100-103
human	O	104-109
Lesch	B	110-115
-	I	115-116
Nyhan	I	116-121
syndrome	I	122-130
is	O	131-133
a	O	134-135
rare	O	136-140
neurological	B	141-153
and	I	154-157
behavioural	I	158-169
disorder	I	170-178
,	O	178-179
affecting	O	180-189
only	O	190-194
males	O	195-200
,	O	200-201
which	O	202-207
is	O	208-210
caused	O	211-217
by	O	218-220
an	O	221-223
inherited	B	224-233
deficiency	I	234-244
in	O	245-247
the	O	248-251
level	O	252-257
of	O	258-260
activity	O	261-269
of	O	270-272
the	O	273-276
purine	O	277-283
salvage	O	284-291
enzyme	O	292-298
hypoxanthine	O	299-311
-	O	311-312
guanosine	O	312-321
phosphoribosyl	O	322-336
transferase	O	337-348
(	O	349-350
HPRT	O	350-354
)	O	354-355
.	O	355-356

How	O	357-360
the	O	361-364
resulting	O	365-374
alterations	O	375-386
in	O	387-389
purine	O	390-396
metabolism	O	397-407
lead	O	408-412
to	O	413-415
the	O	416-419
severe	O	420-426
symptoms	O	427-435
characteristic	O	436-450
of	O	451-453
Lesch	B	454-459
-	I	459-460
Nyhan	I	460-465
patients	O	466-474
is	O	475-477
still	O	478-483
not	O	484-487
understood	O	488-498
.	O	498-499

No	O	500-502
mutations	O	503-512
at	O	513-515
the	O	516-519
Hprt	O	520-524
locus	O	525-530
leading	O	531-538
to	O	539-541
loss	O	542-546
of	O	547-549
activity	O	550-558
have	O	559-563
been	O	564-568
described	O	569-578
in	O	579-581
laboratory	O	582-592
animals	O	593-600
.	O	600-601

To	O	602-604
derive	O	605-611
an	O	612-614
animal	O	615-621
model	O	622-627
for	O	628-631
the	O	632-635
Lesch	B	636-641
-	I	641-642
Nyhan	I	642-647
syndrome	I	648-656
,	O	656-657
we	O	658-660
have	O	661-665
used	O	666-670
cultured	O	671-679
mouse	O	680-685
embryonic	O	686-695
stem	O	696-700
cells	O	701-706
,	O	706-707
mutagenized	O	708-719
by	O	720-722
retroviral	O	723-733
insertion	O	734-743
and	O	744-747
selected	O	748-756
for	O	757-760
loss	O	761-765
of	O	766-768
HPRT	O	769-773
activity	O	774-782
,	O	782-783
to	O	784-786
construct	O	787-796
chimaeric	O	797-806
mice	O	807-811
.	O	811-812

Two	O	813-816
clonal	O	817-823
lines	O	824-829
carrying	O	830-838
different	O	839-848
mutant	O	849-855
Hprt	O	856-860
alleles	O	861-868
have	O	869-873
given	O	874-879
rise	O	880-884
to	O	885-887
germ	O	888-892
cells	O	893-898
in	O	899-901
chimaeras	O	902-911
,	O	911-912
allowing	O	913-921
the	O	922-925
derivation	O	926-936
of	O	937-939
strains	O	940-947
of	O	948-950
mutant	O	951-957
mice	O	958-962
having	O	963-969
the	O	970-973
same	O	974-978
biochemical	O	979-990
defect	O	991-997
as	O	998-1000
Lesch	B	1001-1006
-	I	1006-1007
Nyhan	I	1007-1012
patients	O	1013-1021
.	O	1021-1022

Male	O	1023-1027
mice	O	1028-1032
carrying	O	1033-1041
the	O	1042-1045
mutant	O	1046-1052
alleles	O	1053-1060
are	O	1061-1064
viable	O	1065-1071
and	O	1072-1075
analysis	O	1076-1084
of	O	1085-1087
their	O	1088-1093
cells	O	1094-1099
shows	O	1100-1105
a	O	1106-1107
total	O	1108-1113
lack	O	1114-1118
of	O	1119-1121
HPRT	O	1122-1126
activity	O	1127-1135
.	O	1135-1136
.	O	1135-1136

Duplicational	O	0-13
mutation	O	14-22
at	O	23-25
the	O	26-29
Duchenne	B	30-38
muscular	I	39-47
dystrophy	I	48-57
locus	O	58-63
:	O	63-64
its	O	65-68
frequency	O	69-78
,	O	78-79
distribution	O	80-92
,	O	92-93
origin	O	94-100
,	O	100-101
and	O	102-105
phenotypegenotype	O	106-123
correlation	O	124-135
.	O	135-136

Partial	O	137-144
gene	O	145-149
deletion	O	150-158
is	O	159-161
the	O	162-165
major	O	166-171
cause	O	172-177
of	O	178-180
mutation	O	181-189
leading	O	190-197
to	O	198-200
Duchenne	B	201-209
muscular	I	210-218
dystrophy	I	219-228
(	O	229-230
DMD	B	230-233
)	O	233-234
and	O	235-238
Becker	B	239-245
muscular	I	246-254
dystrophy	I	255-264
(	O	265-266
BMD	B	266-269
)	O	269-270
.	O	270-271

Partial	O	272-279
gene	O	280-284
duplication	O	285-296
has	O	297-300
also	O	301-305
been	O	306-310
recognized	O	311-321
in	O	322-324
a	O	325-326
few	O	327-330
cases	O	331-336
.	O	336-337

We	O	338-340
have	O	341-345
conducted	O	346-355
a	O	356-357
survey	O	358-364
for	O	365-368
duplication	O	369-380
in	O	381-383
72	O	384-386
unrelated	O	387-396
nondeletion	O	397-408
patients	O	409-417
,	O	417-418
analyzed	O	419-427
by	O	428-430
Southern	O	431-439
blot	O	440-444
hybridization	O	445-458
with	O	459-463
clones	O	464-470
representing	O	471-483
the	O	484-487
entire	O	488-494
DMD	B	495-498
cDNA	O	499-503
.	O	503-504

With	O	505-509
careful	O	510-517
quantitative	O	518-530
analysis	O	531-539
of	O	540-542
hybridization	O	543-556
band	O	557-561
intensity	O	562-571
,	O	571-572
10	O	573-575
cases	O	576-581
were	O	582-586
found	O	587-592
to	O	593-595
carry	O	596-601
a	O	602-603
duplication	O	604-615
of	O	616-618
part	O	619-623
of	O	624-626
the	O	627-630
gene	O	631-635
,	O	635-636
a	O	637-638
frequency	O	639-648
of	O	649-651
14	O	652-654
%	O	654-655
for	O	656-659
nondeletion	O	660-671
cases	O	672-677
(	O	678-679
10	O	679-681
/	O	681-682
72	O	682-684
)	O	684-685
,	O	685-686
or	O	687-689
6	O	690-691
%	O	691-692
for	O	693-696
all	O	697-700
cases	O	701-706
(	O	707-708
10	O	708-710
/	O	710-711
181	O	711-714
)	O	714-715
.	O	715-716

The	O	717-720
extent	O	721-727
of	O	728-730
these	O	731-736
duplications	O	737-749
has	O	750-753
been	O	754-758
characterized	O	759-772
according	O	773-782
to	O	783-785
the	O	786-789
published	O	790-799
exon	O	800-804
-	O	804-805
containing	O	805-815
HindIII	O	816-823
fragment	O	824-832
map	O	833-836
,	O	836-837
and	O	838-841
in	O	842-844
six	O	845-848
of	O	849-851
the	O	852-855
10	O	856-858
duplications	O	859-871
a	O	872-873
novel	O	874-879
restriction	O	880-891
fragment	O	892-900
that	O	901-905
spanned	O	906-913
the	O	914-917
duplication	O	918-929
junction	O	930-938
was	O	939-942
detected	O	943-951
.	O	951-952

The	O	953-956
resulting	O	957-966
translational	O	967-980
reading	O	981-988
frame	O	989-994
of	O	995-997
mRNA	O	998-1002
has	O	1003-1006
been	O	1007-1011
predicted	O	1012-1021
for	O	1022-1025
nine	O	1026-1030
duplications	O	1031-1043
.	O	1043-1044

A	O	1045-1046
shift	O	1047-1052
of	O	1053-1055
the	O	1056-1059
reading	O	1060-1067
frame	O	1068-1073
was	O	1074-1077
predicted	O	1078-1087
in	O	1088-1090
four	O	1091-1095
of	O	1096-1098
the	O	1099-1102
six	O	1103-1106
DMD	B	1107-1110
cases	O	1111-1116
and	O	1117-1120
in	O	1121-1123
one	O	1124-1127
of	O	1128-1130
the	O	1131-1134
two	O	1135-1138
intermediate	O	1139-1151
cases	O	1152-1157
,	O	1157-1158
while	O	1159-1164
the	O	1165-1168
reading	O	1169-1176
frame	O	1177-1182
remained	O	1183-1191
uninterrupted	O	1192-1205
in	O	1206-1208
both	O	1209-1213
BMD	B	1214-1217
cases	O	1218-1223
.	O	1223-1224

RFLP	O	1225-1229
and	O	1230-1233
quantitative	O	1234-1246
Southern	O	1247-1255
blot	O	1256-1260
analyses	O	1261-1269
revealed	O	1270-1278
a	O	1279-1280
grandpaternal	O	1281-1294
origin	O	1295-1301
of	O	1302-1304
duplication	O	1305-1316
in	O	1317-1319
four	O	1320-1324
families	O	1325-1333
and	O	1334-1337
grandmaternal	O	1338-1351
origin	O	1352-1358
in	O	1359-1361
one	O	1362-1365
family	O	1366-1372
.	O	1372-1373

In	O	1374-1376
all	O	1377-1380
five	O	1381-1385
families	O	1386-1394
,	O	1394-1395
the	O	1396-1399
duplication	O	1400-1411
was	O	1412-1415
found	O	1416-1421
to	O	1422-1424
originate	O	1425-1434
from	O	1435-1439
a	O	1440-1441
single	O	1442-1448
X	O	1449-1450
chromosome	O	1451-1461
.	O	1461-1462

Unequal	O	1463-1470
sister	O	1471-1477
-	O	1477-1478
chromatid	O	1478-1487
exchange	O	1488-1496
is	O	1497-1499
proposed	O	1500-1508
to	O	1509-1511
be	O	1512-1514
the	O	1515-1518
mechanism	O	1519-1528
for	O	1529-1532
the	O	1533-1536
formation	O	1537-1546
of	O	1547-1549
these	O	1550-1555
duplications	O	1556-1568
.	O	1568-1569
.	O	1568-1569

Molecular	O	0-9
evidence	O	10-18
for	O	19-22
new	O	23-26
mutation	O	27-35
at	O	36-38
the	O	39-42
hprt	O	43-47
locus	O	48-53
in	O	54-56
Lesch	B	57-62
-	I	62-63
Nyhan	I	63-68
patients	O	69-77
.	O	77-78

Hypoxanthine	O	79-91
-	O	91-92
guanine	O	92-99
phosphoribosyltransferase	O	100-125
(	O	126-127
HPRT	O	127-131
;	O	131-132
EC2	O	133-136
.	O	136-137
4	O	138-139
.	O	139-140
2	O	141-142
.	O	142-143
8	O	144-145
)	O	145-146
,	O	146-147
which	O	148-153
functions	O	154-163
in	O	164-166
the	O	167-170
metabolic	O	171-180
salvage	O	181-188
of	O	189-191
purines	O	192-199
,	O	199-200
is	O	201-203
encoded	O	204-211
by	O	212-214
an	O	215-217
X	O	218-219
-	O	219-220
linked	O	220-226
gene	O	227-231
in	O	232-234
man	O	235-238
.	O	238-239

Partial	O	240-247
HPRT	B	248-252
deficiencies	I	253-265
are	O	266-269
associated	O	270-280
with	O	281-285
gouty	B	286-291
arthritis	I	292-301
,	O	301-302
while	O	303-308
absence	O	309-316
of	O	317-319
activity	O	320-328
results	O	329-336
in	O	337-339
Lesch	B	340-345
-	I	345-346
Nyhan	I	346-351
syndrome	I	352-360
(	O	361-362
L	B	362-363
-	I	363-364
N	I	364-365
)	O	365-366
.	O	366-367

L	B	368-369
-	I	369-370
N	I	370-371
patients	O	372-380
fail	O	381-385
to	O	386-388
reproduce	O	389-398
and	O	399-402
the	O	403-406
heterozygous	O	407-419
state	O	420-425
appears	O	426-433
to	O	434-436
confer	O	437-443
no	O	444-446
selective	O	447-456
advantage	O	457-466
.	O	466-467

Thus	O	468-472
,	O	472-473
Haldanes	O	474-482
principle	O	483-492
predicts	O	493-501
that	O	502-506
new	O	507-510
mutations	O	511-520
at	O	521-523
the	O	524-527
hprt	O	528-532
locus	O	533-538
must	O	539-543
occur	O	544-549
frequently	O	550-560
in	O	561-563
order	O	564-569
for	O	570-573
L	B	574-575
-	I	575-576
N	I	576-577
syndrome	I	578-586
to	O	587-589
be	O	590-592
maintained	O	593-603
in	O	604-606
the	O	607-610
population	O	611-621
.	O	621-622

This	O	623-627
constant	O	628-636
introduction	O	637-649
of	O	650-652
new	O	653-656
mutations	O	657-666
would	O	667-672
be	O	673-675
expected	O	676-684
to	O	685-687
result	O	688-694
in	O	695-697
a	O	698-699
heterogeneous	O	700-713
collection	O	714-724
of	O	725-727
genetic	B	728-735
lesions	I	736-743
,	O	743-744
some	O	745-749
of	O	750-752
which	O	753-758
may	O	759-762
be	O	763-765
novel	O	766-771
.	O	771-772

As	O	773-775
we	O	776-778
report	O	779-785
here	O	786-790
,	O	790-791
the	O	792-795
mutations	O	796-805
in	O	806-808
the	O	809-812
hprt	O	813-817
gene	O	818-822
of	O	823-825
seven	O	826-831
L	B	832-833
-	I	833-834
N	I	834-835
patients	O	836-844
,	O	844-845
selected	O	846-854
from	O	855-859
an	O	860-862
initial	O	863-870
survey	O	871-877
of	O	878-880
28	O	881-883
patients	O	884-892
,	O	892-893
have	O	894-898
been	O	899-903
characterized	O	904-917
and	O	918-921
all	O	922-925
were	O	926-930
found	O	931-936
to	O	937-939
be	O	940-942
distinctly	O	943-953
different	O	954-963
,	O	963-964
as	O	965-967
predicted	O	968-977
.	O	977-978

The	O	979-982
origin	O	983-989
of	O	990-992
one	O	993-996
unusual	O	997-1004
mutation	O	1005-1013
has	O	1014-1017
been	O	1018-1022
identified	O	1023-1033
by	O	1034-1036
analysis	O	1037-1045
of	O	1046-1048
DNA	O	1049-1052
from	O	1053-1057
four	O	1058-1062
generations	O	1063-1074
of	O	1075-1077
family	O	1078-1084
members	O	1085-1092
.	O	1092-1093

Further	O	1094-1101
molecular	O	1102-1111
analysis	O	1112-1120
of	O	1121-1123
the	O	1124-1127
origin	O	1128-1134
of	O	1135-1137
new	O	1138-1141
mutations	O	1142-1151
at	O	1152-1154
the	O	1155-1158
hprt	O	1159-1163
locus	O	1164-1169
should	O	1170-1176
aid	O	1177-1180
in	O	1181-1183
resolving	O	1184-1193
the	O	1194-1197
issue	O	1198-1203
of	O	1204-1206
an	O	1207-1209
apparent	O	1210-1218
difference	O	1219-1229
in	O	1230-1232
the	O	1233-1236
frequency	O	1237-1246
of	O	1247-1249
hprt	O	1250-1254
mutations	O	1255-1264
in	O	1265-1267
males	O	1268-1273
and	O	1274-1277
females	O	1278-1285

The	O	0-3
mapping	O	4-11
of	O	12-14
a	O	15-16
cDNA	O	17-21
from	O	22-26
the	O	27-30
human	O	31-36
X	B	37-38
-	I	38-39
linked	I	39-45
Duchenne	I	46-54
muscular	I	55-63
dystrophy	I	64-73
gene	O	74-78
to	O	79-81
the	O	82-85
mouse	O	86-91
X	O	92-93
chromosome	O	94-104
.	O	104-105

The	O	106-109
recent	O	110-116
discovery	O	117-126
of	O	127-129
sequences	O	130-139
at	O	140-142
the	O	143-146
site	O	147-151
of	O	152-154
the	O	155-158
Duchenne	B	159-167
muscular	I	168-176
dystrophy	I	177-186
(	O	187-188
DMD	B	188-191
)	O	191-192
gene	O	193-197
in	O	198-200
humans	O	201-207
has	O	208-211
opened	O	212-218
up	O	219-221
the	O	222-225
possibility	O	226-237
of	O	238-240
a	O	241-242
detailed	O	243-251
molecular	O	252-261
analysis	O	262-270
of	O	271-273
the	O	274-277
genes	O	278-283
in	O	284-286
humans	O	287-293
and	O	294-297
in	O	298-300
related	O	301-308
mammalian	O	309-318
species	O	319-326
.	O	326-327

Until	O	328-333
relatively	O	334-344
recently	O	345-353
,	O	353-354
there	O	355-360
was	O	361-364
no	O	365-367
obvious	O	368-375
mouse	O	376-381
model	O	382-387
of	O	388-390
this	O	391-395
genetic	B	396-403
disease	I	404-411
for	O	412-415
the	O	416-419
development	O	420-431
of	O	432-434
therapeutic	O	435-446
strategies	O	447-457
.	O	457-458

The	O	459-462
identification	O	463-477
of	O	478-480
a	O	481-482
mouse	O	483-488
X	O	489-490
-	O	490-491
linked	O	491-497
mutant	O	498-504
showing	O	505-512
muscular	B	513-521
dystrophy	I	522-531
,	O	531-532
mdx	O	533-536
,	O	536-537
has	O	538-541
provided	O	542-550
a	O	551-552
candidate	O	553-562
mouse	O	563-568
genetic	O	569-576
homologue	O	577-586
to	O	587-589
the	O	590-593
DMD	B	594-597
locus	O	598-603
;	O	603-604
the	O	605-608
relatively	O	609-619
mild	O	620-624
pathological	O	625-637
features	O	638-646
of	O	647-649
mdx	O	650-653
suggest	O	654-661
it	O	662-664
may	O	665-668
have	O	669-673
more	O	674-678
in	O	679-681
common	O	682-688
with	O	689-693
mutations	O	694-703
of	O	704-706
the	O	707-710
Becker	B	711-717
muscular	I	718-726
dystrophy	I	727-736
type	O	737-741
at	O	742-744
the	O	745-748
same	O	749-753
human	O	754-759
locus	O	760-765
,	O	765-766
however	O	767-774
.	O	774-775

But	O	776-779
the	O	780-783
close	O	784-789
genetic	O	790-797
linkage	O	798-805
of	O	806-808
mdx	O	809-812
to	O	813-815
G6PD	O	816-820
and	O	821-824
Hprt	O	825-829
on	O	830-832
the	O	833-836
mouse	O	837-842
X	O	843-844
chromosome	O	845-855
,	O	855-856
coupled	O	857-864
with	O	865-869
its	O	870-873
comparatively	O	874-887
mild	O	888-892
pathology	O	893-902
,	O	902-903
have	O	904-908
suggested	O	909-918
that	O	919-923
the	O	924-927
mdx	O	928-931
mutation	O	932-940
may	O	941-944
instead	O	945-952
correspond	O	953-963
to	O	964-966
Emery	B	967-972
Dreifuss	I	973-981
muscular	I	982-990
dystrophy	I	991-1000
which	O	1001-1006
itself	O	1007-1013
is	O	1014-1016
closely	O	1017-1024
linked	O	1025-1031
to	O	1032-1034
DNA	O	1035-1038
markers	O	1039-1046
at	O	1047-1049
Xq28	O	1050-1054
-	O	1054-1055
qter	O	1055-1059
in	O	1060-1062
the	O	1063-1066
region	O	1067-1073
of	O	1074-1076
G6PD	O	1077-1081
on	O	1082-1084
the	O	1085-1088
human	O	1089-1094
X	O	1095-1096
chromosome	O	1097-1107
.	O	1107-1108

Using	O	1109-1114
an	O	1115-1117
interspecific	O	1118-1131
mouse	O	1132-1137
domesticus	O	1138-1148
/	O	1148-1149
spretus	O	1149-1156
cross	O	1157-1162
,	O	1162-1163
segregating	O	1164-1175
for	O	1176-1179
a	O	1180-1181
variety	O	1182-1189
of	O	1190-1192
markers	O	1193-1200
on	O	1201-1203
the	O	1204-1207
mouse	O	1208-1213
X	O	1214-1215
chromosome	O	1216-1226
,	O	1226-1227
we	O	1228-1230
have	O	1231-1235
positioned	O	1236-1246
on	O	1247-1249
the	O	1250-1253
mouse	O	1254-1259
X	O	1260-1261
chromosome	O	1262-1272
sequences	O	1273-1282
homologous	O	1283-1293
to	O	1294-1296
a	O	1297-1298
DMD	B	1299-1302
cDNA	O	1303-1307
clone	O	1308-1313
.	O	1313-1314

These	O	1315-1320
sequences	O	1321-1330
map	O	1331-1334
provocatively	O	1335-1348
close	O	1349-1354
to	O	1355-1357
the	O	1358-1361
mdx	O	1362-1365
mutation	O	1366-1374
and	O	1375-1378
unexpectedly	O	1379-1391
distant	O	1392-1399
from	O	1400-1404
sparse	O	1405-1411
fur	O	1412-1415
,	O	1415-1416
spf	O	1417-1420
,	O	1420-1421
the	O	1422-1425
mouse	O	1426-1431
homologue	O	1432-1441
of	O	1442-1444
OTC	O	1445-1448
(	O	1449-1450
ornithine	O	1450-1459
transcarbamylase	O	1460-1476
)	O	1476-1477
which	O	1478-1483
is	O	1484-1486
closely	O	1487-1494
linked	O	1495-1501
to	O	1502-1504
DMD	B	1505-1508
on	O	1509-1511
the	O	1512-1515
human	O	1516-1521
X	O	1522-1523
chromosome	O	1524-1534
.	O	1534-1535
.	O	1534-1535

Identification	O	0-14
of	O	15-17
the	O	18-21
mutation	O	22-30
in	O	31-33
the	O	34-37
alkaptonuria	B	38-50
mouse	O	51-56
model	O	57-62
.	O	62-63

Alkaptonuria	B	64-76
(	O	77-78
aku	B	78-81
)	O	81-82
,	O	82-83
an	O	84-86
inborn	B	87-93
error	I	94-99
of	I	100-102
metabolism	I	103-113
caused	O	114-120
by	O	121-123
the	O	124-127
loss	O	128-132
of	O	133-135
homogentisate	O	136-149
1	O	150-151
,	O	151-152
2	O	153-154
-	O	154-155
dioxygenase	O	155-166
(	O	167-168
HGD	O	168-171
)	O	171-172
,	O	172-173
has	O	174-177
been	O	178-182
described	O	183-192
in	O	193-195
a	O	196-197
mouse	O	198-203
model	O	204-209
created	O	210-217
by	O	218-220
ethylnitrosourea	O	221-237
mutagenesis	O	238-249
but	O	250-253
the	O	254-257
mutation	O	258-266
in	O	267-269
these	O	270-275
mice	O	276-280
has	O	281-284
not	O	285-288
previously	O	289-299
been	O	300-304
identified	O	305-315
.	O	315-316

We	O	317-319
used	O	320-324
RT	O	325-327
-	O	327-328
PCR	O	328-331
to	O	332-334
amplify	O	335-342
the	O	343-346
Hgd	O	347-350
cDNA	O	351-355
from	O	356-360
Hgd	O	361-364
(	O	365-366
aku	O	366-369
)	O	369-370
/	O	370-371
Hgd	O	371-374
(	O	375-376
aku	O	376-379
)	O	379-380
mice	O	381-385
.	O	385-386

Two	O	387-390
products	O	391-399
shorter	O	400-407
than	O	408-412
the	O	413-416
wild	O	417-421
-	O	421-422
type	O	422-426
product	O	427-434
were	O	435-439
amplified	O	440-449
.	O	449-450

Restriction	O	451-462
mapping	O	463-470
and	O	471-474
DNA	O	475-478
sequencing	O	479-489
were	O	490-494
then	O	495-499
used	O	500-504
to	O	505-507
identify	O	508-516
the	O	517-520
Hgd	O	521-524
(	O	525-526
aku	O	526-529
)	O	529-530
mouse	O	531-536
mutation	O	537-545
,	O	545-546
found	O	547-552
to	O	553-555
be	O	556-558
a	O	559-560
single	O	561-567
base	O	568-572
change	O	573-579
in	O	580-582
a	O	583-584
splice	O	585-591
donor	O	592-597
consensus	O	598-607
sequence	O	608-616
,	O	616-617
causing	O	618-625
exon	O	626-630
skipping	O	631-639
and	O	640-643
frame	O	644-649
-	O	649-650
shifted	O	650-657
products	O	658-666
.	O	666-667

This	O	668-672
base	O	673-677
change	O	678-684
allowed	O	685-692
us	O	693-695
to	O	696-698
create	O	699-705
a	O	706-707
non	O	708-711
-	O	711-712
radioactive	O	712-723
genotyping	O	724-734
assay	O	735-740
for	O	741-744
this	O	745-749
allele	O	750-756
.	O	756-757

Common	O	0-6
sequence	O	7-15
motifs	O	16-22
at	O	23-25
the	O	26-29
rearrangement	O	30-43
sites	O	44-49
of	O	50-52
a	O	53-54
constitutional	O	55-69
X	O	70-71
/	O	71-72
autosome	O	72-80
translocation	O	81-94
and	O	95-98
associated	O	99-109
deletion	O	110-118
.	O	118-119

Reciprocal	O	120-130
chromosome	O	131-141
translocations	O	142-156
are	O	157-160
common	O	161-167
de	O	168-170
novo	O	171-175
rearrangements	O	176-190
that	O	191-195
occur	O	196-201
randomly	O	202-210
throughout	O	211-221
the	O	222-225
human	O	226-231
genome	O	232-238
.	O	238-239

To	O	240-242
learn	O	243-248
about	O	249-254
causative	O	255-264
mechanisms	O	265-275
,	O	275-276
we	O	277-279
have	O	280-284
cloned	O	285-291
and	O	292-295
sequenced	O	296-305
the	O	306-309
breakpoints	O	310-321
of	O	322-324
a	O	325-326
cytologically	O	327-340
balanced	O	341-349
constitutional	O	350-364
reciprocal	O	365-375
translocation	O	376-389
,	O	389-390
t	O	391-392
(	O	393-394
X	O	394-395
;	O	395-396
4	O	397-398
)	O	398-399
(	O	400-401
p21	O	401-404
.	O	404-405

2	O	406-407
;	O	407-408
q31	O	409-412
.	O	412-413

22	O	414-416
)	O	416-417
,	O	417-418
present	O	419-426
in	O	427-429
a	O	430-431
girl	O	432-436
with	O	437-441
Duchenne	B	442-450
muscular	I	451-459
dystrophy	I	460-469
(	O	470-471
DMD	B	471-474
)	O	474-475
.	O	475-476

Physical	O	477-485
mapping	O	486-493
of	O	494-496
the	O	497-500
derivative	O	501-511
chromosomes	O	512-523
,	O	523-524
after	O	525-530
their	O	531-536
separation	O	537-547
in	O	548-550
somatic	O	551-558
cell	O	559-563
hybrids	O	564-571
,	O	571-572
reveals	O	573-580
that	O	581-585
the	O	586-589
translocation	O	590-603
disrupts	O	604-612
the	O	613-616
DMD	B	617-620
gene	O	621-625
in	O	626-628
Xp21	O	629-633
within	O	634-640
the	O	641-644
18	O	645-647
-	O	647-648
kb	O	648-650
intron	O	651-657
16	O	658-660
.	O	660-661

Restriction	O	662-673
mapping	O	674-681
and	O	682-685
sequencing	O	686-696
of	O	697-699
clones	O	700-706
that	O	707-711
span	O	712-716
both	O	717-721
translocation	O	722-735
breakpoints	O	736-747
as	O	748-750
well	O	751-755
as	O	756-758
the	O	759-762
corresponding	O	763-776
normal	O	777-783
regions	O	784-791
indicate	O	792-800
the	O	801-804
loss	O	805-809
of	O	810-812
approximately	O	813-826
5	O	827-828
kb	O	829-831
in	O	832-834
the	O	835-838
formation	O	839-848
of	O	849-851
the	O	852-855
derivative	O	856-866
X	O	867-868
chromosome	O	869-879
,	O	879-880
with	O	881-885
4	O	886-887
-	O	887-888
6	O	888-889
bp	O	890-892
deleted	O	893-900
from	O	901-905
chromosome	O	906-916
4	O	917-918
.	O	918-919
RFLP	O	920-924
and	O	925-928
Southern	O	929-937
analyses	O	938-946
indicate	O	947-955
that	O	956-960
the	O	961-964
de	O	965-967
novo	O	968-972
translocation	O	973-986
is	O	987-989
a	O	990-991
paternal	O	992-1000
origin	O	1001-1007
and	O	1008-1011
that	O	1012-1016
the	O	1017-1020
fathers	O	1021-1028
X	O	1029-1030
chromosome	O	1031-1041
contains	O	1042-1050
the	O	1051-1054
DNA	O	1055-1058
that	O	1059-1063
is	O	1064-1066
deleted	O	1067-1074
in	O	1075-1077
the	O	1078-1081
derivative	O	1082-1092
X	O	1093-1094
.	O	1094-1095

Most	O	1096-1100
likely	O	1101-1107
,	O	1107-1108
deletion	O	1109-1117
and	O	1118-1121
translation	O	1122-1133
arose	O	1134-1139
simultaneously	O	1140-1154
from	O	1155-1159
a	O	1160-1161
complex	O	1162-1169
rearrangement	O	1170-1183
event	O	1184-1189
that	O	1190-1194
involves	O	1195-1203
three	O	1204-1209
chromosomal	O	1210-1221
breakpoints	O	1222-1233
.	O	1233-1234

Short	O	1235-1240
regions	O	1241-1248
of	O	1249-1251
sequence	O	1252-1260
homology	O	1261-1269
were	O	1270-1274
present	O	1275-1282
at	O	1283-1285
the	O	1286-1289
three	O	1290-1295
sites	O	1296-1301
.	O	1301-1302

A	O	1303-1304
5	O	1305-1306
-	O	1306-1307
bp	O	1307-1309
sequence	O	1310-1318
,	O	1318-1319
GGAAT	O	1320-1325
,	O	1325-1326
found	O	1327-1332
exactly	O	1333-1340
at	O	1341-1343
the	O	1344-1347
translocation	O	1348-1361
breakpoints	O	1362-1373
on	O	1374-1376
both	O	1377-1381
normal	O	1382-1388
chromosomes	O	1389-1400
X	O	1401-1402
and	O	1403-1406
4	O	1407-1408
,	O	1408-1409
has	O	1410-1413
been	O	1414-1418
preserved	O	1419-1428
only	O	1429-1433
on	O	1434-1436
the	O	1437-1440
der	O	1441-1444
(	O	1445-1446
4	O	1446-1447
)	O	1447-1448
chromosome	O	1449-1459
.	O	1459-1460

It	O	1461-1463
is	O	1464-1466
likely	O	1467-1473
that	O	1474-1478
the	O	1479-1482
X	O	1483-1484
-	O	1484-1485
derived	O	1485-1492
sequence	O	1493-1501
GGAATCA	O	1502-1509
has	O	1510-1513
been	O	1514-1518
lost	O	1519-1523
in	O	1524-1526
the	O	1527-1530
formation	O	1531-1540
of	O	1541-1543
the	O	1544-1547
der	O	1548-1551
(	O	1552-1553
X	O	1553-1554
)	O	1554-1555
chromosome	O	1556-1566
,	O	1566-1567
as	O	1568-1570
it	O	1571-1573
matches	O	1574-1581
an	O	1582-1584
inverted	O	1585-1593
GAATCA	O	1594-1600
sequence	O	1601-1609
present	O	1610-1617
on	O	1618-1620
the	O	1621-1624
opposite	O	1625-1633
strand	O	1634-1640
exactly	O	1641-1648
at	O	1649-1651
the	O	1652-1655
other	O	1656-1661
end	O	1662-1665
of	O	1666-1668
the	O	1669-1672
deleted	O	1673-1680
5	O	1681-1682
-	O	1682-1683
kb	O	1683-1685
fragment	O	1686-1694
.	O	1694-1695

The	O	0-3
human	O	4-9
factor	O	10-16
IX	O	17-19
gene	O	20-24
as	O	25-27
germline	O	28-36
mutagen	O	37-44
test	O	45-49
:	O	49-50
samples	O	51-58
from	O	59-63
Mainland	O	64-72
China	O	73-78
have	O	79-83
the	O	84-87
putatively	O	88-98
endogenous	O	99-109
pattern	O	110-117
of	O	118-120
mutation	O	121-129
.	O	129-130

Germline	O	131-139
mutations	O	140-149
are	O	150-153
the	O	154-157
major	O	158-163
source	O	164-170
of	O	171-173
genetic	O	174-181
variation	O	182-191
that	O	192-196
allows	O	197-203
a	O	204-205
species	O	206-213
to	O	214-216
evolve	O	217-223
over	O	224-228
time	O	229-233
but	O	234-237
at	O	238-240
the	O	241-244
cost	O	245-249
of	O	250-252
Mendelian	B	253-262
disease	I	263-270
and	O	271-274
genetic	O	275-282
predisposition	O	283-297
to	O	298-300
multifactorial	B	301-315
diseases	I	316-324
.	O	324-325

Previous	O	326-334
analyses	O	335-343
have	O	344-348
revealed	O	349-357
that	O	358-362
the	O	363-366
pattern	O	367-374
of	O	375-377
germline	O	378-386
mutations	O	387-396
in	O	397-399
the	O	400-403
factor	O	404-410
IX	O	411-413
gene	O	414-418
(	O	419-420
F9	O	420-422
)	O	422-423
is	O	424-426
similar	O	427-434
among	O	435-440
a	O	441-442
variety	O	443-450
of	O	451-453
ethnically	O	454-464
and	O	465-468
geographically	O	469-483
diverse	O	484-491
populations	O	492-503
and	O	504-507
compatible	O	508-518
with	O	519-523
the	O	524-527
ancient	O	528-535
pattern	O	536-543
that	O	544-548
has	O	549-552
shaped	O	553-559
the	O	560-563
mammalian	O	564-573
genome	O	574-580
.	O	580-581

Here	O	582-586
,	O	586-587
we	O	588-590
compare	O	591-598
the	O	599-602
pattern	O	603-610
of	O	611-613
germline	O	614-622
mutation	O	623-631
in	O	632-634
a	O	635-636
population	O	637-647
of	O	648-650
hemophilia	B	651-661
B	I	662-663
patients	O	664-672
from	O	673-677
Mainland	O	678-686
China	O	687-692
(	O	693-694
n	O	694-695
=	O	696-697
66	O	698-700
)	O	700-701
to	O	702-704
that	O	705-709
in	O	710-712
U	O	713-714
.	O	714-715
S	O	716-717
.	O	717-718
Caucasians	O	719-729
,	O	729-730
Blacks	O	731-737
,	O	737-738
and	O	739-742
Mexican	O	743-750
Hispanics	O	751-760
and	O	761-764
stratify	O	765-773
by	O	774-776
disease	O	777-784
severity	O	785-793
and	O	794-797
ethnicity	O	798-807
.	O	807-808

The	O	809-812
similar	O	813-820
pattern	O	821-828
of	O	829-831
germline	O	832-840
mutation	O	841-849
in	O	850-852
all	O	853-856
ethnic	O	857-863
groups	O	864-870
studied	O	871-878
to	O	879-881
date	O	882-886
provides	O	887-895
additional	O	896-906
data	O	907-911
compatible	O	912-922
with	O	923-927
the	O	928-931
inference	O	932-941
that	O	942-946
endogenous	O	947-957
processes	O	958-967
predominate	O	968-979
in	O	980-982
germline	O	983-991
mutations	O	992-1001
.	O	1001-1002

Phenotype	O	0-9
heterogeneity	O	10-23
among	O	24-29
hemizygotes	O	30-41
in	O	42-44
a	O	45-46
family	O	47-53
biochemically	O	54-67
screened	O	68-76
for	O	77-80
adrenoleukodystrophy	B	81-101
.	O	101-102

We	O	103-105
report	O	106-112
on	O	113-115
two	O	116-119
clinically	O	120-130
,	O	130-131
neurologically	O	132-146
normal	O	147-153
relatives	O	154-163
of	O	164-166
a	O	167-168
boy	O	169-172
affected	O	173-181
by	O	182-184
adrenoleukodystrophy	B	185-205
(	O	206-207
ALD	B	207-210
)	O	210-211
;	O	211-212
they	O	213-217
were	O	218-222
found	O	223-228
repeatedly	O	229-239
to	O	240-242
have	O	243-247
the	O	248-251
biochemical	O	252-263
defect	O	264-270
of	O	271-273
an	O	274-276
ALD	B	277-280
hemizygote	O	281-291
.	O	291-292

The	O	293-296
assay	O	297-302
consisted	O	303-312
in	O	313-315
the	O	316-319
determination	O	320-333
of	O	334-336
very	O	337-341
-	O	341-342
long	O	342-346
-	O	341-342
chain	O	347-352
fatty	O	353-358
acids	O	359-364
in	O	365-367
lyophilized	O	368-379
and	O	380-383
reconstituted	O	384-397
plasma	O	398-404
.	O	404-405

While	O	406-411
no	O	412-414
evidence	O	415-423
of	O	424-426
neurologic	B	427-437
disease	I	438-445
(	O	446-447
leukodystrophy	B	447-461
or	O	462-464
myeloneuropathy	B	465-480
)	O	480-481
was	O	482-485
present	O	486-493
in	O	494-496
these	O	497-502
hemizygotes	O	503-514
,	O	514-515
adrenocortical	B	516-530
insufficiency	I	531-544
provoking	O	545-554
compensatory	O	555-567
high	O	568-572
ACTH	O	573-577
release	O	578-585
was	O	586-589
found	O	590-595
in	O	596-598
both	O	599-603
.	O	603-604

These	O	605-610
findings	O	611-619
should	O	620-626
be	O	627-629
taken	O	630-635
into	O	636-640
consideration	O	641-654
when	O	655-659
counseling	O	660-670
families	O	671-679
in	O	680-682
which	O	683-688
cases	O	689-694
with	O	695-699
clinically	O	700-710
expressed	O	711-720
ALD	B	721-724
are	O	725-728
represented	O	729-740
in	O	741-743
several	O	744-751
generations	O	752-763
.	O	763-764
.	O	763-764

Novel	O	0-5
mutations	O	6-15
of	O	16-18
the	O	19-22
ATP7B	O	23-28
gene	O	29-33
in	O	34-36
Japanese	O	37-45
patients	O	46-54
with	O	55-59
Wilson	B	60-66
disease	I	67-74
.	O	74-75

Wilson	B	76-82
disease	I	83-90
(	O	91-92
WD	B	92-94
)	O	94-95
is	O	96-98
an	O	99-101
autosomal	B	102-111
recessive	I	112-121
disorder	I	122-130
characterized	O	131-144
by	O	145-147
copper	O	148-154
accumulation	O	155-167
in	O	168-170
the	O	171-174
liver	O	175-180
,	O	180-181
brain	O	182-187
,	O	187-188
kidneys	O	189-196
,	O	196-197
and	O	198-201
corneas	O	202-209
,	O	209-210
and	O	211-214
culminating	O	215-226
in	O	227-229
copper	O	230-236
toxication	O	237-247
in	O	248-250
these	O	251-256
organs	O	257-263
.	O	263-264

In	O	265-267
this	O	268-272
study	O	273-278
,	O	278-279
we	O	280-282
analyzed	O	283-291
mutations	O	292-301
of	O	302-304
the	O	305-308
responsible	O	309-320
gene	O	321-325
,	O	325-326
ATP7B	O	327-332
,	O	332-333
in	O	334-336
four	O	337-341
Japanese	O	342-350
patients	O	351-359
with	O	360-364
WD	B	365-367
.	O	367-368

By	O	369-371
direct	O	372-378
sequencing	O	379-389
,	O	389-390
we	O	391-393
identified	O	394-404
five	O	405-409
mutations	O	410-419
,	O	419-420
of	O	421-423
which	O	424-429
two	O	430-433
were	O	434-438
novel	O	439-444
,	O	444-445
and	O	446-449
16	O	450-452
polymorphisms	O	453-466
,	O	466-467
of	O	468-470
which	O	471-476
6	O	477-478
were	O	479-483
novel	O	484-489
.	O	489-490

The	O	491-494
mutations	O	495-504
2871delC	O	505-513
and	O	514-517
2513delA	O	518-526
shift	O	527-532
the	O	533-536
reading	O	537-544
frame	O	545-550
so	O	551-553
that	O	554-558
truncated	O	559-568
abnormal	O	569-577
protein	O	578-585
is	O	586-588
expected	O	589-597
.	O	597-598

In	O	599-601
contrast	O	602-610
to	O	611-613
these	O	614-619
mutations	O	620-629
found	O	630-635
in	O	636-638
patients	O	639-647
with	O	648-652
hepatic	O	653-660
-	O	660-661
type	O	661-665
of	O	666-668
early	O	669-674
onset	O	675-680
,	O	680-681
the	O	682-685
mutations	O	686-695
A874V	O	696-701
,	O	701-702
R778L	O	703-708
,	O	708-709
and	O	710-713
3892delGTC	O	714-724
were	O	725-729
either	O	730-736
missense	O	737-745
mutations	O	746-755
or	O	756-758
in	O	759-761
frame	O	762-767
1	O	768-769
-	O	769-770
amino	O	770-775
acid	O	776-780
deletion	O	781-789
,	O	789-790
and	O	791-794
occurred	O	795-803
in	O	804-806
the	O	807-810
patients	O	811-819
with	O	820-824
hepato	O	825-831
-	O	831-832
neurologic	O	832-842
type	O	843-847
of	O	848-850
late	O	851-855
onset	O	856-861
.	O	861-862

The	O	863-866
mutations	O	867-876
2871delC	O	877-885
and	O	886-889
R778L	O	890-895
have	O	896-900
been	O	901-905
previously	O	906-916
reported	O	917-925
in	O	926-928
a	O	929-930
relatively	O	931-941
large	O	942-947
number	O	948-954
of	O	955-957
Japanese	O	958-966
patients	O	967-975
.	O	975-976

In	O	977-979
particular	O	980-990
,	O	990-991
R778L	O	992-997
is	O	998-1000
known	O	1001-1006
to	O	1007-1009
be	O	1010-1012
more	O	1013-1017
prevalent	O	1018-1027
in	O	1028-1030
Asian	O	1031-1036
countries	O	1037-1046
than	O	1047-1051
in	O	1052-1054
other	O	1055-1060
countries	O	1061-1070
of	O	1071-1073
the	O	1074-1077
world	O	1078-1083
.	O	1083-1084

Our	O	1085-1088
data	O	1089-1093
are	O	1094-1097
compatible	O	1098-1108
with	O	1109-1113
the	O	1114-1117
hypothesis	O	1118-1128
that	O	1129-1133
the	O	1134-1137
mutations	O	1138-1147
tend	O	1148-1152
to	O	1153-1155
occur	O	1156-1161
in	O	1162-1164
a	O	1165-1166
population	O	1167-1177
-	O	1177-1178
specific	O	1178-1186
manner	O	1187-1193
.	O	1193-1194

Therefore	O	1195-1204
,	O	1204-1205
the	O	1206-1209
accumulation	O	1210-1222
of	O	1223-1225
the	O	1226-1229
types	O	1230-1235
of	O	1236-1238
mutations	O	1239-1248
in	O	1249-1251
Japanese	O	1252-1260
patients	O	1261-1269
with	O	1270-1274
WD	B	1275-1277
will	O	1278-1282
facilitate	O	1283-1293
the	O	1294-1297
fast	O	1298-1302
and	O	1303-1306
effective	O	1307-1316
genetic	O	1317-1324
diagnosis	O	1325-1334
of	O	1335-1337
WD	B	1338-1340
in	O	1341-1343
Japanese	O	1344-1352
patients	O	1353-1361
.	O	1361-1362
.	O	1361-1362

Structural	O	0-10
analysis	O	11-19
of	O	20-22
the	O	23-26
5	O	27-28
'	O	28-29
region	O	30-36
of	O	37-39
mouse	O	40-45
and	O	46-49
human	O	50-55
Huntington	B	56-66
disease	I	67-74
genes	O	75-80
reveals	O	81-88
conservation	O	89-101
of	O	102-104
putative	O	105-113
promoter	O	114-122
region	O	123-129
and	O	130-133
di	O	134-136
-	O	136-137
and	O	138-141
trinucleotide	O	142-155
polymorphisms	O	156-169
.	O	169-170

We	O	171-173
have	O	174-178
previously	O	179-189
cloned	O	190-196
and	O	197-200
characterized	O	201-214
the	O	215-218
murine	O	219-225
homologue	O	226-235
of	O	236-238
the	O	239-242
Huntington	B	243-253
disease	I	254-261
(	O	262-263
HD	B	263-265
)	O	265-266
gene	O	267-271
and	O	272-275
shown	O	276-281
that	O	282-286
it	O	287-289
maps	O	290-294
to	O	295-297
mouse	O	298-303
chromosome	O	304-314
5	O	315-316
within	O	317-323
a	O	324-325
region	O	326-332
of	O	333-335
conserved	O	336-345
synteny	O	346-353
with	O	354-358
human	O	359-364
chromosome	O	365-375
4p16	O	376-380
.	O	380-381

3	O	382-383
3	O	384-385
.	O	385-386

Here	O	387-391
we	O	392-394
present	O	395-402
a	O	403-404
detailed	O	405-413
comparison	O	414-424
of	O	425-427
the	O	428-431
sequence	O	432-440
of	O	441-443
the	O	444-447
putative	O	448-456
promoter	O	457-465
and	O	466-469
the	O	470-473
organization	O	474-486
of	O	487-489
the	O	490-493
5	O	494-495
genomic	O	496-503
region	O	504-510
of	O	511-513
the	O	514-517
murine	O	518-524
(	O	525-526
Hdh	O	526-529
)	O	529-530
and	O	531-534
human	O	535-540
HD	B	541-543
genes	O	544-549
encompassing	O	550-562
the	O	563-566
first	O	567-572
five	O	573-577
exons	O	578-583
.	O	583-584

We	O	585-587
show	O	588-592
that	O	593-597
in	O	598-600
this	O	601-605
region	O	606-612
these	O	613-618
two	O	619-622
genes	O	623-628
share	O	629-634
identical	O	635-644
exon	O	645-649
boundaries	O	650-660
,	O	660-661
but	O	662-665
have	O	666-670
different	O	671-680
-	O	680-681
size	O	681-685
introns	O	686-693
.	O	693-694

Two	O	695-698
dinucleotide	O	699-711
(	O	712-713
CT	O	713-715
)	O	715-716
and	O	717-720
one	O	721-724
trinucleotide	O	725-738
intronic	O	739-747
polymorphism	O	748-760
in	O	761-763
Hdh	O	764-767
and	O	768-771
an	O	772-774
intronic	O	775-783
CA	O	784-786
polymorphism	O	787-799
in	O	800-802
the	O	803-806
HD	B	807-809
gene	O	810-814
were	O	815-819
identified	O	820-830
.	O	830-831

Comparison	O	832-842
of	O	843-845
940	O	846-849
-	O	849-850
bp	O	850-852
sequence	O	853-861
5	O	862-863
to	O	864-866
the	O	867-870
putative	O	871-879
translation	O	880-891
start	O	892-897
site	O	898-902
reveals	O	903-910
a	O	911-912
highly	O	913-919
conserved	O	920-929
region	O	930-936
(	O	937-938
78	O	938-940
.	O	940-941

8	O	942-943
%	O	943-944
nucleotide	O	945-955
identity	O	956-964
)	O	964-965
between	O	966-973
Hdh	O	974-977
and	O	978-981
the	O	982-985
HD	B	986-988
gene	O	989-993
from	O	994-998
nucleotide	O	999-1009
-	O	1010-1011
56	O	1011-1013
to	O	1014-1016
-	O	1017-1018
206	O	1018-1021
(	O	1022-1023
of	O	1023-1025
Hdh	O	1026-1029
)	O	1029-1030
.	O	1030-1031

Neither	O	1032-1039
Hdh	O	1040-1043
nor	O	1044-1047
the	O	1048-1051
HD	B	1052-1054
gene	O	1055-1059
have	O	1060-1064
typical	O	1065-1072
TATA	O	1073-1077
or	O	1078-1080
CCAAT	O	1081-1086
elements	O	1087-1095
,	O	1095-1096
but	O	1097-1100
both	O	1101-1105
show	O	1106-1110
one	O	1111-1114
putative	O	1115-1123
AP2	O	1124-1127
binding	O	1128-1135
site	O	1136-1140
and	O	1141-1144
numerous	O	1145-1153
potential	O	1154-1163
Sp1	O	1164-1167
binding	O	1168-1175
sites	O	1176-1181
.	O	1181-1182

The	O	1183-1186
high	O	1187-1191
sequence	O	1192-1200
identity	O	1201-1209
between	O	1210-1217
Hdh	O	1218-1221
and	O	1222-1225
the	O	1226-1229
HD	B	1230-1232
gene	O	1233-1237
for	O	1238-1241
approximately	O	1242-1255
200	O	1256-1259
bp	O	1260-1262
5	O	1263-1264
to	O	1265-1267
the	O	1268-1271
putative	O	1272-1280
translation	O	1281-1292
start	O	1293-1298
site	O	1299-1303
indicates	O	1304-1313
that	O	1314-1318
these	O	1319-1324
sequences	O	1325-1334
may	O	1335-1338
play	O	1339-1343
a	O	1344-1345
role	O	1346-1350
in	O	1351-1353
regulating	O	1354-1364
expression	O	1365-1375
of	O	1376-1378
the	O	1379-1382
Huntington	B	1383-1393
disease	I	1394-1401
gene	O	1402-1406

Complement	B	0-10
deficiency	I	11-21
and	O	22-25
nephritis	B	26-35
.	O	35-36

A	O	37-38
report	O	39-45
of	O	46-48
a	O	49-50
family	O	51-57
.	O	57-58

A	O	59-60
family	O	61-67
is	O	68-70
described	O	71-80
in	O	81-83
which	O	84-89
three	O	90-95
children	O	96-104
had	O	105-108
homozygous	O	109-119
deficiency	B	120-130
of	I	131-133
C3	I	134-136
and	O	137-140
in	O	141-143
which	O	144-149
both	O	150-154
parents	O	155-162
and	O	163-166
two	O	167-170
other	O	171-176
children	O	177-185
were	O	186-190
heterozygous	O	191-203
for	O	204-207
the	O	208-211
C3	O	212-214
null	O	215-219
gene	O	220-224
.	O	224-225

One	O	226-229
child	O	230-235
with	O	236-240
heterozygous	O	241-253
C3	B	254-256
deficiency	I	257-267
was	O	268-271
found	O	272-277
to	O	278-280
have	O	281-285
membranoproliferative	O	286-307
glomerulonephritis	B	308-326
;	O	326-327
proteinuria	B	328-339
and	O	340-343
/	O	343-344
or	O	344-346
microscopical	O	347-360
haematuria	B	361-371
was	O	372-375
present	O	376-383
in	O	384-386
all	O	387-390
three	O	391-396
homozygous	O	397-407
C3	B	408-410
-	I	410-411
deficient	I	411-420
children	O	421-429
.	O	429-430

All	O	431-434
children	O	435-443
with	O	444-448
homozygous	O	449-459
or	O	460-462
heterozygous	O	463-475
C3	B	476-478
deficiency	I	479-489
were	O	490-494
,	O	494-495
to	O	496-498
a	O	499-500
varying	O	501-508
degree	O	509-515
,	O	515-516
susceptible	O	517-528
to	O	529-531
infection	O	532-541
.	O	541-542

The	O	543-546
only	O	547-551
child	O	552-557
of	O	558-560
the	O	561-564
family	O	565-571
with	O	572-576
normal	O	577-583
complement	O	584-594
had	O	595-598
no	O	599-601
increased	O	602-611
risk	O	612-616
of	O	617-619
infection	O	620-629
and	O	630-633
no	O	634-636
renal	B	637-642
disease	I	643-650
.	O	650-651

This	O	652-656
family	O	657-663
study	O	664-669
provides	O	670-678
further	O	679-686
support	O	687-694
for	O	695-698
the	O	699-702
proposal	O	703-711
that	O	712-716
C3	B	717-719
deficiency	I	720-730
predisposes	O	731-742
to	O	743-745
nephritis	B	746-755
.	O	755-756
.	O	755-756

Cytogenetic	O	0-11
investigations	O	12-26
in	O	27-29
families	O	30-38
with	O	39-43
ataxia	B	44-50
-	I	50-51
telangiectasia	I	51-65
.	O	65-66

Chromosomal	O	67-78
studies	O	79-86
were	O	87-91
performed	O	92-101
on	O	102-104
peripheral	O	105-115
blood	O	116-121
lymphocytes	O	122-133
and	O	134-137
cultured	O	138-146
skin	O	147-151
fibroblasts	O	152-163
from	O	164-168
five	O	169-173
Israeli	O	174-181
-	O	181-182
Moroccan	O	182-190
families	O	191-199
with	O	200-204
ataxia	B	205-211
-	I	211-212
telangiectasia	I	212-226
.	O	226-227

A	O	228-229
total	O	230-235
of	O	236-238
24	O	239-241
individuals	O	242-253
,	O	253-254
including	O	255-264
seven	O	265-270
propositi	O	271-280
,	O	280-281
was	O	282-285
investigated	O	286-298
.	O	298-299

Among	O	300-305
the	O	306-309
probands	O	310-318
,	O	318-319
significantly	O	320-333
elevated	O	334-342
rates	O	343-348
of	O	349-351
chromosome	O	352-362
damage	O	363-369
were	O	370-374
observed	O	375-383
in	O	384-386
both	O	387-391
blood	O	392-397
and	O	398-401
skin	O	402-406
.	O	406-407

Skin	O	408-412
fibroblasts	O	413-424
of	O	425-427
affected	O	428-436
individuals	O	437-448
showed	O	449-455
several	O	456-463
orders	O	464-470
of	O	471-473
magnitude	O	474-483
more	O	484-488
chromosome	O	489-499
breakage	O	500-508
than	O	509-513
lymphocytes	O	514-525
.	O	525-526

Increased	O	527-536
rates	O	537-542
of	O	543-545
chromosome	O	546-556
damage	O	557-563
were	O	564-568
also	O	569-573
observed	O	574-582
in	O	583-585
the	O	586-589
fibroblasts	O	590-601
of	O	602-604
some	O	605-609
phenotypically	O	610-624
normal	O	625-631
family	O	632-638
members	O	639-646
(	O	647-648
obligate	O	648-656
heterozygotes	O	657-670
and	O	671-674
sibs	O	675-679
)	O	679-680
when	O	681-685
compared	O	686-694
to	O	695-697
normal	O	698-704
controls	O	705-713
.	O	713-714

An	O	715-717
apparent	O	718-726
abnormal	O	727-735
clone	O	736-741
of	O	742-744
cells	O	745-750
,	O	750-751
possessing	O	752-762
a	O	763-764
large	O	765-770
acrocentric	O	771-782
marker	O	783-789
chromosome	O	790-800
(	O	801-802
14q	O	802-805
+	O	806-807
)	O	807-808
,	O	808-809
was	O	810-813
observed	O	814-822
in	O	823-825
varying	O	826-833
proportions	O	834-845
among	O	846-851
cells	O	852-857
of	O	858-860
all	O	861-864
the	O	865-868
propositi	O	869-878
(	O	879-880
2	O	880-881
-	O	881-882
5	O	882-883
%	O	883-884
of	O	885-887
lymphocytes	O	888-899
;	O	899-900
1	O	901-902
-	O	902-903
9	O	903-904
%	O	904-905
of	O	906-908
fibroblasts	O	909-920
)	O	920-921
.	O	921-922
.	O	921-922

Predominance	O	0-12
of	O	13-15
the	O	16-19
adrenomyeloneuropathy	B	20-41
phenotype	O	42-51
of	O	52-54
X	B	55-56
-	I	56-57
linked	I	57-63
adrenoleukodystrophy	I	64-84
in	O	85-87
The	O	88-91
Netherlands	O	92-103
:	O	103-104
a	O	105-106
survey	O	107-113
of	O	114-116
30	O	117-119
kindreds	O	120-128
.	O	128-129

X	B	130-131
-	I	131-132
linked	I	132-138
adrenoleukodystrophy	I	139-159
(	O	160-161
X	B	161-162
-	I	162-163
ALD	I	163-166
)	O	166-167
is	O	168-170
an	O	171-173
inherited	B	174-183
disorder	I	184-192
of	O	193-195
peroxisomal	O	196-207
beta	O	208-212
-	O	212-213
oxidation	O	213-222
associated	O	223-233
with	O	234-238
accumulation	O	239-251
of	O	252-254
saturated	O	255-264
very	O	265-269
long	O	270-274
-	O	274-275
chain	O	275-280
fatty	O	281-286
acids	O	287-292
,	O	292-293
which	O	294-299
results	O	300-307
in	O	308-310
central	O	311-318
and	O	319-322
peripheral	O	323-333
demyelination	B	334-347
and	O	348-351
in	O	352-354
impaired	B	355-363
function	I	364-372
of	I	373-375
adrenal	I	376-383
cortex	I	384-390
and	I	391-394
testes	I	395-401
.	O	401-402

The	O	403-406
phenotypic	O	407-417
expression	O	418-428
is	O	429-431
highly	O	432-438
variable	O	439-447
,	O	447-448
childhood	B	449-458
cerebral	I	459-467
ALD	I	468-471
(	O	472-473
CCALD	B	473-478
)	O	478-479
and	O	480-483
adrenomyeloneuropathy	B	484-505
(	O	506-507
AMN	B	507-510
)	O	510-511
being	O	512-517
the	O	518-521
main	O	522-526
variants	O	527-535
.	O	535-536

We	O	537-539
explored	O	540-548
the	O	549-552
30	O	553-555
Dutch	O	556-561
kindreds	O	562-570
well	O	571-575
known	O	576-581
to	O	582-584
the	O	585-588
Dutch	O	589-594
X	B	595-596
-	I	596-597
ALD	I	597-600
/	O	600-601
AMN	B	601-604
Study	O	605-610
Group	O	611-616
and	O	617-620
phenotyped	O	621-631
77	O	632-634
male	O	635-639
patients	O	640-648
35	O	650-652
(	O	653-654
46	O	654-656
%	O	656-657
)	O	657-658
had	O	659-662
AMN	B	663-666
and	O	667-670
24	O	671-673
(	O	674-675
31	O	675-677
%	O	677-678
)	O	678-679
CCALD	B	680-685
or	O	686-688
adolescent	B	689-699
cerebral	I	700-708
ALD	I	709-712
(	O	713-714
AdolCALD	B	714-722
)	O	722-723
.	O	723-724

These	O	725-730
percentages	O	731-742
differ	O	743-749
significantly	O	750-763
from	O	764-768
previous	O	769-777
reports	O	778-785
,	O	785-786
in	O	787-789
which	O	790-795
25	O	796-798
to	O	799-801
28	O	802-804
%	O	804-805
of	O	806-808
the	O	809-812
patients	O	813-821
developed	O	822-831
AMN	B	832-835
and	O	836-839
53	O	840-842
to	O	843-845
57	O	846-848
%	O	848-849
CCALD	B	850-855
or	O	856-858
AdolCALD	B	859-867
.	O	867-868

Our	O	869-872
findings	O	873-881
indicate	O	882-890
that	O	891-895
-	O	895-896
-	O	895-896
at	O	893-895
least	O	900-905
in	O	906-908
the	O	909-912
Netherlands	O	913-924
-	O	924-925
-	O	924-925
AMN	B	926-929
may	O	930-933
be	O	934-936
the	O	937-940
most	O	941-945
frequent	O	946-954
phenotype	O	955-964
of	O	965-967
X	B	968-969
-	I	969-970
ALD	I	970-973
.	O	973-974
.	O	973-974

Three	O	0-5
novel	O	6-11
aniridia	B	12-20
mutations	O	21-30
in	O	31-33
the	O	34-37
human	O	38-43
PAX6	O	44-48
gene	O	49-53
.	O	53-54

Aniridia	B	55-63
(	O	64-65
iris	B	65-69
hypoplasia	I	70-80
)	O	80-81
is	O	82-84
an	O	85-87
autosomal	B	88-97
dominant	I	98-106
congenital	I	107-117
disorder	I	118-126
of	I	127-129
the	I	130-133
eye	I	134-137
.	O	137-138

Mutations	O	139-148
in	O	149-151
the	O	152-155
human	O	156-161
aniridia	B	162-170
(	O	171-172
PAX6	O	172-176
)	O	176-177
gene	O	178-182
have	O	183-187
now	O	188-191
been	O	192-196
identified	O	197-207
in	O	208-210
many	O	211-215
patients	O	216-224
from	O	225-229
various	O	230-237
ethnic	O	238-244
groups	O	245-251
.	O	251-252

In	O	253-255
the	O	256-259
study	O	260-265
reported	O	266-274
here	O	275-279
we	O	280-282
describe	O	283-291
PAX6	O	292-296
mutations	O	297-306
in	O	307-309
one	O	310-313
sporadic	O	314-322
and	O	323-326
five	O	327-331
familial	O	332-340
cases	O	341-346
with	O	347-351
aniridia	B	352-360
.	O	360-361

Of	O	362-364
the	O	365-368
four	O	369-373
different	O	374-383
mutations	O	384-393
identified	O	394-404
,	O	404-405
one	O	406-409
was	O	410-413
identical	O	414-423
to	O	424-426
a	O	427-428
previously	O	429-439
reported	O	440-448
mutation	O	449-457
(	O	458-459
C	O	459-460
-	O	460-461
-	O	460-461
>	O	463-464
T	O	465-466
transition	O	467-477
at	O	478-480
codon	O	481-486
240	O	487-490
)	O	490-491
,	O	491-492
and	O	493-496
three	O	497-502
were	O	503-507
novel	O	508-513
two	O	515-518
in	O	519-521
the	O	522-525
glycine	O	526-533
-	O	533-534
rich	O	534-538
region	O	539-545
and	O	546-549
one	O	550-553
in	O	554-556
the	O	557-560
proline	O	561-568
/	O	568-569
serine	O	569-575
/	O	568-569
threonine	O	576-585
-	O	585-586
rich	O	586-590
(	O	591-592
PST	O	592-595
)	O	595-596
region	O	597-603
.	O	603-604

One	O	605-608
PAX6	O	609-613
mutation	O	614-622
found	O	623-628
in	O	629-631
the	O	632-635
PST	O	636-639
region	O	640-646
was	O	647-650
associated	O	651-661
with	O	662-666
cataracts	B	667-676
in	O	677-679
an	O	680-682
aniridia	B	683-691
family	O	692-698
.	O	698-699

Another	O	700-707
splice	O	708-714
mutation	O	715-723
in	O	724-726
the	O	727-730
PST	O	731-734
domain	O	735-741
occurred	O	742-750
in	O	751-753
an	O	754-756
aniridia	B	757-765
patient	O	766-773
with	O	774-778
anosmia	B	779-786
(	O	787-788
inability	O	788-797
to	O	798-800
smell	O	801-806
)	O	806-807
.	O	807-808

The	O	809-812
six	O	813-816
new	O	817-820
aniridia	B	821-829
cases	O	830-835
reported	O	836-844
here	O	845-849
have	O	850-854
mutations	O	855-864
predicted	O	865-874
to	O	875-877
generate	O	878-886
incomplete	O	887-897
PAX6	O	898-902
proteins	O	903-911
.	O	911-912

These	O	913-918
results	O	919-926
support	O	927-934
the	O	935-938
theory	O	939-945
that	O	946-950
human	O	951-956
aniridia	B	957-965
is	O	966-968
caused	O	969-975
by	O	976-978
haploinsufficiency	B	979-997
of	I	998-1000
PAX6	I	1001-1005
.	O	1005-1006
.	O	1005-1006

Hepatoblastoma	B	0-14
,	O	14-15
pigmented	B	16-25
ocular	I	26-32
fundus	I	33-39
lesions	I	40-47
and	O	48-51
jaw	B	52-55
lesions	I	56-63
in	O	64-66
Gardner	B	67-74
syndrome	I	75-83
.	O	83-84

Hepatoblastoma	B	85-99
is	O	100-102
a	O	103-104
rare	O	105-109
neoplasm	B	110-118
of	O	119-121
infants	O	122-129
and	O	130-133
children	O	134-142
only	O	143-147
recently	O	148-156
documented	O	157-167
in	O	168-170
association	O	171-182
with	O	183-187
hereditary	B	188-198
adenomatous	I	199-210
polyposis	I	211-220
of	I	221-223
the	I	224-227
colon	I	228-233
[	O	234-235
Kingston	O	235-243
et	O	244-246
al	O	247-249
.	O	249-250
,	O	250-251
1983	O	252-256
]	O	256-257
.	O	257-258

We	O	259-261
report	O	262-268
four	O	269-273
children	O	274-282
with	O	283-287
hepatoblastoma	B	288-302
from	O	303-307
four	O	308-312
unrelated	O	313-322
families	O	323-331
with	O	332-336
Gardner	B	337-344
syndrome	I	345-353
(	O	354-355
GS	B	355-357
)	O	357-358
.	O	358-359

One	O	360-363
child	O	364-369
,	O	369-370
now	O	371-374
19	O	375-377
years	O	378-383
old	O	384-387
,	O	387-388
survived	O	389-397
after	O	398-403
a	O	404-405
resection	O	406-415
of	O	416-418
a	O	419-420
hepatoblastoma	B	421-435
in	O	436-438
infancy	O	439-446
and	O	447-450
recently	O	451-459
was	O	460-463
found	O	464-469
to	O	470-472
have	O	473-477
GS	B	478-480
.	O	480-481

He	O	482-484
has	O	485-488
an	O	489-491
associated	O	492-502
odontoma	B	503-511
and	O	512-515
pigmented	B	516-525
ocular	I	526-532
fundus	I	533-539
lesions	I	540-547
,	O	547-548
both	O	549-553
of	O	554-556
which	O	557-562
have	O	563-567
been	O	568-572
shown	O	573-578
to	O	579-581
be	O	582-584
clinical	O	585-593
markers	O	594-601
of	O	602-604
GS	B	605-607
.	O	607-608

Many	O	609-613
individuals	O	614-625
in	O	626-628
these	O	629-634
four	O	635-639
GS	B	640-642
families	O	643-651
,	O	651-652
both	O	653-657
affected	O	658-666
and	O	667-670
at	O	671-673
risk	O	674-678
,	O	678-679
have	O	680-684
osteomatous	B	685-696
jaw	I	697-700
lesions	I	701-708
and	O	709-712
pigmented	B	713-722
ocular	I	723-729
fundus	I	730-736
lesions	I	737-744
.	O	744-745

A	O	746-747
search	O	748-754
for	O	755-758
colonic	B	759-766
polyps	I	767-773
should	O	774-780
be	O	781-783
made	O	784-788
in	O	789-791
families	O	792-800
of	O	801-803
infants	O	804-811
and	O	812-815
children	O	816-824
with	O	825-829
hepatoblastoma	B	830-844
.	O	844-845

If	O	846-848
the	O	849-852
child	O	853-858
survives	O	859-867
,	O	867-868
he	O	869-871
or	O	872-874
she	O	875-878
should	O	879-885
be	O	886-888
monitored	O	889-898
for	O	899-902
the	O	903-906
later	O	907-912
appearance	O	913-923
of	O	924-926
colonic	B	927-934
polyps	I	935-941
.	O	941-942

The	O	943-946
finding	O	947-954
of	O	955-957
jaw	B	958-961
lesions	I	962-969
and	O	970-973
/	O	973-974
or	O	974-976
pigmented	B	977-986
ocular	I	987-993
fundus	I	994-1000
lesions	I	1001-1008
in	O	1009-1011
relatives	O	1012-1021
at	O	1022-1024
risk	O	1025-1029
are	O	1030-1033
indications	O	1034-1045
of	O	1046-1048
the	O	1049-1052
possible	O	1053-1061
presence	O	1062-1070
of	O	1071-1073
the	O	1074-1077
GS	B	1078-1080
gene	O	1081-1085
.	O	1085-1086

Mutation	O	0-8
spectrum	O	9-17
in	O	18-20
the	O	21-24
CHM	B	25-28
gene	O	29-33
of	O	34-36
Danish	O	37-43
and	O	44-47
Swedish	O	48-55
choroideremia	B	56-69
patients	O	70-78
.	O	78-79

The	O	80-83
recent	O	84-90
isolation	O	91-100
of	O	101-103
the	O	104-107
complete	O	108-116
open	O	117-121
reading	O	122-129
frame	O	130-135
of	O	136-138
the	O	139-142
choroideremia	B	143-156
(	O	157-158
CHM	B	158-161
)	O	161-162
gene	O	163-167
and	O	168-171
the	O	172-175
characterization	O	176-192
of	O	193-195
the	O	196-199
exon	O	200-204
-	O	204-205
intron	O	205-211
boundaries	O	212-222
has	O	223-226
paved	O	227-232
the	O	233-236
way	O	237-240
to	O	241-243
mutation	O	244-252
detection	O	253-262
in	O	263-265
patients	O	266-274
with	O	275-279
classical	O	280-289
choroideremia	B	290-303
.	O	303-304

We	O	305-307
have	O	308-312
performed	O	313-322
mutation	O	323-331
screening	O	332-341
in	O	342-344
patients	O	345-353
from	O	354-358
15	O	359-361
Danish	O	362-368
and	O	369-372
Swedish	O	373-380
families	O	381-389
by	O	390-392
using	O	393-398
Southern	O	399-407
blot	O	408-412
hybridization	O	413-426
and	O	427-430
the	O	431-434
polymerase	O	435-445
chain	O	446-451
reaction	O	452-460
single	O	461-467
-	O	467-468
strand	O	468-474
conformation	O	475-487
polymorphism	O	488-500
(	O	501-502
PCR	O	502-505
-	O	505-506
SSCP	O	506-510
)	O	510-511
technique	O	512-521
.	O	521-522

Causative	O	523-532
mutations	O	533-542
in	O	543-545
the	O	546-549
CHM	B	550-553
gene	O	554-558
were	O	559-563
detected	O	564-572
in	O	573-575
at	O	576-578
least	O	579-584
12	O	585-587
families	O	588-596
,	O	596-597
indicating	O	598-608
that	O	609-613
a	O	614-615
substantial	O	616-627
part	O	628-632
of	O	633-635
the	O	636-639
mutations	O	640-649
can	O	650-653
be	O	654-656
identified	O	657-667
by	O	668-670
this	O	671-675
approach	O	676-684
.	O	684-685

In	O	686-688
four	O	689-693
of	O	694-696
these	O	697-702
families	O	703-711
deletions	O	712-721
of	O	722-724
different	O	725-734
sizes	O	735-740
were	O	741-745
found	O	746-751
.	O	751-752

Thus	O	753-757
,	O	757-758
in	O	759-761
one	O	762-765
patient	O	766-773
,	O	773-774
the	O	775-778
deletion	O	779-787
resulted	O	788-796
in	O	797-799
the	O	800-803
absence	O	804-811
of	O	812-814
only	O	815-819
one	O	820-823
exon	O	824-828
,	O	828-829
while	O	830-835
in	O	836-838
another	O	839-846
the	O	847-850
deletion	O	851-859
comprised	O	860-869
the	O	870-873
entire	O	874-880
CHM	B	881-884
gene	O	885-889
.	O	889-890

Mapping	O	891-898
of	O	899-901
the	O	902-905
deletion	O	906-914
endpoints	O	915-924
in	O	925-927
these	O	928-933
four	O	934-938
patients	O	939-947
and	O	948-951
in	O	952-954
another	O	955-962
11	O	963-965
male	O	966-970
patients	O	971-979
with	O	980-984
sizeable	O	985-993
deletions	O	994-1003
enabled	O	1004-1011
us	O	1012-1014
to	O	1015-1017
construct	O	1018-1027
a	O	1028-1029
very	O	1030-1034
detailed	O	1035-1043
map	O	1044-1047
of	O	1048-1050
intervals	O	1051-1060
2	O	1061-1062
and	O	1063-1066
3	O	1067-1068
of	O	1069-1071
Xq21	O	1072-1076
.	O	1076-1077

In	O	1078-1080
the	O	1081-1084
remaining	O	1085-1094
11	O	1095-1097
Danish	O	1098-1104
and	O	1105-1108
Swedish	O	1109-1116
families	O	1117-1125
at	O	1126-1128
least	O	1129-1134
8	O	1135-1136
causative	O	1137-1146
mutations	O	1147-1156
were	O	1157-1161
found	O	1162-1167
by	O	1168-1170
PCR	O	1171-1174
-	O	1174-1175
SSCP	O	1175-1179
analysis	O	1180-1188
and	O	1189-1192
direct	O	1193-1199
sequencing	O	1200-1210
.	O	1210-1211

Interestingly	O	1212-1225
,	O	1225-1226
all	O	1227-1230
CHM	B	1231-1234
gene	O	1235-1239
mutations	O	1240-1249
detected	O	1250-1258
thus	O	1259-1263
far	O	1264-1267
in	O	1268-1270
choroideremia	B	1271-1284
patients	O	1285-1293
give	O	1294-1298
rise	O	1299-1303
to	O	1304-1306
the	O	1307-1310
introduction	O	1311-1323
of	O	1324-1326
a	O	1327-1328
premature	O	1329-1338
stop	O	1339-1343
codon	O	1344-1349
.	O	1349-1350
.	O	1349-1350

Diverse	O	0-7
point	O	8-13
mutations	O	14-23
result	O	24-30
in	O	31-33
glucose	O	34-41
-	O	41-42
6	O	42-43
-	O	41-42
phosphate	O	44-53
dehydrogenase	O	54-67
(	O	68-69
G6PD	O	69-73
)	O	73-74
polymorphism	O	75-87
in	O	88-90
Taiwan	O	91-97
.	O	97-98

Glucose	O	99-106
-	O	106-107
6	O	107-108
-	O	106-107
PHOSPHATE	O	109-118
dehydrogenase	O	119-132
(	O	133-134
G6PD	O	134-138
;	O	138-139
EC	O	140-142
1	O	143-144
.	O	144-145
1	O	143-144
.	O	144-145

1	O	148-149
.	O	149-150
49	O	151-153
)	O	153-154
deficiency	O	155-165
is	O	166-168
the	O	169-172
most	O	173-177
common	O	178-184
human	O	185-190
enzymopathy	B	191-202
,	O	202-203
affecting	O	204-213
more	O	214-218
than	O	219-223
200	O	224-227
million	O	228-235
people	O	236-242
worldwide	O	243-252
.	O	252-253

Although	O	254-262
greater	O	263-270
than	O	271-275
400	O	276-279
variants	O	280-288
have	O	289-293
been	O	294-298
described	O	299-308
based	O	309-314
on	O	315-317
clinical	O	318-326
and	O	327-330
biochemical	O	331-342
criteria	O	343-351
,	O	351-352
little	O	353-359
is	O	360-362
known	O	363-368
about	O	369-374
the	O	375-378
molecular	O	379-388
basis	O	389-394
of	O	395-397
these	O	398-403
G6PD	B	404-408
deficiencies	I	409-421
.	O	421-422

Recently	O	423-431
,	O	431-432
the	O	433-436
gene	O	437-441
that	O	442-446
encodes	O	447-454
human	O	455-460
G6PD	O	461-465
has	O	466-469
been	O	470-474
cloned	O	475-481
and	O	482-485
sequenced	O	486-495
,	O	495-496
which	O	497-502
enables	O	503-510
us	O	511-513
to	O	514-516
examine	O	517-524
directly	O	525-533
the	O	534-537
heterogeneity	O	538-551
of	O	552-554
G6PD	O	555-559
at	O	560-562
the	O	563-566
DNA	O	567-570
level	O	571-576
.	O	576-577

During	O	578-584
the	O	585-588
past	O	589-593
10	O	594-596
years	O	597-602
,	O	602-603
we	O	604-606
examined	O	607-615
the	O	616-619
G6PD	O	620-624
activity	O	625-633
in	O	634-636
21	O	637-639
,	O	639-640
271	O	641-644
newborn	O	645-652
Chinese	O	653-660
infants	O	661-668
(	O	669-670
11	O	670-672
,	O	672-673
400	O	674-677
males	O	678-683
and	O	684-687
9	O	688-689
,	O	689-690
871	O	691-694
females	O	695-702
)	O	702-703
and	O	704-707
identified	O	708-718
314	O	719-722
(	O	723-724
2	O	724-725
.	O	725-726

8	O	727-728
%	O	728-729
)	O	729-730
males	O	731-736
and	O	737-740
246	O	741-744
(	O	745-746
2	O	746-747
.	O	747-748

5	O	749-750
%	O	750-751
)	O	751-752
females	O	753-760
having	O	761-767
low	O	768-771
G6PD	O	772-776
activity	O	777-785
.	O	785-786

The	O	787-790
G6PD	O	791-795
gene	O	796-800
from	O	801-805
10	O	806-808
randomly	O	809-817
selected	O	818-826
affected	O	827-835
individuals	O	836-847
and	O	848-851
their	O	852-857
relatives	O	858-867
was	O	868-871
polymerase	O	872-882
chain	O	883-888
reaction	O	889-897
(	O	898-899
PCR	O	899-902
)	O	902-903
amplified	O	904-913
,	O	913-914
subcloned	O	915-924
,	O	924-925
and	O	926-929
sequenced	O	930-939
.	O	939-940

Our	O	941-944
results	O	945-952
indicate	O	953-961
that	O	962-966
at	O	967-969
least	O	970-975
four	O	976-980
types	O	981-986
of	O	987-989
mutation	O	990-998
are	O	999-1002
responsible	O	1003-1014
for	O	1015-1018
the	O	1019-1022
G6PD	O	1023-1027
polymorphism	O	1028-1040
in	O	1041-1043
Taiwan	O	1044-1050
.	O	1050-1051

The	O	1052-1055
first	O	1056-1061
type	O	1062-1066
of	O	1067-1069
mutation	O	1070-1078
(	O	1079-1080
487	O	1080-1083
G	O	1084-1085
-	O	1085-1086
-	O	1085-1086
-	O	1085-1086
-	O	1085-1086
A	O	1089-1090
)	O	1090-1091
was	O	1092-1095
found	O	1096-1101
in	O	1102-1104
an	O	1105-1107
affected	O	1108-1116
Chinese	O	1117-1124
with	O	1125-1129
a	O	1130-1131
G	O	1132-1133
to	O	1134-1136
A	O	1137-1138
change	O	1139-1145
at	O	1146-1148
nucleotide	O	1149-1159
487	O	1160-1163
,	O	1163-1164
which	O	1165-1170
results	O	1171-1178
in	O	1179-1181
a	O	1182-1183
(	O	1184-1185
163	O	1185-1188
)	O	1188-1189
Gly	O	1190-1193
to	O	1194-1196
Ser	O	1197-1200
substitution	O	1201-1213
.	O	1213-1214

The	O	1215-1218
second	O	1219-1225
type	O	1226-1230
of	O	1231-1233
mutation	O	1234-1242
(	O	1243-1244
493	O	1244-1247
A	O	1248-1249
-	O	1249-1250
-	O	1249-1250
-	O	1249-1250
-	O	1249-1250
G	O	1253-1254
)	O	1254-1255
is	O	1256-1258
a	O	1259-1260
novel	O	1261-1266
mutation	O	1267-1275
that	O	1276-1280
has	O	1281-1284
not	O	1285-1288
been	O	1289-1293
reported	O	1294-1302
in	O	1303-1305
any	O	1306-1309
other	O	1310-1315
ethnic	O	1316-1322
group	O	1323-1328
and	O	1329-1332
was	O	1333-1336
identified	O	1337-1347
in	O	1348-1350
two	O	1351-1354
affected	O	1355-1363
Chinese	O	1364-1371
.	O	1371-1372

This	O	1373-1377
mutation	O	1378-1386
causes	O	1387-1393
an	O	1394-1396
A	O	1397-1398
to	O	1399-1401
G	O	1402-1403
change	O	1404-1410
at	O	1411-1413
nucleotide	O	1414-1424
position	O	1425-1433
493	O	1434-1437
,	O	1437-1438
producing	O	1439-1448
an	O	1449-1451
(	O	1452-1453
165	O	1453-1456
)	O	1456-1457
Asn	O	1458-1461
to	O	1462-1464
Asp	O	1465-1468
substitution	O	1469-1481
.	O	1481-1482

Interestingly	O	1483-1496
,	O	1496-1497
the	O	1498-1501
487	O	1502-1505
G	O	1506-1507
-	O	1507-1508
-	O	1507-1508
-	O	1507-1508
-	O	1507-1508
A	O	1511-1512
and	O	1513-1516
493	O	1517-1520
A	O	1521-1522
-	O	1522-1523
-	O	1522-1523
-	O	1522-1523
-	O	1522-1523
G	O	1526-1527
mutations	O	1528-1537
create	O	1538-1544
Alu	O	1545-1548
I	O	1549-1550
and	O	1551-1554
Ava	O	1555-1558
II	O	1559-1561
recognition	O	1562-1573
sites	O	1574-1579
,	O	1579-1580
respectively	O	1581-1593
,	O	1593-1594
which	O	1595-1600
enabled	O	1601-1608
us	O	1609-1611
to	O	1612-1614
rapidly	O	1615-1622
detect	O	1623-1629
these	O	1630-1635
two	O	1636-1639
mutations	O	1640-1649
by	O	1650-1652
PCR	O	1653-1656
/	O	1656-1657
restriction	O	1657-1668
enzyme	O	1669-1675
(	O	1676-1677
RE	O	1677-1679
)	O	1679-1680
digestion	O	1681-1690
method	O	1691-1697
.	O	1697-1698

The	O	1699-1702
third	O	1703-1708
mutation	O	1709-1717
(	O	1718-1719
1376	O	1719-1723
G	O	1724-1725
-	O	1725-1726
-	O	1725-1726
-	O	1725-1726
-	O	1725-1726
T	O	1729-1730
)	O	1730-1731
was	O	1732-1735
found	O	1736-1741
in	O	1742-1744
four	O	1745-1749
affected	O	1750-1758
Chinese	O	1759-1766
.	O	1766-1767

This	O	1768-1772
mutation	O	1773-1781
causes	O	1782-1788
a	O	1789-1790
G	O	1791-1792
to	O	1793-1795
T	O	1796-1797
change	O	1798-1804
at	O	1805-1807
nucleotide	O	1808-1818
position	O	1819-1827
1376	O	1828-1832
that	O	1833-1837
results	O	1838-1845
in	O	1846-1848
an	O	1849-1851
(	O	1852-1853
459	O	1853-1856
)	O	1856-1857
Arg	O	1858-1861
to	O	1862-1864
Leu	O	1865-1868
substitution	O	1869-1881
.	O	1881-1882

The	O	1883-1886
1376	O	1887-1891
G	O	1892-1893
-	O	1893-1894
-	O	1893-1894
-	O	1893-1894
-	O	1893-1894
T	O	1897-1898
mutation	O	1899-1907
seems	O	1908-1913
to	O	1914-1916
be	O	1917-1919
the	O	1920-1923
dominant	O	1924-1932
allele	O	1933-1939
that	O	1940-1944
causes	O	1945-1951
G6PD	B	1952-1956
deficiency	I	1957-1967
in	O	1968-1970
Taiwan	O	1971-1977
.	O	1977-1978

Finally	O	1979-1986
,	O	1986-1987
two	O	1988-1991
affected	O	1992-2000
Chinese	O	2001-2008
were	O	2009-2013
identified	O	2014-2024
as	O	2025-2027
having	O	2028-2034
the	O	2035-2038
fourth	O	2039-2045
mutation	O	2046-2054
(	O	2055-2056
1388	O	2056-2060
G	O	2061-2062
-	O	2062-2063
-	O	2062-2063
-	O	2062-2063
-	O	2062-2063
A	O	2066-2067
)	O	2067-2068
.	O	2068-2069

This	O	2070-2074
mutation	O	2075-2083
causes	O	2084-2090
a	O	2091-2092
G	O	2093-2094
to	O	2095-2097
A	O	2098-2099
change	O	2100-2106
at	O	2107-2109
nucleotide	O	2110-2120
1388	O	2121-2125
that	O	2126-2130
produces	O	2131-2139
an	O	2140-2142
(	O	2143-2144
463	O	2144-2147
)	O	2147-2148
Arg	O	2149-2152
to	O	2153-2155
His	O	2156-2159
substitution	O	2160-2172
.	O	2172-2173

Our	O	2174-2177
studies	O	2178-2185
provide	O	2186-2193
the	O	2194-2197
direct	O	2198-2204
proof	O	2205-2210
of	O	2211-2213
the	O	2214-2217
genetic	O	2218-2225
heterogeneity	O	2226-2239
of	O	2240-2242
G6PD	B	2243-2247
deficiency	I	2248-2258
in	O	2259-2261
the	O	2262-2265
Chinese	O	2266-2273
populations	O	2274-2285
of	O	2286-2288
Taiwan	O	2289-2295
and	O	2296-2299
the	O	2300-2303
PCR	O	2304-2307
/	O	2307-2308
RE	O	2308-2310
digestion	O	2311-2320
method	O	2321-2327
is	O	2328-2330
suitable	O	2331-2339
for	O	2340-2343
simultaneous	O	2344-2356
detection	O	2357-2366
of	O	2367-2369
the	O	2370-2373
487	O	2374-2377
G	O	2378-2379
-	O	2379-2380
-	O	2379-2380
-	O	2379-2380
-	O	2379-2380
A	O	2383-2384
and	O	2385-2388
493	O	2389-2392
A	O	2393-2394
-	O	2394-2395
-	O	2394-2395
-	O	2394-2395
-	O	2394-2395
G	O	2398-2399
mutations	O	2400-2409
.	O	2409-2410

Fas	O	0-3
preassociation	O	4-18
required	O	19-27
for	O	28-31
apoptosis	O	32-41
signaling	O	42-51
and	O	52-55
dominant	O	56-64
inhibition	O	65-75
by	O	76-78
pathogenic	O	79-89
mutations	O	90-99
.	O	99-100

Heterozygous	O	101-113
mutations	O	114-123
encoding	O	124-132
abnormal	O	133-141
forms	O	142-147
of	O	148-150
the	O	151-154
death	O	155-160
receptor	O	161-169
Fas	O	170-173
dominantly	O	174-184
interfere	O	185-194
with	O	195-199
Fas	O	200-203
-	O	203-204
induced	O	204-211
lymphocyte	O	212-222
apoptosis	O	223-232
in	O	233-235
human	O	236-241
autoimmune	B	242-252
lymphoproliferative	I	253-272
syndrome	I	273-281
.	O	281-282

This	O	283-287
effect	O	288-294
,	O	294-295
rather	O	296-302
than	O	303-307
depending	O	308-317
on	O	318-320
ligand	O	321-327
-	O	327-328
induced	O	328-335
receptor	O	336-344
oligomerization	O	345-360
,	O	360-361
was	O	362-365
found	O	366-371
to	O	372-374
stem	O	375-379
from	O	380-384
ligand	O	385-391
-	O	391-392
independent	O	393-404
interaction	O	405-416
of	O	417-419
wild	O	420-424
-	O	424-425
type	O	425-429
and	O	430-433
mutant	O	434-440
Fas	O	441-444
receptors	O	445-454
through	O	455-462
a	O	463-464
specific	O	465-473
region	O	474-480
in	O	481-483
the	O	484-487
extracellular	O	488-501
domain	O	502-508
.	O	508-509

Preassociated	O	510-523
Fas	O	524-527
complexes	O	528-537
were	O	538-542
found	O	543-548
in	O	549-551
living	O	552-558
cells	O	559-564
by	O	565-567
means	O	568-573
of	O	574-576
fluorescence	O	577-589
resonance	O	590-599
energy	O	600-606
transfer	O	607-615
between	O	616-623
variants	O	624-632
of	O	633-635
green	O	636-641
fluorescent	O	642-653
protein	O	654-661
.	O	661-662

These	O	663-668
results	O	669-676
show	O	677-681
that	O	682-686
formation	O	687-696
of	O	697-699
preassociated	O	700-713
receptor	O	714-722
complexes	O	723-732
is	O	733-735
necessary	O	736-745
for	O	746-749
Fas	O	750-753
signaling	O	754-763
and	O	764-767
dominant	O	768-776
interference	O	777-789
in	O	790-792
human	O	793-798
disease	O	799-806
.	O	806-807
.	O	806-807

Familial	B	0-8
Mediterranean	I	9-22
fever	I	23-28
in	O	29-31
the	O	32-35
colchicine	O	36-46
era	O	47-50
:	O	50-51
the	O	52-55
fate	O	56-60
of	O	61-63
one	O	64-67
family	O	68-74
.	O	74-75

In	O	76-78
order	O	79-84
to	O	85-87
demonstrate	O	88-99
the	O	100-103
effect	O	104-110
of	O	111-113
prophylactic	O	114-126
colchicine	O	127-137
treatment	O	138-147
on	O	148-150
the	O	151-154
natural	O	155-162
history	O	163-170
of	O	171-173
familial	B	174-182
Mediterranean	I	183-196
fever	I	197-202
(	O	203-204
FMF	B	204-207
)	O	207-208
,	O	208-209
a	O	210-211
family	O	212-218
is	O	219-221
presented	O	222-231
with	O	232-236
6	O	237-238
out	O	239-242
of	O	243-245
9	O	246-247
siblings	O	248-256
affected	O	257-265
by	O	266-268
FMF	B	269-272
.	O	272-273

Each	O	274-278
patient	O	279-286
represents	O	287-297
a	O	298-299
different	O	300-309
stage	O	310-315
of	O	316-318
the	O	319-322
amyloidotic	B	323-334
kidney	I	335-341
disease	I	342-349
of	O	350-352
FMF	B	353-356
and	O	357-360
the	O	361-364
effect	O	365-371
of	O	372-374
continuous	O	375-385
colchicine	O	386-396
treatment	O	397-406
on	O	407-409
its	O	410-413
course	O	414-420
.	O	420-421

Considered	O	422-432
together	O	433-441
,	O	441-442
the	O	443-446
members	O	447-454
of	O	455-457
this	O	458-462
family	O	463-469
present	O	470-477
an	O	478-480
almost	O	481-487
complete	O	488-496
clinical	O	497-505
,	O	505-506
genetic	O	507-514
,	O	514-515
and	O	516-519
behavioral	O	520-530
picture	O	531-538
of	O	539-541
the	O	542-545
disease	O	546-553
.	O	553-554
.	O	553-554

Two	O	0-3
new	O	4-7
arylsulfatase	O	8-21
A	O	22-23
(	O	24-25
ARSA	O	25-29
)	O	29-30
mutations	O	31-40
in	O	41-43
a	O	44-45
juvenile	O	46-54
metachromatic	B	55-68
leukodystrophy	I	69-83
(	O	84-85
MLD	B	85-88
)	O	88-89
patient	O	90-97
.	O	97-98

Fragments	O	99-108
of	O	109-111
the	O	112-115
arylsulfatase	O	116-129
A	O	130-131
(	O	132-133
ARSA	O	133-137
)	O	137-138
gene	O	139-143
from	O	144-148
a	O	149-150
patient	O	151-158
with	O	159-163
juvenile	O	164-172
-	O	172-173
onset	O	173-178
metachromatic	B	179-192
leukodystrophy	I	193-207
(	O	208-209
MLD	B	209-212
)	O	212-213
were	O	214-218
amplified	O	219-228
by	O	229-231
PCR	O	232-235
and	O	236-239
ligated	O	240-247
into	O	248-252
MP13	O	253-257
cloning	O	258-265
vectors	O	266-273
.	O	273-274

Clones	O	275-281
hybridizing	O	282-293
with	O	294-298
cDNA	O	299-303
for	O	304-307
human	O	308-313
ARSA	O	314-318
were	O	319-323
selected	O	324-332
,	O	332-333
examined	O	334-342
for	O	343-346
appropriate	O	347-358
size	O	359-363
inserts	O	364-371
,	O	371-372
and	O	373-376
used	O	377-381
to	O	382-384
prepare	O	385-392
single	O	393-399
-	O	399-400
stranded	O	400-408
phage	O	409-414
DNA	O	415-418
.	O	418-419

Examination	O	420-431
of	O	432-434
the	O	435-438
entire	O	439-445
coding	O	446-452
and	O	453-456
most	O	457-461
of	O	462-464
the	O	465-468
intronic	O	469-477
sequence	O	478-486
revealed	O	487-495
two	O	496-499
putative	O	500-508
disease	O	509-516
-	O	516-517
related	O	517-524
mutations	O	525-534
.	O	534-535

One	O	536-539
,	O	539-540
a	O	541-542
point	O	543-548
mutation	O	549-557
in	O	558-560
exon	O	561-565
3	O	566-567
,	O	567-568
resulted	O	569-577
in	O	578-580
the	O	581-584
substitution	O	585-597
of	O	598-600
isoleucine	O	601-611
by	O	612-614
serine	O	615-621
.	O	621-622

Introduction	O	623-635
of	O	636-638
this	O	639-643
alteration	O	644-654
into	O	655-659
the	O	660-663
normal	O	664-670
ARSA	O	671-675
cDNA	O	676-680
sequence	O	681-689
resulted	O	690-698
in	O	699-701
a	O	702-703
substantial	O	704-715
decrease	O	716-724
in	O	725-727
ARSA	O	728-732
activity	O	733-741
on	O	742-744
transient	O	745-754
expression	O	755-765
in	O	766-768
cultured	O	769-777
baby	O	778-782
hamster	O	783-790
kidney	O	791-797
cells	O	798-803
.	O	803-804

About	O	805-810
5	O	811-812
%	O	812-813
of	O	814-816
the	O	817-820
control	O	821-828
expression	O	829-839
was	O	840-843
observed	O	844-852
,	O	852-853
suggesting	O	854-864
a	O	865-866
small	O	867-872
residual	O	873-881
activity	O	882-890
in	O	891-893
the	O	894-897
mutated	O	898-905
ARSA	O	906-910
.	O	910-911

The	O	912-915
second	O	916-922
mutation	O	923-931
,	O	931-932
a	O	933-934
G	O	935-936
-	O	936-937
to	O	937-939
-	O	936-937
A	O	940-941
transition	O	942-952
,	O	952-953
occurred	O	954-962
in	O	963-965
the	O	966-969
other	O	970-975
allele	O	976-982
and	O	983-986
resulted	O	987-995
in	O	996-998
an	O	999-1001
altered	O	1002-1009
splice	O	1010-1016
-	O	1016-1017
recognition	O	1017-1028
sequence	O	1029-1037
between	O	1038-1045
exon	O	1046-1050
7	O	1051-1052
and	O	1053-1056
the	O	1057-1060
following	O	1061-1070
intron	O	1071-1077
.	O	1077-1078

The	O	1079-1082
mutation	O	1083-1091
also	O	1092-1096
resulted	O	1097-1105
in	O	1106-1108
the	O	1109-1112
loss	O	1113-1117
of	O	1118-1120
a	O	1121-1122
restriction	O	1123-1134
site	O	1135-1139
.	O	1139-1140

Apparently	O	1141-1151
normal	O	1152-1158
levels	O	1159-1165
of	O	1166-1168
mRNA	O	1169-1173
were	O	1174-1178
generated	O	1179-1188
from	O	1189-1193
this	O	1194-1198
allele	O	1199-1205
,	O	1205-1206
but	O	1207-1210
no	O	1211-1213
ARSA	O	1214-1218
activity	O	1219-1227
or	O	1228-1230
immuno	O	1231-1237
-	O	1237-1238
cross	O	1238-1243
-	O	1237-1238
reactive	O	1244-1252
material	O	1253-1261
could	O	1262-1267
be	O	1268-1270
detected	O	1271-1279
.	O	1279-1280

A	O	1281-1282
collection	O	1283-1293
of	O	1294-1296
DNA	O	1297-1300
samples	O	1301-1308
from	O	1309-1313
known	O	1314-1319
or	O	1320-1322
suspected	O	1323-1332
MLD	B	1333-1336
patients	O	1337-1345
,	O	1345-1346
members	O	1347-1354
of	O	1355-1357
their	O	1358-1363
families	O	1364-1372
,	O	1372-1373
and	O	1374-1377
normal	O	1378-1384
controls	O	1385-1393
was	O	1394-1397
screened	O	1398-1406
for	O	1407-1410
these	O	1411-1416
mutations	O	1417-1426
.	O	1426-1427

Four	O	1428-1432
additional	O	1433-1443
individuals	O	1444-1455
carrying	O	1456-1464
each	O	1465-1469
of	O	1470-1472
the	O	1473-1476
mutations	O	1477-1486
were	O	1487-1491
found	O	1492-1497
among	O	1498-1503
the	O	1504-1507
nearly	O	1508-1514
100	O	1515-1518
MLD	B	1519-1522
patients	O	1523-1531
in	O	1532-1534
the	O	1535-1538
sample	O	1539-1545
.	O	1545-1546

Gene	O	1547-1551
segregation	O	1552-1563
in	O	1564-1566
the	O	1567-1570
original	O	1571-1579
patients	O	1580-1588
family	O	1589-1595
was	O	1596-1599
consistent	O	1600-1610
with	O	1611-1615
available	O	1616-1625
clinical	O	1626-1634
and	O	1635-1638
biochemical	O	1639-1650
data	O	1651-1655
.	O	1655-1656

No	O	1657-1659
individuals	O	1660-1671
homozygous	O	1672-1682
for	O	1683-1686
either	O	1687-1693
of	O	1694-1696
these	O	1697-1702
two	O	1703-1706
mutations	O	1707-1716
were	O	1717-1721
identified	O	1722-1732
.	O	1732-1733

However	O	1734-1741
,	O	1741-1742
combinations	O	1743-1755
with	O	1756-1760
other	O	1761-1766
MLD	B	1767-1770
mutations	O	1771-1780
suggest	O	1781-1788
that	O	1789-1793
the	O	1794-1797
point	O	1798-1803
mutation	O	1804-1812
in	O	1813-1815
exon	O	1816-1820
3	O	1821-1822
does	O	1823-1827
result	O	1828-1834
in	O	1835-1837
some	O	1838-1842
residual	O	1843-1851
enzyme	O	1852-1858
activity	O	1859-1867
and	O	1868-1871
is	O	1872-1874
associated	O	1875-1885
with	O	1886-1890
late	O	1891-1895
-	O	1895-1896
onset	O	1896-1901
forms	O	1902-1907
of	O	1908-1910
the	O	1911-1914
disease	O	1915-1922
.	O	1922-1923

The	O	1924-1927
splice	O	1928-1934
-	O	1934-1935
site	O	1935-1939
mutation	O	1940-1948
following	O	1949-1958
exon	O	1959-1963
7	O	1964-1965
produces	O	1966-1974
late	O	1975-1979
-	O	1979-1980
infantile	O	1980-1989
MLD	B	1990-1993
when	O	1994-1998
combined	O	1999-2007
with	O	2008-2012
other	O	2013-2018
enzyme	O	2019-2025
-	O	2025-2026
null	O	2026-2030
mutations	O	2031-2040
,	O	2040-2041
implying	O	2042-2050
that	O	2051-2055
it	O	2056-2058
is	O	2059-2061
completely	O	2062-2072
silent	O	2073-2079
enzymatically	O	2080-2093
.	O	2093-2094
.	O	2093-2094

Null	O	0-4
mutation	O	5-13
of	O	14-16
the	O	17-20
murine	O	21-27
ATP7B	O	28-33
(	O	34-35
Wilson	B	35-41
disease	I	42-49
)	O	49-50
gene	O	51-55
results	O	56-63
in	O	64-66
intracellular	B	67-80
copper	I	81-87
accumulation	I	88-100
and	O	101-104
late	B	105-109
-	I	109-110
onset	I	110-115
hepatic	I	116-123
nodular	I	124-131
transformation	I	132-146
.	O	146-147

The	O	148-151
Atp7b	O	152-157
protein	O	158-165
is	O	166-168
a	O	169-170
copper	O	171-177
-	O	177-178
transporting	O	178-190
ATPase	O	191-197
expressed	O	198-207
predominantly	O	208-221
in	O	222-224
the	O	225-228
liver	O	229-234
and	O	235-238
to	O	239-241
a	O	242-243
lesser	O	244-250
extent	O	251-257
in	O	258-260
most	O	261-265
other	O	266-271
tissues	O	272-279
.	O	279-280

Mutations	O	281-290
in	O	291-293
the	O	294-297
ATP7B	O	298-303
gene	O	304-308
lead	O	309-313
to	O	314-316
Wilson	B	317-323
disease	I	324-331
,	O	331-332
a	O	333-334
copper	B	335-341
toxicity	I	342-350
disorder	I	351-359
characterized	O	360-373
by	O	374-376
dramatic	O	377-385
build	O	386-391
-	O	391-392
up	O	392-394
of	O	395-397
intracellular	O	398-411
hepatic	O	412-419
copper	O	420-426
with	O	427-431
subsequent	O	432-442
hepatic	B	443-450
and	I	451-454
neuro	I	455-460
-	I	460-461
logical	I	461-468
abnormalities	I	469-482
.	O	482-483

Using	O	484-489
homologous	O	490-500
recombination	O	501-514
to	O	515-517
disrupt	O	518-525
the	O	526-529
normal	O	530-536
translation	O	537-548
of	O	549-551
ATP7B	O	552-557
,	O	557-558
we	O	559-561
have	O	562-566
generated	O	567-576
a	O	577-578
strain	O	579-585
of	O	586-588
mice	O	589-593
that	O	594-598
are	O	599-602
homozygous	O	603-613
mutants	O	614-621
(	O	622-623
null	O	623-627
)	O	627-628
for	O	629-632
the	O	633-636
Wilson	B	637-643
disease	I	644-651
gene	O	652-656
.	O	656-657

The	O	658-661
ATP7B	O	662-667
null	O	668-672
mice	O	673-677
display	O	678-685
a	O	686-687
gradual	O	688-695
accumulation	O	696-708
of	O	709-711
hepatic	O	712-719
copper	O	720-726
that	O	727-731
increases	O	732-741
to	O	742-744
a	O	745-746
level	O	747-752
60	O	753-755
-	O	755-756
fold	O	756-760
greater	O	761-768
than	O	769-773
normal	O	774-780
by	O	781-783
5	O	784-785
months	O	786-792
of	O	793-795
age	O	796-799
.	O	799-800

An	O	801-803
increase	O	804-812
in	O	813-815
copper	O	816-822
concentration	O	823-836
was	O	837-840
also	O	841-845
observed	O	846-854
in	O	855-857
the	O	858-861
kidney	O	862-868
,	O	868-869
brain	O	870-875
,	O	875-876
placenta	O	877-885
and	O	886-889
lactating	O	890-899
mammary	O	900-907
glands	O	908-914
of	O	915-917
homo	O	918-922
-	O	922-923
zygous	O	923-929
mutants	O	930-937
,	O	937-938
although	O	939-947
milk	O	948-952
from	O	953-957
the	O	958-961
mutant	O	962-968
glands	O	969-975
was	O	976-979
copper	B	980-986
deficient	I	987-996
.	O	996-997

Morphological	B	998-1011
abnormalities	I	1012-1025
resembling	O	1026-1036
cirrhosis	B	1037-1046
developed	O	1047-1056
in	O	1057-1059
the	O	1060-1063
majority	O	1064-1072
of	O	1073-1075
the	O	1076-1079
livers	O	1080-1086
from	O	1087-1091
homozygous	O	1092-1102
mutants	O	1103-1110
older	O	1111-1116
than	O	1117-1121
7	O	1122-1123
months	O	1124-1130
of	O	1131-1133
age	O	1134-1137
.	O	1137-1138

Progeny	O	1139-1146
of	O	1147-1149
the	O	1150-1153
homozygous	O	1154-1164
mutant	O	1165-1171
females	O	1172-1179
demonstrated	O	1180-1192
neurological	B	1193-1205
abnormalities	I	1206-1219
and	O	1220-1223
growth	B	1224-1230
retardation	I	1231-1242
characteristic	O	1243-1257
of	O	1258-1260
copper	B	1261-1267
deficiency	I	1268-1278
.	O	1278-1279

Copper	O	1280-1286
concentration	O	1287-1300
in	O	1301-1303
the	O	1304-1307
livers	O	1308-1314
of	O	1315-1317
the	O	1318-1321
newborn	O	1322-1329
homozygous	O	1330-1340
null	O	1341-1345
mutants	O	1346-1353
was	O	1354-1357
decreased	O	1358-1367
dramatically	O	1368-1380
.	O	1380-1381

In	O	1382-1384
summary	O	1385-1392
,	O	1392-1393
inactivation	O	1394-1406
of	O	1407-1409
the	O	1410-1413
murine	O	1414-1420
ATP7B	O	1421-1426
gene	O	1427-1431
produces	O	1432-1440
a	O	1441-1442
form	O	1443-1447
of	O	1448-1450
cirrhotic	B	1451-1460
liver	I	1461-1466
disease	I	1467-1474
that	O	1475-1479
resembles	O	1480-1489
Wilson	B	1490-1496
disease	I	1497-1504
in	O	1505-1507
humans	O	1508-1514
and	O	1515-1518
the	O	1519-1522
toxic	O	1523-1528
milk	O	1529-1533
phenotype	O	1534-1543
in	O	1544-1546
the	O	1547-1550
mouse	O	1551-1556
.	O	1556-1557
.	O	1556-1557

Adrenoleukodystrophy	B	0-20
and	O	21-24
adrenomyeloneuropathy	B	25-46
associated	O	47-57
with	O	58-62
partial	O	63-70
adrenal	B	71-78
insufficiency	I	79-92
in	O	93-95
three	O	96-101
generations	O	102-113
of	O	114-116
a	O	117-118
kindred	O	119-126
.	O	126-127

Four	O	128-132
cases	O	133-138
of	O	139-141
adrenoleukodystrophy	B	142-162
(	O	163-164
ALD	B	164-167
)	O	167-168
and	O	169-172
one	O	173-176
case	O	177-181
of	O	182-184
adrenomyeloneuropathy	B	185-206
(	O	207-208
AMN	B	208-211
)	O	211-212
have	O	213-217
developed	O	218-227
in	O	228-230
a	O	231-232
kindred	O	233-240
over	O	241-245
three	O	246-251
generations	O	252-263
demonstrating	O	264-277
that	O	278-282
AMN	B	283-286
is	O	287-289
a	O	290-291
clinical	O	292-300
variant	O	301-308
of	O	309-311
ALD	B	312-315
.	O	315-316

Pituitary	O	317-326
-	O	326-327
adrenal	O	327-334
function	O	335-343
studies	O	344-351
were	O	352-356
performed	O	357-366
in	O	367-369
10	O	370-372
family	O	373-379
members	O	380-387
,	O	387-388
including	O	389-398
two	O	399-402
affected	O	403-411
males	O	412-417
and	O	418-421
four	O	422-426
females	O	427-434
identified	O	435-445
as	O	446-448
carriers	O	449-457
of	O	458-460
ALD	B	461-464
/	O	464-465
AMN	B	465-468
.	O	468-469

No	O	470-472
pituitary	B	473-482
-	I	482-483
adrenal	I	483-490
abnormality	I	491-502
was	O	503-506
found	O	507-512
in	O	513-515
the	O	516-519
carriers	O	520-528
.	O	528-529

However	O	530-537
,	O	537-538
basal	O	539-544
morning	O	545-552
plasma	O	553-559
adrenocorticotropic	O	560-579
hormone	O	580-587
(	O	588-589
ACTH	O	589-593
)	O	593-594
levels	O	595-601
were	O	602-606
markedly	O	607-615
elevated	O	616-624
in	O	625-627
the	O	628-631
two	O	632-635
males	O	636-641
with	O	642-646
ALD	B	647-650
and	O	651-654
AMN	B	655-658
,	O	658-659
despite	O	660-667
the	O	668-671
fact	O	672-676
that	O	677-681
they	O	682-686
had	O	687-690
no	O	691-693
clinical	O	694-702
signs	O	703-708
of	O	709-711
adrenal	B	712-719
insufficiency	I	720-733
and	O	734-737
that	O	738-742
morning	O	743-750
plasma	O	751-757
cortisol	O	758-766
levels	O	767-773
and	O	774-777
their	O	778-783
response	O	784-792
to	O	793-795
maximal	O	796-803
exogenous	O	804-813
ACTH	O	814-818
stimulation	O	819-830
appeared	O	831-839
to	O	840-842
be	O	843-845
normal	O	846-852
.	O	852-853

In	O	854-856
addition	O	857-865
,	O	865-866
the	O	867-870
integrated	O	871-881
24	O	882-884
-	O	884-885
hour	O	885-889
response	O	890-898
to	O	899-901
the	O	902-905
administration	O	906-920
were	O	921-925
also	O	926-930
subnormal	O	931-940
in	O	941-943
these	O	944-949
two	O	950-953
cases	O	954-959
.	O	959-960

Thus	O	961-965
,	O	965-966
people	O	967-973
with	O	974-978
ALD	B	979-982
and	O	983-986
AMN	B	987-990
may	O	991-994
have	O	995-999
subclinical	O	1000-1011
partial	O	1012-1019
adrenocrotical	B	1020-1034
insufficiency	I	1035-1048
.	O	1048-1049

No	O	1050-1052
other	O	1053-1058
endocrinologic	B	1059-1073
dysfunction	I	1074-1085
was	O	1086-1089
identified	O	1090-1100
.	O	1100-1101
.	O	1100-1101

Identification	O	0-14
of	O	15-17
mutations	O	18-27
in	O	28-30
the	O	31-34
ALD	O	35-38
-	O	38-39
gene	O	39-43
of	O	44-46
20	O	47-49
families	O	50-58
with	O	59-63
adrenoleukodystrophy	B	64-84
/	O	84-85
adrenomyeloneuropathy	B	85-106
.	O	106-107

Adrenoleukodystrophy	B	108-128
(	O	129-130
ALD	B	130-133
)	O	133-134
,	O	134-135
an	O	136-138
X	B	139-140
-	I	140-141
linked	I	141-147
inherited	I	148-157
metabolic	I	158-167
disorder	I	168-176
,	O	176-177
is	O	178-180
the	O	181-184
most	O	185-189
frequent	O	190-198
inborn	B	199-205
peroxisomal	I	206-217
disease	I	218-225
.	O	225-226

It	O	227-229
leads	O	230-235
to	O	236-238
demyelination	B	239-252
in	I	253-255
the	I	256-259
central	I	260-267
and	I	268-271
peripheral	I	272-282
nervous	I	283-290
system	I	291-297
.	O	297-298

Defective	O	299-308
beta	O	309-313
-	O	313-314
oxidation	O	314-323
of	O	324-326
saturated	O	327-336
very	O	337-341
long	O	342-346
chain	O	347-352
fatty	O	353-358
acids	O	359-364
(	O	365-366
VLCFAs	O	366-372
;	O	372-373
C22	O	374-377
0	O	379-380
-	O	380-381
C26	O	381-384
0	O	386-387
)	O	387-388
in	O	389-391
peroxisomes	O	392-403
has	O	404-407
been	O	408-412
shown	O	413-418
to	O	419-421
lead	O	422-426
to	O	427-429
an	O	430-432
accumulation	O	433-445
of	O	446-448
VLCFAs	O	449-455
in	O	456-458
leukoid	O	459-466
areas	O	467-472
of	O	473-475
the	O	476-479
central	O	480-487
nervous	O	488-495
system	O	496-502
,	O	502-503
peripheral	O	504-514
nerves	O	515-521
,	O	521-522
adrenal	O	523-530
gland	O	531-536
,	O	536-537
and	O	538-541
blood	O	542-547
.	O	547-548

The	O	549-552
ALD	B	553-556
gene	O	557-561
has	O	562-565
been	O	566-570
recently	O	571-579
identified	O	580-590
and	O	591-594
encodes	O	595-602
a	O	603-604
745	O	605-608
-	O	608-609
amino	O	609-614
-	O	608-609
acid	O	615-619
protein	O	620-627
.	O	627-628

We	O	629-631
screened	O	632-640
patients	O	641-649
with	O	650-654
adrenoleukodystrophy	B	655-675
/	O	675-676
adrenomyeloneuropathy	B	676-697
(	O	698-699
ALD	B	699-702
/	O	702-703
AMN	B	703-706
)	O	706-707
from	O	708-712
20	O	713-715
kindreds	O	716-724
for	O	725-728
mutations	O	729-738
in	O	739-741
the	O	742-745
ALD	B	746-749
gene	O	750-754
.	O	754-755

Eleven	O	756-762
missense	O	763-771
and	O	772-775
two	O	776-779
nonsense	O	780-788
mutations	O	789-798
,	O	798-799
five	O	800-804
deletions	O	805-814
,	O	814-815
and	O	816-819
one	O	820-823
insertion	O	824-833
were	O	834-838
detected	O	839-847
by	O	848-850
direct	O	851-857
sequencing	O	858-868
of	O	869-871
eight	O	872-877
reverse	O	878-885
transcribed	O	886-897
fragments	O	898-907
of	O	908-910
the	O	911-914
ALD	B	915-918
-	O	918-919
gene	O	919-923
mRNA	O	924-928
.	O	928-929

Four	O	930-934
mutations	O	935-944
could	O	945-950
be	O	951-953
shown	O	954-959
to	O	960-962
be	O	963-965
de	O	966-968
novo	O	969-973
.	O	973-974

All	O	975-978
mutations	O	979-988
could	O	989-994
be	O	995-997
confirmed	O	998-1007
in	O	1008-1010
carriers	O	1011-1019
by	O	1020-1022
sequencing	O	1023-1033
genomic	O	1034-1041
DNA	O	1042-1045
.	O	1045-1046

No	O	1047-1049
correlation	O	1050-1061
between	O	1062-1069
the	O	1070-1073
type	O	1074-1078
of	O	1079-1081
mutation	O	1082-1090
and	O	1091-1094
the	O	1095-1098
severity	O	1099-1107
of	O	1108-1110
the	O	1111-1114
phenotype	O	1115-1124
could	O	1125-1130
be	O	1131-1133
observed	O	1134-1142
.	O	1142-1143

The	O	1144-1147
mutations	O	1148-1157
were	O	1158-1162
not	O	1163-1166
detected	O	1167-1175
in	O	1176-1178
the	O	1179-1182
ALD	B	1183-1186
gene	O	1187-1191
of	O	1192-1194
30	O	1195-1197
healthy	O	1198-1205
persons	O	1206-1213
.	O	1213-1214
.	O	1213-1214

Gonosomal	O	0-9
mosaicism	O	10-19
in	O	20-22
myotonic	B	23-31
dystrophy	I	32-41
patients	O	42-50
:	O	50-51
involvement	O	52-63
of	O	64-66
mitotic	O	67-74
events	O	75-81
in	O	82-84
(	O	85-86
CTG	O	86-89
)	O	89-90
n	O	90-91
repeat	O	92-98
variation	O	99-108
and	O	109-112
selection	O	113-122
against	O	123-130
extreme	O	131-138
expansion	O	139-148
in	O	149-151
sperm	O	152-157
.	O	157-158

Myotonic	B	159-167
dystrophy	I	168-177
(	O	178-179
DM	B	179-181
)	O	181-182
is	O	183-185
caused	O	186-192
by	O	193-195
abnormal	O	196-204
expansion	O	205-214
of	O	215-217
a	O	218-219
polymorphic	O	220-231
(	O	232-233
CTG	O	233-236
)	O	236-237
n	O	238-239
repeat	O	240-246
,	O	246-247
located	O	248-255
in	O	256-258
the	O	259-262
DM	B	263-265
protein	O	266-273
kinase	O	274-280
gene	O	281-285
.	O	285-286

We	O	287-289
determined	O	290-300
the	O	301-304
(	O	305-306
CTG	O	306-309
)	O	309-310
n	O	311-312
repeat	O	313-319
lengths	O	320-327
in	O	328-330
a	O	331-332
broad	O	333-338
range	O	339-344
of	O	345-347
tissue	O	348-354
DNAs	O	355-359
from	O	360-364
patients	O	365-373
with	O	374-378
mild	O	379-383
,	O	383-384
classical	O	385-394
,	O	394-395
or	O	396-398
congenital	O	399-409
manifestation	O	410-423
of	O	424-426
DM	B	427-429
.	O	429-430

Differences	O	431-442
in	O	443-445
the	O	446-449
repeat	O	450-456
length	O	457-463
were	O	464-468
seen	O	469-473
in	O	474-476
somatic	O	477-484
tissues	O	485-492
from	O	493-497
single	O	498-504
DM	B	505-507
individuals	O	508-519
and	O	520-523
twins	O	524-529
.	O	529-530

Repeats	O	531-538
appeared	O	539-547
to	O	548-550
expand	O	551-557
to	O	558-560
a	O	561-562
similar	O	563-570
extent	O	571-577
in	O	578-580
tissues	O	581-588
originating	O	589-600
from	O	601-605
the	O	606-609
same	O	610-614
embryonal	O	615-624
origin	O	625-631
.	O	631-632

In	O	633-635
most	O	636-640
male	O	641-645
patients	O	646-654
carrying	O	655-663
intermediate	O	664-676
-	O	676-677
or	O	678-680
small	O	681-686
-	O	686-687
sized	O	687-692
expansions	O	693-703
in	O	704-706
blood	O	707-712
,	O	712-713
the	O	714-717
repeat	O	718-724
lengths	O	725-732
covered	O	733-740
a	O	741-742
markedly	O	743-751
wider	O	752-757
range	O	758-763
in	O	764-766
sperm	O	767-772
.	O	772-773

In	O	774-776
contrast	O	777-785
,	O	785-786
male	O	787-791
patients	O	792-800
with	O	801-805
large	O	806-811
allele	O	812-818
expansions	O	819-829
in	O	830-832
blood	O	833-838
(	O	839-840
>	O	840-841
700	O	842-845
CTGs	O	846-850
)	O	850-851
had	O	852-855
similar	O	856-863
or	O	864-866
smaller	O	867-874
repeats	O	875-882
in	O	883-885
sperm	O	886-891
,	O	891-892
when	O	893-897
detectable	O	898-908
.	O	908-909

Sperm	O	910-915
alleles	O	916-923
with	O	924-928
>	O	929-930
1	O	931-932
,	O	932-933
000	O	934-937
CTGs	O	938-942
were	O	943-947
not	O	948-951
seen	O	952-956
.	O	956-957

We	O	958-960
conclude	O	961-969
that	O	970-974
DM	B	975-977
patients	O	978-986
can	O	987-990
be	O	991-993
considered	O	994-1004
gonosomal	O	1005-1014
mosaics	O	1015-1022
,	O	1022-1023
i	O	1024-1025
.	O	1025-1026
e	O	1027-1028
e	O	1029-1030
.	O	1030-1031
,	O	1031-1032
combined	O	1033-1041
somatic	O	1042-1049
and	O	1050-1053
germ	O	1054-1058
-	O	1058-1059
line	O	1059-1063
tissue	O	1064-1070
mosaics	O	1071-1078
.	O	1078-1079

Most	O	1080-1084
remarkably	O	1085-1095
,	O	1095-1096
we	O	1097-1099
observed	O	1100-1108
multiple	O	1109-1117
cases	O	1118-1123
where	O	1124-1129
the	O	1130-1133
length	O	1134-1140
distributions	O	1141-1154
of	O	1155-1157
intermediate	O	1158-1170
-	O	1170-1171
or	O	1172-1174
small	O	1175-1180
-	O	1180-1181
sized	O	1181-1186
alleles	O	1187-1194
in	O	1195-1197
fathers	O	1198-1205
sperm	O	1206-1211
were	O	1212-1216
significantly	O	1217-1230
different	O	1231-1240
from	O	1241-1245
that	O	1246-1250
in	O	1251-1253
their	O	1254-1259
offsprings	O	1260-1270
blood	O	1271-1276
.	O	1276-1277

Our	O	1278-1281
combined	O	1282-1290
findings	O	1291-1299
indicate	O	1300-1308
that	O	1309-1313
intergenerational	O	1314-1331
length	O	1332-1338
changes	O	1339-1346
in	O	1347-1349
the	O	1350-1353
unstable	O	1354-1362
CTG	O	1363-1366
repeat	O	1367-1373
are	O	1374-1377
most	O	1378-1382
likely	O	1383-1389
to	O	1390-1392
occur	O	1393-1398
during	O	1399-1405
early	O	1406-1411
embryonic	O	1412-1421
mitotic	O	1422-1429
divisions	O	1430-1439
in	O	1440-1442
both	O	1443-1447
somatic	O	1448-1455
and	O	1456-1459
germ	O	1460-1464
-	O	1464-1465
line	O	1465-1469
tissue	O	1470-1476
formation	O	1477-1486
.	O	1486-1487

Both	O	1488-1492
the	O	1493-1496
initial	O	1497-1504
CTG	O	1505-1508
length	O	1509-1515
,	O	1515-1516
the	O	1517-1520
overall	O	1521-1528
number	O	1529-1535
of	O	1536-1538
cell	O	1539-1543
divisions	O	1544-1553
involved	O	1554-1562
in	O	1563-1565
tissue	O	1566-1572
formation	O	1573-1582
,	O	1582-1583
and	O	1584-1587
perhaps	O	1588-1595
a	O	1596-1597
specific	O	1598-1606
selection	O	1607-1616
process	O	1617-1624
in	O	1625-1627
spermatogenesis	O	1628-1643
may	O	1644-1647
influence	O	1648-1657
the	O	1658-1661
dynamics	O	1662-1670
of	O	1671-1673
this	O	1674-1678
process	O	1679-1686
.	O	1686-1687

A	O	1688-1689
model	O	1690-1695
explaining	O	1696-1706
mitotic	O	1707-1714
instability	O	1715-1726
and	O	1727-1730
sex	O	1731-1734
-	O	1734-1735
dependent	O	1735-1744
segregation	O	1745-1756
phenomena	O	1757-1766
in	O	1767-1769
DM	B	1770-1772
manifestation	O	1773-1786
is	O	1787-1789
discussed	O	1790-1799

Combined	O	0-8
analysis	O	9-17
of	O	18-20
hereditary	B	21-31
prostate	I	32-40
cancer	I	41-47
linkage	O	48-55
to	O	56-58
1q24	O	59-63
-	O	63-64
25	O	64-66
:	O	66-67
results	O	68-75
from	O	76-80
772	O	81-84
hereditary	B	85-95
prostate	I	96-104
cancer	I	105-111
families	O	112-120
from	O	121-125
the	O	126-129
International	O	130-143
Consortium	O	144-154
for	O	155-158
Prostate	B	159-167
Cancer	I	168-174
Genetics	O	175-183
.	O	183-184

A	O	185-186
previous	O	187-195
linkage	O	196-203
study	O	204-209
provided	O	210-218
evidence	O	219-227
for	O	228-231
a	O	232-233
prostate	B	234-242
cancer	I	243-249
-	O	249-250
susceptibility	O	250-264
locus	O	265-270
at	O	271-273
1q24	O	274-278
-	O	278-279
25	O	279-281
.	O	281-282

Subsequent	O	283-293
reports	O	294-301
in	O	302-304
additional	O	305-315
collections	O	316-327
of	O	328-330
families	O	331-339
have	O	340-344
yielded	O	345-352
conflicting	O	353-364
results	O	365-372
.	O	372-373

In	O	374-376
addition	O	377-385
,	O	385-386
evidence	O	387-395
for	O	396-399
locus	O	400-405
heterogeneity	O	406-419
has	O	420-423
been	O	424-428
provided	O	429-437
by	O	438-440
the	O	441-444
identification	O	445-459
of	O	460-462
other	O	463-468
putative	O	469-477
hereditary	B	478-488
prostate	I	489-497
cancer	I	498-504
loci	O	505-509
on	O	510-512
Xq27	O	513-517
-	O	517-518
28	O	518-520
,	O	520-521
1q42	O	522-526
-	O	526-527
43	O	527-529
,	O	529-530
and	O	531-534
1p36	O	535-539
.	O	539-540

The	O	541-544
present	O	545-552
study	O	553-558
describes	O	559-568
a	O	569-570
combined	O	571-579
analysis	O	580-588
for	O	589-592
six	O	593-596
markers	O	597-604
in	O	605-607
the	O	608-611
1q24	O	612-616
-	O	616-617
25	O	617-619
region	O	620-626
in	O	627-629
772	O	630-633
families	O	634-642
affected	O	643-651
by	O	652-654
hereditary	B	655-665
prostate	I	666-674
cancer	I	675-681
and	O	682-685
ascertained	O	686-697
by	O	698-700
the	O	701-704
members	O	705-712
of	O	713-715
the	O	716-719
International	O	720-733
Consortium	O	734-744
for	O	745-748
Prostate	B	749-757
Cancer	I	758-764
Genetics	O	765-773
(	O	774-775
ICPCG	O	775-780
)	O	780-781
from	O	782-786
North	O	787-792
America	O	793-800
,	O	800-801
Australia	O	802-811
,	O	811-812
Finland	O	813-820
,	O	820-821
Norway	O	822-828
,	O	828-829
Sweden	O	830-836
,	O	836-837
and	O	838-841
the	O	842-845
United	O	846-852
Kingdom	O	853-860
.	O	860-861

Overall	O	862-869
,	O	869-870
there	O	871-876
was	O	877-880
some	O	881-885
evidence	O	886-894
for	O	895-898
linkage	O	899-906
,	O	906-907
with	O	908-912
a	O	913-914
peak	O	915-919
parametric	O	920-930
multipoint	O	931-941
LOD	O	942-945
score	O	946-951
assuming	O	952-960
heterogeneity	O	961-974
(	O	975-976
HLOD	O	976-980
)	O	980-981
of	O	982-984
1	O	985-986
.	O	986-987
40	O	988-990
(	O	991-992
P	O	992-993
=	O	994-995
.	O	995-996
01	O	997-999
)	O	999-1000
at	O	1001-1003
D1S212	O	1004-1010
.	O	1010-1011

The	O	1012-1015
estimated	O	1016-1025
proportion	O	1026-1036
of	O	1037-1039
families	O	1040-1048
(	O	1049-1050
alpha	O	1050-1055
)	O	1055-1056
linked	O	1057-1063
to	O	1064-1066
the	O	1067-1070
locus	O	1071-1076
was	O	1077-1080
.	O	1080-1081

06	O	1082-1084
(	O	1085-1086
1	O	1086-1087
-	O	1087-1088
LOD	O	1088-1091
support	O	1092-1099
interval	O	1100-1108
.	O	1108-1109

01	O	1110-1112
-	O	1112-1113
.	O	1113-1114

12	O	1115-1117
)	O	1117-1118
.	O	1118-1119

This	O	1120-1124
evidence	O	1125-1133
was	O	1134-1137
not	O	1138-1141
observed	O	1142-1150
by	O	1151-1153
a	O	1154-1155
nonparametric	O	1156-1169
approach	O	1170-1178
,	O	1178-1179
presumably	O	1180-1190
because	O	1191-1198
of	O	1199-1201
the	O	1202-1205
extensive	O	1206-1215
heterogeneity	O	1216-1229
.	O	1229-1230

Further	O	1231-1238
parametric	O	1239-1249
analysis	O	1250-1258
revealed	O	1259-1267
a	O	1268-1269
significant	O	1270-1281
effect	O	1282-1288
of	O	1289-1291
the	O	1292-1295
presence	O	1296-1304
of	O	1305-1307
male	O	1308-1312
-	O	1312-1313
to	O	1313-1315
-	O	1312-1313
male	O	1308-1312
disease	O	1321-1328
transmission	O	1329-1341
within	O	1342-1348
the	O	1349-1352
families	O	1353-1361
.	O	1361-1362

In	O	1363-1365
the	O	1366-1369
subset	O	1370-1376
of	O	1377-1379
491	O	1380-1383
such	O	1384-1388
families	O	1389-1397
,	O	1397-1398
the	O	1399-1402
peak	O	1403-1407
HLOD	O	1408-1412
was	O	1413-1416
2	O	1417-1418
.	O	1418-1419
In	O	1420-1422
the	O	1423-1426
subset	O	1427-1433
of	O	1434-1436
491	O	1437-1440
such	O	1441-1445
families	O	1446-1454
,	O	1454-1455
the	O	1456-1459
peak	O	1460-1464
HLOD	O	1465-1469
was	O	1470-1473
2	O	1474-1475
.	O	1475-1476
56	O	1477-1479
(	O	1480-1481
P	O	1481-1482
=	O	1483-1484
.	O	1484-1485
0006	O	1486-1490
)	O	1490-1491
and	O	1492-1495
alpha	O	1496-1501
=	O	1502-1503
.	O	1503-1504
11	O	1505-1507
(	O	1508-1509
1	O	1509-1510
-	O	1510-1511
LOD	O	1511-1514
support	O	1515-1522
interval	O	1523-1531
.	O	1531-1532

04	O	1533-1535
-	O	1535-1536
.	O	1536-1537

19	O	1538-1540
)	O	1540-1541
,	O	1541-1542
compared	O	1543-1551
with	O	1552-1556
HLODs	O	1557-1562
of	O	1563-1565
0	O	1566-1567
in	O	1568-1570
the	O	1571-1574
remaining	O	1575-1584
281	O	1585-1588
families	O	1589-1597
.	O	1597-1598

Within	O	1599-1605
the	O	1606-1609
families	O	1610-1618
with	O	1619-1623
male	O	1624-1628
-	O	1628-1629
to	O	1629-1631
-	O	1628-1629
male	O	1624-1628
disease	O	1637-1644
transmission	O	1645-1657
,	O	1657-1658
alpha	O	1659-1664
increased	O	1665-1674
with	O	1675-1679
the	O	1680-1683
early	O	1684-1689
mean	O	1690-1694
age	O	1695-1698
at	O	1699-1701
diagnosis	O	1702-1711
(	O	1712-1713
<	O	1713-1714
65	O	1715-1717
years	O	1718-1723
,	O	1723-1724
alpha	O	1725-1730
=	O	1731-1732
.	O	1732-1733
19	O	1734-1736
,	O	1736-1737
with	O	1738-1742
1	O	1743-1744
-	O	1744-1745
LOD	O	1745-1748
support	O	1749-1756
interval	O	1757-1765
.	O	1765-1766

06	O	1767-1769
-	O	1769-1770
.	O	1770-1771

34	O	1772-1774
)	O	1774-1775
and	O	1776-1779
the	O	1780-1783
number	O	1784-1790
of	O	1791-1793
affected	O	1794-1802
family	O	1803-1809
members	O	1810-1817
(	O	1818-1819
five	O	1819-1823
or	O	1824-1826
more	O	1827-1831
family	O	1832-1838
members	O	1839-1846
,	O	1846-1847
alpha	O	1848-1853
=	O	1854-1855
.	O	1855-1856
15	O	1857-1859
,	O	1859-1860
with	O	1861-1865
1	O	1866-1867
-	O	1867-1868
LOD	O	1868-1871
support	O	1872-1879
interval	O	1880-1888
.	O	1888-1889

04	O	1890-1892
-	O	1892-1893
.	O	1893-1894

28	O	1895-1897
)	O	1897-1898
.	O	1898-1899

The	O	1900-1903
highest	O	1904-1911
value	O	1912-1917
of	O	1918-1920
alpha	O	1921-1926
was	O	1927-1930
observed	O	1931-1939
for	O	1940-1943
the	O	1944-1947
48	O	1948-1950
families	O	1951-1959
that	O	1960-1964
met	O	1965-1968
all	O	1969-1972
three	O	1973-1978
criteria	O	1979-1987
(	O	1988-1989
peak	O	1989-1993
HLOD	O	1994-1998
=	O	1999-2000
2	O	2001-2002
.	O	2002-2003
25	O	2004-2006
,	O	2006-2007
P	O	2008-2009
=	O	2010-2011
.	O	2011-2012
001	O	2013-2016
,	O	2016-2017
alpha	O	2018-2023
=	O	2024-2025
.	O	2025-2026
29	O	2027-2029
,	O	2029-2030
with	O	2031-2035
1	O	2036-2037
-	O	2037-2038
LOD	O	2038-2041
support	O	2042-2049
interval	O	2050-2058
.	O	2058-2059

08	O	2060-2062
-	O	2062-2063
.	O	2063-2064

53	O	2065-2067
)	O	2067-2068
.	O	2068-2069

These	O	2070-2075
results	O	2076-2083
support	O	2084-2091
the	O	2092-2095
finding	O	2096-2103
of	O	2104-2106
a	O	2107-2108
prostate	B	2109-2117
cancer	I	2118-2124
-	O	2124-2125
susceptibility	O	2125-2139
gene	O	2140-2144
linked	O	2145-2151
to	O	2152-2154
1q24	O	2155-2159
-	O	2159-2160
25	O	2160-2162
,	O	2162-2163
albeit	O	2164-2170
in	O	2171-2173
a	O	2174-2175
defined	O	2176-2183
subset	O	2184-2190
of	O	2191-2193
prostate	B	2194-2202
cancer	I	2203-2209
families	O	2210-2218
.	O	2218-2219

Although	O	2220-2228
HPC1	O	2229-2233
accounts	O	2234-2242
for	O	2243-2246
only	O	2247-2251
a	O	2252-2253
small	O	2254-2259
proportion	O	2260-2270
of	O	2271-2273
all	O	2274-2277
families	O	2278-2286
affected	O	2287-2295
by	O	2296-2298
hereditary	B	2299-2309
prostate	I	2310-2318
cancer	I	2319-2325
,	O	2325-2326
it	O	2327-2329
appears	O	2330-2337
to	O	2338-2340
play	O	2341-2345
a	O	2346-2347
more	O	2348-2352
prominent	O	2353-2362
role	O	2363-2367
in	O	2368-2370
the	O	2371-2374
subset	O	2375-2381
of	O	2382-2384
families	O	2385-2393
with	O	2394-2398
several	O	2399-2406
members	O	2407-2414
affected	O	2415-2423
at	O	2424-2426
an	O	2427-2429
early	O	2430-2435
age	O	2436-2439
and	O	2440-2443
with	O	2444-2448
male	O	2449-2453
-	O	2453-2454
to	O	2454-2456
-	O	2453-2454
male	O	2449-2453
disease	O	2462-2469
transmission	O	2470-2482
.	O	2482-2483

A	O	0-1
novel	O	2-7
disease	O	8-15
with	O	16-20
deficiency	B	21-31
of	I	32-34
mitochondrial	I	35-48
very	I	49-53
-	I	53-54
long	I	54-58
-	I	53-54
chain	I	59-64
acyl	I	65-69
-	I	69-70
CoA	I	70-73
dehydrogenase	I	74-87
.	O	87-88

Palmitoyl	O	89-98
-	O	98-99
CoA	O	99-102
dehydrogenase	O	103-116
activity	O	117-125
in	O	126-128
skin	O	129-133
fibroblasts	O	134-145
from	O	146-150
seven	O	151-156
patients	O	157-165
with	O	166-170
unidentified	O	171-183
defects	O	184-191
of	O	192-194
fatty	O	195-200
acid	O	201-205
oxidation	O	206-215
was	O	216-219
measured	O	220-228
in	O	229-231
the	O	232-235
presence	O	236-244
and	O	245-248
absence	O	249-256
of	O	257-259
antibodies	O	260-270
against	O	271-278
medium	O	279-285
-	O	285-286
chain	O	286-291
,	O	291-292
long	O	293-297
-	O	297-298
chain	O	298-303
,	O	303-304
and	O	305-308
very	O	309-313
-	O	313-314
long	O	314-318
-	O	313-314
chain	O	319-324
acyl	O	325-329
-	O	329-330
CoA	O	330-333
dehydrogenases	O	334-348
(	O	349-350
VLCAD	O	350-355
)	O	355-356
.	O	356-357

Two	O	358-361
of	O	362-364
the	O	365-368
patients	O	369-377
,	O	377-378
4	O	379-380
-	O	380-381
5	O	381-382
month	O	383-388
old	O	389-392
boys	O	393-397
,	O	397-398
were	O	399-403
found	O	404-409
to	O	410-412
have	O	413-417
a	O	418-419
novel	O	420-425
disease	O	426-433
,	O	433-434
VLCAD	B	435-440
deficiency	I	441-451
,	O	451-452
as	O	453-455
judged	O	456-462
from	O	463-467
the	O	468-471
results	O	472-479
of	O	480-482
very	O	483-487
low	O	488-491
palmitoyl	O	492-501
-	O	501-502
CoA	O	502-505
dehydrogenase	O	506-519
activity	O	520-528
and	O	529-532
the	O	533-536
lack	O	537-541
of	O	542-544
immunoreactivity	O	545-561
toward	O	562-568
antibody	O	569-577
raised	O	578-584
to	O	585-587
purified	O	588-596
VLCAD	O	597-602
.	O	602-603
.	O	602-603

Inherited	O	0-9
WT1	O	10-13
mutation	O	14-22
in	O	23-25
Denys	B	26-31
-	I	31-32
Drash	I	32-37
syndrome	I	38-46
.	O	46-47

Patients	O	48-56
with	O	57-61
the	O	62-65
Denys	B	66-71
-	I	71-72
Drash	I	72-77
syndrome	I	78-86
(	O	87-88
Wilms	B	88-93
tumor	I	94-99
,	O	99-100
genital	B	101-108
anomalies	I	109-118
,	O	118-119
and	O	120-123
nephropathy	B	124-135
)	O	135-136
have	O	137-141
been	O	142-146
demonstrated	O	147-159
to	O	160-162
carry	O	163-168
de	O	169-171
novo	O	172-176
constitutional	O	177-191
mutations	O	192-201
in	O	202-204
WT1	O	205-208
,	O	208-209
the	O	210-213
Wilms	B	214-219
tumor	I	220-225
gene	O	226-230
at	O	231-233
chromosome	O	234-244
11p13	O	245-250
.	O	250-251

We	O	252-254
report	O	255-261
three	O	262-267
new	O	268-271
cases	O	272-277
,	O	277-278
two	O	279-282
carrying	O	283-291
a	O	292-293
previously	O	294-304
described	O	305-314
WT1	O	315-318
exon	O	319-323
9	O	324-325
mutation	O	326-334
and	O	335-338
one	O	339-342
with	O	343-347
a	O	348-349
novel	O	350-355
WT1	O	356-359
exon	O	360-364
8	O	365-366
mutation	O	367-375
.	O	375-376

However	O	377-384
,	O	384-385
unlike	O	386-392
patients	O	393-401
in	O	402-404
previous	O	405-413
reports	O	414-421
,	O	421-422
one	O	423-426
of	O	427-429
our	O	430-433
three	O	434-439
patients	O	440-448
inherited	O	449-458
the	O	459-462
affected	O	463-471
allele	O	472-478
from	O	479-483
his	O	484-487
phenotypically	O	488-502
unaffected	O	503-513
father	O	514-520
.	O	520-521

This	O	522-526
observation	O	527-538
indicates	O	539-548
that	O	549-553
the	O	554-557
WT1	O	558-561
exon	O	562-566
9	O	567-568
mutation	O	569-577
affecting	O	578-587
394Arg	O	588-594
demonstrated	O	595-607
in	O	608-610
over	O	611-615
one	O	616-619
-	O	619-620
half	O	620-624
of	O	625-627
the	O	628-631
patients	O	632-640
with	O	641-645
the	O	646-649
Denys	B	650-655
-	I	655-656
Drash	I	656-661
syndrome	I	662-670
may	O	671-674
exhibit	O	675-682
incomplete	O	683-693
penetrance	O	694-704
.	O	704-705

Consequently	O	706-718
,	O	718-719
familial	O	720-728
studies	O	729-736
in	O	737-739
patients	O	740-748
affected	O	749-757
by	O	758-760
this	O	761-765
syndrome	O	766-774
are	O	775-778
recommended	O	779-790
.	O	790-791
.	O	790-791

Glucose	B	0-7
/	I	7-8
galactose	I	8-17
malabsorption	I	18-31
caused	O	32-38
by	O	39-41
a	O	42-43
defect	O	44-50
in	O	51-53
the	O	54-57
Na	O	58-60
+	O	60-61
/	O	61-62
glucose	O	62-69
cotransporter	O	70-83
.	O	83-84

Glucose	B	85-92
/	I	92-93
galactose	I	93-102
malabsorption	I	103-116
(	O	117-118
GGM	B	118-121
)	O	121-122
is	O	123-125
an	O	126-128
autosomal	B	129-138
recessive	I	139-148
disease	I	149-156
manifesting	O	157-168
within	O	169-175
the	O	176-179
first	O	180-185
weeks	O	186-191
of	O	192-194
life	O	195-199
and	O	200-203
characterized	O	204-217
by	O	218-220
a	O	221-222
selective	O	223-232
failure	O	233-240
to	O	241-243
absorb	O	244-250
dietary	O	251-258
glucose	O	259-266
and	O	267-270
galactose	O	271-280
from	O	281-285
the	O	286-289
intestine	O	290-299
.	O	299-300

The	O	301-304
consequent	O	305-315
severe	O	316-322
diarrhoea	B	323-332
and	O	333-336
dehydration	B	337-348
are	O	349-352
usually	O	353-360
fatal	O	361-366
unless	O	367-373
these	O	374-379
sugars	O	380-386
are	O	387-390
eliminated	O	391-401
from	O	402-406
the	O	407-410
diet	O	411-415
.	O	415-416

Intestinal	O	417-427
biopsies	O	428-436
of	O	437-439
GGM	B	440-443
patients	O	444-452
have	O	453-457
revealed	O	458-466
a	O	467-468
specific	O	469-477
defect	O	478-484
in	O	485-487
Na	O	488-490
(	O	491-492
+	O	492-493
)	O	493-494
-	O	495-496
dependent	O	496-505
absorption	O	506-516
of	O	517-519
glucose	O	520-527
in	O	528-530
the	O	531-534
brush	O	535-540
border	O	541-547
.	O	547-548

Normal	O	549-555
glucose	O	556-563
absorption	O	564-574
is	O	575-577
mediated	O	578-586
by	O	587-589
the	O	590-593
Na	O	594-596
+	O	597-598
/	O	598-599
glucose	O	599-606
cotransporter	O	607-620
in	O	621-623
the	O	624-627
brush	O	628-633
border	O	634-640
membrane	O	641-649
of	O	650-652
the	O	653-656
intestinal	O	657-667
epithelium	O	668-678
.	O	678-679

Cellular	O	680-688
influx	O	689-695
is	O	696-698
driven	O	699-705
by	O	706-708
the	O	709-712
transmembrane	O	713-726
Na	O	727-729
+	O	730-731
electrochemical	O	732-747
potential	O	748-757
gradient	O	758-766
;	O	766-767
thereafter	O	768-778
the	O	779-782
sugar	O	783-788
moves	O	789-794
to	O	795-797
the	O	798-801
blood	O	802-807
across	O	808-814
the	O	815-818
basolateral	O	819-830
membrane	O	831-839
via	O	840-843
the	O	844-847
facilitated	O	848-859
glucose	O	860-867
carrier	O	868-875
.	O	875-876

We	O	877-879
have	O	880-884
previously	O	885-895
cloned	O	896-902
and	O	903-906
sequenced	O	907-916
a	O	917-918
Na	O	919-921
+	O	922-923
/	O	923-924
glucose	O	924-931
cotransporter	O	932-945
from	O	946-950
normal	O	951-957
human	O	958-963
ileum	O	964-969
and	O	970-973
shown	O	974-979
that	O	980-984
this	O	985-989
gene	O	990-994
,	O	994-995
SGLT1	O	996-1001
,	O	1001-1002
resides	O	1003-1010
on	O	1011-1013
the	O	1014-1017
distal	O	1018-1024
q	O	1025-1026
arm	O	1027-1030
of	O	1031-1033
chromosome	O	1034-1044
22	O	1045-1047
.	O	1047-1048

We	O	1049-1051
have	O	1052-1056
now	O	1057-1060
amplified	O	1061-1070
SGLT1	O	1071-1076
complementary	O	1077-1090
DNA	O	1091-1094
and	O	1095-1098
genomic	O	1099-1106
DNA	O	1107-1110
from	O	1111-1115
members	O	1116-1123
of	O	1124-1126
a	O	1127-1128
family	O	1129-1135
affected	O	1136-1144
with	O	1145-1149
GGM	B	1150-1153
by	O	1154-1156
the	O	1157-1160
polymerase	O	1161-1171
chain	O	1172-1177
reaction	O	1178-1186
.	O	1186-1187

Sequence	O	1188-1196
analysis	O	1197-1205
of	O	1206-1208
the	O	1209-1212
amplified	O	1213-1222
products	O	1223-1231
has	O	1232-1235
revealed	O	1236-1244
a	O	1245-1246
single	O	1247-1253
missense	O	1254-1262
mutation	O	1263-1271
in	O	1272-1274
SGLT1	O	1275-1280
which	O	1281-1286
cosegregates	O	1287-1299
with	O	1300-1304
the	O	1305-1308
GGM	B	1309-1312
phenotype	O	1313-1322
and	O	1323-1326
results	O	1327-1334
in	O	1335-1337
a	O	1338-1339
complete	O	1340-1348
loss	O	1349-1353
of	O	1354-1356
Na	O	1357-1359
(	O	1360-1361
+	O	1361-1362
)	O	1362-1363
-	O	1364-1365
dependent	O	1365-1374
glucose	O	1375-1382
transport	O	1383-1392
in	O	1393-1395
Xenopus	O	1396-1403
oocytes	O	1404-1411
injected	O	1412-1420
with	O	1421-1425
this	O	1426-1430
complementary	O	1431-1444
RNA	O	1445-1448
.	O	1448-1449
.	O	1448-1449

Atm	O	0-3
and	O	4-7
Bax	O	8-11
cooperate	O	12-21
in	O	22-24
ionizing	O	25-33
radiation	O	34-43
-	O	43-44
induced	O	44-51
apoptosis	O	52-61
in	O	62-64
the	O	65-68
central	O	69-76
nervous	O	77-84
system	O	85-91
.	O	91-92

Ataxia	B	93-99
-	I	99-100
telangiectasia	I	100-114
is	O	115-117
a	O	118-119
hereditary	B	120-130
multisystemic	I	131-144
disease	I	145-152
resulting	O	153-162
from	O	163-167
mutations	O	168-177
of	O	178-180
ataxia	B	181-187
telangiectasia	I	188-202
,	O	202-203
mutated	O	204-211
(	O	212-213
ATM	O	213-216
)	O	216-217
and	O	218-221
is	O	222-224
characterized	O	225-238
by	O	239-241
neurodegeneration	B	242-259
,	O	259-260
cancer	B	261-267
,	O	267-268
immune	B	269-275
defects	I	276-283
,	O	283-284
and	O	285-288
hypersensitivity	B	289-305
to	I	306-308
ionizing	I	309-317
radiation	I	318-327
.	O	327-328

The	O	329-332
molecular	O	333-342
details	O	343-350
of	O	351-353
ATM	O	354-357
function	O	358-366
in	O	367-369
the	O	370-373
nervous	O	374-381
system	O	382-388
are	O	389-392
unclear	O	393-400
,	O	400-401
although	O	402-410
the	O	411-414
neurological	B	415-427
lesion	I	428-434
in	O	435-437
ataxia	B	438-444
-	I	444-445
telangiectasia	I	445-459
becomes	O	460-467
apparent	O	468-476
early	O	477-482
in	O	483-485
life	O	486-490
,	O	490-491
suggesting	O	492-502
a	O	503-504
developmental	O	505-518
origin	O	519-525
.	O	525-526

The	O	527-530
central	O	531-538
nervous	O	539-546
system	O	547-553
(	O	554-555
CNS	O	555-558
)	O	558-559
of	O	560-562
Atm	O	563-566
-	O	566-567
null	O	567-571
mice	O	572-576
shows	O	577-582
a	O	583-584
pronounced	O	585-595
defect	O	596-602
in	O	603-605
apoptosis	O	606-615
induced	O	616-623
by	O	624-626
genotoxic	O	627-636
stress	O	637-643
,	O	643-644
suggesting	O	645-655
ATM	O	656-659
functions	O	660-669
to	O	670-672
eliminate	O	673-682
neurons	O	683-690
with	O	691-695
excessive	O	696-705
genomic	O	706-713
damage	O	714-720
.	O	720-721

Here	O	722-726
,	O	726-727
we	O	728-730
report	O	731-737
that	O	738-742
the	O	743-746
death	O	747-752
effector	O	753-761
Bax	O	762-765
is	O	766-768
required	O	769-777
for	O	778-781
a	O	782-783
large	O	784-789
proportion	O	790-800
of	O	801-803
Atm	O	804-807
-	O	807-808
dependent	O	808-817
apoptosis	O	818-827
in	O	828-830
the	O	831-834
developing	O	835-845
CNS	O	846-849
after	O	850-855
ionizing	O	856-864
radiation	O	865-874
(	O	875-876
IR	O	876-878
)	O	878-879
.	O	879-880

Although	O	881-889
many	O	890-894
of	O	895-897
the	O	898-901
same	O	902-906
regions	O	907-914
of	O	915-917
the	O	918-921
CNS	O	922-925
in	O	926-928
both	O	929-933
Bax	O	934-937
-	O	937-938
/	O	938-939
-	O	937-938
and	O	941-944
Atm	O	945-948
-	O	948-949
/	O	949-950
-	O	948-949
mice	O	952-956
were	O	957-961
radioresistant	O	962-976
,	O	976-977
mice	O	978-982
nullizygous	O	983-994
for	O	995-998
both	O	999-1003
Bax	O	1004-1007
and	O	1008-1011
Atm	O	1012-1015
showed	O	1016-1022
additional	O	1023-1033
reduction	O	1034-1043
in	O	1044-1046
IR	O	1047-1049
-	O	1049-1050
induced	O	1050-1057
apoptosis	O	1058-1067
in	O	1068-1070
the	O	1071-1074
CNS	O	1075-1078
.	O	1078-1079

Therefore	O	1080-1089
,	O	1089-1090
although	O	1091-1099
the	O	1100-1103
major	O	1104-1109
IR	O	1110-1112
-	O	1112-1113
induced	O	1113-1120
apoptotic	O	1121-1130
pathway	O	1131-1138
in	O	1139-1141
the	O	1142-1145
CNS	O	1146-1149
requires	O	1150-1158
Atm	O	1159-1162
and	O	1163-1166
Bax	O	1167-1170
,	O	1170-1171
a	O	1172-1173
p53	O	1174-1177
-	O	1177-1178
dependent	O	1178-1187
collateral	O	1188-1198
pathway	O	1199-1206
exists	O	1207-1213
that	O	1214-1218
has	O	1219-1222
both	O	1223-1227
Atm	O	1228-1231
-	O	1231-1232
and	O	1233-1236
Bax	O	1237-1240
-	O	1240-1241
independent	O	1241-1252
branches	O	1253-1261
.	O	1261-1262

Further	O	1263-1270
,	O	1270-1271
Atm	O	1272-1275
-	O	1275-1276
and	O	1277-1280
Bax	O	1281-1284
-	O	1284-1285
dependent	O	1285-1294
apoptosis	O	1295-1304
in	O	1305-1307
the	O	1308-1311
CNS	O	1312-1315
also	O	1316-1320
required	O	1321-1329
caspase	O	1330-1337
-	O	1337-1338
3	O	1338-1339
activation	O	1340-1350
.	O	1350-1351

These	O	1352-1357
data	O	1358-1362
implicate	O	1363-1372
Bax	O	1373-1376
and	O	1377-1380
caspase	O	1381-1388
-	O	1388-1389
3	O	1389-1390
as	O	1391-1393
death	O	1394-1399
effectors	O	1400-1409
in	O	1410-1412
neurodegenerative	O	1413-1430
pathways	O	1431-1439
.	O	1439-1440
.	O	1439-1440

Novel	O	0-5
Tay	B	6-9
-	I	9-10
Sachs	I	10-15
disease	I	16-23
mutations	O	24-33
from	O	34-38
China	O	39-44
.	O	44-45

We	O	46-48
describe	O	49-57
three	O	58-63
HEXA	O	64-68
mutations	O	69-78
associated	O	79-89
with	O	90-94
infantile	O	95-104
Tay	B	105-108
-	I	108-109
Sachs	I	109-114
disease	I	115-122
(	O	123-124
TSD	B	124-127
)	O	127-128
in	O	129-131
three	O	132-137
unrelated	O	138-147
nonconsanguineous	O	148-165
Chinese	O	166-173
families	O	174-182
.	O	182-183

Novel	O	184-189
mutations	O	190-199
were	O	200-204
found	O	205-210
in	O	211-213
two	O	214-217
of	O	218-220
these	O	221-226
families	O	227-235
.	O	235-236

The	O	237-240
third	O	241-246
is	O	247-249
a	O	250-251
previously	O	252-262
reported	O	263-271
mutation	O	272-280
(	O	281-282
G	O	282-283
-	O	283-284
-	O	283-284
>	O	286-287
A	O	288-289
transition	O	290-300
at	O	301-303
nt	O	304-306
1444	O	307-311
)	O	311-312
(	O	313-314
Nakano	O	314-320
et	O	321-323
al	O	324-326
.	O	326-327
,	O	327-328
1988	O	329-333
)	O	333-334
.	O	334-335

Direct	O	336-342
sequencing	O	343-353
of	O	354-356
PCR	O	357-360
products	O	361-369
identified	O	370-380
a	O	381-382
novel	O	383-388
insertion	O	389-398
of	O	399-401
an	O	402-404
A	O	405-406
after	O	407-412
nt	O	413-415
547	O	416-419
in	O	420-422
family	O	423-429
1	O	430-431
.	O	431-432

This	O	433-437
change	O	438-444
generates	O	445-454
an	O	455-457
early	O	458-463
termination	O	464-475
codon	O	476-481
6	O	482-483
bp	O	484-486
downstream	O	487-497
from	O	498-502
the	O	503-506
insertion	O	507-516
site	O	517-521
.	O	521-522

Allele	O	523-529
-	O	529-530
specific	O	530-538
oligonucleotide	O	539-554
hybridization	O	555-568
confirmed	O	569-578
homozygosity	O	579-591
in	O	592-594
the	O	595-598
proband	O	599-606
.	O	606-607

Single	O	608-614
strand	O	615-621
conformational	O	622-636
polymorphism	O	637-649
analysis	O	650-658
and	O	659-662
direct	O	663-669
sequencing	O	670-680
of	O	681-683
amplified	O	684-693
exon	O	694-698
13	O	699-701
revealed	O	702-710
a	O	711-712
T	O	713-714
-	O	714-715
-	O	714-715
>	O	717-718
C	O	719-720
transition	O	721-731
at	O	732-734
nt	O	735-737
1453	O	738-742
with	O	743-747
the	O	748-751
corresponding	O	752-765
amino	O	766-771
acid	O	772-776
substitution	O	777-789
W485R	O	790-795
in	O	796-798
the	O	799-802
second	O	803-809
family	O	810-816
.	O	816-817

This	O	818-822
mutation	O	823-831
creates	O	832-839
an	O	840-842
Fnu4HI	O	843-849
restriction	O	850-861
site	O	862-866
.	O	866-867

The	O	868-871
proband	O	872-879
is	O	880-882
homozygous	O	883-893
for	O	894-897
this	O	898-902
allele	O	903-909
.	O	909-910

When	O	911-915
the	O	916-919
site	O	920-924
-	O	924-925
specific	O	925-933
mutagenized	O	934-945
alpha	O	946-951
cDNA	O	952-956
carrying	O	957-965
the	O	966-969
T	O	970-971
-	O	971-972
-	O	971-972
>	O	974-975
C	O	976-977
transition	O	978-988
at	O	989-991
nt	O	992-994
1453	O	995-999
was	O	1000-1003
expressed	O	1004-1013
in	O	1014-1016
COS	O	1017-1020
1	O	1021-1022
cells	O	1023-1028
hexosaminidase	O	1029-1043
S	O	1044-1045
activity	O	1046-1054
was	O	1055-1058
not	O	1059-1062
detectable	O	1063-1073
above	O	1074-1079
background	O	1080-1090
.	O	1090-1091

A	O	1092-1093
G	O	1094-1095
-	O	1095-1096
-	O	1095-1096
>	O	1098-1099
A	O	1100-1101
transition	O	1102-1112
at	O	1113-1115
nt	O	1116-1118
1444	O	1119-1123
(	O	1124-1125
exon	O	1125-1129
13	O	1130-1132
)	O	1132-1133
corresponding	O	1134-1147
to	O	1148-1150
the	O	1151-1154
E482K	O	1155-1160
substitution	O	1161-1173
was	O	1174-1177
found	O	1178-1183
in	O	1184-1186
the	O	1187-1190
third	O	1191-1196
family	O	1197-1203
.	O	1203-1204

This	O	1205-1209
mutation	O	1210-1218
occurs	O	1219-1225
at	O	1226-1228
a	O	1229-1230
CpG	O	1231-1234
dinucleotide	O	1235-1247
.	O	1247-1248

It	O	1249-1251
has	O	1252-1255
been	O	1256-1260
reported	O	1261-1269
in	O	1270-1272
an	O	1273-1275
Italian	O	1276-1283
TSD	B	1284-1287
proband	O	1288-1295
and	O	1296-1299
causes	O	1300-1306
defective	O	1307-1316
intracellular	O	1317-1330
transport	O	1331-1340
of	O	1341-1343
the	O	1344-1347
alpha	O	1348-1353
-	O	1353-1354
subunit	O	1354-1361
from	O	1362-1366
the	O	1367-1370
rough	O	1371-1376
endoplasmic	O	1377-1388
reticulum	O	1389-1398
to	O	1399-1401
the	O	1402-1405
Golgi	O	1406-1411
apparatus	O	1412-1421
.	O	1421-1422

Glucose	B	0-7
6	I	8-9
-	I	9-10
phosphate	I	10-19
dehydrogenase	I	20-33
deficiency	I	34-44
and	O	45-48
incidence	O	49-58
of	O	59-61
hematologic	B	62-73
malignancy	I	74-84
.	O	84-85

We	O	86-88
have	O	89-93
evaluated	O	94-103
the	O	104-107
hypothesis	O	108-118
of	O	119-121
a	O	122-123
negative	O	124-132
association	O	133-144
between	O	145-152
glucose	B	153-160
6	I	161-162
-	I	162-163
phosphate	I	163-172
dehydrogenase	I	173-186
(	I	187-188
G6PD	I	188-192
)	I	192-193
deficiency	I	194-204
and	O	205-208
cancer	B	209-215
in	O	216-218
a	O	219-220
cohort	O	221-227
of	O	228-230
481	O	231-234
Sardinian	O	235-244
males	O	245-250
with	O	251-255
hematological	B	256-269
malignancies	I	270-282
.	O	282-283

The	O	284-287
frequency	O	288-297
of	O	298-300
G6PD	B	301-305
deficiency	I	306-316
in	O	317-319
the	O	320-323
patients	O	324-332
was	O	333-336
not	O	337-340
different	O	341-350
from	O	351-355
the	O	356-359
incidence	O	360-369
in	O	370-372
a	O	373-374
group	O	375-380
of	O	381-383
16	O	384-386
,	O	386-387
219	O	388-391
controls	O	392-400
.	O	400-401

The	O	402-405
same	O	406-410
conclusion	O	411-421
resulted	O	422-430
from	O	431-435
the	O	436-439
comparison	O	440-450
of	O	451-453
the	O	454-457
frequency	O	458-467
of	O	468-470
expression	O	471-481
of	O	482-484
the	O	485-488
GdB	O	489-492
gene	O	493-497
in	O	498-500
23	O	501-503
heterozygous	O	504-516
women	O	517-522
having	O	523-529
a	O	530-531
clonal	O	532-538
hematologic	B	539-550
disease	I	551-558
and	O	559-562
a	O	563-564
control	O	565-572
group	O	573-578
of	O	579-581
37	O	582-584
healthy	O	585-592
heterozygotes	O	593-606
.	O	606-607

Therefore	O	608-617
at	O	618-620
present	O	621-628
there	O	629-634
is	O	635-637
no	O	638-640
evidence	O	641-649
that	O	650-654
G6PD	B	655-659
deficiency	I	660-670
has	O	671-674
a	O	675-676
protective	O	677-687
effect	O	688-694
against	O	695-702
development	O	703-714
of	O	715-717
hematologic	B	718-729
neoplasms	I	730-739
.	O	739-740
.	O	739-740

A	O	0-1
physical	O	2-10
map	O	11-14
and	O	15-18
candidate	O	19-28
genes	O	29-34
in	O	35-37
the	O	38-41
BRCA1	O	42-47
region	O	48-54
on	O	55-57
chromosome	O	58-68
17q12	O	69-74
-	O	74-75
21	O	75-77
.	O	77-78

We	O	79-81
have	O	82-86
constructed	O	87-98
a	O	99-100
physical	O	101-109
map	O	110-113
of	O	114-116
a	O	117-118
4	O	119-120
cM	O	121-123
region	O	124-130
on	O	131-133
chromosome	O	134-144
17q12	O	145-150
-	O	150-151
21	O	151-153
that	O	154-158
contains	O	159-167
the	O	168-171
hereditary	B	172-182
breast	I	183-189
and	I	190-193
ovarian	I	194-201
cancer	I	202-208
gene	O	209-213
BRCA1	O	214-219
.	O	219-220

The	O	221-224
map	O	225-228
comprises	O	229-238
a	O	239-240
contig	O	241-247
of	O	248-250
137	O	251-254
overlapping	O	255-266
yeast	O	267-272
artificial	O	273-283
chromosomes	O	284-295
and	O	296-299
P1	O	300-302
clones	O	303-309
,	O	309-310
onto	O	311-315
which	O	316-321
we	O	322-324
have	O	325-329
placed	O	330-336
112	O	337-340
PCR	O	341-344
markers	O	345-352
.	O	352-353

We	O	354-356
have	O	357-361
localized	O	362-371
more	O	372-376
than	O	377-381
20	O	382-384
genes	O	385-390
on	O	391-393
this	O	394-398
map	O	399-402
,	O	402-403
ten	O	404-407
of	O	408-410
which	O	411-416
had	O	417-420
not	O	421-424
been	O	425-429
mapped	O	430-436
to	O	437-439
the	O	440-443
region	O	444-450
previously	O	451-461
,	O	461-462
and	O	463-466
have	O	467-471
isolated	O	472-480
30	O	481-483
cDNA	O	484-488
clones	O	489-495
representing	O	496-508
partial	O	509-516
sequences	O	517-526
of	O	527-529
as	O	530-532
yet	O	533-536
unidentified	O	537-549
genes	O	550-555
.	O	555-556

Two	O	557-560
genes	O	561-566
that	O	567-571
lie	O	572-575
within	O	576-582
a	O	583-584
narrow	O	585-591
region	O	592-598
defined	O	599-606
by	O	607-609
meiotic	O	610-617
breakpoints	O	618-629
in	O	630-632
BRCA1	O	633-638
patients	O	639-647
have	O	648-652
been	O	653-657
sequenced	O	658-667
in	O	668-670
breast	B	671-677
cancer	I	678-684
patients	O	685-693
without	O	694-701
revealing	O	702-711
any	O	712-715
deleterious	O	716-727
mutations	O	728-737
.	O	737-738

These	O	739-744
new	O	745-748
reagents	O	749-757
should	O	758-764
facilitate	O	765-775
the	O	776-779
identification	O	780-794
of	O	795-797
BRCA1	O	798-803
.	O	803-804
.	O	803-804

Sulfate	O	0-7
transport	O	8-17
is	O	18-20
not	O	21-24
impaired	O	25-33
in	O	34-36
pendred	B	37-44
syndrome	I	45-53
thyrocytes	O	54-64
.	O	64-65

Pendred	B	66-73
syndrome	I	74-82
is	O	83-85
the	O	86-89
most	O	90-94
common	O	95-101
form	O	102-106
of	O	107-109
syndromic	B	110-119
deafness	I	120-128
,	O	128-129
characterized	O	130-143
by	O	144-146
dyshormonogenic	B	147-162
goiter	I	163-169
associated	O	170-180
with	O	181-185
sensory	B	186-193
-	I	193-194
neural	I	194-200
deafness	I	201-209
.	O	209-210

The	O	211-214
gene	O	215-219
responsible	O	220-231
for	O	232-235
the	O	236-239
disease	O	240-247
(	O	248-249
PDS	B	249-252
)	O	252-253
has	O	254-257
been	O	258-262
cloned	O	263-269
,	O	269-270
but	O	271-274
its	O	275-278
function	O	279-287
is	O	288-290
as	O	291-293
yet	O	294-297
unknown	O	298-305
and	O	306-309
the	O	310-313
connection	O	314-324
between	O	325-332
thyroid	B	333-340
goiter	I	341-347
and	O	348-351
sensory	B	352-359
-	I	359-360
neural	I	360-366
deafness	I	367-375
remains	O	376-383
an	O	384-386
enigma	O	387-393
.	O	393-394

PDS	O	395-398
codes	O	399-404
for	O	405-408
a	O	409-410
novel	O	411-416
protein	O	417-424
,	O	424-425
pendrin	O	426-433
,	O	433-434
which	O	435-440
is	O	441-443
closely	O	444-451
related	O	452-459
to	O	460-462
a	O	463-464
number	O	465-471
of	O	472-474
sufate	O	475-481
transporters	O	482-494
.	O	494-495

Mechanisms	O	496-506
by	O	507-509
which	O	510-515
abnormal	O	516-524
sulfate	O	525-532
transport	O	533-542
could	O	543-548
deleteriously	O	549-562
affect	O	563-569
iodide	O	570-576
organification	O	577-591
have	O	592-596
been	O	597-601
proposed	O	602-610
.	O	610-611

We	O	612-614
tested	O	615-621
sulfate	O	622-629
transport	O	630-639
in	O	640-642
thyrocytes	O	643-653
obtained	O	654-662
from	O	663-667
Pendred	B	668-675
syndrome	I	676-684
patients	O	685-693
and	O	694-697
found	O	698-703
that	O	704-708
it	O	709-711
was	O	712-715
not	O	716-719
defective	O	720-729
.	O	729-730

This	O	731-735
suggests	O	736-744
that	O	745-749
pendrin	O	750-757
in	O	758-760
fact	O	761-765
may	O	766-769
not	O	770-773
be	O	774-776
a	O	777-778
sulfate	O	779-786
transporter	O	787-798
,	O	798-799
and	O	800-803
emphasizes	O	804-814
the	O	815-818
importance	O	819-829
of	O	830-832
functional	O	833-843
studies	O	844-851
on	O	852-854
this	O	855-859
novel	O	860-865
protein	O	866-873
.	O	873-874
.	O	873-874

Spinal	B	0-6
xanthomatosis	I	7-20
:	O	20-21
a	O	22-23
variant	O	24-31
of	O	32-34
cerebrotendinous	B	35-51
xanthomatosis	I	52-65
.	O	65-66

We	O	67-69
describe	O	70-78
seven	O	79-84
Dutch	O	85-90
patients	O	91-99
from	O	100-104
six	O	105-108
families	O	109-117
with	O	118-122
a	O	123-124
slowly	O	125-131
progressive	O	132-143
,	O	143-144
mainly	O	145-151
spinal	B	152-158
cord	I	159-163
syndrome	I	164-172
that	O	173-177
remained	O	178-186
for	O	187-190
many	O	191-195
years	O	196-201
the	O	202-205
sole	O	206-210
expression	O	211-221
of	O	222-224
cerebrotendinous	B	225-241
xanthomatosis	I	242-255
(	O	256-257
CTX	B	257-260
)	O	260-261
.	O	261-262

MRI	O	263-266
demonstrated	O	267-279
white	B	280-285
matter	I	286-292
abnormalities	I	293-306
in	O	307-309
the	O	310-313
lateral	O	314-321
and	O	322-325
dorsal	O	326-332
columns	O	333-340
of	O	341-343
the	O	344-347
spinal	O	348-354
cord	O	355-359
.	O	359-360

Post	O	361-365
-	O	365-366
mortem	O	366-372
examination	O	373-384
of	O	385-387
one	O	388-391
of	O	392-394
the	O	395-398
patients	O	399-407
showed	O	408-414
extensive	O	415-424
myelin	O	425-431
loss	O	432-436
in	O	437-439
these	O	440-445
columns	O	446-453
.	O	453-454

An	O	455-457
array	O	458-463
of	O	464-466
genotypes	O	467-476
was	O	477-480
found	O	481-486
in	O	487-489
these	O	490-495
patients	O	496-504
.	O	504-505

We	O	506-508
conclude	O	509-517
that	O	518-522
spinal	B	523-529
xanthomatosis	I	530-543
is	O	544-546
a	O	547-548
clinical	O	549-557
and	O	558-561
radiological	O	562-574
separate	O	575-583
entity	O	584-590
of	O	591-593
CTX	B	594-597
that	O	598-602
should	O	603-609
be	O	610-612
included	O	613-621
in	O	622-624
the	O	625-628
differential	O	629-641
diagnosis	O	642-651
of	O	652-654
chronic	B	655-662
myelopathy	I	663-673
.	O	673-674
.	O	673-674

The	O	0-3
exon	O	4-8
13	O	9-11
duplication	O	12-23
in	O	24-26
the	O	27-30
BRCA1	O	31-36
gene	O	37-41
is	O	42-44
a	O	45-46
founder	O	47-54
mutation	O	55-63
present	O	64-71
in	O	72-74
geographically	O	75-89
diverse	O	90-97
populations	O	98-109
.	O	109-110

The	O	111-114
BRCA1	O	115-120
Exon	O	121-125
13	O	126-128
Duplication	O	129-140
Screening	O	141-150
Group	O	151-156
.	O	156-157

Recently	O	158-166
,	O	166-167
a	O	168-169
6	O	170-171
-	O	171-172
kb	O	172-174
duplication	O	175-186
of	O	187-189
exon	O	190-194
13	O	195-197
,	O	197-198
which	O	199-204
creates	O	205-212
a	O	213-214
frameshift	O	215-225
in	O	226-228
the	O	229-232
coding	O	233-239
sequence	O	240-248
of	O	249-251
the	O	252-255
BRCA1	O	256-261
gene	O	262-266
,	O	266-267
has	O	268-271
been	O	272-276
described	O	277-286
in	O	287-289
three	O	290-295
unrelated	O	296-305
U	O	306-307
.	O	307-308
S	O	309-310
S	O	311-312
.	O	312-313
families	O	314-322
of	O	323-325
European	O	326-334
ancestry	O	335-343
and	O	344-347
in	O	348-350
one	O	351-354
Portuguese	O	355-365
family	O	366-372
.	O	372-373

Here	O	374-378
,	O	378-379
our	O	380-383
goal	O	384-388
was	O	389-392
to	O	393-395
estimate	O	396-404
the	O	405-408
frequency	O	409-418
and	O	419-422
geographic	O	423-433
diversity	O	434-443
of	O	444-446
carriers	O	447-455
of	O	456-458
this	O	459-463
duplication	O	464-475
.	O	475-476

To	O	477-479
do	O	480-482
this	O	483-487
,	O	487-488
a	O	489-490
collaborative	O	491-504
screening	O	505-514
study	O	515-520
was	O	521-524
set	O	525-528
up	O	529-531
that	O	532-536
involved	O	537-545
39	O	546-548
institutions	O	549-561
from	O	562-566
19	O	567-569
countries	O	570-579
and	O	580-583
included	O	584-592
3	O	593-594
,	O	594-595
580	O	596-599
unrelated	O	600-609
individuals	O	610-621
with	O	622-626
a	O	627-628
family	O	629-635
history	O	636-643
of	O	644-646
the	O	647-650
disease	O	651-658
and	O	659-662
934	O	663-666
early	O	667-672
-	O	672-673
onset	O	673-678
breast	B	679-685
and	I	686-689
/	I	689-690
or	I	690-692
ovarian	I	693-700
cancer	I	701-707
cases	O	708-713
.	O	713-714

A	O	715-716
total	O	717-722
of	O	723-725
11	O	726-728
additional	O	729-739
families	O	740-748
carrying	O	749-757
this	O	758-762
mutation	O	763-771
were	O	772-776
identified	O	777-787
in	O	788-790
Australia	O	791-800
(	O	801-802
1	O	802-803
)	O	803-804
,	O	804-805
Belgium	O	806-813
(	O	814-815
1	O	815-816
)	O	816-817
,	O	817-818
Canada	O	819-825
(	O	826-827
1	O	827-828
)	O	828-829
,	O	829-830
Great	O	831-836
Britain	O	837-844
(	O	845-846
6	O	846-847
)	O	847-848
,	O	848-849
and	O	850-853
the	O	854-857
United	O	858-864
States	O	865-871
(	O	872-873
2	O	873-874
)	O	874-875
.	O	875-876

Haplotyping	O	877-888
showed	O	889-895
that	O	896-900
they	O	901-905
are	O	906-909
likely	O	910-916
to	O	917-919
derive	O	920-926
from	O	927-931
a	O	932-933
common	O	934-940
ancestor	O	941-949
,	O	949-950
possibly	O	951-959
of	O	960-962
northern	O	963-971
British	O	972-979
origin	O	980-986
.	O	986-987

Our	O	988-991
results	O	992-999
demonstrate	O	1000-1011
that	O	1012-1016
it	O	1017-1019
is	O	1020-1022
strongly	O	1023-1031
advisable	O	1032-1041
,	O	1041-1042
for	O	1043-1046
laboratories	O	1047-1059
carrying	O	1060-1068
out	O	1069-1072
screening	O	1073-1082
either	O	1083-1089
in	O	1090-1092
English	O	1093-1100
-	O	1100-1101
speaking	O	1101-1109
countries	O	1110-1119
or	O	1120-1122
in	O	1123-1125
countries	O	1126-1135
with	O	1136-1140
historical	O	1141-1151
links	O	1152-1157
with	O	1158-1162
Britain	O	1163-1170
,	O	1170-1171
to	O	1172-1174
include	O	1175-1182
within	O	1183-1189
their	O	1190-1195
BRCA1	O	1196-1201
screening	O	1202-1211
protocols	O	1212-1221
the	O	1222-1225
polymerase	O	1226-1236
chain	O	1237-1242
reaction	O	1243-1251
-	O	1251-1252
based	O	1252-1257
assay	O	1258-1263
described	O	1264-1273
in	O	1274-1276
this	O	1277-1281
report	O	1282-1288
.	O	1288-1289

Germline	O	0-8
mutations	O	9-18
of	O	19-21
the	O	22-25
BRCA1	O	26-31
gene	O	32-36
in	O	37-39
breast	B	40-46
and	I	47-50
ovarian	I	51-58
cancer	I	59-65
families	O	66-74
provide	O	75-82
evidence	O	83-91
for	O	92-95
a	O	96-97
genotype	O	98-106
-	O	106-107
phenotype	O	107-116
correlation	O	117-128
.	O	128-129

Mutations	O	130-139
in	O	140-142
the	O	143-146
BRCA1	O	147-152
gene	O	153-157
,	O	157-158
discovered	O	159-169
in	O	170-172
1994	O	173-177
,	O	177-178
are	O	179-182
associated	O	183-193
with	O	194-198
an	O	199-201
80	O	202-204
-	O	204-205
90	O	205-207
%	O	207-208
lifetime	O	209-217
risk	O	218-222
of	O	223-225
breast	B	226-232
cancer	I	233-239
.	O	239-240

We	O	241-243
have	O	244-248
analysed	O	249-257
60	O	258-260
families	O	261-269
with	O	270-274
a	O	275-276
history	O	277-284
of	O	285-287
breast	B	288-294
and	I	295-298
/	I	298-299
or	I	299-301
ovarian	I	302-309
cancer	I	310-316
for	O	317-320
germline	O	321-329
mutations	O	330-339
in	O	340-342
BRCA1	O	343-348
.	O	348-349

Twenty	O	350-356
-	O	356-357
two	O	357-360
different	O	361-370
mutations	O	371-380
were	O	381-385
detected	O	386-394
in	O	395-397
32	O	398-400
families	O	401-409
(	O	410-411
53	O	411-413
%	O	413-414
)	O	414-415
,	O	415-416
of	O	417-419
which	O	420-425
14	O	426-428
are	O	429-432
previously	O	433-443
unreported	O	444-454
.	O	454-455

We	O	456-458
observed	O	459-467
a	O	468-469
significant	O	470-481
correlation	O	482-493
between	O	494-501
the	O	502-505
location	O	506-514
of	O	515-517
the	O	518-521
mutation	O	522-530
in	O	531-533
the	O	534-537
gene	O	538-542
and	O	543-546
the	O	547-550
ratio	O	551-556
of	O	557-559
breast	B	560-566
to	I	567-569
ovarian	I	570-577
cancer	I	578-584
incidence	O	585-594
within	O	595-601
each	O	602-606
family	O	607-613
.	O	613-614

Our	O	615-618
data	O	619-623
suggest	O	624-631
a	O	632-633
transition	O	634-644
in	O	645-647
risk	O	648-652
such	O	653-657
that	O	658-662
mutations	O	663-672
in	O	673-675
the	O	676-679
3	O	680-681
third	O	682-687
of	O	688-690
the	O	691-694
gene	O	695-699
are	O	700-703
associated	O	704-714
with	O	715-719
a	O	720-721
lower	O	722-727
proportion	O	728-738
of	O	739-741
ovarian	B	742-749
cancer	I	750-756
.	O	756-757

Haplotype	O	758-767
analysis	O	768-776
supports	O	777-785
previous	O	786-794
data	O	795-799
which	O	800-805
suggest	O	806-813
some	O	814-818
BRCA1	O	819-824
mutation	O	825-833
carriers	O	834-842
have	O	843-847
common	O	848-854
ancestors	O	855-864
;	O	864-865
however	O	866-873
,	O	873-874
we	O	875-877
have	O	878-882
found	O	883-888
at	O	889-891
least	O	892-897
two	O	898-901
examples	O	902-910
where	O	911-916
recurrent	O	917-926
mutations	O	927-936
appear	O	937-943
to	O	944-946
have	O	947-951
arisen	O	952-958
independently	O	959-972
.	O	972-973
.	O	972-973

Inactivation	O	0-12
of	O	13-15
the	O	16-19
Friedreich	B	20-30
ataxia	I	31-37
mouse	O	38-43
gene	O	44-48
leads	O	49-54
to	O	55-57
early	O	58-63
embryonic	B	64-73
lethality	I	74-83
without	O	84-91
iron	O	92-96
accumulation	O	97-109
.	O	109-110

Friedreich	B	111-121
ataxia	I	122-128
(	O	129-130
FRDA	B	130-134
)	O	134-135
,	O	135-136
the	O	137-140
most	O	141-145
common	O	146-152
autosomal	B	153-162
recessive	I	163-172
ataxia	I	173-179
,	O	179-180
is	O	181-183
caused	O	184-190
in	O	191-193
almost	O	194-200
all	O	201-204
cases	O	205-210
by	O	211-213
homozygous	O	214-224
intronic	O	225-233
expansions	O	234-244
resulting	O	245-254
in	O	255-257
the	O	258-261
loss	O	262-266
of	O	267-269
frataxin	O	270-278
,	O	278-279
a	O	280-281
mitochondrial	O	282-295
protein	O	296-303
conserved	O	304-313
through	O	314-321
evolution	O	322-331
,	O	331-332
and	O	333-336
involved	O	337-345
in	O	346-348
mitochondrial	O	349-362
iron	O	363-367
homeostasis	O	368-379
.	O	379-380

Yeast	O	381-386
knockout	O	387-395
models	O	396-402
,	O	402-403
and	O	404-407
histological	O	408-420
and	O	421-424
biochemical	O	425-436
data	O	437-441
from	O	442-446
patient	O	447-454
heart	O	455-460
biopsies	O	461-469
or	O	470-472
autopsies	O	473-482
indicate	O	483-491
that	O	492-496
the	O	497-500
frataxin	O	501-509
defect	O	510-516
causes	O	517-523
a	O	524-525
specific	O	526-534
iron	B	535-539
-	I	539-540
sulfur	I	540-546
protein	I	547-554
deficiency	I	555-565
and	O	566-569
mitochondrial	O	570-583
iron	O	584-588
accumulation	O	589-601
leading	O	602-609
to	O	610-612
the	O	613-616
pathological	O	617-629
changes	O	630-637
.	O	637-638

Affected	O	639-647
human	O	648-653
tissues	O	654-661
are	O	662-665
rarely	O	666-672
available	O	673-682
to	O	683-685
further	O	686-693
examine	O	694-701
this	O	702-706
hypothesis	O	707-717
.	O	717-718

To	O	719-721
study	O	722-727
the	O	728-731
mechanism	O	732-741
of	O	742-744
the	O	745-748
disease	O	749-756
,	O	756-757
we	O	758-760
generated	O	761-770
a	O	771-772
mouse	O	773-778
model	O	779-784
by	O	785-787
deletion	O	788-796
of	O	797-799
exon	O	800-804
4	O	805-806
leading	O	807-814
to	O	815-817
inactivation	O	818-830
of	O	831-833
the	O	834-837
Frda	B	838-842
gene	O	843-847
product	O	848-855
.	O	855-856

We	O	857-859
show	O	860-864
that	O	865-869
homozygous	O	870-880
deletions	O	881-890
cause	O	891-896
embryonic	B	897-906
lethality	I	907-916
a	O	917-918
few	O	919-922
days	O	923-927
after	O	928-933
implantation	O	934-946
,	O	946-947
demonstrating	O	948-961
an	O	962-964
important	O	965-974
role	O	975-979
for	O	980-983
frataxin	O	984-992
during	O	993-999
early	O	1000-1005
development	O	1006-1017
.	O	1017-1018

These	O	1019-1024
results	O	1025-1032
suggest	O	1033-1040
that	O	1041-1045
the	O	1046-1049
milder	O	1050-1056
phenotype	O	1057-1066
in	O	1067-1069
humans	O	1070-1076
is	O	1077-1079
due	O	1080-1083
to	O	1084-1086
residual	O	1087-1095
frataxin	O	1096-1104
expression	O	1105-1115
associated	O	1116-1126
with	O	1127-1131
the	O	1132-1135
expansion	O	1136-1145
mutations	O	1146-1155
.	O	1155-1156

Surprisingly	O	1157-1169
,	O	1169-1170
in	O	1171-1173
the	O	1174-1177
frataxin	O	1178-1186
knockout	O	1187-1195
mouse	O	1196-1201
,	O	1201-1202
no	O	1203-1205
iron	O	1206-1210
accumulation	O	1211-1223
was	O	1224-1227
observed	O	1228-1236
during	O	1237-1243
embryonic	O	1244-1253
resorption	O	1254-1264
,	O	1264-1265
suggesting	O	1266-1276
that	O	1277-1281
cell	O	1282-1286
death	O	1287-1292
could	O	1293-1298
be	O	1299-1301
due	O	1302-1305
to	O	1306-1308
a	O	1309-1310
mechanism	O	1311-1320
independent	O	1321-1332
of	O	1333-1335
iron	O	1336-1340
accumulation	O	1341-1353
.	O	1353-1354
.	O	1353-1354

A	O	0-1
glycine250	O	2-12
-	O	12-13
-	O	12-13
>	O	14-15
aspartate	O	16-25
substitution	O	26-38
in	O	39-41
the	O	42-45
alpha	O	46-51
-	O	51-52
subunit	O	52-59
of	O	60-62
hexosaminidase	O	63-77
A	O	78-79
causes	O	80-86
juvenile	O	87-95
-	O	95-96
onset	O	96-101
Tay	B	102-105
-	I	105-106
Sachs	I	106-111
disease	I	112-119
in	O	120-122
a	O	123-124
Lebanese	O	125-133
-	O	133-134
Canadian	O	134-142
family	O	143-149
.	O	149-150

The	O	151-154
mutation	O	155-163
causing	O	164-171
juvenile	O	172-180
Tay	B	181-184
-	I	184-185
Sachs	I	185-190
disease	I	191-198
(	O	199-200
TSD	B	200-203
)	O	203-204
in	O	205-207
two	O	208-211
sibs	O	212-216
of	O	217-219
Lebanese	O	220-228
-	O	228-229
Maronite	O	229-237
origin	O	238-244
is	O	245-247
described	O	248-257
.	O	257-258

An	O	259-261
mRNA	O	262-266
-	O	266-267
containing	O	267-277
extract	O	278-285
of	O	286-288
cultured	O	289-297
fibroblasts	O	298-309
obtained	O	310-318
from	O	319-323
one	O	324-327
of	O	328-330
the	O	331-334
probands	O	335-343
was	O	344-347
used	O	348-352
as	O	353-355
a	O	356-357
template	O	358-366
to	O	367-369
amplify	O	370-377
the	O	378-381
coding	O	382-388
sequence	O	389-397
of	O	398-400
the	O	401-404
hexosaminidase	O	405-419
A	O	420-421
(	O	422-423
Hex	O	423-426
A	O	427-428
)	O	428-429
alpha	O	430-435
-	O	435-436
subunit	O	436-443
.	O	443-444

Sequencing	O	445-455
of	O	456-458
amplified	O	459-468
cDNA	O	469-473
fragments	O	474-483
revealed	O	484-492
a	O	493-494
single	O	495-501
alteration	O	502-512
,	O	512-513
guanine	O	514-521
to	O	522-524
adenine	O	525-532
at	O	533-535
nt	O	536-538
749	O	539-542
creating	O	543-551
a	O	552-553
G250D	O	554-559
mutation	O	560-568
.	O	568-569

The	O	570-573
mutation	O	574-582
introduces	O	583-593
a	O	594-595
new	O	596-599
recognition	O	600-611
site	O	612-616
for	O	617-620
the	O	621-624
restriction	O	625-636
enzyme	O	637-643
Eco	O	644-647
RV	O	648-650
,	O	650-651
permitting	O	652-662
identification	O	663-677
of	O	678-680
heterozygotes	O	681-694
for	O	695-698
this	O	699-703
allele	O	704-710
following	O	711-720
PCR	O	721-724
amplification	O	725-738
and	O	739-742
Eco	O	743-746
RV	O	747-749
digestion	O	750-759
of	O	760-762
exon	O	763-767
7	O	768-769
sequences	O	770-779
from	O	780-784
genomic	O	785-792
DNA	O	793-796
templates	O	797-806
.	O	806-807

In	O	808-810
order	O	811-816
to	O	817-819
test	O	820-824
the	O	825-828
effect	O	829-835
of	O	836-838
this	O	839-843
substitution	O	844-856
,	O	856-857
an	O	858-860
in	O	861-863
vitro	O	864-869
mutagenized	O	870-881
cDNA	O	882-886
construct	O	887-896
was	O	897-900
introduced	O	901-911
into	O	912-916
a	O	917-918
mammalian	O	919-928
expression	O	929-939
vector	O	940-946
and	O	947-950
transfected	O	951-962
into	O	963-967
monkey	O	968-974
Cos	O	975-978
-	O	978-979
1	O	979-980
cells	O	981-986
separately	O	987-997
or	O	998-1000
along	O	1001-1006
with	O	1007-1011
a	O	1012-1013
beta	O	1014-1018
-	O	1018-1019
cDNA	O	1019-1023
expression	O	1024-1034
vector	O	1035-1041
.	O	1041-1042

When	O	1043-1047
the	O	1048-1051
mutant	O	1052-1058
alpha	O	1059-1064
-	O	1064-1065
cDNA	O	1065-1069
was	O	1070-1073
the	O	1074-1077
only	O	1078-1082
gene	O	1083-1087
introduced	O	1088-1098
into	O	1099-1103
COS	O	1104-1107
cells	O	1108-1113
no	O	1114-1116
enzymatic	O	1117-1126
activity	O	1127-1135
above	O	1136-1141
endogenous	O	1142-1152
COS	O	1153-1156
cell	O	1157-1161
activity	O	1162-1170
was	O	1171-1174
detected	O	1175-1183
.	O	1183-1184

Cotransfection	O	1185-1199
of	O	1200-1202
normal	O	1203-1209
alpha	O	1210-1215
-	O	1215-1216
cDNA	O	1216-1220
and	O	1221-1224
beta	O	1225-1229
-	O	1229-1230
cDNA	O	1230-1234
followed	O	1235-1243
by	O	1244-1246
immunoprecipitation	O	1247-1266
of	O	1267-1269
human	O	1270-1275
Hex	O	1276-1279
A	O	1280-1281
resulted	O	1282-1290
in	O	1291-1293
20	O	1294-1296
-	O	1296-1297
fold	O	1297-1301
increase	O	1302-1310
in	O	1311-1313
the	O	1314-1317
ratio	O	1318-1323
between	O	1324-1331
positive	O	1332-1340
and	O	1341-1344
negative	O	1345-1353
(	O	1354-1355
mock	O	1355-1359
transfection	O	1360-1372
)	O	1372-1373
control	O	1374-1381
values	O	1382-1388
.	O	1388-1389

This	O	1390-1394
allowed	O	1395-1402
the	O	1403-1406
detection	O	1407-1416
of	O	1417-1419
some	O	1420-1424
residual	O	1425-1433
activity	O	1434-1442
(	O	1443-1444
12	O	1444-1446
%	O	1446-1447
of	O	1448-1450
the	O	1451-1454
positive	O	1455-1463
control	O	1464-1471
)	O	1471-1472
when	O	1473-1477
the	O	1478-1481
mutant	O	1482-1488
alpha	O	1489-1494
-	O	1494-1495
cDNA	O	1495-1499
replaced	O	1500-1508
its	O	1509-1512
wild	O	1513-1517
-	O	1517-1518
type	O	1518-1522
counterpart	O	1523-1534
.	O	1534-1535

The	O	1536-1539
predicted	O	1540-1549
protein	O	1550-1557
environment	O	1558-1569
in	O	1570-1572
which	O	1573-1578
the	O	1579-1582
mutation	O	1583-1591
occurs	O	1592-1598
is	O	1599-1601
compared	O	1602-1610
to	O	1611-1613
that	O	1614-1618
of	O	1619-1621
the	O	1622-1625
adult	O	1626-1631
-	O	1631-1632
onset	O	1632-1637
Tay	B	1638-1641
-	I	1641-1642
Sachs	I	1642-1647
disease	I	1648-1655
mutation	O	1656-1664
caused	O	1665-1671
by	O	1672-1674
a	O	1675-1676
Gly269	O	1677-1683
-	O	1683-1684
-	O	1683-1684
>	O	1686-1687
Ser	O	1688-1691
substitution	O	1692-1704
in	O	1705-1707
exon	O	1708-1712
7	O	1713-1714
.	O	1714-1715
(	O	1716-1717
ABSTRACT	O	1717-1725
TRUNCATED	O	1726-1735
AT	O	1736-1738
250	O	1739-1742
WORDS	O	1743-1748
)	O	1748-1749
.	O	1749-1750

Restriction	O	0-11
of	O	12-14
ocular	O	15-21
fundus	O	22-28
lesions	O	29-36
to	O	37-39
a	O	40-41
specific	O	42-50
subgroup	O	51-59
of	O	60-62
APC	B	63-66
mutations	O	67-76
in	O	77-79
adenomatous	B	80-91
polyposis	I	92-101
coli	I	102-106
patients	O	107-115
.	O	115-116

In	O	117-119
humans	O	120-126
,	O	126-127
alteration	O	128-138
of	O	139-141
the	O	142-145
tumor	B	146-151
suppressor	O	152-162
gene	O	163-167
,	O	167-168
APC	B	169-172
,	O	172-173
causes	O	174-180
adenomatous	B	181-192
polyposis	I	193-202
coli	I	203-207
,	O	207-208
a	O	209-210
condition	O	211-220
causing	O	221-228
predisposition	O	229-243
to	O	244-246
colorectal	B	247-257
cancer	I	258-264
.	O	264-265

The	O	266-269
syndrome	O	270-278
inconsistently	O	279-293
associates	O	294-304
characteristic	O	305-319
patches	O	320-327
of	O	328-330
congenital	B	331-341
hypertrophy	I	342-353
of	I	354-356
the	I	357-360
retinal	I	361-368
pigment	I	369-376
epithelium	I	377-387
(	O	388-389
CHRPE	B	389-394
)	O	394-395
.	O	395-396

Ocular	O	397-403
examination	O	404-415
revealed	O	416-424
that	O	425-429
patients	O	430-438
expressing	O	439-449
CHRPE	B	450-455
tend	O	456-460
to	O	461-463
cluster	O	464-471
within	O	472-478
specific	O	479-487
families	O	488-496
.	O	496-497

The	O	498-501
exact	O	502-507
APC	B	508-511
mutation	O	512-520
was	O	521-524
identified	O	525-535
in	O	536-538
42	O	539-541
unrelated	O	542-551
patients	O	552-560
.	O	560-561

In	O	562-564
all	O	565-568
cases	O	569-574
these	O	575-580
mutations	O	581-590
were	O	591-595
predicted	O	596-605
to	O	606-608
lead	O	609-613
to	O	614-616
the	O	617-620
synthesis	O	621-630
of	O	631-633
a	O	634-635
truncated	O	636-645
protein	O	646-653
.	O	653-654

The	O	655-658
extent	O	659-665
of	O	666-668
CHRPE	B	669-674
was	O	675-678
found	O	679-684
to	O	685-687
be	O	688-690
dependent	O	691-700
on	O	701-703
the	O	704-707
position	O	708-716
of	O	717-719
the	O	720-723
mutation	O	724-732
along	O	733-738
the	O	739-742
coding	O	743-749
sequence	O	750-758
.	O	758-759

CHRPE	B	760-765
lesions	O	766-773
are	O	774-777
almost	O	778-784
always	O	785-791
absent	O	792-798
if	O	799-801
the	O	802-805
mutation	O	806-814
occurs	O	815-821
before	O	822-828
exon	O	829-833
9	O	834-835
,	O	835-836
but	O	837-840
are	O	841-844
systematically	O	845-859
present	O	860-867
if	O	868-870
it	O	871-873
occurs	O	874-880
after	O	881-886
this	O	887-891
exon	O	892-896
.	O	896-897

Thus	O	898-902
,	O	902-903
the	O	904-907
range	O	908-913
of	O	914-916
phenotypic	O	917-927
expression	O	928-938
observed	O	939-947
among	O	948-953
affected	O	954-962
patients	O	963-971
may	O	972-975
result	O	976-982
in	O	983-985
part	O	986-990
from	O	991-995
different	O	996-1005
allelic	O	1006-1013
manifestations	O	1014-1028
of	O	1029-1031
APC	B	1032-1035
mutations	O	1036-1045
.	O	1045-1046
.	O	1045-1046

Linkage	O	0-7
analysis	O	8-16
of	O	17-19
26	O	20-22
Canadian	O	23-31
breast	B	32-38
and	I	39-42
breast	I	43-49
-	I	49-50
ovarian	I	50-57
cancer	I	58-64
families	O	65-73
.	O	73-74

We	O	75-77
have	O	78-82
examined	O	83-91
26	O	92-94
Canadian	O	95-103
families	O	104-112
with	O	113-117
hereditary	B	118-128
breast	I	129-135
or	I	136-138
ovarian	I	139-146
cancer	I	147-153
for	O	154-157
linkage	O	158-165
to	O	166-168
markers	O	169-176
flanking	O	177-185
the	O	186-189
BRCA1	O	190-195
gene	O	196-200
on	O	201-203
chromosome	O	204-214
17q12	O	215-220
-	O	220-221
q21	O	221-224
.	O	224-225

Of	O	226-228
the	O	229-232
15	O	233-235
families	O	236-244
that	O	245-249
contain	O	250-257
cases	O	258-263
of	O	264-266
ovarian	B	267-274
cancer	I	275-281
,	O	281-282
94	O	283-285
%	O	285-286
were	O	287-291
estimated	O	292-301
to	O	302-304
be	O	305-307
linked	O	308-314
to	O	315-317
BRCA1	O	318-323
.	O	323-324

In	O	325-327
contrast	O	328-336
,	O	336-337
there	O	338-343
was	O	344-347
no	O	348-350
overall	O	351-358
evidence	O	359-367
of	O	368-370
linkage	O	371-378
in	O	379-381
the	O	382-385
group	O	386-391
of	O	392-394
10	O	395-397
families	O	398-406
with	O	407-411
breast	B	412-418
cancer	I	419-425
without	O	426-433
ovarian	B	434-441
cancer	I	442-448
.	O	448-449

A	O	450-451
genetic	O	452-459
recombinant	O	460-471
in	O	472-474
a	O	475-476
breast	B	477-483
-	I	483-484
ovarian	I	484-491
cancer	I	492-498
family	O	499-505
indicates	O	506-515
a	O	516-517
placement	O	518-527
of	O	528-530
BRCA1	O	531-536
telomeric	O	537-546
to	O	547-549
D17S776	O	550-557
,	O	557-558
and	O	559-562
helps	O	563-568
to	O	569-571
define	O	572-578
the	O	579-582
region	O	583-589
of	O	590-592
assignment	O	593-603
of	O	604-606
the	O	607-610
cancer	B	611-617
susceptibility	O	618-632
gene	O	633-637
.	O	637-638

Other	O	639-644
cancers	B	645-652
of	O	653-655
interest	O	656-664
that	O	665-669
appeared	O	670-678
in	O	679-681
the	O	682-685
BRCA1	O	686-691
-	O	691-692
linked	O	692-698
families	O	699-707
included	O	708-716
primary	B	717-724
peritoneal	I	725-735
cancer	I	736-742
,	O	742-743
cancer	B	744-750
of	I	751-753
the	I	754-757
fallopian	I	758-767
tube	I	768-772
,	O	772-773
and	O	774-777
malignant	B	778-787
melanoma	I	788-796
.	O	796-797
.	O	796-797

Malignant	B	0-9
neoplasms	I	10-19
in	O	20-22
the	O	23-26
families	O	27-35
of	O	36-38
patients	O	39-47
with	O	48-52
ataxia	B	53-59
-	I	59-60
telangiectasia	I	60-74
.	O	74-75

Ataxia	B	76-82
-	I	82-83
telangiectasia	I	83-97
(	O	98-99
A	B	99-100
-	I	100-101
T	I	101-102
)	O	102-103
is	O	104-106
an	O	107-109
autosomal	B	110-119
recessive	I	120-129
syndrome	I	130-138
associated	O	139-149
with	O	150-154
a	O	155-156
greatly	O	157-164
increased	O	165-174
incidence	O	175-184
of	O	185-187
malignant	B	188-197
neoplasms	I	198-207
in	O	208-210
homozygous	O	211-221
affected	O	222-230
individuals	O	231-242
.	O	242-243

Heterozygotes	O	244-257
for	O	258-261
the	O	262-265
gene	O	266-270
for	O	271-274
A	B	275-276
-	I	276-277
T	I	277-278
are	O	279-282
thought	O	283-290
to	O	291-293
comprise	O	294-302
about	O	303-308
1	O	309-310
%	O	310-311
of	O	312-314
the	O	315-318
general	O	319-326
population	O	327-337
and	O	338-341
,	O	341-342
therefore	O	343-352
,	O	352-353
it	O	354-356
is	O	357-359
important	O	360-369
to	O	370-372
know	O	373-377
whether	O	378-385
this	O	386-390
gene	O	391-395
also	O	396-400
predisposes	O	401-412
the	O	413-416
heterozygous	O	417-429
carrier	O	430-437
to	O	438-440
cancers	B	441-448
.	O	448-449

Heterozygous	O	450-462
carriers	O	463-471
of	O	472-474
this	O	475-479
gene	O	480-484
are	O	485-488
common	O	489-495
among	O	496-501
the	O	502-505
close	O	506-511
relatives	O	512-521
of	O	522-524
patients	O	525-533
with	O	534-538
A	B	539-540
-	I	540-541
T	I	541-542
,	O	542-543
although	O	544-552
individual	O	553-563
carriers	O	564-572
cannot	O	573-579
be	O	580-582
identified	O	583-593
by	O	594-596
any	O	597-600
clinical	O	601-609
criterion	O	610-619
or	O	620-622
laboratory	O	623-633
test	O	634-638
.	O	638-639

For	O	640-643
this	O	644-648
reason	O	649-655
,	O	655-656
we	O	657-659
compared	O	660-668
the	O	669-672
incidence	O	673-682
of	O	683-685
death	O	686-691
from	O	692-696
malignant	B	697-706
neoplasms	I	707-716
in	O	717-719
2	O	720-721
families	O	722-730
of	O	731-733
patients	O	734-742
with	O	743-747
A	B	748-749
-	I	749-750
T	I	750-751
to	O	752-754
that	O	755-759
expected	O	760-768
in	O	769-771
a	O	772-773
random	O	774-780
sample	O	781-787
of	O	788-790
the	O	791-794
general	O	795-802
population	O	803-813
.	O	813-814

There	O	815-820
were	O	821-825
59	O	826-828
deaths	O	829-835
from	O	836-840
malignant	B	841-850
neoplasms	I	851-860
in	O	861-863
relatives	O	864-873
dying	O	874-879
before	O	880-886
age	O	887-890
75	O	891-893
,	O	893-894
compared	O	895-903
to	O	904-906
42	O	907-909
.	O	909-910
6	O	911-912
expected	O	913-921
(	O	922-923
p	O	923-924
less	O	925-929
than	O	930-934
0	O	935-936
.	O	936-937
02	O	938-940
)	O	940-941
.	O	941-942

For	O	943-946
A	B	947-948
-	I	948-949
T	I	949-950
heterozygotes	O	951-964
younger	O	965-972
than	O	973-977
age	O	978-981
45	O	982-984
,	O	984-985
the	O	986-989
risk	O	990-994
of	O	995-997
dying	O	998-1003
from	O	1004-1008
a	O	1009-1010
malignant	B	1011-1020
neoplasm	I	1021-1029
was	O	1030-1033
estimated	O	1034-1043
to	O	1044-1046
be	O	1047-1049
greater	O	1050-1057
than	O	1058-1062
5	O	1063-1064
times	O	1065-1070
the	O	1071-1074
risk	O	1075-1079
for	O	1080-1083
the	O	1084-1087
general	O	1088-1095
population	O	1096-1106
.	O	1106-1107

A	B	1108-1109
-	I	1109-1110
T	I	1110-1111
heterozygotes	O	1112-1125
may	O	1126-1129
comprise	O	1130-1138
more	O	1139-1143
than	O	1144-1148
5	O	1149-1150
%	O	1150-1151
of	O	1152-1154
all	O	1155-1158
persons	O	1159-1166
dying	O	1167-1172
from	O	1173-1177
a	O	1178-1179
cancer	B	1180-1186
before	O	1187-1193
age	O	1194-1197
45	O	1198-1200
.	O	1200-1201

The	O	1202-1205
incidence	O	1206-1215
of	O	1216-1218
ovarian	B	1219-1226
,	I	1226-1227
gastric	I	1228-1235
,	I	1235-1236
and	I	1237-1240
biliary	I	1241-1248
system	I	1249-1255
carcinomas	I	1256-1266
and	O	1267-1270
of	O	1271-1273
leukemia	B	1274-1282
and	O	1283-1286
lymphoma	B	1287-1295
was	O	1296-1299
increased	O	1300-1309
in	O	1310-1312
these	O	1313-1318
A	B	1319-1320
-	I	1320-1321
T	I	1321-1322
families	O	1323-1331
.	O	1331-1332

Other	O	1333-1338
neoplasms	B	1339-1348
that	O	1349-1353
may	O	1354-1357
be	O	1358-1360
associated	O	1361-1371
with	O	1372-1376
this	O	1377-1381
gene	O	1382-1386
in	O	1387-1389
heterozygotes	O	1390-1403
include	O	1404-1411
pancreatic	B	1412-1422
,	I	1422-1423
basal	I	1424-1429
cell	I	1430-1434
,	I	1434-1435
colonic	I	1436-1443
,	I	1443-1444
breast	I	1445-1451
,	I	1451-1452
and	I	1453-1456
cervical	I	1457-1465
carcinomas	I	1466-1476
.	O	1476-1477

Molecular	O	0-9
genetics	O	10-18
of	O	19-21
PKU	B	22-25
in	O	26-28
eastern	O	29-36
Europe	O	37-43
:	O	43-44
a	O	45-46
nonsense	O	47-55
mutation	O	56-64
associated	O	65-75
with	O	76-80
haplotype	O	81-90
4	O	91-92
of	O	93-95
the	O	96-99
phenylalanine	O	100-113
hydroxylase	O	114-125
gene	O	126-130
.	O	130-131

Phenylketonuria	B	132-147
(	O	148-149
PKU	B	149-152
)	O	152-153
is	O	154-156
a	O	157-158
genetic	B	159-166
disorder	I	167-175
secondary	O	176-185
to	O	186-188
a	O	189-190
deficiency	B	191-201
of	I	202-204
hepatic	I	205-212
phenylalanine	I	213-226
hydroxylase	I	227-238
(	O	239-240
PAH	O	240-243
)	O	243-244
.	O	244-245

Several	O	246-253
mutations	O	254-263
in	O	264-266
the	O	267-270
PAH	O	271-274
gene	O	275-279
have	O	280-284
recently	O	285-293
been	O	294-298
reported	O	299-307
,	O	307-308
and	O	309-312
linkage	O	313-320
disequilibrium	O	321-335
was	O	336-339
observed	O	340-348
between	O	349-356
RFLP	O	357-361
haplotypes	O	362-372
and	O	373-376
specific	O	377-385
mutations	O	386-395
.	O	395-396

A	O	397-398
new	O	399-402
molecular	B	403-412
lesion	I	413-419
has	O	420-423
been	O	424-428
identified	O	429-439
in	O	440-442
exon	O	443-447
7	O	448-449
of	O	450-452
the	O	453-456
PAH	O	457-460
gene	O	461-465
in	O	466-468
a	O	469-470
Hungarian	O	471-480
PKU	B	481-484
patient	O	485-492
by	O	493-495
direct	O	496-502
sequencing	O	503-513
of	O	514-516
PCR	O	517-520
-	O	520-521
amplified	O	521-530
DNA	O	531-534
.	O	534-535

The	O	536-539
C	O	540-541
-	O	541-542
to	O	542-544
-	O	541-542
T	O	545-546
transition	O	547-557
causes	O	558-564
the	O	565-568
substitution	O	569-581
of	O	582-584
Arg243	O	585-591
to	O	592-594
a	O	595-596
termination	O	597-608
codon	O	609-614
,	O	614-615
and	O	616-619
the	O	620-623
mutant	O	624-630
allele	O	631-637
is	O	638-640
associated	O	641-651
with	O	652-656
haplotype	O	657-666
4	O	667-668
of	O	669-671
the	O	672-675
PAH	O	676-679
gene	O	680-684
.	O	684-685

The	O	686-689
mutation	O	690-698
is	O	699-701
present	O	702-709
in	O	710-712
two	O	713-716
of	O	717-719
nine	O	720-724
mutant	O	725-731
haplotype	O	732-741
4	O	742-743
alleles	O	744-751
among	O	752-757
Eastern	O	758-765
Europeans	O	766-775
and	O	776-779
is	O	780-782
not	O	783-786
present	O	787-794
among	O	795-800
Western	O	801-808
Europeans	O	809-818
and	O	819-822
Asians	O	823-829
.	O	829-830

The	O	831-834
rarity	O	835-841
of	O	842-844
this	O	845-849
mutant	O	850-856
allele	O	857-863
and	O	864-867
its	O	868-871
restricted	O	872-882
geographic	O	883-893
distribution	O	894-906
suggest	O	907-914
that	O	915-919
the	O	920-923
mutational	O	924-934
event	O	935-940
occurred	O	941-949
recently	O	950-958
on	O	959-961
a	O	962-963
normal	O	964-970
haplotype	O	971-980
4	O	981-982
background	O	983-993
in	O	994-996
Eastern	O	997-1004
Europe	O	1005-1011
.	O	1011-1012
.	O	1011-1012

Isolation	O	0-9
of	O	10-12
the	O	13-16
mouse	O	17-22
homologue	O	23-32
of	O	33-35
BRCA1	O	36-41
and	O	42-45
genetic	O	46-53
mapping	O	54-61
to	O	62-64
mouse	O	65-70
chromosome	O	71-81
11	O	82-84
.	O	84-85

The	O	86-89
BRCA1	O	90-95
gene	O	96-100
is	O	101-103
in	O	104-106
large	O	107-112
part	O	113-117
responsible	O	118-129
for	O	130-133
hereditary	B	134-144
human	I	145-150
breast	I	151-157
and	I	158-161
ovarian	I	162-169
cancer	I	170-176
.	O	176-177

Here	O	178-182
we	O	183-185
report	O	186-192
the	O	193-196
isolation	O	197-206
of	O	207-209
the	O	210-213
murine	O	214-220
Brca1	O	221-226
homologue	O	227-236
cDNA	O	237-241
clones	O	242-248
.	O	248-249

In	O	250-252
addition	O	253-261
,	O	261-262
we	O	263-265
identified	O	266-276
genomic	O	277-284
P1	O	285-287
clones	O	288-294
that	O	295-299
contain	O	300-307
most	O	308-312
,	O	312-313
if	O	314-316
not	O	317-320
all	O	321-324
,	O	324-325
of	O	326-328
the	O	329-332
mouse	O	333-338
Brca1	O	339-344
locus	O	345-350
.	O	350-351

DNA	O	352-355
sequence	O	356-364
analysis	O	365-373
revealed	O	374-382
that	O	383-387
the	O	388-391
mouse	O	392-397
and	O	398-401
human	O	402-407
coding	O	408-414
regions	O	415-422
are	O	423-426
75	O	427-429
%	O	429-430
identical	O	431-440
at	O	441-443
the	O	444-447
nucleotide	O	448-458
level	O	459-464
while	O	465-470
the	O	471-474
predicted	O	475-484
amino	O	485-490
acid	O	491-495
identity	O	496-504
is	O	505-507
only	O	508-512
58	O	513-515
%	O	515-516
.	O	516-517

A	O	518-519
DNA	O	520-523
sequence	O	524-532
variant	O	533-540
in	O	541-543
the	O	544-547
Brca1	O	548-553
locus	O	554-559
was	O	560-563
identified	O	564-574
and	O	575-578
used	O	579-583
to	O	584-586
map	O	587-590
this	O	591-595
gene	O	596-600
on	O	601-603
a	O	604-605
(	O	606-607
Mus	O	607-610
m	O	611-612
.	O	612-613
musculus	O	614-622
Czech	O	623-628
II	O	629-631
x	O	632-633
C57BL	O	634-639
/	O	639-640
KsJ	O	640-643
)	O	643-644
F1	O	645-647
x	O	648-649
C57BL	O	650-655
/	O	655-656
KsJ	O	656-659
intersubspecific	O	660-676
backcross	O	677-686
to	O	687-689
distal	O	690-696
mouse	O	697-702
chromosome	O	703-713
11	O	714-716
.	O	716-717

The	O	718-721
mapping	O	722-729
of	O	730-732
this	O	733-737
gene	O	738-742
to	O	743-745
a	O	746-747
region	O	748-754
highly	O	755-761
syntenic	O	762-770
with	O	771-775
human	O	776-781
chromosome	O	782-792
17	O	793-795
,	O	795-796
coupled	O	797-804
with	O	805-809
Southern	O	810-818
and	O	819-822
Northern	O	823-831
analyses	O	832-840
,	O	840-841
confirms	O	842-850
that	O	851-855
we	O	856-858
isolated	O	859-867
the	O	868-871
murine	O	872-878
Brca1	O	879-884
homologue	O	885-894
rather	O	895-901
than	O	902-906
a	O	907-908
related	O	909-916
RING	O	917-921
finger	O	922-928
gene	O	929-933
.	O	933-934

The	O	935-938
isolation	O	939-948
of	O	949-951
the	O	952-955
mouse	O	956-961
Brca1	O	962-967
homologue	O	968-977
will	O	978-982
facilitate	O	983-993
the	O	994-997
creation	O	998-1006
of	O	1007-1009
mouse	O	1010-1015
models	O	1016-1022
for	O	1023-1026
germline	O	1027-1035
BRCA1	B	1036-1041
defects	I	1042-1049
.	O	1049-1050
.	O	1049-1050

Human	O	0-5
deficiency	B	6-16
of	I	17-19
the	I	20-23
sixth	I	24-29
component	I	30-39
of	I	40-42
complement	I	43-53
in	O	54-56
a	O	57-58
patient	O	59-66
with	O	67-71
meningococcal	B	72-85
meningitis	I	86-96
and	O	97-100
no	O	101-103
haemostasis	B	104-115
abnormality	I	116-127
.	O	127-128

A	O	129-130
case	O	131-135
of	O	136-138
human	O	139-144
complete	O	145-153
C6	B	154-156
deficiency	I	157-167
is	O	168-170
reported	O	171-179
.	O	179-180

The	O	181-184
patient	O	185-192
,	O	192-193
a	O	194-195
31	O	196-198
year	O	199-203
old	O	204-207
white	O	208-213
male	O	214-218
,	O	218-219
was	O	220-223
seen	O	224-228
on	O	229-231
the	O	232-235
occasion	O	236-244
of	O	245-247
an	O	248-250
isolated	O	251-259
episode	O	260-267
of	O	268-270
meningococcal	B	271-284
meningitis	I	285-295
.	O	295-296

Serum	O	297-302
complement	O	303-313
hemolytic	O	314-323
and	O	324-327
bactericidal	O	328-340
activities	O	341-351
were	O	352-356
lacking	O	357-364
and	O	365-368
could	O	369-374
be	O	375-377
restored	O	378-386
to	O	387-389
normal	O	390-396
by	O	397-399
addition	O	400-408
of	O	409-411
appropriate	O	412-423
amounts	O	424-431
of	O	432-434
purified	O	435-443
C6	O	444-446
.	O	446-447

No	O	448-450
hemostatic	B	451-461
abnormalities	I	462-475
were	O	476-480
observed	O	481-489
.	O	489-490
.	O	489-490

The	O	0-3
Wiskott	B	4-11
-	I	11-12
Aldrich	I	12-19
syndrome	I	20-28
:	O	28-29
refinement	O	30-40
of	O	41-43
the	O	44-47
localization	O	48-60
on	O	61-63
Xp	O	64-66
and	O	67-70
identification	O	71-85
of	O	86-88
another	O	89-96
closely	O	97-104
linked	O	105-111
marker	O	112-118
locus	O	119-124
,	O	124-125
OATL1	O	126-131
.	O	131-132

The	O	133-136
Wiskott	B	137-144
-	I	144-145
Aldrich	I	145-152
syndrome	I	153-161
(	O	162-163
WAS	B	163-166
)	O	166-167
has	O	168-171
previously	O	172-182
been	O	183-187
mapped	O	188-194
to	O	195-197
the	O	198-201
proximal	O	202-210
short	O	211-216
arm	O	217-220
of	O	221-223
the	O	224-227
X	O	228-229
chromosome	O	230-240
between	O	241-248
the	O	249-252
DXS14	O	253-258
and	O	259-262
DXS7	O	263-267
loci	O	268-272
.	O	272-273

In	O	274-276
this	O	277-281
study	O	282-287
,	O	287-288
further	O	289-296
segregation	O	297-308
analysis	O	309-317
has	O	318-321
been	O	322-326
performed	O	327-336
using	O	337-342
a	O	343-344
newly	O	345-350
identified	O	351-361
WAS	B	362-365
family	O	366-372
as	O	373-375
well	O	376-380
as	O	381-383
an	O	384-386
additional	O	387-397
marker	O	398-404
probe	O	405-410
,	O	410-411
HOATL1	O	412-418
.	O	418-419

The	O	420-423
results	O	424-431
indicate	O	432-440
close	O	441-446
linkage	O	447-454
between	O	455-462
the	O	463-466
WAS	B	467-470
and	O	471-474
OATL1	O	475-480
loci	O	481-485
(	O	486-487
Z	O	487-488
=	O	489-490
6	O	491-492
.	O	492-493

08	O	494-496
at	O	497-499
theta	O	500-505
=	O	506-507
0	O	508-509
.	O	509-510
00	O	511-513
)	O	513-514
and	O	515-518
localize	O	519-527
the	O	528-531
TIMP	O	532-536
,	O	536-537
OATL1	O	538-543
,	O	543-544
DXS255	O	545-551
,	O	551-552
and	O	553-556
WAS	B	557-560
loci	O	561-565
distal	O	566-572
to	O	573-575
DXS146	O	576-582
and	O	583-586
the	O	587-590
OATL1	O	591-596
and	O	597-600
WAS	B	601-604
loci	O	605-609
proximal	O	610-618
to	O	619-621
TIMP	O	622-626
.	O	626-627

These	O	628-633
linkage	O	634-641
data	O	642-646
narrow	O	647-653
the	O	654-657
boundaries	O	658-668
within	O	669-675
which	O	676-681
the	O	682-685
WAS	B	686-689
locus	O	690-695
maps	O	696-700
to	O	701-703
the	O	704-707
chromosomal	O	708-719
region	O	720-726
bracketed	O	727-736
by	O	737-739
TIMP	O	740-744
and	O	745-748
DXS146	O	749-755
and	O	756-759
support	O	760-767
the	O	768-771
loci	O	772-776
order	O	777-782
Xpter	O	783-788
-	O	788-789
DXS7	O	789-793
-	O	788-789
TIMP	O	794-798
-	O	788-789
(	O	800-801
OATL1	O	801-806
,	O	806-807
WAS	O	808-811
,	O	811-812
DXS255	O	813-819
)	O	819-820
-	O	821-822
DXS146	O	822-828
.	O	828-829

Hereditary	B	0-10
deficiency	I	11-21
of	I	22-24
the	I	25-28
third	I	29-34
component	I	35-44
of	I	45-47
complement	I	48-58
in	O	59-61
a	O	62-63
child	O	64-69
with	O	70-74
fever	B	75-80
,	O	80-81
skin	B	82-86
rash	I	87-91
,	O	91-92
and	O	93-96
arthralgias	B	97-108
:	O	108-109
response	O	110-118
to	O	119-121
transfusion	O	122-133
of	O	134-136
whole	O	137-142
blood	O	143-148
.	O	148-149

A	O	150-151
previously	O	152-162
well	O	163-167
34	O	168-170
-	O	170-171
month	O	171-176
-	O	170-171
old	O	177-180
male	O	181-185
presenting	O	186-196
with	O	197-201
fever	B	202-207
,	O	207-208
skin	B	209-213
rash	I	214-218
,	O	218-219
and	O	220-223
arthralgias	B	224-235
was	O	236-239
found	O	240-245
to	O	246-248
lack	O	249-253
C3	O	254-256
by	O	257-259
immunochemical	O	260-274
(	O	275-276
undetectable	O	276-288
)	O	288-289
and	O	290-293
hemolytic	O	294-303
(	O	304-305
1	O	305-306
%	O	306-307
normal	O	308-314
)	O	314-315
assays	O	316-322
.	O	322-323

No	O	324-326
infectious	O	327-337
agent	O	338-343
could	O	344-349
be	O	350-352
demonstrated	O	353-365
.	O	365-366

Protein	O	367-374
levels	O	375-381
of	O	382-384
Clq	O	385-388
.	O	388-389

C4	O	390-392
,	O	392-393
C5	O	394-396
,	O	396-397
properdin	O	398-407
,	O	407-408
and	O	409-412
C3b	O	413-416
-	O	416-417
INA	O	417-420
and	O	421-424
hemolytic	O	425-434
activities	O	435-445
of	O	446-448
complement	O	449-459
components	O	460-470
C1	O	471-473
to	O	474-476
C9	O	477-479
except	O	480-486
C3	O	487-489
were	O	490-494
normal	O	495-501
or	O	502-504
elevated	O	505-513
;	O	513-514
total	O	515-520
hemolytic	O	521-530
complement	O	531-541
activity	O	542-550
was	O	551-554
13	O	555-557
%	O	557-558
of	O	559-561
normal	O	562-568
and	O	569-572
was	O	573-576
reconstituted	O	577-590
by	O	591-593
purified	O	594-602
C3	O	603-605
.	O	605-606

Properdin	O	607-616
factor	O	617-623
B	O	624-625
was	O	626-629
702	O	630-633
(	O	634-635
normal	O	635-641
175	O	642-645
to	O	646-648
275	O	649-652
)	O	652-653
mug	O	654-657
/	O	657-658
ml	O	658-660
,	O	660-661
and	O	662-665
was	O	666-669
not	O	670-673
cleaver	O	674-681
upon	O	682-686
addition	O	687-695
of	O	696-698
zymosan	O	699-706
or	O	707-709
cobra	O	710-715
venom	O	716-721
factor	O	722-728
.	O	728-729

The	O	730-733
serum	O	734-739
had	O	740-743
normal	O	744-750
immune	O	751-757
adherence	O	758-767
activity	O	768-776
,	O	776-777
but	O	778-781
was	O	782-785
deficient	O	786-795
in	O	796-798
ability	O	799-806
to	O	807-809
opsonize	O	810-818
Candida	O	819-826
albicans	O	827-835
for	O	836-839
uptake	O	840-846
and	O	847-850
Escherichia	O	851-862
coli	O	863-867
for	O	868-871
killing	O	872-879
by	O	880-882
neurophils	O	883-893
,	O	893-894
generate	O	895-903
neutrophil	O	904-914
chemotactic	O	915-926
factors	O	927-934
and	O	935-938
inhibit	O	939-946
the	O	947-950
growth	O	951-957
of	O	958-960
E	O	961-962
.	O	962-963
coli	O	964-968
;	O	968-969
these	O	970-975
activities	O	976-986
were	O	987-991
restored	O	992-1000
by	O	1001-1003
purified	O	1004-1012
C3	O	1013-1015
.	O	1015-1016

A	O	1017-1018
transfusion	O	1019-1030
of	O	1031-1033
320	O	1034-1037
ml	O	1038-1040
1	O	1041-1042
-	O	1042-1043
hour	O	1043-1047
-	O	1042-1043
old	O	1048-1051
normal	O	1052-1058
whole	O	1059-1064
blood	O	1065-1070
on	O	1071-1073
the	O	1074-1077
fifty	O	1078-1083
-	O	1083-1084
second	O	1084-1090
day	O	1091-1094
resulted	O	1095-1103
in	O	1104-1106
transitory	O	1107-1117
elevation	O	1118-1127
of	O	1128-1130
the	O	1131-1134
C3	O	1135-1137
level	O	1138-1143
to	O	1144-1146
25	O	1147-1149
mg	O	1150-1152
/	O	1152-1153
dl	O	1153-1155
with	O	1156-1160
a	O	1161-1162
fall	O	1163-1167
-	O	1167-1168
off	O	1168-1171
(	O	1172-1173
approximately	O	1173-1186
2	O	1187-1188
1	O	1189-1190
/	O	1190-1191
2	O	1191-1192
%	O	1192-1193
per	O	1194-1197
hour	O	1198-1202
)	O	1202-1203
to	O	1204-1206
undetectable	O	1207-1219
levels	O	1220-1226
by	O	1227-1229
69	O	1230-1232
hours	O	1233-1238
;	O	1238-1239
it	O	1240-1242
was	O	1243-1246
followed	O	1247-1255
by	O	1256-1258
disappearance	O	1259-1272
of	O	1273-1275
the	O	1276-1279
skin	B	1280-1284
rash	I	1285-1289
and	O	1290-1293
arthralgias	B	1294-1305
and	O	1306-1309
return	O	1310-1316
to	O	1317-1319
normal	O	1320-1326
of	O	1327-1329
the	O	1330-1333
previously	O	1334-1344
elevated	O	1345-1353
temperature	O	1354-1365
and	O	1366-1369
CRP	O	1370-1373
levels	O	1374-1380
.	O	1380-1381

C3	O	1382-1384
levels	O	1385-1391
in	O	1392-1394
family	O	1395-1401
members	O	1402-1409
(	O	1410-1411
seven	O	1411-1416
of	O	1417-1419
24	O	1420-1422
half	O	1423-1427
-	O	1427-1428
normal	O	1428-1434
)	O	1434-1435
,	O	1435-1436
lack	O	1437-1441
of	O	1442-1444
anti	O	1445-1449
-	O	1449-1450
C3	O	1450-1452
activity	O	1453-1461
,	O	1461-1462
normal	O	1463-1469
C3b	O	1470-1473
-	O	1473-1474
INA	O	1474-1477
levels	O	1478-1484
and	O	1485-1488
a	O	1489-1490
normal	O	1491-1497
rate	O	1498-1502
of	O	1503-1505
catabolism	O	1506-1516
of	O	1517-1519
transfused	O	1520-1530
C3	O	1531-1533
indicated	O	1534-1543
that	O	1544-1548
the	O	1549-1552
deficiency	O	1553-1563
was	O	1564-1567
inherited	O	1568-1577
with	O	1578-1582
autosomal	O	1583-1592
codominance	O	1593-1604
and	O	1605-1608
involved	O	1609-1617
decreased	B	1618-1627
synthesis	I	1628-1637
of	I	1638-1640
C3	I	1641-1643
.	O	1643-1644

Thus	O	1645-1649
,	O	1649-1650
this	O	1651-1655
child	O	1656-1661
is	O	1662-1664
a	O	1665-1666
unique	O	1667-1673
individual	O	1674-1684
with	O	1685-1689
inherited	B	1690-1699
C3	I	1700-1702
deficiency	I	1703-1713
presenting	O	1714-1724
with	O	1725-1729
absence	O	1730-1737
of	O	1738-1740
repeated	O	1741-1749
infections	O	1750-1760
,	O	1760-1761
whose	O	1762-1767
symptoms	O	1768-1776
of	O	1777-1779
fever	B	1780-1785
,	O	1785-1786
skin	B	1787-1791
rash	I	1792-1796
,	O	1796-1797
and	O	1798-1801
arthralgia	B	1802-1812
were	O	1813-1817
abated	O	1818-1824
by	O	1825-1827
whole	O	1828-1833
blood	O	1834-1839
transfusion	O	1840-1851
.	O	1851-1852
.	O	1851-1852

Cloning	O	0-7
of	O	8-10
breakpoints	O	11-22
of	O	23-25
a	O	26-27
chromosome	O	28-38
translocation	O	39-52
identifies	O	53-63
the	O	64-67
AN2	O	68-71
locus	O	72-77
.	O	77-78

Chromosome	O	79-89
translocations	O	90-104
involving	O	105-114
11p13	O	115-120
have	O	121-125
been	O	126-130
associated	O	131-141
with	O	142-146
familial	B	147-155
aniridia	I	156-164
in	O	165-167
two	O	168-171
kindreds	O	172-180
highlighting	O	181-193
the	O	194-197
chromosomal	O	198-209
localization	O	210-222
of	O	223-225
the	O	226-229
AN2	O	230-233
locus	O	234-239
.	O	239-240

This	O	241-245
locus	O	246-251
is	O	252-254
also	O	255-259
part	O	260-264
of	O	265-267
the	O	268-271
WAGR	B	272-276
complex	O	277-284
(	O	285-286
Wilms	B	286-291
tumor	I	292-297
,	O	297-298
aniridia	B	299-307
,	O	307-308
genitourinary	B	309-322
abnormalities	I	323-336
,	O	336-337
and	O	338-341
mental	B	342-348
retardation	I	349-360
)	O	360-361
.	O	361-362

In	O	363-365
one	O	366-369
kindred	O	370-377
,	O	377-378
the	O	379-382
translocation	O	383-396
is	O	397-399
associated	O	400-410
with	O	411-415
a	O	416-417
deletion	O	418-426
,	O	426-427
and	O	428-431
probes	O	432-438
for	O	439-442
this	O	443-447
region	O	448-454
were	O	455-459
used	O	460-464
to	O	465-467
identify	O	468-476
and	O	477-480
clone	O	481-486
the	O	487-490
breakpoints	O	491-502
of	O	503-505
the	O	506-509
translocation	O	510-523
in	O	524-526
the	O	527-530
second	O	531-537
kindred	O	538-545
.	O	545-546

Comparison	O	547-557
of	O	558-560
phage	O	561-566
restriction	O	567-578
maps	O	579-583
exclude	O	584-591
the	O	592-595
presence	O	596-604
of	O	605-607
any	O	608-611
sizable	O	612-619
deletion	O	620-628
in	O	629-631
this	O	632-636
case	O	637-641
.	O	641-642

Sequences	O	643-652
at	O	653-655
the	O	656-659
chromosome	O	660-670
11	O	671-673
breakpoint	O	674-684
are	O	685-688
conserved	O	689-698
in	O	699-701
multiple	O	702-710
species	O	711-718
,	O	718-719
suggesting	O	720-730
that	O	731-735
the	O	736-739
translocation	O	740-753
falls	O	754-759
within	O	760-766
the	O	767-770
AN2	O	771-774
gene	O	775-779
.	O	779-780
.	O	779-780

Study	O	0-5
of	O	6-8
the	O	9-12
voltage	O	13-20
-	O	20-21
gated	O	21-26
sodium	O	27-33
channel	O	34-41
beta	O	42-46
1	O	47-48
subunit	O	49-56
gene	O	57-61
(	O	62-63
SCN1B	O	63-68
)	O	68-69
in	O	70-72
the	O	73-76
benign	B	77-83
familial	I	84-92
infantile	I	93-102
convulsions	I	103-114
syndrome	I	115-123
(	O	124-125
BFIC	B	125-129
)	O	129-130
.	O	130-131

Benign	B	132-138
familial	I	139-147
infantile	I	148-157
convulsions	I	158-169
(	O	170-171
BFIC	B	171-175
)	O	175-176
is	O	177-179
a	O	180-181
rare	O	182-186
autosomal	B	187-196
dominant	I	197-205
epilepsy	I	206-214
syndrome	I	215-223
.	O	223-224

This	O	225-229
syndrome	O	230-238
has	O	239-242
been	O	243-247
recently	O	248-256
described	O	257-266
in	O	267-269
Italian	O	270-277
and	O	278-281
French	O	282-288
pedigrees	O	289-298
.	O	298-299

Patients	O	300-308
present	O	309-316
with	O	317-321
partial	O	322-329
,	O	329-330
then	O	331-335
generalized	O	336-347
seizures	O	348-356
,	O	356-357
with	O	358-362
onset	O	363-368
at	O	369-371
age	O	372-375
three	O	376-381
months	O	382-388
.	O	388-389

The	O	390-393
seizures	O	394-402
usually	O	403-410
spontaneously	O	411-424
cease	O	425-430
after	O	431-436
one	O	437-440
year	O	441-445
without	O	446-453
treatment	O	454-463
,	O	463-464
leaving	O	465-472
no	O	473-475
neurological	B	476-488
abnormalities	I	489-502
.	O	502-503

We	O	504-506
have	O	507-511
mapped	O	512-518
BFIC	B	519-523
to	O	524-526
chromosome	O	527-537
19q	O	538-541
in	O	542-544
five	O	545-549
Italian	O	550-557
pedigrees	O	558-567
.	O	567-568

The	O	569-572
sodium	O	573-579
channel	O	580-587
beta1	O	588-593
subunit	O	594-601
gene	O	602-606
(	O	607-608
SCN1B	O	608-613
)	O	613-614
maps	O	615-619
to	O	620-622
this	O	623-627
candidate	O	628-637
region	O	638-644
and	O	645-648
has	O	649-652
been	O	653-657
shown	O	658-663
to	O	664-666
be	O	667-669
involved	O	670-678
in	O	679-681
one	O	682-685
Australian	O	686-696
pedigree	O	697-705
with	O	706-710
generalized	B	711-722
epilepsy	I	723-731
and	I	732-735
febrile	I	736-743
seizures	I	744-752
"	I	753-754
plus	I	755-759
"	I	760-761
(	O	762-763
GEFS	O	763-767
+	O	768-769
)	O	769-770
.	O	770-771

In	O	772-774
this	O	775-779
family	O	780-786
,	O	786-787
a	O	788-789
missense	O	790-798
mutation	O	799-807
in	O	808-810
SCN1B	O	811-816
cosegregates	O	817-829
with	O	830-834
the	O	835-838
GEFS	O	839-843
+	O	844-845
phenotype	O	846-855
.	O	855-856

BFIC	B	857-861
and	O	862-865
GEFS	O	866-870
+	O	871-872
have	O	873-877
clinical	O	878-886
features	O	887-895
in	O	896-898
common	O	899-905
,	O	905-906
therefore	O	907-916
SCN1B	O	917-922
is	O	923-925
a	O	926-927
candidate	O	928-937
gene	O	938-942
for	O	943-946
BFIC	B	947-951
.	O	951-952

We	O	953-955
studied	O	956-963
SCN1B	O	964-969
exons	O	970-975
1	O	976-977
,	O	977-978
2	O	979-980
,	O	980-981
3	O	982-983
,	O	983-984
4	O	985-986
,	O	986-987
and	O	988-991
5	O	992-993
,	O	993-994
using	O	995-1000
four	O	1001-1005
SSCP	O	1006-1010
methods	O	1011-1018
in	O	1019-1021
10	O	1022-1024
Caucasian	O	1025-1034
BFIC	B	1035-1039
probands	O	1040-1048
of	O	1049-1051
Western	O	1052-1059
Europe	O	1060-1066
.	O	1066-1067

We	O	1068-1070
found	O	1071-1076
no	O	1077-1079
exon	O	1080-1084
variants	O	1085-1093
.	O	1093-1094

One	O	1095-1098
variant	O	1099-1106
was	O	1107-1110
identified	O	1111-1121
in	O	1122-1124
intron	O	1125-1131
5	O	1132-1133
(	O	1134-1135
IVS5	O	1135-1139
-	O	1139-1140
10C	O	1140-1143
>	O	1144-1145
G	O	1146-1147
)	O	1147-1148
,	O	1148-1149
which	O	1150-1155
did	O	1156-1159
not	O	1160-1163
segregate	O	1164-1173
with	O	1174-1178
BFIC	B	1179-1183
and	O	1184-1187
was	O	1188-1191
observed	O	1192-1200
in	O	1201-1203
9	O	1204-1205
.	O	1205-1206
2	O	1207-1208
%	O	1208-1209
controls	O	1210-1218
.	O	1218-1219

A	O	1220-1221
second	O	1222-1228
variant	O	1229-1236
in	O	1237-1239
intron	O	1240-1246
5	O	1247-1248
was	O	1249-1252
identified	O	1253-1263
(	O	1264-1265
IVS5	O	1265-1269
+	O	1270-1271
30G	O	1272-1275
>	O	1276-1277
A	O	1278-1279
)	O	1279-1280
.	O	1280-1281

It	O	1282-1284
was	O	1285-1288
rare	O	1289-1293
,	O	1293-1294
as	O	1295-1297
not	O	1298-1301
observed	O	1302-1310
in	O	1311-1313
controls	O	1314-1322
,	O	1322-1323
but	O	1324-1327
not	O	1328-1331
segregating	O	1332-1343
with	O	1344-1348
the	O	1349-1352
BFIC	B	1353-1357
phenotype	O	1358-1367
.	O	1367-1368

Brain	B	0-5
disease	I	6-13
and	O	14-17
molecular	O	18-27
analysis	O	28-36
in	O	37-39
myotonic	B	40-48
dystrophy	I	49-58
.	O	58-59

Abnormal	O	60-68
amplification	O	69-82
of	O	83-85
a	O	86-87
CTG	O	88-91
repeat	O	92-98
on	O	99-101
chromosome	O	102-112
19	O	113-115
is	O	116-118
the	O	119-122
molecular	O	123-132
basis	O	133-138
of	O	139-141
myotonic	B	142-150
dystrophy	I	151-160
(	O	161-162
DM	B	162-164
)	O	164-165
.	O	165-166

Expansion	O	167-176
of	O	177-179
the	O	180-183
repeat	O	184-190
has	O	191-194
been	O	195-199
correlated	O	200-210
with	O	211-215
severity	O	216-224
of	O	225-227
several	O	228-235
clinical	O	236-244
features	O	245-253
of	O	254-256
the	O	257-260
disease	O	261-268
.	O	268-269

We	O	270-272
performed	O	273-282
extensive	O	283-292
cognitive	O	293-302
testing	O	303-310
,	O	310-311
cerebral	O	312-320
magnetic	O	321-329
resonance	O	330-339
imaging	O	340-347
(	O	348-349
MRI	O	349-352
)	O	352-353
and	O	354-357
a	O	358-359
molecular	O	360-369
analysis	O	370-378
in	O	379-381
28	O	382-384
cases	O	385-390
of	O	391-393
DM	B	394-396
to	O	397-399
determine	O	400-409
the	O	410-413
relationship	O	414-426
between	O	427-434
the	O	435-438
molecular	O	439-448
defect	O	449-455
and	O	456-459
brain	B	460-465
disease	I	466-473
.	O	473-474

Performance	O	475-486
in	O	487-489
two	O	490-493
or	O	494-496
more	O	497-501
cognitive	O	502-511
tests	O	512-517
was	O	518-521
pathological	O	522-534
in	O	535-537
10	O	538-540
cases	O	541-546
.	O	546-547

Fourteen	O	548-556
patients	O	557-565
had	O	566-569
subcortical	O	570-581
white	B	582-587
matter	I	588-594
lesions	I	595-602
on	O	603-605
MRI	O	606-609
,	O	609-610
14	O	611-613
had	O	614-617
cerebral	B	618-626
atrophy	I	627-634
.	O	634-635

Amplification	O	636-649
of	O	650-652
the	O	653-656
CTG	O	657-660
repeat	O	661-667
showed	O	668-674
a	O	675-676
strong	O	677-683
correlation	O	684-695
with	O	696-700
cognitive	O	701-710
test	O	711-715
deficits	O	716-724
when	O	725-729
exceeding	O	730-739
a	O	740-741
length	O	742-748
of	O	749-751
over	O	752-756
1000	O	757-761
trinucleotides	O	762-776
.	O	776-777

MRI	O	778-781
lesions	O	782-789
were	O	790-794
associated	O	795-805
with	O	806-810
impaired	O	811-819
psychometric	O	820-832
performance	O	833-844
,	O	844-845
but	O	846-849
MRI	O	850-853
and	O	854-857
molecular	O	858-867
findings	O	868-876
were	O	877-881
only	O	882-886
weakly	O	887-893
related	O	894-901
.	O	901-902

Disease	O	903-910
duration	O	911-919
influenced	O	920-930
the	O	931-934
appearance	O	935-945
and	O	946-949
amount	O	950-956
of	O	957-959
white	B	960-965
matter	I	966-972
lesions	I	973-980
on	O	981-983
MRI	O	984-987
.	O	987-988

Quantification	O	989-1003
of	O	1004-1006
CTG	O	1007-1010
repeat	O	1011-1017
size	O	1018-1022
may	O	1023-1026
allow	O	1027-1032
an	O	1033-1035
early	O	1036-1041
estimate	O	1042-1050
on	O	1051-1053
the	O	1054-1057
probability	O	1058-1069
of	O	1070-1072
brain	O	1073-1078
involvement	O	1079-1090
in	O	1091-1093
DM	B	1094-1096
;	O	1096-1097
cognitive	B	1098-1107
dysfunction	I	1108-1119
is	O	1120-1122
associated	O	1123-1133
with	O	1134-1138
white	B	1139-1144
matter	I	1145-1151
lesions	I	1152-1159
and	O	1160-1163
cerebral	B	1164-1172
atrophy	I	1173-1180
later	O	1181-1186
on	O	1187-1189
in	O	1190-1192
the	O	1193-1196
course	O	1197-1203
.	O	1203-1204
.	O	1203-1204

A	O	0-1
highly	O	2-8
accurate	O	9-17
,	O	17-18
low	O	19-22
cost	O	23-27
test	O	28-32
for	O	33-36
BRCA1	O	37-42
mutations	O	43-52
.	O	52-53

The	O	54-57
hereditary	B	58-68
breast	I	69-75
and	I	76-79
ovarian	I	80-87
cancer	I	88-94
syndrome	I	95-103
is	O	104-106
associated	O	107-117
with	O	118-122
a	O	123-124
high	O	125-129
frequency	O	130-139
of	O	140-142
BRCA1	O	143-148
mutations	O	149-158
.	O	158-159

However	O	160-167
,	O	167-168
the	O	169-172
widespread	O	173-183
use	O	184-187
of	O	188-190
BRCA1	O	191-196
testing	O	197-204
has	O	205-208
been	O	209-213
limited	O	214-221
to	O	222-224
date	O	225-229
by	O	230-232
three	O	233-238
principal	O	239-248
concerns	O	249-257
the	O	259-262
fear	O	263-267
of	O	268-270
loss	O	271-275
of	O	276-278
health	O	279-285
and	O	286-289
life	O	290-294
insurance	O	295-304
,	O	304-305
the	O	306-309
uncertain	O	310-319
clinical	O	320-328
value	O	329-334
of	O	335-337
a	O	338-339
positive	O	340-348
test	O	349-353
result	O	354-360
,	O	360-361
and	O	362-365
the	O	366-369
current	O	370-377
lack	O	378-382
of	O	383-385
an	O	386-388
inexpensive	O	389-400
and	O	401-404
sensitive	O	405-414
screening	O	415-424
test	O	425-429
for	O	430-433
BRCA1	O	434-439
mutations	O	440-449
.	O	449-450

We	O	451-453
have	O	454-458
developed	O	459-468
an	O	469-471
inexpensive	O	472-483
system	O	484-490
for	O	491-494
gene	O	495-499
mutational	O	500-510
scanning	O	511-519
,	O	519-520
based	O	521-526
on	O	527-529
a	O	530-531
combination	O	532-543
of	O	544-546
extensive	O	547-556
multiplex	O	557-566
PCR	O	567-570
amplification	O	571-584
and	O	585-588
two	O	589-592
dimensional	O	593-604
electrophoresis	O	605-620
.	O	620-621

The	O	622-625
efficiency	O	626-636
of	O	637-639
this	O	640-644
system	O	645-651
,	O	651-652
as	O	653-655
a	O	656-657
screening	O	658-667
test	O	668-672
for	O	673-676
BRCA1	O	677-682
mutations	O	683-692
,	O	692-693
was	O	694-697
evaluated	O	698-707
in	O	708-710
a	O	711-712
panel	O	713-718
of	O	719-721
60	O	722-724
samples	O	725-732
from	O	733-737
high	O	738-742
risk	O	743-747
women	O	748-753
,	O	753-754
14	O	755-757
of	O	758-760
which	O	761-766
contained	O	767-776
a	O	777-778
previously	O	779-789
identified	O	790-800
mutation	O	801-809
in	O	810-812
BRCA1	O	813-818
.	O	818-819

All	O	820-823
14	O	824-826
mutations	O	827-836
were	O	837-841
identified	O	842-852
,	O	852-853
as	O	854-856
well	O	857-861
as	O	862-864
an	O	865-867
additional	O	868-878
five	O	879-883
that	O	884-888
had	O	889-892
previously	O	893-903
escaped	O	904-911
detection	O	912-921
.	O	921-922

In	O	923-925
addition	O	926-934
to	O	935-937
the	O	938-941
19	O	942-944
mutations	O	945-954
,	O	954-955
a	O	956-957
total	O	958-963
of	O	964-966
15	O	967-969
different	O	970-979
polymorphic	O	980-991
variants	O	992-1000
were	O	1001-1005
scored	O	1006-1012
,	O	1012-1013
most	O	1014-1018
of	O	1019-1021
which	O	1022-1027
were	O	1028-1032
recurring	O	1033-1042
.	O	1042-1043

All	O	1044-1047
were	O	1048-1052
confirmed	O	1053-1062
by	O	1063-1065
nucleotide	O	1066-1076
sequencing	O	1077-1087
.	O	1087-1088

The	O	1089-1092
cost	O	1093-1097
of	O	1098-1100
screening	O	1101-1110
per	O	1111-1114
sample	O	1115-1121
was	O	1122-1125
calculated	O	1126-1136
to	O	1137-1139
be	O	1140-1142
approximately	O	1143-1156
US	O	1157-1159
$	O	1160-1161
70	O	1162-1164
for	O	1165-1168
the	O	1169-1172
manual	O	1173-1179
technique	O	1180-1189
used	O	1190-1194
in	O	1195-1197
this	O	1198-1202
study	O	1203-1208
,	O	1208-1209
and	O	1210-1213
may	O	1214-1217
be	O	1218-1220
reduced	O	1221-1228
to	O	1229-1231
approximately	O	1232-1245
US	O	1246-1248
$	O	1249-1250
10	O	1251-1253
with	O	1254-1258
the	O	1259-1262
introduction	O	1263-1275
of	O	1276-1278
commercially	O	1279-1291
available	O	1292-1301
PCR	O	1302-1305
robotics	O	1306-1314
and	O	1315-1318
fluorescent	O	1319-1330
imaging	O	1331-1338
.	O	1338-1339

Implementation	O	1340-1354
of	O	1355-1357
this	O	1358-1362
method	O	1363-1369
of	O	1370-1372
mutation	O	1373-1381
screening	O	1382-1391
in	O	1392-1394
the	O	1395-1398
research	O	1399-1407
and	O	1408-1411
clinical	O	1412-1420
setting	O	1421-1428
should	O	1429-1435
permit	O	1436-1442
rapid	O	1443-1448
accrual	O	1449-1456
of	O	1457-1459
quantitative	O	1460-1472
data	O	1473-1477
on	O	1478-1480
genotype	O	1481-1489
-	O	1489-1490
phenotype	O	1490-1499
associations	O	1500-1512
for	O	1513-1516
the	O	1517-1520
evaluation	O	1521-1531
of	O	1532-1534
diagnostic	O	1535-1545
testing	O	1546-1553
.	O	1553-1554
.	O	1553-1554

Germline	O	0-8
mutations	O	9-18
of	O	19-21
the	O	22-25
APC	B	26-29
gene	O	30-34
in	O	35-37
Korean	O	38-44
familial	B	45-53
adenomatous	I	54-65
polyposis	I	66-75
patients	O	76-84
.	O	84-85

We	O	86-88
extensively	O	89-100
analyzed	O	101-109
genomic	O	110-117
DNA	O	118-121
and	O	122-125
messenger	O	126-135
RNA	O	136-139
(	O	140-141
mRNA	O	141-145
)	O	145-146
from	O	147-151
62	O	152-154
unrelated	O	155-164
Korean	O	165-171
patients	O	172-180
with	O	181-185
familial	B	186-194
adenomatous	I	195-206
polyposis	I	207-216
(	O	217-218
FAP	B	218-221
)	O	221-222
for	O	223-226
identification	O	227-241
of	O	242-244
germline	O	245-253
adenomatous	B	254-265
polyposis	I	266-275
coli	I	276-280
(	O	281-282
APC	B	282-285
)	O	285-286
gene	O	287-291
mutations	O	292-301
.	O	301-302

We	O	303-305
adopted	O	306-313
both	O	314-318
single	O	319-325
-	O	325-326
strand	O	326-332
conformation	O	333-345
polymorphism	O	346-358
(	O	359-360
SSCP	O	360-364
)	O	364-365
analysis	O	366-374
and	O	375-378
a	O	379-380
method	O	381-387
of	O	388-390
analysis	O	391-399
involving	O	400-409
the	O	410-413
reverse	O	414-421
transcription	O	422-435
-	O	435-436
polymerase	O	436-446
chain	O	447-452
reaction	O	453-461
(	O	462-463
RT	O	463-465
-	O	465-466
PCR	O	466-469
)	O	469-470
followed	O	471-479
by	O	480-482
a	O	483-484
protein	O	485-492
truncation	O	493-503
test	O	504-508
(	O	509-510
PTT	O	510-513
)	O	513-514
.	O	514-515

DNA	O	516-519
sequencing	O	520-530
confirmed	O	531-540
all	O	541-544
alterations	O	545-556
represented	O	557-568
by	O	569-571
aberrant	O	572-580
bands	O	581-586
.	O	586-587

Germline	O	588-596
mutations	O	597-606
were	O	607-611
identified	O	612-622
in	O	623-625
38	O	626-628
patients	O	629-637
(	O	638-639
61	O	639-641
%	O	641-642
)	O	642-643
.	O	643-644

Nineteen	O	645-653
of	O	654-656
the	O	657-660
detected	O	661-669
mutations	O	670-679
were	O	680-684
presumed	O	685-693
to	O	694-696
be	O	697-699
novel	O	700-705
,	O	705-706
thus	O	707-711
emphasizing	O	712-723
the	O	724-727
heterogeneity	O	728-741
of	O	742-744
the	O	745-748
mutational	O	749-759
spectrum	O	760-768
in	O	769-771
Korean	O	772-778
FAP	B	779-782
patients	O	783-791
.	O	791-792

In	O	793-795
the	O	796-799
initial	O	800-807
48	O	808-810
patients	O	811-819
,	O	819-820
SSCP	O	821-825
analysis	O	826-834
was	O	835-838
followed	O	839-847
by	O	848-850
PTT	O	851-854
for	O	855-858
those	O	859-864
patients	O	865-873
for	O	874-877
whom	O	878-882
no	O	883-885
detectable	O	886-896
mutations	O	897-906
were	O	907-911
found	O	912-917
by	O	918-920
SSCP	O	921-925
.	O	925-926

Using	O	927-932
this	O	933-937
combined	O	938-946
approach	O	947-955
,	O	955-956
we	O	957-959
identified	O	960-970
germline	O	971-979
APC	B	980-983
gene	O	984-988
mutations	O	989-998
in	O	999-1001
29	O	1002-1004
of	O	1005-1007
the	O	1008-1011
48	O	1012-1014
FAP	B	1015-1018
patients	O	1019-1027
(	O	1028-1029
60	O	1029-1031
%	O	1031-1032
)	O	1032-1033
,	O	1033-1034
including	O	1035-1044
6	O	1045-1046
patients	O	1047-1055
in	O	1056-1058
whom	O	1059-1063
SSCP	O	1064-1068
analysis	O	1069-1077
failed	O	1078-1084
to	O	1085-1087
distinguish	O	1088-1099
the	O	1100-1103
mutant	O	1104-1110
allele	O	1111-1117
.	O	1117-1118

In	O	1119-1121
the	O	1122-1125
14	O	1126-1128
later	O	1129-1134
patients	O	1135-1143
,	O	1143-1144
we	O	1145-1147
identified	O	1148-1158
truncating	O	1159-1169
mutations	O	1170-1179
in	O	1180-1182
9	O	1183-1184
patients	O	1185-1193
(	O	1194-1195
64	O	1195-1197
%	O	1197-1198
)	O	1198-1199
using	O	1200-1205
PTT	O	1206-1209
only	O	1210-1214
.	O	1214-1215

Our	O	1216-1219
results	O	1220-1227
confirm	O	1228-1235
that	O	1236-1240
the	O	1241-1244
mutation	O	1245-1253
detection	O	1254-1263
rate	O	1264-1268
with	O	1269-1273
PTT	O	1274-1277
was	O	1278-1281
superior	O	1282-1290
to	O	1291-1293
that	O	1294-1298
with	O	1299-1303
SSCP	O	1304-1308
,	O	1308-1309
and	O	1310-1313
suggest	O	1314-1321
that	O	1322-1326
PTT	O	1327-1330
would	O	1331-1336
be	O	1337-1339
a	O	1340-1341
more	O	1342-1346
practical	O	1347-1356
screening	O	1357-1366
method	O	1367-1373
to	O	1374-1376
detect	O	1377-1383
germline	O	1384-1392
mutations	O	1393-1402
of	O	1403-1405
the	O	1406-1409
APC	B	1410-1413
gene	O	1414-1418
in	O	1419-1421
FAP	B	1422-1425
patients	O	1426-1434
.	O	1434-1435

Homozygosity	O	0-12
mapping	O	13-20
in	O	21-23
a	O	24-25
family	O	26-32
with	O	33-37
microcephaly	B	38-50
,	O	50-51
mental	B	52-58
retardation	I	59-70
,	O	70-71
and	O	72-75
short	B	76-81
stature	I	82-89
to	O	90-92
a	O	93-94
Cohen	B	95-100
syndrome	I	101-109
region	O	110-116
on	O	117-119
8q21	O	120-124
.	O	124-125
3	O	125-126
-	O	126-127
8q22	O	127-131
.	O	124-125
1	O	123-124
:	O	133-134

redefining	O	135-145
a	O	146-147
clinical	O	148-156
entity	O	157-163
.	O	163-164

A	O	165-166
syndrome	O	167-175
of	O	176-178
microcephaly	B	179-191
,	O	191-192
progressive	O	193-204
postnatal	B	205-214
growth	I	215-221
deficiency	I	222-232
,	O	232-233
and	O	234-237
mental	B	238-244
retardation	I	245-256
was	O	257-260
observed	O	261-269
in	O	270-272
two	O	273-276
brothers	O	277-285
and	O	286-289
their	O	290-295
cousin	O	296-302
from	O	303-307
a	O	308-309
multiply	O	310-318
consanguineous	O	319-333
kindred	O	334-341
of	O	342-344
Lebanese	O	345-353
descent	O	354-361
.	O	361-362

Hypotonia	B	363-372
,	O	372-373
chorioretinal	B	374-387
dystrophy	I	388-397
,	O	397-398
and	O	399-402
myopia	B	403-409
were	O	410-414
also	O	415-419
identified	O	420-430
.	O	430-431

The	O	432-435
severity	O	436-444
of	O	445-447
the	O	448-451
condition	O	452-461
varied	O	462-468
among	O	469-474
the	O	475-478
closely	O	479-486
related	O	487-494
patients	O	495-503
.	O	503-504

Because	O	505-512
of	O	513-515
absence	O	516-523
of	O	524-526
a	O	527-528
distinctive	O	529-540
facial	O	541-547
appearance	O	548-558
,	O	558-559
the	O	560-563
degree	O	564-570
of	O	571-573
mental	B	574-580
retardation	I	581-592
,	O	592-593
and	O	594-597
short	B	598-603
stature	I	604-611
,	O	611-612
the	O	613-616
initially	O	617-626
considered	O	627-637
clinical	O	638-646
diagnosis	O	647-656
of	O	657-659
Cohen	B	660-665
syndrome	I	666-674
was	O	675-678
withdrawn	O	679-688
and	O	689-692
a	O	693-694
novel	O	695-700
genetic	O	701-708
entity	O	709-715
was	O	716-719
assumed	O	720-727
.	O	727-728

Homozygosity	O	729-741
mapping	O	742-749
in	O	750-752
this	O	753-757
family	O	758-764
assigned	O	765-773
the	O	774-777
gene	O	778-782
to	O	783-785
a	O	786-787
26	O	788-790
.	O	790-791

8	O	792-793
-	O	793-794
cM	O	794-796
region	O	797-803
on	O	804-806
the	O	807-810
chromosome	O	811-821
band	O	822-826
8q21	O	827-831
.	O	831-832

3	O	833-834
-	O	835-836
22	O	836-838
.	O	838-839

1	O	840-841
,	O	841-842
between	O	843-850
the	O	851-854
microsatellites	O	855-870
at	O	871-873
D8S270	O	874-880
and	O	881-884
D8S514	O	885-891
.	O	891-892

The	O	893-896
maximum	O	897-904
two	O	905-908
-	O	908-909
point	O	909-914
LOD	O	915-918
score	O	919-924
was	O	925-928
found	O	929-934
for	O	935-938
marker	O	939-945
at	O	946-948
D8S267	O	949-955
(	O	956-957
Zmax	O	957-961
=	O	962-963
3	O	964-965
.	O	965-966
.	O	965-966
237	O	968-971
at	O	972-974
Omax	O	975-979
=	O	980-981
0	O	982-983
.	O	983-984
00	O	985-987
)	O	987-988
.	O	988-989

Intriguingly	O	990-1002
enough	O	1003-1009
,	O	1009-1010
the	O	1011-1014
identified	O	1015-1025
gene	O	1026-1030
region	O	1031-1037
overlaps	O	1038-1046
the	O	1047-1050
refined	O	1051-1058
gene	O	1059-1063
region	O	1064-1070
for	O	1071-1074
Cohen	B	1075-1080
syndrome	I	1081-1089
(	O	1090-1091
COH1	O	1091-1095
)	O	1095-1096
[	O	1097-1098
Kolehmainen	O	1098-1109
et	O	1110-1112
al	O	1113-1115
.	O	1115-1116
,	O	1116-1117
1997	O	1118-1122
Euro	O	1124-1128
J	O	1129-1130
Hum	O	1131-1134
Genet	O	1135-1140
5	O	1141-1142
206	O	1144-1147
-	O	1147-1148
213	O	1148-1151
]	O	1151-1152
.	O	1152-1153

This	O	1154-1158
fact	O	1159-1163
encourages	O	1164-1174
the	O	1175-1178
hypothesis	O	1179-1189
that	O	1190-1194
the	O	1195-1198
described	O	1199-1208
kindred	O	1209-1216
segregates	O	1217-1227
for	O	1228-1231
a	O	1232-1233
variant	O	1234-1241
of	O	1242-1244
Cohen	B	1245-1250
syndrome	I	1251-1259
and	O	1260-1263
suggests	O	1264-1272
a	O	1273-1274
redefinition	O	1275-1287
of	O	1288-1290
its	O	1291-1294
phenotype	O	1295-1304

Spontaneous	O	0-11
reversion	O	12-21
of	O	22-24
novel	O	25-30
Lesch	B	31-36
-	I	36-37
Nyhan	I	37-42
mutation	O	43-51
by	O	52-54
HPRT	O	55-59
gene	O	60-64
rearrangement	O	65-78
.	O	78-79

Molecular	O	80-89
analysis	O	90-98
of	O	99-101
an	O	102-104
unusual	O	105-112
patient	O	113-120
with	O	121-125
the	O	126-129
Lesch	B	130-135
-	I	135-136
Nyhan	I	136-141
syndrome	I	142-150
has	O	151-154
suggested	O	155-164
that	O	165-169
the	O	170-173
mutation	O	174-182
is	O	183-185
due	O	186-189
to	O	190-192
a	O	193-194
partial	O	195-202
HPRT	O	203-207
gene	O	208-212
duplication	O	213-224
.	O	224-225

We	O	226-228
now	O	229-232
report	O	233-239
the	O	240-243
cloning	O	244-251
and	O	252-255
sequencing	O	256-266
of	O	267-269
the	O	270-273
mutant	O	274-280
HPRT	O	281-285
cDNA	O	286-290
which	O	291-296
shows	O	297-302
the	O	303-306
precise	O	307-314
duplication	O	315-326
of	O	327-329
exons	O	330-335
2	O	336-337
and	O	338-341
3	O	342-343
.	O	343-344

This	O	345-349
mutation	O	350-358
is	O	359-361
the	O	362-365
result	O	366-372
of	O	373-375
an	O	376-378
internal	O	379-387
duplication	O	388-399
of	O	400-402
16	O	403-405
-	O	405-406
20	O	406-408
kilobases	O	409-418
of	O	419-421
the	O	422-425
gene	O	426-430
.	O	430-431

The	O	432-435
structure	O	436-445
of	O	446-448
the	O	449-452
mutant	O	453-459
gene	O	460-464
suggests	O	465-473
that	O	474-478
the	O	479-482
duplication	O	483-494
was	O	495-498
not	O	499-502
generated	O	503-512
by	O	513-515
a	O	516-517
single	O	518-524
unequal	O	525-532
crossing	O	533-541
-	O	541-542
over	O	542-546
event	O	547-552
between	O	553-560
two	O	561-564
normal	O	565-571
HPRT	O	572-576
alleles	O	577-584
.	O	584-585

Growth	O	586-592
of	O	593-595
Epstein	B	596-603
-	I	603-604
Barr	I	604-608
virus	O	609-614
-	O	614-615
transformed	O	615-626
lymphoblasts	O	627-639
from	O	640-644
this	O	645-649
patient	O	650-657
in	O	658-660
selective	O	661-670
medium	O	671-677
has	O	678-681
permitted	O	682-691
isolation	O	692-701
of	O	702-704
spontaneous	O	705-716
HPRT	O	717-721
+	O	722-723
revertants	O	724-734
of	O	735-737
this	O	738-742
mutation	O	743-751
.	O	751-752

The	O	753-756
reversion	O	757-766
event	O	767-772
involves	O	773-781
a	O	782-783
second	O	784-790
major	O	791-796
HPRT	O	797-801
gene	O	802-806
rearrangement	O	807-820
where	O	821-826
most	O	827-831
or	O	832-834
all	O	835-838
of	O	839-841
the	O	842-845
duplicated	O	846-856
portion	O	857-864
of	O	865-867
the	O	868-871
mutant	O	872-878
gene	O	879-883
is	O	884-886
deleted	O	887-894
.	O	894-895

The	O	896-899
original	O	900-908
mutation	O	909-917
therefore	O	918-927
has	O	928-931
the	O	932-935
potential	O	936-945
for	O	946-949
spontaneous	O	950-961
somatic	O	962-969
reversion	O	970-979
.	O	979-980

This	O	981-985
may	O	986-989
explain	O	990-997
the	O	998-1001
relatively	O	1002-1012
mild	O	1013-1017
symptoms	O	1018-1026
of	O	1027-1029
the	O	1030-1033
Lesch	B	1034-1039
-	I	1039-1040
Nyhan	I	1040-1045
syndrome	I	1046-1054
exhibited	O	1055-1064
by	O	1065-1067
this	O	1068-1072
patient	O	1073-1080
.	O	1080-1081
.	O	1080-1081

Nephropathy	B	0-11
in	O	12-14
the	O	15-18
Wiskott	B	19-26
-	I	26-27
Aldrich	I	27-34
syndrome	I	35-43
.	O	43-44

Nephropathy	B	45-56
was	O	57-60
detected	O	61-69
in	O	70-72
five	O	73-77
of	O	78-80
32	O	81-83
patients	O	84-92
with	O	93-97
the	O	98-101
Wiskott	B	102-109
-	I	109-110
Aldrich	I	110-117
syndrome	I	118-126
who	O	127-130
were	O	131-135
participating	O	136-149
in	O	150-152
a	O	153-154
study	O	155-160
of	O	161-163
transfer	O	164-172
factor	O	173-179
(	O	180-181
TF	O	181-183
)	O	183-184
therapy	O	185-192
.	O	192-193

In	O	194-196
two	O	197-200
patients	O	201-209
,	O	209-210
nephropathy	B	211-222
was	O	223-226
present	O	227-234
before	O	235-241
TF	O	242-244
and	O	245-248
did	O	249-252
not	O	253-256
appear	O	257-263
changed	O	264-271
by	O	272-274
TF	O	275-277
therapy	O	278-285
.	O	285-286

One	O	287-290
of	O	291-293
these	O	294-299
patients	O	300-308
subsequently	O	309-321
developed	O	322-331
progressive	O	332-343
renal	B	344-349
failure	I	350-357
requiring	O	358-367
dialysis	O	368-376
beginning	O	377-386
5	O	387-388
1	O	389-390
/	O	390-391
2	O	391-392
years	O	393-398
after	O	399-404
TF	O	405-407
therapy	O	408-415
.	O	415-416

In	O	417-419
two	O	420-423
patients	O	424-432
,	O	432-433
decreased	O	434-443
renal	O	444-449
function	O	450-458
appeared	O	459-467
very	O	468-472
soon	O	473-477
after	O	478-483
the	O	484-487
administration	O	488-502
of	O	503-505
TF	O	506-508
.	O	508-509

One	O	510-513
patient	O	514-521
showed	O	522-528
gradually	O	529-538
decreasing	O	539-549
renal	O	550-555
function	O	556-564
beginning	O	565-574
after	O	575-580
two	O	581-584
years	O	585-590
of	O	591-593
TF	O	594-596
therapy	O	597-604
.	O	604-605

An	O	606-608
additional	O	609-619
patient	O	620-627
was	O	628-631
identified	O	632-642
who	O	643-646
died	O	647-651
with	O	652-656
renal	B	657-662
failure	I	663-670
without	O	671-678
having	O	679-685
received	O	686-694
TF	O	695-697
.	O	697-698

The	O	699-702
results	O	703-710
suggest	O	711-718
that	O	719-723
renal	B	724-729
failure	I	730-737
occurs	O	738-744
in	O	745-747
the	O	748-751
Wiskott	B	752-759
-	I	759-760
Aldrich	I	760-767
syndrome	I	768-776
more	O	777-781
frequently	O	782-792
than	O	793-797
generally	O	798-807
recognized	O	808-818
and	O	819-822
that	O	823-827
administration	O	828-842
of	O	843-845
TF	O	846-848
may	O	849-852
precipitate	O	853-864
or	O	865-867
accelerate	O	868-878
the	O	879-882
renal	B	883-888
disease	I	889-896
in	O	897-899
patients	O	900-908
with	O	909-913
this	O	914-918
syndrome	O	919-927
.	O	927-928
.	O	927-928

Aniridia	B	0-8
-	O	8-9
associated	O	9-19
cytogenetic	O	20-31
rearrangements	O	32-46
suggest	O	47-54
that	O	55-59
a	O	60-61
position	O	62-70
effect	O	71-77
may	O	78-81
cause	O	82-87
the	O	88-91
mutant	O	92-98
phenotype	O	99-108
.	O	108-109

Current	O	110-117
evidence	O	118-126
suggests	O	127-135
that	O	136-140
aniridia	B	141-149
(	O	150-151
absence	B	151-158
of	I	159-161
iris	I	162-166
)	O	166-167
is	O	168-170
caused	O	171-177
by	O	178-180
loss	O	181-185
of	O	186-188
function	O	189-197
of	O	198-200
one	O	201-204
copy	O	205-209
of	O	210-212
the	O	213-216
PAX6	O	217-221
gene	O	222-226
,	O	226-227
which	O	228-233
maps	O	234-238
to	O	239-241
11p13	O	242-247
.	O	247-248

We	O	249-251
present	O	252-259
the	O	260-263
further	O	264-271
characterisation	O	272-288
of	O	289-291
two	O	292-295
aniridia	B	296-304
pedigrees	O	305-314
in	O	315-317
which	O	318-323
the	O	324-327
disease	O	328-335
segregates	O	336-346
with	O	347-351
chromosomal	O	352-363
rearrangements	O	364-378
which	O	379-384
involve	O	385-392
11p13	O	393-398
but	O	399-402
do	O	403-405
not	O	406-409
disrupt	O	410-417
the	O	418-421
PAX6	O	422-426
gene	O	427-431
.	O	431-432

We	O	433-435
have	O	436-440
isolated	O	441-449
three	O	450-455
human	O	456-461
YAC	O	462-465
clones	O	466-472
which	O	473-478
encompass	O	479-488
the	O	489-492
PAX6	O	493-497
locus	O	498-503
and	O	504-507
we	O	508-510
have	O	511-515
used	O	516-520
these	O	521-526
to	O	527-529
show	O	530-534
that	O	535-539
in	O	540-542
both	O	543-547
cases	O	548-553
the	O	554-557
chromosomal	O	558-569
breakpoint	O	570-580
is	O	581-583
at	O	584-586
least	O	587-592
85	O	593-595
kb	O	596-598
distal	O	599-605
of	O	606-608
the	O	609-612
3	O	613-614
end	O	615-618
of	O	619-621
PAX6	O	622-626
.	O	626-627

In	O	628-630
addition	O	631-639
,	O	639-640
the	O	641-644
open	O	645-649
reading	O	650-657
frame	O	658-663
of	O	664-666
PAX6	O	667-671
is	O	672-674
apparently	O	675-685
free	O	686-690
of	O	691-693
mutations	O	694-703
.	O	703-704

We	O	705-707
propose	O	708-715
that	O	716-720
the	O	721-724
PAX6	O	725-729
gene	O	730-734
on	O	735-737
the	O	738-741
rearranged	O	742-752
chromosome	O	753-763
11	O	764-766
is	O	767-769
in	O	770-772
an	O	773-775
inappropriate	O	776-789
chromatin	O	790-799
environment	O	800-811
for	O	812-815
normal	O	816-822
expression	O	823-833
and	O	834-837
therefore	O	838-847
that	O	848-852
a	O	853-854
position	O	855-863
effect	O	864-870
is	O	871-873
the	O	874-877
underlying	O	878-888
mechanism	O	889-898
of	O	899-901
disease	O	902-909
in	O	910-912
these	O	913-918
families	O	919-927
.	O	927-928
.	O	927-928

Genetic	O	0-7
cholesteryl	B	8-19
ester	I	20-25
transfer	I	26-34
protein	I	35-42
deficiency	I	43-53
caused	O	54-60
by	O	61-63
two	O	64-67
prevalent	O	68-77
mutations	O	78-87
as	O	88-90
a	O	91-92
major	O	93-98
determinant	O	99-110
of	O	111-113
increased	O	114-123
levels	O	124-130
of	O	131-133
high	O	134-138
density	O	139-146
lipoprotein	O	147-158
cholesterol	O	159-170
.	O	170-171

Genetic	O	172-179
determinants	O	180-192
of	O	193-195
HDL	O	196-199
cholesterol	O	200-211
(	O	212-213
HDL	O	213-216
-	O	216-217
C	O	217-218
)	O	218-219
levels	O	220-226
in	O	227-229
the	O	230-233
general	O	234-241
population	O	242-252
are	O	253-256
poorly	O	257-263
understood	O	264-274
.	O	274-275

We	O	276-278
previously	O	279-289
described	O	290-299
plasma	O	300-306
cholesteryl	B	307-318
ester	I	319-324
transfer	I	325-333
protein	I	334-341
(	I	342-343
CETP	I	343-347
)	I	347-348
deficiency	I	349-359
due	O	360-363
to	O	364-366
an	O	367-369
intron	O	370-376
14	O	377-379
G	O	380-381
(	O	382-383
+	O	383-384
1	O	385-386
)	O	386-387
-	O	388-389
to	O	389-391
-	O	388-389
A	O	392-393
mutation	O	394-402
(	O	403-404
Int14	O	404-409
A	O	410-411
)	O	411-412
in	O	413-415
several	O	416-423
families	O	424-432
with	O	433-437
very	O	438-442
high	O	443-447
HDL	O	448-451
-	O	451-452
C	O	452-453
levels	O	454-460
in	O	461-463
Japan	O	464-469
.	O	469-470

Subjects	O	471-479
with	O	480-484
HDL	O	485-488
-	O	488-489
C	O	489-490
>	O	491-492
or	O	493-495
=	O	496-497
100	O	498-501
mg	O	502-504
/	O	504-505
dl	O	505-507
(	O	508-509
n	O	509-510
=	O	511-512
130	O	513-516
)	O	516-517
were	O	518-522
screened	O	523-531
by	O	532-534
PCR	O	535-538
single	O	539-545
strand	O	546-552
conformational	O	553-567
polymorphism	O	568-580
analysis	O	581-589
of	O	590-592
the	O	593-596
CETP	O	597-601
gene	O	602-606
.	O	606-607

Two	O	608-611
other	O	612-617
mutations	O	618-627
were	O	628-632
identified	O	633-643
by	O	644-646
DNA	O	647-650
sequencing	O	651-661
or	O	662-664
primer	O	665-671
-	O	671-672
mediated	O	672-680
restriction	O	681-692
map	O	693-696
modification	O	697-709
of	O	710-712
PCR	O	713-716
products	O	717-725
a	O	727-728
novel	O	729-734
intron	O	735-741
14	O	742-744
splice	O	745-751
donor	O	752-757
site	O	758-762
mutation	O	763-771
caused	O	772-778
by	O	779-781
a	O	782-783
T	O	784-785
insertion	O	786-795
at	O	796-798
position	O	799-807
+	O	808-809
3	O	810-811
from	O	812-816
the	O	817-820
exon14	O	821-827
/	O	827-828
intron14	O	828-836
boundary	O	837-845
(	O	846-847
Int14	O	847-852
T	O	853-854
)	O	854-855
and	O	856-859
a	O	860-861
missense	O	862-870
mutation	O	871-879
(	O	880-881
Asp442	O	881-887
to	O	888-890
Gly	O	891-894
)	O	894-895
within	O	896-902
exon	O	903-907
15	O	908-910
(	O	911-912
D442G	O	912-917
)	O	917-918
.	O	918-919

The	O	920-923
Int14	O	924-929
T	O	930-931
mutation	O	932-940
was	O	941-944
only	O	945-949
found	O	950-955
in	O	956-958
one	O	959-962
family	O	963-969
.	O	969-970

However	O	971-978
,	O	978-979
the	O	980-983
D442G	O	984-989
and	O	990-993
Int14	O	994-999
A	O	1000-1001
mutations	O	1002-1011
were	O	1012-1016
highly	O	1017-1023
prevalent	O	1024-1033
in	O	1034-1036
subjects	O	1037-1045
with	O	1046-1050
HDL	O	1051-1054
-	O	1054-1055
C	O	1055-1056
>	O	1057-1058
or	O	1059-1061
=	O	1062-1063
60	O	1064-1066
mg	O	1067-1069
/	O	1069-1070
dl	O	1070-1072
,	O	1072-1073
with	O	1074-1078
combined	O	1079-1087
allele	O	1088-1094
frequencies	O	1095-1106
of	O	1107-1109
9	O	1110-1111
%	O	1111-1112
,	O	1112-1113
12	O	1114-1116
%	O	1116-1117
,	O	1117-1118
21	O	1119-1121
%	O	1121-1122
and	O	1123-1126
43	O	1127-1129
%	O	1129-1130
for	O	1131-1134
HDL	O	1135-1138
-	O	1138-1139
C	O	1139-1140
60	O	1141-1143
-	O	1143-1144
79	O	1144-1146
,	O	1146-1147
80	O	1148-1150
-	O	1150-1151
99	O	1151-1153
,	O	1153-1154
100	O	1155-1158
-	O	1158-1159
119	O	1159-1162
,	O	1162-1163
and	O	1164-1167
>	O	1168-1169
or	O	1170-1172
=	O	1173-1174
120	O	1175-1178
mg	O	1179-1181
/	O	1181-1182
dl	O	1182-1184
,	O	1184-1185
respectively	O	1186-1198
.	O	1198-1199

Furthermore	O	1200-1211
,	O	1211-1212
prevalences	O	1213-1224
of	O	1225-1227
the	O	1228-1231
D442G	O	1232-1237
and	O	1238-1241
Int14	O	1242-1247
A	O	1248-1249
mutations	O	1250-1259
were	O	1260-1264
extremely	O	1265-1274
high	O	1275-1279
in	O	1280-1282
a	O	1283-1284
general	O	1285-1292
sample	O	1293-1299
of	O	1300-1302
Japanese	O	1303-1311
men	O	1312-1315
(	O	1316-1317
n	O	1317-1318
=	O	1319-1320
236	O	1321-1324
)	O	1324-1325
,	O	1325-1326
with	O	1327-1331
heterozygote	O	1332-1344
frequencies	O	1345-1356
of	O	1357-1359
7	O	1360-1361
%	O	1361-1362
and	O	1363-1366
2	O	1367-1368
%	O	1368-1369
,	O	1369-1370
respectively	O	1371-1383
.	O	1383-1384

These	O	1385-1390
two	O	1391-1394
mutations	O	1395-1404
accounted	O	1405-1414
for	O	1415-1418
about	O	1419-1424
10	O	1425-1427
%	O	1427-1428
of	O	1429-1431
the	O	1432-1435
total	O	1436-1441
variance	O	1442-1450
of	O	1451-1453
HDL	O	1454-1457
-	O	1457-1458
C	O	1458-1459
in	O	1460-1462
this	O	1463-1467
population	O	1468-1478
.	O	1478-1479

The	O	1480-1483
phenotype	O	1484-1493
in	O	1494-1496
a	O	1497-1498
genetic	O	1499-1506
compound	O	1507-1515
heterozygote	O	1516-1528
(	O	1529-1530
Int14	O	1530-1535
T	O	1536-1537
and	O	1538-1541
Int14	O	1542-1547
A	O	1548-1549
)	O	1549-1550
was	O	1551-1554
similar	O	1555-1562
to	O	1563-1565
that	O	1566-1570
of	O	1571-1573
Int14	O	1574-1579
A	O	1580-1581
homozygotes	O	1582-1593
(	O	1594-1595
no	O	1595-1597
detectable	O	1598-1608
CETP	O	1609-1613
and	O	1614-1617
markedly	O	1618-1626
increased	O	1627-1636
HDL	O	1637-1640
-	O	1640-1641
C	O	1641-1642
)	O	1642-1643
,	O	1643-1644
indicating	O	1645-1655
that	O	1656-1660
the	O	1661-1664
Int14	O	1665-1670
T	O	1671-1672
produces	O	1673-1681
a	O	1682-1683
null	O	1684-1688
allele	O	1689-1695
.	O	1695-1696

In	O	1697-1699
four	O	1700-1704
D442G	O	1705-1710
homozygotes	O	1711-1722
,	O	1722-1723
mean	O	1724-1728
HDL	O	1729-1732
-	O	1732-1733
C	O	1733-1734
levels	O	1735-1741
(	O	1742-1743
86	O	1743-1745
+	O	1746-1747
/	O	1747-1748
-	O	1748-1749
26	O	1750-1752
mg	O	1753-1755
/	O	1755-1756
dl	O	1756-1758
)	O	1758-1759
were	O	1760-1764
lower	O	1765-1770
than	O	1771-1775
in	O	1776-1778
Int14	O	1779-1784
A	O	1785-1786
homozygotes	O	1787-1798
(	O	1799-1800
158	O	1800-1803
+	O	1804-1805
/	O	1805-1806
-	O	1806-1807
35	O	1808-1810
mg	O	1811-1813
/	O	1813-1814
dl	O	1814-1816
)	O	1816-1817
,	O	1817-1818
reflecting	O	1819-1829
residual	O	1830-1838
CETP	O	1839-1843
activity	O	1844-1852
in	O	1853-1855
plasma	O	1856-1862
.	O	1862-1863

In	O	1864-1866
47	O	1867-1869
D442G	O	1870-1875
heterozygotes	O	1876-1889
,	O	1889-1890
mean	O	1891-1895
HDL	O	1896-1899
-	O	1899-1900
C	O	1900-1901
levels	O	1902-1908
were	O	1909-1913
91	O	1914-1916
+	O	1917-1918
/	O	1918-1919
-	O	1919-1920
23	O	1921-1923
mg	O	1924-1926
/	O	1926-1927
dl	O	1927-1929
,	O	1929-1930
similar	O	1931-1938
to	O	1939-1941
the	O	1942-1945
level	O	1946-1951
in	O	1952-1954
D442G	O	1955-1960
homozygotes	O	1961-1972
,	O	1972-1973
and	O	1974-1977
significantly	O	1978-1991
greater	O	1992-1999
than	O	2000-2004
mean	O	2005-2009
HDL	O	2010-2013
-	O	2013-2014
C	O	2014-2015
levels	O	2016-2022
in	O	2023-2025
Int14	O	2026-2031
A	O	2032-2033
heterozygotes	O	2034-2047
(	O	2048-2049
69	O	2049-2051
+	O	2052-2053
/	O	2053-2054
-	O	2054-2055
15	O	2056-2058
mg	O	2059-2061
/	O	2061-2062
dl	O	2062-2064
)	O	2064-2065
.	O	2065-2066

Thus	O	2067-2071
,	O	2071-2072
the	O	2073-2076
D442G	O	2077-2082
mutation	O	2083-2091
acts	O	2092-2096
differently	O	2097-2108
to	O	2109-2111
the	O	2112-2115
null	O	2116-2120
mutations	O	2121-2130
with	O	2131-2135
weaker	O	2136-2142
effects	O	2143-2150
on	O	2151-2153
HDL	O	2154-2157
in	O	2158-2160
the	O	2161-2164
homozygous	O	2165-2175
state	O	2176-2181
and	O	2182-2185
stronger	O	2186-2194
effects	O	2195-2202
in	O	2203-2205
the	O	2206-2209
heterozygotes	O	2210-2223
,	O	2223-2224
suggesting	O	2225-2235
dominant	O	2236-2244
expression	O	2245-2255
of	O	2256-2258
a	O	2259-2260
partially	O	2261-2270
defective	O	2271-2280
allele	O	2281-2287
.	O	2287-2288

CETP	B	2289-2293
deficiency	I	2294-2304
,	O	2304-2305
reflecting	O	2306-2316
two	O	2317-2320
prevalent	O	2321-2330
mutations	O	2331-2340
(	O	2341-2342
D442G	O	2342-2347
and	O	2348-2351
Int14	O	2352-2357
A	O	2358-2359
)	O	2359-2360
,	O	2360-2361
is	O	2362-2364
the	O	2365-2368
first	O	2369-2374
example	O	2375-2382
of	O	2383-2385
a	O	2386-2387
genetic	B	2388-2395
deficiency	I	2396-2406
state	O	2407-2412
which	O	2413-2418
is	O	2419-2421
sufficiently	O	2422-2434
common	O	2435-2441
to	O	2442-2444
explain	O	2445-2452
a	O	2453-2454
significant	O	2455-2466
fraction	O	2467-2475
of	O	2476-2478
the	O	2479-2482
variation	O	2483-2492
in	O	2493-2495
HDL	O	2496-2499
-	O	2499-2500
C	O	2500-2501
in	O	2502-2504
the	O	2505-2508
general	O	2509-2516
population	O	2517-2527
.	O	2527-2528
.	O	2527-2528

X	B	0-1
-	I	1-2
linked	I	2-8
glucose	I	9-16
-	I	16-17
6	I	17-18
-	I	16-17
phosphate	I	19-28
dehydrogenase	I	29-42
deficiency	I	43-53
in	O	54-56
Mus	O	57-60
musculus	O	61-69
.	O	69-70

A	O	71-72
mouse	O	73-78
with	O	79-83
X	B	84-85
-	I	85-86
linked	I	86-92
glucose	I	93-100
-	I	100-101
6	I	101-102
-	I	100-101
phosphate	I	103-112
dehydrogenase	I	113-126
(	I	127-128
G6PD	I	128-132
)	I	132-133
deficiency	I	134-144
has	O	145-148
been	O	149-153
recovered	O	154-163
in	O	164-166
offspring	O	167-176
of	O	177-179
1	O	180-181
-	O	181-182
ethyl	O	182-187
-	O	181-182
1	O	180-181
-	O	181-182
nitrosourea	O	190-201
-	O	181-182
treated	O	202-209
male	O	210-214
mice	O	215-219
.	O	219-220

The	O	221-224
activity	O	225-233
alteration	O	234-244
was	O	245-248
detected	O	249-257
in	O	258-260
blood	O	261-266
but	O	267-270
can	O	271-274
also	O	275-279
be	O	280-282
observed	O	283-291
in	O	292-294
other	O	295-300
tissue	O	301-307
extracts	O	308-316
.	O	316-317

Hemizygous	O	318-328
,	O	328-329
heterozygous	O	330-342
,	O	342-343
and	O	344-347
homozygous	O	348-358
mutants	O	359-366
have	O	367-371
,	O	371-372
respectively	O	373-385
,	O	385-386
about	O	387-392
15	O	393-395
,	O	395-396
60	O	397-399
,	O	399-400
and	O	401-404
15	O	405-407
%	O	407-408
G6PD	O	409-413
remaining	O	414-423
activity	O	424-432
in	O	433-435
the	O	436-439
blood	O	440-445
as	O	446-448
compared	O	449-457
to	O	458-460
the	O	461-464
wild	O	465-469
type	O	470-474
.	O	474-475

Erythrocyte	O	476-487
indices	O	488-495
did	O	496-499
not	O	500-503
show	O	504-508
differences	O	509-520
between	O	521-528
mutants	O	529-536
and	O	537-540
wild	O	541-545
types	O	546-551
.	O	551-552

The	O	553-556
mutation	O	557-565
does	O	566-570
not	O	571-574
affect	O	575-581
the	O	582-585
electrophoretic	O	586-601
migration	O	602-611
,	O	611-612
the	O	613-616
isoelectric	O	617-628
point	O	629-634
,	O	634-635
or	O	636-638
the	O	639-642
thermal	O	643-650
stability	O	651-660
.	O	660-661

Kinetic	O	662-669
properties	O	670-680
,	O	680-681
such	O	682-686
as	O	687-689
the	O	690-693
Km	O	694-696
for	O	697-700
glucose	O	701-708
-	O	708-709
6	O	709-710
-	O	708-709
phosphate	O	711-720
or	O	721-723
for	O	724-727
NADP	O	728-732
and	O	733-736
the	O	737-740
relative	O	741-749
utilization	O	750-761
of	O	762-764
substrate	O	765-774
analogues	O	775-784
,	O	784-785
showed	O	786-792
no	O	793-795
differences	O	796-807
between	O	808-815
wild	O	816-820
types	O	821-826
and	O	827-830
mutants	O	831-838
with	O	839-843
the	O	844-847
exception	O	848-857
of	O	858-860
the	O	861-864
relative	O	865-873
utilization	O	874-885
of	O	886-888
deamino	O	889-896
-	O	896-897
NADP	O	897-901
which	O	902-907
was	O	908-911
significantly	O	912-925
lower	O	926-931
in	O	932-934
mutants	O	935-942
.	O	942-943

This	O	944-948
is	O	949-951
presently	O	952-961
the	O	962-965
only	O	966-970
animal	O	971-977
model	O	978-983
for	O	984-987
X	B	988-989
-	I	989-990
linked	I	990-996
G6PD	I	997-1001
deficiency	I	1002-1012
in	O	1013-1015
humans	O	1016-1022
.	O	1022-1023
.	O	1022-1023

Human	O	0-5
glycine	O	6-13
decarboxylase	O	14-27
gene	O	28-32
(	O	33-34
GLDC	O	34-38
)	O	38-39
and	O	40-43
its	O	44-47
highly	O	48-54
conserved	O	55-64
processed	O	65-74
pseudogene	O	75-85
(	O	86-87
psiGLDC	O	87-94
)	O	94-95
:	O	95-96
their	O	97-102
structure	O	103-112
and	O	113-116
expression	O	117-127
,	O	127-128
and	O	129-132
the	O	133-136
identification	O	137-151
of	O	152-154
a	O	155-156
large	O	157-162
deletion	O	163-171
in	O	172-174
a	O	175-176
family	O	177-183
with	O	184-188
nonketotic	B	189-199
hyperglycinemia	I	200-215
.	O	215-216

Mutations	O	217-226
in	O	227-229
the	O	230-233
glycine	O	234-241
decarboxylase	O	242-255
gene	O	256-260
(	O	261-262
GLDC	O	262-266
)	O	266-267
cause	O	268-273
nonketotic	B	274-284
hyperglycinemia	I	285-300
(	O	301-302
NKH	B	302-305
)	O	305-306
,	O	306-307
an	O	308-310
in	B	311-313
-	I	313-314
born	I	314-318
error	I	319-324
of	I	325-327
metabolism	I	328-338
characterized	O	339-352
by	O	353-355
severe	O	356-362
neurological	B	363-375
disturbance	I	376-387
.	O	387-388

We	O	389-391
have	O	392-396
determined	O	397-407
the	O	408-411
structure	O	412-421
of	O	422-424
GLDC	O	425-429
and	O	430-433
of	O	434-436
its	O	437-440
pseudogene	O	441-451
(	O	452-453
psiGLDC	O	453-460
)	O	460-461
and	O	462-465
studied	O	466-473
their	O	474-479
expression	O	480-490
for	O	491-494
a	O	495-496
molecular	O	497-506
analysis	O	507-515
of	O	516-518
NKH	B	519-522
.	O	522-523

The	O	524-527
GLDC	O	528-532
gene	O	533-537
spans	O	538-543
at	O	544-546
least	O	547-552
135	O	553-556
kb	O	557-559
and	O	560-563
consists	O	564-572
of	O	573-575
25	O	576-578
exons	O	579-584
.	O	584-585

All	O	586-589
donor	O	590-595
and	O	596-599
acceptor	O	600-608
sites	O	609-614
adhere	O	615-621
to	O	622-624
the	O	625-628
canonical	O	629-638
GT	O	639-641
-	O	641-642
AG	O	642-644
rule	O	645-649
,	O	649-650
except	O	651-657
for	O	658-661
the	O	662-665
donor	O	666-671
site	O	672-676
of	O	677-679
intron	O	680-686
21	O	687-689
,	O	689-690
where	O	691-696
a	O	697-698
variant	O	699-706
form	O	707-711
GC	O	712-714
is	O	715-717
used	O	718-722
instead	O	723-730
of	O	731-733
GT	O	734-736
.	O	736-737

The	O	738-741
transcription	O	742-755
initiation	O	756-766
site	O	767-771
has	O	772-775
been	O	776-780
assigned	O	781-789
to	O	790-792
a	O	793-794
residue	O	795-802
163	O	803-806
bp	O	807-809
upstream	O	810-818
from	O	819-823
the	O	824-827
translation	O	828-839
initiation	O	840-850
triplet	O	851-858
by	O	859-861
primer	O	862-868
extension	O	869-878
analysis	O	879-887
.	O	887-888

The	O	889-892
psiGLDC	O	893-900
gene	O	901-905
has	O	906-909
no	O	910-912
intron	O	913-919
and	O	920-923
shares	O	924-930
97	O	931-933
.	O	933-934
5	O	935-936
%	O	936-937
homology	O	938-946
with	O	947-951
the	O	952-955
coding	O	956-962
region	O	963-969
of	O	970-972
functional	O	973-983
GLDC	O	984-988
,	O	988-989
suggesting	O	990-1000
that	O	1001-1005
psiGLDC	O	1006-1013
is	O	1014-1016
a	O	1017-1018
processed	O	1019-1028
pseudogene	O	1029-1039
that	O	1040-1044
arose	O	1045-1050
from	O	1051-1055
the	O	1056-1059
GLDC	O	1060-1064
transcript	O	1065-1075
about	O	1076-1081
4	O	1082-1083
-	O	1083-1084
8	O	1084-1085
million	O	1086-1093
years	O	1094-1099
ago	O	1100-1103
.	O	1103-1104

RNA	O	1105-1108
blotting	O	1109-1117
analysis	O	1118-1126
has	O	1127-1130
revealed	O	1131-1139
that	O	1140-1144
GLDC	O	1145-1149
is	O	1150-1152
expressed	O	1153-1162
in	O	1163-1165
human	O	1166-1171
liver	O	1172-1177
,	O	1177-1178
kidney	O	1179-1185
,	O	1185-1186
brain	O	1187-1192
,	O	1192-1193
and	O	1194-1197
placenta	O	1198-1206
.	O	1206-1207

We	O	1208-1210
have	O	1211-1215
also	O	1216-1220
examined	O	1221-1229
a	O	1230-1231
patient	O	1232-1239
with	O	1240-1244
NKH	B	1245-1248
with	O	1249-1253
no	O	1254-1256
detectable	O	1257-1267
GLDC	O	1268-1272
mRNA	O	1273-1277
in	O	1278-1280
his	O	1281-1284
lymphoblasts	O	1285-1297
.	O	1297-1298

Exons	O	1299-1304
1	O	1305-1306
-	O	1306-1307
3	O	1307-1308
of	O	1309-1311
the	O	1312-1315
functional	O	1316-1326
GLDC	O	1327-1331
gene	O	1332-1336
from	O	1337-1341
this	O	1342-1346
patient	O	1347-1354
are	O	1355-1358
not	O	1359-1362
amplified	O	1363-1372
by	O	1373-1375
polymerase	O	1376-1386
chain	O	1387-1392
reaction	O	1393-1401
(	O	1402-1403
PCR	O	1403-1406
)	O	1406-1407
,	O	1407-1408
whereas	O	1409-1416
those	O	1417-1422
from	O	1423-1427
control	O	1428-1435
subjects	O	1436-1444
are	O	1445-1448
.	O	1448-1449

These	O	1450-1455
results	O	1456-1463
suggest	O	1464-1471
a	O	1472-1473
large	O	1474-1479
homozygous	O	1480-1490
deletion	O	1491-1499
(	O	1500-1501
at	O	1501-1503
least	O	1504-1509
30	O	1510-1512
kb	O	1513-1515
)	O	1515-1516
in	O	1517-1519
the	O	1520-1523
patient	O	1524-1531
.	O	1531-1532

Furthermore	O	1533-1544
,	O	1544-1545
we	O	1546-1548
have	O	1549-1553
devised	O	1554-1561
a	O	1562-1563
semi	O	1564-1568
-	O	1568-1569
quantitative	O	1569-1581
PCR	O	1582-1585
to	O	1586-1588
estimate	O	1589-1597
the	O	1598-1601
number	O	1602-1608
of	O	1609-1611
GLDC	O	1612-1616
alleles	O	1617-1624
by	O	1625-1627
using	O	1628-1633
psiGLDC	O	1634-1641
as	O	1642-1644
an	O	1645-1647
internal	O	1648-1656
control	O	1657-1664
and	O	1665-1668
have	O	1669-1673
confirmed	O	1674-1683
the	O	1684-1687
homozygosity	O	1688-1700
and	O	1701-1704
heterozygosity	O	1705-1719
of	O	1720-1722
the	O	1723-1726
deletion	O	1727-1735
in	O	1736-1738
the	O	1739-1742
patient	O	1743-1750
and	O	1751-1754
his	O	1755-1758
parents	O	1759-1766
,	O	1766-1767
respectively	O	1768-1780
.	O	1780-1781

Structural	O	1782-1792
information	O	1793-1804
of	O	1805-1807
GLDC	O	1808-1812
and	O	1813-1816
psiGLDC	O	1817-1824
should	O	1825-1831
facilitate	O	1832-1842
the	O	1843-1846
molecular	O	1847-1856
analysis	O	1857-1865
of	O	1866-1868
NKH	B	1869-1872
.	O	1872-1873

Growth	B	0-6
retardation	I	7-18
and	O	19-22
tumour	B	23-29
inhibition	O	30-40
by	O	41-43
BRCA1	O	44-49
.	O	49-50

Inherited	O	51-60
mutations	O	61-70
in	O	71-73
BRCA1	O	74-79
predispose	O	80-90
to	O	91-93
breast	B	94-100
and	I	101-104
ovarian	I	105-112
cancer	I	113-119
,	O	119-120
but	O	121-124
the	O	125-128
role	O	129-133
of	O	134-136
BRCA1	O	137-142
in	O	143-145
sporadic	O	146-154
breast	B	155-161
and	I	162-165
ovarian	I	166-173
cancer	I	174-180
has	O	181-184
previously	O	185-195
been	O	196-200
elusive	O	201-208
.	O	208-209

Here	O	210-214
,	O	214-215
we	O	216-218
show	O	219-223
that	O	224-228
retroviral	O	229-239
transfer	O	240-248
of	O	249-251
the	O	252-255
wild	O	256-260
-	O	260-261
type	O	261-265
BRCA1	O	266-271
gene	O	272-276
inhibits	O	277-285
growth	O	286-292
in	O	293-295
vitro	O	296-301
of	O	302-304
all	O	305-308
breast	B	309-315
and	I	316-319
ovarian	I	320-327
cancer	I	328-334
cell	O	335-339
lines	O	340-345
tested	O	346-352
,	O	352-353
but	O	354-357
not	O	358-361
colon	B	362-367
or	I	368-370
lung	I	371-375
cancer	I	376-382
cells	O	383-388
or	O	389-391
fibroblasts	O	392-403
.	O	403-404

Mutant	O	405-411
BRCA1	O	412-417
has	O	418-421
no	O	422-424
effect	O	425-431
on	O	432-434
growth	O	435-441
of	O	442-444
breast	B	445-451
cancer	I	452-458
cells	O	459-464
;	O	464-465
ovarian	B	466-473
cancer	I	474-480
cell	O	481-485
growth	O	486-492
is	O	493-495
not	O	496-499
affected	O	500-508
by	O	509-511
BRCA1	O	512-517
mutations	O	518-527
in	O	528-530
the	O	531-534
5	O	535-536
portion	O	537-544
of	O	545-547
the	O	548-551
gene	O	552-556
,	O	556-557
but	O	558-561
is	O	562-564
inhibited	O	565-574
by	O	575-577
3	O	578-579
BRCA1	O	580-585
mutations	O	586-595
.	O	595-596

Development	O	597-608
of	O	609-611
MCF	B	612-615
-	I	615-616
7	I	616-617
tumours	I	618-625
in	O	626-628
nude	O	629-633
mice	O	634-638
is	O	639-641
inhibited	O	642-651
when	O	652-656
MCF	O	657-660
-	O	660-661
7	O	661-662
cells	O	663-668
are	O	669-672
transfected	O	673-684
with	O	685-689
wild	O	690-694
-	O	694-695
type	O	695-699
,	O	699-700
but	O	701-704
not	O	705-708
mutant	O	709-715
,	O	715-716
BRCA1	O	717-722
.	O	722-723

Most	O	724-728
importantly	O	729-740
,	O	740-741
among	O	742-747
mice	O	748-752
with	O	753-757
established	O	758-769
MCF	B	770-773
-	I	773-774
7	I	774-775
tumours	I	776-783
,	O	783-784
peritoneal	O	785-795
treatment	O	796-805
with	O	806-810
a	O	811-812
retroviral	O	813-823
vector	O	824-830
expressing	O	831-841
wild	O	842-846
-	O	846-847
type	O	847-851
BRCA1	O	852-857
significantly	O	858-871
inhibits	O	872-880
tumour	B	881-887
growth	O	888-894
and	O	895-898
increased	O	899-908
survival	O	909-917
.	O	917-918
.	O	917-918

Striking	O	0-8
prevalence	O	9-19
of	O	20-22
ankylosing	B	23-33
spondylitis	I	34-45
in	O	46-48
"	O	49-50
healthy	O	50-57
"	O	49-50
w27	O	59-62
positive	O	63-71
males	O	72-77
and	O	78-81
females	O	82-89
.	O	89-90

Ankylosing	B	91-101
spondylitis	I	102-113
is	O	114-116
diagnosed	O	117-126
once	O	127-131
or	O	132-134
twice	O	135-140
in	O	141-143
each	O	144-148
1000	O	149-153
males	O	154-159
and	O	160-163
one	O	164-167
tenth	O	168-173
as	O	174-176
frequently	O	177-187
in	O	188-190
females	O	191-198
,	O	198-199
but	O	200-203
the	O	204-207
true	O	208-212
prevalence	O	213-223
is	O	224-226
unknown	O	227-234
.	O	234-235

Indentification	O	236-251
of	O	252-254
genetic	O	255-262
marker	O	263-269
,	O	269-270
HL	O	271-273
-	O	273-274
A	O	274-275
W27	O	276-279
,	O	279-280
for	O	281-284
susceptible	O	285-296
persons	O	297-304
has	O	305-308
provided	O	309-317
a	O	318-319
tool	O	320-324
facilitating	O	325-337
epidemiologic	O	338-351
studies	O	352-359
and	O	360-363
allowing	O	364-372
identification	O	373-387
of	O	388-390
"	O	391-392
control	O	393-400
"	O	401-402
populations	O	403-414
without	O	415-422
the	O	423-426
marker	O	427-433
.	O	433-434

Evaluation	O	435-445
by	O	446-448
postal	O	449-455
questionnaires	O	456-470
,	O	470-471
and	O	472-475
pelvic	O	476-482
radiography	O	483-494
of	O	495-497
78	O	498-500
HL	O	501-503
-	O	503-504
A	O	504-505
27W	O	506-509
-	O	509-510
positive	O	510-518
blood	O	519-524
donors	O	525-531
selected	O	532-540
from	O	541-545
a	O	546-547
group	O	548-553
of	O	554-556
apparently	O	557-567
healthy	O	568-575
subjects	O	576-584
revealed	O	585-593
14	O	594-596
who	O	597-600
satisfied	O	601-610
the	O	611-614
criteria	O	615-623
for	O	624-627
definite	O	628-636
ankylosing	B	637-647
spondylitis	I	648-659
.	O	659-660

The	O	661-664
prevalence	O	665-675
was	O	676-679
similar	O	680-687
in	O	688-690
both	O	691-695
sexes	O	696-701
.	O	701-702

One	O	703-706
hundred	O	707-714
and	O	715-718
twenty	O	719-725
-	O	725-726
six	O	726-729
W27	O	730-733
-	O	733-734
negative	O	734-742
controls	O	743-751
matched	O	752-759
for	O	760-763
race	O	764-768
,	O	768-769
sex	O	770-773
,	O	773-774
and	O	775-778
age	O	779-782
failed	O	783-789
to	O	790-792
yield	O	793-798
a	O	799-800
single	O	801-807
case	O	808-812
.	O	812-813

For	O	814-817
a	O	818-819
person	O	820-826
of	O	827-829
either	O	830-836
sex	O	837-840
with	O	841-845
HL	O	846-848
-	O	848-849
A	O	849-850
W27	O	851-854
,	O	854-855
there	O	856-861
appears	O	862-869
to	O	870-872
be	O	873-875
about	O	876-881
a	O	882-883
20	O	884-886
per	O	887-890
cent	O	891-895
chance	O	896-902
that	O	903-907
ankylosing	B	908-918
spondylitis	I	919-930
will	O	931-935
develop	O	936-943
,	O	943-944
suggesting	O	945-955
a	O	956-957
prevalence	O	958-968
of	O	969-971
10	O	972-974
to	O	975-977
15	O	978-980
per	O	981-984
thousand	O	985-993
.	O	993-994

Hitherto	O	995-1003
accepted	O	1004-1012
figures	O	1013-1020
may	O	1021-1024
underestimate	O	1025-1038
the	O	1039-1042
frequency	O	1043-1052
by	O	1053-1055
a	O	1056-1057
factor	O	1058-1064
of	O	1065-1067
10	O	1068-1070
to	O	1071-1073
20	O	1074-1076
.	O	1076-1077
.	O	1076-1077

Rapid	O	0-5
detection	O	6-15
of	O	16-18
BRCA1	O	19-24
mutations	O	25-34
by	O	35-37
the	O	38-41
protein	O	42-49
truncation	O	50-60
test	O	61-65
.	O	65-66

More	O	67-71
than	O	72-76
75	O	77-79
%	O	79-80
of	O	81-83
the	O	84-87
reported	O	88-96
mutations	O	97-106
in	O	107-109
the	O	110-113
hereditary	B	114-124
breast	I	125-131
and	I	132-135
ovarian	I	136-143
cancer	I	144-150
gene	O	151-155
,	O	155-156
BRCA1	O	157-162
,	O	162-163
result	O	164-170
in	O	171-173
truncated	O	174-183
proteins	O	184-192
.	O	192-193

We	O	194-196
have	O	197-201
used	O	202-206
the	O	207-210
protein	O	211-218
truncation	O	219-229
test	O	230-234
(	O	235-236
PTT	O	236-239
)	O	239-240
to	O	241-243
screen	O	244-250
for	O	251-254
mutations	O	255-264
in	O	265-267
exon	O	268-272
11	O	273-275
,	O	275-276
which	O	277-282
encodes	O	283-290
61	O	291-293
%	O	293-294
of	O	295-297
BRCA1	O	298-303
.	O	303-304

In	O	305-307
45	O	308-310
patients	O	311-319
from	O	320-324
breast	B	325-331
and	I	332-335
/	I	335-336
or	I	336-338
ovarian	I	339-346
cancer	I	347-353
families	O	354-362
we	O	363-365
found	O	366-371
six	O	372-375
novel	O	376-381
mutations	O	382-391
two	O	393-396
single	O	397-403
nucleotide	O	404-414
insertions	O	415-425
,	O	425-426
three	O	427-432
small	O	433-438
deletions	O	439-448
(	O	449-450
1	O	450-451
-	O	451-452
5	O	452-453
bp	O	454-456
)	O	456-457
and	O	458-461
a	O	462-463
nonsense	O	464-472
mutation	O	473-481
identified	O	482-492
two	O	493-496
unrelated	O	497-506
families	O	507-515
.	O	515-516

Furthermore	O	517-528
,	O	528-529
we	O	530-532
were	O	533-537
able	O	538-542
to	O	543-545
amplify	O	546-553
the	O	554-557
remaining	O	558-567
coding	O	568-574
region	O	575-581
by	O	582-584
RT	O	585-587
-	O	587-588
PCR	O	588-591
using	O	592-597
lymphocyte	O	598-608
RNA	O	609-612
.	O	612-613

Combined	O	614-622
with	O	623-627
PTT	O	628-631
,	O	631-632
we	O	633-635
detected	O	636-644
aberrantly	O	645-655
spliced	O	656-663
products	O	664-672
affecting	O	673-682
exons	O	683-688
5	O	689-690
and	O	691-694
6	O	695-696
in	O	697-699
one	O	700-703
of	O	704-706
two	O	707-710
BRCA1	O	711-716
-	O	716-717
linked	O	717-723
families	O	724-732
examined	O	733-741
.	O	741-742

The	O	743-746
protein	O	747-754
truncation	O	755-765
test	O	766-770
promises	O	771-779
to	O	780-782
become	O	783-789
a	O	790-791
valuable	O	792-800
technique	O	801-810
in	O	811-813
detecting	O	814-823
BRCA1	O	824-829
mutations	O	830-839
.	O	839-840
.	O	839-840

New	O	0-3
variant	O	4-11
in	O	12-14
exon	O	15-19
3	O	20-21
of	O	22-24
the	O	25-28
proteolipid	O	29-40
protein	O	41-48
(	O	49-50
PLP	O	50-53
)	O	53-54
gene	O	55-59
in	O	60-62
a	O	63-64
family	O	65-71
with	O	72-76
Pelizaeus	B	77-86
-	I	86-87
Merzbacher	I	87-97
disease	I	98-105
.	O	105-106

A	O	107-108
C	O	109-110
-	O	110-111
-	O	110-111
greater	O	112-119
than	O	120-124
G	O	125-126
transversion	O	127-139
has	O	140-143
been	O	144-148
found	O	149-154
in	O	155-157
exon	O	158-162
3	O	163-164
of	O	165-167
the	O	168-171
PLP	O	172-175
gene	O	176-180
of	O	181-183
affected	O	184-192
males	O	193-198
and	O	199-202
their	O	203-208
mother	O	209-215
in	O	216-218
a	O	219-220
single	O	221-227
sibship	O	228-235
with	O	236-240
Pelizaeus	B	241-250
-	I	250-251
merzbacher	I	251-261
disease	I	262-269
(	O	270-271
PMD	B	271-274
)	O	274-275
.	O	275-276

The	O	277-280
transversion	O	281-293
should	O	294-300
not	O	301-304
result	O	305-311
in	O	312-314
an	O	315-317
amino	O	318-323
acid	O	324-328
change	O	329-335
in	O	336-338
the	O	339-342
protein	O	343-350
but	O	351-354
it	O	355-357
does	O	358-362
result	O	363-369
in	O	370-372
the	O	373-376
loss	O	377-381
of	O	382-384
a	O	385-386
HaeIII	O	387-393
restriction	O	394-405
endonuclease	O	406-418
cleavage	O	419-427
site	O	428-432
.	O	432-433

It	O	434-436
is	O	437-439
concordant	O	440-450
with	O	451-455
the	O	456-459
disease	O	460-467
in	O	468-470
this	O	471-475
family	O	476-482
.	O	482-483

One	O	484-487
-	O	487-488
hundred	O	488-495
-	O	487-488
ten	O	496-499
unrelated	O	500-509
X	O	510-511
chromosomes	O	512-523
are	O	524-527
negative	O	528-536
for	O	537-540
this	O	541-545
mutation	O	546-554
.	O	554-555

No	O	556-558
other	O	559-564
sequence	O	565-573
defect	O	574-580
was	O	581-584
found	O	585-590
in	O	591-593
the	O	594-597
PLP	O	598-601
exons	O	602-607
of	O	608-610
the	O	611-614
affected	O	615-623
males	O	624-629
.	O	629-630

The	O	631-634
cause	O	635-640
of	O	641-643
disease	O	644-651
in	O	652-654
this	O	655-659
family	O	660-666
remains	O	667-674
unknown	O	675-682
,	O	682-683
but	O	684-687
the	O	688-691
association	O	692-703
between	O	704-711
this	O	712-716
rare	O	717-721
mutation	O	722-730
and	O	731-734
PMD	B	735-738
is	O	739-741
intriguing	O	742-752
.	O	752-753

The	O	754-757
mutation	O	758-766
can	O	767-770
serve	O	771-776
as	O	777-779
a	O	780-781
marker	O	782-788
for	O	789-792
following	O	793-802
segregation	O	803-814
of	O	815-817
the	O	818-821
PLP	O	822-825
gene	O	826-830
.	O	830-831
.	O	830-831

Variants	O	0-8
of	O	9-11
erythrocyte	O	12-23
glucose	O	24-31
-	O	31-32
6	O	32-33
-	O	31-32
phosphate	O	34-43
dehydrogenase	O	44-57
(	O	58-59
G6PD	O	59-63
)	O	63-64
in	O	65-67
Bulgarian	O	68-77
populations	O	78-89
.	O	89-90

Ten	O	91-94
variants	O	95-103
of	O	104-106
erythrocyte	O	107-118
glucose	O	119-126
-	O	126-127
6	O	127-128
-	O	126-127
phosphate	O	129-138
dehydrogenase	O	139-152
were	O	153-157
identified	O	158-168
in	O	169-171
22	O	172-174
patients	O	175-183
with	O	184-188
G6PD	B	189-193
deficiency	I	194-204
from	O	205-209
three	O	210-215
districts	O	216-225
of	O	226-228
Bulgaria	O	229-237
.	O	237-238

Corinth	O	239-246
-	O	246-247
like	O	247-251
and	O	252-255
Fayoum	O	256-262
-	O	262-263
like	O	263-267
variants	O	268-276
were	O	277-281
the	O	282-285
most	O	286-290
frequent	O	291-299
;	O	299-300
Mediterranean	O	301-314
,	O	314-315
Ohut	O	316-320
II	O	321-323
,	O	323-324
Kilgore	O	325-332
,	O	332-333
Boston	O	334-340
,	O	340-341
Poznan	O	342-348
,	O	348-349
and	O	350-353
Panay	O	354-359
variants	O	360-368
and	O	369-372
two	O	373-376
new	O	377-380
variants	O	381-389
,	O	389-390
Petrich	O	391-398
and	O	399-402
Gotze	O	403-408
Delchev	O	409-416
,	O	416-417
were	O	418-422
each	O	423-427
found	O	428-433
in	O	434-436
one	O	437-440
or	O	441-443
two	O	444-447
carriers	O	448-456
.	O	456-457

No	O	458-460
correlation	O	461-472
was	O	473-476
revealed	O	477-485
between	O	486-493
clinical	O	494-502
and	O	503-506
biochemical	O	507-518
polymorphism	O	519-531
.	O	531-532
.	O	531-532

The	O	0-3
C282Y	O	4-9
mutation	O	10-18
causing	O	19-26
hereditary	B	27-37
hemochromatosis	I	38-53
does	O	54-58
not	O	59-62
produce	O	63-70
a	O	71-72
null	O	73-77
allele	O	78-84
.	O	84-85

Targeted	O	86-94
mutagenesis	O	95-106
was	O	107-110
used	O	111-115
to	O	116-118
produce	O	119-126
two	O	127-130
mutations	O	131-140
in	O	141-143
the	O	144-147
murine	O	148-154
hemochromatosis	B	155-170
gene	O	171-175
(	O	176-177
Hfe	O	177-180
)	O	180-181
locus	O	182-187
.	O	187-188

The	O	189-192
first	O	193-198
mutation	O	199-207
deletes	O	208-215
a	O	216-217
large	O	218-223
portion	O	224-231
of	O	232-234
the	O	235-238
coding	O	239-245
sequence	O	246-254
,	O	254-255
generating	O	256-266
a	O	267-268
null	O	269-273
allele	O	274-280
.	O	280-281

The	O	282-285
second	O	286-292
mutation	O	293-301
introduces	O	302-312
a	O	313-314
missense	O	315-323
mutation	O	324-332
(	O	333-334
C282Y	O	334-339
)	O	339-340
into	O	341-345
the	O	346-349
Hfe	O	350-353
locus	O	354-359
,	O	359-360
but	O	361-364
otherwise	O	365-374
leaves	O	375-381
the	O	382-385
gene	O	386-390
intact	O	391-397
.	O	397-398

This	O	399-403
mutation	O	404-412
is	O	413-415
identical	O	416-425
to	O	426-428
the	O	429-432
disease	O	433-440
-	O	440-441
causing	O	441-448
mutation	O	449-457
in	O	458-460
patients	O	461-469
with	O	470-474
hereditary	B	475-485
hemochromatosis	I	486-501
.	O	501-502

Mice	O	503-507
carrying	O	508-516
each	O	517-521
of	O	522-524
the	O	525-528
two	O	529-532
mutations	O	533-542
were	O	543-547
bred	O	548-552
and	O	553-556
analyzed	O	557-565
.	O	565-566

Homozygosity	O	567-579
for	O	580-583
either	O	584-590
mutation	O	591-599
results	O	600-607
in	O	608-610
postnatal	O	611-620
iron	O	621-625
loading	O	626-633
.	O	633-634

The	O	635-638
effects	O	639-646
of	O	647-649
the	O	650-653
null	O	654-658
mutation	O	659-667
are	O	668-671
more	O	672-676
severe	O	677-683
than	O	684-688
the	O	689-692
effects	O	693-700
of	O	701-703
the	O	704-707
C282Y	O	708-713
mutation	O	714-722
.	O	722-723

Mice	O	724-728
heterozygous	O	729-741
for	O	742-745
either	O	746-752
mutation	O	753-761
accumulate	O	762-772
more	O	773-777
iron	O	778-782
than	O	783-787
normal	O	788-794
controls	O	795-803
.	O	803-804

Interestingly	O	805-818
,	O	818-819
although	O	820-828
liver	O	829-834
iron	O	835-839
stores	O	840-846
are	O	847-850
greatly	O	851-858
increased	O	859-868
,	O	868-869
splenic	O	870-877
iron	O	878-882
is	O	883-885
decreased	O	886-895
.	O	895-896

We	O	897-899
conclude	O	900-908
that	O	909-913
the	O	914-917
C282Y	O	918-923
mutation	O	924-932
does	O	933-937
not	O	938-941
result	O	942-948
in	O	949-951
a	O	952-953
null	O	954-958
allele	O	959-965
.	O	965-966
.	O	965-966

Regional	O	0-8
localisation	O	9-21
of	O	22-24
the	O	25-28
Friedreich	B	29-39
ataxia	I	40-46
locus	O	47-52
to	O	53-55
human	O	56-61
chromosome	O	62-72
9q13	O	73-77
-	O	77-78
-	O	77-78
-	O	77-78
-	O	77-78
q21	O	81-84
.	O	84-85
1	O	75-76
.	O	84-85

We	O	88-90
have	O	91-95
previously	O	96-106
assigned	O	107-115
the	O	116-119
Friedreich	B	120-130
ataxia	I	131-137
locus	O	138-143
(	O	144-145
FRDA	O	145-149
)	O	149-150
to	O	151-153
chromosome	O	154-164
9	O	165-166
;	O	166-167
the	O	168-171
current	O	172-179
maximal	O	180-187
lod	O	188-191
score	O	192-197
between	O	198-205
FRDA	O	206-210
and	O	211-214
MCT112	O	215-221
(	O	222-223
D9S15	O	223-228
)	O	228-229
is	O	230-232
greater	O	233-240
than	O	241-245
50	O	246-248
at	O	249-251
a	O	252-253
recombination	O	254-267
fraction	O	268-276
of	O	277-279
theta	O	280-285
=	O	286-287
0	O	288-289
.	O	289-290

The	O	291-294
physical	O	295-303
assignment	O	304-314
of	O	315-317
the	O	318-321
locus	O	322-327
defined	O	328-335
by	O	336-338
MCT112	O	339-345
,	O	345-346
and	O	347-350
hence	O	351-356
FRDA	O	357-361
,	O	361-362
has	O	363-366
not	O	367-370
been	O	371-375
determined	O	376-386
,	O	386-387
although	O	388-396
linkage	O	397-404
analysis	O	405-413
of	O	414-416
MCT112	O	417-423
with	O	424-428
other	O	429-434
chromosome	O	435-445
9	O	446-447
markers	O	448-455
inferred	O	456-464
a	O	465-466
location	O	467-475
close	O	476-481
to	O	482-484
the	O	485-488
centromere	O	489-499
.	O	499-500

We	O	501-503
have	O	504-508
used	O	509-513
in	O	514-516
situ	O	517-521
hybridisation	O	522-535
with	O	536-540
MCT112	O	541-547
,	O	547-548
a	O	549-550
corresponding	O	551-564
cosmid	O	565-571
MJ1	O	572-575
,	O	575-576
and	O	577-580
DR47	O	581-585
(	O	586-587
D9S5	O	587-591
)	O	591-592
,	O	592-593
coupled	O	594-601
with	O	602-606
mapping	O	607-614
studies	O	615-622
on	O	623-625
hybrid	O	626-632
cell	O	633-637
panels	O	638-644
,	O	644-645
to	O	646-648
define	O	649-655
more	O	656-660
precisely	O	661-670
the	O	671-674
location	O	675-683
of	O	684-686
the	O	687-690
disease	O	691-698
locus	O	699-704
.	O	704-705

The	O	706-709
in	O	710-712
situ	O	713-717
location	O	718-726
of	O	727-729
all	O	730-733
three	O	734-739
probes	O	740-746
is	O	747-749
9q13	O	750-754
-	O	754-755
-	O	754-755
-	O	754-755
-	O	754-755
q21	O	758-761
.	O	761-762

1	O	763-764
,	O	764-765
distal	O	766-772
to	O	773-775
the	O	776-779
variable	O	780-788
heterochromatin	O	789-804
region	O	805-811
.	O	811-812

Physical	O	813-821
assignment	O	822-832
of	O	833-835
FRDA	O	836-840
will	O	841-845
allow	O	846-851
us	O	852-854
to	O	855-857
identify	O	858-866
hybrid	O	867-873
cell	O	874-878
lines	O	879-884
containing	O	885-895
the	O	896-899
mutated	O	900-907
gene	O	908-912
.	O	912-913

Mxi1	O	0-4
mutations	O	5-14
in	O	15-17
human	O	18-23
neurofibrosarcomas	B	24-42
.	O	42-43

Mxi1	O	44-48
is	O	49-51
thought	O	52-59
to	O	60-62
negatively	O	63-73
regulate	O	74-82
Myc	O	83-86
function	O	87-95
and	O	96-99
may	O	100-103
therefore	O	104-113
be	O	114-116
a	O	117-118
potential	O	119-128
tumor	B	129-134
suppressor	O	135-145
gene	O	146-150
.	O	150-151

Little	O	152-158
effort	O	159-165
has	O	166-169
yet	O	170-173
been	O	174-178
made	O	179-183
to	O	184-186
find	O	187-191
alterations	O	192-203
involving	O	204-213
this	O	214-218
gene	O	219-223
in	O	224-226
human	O	227-232
solid	B	233-238
tumors	I	239-245
.	O	245-246

We	O	247-249
screened	O	250-258
31	O	259-261
human	O	262-267
gastric	B	268-275
cancers	I	276-283
,	O	283-284
7	O	285-286
esophageal	B	287-297
cancers	I	298-305
,	O	305-306
85	O	307-309
bone	B	310-314
and	I	315-318
soft	I	319-323
tissue	I	324-330
tumors	I	331-337
of	O	338-340
various	O	341-348
types	O	349-354
,	O	354-355
including	O	356-365
4	O	366-367
neurofibrosarcomas	B	368-386
.	O	386-387

We	O	388-390
also	O	391-395
examined	O	396-404
29	O	405-407
human	O	408-413
tumor	B	414-419
cell	O	420-424
lines	O	425-430
consisting	O	431-441
of	O	442-444
12	O	445-447
esophageal	B	448-458
cancers	I	459-466
,	O	466-467
7	O	468-469
glioma	B	470-476
/	O	476-477
glioblastomas	B	477-490
and	O	491-494
10	O	495-497
others	O	498-504
for	O	505-508
Mxi1	O	509-513
mutations	O	514-523
in	O	524-526
exons	O	527-532
1	O	533-534
,	O	534-535
2	O	536-537
,	O	537-538
4	O	539-540
(	O	541-542
HLH	O	542-545
domain	O	546-552
)	O	552-553
,	O	553-554
5	O	555-556
and	O	557-560
6	O	561-562
.	O	562-563

Polymerase	O	564-574
chain	O	575-580
reaction	O	581-589
-	O	589-590
single	O	590-596
-	O	589-590
strand	O	597-603
conformation	O	604-616
polymorphism	O	617-629
(	O	630-631
PCR	O	631-634
-	O	634-635
SSCP	O	635-639
)	O	639-640
and	O	641-644
subsequent	O	645-655
sequencing	O	656-666
revealed	O	667-675
three	O	676-681
distinct	O	682-690
polymorphisms	O	691-704
in	O	705-707
the	O	708-711
intron	O	712-718
-	O	718-719
exon	O	719-723
boundary	O	724-732
upstream	O	733-741
from	O	742-746
exon	O	747-751
6	O	752-753
.	O	753-754

We	O	755-757
discovered	O	758-768
a	O	769-770
missense	O	771-779
mutation	O	780-788
,	O	788-789
GCA	O	790-793
to	O	794-796
GTA	O	797-800
(	O	801-802
Ala	O	802-805
54	O	806-808
Val	O	809-812
)	O	812-813
,	O	813-814
in	O	815-817
exon	O	818-822
2	O	823-824
in	O	825-827
a	O	828-829
neurofibrosarcoma	B	830-847
patient	O	848-855
(	O	856-857
case	O	857-861
1	O	862-863
)	O	863-864
,	O	864-865
two	O	866-869
missense	O	870-878
mutations	O	879-888
,	O	888-889
AAA	O	890-893
to	O	894-896
CAA	O	897-900
(	O	901-902
Lys	O	902-905
118	O	906-909
Gln	O	910-913
)	O	913-914
and	O	915-918
GAA	O	919-922
to	O	923-925
GGA	O	926-929
(	O	930-931
Glu	O	931-934
154	O	935-938
Gly	O	939-942
)	O	942-943
in	O	944-946
exon	O	947-951
5	O	952-953
of	O	954-956
another	O	957-964
neurofibrosarcoma	B	965-982
patient	O	983-990
(	O	991-992
case	O	992-996
2	O	997-998
)	O	998-999
,	O	999-1000
and	O	1001-1004
3	O	1005-1006
amino	O	1007-1012
acid	O	1013-1017
substitutions	O	1018-1031
,	O	1031-1032
GTG	O	1033-1036
to	O	1037-1039
GCG	O	1040-1043
(	O	1044-1045
Val	O	1045-1048
179	O	1049-1052
Ala	O	1053-1056
)	O	1056-1057
,	O	1057-1058
GTT	O	1059-1062
to	O	1063-1065
GCT	O	1066-1069
(	O	1070-1071
Val	O	1071-1074
181	O	1075-1078
Ala	O	1079-1082
)	O	1082-1083
and	O	1084-1087
TTC	O	1088-1091
to	O	1092-1094
CTC	O	1095-1098
(	O	1099-1100
Phe	O	1100-1103
186	O	1104-1107
Leu	O	1108-1111
)	O	1111-1112
,	O	1112-1113
in	O	1114-1116
a	O	1117-1118
third	O	1119-1124
neurofibrosarcoma	B	1125-1142
patient	O	1143-1150
(	O	1151-1152
case	O	1152-1156
3	O	1157-1158
)	O	1158-1159
.	O	1159-1160

In	O	1161-1163
case	O	1164-1168
3	O	1169-1170
,	O	1170-1171
loss	O	1172-1176
of	O	1177-1179
heterozygosity	O	1180-1194
was	O	1195-1198
also	O	1199-1203
demonstrated	O	1204-1216
by	O	1217-1219
informative	O	1220-1231
(	O	1232-1233
TTC	O	1233-1236
)	O	1236-1237
3	O	1238-1239
/	O	1239-1240
(	O	1240-1241
TTC	O	1241-1244
)	O	1244-1245
2	O	1246-1247
polymorphism	O	1248-1260
.	O	1260-1261

Our	O	1262-1265
data	O	1266-1270
demonstrate	O	1271-1282
that	O	1283-1287
mutations	O	1288-1297
occur	O	1298-1303
in	O	1304-1306
the	O	1307-1310
Mxi1	O	1311-1315
gene	O	1316-1320
in	O	1321-1323
neurofibrosarcoma	B	1324-1341
.	O	1341-1342

Missense	O	1343-1351
mutations	O	1352-1361
in	O	1362-1364
the	O	1365-1368
functional	O	1369-1379
domain	O	1380-1386
of	O	1387-1389
Mxi1	O	1390-1394
in	O	1395-1397
these	O	1398-1403
cases	O	1404-1409
may	O	1410-1413
be	O	1414-1416
involved	O	1417-1425
in	O	1426-1428
the	O	1429-1432
pathogenesis	O	1433-1445
of	O	1446-1448
neurofibrosarcoma	B	1449-1466
.	O	1466-1467
.	O	1466-1467

Molecular	O	0-9
basis	O	10-15
of	O	16-18
essential	B	19-28
fructosuria	I	29-40
:	O	40-41
molecular	O	42-51
cloning	O	52-59
and	O	60-63
mutational	O	64-74
analysis	O	75-83
of	O	84-86
human	O	87-92
ketohexokinase	O	93-107
(	O	108-109
fructokinase	O	109-121
)	O	121-122
.	O	122-123

Essential	B	124-133
fructosuria	I	134-145
is	O	146-148
one	O	149-152
of	O	153-155
the	O	156-159
oldest	O	160-166
known	O	167-172
inborn	B	173-179
errors	I	180-186
of	I	187-189
metabolism	I	190-200
.	O	200-201

It	O	202-204
is	O	205-207
a	O	208-209
benign	O	210-216
condition	O	217-226
which	O	227-232
is	O	233-235
believed	O	236-244
to	O	245-247
result	O	248-254
from	O	255-259
deficiency	B	260-270
of	I	271-273
hepatic	I	274-281
fructokinase	I	282-294
(	O	295-296
ketohexokinase	O	296-310
,	O	310-311
KHK	O	312-315
,	O	315-316
E	O	317-318
.	O	318-319
C	O	320-321
.	O	321-322
2	O	323-324
.	O	324-325
7	O	326-327
.	O	327-328
1	O	329-330
.	O	330-331
3	O	332-333
)	O	333-334
.	O	334-335

This	O	336-340
enzyme	O	341-347
catalyses	O	348-357
the	O	358-361
first	O	362-367
step	O	368-372
of	O	373-375
metabolism	O	376-386
of	O	387-389
dietary	O	390-397
fructose	O	398-406
,	O	406-407
conversion	O	408-418
of	O	419-421
fructose	O	422-430
to	O	431-433
fructose	O	434-442
-	O	442-443
1	O	443-444
-	O	442-443
phosphate	O	445-454
.	O	454-455
Despite	O	456-463
the	O	464-467
early	O	468-473
recognition	O	474-485
of	O	486-488
this	O	489-493
disorder	O	494-502
,	O	502-503
the	O	504-507
primary	O	508-515
structure	O	516-525
of	O	526-528
human	O	529-534
KHK	O	535-538
and	O	539-542
the	O	543-546
molecular	O	547-556
basis	O	557-562
of	O	563-565
essential	B	566-575
fructosuria	I	576-587
have	O	588-592
not	O	593-596
been	O	597-601
previously	O	602-612
defined	O	613-620
.	O	620-621

In	O	622-624
this	O	625-629
report	O	630-636
,	O	636-637
the	O	638-641
isolation	O	642-651
and	O	652-655
sequencing	O	656-666
of	O	667-669
full	O	670-674
-	O	674-675
length	O	675-681
cDNA	O	682-686
clones	O	687-693
encoding	O	694-702
human	O	703-708
ketohexokinase	O	709-723
are	O	724-727
described	O	728-737
.	O	737-738

Alternative	O	739-750
mRNA	O	751-755
species	O	756-763
and	O	764-767
alternative	O	768-779
KHK	O	780-783
isozymes	O	784-792
are	O	793-796
produced	O	797-805
by	O	806-808
alternative	O	809-820
polyadenylation	O	821-836
and	O	837-840
splicing	O	841-849
of	O	850-852
the	O	853-856
KHK	O	857-860
gene	O	861-865
.	O	865-866

The	O	867-870
KHK	O	871-874
proteins	O	875-883
show	O	884-888
a	O	889-890
high	O	891-895
level	O	896-901
of	O	902-904
sequence	O	905-913
conservation	O	914-926
relative	O	927-935
to	O	936-938
rat	O	939-942
KHK	O	943-946
.	O	946-947

Direct	O	948-954
evidence	O	955-963
that	O	964-968
mutation	O	969-977
of	O	978-980
the	O	981-984
KHK	O	985-988
structural	O	989-999
gene	O	1000-1004
is	O	1005-1007
the	O	1008-1011
cause	O	1012-1017
of	O	1018-1020
essential	B	1021-1030
fructosuria	I	1031-1042
was	O	1043-1046
also	O	1047-1051
obtained	O	1052-1060
.	O	1060-1061

In	O	1062-1064
a	O	1065-1066
well	O	1067-1071
-	O	1071-1072
characterized	O	1072-1085
family	O	1086-1092
,	O	1092-1093
in	O	1094-1096
which	O	1097-1102
three	O	1103-1108
of	O	1109-1111
eight	O	1112-1117
siblings	O	1118-1126
have	O	1127-1131
fructosuria	B	1132-1143
,	O	1143-1144
all	O	1145-1148
affected	O	1149-1157
individuals	O	1158-1169
are	O	1170-1173
compound	O	1174-1182
heterozygotes	O	1183-1196
for	O	1197-1200
two	O	1201-1204
mutations	O	1205-1214
Gly40Arg	O	1215-1223
and	O	1224-1227
Ala43Thr	O	1228-1236
.	O	1236-1237

Both	O	1238-1242
mutations	O	1243-1252
result	O	1253-1259
from	O	1260-1264
G	O	1265-1266
-	O	1266-1267
-	O	1266-1267
>	O	1269-1270
A	O	1271-1272
transitions	O	1273-1284
,	O	1284-1285
and	O	1286-1289
each	O	1290-1294
alters	O	1295-1301
the	O	1302-1305
same	O	1306-1310
conserved	O	1311-1320
region	O	1321-1327
of	O	1328-1330
the	O	1331-1334
KHK	O	1335-1338
protein	O	1339-1346
.	O	1346-1347

Neither	O	1348-1355
mutation	O	1356-1364
was	O	1365-1368
seen	O	1369-1373
in	O	1374-1376
a	O	1377-1378
sample	O	1379-1385
of	O	1386-1388
52	O	1389-1391
unrelated	O	1392-1401
control	O	1402-1409
individuals	O	1410-1421
.	O	1421-1422

An	O	1423-1425
additional	O	1426-1436
conservative	O	1437-1449
amino	O	1450-1455
acid	O	1456-1460
change	O	1461-1467
(	O	1468-1469
Val49IIe	O	1469-1477
)	O	1477-1478
was	O	1479-1482
present	O	1483-1490
on	O	1491-1493
the	O	1494-1497
KHK	O	1498-1501
allele	O	1502-1508
bearing	O	1509-1516
Ala43Thr	O	1517-1525

Loss	O	0-4
of	O	5-7
the	O	8-11
ataxia	B	12-18
-	I	18-19
telangiectasia	I	19-33
gene	O	34-38
product	O	39-46
causes	O	47-53
oxidative	O	54-63
damage	O	64-70
in	O	71-73
target	O	74-80
organs	O	81-87
.	O	87-88

Ataxia	B	89-95
-	I	95-96
telangiectasia	I	96-110
(	O	111-112
A	B	112-113
-	I	113-114
T	I	114-115
)	O	115-116
is	O	117-119
characterized	O	120-133
by	O	134-136
a	O	137-138
markedly	O	139-147
increased	O	148-157
sensitivity	O	158-169
to	O	170-172
ionizing	O	173-181
radiation	O	182-191
,	O	191-192
increased	O	193-202
incidence	O	203-212
of	O	213-215
cancer	B	216-222
,	O	222-223
and	O	224-227
neurodegeneration	B	228-245
,	O	245-246
especially	O	247-257
of	O	258-260
the	O	261-264
cerebellar	O	265-275
Purkinje	O	276-284
cells	O	285-290
.	O	290-291

Ionizing	O	292-300
radiation	O	301-310
oxidizes	O	311-319
macromolecules	O	320-334
and	O	335-338
causes	O	339-345
tissue	O	346-352
damage	O	353-359
through	O	360-367
the	O	368-371
generation	O	372-382
of	O	383-385
reactive	O	386-394
oxygen	O	395-401
species	O	402-409
(	O	410-411
ROS	O	411-414
)	O	414-415
.	O	415-416

We	O	417-419
therefore	O	420-429
hypothesized	O	430-442
that	O	443-447
A	B	448-449
-	I	449-450
T	I	450-451
is	O	452-454
due	O	455-458
to	O	459-461
oxidative	O	462-471
damage	O	472-478
resulting	O	479-488
from	O	489-493
loss	O	494-498
of	O	499-501
function	O	502-510
of	O	511-513
the	O	514-517
A	B	518-519
-	I	519-520
T	I	520-521
gene	O	522-526
product	O	527-534
.	O	534-535

To	O	536-538
assess	O	539-545
this	O	546-550
hypothesis	O	551-561
,	O	561-562
we	O	563-565
employed	O	566-574
an	O	575-577
animal	O	578-584
model	O	585-590
of	O	591-593
A	B	594-595
-	I	595-596
T	I	596-597
,	O	597-598
the	O	599-602
mouse	O	603-608
with	O	609-613
a	O	614-615
disrupted	O	616-625
Atm	O	626-629
gene	O	630-634
.	O	634-635

We	O	636-638
show	O	639-643
that	O	644-648
organs	O	649-655
which	O	656-661
develop	O	662-669
pathologic	O	670-680
changes	O	681-688
in	O	689-691
the	O	692-695
Atm	O	696-699
-	O	699-700
deficient	O	700-709
mice	O	710-714
are	O	715-718
targets	O	719-726
of	O	727-729
oxidative	O	730-739
damage	O	740-746
,	O	746-747
and	O	748-751
that	O	752-756
cerebellar	O	757-767
Purkinje	O	768-776
cells	O	777-782
are	O	783-786
particularly	O	787-799
affected	O	800-808
.	O	808-809

These	O	810-815
observations	O	816-828
provide	O	829-836
a	O	837-838
mechanistic	O	839-850
basis	O	851-856
for	O	857-860
the	O	861-864
A	B	865-866
-	I	866-867
T	I	867-868
phenotype	O	869-878
and	O	879-882
lay	O	883-886
a	O	887-888
rational	O	889-897
foundation	O	898-908
for	O	909-912
therapeutic	O	913-924
intervention	O	925-937
.	O	937-938
.	O	937-938

Family	O	0-6
studies	O	7-14
in	O	15-17
Bechterew	B	18-27
'	I	27-28
s	I	28-29
syndrome	I	30-38
(	O	39-40
ankylosing	B	40-50
spondylitis	I	51-62
)	O	62-63
III	O	64-67
.	O	67-68

Genetics	O	69-77
.	O	77-78

The	O	79-82
results	O	83-90
of	O	91-93
segregation	O	94-105
analyses	O	106-114
in	O	115-117
75	O	118-120
families	O	121-129
where	O	130-135
the	O	136-139
proband	O	140-147
had	O	148-151
ankylosing	B	152-162
spondylitis	I	163-174
,	O	174-175
are	O	176-179
presented	O	180-189
.	O	189-190

Of	O	191-193
the	O	194-197
278	O	198-201
adult	O	202-207
,	O	207-208
living	O	209-215
first	O	216-221
degree	O	222-228
relatives	O	229-238
,	O	238-239
approximately	O	240-253
85	O	254-256
%	O	256-257
cooperated	O	258-268
in	O	269-271
the	O	272-275
study	O	276-281
.	O	281-282

Clinical	O	283-291
and	O	292-295
radiographical	O	296-310
examinations	O	311-323
were	O	324-328
performed	O	329-338
and	O	339-342
HLA	O	343-346
typing	O	347-353
was	O	354-357
conducted	O	358-367
.	O	367-368

The	O	369-372
results	O	373-380
were	O	381-385
in	O	386-388
agreement	O	389-398
with	O	399-403
our	O	404-407
hypothesis	O	408-418
that	O	419-423
ankylosing	B	424-434
spondylitis	I	435-446
is	O	447-449
part	O	450-454
of	O	455-457
a	O	458-459
syndrome	O	460-468
where	O	469-474
different	O	475-484
genetic	O	485-492
factors	O	493-500
interact	O	501-509
.	O	509-510

Such	O	511-515
known	O	516-521
factors	O	522-529
are	O	530-533
HLA	O	534-537
B27	O	538-541
associated	O	542-552
disease	O	553-560
susceptibility	O	561-575
,	O	575-576
susceptibility	O	577-591
to	O	592-594
psoriatic	B	595-604
arthropathy	I	605-616
and	O	617-620
susceptibility	O	621-635
to	O	636-638
entero	B	639-645
-	I	645-646
arthropathy	I	646-657
.	O	657-658

Radiographical	O	659-673
sacro	B	674-679
-	I	679-680
iliitis	I	680-687
was	O	688-691
restricted	O	692-702
to	O	703-705
HLA	O	706-709
B27	O	710-713
positive	O	714-722
relatives	O	723-732
,	O	732-733
and	O	734-737
was	O	738-741
more	O	742-746
frequently	O	747-757
found	O	758-763
in	O	764-766
relatives	O	767-776
to	O	777-779
probands	O	780-788
with	O	789-793
psoriasis	B	794-803
than	O	804-808
in	O	809-811
relatives	O	812-821
to	O	822-824
probands	O	825-833
without	O	834-841
psoriasis	B	842-851
.	O	851-852

Environmental	O	853-866
factors	O	867-874
(	O	875-876
intestinal	O	876-886
bacteria	O	887-895
)	O	895-896
are	O	897-900
known	O	901-906
to	O	907-909
trigger	O	910-917
the	O	918-921
disease	O	922-929
at	O	930-932
least	O	933-938
in	O	939-941
some	O	942-946
persons	O	947-954
,	O	954-955
and	O	956-959
we	O	960-962
have	O	963-967
postulated	O	968-978
that	O	979-983
all	O	984-987
or	O	988-990
most	O	991-995
of	O	996-998
them	O	999-1003
have	O	1004-1008
the	O	1009-1012
predisposition	O	1013-1027
to	O	1028-1030
develop	O	1031-1038
disease	O	1039-1046
.	O	1046-1047

Thus	O	1048-1052
,	O	1052-1053
the	O	1054-1057
syndrome	O	1058-1066
has	O	1067-1070
a	O	1071-1072
multifactorial	O	1073-1087
etiology	O	1088-1096
.	O	1096-1097

The	O	1098-1101
phenotypic	O	1102-1112
expressions	O	1113-1124
of	O	1125-1127
the	O	1128-1131
different	O	1132-1141
genetic	O	1142-1149
predispositions	O	1150-1165
involved	O	1166-1174
,	O	1174-1175
include	O	1176-1183
sacro	B	1184-1189
-	I	1189-1190
iliitis	I	1190-1197
,	O	1197-1198
psoriasis	B	1199-1208
,	O	1208-1209
acute	B	1210-1215
anterior	I	1216-1224
uveitis	I	1225-1232
,	O	1232-1233
peripheral	O	1234-1244
arthropathy	B	1245-1256
and	O	1257-1260
inflammatory	B	1261-1273
bowel	I	1274-1279
disease	I	1280-1287
.	O	1287-1288

We	O	1289-1291
suggest	O	1292-1299
the	O	1300-1303
descriptive	O	1304-1315
name	O	1316-1320
HEREDITARY	B	1321-1331
MULTIFOCAL	I	1332-1342
RELAPSING	I	1343-1352
INFLAMMATION	I	1353-1365
(	O	1366-1367
HEMRI	B	1367-1372
)	O	1372-1373
for	O	1374-1377
this	O	1378-1382
syndrome	O	1383-1391
.	O	1391-1392

Ankylosing	B	1393-1403
spondylitis	I	1404-1415
,	O	1415-1416
psoriatic	B	1417-1426
arthropathy	I	1427-1438
and	O	1439-1442
entero	B	1443-1449
-	I	1449-1450
arthropathy	I	1450-1461
may	O	1462-1465
be	O	1466-1468
regarded	O	1469-1477
as	O	1478-1480
clinical	O	1481-1489
sub	O	1490-1493
-	O	1493-1494
types	O	1494-1499
of	O	1500-1502
the	O	1503-1506
syndrome	O	1507-1515
.	O	1515-1516
.	O	1515-1516

Chromosome	O	0-10
mapping	O	11-18
of	O	19-21
the	O	22-25
rod	O	26-29
photoreceptor	O	30-43
cGMP	O	44-48
phosphodiesterase	O	49-66
beta	O	67-71
-	O	71-72
subunit	O	72-79
gene	O	80-84
in	O	85-87
mouse	O	88-93
and	O	94-97
human	O	98-103
:	O	103-104
tight	O	105-110
linkage	O	111-118
to	O	119-121
the	O	122-125
Huntington	B	126-136
disease	I	137-144
region	O	145-151
(	O	152-153
4p16	O	153-157
.	O	157-158
3	O	158-159
)	O	159-160
.	O	157-158

The	O	162-165
retinal	B	166-173
degeneration	I	174-186
mouse	O	187-192
(	O	193-194
gene	O	194-198
symbol	O	199-205
,	O	205-206
rd	O	207-209
)	O	209-210
is	O	211-213
an	O	214-216
animal	O	217-223
model	O	224-229
for	O	230-233
certain	O	234-241
forms	O	242-247
of	O	248-250
human	O	251-256
hereditary	B	257-267
retinopathies	I	268-281
.	O	281-282

Recent	O	283-289
findings	O	290-298
of	O	299-301
a	O	302-303
nonsense	O	304-312
mutation	O	313-321
in	O	322-324
the	O	325-328
rd	O	329-331
mouse	O	332-337
PDE	O	338-341
beta	O	342-346
-	O	346-347
subunit	O	347-354
gene	O	355-359
(	O	360-361
Pdeb	O	361-365
)	O	365-366
prompted	O	367-375
us	O	376-378
to	O	379-381
investigate	O	382-393
the	O	394-397
chromosome	O	398-408
locations	O	409-418
of	O	419-421
the	O	422-425
mouse	O	426-431
and	O	432-435
human	O	436-441
genes	O	442-447
.	O	447-448

We	O	449-451
have	O	452-456
utilized	O	457-465
backcross	O	466-475
analysis	O	476-484
in	O	485-487
mice	O	488-492
to	O	493-495
verify	O	496-502
and	O	503-506
define	O	507-513
more	O	514-518
precisely	O	519-528
the	O	529-532
location	O	533-541
of	O	542-544
the	O	545-548
Pdeb	O	549-553
locus	O	554-559
6	O	560-561
.	O	561-562
1	O	563-564
+	O	565-566
/	O	566-567
-	O	567-568
2	O	569-570
.	O	570-571
3	O	572-573
cM	O	574-576
distal	O	577-583
of	O	584-586
Mgsa	O	587-591
on	O	592-594
mouse	O	595-600
chromosome	O	601-611
5	O	612-613
.	O	613-614

We	O	615-617
have	O	618-622
determined	O	623-633
that	O	634-638
the	O	639-642
human	O	643-648
gene	O	649-653
(	O	654-655
PDEB	O	655-659
)	O	659-660
maps	O	661-665
to	O	666-668
4p16	O	669-673
.	O	673-674

3	O	675-676
,	O	676-677
very	O	678-682
close	O	683-688
to	O	689-691
the	O	692-695
Huntington	B	696-706
disease	I	707-714
(	O	715-716
HD	B	716-718
)	O	718-719
region	O	720-726
.	O	726-727

Analysis	O	728-736
of	O	737-739
the	O	740-743
comparative	O	744-755
map	O	756-759
for	O	760-763
mice	O	764-768
and	O	769-772
humans	O	773-779
shows	O	780-785
that	O	786-790
the	O	791-794
mouse	O	795-800
homologue	O	801-810
of	O	811-813
the	O	814-817
HD	B	818-820
gene	O	821-825
will	O	826-830
reside	O	831-837
on	O	838-840
chromosome	O	841-851
5	O	852-853
.	O	853-854
Linkage	O	855-862
of	O	863-865
the	O	866-869
mouse	O	870-875
Pdeb	O	876-880
locus	O	881-886
with	O	887-891
other	O	892-897
homologues	O	898-908
in	O	909-911
the	O	912-915
human	O	916-921
4p16	O	922-926
.	O	926-927

3	O	928-929
region	O	930-936
is	O	937-939
maintained	O	940-950
but	O	951-954
gene	O	955-959
order	O	960-965
is	O	966-968
not	O	969-972
,	O	972-973
suggesting	O	974-984
at	O	985-987
least	O	988-993
three	O	994-999
possible	O	1000-1008
sites	O	1009-1014
for	O	1015-1018
the	O	1019-1022
corresponding	O	1023-1036
mouse	O	1037-1042
HD	B	1043-1045
gene	O	1046-1050
.	O	1050-1051

Hereditary	B	0-10
deficiency	I	11-21
of	I	22-24
the	I	25-28
fifth	I	29-34
component	I	35-44
of	I	45-47
complement	I	48-58
in	O	59-61
man	O	62-65
.	O	65-66

II	O	67-69
.	O	69-70

Biological	O	71-81
properties	O	82-92
of	O	93-95
C5	B	96-98
-	I	98-99
deficient	I	99-108
human	O	109-114
serum	O	115-120
.	O	120-121

The	O	122-125
first	O	126-131
known	O	132-137
human	O	138-143
kindred	O	144-151
with	O	152-156
hereditary	B	157-167
deficiency	I	168-178
of	I	179-181
the	I	182-185
fifth	I	186-191
component	I	192-201
of	I	202-204
complement	I	205-215
(	O	216-217
C5	O	217-219
)	O	219-220
was	O	221-224
documented	O	225-235
in	O	236-238
the	O	239-242
accompanying	O	243-255
report	O	256-262
.	O	262-263

This	O	264-268
study	O	269-274
examines	O	275-283
several	O	284-291
biological	O	292-302
properties	O	303-313
of	O	314-316
C5	B	317-319
-	I	319-320
deficient	I	320-329
(	O	330-331
C5D	B	331-334
)	O	334-335
human	O	336-341
serum	O	342-347
,	O	347-348
particularly	O	349-361
sera	O	362-366
obtained	O	367-375
from	O	376-380
two	O	381-384
C5D	B	385-388
homozygotes	O	389-400
.	O	400-401

The	O	402-405
proband	O	406-413
,	O	413-414
who	O	415-418
has	O	419-422
inactive	O	423-431
systemic	B	432-440
lupus	I	441-446
erythematosus	I	447-460
is	O	461-463
completely	O	464-474
lacking	O	475-482
C5	O	483-485
,	O	485-486
while	O	487-492
her	O	493-496
healthy	O	497-504
half	O	505-509
-	O	509-510
sister	O	510-516
has	O	517-520
1	O	521-522
-	O	522-523
2	O	523-524
%	O	524-525
of	O	526-528
normal	O	529-535
levels	O	536-542
.	O	542-543

Both	O	544-548
sera	O	549-553
were	O	554-558
severely	O	559-567
impaired	O	568-576
in	O	577-579
their	O	580-585
ability	O	586-593
to	O	594-596
generate	O	597-605
chemotactic	O	606-617
activity	O	618-626
for	O	627-630
normal	O	631-637
human	O	638-643
neutrophils	O	644-655
upon	O	656-660
incubation	O	661-671
with	O	672-676
aggregated	O	677-687
human	O	688-693
gamma	O	694-699
-	O	699-700
globulin	O	700-708
or	O	709-711
Escherichia	O	712-723
coli	O	724-728
endotoxin	O	729-738
.	O	738-739

This	O	740-744
function	O	745-753
was	O	754-757
fully	O	758-763
restored	O	764-772
in	O	773-775
the	O	776-779
siblings	O	780-788
serum	O	789-794
,	O	794-795
and	O	796-799
substantially	O	800-813
improved	O	814-822
in	O	823-825
the	O	826-829
probands	O	830-838
serum	O	839-844
,	O	844-845
by	O	846-848
addition	O	849-857
of	O	858-860
highly	O	861-867
purified	O	868-876
human	O	877-882
C5	O	883-885
to	O	886-888
normal	O	889-895
serum	O	896-901
concentrations	O	902-916
.	O	916-917

Sera	O	918-922
from	O	923-927
eight	O	928-933
family	O	934-940
members	O	941-948
who	O	949-952
were	O	953-957
apparently	O	958-968
heterozygous	O	969-981
for	O	982-985
C5	B	986-988
deficiency	I	989-999
gave	O	1000-1004
normal	O	1005-1011
chemotactic	O	1012-1023
scores	O	1024-1030
.	O	1030-1031

The	O	1032-1035
ability	O	1036-1043
of	O	1044-1046
C5D	B	1047-1050
serum	O	1051-1056
to	O	1057-1059
opsonize	O	1060-1068
Saccharomyces	O	1069-1082
cerevisiae	O	1083-1093
(	O	1094-1095
bakers	O	1095-1101
yeast	O	1102-1107
)	O	1107-1108
or	O	1109-1111
Candida	O	1112-1119
albicans	O	1120-1128
for	O	1129-1132
ingestion	O	1133-1142
by	O	1143-1145
normal	O	1146-1152
neutrophils	O	1153-1164
was	O	1165-1168
completely	O	1169-1179
normal	O	1180-1186
.	O	1186-1187

In	O	1188-1190
addition	O	1191-1199
,	O	1199-1200
C5D	B	1201-1204
serum	O	1205-1210
was	O	1211-1214
capable	O	1215-1222
of	O	1223-1225
promoting	O	1226-1235
normal	O	1236-1242
phagocytosis	O	1243-1255
and	O	1256-1259
intracellular	O	1260-1273
killing	O	1274-1281
of	O	1282-1284
Staphylococcus	O	1285-1299
aureus	O	1300-1306
.	O	1306-1307

The	O	1308-1311
probands	O	1312-1320
serum	O	1321-1326
was	O	1327-1330
incapable	O	1331-1340
of	O	1341-1343
mediating	O	1344-1353
lysis	O	1354-1359
of	O	1360-1362
erythrocytes	O	1363-1375
from	O	1376-1380
a	O	1381-1382
patient	O	1383-1390
with	O	1391-1395
paroxysmal	B	1396-1406
nocturnal	I	1407-1416
hemoglobinuria	I	1417-1431
in	O	1432-1434
both	O	1435-1439
the	O	1440-1443
sucrose	O	1444-1451
hemolysia	O	1452-1461
and	O	1462-1465
acid	O	1466-1470
hemolysis	O	1471-1480
tests	O	1481-1486
,	O	1486-1487
and	O	1488-1491
also	O	1492-1496
lacked	O	1497-1503
bactericidal	O	1504-1516
activity	O	1517-1525
against	O	1526-1533
sensitized	O	1534-1544
or	O	1545-1547
unsensitized	O	1548-1560
Salmonella	O	1561-1571
typhi	O	1572-1577
.	O	1577-1578

The	O	1579-1582
siblings	O	1583-1591
serum	O	1592-1597
,	O	1597-1598
containing	O	1599-1609
only	O	1610-1614
1	O	1615-1616
-	O	1616-1617
2	O	1617-1618
%	O	1618-1619
of	O	1620-1622
normal	O	1623-1629
C5	O	1630-1632
,	O	1632-1633
effectively	O	1634-1645
lysed	O	1646-1651
S	O	1652-1653
.	O	1653-1654
typhi	O	1655-1660
,	O	1660-1661
but	O	1662-1665
only	O	1666-1670
at	O	1671-1673
eightfold	O	1674-1683
lower	O	1684-1689
serum	O	1690-1695
dilutions	O	1696-1705
as	O	1706-1708
compared	O	1709-1717
to	O	1718-1720
normals	O	1721-1728
.	O	1728-1729

These	O	1730-1735
findings	O	1736-1744
underscore	O	1745-1755
the	O	1756-1759
critical	O	1760-1768
role	O	1769-1773
of	O	1774-1776
C5	O	1777-1779
in	O	1780-1782
the	O	1783-1786
generation	O	1787-1797
of	O	1798-1800
chemotactic	O	1801-1812
activity	O	1813-1821
and	O	1822-1825
in	O	1826-1828
cytolytic	O	1829-1838
reactions	O	1839-1848
,	O	1848-1849
as	O	1850-1852
opposed	O	1853-1860
to	O	1861-1863
a	O	1864-1865
nonobligatory	O	1866-1879
or	O	1880-1882
minimal	O	1883-1890
role	O	1891-1895
in	O	1896-1898
opsonization	O	1899-1911
,	O	1911-1912
at	O	1913-1915
least	O	1916-1921
for	O	1922-1925
the	O	1926-1929
organisms	O	1930-1939
under	O	1940-1945
study	O	1946-1951
.	O	1951-1952
.	O	1951-1952

The	O	0-3
gene	O	4-8
for	O	9-12
familial	B	13-21
Mediterranean	I	22-35
fever	I	36-41
,	O	41-42
MEFV	O	43-47
,	O	47-48
is	O	49-51
expressed	O	52-61
in	O	62-64
early	O	65-70
leukocyte	O	71-80
development	O	81-92
and	O	93-96
is	O	97-99
regulated	O	100-109
in	O	110-112
response	O	113-121
to	O	122-124
inflammatory	O	125-137
mediators	O	138-147
.	O	147-148

Familial	B	149-157
Mediterranean	I	158-171
fever	I	172-177
(	O	178-179
FMF	B	179-182
)	O	182-183
is	O	184-186
a	O	187-188
recessive	B	189-198
disorder	I	199-207
characterized	O	208-221
by	O	222-224
episodes	O	225-233
of	O	234-236
fever	B	237-242
and	O	243-246
neutrophil	B	247-257
-	I	257-258
mediated	I	258-266
serosal	I	267-274
inflammation	I	275-287
.	O	287-288

We	O	289-291
recently	O	292-300
identified	O	301-311
the	O	312-315
gene	O	316-320
causing	O	321-328
FMF	B	329-332
,	O	332-333
designated	O	334-344
MEFV	O	345-349
,	O	349-350
and	O	351-354
found	O	355-360
it	O	361-363
to	O	364-366
be	O	367-369
expressed	O	370-379
in	O	380-382
mature	O	383-389
neutrophils	O	390-401
,	O	401-402
suggesting	O	403-413
that	O	414-418
it	O	419-421
functions	O	422-431
as	O	432-434
an	O	435-437
inflammatory	O	438-450
regulator	O	451-460
.	O	460-461

To	O	462-464
facilitate	O	465-475
our	O	476-479
understanding	O	480-493
of	O	494-496
the	O	497-500
normal	O	501-507
function	O	508-516
of	O	517-519
MEFV	O	520-524
,	O	524-525
we	O	526-528
extended	O	529-537
our	O	538-541
previous	O	542-550
studies	O	551-558
.	O	558-559

MEFV	O	560-564
messenger	O	565-574
RNA	O	575-578
was	O	579-582
detected	O	583-591
by	O	592-594
reverse	O	595-602
transcriptase	O	603-616
-	O	616-617
polymerase	O	617-627
chain	O	628-633
reaction	O	634-642
in	O	643-645
bone	O	646-650
marrow	O	651-657
leukocytes	O	658-668
,	O	668-669
with	O	670-674
differential	O	675-687
expression	O	688-698
observed	O	699-707
among	O	708-713
cells	O	714-719
by	O	720-722
in	O	723-725
situ	O	726-730
hybridization	O	731-744
.	O	744-745

CD34	O	746-750
hematopoietic	O	751-764
stem	O	765-769
-	O	769-770
cell	O	770-774
cultures	O	775-783
induced	O	784-791
toward	O	792-798
the	O	799-802
granulocytic	O	803-815
lineage	O	816-823
expressed	O	824-833
MEFV	O	834-838
at	O	839-841
the	O	842-845
myelocyte	O	846-855
stage	O	856-861
,	O	861-862
concurrently	O	863-875
with	O	876-880
lineage	O	881-888
commitment	O	889-899
.	O	899-900

The	O	901-904
prepromyelocytic	O	905-921
cell	O	922-926
line	O	927-931
HL60	O	932-936
expressed	O	937-946
MEFV	O	947-951
only	O	952-956
at	O	957-959
granulocytic	O	960-972
and	O	973-976
monocytic	O	977-986
differentiation	O	987-1002
.	O	1002-1003

MEFV	O	1004-1008
was	O	1009-1012
also	O	1013-1017
expressed	O	1018-1027
in	O	1028-1030
the	O	1031-1034
monocytic	O	1035-1044
cell	O	1045-1049
lines	O	1050-1055
U937	O	1056-1060
and	O	1061-1064
THP	O	1065-1068
-	O	1068-1069
1	O	1069-1070
.	O	1070-1071

Among	O	1072-1077
peripheral	O	1078-1088
blood	O	1089-1094
leukocytes	O	1095-1105
,	O	1105-1106
MEFV	O	1107-1111
expression	O	1112-1122
was	O	1123-1126
detected	O	1127-1135
in	O	1136-1138
neutrophils	O	1139-1150
,	O	1150-1151
eosinophils	O	1152-1163
,	O	1163-1164
and	O	1165-1168
to	O	1169-1171
varying	O	1172-1179
degrees	O	1180-1187
,	O	1187-1188
monocytes	O	1189-1198
.	O	1198-1199

Consistent	O	1200-1210
with	O	1211-1215
the	O	1216-1219
tissue	O	1220-1226
specificity	O	1227-1238
of	O	1239-1241
expression	O	1242-1252
,	O	1252-1253
complete	O	1254-1262
sequencing	O	1263-1273
and	O	1274-1277
analysis	O	1278-1286
of	O	1287-1289
upstream	O	1290-1298
regulatory	O	1299-1309
regions	O	1310-1317
of	O	1318-1320
MEFV	O	1321-1325
revealed	O	1326-1334
homology	O	1335-1343
to	O	1344-1346
myeloid	O	1347-1354
-	O	1354-1355
specific	O	1355-1363
promoters	O	1364-1373
and	O	1374-1377
to	O	1378-1380
more	O	1381-1385
broadly	O	1386-1393
expressed	O	1394-1403
inflammatory	O	1404-1416
promoter	O	1417-1425
elements	O	1426-1434
.	O	1434-1435

In	O	1436-1438
vitro	O	1439-1444
stimulation	O	1445-1456
of	O	1457-1459
monocytes	O	1460-1469
with	O	1470-1474
the	O	1475-1478
proinflammatory	O	1479-1494
agents	O	1495-1501
interferon	O	1502-1512
(	O	1513-1514
IFN	O	1514-1517
)	O	1517-1518
gamma	O	1519-1524
,	O	1524-1525
tumor	B	1526-1531
necrosis	O	1532-1540
factor	O	1541-1547
,	O	1547-1548
and	O	1549-1552
lipopolysaccharide	O	1553-1571
induced	O	1572-1579
MEFV	O	1580-1584
expression	O	1585-1595
,	O	1595-1596
whereas	O	1597-1604
the	O	1605-1608
antiinflammatory	O	1609-1625
cytokines	O	1626-1635
interleukin	O	1636-1647
(	O	1648-1649
IL	O	1649-1651
)	O	1651-1652
4	O	1653-1654
,	O	1654-1655
IL	O	1656-1658
-	O	1658-1659
10	O	1659-1661
,	O	1661-1662
and	O	1663-1666
transforming	O	1667-1679
growth	O	1680-1686
factor	O	1687-1693
beta	O	1694-1698
inhibited	O	1699-1708
such	O	1709-1713
expression	O	1714-1724
.	O	1724-1725

Induction	O	1726-1735
by	O	1736-1738
IFN	O	1739-1742
-	O	1742-1743
gamma	O	1743-1748
occurred	O	1749-1757
rapidly	O	1758-1765
and	O	1766-1769
was	O	1770-1773
resistant	O	1774-1783
to	O	1784-1786
cycloheximide	O	1787-1800
.	O	1800-1801

IFN	O	1802-1805
-	O	1805-1806
alpha	O	1806-1811
also	O	1812-1816
induced	O	1817-1824
MEFV	O	1825-1829
expression	O	1830-1840
.	O	1840-1841

In	O	1842-1844
granulocytes	O	1845-1857
,	O	1857-1858
MEFV	O	1859-1863
was	O	1864-1867
up	O	1868-1870
-	O	1870-1871
regulated	O	1871-1880
by	O	1881-1883
IFN	O	1884-1887
-	O	1887-1888
gamma	O	1888-1893
and	O	1894-1897
the	O	1898-1901
combination	O	1902-1913
of	O	1914-1916
IFN	O	1917-1920
-	O	1920-1921
alpha	O	1921-1926
and	O	1927-1930
colchicine	O	1931-1941
.	O	1941-1942

These	O	1943-1948
results	O	1949-1956
refine	O	1957-1963
understanding	O	1964-1977
of	O	1978-1980
MEFV	O	1981-1985
by	O	1986-1988
placing	O	1989-1996
the	O	1997-2000
gene	O	2001-2005
in	O	2006-2008
the	O	2009-2012
myelomonocytic	O	2013-2027
-	O	2027-2028
specific	O	2028-2036
proinflammatory	O	2037-2052
pathway	O	2053-2060
and	O	2061-2064
identifying	O	2065-2076
it	O	2077-2079
as	O	2080-2082
an	O	2083-2085
IFN	O	2086-2089
-	O	2089-2090
gamma	O	2090-2095
immediate	O	2096-2105
early	O	2106-2111
gene	O	2112-2116
.	O	2116-2117
.	O	2116-2117

Spectrum	O	0-8
of	O	9-11
hSNF5	O	12-17
/	O	17-18
INI1	O	18-22
somatic	O	23-30
mutations	O	31-40
in	O	41-43
human	O	44-49
cancer	B	50-56
and	O	57-60
genotype	O	61-69
-	O	69-70
phenotype	O	70-79
correlations	O	80-92
.	O	92-93

The	O	94-97
hSNF5	O	98-103
/	O	103-104
INI1	O	104-108
gene	O	109-113
which	O	114-119
encodes	O	120-127
a	O	128-129
member	O	130-136
of	O	137-139
the	O	140-143
SWI	O	144-147
/	O	147-148
SNF	O	148-151
chromatin	O	152-161
ATP	O	162-165
-	O	165-166
dependent	O	166-175
remodeling	O	176-186
complex	O	187-194
,	O	194-195
is	O	196-198
a	O	199-200
new	O	201-204
tumor	B	205-210
suppressor	O	211-221
gene	O	222-226
localized	O	227-236
on	O	237-239
chromosome	O	240-250
22q11	O	251-256
.	O	256-257

2	O	258-259
and	O	260-263
recently	O	264-272
shown	O	273-278
to	O	279-281
be	O	282-284
mutated	O	285-292
in	O	293-295
malignant	B	296-305
rhabdoid	I	306-314
tumors	I	315-321
.	O	321-322

We	O	323-325
have	O	326-330
searched	O	331-339
for	O	340-343
hSNF5	O	344-349
/	O	349-350
INI1	O	350-354
mutations	O	355-364
in	O	365-367
229	O	368-371
tumors	B	372-378
of	O	379-381
various	O	382-389
origins	O	390-397
using	O	398-403
a	O	404-405
screening	O	406-415
method	O	416-422
based	O	423-428
on	O	429-431
denaturing	O	432-442
high	O	443-447
-	O	447-448
performance	O	448-459
liquid	O	460-466
chromatography	O	467-481
.	O	481-482

A	O	483-484
total	O	485-490
of	O	491-493
31	O	494-496
homozygous	O	497-507
deletions	O	508-517
and	O	518-521
36	O	522-524
point	O	525-530
alterations	O	531-542
were	O	543-547
identified	O	548-558
.	O	558-559

Point	O	560-565
mutations	O	566-575
were	O	576-580
scattered	O	581-590
along	O	591-596
the	O	597-600
coding	O	601-607
sequence	O	608-616
and	O	617-620
included	O	621-629
15	O	630-632
nonsense	O	633-641
,	O	641-642
15	O	643-645
frameshift	O	646-656
,	O	656-657
three	O	658-663
splice	O	664-670
site	O	671-675
,	O	675-676
two	O	677-680
missense	O	681-689
and	O	690-693
one	O	694-697
editing	O	698-705
mutations	O	706-715
.	O	715-716

Mutations	O	717-726
were	O	727-731
retrieved	O	732-741
in	O	742-744
most	O	745-749
rhabdoid	B	750-758
tumors	I	759-765
,	O	765-766
whatever	O	767-775
their	O	776-781
sites	O	782-787
of	O	788-790
occurrence	O	791-801
,	O	801-802
indicating	O	803-813
the	O	814-817
common	O	818-824
pathogenetic	O	825-837
origin	O	838-844
of	O	845-847
these	O	848-853
tumors	B	854-860
.	O	860-861

Recurrent	O	862-871
hSNF5	O	872-877
/	O	877-878
INI1	O	878-882
alterations	O	883-894
were	O	895-899
also	O	900-904
observed	O	905-913
in	O	914-916
choroid	B	917-924
plexus	I	925-931
carcinomas	I	932-942
and	O	943-946
in	O	947-949
a	O	950-951
subset	O	952-958
of	O	959-961
central	O	962-969
primitive	O	970-979
neuroectodermal	B	980-995
tumors	I	996-1002
(	O	1003-1004
cPNETs	O	1004-1010
)	O	1010-1011
and	O	1012-1015
medulloblastomas	B	1016-1032
.	O	1032-1033

In	O	1034-1036
contrast	O	1037-1045
,	O	1045-1046
hSNF5	O	1047-1052
/	O	1052-1053
INI1	O	1053-1057
point	O	1058-1063
mutations	O	1064-1073
were	O	1074-1078
not	O	1079-1082
detected	O	1083-1091
in	O	1092-1094
breast	B	1095-1101
cancers	I	1102-1109
,	O	1109-1110
Wilms	B	1111-1116
tumors	I	1117-1123
,	O	1123-1124
gliomas	B	1125-1132
,	O	1132-1133
ependymomas	B	1134-1145
,	O	1145-1146
sarcomas	B	1147-1155
and	O	1156-1159
other	O	1160-1165
tumor	B	1166-1171
types	O	1172-1177
,	O	1177-1178
even	O	1179-1183
though	O	1184-1190
most	O	1191-1195
analyzed	O	1196-1204
cases	O	1205-1210
harbored	O	1211-1219
loss	O	1220-1224
of	O	1225-1227
heterozygosity	O	1228-1242
at	O	1243-1245
22q11	O	1246-1251
.	O	1251-1252
2	O	1253-1254
loci	O	1255-1259
.	O	1259-1260

These	O	1261-1266
results	O	1267-1274
suggest	O	1275-1282
that	O	1283-1287
rhabdoid	B	1288-1296
tumors	I	1297-1303
,	O	1303-1304
choroid	B	1305-1312
plexus	I	1313-1319
carcinomas	I	1320-1330
and	O	1331-1334
a	O	1335-1336
subset	O	1337-1343
of	O	1344-1346
medulloblastomas	B	1347-1363
and	O	1364-1367
cPNETs	O	1368-1374
share	O	1375-1380
common	O	1381-1387
pathways	O	1388-1396
of	O	1397-1399
oncogenesis	O	1400-1411
related	O	1412-1419
to	O	1420-1422
hSNF5	O	1423-1428
/	O	1428-1429
INI1	O	1429-1433
alteration	O	1434-1444
and	O	1445-1448
that	O	1449-1453
hSNF5	O	1454-1459
/	O	1459-1460
INI1	O	1460-1464
mutations	O	1465-1474
define	O	1475-1481
a	O	1482-1483
genetically	O	1484-1495
homogeneous	O	1496-1507
family	O	1508-1514
of	O	1515-1517
highly	O	1518-1524
aggressive	O	1525-1535
cancers	B	1536-1543
mainly	O	1544-1550
occurring	O	1551-1560
in	O	1561-1563
young	O	1564-1569
children	O	1570-1578
and	O	1579-1582
frequently	O	1583-1593
,	O	1593-1594
but	O	1595-1598
not	O	1599-1602
always	O	1603-1609
,	O	1609-1610
exhibiting	O	1611-1621
a	O	1622-1623
rhabdoid	B	1624-1632
phenotype	O	1633-1642

Heterogeneity	O	0-13
of	O	14-16
glucose	B	17-24
-	I	24-25
6	I	25-26
-	I	24-25
phosphate	I	27-36
dehydrogenase	I	37-50
deficiency	I	51-61
in	O	62-64
Algeria	O	65-72
.	O	72-73

Study	O	74-79
in	O	80-82
Northern	O	83-91
Algeria	O	92-99
with	O	100-104
description	O	105-116
of	O	117-119
five	O	120-124
new	O	125-128
variants	O	129-137
.	O	137-138

Glucose	B	139-146
-	I	146-147
6	I	147-148
-	I	146-147
phosphate	I	149-158
dehydrogenase	I	159-172
(	I	173-174
G6PD	I	174-178
)	I	178-179
deficiency	I	180-190
was	O	191-194
found	O	195-200
in	O	201-203
3	O	204-205
.	O	205-206
2	O	207-208
%	O	208-209
of	O	210-212
the	O	213-216
male	O	217-221
population	O	222-232
living	O	233-239
in	O	240-242
the	O	243-246
urban	O	247-252
area	O	253-257
of	O	258-260
Algiers	O	261-268
.	O	268-269

The	O	270-273
deficient	O	274-283
subjects	O	284-292
originated	O	293-303
from	O	304-308
multiple	O	309-317
geographic	O	318-328
regions	O	329-336
of	O	337-339
Northern	O	340-348
Algeria	O	349-356
,	O	356-357
with	O	358-362
prevalence	O	363-373
of	O	374-376
individuals	O	377-388
of	O	389-391
Berber	O	392-398
-	O	398-399
Kabyle	O	399-405
origin	O	406-412
.	O	412-413

Red	O	414-417
blood	O	418-423
cell	O	424-428
G6PD	O	429-433
was	O	434-437
partially	O	438-447
purified	O	448-456
and	O	457-460
characterized	O	461-474
in	O	475-477
deficient	O	478-487
males	O	488-493
from	O	494-498
17	O	499-501
families	O	502-510
,	O	510-511
and	O	512-515
six	O	516-519
different	O	520-529
variants	O	530-538
were	O	539-543
found	O	544-549
.	O	549-550

Among	O	551-556
them	O	557-561
,	O	561-562
only	O	563-567
one	O	568-571
,	O	571-572
the	O	573-576
Gd	O	577-579
(	O	580-581
-	O	581-582
)	O	582-583
Kabyle	O	584-590
variant	O	591-598
,	O	598-599
had	O	600-603
been	O	604-608
previously	O	609-619
described	O	620-629
.	O	629-630

It	O	631-633
was	O	634-637
detected	O	638-646
in	O	647-649
nine	O	650-654
families	O	655-663
.	O	663-664

The	O	665-668
other	O	669-674
five	O	675-679
variants	O	680-688
were	O	689-693
new	O	694-697
Gd	O	699-701
(	O	702-703
-	O	703-704
)	O	704-705
Laghouat	O	706-714
(	O	715-716
four	O	716-720
cases	O	721-726
)	O	726-727
,	O	727-728
Gd	O	729-731
(	O	732-733
-	O	733-734
)	O	734-735
Blida	O	736-741
(	O	742-743
one	O	743-746
case	O	747-751
)	O	751-752
,	O	752-753
Gd	O	754-756
(	O	757-758
-	O	758-759
)	O	759-760
Thenia	O	761-767
(	O	768-769
one	O	769-772
case	O	773-777
)	O	777-778
,	O	778-779
Gd	O	780-782
(	O	783-784
-	O	784-785
)	O	785-786
Titteri	O	787-794
(	O	795-796
one	O	796-799
case	O	800-804
)	O	804-805
,	O	805-806
and	O	807-810
Gd	O	811-813
(	O	814-815
-	O	815-816
)	O	816-817
Alger	O	818-823
(	O	824-825
two	O	825-828
brothers	O	829-837
)	O	837-838
.	O	838-839

Strikingly	O	840-850
,	O	850-851
the	O	852-855
common	O	856-862
Mediterranean	O	863-876
variant	O	877-884
was	O	885-888
not	O	889-892
found	O	893-898
.	O	898-899

G6PD	B	900-904
deficiency	I	905-915
is	O	916-918
heterogeneous	O	919-932
in	O	933-935
northern	O	936-944
Algeria	O	945-952
where	O	953-958
autochtonous	O	959-971
variants	O	972-980
seem	O	981-985
to	O	986-988
prevail	O	989-996
.	O	996-997

The	O	998-1001
Kabyle	O	1002-1008
variant	O	1009-1016
may	O	1017-1020
be	O	1021-1023
common	O	1024-1030
in	O	1031-1033
this	O	1034-1038
country	O	1039-1046
.	O	1046-1047

Fragile	B	0-7
X	I	8-9
syndrome	I	10-18
without	O	19-26
CCG	O	27-30
amplification	O	31-44
has	O	45-48
an	O	49-51
FMR1	O	52-56
deletion	O	57-65
.	O	65-66

We	O	67-69
describe	O	70-78
a	O	79-80
patient	O	81-88
with	O	89-93
typical	O	94-101
clinical	O	102-110
features	O	111-119
of	O	120-122
the	O	123-126
fragile	B	127-134
X	I	135-136
syndrome	I	137-145
,	O	145-146
but	O	147-150
without	O	151-158
cytogenetic	O	159-170
expression	O	171-181
of	O	182-184
the	O	185-188
fragile	B	189-196
X	I	197-198
or	O	199-201
an	O	202-204
amplified	O	205-214
CCG	O	215-218
trinucleotide	O	219-232
repeat	O	233-239
fragment	O	240-248
.	O	248-249

The	O	250-253
patient	O	254-261
has	O	262-265
a	O	266-267
previously	O	268-278
uncharacterized	O	279-294
submicroscopic	O	295-309
deletion	O	310-318
encompassing	O	319-331
the	O	332-335
CCG	O	336-339
repeat	O	340-346
,	O	346-347
the	O	348-351
entire	O	352-358
FMR1	O	359-363
gene	O	364-368
and	O	369-372
about	O	373-378
2	O	379-380
.	O	380-381
5	O	382-383
megabases	O	384-393
of	O	394-396
flanking	O	397-405
sequences	O	406-415
.	O	415-416

This	O	417-421
finding	O	422-429
confirms	O	430-438
that	O	439-443
the	O	444-447
fragile	B	448-455
X	I	456-457
phenotype	O	458-467
can	O	468-471
exist	O	472-477
,	O	477-478
without	O	479-486
amplification	O	487-500
of	O	501-503
the	O	504-507
CCG	O	508-511
repeat	O	512-518
or	O	519-521
cytogenetic	O	522-533
expression	O	534-544
of	O	545-547
the	O	548-551
fragile	B	552-559
X	I	560-561
,	O	561-562
and	O	563-566
that	O	567-571
fragile	B	572-579
X	I	580-581
syndrome	I	582-590
is	O	591-593
a	O	594-595
genetically	O	596-607
homogeneous	O	608-619
disorder	O	620-628
involving	O	629-638
FMR1	O	639-643
.	O	643-644

We	O	645-647
also	O	648-652
found	O	653-658
random	O	659-665
X	O	666-667
-	O	667-668
inactivation	O	668-680
in	O	681-683
the	O	684-687
mother	O	688-694
of	O	695-697
the	O	698-701
patient	O	702-709
who	O	710-713
was	O	714-717
shown	O	718-723
to	O	724-726
be	O	727-729
a	O	730-731
carrier	O	732-739
of	O	740-742
this	O	743-747
deletion	O	748-756
.	O	756-757

Confirmation	O	0-12
of	O	13-15
linkage	O	16-23
of	O	24-26
Van	B	27-30
der	I	31-34
Woude	I	35-40
syndrome	I	41-49
to	O	50-52
chromosome	O	53-63
1q32	O	64-68
:	O	68-69
evidence	O	70-78
of	O	79-81
association	O	82-93
with	O	94-98
STR	O	99-102
alleles	O	103-110
suggests	O	111-119
possible	O	120-128
unique	O	129-135
origin	O	136-142
of	O	143-145
the	O	146-149
disease	O	150-157
mutation	O	158-166
.	O	166-167

Van	B	168-171
der	I	172-175
Woude	I	176-181
syndrome	I	182-190
(	O	191-192
VWS	B	192-195
)	O	195-196
is	O	197-199
an	O	200-202
autosomal	B	203-212
dominant	I	213-221
craniofacial	I	222-234
disorder	I	235-243
with	O	244-248
high	O	249-253
penetrance	O	254-264
and	O	265-268
variable	O	269-277
expression	O	278-288
.	O	288-289

Its	O	290-293
clinical	O	294-302
features	O	303-311
are	O	312-315
variably	O	316-324
expressed	O	325-334
,	O	334-335
but	O	336-339
include	O	340-347
cleft	B	348-353
lip	I	354-357
and	O	358-361
/	O	361-362
or	O	362-364
cleft	B	365-370
palate	I	371-377
,	O	377-378
lip	B	379-382
pits	I	383-387
and	O	388-391
hypodontia	B	392-402
.	O	402-403

All	O	404-407
VWS	B	408-411
families	O	412-420
studied	O	421-428
to	O	429-431
date	O	432-436
map	O	437-440
the	O	441-444
disease	O	445-452
gene	O	453-457
to	O	458-460
a	O	461-462
<	O	463-464
2	O	465-466
cM	O	467-469
region	O	470-476
of	O	477-479
chromosome	O	480-490
1q32	O	491-495
,	O	495-496
with	O	497-501
no	O	502-504
evidence	O	505-513
of	O	514-516
locus	O	517-522
heterogeneity	O	523-536
.	O	536-537

The	O	538-541
aim	O	542-545
of	O	546-548
this	O	549-553
study	O	554-559
is	O	560-562
to	O	563-565
refine	O	566-572
the	O	573-576
localization	O	577-589
of	O	590-592
the	O	593-596
VWS	B	597-600
gene	O	601-605
and	O	606-609
to	O	610-612
further	O	613-620
assess	O	621-627
possible	O	628-636
heterogeneity	O	637-650
.	O	650-651

We	O	652-654
analyzed	O	655-663
four	O	664-668
multiplex	O	669-678
VWS	B	679-682
families	O	683-691
.	O	691-692

All	O	693-696
available	O	697-706
members	O	707-714
were	O	715-719
clinically	O	720-730
assessed	O	731-739
and	O	740-743
genotyped	O	744-753
for	O	754-757
19	O	758-760
short	O	761-766
tandem	O	767-773
repeat	O	774-780
markers	O	781-788
on	O	789-791
chromosome	O	792-802
1	O	803-804
in	O	805-807
the	O	808-811
VWS	B	812-815
candidate	O	816-825
gene	O	826-830
region	O	831-837
.	O	837-838

We	O	839-841
performed	O	842-851
two	O	852-855
-	O	855-856
point	O	856-861
and	O	862-865
multipoint	O	866-876
limit	O	877-882
of	O	883-885
detection	O	886-895
(	O	896-897
LOD	O	897-900
)	O	900-901
score	O	902-907
analyses	O	908-916
using	O	917-922
a	O	923-924
high	O	925-929
penetrance	O	930-940
autosomal	O	941-950
dominant	O	951-959
model	O	960-965
.	O	965-966

All	O	967-970
families	O	971-979
showed	O	980-986
positive	O	987-995
LOD	O	996-999
scores	O	1000-1006
without	O	1007-1014
any	O	1015-1018
recombination	O	1019-1032
in	O	1033-1035
the	O	1036-1039
candidate	O	1040-1049
region	O	1050-1056
.	O	1056-1057

The	O	1058-1061
largest	O	1062-1069
two	O	1070-1073
-	O	1073-1074
point	O	1074-1079
LOD	O	1080-1083
score	O	1084-1089
was	O	1090-1093
5	O	1094-1095
.	O	1095-1096
87	O	1097-1099
87	O	1100-1102
.	O	1102-1103

Our	O	1104-1107
assay	O	1108-1113
method	O	1114-1120
for	O	1121-1124
short	O	1125-1130
tandem	O	1131-1137
repeat	O	1138-1144
(	O	1145-1146
STR	O	1146-1149
)	O	1149-1150
markers	O	1151-1158
provided	O	1159-1167
highly	O	1168-1174
accurate	O	1175-1183
size	O	1184-1188
estimation	O	1189-1199
of	O	1200-1202
marker	O	1203-1209
allele	O	1210-1216
fragment	O	1217-1225
sizes	O	1226-1231
,	O	1231-1232
and	O	1233-1236
therefore	O	1237-1246
enabled	O	1247-1254
us	O	1255-1257
to	O	1258-1260
determine	O	1261-1270
the	O	1271-1274
specific	O	1275-1283
alleles	O	1284-1291
segregating	O	1292-1303
with	O	1304-1308
the	O	1309-1312
VWS	B	1313-1316
gene	O	1317-1321
in	O	1322-1324
each	O	1325-1329
of	O	1330-1332
our	O	1333-1336
four	O	1337-1341
families	O	1342-1350
.	O	1350-1351

We	O	1352-1354
observed	O	1355-1363
a	O	1364-1365
striking	O	1366-1374
pattern	O	1375-1382
of	O	1383-1385
STR	O	1386-1389
allele	O	1390-1396
sharing	O	1397-1404
at	O	1405-1407
several	O	1408-1415
closely	O	1416-1423
linked	O	1424-1430
loci	O	1431-1435
among	O	1436-1441
our	O	1442-1445
four	O	1446-1450
Caucasian	O	1451-1460
VWS	B	1461-1464
families	O	1465-1473
recruited	O	1474-1483
at	O	1484-1486
three	O	1487-1492
different	O	1493-1502
locations	O	1503-1512
in	O	1513-1515
the	O	1516-1519
US	O	1520-1522
.	O	1522-1523

These	O	1524-1529
results	O	1530-1537
suggest	O	1538-1545
the	O	1546-1549
possibility	O	1550-1561
of	O	1562-1564
a	O	1565-1566
unique	O	1567-1573
origin	O	1574-1580
for	O	1581-1584
a	O	1585-1586
mutation	O	1587-1595
responsible	O	1596-1607
for	O	1608-1611
many	O	1612-1616
or	O	1617-1619
most	O	1620-1624
cases	O	1625-1630
of	O	1631-1633
VWS	B	1634-1637
.	O	1637-1638

The	O	0-3
carrier	O	4-11
frequency	O	12-21
of	O	22-24
the	O	25-28
BRCA1	O	29-34
185delAG	O	35-43
mutation	O	44-52
is	O	53-55
approximately	O	56-69
1	O	70-71
percent	O	72-79
in	O	80-82
Ashkenazi	O	83-92
Jewish	O	93-99
individuals	O	100-111
.	O	111-112

Since	O	113-118
BRCA1	O	119-124
,	O	124-125
the	O	126-129
first	O	130-135
major	O	136-141
gene	O	142-146
responsible	O	147-158
for	O	159-162
inherited	B	163-172
breast	I	173-179
cancer	I	180-186
,	O	186-187
was	O	188-191
cloned	O	192-198
,	O	198-199
more	O	200-204
than	O	205-209
50	O	210-212
unique	O	213-219
mutations	O	220-229
have	O	230-234
been	O	235-239
detected	O	240-248
in	O	249-251
the	O	252-255
germline	O	256-264
of	O	265-267
individuals	O	268-279
with	O	280-284
breast	B	285-291
and	I	292-295
ovarian	I	296-303
cancer	I	304-310
.	O	310-311

In	O	312-314
high	O	315-319
-	O	319-320
risk	O	320-324
pedigrees	O	325-334
,	O	334-335
female	O	336-342
carriers	O	343-351
of	O	352-354
BRCA1	O	355-360
mutations	O	361-370
have	O	371-375
an	O	376-378
80	O	379-381
-	O	381-382
90	O	382-384
%	O	384-385
lifetime	O	386-394
risk	O	395-399
of	O	400-402
breast	B	403-409
cancer	I	410-416
,	O	416-417
and	O	418-421
a	O	422-423
40	O	424-426
-	O	426-427
50	O	427-429
%	O	429-430
risk	O	431-435
of	O	436-438
ovarian	B	439-446
cancer	I	447-453
.	O	453-454

However	O	455-462
,	O	462-463
the	O	464-467
mutation	O	468-476
stats	O	477-482
of	O	483-485
individuals	O	486-497
unselected	O	498-508
for	O	509-512
breast	B	513-519
or	I	520-522
ovarian	I	523-530
cancer	I	531-537
has	O	538-541
not	O	542-545
been	O	546-550
determined	O	551-561
,	O	561-562
and	O	563-566
it	O	567-569
is	O	570-572
not	O	573-576
known	O	577-582
whether	O	583-590
mutations	O	591-600
in	O	601-603
such	O	604-608
individuals	O	609-620
confer	O	621-627
the	O	628-631
same	O	632-636
risk	O	637-641
of	O	642-644
cancer	B	645-651
as	O	652-654
in	O	655-657
individuals	O	658-669
from	O	670-674
the	O	675-678
high	O	679-683
-	O	683-684
risk	O	684-688
families	O	689-697
studied	O	698-705
so	O	706-708
far	O	709-712
.	O	712-713

Following	O	714-723
the	O	724-727
finding	O	728-735
of	O	736-738
a	O	739-740
185delAG	O	741-749
frameshift	O	750-760
mutation	O	761-769
in	O	770-772
several	O	773-780
Ashkenazi	O	781-790
Jewish	O	791-797
breast	O	798-804
/	O	804-805
ovarian	O	805-812
families	O	813-821
,	O	821-822
we	O	823-825
have	O	826-830
determined	O	831-841
the	O	842-845
frequency	O	846-855
of	O	856-858
this	O	859-863
mutation	O	864-872
in	O	873-875
858	O	876-879
Ashkenazim	O	880-890
seeking	O	891-898
genetic	O	899-906
testing	O	907-914
for	O	915-918
conditions	O	919-929
unrelated	O	930-939
to	O	940-942
cancer	B	943-949
,	O	949-950
and	O	951-954
in	O	955-957
815	O	958-961
reference	O	962-971
individuals	O	972-983
not	O	984-987
selected	O	988-996
for	O	997-1000
ethnic	O	1001-1007
origin	O	1008-1014
.	O	1014-1015

We	O	1016-1018
observed	O	1019-1027
the	O	1028-1031
185delAG	O	1032-1040
mutation	O	1041-1049
in	O	1050-1052
0	O	1053-1054
.	O	1054-1055
9	O	1056-1057
%	O	1057-1058
of	O	1059-1061
Ashkenazim	O	1062-1072
(	O	1073-1074
95	O	1074-1076
%	O	1076-1077
confidence	O	1078-1088
limit	O	1089-1094
,	O	1094-1095
0	O	1096-1097
.	O	1097-1098
4	O	1099-1100
-	O	1100-1101
1	O	1101-1102
.	O	1102-1103

8	O	1104-1105
%	O	1105-1106
)	O	1106-1107
and	O	1108-1111
in	O	1112-1114
none	O	1115-1119
of	O	1120-1122
the	O	1123-1126
reference	O	1127-1136
samples	O	1137-1144
.	O	1144-1145

Our	O	1146-1149
results	O	1150-1157
suggest	O	1158-1165
that	O	1166-1170
one	O	1171-1174
in	O	1175-1177
a	O	1178-1179
hundred	O	1180-1187
women	O	1188-1193
of	O	1194-1196
Ashkenazi	O	1197-1206
descent	O	1207-1214
may	O	1215-1218
be	O	1219-1221
at	O	1222-1224
especially	O	1225-1235
high	O	1236-1240
risk	O	1241-1245
of	O	1246-1248
developing	O	1249-1259
breast	B	1260-1266
and	I	1267-1270
/	I	1270-1271
or	I	1271-1273
ovarian	I	1274-1281
cancer	I	1282-1288
.	O	1288-1289

Targeted	O	0-8
modification	O	9-21
of	O	22-24
the	O	25-28
apolipoprotein	O	29-43
B	O	44-45
gene	O	46-50
results	O	51-58
in	O	59-61
hypobetalipoproteinemia	B	62-85
and	O	86-89
developmental	B	90-103
abnormalities	I	104-117
in	O	118-120
mice	O	121-125
.	O	125-126

Familial	B	127-135
hypobetalipoproteinemia	I	136-159
is	O	160-162
an	O	163-165
autosomal	B	166-175
codominant	I	176-186
disorder	I	187-195
resulting	O	196-205
in	O	206-208
a	O	209-210
dramatic	O	211-219
reduction	O	220-229
in	O	230-232
plasma	O	233-239
concentrations	O	240-254
of	O	255-257
apolipoprotein	O	258-272
(	O	273-274
apo	O	274-277
)	O	277-278
B	O	279-280
,	O	280-281
cholesterol	O	282-293
,	O	293-294
and	O	295-298
beta	O	299-303
-	O	303-304
migrating	O	304-313
lipoproteins	O	314-326
.	O	326-327

A	O	328-329
benefit	O	330-337
of	O	338-340
hypobetalipoproteinemia	B	341-364
is	O	365-367
that	O	368-372
mildly	O	373-379
affected	O	380-388
individuals	O	389-400
may	O	401-404
be	O	405-407
protected	O	408-417
from	O	418-422
coronary	B	423-431
vascular	I	432-440
disease	I	441-448
.	O	448-449

We	O	450-452
have	O	453-457
used	O	458-462
gene	O	463-467
targeting	O	468-477
to	O	478-480
generate	O	481-489
mice	O	490-494
with	O	495-499
a	O	500-501
modified	O	502-510
Apob	O	511-515
allele	O	516-522
.	O	522-523

Mice	O	524-528
containing	O	529-539
this	O	540-544
allele	O	545-551
display	O	552-559
all	O	560-563
of	O	564-566
the	O	567-570
hallmarks	O	571-580
of	O	581-583
human	O	584-589
hypobetalipoproteinemia	B	590-613
they	O	615-619
produce	O	620-627
a	O	628-629
truncated	O	630-639
apoB	O	640-644
protein	O	645-652
,	O	652-653
apoB70	O	654-660
,	O	660-661
and	O	662-665
have	O	666-670
markedly	O	671-679
decreased	O	680-689
plasma	O	690-696
concentrations	O	697-711
of	O	712-714
apoB	O	715-719
,	O	719-720
beta	O	721-725
-	O	725-726
lipoproteins	O	726-738
,	O	738-739
and	O	740-743
total	O	744-749
cholesterol	O	750-761
.	O	761-762

In	O	763-765
addition	O	766-774
,	O	774-775
the	O	776-779
mice	O	780-784
manifest	O	785-793
several	O	794-801
characteristics	O	802-817
that	O	818-822
are	O	823-826
occasionally	O	827-839
observed	O	840-848
in	O	849-851
human	O	852-857
hypobetalipoproteinemia	B	858-881
,	O	881-882
including	O	883-892
reduced	O	893-900
plasma	O	901-907
triglyceride	O	908-920
concentrations	O	921-935
,	O	935-936
fasting	O	937-944
chylomicronemia	B	945-960
,	O	960-961
and	O	962-965
reduced	O	966-973
high	O	974-978
density	O	979-986
lipoprotein	O	987-998
cholesterol	O	999-1010
.	O	1010-1011

An	O	1012-1014
unexpected	O	1015-1025
finding	O	1026-1033
is	O	1034-1036
that	O	1037-1041
the	O	1042-1045
modified	O	1046-1054
Apob	O	1055-1059
allele	O	1060-1066
is	O	1067-1069
strongly	O	1070-1078
associated	O	1079-1089
with	O	1090-1094
exencephalus	B	1095-1107
and	O	1108-1111
hydrocephalus	B	1112-1125
.	O	1125-1126

These	O	1127-1132
mice	O	1133-1137
should	O	1138-1144
help	O	1145-1149
increase	O	1150-1158
our	O	1159-1162
understanding	O	1163-1176
of	O	1177-1179
hypobetalipoproteinemia	B	1180-1203
,	O	1203-1204
atherogenesis	B	1205-1218
,	O	1218-1219
and	O	1220-1223
the	O	1224-1227
etiology	O	1228-1236
of	O	1237-1239
exencephalus	B	1240-1252
and	O	1253-1256
hydrocephalus	B	1257-1270
.	O	1270-1271
.	O	1270-1271

Common	O	0-6
mutations	O	7-16
in	O	17-19
BRCA1	O	20-25
and	O	26-29
BRCA2	O	30-35
do	O	36-38
not	O	39-42
contribute	O	43-53
to	O	54-56
early	O	57-62
prostate	B	63-71
cancer	I	72-78
in	O	79-81
Jewish	O	82-88
men	O	89-92
.	O	92-93

BACKGROUND	O	94-104
Families	O	106-114
with	O	115-119
a	O	120-121
high	O	122-126
incidence	O	127-136
of	O	137-139
hereditary	B	140-150
breast	I	151-157
cancer	I	158-164
,	O	164-165
and	O	166-169
subsequently	O	170-182
shown	O	183-188
to	O	189-191
have	O	192-196
terminating	O	197-208
mutations	O	209-218
in	O	219-221
BRCA1	O	222-227
or	O	228-230
BRCA2	O	231-236
,	O	236-237
appear	O	238-244
to	O	245-247
have	O	248-252
a	O	253-254
higher	O	255-261
incidence	O	262-271
of	O	272-274
prostate	B	275-283
cancer	I	284-290
among	O	291-296
male	O	297-301
relatives	O	302-311
.	O	311-312

We	O	313-315
aimed	O	316-321
to	O	322-324
determine	O	325-334
whether	O	335-342
the	O	343-346
common	O	347-353
germline	O	354-362
mutations	O	363-372
of	O	373-375
BRCA1	O	376-381
or	O	382-384
BRCA2	O	385-390
in	O	391-393
Ashkenazi	O	394-403
Jewish	O	404-410
men	O	411-414
predisposed	O	415-426
them	O	427-431
to	O	432-434
prostate	B	435-443
cancer	I	444-450
.	O	450-451

METHODS	O	452-459
We	O	461-463
examined	O	464-472
genomic	O	473-480
DNA	O	481-484
from	O	485-489
83	O	490-492
(	O	493-494
for	O	494-497
BRCA1	O	498-503
185delAG	O	504-512
)	O	512-513
or	O	514-516
82	O	517-519
(	O	520-521
for	O	521-524
BRCA2	O	525-530
6174delT	O	531-539
)	O	539-540
Ashkenazi	O	541-550
Jewish	O	551-557
prostate	B	558-566
cancer	I	567-573
patients	O	574-582
,	O	582-583
most	O	584-588
of	O	589-591
whom	O	592-596
were	O	597-601
treated	O	602-609
at	O	610-612
a	O	613-614
relatively	O	615-625
young	O	626-631
age	O	632-635
,	O	635-636
for	O	637-640
the	O	641-644
most	O	645-649
common	O	650-656
germline	O	657-665
mutation	O	666-674
in	O	675-677
each	O	678-682
gene	O	683-687
seen	O	688-692
in	O	693-695
the	O	696-699
Ashkenazi	O	700-709
population	O	710-720
.	O	720-721

RESULTS	O	722-729
Our	O	731-734
study	O	735-740
should	O	741-747
have	O	748-752
been	O	753-757
able	O	758-762
to	O	763-765
detect	O	766-772
a	O	773-774
4	O	775-776
-	O	776-777
5	O	777-778
-	O	776-777
fold	O	779-783
increase	O	784-792
in	O	793-795
the	O	796-799
risk	O	800-804
of	O	805-807
prostate	B	808-816
cancer	I	817-823
due	O	824-827
to	O	828-830
mutation	O	831-839
of	O	840-842
BRCA1	O	843-848
or	O	849-851
BRCA2	O	852-857
.	O	857-858

However	O	859-866
,	O	866-867
only	O	868-872
one	O	873-876
(	O	877-878
1	O	878-879
.	O	879-880

15	O	881-883
%	O	883-884
;	O	884-885
95	O	886-888
%	O	888-889
confidence	O	890-900
interval	O	901-909
,	O	909-910
0	O	911-912
-	O	912-913
3	O	913-914
.	O	914-915

6	O	916-917
%	O	917-918
)	O	918-919
of	O	920-922
the	O	923-926
patients	O	927-935
was	O	936-939
heterozygous	O	940-952
for	O	953-956
the	O	957-960
BRCA1	O	961-966
mutant	O	967-973
allele	O	974-980
,	O	980-981
and	O	982-985
only	O	986-990
two	O	991-994
were	O	995-999
heterozygous	O	1000-1012
for	O	1013-1016
the	O	1017-1020
BRCA2	O	1021-1026
mutation	O	1027-1035
(	O	1036-1037
2	O	1037-1038
.	O	1038-1039

4	O	1040-1041
%	O	1041-1042
;	O	1042-1043
95	O	1044-1046
%	O	1046-1047
confidence	O	1048-1058
interval	O	1059-1067
,	O	1067-1068
0	O	1069-1070
-	O	1070-1071
6	O	1071-1072
.	O	1072-1073

2	O	1074-1075
%	O	1075-1076
)	O	1076-1077
.	O	1077-1078

CONCLUSIONS	O	1079-1090
The	O	1092-1095
incidence	O	1096-1105
of	O	1106-1108
each	O	1109-1113
of	O	1114-1116
the	O	1117-1120
germline	O	1121-1129
mutations	O	1130-1139
in	O	1140-1142
these	O	1143-1148
prostate	B	1149-1157
cancer	I	1158-1164
patients	O	1165-1173
closely	O	1174-1181
matched	O	1182-1189
their	O	1190-1195
incidence	O	1196-1205
(	O	1206-1207
about	O	1207-1212
1	O	1213-1214
%	O	1214-1215
)	O	1215-1216
in	O	1217-1219
the	O	1220-1223
general	O	1224-1231
Ashkenazi	O	1232-1241
Jewish	O	1242-1248
population	O	1249-1259
.	O	1259-1260

This	O	1261-1265
suggests	O	1266-1274
that	O	1275-1279
unlike	O	1280-1286
cases	O	1287-1292
of	O	1293-1295
breast	B	1296-1302
and	I	1303-1306
ovarian	I	1307-1314
cancers	I	1315-1322
,	O	1322-1323
mutations	O	1324-1333
in	O	1334-1336
BRCA1	O	1337-1342
or	O	1343-1345
BRCA2	O	1346-1351
do	O	1352-1354
not	O	1355-1358
significantly	O	1359-1372
predispose	O	1373-1383
men	O	1384-1387
to	O	1388-1390
prostate	B	1391-1399
cancer	I	1400-1406

Two	O	0-3
new	O	4-7
variants	O	8-16
of	O	17-19
glucose	O	20-27
-	O	27-28
6	O	28-29
-	O	27-28
phosphate	O	30-39
dehydrogenase	O	40-53
associated	O	54-64
with	O	65-69
hereditary	B	70-80
non	I	81-84
-	I	84-85
spherocytic	I	85-96
hemolytic	I	97-106
anemia	I	107-113
:	O	113-114
G6PD	O	115-119
Wayne	O	120-125
and	O	126-129
G6PD	O	130-134
Huron	O	135-140
.	O	140-141

Two	O	142-145
new	O	146-149
deficient	O	150-159
variants	O	160-168
of	O	169-171
glucose	O	172-179
-	O	179-180
6	O	180-181
-	O	179-180
phosphate	O	182-191
dehydrogenase	O	192-205
(	O	206-207
G6PD	O	207-211
)	O	211-212
causing	O	213-220
hereditary	B	221-231
nonspherocytic	I	232-246
hemolytic	I	247-256
anemia	I	257-263
(	O	264-265
HNSHA	B	265-270
)	O	270-271
are	O	272-275
described	O	276-285
.	O	285-286

Both	O	287-291
of	O	292-294
these	O	295-300
are	O	301-304
unique	O	305-311
and	O	312-315
they	O	316-320
have	O	321-325
been	O	326-330
named	O	331-336
G6PD	O	337-341
Wayne	O	342-347
and	O	348-351
G6PD	O	352-356
Huron	O	357-362
.	O	362-363

Patients	O	364-372
with	O	373-377
G6PD	O	378-382
Wayne	O	383-388
underwent	O	389-398
splenectomy	O	399-410
and	O	411-414
no	O	415-417
objective	O	418-427
improvement	O	428-439
was	O	440-443
noted	O	444-449
.	O	449-450

The	O	451-454
patients	O	455-463
with	O	464-468
G6PD	O	469-473
Huron	O	474-479
were	O	480-484
under	O	485-490
medical	O	491-498
observation	O	499-510
for	O	511-514
a	O	515-516
considerable	O	517-529
period	O	530-536
of	O	537-539
time	O	540-544
without	O	545-552
the	O	553-556
diagnosis	O	557-566
of	O	567-569
G6PD	B	570-574
deficiency	I	575-585
being	O	586-591
entertained	O	592-603
because	O	604-611
the	O	612-615
family	O	616-622
was	O	623-626
of	O	627-629
Northern	O	630-638
European	O	639-647
origin	O	648-654
.	O	654-655

Since	O	656-661
sporadic	O	662-670
variants	O	671-679
of	O	680-682
G6PD	O	683-687
causing	O	688-695
HNSHA	B	696-701
show	O	702-706
no	O	707-709
special	O	710-717
racial	O	718-724
predilection	O	725-737
,	O	737-738
the	O	739-742
diagnosis	O	743-752
of	O	753-755
G6PD	B	756-760
deficiency	I	761-771
should	O	772-778
always	O	779-785
be	O	786-788
considered	O	789-799
in	O	800-802
patients	O	803-811
with	O	812-816
this	O	817-821
syndrome	O	822-830
.	O	830-831
.	O	830-831

The	O	0-3
Tay	B	4-7
-	I	7-8
Sachs	I	8-13
disease	I	14-21
gene	O	22-26
in	O	27-29
North	O	30-35
American	O	36-44
Jewish	O	45-51
populations	O	52-63
:	O	63-64
geographic	O	65-75
variations	O	76-86
and	O	87-90
origin	O	91-97
.	O	97-98

From	O	99-103
data	O	104-108
collected	O	109-118
in	O	119-121
a	O	122-123
North	O	124-129
American	O	130-138
Tay	B	139-142
-	I	142-143
Sachs	I	143-148
disease	I	149-156
(	O	157-158
TSD	B	158-161
)	O	161-162
heterozygote	O	163-175
screening	O	176-185
program	O	186-193
,	O	193-194
the	O	195-198
TSD	B	199-202
carrier	O	203-210
frequency	O	211-220
among	O	221-226
46	O	227-229
,	O	229-230
304	O	231-234
Jewish	O	235-241
individuals	O	242-253
was	O	254-257
found	O	258-263
to	O	264-266
be	O	267-269
.	O	269-270

0324	O	271-275
(	O	276-277
1	O	277-278
in	O	279-281
31	O	282-284
individuals	O	285-296
)	O	296-297
.	O	297-298

This	O	299-303
frequency	O	304-313
is	O	314-316
consistent	O	317-327
with	O	328-332
earlier	O	333-340
estimates	O	341-350
based	O	351-356
on	O	357-359
TSD	B	360-363
incidence	O	364-373
data	O	374-378
.	O	378-379

TSD	B	380-383
carrier	O	384-391
frequencies	O	392-403
were	O	404-408
then	O	409-413
examined	O	414-422
by	O	423-425
single	O	426-432
country	O	433-440
and	O	441-444
single	O	445-451
region	O	452-458
of	O	459-461
origin	O	462-468
in	O	469-471
28	O	472-474
,	O	474-475
029	O	476-479
Jews	O	480-484
within	O	485-491
this	O	492-496
sample	O	497-503
for	O	504-507
whom	O	508-512
such	O	513-517
data	O	518-522
were	O	523-527
available	O	528-537
for	O	538-541
analysis	O	542-550
.	O	550-551

Jews	O	552-556
with	O	557-561
Polish	O	562-568
and	O	569-572
/	O	572-573
or	O	573-575
Russian	O	576-583
ancestry	O	584-592
constituted	O	593-604
88	O	605-607
%	O	607-608
of	O	609-611
this	O	612-616
sample	O	617-623
and	O	624-627
had	O	628-631
a	O	632-633
TSD	B	634-637
carrier	O	638-645
frequency	O	646-655
of	O	656-658
.	O	658-659

0327	O	660-664
.	O	664-665

No	O	666-668
TSD	B	669-672
carriers	O	673-681
were	O	682-686
observed	O	687-695
among	O	696-701
the	O	702-705
166	O	706-709
Jews	O	710-714
of	O	715-717
Near	O	718-722
Eastern	O	723-730
origins	O	731-738
.	O	738-739

Relative	O	740-748
to	O	749-751
Jews	O	752-756
of	O	757-759
Polish	O	760-766
and	O	767-770
Russian	O	771-778
origins	O	779-786
,	O	786-787
there	O	788-793
was	O	794-797
at	O	798-800
least	O	801-806
a	O	807-808
twofold	O	809-816
increase	O	817-825
in	O	826-828
the	O	829-832
TSD	B	833-836
carrier	O	837-844
frequency	O	845-854
in	O	855-857
Jews	O	858-862
of	O	863-865
Austrian	O	866-874
,	O	874-875
Hungarian	O	876-885
,	O	885-886
and	O	887-890
Czechoslovakian	O	891-906
origins	O	907-914
(	O	915-916
P	O	916-917
less	O	918-922
than	O	923-927
.	O	927-928

005	O	929-932
)	O	932-933
.	O	933-934

These	O	935-940
findings	O	941-949
suggest	O	950-957
that	O	958-962
the	O	963-966
TSD	B	967-970
gene	O	971-975
proliferated	O	976-988
among	O	989-994
the	O	995-998
antecedents	O	999-1010
of	O	1011-1013
modern	O	1014-1020
Ashkenazi	O	1021-1030
Jewry	O	1031-1036
after	O	1037-1042
the	O	1043-1046
Second	O	1047-1053
Diaspora	O	1054-1062
(	O	1063-1064
70	O	1064-1066
A	O	1067-1068
.	O	1068-1069
D	O	1070-1071
.	O	1071-1072
)	O	1072-1073
and	O	1074-1077
before	O	1078-1084
their	O	1085-1090
major	O	1091-1096
migrations	O	1097-1107
to	O	1108-1110
regions	O	1111-1118
of	O	1119-1121
Poland	O	1122-1128
and	O	1129-1132
Russia	O	1133-1139
(	O	1140-1141
before	O	1141-1147
1100	O	1148-1152
A	O	1153-1154
.	O	1154-1155
D	O	1156-1157
.	O	1157-1158
)	O	1158-1159
.	O	1157-1158

Novel	O	0-5
inherited	O	6-15
mutations	O	16-25
and	O	26-29
variable	O	30-38
expressivity	O	39-51
of	O	52-54
BRCA1	O	55-60
alleles	O	61-68
,	O	68-69
including	O	70-79
the	O	80-83
founder	O	84-91
mutation	O	92-100
185delAG	O	101-109
in	O	110-112
Ashkenazi	O	113-122
Jewish	O	123-129
families	O	130-138
.	O	138-139

Thirty	O	140-146
-	O	146-147
seven	O	147-152
families	O	153-161
with	O	162-166
four	O	167-171
or	O	172-174
more	O	175-179
cases	O	180-185
of	O	186-188
breast	B	189-195
cancer	I	196-202
or	O	203-205
breast	B	206-212
and	I	213-216
ovarian	I	217-224
cancer	I	225-231
were	O	232-236
analyzed	O	237-245
for	O	246-249
mutations	O	250-259
in	O	260-262
BRCA1	O	263-268
.	O	268-269

Twelve	O	270-276
different	O	277-286
germ	O	287-291
-	O	291-292
line	O	292-296
mutations	O	297-306
,	O	306-307
four	O	308-312
novel	O	313-318
and	O	319-322
eight	O	323-328
previously	O	329-339
observed	O	340-348
,	O	348-349
were	O	350-354
detected	O	355-363
in	O	364-366
16	O	367-369
families	O	370-378
.	O	378-379

Five	O	380-384
families	O	385-393
of	O	394-396
Ashkenazi	O	397-406
Jewish	O	407-413
descent	O	414-421
carried	O	422-429
the	O	430-433
185delAG	O	434-442
mutation	O	443-451
and	O	452-455
shared	O	456-462
the	O	463-466
same	O	467-471
haplotype	O	472-481
at	O	482-484
eight	O	485-490
polymorphic	O	491-502
markers	O	503-510
spanning	O	511-519
approximately	O	520-533
850	O	534-537
kb	O	538-540
at	O	541-543
BRCA1	O	544-549
.	O	549-550

Expressivity	O	551-563
of	O	564-566
185delAG	O	567-575
in	O	576-578
these	O	579-584
families	O	585-593
varied	O	594-600
,	O	600-601
from	O	602-606
early	O	607-612
-	O	612-613
onset	O	613-618
breast	B	619-625
cancer	I	626-632
without	O	633-640
ovarian	B	641-648
cancer	I	649-655
.	O	655-656

Mutation	O	657-665
4184delTCAA	O	666-677
occurred	O	678-686
independently	O	687-700
in	O	701-703
two	O	704-707
families	O	708-716
.	O	716-717

In	O	718-720
one	O	721-724
family	O	725-731
,	O	731-732
penetrance	O	733-743
was	O	744-747
complete	O	748-756
,	O	756-757
with	O	758-762
females	O	763-770
developing	O	771-781
early	O	782-787
-	O	787-788
onset	O	788-793
breast	B	794-800
cancer	I	801-807
or	O	808-810
ovarian	B	811-818
cancer	I	819-825
and	O	826-829
the	O	830-833
male	O	834-838
carrier	O	839-846
developing	O	847-857
prostatic	B	858-867
cancer	I	868-874
,	O	874-875
whereas	O	876-883
,	O	883-884
in	O	885-887
the	O	888-891
other	O	892-897
family	O	898-904
,	O	904-905
penetrance	O	906-916
was	O	917-920
incomplete	O	921-931
and	O	932-935
only	O	936-940
breast	B	941-947
cancer	I	948-954
occurred	O	955-963
,	O	963-964
diagnosed	O	965-974
at	O	975-977
ages	O	978-982
38	O	983-985
-	O	985-986
81	O	986-988
years	O	989-994
.	O	994-995

Two	O	996-999
novel	O	1000-1005
nonsense	O	1006-1014
mutations	O	1015-1024
led	O	1025-1028
to	O	1029-1031
the	O	1032-1035
loss	O	1036-1040
of	O	1041-1043
mutant	O	1044-1050
BRCA1	O	1051-1056
transcript	O	1057-1067
in	O	1068-1070
families	O	1071-1079
with	O	1080-1084
10	O	1085-1087
and	O	1088-1091
6	O	1092-1093
cases	O	1094-1099
of	O	1100-1102
early	O	1103-1108
-	O	1108-1109
onset	O	1109-1114
breast	B	1115-1121
cancer	I	1122-1128
and	O	1129-1132
ovarian	B	1133-1140
cancer	I	1141-1147
.	O	1147-1148

A	O	1149-1150
665	O	1151-1154
-	O	1154-1155
nt	O	1155-1157
segment	O	1158-1165
of	O	1166-1168
the	O	1169-1172
BRCA1	O	1173-1178
3	O	1179-1180
-	O	1180-1181
UTR	O	1181-1184
and	O	1185-1188
1	O	1189-1190
.	O	1190-1191
3	O	1192-1193
kb	O	1194-1196
of	O	1197-1199
genomic	O	1200-1207
sequence	O	1208-1216
including	O	1217-1226
the	O	1227-1230
putative	O	1231-1239
promoter	O	1240-1248
region	O	1249-1255
were	O	1256-1260
invariant	O	1261-1270
by	O	1271-1273
single	O	1274-1280
-	O	1280-1281
strand	O	1281-1287
conformation	O	1288-1300
analysis	O	1301-1309
in	O	1310-1312
13	O	1313-1315
families	O	1316-1324
without	O	1325-1332
coding	O	1333-1339
-	O	1339-1340
sequence	O	1340-1348
mutations	O	1349-1358
.	O	1358-1359

Overall	O	1360-1367
in	O	1368-1370
our	O	1371-1374
series	O	1375-1381
,	O	1381-1382
BRCA1	O	1383-1388
mutations	O	1389-1398
have	O	1399-1403
been	O	1404-1408
detected	O	1409-1417
in	O	1418-1420
26	O	1421-1423
families	O	1424-1432
16	O	1434-1436
with	O	1437-1441
positive	O	1442-1450
BRCA1	O	1451-1456
lod	O	1457-1460
scores	O	1461-1467
,	O	1467-1468
7	O	1469-1470
with	O	1471-1475
negative	O	1476-1484
lod	O	1485-1488
scores	O	1489-1495
(	O	1496-1497
reflecting	O	1497-1507
multiple	O	1508-1516
sporadic	O	1517-1525
breast	B	1526-1532
cancers	I	1533-1540
)	O	1540-1541
,	O	1541-1542
and	O	1543-1546
3	O	1547-1548
not	O	1549-1552
tested	O	1553-1559
for	O	1560-1563
linkage	O	1564-1571
.	O	1571-1572

Three	O	1573-1578
other	O	1579-1584
families	O	1585-1593
have	O	1594-1598
positive	O	1599-1607
lod	O	1608-1611
scores	O	1612-1618
for	O	1619-1622
linkage	O	1623-1630
to	O	1631-1633
BRCA2	O	1634-1639
,	O	1639-1640
but	O	1641-1644
13	O	1645-1647
families	O	1648-1656
without	O	1657-1664
detected	O	1665-1673
BRCA1	O	1674-1679
mutations	O	1680-1689
have	O	1690-1694
negative	O	1695-1703
lod	O	1704-1707
scores	O	1708-1714
for	O	1715-1718
both	O	1719-1723
BRCA1	O	1724-1729
and	O	1730-1733
BRCA2	O	1734-1739
.	O	1739-1740

Transgenic	O	0-10
mice	O	11-15
carrying	O	16-24
large	O	25-30
human	O	31-36
genomic	O	37-44
sequences	O	45-54
with	O	55-59
expanded	O	60-68
CTG	O	69-72
repeat	O	73-79
mimic	O	80-85
closely	O	86-93
the	O	94-97
DM	B	98-100
CTG	O	101-104
repeat	O	105-111
intergenerational	O	112-129
and	O	130-133
somatic	O	134-141
instability	O	142-153
.	O	153-154

Myotonic	B	155-163
dystrophy	I	164-173
(	O	174-175
DM	B	175-177
)	O	177-178
is	O	179-181
caused	O	182-188
by	O	189-191
a	O	192-193
CTG	O	194-197
repeat	O	198-204
expansion	O	205-214
in	O	215-217
the	O	218-221
3UTR	O	222-226
of	O	227-229
the	O	230-233
DM	B	234-236
protein	O	237-244
kinase	O	245-251
(	O	252-253
DMPK	O	253-257
)	O	257-258
gene	O	259-263
.	O	263-264

A	O	265-266
very	O	267-271
high	O	272-276
level	O	277-282
of	O	283-285
instability	O	286-297
is	O	298-300
observed	O	301-309
through	O	310-317
successive	O	318-328
generations	O	329-340
and	O	341-344
the	O	345-348
size	O	349-353
of	O	354-356
the	O	357-360
repeat	O	361-367
is	O	368-370
generally	O	371-380
correlated	O	381-391
with	O	392-396
the	O	397-400
severity	O	401-409
of	O	410-412
the	O	413-416
disease	O	417-424
and	O	425-428
with	O	429-433
age	O	434-437
at	O	438-440
onset	O	441-446
.	O	446-447

Furthermore	O	448-459
,	O	459-460
tissues	O	461-468
from	O	469-473
DM	B	474-476
patients	O	477-485
exhibit	O	486-493
somatic	O	494-501
mosaicism	O	502-511
that	O	512-516
increases	O	517-526
with	O	527-531
age	O	532-535
.	O	535-536

We	O	537-539
generated	O	540-549
transgenic	O	550-560
mice	O	561-565
carrying	O	566-574
large	O	575-580
human	O	581-586
genomic	O	587-594
sequences	O	595-604
with	O	605-609
20	O	610-612
,	O	612-613
55	O	614-616
or	O	617-619
>	O	620-621
300	O	622-625
CTG	O	626-629
,	O	629-630
cloned	O	631-637
from	O	638-642
patients	O	643-651
from	O	652-656
the	O	657-660
same	O	661-665
affected	O	666-674
DM	B	675-677
family	O	678-684
.	O	684-685

Using	O	686-691
large	O	692-697
human	O	698-703
flanking	O	704-712
sequences	O	713-722
and	O	723-726
a	O	727-728
large	O	729-734
amplification	O	735-748
,	O	748-749
we	O	750-752
demonstrate	O	753-764
that	O	765-769
the	O	770-773
intergenerational	O	774-791
CTG	O	792-795
repeat	O	796-802
instability	O	803-814
is	O	815-817
reproduced	O	818-828
in	O	829-831
mice	O	832-836
,	O	836-837
with	O	838-842
a	O	843-844
strong	O	845-851
bias	O	852-856
towards	O	857-864
expansions	O	865-875
and	O	876-879
with	O	880-884
the	O	885-888
same	O	889-893
sex	O	894-897
-	O	897-898
and	O	899-902
size	O	903-907
-	O	907-908
dependent	O	908-917
characteristics	O	918-933
as	O	934-936
in	O	937-939
humans	O	940-946
.	O	946-947

Moreover	O	948-956
,	O	956-957
a	O	958-959
high	O	960-964
level	O	965-970
of	O	971-973
instability	O	974-985
,	O	985-986
increasing	O	987-997
with	O	998-1002
age	O	1003-1006
,	O	1006-1007
can	O	1008-1011
be	O	1012-1014
observed	O	1015-1023
in	O	1024-1026
tissues	O	1027-1034
and	O	1035-1038
in	O	1039-1041
sperm	O	1042-1047
.	O	1047-1048

Although	O	1049-1057
we	O	1058-1060
did	O	1061-1064
not	O	1065-1068
observe	O	1069-1076
dramatic	O	1077-1085
expansions	O	1086-1096
(	O	1097-1098
or	O	1098-1100
big	O	1101-1104
jumps	O	1105-1110
over	O	1111-1115
several	O	1116-1123
hundred	O	1124-1131
CTG	O	1132-1135
repeats	O	1136-1143
)	O	1143-1144
as	O	1145-1147
in	O	1148-1150
congenital	O	1151-1161
forms	O	1162-1167
of	O	1168-1170
DM	B	1171-1173
,	O	1173-1174
our	O	1175-1178
model	O	1179-1184
carrying	O	1185-1193
>	O	1194-1195
300	O	1196-1199
CTG	O	1200-1203
is	O	1204-1206
the	O	1207-1210
first	O	1211-1216
to	O	1217-1219
show	O	1220-1224
instability	O	1225-1236
so	O	1237-1239
close	O	1240-1245
to	O	1246-1248
the	O	1249-1252
human	O	1253-1258
DM	B	1259-1261
situation	O	1262-1271
.	O	1271-1272

Our	O	1273-1276
three	O	1277-1282
models	O	1283-1289
carrying	O	1290-1298
different	O	1299-1308
sizes	O	1309-1314
of	O	1315-1317
CTG	O	1318-1321
repeat	O	1322-1328
provide	O	1329-1336
insight	O	1337-1344
on	O	1345-1347
the	O	1348-1351
different	O	1352-1361
factors	O	1362-1369
modulating	O	1370-1380
the	O	1381-1384
CTG	O	1385-1388
repeat	O	1389-1395
instability	O	1396-1407
.	O	1407-1408
.	O	1407-1408

Linkage	O	0-7
of	O	8-10
gene	O	11-15
for	O	16-19
C2	B	20-22
deficiency	I	23-33
and	O	34-37
the	O	38-41
major	O	42-47
histocompatibility	O	48-66
complex	O	67-74
MHC	O	75-78
in	O	79-81
man	O	82-85
.	O	85-86

Family	O	87-93
study	O	94-99
of	O	100-102
a	O	103-104
further	O	105-112
case	O	113-117
.	O	117-118

Close	O	119-124
linkage	O	125-132
between	O	133-140
HL	O	141-143
-	O	143-144
A	O	144-145
and	O	146-149
C2	B	150-152
deficiency	I	153-163
was	O	164-167
first	O	168-173
reported	O	174-182
by	O	183-185
FU	O	186-188
and	O	189-192
co	O	193-195
-	O	195-196
workers	O	196-203
in	O	204-206
1974	O	207-211
.	O	211-212

We	O	213-215
present	O	216-223
here	O	224-228
a	O	229-230
pedigree	O	231-239
of	O	240-242
a	O	243-244
31	O	245-247
-	O	247-248
year	O	248-252
-	O	247-248
old	O	253-256
C2	B	257-259
-	I	259-260
deficient	I	260-269
individual	O	270-280
with	O	281-285
clinical	O	286-294
manifestations	O	295-309
of	O	310-312
Hodgkins	B	313-321
disease	I	322-329
.	O	329-330

The	O	331-334
following	O	335-344
markers	O	345-352
were	O	353-357
tested	O	358-364
C2	O	366-368
levels	O	369-375
,	O	375-376
factor	O	377-383
B	O	384-385
polymorphism	O	386-398
,	O	398-399
blood	O	400-405
groups	O	406-412
,	O	412-413
and	O	414-417
enzyme	O	418-424
typing	O	425-431
.	O	431-432

In	O	433-435
addition	O	436-444
to	O	445-447
close	O	448-453
linkage	O	454-461
between	O	462-469
HL	O	470-472
-	O	472-473
A	O	473-474
and	O	475-478
C2	B	479-481
deficiency	I	482-492
,	O	492-493
both	O	494-498
parents	O	499-506
were	O	507-511
heterozygous	O	512-524
for	O	525-528
Bf	O	529-531
(	O	532-533
HL	O	533-535
-	O	535-536
A	O	536-537
linked	O	538-544
,	O	544-545
electrophoretic	O	546-561
variation	O	562-571
of	O	572-574
B	O	575-576
)	O	576-577
.	O	577-578

The	O	579-582
two	O	583-586
HL	O	587-589
-	O	589-590
A	O	590-591
haplotypes	O	592-602
closely	O	603-610
linked	O	611-617
to	O	618-620
C2	B	621-623
deficiency	I	624-634
are	O	635-638
different	O	639-648
2	O	650-651
,	O	651-652
W18	O	653-656
and	O	657-660
W24	O	661-664
,	O	664-665
W18	O	666-669
.	O	669-670

They	O	671-675
share	O	676-681
,	O	681-682
however	O	683-690
,	O	690-691
the	O	692-695
SD2	O	696-699
antigen	O	700-707
W18	O	708-711
and	O	712-715
the	O	716-719
LD	O	720-722
type	O	723-727
7a	O	728-730
.	O	730-731
.	O	730-731

Age	O	0-3
of	O	4-6
onset	O	7-12
in	O	13-15
Huntington	B	16-26
disease	I	27-34
:	O	35-36
sex	O	37-40
specific	O	41-49
influence	O	50-59
of	O	60-62
apolipoprotein	O	63-77
E	O	78-79
genotype	O	80-88
and	O	89-92
normal	O	93-99
CAG	O	100-103
repeat	O	104-110
length	O	111-117
.	O	117-118

Age	O	119-122
of	O	123-125
onset	O	126-131
(	O	132-133
AO	O	133-135
)	O	135-136
of	O	137-139
Huntington	B	140-150
disease	I	151-158
(	O	159-160
HD	B	160-162
)	O	162-163
is	O	164-166
known	O	167-172
to	O	173-175
be	O	176-178
correlated	O	179-189
with	O	190-194
the	O	195-198
length	O	199-205
of	O	206-208
an	O	209-211
expanded	O	212-220
CAG	O	221-224
repeat	O	225-231
in	O	232-234
the	O	235-238
HD	B	239-241
gene	O	242-246
.	O	246-247

Apolipoprotein	O	248-262
E	O	263-264
(	O	265-266
APOE	O	266-270
)	O	270-271
genotype	O	272-280
,	O	280-281
in	O	282-284
turn	O	285-289
,	O	289-290
is	O	291-293
known	O	294-299
to	O	300-302
influence	O	303-312
AO	O	313-315
in	O	316-318
Alzheimer	B	319-328
disease	I	329-336
,	O	336-337
rendering	O	338-347
the	O	348-351
APOE	O	352-356
gene	O	357-361
a	O	362-363
likely	O	364-370
candidate	O	371-380
to	O	381-383
affect	O	384-390
AO	O	391-393
in	O	394-396
other	O	397-402
neurological	B	403-415
diseases	I	416-424
too	O	425-428
.	O	428-429

We	O	430-432
therefore	O	433-442
determined	O	443-453
APOE	O	454-458
genotype	O	459-467
and	O	468-471
normal	O	472-478
CAG	O	479-482
repeat	O	483-489
length	O	490-496
in	O	497-499
the	O	500-503
HD	B	504-506
gene	O	507-511
for	O	512-515
138	O	516-519
HD	B	520-522
patients	O	523-531
who	O	532-535
were	O	536-540
previously	O	541-551
analysed	O	552-560
with	O	561-565
respect	O	566-573
to	O	574-576
CAG	O	577-580
repeat	O	581-587
length	O	588-594
.	O	594-595

Genotyping	O	596-606
for	O	607-610
APOE	O	611-615
was	O	616-619
performed	O	620-629
blind	O	630-635
to	O	636-638
clinical	O	639-647
information	O	648-659
.	O	659-660

In	O	661-663
addition	O	664-672
to	O	673-675
highlighting	O	676-688
the	O	689-692
effect	O	693-699
of	O	700-702
the	O	703-706
normal	O	707-713
repeat	O	714-720
length	O	721-727
upon	O	728-732
AO	O	733-735
in	O	736-738
maternally	O	739-749
inherited	O	750-759
HD	B	760-762
and	O	763-766
in	O	767-769
male	O	770-774
patients	O	775-783
,	O	783-784
we	O	785-787
show	O	788-792
that	O	793-797
the	O	798-801
APOE	O	802-806
epsilon2epsilon3	O	807-823
genotype	O	824-832
is	O	833-835
associated	O	836-846
with	O	847-851
significantly	O	852-865
earlier	O	866-873
AO	O	874-876
in	O	877-879
males	O	880-885
than	O	886-890
in	O	891-893
females	O	894-901
.	O	901-902

Such	O	903-907
a	O	908-909
sex	O	910-913
difference	O	914-924
in	O	925-927
AO	O	928-930
was	O	931-934
not	O	935-938
apparent	O	939-947
for	O	948-951
any	O	952-955
of	O	956-958
the	O	959-962
other	O	963-968
APOE	O	969-973
genotypes	O	974-983
.	O	983-984

Our	O	985-988
findings	O	989-997
suggest	O	998-1005
that	O	1006-1010
subtle	O	1011-1017
differences	O	1018-1029
in	O	1030-1032
the	O	1033-1036
course	O	1037-1043
of	O	1044-1046
the	O	1047-1050
neurodegeneration	B	1051-1068
in	O	1070-1072
HD	B	1073-1075
may	O	1077-1080
allow	O	1081-1086
interacting	O	1087-1098
genes	O	1099-1104
to	O	1105-1107
exert	O	1108-1113
gender	O	1114-1120
specific	O	1121-1129
effects	O	1130-1137
upon	O	1138-1142
AO	O	1143-1145
.	O	1145-1146

Genetic	O	0-7
linkage	O	8-15
map	O	16-19
of	O	20-22
six	O	23-26
polymorphic	O	27-38
DNA	O	39-42
markers	O	43-50
around	O	51-57
the	O	58-61
gene	O	62-66
for	O	67-70
familial	B	71-79
adenomatous	I	80-91
polyposis	I	92-101
on	O	102-104
chromosome	O	105-115
5	O	116-117
.	O	117-118

A	O	119-120
genetic	O	121-128
linkage	O	129-136
map	O	137-140
of	O	141-143
six	O	144-147
polymorphic	O	148-159
DNA	O	160-163
markers	O	164-171
close	O	172-177
to	O	178-180
the	O	181-184
gene	O	185-189
(	O	190-191
APC	O	191-194
)	O	194-195
for	O	196-199
familial	B	200-208
adenomatous	I	209-220
polyposis	I	221-230
(	O	231-232
FAP	B	232-235
)	O	235-236
on	O	237-239
chromosome	O	240-250
5q	O	251-253
is	O	254-256
reported	O	257-265
.	O	265-266

One	O	267-270
hundred	O	271-278
fifty	O	279-284
-	O	284-285
five	O	285-289
typed	O	290-295
members	O	296-303
of	O	304-306
nine	O	307-311
FAP	B	312-315
kindred	O	316-323
provided	O	324-332
more	O	333-337
than	O	338-342
90	O	343-345
meioses	O	346-353
for	O	354-357
linkage	O	358-365
analysis	O	366-374
.	O	374-375

A	O	376-377
number	O	378-384
of	O	385-387
crucial	O	388-395
recombination	O	396-409
events	O	410-416
have	O	417-421
been	O	422-426
identified	O	427-437
which	O	438-443
are	O	444-447
informative	O	448-459
at	O	460-462
three	O	463-468
or	O	469-471
more	O	472-476
loci	O	477-481
,	O	481-482
allowing	O	483-491
confident	O	492-501
ordering	O	502-510
of	O	511-513
parts	O	514-519
of	O	520-522
the	O	523-526
map	O	527-530
.	O	530-531

There	O	532-537
was	O	538-541
no	O	542-544
evidence	O	545-553
of	O	554-556
genetic	O	557-564
heterogeneity	O	565-578
,	O	578-579
with	O	580-584
all	O	585-588
families	O	589-597
showing	O	598-605
linkage	O	606-613
of	O	614-616
at	O	617-619
least	O	620-625
one	O	626-629
chromosome	O	630-640
5	O	641-642
marker	O	643-649
to	O	650-652
the	O	653-656
gene	O	657-661
.	O	661-662

Recombination	O	663-676
data	O	677-681
and	O	682-685
two	O	686-689
-	O	689-690
point	O	690-695
linkage	O	696-703
analysis	O	704-712
support	O	713-720
a	O	721-722
locus	O	723-728
order	O	729-734
of	O	735-737
centromere	O	738-748
-	O	748-749
pi	O	749-751
227	O	752-755
-	O	755-756
C11P11	O	756-762
-	O	755-756
ECB27	O	763-768
-	O	755-756
L5	O	769-771
.	O	771-772
62	O	773-775
-	O	775-776
APC	O	776-779
-	O	775-776
EF5	O	780-783
62	O	784-786
-	O	786-787
APC	O	787-790
-	O	786-787
EF5	O	791-794
.	O	794-795

44	O	796-798
-	O	798-799
YN5	O	799-802
44	O	803-805
-	O	805-806
YN5	O	806-809
.	O	809-810

48	O	811-813
-	O	813-814
telomer	O	814-821
e	O	822-823
,	O	823-824
although	O	825-833
EF5	O	834-837
.	O	837-838

44	O	839-841
could	O	842-847
lie	O	848-851
in	O	852-854
the	O	855-858
interval	O	859-867
L5	O	868-870
.	O	870-871
62	O	872-874
-	O	874-875
APC	O	875-878
or	O	879-881
ECB27	O	882-887
-	O	887-888
L5	O	888-890
.	O	890-891

62	O	892-894
.	O	894-895

No	O	896-898
recombinants	O	899-911
were	O	912-916
identified	O	917-927
between	O	928-935
APC	O	936-939
and	O	940-943
either	O	944-950
EF5	O	951-954
.	O	954-955

44	O	956-958
or	O	959-961
YN5	O	962-965
.	O	965-966

48	O	967-969
,	O	969-970
but	O	971-974
published	O	975-984
deletion	O	985-993
mapping	O	994-1001
in	O	1002-1004
colorectal	B	1005-1015
carcinomas	I	1016-1026
and	O	1027-1030
linkage	O	1031-1038
analysis	O	1039-1047
in	O	1048-1050
FAP	B	1051-1054
suggest	O	1055-1062
that	O	1063-1067
YN5	O	1068-1071
.	O	1071-1072

48	O	1073-1075
is	O	1076-1078
1	O	1079-1080
-	O	1080-1081
3	O	1081-1082
cM	O	1083-1085
from	O	1086-1090
APC	O	1091-1094
.	O	1094-1095

The	O	1096-1099
present	O	1100-1107
study	O	1108-1113
suggests	O	1114-1122
that	O	1123-1127
YN5	O	1128-1131
.	O	1131-1132

48	O	1133-1135
and	O	1136-1139
L5	O	1140-1142
.	O	1142-1143

62	O	1144-1146
delineate	O	1147-1156
a	O	1157-1158
small	O	1159-1164
region	O	1165-1171
of	O	1172-1174
chromosome	O	1175-1185
5	O	1186-1187
within	O	1188-1194
which	O	1195-1200
the	O	1201-1204
EF5	O	1205-1208
.	O	1208-1209

44	O	1210-1212
locus	O	1213-1218
lies	O	1219-1223
very	O	1224-1228
close	O	1229-1234
to	O	1235-1237
the	O	1238-1241
APC	B	1242-1245
gene	O	1246-1250
.	O	1250-1251

These	O	1252-1257
data	O	1258-1262
not	O	1263-1266
only	O	1267-1271
allow	O	1272-1277
use	O	1278-1281
of	O	1282-1284
flanking	O	1285-1293
markers	O	1294-1301
for	O	1302-1305
presymptomatic	O	1306-1320
diagnosis	O	1321-1330
of	O	1331-1333
FAP	B	1334-1337
but	O	1338-1341
also	O	1342-1346
provide	O	1347-1354
a	O	1355-1356
high	O	1357-1361
-	O	1361-1362
density	O	1362-1369
map	O	1370-1373
of	O	1374-1376
the	O	1377-1380
region	O	1381-1387
for	O	1388-1391
isolation	O	1392-1401
of	O	1402-1404
the	O	1405-1408
APC	B	1409-1412
gene	O	1413-1417
itself	O	1418-1424
and	O	1425-1428
for	O	1429-1432
further	O	1433-1440
assessment	O	1441-1451
of	O	1452-1454
the	O	1455-1458
role	O	1459-1463
of	O	1464-1466
chromosome	O	1467-1477
5	O	1478-1479
deletions	O	1480-1489
in	O	1490-1492
the	O	1493-1496
biology	O	1497-1504
of	O	1505-1507
sporadic	O	1508-1516
colorectal	B	1517-1527
cancer	I	1528-1534
.	O	1534-1535

Detection	O	0-9
of	O	10-12
a	O	13-14
novel	O	15-20
arginine	O	21-29
vasopressin	O	30-41
defect	O	42-48
by	O	49-51
dideoxy	O	52-59
fingerprinting	O	60-74
.	O	74-75

Autosomal	B	76-85
dominant	I	86-94
neurohypophyseal	I	95-111
diabetes	I	112-120
insipidus	I	121-130
is	O	131-133
a	O	134-135
familial	O	136-144
form	O	145-149
of	O	150-152
diabetes	B	153-161
insipidus	I	162-171
.	O	171-172

This	O	173-177
disorder	O	178-186
is	O	187-189
associated	O	190-200
with	O	201-205
variable	O	206-214
levels	O	215-221
of	O	222-224
arginine	O	225-233
vasopressin	O	234-245
(	O	246-247
AVP	O	247-250
)	O	250-251
and	O	252-255
diabetes	B	256-264
insipidus	I	265-274
of	O	275-277
varying	O	278-285
severity	O	286-294
,	O	294-295
which	O	296-301
responds	O	302-310
to	O	311-313
exogenous	O	314-323
AVP	O	324-327
.	O	327-328

To	O	329-331
determine	O	332-341
the	O	342-345
molecular	O	346-355
basis	O	356-361
of	O	362-364
autosomal	B	365-374
dominant	I	375-383
neurohypophyseal	I	384-400
diabetes	I	401-409
insipidus	I	410-419
,	O	419-420
the	O	421-424
AVP	O	425-428
genes	O	429-434
of	O	435-437
members	O	438-445
of	O	446-448
a	O	449-450
large	O	451-456
kindred	O	457-464
were	O	465-469
analyzed	O	470-478
.	O	478-479

A	O	480-481
new	O	482-485
method	O	486-492
,	O	492-493
called	O	494-500
dideoxy	O	501-508
fingerprinting	O	509-523
,	O	523-524
was	O	525-528
used	O	529-533
to	O	534-536
detect	O	537-543
an	O	544-546
AVP	O	547-550
mutation	O	551-559
that	O	560-564
was	O	565-568
characterized	O	569-582
by	O	583-585
DNA	O	586-589
sequencing	O	590-600
.	O	600-601

The	O	602-605
novel	O	606-611
defect	O	612-618
found	O	619-624
changes	O	625-632
the	O	633-636
last	O	637-641
codon	O	642-647
of	O	648-650
the	O	651-654
AVP	O	655-658
signal	O	659-665
peptide	O	666-673
from	O	674-678
alanine	O	679-686
to	O	687-689
threonine	O	690-699
,	O	699-700
which	O	701-706
should	O	707-713
perturb	O	714-721
cleavage	O	722-730
of	O	731-733
mature	O	734-740
AVP	O	741-744
from	O	745-749
its	O	750-753
precursor	O	754-763
protein	O	764-771
and	O	772-775
inhibit	O	776-783
its	O	784-787
secretion	O	788-797
or	O	798-800
action	O	801-807
.	O	807-808
.	O	807-808

Association	O	0-11
of	O	12-14
the	O	15-18
APC	B	19-22
tumor	I	23-28
suppressor	O	29-39
protein	O	40-47
with	O	48-52
catenins	O	53-61
.	O	61-62

Mutations	O	63-72
of	O	73-75
APC	O	76-79
appear	O	80-86
to	O	87-89
initiate	O	90-98
sporadic	O	99-107
and	O	108-111
inherited	O	112-121
forms	O	122-127
of	O	128-130
human	O	131-136
colorectal	B	137-147
cancer	I	148-154
.	O	154-155

Although	O	156-164
these	O	165-170
mutations	O	171-180
have	O	181-185
been	O	186-190
well	O	191-195
characterized	O	196-209
,	O	209-210
little	O	211-217
is	O	218-220
known	O	221-226
about	O	227-232
the	O	233-236
function	O	237-245
of	O	246-248
the	O	249-252
APC	B	253-256
gene	O	257-261
product	O	262-269
.	O	269-270

Two	O	271-274
cellular	O	275-283
proteins	O	284-292
that	O	293-297
associate	O	298-307
with	O	308-312
APC	B	313-316
were	O	317-321
identified	O	322-332
by	O	333-335
nucleotide	O	336-346
sequence	O	347-355
analysis	O	356-364
and	O	365-368
peptide	O	369-376
mapping	O	377-384
as	O	385-387
the	O	388-391
E	O	392-393
-	O	393-394
cadherin	O	394-402
-	O	393-394
associated	O	403-413
proteins	O	414-422
alpha	O	423-428
-	O	428-429
and	O	430-433
beta	O	434-438
-	O	438-439
catenin	O	439-446
.	O	446-447

A	O	448-449
27	O	450-452
-	O	452-453
residue	O	453-460
fragment	O	461-469
of	O	470-472
APC	O	473-476
containing	O	477-487
a	O	488-489
15	O	490-492
-	O	492-493
amino	O	493-498
acid	O	499-503
repeat	O	504-510
was	O	511-514
sufficient	O	515-525
for	O	526-529
the	O	530-533
interaction	O	534-545
with	O	546-550
the	O	551-554
catenins	O	555-563
.	O	563-564

These	O	565-570
results	O	571-578
suggest	O	579-586
an	O	587-589
important	O	590-599
link	O	600-604
between	O	605-612
tumor	B	613-618
initiation	O	619-629
and	O	630-633
cell	O	634-638
adhesion	O	639-647
.	O	647-648
.	O	647-648

Myotonic	B	0-8
dystrophy	I	9-18
is	O	19-21
closely	O	22-29
linked	O	30-36
to	O	37-39
the	O	40-43
gene	O	44-48
for	O	49-52
muscle	O	53-59
-	O	59-60
type	O	60-64
creatine	O	65-73
kinase	O	74-80
(	O	81-82
CKMM	O	82-86
)	O	86-87
.	O	87-88

We	O	89-91
have	O	92-96
studied	O	97-104
genetic	O	105-112
linkage	O	113-120
between	O	121-128
the	O	129-132
gene	O	133-137
for	O	138-141
creatine	O	142-150
kinase	O	151-157
muscle	O	158-164
type	O	165-169
(	O	170-171
CKMM	O	171-175
)	O	175-176
and	O	177-180
the	O	181-184
gene	O	185-189
for	O	190-193
myotonic	B	194-202
dystrophy	I	203-212
(	O	213-214
DM	B	214-216
)	O	216-217
.	O	217-218

In	O	219-221
a	O	222-223
panel	O	224-229
of	O	230-232
65	O	233-235
myotonic	B	236-244
dystrophy	I	245-254
families	O	255-263
from	O	264-268
Canada	O	269-275
and	O	276-279
the	O	280-283
Netherlands	O	284-295
,	O	295-296
a	O	297-298
maximum	O	299-306
lod	O	307-310
score	O	311-316
(	O	317-318
Zmax	O	318-322
)	O	322-323
of	O	324-326
22	O	327-329
.	O	329-330
8	O	331-332
at	O	333-335
a	O	336-337
recombination	O	338-351
frequency	O	352-361
(	O	362-363
theta	O	363-368
)	O	368-369
of	O	370-372
0	O	373-374
.	O	374-375
03	O	376-378
was	O	379-382
obtained	O	383-391
.	O	391-392

Tight	O	393-398
linkage	O	399-406
was	O	407-410
also	O	411-415
demonstrated	O	416-428
for	O	429-432
CKMM	O	433-437
and	O	438-441
the	O	442-445
gene	O	446-450
for	O	451-454
apolipoprotein	O	455-469
C2	O	470-472
(	O	473-474
ApoC2	O	474-479
)	O	479-480
.	O	480-481

This	O	482-486
establishes	O	487-498
CKMM	O	499-503
as	O	504-506
a	O	507-508
useful	O	509-515
marker	O	516-522
for	O	523-526
myotonic	B	527-535
dystrophy	I	536-545

Discordant	O	0-10
clinical	O	11-19
outcome	O	20-27
in	O	28-30
myotonic	B	31-39
dystrophy	I	40-49
relatives	O	50-59
showing	O	60-67
(	O	68-69
CTG	O	69-72
)	O	72-73
n	O	73-74
>	O	75-76
700	O	77-80
repeats	O	81-88
.	O	88-89

A	O	90-91
myotonic	B	92-100
dystrophy	I	101-110
(	O	111-112
DM	B	112-114
)	O	114-115
family	O	116-122
is	O	123-125
described	O	126-135
in	O	136-138
which	O	139-144
discordant	O	145-155
DM	B	156-158
phenotypes	O	159-169
were	O	170-174
found	O	175-180
in	O	181-183
the	O	184-187
children	O	188-196
of	O	197-199
two	O	200-203
affected	O	204-212
sisters	O	213-220
with	O	221-225
similar	O	226-233
CTG	O	234-237
expansion	O	238-247
and	O	248-251
clinical	O	252-260
manifestations	O	261-275
.	O	275-276

In	O	277-279
this	O	280-284
family	O	285-291
,	O	291-292
congenital	O	293-303
as	O	304-306
well	O	307-311
as	O	312-314
early	O	315-320
severe	O	321-327
childhood	O	328-337
and	O	338-341
later	O	342-347
childhood	O	348-357
onset	O	358-363
DM	B	364-366
coexist	O	367-374
.	O	374-375

This	O	376-380
observation	O	381-392
strengthens	O	393-404
the	O	405-408
limited	O	409-416
ability	O	417-424
of	O	425-427
lymphocytes	O	428-439
CTG	O	440-443
repeat	O	444-450
number	O	451-457
analysis	O	458-466
in	O	467-469
predicting	O	470-480
genotype	O	481-489
-	O	489-490
phenotype	O	490-499
correlations	O	500-512
in	O	513-515
DM	B	516-518
patients	O	519-527
.	O	527-528
.	O	527-528

Constitutional	O	0-14
von	B	15-18
Hippel	I	19-25
-	I	25-26
Lindau	I	26-32
(	O	33-34
VHL	B	34-37
)	O	37-38
gene	O	39-43
deletions	O	44-53
detected	O	54-62
in	O	63-65
VHL	B	66-69
families	O	70-78
by	O	79-81
fluorescence	O	82-94
in	O	95-97
situ	O	98-102
hybridization	O	103-116
.	O	116-117

von	B	118-121
Hippel	I	122-128
-	I	128-129
Lindau	I	129-135
(	I	136-137
VHL	I	137-140
)	I	140-141
disease	I	142-149
is	O	150-152
an	O	153-155
autosomal	B	156-165
dominantly	I	166-176
inherited	I	177-186
cancer	I	187-193
syndrome	I	194-202
predisposing	O	203-215
to	O	216-218
a	O	219-220
variety	O	221-228
of	O	229-231
tumor	B	232-237
types	O	238-243
that	O	244-248
include	O	249-256
retinal	O	257-264
hemangioblastomas	B	265-282
,	O	282-283
hemangioblastomas	B	284-301
of	O	302-304
the	O	305-308
central	O	309-316
nervous	O	317-324
system	O	325-331
,	O	331-332
renal	B	333-338
cell	I	339-343
carcinomas	I	344-354
,	O	354-355
pancreatic	B	356-366
cysts	I	367-372
and	I	373-376
tumors	I	377-383
,	O	383-384
pheochromocytomas	B	385-402
,	O	402-403
endolymphatic	B	404-417
sac	I	418-421
tumors	I	422-428
,	O	428-429
and	O	430-433
epididymal	B	434-444
cystadenomas	I	445-457
[	O	458-459
W	O	459-460
.	O	460-461

M	O	462-463
.	O	463-464
Linehan	O	465-472
et	O	473-475
al	O	476-478
.	O	478-479
,	O	479-480
J	O	481-482
.	O	482-483
Am	O	484-486
.	O	486-487

Med	O	488-491
.	O	491-492

Assoc	O	493-498
.	O	498-499
,	O	499-500
273	O	501-504
564	O	506-509
-	O	509-510
570	O	510-513
,	O	513-514
1995	O	515-519
;	O	519-520
E	O	521-522
.	O	522-523
A	O	524-525
.	O	525-526
Maher	O	527-532
and	O	533-536
W	O	537-538
.	O	538-539
G	O	540-541
.	O	541-542
Kaelin	O	543-549
,	O	549-550
Jr	O	551-553
.	O	553-554
,	O	554-555
Medicine	O	556-564
(	O	565-566
Baltimore	O	566-575
)	O	575-576
,	O	576-577
76	O	578-580
381	O	582-585
-	O	585-586
391	O	586-589
,	O	589-590
1997	O	591-595
;	O	595-596
W	O	597-598
.	O	598-599
M	O	600-601
.	O	601-602
Linehan	O	603-610
and	O	611-614
R	O	615-616
.	O	616-617
D	O	618-619
.	O	619-620
Klausner	O	621-629
,	O	629-630
In	O	631-633
B	O	635-636
.	O	636-637
Vogelstein	O	638-648
and	O	649-652
K	O	653-654
.	O	654-655
Kinzler	O	656-663
(	O	664-665
eds	O	665-668
.	O	668-669
)	O	669-670
,	O	670-671

The	O	672-675
Genetic	O	676-683
Basis	O	684-689
of	O	690-692
Human	O	693-698
Cancer	O	699-705
,	O	705-706
pp	O	707-709
.	O	709-710

455	O	711-714
-	O	714-715
473	O	715-718
,	O	718-719
McGraw	O	720-726
-	O	726-727
Hill	O	727-731
,	O	731-732
1998	O	733-737
]	O	737-738
.	O	738-739

The	O	740-743
VHL	B	744-747
gene	O	748-752
was	O	753-756
localized	O	757-766
to	O	767-769
chromosome	O	770-780
3p25	O	781-785
-	O	785-786
26	O	786-788
and	O	789-792
cloned	O	793-799
[	O	800-801
F	O	801-802
.	O	802-803

Latif	O	804-809
et	O	810-812
al	O	813-815
.	O	815-816
,	O	816-817
Science	O	818-825
(	O	826-827
Washington	O	827-837
DC	O	838-840
)	O	840-841
,	O	841-842
260	O	843-846
1317	O	848-852
-	O	852-853
1320	O	853-857
,	O	857-858
1993	O	859-863
]	O	863-864
.	O	864-865

Germline	O	866-874
mutations	O	875-884
in	O	885-887
the	O	888-891
VHL	B	892-895
gene	O	896-900
have	O	901-905
been	O	906-910
detected	O	911-919
in	O	920-922
the	O	923-926
majority	O	927-935
of	O	936-938
VHL	B	939-942
kindreds	O	943-951
.	O	951-952

The	O	953-956
reported	O	957-965
frequency	O	966-975
of	O	976-978
detection	O	979-988
of	O	989-991
VHL	B	992-995
germline	O	996-1004
mutations	O	1005-1014
has	O	1015-1018
varied	O	1019-1025
from	O	1026-1030
39	O	1031-1033
to	O	1034-1036
80	O	1037-1039
%	O	1039-1040
(	O	1041-1042
J	O	1042-1043
.	O	1043-1044

M	O	1045-1046
.	O	1046-1047
Whaley	O	1048-1054
et	O	1055-1057
al	O	1058-1060
.	O	1060-1061
,	O	1061-1062
Am	O	1063-1065
.	O	1065-1066

J	O	1067-1068
.	O	1068-1069
Hum	O	1070-1073
.	O	1073-1074

Genet	O	1075-1080
.	O	1080-1081
,	O	1081-1082
55	O	1083-1085
1092	O	1087-1091
-	O	1091-1092
1102	O	1092-1096
,	O	1096-1097
1994	O	1098-1102
;	O	1102-1103
Clinical	O	1104-1112
Research	O	1113-1121
Group	O	1122-1127
for	O	1128-1131
Japan	O	1132-1137
,	O	1137-1138
Hum	O	1139-1142
.	O	1142-1143

Mol	O	1144-1147
.	O	1147-1148

Genet	O	1149-1154
.	O	1154-1155
,	O	1155-1156
4	O	1157-1158
2233	O	1160-1164
-	O	1164-1165
2237	O	1165-1169
,	O	1169-1170
1995	O	1171-1175
;	O	1175-1176
F	O	1177-1178
.	O	1178-1179
Chen	O	1180-1184
et	O	1185-1187
al	O	1188-1190
.	O	1190-1191
,	O	1191-1192
Hum	O	1193-1196
.	O	1196-1197

Mutat	O	1198-1203
.	O	1203-1204
,	O	1204-1205
5	O	1206-1207
66	O	1209-1211
-	O	1211-1212
75	O	1212-1214
,	O	1214-1215
1995	O	1216-1220
;	O	1220-1221
E	O	1222-1223
.	O	1223-1224
R	O	1225-1226
.	O	1226-1227
Maher	O	1228-1233
et	O	1234-1236
al	O	1237-1239
.	O	1239-1240
,	O	1240-1241
J	O	1242-1243
.	O	1243-1244
Med	O	1245-1248
.	O	1248-1249

Genet	O	1250-1255
.	O	1255-1256
,	O	1256-1257
33	O	1258-1260
328	O	1262-1265
-	O	1265-1266
332	O	1266-1269
,	O	1269-1270
1996	O	1271-1275
;	O	1275-1276
B	O	1277-1278
.	O	1278-1279
Zbar	O	1280-1284
,	O	1284-1285
Cancer	O	1286-1292
Surv	O	1293-1297
.	O	1297-1298
,	O	1298-1299
25	O	1300-1302
219	O	1304-1307
-	O	1307-1308
232	O	1308-1311
,	O	1311-1312
1995	O	1313-1317
)	O	1317-1318
.	O	1318-1319

Recently	O	1320-1328
a	O	1329-1330
quantitative	O	1331-1343
Southern	O	1344-1352
blotting	O	1353-1361
procedure	O	1362-1371
was	O	1372-1375
found	O	1376-1381
to	O	1382-1384
improve	O	1385-1392
this	O	1393-1397
frequency	O	1398-1407
(	O	1408-1409
C	O	1409-1410
.	O	1410-1411

Stolle	O	1412-1418
et	O	1419-1421
al	O	1422-1424
.	O	1424-1425
,	O	1425-1426
Hum	O	1427-1430
.	O	1430-1431

Mutat	O	1432-1437
.	O	1437-1438
,	O	1438-1439
12	O	1440-1442
417	O	1444-1447
-	O	1447-1448
423	O	1448-1451
,	O	1451-1452
1998	O	1453-1457
)	O	1457-1458
.	O	1458-1459

In	O	1460-1462
the	O	1463-1466
present	O	1467-1474
study	O	1475-1480
,	O	1480-1481
we	O	1482-1484
report	O	1485-1491
the	O	1492-1495
use	O	1496-1499
of	O	1500-1502
fluorescence	O	1503-1515
in	O	1516-1518
situ	O	1519-1523
hybridization	O	1524-1537
(	O	1538-1539
FISH	O	1539-1543
)	O	1543-1544
as	O	1545-1547
a	O	1548-1549
method	O	1550-1556
to	O	1557-1559
detect	O	1560-1566
and	O	1567-1570
characterize	O	1571-1583
VHL	B	1584-1587
germline	O	1588-1596
deletions	O	1597-1606
.	O	1606-1607

We	O	1608-1610
reexamined	O	1611-1621
a	O	1622-1623
group	O	1624-1629
of	O	1630-1632
VHL	B	1633-1636
patients	O	1637-1645
shown	O	1646-1651
previously	O	1652-1662
by	O	1663-1665
single	O	1666-1672
-	O	1672-1673
strand	O	1673-1679
conformation	O	1680-1692
and	O	1693-1696
sequencing	O	1697-1707
analysis	O	1708-1716
not	O	1717-1720
to	O	1721-1723
harbor	O	1724-1730
point	O	1731-1736
mutations	O	1737-1746
in	O	1747-1749
the	O	1750-1753
VHL	B	1754-1757
locus	O	1758-1763
.	O	1763-1764

We	O	1765-1767
found	O	1768-1773
constitutional	O	1774-1788
deletions	O	1789-1798
in	O	1799-1801
29	O	1802-1804
of	O	1805-1807
30	O	1808-1810
VHL	B	1811-1814
patients	O	1815-1823
in	O	1824-1826
this	O	1827-1831
group	O	1832-1837
using	O	1838-1843
cosmid	O	1844-1850
and	O	1851-1854
P1	O	1855-1857
probes	O	1858-1864
that	O	1865-1869
cover	O	1870-1875
the	O	1876-1879
VHL	B	1880-1883
locus	O	1884-1889
.	O	1889-1890

We	O	1891-1893
then	O	1894-1898
tested	O	1899-1905
six	O	1906-1909
phenotypically	O	1910-1924
normal	O	1925-1931
offspring	O	1932-1941
from	O	1942-1946
four	O	1947-1951
of	O	1952-1954
these	O	1955-1960
VHL	B	1961-1964
families	O	1965-1973
two	O	1975-1978
were	O	1979-1983
found	O	1984-1989
to	O	1990-1992
carry	O	1993-1998
the	O	1999-2002
deletion	O	2003-2011
and	O	2012-2015
the	O	2016-2019
other	O	2020-2025
four	O	2026-2030
were	O	2031-2035
deletion	O	2036-2044
-	O	2044-2045
free	O	2045-2049
.	O	2049-2050

In	O	2051-2053
addition	O	2054-2062
,	O	2062-2063
germline	O	2064-2072
mosaicism	O	2073-2082
of	O	2083-2085
the	O	2086-2089
VHL	B	2090-2093
gene	O	2094-2098
was	O	2099-2102
identified	O	2103-2113
in	O	2114-2116
one	O	2117-2120
family	O	2121-2127
.	O	2127-2128

In	O	2129-2131
sum	O	2132-2135
,	O	2135-2136
FISH	O	2137-2141
was	O	2142-2145
found	O	2146-2151
to	O	2152-2154
be	O	2155-2157
a	O	2158-2159
simple	O	2160-2166
and	O	2167-2170
reliable	O	2171-2179
method	O	2180-2186
to	O	2187-2189
detect	O	2190-2196
VHL	B	2197-2200
germline	O	2201-2209
deletions	O	2210-2219
and	O	2220-2223
practically	O	2224-2235
useful	O	2236-2242
in	O	2243-2245
cases	O	2246-2251
where	O	2252-2257
other	O	2258-2263
methods	O	2264-2271
of	O	2272-2274
screening	O	2275-2284
have	O	2285-2289
failed	O	2290-2296
to	O	2297-2299
detect	O	2300-2306
a	O	2307-2308
VHL	B	2309-2312
gene	I	2313-2317
abnormality	I	2318-2329

Aberrant	O	0-8
subcellular	O	9-20
localization	O	21-33
of	O	34-36
BRCA1	O	37-42
in	O	43-45
breast	B	46-52
cancer	I	53-59
.	O	59-60

The	O	61-64
BRCA1	O	65-70
gene	O	71-75
product	O	76-83
was	O	84-87
identified	O	88-98
as	O	99-101
a	O	102-103
220	O	104-107
-	O	107-108
kilodalton	O	108-118
nuclear	O	119-126
phosphoprotein	O	127-141
in	O	142-144
normal	O	145-151
cells	O	152-157
,	O	157-158
including	O	159-168
breast	O	169-175
ductal	O	176-182
epithelial	O	183-193
cells	O	194-199
,	O	199-200
and	O	201-204
in	O	205-207
18	O	208-210
of	O	211-213
20	O	214-216
tumor	B	217-222
cell	O	223-227
lines	O	228-233
derived	O	234-241
from	O	242-246
tissues	O	247-254
other	O	255-260
than	O	261-265
breast	O	266-272
and	O	273-276
ovary	O	277-282
.	O	282-283

In	O	284-286
16	O	287-289
of	O	290-292
17	O	293-295
breast	B	296-302
and	I	303-306
ovarian	I	307-314
cancer	I	315-321
lines	O	322-327
and	O	328-331
17	O	332-334
of	O	335-337
17	O	338-340
samples	O	341-348
of	O	349-351
cells	O	352-357
obtained	O	358-366
from	O	367-371
malignant	O	372-381
effusions	O	382-391
,	O	391-392
however	O	393-400
,	O	400-401
BRCA1	O	402-407
localized	O	408-417
mainly	O	418-424
in	O	425-427
cytoplasm	O	428-437
.	O	437-438

Absence	O	439-446
of	O	447-449
BRCA1	O	450-455
or	O	456-458
aberrant	O	459-467
subcellular	O	468-479
location	O	480-488
was	O	489-492
also	O	493-497
observed	O	498-506
to	O	507-509
a	O	510-511
variable	O	512-520
extent	O	521-527
in	O	528-530
histological	O	531-543
sections	O	544-552
of	O	553-555
many	O	556-560
breast	B	561-567
cancer	I	568-574
biopsies	O	575-583
.	O	583-584

These	O	585-590
findings	O	591-599
suggest	O	600-607
that	O	608-612
BRCA1	B	613-618
abnormalities	I	619-632
may	O	633-636
be	O	637-639
involved	O	640-648
in	O	649-651
the	O	652-655
pathogenesis	O	656-668
of	O	669-671
many	O	672-676
breast	B	677-683
cancers	I	684-691
,	O	691-692
sporadic	O	693-701
as	O	702-704
well	O	705-709
as	O	710-712
familial	O	713-721
.	O	721-722
.	O	721-722

HLA	O	0-3
B27	O	4-7
and	O	8-11
the	O	12-15
genetics	O	16-24
of	O	25-27
ankylosing	B	28-38
spondylitis	I	39-50
.	O	50-51

One	O	52-55
hundred	O	56-63
and	O	64-67
twenty	O	68-74
-	O	74-75
eight	O	75-80
of	O	81-83
145	O	84-87
patients	O	88-96
with	O	97-101
ankylosing	B	102-112
spondylitis	I	113-124
(	O	125-126
AS	B	126-128
)	O	128-129
were	O	130-134
found	O	135-140
to	O	141-143
be	O	144-146
HLA	O	147-150
B27	O	151-154
positive	O	155-163
.	O	163-164

Five	O	165-169
patients	O	170-178
had	O	179-182
evidence	O	183-191
of	O	192-194
a	O	195-196
sero	O	197-201
-	O	201-202
negative	O	202-210
peripheral	B	211-221
arthritis	I	222-231
resembling	O	232-242
peripheral	B	243-253
psoriatic	I	254-263
arthritis	I	264-273
and	O	274-277
3	O	278-279
of	O	280-282
these	O	283-288
were	O	289-293
B27	O	294-297
negative	O	298-306
.	O	306-307

One	O	308-311
further	O	312-319
B27	O	320-323
negative	O	324-332
patients	O	333-341
had	O	342-345
a	O	346-347
sister	O	348-354
with	O	355-359
ankylosing	B	360-370
spondylitis	I	371-382
and	O	383-386
ulcerative	B	387-397
colitis	I	398-405
and	O	406-409
a	O	410-411
mother	O	412-418
with	O	419-423
ulcerative	B	424-434
colitis	I	435-442
.	O	442-443

There	O	444-449
was	O	450-453
evidence	O	454-462
of	O	463-465
a	O	466-467
somewhat	O	468-476
later	O	477-482
age	O	483-486
of	O	487-489
onset	O	490-495
of	O	496-498
symptoms	O	499-507
in	O	508-510
B27	O	511-514
negative	O	515-523
patients	O	524-532
.	O	532-533

These	O	534-539
findings	O	540-548
are	O	549-552
interpreted	O	553-564
as	O	565-567
suggesting	O	568-578
some	O	579-583
degree	O	584-590
of	O	591-593
clinical	O	594-602
and	O	603-606
genetic	O	607-614
heterogeneity	O	615-628
in	O	629-631
ankylosing	B	632-642
spondylitis	I	643-654
with	O	655-659
genes	O	660-665
for	O	666-669
psoriasis	B	670-679
and	O	680-683
inflammatory	B	684-696
bowel	I	697-702
disease	I	703-710
being	O	711-716
important	O	717-726
in	O	727-729
some	O	730-734
individuals	O	735-746
,	O	746-747
particularly	O	748-760
those	O	761-766
who	O	767-770
are	O	771-774
B27	O	775-778
negative	O	779-787
.	O	787-788

Twenty	O	789-795
-	O	795-796
five	O	796-800
first	O	801-806
-	O	806-807
degree	O	807-813
relatives	O	814-823
with	O	824-828
ankylosing	B	829-839
spondylitis	I	840-851
were	O	852-856
all	O	857-860
B27	O	861-864
positive	O	865-873
.	O	873-874

The	O	875-878
only	O	879-883
instance	O	884-892
of	O	893-895
disassociation	O	896-910
of	O	911-913
B27	O	914-917
and	O	918-921
spondylitis	B	922-933
in	O	934-936
a	O	937-938
family	O	939-945
was	O	946-949
where	O	950-955
the	O	956-959
proband	O	960-967
had	O	968-971
ulcerative	B	972-982
colitis	I	983-990
as	O	991-993
well	O	994-998
as	O	999-1001
spondylitis	B	1002-1013
.	O	1013-1014

Of	O	1015-1017
13	O	1018-1020
B27	O	1021-1024
positive	O	1025-1033
fathers	O	1034-1041
3	O	1042-1043
could	O	1044-1049
be	O	1050-1052
diagnosed	O	1053-1062
as	O	1063-1065
having	O	1066-1072
definite	O	1073-1081
ankylosing	B	1082-1092
spondylitis	I	1093-1104
(	O	1105-1106
23	O	1106-1108
%	O	1108-1109
)	O	1109-1110
.	O	1110-1111

These	O	1112-1117
findings	O	1118-1126
are	O	1127-1130
thought	O	1131-1138
to	O	1139-1141
provide	O	1142-1149
evidence	O	1150-1158
against	O	1159-1166
the	O	1167-1170
concept	O	1171-1178
that	O	1179-1183
the	O	1184-1187
gene	O	1188-1192
for	O	1193-1196
ankylosing	B	1197-1207
spondylitis	I	1208-1219
is	O	1220-1222
not	O	1223-1226
B27	O	1227-1230
but	O	1231-1234
a	O	1235-1236
closely	O	1237-1244
linked	O	1245-1251
gene	O	1252-1256
and	O	1257-1260
favour	O	1261-1267
the	O	1268-1271
occurrence	O	1272-1282
of	O	1283-1285
an	O	1286-1288
environmental	O	1289-1302
event	O	1303-1308
affecting	O	1309-1318
approximately	O	1319-1332
one	O	1333-1336
-	O	1336-1337
fifth	O	1337-1342
of	O	1343-1345
B27	O	1346-1349
positive	O	1350-1358
males	O	1359-1364
to	O	1365-1367
result	O	1368-1374
in	O	1375-1377
disease	O	1378-1385
.	O	1385-1386
.	O	1385-1386

Late	O	0-4
infantile	O	5-14
metachromatic	B	15-28
leukodystrophy	I	29-43
in	O	44-46
Israel	O	47-53
.	O	53-54

Metachromatic	B	55-68
Leukodystrophy	I	69-83
(	O	84-85
MLD	B	85-88
)	O	88-89
is	O	90-92
a	O	93-94
neurodegenerative	B	95-112
disease	I	113-120
in	O	121-123
which	O	124-129
the	O	130-133
lysosomal	O	134-143
enzyme	O	144-150
,	O	150-151
Aryl	O	152-156
sulfatase	O	157-166
A	O	167-168
(	O	169-170
ARSA	O	170-174
)	O	174-175
is	O	176-178
deficient	O	179-188
.	O	188-189

The	O	190-193
disease	O	194-201
is	O	202-204
inherited	O	205-214
as	O	215-217
an	O	218-220
autosomal	O	221-230
recessive	O	231-240
trait	O	241-246
and	O	247-250
its	O	251-254
frequency	O	255-264
is	O	265-267
estimated	O	268-277
to	O	278-280
be	O	281-283
1	O	284-285
/	O	285-286
40	O	286-288
,	O	288-289
000	O	290-293
live	O	294-298
births	O	299-305
.	O	305-306

The	O	307-310
gene	O	311-315
of	O	316-318
ARSA	O	319-323
has	O	324-327
been	O	328-332
cloned	O	333-339
and	O	340-343
up	O	344-346
to	O	347-349
now	O	350-353
eight	O	354-359
mutations	O	360-369
causing	O	370-377
MLD	B	378-381
have	O	382-386
been	O	387-391
reported	O	392-400
.	O	400-401

Another	O	402-409
mutation	O	410-418
,	O	418-419
PD	O	420-422
,	O	422-423
leads	O	424-429
to	O	430-432
the	O	433-436
deficiency	O	437-447
of	O	448-450
the	O	451-454
enzyme	O	455-461
in	O	462-464
vitro	O	465-470
(	O	471-472
pseudodeficiency	O	472-488
)	O	488-489
without	O	490-497
any	O	498-501
known	O	502-507
clinical	O	508-516
effect	O	517-523
.	O	523-524

The	O	525-528
PD	O	529-531
mutation	O	532-540
is	O	541-543
frequent	O	544-552
in	O	553-555
all	O	556-559
populations	O	560-571
.	O	571-572

In	O	573-575
Israel	O	576-582
,	O	582-583
late	O	584-588
infantile	O	589-598
MLD	B	599-602
was	O	603-606
found	O	607-612
to	O	613-615
be	O	616-618
very	O	619-623
frequent	O	624-632
in	O	633-635
a	O	636-637
small	O	638-643
Jewish	O	644-650
isolate	O	651-658
,	O	658-659
the	O	660-663
Habbanite	O	664-673
Jews	O	674-678
(	O	679-680
1	O	680-681
/	O	681-682
75	O	682-684
live	O	685-689
births	O	690-696
)	O	696-697
.	O	697-698

The	O	699-702
molecular	O	703-712
analysis	O	713-721
demonstrated	O	722-734
that	O	735-739
in	O	740-742
the	O	743-746
Habbanite	O	747-756
population	O	757-767
,	O	767-768
the	O	769-772
mutation	O	773-781
occurred	O	782-790
on	O	791-793
an	O	794-796
allele	O	797-803
with	O	804-808
the	O	809-812
PD	O	813-815
mutation	O	816-824
.	O	824-825

The	O	826-829
loss	O	830-834
of	O	835-837
ARSA	O	838-842
activity	O	843-851
is	O	852-854
due	O	855-858
to	O	859-861
a	O	862-863
point	O	864-869
mutation	O	870-878
C	O	879-880
>	O	881-882
T	O	883-884
leading	O	885-892
to	O	893-895
a	O	896-897
change	O	898-904
of	O	905-907
proline	O	908-915
to	O	916-918
leucine	O	919-926
.	O	926-927

MLD	B	928-931
is	O	932-934
also	O	935-939
frequent	O	940-948
among	O	949-954
Moslem	O	955-961
Arabs	O	962-967
in	O	968-970
Jerusalem	O	971-980
.	O	980-981

The	O	982-985
mutation	O	986-994
is	O	995-997
a	O	998-999
transition	O	1000-1010
G	O	1011-1012
>	O	1013-1014
A	O	1015-1016
destroying	O	1017-1027
the	O	1028-1031
splice	O	1032-1038
donor	O	1039-1044
site	O	1045-1049
of	O	1050-1052
exon	O	1053-1057
2	O	1058-1059
.	O	1059-1060
This	O	1061-1065
mutation	O	1066-1074
has	O	1075-1078
been	O	1079-1083
reported	O	1084-1092
in	O	1093-1095
patients	O	1096-1104
with	O	1105-1109
the	O	1110-1113
late	O	1114-1118
infantile	O	1119-1128
MLD	B	1129-1132
from	O	1133-1137
different	O	1138-1147
ethnic	O	1148-1154
groups	O	1155-1161
.	O	1161-1162

The	O	1163-1166
Christian	O	1167-1176
Arabs	O	1177-1182
in	O	1183-1185
Israel	O	1186-1192
also	O	1193-1197
have	O	1198-1202
a	O	1203-1204
high	O	1205-1209
incidence	O	1210-1219
of	O	1220-1222
the	O	1223-1226
disease	O	1227-1234
(	O	1235-1236
1	O	1236-1237
/	O	1237-1238
10	O	1238-1240
,	O	1240-1241
000	O	1242-1245
live	O	1246-1250
births	O	1251-1257
)	O	1257-1258
;	O	1258-1259
the	O	1260-1263
mutation	O	1264-1272
in	O	1273-1275
this	O	1276-1280
population	O	1281-1291
is	O	1292-1294
still	O	1295-1300
unknown	O	1301-1308
.	O	1308-1309

Knowledge	O	1310-1319
of	O	1320-1322
the	O	1323-1326
different	O	1327-1336
mutations	O	1337-1346
causing	O	1347-1354
MLD	B	1355-1358
in	O	1359-1361
these	O	1362-1367
defined	O	1368-1375
populations	O	1376-1387
will	O	1388-1392
allow	O	1393-1398
a	O	1399-1400
carrier	O	1401-1408
screening	O	1409-1418
program	O	1419-1426
to	O	1427-1429
be	O	1430-1432
carried	O	1433-1440
out	O	1441-1444
and	O	1445-1448
prevent	O	1449-1456
the	O	1457-1460
birth	O	1461-1466
of	O	1467-1469
additional	O	1470-1480
affected	O	1481-1489
children	O	1490-1498
.	O	1498-1499
.	O	1498-1499

Genomic	O	0-7
rearrangements	O	8-22
of	O	23-25
the	O	26-29
APC	B	30-33
tumor	I	34-39
-	O	39-40
suppressor	O	40-50
gene	O	51-55
in	O	56-58
familial	B	59-67
adenomatous	I	68-79
polyposis	I	80-89
.	O	89-90

Germline	O	91-99
mutations	O	100-109
of	O	110-112
the	O	113-116
adenomatous	B	117-128
polyposis	I	129-138
coli	I	139-143
(	I	144-145
APC	I	145-148
)	I	148-149
tumor	I	150-155
-	O	155-156
suppressor	O	156-166
gene	O	167-171
result	O	172-178
in	O	179-181
the	O	182-185
hereditary	B	186-196
colorectal	I	197-207
cancer	I	208-214
syndrome	I	215-223
familial	B	224-232
adenomatous	I	233-244
polyposis	I	245-254
(	O	255-256
FAP	B	256-259
)	O	259-260
.	O	260-261

Almost	O	262-268
all	O	269-272
APC	B	273-276
mutations	O	277-286
that	O	287-291
have	O	292-296
been	O	297-301
identified	O	302-312
are	O	313-316
single	O	317-323
-	O	323-324
nucleotide	O	324-334
alterations	O	335-346
,	O	346-347
small	O	348-353
insertions	O	354-364
,	O	364-365
or	O	366-368
small	O	369-374
deletions	O	375-384
that	O	385-389
would	O	390-395
truncate	O	396-404
the	O	405-408
protein	O	409-416
product	O	417-424
of	O	425-427
the	O	428-431
gene	O	432-436
.	O	436-437

No	O	438-440
well	O	441-445
-	O	445-446
characterized	O	446-459
intragenic	O	460-470
rearrangement	O	471-484
of	O	485-487
APC	O	488-491
has	O	492-495
been	O	496-500
described	O	501-510
,	O	510-511
and	O	512-515
the	O	516-519
prevalence	O	520-530
of	O	531-533
this	O	534-538
type	O	539-543
of	O	544-546
mutation	O	547-555
in	O	556-558
FAP	B	559-562
patients	O	563-571
is	O	572-574
not	O	575-578
clear	O	579-584
.	O	584-585

We	O	586-588
screened	O	589-597
49	O	598-600
potential	O	601-610
FAP	B	611-614
families	O	615-623
and	O	624-627
identified	O	628-638
26	O	639-641
different	O	642-651
germline	O	652-660
APC	B	661-664
mutations	O	665-674
in	O	675-677
30	O	678-680
families	O	681-689
.	O	689-690

Four	O	691-695
of	O	696-698
these	O	699-704
mutations	O	705-714
were	O	715-719
genomic	O	720-727
rearrangements	O	728-742
resulting	O	743-752
from	O	753-757
homologous	O	758-768
and	O	769-772
nonhomologous	O	773-786
recombinations	O	787-801
mediated	O	802-810
by	O	811-813
Alu	O	814-817
elements	O	818-826
.	O	826-827

Two	O	828-831
of	O	832-834
these	O	835-840
four	O	841-845
rearrangements	O	846-860
were	O	861-865
complex	O	866-873
,	O	873-874
involving	O	875-884
deletion	O	885-893
and	O	894-897
insertion	O	898-907
of	O	908-910
nucleotides	O	911-922
.	O	922-923

Of	O	924-926
these	O	927-932
four	O	933-937
rearrangements	O	938-952
,	O	952-953
one	O	954-957
resulted	O	958-966
in	O	967-969
the	O	970-973
deletion	O	974-982
of	O	983-985
exons	O	986-991
11	O	992-994
and	O	995-998
12	O	999-1001
and	O	1002-1005
two	O	1006-1009
others	O	1010-1016
resulted	O	1017-1025
in	O	1026-1028
either	O	1029-1035
complete	O	1036-1044
or	O	1045-1047
partial	O	1048-1055
deletion	O	1056-1064
of	O	1065-1067
exon	O	1068-1072
14	O	1073-1075
.	O	1075-1076

The	O	1077-1080
fourth	O	1081-1087
rearrangement	O	1088-1101
grossly	O	1102-1109
altered	O	1110-1117
the	O	1118-1121
sequence	O	1122-1130
within	O	1131-1137
intron	O	1138-1144
14	O	1145-1147
.	O	1147-1148

Although	O	1149-1157
this	O	1158-1162
rearrangement	O	1163-1176
did	O	1177-1180
not	O	1181-1184
affect	O	1185-1191
any	O	1192-1195
coding	O	1196-1202
sequence	O	1203-1211
of	O	1212-1214
APC	O	1215-1218
at	O	1219-1221
the	O	1222-1225
genomic	O	1226-1233
DNA	O	1234-1237
level	O	1238-1243
,	O	1243-1244
it	O	1245-1247
caused	O	1248-1254
inappropriate	O	1255-1268
splicing	O	1269-1277
of	O	1278-1280
exon	O	1281-1285
14	O	1286-1288
.	O	1288-1289

These	O	1290-1295
rearrangements	O	1296-1310
were	O	1311-1315
initially	O	1316-1325
revealed	O	1326-1334
by	O	1335-1337
analyzing	O	1338-1347
cDNAs	O	1348-1353
and	O	1354-1357
could	O	1358-1363
not	O	1364-1367
have	O	1368-1372
been	O	1373-1377
identified	O	1378-1388
by	O	1389-1391
using	O	1392-1397
mutation	O	1398-1406
detection	O	1407-1416
methods	O	1417-1424
that	O	1425-1429
screened	O	1430-1438
each	O	1439-1443
exon	O	1444-1448
individually	O	1449-1461
.	O	1461-1462

The	O	1463-1466
identification	O	1467-1481
of	O	1482-1484
a	O	1485-1486
rearrangement	O	1487-1500
that	O	1501-1505
did	O	1506-1509
not	O	1510-1513
alter	O	1514-1519
any	O	1520-1523
coding	O	1524-1530
exons	O	1531-1536
yet	O	1537-1540
affected	O	1541-1549
the	O	1550-1553
splicing	O	1554-1562
further	O	1563-1570
underscores	O	1571-1582
the	O	1583-1586
importance	O	1587-1597
of	O	1598-1600
using	O	1601-1606
cDNA	O	1607-1611
for	O	1612-1615
mutation	O	1616-1624
analysis	O	1625-1633
.	O	1633-1634

The	O	1635-1638
identification	O	1639-1653
of	O	1654-1656
four	O	1657-1661
genomic	O	1662-1669
rearrangements	O	1670-1684
among	O	1685-1690
30	O	1691-1693
mutations	O	1694-1703
suggests	O	1704-1712
that	O	1713-1717
genomic	O	1718-1725
rearrangements	O	1726-1740
are	O	1741-1744
frequent	O	1745-1753
germline	O	1754-1762
APC	B	1763-1766
mutations	O	1767-1776
.	O	1776-1777
.	O	1776-1777

Familial	B	0-8
male	I	9-13
breast	I	14-20
cancer	I	21-27
is	O	28-30
not	O	31-34
linked	O	35-41
to	O	42-44
the	O	45-48
BRCA1	O	49-54
locus	O	55-60
on	O	61-63
chromosome	O	64-74
17q	O	75-78
.	O	78-79

Breast	B	80-86
cancer	I	87-93
in	O	94-96
men	O	97-100
is	O	101-103
about	O	104-109
a	O	110-111
hundredfold	O	112-123
less	O	124-128
common	O	129-135
than	O	136-140
in	O	141-143
women	O	144-149
and	O	150-153
this	O	154-158
has	O	159-162
hindered	O	163-171
research	O	172-180
into	O	181-185
its	O	186-189
genetic	O	190-197
basis	O	198-203
.	O	203-204

We	O	205-207
have	O	208-212
examined	O	213-221
22	O	222-224
families	O	225-233
with	O	234-238
at	O	239-241
least	O	242-247
one	O	248-251
case	O	252-256
of	O	257-259
male	B	260-264
breast	I	265-271
cancer	I	272-278
for	O	279-282
linkage	O	283-290
to	O	291-293
the	O	294-297
hereditary	B	298-308
breast	I	309-315
and	I	316-319
ovarian	I	320-327
cancer	I	328-334
locus	O	335-340
,	O	340-341
BRCA1	O	342-347
,	O	347-348
on	O	349-351
chromosome	O	352-362
17q	O	363-366
.	O	366-367

We	O	368-370
found	O	371-376
strong	O	377-383
evidence	O	384-392
against	O	393-400
linkage	O	401-408
to	O	409-411
BRCA1	O	412-417
(	O	418-419
lod	O	419-422
score	O	423-428
-	O	428-429
16	O	429-431
.	O	431-432

63	O	433-435
)	O	435-436
and	O	437-440
the	O	441-444
best	O	445-449
estimate	O	450-458
of	O	459-461
the	O	462-465
proportion	O	466-476
of	O	477-479
linked	O	480-486
families	O	487-495
was	O	496-499
0	O	500-501
%	O	501-502
(	O	503-504
95	O	504-506
%	O	506-507
CI	O	508-510
0	O	511-512
-	O	512-513
18	O	513-515
%	O	515-516
)	O	516-517
.	O	517-518

Our	O	519-522
results	O	523-530
indicate	O	531-539
that	O	540-544
there	O	545-550
is	O	551-553
a	O	554-555
gene	O	556-560
(	O	561-562
s	O	562-563
)	O	563-564
other	O	565-570
than	O	571-575
BRCA1	O	576-581
which	O	582-587
predisposes	O	588-599
to	O	600-602
early	O	603-608
-	O	608-609
onset	O	609-614
breast	B	615-621
cancer	I	622-628
in	O	629-631
women	O	632-637
and	O	638-641
which	O	642-647
confers	O	648-655
a	O	656-657
higher	O	658-664
risk	O	665-669
of	O	670-672
male	B	673-677
breast	I	678-684
cancer	I	685-691
.	O	691-692

Identification	O	693-707
of	O	708-710
additional	O	711-721
pedigrees	O	722-731
that	O	732-736
include	O	737-744
cases	O	745-750
of	O	751-753
male	B	754-758
breast	I	759-765
cancer	I	766-772
may	O	773-776
therefore	O	777-786
facilitate	O	787-797
the	O	798-801
mapping	O	802-809
and	O	810-813
isolation	O	814-823
of	O	824-826
this	O	827-831
gene	O	832-836
.	O	836-837

Familial	O	0-8
Prader	B	9-15
-	I	15-16
Willi	I	16-21
syndrome	I	22-30
with	O	31-35
apparently	O	36-46
normal	O	47-53
chromosomes	O	54-65
.	O	65-66

We	O	67-69
report	O	70-76
on	O	77-79
4	O	80-81
sibs	O	82-86
(	O	87-88
2F	O	88-90
,	O	90-91
2M	O	92-94
)	O	94-95
with	O	96-100
Prader	B	101-107
-	I	107-108
Willi	I	108-113
syndrome	I	114-122
(	O	123-124
PWS	B	124-127
)	O	127-128
.	O	128-129

Diagnosis	O	130-139
was	O	140-143
made	O	144-148
clinically	O	149-159
on	O	160-162
the	O	163-166
basis	O	167-172
of	O	173-175
history	O	176-183
,	O	183-184
behavior	O	185-193
,	O	193-194
and	O	195-198
physical	O	199-207
findings	O	208-216
in	O	217-219
3	O	220-221
of	O	222-224
the	O	225-228
sibs	O	229-233
.	O	233-234

The	O	235-238
other	O	239-244
child	O	245-250
had	O	251-254
died	O	255-259
at	O	260-262
age	O	263-266
10	O	267-269
months	O	270-276
with	O	277-281
a	O	282-283
history	O	284-291
and	O	292-295
clinical	O	296-304
findings	O	305-313
typical	O	314-321
of	O	322-324
first	O	325-330
phase	O	331-336
of	O	337-339
PWS	B	340-343
.	O	343-344

Results	O	345-352
of	O	353-355
chromosome	O	356-366
studies	O	367-374
on	O	375-377
the	O	378-381
parents	O	382-389
and	O	390-393
surviving	O	394-403
sibs	O	404-408
were	O	409-413
normal	O	414-420
.	O	420-421

The	O	422-425
implications	O	426-438
of	O	439-441
this	O	442-446
unusual	O	447-454
familial	O	455-463
occurrence	O	464-474
for	O	475-478
our	O	479-482
understanding	O	483-496
of	O	497-499
PWS	B	500-503
are	O	504-507
discussed	O	508-517
.	O	517-518
.	O	517-518

Age	O	0-3
at	O	4-6
diagnosis	O	7-16
as	O	17-19
an	O	20-22
indicator	O	23-32
of	O	33-35
eligibility	O	36-47
for	O	48-51
BRCA1	O	52-57
DNA	O	58-61
testing	O	62-69
in	O	70-72
familial	B	73-81
breast	I	82-88
cancer	I	89-95
.	O	95-96

We	O	97-99
searched	O	100-108
for	O	109-112
criteria	O	113-121
that	O	122-126
could	O	127-132
indicate	O	133-141
breast	B	142-148
cancer	I	149-155
families	O	156-164
with	O	165-169
a	O	170-171
high	O	172-176
prior	O	177-182
probability	O	183-194
of	O	195-197
being	O	198-203
caused	O	204-210
by	O	211-213
the	O	214-217
breast	B	218-224
/	I	224-225
ovarian	I	225-232
cancer	I	233-239
susceptibility	O	240-254
locus	O	255-260
BRCA1	O	261-266
on	O	267-269
chromosome	O	270-280
17	O	281-283
.	O	283-284

To	O	285-287
this	O	288-292
end	O	293-296
,	O	296-297
we	O	298-300
performed	O	301-310
a	O	311-312
linkage	O	313-320
study	O	321-326
with	O	327-331
59	O	332-334
consecutively	O	335-348
collected	O	349-358
Dutch	O	359-364
breast	B	365-371
cancer	I	372-378
families	O	379-387
,	O	387-388
including	O	389-398
16	O	399-401
with	O	402-406
at	O	407-409
least	O	410-415
one	O	416-419
case	O	420-424
of	O	425-427
ovarian	B	428-435
cancer	I	436-442
.	O	442-443

We	O	444-446
used	O	447-451
an	O	452-454
intake	O	455-461
cut	O	462-465
-	O	465-466
off	O	466-469
of	O	470-472
at	O	473-475
least	O	476-481
three	O	482-487
first	O	488-493
-	O	493-494
degree	O	494-500
relatives	O	501-510
with	O	511-515
breast	B	516-522
and	I	523-526
/	I	526-527
or	I	527-529
ovarian	I	530-537
cancer	I	538-544
at	O	545-547
any	O	548-551
age	O	552-555
.	O	555-556

Significant	O	557-568
evidence	O	569-577
for	O	578-581
linkage	O	582-589
was	O	590-593
found	O	594-599
only	O	600-604
among	O	605-610
the	O	611-614
13	O	615-617
breast	B	618-624
cancer	I	625-631
families	O	632-640
with	O	641-645
a	O	646-647
mean	O	648-652
age	O	653-656
at	O	657-659
diagnosis	O	660-669
of	O	670-672
less	O	673-677
than	O	678-682
45	O	683-685
years	O	686-691
.	O	691-692

An	O	693-695
unexpectedly	O	696-708
low	O	709-712
proportion	O	713-723
of	O	724-726
the	O	727-730
breast	B	731-737
-	I	737-738
ovarian	I	738-745
cancer	I	746-752
families	O	753-761
were	O	762-766
estimated	O	767-776
to	O	777-779
be	O	780-782
linked	O	783-789
to	O	790-792
BRCA1	O	793-798
,	O	798-799
which	O	800-805
could	O	806-811
be	O	812-814
due	O	815-818
to	O	819-821
a	O	822-823
founder	O	824-831
effect	O	832-838
in	O	839-841
the	O	842-845
Dutch	O	846-851
population	O	852-862
.	O	862-863

Given	O	864-869
the	O	870-873
expected	O	874-882
logistical	O	883-893
problems	O	894-902
in	O	903-905
clinical	O	906-914
management	O	915-925
now	O	926-929
that	O	930-934
BRCA1	O	935-940
has	O	941-944
been	O	945-949
identified	O	950-960
,	O	960-961
we	O	962-964
propose	O	965-972
an	O	973-975
interim	O	976-983
period	O	984-990
in	O	991-993
which	O	994-999
only	O	1000-1004
families	O	1005-1013
with	O	1014-1018
a	O	1019-1020
strong	O	1021-1027
positive	O	1028-1036
family	O	1037-1043
history	O	1044-1051
for	O	1052-1055
early	O	1056-1061
onset	O	1062-1067
breast	B	1068-1074
and	I	1075-1078
/	I	1078-1079
or	I	1079-1081
ovarian	I	1082-1089
cancer	I	1090-1096
will	O	1097-1101
be	O	1102-1104
offered	O	1105-1112
BRCA1	O	1113-1118
mutation	O	1119-1127
testing	O	1128-1135
.	O	1135-1136
.	O	1135-1136

Some	O	0-4
Mexican	O	5-12
glucose	O	13-20
-	O	20-21
6	O	21-22
-	O	20-21
phosphate	O	23-32
dehydrogenase	O	33-46
variants	O	47-55
revisited	O	56-65
.	O	65-66

Glucose	B	67-74
-	I	74-75
6	I	75-76
-	I	74-75
phosphate	I	77-86
dehydrogenase	I	87-100
(	I	101-102
G6PD	I	102-106
)	I	106-107
deficiency	I	108-118
appears	O	119-126
to	O	127-129
be	O	130-132
fairly	O	133-139
common	O	140-146
in	O	147-149
Mexico	O	150-156
.	O	156-157

We	O	158-160
have	O	161-165
now	O	166-169
examined	O	170-178
the	O	179-182
DNA	O	183-186
of	O	187-189
three	O	190-195
previously	O	196-206
reported	O	207-215
electrophoretically	O	216-235
fast	O	236-240
Mexican	O	241-248
G6PD	O	249-253
variants	O	254-262
,	O	262-263
-	O	264-265
G6PD	O	265-269
Distrito	O	270-278
Federal	O	279-286
,	O	286-287
G6PD	O	288-292
Tepic	O	293-298
,	O	298-299
and	O	300-303
G6PD	O	304-308
Castilla	O	309-317
.	O	317-318

All	O	319-322
three	O	323-328
of	O	329-331
these	O	332-337
variants	O	338-346
,	O	346-347
believed	O	348-356
on	O	357-359
the	O	360-363
basis	O	364-369
of	O	370-372
biochemical	O	373-384
characterization	O	385-401
and	O	402-405
population	O	406-416
origin	O	417-423
to	O	424-426
be	O	427-429
unique	O	430-436
,	O	436-437
have	O	438-442
the	O	443-446
G	O	447-448
-	O	448-449
-	O	448-449
-	O	448-449
-	O	448-449
A	O	452-453
transition	O	454-464
at	O	465-467
nucleotide	O	468-478
202	O	479-482
and	O	483-486
the	O	487-490
A	O	491-492
-	O	492-493
-	O	492-493
-	O	492-493
-	O	492-493
G	O	496-497
transition	O	498-508
at	O	509-511
nucleotide	O	512-522
376	O	523-526
,	O	526-527
mutations	O	528-537
that	O	538-542
we	O	543-545
now	O	546-549
recognize	O	550-559
to	O	560-562
be	O	563-565
characteristic	O	566-580
of	O	581-583
G6PD	O	584-588
A	O	589-590
-	O	590-591
.	O	591-592

Two	O	593-596
other	O	597-602
Mexican	O	603-610
males	O	611-616
with	O	617-621
G6PD	B	622-626
deficiency	I	627-637
were	O	638-642
found	O	643-648
to	O	649-651
have	O	652-656
the	O	657-660
same	O	661-665
mutation	O	666-674
.	O	674-675

All	O	676-679
five	O	680-684
have	O	685-689
the	O	690-693
(	O	694-695
NlaIII	O	695-701
/	O	701-702
FokI	O	702-706
/	O	701-702
PvuII	O	707-712
/	O	701-702
PstI	O	713-717
)	O	717-718
haplotype	O	719-728
characteristic	O	729-743
of	O	744-746
G6PD	O	747-751
A	O	752-753
-	O	754-755
in	O	755-757
Africa	O	758-764
.	O	764-765

Since	O	766-771
the	O	772-775
PvuII	O	776-781
+	O	782-783
genotype	O	784-792
seems	O	793-798
to	O	799-801
be	O	802-804
rare	O	805-809
in	O	810-812
Europe	O	813-819
,	O	819-820
we	O	821-823
conclude	O	824-832
that	O	833-837
all	O	838-841
of	O	842-844
these	O	845-850
G6PD	O	851-855
A	O	856-857
-	O	858-859
genes	O	860-865
had	O	866-869
their	O	870-875
ancient	O	876-883
origin	O	884-890
in	O	891-893
Africa	O	894-900
,	O	900-901
although	O	902-910
in	O	911-913
many	O	914-918
of	O	919-921
the	O	922-925
Mexican	O	926-933
patients	O	934-942
with	O	943-947
G6PD	O	948-952
A	O	953-954
-	O	955-956
202A	O	956-960
/	O	960-961
376G	O	961-965
the	O	966-969
gene	O	970-974
may	O	975-978
have	O	979-983
been	O	984-988
imported	O	989-997
more	O	998-1002
recently	O	1003-1011
from	O	1012-1016
Spain	O	1017-1022
,	O	1022-1023
where	O	1024-1029
this	O	1030-1034
variant	O	1035-1042
,	O	1042-1043
formerly	O	1044-1052
known	O	1053-1058
as	O	1059-1061
G6PD	O	1062-1066
Betica	O	1067-1073
,	O	1073-1074
is	O	1075-1077
also	O	1078-1082
prevalent	O	1083-1092
.	O	1092-1093
.	O	1092-1093

Inactivation	O	0-12
of	O	13-15
germline	O	16-24
mutant	O	25-31
APC	B	32-35
alleles	O	36-43
by	O	44-46
attenuated	O	47-57
somatic	O	58-65
mutations	O	66-75
:	O	75-76
a	O	77-78
molecular	O	79-88
genetic	O	89-96
mechanism	O	97-106
for	O	107-110
attenuated	B	111-121
familial	I	122-130
adenomatous	I	131-142
polyposis	I	143-152
.	O	152-153

Germline	O	154-162
mutations	O	163-172
of	O	173-175
the	O	176-179
adenomatous	B	180-191
polyposis	I	192-201
coli	I	202-206
(	I	207-208
APC	I	208-211
)	I	211-212
tumor	I	213-218
-	O	218-219
suppressor	O	219-229
gene	O	230-234
result	O	235-241
in	O	242-244
familial	B	245-253
adenomatous	I	254-265
polyposis	I	266-275
(	O	276-277
FAP	B	277-280
)	O	280-281
.	O	281-282

Patients	O	283-291
with	O	292-296
FAP	B	297-300
typically	O	301-310
develop	O	311-318
hundreds	O	319-327
to	O	328-330
thousands	O	331-340
of	O	341-343
benign	B	344-350
colorectal	I	351-361
tumors	I	362-368
and	O	369-372
early	O	373-378
-	O	378-379
onset	O	379-384
colorectal	B	385-395
cancer	I	396-402
.	O	402-403

A	O	404-405
subset	O	406-412
of	O	413-415
germline	O	416-424
APC	B	425-428
mutations	O	429-438
results	O	439-446
in	O	447-449
an	O	450-452
attenuated	B	453-463
FAP	I	464-467
(	O	468-469
AFAP	B	469-473
)	O	473-474
phenotype	O	475-484
,	O	484-485
in	O	486-488
which	O	489-494
patients	O	495-503
develop	O	504-511
fewer	O	512-517
tumors	B	518-524
and	O	525-528
develop	O	529-536
them	O	537-541
at	O	542-544
an	O	545-547
older	O	548-553
age	O	554-557
.	O	557-558

Although	O	559-567
a	O	568-569
genotype	O	570-578
-	O	578-579
phenotype	O	579-588
correlation	O	589-600
between	O	601-608
the	O	609-612
locations	O	613-622
of	O	623-625
APC	B	626-629
germline	O	630-638
mutations	O	639-648
and	O	649-652
the	O	653-656
development	O	657-668
of	O	669-671
AFAP	B	672-676
has	O	677-680
been	O	681-685
well	O	686-690
documented	O	691-701
,	O	701-702
the	O	703-706
mechanism	O	707-716
for	O	717-720
AFAP	B	721-725
has	O	726-729
not	O	730-733
been	O	734-738
well	O	739-743
defined	O	744-751
.	O	751-752

We	O	753-755
investigated	O	756-768
the	O	769-772
mechanism	O	773-782
for	O	783-786
AFAP	B	787-791
in	O	792-794
patients	O	795-803
carrying	O	804-812
a	O	813-814
mutant	O	815-821
APC	B	822-825
allele	O	826-832
(	O	833-834
APC	O	834-837
(	O	838-839
AS9	O	839-842
)	O	842-843
)	O	842-843
that	O	845-849
has	O	850-853
a	O	854-855
mutation	O	856-864
in	O	865-867
the	O	868-871
alternatively	O	872-885
spliced	O	886-893
region	O	894-900
of	O	901-903
exon	O	904-908
9	O	909-910
.	O	910-911
APC	O	912-915
(	O	916-917
AS9	O	917-920
)	O	920-921
was	O	922-925
found	O	926-931
to	O	932-934
down	O	935-939
-	O	939-940
regulate	O	940-948
beta	O	949-953
-	O	953-954
catenin	O	954-961
-	O	953-954
regulated	O	962-971
transcription	O	972-985
,	O	985-986
the	O	987-990
major	O	991-996
tumor	B	997-1002
-	O	1002-1003
suppressor	O	1003-1013
function	O	1014-1022
of	O	1023-1025
APC	O	1026-1029
,	O	1029-1030
as	O	1031-1033
did	O	1034-1037
the	O	1038-1041
wild	O	1042-1046
-	O	1046-1047
type	O	1047-1051
APC	O	1052-1055
.	O	1055-1056

Mutation	O	1057-1065
analysis	O	1066-1074
showed	O	1075-1081
that	O	1082-1086
both	O	1087-1091
APC	O	1092-1095
(	O	1096-1097
AS9	O	1097-1100
)	O	1100-1101
and	O	1102-1105
the	O	1106-1109
wild	O	1110-1114
-	O	1114-1115
type	O	1115-1119
APC	B	1120-1123
alleles	O	1124-1131
were	O	1132-1136
somatically	O	1137-1148
mutated	O	1149-1156
in	O	1157-1159
most	O	1160-1164
colorectal	B	1165-1175
tumors	I	1176-1182
from	O	1183-1187
these	O	1188-1193
patients	O	1194-1202
.	O	1202-1203

Functional	O	1204-1214
analysis	O	1215-1223
showed	O	1224-1230
that	O	1231-1235
4666insA	O	1236-1244
,	O	1244-1245
a	O	1246-1247
common	O	1248-1254
somatic	O	1255-1262
mutation	O	1263-1271
in	O	1272-1274
APC	O	1275-1278
(	O	1279-1280
AS9	O	1280-1283
)	O	1283-1284
in	O	1285-1287
these	O	1288-1293
tumors	B	1294-1300
,	O	1300-1301
did	O	1302-1305
not	O	1306-1309
inactivate	O	1310-1320
the	O	1321-1324
wild	O	1325-1329
-	O	1329-1330
type	O	1330-1334
APC	O	1335-1338
.	O	1338-1339

Our	O	1340-1343
results	O	1344-1351
indicate	O	1352-1360
that	O	1361-1365
carriers	O	1366-1374
of	O	1375-1377
APC	O	1378-1381
(	O	1382-1383
AS9	O	1383-1386
)	O	1386-1387
develop	O	1388-1395
fewer	O	1396-1401
colorectal	B	1402-1412
tumors	I	1413-1419
than	O	1420-1424
do	O	1425-1427
typical	O	1428-1435
patients	O	1436-1444
with	O	1445-1449
FAP	B	1450-1453
because	O	1454-1461
somatic	O	1462-1469
inactivation	O	1470-1482
of	O	1483-1485
both	O	1486-1490
APC	B	1491-1494
alleles	O	1495-1502
is	O	1503-1505
necessary	O	1506-1515
for	O	1516-1519
colorectal	O	1520-1530
tumorigenesis	O	1531-1544
.	O	1544-1545

However	O	1546-1553
,	O	1553-1554
these	O	1555-1560
patients	O	1561-1569
develop	O	1570-1577
colorectal	B	1578-1588
tumors	I	1589-1595
more	O	1596-1600
frequently	O	1601-1611
than	O	1612-1616
does	O	1617-1621
the	O	1622-1625
general	O	1626-1633
population	O	1634-1644
because	O	1645-1652
APC	O	1653-1656
(	O	1657-1658
AS9	O	1658-1661
)	O	1661-1662
is	O	1663-1665
inactivated	O	1666-1677
by	O	1678-1680
mutations	O	1681-1690
that	O	1691-1695
do	O	1696-1698
not	O	1699-1702
inactivate	O	1703-1713
the	O	1714-1717
wild	O	1718-1722
-	O	1722-1723
type	O	1723-1727
APC	O	1728-1731
.	O	1731-1732
.	O	1731-1732

Submicroscopic	O	0-14
deletions	O	15-24
at	O	25-27
the	O	28-31
WAGR	B	32-36
locus	O	37-42
,	O	42-43
revealed	O	44-52
by	O	53-55
nonradioactive	O	56-70
in	O	71-73
situ	O	74-78
hybridization	O	79-92
.	O	92-93

Fluorescence	O	94-106
in	O	107-109
situ	O	110-114
hybridization	O	115-128
(	O	129-130
FISH	O	130-134
)	O	134-135
with	O	136-140
biotin	O	141-147
-	O	147-148
labeled	O	148-155
probes	O	156-162
mapping	O	163-170
to	O	171-173
11p13	O	174-179
has	O	180-183
been	O	184-188
used	O	189-193
for	O	194-197
the	O	198-201
molecular	O	202-211
analysis	O	212-220
of	O	221-223
deletions	O	224-233
of	O	234-236
the	O	237-240
WAGR	B	241-245
(	O	246-247
Wilms	B	247-252
tumor	I	253-258
,	O	258-259
aniridia	B	260-268
,	O	268-269
genitourinary	B	270-283
abnormalities	I	284-297
,	O	297-298
and	O	299-302
mental	B	303-309
retardation	I	310-321
)	O	321-322
locus	O	323-328
.	O	328-329

We	O	330-332
have	O	333-337
detected	O	338-346
a	O	347-348
submicroscopic	O	349-363
11p13	O	364-369
deletion	O	370-378
in	O	379-381
a	O	382-383
child	O	384-389
with	O	390-394
inherited	O	395-404
aniridia	B	405-413
who	O	414-417
subsequently	O	418-430
presented	O	431-440
with	O	441-445
Wilms	B	446-451
tumor	I	452-457
in	O	458-460
a	O	461-462
horseshoe	O	463-472
kidney	O	473-479
,	O	479-480
only	O	481-485
revealed	O	486-494
at	O	495-497
surgery	O	498-505
.	O	505-506

The	O	507-510
mother	O	511-517
,	O	517-518
who	O	519-522
has	O	523-526
aniridia	B	527-535
,	O	535-536
was	O	537-540
also	O	541-545
found	O	546-551
to	O	552-554
carry	O	555-560
a	O	561-562
deletion	O	563-571
including	O	572-581
both	O	582-586
the	O	587-590
aniridia	B	591-599
candidate	O	600-609
gene	O	610-614
(	O	615-616
AN2	O	616-619
)	O	619-620
and	O	621-624
the	O	625-628
Wilms	B	629-634
tumor	I	635-640
predisposition	O	641-655
gene	O	656-660
(	O	661-662
WT1	O	662-665
)	O	665-666
.	O	666-667

This	O	668-672
is	O	673-675
therefore	O	676-685
a	O	686-687
rare	O	688-692
case	O	693-697
of	O	698-700
an	O	701-703
inherited	O	704-713
WAGR	B	714-718
deletion	O	719-727
.	O	727-728

Wilms	B	729-734
tumor	I	735-740
has	O	741-744
so	O	745-747
far	O	748-751
only	O	752-756
been	O	757-761
associated	O	762-772
with	O	773-777
sporadic	O	778-786
de	O	787-789
novo	O	790-794
aniridia	B	795-803
cases	O	804-809
.	O	809-810

We	O	811-813
have	O	814-818
shown	O	819-824
that	O	825-829
a	O	830-831
cosmid	O	832-838
probe	O	839-844
for	O	845-848
a	O	849-850
candidate	O	851-860
aniridia	B	861-869
gene	O	870-874
,	O	874-875
homologous	O	876-886
to	O	887-889
the	O	890-893
mouse	O	894-899
Pax	O	900-903
-	O	903-904
6	O	904-905
gene	O	906-910
,	O	910-911
is	O	912-914
deleted	O	915-922
in	O	923-925
cell	O	926-930
lines	O	931-936
from	O	937-941
aniridia	B	942-950
patients	O	951-959
with	O	960-964
previously	O	965-975
characterized	O	976-989
deletions	O	990-999
at	O	1000-1002
11p13	O	1003-1008
,	O	1008-1009
while	O	1010-1015
another	O	1016-1023
cosmid	O	1024-1030
marker	O	1031-1037
mapping	O	1038-1045
between	O	1046-1053
two	O	1054-1057
aniridia	B	1058-1066
-	O	1066-1067
associated	O	1067-1077
translocation	O	1078-1091
breakpoints	O	1092-1103
(	O	1104-1105
and	O	1105-1108
hence	O	1109-1114
a	O	1115-1116
second	O	1117-1123
candidate	O	1124-1133
marker	O	1134-1140
)	O	1140-1141
is	O	1142-1144
present	O	1145-1152
on	O	1153-1155
both	O	1156-1160
chromosomes	O	1161-1172
.	O	1172-1173

These	O	1174-1179
results	O	1180-1187
support	O	1188-1195
the	O	1196-1199
Pax	O	1200-1203
-	O	1203-1204
6	O	1204-1205
homologue	O	1206-1215
as	O	1216-1218
a	O	1219-1220
strong	O	1221-1227
candidate	O	1228-1237
for	O	1238-1241
the	O	1242-1245
AN2	O	1246-1249
gene	O	1250-1254
.	O	1254-1255

FISH	O	1256-1260
with	O	1261-1265
cosmid	O	1266-1272
probes	O	1273-1279
has	O	1280-1283
proved	O	1284-1290
to	O	1291-1293
be	O	1294-1296
a	O	1297-1298
fast	O	1299-1303
and	O	1304-1307
reliable	O	1308-1316
technique	O	1317-1326
for	O	1327-1330
the	O	1331-1334
molecular	O	1335-1344
analysis	O	1345-1353
of	O	1354-1356
deletions	O	1357-1366
.	O	1366-1367

It	O	1368-1370
can	O	1371-1374
be	O	1375-1377
used	O	1378-1382
with	O	1383-1387
limited	O	1388-1395
amounts	O	1396-1403
of	O	1404-1406
material	O	1407-1415
and	O	1416-1419
has	O	1420-1423
strong	O	1424-1430
potential	O	1431-1440
for	O	1441-1444
clinical	O	1445-1453
applications	O	1454-1466
.	O	1466-1467
.	O	1466-1467

Haplotype	O	0-9
studies	O	10-17
in	O	18-20
Wilson	B	21-27
disease	I	28-35
.	O	35-36

In	O	37-39
51	O	40-42
families	O	43-51
with	O	52-56
Wilson	B	57-63
disease	I	64-71
,	O	71-72
we	O	73-75
have	O	76-80
studied	O	81-88
DNA	O	89-92
haplotypes	O	93-103
of	O	104-106
dinucleotide	O	107-119
repeat	O	120-126
polymorphisms	O	127-140
(	O	141-142
CA	O	142-144
repeats	O	145-152
)	O	152-153
in	O	154-156
the	O	157-160
13q14	O	161-166
.	O	166-167

3	O	168-169
region	O	170-176
,	O	176-177
to	O	178-180
examine	O	181-188
these	O	189-194
markers	O	195-202
for	O	203-206
association	O	207-218
with	O	219-223
the	O	224-227
Wilson	B	228-234
disease	I	235-242
gene	O	243-247
(	O	248-249
WND	B	249-252
)	O	252-253
.	O	253-254

In	O	255-257
addition	O	258-266
to	O	267-269
a	O	270-271
marker	O	272-278
(	O	279-280
D13S133	O	280-287
)	O	287-288
described	O	289-298
elsewhere	O	299-308
,	O	308-309
we	O	310-312
have	O	313-317
developed	O	318-327
three	O	328-333
new	O	334-337
highly	O	338-344
polymorphic	O	345-356
markers	O	357-364
(	O	365-366
D13S314	O	366-373
,	O	373-374
D13S315	O	375-382
,	O	382-383
and	O	384-387
D13S316	O	388-395
)	O	395-396
close	O	397-402
to	O	403-405
the	O	406-409
WND	B	410-413
locus	O	414-419
.	O	419-420

We	O	421-423
have	O	424-428
examined	O	429-437
the	O	438-441
distribution	O	442-454
of	O	455-457
marker	O	458-464
alleles	O	465-472
at	O	473-475
the	O	476-479
loci	O	480-484
studied	O	485-492
and	O	493-496
have	O	497-501
found	O	502-507
that	O	508-512
D13S314	O	513-520
,	O	520-521
D13S133	O	522-529
,	O	529-530
and	O	531-534
D13S316	O	535-542
each	O	543-547
show	O	548-552
nonrandom	O	553-562
distribution	O	563-575
on	O	576-578
chromosomes	O	579-590
carrying	O	591-599
the	O	600-603
WND	B	604-607
mutation	O	608-616
.	O	616-617

We	O	618-620
have	O	621-625
studied	O	626-633
haplotypes	O	634-644
of	O	645-647
these	O	648-653
three	O	654-659
markers	O	660-667
and	O	668-671
have	O	672-676
found	O	677-682
that	O	683-687
there	O	688-693
are	O	694-697
highly	O	698-704
significant	O	705-716
differences	O	717-728
between	O	729-736
WND	B	737-740
and	O	741-744
normal	O	745-751
haplotypes	O	752-762
in	O	763-765
northern	O	766-774
European	O	775-783
families	O	784-792
.	O	792-793

These	O	794-799
findings	O	800-808
have	O	809-813
important	O	814-823
implications	O	824-836
for	O	837-840
mutation	O	841-849
detection	O	850-859
and	O	860-863
molecular	O	864-873
diagnosis	O	874-883
in	O	884-886
families	O	887-895
with	O	896-900
Wilson	B	901-907
disease	I	908-915
.	O	915-916

Growth	O	0-6
hormone	O	7-14
treatment	O	15-24
increases	O	25-34
CO	O	35-37
(	O	37-38
2	O	38-39
)	O	39-40
response	O	41-49
,	O	49-50
ventilation	O	51-62
and	O	63-66
central	O	67-74
inspiratory	O	75-86
drive	O	87-92
in	O	93-95
children	O	96-104
with	O	105-109
Prader	B	110-116
-	I	116-117
Willi	I	117-122
syndrome	I	123-131
.	O	131-132

We	O	133-135
studied	O	136-143
whether	O	144-151
the	O	152-155
beneficial	O	156-166
effects	O	167-174
of	O	175-177
growth	O	178-184
hormone	O	185-192
(	O	193-194
GH	O	194-196
)	O	196-197
treatment	O	198-207
on	O	208-210
growth	O	211-217
and	O	218-221
body	O	222-226
composition	O	227-238
in	O	239-241
PWS	B	242-245
are	O	246-249
accompanied	O	250-261
by	O	262-264
an	O	265-267
improvement	O	268-279
in	O	280-282
respiratory	O	283-294
function	O	295-303
.	O	303-304

We	O	305-307
measured	O	308-316
resting	O	317-324
ventilation	O	325-336
,	O	336-337
airway	O	338-344
occlusion	O	345-354
pressure	O	355-363
(	O	364-365
P	O	365-366
(	O	367-368
0	O	368-369
.	O	369-370
1	O	371-372
)	O	372-373
)	O	372-373
and	O	375-378
ventilatory	O	379-390
response	O	391-399
to	O	400-402
CO	O	403-405
(	O	406-407
2	O	407-408
)	O	408-409
in	O	410-412
nine	O	413-417
children	O	418-426
,	O	426-427
aged	O	428-432
7	O	433-434
-	O	434-435
14	O	435-437
years	O	438-443
,	O	443-444
before	O	445-451
and	O	452-455
6	O	456-457
-	O	457-458
9	O	458-459
months	O	460-466
after	O	467-472
the	O	473-476
start	O	477-482
of	O	483-485
GH	O	486-488
treatment	O	489-498
.	O	498-499

During	O	500-506
GH	O	507-509
treatment	O	510-519
,	O	519-520
resting	O	521-528
ventilation	O	529-540
increased	O	541-550
by	O	551-553
26	O	554-556
%	O	556-557
,	O	557-558
P	O	559-560
(	O	561-562
0	O	562-563
.	O	563-564
1	O	565-566
)	O	566-567
by	O	568-570
72	O	571-573
%	O	573-574
and	O	575-578
the	O	579-582
response	O	583-591
to	O	592-594
CO	O	595-597
(	O	598-599
2	O	599-600
)	O	600-601
by	O	602-604
65	O	605-607
%	O	607-608
(	O	609-610
P	O	610-611
<	O	612-613
0	O	614-615
.	O	615-616
002	O	617-620
,	O	620-621
<	O	622-623
0	O	624-625
.	O	625-626
04	O	627-629
and	O	630-633
<	O	634-635
0	O	636-637
.	O	637-638
02	O	639-641
,	O	641-642
respectively	O	643-655
)	O	655-656
.	O	656-657

This	O	658-662
observed	O	663-671
increase	O	672-680
in	O	681-683
ventilatory	O	684-695
output	O	696-702
was	O	703-706
not	O	707-710
correlated	O	711-721
to	O	722-724
changes	O	725-732
in	O	733-735
body	O	736-740
mass	O	741-745
index	O	746-751
.	O	751-752

CONCLUSION	O	753-763
Treatment	O	765-774
of	O	775-777
children	O	778-786
with	O	787-791
Prader	B	792-798
-	I	798-799
Willi	I	799-804
syndrome	I	805-813
(	O	814-815
PWS	B	815-818
)	O	818-819
seems	O	820-825
to	O	826-828
have	O	829-833
a	O	834-835
stimulatory	O	836-847
effect	O	848-854
on	O	855-857
central	O	858-865
respiratory	O	866-877
structures	O	878-888
.	O	888-889

The	O	890-893
observed	O	894-902
increase	O	903-911
in	O	912-914
ventilation	O	915-926
and	O	927-930
inspiratory	O	931-942
drive	O	943-948
may	O	949-952
contribute	O	953-963
to	O	964-966
the	O	967-970
improved	O	971-979
activity	O	980-988
level	O	989-994
reported	O	995-1003
by	O	1004-1006
parents	O	1007-1014
of	O	1015-1017
PWS	B	1018-1021
children	O	1022-1030
during	O	1031-1037
growth	O	1038-1044
hormone	O	1045-1052
therapy	O	1053-1060

Somatic	O	0-7
von	B	8-11
Hippel	I	12-18
-	I	18-19
Lindau	I	19-25
mutation	O	26-34
in	O	35-37
clear	O	38-43
cell	O	44-48
papillary	B	49-58
cystadenoma	I	59-70
of	I	71-73
the	I	74-77
epididymis	I	78-88
.	O	88-89

Papillary	B	90-99
cystadenoma	I	100-111
of	I	112-114
the	I	115-118
epididymis	I	119-129
is	O	130-132
an	O	133-135
uncommon	O	136-144
benign	O	145-151
lesion	O	152-158
that	O	159-163
may	O	164-167
occur	O	168-173
sporadically	O	174-186
or	O	187-189
as	O	190-192
a	O	193-194
manifestation	O	195-208
of	O	209-211
von	B	212-215
Hippel	I	216-222
-	I	222-223
Lindau	I	223-229
(	I	230-231
VHL	I	231-234
)	I	234-235
disease	I	236-243
.	O	243-244

Neither	O	245-252
immunohistochemical	O	253-272
studies	O	273-280
nor	O	281-284
molecular	O	285-294
genetic	O	295-302
analyses	O	303-311
of	O	312-314
the	O	315-318
VHL	B	319-322
gene	O	323-327
have	O	328-332
been	O	333-337
reported	O	338-346
previously	O	347-357
for	O	358-361
this	O	362-366
lesion	O	367-373
.	O	373-374

The	O	375-378
authors	O	379-386
describe	O	387-395
two	O	396-399
cases	O	400-405
of	O	406-408
clear	O	409-414
cell	O	415-419
papillary	B	420-429
cystadenoma	I	430-441
of	I	442-444
the	I	445-448
epididymis	I	449-459
,	O	459-460
both	O	461-465
of	O	466-468
which	O	469-474
were	O	475-479
initially	O	480-489
confused	O	490-498
with	O	499-503
metastatic	B	504-514
renal	I	515-520
cell	I	521-525
carcinoma	I	526-535
.	O	535-536

Both	O	537-541
lesions	O	542-549
showed	O	550-556
positive	O	557-565
immunohistochemical	O	566-585
staining	O	586-594
for	O	595-598
low	O	599-602
and	O	603-606
intermediate	O	607-619
molecular	O	620-629
weight	O	630-636
keratins	O	637-645
(	O	646-647
Cam	O	647-650
5	O	651-652
.	O	652-653
2	O	654-655
and	O	656-659
AE1	O	660-663
/	O	663-664
AE3	O	664-667
)	O	667-668
,	O	668-669
EMA	O	670-673
,	O	673-674
vimentin	O	675-683
,	O	683-684
alpha	O	685-690
1	O	691-692
-	O	692-693
antitrypsin	O	693-704
,	O	704-705
and	O	706-709
alpha	O	710-715
1	O	716-717
-	O	717-718
antichymotrypsin	O	718-734
.	O	734-735

Each	O	736-740
was	O	741-744
negative	O	745-753
for	O	754-757
CEA	O	758-761
.	O	761-762

Because	O	763-770
clear	O	771-776
cell	O	777-781
papillary	B	782-791
cystadenoma	I	792-803
is	O	804-806
similar	O	807-814
to	O	815-817
renal	B	818-823
cell	I	824-828
carcinoma	I	829-838
histologically	O	839-853
,	O	853-854
and	O	855-858
because	O	859-866
both	O	867-871
occur	O	872-877
as	O	878-880
components	O	881-891
of	O	892-894
the	O	895-898
von	B	899-902
Hippel	I	903-909
-	I	909-910
Lindau	I	910-916
disease	I	917-924
complex	O	925-932
,	O	932-933
the	O	934-937
authors	O	938-945
analyzed	O	946-954
both	O	955-959
cases	O	960-965
for	O	966-969
the	O	970-973
presence	O	974-982
of	O	983-985
mutations	O	986-995
in	O	996-998
the	O	999-1002
VHL	B	1003-1006
gene	O	1007-1011
.	O	1011-1012

A	O	1013-1014
somatic	O	1015-1022
VHL	B	1023-1026
gene	O	1027-1031
mutation	O	1032-1040
was	O	1041-1044
detected	O	1045-1053
in	O	1054-1056
one	O	1057-1060
of	O	1061-1063
the	O	1064-1067
two	O	1068-1071
tumors	B	1072-1078
by	O	1079-1081
polymerase	O	1082-1092
chain	O	1093-1098
reaction	O	1099-1107
followed	O	1108-1116
by	O	1117-1119
single	O	1120-1126
-	O	1126-1127
strand	O	1127-1133
conformation	O	1134-1146
polymorphism	O	1147-1159
analysis	O	1160-1168
.	O	1168-1169

Direct	O	1170-1176
sequencing	O	1177-1187
revealed	O	1188-1196
a	O	1197-1198
cytosine	O	1199-1207
to	O	1208-1210
thymine	O	1211-1218
transition	O	1219-1229
at	O	1230-1232
nucleotide	O	1233-1243
694	O	1244-1247
,	O	1247-1248
resulting	O	1249-1258
in	O	1259-1261
the	O	1262-1265
replacement	O	1266-1277
of	O	1278-1280
an	O	1281-1283
arginine	O	1284-1292
with	O	1293-1297
a	O	1298-1299
stop	O	1300-1304
codon	O	1305-1310
after	O	1311-1316
the	O	1317-1320
sixth	O	1321-1326
amino	O	1327-1332
acid	O	1333-1337
of	O	1338-1340
exon	O	1341-1345
3	O	1346-1347
.	O	1347-1348

As	O	1349-1351
the	O	1352-1355
VHL	B	1356-1359
gene	O	1360-1364
is	O	1365-1367
believed	O	1368-1376
to	O	1377-1379
function	O	1380-1388
as	O	1389-1391
a	O	1392-1393
tumor	B	1394-1399
suppressor	O	1400-1410
gene	O	1411-1415
,	O	1415-1416
VHL	B	1417-1420
gene	O	1421-1425
mutations	O	1426-1435
may	O	1436-1439
play	O	1440-1444
a	O	1445-1446
role	O	1447-1451
in	O	1452-1454
the	O	1455-1458
initiation	O	1459-1469
of	O	1470-1472
tumorigenesis	O	1473-1486
in	O	1487-1489
sporadic	O	1490-1498
cystadenomas	B	1499-1511
of	I	1512-1514
the	I	1515-1518
epididymis	I	1519-1529
.	O	1529-1530

An	O	0-2
evaluation	O	3-13
of	O	14-16
genetic	O	17-24
heterogeneity	O	25-38
in	O	39-41
145	O	42-45
breast	B	46-52
-	I	52-53
ovarian	I	53-60
cancer	I	61-67
families	O	68-76
.	O	76-77

Breast	B	78-84
Cancer	I	85-91
Linkage	O	92-99
Consortium	O	100-110
.	O	110-111

The	O	112-115
breast	B	116-122
-	I	122-123
ovary	I	123-128
cancer	I	129-135
-	I	135-136
family	I	136-142
syndrome	I	143-151
is	O	152-154
a	O	155-156
dominant	O	157-165
predisposition	O	166-180
to	O	181-183
cancer	B	184-190
of	I	191-193
the	I	194-197
breast	I	198-204
and	I	205-208
ovaries	I	209-216
which	O	217-222
has	O	223-226
been	O	227-231
mapped	O	232-238
to	O	239-241
chromosome	O	242-252
region	O	253-259
17q12	O	260-265
-	O	265-266
q21	O	266-269
.	O	269-270

The	O	271-274
majority	O	275-283
,	O	283-284
but	O	285-288
not	O	289-292
all	O	293-296
,	O	296-297
of	O	298-300
breast	B	301-307
-	I	307-308
ovary	I	308-313
cancer	I	314-320
families	O	321-329
show	O	330-334
linkage	O	335-342
to	O	343-345
this	O	346-350
susceptibility	O	351-365
locus	O	366-371
,	O	371-372
designated	O	373-383
BRCA1	O	384-389
.	O	389-390

We	O	391-393
report	O	394-400
here	O	401-405
the	O	406-409
results	O	410-417
of	O	418-420
a	O	421-422
linkage	O	423-430
analysis	O	431-439
of	O	440-442
145	O	443-446
families	O	447-455
with	O	456-460
both	O	461-465
breast	B	466-472
and	I	473-476
ovarian	I	477-484
cancer	I	485-491
.	O	491-492

These	O	493-498
families	O	499-507
contain	O	508-515
either	O	516-522
a	O	523-524
total	O	525-530
of	O	531-533
three	O	534-539
or	O	540-542
more	O	543-547
cases	O	548-553
of	O	554-556
early	O	557-562
-	O	562-563
onset	O	563-568
(	O	569-570
before	O	570-576
age	O	577-580
60	O	581-583
years	O	584-589
)	O	589-590
breast	B	591-597
cancer	I	598-604
or	O	605-607
ovarian	B	608-615
cancer	I	616-622
.	O	622-623

All	O	624-627
families	O	628-636
contained	O	637-646
at	O	647-649
least	O	650-655
one	O	656-659
case	O	660-664
of	O	665-667
ovarian	B	668-675
cancer	I	676-682
.	O	682-683

Overall	O	684-691
,	O	691-692
an	O	693-695
estimated	O	696-705
76	O	706-708
%	O	708-709
of	O	710-712
the	O	713-716
145	O	717-720
families	O	721-729
are	O	730-733
linked	O	734-740
to	O	741-743
the	O	744-747
BRCA1	O	748-753
locus	O	754-759
.	O	759-760

None	O	761-765
of	O	766-768
the	O	769-772
13	O	773-775
families	O	776-784
with	O	785-789
cases	O	790-795
of	O	796-798
male	B	799-803
breast	I	804-810
cancer	I	811-817
appear	O	818-824
to	O	825-827
be	O	828-830
linked	O	831-837
,	O	837-838
but	O	839-842
it	O	843-845
is	O	846-848
estimated	O	849-858
that	O	859-863
92	O	864-866
%	O	866-867
(	O	868-869
95	O	869-871
%	O	871-872
confidence	O	873-883
interval	O	884-892
76	O	893-895
%	O	895-896
-	O	897-898
100	O	898-901
%	O	901-902
)	O	902-903
of	O	904-906
families	O	907-915
with	O	916-920
no	O	921-923
male	B	924-928
breast	I	929-935
cancer	I	936-942
and	O	943-946
with	O	947-951
two	O	952-955
or	O	956-958
more	O	959-963
ovarian	B	964-971
cancers	I	972-979
are	O	980-983
linked	O	984-990
to	O	991-993
BRCA1	O	994-999
.	O	999-1000

These	O	1001-1006
data	O	1007-1011
suggest	O	1012-1019
that	O	1020-1024
the	O	1025-1028
breast	B	1029-1035
-	I	1035-1036
ovarian	I	1036-1043
cancer	I	1044-1050
-	I	1050-1051
family	I	1051-1057
syndrome	I	1058-1066
is	O	1067-1069
genetically	O	1070-1081
heterogeneous	O	1082-1095
.	O	1095-1096

However	O	1097-1104
,	O	1104-1105
the	O	1106-1109
large	O	1110-1115
majority	O	1116-1124
of	O	1125-1127
families	O	1128-1136
with	O	1137-1141
early	O	1142-1147
-	O	1147-1148
onset	O	1148-1153
breast	B	1154-1160
cancer	I	1161-1167
and	O	1168-1171
with	O	1172-1176
two	O	1177-1180
or	O	1181-1183
more	O	1184-1188
cases	O	1189-1194
of	O	1195-1197
ovarian	B	1198-1205
cancer	I	1206-1212
are	O	1213-1216
likely	O	1217-1223
to	O	1224-1226
be	O	1227-1229
due	O	1230-1233
to	O	1234-1236
BRCA1	O	1237-1242
mutations	O	1243-1252
.	O	1252-1253
.	O	1252-1253

Genetic	O	0-7
analysis	O	8-16
in	O	17-19
families	O	20-28
with	O	29-33
van	B	34-37
der	I	38-41
Woude	I	42-47
syndrome	I	48-56
.	O	56-57

We	O	58-60
have	O	61-65
brought	O	66-73
together	O	74-82
information	O	83-94
on	O	95-97
864	O	98-101
affected	O	102-110
individuals	O	111-122
in	O	123-125
164	O	126-129
families	O	130-138
(	O	139-140
including	O	140-149
three	O	150-155
new	O	156-159
pedigrees	O	160-169
)	O	169-170
reported	O	171-179
in	O	180-182
the	O	183-186
137	O	187-190
year	O	191-195
period	O	196-202
since	O	203-208
1845	O	209-213
when	O	214-218
Demarquay	O	219-228
first	O	229-234
described	O	235-244
a	O	245-246
family	O	247-253
with	O	254-258
what	O	259-263
was	O	264-267
later	O	268-273
called	O	274-280
van	B	281-284
der	I	285-288
Woude	I	289-294
syndrome	I	295-303
(	O	304-305
VWS	B	305-308
)	O	308-309
.	O	309-310

Both	O	311-315
types	O	316-321
of	O	322-324
oral	B	325-329
cleft	I	330-335
,	O	335-336
cleft	B	337-342
palate	I	343-349
(	O	350-351
CP	B	351-353
)	O	353-354
and	O	355-358
cleft	B	359-364
lip	I	365-368
with	O	369-373
or	O	374-376
without	O	377-384
CP	B	385-387
(	O	388-389
CLP	B	389-392
)	O	392-393
,	O	393-394
segregate	O	395-404
in	O	405-407
these	O	408-413
families	O	414-422
together	O	423-431
with	O	432-436
lower	O	437-442
lip	B	443-446
pits	I	447-451
or	O	452-454
fistulae	B	455-463
in	O	464-466
an	O	467-469
autosomal	O	470-479
dominant	O	480-488
mode	O	489-493
with	O	494-498
high	O	499-503
penetrance	O	504-514
estimated	O	515-524
to	O	525-527
be	O	528-530
K	O	531-532
=	O	533-534
.	O	534-535
89	O	536-538
and	O	539-542
.	O	542-543

99	O	544-546
by	O	547-549
different	O	550-559
methods	O	560-567
.	O	567-568

Cleft	O	569-574
types	O	575-580
(	O	581-582
CLP	B	582-585
and	O	586-589
CP	B	590-592
)	O	592-593
occur	O	594-599
in	O	600-602
VWS	B	603-606
in	O	607-609
the	O	610-613
same	O	614-618
proportions	O	619-630
as	O	631-633
in	O	634-636
the	O	637-640
general	O	641-648
non	O	649-652
-	O	652-653
VWS	O	653-656
population	O	657-667
,	O	667-668
ie	O	669-671
,	O	671-672
about	O	673-678
twice	O	679-684
as	O	685-687
many	O	688-692
cleft	O	693-698
-	O	698-699
bearing	O	699-706
individuals	O	707-718
have	O	719-723
CLP	B	724-727
as	O	728-730
have	O	731-735
CP	B	736-738
.	O	738-739

On	O	740-742
the	O	743-746
other	O	747-752
hand	O	753-757
,	O	757-758
we	O	759-761
do	O	762-764
not	O	765-768
find	O	769-773
the	O	774-777
usually	O	778-785
observed	O	786-794
excess	O	795-801
of	O	802-804
females	O	805-812
with	O	813-817
CP	B	818-820
and	O	821-824
excess	O	825-831
of	O	832-834
males	O	835-840
with	O	841-845
CLP	B	846-849
;	O	849-850
in	O	851-853
VWS	B	854-857
the	O	858-861
sex	O	862-865
ratios	O	866-872
are	O	873-876
more	O	877-881
nearly	O	882-888
equal	O	889-894
.	O	894-895

Lip	B	896-899
pits	I	900-904
also	O	905-909
are	O	910-913
equally	O	914-921
distributed	O	922-933
between	O	934-941
the	O	942-945
sexes	O	946-951
.	O	951-952

Affected	O	953-961
males	O	962-967
and	O	968-971
females	O	972-979
are	O	980-983
equally	O	984-991
likely	O	992-998
to	O	999-1001
transmit	O	1002-1010
VWS	B	1011-1014
.	O	1014-1015

However	O	1016-1023
,	O	1023-1024
there	O	1025-1030
is	O	1031-1033
an	O	1034-1036
excess	O	1037-1043
of	O	1044-1046
less	O	1047-1051
severely	O	1052-1060
affected	O	1061-1069
individuals	O	1070-1081
among	O	1082-1087
transmitters	O	1088-1100
and	O	1101-1104
a	O	1105-1106
deficiency	O	1107-1117
of	O	1118-1120
more	O	1121-1125
severely	O	1126-1134
affected	O	1135-1143
,	O	1143-1144
brought	O	1145-1152
about	O	1153-1158
by	O	1159-1161
a	O	1162-1163
proband	O	1164-1171
bias	O	1172-1176
and	O	1177-1180
differential	O	1181-1193
fecundity	O	1194-1203
.	O	1203-1204

The	O	1205-1208
expression	O	1209-1219
of	O	1220-1222
VWS	B	1223-1226
is	O	1227-1229
significantly	O	1230-1243
modified	O	1244-1252
by	O	1253-1255
the	O	1256-1259
genetic	O	1260-1267
background	O	1268-1278
More	O	1280-1284
extreme	O	1285-1292
phenotypes	O	1293-1303
in	O	1304-1306
parents	O	1307-1314
tend	O	1315-1319
to	O	1320-1322
produce	O	1323-1330
more	O	1331-1335
extreme	O	1336-1343
expression	O	1344-1354
in	O	1355-1357
their	O	1358-1363
children	O	1364-1372
.	O	1372-1373

For	O	1374-1377
a	O	1378-1379
VWS	B	1380-1383
gene	O	1384-1388
carrier	O	1389-1396
the	O	1397-1400
relative	O	1401-1409
risk	O	1410-1414
of	O	1415-1417
transmitting	O	1418-1430
a	O	1431-1432
cleft	O	1433-1438
is	O	1439-1441
26	O	1442-1444
.	O	1444-1445

45	O	1446-1448
%	O	1448-1449
;	O	1449-1450
that	O	1451-1455
of	O	1456-1458
transmitting	O	1459-1471
lower	O	1472-1477
lip	B	1478-1481
pits	I	1482-1486
is	O	1487-1489
23	O	1490-1492
.	O	1492-1493

55	O	1494-1496
%	O	1496-1497
.	O	1497-1498

Three	O	1499-1504
pedigrees	O	1505-1514
of	O	1515-1517
lip	B	1518-1521
pits	I	1522-1526
in	O	1527-1529
the	O	1530-1533
literature	O	1534-1544
show	O	1545-1549
no	O	1550-1552
clefts	O	1553-1559
among	O	1560-1565
a	O	1566-1567
significant	O	1568-1579
number	O	1580-1586
of	O	1587-1589
affected	O	1590-1598
individuals	O	1599-1610
.	O	1610-1611

Control	O	1612-1619
of	O	1620-1622
gene	O	1623-1627
expression	O	1628-1638
in	O	1639-1641
VWS	B	1642-1645
in	O	1646-1648
the	O	1649-1652
three	O	1653-1658
target	O	1659-1665
tissues	O	1666-1673
appears	O	1674-1681
to	O	1682-1684
be	O	1685-1687
independent	O	1688-1699
and	O	1700-1703
separately	O	1704-1714
designated	O	1715-1725
.	O	1725-1726

Mutation	O	1727-1735
rate	O	1736-1740
of	O	1741-1743
the	O	1744-1747
VWS	B	1748-1751
gene	O	1752-1756
is	O	1757-1759
calculated	O	1760-1770
to	O	1771-1773
be	O	1774-1776
1	O	1777-1778
.	O	1778-1779
8	O	1780-1781
X	O	1782-1783
10	O	1784-1786
(	O	1787-1788
-	O	1788-1789
5	O	1789-1790
)	O	1790-1791

Molecular	O	0-9
and	O	10-13
phenotypic	O	14-24
analysis	O	25-33
of	O	34-36
patients	O	37-45
with	O	46-50
deletions	O	51-60
within	O	61-67
the	O	68-71
deletion	O	72-80
-	O	80-81
rich	O	81-85
region	O	86-92
of	O	93-95
the	O	96-99
Duchenne	B	100-108
muscular	I	109-117
dystrophy	I	118-127
(	O	128-129
DMD	B	129-132
)	O	132-133
gene	O	134-138
.	O	138-139

Eighty	O	140-146
unrelated	O	147-156
individuals	O	157-168
with	O	169-173
Duchenne	B	174-182
muscular	I	183-191
dystrophy	I	192-201
(	O	202-203
DMD	B	203-206
)	O	206-207
or	O	207-209
Becker	B	210-216
muscular	I	217-225
dystrophy	I	226-235
(	O	236-237
BMD	B	237-240
)	O	240-241
were	O	242-246
found	O	247-252
to	O	253-255
have	O	256-260
deletions	O	261-270
in	O	271-273
the	O	274-277
major	O	278-283
deletion	O	284-292
-	O	292-293
rich	O	293-297
region	O	298-304
of	O	305-307
the	O	308-311
DMD	B	312-315
locus	O	316-321
.	O	321-322

This	O	323-327
region	O	328-334
includes	O	335-343
the	O	344-347
last	O	348-352
five	O	353-357
exons	O	358-363
detected	O	364-372
by	O	373-375
cDNA5b	O	376-382
-	O	382-383
7	O	383-384
,	O	384-385
all	O	386-389
exons	O	390-395
detected	O	396-404
by	O	405-407
cDNA8	O	408-413
,	O	413-414
and	O	415-418
the	O	419-422
first	O	423-428
two	O	429-432
exons	O	433-438
detected	O	439-447
by	O	448-450
cDNA9	O	451-456
.	O	456-457

These	O	458-463
80	O	464-466
individuals	O	467-478
account	O	479-486
for	O	487-490
approximately	O	491-504
75	O	505-507
%	O	507-508
of	O	509-511
109	O	512-515
deletions	O	516-525
of	O	526-528
the	O	529-532
gene	O	533-537
,	O	537-538
detected	O	539-547
among	O	548-553
181	O	554-557
patients	O	558-566
analyzed	O	567-575
with	O	576-580
the	O	581-584
entire	O	585-591
dystrophin	O	592-602
cDNA	O	603-607
.	O	607-608

Endpoints	O	609-618
for	O	619-622
many	O	623-627
of	O	628-630
these	O	631-636
deletions	O	637-646
were	O	647-651
further	O	652-659
characterized	O	660-673
using	O	674-679
two	O	680-683
genomic	O	684-691
probes	O	692-698
,	O	698-699
p20	O	700-703
(	O	704-705
DXS269	O	705-711
;	O	711-712
Wapenaar	O	713-721
et	O	722-724
al	O	725-727
.	O	727-728
)	O	728-729
and	O	730-733
GMGX11	O	734-740
(	O	741-742
DXS239	O	742-748
;	O	748-749
present	O	750-757
paper	O	758-763
)	O	763-764
.	O	764-765

Clinical	O	766-774
findings	O	775-783
are	O	784-787
presented	O	788-797
for	O	798-801
all	O	802-805
80	O	806-808
patients	O	809-817
allowing	O	818-826
a	O	827-828
correlation	O	829-840
of	O	841-843
phenotypic	O	844-854
severity	O	855-863
with	O	864-868
the	O	869-872
genotype	O	873-881
.	O	881-882

Thirty	O	883-889
-	O	889-890
eight	O	890-895
independent	O	896-907
patients	O	908-916
were	O	917-921
old	O	922-925
enough	O	926-932
to	O	933-935
be	O	936-938
classified	O	939-949
as	O	950-952
DMD	B	953-956
,	O	956-957
BMD	B	958-961
,	O	961-962
or	O	963-965
intermediate	O	966-978
phenotype	O	979-988
and	O	989-992
had	O	993-996
deletions	O	997-1006
of	O	1007-1009
exons	O	1010-1015
with	O	1016-1020
sequenced	O	1021-1030
intron	O	1031-1037
/	O	1037-1038
exon	O	1038-1042
boundaries	O	1043-1053
.	O	1053-1054

Of	O	1055-1057
these	O	1058-1063
,	O	1063-1064
eight	O	1065-1070
BMD	B	1071-1074
patients	O	1075-1083
and	O	1084-1087
one	O	1088-1091
intermediate	O	1092-1104
patient	O	1105-1112
had	O	1113-1116
gene	O	1117-1121
deletions	O	1122-1131
predicted	O	1132-1141
to	O	1142-1144
leave	O	1145-1150
the	O	1151-1154
reading	O	1155-1162
frame	O	1163-1168
intact	O	1169-1175
,	O	1175-1176
while	O	1177-1182
21	O	1183-1185
DMD	B	1186-1189
patients	O	1190-1198
,	O	1198-1199
7	O	1200-1201
intermediate	O	1202-1214
patients	O	1215-1223
,	O	1223-1224
and	O	1225-1228
1	O	1229-1230
BMD	B	1231-1234
patient	O	1235-1242
had	O	1243-1246
gene	O	1247-1251
deletions	O	1252-1261
predicted	O	1262-1271
to	O	1272-1274
disrupt	O	1275-1282
the	O	1283-1286
reading	O	1287-1294
frame	O	1295-1300
.	O	1300-1301

Thus	O	1302-1306
,	O	1306-1307
with	O	1308-1312
two	O	1313-1316
exceptions	O	1317-1327
,	O	1327-1328
frameshift	O	1329-1339
deletions	O	1340-1349
of	O	1350-1352
the	O	1353-1356
gene	O	1357-1361
resulted	O	1362-1370
in	O	1371-1373
more	O	1374-1378
severe	O	1379-1385
phenotype	O	1386-1395
than	O	1396-1400
did	O	1401-1404
in	O	1405-1407
-	O	1407-1408
frame	O	1408-1413
deletions	O	1414-1423
.	O	1423-1424

This	O	1425-1429
is	O	1430-1432
in	O	1433-1435
agreement	O	1436-1445
with	O	1446-1450
recent	O	1451-1457
findings	O	1458-1466
by	O	1467-1469
Baumbach	O	1470-1478
et	O	1479-1481
al	O	1482-1484
.	O	1484-1485
and	O	1486-1489
Koenig	O	1490-1496
et	O	1497-1499
al	O	1500-1502
.	O	1502-1503
but	O	1504-1507
is	O	1508-1510
in	O	1511-1513
contrast	O	1514-1522
to	O	1523-1525
findings	O	1526-1534
,	O	1534-1535
by	O	1536-1538
Malhotra	O	1539-1547
et	O	1548-1550
al	O	1551-1553
.	O	1553-1554
at	O	1555-1557
the	O	1558-1561
5	O	1562-1563
'	O	1564-1565
end	O	1566-1569
of	O	1570-1572
the	O	1573-1576
gene	O	1577-1581
.	O	1581-1582

Proteolipoprotein	O	0-17
gene	O	18-22
analysis	O	23-31
in	O	32-34
82	O	35-37
patients	O	38-46
with	O	47-51
sporadic	O	52-60
Pelizaeus	B	61-70
-	I	70-71
Merzbacher	I	71-81
Disease	I	82-89
:	O	89-90
duplications	O	91-103
,	O	103-104
the	O	105-108
major	O	109-114
cause	O	115-120
of	O	121-123
the	O	124-127
disease	O	128-135
,	O	135-136
originate	O	137-146
more	O	147-151
frequently	O	152-162
in	O	163-165
male	O	166-170
germ	O	171-175
cells	O	176-181
,	O	181-182
but	O	183-186
point	O	187-192
mutations	O	193-202
do	O	203-205
not	O	206-209
.	O	209-210

The	O	211-214
Clinical	O	215-223
European	O	224-232
Network	O	233-240
on	O	241-243
Brain	B	244-249
Dysmyelinating	I	250-264
Disease	I	265-272
.	O	272-273

Pelizaeus	B	274-283
-	I	283-284
Merzbacher	I	284-294
Disease	I	295-302
(	O	303-304
PMD	B	304-307
)	O	307-308
is	O	309-311
an	O	312-314
X	B	315-316
-	I	316-317
linked	I	317-323
developmental	I	324-337
defect	I	338-344
of	I	345-347
myelination	I	348-359
affecting	O	360-369
the	O	370-373
central	O	374-381
nervous	O	382-389
system	O	390-396
and	O	397-400
segregating	O	401-412
with	O	413-417
the	O	418-421
proteolipoprotein	O	422-439
(	O	440-441
PLP	O	441-444
)	O	444-445
locus	O	446-451
.	O	451-452

Investigating	O	453-466
82	O	467-469
strictly	O	470-478
selected	O	479-487
sporadic	O	488-496
cases	O	497-502
of	O	503-505
PMD	B	506-509
,	O	509-510
we	O	511-513
found	O	514-519
PLP	O	520-523
mutations	O	524-533
in	O	534-536
77	O	537-539
%	O	539-540
;	O	540-541
complete	O	542-550
PLP	O	551-554
-	O	554-555
gene	O	555-559
duplications	O	560-572
were	O	573-577
the	O	578-581
most	O	582-586
frequent	O	587-595
abnormality	O	596-607
(	O	608-609
62	O	609-611
%	O	611-612
)	O	612-613
,	O	613-614
whereas	O	615-622
point	O	623-628
mutations	O	629-638
in	O	639-641
coding	O	642-648
or	O	649-651
splice	O	652-658
-	O	658-659
site	O	659-663
regions	O	664-671
of	O	672-674
the	O	675-678
gene	O	679-683
were	O	684-688
involved	O	689-697
less	O	698-702
frequently	O	703-713
(	O	714-715
38	O	715-717
%	O	717-718
)	O	718-719
.	O	719-720

We	O	721-723
analyzed	O	724-732
the	O	733-736
maternal	O	737-745
status	O	746-752
of	O	753-755
56	O	756-758
cases	O	759-764
to	O	765-767
determine	O	768-777
the	O	778-781
origin	O	782-788
of	O	789-791
both	O	792-796
types	O	797-802
of	O	803-805
PLP	O	806-809
mutation	O	810-818
,	O	818-819
since	O	820-825
this	O	826-830
is	O	831-833
relevant	O	834-842
to	O	843-845
genetic	O	846-853
counseling	O	854-864
.	O	864-865

In	O	866-868
the	O	869-872
22	O	873-875
point	O	876-881
mutations	O	882-891
,	O	891-892
68	O	893-895
%	O	895-896
of	O	897-899
mothers	O	900-907
were	O	908-912
heterozygous	O	913-925
for	O	926-929
the	O	930-933
mutation	O	934-942
,	O	942-943
a	O	944-945
value	O	946-951
identical	O	952-961
to	O	962-964
the	O	965-968
two	O	969-972
-	O	972-973
thirds	O	973-979
of	O	980-982
carrier	O	983-990
mothers	O	991-998
that	O	999-1003
would	O	1004-1009
be	O	1010-1012
expected	O	1013-1021
if	O	1022-1024
there	O	1025-1030
were	O	1031-1035
an	O	1036-1038
equal	O	1039-1044
mutation	O	1045-1053
rate	O	1054-1058
in	O	1059-1061
male	O	1062-1066
and	O	1067-1070
female	O	1071-1077
germ	O	1078-1082
cells	O	1083-1088
.	O	1088-1089

In	O	1090-1092
sharp	O	1093-1098
contrast	O	1099-1107
,	O	1107-1108
among	O	1109-1114
the	O	1115-1118
34	O	1119-1121
duplicated	O	1122-1132
cases	O	1133-1138
,	O	1138-1139
91	O	1140-1142
%	O	1142-1143
of	O	1144-1146
mothers	O	1147-1154
were	O	1155-1159
carriers	O	1160-1168
,	O	1168-1169
a	O	1170-1171
value	O	1172-1177
significantly	O	1178-1191
(	O	1192-1193
chi2	O	1193-1197
=	O	1198-1199
9	O	1200-1201
.	O	1201-1202
20	O	1203-1205
,	O	1205-1206
P	O	1207-1208
<	O	1209-1210
.	O	1210-1211
01	O	1212-1214
)	O	1214-1215
in	O	1216-1218
favor	O	1219-1224
of	O	1225-1227
a	O	1228-1229
male	O	1230-1234
bias	O	1235-1239
,	O	1239-1240
with	O	1241-1245
an	O	1246-1248
estimation	O	1249-1259
of	O	1260-1262
the	O	1263-1266
male	O	1267-1271
/	O	1271-1272
female	O	1272-1278
mutation	O	1279-1287
frequency	O	1288-1297
(	O	1298-1299
k	O	1299-1300
)	O	1300-1301
of	O	1302-1304
9	O	1305-1306
.	O	1306-1307
3	O	1308-1309
3	O	1310-1311
.	O	1311-1312

Moreover	O	1313-1321
,	O	1321-1322
we	O	1323-1325
observed	O	1326-1334
the	O	1335-1338
occurrence	O	1339-1349
of	O	1350-1352
de	O	1353-1355
novo	O	1356-1360
mutations	O	1361-1370
between	O	1371-1378
parental	O	1379-1387
and	O	1388-1391
grandparental	O	1392-1405
generations	O	1406-1417
in	O	1418-1420
17	O	1421-1423
three	O	1424-1429
-	O	1429-1430
generation	O	1430-1440
families	O	1441-1449
,	O	1449-1450
which	O	1451-1456
allowed	O	1457-1464
a	O	1465-1466
direct	O	1467-1473
estimation	O	1474-1484
of	O	1485-1487
the	O	1488-1491
k	O	1492-1493
value	O	1494-1499
(	O	1500-1501
k	O	1501-1502
=	O	1503-1504
11	O	1505-1507
)	O	1507-1508
.	O	1508-1509

Again	O	1510-1515
,	O	1515-1516
a	O	1517-1518
significant	O	1519-1530
male	O	1531-1535
mutation	O	1536-1544
imbalance	O	1545-1554
was	O	1555-1558
observed	O	1559-1567
only	O	1568-1572
for	O	1573-1576
the	O	1577-1580
duplications	O	1581-1593
.	O	1593-1594

Haplotype	O	0-9
analysis	O	10-18
of	O	19-21
the	O	22-25
phenylalanine	O	26-39
hydroxylase	O	40-51
gene	O	52-56
in	O	57-59
Turkish	O	60-67
phenylketonuria	B	68-83
families	O	84-92
.	O	92-93

We	O	94-96
have	O	97-101
estimated	O	102-111
the	O	112-115
haplotype	O	116-125
distribution	O	126-138
of	O	139-141
mutant	O	142-148
and	O	149-152
normal	O	153-159
phenylalanine	O	160-173
hydroxylase	O	174-185
(	O	186-187
PAH	O	187-190
)	O	190-191
alleles	O	192-199
for	O	200-203
17	O	204-206
Turkish	O	207-214
phenylketonuria	B	215-230
(	O	231-232
PKU	B	232-235
)	O	235-236
families	O	237-245
20	O	247-249
normal	O	250-256
and	O	257-260
27	O	261-263
mutated	O	264-271
PAH	O	272-275
alleles	O	276-283
could	O	284-289
be	O	290-292
identified	O	293-303
.	O	303-304

Of	O	305-307
the	O	308-311
latter	O	312-318
,	O	318-319
the	O	320-323
most	O	324-328
prevalent	O	329-338
were	O	339-343
associated	O	344-354
with	O	355-359
haplotype	O	360-369
6	O	370-371
(	O	372-373
29	O	373-375
.	O	375-376

6	O	377-378
%	O	378-379
)	O	379-380
,	O	380-381
1	O	382-383
(	O	384-385
18	O	385-387
.	O	387-388

5	O	389-390
%	O	390-391
)	O	391-392
and	O	393-396
36	O	397-399
(	O	400-401
11	O	401-403
.	O	403-404

1	O	405-406
%	O	406-407
)	O	407-408
,	O	408-409
while	O	410-415
the	O	416-419
normal	O	420-426
alleles	O	427-434
were	O	435-439
preferentially	O	440-454
associated	O	455-465
with	O	466-470
haplotype	O	471-480
1	O	481-482
(	O	483-484
20	O	484-486
%	O	486-487
)	O	487-488
.	O	488-489

Of	O	490-492
the	O	493-496
19	O	497-499
different	O	500-509
haplotypes	O	510-520
observed	O	521-529
,	O	529-530
5	O	531-532
have	O	533-537
not	O	538-541
been	O	542-546
described	O	547-556
previously	O	557-567
.	O	567-568

The	O	569-572
haplotype	O	573-582
distribution	O	583-595
differed	O	596-604
significantly	O	605-618
from	O	619-623
that	O	624-628
of	O	629-631
the	O	632-635
Northern	O	636-644
European	O	645-653
population	O	654-664
.	O	664-665

Two	O	666-669
of	O	670-672
the	O	673-676
eight	O	677-682
polymorphic	O	683-694
sites	O	695-700
were	O	701-705
in	O	706-708
association	O	709-720
with	O	721-725
PKU	B	726-729
.	O	729-730

No	O	731-733
deletions	O	734-743
of	O	744-746
exon	O	747-751
sequences	O	752-761
were	O	762-766
found	O	767-772
in	O	773-775
the	O	776-779
families	O	780-788
analysed	O	789-797
.	O	797-798

Cloning	O	0-7
of	O	8-10
human	O	11-16
very	O	17-21
-	O	21-22
long	O	22-26
-	O	21-22
chain	O	27-32
acyl	O	33-37
-	O	37-38
coenzyme	O	38-46
A	O	47-48
dehydrogenase	O	49-62
and	O	63-66
molecular	O	67-76
characterization	O	77-93
of	O	94-96
its	O	97-100
deficiency	O	101-111
in	O	112-114
two	O	115-118
patients	O	119-127
.	O	127-128

Two	O	129-132
overlapping	O	133-144
cDNA	O	145-149
clones	O	150-156
(	O	157-158
1	O	158-159
,	O	159-160
991	O	161-164
bp	O	165-167
and	O	168-171
736	O	172-175
bp	O	176-178
,	O	178-179
respectively	O	180-192
)	O	192-193
encoding	O	194-202
the	O	203-206
precursor	O	207-216
of	O	217-219
human	O	220-225
mitochondrial	O	226-239
very	O	240-244
-	O	244-245
long	O	245-249
-	O	244-245
chain	O	250-255
acyl	O	256-260
-	O	260-261
coenzyme	O	261-269
A	O	270-271
dehydrogenase	O	272-285
(	O	286-287
VLCAD	O	287-292
)	O	292-293
were	O	294-298
cloned	O	299-305
and	O	306-309
sequenced	O	310-319
.	O	319-320

The	O	321-324
cDNA	O	325-329
inserts	O	330-337
of	O	338-340
these	O	341-346
clones	O	347-353
together	O	354-362
encompass	O	363-372
a	O	373-374
region	O	375-381
of	O	382-384
2	O	385-386
,	O	386-387
177	O	388-391
bases	O	392-397
,	O	397-398
encoding	O	399-407
the	O	408-411
entire	O	412-418
protein	O	419-426
of	O	427-429
655	O	430-433
amino	O	434-439
acids	O	440-445
,	O	445-446
including	O	447-456
a	O	457-458
40	O	459-461
-	O	461-462
amino	O	462-467
acid	O	468-472
leader	O	473-479
peptide	O	480-487
and	O	488-491
a	O	492-493
615	O	494-497
-	O	497-498
amino	O	498-503
acid	O	504-508
mature	O	509-515
polypeptide	O	516-527
.	O	527-528

PCR	O	529-532
-	O	532-533
amplified	O	533-542
VLCAD	O	543-548
cDNAs	O	549-554
were	O	555-559
sequenced	O	560-569
in	O	570-572
cultured	O	573-581
fibroblasts	O	582-593
from	O	594-598
two	O	599-602
VLCAD	B	603-608
-	I	608-609
deficient	I	609-618
patients	O	619-627
.	O	627-628

In	O	629-631
both	O	632-636
patients	O	637-645
,	O	645-646
a	O	647-648
105	O	649-652
-	O	652-653
bp	O	653-655
deletion	O	656-664
encompassing	O	665-677
bases	O	678-683
1078	O	684-688
-	O	688-689
1182	O	689-693
in	O	694-696
VLCAD	O	697-702
cDNA	O	703-707
was	O	708-711
identified	O	712-722
.	O	722-723

The	O	724-727
deletion	O	728-736
seems	O	737-742
to	O	743-745
occur	O	746-751
due	O	752-755
to	O	756-758
exon	O	759-763
skipping	O	764-772
during	O	773-779
processing	O	780-790
of	O	791-793
VLCAD	O	794-799
pre	O	800-803
-	O	803-804
mRNA	O	804-808
.	O	808-809

This	O	810-814
is	O	815-817
the	O	818-821
first	O	822-827
demonstration	O	828-841
of	O	842-844
a	O	845-846
mutation	O	847-855
causing	O	856-863
VLCAD	B	864-869
deficiency	I	870-880
.	O	880-881

Quantitative	O	882-894
cDNA	O	895-899
expression	O	900-910
of	O	911-913
normal	O	914-920
human	O	921-926
VLCAD	O	927-932
was	O	933-936
performed	O	937-946
in	O	947-949
the	O	950-953
patients	O	954-962
fibroblasts	O	963-974
,	O	974-975
using	O	976-981
vaccinia	O	982-990
viral	O	991-996
system	O	997-1003
,	O	1003-1004
which	O	1005-1010
demonstrated	O	1011-1023
that	O	1024-1028
the	O	1029-1032
deficiency	B	1033-1043
of	I	1044-1046
the	I	1047-1050
normal	I	1051-1057
VLCAD	I	1058-1063
protein	I	1064-1071
causes	O	1072-1078
impaired	O	1079-1087
long	O	1088-1092
-	O	1092-1093
chain	O	1093-1098
fatty	O	1099-1104
acid	O	1105-1109
beta	O	1110-1114
-	O	1114-1115
oxidation	O	1115-1124
activity	O	1125-1133
in	O	1134-1136
the	O	1137-1140
patients	O	1141-1149
fibroblasts	O	1150-1161
.	O	1161-1162

In	O	1163-1165
patient	O	1166-1173
fibroblasts	O	1174-1185
,	O	1185-1186
raising	O	1187-1194
VLCAD	O	1195-1200
activity	O	1201-1209
to	O	1210-1212
approximately	O	1213-1226
20	O	1227-1229
%	O	1229-1230
of	O	1231-1233
normal	O	1234-1240
control	O	1241-1248
fibroblast	O	1249-1259
activity	O	1260-1268
raised	O	1269-1275
palmitic	O	1276-1284
acid	O	1285-1289
beta	O	1290-1294
-	O	1294-1295
oxidation	O	1295-1304
flux	O	1305-1309
to	O	1310-1312
the	O	1313-1316
level	O	1317-1322
found	O	1323-1328
in	O	1329-1331
control	O	1332-1339
fibroblasts	O	1340-1351
,	O	1351-1352
which	O	1353-1358
may	O	1359-1362
offer	O	1363-1368
important	O	1369-1378
information	O	1379-1390
for	O	1391-1394
the	O	1395-1398
rational	O	1399-1407
design	O	1408-1414
of	O	1415-1417
future	O	1418-1424
somatic	O	1425-1432
gene	O	1433-1437
therapy	O	1438-1445
for	O	1446-1449
VLCAD	B	1450-1455
deficiency	I	1456-1466
.	O	1466-1467
.	O	1466-1467

Mutations	O	0-9
in	O	10-12
the	O	13-16
RB1	O	17-20
gene	O	21-25
and	O	26-29
their	O	30-35
effects	O	36-43
on	O	44-46
transcription	O	47-60
.	O	60-61

Inactivation	O	62-74
of	O	75-77
both	O	78-82
alleles	O	83-90
of	O	91-93
the	O	94-97
RB1	O	98-101
gene	O	102-106
during	O	107-113
normal	O	114-120
retinal	O	121-128
development	O	129-140
initiates	O	141-150
the	O	151-154
formation	O	155-164
of	O	165-167
a	O	168-169
retinoblastoma	B	170-184
(	I	185-186
RB	I	186-188
)	I	188-189
tumor	I	190-195
.	O	195-196

To	O	197-199
identify	O	200-208
the	O	209-212
mutations	O	213-222
which	O	223-228
inactivate	O	229-239
RB1	O	240-243
,	O	243-244
21	O	245-247
RB	B	248-250
tumors	I	251-257
isolated	O	258-266
from	O	267-271
19	O	272-274
patients	O	275-283
were	O	284-288
analyzed	O	289-297
with	O	298-302
the	O	303-306
polymerase	O	307-317
chain	O	318-323
reaction	O	324-332
or	O	333-335
an	O	336-338
RNase	O	339-344
protection	O	345-355
assay	O	356-361
or	O	362-364
both	O	365-369
.	O	369-370

Mutations	O	371-380
were	O	381-385
identified	O	386-396
in	O	397-399
13	O	400-402
of	O	403-405
21	O	406-408
RB	B	409-411
tumors	I	412-418
;	O	418-419
in	O	420-422
8	O	423-424
tumors	B	425-431
,	O	431-432
the	O	433-436
precise	O	437-444
errors	O	445-451
in	O	452-454
nucleotide	O	455-465
sequence	O	466-474
were	O	475-479
characterized	O	480-493
.	O	493-494

Each	O	495-499
of	O	500-502
four	O	503-507
germ	O	508-512
line	O	513-517
mutations	O	518-527
involved	O	528-536
a	O	537-538
small	O	539-544
deletion	O	545-553
or	O	554-556
duplication	O	557-568
,	O	568-569
while	O	570-575
three	O	576-581
somatic	O	582-589
mutations	O	590-599
were	O	600-604
point	O	605-610
mutations	O	611-620
leading	O	621-628
to	O	629-631
splice	O	632-638
alterations	O	639-650
and	O	651-654
loss	O	655-659
of	O	660-662
an	O	663-665
exon	O	666-670
from	O	671-675
the	O	676-679
mature	O	680-686
RB1	O	687-690
mRNA	O	691-695
.	O	695-696

We	O	697-699
were	O	700-704
unable	O	705-711
to	O	712-714
detect	O	715-721
expression	O	722-732
of	O	733-735
the	O	736-739
mutant	O	740-746
allele	O	747-753
in	O	754-756
lymphoblasts	O	757-769
of	O	770-772
three	O	773-778
bilaterally	O	779-790
affected	O	791-799
patients	O	800-808
,	O	808-809
although	O	810-818
the	O	819-822
mutation	O	823-831
was	O	832-835
present	O	836-843
in	O	844-846
the	O	847-850
genomic	O	851-858
DNA	O	859-862
and	O	863-866
transcripts	O	867-878
containing	O	879-889
the	O	890-893
mutations	O	894-903
were	O	904-908
obvious	O	909-916
in	O	917-919
the	O	920-923
RB	B	924-926
tumors	I	927-933
in	O	934-936
the	O	937-940
absence	O	941-948
of	O	949-951
a	O	952-953
normal	O	954-960
RB1	O	961-964
allele	O	965-971
.	O	971-972

The	O	973-976
variations	O	977-987
in	O	988-990
the	O	991-994
level	O	995-1000
of	O	1001-1003
expression	O	1004-1014
of	O	1015-1017
mutant	O	1018-1024
transcripts	O	1025-1036
suggest	O	1037-1044
deregulation	O	1045-1057
of	O	1058-1060
RB1	O	1061-1064
transcription	O	1065-1078
in	O	1079-1081
the	O	1082-1085
absence	O	1086-1093
of	O	1094-1096
a	O	1097-1098
functional	O	1099-1109
RB1	O	1110-1113
gene	O	1114-1118
product	O	1119-1126
.	O	1126-1127
.	O	1126-1127

Resolution	O	0-10
of	O	11-13
the	O	14-17
two	O	18-21
loci	O	22-26
for	O	27-30
autosomal	O	31-40
dominant	O	41-49
aniridia	B	50-58
,	O	58-59
AN1	O	60-63
and	O	64-67
AN2	O	68-71
,	O	71-72
to	O	73-75
a	O	76-77
single	O	78-84
locus	O	85-90
on	O	91-93
chromosome	O	94-104
11p13	O	105-110
.	O	110-111

Two	O	112-115
distinct	O	116-124
loci	O	125-129
have	O	130-134
been	O	135-139
proposed	O	140-148
for	O	149-152
aniridia	B	153-161
;	O	161-162
AN1	O	163-166
for	O	167-170
autosomal	O	171-180
dominant	O	181-189
aniridia	B	190-198
on	O	199-201
chromosome	O	202-212
2p	O	213-215
and	O	216-219
AN2	O	220-223
for	O	224-227
the	O	228-231
aniridia	B	232-240
in	O	241-243
the	O	244-247
WAGR	B	248-252
contiguous	I	253-263
gene	I	264-268
syndrome	I	269-277
on	O	278-280
chromosome	O	281-291
11p13	O	292-297
.	O	297-298

In	O	299-301
this	O	302-306
report	O	307-313
,	O	313-314
the	O	315-318
kindred	O	319-326
segregating	O	327-338
for	O	339-342
autosomal	O	343-352
dominant	O	353-361
aniridia	B	362-370
,	O	370-371
which	O	372-377
suggested	O	378-387
linkage	O	388-395
to	O	396-398
acid	O	399-403
phosphatase	O	404-415
-	O	415-416
1	O	416-417
(	O	418-419
ACP1	O	419-423
)	O	423-424
and	O	425-428
led	O	429-432
to	O	433-435
the	O	436-439
assignment	O	440-450
of	O	451-453
the	O	454-457
AN1	O	458-461
locus	O	462-467
on	O	468-470
chromosome	O	471-481
2p	O	482-484
,	O	484-485
has	O	486-489
been	O	490-494
updated	O	495-502
and	O	503-506
expanded	O	507-515
.	O	515-516

Linkage	O	517-524
analysis	O	525-533
between	O	534-541
the	O	542-545
aniridia	B	546-554
phenotype	O	555-564
and	O	565-568
ACP1	O	569-573
does	O	574-578
not	O	579-582
support	O	583-590
the	O	591-594
original	O	595-603
linkage	O	604-611
results	O	612-619
,	O	619-620
excluding	O	621-630
linkage	O	631-638
up	O	639-641
to	O	642-644
theta	O	645-650
=	O	651-652
0	O	653-654
.	O	654-655
17	O	656-658
with	O	659-663
Z	O	664-665
=	O	666-667
-	O	668-669
2	O	669-670
.	O	670-671

Tests	O	672-677
for	O	678-681
linkage	O	682-689
to	O	690-692
other	O	693-698
chromosome	O	699-709
2p	O	710-712
markers	O	713-720
.	O	720-721

APOB	O	722-726
,	O	726-727
D2S71	O	728-733
,	O	733-734
D2S5	O	735-739
,	O	739-740
and	O	741-744
D2S1	O	745-749
,	O	749-750
also	O	751-755
excluded	O	756-764
linkage	O	765-772
to	O	773-775
aniridia	B	776-784
.	O	784-785

Markers	O	786-793
that	O	794-798
have	O	799-803
been	O	804-808
isolated	O	809-817
from	O	818-822
the	O	823-826
chromosome	O	827-837
11p13	O	838-843
region	O	844-850
were	O	851-855
then	O	856-860
analyzed	O	861-869
in	O	870-872
this	O	873-877
aniridia	B	878-886
family	O	887-893
.	O	893-894

Two	O	895-898
RFLPs	O	899-904
at	O	905-907
the	O	908-911
D11S323	O	912-919
locus	O	920-925
give	O	926-930
significant	O	931-942
evidence	O	943-951
for	O	952-955
linkage	O	956-963
.	O	963-964

The	O	965-968
PvuII	O	969-974
polymorphism	O	975-987
detected	O	988-996
by	O	997-999
probe	O	1000-1005
p5S1	O	1006-1010
.	O	1010-1011

6	O	1012-1013
detects	O	1014-1021
no	O	1022-1024
recombinants	O	1025-1037
,	O	1037-1038
with	O	1039-1043
a	O	1044-1045
maximum	O	1046-1053
lod	O	1054-1057
score	O	1058-1063
of	O	1064-1066
Z	O	1067-1068
=	O	1069-1070
6	O	1071-1072
.	O	1072-1073

97	O	1074-1076
at	O	1077-1079
theta	O	1080-1085
=	O	1086-1087
0	O	1088-1089
.	O	1089-1090
00	O	1091-1093
00	O	1094-1096
.	O	1096-1097

The	O	1098-1101
HaeIII	O	1102-1108
polymorphism	O	1109-1121
detected	O	1122-1130
by	O	1131-1133
the	O	1134-1137
probe	O	1138-1143
p5BE1	O	1144-1149
.	O	1149-1150

2	O	1151-1152
gives	O	1153-1158
a	O	1159-1160
maximum	O	1161-1168
lod	O	1169-1172
score	O	1173-1178
of	O	1179-1181
Z	O	1182-1183
=	O	1184-1185
2	O	1186-1187
.	O	1187-1188
57	O	1189-1191
at	O	1192-1194
theta	O	1195-1200
=	O	1201-1202
0	O	1203-1204
.	O	1204-1205
00	O	1206-1208
00	O	1209-1211
.	O	1211-1212

Locus	O	1213-1218
D11S325	O	1219-1226
gives	O	1227-1232
a	O	1233-1234
lod	O	1235-1238
score	O	1239-1244
of	O	1245-1247
Z	O	1248-1249
=	O	1250-1251
1	O	1252-1253
.	O	1253-1254

53	O	1255-1257
at	O	1258-1260
theta	O	1261-1266
=	O	1267-1268
0	O	1269-1270
.	O	1270-1271
00	O	1272-1274
00	O	1275-1277
.	O	1277-1278

These	O	1279-1284
data	O	1285-1289
suggest	O	1290-1297
that	O	1298-1302
a	O	1303-1304
locus	O	1305-1310
for	O	1311-1314
aniridia	B	1315-1323
(	O	1324-1325
AN1	O	1325-1328
)	O	1328-1329
on	O	1330-1332
chromosome	O	1333-1343
2p	O	1344-1346
has	O	1347-1350
been	O	1351-1355
misassigned	O	1356-1367
and	O	1368-1371
that	O	1372-1376
this	O	1377-1381
autosomal	O	1382-1391
dominant	O	1392-1400
aniridia	B	1401-1409
family	O	1410-1416
is	O	1417-1419
segregating	O	1420-1431
for	O	1432-1435
an	O	1436-1438
aniridia	B	1439-1447
mutation	O	1448-1456
linked	O	1457-1463
to	O	1464-1466
markers	O	1467-1474
in	O	1475-1477
the	O	1478-1481
11p13	O	1482-1487
region	O	1488-1494
.	O	1494-1495

GT	O	0-2
to	O	3-5
AT	O	6-8
transition	O	9-19
at	O	20-22
a	O	23-24
splice	O	25-31
donor	O	32-37
site	O	38-42
causes	O	43-49
skipping	O	50-58
of	O	59-61
the	O	62-65
preceding	O	66-75
exon	O	76-80
in	O	81-83
phenylketonuria	B	84-99
.	O	99-100

Classical	B	101-110
Phenylketonuria	I	111-126
(	O	127-128
PKU	B	128-131
)	O	131-132
is	O	133-135
an	O	136-138
autosomal	B	139-148
recessive	I	149-158
human	I	159-164
genetic	I	165-172
disorder	I	173-181
caused	O	182-188
by	O	189-191
a	O	192-193
deficiency	B	194-204
of	I	205-207
hepatic	I	208-215
phenylalanine	I	216-229
hydroxylase	I	230-241
(	O	242-243
PAH	O	243-246
)	O	246-247
.	O	247-248

We	O	249-251
isolated	O	252-260
several	O	261-268
mutant	O	269-275
PAH	O	276-279
cDNA	O	280-284
clones	O	285-291
from	O	292-296
a	O	297-298
PKU	B	299-302
carrier	O	303-310
individual	O	311-321
and	O	322-325
showed	O	326-332
that	O	333-337
they	O	338-342
contained	O	343-352
an	O	353-355
internal	O	356-364
116	O	365-368
base	O	369-373
pair	O	374-378
deletion	O	379-387
,	O	387-388
corresponding	O	389-402
precisely	O	403-412
to	O	413-415
exon	O	416-420
12	O	421-423
of	O	424-426
the	O	427-430
human	O	431-436
chromosomal	O	437-448
PAH	O	449-452
gene	O	453-457
.	O	457-458

The	O	459-462
deletion	O	463-471
causes	O	472-478
the	O	479-482
synthesis	O	483-492
of	O	493-495
a	O	496-497
truncated	O	498-507
protein	O	508-515
lacking	O	516-523
the	O	524-527
C	O	528-529
-	O	529-530
terminal	O	530-538
52	O	539-541
amino	O	542-547
acids	O	548-553
.	O	553-554

Gene	O	555-559
transfer	O	560-568
and	O	569-572
expression	O	573-583
studies	O	584-591
using	O	592-597
the	O	598-601
mutant	O	602-608
PAH	O	609-612
cDNA	O	613-617
indicated	O	618-627
that	O	628-632
the	O	633-636
deletion	O	637-645
abolishes	O	646-655
PAH	O	656-659
activity	O	660-668
in	O	669-671
the	O	672-675
cell	O	676-680
as	O	681-683
a	O	684-685
result	O	686-692
of	O	693-695
protein	O	696-703
instability	O	704-715
.	O	715-716

To	O	717-719
determine	O	720-729
the	O	730-733
molecular	O	734-743
basis	O	744-749
of	O	750-752
the	O	753-756
deletion	O	757-765
,	O	765-766
the	O	767-770
mutant	O	771-777
chromosomal	O	778-789
PAH	O	790-793
gene	O	794-798
was	O	799-802
isolated	O	803-811
from	O	812-816
this	O	817-821
individual	O	822-832
and	O	833-836
shown	O	837-842
to	O	843-845
contain	O	846-853
a	O	854-855
GT	O	856-858
-	O	858-859
-	O	858-859
greater	O	861-868
than	O	869-873
AT	O	874-876
substitution	O	877-889
at	O	890-892
the	O	893-896
5	O	897-898
splice	O	899-905
donor	O	906-911
site	O	912-916
of	O	917-919
intron	O	920-926
12	O	927-929
.	O	929-930
Thus	O	931-935
,	O	935-936
the	O	937-940
consequence	O	941-952
of	O	953-955
the	O	956-959
splice	O	960-966
donor	O	967-972
site	O	973-977
mutation	O	978-986
in	O	987-989
the	O	990-993
human	O	994-999
liver	O	1000-1005
is	O	1006-1008
the	O	1009-1012
skipping	O	1013-1021
of	O	1022-1024
the	O	1025-1028
preceding	O	1029-1038
exon	O	1039-1043
during	O	1044-1050
RNA	O	1051-1054
splicing	O	1055-1063
.	O	1063-1064
.	O	1063-1064

Clinical	O	0-8
and	O	9-12
molecular	O	13-22
genetic	O	23-30
analysis	O	31-39
of	O	40-42
19	O	43-45
Wolfram	B	46-53
syndrome	I	54-62
kindreds	O	63-71
demonstrating	O	72-85
a	O	86-87
wide	O	88-92
spectrum	O	93-101
of	O	102-104
mutations	O	105-114
in	O	115-117
WFS1	O	118-122
.	O	122-123

Wolfram	B	124-131
syndrome	I	132-140
is	O	141-143
an	O	144-146
autosomal	B	147-156
recessive	I	157-166
neurodegenerative	I	167-184
disorder	I	185-193
characterized	O	194-207
by	O	208-210
juvenile	B	211-219
-	I	219-220
onset	I	220-225
diabetes	I	226-234
mellitus	I	235-243
and	O	244-247
progressive	O	248-259
optic	B	260-265
atrophy	I	266-273
.	O	273-274

mtDNA	O	275-280
deletions	O	281-290
have	O	291-295
been	O	296-300
described	O	301-310
,	O	310-311
and	O	312-315
a	O	316-317
gene	O	318-322
(	O	323-324
WFS1	O	324-328
)	O	328-329
recently	O	330-338
has	O	339-342
been	O	343-347
identified	O	348-358
,	O	358-359
on	O	360-362
chromosome	O	363-373
4p16	O	374-378
,	O	378-379
encoding	O	380-388
a	O	389-390
predicted	O	391-400
890	O	401-404
amino	O	405-410
acid	O	411-415
transmembrane	O	416-429
protein	O	430-437
.	O	437-438

Direct	O	439-445
DNA	O	446-449
sequencing	O	450-460
was	O	461-464
done	O	465-469
to	O	470-472
screen	O	473-479
the	O	480-483
entire	O	484-490
coding	O	491-497
region	O	498-504
of	O	505-507
the	O	508-511
WFS1	O	512-516
gene	O	517-521
in	O	522-524
30	O	525-527
patients	O	528-536
from	O	537-541
19	O	542-544
British	O	545-552
kindreds	O	553-561
with	O	562-566
Wolfram	B	567-574
syndrome	I	575-583
.	O	583-584

DNA	O	585-588
was	O	589-592
also	O	593-597
screened	O	598-606
for	O	607-610
structural	O	611-621
rearrangements	O	622-636
(	O	637-638
deletions	O	638-647
and	O	648-651
duplications	O	652-664
)	O	664-665
and	O	666-669
point	O	670-675
mutations	O	676-685
in	O	686-688
mtDNA	O	689-694
.	O	694-695

No	O	696-698
pathogenic	O	699-709
mtDNA	O	710-715
mutations	O	716-725
were	O	726-730
found	O	731-736
in	O	737-739
our	O	740-743
cohort	O	744-750
.	O	750-751

We	O	752-754
identified	O	755-765
24	O	766-768
mutations	O	769-778
in	O	779-781
the	O	782-785
WFS1	O	786-790
gene	O	791-795
8	O	797-798
nonsense	O	799-807
mutations	O	808-817
,	O	817-818
8	O	819-820
missense	O	821-829
mutations	O	830-839
,	O	839-840
3	O	841-842
in	O	843-845
-	O	845-846
frame	O	846-851
deletions	O	852-861
,	O	861-862
1	O	863-864
in	O	865-867
-	O	867-868
frame	O	868-873
insertion	O	874-883
,	O	883-884
and	O	885-888
4	O	889-890
frameshift	O	891-901
mutations	O	902-911
.	O	911-912

Of	O	913-915
these	O	916-921
,	O	921-922
23	O	923-925
were	O	926-930
novel	O	931-936
mutations	O	937-946
,	O	946-947
and	O	948-951
most	O	952-956
occurred	O	957-965
in	O	966-968
exon	O	969-973
8	O	974-975
.	O	975-976

The	O	977-980
majority	O	981-989
of	O	990-992
patients	O	993-1001
were	O	1002-1006
compound	O	1007-1015
heterozygotes	O	1016-1029
for	O	1030-1033
two	O	1034-1037
mutations	O	1038-1047
,	O	1047-1048
and	O	1049-1052
there	O	1053-1058
was	O	1059-1062
no	O	1063-1065
common	O	1066-1072
founder	O	1073-1080
mutation	O	1081-1089
.	O	1089-1090

The	O	1091-1094
data	O	1095-1099
were	O	1100-1104
also	O	1105-1109
analyzed	O	1110-1118
for	O	1119-1122
genotype	O	1123-1131
-	O	1131-1132
phenotype	O	1132-1141
relationships	O	1142-1155
.	O	1155-1156

Although	O	1157-1165
some	O	1166-1170
interesting	O	1171-1182
cases	O	1183-1188
were	O	1189-1193
noted	O	1194-1199
,	O	1199-1200
consideration	O	1201-1214
of	O	1215-1217
the	O	1218-1221
small	O	1222-1227
sample	O	1228-1234
size	O	1235-1239
and	O	1240-1243
frequency	O	1244-1253
of	O	1254-1256
each	O	1257-1261
mutation	O	1262-1270
indicated	O	1271-1280
no	O	1281-1283
clear	O	1284-1289
-	O	1289-1290
cut	O	1290-1293
correlations	O	1294-1306
between	O	1307-1314
any	O	1315-1318
of	O	1319-1321
the	O	1322-1325
observed	O	1326-1334
mutations	O	1335-1344
and	O	1345-1348
disease	O	1349-1356
severity	O	1357-1365
.	O	1365-1366

There	O	1367-1372
were	O	1373-1377
no	O	1378-1380
obvious	O	1381-1388
mutation	O	1389-1397
hot	O	1398-1401
spots	O	1402-1407
or	O	1408-1410
clusters	O	1411-1419
.	O	1419-1420

Hence	O	1421-1426
,	O	1426-1427
molecular	O	1428-1437
screening	O	1438-1447
for	O	1448-1451
Wolfram	B	1452-1459
syndrome	I	1460-1468
in	O	1469-1471
affected	O	1472-1480
families	O	1481-1489
and	O	1490-1493
for	O	1494-1497
Wolfram	B	1498-1505
syndrome	I	1506-1514
-	O	1514-1515
carrier	O	1515-1522
status	O	1523-1529
in	O	1530-1532
subjects	O	1533-1541
with	O	1542-1546
psychiatric	B	1547-1558
disorders	I	1559-1568
or	O	1569-1571
diabetes	B	1572-1580
mellitus	I	1581-1589
will	O	1590-1594
require	O	1595-1602
complete	O	1603-1611
analysis	O	1612-1620
of	O	1621-1623
exon	O	1624-1628
8	O	1629-1630
and	O	1631-1634
upstream	O	1635-1643
exons	O	1644-1649
.	O	1649-1650
.	O	1649-1650

Maternal	B	0-8
uniparental	I	9-20
disomy	I	21-27
for	I	28-31
chromosome	I	32-42
14	I	43-45
in	O	46-48
a	O	49-50
boy	O	51-54
with	O	55-59
a	O	60-61
normal	O	62-68
karyotype	O	69-78
.	O	78-79

We	O	80-82
report	O	83-89
on	O	90-92
a	O	93-94
boy	O	95-98
with	O	99-103
a	O	104-105
maternal	B	106-114
uniparental	I	115-126
disomy	I	127-133
for	I	134-137
chromosome	I	138-148
14	I	149-151
(	O	152-153
UPD	B	153-156
(	O	157-158
14	O	158-160
)	O	160-161
)	O	160-161
.	O	162-163

At	O	164-166
7	O	167-168
years	O	169-174
of	O	175-177
age	O	178-181
he	O	182-184
was	O	185-188
referred	O	189-197
to	O	198-200
us	O	201-203
by	O	204-206
the	O	207-210
paediatrician	O	211-224
because	O	225-232
of	O	233-235
symptoms	O	236-244
of	O	245-247
Prader	B	248-254
-	I	254-255
Willi	I	255-260
syndrome	I	261-269
(	O	270-271
PWS	B	271-274
)	O	274-275
.	O	275-276

He	O	277-279
showed	O	280-286
short	B	287-292
stature	I	293-300
,	O	300-301
obesity	B	302-309
,	O	309-310
mild	O	311-315
developmental	B	316-329
delay	I	330-335
,	O	335-336
cryptorchidism	B	337-351
,	O	351-352
and	O	353-356
some	O	357-361
mild	O	362-366
dysmorphic	B	367-377
features	I	378-386
.	O	386-387

The	O	388-391
history	O	392-399
further	O	400-407
indicated	O	408-417
intrauterine	B	418-430
growth	I	431-437
retardation	I	438-449
at	O	450-452
the	O	453-456
end	O	457-460
of	O	461-463
the	O	464-467
pregnancy	O	468-477
.	O	477-478

His	O	479-482
mother	O	483-489
was	O	490-493
44	O	494-496
years	O	497-502
of	O	503-505
age	O	506-509
at	O	510-512
the	O	513-516
time	O	517-521
of	O	522-524
his	O	525-528
birth	O	529-534
.	O	534-535

After	O	536-541
birth	O	542-547
he	O	548-550
showed	O	551-557
hypotonia	B	558-567
with	O	568-572
poor	O	573-577
sucking	O	578-585
,	O	585-586
for	O	587-590
which	O	591-596
gavage	O	597-603
feeding	O	604-611
was	O	612-615
needed	O	616-622
.	O	622-623

Motor	O	624-629
development	O	630-641
was	O	642-645
delayed	O	646-653
.	O	653-654

After	O	655-660
1	O	661-662
year	O	663-667
he	O	668-670
became	O	671-677
obese	B	678-683
despite	O	684-691
a	O	692-693
normal	O	694-700
appetite	O	701-709
.	O	709-710

Recurrent	O	711-720
middle	B	721-727
ear	I	728-731
infections	I	732-742
,	O	742-743
a	O	744-745
high	O	746-750
pain	O	751-755
threshold	O	756-765
,	O	765-766
and	O	767-770
a	O	771-772
great	O	773-778
skill	O	779-784
with	O	785-789
jigsaw	O	790-796
puzzles	O	797-804
were	O	805-809
reported	O	810-818
.	O	818-819

There	O	820-825
were	O	826-830
no	O	831-833
behavioural	O	834-845
problems	O	846-854
or	O	855-857
sleep	O	858-863
disturbance	O	864-875
.	O	875-876

Chromosomal	O	877-888
analysis	O	889-897
was	O	898-901
normal	O	902-908
(	O	909-910
46	O	910-912
,	O	912-913
XY	O	914-916
)	O	916-917
.	O	917-918

DNA	O	919-922
analysis	O	923-931
for	O	932-935
Prader	B	936-942
-	I	942-943
Willi	I	943-948
syndrome	I	949-957
showed	O	958-964
no	O	965-967
abnormalities	O	968-981
.	O	981-982

Two	O	983-986
years	O	987-992
later	O	993-998
he	O	999-1001
was	O	1002-1005
re	O	1006-1008
-	O	1008-1009
examined	O	1009-1017
because	O	1018-1025
we	O	1026-1028
thought	O	1029-1036
his	O	1037-1040
features	O	1041-1049
fitted	O	1050-1056
the	O	1057-1060
PWS	B	1061-1064
-	O	1064-1065
like	O	1065-1069
phenotype	O	1070-1079
associated	O	1080-1090
with	O	1091-1095
maternal	O	1096-1104
UPD	B	1105-1108
(	O	1109-1110
14	O	1110-1112
)	O	1112-1113
.	O	1113-1114

At	O	1115-1117
that	O	1118-1122
time	O	1123-1127
precocious	O	1128-1138
puberty	O	1139-1146
was	O	1147-1150
evident	O	1151-1158
.	O	1158-1159

DNA	O	1160-1163
analysis	O	1164-1172
showed	O	1173-1179
maternal	B	1180-1188
heterodisomy	I	1189-1201
for	O	1202-1205
chromosome	O	1206-1216
14	O	1217-1219
.	O	1219-1220

In	O	1221-1223
all	O	1224-1227
the	O	1228-1231
previously	O	1232-1242
described	O	1243-1252
11	O	1253-1255
cases	O	1256-1261
with	O	1262-1266
maternal	O	1267-1275
UPD	B	1276-1279
(	O	1280-1281
14	O	1281-1283
)	O	1283-1284
,	O	1284-1285
a	O	1286-1287
Robertsonian	O	1288-1300
translocation	O	1301-1314
involving	O	1315-1324
chromosome	O	1325-1335
14	O	1336-1338
was	O	1339-1342
detected	O	1343-1351
cytogenetically	O	1352-1367
before	O	1368-1374
DNA	O	1375-1378
analysis	O	1379-1387
.	O	1387-1388

This	O	1389-1393
is	O	1394-1396
the	O	1397-1400
first	O	1401-1406
report	O	1407-1413
of	O	1414-1416
diagnosis	O	1417-1426
of	O	1427-1429
maternal	O	1430-1438
UPD	B	1439-1442
(	O	1443-1444
14	O	1444-1446
)	O	1446-1447
based	O	1448-1453
on	O	1454-1456
clinical	O	1457-1465
features	O	1466-1474
.	O	1474-1475

This	O	1476-1480
finding	O	1481-1488
underlines	O	1489-1499
the	O	1500-1503
importance	O	1504-1514
of	O	1515-1517
DNA	O	1518-1521
analysis	O	1522-1530
for	O	1531-1534
maternal	O	1535-1543
UPD	O	1544-1547
(	O	1548-1549
14	O	1549-1551
)	O	1551-1552
in	O	1553-1555
patients	O	1556-1564
with	O	1565-1569
a	O	1570-1571
similar	O	1572-1579
PWS	B	1580-1583
-	O	1583-1584
like	O	1584-1588
phenotype	O	1589-1598
even	O	1599-1603
without	O	1604-1611
previous	O	1612-1620
identification	O	1621-1635
of	O	1636-1638
a	O	1639-1640
Robertsonian	O	1641-1653
translocation	O	1654-1667
involving	O	1668-1677
chromosome	O	1678-1688
14	O	1689-1691
.	O	1691-1692
.	O	1691-1692

Detection	O	0-9
of	O	10-12
eight	O	13-18
BRCA1	O	19-24
mutations	O	25-34
in	O	35-37
10	O	38-40
breast	B	41-47
/	I	47-48
ovarian	I	48-55
cancer	I	56-62
families	O	63-71
,	O	71-72
including	O	73-82
1	O	83-84
family	O	85-91
with	O	92-96
male	B	97-101
breast	I	102-108
cancer	I	109-115
.	O	115-116

Genetic	O	117-124
epidemiological	O	125-140
evidence	O	141-149
suggests	O	150-158
that	O	159-163
mutations	O	164-173
in	O	174-176
BRCA1	O	177-182
may	O	183-186
be	O	187-189
responsible	O	190-201
for	O	202-205
approximately	O	206-219
one	O	220-223
half	O	224-228
of	O	229-231
early	O	232-237
onset	O	238-243
familial	B	244-252
breast	I	253-259
cancer	I	260-266
and	O	267-270
the	O	271-274
majority	O	275-283
of	O	284-286
familial	B	287-295
breast	I	296-302
/	I	302-303
ovarian	I	303-310
cancer	I	311-317
.	O	317-318

The	O	319-322
recent	O	323-329
cloning	O	330-337
of	O	338-340
BRCA1	O	341-346
allows	O	347-353
for	O	354-357
the	O	358-361
direct	O	362-368
detection	O	369-378
of	O	379-381
mutations	O	382-391
,	O	391-392
but	O	393-396
the	O	397-400
feasibility	O	401-412
of	O	413-415
presymptomatic	O	416-430
screening	O	431-440
for	O	441-444
cancer	B	445-451
susceptibility	O	452-466
is	O	467-469
unknown	O	470-477
.	O	477-478

We	O	479-481
analyzed	O	482-490
genomic	O	491-498
DNA	O	499-502
from	O	503-507
one	O	508-511
affected	O	512-520
individual	O	521-531
from	O	532-536
each	O	537-541
of	O	542-544
24	O	545-547
families	O	548-556
with	O	557-561
at	O	562-564
least	O	565-570
three	O	571-576
cases	O	577-582
of	O	583-585
ovarian	B	586-593
or	I	594-596
breast	I	597-603
cancer	I	604-610
,	O	610-611
using	O	612-617
SSCP	O	618-622
assays	O	623-629
.	O	629-630

Variant	O	631-638
SSCP	O	639-643
bands	O	644-649
were	O	650-654
subcloned	O	655-664
and	O	665-668
sequenced	O	669-678
.	O	678-679

Allele	O	680-686
-	O	686-687
specific	O	687-695
oligonucleotide	O	696-711
hybridization	O	712-725
was	O	726-729
used	O	730-734
to	O	735-737
verify	O	738-744
sequence	O	745-753
changes	O	754-761
and	O	762-765
to	O	766-768
screen	O	769-775
DNA	O	776-779
from	O	780-784
control	O	785-792
individuals	O	793-804
.	O	804-805

Six	O	806-809
frameshift	O	810-820
and	O	821-824
two	O	825-828
missense	O	829-837
mutations	O	838-847
were	O	848-852
detected	O	853-861
in	O	862-864
10	O	865-867
different	O	868-877
families	O	878-886
.	O	886-887

A	O	888-889
frameshift	O	890-900
mutation	O	901-909
was	O	910-913
detected	O	914-922
in	O	923-925
a	O	926-927
male	O	928-932
proband	O	933-940
affected	O	941-949
with	O	950-954
both	O	955-959
breast	B	960-966
and	I	967-970
prostate	I	971-979
cancer	I	980-986
.	O	986-987

A	O	988-989
40	O	990-992
-	O	992-993
bp	O	993-995
deletion	O	996-1004
was	O	1005-1008
detected	O	1009-1017
in	O	1018-1020
a	O	1021-1022
patient	O	1023-1030
who	O	1031-1034
developed	O	1035-1044
intra	B	1045-1050
-	I	1050-1051
abdominal	I	1051-1060
carcinomatosis	I	1061-1075
1	O	1076-1077
year	O	1078-1082
after	O	1083-1088
prophylactic	O	1089-1101
oophorectomy	O	1102-1114
.	O	1114-1115

Mutations	O	1116-1125
were	O	1126-1130
detected	O	1131-1139
throughout	O	1140-1150
the	O	1151-1154
gene	O	1155-1159
,	O	1159-1160
and	O	1161-1164
only	O	1165-1169
one	O	1170-1173
was	O	1174-1177
detected	O	1178-1186
in	O	1187-1189
more	O	1190-1194
than	O	1195-1199
a	O	1200-1201
single	O	1202-1208
family	O	1209-1215
.	O	1215-1216

These	O	1217-1222
results	O	1223-1230
provide	O	1231-1238
further	O	1239-1246
evidence	O	1247-1255
that	O	1256-1260
inherited	B	1261-1270
breast	I	1271-1277
and	I	1278-1281
ovarian	I	1282-1289
cancer	I	1290-1296
can	O	1297-1300
occur	O	1301-1306
as	O	1307-1309
a	O	1310-1311
consequence	O	1312-1323
of	O	1324-1326
a	O	1327-1328
wide	O	1329-1333
array	O	1334-1339
of	O	1340-1342
BRCA1	O	1343-1348
mutations	O	1349-1358
.	O	1358-1359

These	O	1360-1365
results	O	1366-1373
suggests	O	1374-1382
that	O	1383-1387
development	O	1388-1399
of	O	1400-1402
a	O	1403-1404
screening	O	1405-1414
test	O	1415-1419
for	O	1420-1423
BRCA1	O	1424-1429
mutations	O	1430-1439
will	O	1440-1444
be	O	1445-1447
technically	O	1448-1459
challenging	O	1460-1471
.	O	1471-1472

The	O	1473-1476
finding	O	1477-1484
of	O	1485-1487
a	O	1488-1489
mutation	O	1490-1498
in	O	1499-1501
a	O	1502-1503
family	O	1504-1510
with	O	1511-1515
male	B	1516-1520
breast	I	1521-1527
cancer	I	1528-1534
,	O	1534-1535
not	O	1536-1539
previously	O	1540-1550
thought	O	1551-1558
to	O	1559-1561
be	O	1562-1564
related	O	1565-1572
to	O	1573-1575
BRCA1	O	1576-1581
,	O	1581-1582
also	O	1583-1587
illustrates	O	1588-1599
the	O	1600-1603
potential	O	1604-1613
difficulties	O	1614-1626
of	O	1627-1629
genetic	O	1630-1637
counseling	O	1638-1648
for	O	1649-1652
individuals	O	1653-1664
known	O	1665-1670
to	O	1671-1673
carry	O	1674-1679
mutations	O	1680-1689
.	O	1689-1690
.	O	1689-1690

Color	B	0-5
vision	I	6-12
defects	I	13-20
in	O	21-23
adrenomyeloneuropathy	B	24-45
.	O	45-46

The	O	47-50
relationship	O	51-63
between	O	64-71
abnormal	B	72-80
color	I	81-86
vision	I	87-93
and	O	94-97
adrenomyeloneuropathy	B	98-119
(	O	120-121
AMN	B	121-124
)	O	124-125
was	O	126-129
investigated	O	130-142
in	O	143-145
27	O	146-148
AMN	B	149-152
patients	O	153-161
and	O	162-165
31	O	166-168
age	O	169-172
-	O	172-173
matched	O	173-180
controls	O	181-189
by	O	190-192
using	O	193-198
the	O	199-202
Farnsworth	O	203-213
-	O	213-214
Munsell	O	214-221
100	O	222-225
Hue	O	226-229
test	O	230-234
.	O	234-235

Twelve	O	236-242
(	O	243-244
44	O	244-246
%	O	246-247
)	O	247-248
of	O	249-251
27	O	252-254
patients	O	255-263
showed	O	264-270
test	O	271-275
scores	O	276-282
significantly	O	283-296
above	O	297-302
normal	O	303-309
.	O	309-310

The	O	311-314
axes	O	315-319
of	O	320-322
bipolarity	O	323-333
determined	O	334-344
by	O	345-347
the	O	348-351
testing	O	352-359
differed	O	360-368
widely	O	369-375
between	O	376-383
the	O	384-387
patients	O	388-396
with	O	397-401
abnormal	O	402-410
scores	O	411-417
,	O	417-418
compatible	O	419-429
with	O	430-434
the	O	435-438
notion	O	439-445
that	O	446-450
different	O	451-460
alterations	O	461-472
in	O	473-475
visual	O	476-482
pigment	O	483-490
genes	O	491-496
occur	O	497-502
in	O	503-505
different	O	506-515
AMN	B	516-519
kindreds	O	520-528
.	O	528-529

These	O	530-535
observations	O	536-548
confirm	O	549-556
our	O	557-560
earlier	O	561-568
impression	O	569-579
that	O	580-584
the	O	585-588
frequency	O	589-598
of	O	599-601
abnormal	B	602-610
color	I	611-616
vision	I	617-623
is	O	624-626
increased	O	627-636
in	O	637-639
these	O	640-645
kindreds	O	646-654
,	O	654-655
and	O	656-659
it	O	660-662
supports	O	663-671
our	O	672-675
contentions	O	676-687
that	O	688-692
(	O	693-694
1	O	694-695
)	O	695-696
AMN	B	697-700
(	O	701-702
and	O	702-705
its	O	706-709
companion	O	710-719
,	O	719-720
adrenoleukodystrophy	B	721-741
)	O	741-742
are	O	743-746
very	O	747-751
closely	O	752-759
linked	O	760-766
to	O	767-769
the	O	770-773
visual	O	774-780
pigment	O	781-788
loci	O	789-793
at	O	794-796
Xq28	O	797-801
and	O	802-805
(	O	806-807
2	O	807-808
)	O	808-809
this	O	810-814
proximity	O	815-824
might	O	825-830
provide	O	831-838
the	O	839-842
opportunity	O	843-854
to	O	855-857
observe	O	858-865
contiguous	B	866-876
gene	I	877-881
defects	I	882-889
.	O	889-890
.	O	889-890

Patterns	O	0-8
of	O	9-11
exon	O	12-16
deletions	O	17-26
in	O	27-29
Duchenne	B	30-38
and	I	39-42
Becker	I	43-49
muscular	I	50-58
dystrophy	I	59-68
.	O	68-69

A	O	70-71
panel	O	72-77
of	O	78-80
patients	O	81-89
with	O	90-94
Duchenne	B	95-103
and	I	104-107
Becker	I	108-114
muscular	I	115-123
dystrophy	I	124-133
(	O	134-135
DMD	B	135-138
and	O	139-142
BMD	B	143-146
)	O	146-147
has	O	148-151
been	O	152-156
screened	O	157-165
with	O	166-170
the	O	171-174
cDNA	O	175-179
probes	O	180-186
Cf56a	O	187-192
and	O	193-196
Cf23a	O	197-202
,	O	202-203
which	O	204-209
detect	O	210-216
exons	O	217-222
in	O	223-225
the	O	226-229
central	O	230-237
part	O	238-242
of	O	243-245
the	O	246-249
DMD	B	250-253
gene	O	254-258
.	O	258-259

One	O	260-263
or	O	264-266
more	O	267-271
exons	O	272-277
were	O	278-282
deleted	O	283-290
in	O	291-293
60	O	294-296
%	O	296-297
of	O	298-300
patients	O	301-309
.	O	309-310

The	O	311-314
deletions	O	315-324
were	O	325-329
mapped	O	330-336
and	O	337-340
prove	O	341-346
to	O	347-349
be	O	350-352
heterogeneous	O	353-366
in	O	367-369
size	O	370-374
and	O	375-378
extent	O	379-385
,	O	385-386
particularly	O	387-399
in	O	400-402
DMD	B	403-406
.	O	406-407

Deletions	O	408-417
specific	O	418-426
to	O	427-429
DMD	B	430-433
and	O	434-437
to	O	438-440
BMD	B	441-444
are	O	445-448
described	O	449-458
.	O	458-459

Half	O	460-464
of	O	465-467
all	O	468-471
BMD	B	472-475
patients	O	476-484
have	O	485-489
a	O	490-491
deletion	O	492-500
of	O	501-503
one	O	504-507
particular	O	508-518
small	O	519-524
group	O	525-530
of	O	531-533
exons	O	534-539
;	O	539-540
smaller	O	541-548
deletions	O	549-558
within	O	559-565
this	O	566-570
same	O	571-575
group	O	576-581
produce	O	582-589
the	O	590-593
more	O	594-598
severe	O	599-605
DMD	B	606-609
.	O	609-610
.	O	609-610

The	O	0-3
LEC	O	4-7
rat	O	8-11
has	O	12-15
a	O	16-17
deletion	O	18-26
in	O	27-29
the	O	30-33
copper	O	34-40
transporting	O	41-53
ATPase	O	54-60
gene	O	61-65
homologous	O	66-76
to	O	77-79
the	O	80-83
Wilson	B	84-90
disease	I	91-98
gene	O	99-103
.	O	103-104

The	O	105-108
Long	O	109-113
-	O	113-114
Evans	O	114-119
Cinnamon	O	120-128
(	O	129-130
LEC	O	130-133
)	O	133-134
rat	O	135-138
shows	O	139-144
similarity	O	145-155
to	O	156-158
Wilson	B	159-165
disease	I	166-173
in	O	174-176
many	O	177-181
clinical	O	182-190
and	O	191-194
biochemical	O	195-206
features	O	207-215
.	O	215-216

We	O	217-219
have	O	220-224
cloned	O	225-231
cDNAs	O	232-237
for	O	238-241
the	O	242-245
rat	O	246-249
gene	O	250-254
(	O	255-256
Atp7b	O	256-261
)	O	261-262
homologous	O	263-273
to	O	274-276
the	O	277-280
human	O	281-286
Wilson	B	287-293
disease	I	294-301
gene	O	302-306
(	O	307-308
ATP7B	O	308-313
)	O	313-314
and	O	315-318
have	O	319-323
used	O	324-328
them	O	329-333
to	O	334-336
identify	O	337-345
a	O	346-347
partial	O	348-355
deletion	O	356-364
in	O	365-367
the	O	368-371
Atp7b	O	372-377
gene	O	378-382
in	O	383-385
the	O	386-389
LEC	O	390-393
rat	O	394-397
.	O	397-398

The	O	399-402
deletion	O	403-411
removes	O	412-419
at	O	420-422
least	O	423-428
900	O	429-432
bp	O	433-435
of	O	436-438
the	O	439-442
coding	O	443-449
region	O	450-456
at	O	457-459
the	O	460-463
3	O	464-465
end	O	466-469
,	O	469-470
includes	O	471-479
the	O	480-483
crucial	O	484-491
ATP	O	492-495
binding	O	496-503
domain	O	504-510
and	O	511-514
extends	O	515-522
downstream	O	523-533
of	O	534-536
the	O	537-540
gene	O	541-545
.	O	545-546

Our	O	547-550
results	O	551-558
provide	O	559-566
convincing	O	567-577
evidence	O	578-586
for	O	587-590
defining	O	591-599
the	O	600-603
LEC	O	604-607
rat	O	608-611
as	O	612-614
an	O	615-617
animal	O	618-624
model	O	625-630
for	O	631-634
Wilson	B	635-641
disease	I	642-649
.	O	649-650

This	O	651-655
model	O	656-661
will	O	662-666
be	O	667-669
important	O	670-679
for	O	680-683
studying	O	684-692
liver	O	693-698
pathophysiology	O	699-714
,	O	714-715
for	O	716-719
developing	O	720-730
therapy	O	731-738
for	O	739-742
Wilson	B	743-749
disease	I	750-757
and	O	758-761
for	O	762-765
studying	O	766-774
the	O	775-778
pathway	O	779-786
of	O	787-789
copper	O	790-796
transport	O	797-806
and	O	807-810
its	O	811-814
possible	O	815-823
interaction	O	824-835
with	O	836-840
other	O	841-846
heavy	O	847-852
metals	O	853-859
.	O	859-860
.	O	859-860

Detection	O	0-9
of	O	10-12
a	O	13-14
new	O	15-18
submicroscopic	O	19-33
Norrie	B	34-40
disease	I	41-48
deletion	O	49-57
interval	O	58-66
with	O	67-71
a	O	72-73
novel	O	74-79
DNA	O	80-83
probe	O	84-89
isolated	O	90-98
by	O	99-101
differential	O	102-114
Alu	O	115-118
PCR	O	119-122
fingerprint	O	123-134
cloning	O	135-142
.	O	142-143

Differential	O	144-156
Alu	O	157-160
PCR	O	161-164
fingerprint	O	165-176
cloning	O	177-184
was	O	185-188
used	O	189-193
to	O	194-196
isolate	O	197-204
a	O	205-206
DNA	O	207-210
probe	O	211-216
from	O	217-221
the	O	222-225
Xp11	O	226-230
.	O	230-231

4	O	232-233
-	O	233-234
-	O	233-234
>	O	236-237
p11	O	238-241
.	O	241-242

21	O	243-245
region	O	246-252
of	O	253-255
the	O	256-259
human	O	260-265
X	O	266-267
chromosome	O	268-278
.	O	278-279

This	O	280-284
novel	O	285-290
sequence	O	291-299
,	O	299-300
cpXr318	O	301-308
(	O	309-310
DXS742	O	310-316
)	O	316-317
,	O	317-318
detects	O	319-326
a	O	327-328
new	O	329-332
submicroscopic	O	333-347
deletion	O	348-356
interval	O	357-365
at	O	366-368
the	O	369-372
Norrie	B	373-379
disease	I	380-387
locus	O	388-393
(	O	394-395
NDP	O	395-398
)	O	398-399
.	O	399-400

Combining	O	401-410
our	O	411-414
data	O	415-419
with	O	420-424
the	O	425-428
consensus	O	429-438
genetic	O	439-446
map	O	447-450
of	O	451-453
the	O	454-457
proximal	O	458-466
short	O	467-472
arm	O	473-476
of	O	477-479
the	O	480-483
X	O	484-485
chromosome	O	486-496
,	O	496-497
we	O	498-500
propose	O	501-508
the	O	509-512
physical	O	513-521
order	O	522-527
Xcen	O	528-532
-	O	532-533
DXS14	O	533-538
-	O	532-533
DXS255	O	539-545
-	O	532-533
(	O	547-548
DXS426	O	548-554
,	O	554-555
TIMP	O	556-560
)	O	560-561
-	O	562-563
(	O	564-565
DXS742	O	565-571
-	O	571-572
(	O	573-574
[	O	574-575
MAOB	O	575-579
-	O	579-580
MAOA	O	580-584
-	O	579-580
DXS7	O	585-589
]	O	589-590
,	O	590-591
NDP	O	592-595
)	O	595-596
-	O	597-598
DXS77	O	598-603
-	O	597-598
DXS228	O	604-610
)	O	610-611
-	O	612-613
DXS209	O	613-619
-	O	612-613
DXS148	O	620-626
-	O	612-613
DXS196	O	627-633
-	O	612-613
+	O	635-636
+	O	637-638
+	O	639-640
Xpter	O	641-646
.	O	646-647

The	O	648-651
cpXr318	O	652-659
probe	O	660-665
and	O	666-669
a	O	670-671
subclone	O	672-680
from	O	681-685
a	O	686-687
cosmid	O	688-694
corresponding	O	695-708
to	O	709-711
the	O	712-715
DXS7	O	716-720
locus	O	721-726
were	O	727-731
converted	O	732-741
into	O	742-746
sequence	O	747-755
-	O	755-756
tagged	O	756-762
sites	O	763-768
.	O	768-769

Finally	O	770-777
,	O	777-778
DXS742	O	779-785
,	O	785-786
DSX7	O	787-791
,	O	791-792
DXS77	O	793-798
,	O	798-799
and	O	800-803
MAOA	O	804-808
were	O	809-813
integrated	O	814-824
into	O	825-829
a	O	830-831
physical	O	832-840
map	O	841-844
spanning	O	845-853
the	O	854-857
Norrie	B	858-864
disease	I	865-872
locus	O	873-878

Genetic	O	0-7
analysis	O	8-16
of	O	17-19
a	O	20-21
Japanese	O	22-30
family	O	31-37
with	O	38-42
normotriglyceridemic	B	43-63
abetalipoproteinemia	I	64-84
indicates	O	85-94
a	O	95-96
lack	O	97-101
of	O	102-104
linkage	O	105-112
to	O	113-115
the	O	116-119
apolipoprotein	O	120-134
B	O	135-136
gene	O	137-141
.	O	141-142

Normotriglyceridemic	B	143-163
abetalipoproteinemia	I	164-184
is	O	185-187
a	O	188-189
rare	O	190-194
familial	B	195-203
disorder	I	204-212
characterized	O	213-226
by	O	227-229
an	O	230-232
isolated	O	233-241
deficiency	B	242-252
of	I	253-255
apoB	I	256-260
-	I	260-261
100	I	261-264
.	O	264-265

We	O	266-268
have	O	269-273
previously	O	274-284
reported	O	285-293
a	O	294-295
patient	O	296-303
with	O	304-308
this	O	309-313
disease	O	314-321
,	O	321-322
who	O	323-326
had	O	327-330
normal	O	331-337
apoB	O	338-342
-	O	342-343
48	O	343-345
but	O	346-349
no	O	350-352
apoB	O	353-357
-	O	357-358
100	O	358-361
.	O	361-362

To	O	363-365
elucidate	O	366-375
the	O	376-379
genetic	B	380-387
abnormalities	I	388-401
in	O	402-404
this	O	405-409
family	O	410-416
,	O	416-417
we	O	418-420
studied	O	421-428
the	O	429-432
linkage	O	433-440
of	O	441-443
apoB	O	444-448
gene	O	449-453
using	O	454-459
three	O	460-465
genetic	O	466-473
markers	O	474-481
.	O	481-482

The	O	483-486
proband	O	487-494
and	O	495-498
her	O	499-502
affected	O	503-511
brother	O	512-519
showed	O	520-526
completely	O	527-537
different	O	538-547
apoB	O	548-552
gene	O	553-557
alleles	O	558-565
,	O	565-566
suggesting	O	567-577
that	O	578-582
the	O	583-586
apoB	O	587-591
gene	O	592-596
itself	O	597-603
is	O	604-606
not	O	607-610
related	O	611-618
to	O	619-621
this	O	622-626
disorder	O	627-635
in	O	636-638
this	O	639-643
family	O	644-650
.	O	650-651

By	O	652-654
contrast	O	655-663
,	O	663-664
an	O	665-667
American	O	668-676
case	O	677-681
had	O	682-685
a	O	686-687
point	O	688-693
substitution	O	694-706
in	O	707-709
the	O	710-713
apoB	O	714-718
gene	O	719-723
generating	O	724-734
an	O	735-737
in	O	738-740
-	O	740-741
frame	O	741-746
stop	O	747-751
codon	O	752-757
.	O	757-758

These	O	759-764
results	O	765-772
indicate	O	773-781
that	O	782-786
this	O	787-791
disorder	O	792-800
can	O	801-804
be	O	805-807
caused	O	808-814
by	O	815-817
defect	O	818-824
(	O	825-826
s	O	826-827
)	O	827-828
of	O	829-831
either	O	832-838
an	O	839-841
apoB	O	842-846
gene	O	847-851
or	O	852-854
other	O	855-860
genes	O	861-866
.	O	866-867
.	O	866-867

Founder	O	0-7
mutations	O	8-17
in	O	18-20
the	O	21-24
BRCA1	O	25-30
gene	O	31-35
in	O	36-38
Polish	O	39-45
families	O	46-54
with	O	55-59
breast	B	60-66
-	I	66-67
ovarian	I	67-74
cancer	I	75-81
.	O	81-82

We	O	83-85
have	O	86-90
undertaken	O	91-101
a	O	102-103
hospital	O	104-112
-	O	112-113
based	O	113-118
study	O	119-124
,	O	124-125
to	O	126-128
identify	O	129-137
possible	O	138-146
BRCA1	O	147-152
and	O	153-156
BRCA2	O	157-162
founder	O	163-170
mutations	O	171-180
in	O	181-183
the	O	184-187
Polish	O	188-194
population	O	195-205
.	O	205-206

The	O	207-210
study	O	211-216
group	O	217-222
consisted	O	223-232
of	O	233-235
66	O	236-238
Polish	O	239-245
families	O	246-254
with	O	255-259
cancer	B	260-266
who	O	267-270
have	O	271-275
at	O	276-278
least	O	279-284
three	O	285-290
related	O	291-298
females	O	299-306
affected	O	307-315
with	O	316-320
breast	B	321-327
or	I	328-330
ovarian	I	331-338
cancer	I	339-345
and	O	346-349
who	O	350-353
had	O	354-357
cancer	B	358-364
diagnosed	O	365-374
,	O	374-375
in	O	376-378
at	O	379-381
least	O	382-387
one	O	388-391
of	O	392-394
the	O	395-398
three	O	399-404
affected	O	405-413
females	O	414-421
,	O	421-422
at	O	423-425
age	O	426-429
<	O	430-431
50	O	432-434
years	O	435-440
.	O	440-441

A	O	442-443
total	O	444-449
of	O	450-452
26	O	453-455
families	O	456-464
had	O	465-468
both	O	469-473
breast	B	474-480
and	I	481-484
ovarian	I	485-492
cancers	I	493-500
,	O	500-501
4	O	502-503
families	O	504-512
had	O	513-516
ovarian	B	517-524
cancers	I	525-532
only	O	533-537
,	O	537-538
and	O	539-542
36	O	543-545
families	O	546-554
had	O	555-558
breast	B	559-565
cancers	I	566-573
only	O	574-578
.	O	578-579

Genomic	O	580-587
DNA	O	588-591
was	O	592-595
prepared	O	596-604
from	O	605-609
the	O	610-613
peripheral	O	614-624
blood	O	625-630
leukocytes	O	631-641
of	O	642-644
at	O	645-647
least	O	648-653
one	O	654-657
affected	O	658-666
woman	O	667-672
from	O	673-677
each	O	678-682
family	O	683-689
.	O	689-690

The	O	691-694
entire	O	695-701
coding	O	702-708
region	O	709-715
of	O	716-718
BRCA1	O	719-724
and	O	725-728
BRCA2	O	729-734
was	O	735-738
screened	O	739-747
for	O	748-751
the	O	752-755
presence	O	756-764
of	O	765-767
germline	O	768-776
mutations	O	777-786
,	O	786-787
by	O	788-790
use	O	791-794
of	O	795-797
SSCP	O	798-802
followed	O	803-811
by	O	812-814
direct	O	815-821
sequencing	O	822-832
of	O	833-835
observed	O	836-844
variants	O	845-853
.	O	853-854

Mutations	O	855-864
were	O	865-869
found	O	870-875
in	O	876-878
35	O	879-881
(	O	882-883
53	O	883-885
%	O	885-886
)	O	886-887
of	O	888-890
the	O	891-894
66	O	895-897
families	O	898-906
studied	O	907-914
.	O	914-915

All	O	916-919
but	O	920-923
one	O	924-927
of	O	928-930
the	O	931-934
mutations	O	935-944
were	O	945-949
detected	O	950-958
within	O	959-965
the	O	966-969
BRCA1	O	970-975
gene	O	976-980
.	O	980-981

BRCA1	B	982-987
abnormalities	I	988-1001
were	O	1002-1006
identified	O	1007-1017
in	O	1018-1020
all	O	1021-1024
four	O	1025-1029
families	O	1030-1038
with	O	1039-1043
ovarian	B	1044-1051
cancer	I	1052-1058
only	O	1059-1063
,	O	1063-1064
in	O	1065-1067
67	O	1068-1070
%	O	1070-1071
of	O	1072-1074
27	O	1075-1077
families	O	1078-1086
with	O	1087-1091
both	O	1092-1096
breast	B	1097-1103
and	I	1104-1107
ovarian	I	1108-1115
cancer	I	1116-1122
,	O	1122-1123
and	O	1124-1127
in	O	1128-1130
34	O	1131-1133
%	O	1133-1134
of	O	1135-1137
35	O	1138-1140
families	O	1141-1149
with	O	1150-1154
breast	B	1155-1161
cancer	I	1162-1168
only	O	1169-1173
.	O	1173-1174

The	O	1175-1178
single	O	1179-1185
family	O	1186-1192
with	O	1193-1197
a	O	1198-1199
BRCA2	O	1200-1205
mutation	O	1206-1214
had	O	1215-1218
the	O	1219-1222
breast	B	1223-1229
-	I	1229-1230
ovarian	I	1230-1237
cancer	I	1238-1244
syndrome	I	1245-1253
.	O	1253-1254

Seven	O	1255-1260
distinct	O	1261-1269
mutations	O	1270-1279
were	O	1280-1284
identified	O	1285-1295
;	O	1295-1296
five	O	1297-1301
of	O	1302-1304
these	O	1305-1310
occurred	O	1311-1319
in	O	1320-1322
two	O	1323-1326
or	O	1327-1329
more	O	1330-1334
families	O	1335-1343
.	O	1343-1344

In	O	1345-1347
total	O	1348-1353
,	O	1353-1354
recurrent	O	1355-1364
mutations	O	1365-1374
were	O	1375-1379
found	O	1380-1385
in	O	1386-1388
33	O	1389-1391
(	O	1392-1393
94	O	1393-1395
%	O	1395-1396
)	O	1396-1397
of	O	1398-1400
the	O	1401-1404
35	O	1405-1407
families	O	1408-1416
with	O	1417-1421
detected	O	1422-1430
mutations	O	1431-1440
.	O	1440-1441

Three	O	1442-1447
BRCA1	B	1448-1453
abnormalities	I	1454-1467
-	O	1468-1469
5382insC	O	1470-1478
,	O	1478-1479
C61G	O	1480-1484
,	O	1484-1485
and	O	1486-1489
4153delA	O	1490-1498
-	O	1499-1500
accounted	O	1501-1510
for	O	1511-1514
51	O	1515-1517
%	O	1517-1518
,	O	1518-1519
20	O	1520-1522
%	O	1522-1523
,	O	1523-1524
and	O	1525-1528
11	O	1529-1531
%	O	1531-1532
of	O	1533-1535
the	O	1536-1539
identified	O	1540-1550
mutations	O	1551-1560
,	O	1560-1561
respectively	O	1562-1574
.	O	1574-1575
.	O	1574-1575

New	O	0-3
founder	O	4-11
haplotypes	O	12-22
at	O	23-25
the	O	26-29
myotonic	B	30-38
dystrophy	I	39-48
locus	O	49-54
in	O	55-57
southern	O	58-66
Africa	O	67-73
.	O	73-74

The	O	75-78
association	O	79-90
between	O	91-98
normal	O	99-105
alleles	O	106-113
at	O	114-116
the	O	117-120
CTG	O	121-124
repeat	O	125-131
and	O	132-135
two	O	136-139
nearby	O	140-146
polymorphisms	O	147-160
in	O	161-163
the	O	164-167
myotonin	O	168-176
protein	O	177-184
kinase	O	185-191
gene	O	192-196
,	O	196-197
the	O	198-201
Alu	O	202-205
insertion	O	206-215
/	O	215-216
deletion	O	216-224
polymorphism	O	225-237
and	O	238-241
the	O	242-245
myotonic	B	246-254
dystrophy	I	255-264
kinase	O	265-271
(	O	272-273
DMK	O	273-276
)	O	276-277
(	O	278-279
G	O	279-280
/	O	280-281
T	O	281-282
)	O	282-283
intron	O	284-290
9	O	291-292
/	O	292-293
HinfI	O	293-298
polymorphism	O	299-311
,	O	311-312
has	O	313-316
been	O	317-321
analyzed	O	322-330
in	O	331-333
South	O	334-339
African	O	340-347
Negroids	O	348-356
,	O	356-357
a	O	358-359
population	O	360-370
in	O	371-373
which	O	374-379
myotonic	B	380-388
dystrophy	I	389-398
(	O	399-400
DM	B	400-402
)	O	402-403
has	O	404-407
not	O	408-411
been	O	412-416
described	O	417-426
.	O	426-427

South	O	428-433
African	O	434-441
Negroids	O	442-450
have	O	451-455
a	O	456-457
CTG	O	458-461
allelic	O	462-469
distribution	O	470-482
that	O	483-487
is	O	488-490
significantly	O	491-504
different	O	505-514
from	O	515-519
that	O	520-524
in	O	525-527
Caucasoids	O	528-538
and	O	539-542
Japanese	O	543-551
the	O	553-556
CTG	O	557-560
repeat	O	561-567
lengths	O	568-575
of	O	576-578
>	O	579-580
or	O	581-583
=	O	584-585
19	O	586-588
are	O	589-592
very	O	593-597
rare	O	598-602
.	O	602-603

The	O	604-607
striking	O	608-616
linkage	O	617-624
disequilibrium	O	625-639
between	O	640-647
specific	O	648-656
alleles	O	657-664
at	O	665-667
the	O	668-671
Alu	O	672-675
polymorphism	O	676-688
(	O	689-690
Alu	O	690-693
(	O	694-695
ins	O	695-698
)	O	698-699
and	O	700-703
Alu	O	704-707
(	O	708-709
del	O	709-712
)	O	712-713
)	O	712-713
,	O	714-715
the	O	716-719
HinfI	O	720-725
polymorphism	O	726-738
(	O	739-740
HinfI	O	740-745
-	O	745-746
1	O	746-747
and	O	748-751
HinfI	O	752-757
-	O	757-758
2	O	758-759
)	O	759-760
,	O	760-761
and	O	762-765
the	O	766-769
CTG	O	770-773
repeat	O	774-780
polymorphism	O	781-793
seen	O	794-798
in	O	799-801
Caucasoid	O	802-811
(	O	812-813
Europeans	O	813-822
and	O	823-826
Canadians	O	827-836
)	O	836-837
populations	O	838-849
was	O	850-853
also	O	854-858
found	O	859-864
in	O	865-867
the	O	868-871
South	O	872-877
African	O	878-885
Negroid	O	886-893
population	O	894-904
.	O	904-905

Numerous	O	906-914
haplotypes	O	915-925
,	O	925-926
not	O	927-930
previously	O	931-941
described	O	942-951
in	O	952-954
Europeans	O	955-964
,	O	964-965
were	O	966-970
,	O	970-971
however	O	972-979
,	O	979-980
found	O	981-986
.	O	986-987

It	O	988-990
thus	O	991-995
seems	O	996-1001
likely	O	1002-1008
that	O	1009-1013
only	O	1014-1018
a	O	1019-1020
small	O	1021-1026
number	O	1027-1033
of	O	1034-1036
these	O	1037-1042
"	O	1043-1044
African	O	1045-1052
"	O	1053-1054
chromosomes	O	1055-1066
were	O	1067-1071
present	O	1072-1079
in	O	1080-1082
the	O	1083-1086
progenitors	O	1087-1098
of	O	1099-1101
all	O	1102-1105
non	O	1106-1109
-	O	1109-1110
African	O	1110-1117
peoples	O	1118-1125
.	O	1125-1126

These	O	1127-1132
data	O	1133-1137
provide	O	1138-1145
support	O	1146-1153
for	O	1154-1157
the	O	1158-1161
"	O	1162-1163
out	O	1164-1167
of	O	1168-1170
Africa	O	1171-1177
"	O	1178-1179
model	O	1180-1185
for	O	1186-1189
the	O	1190-1193
origin	O	1194-1200
of	O	1201-1203
modern	O	1204-1210
humans	O	1211-1217
and	O	1218-1221
suggest	O	1222-1229
that	O	1230-1234
the	O	1235-1238
rare	O	1239-1243
ancestral	O	1244-1253
DM	B	1254-1256
mutation	O	1257-1265
event	O	1266-1271
may	O	1272-1275
have	O	1276-1280
occurred	O	1281-1289
after	O	1290-1295
the	O	1296-1299
migration	O	1300-1309
from	O	1310-1314
Africa	O	1315-1321
,	O	1321-1322
hence	O	1323-1328
the	O	1329-1332
absence	O	1333-1340
of	O	1341-1343
DM	B	1344-1346
in	O	1347-1349
sub	O	1350-1353
-	O	1353-1354
Saharan	O	1354-1361
Negroid	O	1362-1369
peoples	O	1370-1377
.	O	1377-1378
.	O	1377-1378

Marked	O	0-6
phenotypic	O	7-17
heterogeneity	O	18-31
associated	O	32-42
with	O	43-47
expansion	O	48-57
of	O	58-60
a	O	61-62
CAG	O	63-66
repeat	O	67-73
sequence	O	74-82
at	O	83-85
the	O	86-89
spinocerebellar	B	90-105
ataxia	I	106-112
3	I	113-114
/	I	114-115
Machado	I	115-122
-	I	122-123
Joseph	I	123-129
disease	I	130-137
locus	O	138-143
.	O	143-144

The	O	145-148
spinocerebellar	B	149-164
ataxia	I	165-171
3	I	172-173
locus	O	174-179
(	O	180-181
SCA3	B	181-185
)	O	185-186
for	O	187-190
type	B	191-195
I	I	196-197
autosomal	I	198-207
dominant	I	208-216
cerebellar	I	217-227
ataxia	I	228-234
(	O	235-236
ADCA	B	236-240
type	I	241-245
I	I	246-247
)	O	247-248
,	O	248-249
a	O	250-251
clinically	O	252-262
and	O	263-266
genetically	O	267-278
heterogeneous	O	279-292
group	O	293-298
of	O	299-301
neurodegenerative	B	302-319
disorders	I	320-329
,	O	329-330
has	O	331-334
been	O	335-339
mapped	O	340-346
to	O	347-349
chromosome	O	350-360
14q32	O	361-366
.	O	366-367

1	O	368-369
1	O	370-371
.	O	371-372

ADCA	B	373-377
type	I	378-382
I	I	383-384
patients	O	385-393
from	O	394-398
families	O	399-407
segregating	O	408-419
SCA3	B	420-424
share	O	425-430
clinical	O	431-439
features	O	440-448
in	O	449-451
common	O	452-458
with	O	459-463
those	O	464-469
with	O	470-474
Machado	B	475-482
-	I	482-483
Joseph	I	483-489
disease	I	490-497
(	O	498-499
MJD	B	499-502
)	O	502-503
,	O	503-504
the	O	505-508
gene	O	509-513
of	O	514-516
which	O	517-522
maps	O	523-527
to	O	528-530
the	O	531-534
same	O	535-539
region	O	540-546
.	O	546-547

We	O	548-550
show	O	551-555
here	O	556-560
that	O	561-565
the	O	566-569
disease	O	570-577
gene	O	578-582
segregating	O	583-594
in	O	595-597
each	O	598-602
of	O	603-605
three	O	606-611
French	O	612-618
ADCA	B	619-623
type	I	624-628
I	I	629-630
kindreds	O	631-639
and	O	640-643
in	O	644-646
a	O	647-648
French	O	649-655
family	O	656-662
with	O	663-667
neuropathological	O	668-685
findings	O	686-694
suggesting	O	695-705
the	O	706-709
ataxochoreic	O	710-722
form	O	723-727
of	O	728-730
dentatorubropallidoluysian	B	731-757
atrophy	I	758-765
carries	O	766-773
an	O	774-776
expanded	O	777-785
CAG	O	786-789
repeat	O	790-796
sequence	O	797-805
located	O	806-813
at	O	814-816
the	O	817-820
same	O	821-825
locus	O	826-831
as	O	832-834
that	O	835-839
for	O	840-843
MJD	B	844-847
.	O	847-848

Analysis	O	849-857
of	O	858-860
the	O	861-864
mutation	O	865-873
in	O	874-876
these	O	877-882
families	O	883-891
shows	O	892-897
a	O	898-899
strong	O	900-906
negative	O	907-915
correlation	O	916-927
between	O	928-935
size	O	936-940
of	O	941-943
the	O	944-947
expanded	O	948-956
CAG	O	957-960
repeat	O	961-967
and	O	968-971
age	O	972-975
at	O	976-978
onset	O	979-984
of	O	985-987
clinical	O	988-996
disease	O	997-1004
.	O	1004-1005

Instability	O	1006-1017
of	O	1018-1020
the	O	1021-1024
expanded	O	1025-1033
triplet	O	1034-1041
repeat	O	1042-1048
was	O	1049-1052
not	O	1053-1056
found	O	1057-1062
to	O	1063-1065
be	O	1066-1068
affected	O	1069-1077
by	O	1078-1080
sex	O	1081-1084
of	O	1085-1087
the	O	1088-1091
parent	O	1092-1098
transmitting	O	1099-1111
the	O	1112-1115
mutation	O	1116-1124
.	O	1124-1125

Evidence	O	1126-1134
was	O	1135-1138
found	O	1139-1144
for	O	1145-1148
somatic	O	1149-1156
and	O	1157-1160
gonadal	O	1161-1168
mosaicism	O	1169-1178
for	O	1179-1182
alleles	O	1183-1190
carrying	O	1191-1199
expanded	O	1200-1208
trinucleotide	O	1209-1222
repeats	O	1223-1230
.	O	1230-1231

The	O	0-3
red	O	4-7
-	O	7-8
green	O	8-13
visual	O	14-20
pigment	O	21-28
gene	O	29-33
region	O	34-40
in	O	41-43
adrenoleukodystrophy	B	44-64
.	O	64-65

Although	O	66-74
recent	O	75-81
data	O	82-86
established	O	87-98
that	O	99-103
a	O	104-105
specific	O	106-114
very	O	115-119
-	O	119-120
long	O	120-124
-	O	119-120
chain	O	125-130
fatty	O	131-136
acyl	O	137-141
-	O	141-142
CoA	O	142-145
synthetase	O	146-156
is	O	157-159
defective	O	160-169
in	O	170-172
X	B	173-174
-	I	174-175
linked	I	175-181
adrenoleukodystrophy	I	182-202
(	O	203-204
ALD	B	204-207
)	O	207-208
,	O	208-209
the	O	210-213
ALD	B	214-217
gene	O	218-222
is	O	223-225
still	O	226-231
unidentified	O	232-244
.	O	244-245

The	O	246-249
ALD	B	250-253
locus	O	254-259
has	O	260-263
been	O	264-268
mapped	O	269-275
to	O	276-278
Xq28	O	279-283
,	O	283-284
like	O	285-289
the	O	290-293
red	O	294-297
and	O	298-301
green	O	302-307
color	O	308-313
pigment	O	314-321
genes	O	322-327
.	O	327-328

Abnormal	B	329-337
color	I	338-343
vision	I	344-350
has	O	351-354
been	O	355-359
observed	O	360-368
in	O	369-371
12	O	372-374
of	O	375-377
27	O	378-380
patients	O	381-389
with	O	390-394
adrenomyeloneuropathy	B	395-416
(	O	417-418
AMN	B	418-421
)	O	421-422
,	O	422-423
a	O	424-425
milder	O	426-432
form	O	433-437
of	O	438-440
ALD	B	441-444
.	O	444-445

Furthermore	O	446-457
,	O	457-458
rearrangements	O	459-473
of	O	474-476
the	O	477-480
color	O	481-486
vision	O	487-493
gene	O	494-498
cluster	O	499-506
were	O	507-511
found	O	512-517
in	O	518-520
four	O	521-525
of	O	526-528
eight	O	529-534
ALD	B	535-538
kindreds	O	539-547
.	O	547-548

This	O	549-553
led	O	554-557
us	O	558-560
to	O	561-563
propose	O	564-571
that	O	572-576
a	O	577-578
single	O	579-585
DNA	O	586-589
rearrangement	O	590-603
could	O	604-609
underlie	O	610-618
both	O	619-623
ALD	B	624-627
and	O	628-631
abnormal	B	632-640
color	I	641-646
vision	I	647-653
in	O	654-656
these	O	657-662
patients	O	663-671
.	O	671-672

Study	O	673-678
of	O	679-681
34	O	682-684
French	O	685-691
ALD	B	692-695
patients	O	696-704
failed	O	705-711
to	O	712-714
reveal	O	715-721
a	O	722-723
higher	O	724-730
than	O	731-735
expected	O	736-744
frequency	O	745-754
of	O	755-757
green	O	758-763
/	O	763-764
red	O	764-767
visual	O	768-774
pigment	O	775-782
rearrangements	O	783-797
3	O	798-799
to	O	800-802
the	O	803-806
red	O	807-810
/	O	810-811
green	O	811-816
color	O	817-822
vision	O	823-829
gene	O	830-834
complex	O	835-842
.	O	842-843

The	O	844-847
previous	O	848-856
report	O	857-863
of	O	864-866
such	O	867-871
rearrangements	O	872-886
was	O	887-890
based	O	891-896
on	O	897-899
small	O	900-905
numbers	O	906-913
and	O	914-917
lack	O	918-922
of	O	923-925
knowledge	O	926-935
that	O	936-940
the	O	941-944
frequency	O	945-954
of	O	955-957
"	O	958-959
abnormal	O	960-968
"	O	969-970
color	O	971-976
vision	O	977-983
arrays	O	984-990
on	O	991-993
molecular	O	994-1003
analysis	O	1004-1012
was	O	1013-1016
twice	O	1017-1022
as	O	1023-1025
high	O	1026-1030
as	O	1031-1033
expected	O	1034-1042
on	O	1043-1045
the	O	1046-1049
basis	O	1050-1055
of	O	1056-1058
the	O	1059-1062
frequency	O	1063-1072
of	O	1073-1075
phenotypic	B	1076-1086
color	I	1087-1092
vision	I	1093-1099
defects	I	1100-1107
.	O	1107-1108

The	O	1109-1112
red	O	1113-1116
/	O	1116-1117
green	O	1117-1122
color	O	1123-1128
pigment	O	1129-1136
(	O	1137-1138
R	O	1138-1139
/	O	1139-1140
GCP	O	1140-1143
)	O	1143-1144
region	O	1145-1151
was	O	1152-1155
studied	O	1156-1163
by	O	1164-1166
pulsed	O	1167-1173
-	O	1173-1174
field	O	1174-1179
gel	O	1180-1183
electrophoresis	O	1184-1199
in	O	1200-1202
14	O	1203-1205
of	O	1206-1208
these	O	1209-1214
patients	O	1215-1223
,	O	1223-1224
and	O	1225-1228
we	O	1229-1231
did	O	1232-1235
not	O	1236-1239
find	O	1240-1244
any	O	1245-1248
fragment	O	1249-1257
size	O	1258-1262
difference	O	1263-1273
between	O	1274-1281
the	O	1282-1285
patients	O	1286-1294
and	O	1295-1298
normal	O	1299-1305
individuals	O	1306-1317
who	O	1318-1321
have	O	1322-1326
the	O	1327-1330
same	O	1331-1335
number	O	1336-1342
of	O	1343-1345
pigment	O	1346-1353
genes	O	1354-1359
.	O	1359-1360

The	O	1361-1364
R	O	1365-1366
/	O	1366-1367
GCP	O	1367-1370
region	O	1371-1377
was	O	1378-1381
also	O	1382-1386
analyzed	O	1387-1395
in	O	1396-1398
29	O	1399-1401
French	O	1402-1408
and	O	1409-1412
seven	O	1413-1418
North	O	1419-1424
American	O	1425-1433
ALD	B	1434-1437
patients	O	1438-1446
by	O	1447-1449
using	O	1450-1455
six	O	1456-1459
genomic	O	1460-1467
DNA	O	1468-1471
probes	O	1472-1478
,	O	1478-1479
isolated	O	1480-1488
from	O	1489-1493
a	O	1494-1495
cosmid	O	1496-1502
walk	O	1503-1507
,	O	1507-1508
that	O	1509-1513
flank	O	1514-1519
the	O	1520-1523
color	O	1524-1529
vision	O	1530-1536
genes	O	1537-1542
.	O	1542-1543

No	O	1544-1546
deletions	O	1547-1556
were	O	1557-1561
found	O	1562-1567
with	O	1568-1572
probes	O	1573-1579
that	O	1580-1584
lie	O	1585-1588
3	O	1589-1590
of	O	1591-1593
the	O	1594-1597
green	O	1598-1603
pigment	O	1604-1611
genes	O	1612-1617
.	O	1617-1618

One	O	1619-1622
of	O	1623-1625
the	O	1626-1629
eight	O	1630-1635
previously	O	1636-1646
reported	O	1647-1655
ALD	B	1656-1659
individuals	O	1660-1671
has	O	1672-1675
a	O	1676-1677
long	O	1678-1682
deletion	O	1683-1691
5	O	1692-1693
of	O	1694-1696
the	O	1697-1700
red	O	1701-1704
pigment	O	1705-1712
gene	O	1713-1717
,	O	1717-1718
a	O	1719-1720
deletion	O	1721-1729
causing	O	1730-1737
blue	O	1738-1742
cone	O	1743-1747
monochromacy	O	1748-1760
.	O	1760-1761

This	O	1762-1766
finding	O	1767-1774
and	O	1775-1778
the	O	1779-1782
previous	O	1783-1791
findings	O	1792-1800
of	O	1801-1803
a	O	1804-1805
45	O	1806-1808
%	O	1808-1809
frequency	O	1810-1819
of	O	1820-1822
phenotypic	O	1823-1833
color	O	1834-1839
vision	O	1840-1846
defects	O	1847-1854
in	O	1855-1857
patients	O	1858-1866
with	O	1867-1871
AMN	B	1872-1875
may	O	1876-1879
suggest	O	1880-1887
that	O	1888-1892
the	O	1893-1896
ALD	B	1897-1900
/	O	1900-1901
AMN	B	1901-1904
gene	O	1905-1909
lies	O	1910-1914
5	O	1915-1916
to	O	1917-1919
the	O	1920-1923
red	O	1924-1927
pigment	O	1928-1935
gene	O	1936-1940
and	O	1941-1944
that	O	1945-1949
the	O	1950-1953
frequent	O	1954-1962
phenotypic	O	1963-1973
color	B	1974-1979
vision	I	1980-1986
anomalies	I	1987-1996
owe	O	1997-2000
their	O	2001-2006
origin	O	2007-2013
to	O	2014-2016
deleted	O	2017-2024
DNA	O	2025-2028
that	O	2029-2033
includes	O	2034-2042
regulatory	O	2043-2053
genes	O	2054-2059
for	O	2060-2063
color	O	2064-2069
vision	O	2070-2076
.	O	2076-2077

It	O	2078-2080
is	O	2081-2083
possible	O	2084-2092
,	O	2092-2093
however	O	2094-2101
,	O	2101-2102
that	O	2103-2107
phenotypic	O	2108-2118
color	B	2119-2124
vision	I	2125-2131
anomalies	I	2132-2141
in	O	2142-2144
AMN	B	2145-2148
may	O	2149-2152
be	O	2153-2155
phenocopies	O	2156-2167
secondary	O	2168-2177
to	O	2178-2180
retinal	O	2181-2188
or	O	2189-2191
neural	O	2192-2198
involvement	O	2199-2210
by	O	2211-2213
the	O	2214-2217
disease	O	2218-2225
.	O	2225-2226

The	O	2227-2230
single	O	2231-2237
case	O	2238-2242
of	O	2243-2245
blue	O	2246-2250
cone	O	2251-2255
monochromacy	O	2256-2268
may	O	2269-2272
therefore	O	2273-2282
be	O	2283-2285
a	O	2286-2287
fortuitous	O	2288-2298
coincidence	O	2299-2310
of	O	2311-2313
two	O	2314-2317
diseases	O	2318-2326
.	O	2326-2327
.	O	2326-2327

Haim	B	0-4
-	I	4-5
Munk	I	5-9
syndrome	I	10-18
and	O	19-22
Papillon	B	23-31
-	I	31-32
Lefevre	I	32-39
syndrome	I	40-48
are	O	49-52
allelic	O	53-60
mutations	O	61-70
in	O	71-73
cathepsin	O	74-83
C	O	84-85
.	O	85-86
Of	O	87-89
the	O	90-93
many	O	94-98
palmoplantar	B	99-111
keratoderma	I	112-123
(	I	124-125
PPK	I	125-128
)	I	128-129
conditions	I	130-140
,	O	140-141
only	O	142-146
Papillon	B	147-155
-	I	155-156
Lefevre	I	156-163
syndrome	I	164-172
(	O	173-174
PLS	B	174-177
)	O	177-178
and	O	179-182
Haim	B	183-187
-	I	187-188
Munk	I	188-192
syndrome	I	193-201
(	O	202-203
HMS	B	203-206
)	O	206-207
are	O	208-211
associated	O	212-222
with	O	223-227
premature	O	228-237
periodontal	O	238-249
destruction	O	250-261
.	O	261-262

Although	O	263-271
both	O	272-276
PLS	B	277-280
and	O	281-284
HMS	B	285-288
share	O	289-294
the	O	295-298
cardinal	O	299-307
features	O	308-316
of	O	317-319
PPK	B	320-323
and	O	324-327
severe	O	328-334
periodontitis	B	335-348
,	O	348-349
a	O	350-351
number	O	352-358
of	O	359-361
additional	O	362-372
findings	O	373-381
are	O	382-385
reported	O	386-394
in	O	395-397
HMS	B	398-401
including	O	402-411
arachnodactyly	B	412-426
,	O	426-427
acro	B	428-432
-	I	432-433
osteolysis	I	433-443
,	O	443-444
atrophic	B	445-453
changes	I	454-461
of	I	462-464
the	I	465-468
nails	I	469-474
,	O	474-475
and	O	476-479
a	O	480-481
radiographic	B	482-494
deformity	I	495-504
of	I	505-507
the	I	508-511
fingers	I	512-519
.	O	519-520

While	O	521-526
PLS	B	527-530
cases	O	531-536
have	O	537-541
been	O	542-546
identified	O	547-557
throughout	O	558-568
the	O	569-572
world	O	573-578
,	O	578-579
HMS	B	580-583
has	O	584-587
only	O	588-592
been	O	593-597
described	O	598-607
among	O	608-613
descendants	O	614-625
of	O	626-628
a	O	629-630
religious	O	631-640
isolate	O	641-648
originally	O	649-659
from	O	660-664
Cochin	O	665-671
,	O	671-672
India	O	673-678
.	O	678-679

Parental	O	680-688
consanguinity	O	689-702
is	O	703-705
a	O	706-707
characteristic	O	708-722
of	O	723-725
many	O	726-730
cases	O	731-736
of	O	737-739
both	O	740-744
conditions	O	745-755
.	O	755-756

Although	O	757-765
autosomal	O	766-775
recessive	O	776-785
transmission	O	786-798
of	O	799-801
PLS	B	802-805
is	O	806-808
evident	O	809-816
,	O	816-817
a	O	818-819
more	O	820-824
"	O	825-826
complex	O	827-834
"	O	835-836
autosomal	O	837-846
recessive	O	847-856
pattern	O	857-864
of	O	865-867
inheritance	O	868-879
with	O	880-884
phenotypic	O	885-895
influences	O	896-906
from	O	907-911
a	O	912-913
closely	O	914-921
linked	O	922-928
modifying	O	929-938
locus	O	939-944
has	O	945-948
been	O	949-953
hypothesised	O	954-966
for	O	967-970
HMS	B	971-974
.	O	974-975

Recently	O	976-984
,	O	984-985
mutations	O	986-995
of	O	996-998
the	O	999-1002
cathepsin	O	1003-1012
C	O	1013-1014
gene	O	1015-1019
have	O	1020-1024
been	O	1025-1029
identified	O	1030-1040
as	O	1041-1043
the	O	1044-1047
underlying	O	1048-1058
genetic	B	1059-1066
defect	I	1067-1073
in	O	1074-1076
PLS	B	1077-1080
.	O	1080-1081

To	O	1082-1084
determine	O	1085-1094
if	O	1095-1097
a	O	1098-1099
cathepsin	O	1100-1109
C	O	1110-1111
mutation	O	1112-1120
is	O	1121-1123
also	O	1124-1128
responsible	O	1129-1140
for	O	1141-1144
HMS	B	1145-1148
,	O	1148-1149
we	O	1150-1152
sequenced	O	1153-1162
the	O	1163-1166
gene	O	1167-1171
in	O	1172-1174
affected	O	1175-1183
and	O	1184-1187
unaffected	O	1188-1198
subjects	O	1199-1207
from	O	1208-1212
the	O	1213-1216
Cochin	O	1217-1223
isolate	O	1224-1231
in	O	1232-1234
which	O	1235-1240
both	O	1241-1245
the	O	1246-1249
PLS	B	1250-1253
and	O	1254-1257
HMS	B	1258-1261
phenotypes	O	1262-1272
appear	O	1273-1279
.	O	1279-1280

Here	O	1281-1285
we	O	1286-1288
report	O	1289-1295
identification	O	1296-1310
of	O	1311-1313
a	O	1314-1315
mutation	O	1316-1324
of	O	1325-1327
cathepsin	O	1328-1337
C	O	1338-1339
(	O	1340-1341
exon	O	1341-1345
6	O	1346-1347
,	O	1347-1348
2127A	O	1349-1354
-	O	1354-1355
-	O	1354-1355
>	O	1357-1358
G	O	1359-1360
)	O	1360-1361
that	O	1362-1366
changes	O	1367-1374
a	O	1375-1376
highly	O	1377-1383
conserved	O	1384-1393
amino	O	1394-1399
acid	O	1400-1404
in	O	1405-1407
the	O	1408-1411
cathepsin	O	1412-1421
C	O	1422-1423
peptide	O	1424-1431
.	O	1431-1432

This	O	1433-1437
mutation	O	1438-1446
segregates	O	1447-1457
with	O	1458-1462
HMS	B	1463-1466
in	O	1467-1469
four	O	1470-1474
nuclear	O	1475-1482
families	O	1483-1491
.	O	1491-1492

Additionally	O	1493-1505
,	O	1505-1506
the	O	1507-1510
existence	O	1511-1520
of	O	1521-1523
a	O	1524-1525
shared	O	1526-1532
common	O	1533-1539
haplotype	O	1540-1549
for	O	1550-1553
genetic	O	1554-1561
loci	O	1562-1566
flanking	O	1567-1575
the	O	1576-1579
cathepsin	O	1580-1589
C	O	1590-1591
gene	O	1592-1596
suggests	O	1597-1605
that	O	1606-1610
affected	O	1611-1619
subjects	O	1620-1628
descended	O	1629-1638
from	O	1639-1643
the	O	1644-1647
Cochin	O	1648-1654
isolate	O	1655-1662
are	O	1663-1666
homozygous	O	1667-1677
for	O	1678-1681
a	O	1682-1683
mutation	O	1684-1692
inherited	O	1693-1702
"	O	1703-1704
identical	O	1705-1714
by	O	1715-1717
descent	O	1718-1725
"	O	1726-1727
from	O	1728-1732
a	O	1733-1734
common	O	1735-1741
ancestor	O	1742-1750
.	O	1750-1751

This	O	1752-1756
finding	O	1757-1764
supports	O	1765-1773
simple	O	1774-1780
autosomal	O	1781-1790
recessive	O	1791-1800
inheritance	O	1801-1812
for	O	1813-1816
HMS	B	1817-1820
in	O	1821-1823
these	O	1824-1829
families	O	1830-1838
.	O	1838-1839

We	O	1840-1842
also	O	1843-1847
report	O	1848-1854
a	O	1855-1856
mutation	O	1857-1865
of	O	1866-1868
the	O	1869-1872
same	O	1873-1877
exon	O	1878-1882
6	O	1883-1884
CTSC	O	1885-1889
codon	O	1890-1895
(	O	1896-1897
2126C	O	1897-1902
-	O	1902-1903
-	O	1902-1903
>	O	1905-1906
T	O	1907-1908
)	O	1908-1909
in	O	1910-1912
a	O	1913-1914
Turkish	O	1915-1922
family	O	1923-1929
with	O	1930-1934
classical	O	1935-1944
PLS	B	1945-1948
.	O	1948-1949

These	O	1950-1955
findings	O	1956-1964
provide	O	1965-1972
evidence	O	1973-1981
that	O	1982-1986
PLS	B	1987-1990
and	O	1991-1994
HMS	B	1995-1998
are	O	1999-2002
allelic	O	2003-2010
variants	O	2011-2019
of	O	2020-2022
cathepsin	O	2023-2032
C	O	2033-2034
gene	O	2035-2039
mutations	O	2040-2049
.	O	2049-2050
.	O	2049-2050

X	O	0-1
inactivation	O	2-14
and	O	15-18
somatic	O	19-26
cell	O	27-31
selection	O	32-41
rescue	O	42-48
female	O	49-55
mice	O	56-60
carrying	O	61-69
a	O	70-71
Piga	O	72-76
-	O	76-77
null	O	77-81
mutation	O	82-90
.	O	90-91

A	O	92-93
somatic	O	94-101
mutation	O	102-110
in	O	111-113
the	O	114-117
X	O	118-119
linked	O	120-126
PIGA	O	127-131
gene	O	132-136
is	O	137-139
responsible	O	140-151
for	O	152-155
the	O	156-159
deficiency	B	160-170
of	I	171-173
glycosyl	I	174-182
phosphatidylinositol	I	183-203
(	I	204-205
GPI	I	205-208
)	I	208-209
-	I	210-211
anchored	I	211-219
proteins	I	220-228
on	O	229-231
blood	O	232-237
cells	O	238-243
from	O	244-248
patients	O	249-257
with	O	258-262
paroxysmal	B	263-273
nocturnal	I	274-283
hemoglobinuria	I	284-298
.	O	298-299

No	O	300-302
inherited	O	303-312
form	O	313-317
of	O	318-320
GPI	B	321-324
-	I	324-325
anchor	I	325-331
deficiency	I	332-342
has	O	343-346
been	O	347-351
described	O	352-361
.	O	361-362

Because	O	363-370
conventional	O	371-383
Piga	O	384-388
gene	O	389-393
knockout	O	394-402
is	O	403-405
associated	O	406-416
with	O	417-421
high	O	422-426
embryonic	B	427-436
lethality	I	437-446
in	O	447-449
chimeric	O	450-458
mice	O	459-463
,	O	463-464
we	O	465-467
used	O	468-472
the	O	473-476
Cre	O	477-480
/	O	480-481
loxP	O	481-485
system	O	486-492
.	O	492-493

We	O	494-496
generated	O	497-506
mice	O	507-511
in	O	512-514
which	O	515-520
two	O	521-524
loxP	O	525-529
sites	O	530-535
flank	O	536-541
part	O	542-546
of	O	547-549
Piga	O	550-554
exon	O	555-559
2	O	560-561
.	O	561-562
After	O	563-568
crossbreeding	O	569-582
with	O	583-587
female	O	588-594
mice	O	595-599
of	O	600-602
the	O	603-606
EIIa	O	607-611
-	O	611-612
cre	O	612-615
strain	O	616-622
,	O	622-623
the	O	624-627
floxed	O	628-634
allele	O	635-641
undergoes	O	642-651
Cre	O	652-655
-	O	655-656
mediated	O	656-664
recombination	O	665-678
with	O	679-683
high	O	684-688
efficiency	O	689-699
during	O	700-706
early	O	707-712
embryonic	O	713-722
development	O	723-734
.	O	734-735

Because	O	736-743
of	O	744-746
X	O	747-748
chromosome	O	749-759
inactivation	O	760-772
,	O	772-773
female	O	774-780
offspring	O	781-790
are	O	791-794
mosaic	O	795-801
for	O	802-805
cells	O	806-811
that	O	812-816
express	O	817-824
or	O	825-827
lack	O	828-832
GPI	O	833-836
-	O	836-837
linked	O	837-843
proteins	O	844-852
.	O	852-853

Analysis	O	854-862
of	O	863-865
mosaic	O	866-872
mice	O	873-877
showed	O	878-884
that	O	885-889
in	O	890-892
heart	O	893-898
,	O	898-899
lung	O	900-904
,	O	904-905
kidney	O	906-912
,	O	912-913
brain	O	914-919
,	O	919-920
and	O	921-924
liver	O	925-930
,	O	930-931
mainly	O	932-938
wild	O	939-943
-	O	943-944
type	O	944-948
Piga	O	949-953
is	O	954-956
active	O	957-963
,	O	963-964
suggesting	O	965-975
that	O	976-980
these	O	981-986
tissues	O	987-994
require	O	995-1002
GPI	O	1003-1006
-	O	1006-1007
linked	O	1007-1013
proteins	O	1014-1022
.	O	1022-1023

The	O	1024-1027
salient	O	1028-1035
exceptions	O	1036-1046
were	O	1047-1051
spleen	O	1052-1058
,	O	1058-1059
thymus	O	1060-1066
,	O	1066-1067
and	O	1068-1071
red	O	1072-1075
blood	O	1076-1081
cells	O	1082-1087
,	O	1087-1088
which	O	1089-1094
had	O	1095-1098
almost	O	1099-1105
equal	O	1106-1111
numbers	O	1112-1119
of	O	1120-1122
cells	O	1123-1128
expressing	O	1129-1139
the	O	1140-1143
wild	O	1144-1148
-	O	1148-1149
type	O	1149-1153
or	O	1154-1156
the	O	1157-1160
recombined	O	1161-1171
allele	O	1172-1178
,	O	1178-1179
implying	O	1180-1188
that	O	1189-1193
GPI	O	1194-1197
-	O	1197-1198
linked	O	1198-1204
proteins	O	1205-1213
are	O	1214-1217
not	O	1218-1221
essential	O	1222-1231
for	O	1232-1235
the	O	1236-1239
derivation	O	1240-1250
of	O	1251-1253
these	O	1254-1259
tissues	O	1260-1267
.	O	1267-1268

PIGA	O	1269-1273
(	O	1274-1275
-	O	1275-1276
)	O	1276-1277
cells	O	1278-1283
had	O	1284-1287
no	O	1288-1290
growth	O	1291-1297
advantage	O	1298-1307
,	O	1307-1308
suggesting	O	1309-1319
that	O	1320-1324
other	O	1325-1330
factors	O	1331-1338
are	O	1339-1342
needed	O	1343-1349
for	O	1350-1353
their	O	1354-1359
clonal	O	1360-1366
dominance	O	1367-1376
in	O	1377-1379
patients	O	1380-1388
with	O	1389-1393
paroxysmal	B	1394-1404
nocturnal	I	1405-1414
hemoglobinuria	I	1415-1429
.	O	1429-1430
.	O	1429-1430

The	O	0-3
Norrie	B	4-10
disease	I	11-18
gene	O	19-23
maps	O	24-28
to	O	29-31
a	O	32-33
150	O	34-37
kb	O	38-40
region	O	41-47
on	O	48-50
chromosome	O	51-61
Xp11	O	62-66
.	O	66-67
3	O	67-68
.	O	66-67

Norrie	B	70-76
disease	I	77-84
is	O	85-87
a	O	88-89
human	O	90-95
X	B	96-97
-	I	97-98
linked	I	98-104
recessive	I	105-114
disorder	I	115-123
of	O	124-126
unknown	O	127-134
etiology	O	135-143
characterized	O	144-157
by	O	158-160
congenital	B	161-171
blindness	I	172-181
,	O	181-182
sensory	B	183-190
neural	I	191-197
deafness	I	198-206
and	O	207-210
mental	B	211-217
retardation	I	218-229
.	O	229-230

This	O	231-235
disease	O	236-243
gene	O	244-248
was	O	249-252
previously	O	253-263
linked	O	264-270
to	O	271-273
the	O	274-277
DXS7	O	278-282
(	O	283-284
L1	O	284-286
.	O	286-287

28	O	288-290
)	O	290-291
locus	O	292-297
and	O	298-301
the	O	302-305
MAO	O	306-309
genes	O	310-315
in	O	316-318
band	O	319-323
Xp11	O	324-328
.	O	328-329
3	O	330-331
3	O	332-333
.	O	333-334

We	O	335-337
report	O	338-344
here	O	345-349
fine	O	350-354
physical	O	355-363
mapping	O	364-371
of	O	372-374
the	O	375-378
obligate	O	379-387
region	O	388-394
containing	O	395-405
the	O	406-409
Norrie	B	410-416
disease	I	417-424
gene	O	425-429
(	O	430-431
NDP	O	431-434
)	O	434-435
defined	O	436-443
by	O	444-446
a	O	447-448
recombination	O	449-462
and	O	463-466
by	O	467-469
the	O	470-473
smallest	O	474-482
submicroscopic	O	483-497
chromosomal	O	498-509
deletion	O	510-518
associated	O	519-529
with	O	530-534
Norrie	B	535-541
disease	I	542-549
identified	O	550-560
to	O	561-563
date	O	564-568
.	O	568-569

Analysis	O	570-578
,	O	578-579
using	O	580-585
in	O	586-588
addition	O	589-597
two	O	598-601
overlapping	O	602-613
YAC	O	614-617
clones	O	618-624
from	O	625-629
this	O	630-634
region	O	635-641
,	O	641-642
allowed	O	643-650
orientation	O	651-662
of	O	663-665
the	O	666-669
MAOA	O	670-674
and	O	675-678
MAOB	O	679-683
genes	O	684-689
in	O	690-692
a	O	693-694
5	O	695-696
-	O	696-697
3	O	697-698
-	O	696-697
3	O	697-698
-	O	696-697
5	O	695-696
configuration	O	703-716
.	O	716-717

A	O	718-719
recombination	O	720-733
event	O	734-739
between	O	740-747
a	O	748-749
(	O	750-751
GT	O	751-753
)	O	753-754
n	O	755-756
polymorphism	O	757-769
in	O	770-772
intron	O	773-779
2	O	780-781
of	O	782-784
the	O	785-788
MAOB	O	789-793
gene	O	794-798
and	O	799-802
the	O	803-806
NDP	O	807-810
locus	O	811-816
,	O	816-817
in	O	818-820
a	O	821-822
family	O	823-829
previously	O	830-840
reported	O	841-849
to	O	850-852
have	O	853-857
a	O	858-859
recombination	O	860-873
between	O	874-881
DXS7	O	882-886
and	O	887-890
NDP	O	891-894
,	O	894-895
delineates	O	896-906
a	O	907-908
flanking	O	909-917
marker	O	918-924
telomeric	O	925-934
to	O	935-937
this	O	938-942
disease	O	943-950
gene	O	951-955
.	O	955-956

An	O	957-959
anonymous	O	960-969
DNA	O	970-973
probe	O	974-979
,	O	979-980
dc12	O	981-985
,	O	985-986
present	O	987-994
in	O	995-997
one	O	998-1001
of	O	1002-1004
the	O	1005-1008
YACs	O	1009-1013
and	O	1014-1017
in	O	1018-1020
a	O	1021-1022
patient	O	1023-1030
with	O	1031-1035
a	O	1036-1037
submicroscopic	O	1038-1052
deletion	O	1053-1061
which	O	1062-1067
includes	O	1068-1076
MAOA	O	1077-1081
and	O	1082-1085
MAOB	O	1086-1090
but	O	1091-1094
not	O	1095-1098
L1	O	1099-1101
.	O	1101-1102

28	O	1103-1105
,	O	1105-1106
serves	O	1107-1113
as	O	1114-1116
a	O	1117-1118
flanking	O	1119-1127
marker	O	1128-1134
centromeric	O	1135-1146
to	O	1147-1149
the	O	1150-1153
disease	O	1154-1161
gene	O	1162-1166
.	O	1166-1167

An	O	1168-1170
Alu	O	1171-1174
-	O	1174-1175
PCR	O	1175-1178
fragment	O	1179-1187
from	O	1188-1192
the	O	1193-1196
right	O	1197-1202
arm	O	1203-1206
of	O	1207-1209
the	O	1210-1213
MAO	O	1214-1217
YAC	O	1218-1221
(	O	1222-1223
YMAO	O	1223-1227
.	O	1227-1228

AluR	O	1229-1233
)	O	1233-1234
is	O	1235-1237
not	O	1238-1241
deleted	O	1242-1249
in	O	1250-1252
this	O	1253-1257
patient	O	1258-1265
and	O	1266-1269
also	O	1270-1274
delineates	O	1275-1285
the	O	1286-1289
centromeric	O	1290-1301
extent	O	1302-1308
of	O	1309-1311
the	O	1312-1315
obligate	O	1316-1324
disease	O	1325-1332
region	O	1333-1339
.	O	1339-1340

The	O	1341-1344
apparent	O	1345-1353
order	O	1354-1359
of	O	1360-1362
these	O	1363-1368
loci	O	1369-1373
is	O	1374-1376
telomere	O	1377-1385
.	O	1385-1386

DXS7	O	1387-1391
-	O	1391-1392
MAOA	O	1392-1396
-	O	1391-1392
MAOB	O	1397-1401
-	O	1391-1392
NDP	O	1402-1405
-	O	1391-1392
dc12	O	1406-1410
-	O	1391-1392
YMAO	O	1411-1415
DXS7	O	1416-1420
-	O	1420-1421
MAOA	O	1421-1425
-	O	1420-1421
MAOB	O	1426-1430
-	O	1420-1421
NDP	O	1431-1434
-	O	1420-1421
dc12	O	1435-1439
-	O	1420-1421
YMAO	O	1440-1444
.	O	1444-1445

AluR	O	1446-1450
.	O	1450-1451

centromere	O	1452-1462
.	O	1462-1463

Together	O	1464-1472
these	O	1473-1478
data	O	1479-1483
define	O	1484-1490
the	O	1491-1494
obligate	O	1495-1503
region	O	1504-1510
containing	O	1511-1521
the	O	1522-1525
NDP	O	1526-1529
gene	O	1530-1534
to	O	1535-1537
a	O	1538-1539
chromosomal	O	1540-1551
segment	O	1552-1559
less	O	1560-1564
than	O	1565-1569
150	O	1570-1573
kb	O	1574-1576
.	O	1576-1577

Molecular	O	0-9
genetics	O	10-18
of	O	19-21
the	O	22-25
glucose	O	26-33
-	O	33-34
6	O	34-35
-	O	33-34
phosphate	O	36-45
dehydrogenase	O	46-59
(	O	60-61
G6PD	O	61-65
)	O	65-66
Mediterranean	O	67-80
variant	O	81-88
and	O	89-92
description	O	93-104
of	O	105-107
a	O	108-109
new	O	110-113
G6PD	O	114-118
mutant	O	119-125
,	O	125-126
G6PD	O	127-131
Andalus1361A	O	132-144
.	O	144-145

Glucose	B	146-153
-	I	153-154
6	I	154-155
-	I	153-154
phosphate	I	156-165
dehydrogenase	I	166-179
(	I	180-181
G6PD	I	181-185
;	I	185-186
E	I	187-188
.	I	188-189
C	I	190-191
.	I	191-192
1	I	193-194
.	I	194-195
1	I	196-197
.	I	197-198
1	I	199-200
.	I	200-201
49	I	202-204
)	I	204-205
deficiency	I	206-216
is	O	217-219
the	O	220-223
most	O	224-228
common	O	229-235
human	O	236-241
enzymopathy	B	242-253
;	O	253-254
more	O	255-259
than	O	260-264
300	O	265-268
different	O	269-278
biochemical	O	279-290
variants	O	291-299
of	O	300-302
the	O	303-306
enzyme	O	307-313
have	O	314-318
been	O	319-323
described	O	324-333
.	O	333-334

In	O	335-337
many	O	338-342
parts	O	343-348
of	O	349-351
the	O	352-355
world	O	356-361
the	O	362-365
Mediterranean	O	366-379
type	O	380-384
of	O	385-387
G6PD	B	388-392
deficiency	I	393-403
is	O	404-406
prevalent	O	407-416
.	O	416-417

However	O	418-425
,	O	425-426
G6PD	O	427-431
Mediterranean	O	432-445
has	O	446-449
come	O	450-454
to	O	455-457
be	O	458-460
regarded	O	461-469
as	O	470-472
a	O	473-474
generic	O	475-482
term	O	483-487
applied	O	488-495
to	O	496-498
similar	O	499-506
G6PD	O	507-511
mutations	O	512-521
thought	O	522-529
,	O	529-530
however	O	531-538
,	O	538-539
to	O	540-542
represent	O	543-552
a	O	553-554
somewhat	O	555-563
heterogeneous	O	564-577
group	O	578-583
.	O	583-584

A	O	585-586
C	O	587-588
-	O	588-589
-	O	588-589
-	O	588-589
-	O	588-589
T	O	592-593
mutation	O	594-602
at	O	603-605
nucleotide	O	606-616
563	O	617-620
of	O	621-623
G6PD	O	624-628
Mediterranean	O	629-642
has	O	643-646
been	O	647-651
identified	O	652-662
by	O	663-665
Vulliamy	O	666-674
et	O	675-677
al	O	678-680
.	O	680-681
,	O	681-682
and	O	683-686
the	O	687-690
same	O	691-695
mutation	O	696-704
has	O	705-708
been	O	709-713
found	O	714-719
by	O	720-722
De	O	723-725
Vita	O	726-730
et	O	731-733
al	O	734-736
.	O	736-737
in	O	738-740
G6PD	O	741-745
Mediterranean	O	746-759
,	O	759-760
G6PD	O	761-765
Sassari	O	766-773
,	O	773-774
and	O	775-778
G6PD	O	779-783
Cagliari	O	784-792
.	O	792-793

The	O	794-797
latter	O	798-804
subjects	O	805-813
had	O	814-817
an	O	818-820
additional	O	821-831
mutation	O	832-840
,	O	840-841
at	O	842-844
nucleotide	O	845-855
1311	O	856-860
,	O	860-861
that	O	862-866
did	O	867-870
not	O	871-874
produce	O	875-882
a	O	883-884
coding	O	885-891
change	O	892-898
.	O	898-899

We	O	900-902
have	O	903-907
examined	O	908-916
genomic	O	917-924
DNA	O	925-928
of	O	929-931
five	O	932-936
patients	O	937-945
-	O	945-946
-	O	945-946
four	O	947-951
of	O	952-954
Spanish	O	955-962
origin	O	963-969
and	O	970-973
one	O	974-977
of	O	978-980
Jewish	O	981-987
origin	O	988-994
-	O	994-995
-	O	994-995
having	O	996-1002
enzymatically	O	1003-1016
documented	O	1017-1027
G6PD	O	1028-1032
Mediterranean	O	1033-1046
.	O	1046-1047

All	O	1048-1051
had	O	1052-1055
both	O	1056-1060
the	O	1061-1064
mutation	O	1065-1073
at	O	1074-1076
nucleotide	O	1077-1087
563	O	1088-1091
and	O	1092-1095
that	O	1096-1100
at	O	1101-1103
nucleotide	O	1104-1114
1311	O	1115-1119
.	O	1119-1120

A	O	1121-1122
sixth	O	1123-1128
sample	O	1129-1135
,	O	1135-1136
resembling	O	1137-1147
G6PD	O	1148-1152
Mediterranean	O	1153-1166
kinetically	O	1167-1178
but	O	1179-1182
with	O	1183-1187
a	O	1188-1189
slightly	O	1190-1198
rapid	O	1199-1204
electrophoretic	O	1205-1220
mobility	O	1221-1229
,	O	1229-1230
was	O	1231-1234
designated	O	1235-1245
G6PD	O	1246-1250
Andalus	O	1251-1258
and	O	1259-1262
was	O	1263-1266
found	O	1267-1272
to	O	1273-1275
have	O	1276-1280
a	O	1281-1282
different	O	1283-1292
mutation	O	1293-1301
,	O	1301-1302
a	O	1303-1304
G	O	1305-1306
-	O	1306-1307
-	O	1306-1307
-	O	1306-1307
-	O	1306-1307
A	O	1310-1311
transition	O	1312-1322
at	O	1323-1325
nucleotide	O	1326-1336
1361	O	1337-1341
,	O	1341-1342
producing	O	1343-1352
an	O	1353-1355
arginine	O	1356-1364
-	O	1364-1365
to	O	1365-1367
-	O	1364-1365
histidine	O	1368-1377
substitution	O	1378-1390
.	O	1390-1391

These	O	1392-1397
studies	O	1398-1405
suggest	O	1406-1413
that	O	1414-1418
G6PD	O	1419-1423
Mediterranean	O	1424-1437
is	O	1438-1440
,	O	1440-1441
after	O	1442-1447
all	O	1448-1451
,	O	1451-1452
relatively	O	1453-1463
homogeneous	O	1464-1475
.	O	1475-1476

Small	O	0-5
nuclear	O	6-13
ribonucleoprotein	O	14-31
polypeptide	O	32-43
N	O	44-45
(	O	46-47
SNRPN	O	47-52
)	O	52-53
,	O	53-54
an	O	55-57
expressed	O	58-67
gene	O	68-72
in	O	73-75
the	O	76-79
Prader	B	80-86
-	I	86-87
Willi	I	87-92
syndrome	I	93-101
critical	O	102-110
region	O	111-117
.	O	117-118

Prader	B	119-125
-	I	125-126
Willi	I	126-131
syndrome	I	132-140
(	O	141-142
PWS	B	142-145
)	O	145-146
is	O	147-149
associated	O	150-160
with	O	161-165
paternally	O	166-176
derived	O	177-184
chromosomal	O	185-196
deletions	O	197-206
in	O	207-209
region	O	210-216
15q11	O	217-222
-	O	222-223
13	O	223-225
or	O	226-228
with	O	229-233
maternal	B	234-242
disomy	I	243-249
for	I	250-253
chromosome	I	254-264
15	I	265-267
.	O	267-268

Therefore	O	269-278
,	O	278-279
loss	O	280-284
of	O	285-287
the	O	288-291
expressed	O	292-301
paternal	O	302-310
alleles	O	311-318
of	O	319-321
maternally	O	322-332
imprinted	O	333-342
genes	O	343-348
must	O	349-353
be	O	354-356
responsible	O	357-368
for	O	369-372
the	O	373-376
PWS	B	377-380
phenotype	O	381-390
.	O	390-391

We	O	392-394
have	O	395-399
mapped	O	400-406
the	O	407-410
gene	O	411-415
encoding	O	416-424
the	O	425-428
small	O	429-434
nuclear	O	435-442
RNA	O	443-446
associated	O	447-457
polypeptide	O	458-469
SmN	O	470-473
(	O	474-475
SNRPN	O	475-480
)	O	480-481
to	O	482-484
human	O	485-490
chromosome	O	491-501
15q12	O	502-507
and	O	508-511
a	O	512-513
processed	O	514-523
pseudogene	O	524-534
SNRPNP1	O	535-542
to	O	543-545
chromosome	O	546-556
region	O	557-563
6pter	O	564-569
-	O	569-570
p21	O	570-573
.	O	573-574

Furthermore	O	575-586
,	O	586-587
SNRPN	O	588-593
was	O	594-597
mapped	O	598-604
to	O	605-607
the	O	608-611
minimal	O	612-619
deletion	O	620-628
interval	O	629-637
that	O	638-642
is	O	643-645
critical	O	646-654
for	O	655-658
PWS	B	659-662
.	O	662-663

The	O	664-667
fact	O	668-672
that	O	673-677
the	O	678-681
mouse	O	682-687
Snrpn	O	688-693
gene	O	694-698
is	O	699-701
maternally	O	702-712
imprinted	O	713-722
in	O	723-725
brain	O	726-731
suggests	O	732-740
that	O	741-745
loss	O	746-750
of	O	751-753
the	O	754-757
paternally	O	758-768
derived	O	769-776
SNRPN	O	777-782
allele	O	783-789
may	O	790-793
be	O	794-796
involved	O	797-805
in	O	806-808
the	O	809-812
PWS	B	813-816
phenotype	O	817-826
.	O	826-827
.	O	826-827

Increased	O	0-9
incidence	O	10-19
of	O	20-22
cancer	B	23-29
in	O	30-32
patients	O	33-41
with	O	42-46
cartilage	B	47-56
-	I	56-57
hair	I	57-61
hypoplasia	I	62-72
.	O	72-73

OBJECTIVE	O	74-83
Previous	O	85-93
reports	O	94-101
have	O	102-106
suggested	O	107-116
an	O	117-119
increased	O	120-129
risk	O	130-134
of	O	135-137
cancer	B	138-144
among	O	145-150
patients	O	151-159
with	O	160-164
cartilage	B	165-174
-	I	174-175
hair	I	175-179
hypoplasia	I	180-190
(	O	191-192
CHH	B	192-195
)	O	195-196
.	O	196-197

This	O	198-202
study	O	203-208
was	O	209-212
carried	O	213-220
out	O	221-224
to	O	225-227
further	O	228-235
evaluate	O	236-244
this	O	245-249
risk	O	250-254
among	O	255-260
patients	O	261-269
with	O	270-274
CHH	B	275-278
and	O	279-282
their	O	283-288
first	O	289-294
-	O	294-295
degree	O	295-301
relatives	O	302-311
.	O	311-312

STUDY	O	313-318
DESIGN	O	319-325
One	O	327-330
hundred	O	331-338
twenty	O	339-345
-	O	345-346
two	O	346-349
patients	O	350-358
with	O	359-363
CHH	B	364-367
were	O	368-372
identified	O	373-383
through	O	384-391
2	O	392-393
countrywide	O	394-405
epidemiologic	O	406-419
surveys	O	420-427
in	O	428-430
1974	O	431-435
and	O	436-439
in	O	440-442
1986	O	443-447
.	O	447-448

Their	O	449-454
parents	O	455-462
and	O	463-466
nonaffected	O	467-478
siblings	O	479-487
were	O	488-492
identified	O	493-503
through	O	504-511
the	O	512-515
Population	O	516-526
Register	O	527-535
Center	O	536-542
.	O	542-543

This	O	544-548
cohort	O	549-555
underwent	O	556-565
follow	O	566-572
-	O	572-573
up	O	573-575
for	O	576-579
cancer	B	580-586
incidence	O	587-596
through	O	597-604
the	O	605-608
Finnish	O	609-616
Cancer	O	617-623
Registry	O	624-632
to	O	633-635
the	O	636-639
end	O	640-643
of	O	644-646
1995	O	647-651
.	O	651-652

RESULTS	O	653-660
A	O	662-663
statistically	O	664-677
significant	O	678-689
excess	O	690-696
risk	O	697-701
of	O	702-704
cancer	B	705-711
was	O	712-715
seen	O	716-720
among	O	721-726
the	O	727-730
patients	O	731-739
with	O	740-744
CHH	B	745-748
(	O	749-750
standardized	O	750-762
incidence	O	763-772
ratio	O	773-778
6	O	779-780
.	O	780-781
9	O	782-783
,	O	783-784
95	O	785-787
%	O	787-788
confidence	O	789-799
interval	O	800-808
2	O	809-810
.	O	810-811
3	O	812-813
to	O	814-816
16	O	817-819
)	O	819-820
,	O	820-821
which	O	822-827
was	O	828-831
mainly	O	832-838
attributable	O	839-851
to	O	852-854
non	B	855-858
-	I	858-859
Hodgkins	I	859-867
lymphoma	I	868-876
(	O	878-879
standardized	O	879-891
incidence	O	892-901
ratio	O	902-907
90	O	908-910
,	O	910-911
95	O	912-914
%	O	914-915
confidence	O	916-926
interval	O	927-935
18	O	936-938
to	O	939-941
264	O	942-945
)	O	945-946
.	O	946-947

In	O	948-950
addition	O	951-959
,	O	959-960
a	O	961-962
significant	O	963-974
excess	O	975-981
risk	O	982-986
of	O	987-989
basal	B	990-995
cell	I	996-1000
carcinoma	I	1001-1010
was	O	1011-1014
seen	O	1015-1019
(	O	1020-1021
standardized	O	1021-1033
incidence	O	1034-1043
ratio	O	1044-1049
35	O	1050-1052
,	O	1052-1053
95	O	1054-1056
%	O	1056-1057
confidence	O	1058-1068
interval	O	1069-1077
7	O	1078-1079
.	O	1079-1080
2	O	1081-1082
to	O	1083-1085
102	O	1086-1089
)	O	1089-1090
.	O	1090-1091

The	O	1092-1095
cancer	B	1096-1102
incidence	O	1103-1112
among	O	1113-1118
the	O	1119-1122
siblings	O	1123-1131
or	O	1132-1134
the	O	1135-1138
parents	O	1139-1146
did	O	1147-1150
not	O	1151-1154
differ	O	1155-1161
from	O	1162-1166
the	O	1167-1170
average	O	1171-1178
cancer	B	1179-1185
incidence	O	1186-1195
in	O	1196-1198
the	O	1199-1202
Finnish	O	1203-1210
population	O	1211-1221
.	O	1221-1222

CONCLUSIONS	O	1223-1234
This	O	1236-1240
study	O	1241-1246
confirms	O	1247-1255
an	O	1256-1258
increased	O	1259-1268
risk	O	1269-1273
of	O	1274-1276
cancer	B	1277-1283
,	O	1283-1284
especially	O	1285-1295
non	B	1296-1299
-	I	1299-1300
Hodgkins	I	1300-1308
lymphoma	I	1309-1317
,	O	1317-1318
probably	O	1319-1327
attributable	O	1328-1340
to	O	1341-1343
defective	O	1344-1353
immunity	O	1354-1362
,	O	1362-1363
among	O	1364-1369
patients	O	1370-1378
with	O	1379-1383
CHH	B	1384-1387
.	O	1387-1388

Genetic	O	0-7
polymorphism	O	8-20
of	O	21-23
G6PD	O	24-28
in	O	29-31
a	O	32-33
Bulgarian	O	34-43
population	O	44-54
.	O	54-55

Considerable	O	56-68
genetic	O	69-76
heterogeneity	O	77-90
in	O	91-93
G6PD	O	94-98
was	O	99-102
found	O	103-108
in	O	109-111
the	O	112-115
Bulgarian	O	116-125
population	O	126-136
-	O	136-137
14	O	137-139
G6PD	O	140-144
variants	O	145-153
isolated	O	154-162
from	O	163-167
117	O	168-171
hemizygous	O	172-182
carriers	O	183-191
of	O	192-194
G6PD	B	195-199
deficiency	I	200-210
.	O	210-211

Of	O	212-214
these	O	215-220
,	O	220-221
G6PD	O	222-226
Mediterranean	O	227-240
type	O	241-245
was	O	246-249
a	O	250-251
polymorphic	O	252-263
variant	O	264-271
and	O	272-275
G6PD	O	276-280
Corinth	O	281-288
occurred	O	289-297
with	O	298-302
high	O	303-307
frequency	O	308-317
.	O	317-318

Two	O	319-322
new	O	323-326
variants	O	327-335
were	O	336-340
identified	O	341-351
-	O	351-352
G6PD	O	352-356
Rudosem	O	357-364
and	O	365-368
G6PD	O	369-373
Nedelino	O	374-382
.	O	382-383

In	O	384-386
a	O	387-388
selected	O	389-397
group	O	398-403
of	O	404-406
78	O	407-409
subjects	O	410-418
with	O	419-423
clinical	O	424-432
manifestations	O	433-447
,	O	447-448
four	O	449-453
variants	O	454-462
were	O	463-467
established	O	468-479
G6PD	O	481-485
Mediterranian	O	486-499
,	O	499-500
G6PD	O	501-505
Corinth	O	506-513
,	O	513-514
G6PD	O	515-519
Seattle	O	520-527
and	O	528-531
G6PD	O	532-536
Ohut	O	537-541
II	O	542-544
.	O	544-545
.	O	544-545

A	O	0-1
genetic	O	2-9
etiology	O	10-18
for	O	19-22
DiGeorge	B	23-31
syndrome	I	32-40
:	O	40-41
consistent	O	42-52
deletions	O	53-62
and	O	63-66
microdeletions	O	67-81
of	O	82-84
22q11	O	85-90
.	O	90-91

DiGeorge	B	92-100
syndrome	I	101-109
(	O	110-111
DGS	B	111-114
)	O	114-115
,	O	115-116
a	O	117-118
developmental	O	119-132
field	O	133-138
defect	O	139-145
of	O	146-148
the	O	149-152
third	O	153-158
and	O	159-162
fourth	O	163-169
pharyngeal	O	170-180
pouches	O	181-188
,	O	188-189
is	O	190-192
characterized	O	193-206
by	O	207-209
aplasia	B	210-217
or	I	218-220
hypoplasia	I	221-231
of	I	232-234
the	I	235-238
thymus	I	239-245
and	I	246-249
parathyroid	I	250-261
glands	I	262-268
and	O	269-272
by	O	273-275
conotruncal	B	276-287
cardiac	I	288-295
malformations	I	296-309
.	O	309-310

Cytogenetic	O	311-322
studies	O	323-330
support	O	331-338
the	O	339-342
presence	O	343-351
of	O	352-354
a	O	355-356
DGS	B	357-360
critical	O	361-369
region	O	370-376
in	O	377-379
band	O	380-384
22q11	O	385-390
.	O	390-391

In	O	392-394
the	O	395-398
present	O	399-406
study	O	407-412
,	O	412-413
we	O	414-416
report	O	417-423
the	O	424-427
results	O	428-435
of	O	436-438
clinical	O	439-447
,	O	447-448
cytogenetic	O	449-460
,	O	460-461
and	O	462-465
molecular	O	466-475
studies	O	476-483
of	O	484-486
14	O	487-489
patients	O	490-498
with	O	499-503
DGS	B	504-507
.	O	507-508

Chromosome	O	509-519
analysis	O	520-528
,	O	528-529
utilizing	O	530-539
high	O	540-544
-	O	544-545
resolution	O	545-555
banding	O	556-563
techniques	O	564-574
,	O	574-575
detected	O	576-584
interstitial	O	585-597
deletions	O	598-607
in	O	608-610
five	O	611-615
probands	O	616-624
and	O	625-628
was	O	629-632
inconclusive	O	633-645
for	O	646-649
a	O	650-651
deletion	O	652-660
in	O	661-663
three	O	664-669
probands	O	670-678
.	O	678-679

The	O	680-683
remaining	O	684-693
six	O	694-697
patients	O	698-706
had	O	707-710
normal	O	711-717
karyotypes	O	718-728
.	O	728-729

In	O	730-732
contrast	O	733-741
,	O	741-742
molecular	O	743-752
analysis	O	753-761
detected	O	762-770
DNA	O	771-774
deletions	O	775-784
in	O	785-787
all	O	788-791
14	O	792-794
probands	O	795-803
.	O	803-804

Two	O	805-808
of	O	809-811
10	O	812-814
loci	O	815-819
tested	O	820-826
,	O	826-827
D22S75	O	828-834
and	O	835-838
D22S259	O	839-846
,	O	846-847
are	O	848-851
deleted	O	852-859
in	O	860-862
all	O	863-866
14	O	867-869
patients	O	870-878
.	O	878-879

A	O	880-881
third	O	882-887
locus	O	888-893
,	O	893-894
D22S66	O	895-901
,	O	901-902
is	O	903-905
deleted	O	906-913
in	O	914-916
the	O	917-920
eight	O	921-926
DGS	B	927-930
probands	O	931-939
tested	O	940-946
.	O	946-947

Physical	O	948-956
mapping	O	957-964
using	O	965-970
somatic	O	971-978
cell	O	979-983
hybrids	O	984-991
places	O	992-998
D22S66	O	999-1005
between	O	1006-1013
D22S75	O	1014-1020
and	O	1021-1024
D22S259	O	1025-1032
,	O	1032-1033
suggesting	O	1034-1044
that	O	1045-1049
it	O	1050-1052
should	O	1053-1059
be	O	1060-1062
deleted	O	1063-1070
in	O	1071-1073
the	O	1074-1077
remaining	O	1078-1087
six	O	1088-1091
cases	O	1092-1097
.	O	1097-1098

Parent	O	1099-1105
-	O	1105-1106
of	O	1106-1108
-	O	1105-1106
origin	O	1109-1115
studies	O	1116-1123
were	O	1124-1128
performed	O	1129-1138
in	O	1139-1141
five	O	1142-1146
families	O	1147-1155
.	O	1155-1156

Four	O	1157-1161
probands	O	1162-1170
failed	O	1171-1177
to	O	1178-1180
inherit	O	1181-1188
a	O	1189-1190
maternal	O	1191-1199
allele	O	1200-1206
,	O	1206-1207
and	O	1208-1211
one	O	1212-1215
failed	O	1216-1222
to	O	1223-1225
inherit	O	1226-1233
a	O	1234-1235
paternal	O	1236-1244
allele	O	1245-1251
.	O	1251-1252

On	O	1253-1255
the	O	1256-1259
basis	O	1260-1265
of	O	1266-1268
these	O	1269-1274
families	O	1275-1283
,	O	1283-1284
and	O	1285-1288
of	O	1289-1291
six	O	1292-1295
maternally	O	1296-1306
and	O	1307-1310
five	O	1311-1315
paternally	O	1316-1326
derived	O	1327-1334
unbalanced	O	1335-1345
-	O	1345-1346
translocation	O	1346-1359
DGS	B	1360-1363
probands	O	1364-1372
in	O	1373-1375
the	O	1376-1379
literature	O	1380-1390
,	O	1390-1391
parent	O	1392-1398
of	O	1399-1401
origin	O	1402-1408
or	O	1409-1411
imprinting	O	1412-1422
does	O	1423-1427
not	O	1428-1431
appear	O	1432-1438
to	O	1439-1441
play	O	1442-1446
an	O	1447-1449
important	O	1450-1459
role	O	1460-1464
in	O	1465-1467
the	O	1468-1471
pathogenesis	O	1472-1484
of	O	1485-1487
DGS	B	1488-1491
.	O	1491-1492

Deletion	O	1493-1501
of	O	1502-1504
the	O	1505-1508
same	O	1509-1513
three	O	1514-1519
loci	O	1520-1524
in	O	1525-1527
all	O	1528-1531
14	O	1532-1534
DGS	B	1535-1538
probands	O	1539-1547
begins	O	1548-1554
to	O	1555-1557
delineate	O	1558-1567
the	O	1568-1571
region	O	1572-1578
of	O	1579-1581
chromosome	O	1582-1592
22	O	1593-1595
critical	O	1596-1604
for	O	1605-1608
DGS	B	1609-1612
and	O	1613-1616
confirms	O	1617-1625
the	O	1626-1629
hypothesis	O	1630-1640
that	O	1641-1645
submicroscopic	O	1646-1660
deletions	O	1661-1670
of	O	1671-1673
22q11	O	1674-1679
are	O	1680-1683
etiologic	O	1684-1693
in	O	1694-1696
the	O	1697-1700
vast	O	1701-1705
majority	O	1706-1714
of	O	1715-1717
cases	O	1718-1723
.	O	1723-1724
.	O	1723-1724

Characterisation	O	0-16
of	O	17-19
a	O	20-21
new	O	22-25
rare	O	26-30
fragile	O	31-38
site	O	39-43
easily	O	44-50
confused	O	51-59
with	O	60-64
the	O	65-68
fragile	B	69-76
X	I	77-78
.	O	78-79

A	O	80-81
new	O	82-85
fragile	O	86-93
site	O	94-98
(	O	99-100
FRAXE	O	100-105
)	O	105-106
in	O	107-109
Xq28	O	110-114
is	O	115-117
described	O	118-127
.	O	127-128

It	O	129-131
appears	O	132-139
to	O	140-142
be	O	143-145
a	O	146-147
typical	O	148-155
folate	O	156-162
sensitive	O	163-172
fragile	O	173-180
site	O	181-185
.	O	185-186

The	O	187-190
fragile	O	191-198
site	O	199-203
is	O	204-206
not	O	207-210
associated	O	211-221
with	O	222-226
mental	B	227-233
retardation	I	234-245
,	O	245-246
it	O	247-249
does	O	250-254
not	O	255-258
give	O	259-263
abnormal	O	264-272
results	O	273-280
when	O	281-285
subjected	O	286-295
to	O	296-298
Southern	O	299-307
analysis	O	308-316
with	O	317-321
probe	O	322-327
pfxa3	O	328-333
which	O	334-339
detects	O	340-347
the	O	348-351
unstable	O	352-360
DNA	O	361-364
sequence	O	365-373
characteristic	O	374-388
of	O	389-391
fragile	B	392-399
X	I	400-401
syndrome	I	402-410
.	O	410-411

In	O	412-414
situ	O	415-419
hybridization	O	420-433
mapping	O	434-441
locates	O	442-449
the	O	450-453
fragile	O	454-461
site	O	462-466
between	O	467-474
150	O	475-478
kb	O	479-481
and	O	482-485
600	O	486-489
kb	O	490-492
distal	O	493-499
to	O	500-502
FRAXA	O	503-508
.	O	508-509

The	O	510-513
distinction	O	514-525
between	O	526-533
the	O	534-537
two	O	538-541
fragile	O	542-549
sites	O	550-555
is	O	556-558
important	O	559-568
clinically	O	569-579
since	O	580-585
cytogenetic	O	586-597
detection	O	598-607
of	O	608-610
FRAXE	O	611-616
,	O	616-617
without	O	618-625
molecular	O	626-635
analysis	O	636-644
,	O	644-645
could	O	646-651
result	O	652-658
in	O	659-661
misdiagnosis	O	662-674
of	O	675-677
fragile	B	678-685
X	I	686-687
syndrome	I	688-696
.	O	696-697
.	O	696-697

BRCA1	O	0-5
mutations	O	6-15
in	O	16-18
primary	O	19-26
breast	B	27-33
and	I	34-37
ovarian	I	38-45
carcinomas	I	46-56
.	O	56-57

Loss	O	58-62
of	O	63-65
heterozygosity	O	66-80
data	O	81-85
from	O	86-90
familial	B	91-99
tumors	I	100-106
suggest	O	107-114
that	O	115-119
BRCA1	O	120-125
,	O	125-126
a	O	127-128
gene	O	129-133
that	O	134-138
confers	O	139-146
susceptibility	O	147-161
to	O	162-164
ovarian	B	165-172
and	I	173-176
early	I	177-182
-	I	182-183
onset	I	183-188
breast	B	189-195
cancer	I	196-202
,	O	202-203
encodes	O	204-211
a	O	212-213
tumor	B	214-219
suppressor	O	220-230
.	O	230-231

The	O	232-235
BRCA1	O	236-241
region	O	242-248
is	O	249-251
also	O	252-256
subject	O	257-264
to	O	265-267
allelic	O	268-275
loss	O	276-280
in	O	281-283
sporadic	B	284-292
breast	I	293-299
and	I	300-303
ovarian	I	304-311
cancers	I	312-319
,	O	319-320
an	O	321-323
indication	O	324-334
that	O	335-339
BRCA1	O	340-345
mutations	O	346-355
may	O	356-359
occur	O	360-365
somatically	O	366-377
in	O	378-380
these	O	381-386
tumors	B	387-393
.	O	393-394

The	O	395-398
BRCA1	O	399-404
coding	O	405-411
region	O	412-418
was	O	419-422
examined	O	423-431
for	O	432-435
mutations	O	436-445
in	O	446-448
primary	O	449-456
breast	B	457-463
and	I	464-467
ovarian	I	468-475
tumors	I	476-482
that	O	483-487
show	O	488-492
allele	O	493-499
loss	O	500-504
at	O	505-507
the	O	508-511
BRCA1	O	512-517
locus	O	518-523
.	O	523-524

Mutations	O	525-534
were	O	535-539
detected	O	540-548
in	O	549-551
3	O	552-553
of	O	554-556
32	O	557-559
breast	O	560-566
and	O	567-570
1	O	571-572
of	O	573-575
12	O	576-578
ovarian	B	579-586
carcinomas	I	587-597
;	O	597-598
all	O	599-602
four	O	603-607
mutations	O	608-617
were	O	618-622
germline	O	623-631
alterations	O	632-643
and	O	644-647
occurred	O	648-656
in	O	657-659
early	O	660-665
-	O	665-666
onset	O	666-671
cancers	B	672-679
.	O	679-680

These	O	681-686
results	O	687-694
suggest	O	695-702
that	O	703-707
mutation	O	708-716
of	O	717-719
BRCA1	O	720-725
may	O	726-729
not	O	730-733
be	O	734-736
critical	O	737-745
in	O	746-748
the	O	749-752
development	O	753-764
of	O	765-767
the	O	768-771
majority	O	772-780
of	O	781-783
breast	B	784-790
and	I	791-794
ovarian	I	795-802
cancers	I	803-810
that	O	811-815
arise	O	816-821
in	O	822-824
the	O	825-828
absence	O	829-836
of	O	837-839
a	O	840-841
mutant	O	842-848
germline	O	849-857
allele	O	858-864
.	O	864-865
.	O	864-865

Genomic	O	0-7
structure	O	8-17
of	O	18-20
the	O	21-24
EWS	O	25-28
gene	O	29-33
and	O	34-37
its	O	38-41
relationship	O	42-54
to	O	55-57
EWSR1	O	58-63
,	O	63-64
a	O	65-66
site	O	67-71
of	O	72-74
tumor	B	75-80
-	O	80-81
associated	O	81-91
chromosome	O	92-102
translocation	O	103-116
.	O	116-117

The	O	118-121
EWS	O	122-125
gene	O	126-130
has	O	131-134
been	O	135-139
identified	O	140-150
based	O	151-156
on	O	157-159
its	O	160-163
location	O	164-172
at	O	173-175
the	O	176-179
chromosome	O	180-190
22	O	191-193
breakpoint	O	194-204
of	O	205-207
the	O	208-211
t	O	212-213
(	O	214-215
11	O	215-217
;	O	217-218
22	O	219-221
)	O	221-222
(	O	223-224
q24	O	224-227
;	O	227-228
q12	O	229-232
)	O	232-233
translocation	O	234-247
that	O	248-252
characterizes	O	253-266
Ewing	B	267-272
sarcoma	I	273-280
and	O	281-284
related	O	285-292
neuroectodermal	B	293-308
tumors	I	309-315
.	O	315-316

The	O	317-320
EWS	O	321-324
gene	O	325-329
spans	O	330-335
about	O	336-341
40	O	342-344
kb	O	345-347
of	O	348-350
DNA	O	351-354
and	O	355-358
is	O	359-361
encoded	O	362-369
by	O	370-372
17	O	373-375
exons	O	376-381
.	O	381-382

The	O	383-386
nucleotide	O	387-397
sequence	O	398-406
of	O	407-409
the	O	410-413
exons	O	414-419
is	O	420-422
identical	O	423-432
to	O	433-435
that	O	436-440
of	O	441-443
the	O	444-447
previously	O	448-458
described	O	459-468
cDNA	O	469-473
.	O	473-474

The	O	475-478
first	O	479-484
7	O	485-486
exons	O	487-492
encode	O	493-499
the	O	500-503
N	O	504-505
-	O	505-506
terminal	O	506-514
domain	O	515-521
of	O	522-524
EWS	O	525-528
,	O	528-529
which	O	530-535
consists	O	536-544
of	O	545-547
a	O	548-549
repeated	O	550-558
degenerated	O	559-570
polypeptide	O	571-582
of	O	583-585
7	O	586-587
to	O	588-590
12	O	591-593
residues	O	594-602
rich	O	603-607
in	O	608-610
tyrosine	O	611-619
,	O	619-620
serine	O	621-627
,	O	627-628
threonine	O	629-638
,	O	638-639
glycine	O	640-647
,	O	647-648
and	O	649-652
glutamine	O	653-662
.	O	662-663

Exons	O	664-669
11	O	670-672
,	O	672-673
12	O	674-676
,	O	676-677
and	O	678-681
13	O	682-684
encode	O	685-691
the	O	692-695
putative	O	696-704
RNA	O	705-708
binding	O	709-716
domain	O	717-723
.	O	723-724

The	O	725-728
three	O	729-734
glycine	O	735-742
-	O	742-743
and	O	744-747
arginine	O	748-756
-	O	756-757
rich	O	757-761
motifs	O	762-768
of	O	769-771
the	O	772-775
gene	O	776-780
are	O	781-784
mainly	O	785-791
encoded	O	792-799
by	O	800-802
exons	O	803-808
8	O	809-810
-	O	810-811
9	O	811-812
,	O	812-813
14	O	814-816
,	O	816-817
and	O	818-821
16	O	822-824
.	O	824-825

The	O	826-829
DNA	O	830-833
sequence	O	834-842
in	O	843-845
the	O	846-849
5	O	850-851
region	O	852-858
of	O	859-861
the	O	862-865
gene	O	866-870
has	O	871-874
features	O	875-883
of	O	884-886
a	O	887-888
CpG	O	889-892
-	O	892-893
rich	O	893-897
island	O	898-904
and	O	905-908
lacks	O	909-914
canonical	O	915-924
promoter	O	925-933
elements	O	934-942
,	O	942-943
such	O	944-948
as	O	949-951
TATA	O	952-956
and	O	957-960
CCAAT	O	961-966
consensus	O	967-976
sequences	O	977-986
.	O	986-987

Positions	O	988-997
of	O	998-1000
the	O	1001-1004
chromosome	O	1005-1015
22	O	1016-1018
breakpoints	O	1019-1030
were	O	1031-1035
determined	O	1036-1046
for	O	1047-1050
19	O	1051-1053
Ewing	B	1054-1059
tumors	I	1060-1066
.	O	1066-1067

They	O	1068-1072
were	O	1073-1077
localized	O	1078-1087
in	O	1088-1090
introns	O	1091-1098
7	O	1099-1100
or	O	1101-1103
8	O	1104-1105
in	O	1106-1108
18	O	1109-1111
cases	O	1112-1117
and	O	1118-1121
in	O	1122-1124
intron	O	1125-1131
10	O	1132-1134
in	O	1135-1137
1	O	1138-1139
case	O	1140-1144
.	O	1144-1145
.	O	1144-1145

PAX6	O	0-4
mutations	O	5-14
in	O	15-17
aniridia	B	18-26
.	O	26-27

Aniridia	B	28-36
is	O	37-39
a	O	40-41
congenital	B	42-52
malformation	I	53-65
of	I	66-68
the	I	69-72
eye	I	73-76
,	O	76-77
chiefly	O	78-85
characterised	O	86-99
by	O	100-102
iris	B	103-107
hypoplasia	I	108-118
,	O	118-119
which	O	120-125
can	O	126-129
cause	O	130-135
blindness	B	136-145
.	O	145-146

The	O	147-150
PAX6	O	151-155
gene	O	156-160
was	O	161-164
isolated	O	165-173
as	O	174-176
a	O	177-178
candidate	O	179-188
aniridia	B	189-197
gene	O	198-202
by	O	203-205
positional	O	206-216
cloning	O	217-224
from	O	225-229
the	O	230-233
smallest	O	234-242
region	O	243-249
of	O	250-252
overlap	O	253-260
of	O	261-263
aniridia	B	264-272
-	O	272-273
associated	O	273-283
deletions	O	284-293
.	O	293-294

Subsequently	O	295-307
PAX6	O	308-312
intragenic	O	313-323
mutations	O	324-333
were	O	334-338
demonstrated	O	339-351
in	O	352-354
Smalleye	O	355-363
,	O	363-364
a	O	365-366
mouse	O	367-372
mutant	O	373-379
which	O	380-385
is	O	386-388
an	O	389-391
animal	O	392-398
model	O	399-404
for	O	405-408
aniridia	B	409-417
,	O	417-418
and	O	419-422
six	O	423-426
human	O	427-432
aniridia	B	433-441
patients	O	442-450
.	O	450-451

In	O	452-454
this	O	455-459
paper	O	460-465
we	O	466-468
describe	O	469-477
four	O	478-482
additional	O	483-493
PAX6	O	494-498
point	O	499-504
mutations	O	505-514
in	O	515-517
aniridia	B	518-526
patients	O	527-535
,	O	535-536
both	O	537-541
sporadic	O	542-550
and	O	551-554
familial	O	555-563
.	O	563-564

These	O	565-570
mutations	O	571-580
highlight	O	581-590
regions	O	591-598
of	O	599-601
the	O	602-605
gene	O	606-610
which	O	611-616
are	O	617-620
essential	O	621-630
for	O	631-634
normal	O	635-641
PAX6	O	642-646
function	O	647-655
.	O	655-656

In	O	657-659
addition	O	660-668
,	O	668-669
the	O	670-673
frequency	O	674-683
at	O	684-686
which	O	687-692
we	O	693-695
have	O	696-700
found	O	701-706
PAX6	O	707-711
mutations	O	712-721
suggests	O	722-730
that	O	731-735
lesions	O	736-743
in	O	744-746
PAX6	O	747-751
will	O	752-756
account	O	757-764
for	O	765-768
most	O	769-773
cases	O	774-779
of	O	780-782
aniridia	B	783-791
.	O	791-792
.	O	791-792

Mutations	O	0-9
in	O	10-12
the	O	13-16
PAX6	O	17-21
gene	O	22-26
in	O	27-29
patients	O	30-38
with	O	39-43
hereditary	O	44-54
aniridia	B	55-63
.	O	63-64

The	O	65-68
14	O	69-71
exons	O	72-77
of	O	78-80
the	O	81-84
PAX6	O	85-89
gene	O	90-94
have	O	95-99
been	O	100-104
analysed	O	105-113
exon	O	114-118
-	O	118-119
by	O	119-121
-	O	118-119
exon	O	114-118
using	O	127-132
SSCP	O	133-137
in	O	138-140
6	O	141-142
aniridia	B	143-151
families	O	152-160
.	O	160-161

In	O	162-164
each	O	165-169
family	O	170-176
band	O	177-181
shifts	O	182-188
were	O	189-193
observed	O	194-202
on	O	203-205
the	O	206-209
SSCP	O	210-214
gels	O	215-219
for	O	220-223
only	O	224-228
one	O	229-232
exon	O	233-237
and	O	238-241
direct	O	242-248
PCR	O	249-252
-	O	252-253
sequencing	O	253-263
revealed	O	264-272
mutations	O	273-282
in	O	283-285
each	O	286-290
case	O	291-295
.	O	295-296

Two	O	297-300
mutations	O	301-310
involved	O	311-319
C	O	320-321
-	O	321-322
-	O	321-322
>	O	324-325
T	O	326-327
transitions	O	328-339
in	O	340-342
CGAarg	O	343-349
codons	O	350-356
in	O	357-359
exons	O	360-365
9	O	366-367
and	O	368-371
11	O	372-374
.	O	374-375

Another	O	376-383
C	O	384-385
-	O	385-386
-	O	385-386
>	O	388-389
T	O	390-391
transition	O	392-402
converted	O	403-412
a	O	413-414
CAG	O	415-418
-	O	418-419
glutamine	O	419-428
to	O	429-431
a	O	432-433
TAG	O	434-437
-	O	437-438
stop	O	438-442
in	O	443-445
exon	O	446-450
7	O	451-452
.	O	452-453
Small	O	454-459
insertions	O	460-470
created	O	471-478
frameshifts	O	479-490
which	O	491-496
produced	O	497-505
downstream	O	506-516
stop	O	517-521
codons	O	522-528
in	O	529-531
another	O	532-539
two	O	540-543
patients	O	544-552
and	O	553-556
an	O	557-559
A	O	560-561
-	O	561-562
-	O	561-562
>	O	564-565
T	O	566-567
mutation	O	568-576
disrupted	O	577-586
the	O	587-590
splice	O	591-597
donor	O	598-603
site	O	604-608
of	O	609-611
exon	O	612-616
5	O	617-618
in	O	619-621
the	O	622-625
remaining	O	626-635
family	O	636-642
.	O	642-643

Thus	O	644-648
,	O	648-649
complete	O	650-658
inactivation	O	659-671
of	O	672-674
the	O	675-678
PAX6	O	679-683
gene	O	684-688
is	O	689-691
predicted	O	692-701
in	O	702-704
all	O	705-708
cases	O	709-714
.	O	714-715

Analysis	O	716-724
of	O	725-727
other	O	728-733
affected	O	734-742
members	O	743-750
of	O	751-753
the	O	754-757
families	O	758-766
showed	O	767-773
that	O	774-778
,	O	778-779
in	O	780-782
each	O	783-787
case	O	788-792
,	O	792-793
all	O	794-797
affected	O	798-806
individuals	O	807-818
carried	O	819-826
the	O	827-830
same	O	831-835
family	O	836-842
-	O	842-843
specific	O	843-851
mutation	O	852-860
.	O	860-861

One	O	862-865
polymorphism	O	866-878
was	O	879-882
found	O	883-888
in	O	889-891
exon	O	892-896
7	O	897-898
.	O	898-899

This	O	900-904
data	O	905-909
strongly	O	910-918
supports	O	919-927
the	O	928-931
candidature	O	932-943
of	O	944-946
PAX6	O	947-951
as	O	952-954
the	O	955-958
gene	O	959-963
responsible	O	964-975
for	O	976-979
hereditary	O	980-990
aniridia	B	991-999
.	O	999-1000
.	O	999-1000

Locus	O	0-5
heterogeneity	O	6-19
in	O	20-22
Friedreich	B	23-33
ataxia	I	34-40
.	O	40-41

Friedreich	B	42-52
ataxia	I	53-59
(	O	60-61
FRDA	B	61-65
)	O	65-66
is	O	67-69
the	O	70-73
most	O	74-78
common	O	79-85
form	O	86-90
of	O	91-93
autosomal	B	94-103
recessive	I	104-113
ataxia	I	114-120
.	O	120-121

The	O	122-125
disease	O	126-133
locus	O	134-139
was	O	140-143
assigned	O	144-152
to	O	153-155
chromosome	O	156-166
9	O	167-168
and	O	169-172
the	O	173-176
disease	O	177-184
gene	O	185-189
,	O	189-190
STM7	O	191-195
/	O	195-196
X25	O	196-199
,	O	199-200
has	O	201-204
been	O	205-209
isolated	O	210-218
.	O	218-219

To	O	220-222
date	O	223-227
most	O	228-232
data	O	233-237
suggest	O	238-245
locus	O	246-251
homogeneity	O	252-263
in	O	264-266
FRDA	B	267-271
.	O	271-272

We	O	273-275
now	O	276-279
provide	O	280-287
strong	O	288-294
evidence	O	295-303
of	O	304-306
a	O	307-308
second	O	309-315
FRDA	B	316-320
locus	O	321-326
.	O	326-327

Studying	O	328-336
two	O	337-340
siblings	O	341-349
with	O	350-354
FRDA	B	355-359
from	O	360-364
two	O	365-368
families	O	369-377
we	O	378-380
did	O	381-384
not	O	385-388
detect	O	389-395
a	O	396-397
mutation	O	398-406
in	O	407-409
STM7	O	410-414
/	O	414-415
X25	O	415-418
.	O	418-419

Haplotype	O	420-429
analysis	O	430-438
of	O	439-441
the	O	442-445
STM7	O	446-450
/	O	450-451
X25	O	451-454
region	O	455-461
of	O	462-464
chromosome	O	465-475
9	O	476-477
demonstrated	O	478-490
that	O	491-495
the	O	496-499
relevant	O	500-508
portion	O	509-516
of	O	517-519
chromosome	O	520-530
9	O	531-532
differs	O	533-540
in	O	541-543
the	O	544-547
patients	O	548-556
.	O	556-557

Although	O	558-566
the	O	567-570
patients	O	571-579
studied	O	580-587
had	O	588-591
typical	O	592-599
FRDA	B	600-604
,	O	604-605
one	O	606-609
sibpair	O	610-617
had	O	618-621
the	O	622-625
uncommon	O	626-634
symptom	O	635-642
of	O	643-645
retained	O	646-654
tendon	O	655-661
reflexes	O	662-670
.	O	670-671

In	O	672-674
order	O	675-680
to	O	681-683
investigate	O	684-695
whether	O	696-703
retained	O	704-712
tendon	O	713-719
reflexes	O	720-728
are	O	729-732
characteristic	O	733-747
of	O	748-750
FRDA	B	751-755
caused	O	756-762
by	O	763-765
the	O	766-769
second	O	770-776
locus	O	777-782
,	O	782-783
FRDA2	O	784-789
,	O	789-790
we	O	791-793
studied	O	794-801
an	O	802-804
unrelated	O	805-814
FRDA	B	815-819
patient	O	820-827
with	O	828-832
retained	O	833-841
tendon	O	842-848
reflexes	O	849-857
.	O	857-858

The	O	859-862
observation	O	863-874
of	O	875-877
typical	O	878-885
mutations	O	886-895
in	O	896-898
STM7	O	899-903
/	O	903-904
X25	O	904-907
(	O	908-909
GAA	O	909-912
expansions	O	913-923
)	O	923-924
in	O	925-927
this	O	928-932
patient	O	933-940
demonstrates	O	941-953
that	O	954-958
the	O	959-962
two	O	963-966
genetically	O	967-978
different	O	979-988
forms	O	989-994
of	O	995-997
FRDA	B	998-1002
cannot	O	1003-1009
be	O	1010-1012
distinguished	O	1013-1026
clinically	O	1027-1037
.	O	1037-1038
.	O	1037-1038

Haploinsufficiency	B	0-18
of	I	19-21
the	I	22-25
transcription	I	26-39
factors	I	40-47
FOXC1	I	48-53
and	I	54-57
FOXC2	I	58-63
results	O	64-71
in	O	72-74
aberrant	O	75-83
ocular	O	84-90
development	O	91-102
.	O	102-103

Anterior	B	104-112
segment	I	113-120
developmental	I	121-134
disorders	I	135-144
,	O	144-145
including	O	146-155
Axenfeld	B	156-164
-	I	164-165
Rieger	I	165-171
anomaly	I	172-179
(	O	180-181
ARA	B	181-184
)	O	184-185
,	O	185-186
variably	O	187-195
associate	O	196-205
with	O	206-210
harmfully	O	211-220
elevated	O	221-229
intraocular	O	230-241
pressure	O	242-250
(	O	251-252
IOP	O	252-255
)	O	255-256
,	O	256-257
which	O	258-263
causes	O	264-270
glaucoma	B	271-279
.	O	279-280

Clinically	O	281-291
observed	O	292-300
dysgenesis	O	301-311
does	O	312-316
not	O	317-320
correlate	O	321-330
with	O	331-335
IOP	O	336-339
,	O	339-340
however	O	341-348
,	O	348-349
and	O	350-353
the	O	354-357
etiology	O	358-366
of	O	367-369
glaucoma	B	370-378
development	O	379-390
is	O	391-393
not	O	394-397
understood	O	398-408
.	O	408-409

The	O	410-413
forkhead	O	414-422
transcription	O	423-436
factor	O	437-443
genes	O	444-449
Foxc1	O	450-455
(	O	456-457
formerly	O	457-465
Mf1	O	466-469
)	O	469-470
and	O	471-474
Foxc2	O	475-480
(	O	481-482
formerly	O	482-490
Mfh1	O	491-495
)	O	495-496
are	O	497-500
expressed	O	501-510
in	O	511-513
the	O	514-517
mesenchyme	O	518-528
from	O	529-533
which	O	534-539
the	O	540-543
ocular	O	544-550
drainage	O	551-559
structures	O	560-570
derive	O	571-577
.	O	577-578

Mutations	O	579-588
in	O	589-591
the	O	592-595
human	O	596-601
homolog	O	602-609
of	O	610-612
Foxc1	O	613-618
,	O	618-619
FKHL7	O	620-625
,	O	625-626
cause	O	627-632
dominant	O	633-641
anterior	B	642-650
segment	I	651-658
defects	I	659-666
and	O	667-670
glaucoma	B	671-679
in	O	680-682
various	O	683-690
families	O	691-699
.	O	699-700

We	O	701-703
show	O	704-708
that	O	709-713
Foxc1	O	714-719
(	O	720-721
+	O	721-722
/	O	722-723
-	O	723-724
)	O	724-725
mice	O	726-730
have	O	731-735
anterior	B	736-744
segment	I	745-752
abnormalities	I	753-766
similar	O	767-774
to	O	775-777
those	O	778-783
reported	O	784-792
in	O	793-795
human	O	796-801
patients	O	802-810
.	O	810-811

These	O	812-817
abnormalities	O	818-831
include	O	832-839
small	O	840-845
or	O	846-848
absent	O	849-855
Schlemms	O	856-864
canal	O	865-870
,	O	870-871
aberrantly	O	872-882
developed	O	883-892
trabecular	O	893-903
meshwork	O	904-912
,	O	912-913
iris	B	914-918
hypoplasia	I	919-929
,	O	929-930
severely	O	931-939
eccentric	O	940-949
pupils	O	950-956
and	O	957-960
displaced	O	961-970
Schwalbes	O	971-980
line	O	981-985
.	O	985-986

The	O	987-990
penetrance	O	991-1001
of	O	1002-1004
clinically	O	1005-1015
obvious	O	1016-1023
abnormalities	O	1024-1037
varies	O	1038-1044
with	O	1045-1049
genetic	O	1050-1057
background	O	1058-1068
.	O	1068-1069

In	O	1070-1072
some	O	1073-1077
affected	O	1078-1086
eyes	O	1087-1091
,	O	1091-1092
collagen	O	1093-1101
bundles	O	1102-1109
were	O	1110-1114
half	O	1115-1119
normal	O	1120-1126
diameter	O	1127-1135
,	O	1135-1136
or	O	1137-1139
collagen	O	1140-1148
and	O	1149-1152
elastic	O	1153-1160
tissue	O	1161-1167
were	O	1168-1172
very	O	1173-1177
sparse	O	1178-1184
.	O	1184-1185

Thus	O	1186-1190
,	O	1190-1191
abnormalities	O	1192-1205
in	O	1206-1208
extracellular	O	1209-1222
matrix	O	1223-1229
synthesis	O	1230-1239
or	O	1240-1242
organization	O	1243-1255
may	O	1256-1259
contribute	O	1260-1270
to	O	1271-1273
development	O	1274-1285
of	O	1286-1288
the	O	1289-1292
ocular	O	1293-1299
phenotypes	O	1300-1310
.	O	1310-1311

Despite	O	1312-1319
the	O	1320-1323
abnormalities	O	1324-1337
in	O	1338-1340
ocular	O	1341-1347
drainage	O	1348-1356
structures	O	1357-1367
in	O	1368-1370
Foxc1	O	1371-1376
(	O	1377-1378
+	O	1378-1379
/	O	1379-1380
-	O	1380-1381
)	O	1381-1382
mice	O	1383-1387
,	O	1387-1388
IOP	O	1389-1392
was	O	1393-1396
normal	O	1397-1403
in	O	1404-1406
almost	O	1407-1413
all	O	1414-1417
mice	O	1418-1422
analyzed	O	1423-1431
,	O	1431-1432
on	O	1433-1435
all	O	1436-1439
genetic	O	1440-1447
backgrounds	O	1448-1459
and	O	1460-1463
at	O	1464-1466
all	O	1467-1470
ages	O	1471-1475
.	O	1475-1476

Similar	O	1477-1484
abnormalities	O	1485-1498
were	O	1499-1503
found	O	1504-1509
in	O	1510-1512
Foxc2	O	1513-1518
(	O	1519-1520
+	O	1520-1521
/	O	1521-1522
-	O	1522-1523
)	O	1523-1524
mice	O	1525-1529
,	O	1529-1530
but	O	1531-1534
no	O	1535-1537
disease	O	1538-1545
-	O	1545-1546
associated	O	1546-1556
mutations	O	1557-1566
were	O	1567-1571
identified	O	1572-1582
in	O	1583-1585
the	O	1586-1589
human	O	1590-1595
homolog	O	1596-1603
FKHL14	O	1604-1610
in	O	1611-1613
32	O	1614-1616
ARA	B	1617-1620
patients	O	1621-1629
.	O	1629-1630

Foxc1	O	1631-1636
(	O	1637-1638
+	O	1638-1639
/	O	1639-1640
-	O	1640-1641
)	O	1641-1642
and	O	1643-1646
Foxc2	O	1647-1652
(	O	1653-1654
+	O	1654-1655
/	O	1655-1656
-	O	1656-1657
)	O	1657-1658
mice	O	1659-1663
are	O	1664-1667
useful	O	1668-1674
models	O	1675-1681
for	O	1682-1685
studying	O	1686-1694
anterior	O	1695-1703
segment	O	1704-1711
development	O	1712-1723
and	O	1724-1727
its	O	1728-1731
anomalies	O	1732-1741
,	O	1741-1742
and	O	1743-1746
may	O	1747-1750
allow	O	1751-1756
identification	O	1757-1771
of	O	1772-1774
genes	O	1775-1780
that	O	1781-1785
interact	O	1786-1794
with	O	1795-1799
Foxc1	O	1800-1805
and	O	1806-1809
Foxc2	O	1810-1815
(	O	1816-1817
or	O	1817-1819
FKHL7	O	1820-1825
and	O	1826-1829
FKHL14	O	1830-1836
)	O	1836-1837
to	O	1838-1840
produce	O	1841-1848
a	O	1849-1850
phenotype	O	1851-1860
with	O	1861-1865
elevated	O	1866-1874
IOP	O	1875-1878
and	O	1879-1882
glaucoma	B	1883-1891
.	O	1891-1892
.	O	1891-1892

The	O	0-3
dermatofibrosarcoma	B	4-23
protuberans	I	24-35
-	O	35-36
associated	O	36-46
collagen	O	47-55
type	O	56-60
Ialpha1	O	61-68
/	O	68-69
platelet	O	69-77
-	O	77-78
derived	O	78-85
growth	O	86-92
factor	O	93-99
(	O	100-101
PDGF	O	101-105
)	O	105-106
B	O	107-108
-	O	108-109
chain	O	109-114
fusion	O	115-121
gene	O	122-126
generates	O	127-136
a	O	137-138
transforming	O	139-151
protein	O	152-159
that	O	160-164
is	O	165-167
processed	O	168-177
to	O	178-180
functional	O	181-191
PDGF	O	192-196
-	O	196-197
BB	O	197-199
.	O	199-200

Dermatofibrosarcoma	B	201-220
protuberans	I	221-232
(	O	233-234
DFSP	B	234-238
)	O	238-239
displays	O	240-248
chromosomal	O	249-260
rearrangements	O	261-275
involving	O	276-285
chromosome	O	286-296
17	O	297-299
and	O	300-303
22	O	304-306
,	O	306-307
which	O	308-313
fuse	O	314-318
the	O	319-322
collagen	O	323-331
type	O	332-336
Ialpha1	O	337-344
(	O	345-346
COLIA1	O	346-352
)	O	352-353
gene	O	354-358
to	O	359-361
the	O	362-365
platelet	O	366-374
-	O	374-375
derived	O	375-382
growth	O	383-389
factor	O	390-396
(	O	397-398
PDGF	O	398-402
)	O	402-403
B	O	404-405
-	O	405-406
chain	O	406-411
(	O	412-413
PDGFB	O	413-418
)	O	418-419
gene	O	420-424
.	O	424-425

To	O	426-428
characterize	O	429-441
the	O	442-445
functional	O	446-456
and	O	457-460
structural	O	461-471
properties	O	472-482
of	O	483-485
the	O	486-489
COLIA1	O	490-496
/	O	496-497
PDGFB	O	497-502
fusion	O	503-509
protein	O	510-517
,	O	517-518
we	O	519-521
generated	O	522-531
a	O	532-533
stable	O	534-540
NIH3T3	O	541-547
cell	O	548-552
line	O	553-557
that	O	558-562
contained	O	563-572
a	O	573-574
tumor	O	575-580
-	O	580-581
derived	O	581-588
chimeric	O	589-597
gene	O	598-602
resulting	O	603-612
from	O	613-617
a	O	618-619
COIA1	O	620-625
intron	O	626-632
7	O	633-634
-	O	634-635
PDGFB	O	635-640
intron	O	641-647
1	O	648-649
fusion	O	650-656
.	O	656-657

Expression	O	658-668
of	O	669-671
the	O	672-675
fusion	O	676-682
protein	O	683-690
led	O	691-694
to	O	695-697
morphological	O	698-711
transformation	O	712-726
and	O	727-730
increased	O	731-740
growth	O	741-747
rate	O	748-752
of	O	753-755
these	O	756-761
cells	O	762-767
.	O	767-768

The	O	769-772
PDGF	O	773-777
receptor	O	778-786
kinase	O	787-793
inhibitor	O	794-803
CGP57148B	O	804-813
reversed	O	814-822
the	O	823-826
transformed	O	827-838
phenotype	O	839-848
and	O	849-852
reduced	O	853-860
the	O	861-864
growth	O	865-871
rate	O	872-876
of	O	877-879
COLIA1	O	880-886
/	O	886-887
PDGFB	O	887-892
-	O	892-893
expressing	O	893-903
cells	O	904-909
but	O	910-913
had	O	914-917
no	O	918-920
effects	O	921-928
on	O	929-931
control	O	932-939
cells	O	940-945
.	O	945-946

The	O	947-950
presence	O	951-959
of	O	960-962
dimeric	O	963-970
COLIA1	O	971-977
/	O	977-978
PDGFB	O	978-983
precursors	O	984-994
was	O	995-998
demonstrated	O	999-1011
through	O	1012-1019
PDGFB	O	1020-1025
immunoprecipitations	O	1026-1046
of	O	1047-1049
metabolically	O	1050-1063
labeled	O	1064-1071
cells	O	1072-1077
and	O	1078-1081
also	O	1082-1086
by	O	1087-1089
PDGFB	O	1090-1095
immunoprecipitations	O	1096-1116
followed	O	1117-1125
by	O	1126-1128
immunoblotting	O	1129-1143
with	O	1144-1148
COLIA1	O	1149-1155
antibodies	O	1156-1166
.	O	1166-1167

Pulse	O	1168-1173
-	O	1173-1174
chase	O	1174-1179
studies	O	1180-1187
demonstrated	O	1188-1200
that	O	1201-1205
the	O	1206-1209
COLIA1	O	1210-1216
/	O	1216-1217
PDGFB	O	1217-1222
precursor	O	1223-1232
was	O	1233-1236
processed	O	1237-1246
to	O	1247-1249
an	O	1250-1252
end	O	1253-1256
product	O	1257-1264
that	O	1265-1269
was	O	1270-1273
indistinguishable	O	1274-1291
from	O	1292-1296
wild	O	1297-1301
-	O	1301-1302
type	O	1302-1306
PDGF	O	1307-1311
-	O	1311-1312
BB	O	1312-1314
.	O	1314-1315

Finally	O	1316-1323
,	O	1323-1324
COLIA1	O	1325-1331
/	O	1331-1332
PDGFB	O	1332-1337
-	O	1337-1338
expressing	O	1338-1348
cells	O	1349-1354
generated	O	1355-1364
tumors	B	1365-1371
after	O	1372-1377
s	O	1378-1379
.	O	1379-1380
c	O	1381-1382
c	O	1383-1384
.	O	1384-1385
injection	O	1386-1395
into	O	1396-1400
nude	O	1401-1405
mice	O	1406-1410
,	O	1410-1411
and	O	1412-1415
tumor	B	1416-1421
growth	O	1422-1428
was	O	1429-1432
reduced	O	1433-1440
by	O	1441-1443
treatment	O	1444-1453
with	O	1454-1458
CGP57148B	O	1459-1468
.	O	1468-1469

We	O	1470-1472
conclude	O	1473-1481
that	O	1482-1486
the	O	1487-1490
COLIA1	O	1491-1497
/	O	1497-1498
PDGFB	O	1498-1503
fusion	O	1504-1510
associated	O	1511-1521
with	O	1522-1526
DFSP	B	1527-1531
contributes	O	1532-1543
to	O	1544-1546
tumor	B	1547-1552
development	O	1553-1564
through	O	1565-1572
ectopic	O	1573-1580
production	O	1581-1591
of	O	1592-1594
PDGF	O	1595-1599
-	O	1599-1600
BB	O	1600-1602
and	O	1603-1606
the	O	1607-1610
formation	O	1611-1620
of	O	1621-1623
an	O	1624-1626
autocrine	O	1627-1636
loop	O	1637-1641
.	O	1641-1642

Our	O	1643-1646
findings	O	1647-1655
,	O	1655-1656
thus	O	1657-1661
,	O	1661-1662
suggest	O	1663-1670
that	O	1671-1675
PDGF	O	1676-1680
receptors	O	1681-1690
could	O	1691-1696
be	O	1697-1699
a	O	1700-1701
target	O	1702-1708
for	O	1709-1712
pharmacological	O	1713-1728
treatment	O	1729-1738
of	O	1739-1741
DFSP	B	1742-1746
and	O	1747-1750
giant	B	1751-1756
cell	I	1757-1761
fibroblastoma	I	1762-1775
,	O	1775-1776
e	O	1777-1778
.	O	1778-1779
g	O	1780-1781
.	O	1781-1782
,	O	1782-1783
through	O	1784-1791
the	O	1792-1795
use	O	1796-1799
of	O	1800-1802
PDGF	O	1803-1807
receptor	O	1808-1816
kinase	O	1817-1823
inhibitors	O	1824-1834
such	O	1835-1839
as	O	1840-1842
CGP57148B	O	1843-1852
.	O	1852-1853

Founder	O	0-7
effect	O	8-14
of	O	15-17
a	O	18-19
prevalent	O	20-29
phenylketonuria	B	30-45
mutation	O	46-54
in	O	55-57
the	O	58-61
Oriental	O	62-70
population	O	71-81
.	O	81-82

A	O	83-84
missense	O	85-93
mutation	O	94-102
has	O	103-106
been	O	107-111
identified	O	112-122
in	O	123-125
the	O	126-129
human	O	130-135
phenylalanine	O	136-149
hydroxylase	O	150-161
[	O	162-163
PAH	O	163-166
;	O	166-167
phenylalanine	O	168-181
4	O	182-183
-	O	183-184
monooxygenase	O	184-197
;	O	197-198
L	O	199-200
-	O	200-201
phenylalanine	O	201-214
,	O	214-215
tetrahydrobiopterin	O	216-235
oxygen	O	237-243
oxidoreductase	O	244-258
(	O	259-260
4	O	260-261
-	O	261-262
hydroxylating	O	262-275
)	O	275-276
,	O	276-277
EC	O	278-280
1	O	281-282
.	O	282-283
14	O	284-286
.	O	286-287
16	O	288-290
.	O	290-291
1	O	292-293
]	O	293-294
gene	O	295-299
in	O	300-302
a	O	303-304
Chinese	O	305-312
patient	O	313-320
with	O	321-325
classic	O	326-333
phenylketonuria	B	334-349
(	O	350-351
PKU	B	351-354
)	O	354-355
.	O	355-356

A	O	357-358
G	O	359-360
-	O	360-361
to	O	361-363
-	O	360-361
C	O	364-365
transition	O	366-376
at	O	377-379
the	O	380-383
second	O	384-390
base	O	391-395
of	O	396-398
codon	O	399-404
413	O	405-408
in	O	409-411
exon	O	412-416
12	O	417-419
of	O	420-422
the	O	423-426
gene	O	427-431
results	O	432-439
in	O	440-442
the	O	443-446
substitution	O	447-459
of	O	460-462
Pro413	O	463-469
for	O	470-473
Arg413	O	474-480
in	O	481-483
the	O	484-487
mutant	O	488-494
protein	O	495-502
.	O	502-503

This	O	504-508
mutation	O	509-517
(	O	518-519
R413P	O	519-524
)	O	524-525
results	O	526-533
in	O	534-536
negligible	O	537-547
enzymatic	O	548-557
activity	O	558-566
when	O	567-571
expressed	O	572-581
in	O	582-584
heterologous	O	585-597
mammalian	O	598-607
cells	O	608-613
and	O	614-617
is	O	618-620
compatible	O	621-631
with	O	632-636
a	O	637-638
classic	O	639-646
PKU	B	647-650
phenotype	O	651-660
in	O	661-663
the	O	664-667
patient	O	668-675
.	O	675-676

Population	O	677-687
genetic	O	688-695
studies	O	696-703
reveal	O	704-710
that	O	711-715
this	O	716-720
mutation	O	721-729
is	O	730-732
tightly	O	733-740
linked	O	741-747
to	O	748-750
restriction	O	751-762
fragment	O	763-771
length	O	772-778
polymorphism	O	779-791
haplotype	O	792-801
4	O	802-803
,	O	803-804
which	O	805-810
is	O	811-813
the	O	814-817
predominant	O	818-829
haplotype	O	830-839
of	O	840-842
the	O	843-846
PAH	O	847-850
locus	O	851-856
in	O	857-859
the	O	860-863
Oriental	O	864-872
population	O	873-883
.	O	883-884

It	O	885-887
accounts	O	888-896
for	O	897-900
13	O	901-903
.	O	903-904

8	O	905-906
%	O	906-907
of	O	908-910
northern	O	911-919
Chinese	O	920-927
and	O	928-931
27	O	932-934
%	O	934-935
of	O	936-938
Japanese	O	939-947
PKU	B	948-951
alleles	O	952-959
,	O	959-960
but	O	961-964
it	O	965-967
is	O	968-970
rare	O	971-975
in	O	976-978
southern	O	979-987
Chinese	O	988-995
(	O	996-997
2	O	997-998
.	O	998-999

2	O	1000-1001
%	O	1001-1002
)	O	1002-1003
and	O	1004-1007
is	O	1008-1010
absent	O	1011-1017
in	O	1018-1020
the	O	1021-1024
Caucasian	O	1025-1034
population	O	1035-1045
.	O	1045-1046

The	O	1047-1050
data	O	1051-1055
demonstrate	O	1056-1067
unambiguously	O	1068-1081
that	O	1082-1086
the	O	1087-1090
mutation	O	1091-1099
occurred	O	1100-1108
after	O	1109-1114
racial	O	1115-1121
divergence	O	1122-1132
of	O	1133-1135
Orientals	O	1136-1145
and	O	1146-1149
Caucasians	O	1150-1160
and	O	1161-1164
suggest	O	1165-1172
that	O	1173-1177
the	O	1178-1181
allele	O	1182-1188
has	O	1189-1192
spread	O	1193-1199
throughout	O	1200-1210
the	O	1211-1214
Orient	O	1215-1221
by	O	1222-1224
a	O	1225-1226
founder	O	1227-1234
effect	O	1235-1241
.	O	1241-1242

Previous	O	1243-1251
protein	O	1252-1259
polymorphism	O	1260-1272
studies	O	1273-1280
in	O	1281-1283
eastern	O	1284-1291
Asia	O	1292-1296
have	O	1297-1301
led	O	1302-1305
to	O	1306-1308
the	O	1309-1312
hypothesis	O	1313-1323
that	O	1324-1328
"	O	1329-1330
northern	O	1331-1339
Mongoloids	O	1340-1350
"	O	1351-1352
represented	O	1353-1364
a	O	1365-1366
founding	O	1367-1375
population	O	1376-1386
in	O	1387-1389
Asia	O	1390-1394
.	O	1394-1395

Our	O	1396-1399
results	O	1400-1407
are	O	1408-1411
compatible	O	1412-1422
with	O	1423-1427
this	O	1428-1432
hypothesis	O	1433-1443
in	O	1444-1446
that	O	1447-1451
the	O	1452-1455
PKU	B	1456-1459
mutation	O	1460-1468
might	O	1469-1474
have	O	1475-1479
occurred	O	1480-1488
in	O	1489-1491
northern	O	1492-1500
Mongoloids	O	1501-1511
and	O	1512-1515
subsequently	O	1516-1528
spread	O	1529-1535
to	O	1536-1538
the	O	1539-1542
Chinese	O	1543-1550
and	O	1551-1554
Japanese	O	1555-1563
populations	O	1564-1575
.	O	1575-1576

Late	O	0-4
-	O	4-5
onset	O	5-10
familial	B	11-19
Mediterranean	I	20-33
fever	I	34-39
(	O	40-41
FMF	B	41-44
)	O	44-45
:	O	45-46
a	O	47-48
subset	O	49-55
with	O	56-60
distinct	O	61-69
clinical	O	70-78
,	O	78-79
demographic	O	80-91
,	O	91-92
and	O	93-96
molecular	O	97-106
genetic	O	107-114
characteristics	O	115-130
.	O	130-131

To	O	132-134
determine	O	135-144
the	O	145-148
prevalence	O	149-159
and	O	160-163
characterize	O	164-176
demographic	O	177-188
,	O	188-189
clinical	O	190-198
,	O	198-199
and	O	200-203
genetic	O	204-211
features	O	212-220
of	O	221-223
familial	B	224-232
Mediterranean	I	233-246
fever	I	247-252
(	O	253-254
FMF	B	254-257
)	O	257-258
of	O	259-261
late	O	262-266
onset	O	267-272
,	O	272-273
all	O	274-277
patients	O	278-286
experiencing	O	287-299
their	O	300-305
first	O	306-311
FMF	B	312-315
attack	O	316-322
at	O	323-325
age	O	326-329
40	O	330-332
years	O	333-338
or	O	339-341
more	O	342-346
were	O	347-351
identified	O	352-362
using	O	363-368
the	O	369-372
computerized	O	373-385
registry	O	386-394
of	O	395-397
our	O	398-401
FMF	B	402-405
clinic	O	406-412
,	O	412-413
and	O	414-417
then	O	418-422
thoroughly	O	423-433
interviewed	O	434-445
and	O	446-449
examined	O	450-458
.	O	458-459

The	O	460-463
control	O	464-471
group	O	472-477
consisted	O	478-487
of	O	488-490
40	O	491-493
consecutive	O	494-505
FMF	B	506-509
patients	O	510-518
,	O	518-519
who	O	520-523
arrived	O	524-531
at	O	532-534
the	O	535-538
FMF	B	539-542
clinic	O	543-549
for	O	550-553
their	O	554-559
regular	O	560-567
follow	O	568-574
-	O	574-575
up	O	575-577
visit	O	578-583
and	O	584-587
were	O	588-592
40	O	593-595
years	O	596-601
of	O	602-604
age	O	605-608
or	O	609-611
older	O	612-617
at	O	618-620
the	O	621-624
time	O	625-629
of	O	630-632
the	O	633-636
examination	O	637-648
.	O	648-649

The	O	650-653
severity	O	654-662
of	O	663-665
the	O	666-669
disease	O	670-677
in	O	678-680
patients	O	681-689
and	O	690-693
controls	O	694-702
was	O	703-706
determined	O	707-717
using	O	718-723
a	O	724-725
modified	O	726-734
score	O	735-740
,	O	740-741
developed	O	742-751
previously	O	752-762
.	O	762-763

Mutational	O	764-774
analysis	O	775-783
in	O	784-786
the	O	787-790
FMF	B	791-794
gene	O	795-799
was	O	800-803
performed	O	804-813
using	O	814-819
a	O	820-821
commercial	O	822-832
kit	O	833-836
.	O	836-837

Only	O	838-842
20	O	843-845
of	O	846-848
4000	O	849-853
(	O	854-855
0	O	855-856
.	O	856-857
5	O	858-859
%	O	859-860
)	O	860-861
patients	O	862-870
had	O	871-874
late	O	875-879
-	O	879-880
onset	O	880-885
FMF	B	886-889
.	O	889-890

These	O	891-896
patients	O	897-905
were	O	906-910
mostly	O	911-917
men	O	918-921
,	O	921-922
of	O	923-925
non	O	926-929
-	O	929-930
North	O	930-935
African	O	936-943
origin	O	944-950
,	O	950-951
P	O	952-953
<	O	954-955
0	O	956-957
.	O	957-958
05	O	959-961
compared	O	962-970
to	O	971-973
controls	O	974-982
.	O	982-983

All	O	984-987
had	O	988-991
abdominal	O	992-1001
attacks	O	1002-1009
and	O	1010-1013
in	O	1014-1016
most	O	1017-1021
these	O	1022-1027
were	O	1028-1032
the	O	1033-1036
only	O	1037-1041
manifestation	O	1042-1055
of	O	1056-1058
their	O	1059-1064
disease	O	1065-1072
,	O	1072-1073
P	O	1074-1075
<	O	1076-1077
0	O	1078-1079
.	O	1079-1080
001	O	1081-1084
001	O	1085-1088
.	O	1088-1089

None	O	1090-1094
had	O	1095-1098
chronic	O	1099-1106
or	O	1107-1109
prolonged	O	1110-1119
manifestations	O	1120-1134
of	O	1135-1137
FMF	B	1138-1141
,	O	1141-1142
for	O	1143-1146
example	O	1147-1154
,	O	1154-1155
amyloidosis	B	1156-1167
,	O	1167-1168
chronic	B	1169-1176
arthritis	I	1177-1186
,	O	1186-1187
or	O	1188-1190
protracted	O	1191-1201
myalgia	B	1202-1209
,	O	1209-1210
P	O	1211-1212
<	O	1213-1214
0	O	1215-1216
.	O	1216-1217
001	O	1218-1221
.	O	1221-1222

The	O	1223-1226
response	O	1227-1235
to	O	1236-1238
treatment	O	1239-1248
was	O	1249-1252
good	O	1253-1257
despite	O	1258-1265
using	O	1266-1271
low	O	1272-1275
colchicine	O	1276-1286
dose	O	1287-1291
,	O	1291-1292
P	O	1293-1294
<	O	1295-1296
0	O	1297-1298
.	O	1298-1299
05	O	1300-1302
.	O	1302-1303

The	O	1304-1307
overall	O	1308-1315
severity	O	1316-1324
score	O	1325-1330
indicated	O	1331-1340
a	O	1341-1342
mild	O	1343-1347
disease	O	1348-1355
,	O	1355-1356
P	O	1357-1358
<	O	1359-1360
0	O	1361-1362
.	O	1362-1363
001	O	1364-1367
.	O	1367-1368

Mutational	O	1369-1379
analysis	O	1380-1388
revealed	O	1389-1397
absence	O	1398-1405
of	O	1406-1408
M694V	O	1409-1414
homozygosity	O	1415-1427
,	O	1427-1428
P	O	1429-1430
<	O	1431-1432
0	O	1433-1434
.	O	1434-1435
01	O	1436-1438
,	O	1438-1439
compared	O	1440-1448
to	O	1449-1451
our	O	1452-1455
regular	O	1456-1463
FMF	B	1464-1467
population	O	1468-1478
.	O	1478-1479

We	O	1480-1482
conclude	O	1483-1491
that	O	1492-1496
the	O	1497-1500
onset	O	1501-1506
of	O	1507-1509
FMF	B	1510-1513
in	O	1514-1516
a	O	1517-1518
late	O	1519-1523
age	O	1524-1527
defines	O	1528-1535
a	O	1536-1537
milder	O	1538-1544
form	O	1545-1549
of	O	1550-1552
disease	O	1553-1560
with	O	1561-1565
typical	O	1566-1573
clinical	O	1574-1582
,	O	1582-1583
demographic	O	1584-1595
,	O	1595-1596
and	O	1597-1600
molecular	O	1601-1610
genetic	O	1611-1618
characteristics	O	1619-1634

Structure	O	0-9
of	O	10-12
the	O	13-16
human	O	17-22
Na	O	23-25
+	O	25-26
/	O	26-27
glucose	O	27-34
cotransporter	O	35-48
gene	O	49-53
SGLT1	O	54-59
.	O	59-60

Intestinal	O	61-71
uptake	O	72-78
of	O	79-81
dietary	O	82-89
glucose	O	90-97
and	O	98-101
galactose	O	102-111
is	O	112-114
mediated	O	115-123
by	O	124-126
the	O	127-130
SGLT1	O	131-136
Na	O	137-139
+	O	140-141
/	O	141-142
glucose	O	142-149
cotransporter	O	150-163
of	O	164-166
the	O	167-170
brush	O	171-176
border	O	177-183
.	O	183-184

An	O	185-187
SGLT1	O	188-193
missense	O	194-202
mutation	O	203-211
underlies	O	212-221
hereditary	B	222-232
glucose	I	233-240
/	I	240-241
galactose	I	241-250
malabsorption	I	251-264
,	O	264-265
characterized	O	266-279
by	O	280-282
potentially	O	283-294
fatal	O	295-300
diarrhea	B	301-309
;	O	309-310
conversely	O	311-321
,	O	321-322
oral	O	323-327
rehydration	O	328-339
therapy	O	340-347
exploits	O	348-356
normal	O	357-363
transport	O	364-373
to	O	374-376
alleviate	O	377-386
life	O	387-391
-	O	391-392
threatening	O	392-403
diarrhea	B	404-412
of	O	413-415
infectious	O	416-426
origin	O	427-433
.	O	433-434

We	O	435-437
have	O	438-442
mapped	O	443-449
the	O	450-453
entire	O	454-460
human	O	461-466
SGLT1	O	467-472
Na	O	473-475
+	O	476-477
/	O	477-478
glucose	O	478-485
cotransporter	O	486-499
gene	O	500-504
from	O	505-509
cosmid	O	510-516
and	O	517-520
lambda	O	521-527
phage	O	528-533
clones	O	534-540
representing	O	541-553
a	O	554-555
genomic	O	556-563
region	O	564-570
of	O	571-573
112	O	574-577
kilobases	O	578-587
.	O	587-588

Transcription	O	589-602
initiation	O	603-613
occurred	O	614-622
from	O	623-627
a	O	628-629
site	O	630-634
27	O	635-637
base	O	638-642
pairs	O	643-648
3	O	649-650
of	O	651-653
a	O	654-655
TATAA	O	656-661
sequence	O	662-670
.	O	670-671

All	O	672-675
exon	O	676-680
-	O	680-681
flanking	O	681-689
regions	O	690-697
were	O	698-702
sequenced	O	703-712
,	O	712-713
and	O	714-717
the	O	718-721
entire	O	722-728
112	O	729-732
-	O	732-733
kilobase	O	733-741
region	O	742-748
mapped	O	749-755
with	O	756-760
four	O	761-765
restriction	O	766-777
enzymes	O	778-785
.	O	785-786

SGLT1	O	787-792
is	O	793-795
comprised	O	796-805
of	O	806-808
15	O	809-811
exons	O	812-817
(	O	818-819
spanning	O	819-827
72	O	828-830
kilobases	O	831-840
)	O	840-841
;	O	841-842
a	O	843-844
possible	O	845-853
evolutionary	O	854-866
origin	O	867-873
from	O	874-878
a	O	879-880
six	O	881-884
-	O	884-885
membrane	O	885-893
-	O	884-885
span	O	894-898
ancestral	O	899-908
precursor	O	909-918
via	O	919-922
a	O	923-924
gene	O	925-929
duplication	O	930-941
event	O	942-947
is	O	948-950
suggested	O	951-960
from	O	961-965
comparison	O	966-976
of	O	977-979
exons	O	980-985
against	O	986-993
protein	O	994-1001
secondary	O	1002-1011
structure	O	1012-1021
and	O	1022-1025
from	O	1026-1030
sequence	O	1031-1039
considerations	O	1040-1054
.	O	1054-1055

A	O	1056-1057
new	O	1058-1061
missense	O	1062-1070
mutation	O	1071-1079
in	O	1080-1082
exon	O	1083-1087
1	O	1088-1089
causing	O	1090-1097
glucose	B	1098-1105
/	I	1105-1106
galactose	I	1106-1115
malabsorption	I	1116-1129
is	O	1130-1132
also	O	1133-1137
described	O	1138-1147
.	O	1147-1148

This	O	1149-1153
is	O	1154-1156
the	O	1157-1160
first	O	1161-1166
Na	O	1167-1169
(	O	1170-1171
+	O	1171-1172
)	O	1172-1173
-	O	1174-1175
dependent	O	1175-1184
cotransporter	O	1185-1198
gene	O	1199-1203
structure	O	1204-1213
reported	O	1214-1222
.	O	1222-1223

These	O	1224-1229
data	O	1230-1234
facilitate	O	1235-1245
the	O	1246-1249
search	O	1250-1256
for	O	1257-1260
new	O	1261-1264
glucose	B	1265-1272
/	I	1272-1273
galactose	I	1273-1282
malabsorption	I	1283-1296
-	O	1296-1297
related	O	1297-1304
mutations	O	1305-1314
in	O	1315-1317
this	O	1318-1322
important	O	1323-1332
gene	O	1333-1337
and	O	1338-1341
provide	O	1342-1349
a	O	1350-1351
basis	O	1352-1357
for	O	1358-1361
future	O	1362-1368
evolutionary	O	1369-1381
comparisons	O	1382-1393
with	O	1394-1398
other	O	1399-1404
Na	O	1405-1407
(	O	1408-1409
+	O	1409-1410
)	O	1410-1411
-	O	1412-1413
dependent	O	1413-1422
cotransporters	O	1423-1437
.	O	1437-1438
.	O	1437-1438

ATM	O	0-3
phosphorylates	O	4-18
p95	O	19-22
/	O	22-23
nbs1	O	23-27
in	O	28-30
an	O	31-33
S	O	34-35
-	O	35-36
phase	O	36-41
checkpoint	O	42-52
pathway	O	53-60
.	O	60-61

The	O	62-65
rare	B	66-70
diseases	I	71-79
ataxia	B	80-86
-	I	86-87
telangiectasia	I	87-101
(	O	102-103
AT	B	103-105
)	O	105-106
,	O	106-107
caused	O	108-114
by	O	115-117
mutations	O	118-127
in	O	128-130
the	O	131-134
ATM	O	135-138
gene	O	139-143
,	O	143-144
and	O	145-148
Nijmegen	B	149-157
breakage	I	158-166
syndrome	I	167-175
(	O	176-177
NBS	B	177-180
)	O	180-181
,	O	181-182
with	O	183-187
mutations	O	188-197
in	O	198-200
the	O	201-204
p95	O	205-208
/	O	208-209
nbs1	O	209-213
gene	O	214-218
,	O	218-219
share	O	220-225
a	O	226-227
variety	O	228-235
of	O	236-238
phenotypic	B	239-249
abnormalities	I	250-263
such	O	264-268
as	O	269-271
chromosomal	B	272-283
instability	I	284-295
,	O	295-296
radiation	O	297-306
sensitivity	O	307-318
and	O	319-322
defects	O	323-330
in	O	331-333
cell	O	334-338
-	O	338-339
cycle	O	339-344
checkpoints	O	345-356
in	O	357-359
response	O	360-368
to	O	369-371
ionizing	O	372-380
radiation	O	381-390
.	O	390-391

The	O	392-395
ATM	O	396-399
gene	O	400-404
encodes	O	405-412
a	O	413-414
protein	O	415-422
kinase	O	423-429
that	O	430-434
is	O	435-437
activated	O	438-447
by	O	448-450
ionizing	O	451-459
radiation	O	460-469
or	O	470-472
radiomimetic	O	473-485
drugs	O	486-491
,	O	491-492
whereas	O	493-500
p95	O	501-504
/	O	504-505
nbs1	O	505-509
is	O	510-512
part	O	513-517
of	O	518-520
a	O	521-522
protein	O	523-530
complex	O	531-538
that	O	539-543
is	O	544-546
involved	O	547-555
in	O	556-558
responses	O	559-568
to	O	569-571
DNA	O	572-575
double	O	576-582
-	O	582-583
strand	O	583-589
breaks	O	590-596
.	O	596-597

Here	O	598-602
,	O	602-603
because	O	604-611
of	O	612-614
the	O	615-618
similarities	O	619-631
between	O	632-639
AT	B	640-642
and	O	643-646
NBS	B	647-650
,	O	650-651
we	O	652-654
evaluated	O	655-664
the	O	665-668
functional	O	669-679
interactions	O	680-692
between	O	693-700
ATM	O	701-704
and	O	705-708
p95	O	709-712
/	O	712-713
nbs1	O	713-717
.	O	717-718

Activation	O	719-729
of	O	730-732
the	O	733-736
ATM	O	737-740
kinase	O	741-747
by	O	748-750
ionizing	O	751-759
radiation	O	760-769
and	O	770-773
induction	O	774-783
of	O	784-786
ATM	O	787-790
-	O	790-791
dependent	O	791-800
responses	O	801-810
in	O	811-813
NBS	B	814-817
cells	O	818-823
indicated	O	824-833
that	O	834-838
p95	O	839-842
/	O	842-843
nbs1	O	843-847
may	O	848-851
not	O	852-855
be	O	856-858
required	O	859-867
for	O	868-871
signalling	O	872-882
to	O	883-885
ATM	O	886-889
after	O	890-895
ionizing	O	896-904
radiation	O	905-914
.	O	914-915

However	O	916-923
,	O	923-924
p95	O	925-928
/	O	928-929
nbs1	O	929-933
was	O	934-937
phosphorylated	O	938-952
on	O	953-955
serine	O	956-962
343	O	963-966
in	O	967-969
an	O	970-972
ATM	O	973-976
-	O	976-977
dependent	O	977-986
manner	O	987-993
in	O	994-996
vitro	O	997-1002
and	O	1003-1006
in	O	1007-1009
vivo	O	1010-1014
after	O	1015-1020
ionizing	O	1021-1029
radiation	O	1030-1039
.	O	1039-1040

A	O	1041-1042
p95	O	1043-1046
/	O	1046-1047
nbs1	O	1047-1051
construct	O	1052-1061
mutated	O	1062-1069
at	O	1070-1072
the	O	1073-1076
ATM	O	1077-1080
phosphorylation	O	1081-1096
site	O	1097-1101
abrogated	O	1102-1111
an	O	1112-1114
S	O	1115-1116
-	O	1116-1117
phase	O	1117-1122
checkpoint	O	1123-1133
induced	O	1134-1141
by	O	1142-1144
ionizing	O	1145-1153
radiation	O	1154-1163
in	O	1164-1166
normal	O	1167-1173
cells	O	1174-1179
and	O	1180-1183
failed	O	1184-1190
to	O	1191-1193
compensate	O	1194-1204
for	O	1205-1208
this	O	1209-1213
functional	O	1214-1224
deficiency	O	1225-1235
in	O	1236-1238
NBS	B	1239-1242
cells	O	1243-1248
.	O	1248-1249

These	O	1250-1255
observations	O	1256-1268
link	O	1269-1273
ATM	O	1274-1277
and	O	1278-1281
p95	O	1282-1285
/	O	1285-1286
nbs1	O	1286-1290
in	O	1291-1293
a	O	1294-1295
common	O	1296-1302
signalling	O	1303-1313
pathway	O	1314-1321
and	O	1322-1325
provide	O	1326-1333
an	O	1334-1336
explanation	O	1337-1348
for	O	1349-1352
phenotypic	O	1353-1363
similarities	O	1364-1376
in	O	1377-1379
these	O	1380-1385
two	O	1386-1389
diseases	O	1390-1398
.	O	1398-1399
.	O	1398-1399

Two	O	0-3
distinct	O	4-12
mutations	O	13-22
at	O	23-25
a	O	26-27
single	O	28-34
BamHI	O	35-40
site	O	41-45
in	O	46-48
phenylketonuria	B	49-64
.	O	64-65

Classical	B	66-75
phenylketonuria	I	76-91
is	O	92-94
an	O	95-97
autosomal	B	98-107
recessive	I	108-117
disease	I	118-125
caused	O	126-132
by	O	133-135
a	O	136-137
deficiency	B	138-148
of	I	149-151
hepatic	I	152-159
phenylalanine	I	160-173
hydroxylase	I	174-185
(	O	186-187
PAH	O	187-190
)	O	190-191
.	O	191-192

The	O	193-196
abolition	O	197-206
of	O	207-209
an	O	210-212
invariant	O	213-222
BamHI	O	223-228
site	O	229-233
located	O	234-241
in	O	242-244
the	O	245-248
coding	O	249-255
sequence	O	256-264
of	O	265-267
the	O	268-271
PAH	O	272-275
gene	O	276-280
(	O	281-282
exon	O	282-286
7	O	287-288
)	O	288-289
led	O	290-293
to	O	294-296
the	O	297-300
recognition	O	301-312
of	O	313-315
two	O	316-319
new	O	320-323
point	O	324-329
mutations	O	330-339
at	O	340-342
codon	O	343-348
272	O	349-352
and	O	353-356
273	O	357-360
(	O	361-362
272gly	O	362-368
-	O	368-369
-	O	368-369
-	O	368-369
-	O	368-369
stop	O	372-376
and	O	377-380
273ser	O	381-387
-	O	387-388
-	O	387-388
-	O	387-388
-	O	387-388
phe	O	391-394
,	O	394-395
respectively	O	396-408
)	O	408-409
.	O	409-410

Both	O	411-415
mutations	O	416-425
were	O	426-430
detected	O	431-439
in	O	440-442
north	O	443-448
eastern	O	449-456
France	O	457-463
or	O	464-466
Belgium	O	467-474
and	O	475-478
occurred	O	479-487
on	O	488-490
the	O	491-494
background	O	495-505
of	O	506-508
RFLP	O	509-513
haplotype	O	514-523
7	O	524-525
alleles	O	526-533
.	O	533-534

The	O	535-538
present	O	539-546
study	O	547-552
supports	O	553-561
the	O	562-565
view	O	566-570
that	O	571-575
the	O	576-579
clinical	O	580-588
heterogeneity	O	589-602
in	O	603-605
PKU	B	606-609
is	O	610-612
accounted	O	613-622
for	O	623-626
by	O	627-629
the	O	630-633
large	O	634-639
variety	O	640-647
of	O	648-650
mutant	O	651-657
genotypes	O	658-667
associated	O	668-678
with	O	679-683
PAH	B	684-687
deficiencies	I	688-700
.	O	700-701
.	O	700-701

Functional	O	0-10
link	O	11-15
between	O	16-23
ataxia	B	24-30
-	I	30-31
telangiectasia	I	31-45
and	O	46-49
Nijmegen	B	50-58
breakage	I	59-67
syndrome	I	68-76
gene	O	77-81
products	O	82-90
.	O	90-91

Ataxia	B	92-98
-	I	98-99
telangiectasia	I	99-113
(	O	114-115
A	B	115-116
-	I	116-117
T	I	117-118
)	O	118-119
and	O	120-123
Nijmegen	B	124-132
breakage	I	133-141
syndrome	I	142-150
(	O	151-152
NBS	B	152-155
)	O	155-156
are	O	157-160
recessive	B	161-170
genetic	I	171-178
disorders	I	179-188
with	O	189-193
susceptibility	O	194-208
to	O	209-211
cancer	B	212-218
and	O	219-222
similar	O	223-230
cellular	O	231-239
phenotypes	O	240-250
.	O	250-251

The	O	252-255
protein	O	256-263
product	O	264-271
of	O	272-274
the	O	275-278
gene	O	279-283
responsible	O	284-295
for	O	296-299
A	B	300-301
-	I	301-302
T	I	302-303
,	O	303-304
designated	O	305-315
ATM	O	316-319
,	O	319-320
is	O	321-323
a	O	324-325
member	O	326-332
of	O	333-335
a	O	336-337
family	O	338-344
of	O	345-347
kinases	O	348-355
characterized	O	356-369
by	O	370-372
a	O	373-374
carboxy	O	375-382
-	O	382-383
terminal	O	383-391
phosphatidylinositol	O	392-412
3	O	413-414
-	O	414-415
kinase	O	415-421
-	O	414-415
like	O	422-426
domain	O	427-433
.	O	433-434

The	O	435-438
NBS1	O	439-443
protein	O	444-451
is	O	452-454
specifically	O	455-467
mutated	O	468-475
in	O	476-478
patients	O	479-487
with	O	488-492
Nijmegen	B	493-501
breakage	I	502-510
syndrome	I	511-519
and	O	520-523
forms	O	524-529
a	O	530-531
complex	O	532-539
with	O	540-544
the	O	545-548
DNA	O	549-552
repair	O	553-559
proteins	O	560-568
Rad50	O	569-574
and	O	575-578
Mrel1	O	579-584
.	O	584-585

Here	O	586-590
we	O	591-593
show	O	594-598
that	O	599-603
phosphorylation	O	604-619
of	O	620-622
NBS1	O	623-627
,	O	627-628
induced	O	629-636
by	O	637-639
ionizing	O	640-648
radiation	O	649-658
,	O	658-659
requires	O	660-668
catalytically	O	669-682
active	O	683-689
ATM	O	690-693
.	O	693-694

Complexes	O	695-704
containing	O	705-715
ATM	O	716-719
and	O	720-723
NBS1	O	724-728
exist	O	729-734
in	O	735-737
vivo	O	738-742
in	O	743-745
both	O	746-750
untreated	O	751-760
cells	O	761-766
and	O	767-770
cells	O	771-776
treated	O	777-784
with	O	785-789
ionizing	O	790-798
radiation	O	799-808
.	O	808-809

We	O	810-812
have	O	813-817
identified	O	818-828
two	O	829-832
residues	O	833-841
of	O	842-844
NBS1	O	845-849
,	O	849-850
Ser	O	851-854
278	O	855-858
and	O	859-862
Ser	O	863-866
343	O	867-870
that	O	871-875
are	O	876-879
phosphorylated	O	880-894
in	O	895-897
vitro	O	898-903
by	O	904-906
ATM	O	907-910
and	O	911-914
whose	O	915-920
modification	O	921-933
in	O	934-936
vivo	O	937-941
is	O	942-944
essential	O	945-954
for	O	955-958
the	O	959-962
cellular	O	963-971
response	O	972-980
to	O	981-983
DNA	O	984-987
damage	O	988-994
.	O	994-995

This	O	996-1000
response	O	1001-1009
includes	O	1010-1018
S	O	1019-1020
-	O	1020-1021
phase	O	1021-1026
checkpoint	O	1027-1037
activation	O	1038-1048
,	O	1048-1049
formation	O	1050-1059
of	O	1060-1062
the	O	1063-1066
NBS1	O	1067-1071
/	O	1071-1072
Mrel1	O	1072-1077
/	O	1071-1072
Rad50	O	1078-1083
nuclear	O	1084-1091
foci	O	1092-1096
and	O	1097-1100
rescue	O	1101-1107
of	O	1108-1110
hypersensitivity	B	1111-1127
to	I	1128-1130
ionizing	I	1131-1139
radiation	I	1140-1149
.	O	1149-1150

Together	O	1151-1159
,	O	1159-1160
these	O	1161-1166
results	O	1167-1174
demonstrate	O	1175-1186
a	O	1187-1188
biochemical	O	1189-1200
link	O	1201-1205
between	O	1206-1213
cell	O	1214-1218
-	O	1218-1219
cycle	O	1219-1224
checkpoints	O	1225-1236
activated	O	1237-1246
by	O	1247-1249
DNA	O	1250-1253
damage	O	1254-1260
and	O	1261-1264
DNA	O	1265-1268
repair	O	1269-1275
in	O	1276-1278
two	O	1279-1282
genetic	B	1283-1290
diseases	I	1291-1299
with	O	1300-1304
overlapping	O	1305-1316
phenotypes	O	1317-1327
.	O	1327-1328
.	O	1327-1328

Structure	O	0-9
and	O	10-13
genomic	O	14-21
sequence	O	22-30
of	O	31-33
the	O	34-37
myotonic	B	38-46
dystrophy	I	47-56
(	O	57-58
DM	B	58-60
kinase	O	61-67
)	O	67-68
gene	O	69-73
.	O	73-74

The	O	75-78
mutation	O	79-87
causing	O	88-95
myotonic	B	96-104
dystrophy	I	105-114
(	O	115-116
DM	B	116-118
)	O	118-119
has	O	120-123
recently	O	124-132
been	O	133-137
identified	O	138-148
as	O	149-151
an	O	152-154
unstable	O	155-163
CTG	O	164-167
trinucleotide	O	168-181
repeat	O	182-188
located	O	189-196
in	O	197-199
the	O	200-203
3	O	204-205
untranslated	O	206-218
region	O	219-225
of	O	226-228
a	O	229-230
gene	O	231-235
encoding	O	236-244
for	O	245-248
a	O	249-250
protein	O	251-258
with	O	259-263
putative	O	264-272
serine	O	273-279
-	O	279-280
threonine	O	280-289
protein	O	290-297
kinase	O	298-304
activity	O	305-313
.	O	313-314

In	O	315-317
this	O	318-322
report	O	323-329
we	O	330-332
present	O	333-340
the	O	341-344
genomic	O	345-352
sequences	O	353-362
of	O	363-365
the	O	366-369
human	O	370-375
and	O	376-379
murine	O	380-386
DM	B	387-389
kinase	O	390-396
gene	O	397-401
.	O	401-402

A	O	403-404
comparison	O	405-415
of	O	416-418
these	O	419-424
sequences	O	425-434
with	O	435-439
each	O	440-444
other	O	445-450
and	O	451-454
with	O	455-459
known	O	460-465
cDNA	O	466-470
sequences	O	471-480
from	O	481-485
both	O	486-490
species	O	491-498
,	O	498-499
led	O	500-503
us	O	504-506
to	O	507-509
predict	O	510-517
a	O	518-519
translation	O	520-531
initiation	O	532-542
codon	O	543-548
,	O	548-549
as	O	550-552
well	O	553-557
as	O	558-560
determine	O	561-570
the	O	571-574
organization	O	575-587
of	O	588-590
the	O	591-594
DM	B	595-597
kinase	O	598-604
gene	O	605-609
.	O	609-610

Several	O	611-618
polymorphisms	O	619-632
within	O	633-639
the	O	640-643
human	O	644-649
DM	B	650-652
kinase	O	653-659
gene	O	660-664
have	O	665-669
been	O	670-674
identified	O	675-685
,	O	685-686
and	O	687-690
PCR	O	691-694
assays	O	695-701
to	O	702-704
detect	O	705-711
two	O	712-715
of	O	716-718
these	O	719-724
are	O	725-728
described	O	729-738
.	O	738-739

The	O	740-743
complete	O	744-752
sequence	O	753-761
and	O	762-765
characterization	O	766-782
of	O	783-785
the	O	786-789
structure	O	790-799
of	O	800-802
the	O	803-806
DM	B	807-809
kinase	O	810-816
gene	O	817-821
,	O	821-822
as	O	823-825
well	O	826-830
as	O	831-833
the	O	834-837
identification	O	838-852
of	O	853-855
novel	O	856-861
polymorphisms	O	862-875
within	O	876-882
the	O	883-886
gene	O	887-891
,	O	891-892
represent	O	893-902
an	O	903-905
important	O	906-915
step	O	916-920
in	O	921-923
a	O	924-925
further	O	926-933
understanding	O	934-947
of	O	948-950
the	O	951-954
genetics	O	955-963
of	O	964-966
myotonic	B	967-975
dystrophy	I	976-985
and	O	986-989
the	O	990-993
molecular	O	994-1003
biology	O	1004-1011
of	O	1012-1014
the	O	1015-1018
gene	O	1019-1023
.	O	1023-1024
.	O	1023-1024

Identification	O	0-14
of	O	15-17
novel	O	18-23
imprinted	O	24-33
transcripts	O	34-45
in	O	46-48
the	O	49-52
Prader	B	53-59
-	I	59-60
Willi	I	60-65
syndrome	I	66-74
and	O	75-78
Angelman	B	79-87
syndrome	I	88-96
deletion	O	97-105
region	O	106-112
:	O	112-113
further	O	114-121
evidence	O	122-130
for	O	131-134
regional	O	135-143
imprinting	O	144-154
control	O	155-162
.	O	162-163

Deletions	O	164-173
and	O	174-177
other	O	178-183
abnormalities	O	184-197
of	O	198-200
human	O	201-206
chromosome	O	207-217
15q11	O	218-223
-	O	223-224
q13	O	224-227
are	O	228-231
associated	O	232-242
with	O	243-247
two	O	248-251
developmental	O	252-265
disorders	O	266-275
,	O	275-276
Prader	B	277-283
-	I	283-284
Willi	I	284-289
syndrome	I	290-298
(	O	299-300
PWS	B	300-303
)	O	303-304
and	O	305-308
Angelman	B	309-317
syndrome	I	318-326
(	O	327-328
AS	B	328-330
)	O	330-331
.	O	331-332

Loss	O	333-337
of	O	338-340
expression	O	341-351
of	O	352-354
imprinted	O	355-364
,	O	364-365
paternally	O	366-376
expressed	O	377-386
genes	O	387-392
has	O	393-396
been	O	397-401
implicated	O	402-412
in	O	413-415
PWS	B	416-419
.	O	419-420

However	O	421-428
,	O	428-429
the	O	430-433
number	O	434-440
of	O	441-443
imprinted	O	444-453
genes	O	454-459
that	O	460-464
contribute	O	465-475
to	O	476-478
PWS	B	479-482
,	O	482-483
and	O	484-487
the	O	488-491
range	O	492-497
over	O	498-502
which	O	503-508
the	O	509-512
imprinting	O	513-523
signal	O	524-530
acts	O	531-535
to	O	536-538
silence	O	539-546
one	O	547-550
copy	O	551-555
of	O	556-558
the	O	559-562
gene	O	563-567
in	O	568-570
a	O	571-572
parent	O	573-579
-	O	579-580
of	O	580-582
-	O	579-580
origin	O	583-589
-	O	579-580
specific	O	590-598
manner	O	599-605
,	O	605-606
are	O	607-610
unknown	O	611-618
.	O	618-619

To	O	620-622
identify	O	623-631
additional	O	632-642
imprinted	O	643-652
genes	O	653-658
that	O	659-663
could	O	664-669
contribute	O	670-680
to	O	681-683
the	O	684-687
PWS	B	688-691
phenotype	O	692-701
and	O	702-705
to	O	706-708
understand	O	709-719
the	O	720-723
regional	O	724-732
control	O	733-740
of	O	741-743
imprinting	O	744-754
in	O	755-757
15q11	O	758-763
-	O	763-764
q13	O	764-767
,	O	767-768
we	O	769-771
have	O	772-776
constructed	O	777-788
an	O	789-791
imprinted	O	792-801
transcript	O	802-812
map	O	813-816
of	O	817-819
the	O	820-823
PWS	O	824-827
-	O	827-828
AS	O	828-830
deletion	O	831-839
interval	O	840-848
.	O	848-849

The	O	850-853
imprinting	O	854-864
status	O	865-871
of	O	872-874
22	O	875-877
expressed	O	878-887
sequence	O	888-896
tags	O	897-901
derived	O	902-909
from	O	910-914
the	O	915-918
radiation	O	919-928
-	O	928-929
hybrid	O	929-935
human	O	936-941
transcript	O	942-952
maps	O	953-957
or	O	958-960
physical	O	961-969
maps	O	970-974
was	O	975-978
determined	O	979-989
in	O	990-992
a	O	993-994
reverse	O	995-1002
transcriptase	O	1003-1016
-	O	1016-1017
PCR	O	1017-1020
assay	O	1021-1026
and	O	1027-1030
correlated	O	1031-1041
with	O	1042-1046
the	O	1047-1050
position	O	1051-1059
of	O	1060-1062
the	O	1063-1066
transcripts	O	1067-1078
on	O	1079-1081
the	O	1082-1085
physical	O	1086-1094
map	O	1095-1098
.	O	1098-1099

Seven	O	1100-1105
new	O	1106-1109
paternally	O	1110-1120
expressed	O	1121-1130
transcripts	O	1131-1142
localize	O	1143-1151
to	O	1152-1154
an	O	1155-1157
approximately	O	1158-1171
1	O	1172-1173
.	O	1173-1174
5	O	1175-1176
-	O	1176-1177
Mb	O	1177-1179
domain	O	1180-1186
surrounding	O	1187-1198
the	O	1199-1202
SNRPN	O	1203-1208
-	O	1208-1209
associated	O	1209-1219
imprinting	O	1220-1230
center	O	1231-1237
,	O	1237-1238
which	O	1239-1244
already	O	1245-1252
includes	O	1253-1261
four	O	1262-1266
imprinted	O	1267-1276
,	O	1276-1277
paternally	O	1278-1288
expressed	O	1289-1298
genes	O	1299-1304
.	O	1304-1305

All	O	1306-1309
other	O	1310-1315
tested	O	1316-1322
new	O	1323-1326
transcripts	O	1327-1338
in	O	1339-1341
the	O	1342-1345
deletion	O	1346-1354
region	O	1355-1361
were	O	1362-1366
expressed	O	1367-1376
from	O	1377-1381
both	O	1382-1386
alleles	O	1387-1394
.	O	1394-1395

A	O	1396-1397
domain	O	1398-1404
of	O	1405-1407
exclusive	O	1408-1417
paternal	O	1418-1426
expression	O	1427-1437
surrounding	O	1438-1449
the	O	1450-1453
imprinting	O	1454-1464
center	O	1465-1471
suggests	O	1472-1480
strong	O	1481-1487
regional	O	1488-1496
control	O	1497-1504
of	O	1505-1507
the	O	1508-1511
imprinting	O	1512-1522
process	O	1523-1530
.	O	1530-1531

This	O	1532-1536
study	O	1537-1542
provides	O	1543-1551
the	O	1552-1555
means	O	1556-1561
for	O	1562-1565
further	O	1566-1573
investigation	O	1574-1587
of	O	1588-1590
additional	O	1591-1601
genes	O	1602-1607
that	O	1608-1612
cause	O	1613-1618
or	O	1619-1621
modify	O	1622-1628
the	O	1629-1632
phenotypes	O	1633-1643
associated	O	1644-1654
with	O	1655-1659
rearrangements	O	1660-1674
of	O	1675-1677
15q11	O	1678-1683
-	O	1683-1684
q13	O	1684-1687
.	O	1687-1688

Penetrances	O	0-11
of	O	12-14
BRCA1	O	15-20
1675delA	O	21-29
and	O	30-33
1135insA	O	34-42
with	O	43-47
respect	O	48-55
to	O	56-58
breast	B	59-65
cancer	I	66-72
and	O	73-76
ovarian	B	77-84
cancer	I	85-91
.	O	91-92

For	O	93-96
genetic	O	97-104
counseling	O	105-115
and	O	116-119
predictive	O	120-130
testing	O	131-138
in	O	139-141
families	O	142-150
with	O	151-155
inherited	B	156-165
breast	I	166-172
-	I	172-173
ovarian	I	173-180
cancer	I	181-187
,	O	187-188
penetrances	O	189-200
and	O	201-204
expressions	O	205-216
of	O	217-219
the	O	220-223
underlying	O	224-234
mutations	O	235-244
should	O	245-251
be	O	252-254
known	O	255-260
.	O	260-261

We	O	262-264
have	O	265-269
previously	O	270-280
reported	O	281-289
two	O	290-293
BRCA1	O	294-299
founder	O	300-307
mutations	O	308-317
in	O	318-320
the	O	321-324
Norwegian	O	325-334
population	O	335-345
.	O	345-346

Index	O	347-352
cases	O	353-358
for	O	359-362
the	O	363-366
present	O	367-374
study	O	375-380
were	O	381-385
found	O	386-391
two	O	392-395
different	O	396-405
ways	O	406-410
through	O	412-419
a	O	420-421
series	O	422-428
of	O	429-431
consecutive	O	432-443
ovarian	B	444-451
cancers	I	452-459
(	O	460-461
n	O	461-462
=	O	463-464
16	O	465-467
)	O	467-468
and	O	469-472
through	O	473-480
our	O	481-484
family	O	485-491
cancer	B	492-498
clinic	O	499-505
(	O	506-507
n	O	507-508
=	O	509-510
14	O	511-513
)	O	513-514
.	O	514-515

Altogether	O	516-526
,	O	526-527
20	O	528-530
of	O	531-533
the	O	534-537
patients	O	538-546
had	O	547-550
BRCA1	O	551-556
1675delA	O	557-565
,	O	565-566
and	O	567-570
10	O	571-573
had	O	574-577
1135insA	O	578-586
.	O	586-587

Their	O	588-593
relatives	O	594-603
were	O	604-608
described	O	609-618
with	O	619-623
respect	O	624-631
to	O	632-634
absence	O	635-642
/	O	642-643
presence	O	643-651
of	O	652-654
breast	B	655-661
and	I	662-665
/	I	665-666
or	I	666-668
ovarian	I	669-676
cancer	I	677-683
.	O	683-684

Of	O	685-687
133	O	688-691
living	O	692-698
female	O	699-705
relatives	O	706-715
,	O	715-716
83	O	717-719
(	O	720-721
62	O	721-723
%	O	723-724
)	O	724-725
were	O	726-730
tested	O	731-737
for	O	738-741
the	O	742-745
presence	O	746-754
of	O	755-757
a	O	758-759
mutation	O	760-768
.	O	768-769

No	O	770-772
difference	O	773-783
,	O	783-784
in	O	785-787
penetrance	O	788-798
and	O	799-802
expression	O	803-813
,	O	813-814
between	O	815-822
the	O	823-826
two	O	827-830
mutations	O	831-840
were	O	841-845
found	O	846-851
,	O	851-852
whereas	O	853-860
differences	O	861-872
according	O	873-882
to	O	883-885
method	O	886-892
of	O	893-895
ascertainment	O	896-909
were	O	910-914
seen	O	915-919
.	O	919-920

The	O	921-924
overall	O	925-932
findings	O	933-941
were	O	942-946
that	O	947-951
disease	O	952-959
started	O	960-967
to	O	968-970
occur	O	971-976
at	O	977-979
age	O	980-983
30	O	984-986
years	O	987-992
and	O	993-996
that	O	997-1001
by	O	1002-1004
age	O	1005-1008
50	O	1009-1011
years	O	1012-1017
48	O	1018-1020
%	O	1020-1021
of	O	1022-1024
the	O	1025-1028
mutation	O	1029-1037
-	O	1037-1038
carrying	O	1038-1046
women	O	1047-1052
had	O	1053-1056
experienced	O	1057-1068
breast	B	1069-1075
and	I	1076-1079
/	I	1079-1080
or	I	1080-1082
ovarian	I	1083-1090
cancer	I	1091-1097
.	O	1097-1098

More	O	1099-1103
ovarian	B	1104-1111
cancers	I	1112-1119
than	O	1120-1124
breast	B	1125-1131
cancers	I	1132-1139
were	O	1140-1144
recorded	O	1145-1153
.	O	1153-1154

Both	O	1155-1159
penetrance	O	1160-1170
and	O	1171-1174
expression	O	1175-1185
(	O	1186-1187
breast	B	1187-1193
cancer	I	1194-1200
vs	O	1201-1203
.	O	1203-1204
ovarian	B	1205-1212
cancer	I	1213-1219
)	O	1219-1220
were	O	1221-1225
different	O	1226-1235
from	O	1236-1240
those	O	1241-1246
in	O	1247-1249
reports	O	1250-1257
of	O	1258-1260
the	O	1261-1264
Ashkenazi	O	1265-1274
founder	O	1275-1282
mutations	O	1283-1292
.	O	1292-1293

Whether	O	1294-1301
the	O	1302-1305
reported	O	1306-1314
differences	O	1315-1326
reflect	O	1327-1334
true	O	1335-1339
differences	O	1340-1351
and	O	1352-1355
/	O	1355-1356
or	O	1356-1358
methodological	O	1359-1373
problems	O	1374-1382
is	O	1383-1385
discussed	O	1386-1395
.	O	1395-1396

An	O	1397-1399
observed	O	1400-1408
excess	O	1409-1415
of	O	1416-1418
mutation	O	1419-1427
carriers	O	1428-1436
could	O	1437-1442
not	O	1443-1446
be	O	1447-1449
accounted	O	1450-1459
for	O	1460-1463
by	O	1464-1466
methodological	O	1467-1481
problems	O	1482-1490
;	O	1490-1491
possible	O	1492-1500
explanations	O	1501-1513
were	O	1514-1518
a	O	1519-1520
"	O	1521-1522
true	O	1523-1527
"	O	1528-1529
low	O	1530-1533
penetrance	O	1534-1544
or	O	1545-1547
preferential	O	1548-1560
segregation	O	1561-1572
.	O	1572-1573
.	O	1572-1573

Molecular	O	0-9
basis	O	10-15
of	O	16-18
subtotal	B	19-27
complement	I	28-38
C6	I	39-41
deficiency	I	42-52
.	O	52-53

A	O	54-55
carboxy	O	56-63
-	O	63-64
terminally	O	64-74
truncated	O	75-84
but	O	85-88
functionally	O	89-101
active	O	102-108
C6	O	109-111
.	O	111-112

Individuals	O	113-124
with	O	125-129
subtotal	B	130-138
complement	I	139-149
C6	I	150-152
deficiency	I	153-163
possess	O	164-171
a	O	172-173
C6	O	174-176
molecule	O	177-185
that	O	186-190
is	O	191-193
14	O	194-196
%	O	196-197
shorter	O	198-205
than	O	206-210
normal	O	211-217
C6	O	218-220
and	O	221-224
present	O	225-232
in	O	233-235
low	O	236-239
but	O	240-243
detectable	O	244-254
concentrations	O	255-269
(	O	270-271
1	O	271-272
-	O	272-273
2	O	273-274
%	O	274-275
of	O	276-278
the	O	279-282
normal	O	283-289
mean	O	290-294
)	O	294-295
.	O	295-296

We	O	297-299
now	O	300-303
show	O	304-308
that	O	309-313
this	O	314-318
dysmorphic	O	319-329
C6	O	330-332
is	O	333-335
bactericidally	O	336-350
active	O	351-357
and	O	358-361
lacks	O	362-367
an	O	368-370
epitope	O	371-378
that	O	379-383
was	O	384-387
mapped	O	388-394
to	O	395-397
the	O	398-401
most	O	402-406
carboxy	O	407-414
-	O	414-415
terminal	O	415-423
part	O	424-428
of	O	429-431
C6	O	432-434
using	O	435-440
C6	O	441-443
cDNA	O	444-448
fragments	O	449-458
expressed	O	459-468
as	O	469-471
fusion	O	472-478
proteins	O	479-487
in	O	488-490
the	O	491-494
pUEX	O	495-499
expression	O	500-510
system	O	511-517
.	O	517-518

We	O	519-521
thus	O	522-526
predicted	O	527-536
that	O	537-541
the	O	542-545
abnormal	O	546-554
C6	O	555-557
molecule	O	558-566
might	O	567-572
be	O	573-575
carboxy	O	576-583
-	O	583-584
terminally	O	584-594
truncated	O	595-604
and	O	605-608
sought	O	609-615
a	O	616-617
mutation	O	618-626
in	O	627-629
an	O	630-632
area	O	633-637
approximately	O	638-651
14	O	652-654
%	O	654-655
from	O	656-660
the	O	661-664
carboxy	O	665-672
-	O	672-673
terminal	O	673-681
end	O	682-685
of	O	686-688
the	O	689-692
coding	O	693-699
sequence	O	700-708
.	O	708-709

By	O	710-712
sequencing	O	713-723
PCR	O	724-727
-	O	727-728
amplified	O	728-737
products	O	738-746
from	O	747-751
this	O	752-756
region	O	757-763
,	O	763-764
we	O	765-767
found	O	768-773
,	O	773-774
in	O	775-777
three	O	778-783
individuals	O	784-795
from	O	796-800
two	O	801-804
families	O	805-813
,	O	813-814
a	O	815-816
mutation	O	817-825
that	O	826-830
might	O	831-836
plausibly	O	837-846
be	O	847-849
responsible	O	850-861
for	O	862-865
the	O	866-869
defect	O	870-876
.	O	876-877

All	O	878-881
three	O	882-887
have	O	888-892
an	O	893-895
abnormal	O	896-904
5	O	905-906
splice	O	907-913
donor	O	914-919
site	O	920-924
of	O	925-927
intron	O	928-934
15	O	935-937
,	O	937-938
which	O	939-944
would	O	945-950
probably	O	951-959
prevent	O	960-967
splicing	O	968-976
.	O	976-977

An	O	978-980
in	O	981-983
-	O	983-984
frame	O	984-989
stop	O	990-994
codon	O	995-1000
is	O	1001-1003
found	O	1004-1009
17	O	1010-1012
codons	O	1013-1019
downstream	O	1020-1030
from	O	1031-1035
the	O	1036-1039
intron	O	1040-1046
boundary	O	1047-1055
,	O	1055-1056
which	O	1057-1062
would	O	1063-1068
lead	O	1069-1073
to	O	1074-1076
a	O	1077-1078
truncated	O	1079-1088
polypeptide	O	1089-1100
13	O	1101-1103
.	O	1103-1104
5	O	1105-1106
%	O	1106-1107
smaller	O	1108-1115
than	O	1116-1120
normal	O	1121-1127
C6	O	1128-1130
.	O	1130-1131

This	O	1132-1136
result	O	1137-1143
was	O	1144-1147
unexpected	O	1148-1158
,	O	1158-1159
as	O	1160-1162
earlier	O	1163-1170
studies	O	1171-1178
mapped	O	1179-1185
the	O	1186-1189
C5b	O	1190-1193
binding	O	1194-1201
site	O	1202-1206
,	O	1206-1207
or	O	1208-1210
a	O	1211-1212
putative	O	1213-1221
enzymatic	O	1222-1231
region	O	1232-1238
,	O	1238-1239
to	O	1240-1242
this	O	1243-1247
part	O	1248-1252
of	O	1253-1255
C6	O	1256-1258
.	O	1258-1259

Interestingly	O	1260-1273
,	O	1273-1274
all	O	1275-1278
three	O	1279-1284
subjects	O	1285-1293
were	O	1294-1298
probably	O	1299-1307
heterozygous	O	1308-1320
for	O	1321-1324
both	O	1325-1329
subtotal	B	1330-1338
C6	I	1339-1341
and	I	1342-1345
complete	I	1346-1354
C6	I	1355-1357
deficiency	I	1358-1368
.	O	1368-1369

Mutations	O	0-9
of	O	10-12
the	O	13-16
VHL	B	17-20
gene	O	21-25
in	O	26-28
sporadic	B	29-37
renal	I	38-43
cell	I	44-48
carcinoma	I	49-58
:	O	58-59
definition	O	60-70
of	O	71-73
a	O	74-75
risk	O	76-80
factor	O	81-87
for	O	88-91
VHL	B	92-95
patients	O	96-104
to	O	105-107
develop	O	108-115
an	O	116-118
RCC	B	119-122
.	O	122-123

To	O	124-126
investigate	O	127-138
the	O	139-142
nature	O	143-149
of	O	150-152
somatic	O	153-160
von	B	161-164
Hippel	I	165-171
-	I	171-172
Lindau	I	172-178
(	O	179-180
VHL	B	180-183
)	O	183-184
mutations	O	185-194
,	O	194-195
we	O	196-198
analyzed	O	199-207
173	O	208-211
primary	O	212-219
sporadic	O	220-228
human	O	229-234
renal	B	235-240
cell	I	241-245
carcinomas	I	246-256
for	O	257-260
mutations	O	261-270
of	O	271-273
the	O	274-277
VHL	B	278-281
tumor	I	282-287
suppressor	O	288-298
gene	O	299-303
,	O	303-304
using	O	305-310
polymerase	O	311-321
chain	O	322-327
reaction	O	328-336
(	O	337-338
PCR	O	338-341
)	O	341-342
and	O	343-346
single	O	347-353
-	O	353-354
strand	O	354-360
conformational	O	361-375
polymorphism	O	376-388
analysis	O	389-397
(	O	398-399
SSCP	O	399-403
)	O	403-404
of	O	405-407
DNA	O	408-411
.	O	411-412

We	O	413-415
detected	O	416-424
abnormal	O	425-433
SSCP	O	434-438
pattern	O	439-446
in	O	447-449
73	O	450-452
samples	O	453-460
.	O	460-461

After	O	462-467
sequencing	O	468-478
,	O	478-479
we	O	480-482
identified	O	483-493
microdeletions	O	494-508
in	O	509-511
58	O	512-514
%	O	514-515
of	O	516-518
cases	O	519-524
,	O	524-525
microinsertions	O	526-541
in	O	542-544
17	O	545-547
%	O	547-548
,	O	548-549
nonsense	O	550-558
mutations	O	559-568
in	O	569-571
8	O	572-573
%	O	573-574
,	O	574-575
and	O	576-579
missense	O	580-588
mutations	O	589-598
in	O	599-601
17	O	602-604
%	O	604-605
.	O	605-606

Among	O	607-612
these	O	613-618
mutations	O	619-628
,	O	628-629
50	O	630-632
%	O	632-633
correspond	O	634-644
to	O	645-647
new	O	648-651
mutations	O	652-661
.	O	661-662

VHL	B	663-666
mutations	O	667-676
were	O	677-681
found	O	682-687
only	O	688-692
in	O	693-695
the	O	696-699
nonpapillary	B	700-712
renal	I	713-718
cell	I	719-723
carcinoma	I	724-733
(	O	734-735
RCC	B	735-738
)	O	738-739
subtype	O	740-747
,	O	747-748
as	O	749-751
previously	O	752-762
reported	O	763-771
.	O	771-772

To	O	773-775
compare	O	776-783
somatic	O	784-791
and	O	792-795
germline	O	796-804
mutations	O	805-814
,	O	814-815
we	O	816-818
used	O	819-823
the	O	824-827
VHL	B	828-831
database	O	832-840
,	O	840-841
which	O	842-847
includes	O	848-856
507	O	857-860
mutations	O	861-870
.	O	870-871

The	O	872-875
study	O	876-881
of	O	882-884
mutational	O	885-895
events	O	896-902
revealed	O	903-911
a	O	912-913
significant	O	914-925
difference	O	926-936
between	O	937-944
somatic	O	945-952
and	O	953-956
germline	O	957-965
mutations	O	966-975
with	O	976-980
mutations	O	981-990
leading	O	991-998
to	O	999-1001
truncated	O	1002-1011
proteins	O	1012-1020
observed	O	1021-1029
in	O	1030-1032
78	O	1033-1035
%	O	1035-1036
of	O	1037-1039
somatic	O	1040-1047
mutations	O	1048-1057
vs	O	1058-1060
only	O	1061-1065
37	O	1066-1068
%	O	1068-1069
in	O	1070-1072
germline	O	1073-1081
mutations	O	1082-1091
(	O	1092-1093
P	O	1093-1094
<	O	1095-1096
0	O	1097-1098
.	O	1098-1099
001	O	1100-1103
)	O	1103-1104
.	O	1104-1105

We	O	1106-1108
postulated	O	1109-1119
that	O	1120-1124
a	O	1125-1126
specific	O	1127-1135
pattern	O	1136-1143
of	O	1144-1146
VHL	B	1147-1150
mutations	O	1151-1160
is	O	1161-1163
associated	O	1164-1174
with	O	1175-1179
sporadic	B	1180-1188
RCC	I	1189-1192
.	O	1192-1193

This	O	1194-1198
pattern	O	1199-1206
corresponds	O	1207-1218
to	O	1219-1221
mutations	O	1222-1231
leading	O	1232-1239
mainly	O	1240-1246
to	O	1247-1249
truncated	O	1250-1259
proteins	O	1260-1268
with	O	1269-1273
few	O	1274-1277
specific	O	1278-1286
missense	O	1287-1295
mutations	O	1296-1305
.	O	1305-1306

We	O	1307-1309
then	O	1310-1314
analyzed	O	1315-1323
the	O	1324-1327
occurrence	O	1328-1338
of	O	1339-1341
RCC	B	1342-1345
in	O	1346-1348
VHL	B	1349-1352
families	O	1353-1361
,	O	1361-1362
based	O	1363-1368
on	O	1369-1371
the	O	1372-1375
nature	O	1376-1382
of	O	1383-1385
mutations	O	1386-1395
.	O	1395-1396

We	O	1397-1399
observed	O	1400-1408
RCC	B	1409-1412
in	O	1413-1415
at	O	1416-1418
least	O	1419-1424
one	O	1425-1428
member	O	1429-1435
of	O	1436-1438
the	O	1439-1442
VHL	B	1443-1446
families	O	1447-1455
in	O	1456-1458
77	O	1459-1461
%	O	1461-1462
of	O	1463-1465
cases	O	1466-1471
with	O	1472-1476
mutations	O	1477-1486
leading	O	1487-1494
to	O	1495-1497
truncated	O	1498-1507
proteins	O	1508-1516
versus	O	1517-1523
55	O	1524-1526
%	O	1526-1527
in	O	1528-1530
cases	O	1531-1536
with	O	1537-1541
missense	O	1542-1550
mutations	O	1551-1560
(	O	1561-1562
P	O	1562-1563
<	O	1564-1565
0	O	1566-1567
.	O	1567-1568
05	O	1569-1571
)	O	1571-1572
.	O	1572-1573

Thus	O	1574-1578
,	O	1578-1579
mutations	O	1580-1589
resulting	O	1590-1599
in	O	1600-1602
truncated	O	1603-1612
proteins	O	1613-1621
may	O	1622-1625
lead	O	1626-1630
to	O	1631-1633
a	O	1634-1635
higher	O	1636-1642
risk	O	1643-1647
of	O	1648-1650
RCC	B	1651-1654
in	O	1655-1657
VHL	B	1658-1661
patients	O	1662-1670

Evidence	O	0-8
for	O	9-12
inter	O	13-18
-	O	18-19
generational	O	19-31
instability	O	32-43
in	O	44-46
the	O	47-50
CAG	O	51-54
repeat	O	55-61
in	O	62-64
the	O	65-68
MJD1	O	69-73
gene	O	74-78
and	O	79-82
for	O	83-86
conserved	O	87-96
haplotypes	O	97-107
at	O	108-110
flanking	O	111-119
markers	O	120-127
amongst	O	128-135
Japanese	O	136-144
and	O	145-148
Caucasian	O	149-158
subjects	O	159-167
with	O	168-172
Machado	B	173-180
-	I	180-181
Joseph	I	181-187
disease	I	188-195
.	O	195-196

The	O	197-200
size	O	201-205
of	O	206-208
the	O	209-212
(	O	213-214
CAG	O	214-217
)	O	217-218
n	O	218-219
repeat	O	220-226
array	O	227-232
in	O	233-235
the	O	236-239
3	O	240-241
'	O	241-242
end	O	243-246
of	O	247-249
the	O	250-253
MJD1	O	254-258
gene	O	259-263
and	O	264-267
the	O	268-271
haplotype	O	272-281
at	O	282-284
a	O	285-286
series	O	287-293
of	O	294-296
microsatellite	O	297-311
markers	O	312-319
surrounding	O	320-331
the	O	332-335
MJD1	O	336-340
gene	O	341-345
were	O	346-350
examined	O	351-359
in	O	360-362
a	O	363-364
large	O	365-370
cohort	O	371-377
of	O	378-380
Japanese	O	381-389
and	O	390-393
Caucasian	O	394-403
subjects	O	404-412
affected	O	413-421
with	O	422-426
Machado	B	427-434
-	I	434-435
Joseph	I	435-441
disease	I	442-449
(	O	450-451
MJD	B	451-454
)	O	454-455
.	O	455-456

Our	O	457-460
data	O	461-465
provide	O	466-473
five	O	474-478
novel	O	479-484
observations	O	485-497
.	O	497-498

First	O	499-504
,	O	504-505
MJD	B	506-509
is	O	510-512
associated	O	513-523
with	O	524-528
expansion	O	529-538
fo	O	539-541
the	O	542-545
array	O	546-551
from	O	552-556
the	O	557-560
normal	O	561-567
range	O	568-573
of	O	574-576
14	O	577-579
-	O	579-580
37	O	580-582
repeats	O	583-590
to	O	591-593
68	O	594-596
-	O	596-597
84	O	597-599
repeats	O	600-607
in	O	608-610
most	O	611-615
Japanese	O	616-624
and	O	625-628
Caucasian	O	629-638
subjects	O	639-647
,	O	647-648
but	O	649-652
no	O	653-655
subjects	O	656-664
were	O	665-669
observed	O	670-678
with	O	679-683
expansions	O	684-694
intermediate	O	695-707
in	O	708-710
size	O	711-715
between	O	716-723
those	O	724-729
of	O	730-732
the	O	733-736
normal	O	737-743
and	O	744-747
MJD	B	748-751
affected	O	752-760
groups	O	761-767
.	O	767-768

Second	O	769-775
,	O	775-776
the	O	777-780
expanded	O	781-789
allele	O	790-796
associated	O	797-807
with	O	808-812
MJD	B	813-816
displays	O	817-825
inter	O	826-831
-	O	831-832
generational	O	832-844
instability	O	845-856
,	O	856-857
particularly	O	858-870
in	O	871-873
male	O	874-878
meioses	O	879-886
,	O	886-887
and	O	888-891
this	O	892-896
instability	O	897-908
was	O	909-912
associated	O	913-923
with	O	924-928
the	O	929-932
clinical	O	933-941
phenomenon	O	942-952
of	O	953-955
anticipation	O	956-968
.	O	968-969

Third	O	970-975
,	O	975-976
the	O	977-980
size	O	981-985
of	O	986-988
the	O	989-992
expanded	O	993-1001
allele	O	1002-1008
is	O	1009-1011
not	O	1012-1015
only	O	1016-1020
inversely	O	1021-1030
correlated	O	1031-1041
with	O	1042-1046
the	O	1047-1050
age	O	1051-1054
-	O	1054-1055
of	O	1055-1057
-	O	1054-1055
onset	O	1058-1063
of	O	1064-1066
MJD	B	1067-1070
(	O	1071-1072
r	O	1072-1073
=	O	1074-1075
-	O	1076-1077
0	O	1077-1078
.	O	1078-1079
738	O	1079-1082
,	O	1082-1083

p	O	1084-1085
<	O	1086-1087
0	O	1088-1089
.	O	1089-1090
001	O	1090-1093
)	O	1093-1094
,	O	1094-1095
but	O	1096-1099
is	O	1100-1102
also	O	1103-1107
correlated	O	1108-1118
with	O	1119-1123
the	O	1124-1127
frequency	O	1128-1137
of	O	1138-1140
other	O	1141-1146
clinical	O	1147-1155
features	O	1156-1164
[	O	1165-1166
e	O	1166-1167
.	O	1167-1168
g	O	1168-1169
.	O	1167-1168

pseudoexophthalmos	O	1171-1189
and	O	1190-1193
pyramidal	O	1194-1203
signs	O	1204-1209
were	O	1210-1214
more	O	1215-1219
frequent	O	1220-1228
in	O	1229-1231
subjects	O	1232-1240
with	O	1241-1245
large	O	1246-1251
repeats	O	1252-1259
(	O	1260-1261
p	O	1261-1262
<	O	1263-1264
0	O	1265-1266
.	O	1266-1267
001	O	1267-1270
and	O	1271-1274
p	O	1275-1276
<	O	1277-1278
0	O	1279-1280
.	O	1280-1281
05	O	1281-1283
respectively	O	1284-1296
)	O	1296-1297
]	O	1297-1298
.	O	1298-1299

Fourth	O	1300-1306
,	O	1306-1307
the	O	1308-1311
disease	O	1312-1319
phenotype	O	1320-1329
is	O	1330-1332
significantly	O	1333-1346
more	O	1347-1351
severe	O	1352-1358
and	O	1359-1362
had	O	1363-1366
an	O	1367-1369
early	O	1370-1375
age	O	1376-1379
of	O	1380-1382
onset	O	1383-1388
(	O	1389-1390
16	O	1390-1392
years	O	1393-1398
)	O	1398-1399
in	O	1400-1402
a	O	1403-1404
subject	O	1405-1412
homozygous	O	1413-1423
for	O	1424-1427
the	O	1428-1431
expanded	O	1432-1440
allele	O	1441-1447
,	O	1447-1448
which	O	1449-1454
contrasts	O	1455-1464
with	O	1465-1469
Huntington	B	1470-1480
disease	I	1481-1488
and	O	1489-1492
suggests	O	1493-1501
that	O	1502-1506
the	O	1507-1510
expanded	O	1511-1519
allele	O	1520-1526
in	O	1527-1529
the	O	1530-1533
MJD1	O	1534-1538
gene	O	1539-1543
could	O	1544-1549
exert	O	1550-1555
its	O	1556-1559
effect	O	1560-1566
either	O	1567-1573
by	O	1574-1576
a	O	1577-1578
dominant	O	1579-1587
negative	O	1588-1596
effect	O	1597-1603
(	O	1604-1605
putatively	O	1605-1615
excluded	O	1616-1624
in	O	1625-1627
HD	B	1628-1630
)	O	1630-1631
or	O	1632-1634
by	O	1635-1637
a	O	1638-1639
gain	O	1640-1644
of	O	1645-1647
function	O	1648-1656
effect	O	1657-1663
as	O	1664-1666
proposed	O	1667-1675
for	O	1676-1679
HD	B	1680-1682
.	O	1682-1683

Finally	O	1684-1691
,	O	1691-1692
Japanese	O	1693-1701
and	O	1702-1705
Caucasian	O	1706-1715
subjects	O	1716-1724
affected	O	1725-1733
with	O	1734-1738
MJD	B	1739-1742
share	O	1743-1748
haplotypes	O	1749-1759
at	O	1760-1762
several	O	1763-1770
markers	O	1771-1778
surrounding	O	1779-1790
the	O	1791-1794
MJD1	O	1795-1799
gene	O	1800-1804
,	O	1804-1805
which	O	1806-1811
are	O	1812-1815
uncommon	O	1816-1824
in	O	1825-1827
the	O	1828-1831
normal	O	1832-1838
Japanese	O	1839-1847
and	O	1848-1851
Caucasian	O	1852-1861
population	O	1862-1872
,	O	1872-1873
and	O	1874-1877
which	O	1878-1883
suggests	O	1884-1892
the	O	1893-1896
existence	O	1897-1906
either	O	1907-1913
of	O	1914-1916
common	O	1917-1923
founders	O	1924-1932
in	O	1933-1935
these	O	1936-1941
populations	O	1942-1953
or	O	1954-1956
of	O	1957-1959
chromosomes	O	1960-1971
susceptible	O	1972-1983
to	O	1984-1986
pathologic	O	1987-1997
expansion	O	1998-2007
of	O	2008-2010
the	O	2011-2014
CAG	O	2015-2018
repeat	O	2019-2025
in	O	2026-2028
the	O	2029-2032
MJD1	O	2033-2037
gene	O	2038-2042
.	O	2042-2043

Myotonic	B	0-8
dystrophy	I	9-18
:	O	18-19
the	O	20-23
role	O	24-28
of	O	29-31
the	O	32-35
CUG	O	36-39
triplet	O	40-47
repeats	O	48-55
in	O	56-58
splicing	O	59-67
of	O	68-70
a	O	71-72
novel	O	73-78
DMPK	O	79-83
exon	O	84-88
and	O	89-92
altered	O	93-100
cytoplasmic	O	101-112
DMPK	O	113-117
mRNA	O	118-122
isoform	O	123-130
ratios	O	131-137
.	O	137-138

The	O	139-142
mechanism	O	143-152
by	O	153-155
which	O	156-161
(	O	162-163
CTG	O	163-166
)	O	166-167
n	O	168-169
expansion	O	170-179
in	O	180-182
the	O	183-186
3	O	187-188
UTR	O	189-192
of	O	193-195
the	O	196-199
DMPK	O	200-204
gene	O	205-209
causes	O	210-216
myotonic	B	217-225
dystrophy	I	226-235
(	O	236-237
DM	B	237-239
)	O	239-240
is	O	241-243
unknown	O	244-251
.	O	251-252

We	O	253-255
identified	O	256-266
four	O	267-271
RNA	O	272-275
splicing	O	276-284
factors	O	285-292
-	O	292-293
-	O	292-293
hnRNP	O	294-299
C	O	300-301
,	O	301-302
U2AF	O	303-307
(	O	308-309
U2	O	309-311
auxiliary	O	312-321
factor	O	322-328
)	O	328-329
,	O	329-330
PTB	O	331-334
(	O	335-336
polypyrimidine	O	336-350
tract	O	351-356
binding	O	357-364
protein	O	365-372
)	O	372-373
,	O	373-374
and	O	375-378
PSF	O	379-382
(	O	383-384
PTB	O	384-387
associated	O	388-398
splicing	O	399-407
factor	O	408-414
)	O	414-415
-	O	416-417
-	O	416-417
that	O	418-422
bind	O	423-427
to	O	428-430
two	O	431-434
short	O	435-440
regions	O	441-448
3	O	449-450
of	O	451-453
the	O	454-457
(	O	458-459
CUG	O	459-462
)	O	462-463
n	O	464-465
,	O	465-466
and	O	467-470
found	O	471-476
a	O	477-478
novel	O	479-484
3	O	485-486
DMPK	O	487-491
exon	O	492-496
resulting	O	497-506
in	O	507-509
an	O	510-512
mRNA	O	513-517
lacking	O	518-525
the	O	526-529
repeats	O	530-537
.	O	537-538

We	O	539-541
propose	O	542-549
that	O	550-554
the	O	555-558
(	O	559-560
CUG	O	560-563
)	O	563-564
n	O	565-566
is	O	567-569
an	O	570-572
essential	O	573-582
cis	O	583-586
acting	O	587-593
element	O	594-601
for	O	602-605
this	O	606-610
splicing	O	611-619
event	O	620-625
.	O	625-626

In	O	627-629
contrast	O	630-638
to	O	639-641
(	O	642-643
CUG	O	643-646
)	O	646-647
n	O	648-649
containing	O	650-660
mRNAs	O	661-666
,	O	666-667
the	O	668-671
novel	O	672-677
isoform	O	678-685
is	O	686-688
not	O	689-692
retained	O	693-701
in	O	702-704
the	O	705-708
nucleus	O	709-716
in	O	717-719
DM	B	720-722
cells	O	723-728
,	O	728-729
resulting	O	730-739
in	O	740-742
imbalances	O	743-753
in	O	754-756
relative	O	757-765
levels	O	766-772
of	O	773-775
cytoplasmic	O	776-787
DMPK	O	788-792
mRNA	O	793-797
isoforms	O	798-806
and	O	807-810
a	O	811-812
new	O	813-816
dominant	O	817-825
effect	O	826-832
of	O	833-835
the	O	836-839
mutation	O	840-848
on	O	849-851
DMPK	O	852-856
.	O	856-857
.	O	856-857

Mechanism	O	0-9
of	O	10-12
increased	O	13-22
iron	O	23-27
absorption	O	28-38
in	O	39-41
murine	O	42-48
model	O	49-54
of	O	55-57
hereditary	B	58-68
hemochromatosis	I	69-84
:	O	85-86
increased	O	87-96
duodenal	O	97-105
expression	O	106-116
of	O	117-119
the	O	120-123
iron	O	124-128
transporter	O	129-140
DMT1	O	141-145
.	O	145-146

Hereditary	B	147-157
hemochromatosis	I	158-173
(	O	174-175
HH	B	175-177
)	O	177-178
is	O	179-181
a	O	182-183
common	O	184-190
autosomal	B	191-200
recessive	I	201-210
disorder	I	211-219
characterized	O	220-233
by	O	234-236
tissue	O	237-243
iron	O	244-248
deposition	O	249-259
secondary	O	260-269
to	O	270-272
excessive	O	273-282
dietary	O	283-290
iron	O	291-295
absorption	O	296-306
.	O	306-307

We	O	308-310
recently	O	311-319
reported	O	320-328
that	O	329-333
HFE	O	334-337
,	O	337-338
the	O	339-342
protein	O	343-350
defective	O	351-360
in	O	361-363
HH	B	364-366
,	O	366-367
was	O	368-371
physically	O	372-382
associated	O	383-393
with	O	394-398
the	O	399-402
transferrin	O	403-414
receptor	O	415-423
(	O	424-425
TfR	O	425-428
)	O	428-429
in	O	430-432
duodenal	O	433-441
crypt	O	442-447
cells	O	448-453
and	O	454-457
proposed	O	458-466
that	O	467-471
mutations	O	472-481
in	O	482-484
HFE	O	485-488
attenuate	O	489-498
the	O	499-502
uptake	O	503-509
of	O	510-512
transferrin	O	513-524
-	O	524-525
bound	O	525-530
iron	O	531-535
from	O	536-540
plasma	O	541-547
by	O	548-550
duodenal	O	551-559
crypt	O	560-565
cells	O	566-571
,	O	571-572
leading	O	573-580
to	O	581-583
up	O	584-586
-	O	586-587
regulation	O	587-597
of	O	598-600
transporters	O	601-613
for	O	614-617
dietary	O	618-625
iron	O	626-630
.	O	630-631

Here	O	632-636
,	O	636-637
we	O	638-640
tested	O	641-647
the	O	648-651
hypothesis	O	652-662
that	O	663-667
HFE	O	668-671
-	O	671-672
/	O	672-673
-	O	671-672
mice	O	675-679
have	O	680-684
increased	O	685-694
duodenal	O	695-703
expression	O	704-714
of	O	715-717
the	O	718-721
divalent	O	722-730
metal	O	731-736
transporter	O	737-748
(	O	749-750
DMT1	O	750-754
)	O	754-755
.	O	755-756

By	O	757-759
4	O	760-761
weeks	O	762-767
of	O	768-770
age	O	771-774
,	O	774-775
the	O	776-779
HFE	O	780-783
-	O	783-784
/	O	784-785
-	O	783-784
mice	O	787-791
demonstrated	O	792-804
iron	O	805-809
loading	O	810-817
when	O	818-822
compared	O	823-831
with	O	832-836
HFE	O	837-840
+	O	841-842
/	O	842-843
+	O	841-842
littermates	O	845-856
,	O	856-857
with	O	858-862
elevated	O	863-871
transferrin	O	872-883
saturations	O	884-895
(	O	896-897
68	O	897-899
.	O	899-900

4	O	901-902
%	O	902-903
vs	O	904-906
.	O	906-907
49	O	908-910
.	O	910-911

8	O	912-913
%	O	913-914
)	O	914-915
and	O	916-919
elevated	O	920-928
liver	O	929-934
iron	O	935-939
concentrations	O	940-954
(	O	955-956
985	O	956-959
micrograms	O	960-970
vs	O	971-973
.	O	973-974
381	O	975-978
micrograms	O	979-989
)	O	989-990
.	O	990-991

By	O	992-994
using	O	995-1000
Northern	O	1001-1009
blot	O	1010-1014
analyses	O	1015-1023
,	O	1023-1024
we	O	1025-1027
quantitated	O	1028-1039
duodenal	O	1040-1048
expression	O	1049-1059
of	O	1060-1062
both	O	1063-1067
classes	O	1068-1075
of	O	1076-1078
DMT1	O	1079-1083
transcripts	O	1084-1095
one	O	1097-1100
containing	O	1101-1111
an	O	1112-1114
iron	O	1115-1119
responsive	O	1120-1130
element	O	1131-1138
(	O	1139-1140
IRE	O	1140-1143
)	O	1143-1144
,	O	1144-1145
called	O	1146-1152
DMT1	O	1153-1157
(	O	1158-1159
IRE	O	1159-1162
)	O	1162-1163
,	O	1163-1164
and	O	1165-1168
one	O	1169-1172
containing	O	1173-1183
no	O	1184-1186
IRE	O	1187-1190
,	O	1190-1191
called	O	1192-1198
DMT1	O	1199-1203
(	O	1204-1205
non	O	1205-1208
-	O	1208-1209
IRE	O	1209-1212
)	O	1212-1213
.	O	1213-1214

The	O	1215-1218
positive	O	1219-1227
control	O	1228-1235
for	O	1236-1239
DMT1	O	1240-1244
up	O	1245-1247
-	O	1247-1248
regulation	O	1248-1258
was	O	1259-1262
a	O	1263-1264
murine	O	1265-1271
model	O	1272-1277
of	O	1278-1280
dietary	B	1281-1288
iron	I	1289-1293
deficiency	I	1294-1304
that	O	1305-1309
demonstrated	O	1310-1322
greatly	O	1323-1330
increased	O	1331-1340
levels	O	1341-1347
of	O	1348-1350
duodenal	O	1351-1359
DMT1	O	1360-1364
(	O	1365-1366
IRE	O	1366-1369
)	O	1369-1370
mRNA	O	1371-1375
.	O	1375-1376

HFE	O	1377-1380
-	O	1380-1381
/	O	1381-1382
-	O	1380-1381
mice	O	1384-1388
also	O	1389-1393
demonstrated	O	1394-1406
an	O	1407-1409
increase	O	1410-1418
in	O	1419-1421
duodenal	O	1422-1430
DMT1	O	1431-1435
(	O	1436-1437
IRE	O	1437-1440
)	O	1440-1441
mRNA	O	1442-1446
(	O	1447-1448
average	O	1448-1455
7	O	1456-1457
.	O	1457-1458
7	O	1459-1460
-	O	1460-1461
fold	O	1461-1465
)	O	1465-1466
,	O	1466-1467
despite	O	1468-1475
their	O	1476-1481
elevated	O	1482-1490
transferrin	O	1491-1502
saturation	O	1503-1513
and	O	1514-1517
hepatic	O	1518-1525
iron	O	1526-1530
content	O	1531-1538
.	O	1538-1539

Duodenal	O	1540-1548
expression	O	1549-1559
of	O	1560-1562
DMT1	O	1563-1567
(	O	1568-1569
non	O	1569-1572
-	O	1572-1573
IRE	O	1573-1576
)	O	1576-1577
was	O	1578-1581
not	O	1582-1585
increased	O	1586-1595
,	O	1595-1596
nor	O	1597-1600
was	O	1601-1604
hepatic	O	1605-1612
expression	O	1613-1623
of	O	1624-1626
DMT1	O	1627-1631
increased	O	1632-1641
.	O	1641-1642

These	O	1643-1648
data	O	1649-1653
support	O	1654-1661
the	O	1662-1665
model	O	1666-1671
for	O	1672-1675
HH	O	1676-1678
in	O	1679-1681
which	O	1682-1687
HFE	O	1688-1691
mutations	O	1692-1701
lead	O	1702-1706
to	O	1707-1709
inappropriately	O	1710-1725
low	O	1726-1729
crypt	O	1730-1735
cell	O	1736-1740
iron	O	1741-1745
,	O	1745-1746
with	O	1747-1751
resultant	O	1752-1761
stabilization	O	1762-1775
of	O	1776-1778
DMT1	O	1779-1783
(	O	1784-1785
IRE	O	1785-1788
)	O	1788-1789
mRNA	O	1790-1794
,	O	1794-1795
up	O	1796-1798
-	O	1798-1799
regulation	O	1799-1809
of	O	1810-1812
DMT1	O	1813-1817
,	O	1817-1818
and	O	1819-1822
increased	O	1823-1832
absorption	O	1833-1843
of	O	1844-1846
dietary	O	1847-1854
iron	O	1855-1859
.	O	1859-1860

Yeast	O	0-5
artificial	O	6-16
chromosomes	O	17-28
for	O	29-32
the	O	33-36
molecular	O	37-46
analysis	O	47-55
of	O	56-58
the	O	59-62
familial	B	63-71
polyposis	I	72-81
APC	I	82-85
gene	O	86-90
region	O	91-97
.	O	97-98

Two	O	99-102
yeast	O	103-108
artificial	O	109-119
chromosomes	O	120-131
(	O	132-133
YACs	O	133-137
)	O	137-138
spanning	O	139-147
a	O	148-149
total	O	150-155
distance	O	156-164
of	O	165-167
1	O	168-169
.	O	169-170
1	O	171-172
megabase	O	173-181
pairs	O	182-187
of	O	188-190
DNA	O	191-194
around	O	195-201
the	O	202-205
MCC	O	206-209
(	O	210-211
for	O	211-214
mutated	O	215-222
in	O	223-225
colorectal	B	226-236
carcinoma	I	237-246
)	O	246-247
and	O	248-251
APC	B	252-255
(	O	256-257
for	O	257-260
adenomatous	B	261-272
polyposis	I	273-282
coli	I	283-287
)	O	287-288
genes	O	289-294
at	O	295-297
5q21	O	298-302
have	O	303-307
been	O	308-312
isolated	O	313-321
and	O	322-325
characterized	O	326-339
.	O	339-340

Starting	O	341-349
from	O	350-354
the	O	355-358
MCC	O	359-362
gene	O	363-367
,	O	367-368
a	O	369-370
strategy	O	371-379
was	O	380-383
undertaken	O	384-394
to	O	395-397
identify	O	398-406
constitutional	O	407-421
submicroscopic	O	422-436
deletions	O	437-446
in	O	447-449
familial	B	450-458
adenomatous	I	459-470
polyposis	I	471-480
patients	O	481-489
that	O	490-494
might	O	495-500
considerably	O	501-513
narrow	O	514-520
down	O	521-525
the	O	526-529
position	O	530-538
of	O	539-541
the	O	542-545
APC	B	546-549
gene	O	550-554
.	O	554-555

To	O	556-558
this	O	559-563
end	O	564-567
,	O	567-568
YACs	O	569-573
identified	O	574-584
by	O	585-587
the	O	588-591
MCC	O	592-595
gene	O	596-600
were	O	601-605
screened	O	606-614
across	O	615-621
a	O	622-623
chromosome	O	624-634
5	O	635-636
-	O	636-637
specific	O	637-645
cosmid	O	646-652
library	O	653-660
to	O	661-663
provide	O	664-671
a	O	672-673
source	O	674-680
of	O	681-683
DNA	O	684-687
probes	O	688-694
for	O	695-698
genomic	O	699-706
scanning	O	707-715
.	O	715-716

The	O	717-720
cosmids	O	721-728
isolated	O	729-737
from	O	738-742
these	O	743-748
experiments	O	749-760
were	O	761-765
used	O	766-770
to	O	771-773
screen	O	774-780
a	O	781-782
panel	O	783-788
of	O	789-791
somatic	O	792-799
cell	O	800-804
hybrids	O	805-812
containing	O	813-823
chromosome	O	824-834
5	O	835-836
segregated	O	837-847
from	O	848-852
patients	O	853-861
suspected	O	862-871
to	O	872-874
carry	O	875-880
putative	O	881-889
interstitial	O	890-902
deletions	O	903-912
.	O	912-913

This	O	914-918
screening	O	919-928
approach	O	929-937
led	O	938-941
to	O	942-944
the	O	945-948
confirmation	O	949-961
of	O	962-964
a	O	965-966
small	O	967-972
heterozygous	O	973-985
deletion	O	986-994
in	O	995-997
a	O	998-999
polyposis	B	1000-1009
patient	O	1010-1017
that	O	1018-1022
overlaps	O	1023-1031
one	O	1032-1035
of	O	1036-1038
the	O	1039-1042
two	O	1043-1046
isolated	O	1047-1055
YACs	O	1056-1060
.	O	1060-1061

This	O	1062-1066
YAC	O	1067-1070
has	O	1071-1074
been	O	1075-1079
shown	O	1080-1085
to	O	1086-1088
contain	O	1089-1096
the	O	1097-1100
entire	O	1101-1107
APC	B	1108-1111
gene	O	1112-1116
,	O	1116-1117
in	O	1118-1120
addition	O	1121-1129
to	O	1130-1132
a	O	1133-1134
significant	O	1135-1146
portion	O	1147-1154
of	O	1155-1157
DNA	O	1158-1161
flanking	O	1162-1170
the	O	1171-1174
5	O	1175-1176
end	O	1177-1180
of	O	1181-1183
the	O	1184-1187
gene	O	1188-1192
,	O	1192-1193
and	O	1194-1197
should	O	1198-1204
therefore	O	1205-1214
prove	O	1215-1220
a	O	1221-1222
valuable	O	1223-1231
resource	O	1232-1240
for	O	1241-1244
functional	O	1245-1255
studies	O	1256-1263
by	O	1264-1266
transfer	O	1267-1275
to	O	1276-1278
colorectal	B	1279-1289
tumor	I	1290-1295
-	O	1295-1296
derived	O	1296-1303
cell	O	1304-1308
lines	O	1309-1314
.	O	1314-1315

Analbuminemia	B	0-13
in	O	14-16
an	O	17-19
American	O	20-28
Indian	O	29-35
girl	O	36-40
.	O	40-41

Analbuminemia	B	42-55
was	O	56-59
fortuitously	O	60-72
detected	O	73-81
in	O	82-84
a	O	85-86
nonedematous	O	87-99
12	O	100-102
-	O	102-103
year	O	103-107
-	O	102-103
old	O	108-111
American	O	112-120
Indian	O	121-127
girl	O	128-132
with	O	133-137
atopic	B	138-144
dermatitis	I	145-155
,	O	155-156
mild	O	157-161
bronchial	B	162-171
asthma	I	172-178
,	O	178-179
a	O	180-181
mild	O	182-186
seizure	B	187-194
disorder	I	195-203
,	O	203-204
and	O	205-208
hyperlipoproteinemia	B	209-229
with	O	230-234
a	O	235-236
corneal	B	237-244
arcus	I	245-250
.	O	250-251

Immunologic	O	252-263
methods	O	264-271
revealed	O	272-280
trace	O	281-286
amounts	O	287-294
(	O	295-296
17	O	296-298
mg	O	299-301
/	O	301-302
100	O	302-305
ml	O	306-308
)	O	308-309
of	O	310-312
apparently	O	313-323
normal	O	324-330
serum	O	331-336
albumin	O	337-344
.	O	344-345

The	O	346-349
patients	O	350-358
parents	O	359-366
were	O	367-371
remotely	O	372-380
related	O	381-388
.	O	388-389

The	O	390-393
pedigree	O	394-402
and	O	403-406
clinical	O	407-415
findings	O	416-424
were	O	425-429
compatible	O	430-440
with	O	441-445
autosomal	O	446-455
recessive	O	456-465
transmission	O	466-478
of	O	479-481
analbuminemia	B	482-495
.	O	495-496

Heterozygotes	O	497-510
had	O	511-514
subnormal	O	515-524
levels	O	525-531
of	O	532-534
serum	O	535-540
albumin	O	541-548
.	O	548-549

The	O	550-553
Gc	O	554-556
-	O	556-557
locus	O	557-562
is	O	563-565
closely	O	566-573
linked	O	574-580
to	O	581-583
the	O	584-587
structural	O	588-598
albumin	O	599-606
locus	O	607-612
.	O	612-613

Gc	O	614-616
-	O	616-617
protein	O	617-624
levels	O	625-631
were	O	632-636
normal	O	637-643
in	O	644-646
the	O	647-650
patient	O	651-658
and	O	659-662
together	O	663-671
with	O	672-676
normal	O	677-683
chromosomal	O	684-695
banding	O	696-703
studies	O	704-711
make	O	712-716
it	O	717-719
unlikely	O	720-728
that	O	729-733
a	O	734-735
chromosomal	O	736-747
deletion	O	748-756
caused	O	757-763
analbuminemia	B	764-777
.	O	777-778

Gc	O	779-781
-	O	781-782
types	O	782-787
in	O	788-790
the	O	791-794
family	O	795-801
were	O	802-806
compatible	O	807-817
with	O	818-822
,	O	822-823
but	O	824-827
did	O	828-831
not	O	832-835
prove	O	836-841
,	O	841-842
linkage	O	843-850
of	O	851-853
analbuminemia	B	854-867
to	O	868-870
the	O	871-874
Gc	O	875-877
-	O	877-878
locus	O	878-883
.	O	883-884

These	O	885-890
findings	O	891-899
suggest	O	900-907
a	O	908-909
"	O	910-911
thalassemia	B	912-923
"	O	924-925
-	O	926-927
like	O	927-931
mutation	O	932-940
for	O	941-944
this	O	945-949
disorder	O	950-958
.	O	958-959
.	O	958-959

Treatment	O	0-9
of	O	10-12
Duchenne	B	13-21
muscular	I	22-30
dystrophy	I	31-40
with	O	41-45
growth	O	46-52
hormone	O	53-60
inhibitors	O	61-71
.	O	71-72

A	O	73-74
controlled	O	75-85
,	O	85-86
double	O	87-93
-	O	93-94
blind	O	94-99
therapeutic	O	100-111
trial	O	112-117
with	O	118-122
the	O	123-126
drug	O	127-131
mazindol	O	132-140
,	O	140-141
a	O	142-143
growth	O	144-150
hormone	O	151-158
inhibitor	O	159-168
,	O	168-169
was	O	170-173
performed	O	174-183
in	O	184-186
a	O	187-188
pair	O	189-193
of	O	194-196
7	O	197-198
1	O	199-200
/	O	200-201
2	O	201-202
year	O	203-207
-	O	207-208
old	O	208-211
monozygotic	O	212-223
twins	O	224-229
,	O	229-230
with	O	231-235
Duchenne	B	236-244
muscular	I	245-253
dystrophy	I	254-263
(	O	264-265
DMD	B	265-268
)	O	268-269
.	O	269-270

The	O	271-274
rationale	O	275-284
for	O	285-288
this	O	289-293
trial	O	294-299
was	O	300-303
based	O	304-309
on	O	310-312
a	O	313-314
patient	O	315-322
(	O	323-324
reported	O	324-332
previously	O	333-343
)	O	343-344
affected	O	345-353
simultaneously	O	354-368
with	O	369-373
DMD	B	374-377
and	O	378-381
growth	B	382-388
hormone	I	389-396
(	I	397-398
GH	I	398-400
)	I	400-401
deficiency	I	402-412
,	O	412-413
who	O	414-417
is	O	418-420
showing	O	421-428
a	O	429-430
benign	O	431-437
course	O	438-444
of	O	445-447
the	O	448-451
dystrophic	B	452-462
process	I	463-470
and	O	471-474
is	O	475-477
still	O	478-483
walking	O	484-491
at	O	492-494
18	O	495-497
years	O	498-503
.	O	503-504

One	O	505-508
of	O	509-511
the	O	512-515
twins	O	516-521
received	O	522-530
2	O	531-532
mg	O	533-535
of	O	536-538
mazindol	O	539-547
daily	O	548-553
,	O	553-554
while	O	555-560
the	O	561-564
other	O	565-570
received	O	571-579
a	O	580-581
placebo	O	582-589
.	O	589-590

The	O	591-594
assessment	O	595-605
,	O	605-606
repeated	O	607-615
every	O	616-621
2	O	622-623
months	O	624-630
,	O	630-631
included	O	632-640
weight	O	641-647
and	O	648-651
height	O	652-658
measurements	O	659-671
,	O	671-672
functional	O	673-683
and	O	684-687
motor	O	688-693
ability	O	694-701
tests	O	702-707
,	O	707-708
ergometry	O	709-718
and	O	719-722
determinations	O	723-737
of	O	738-740
serum	O	741-746
enzymes	O	747-754
and	O	755-758
GH	O	759-761
levels	O	762-768
.	O	768-769

After	O	770-775
one	O	776-779
year	O	780-784
of	O	785-787
trial	O	788-793
the	O	794-797
code	O	798-802
was	O	803-806
broken	O	807-813
and	O	814-817
it	O	818-820
was	O	821-824
seen	O	825-829
that	O	830-834
the	O	835-838
twin	O	839-843
under	O	844-849
placebo	O	850-857
treatment	O	858-867
was	O	868-871
strikingly	O	872-882
worse	O	883-888
than	O	889-893
his	O	894-897
brother	O	898-905
,	O	905-906
the	O	907-910
progression	O	911-922
of	O	923-925
whose	O	926-931
condition	O	932-941
was	O	942-945
practically	O	946-957
arrested	O	958-966
.	O	966-967

These	O	968-973
results	O	974-981
strongly	O	982-990
suggest	O	991-998
that	O	999-1003
treatment	O	1004-1013
with	O	1014-1018
a	O	1019-1020
GH	O	1021-1023
inhibitor	O	1024-1033
is	O	1034-1036
beneficial	O	1037-1047
for	O	1048-1051
DMD	B	1052-1055
patients	O	1056-1064
.	O	1064-1065
.	O	1064-1065

Identification	O	0-14
of	O	15-17
WASP	O	18-22
mutations	O	23-32
in	O	33-35
patients	O	36-44
with	O	45-49
Wiskott	B	50-57
-	I	57-58
Aldrich	I	58-65
syndrome	I	66-74
and	O	75-78
isolated	B	79-87
thrombocytopenia	I	88-104
reveals	O	105-112
allelic	O	113-120
heterogeneity	O	121-134
at	O	135-137
the	O	138-141
WAS	B	142-145
locus	O	146-151
.	O	151-152

Mutation	O	153-161
in	O	162-164
the	O	165-168
gene	O	169-173
encoding	O	174-182
the	O	183-186
recently	O	187-195
isolated	O	196-204
WASP	O	205-209
protein	O	210-217
has	O	218-221
now	O	222-225
been	O	226-230
identified	O	231-241
as	O	242-244
the	O	245-248
genetic	B	249-256
defect	I	257-263
responsible	O	264-275
for	O	276-279
the	O	280-283
X	B	284-285
-	I	285-286
linked	I	286-292
Wiskott	I	293-300
-	I	300-301
Aldrich	I	301-308
syndrome	I	309-317
(	O	318-319
WAS	B	319-322
)	O	322-323
,	O	323-324
a	O	325-326
primary	O	327-334
immunodeficiency	B	335-351
disease	I	352-359
associated	O	360-370
with	O	371-375
extensive	O	376-385
phenotypic	O	386-396
variability	O	397-408
.	O	408-409

To	O	410-412
elucidate	O	413-422
the	O	423-426
range	O	427-432
of	O	433-435
WASP	O	436-440
mutations	O	441-450
responsible	O	451-462
for	O	463-466
WAS	B	467-470
,	O	470-471
we	O	472-474
used	O	475-479
PCR	O	480-483
-	O	483-484
SSCP	O	484-488
analysis	O	489-497
to	O	498-500
screen	O	501-507
for	O	508-511
WASP	O	512-516
gene	O	517-521
mutation	O	522-530
in	O	531-533
19	O	534-536
unrelated	O	537-546
boys	O	547-551
with	O	552-556
the	O	557-560
diagnosis	O	561-570
of	O	571-573
classical	O	574-583
or	O	584-586
attenuated	O	587-597
WAS	B	598-601
or	O	602-604
isolated	B	605-613
thrombocytopenia	I	614-630
.	O	630-631

All	O	632-635
19	O	636-638
patients	O	639-647
had	O	648-651
WASP	O	652-656
mutations	O	657-666
,	O	666-667
each	O	668-672
of	O	673-675
which	O	676-681
localized	O	682-691
to	O	692-694
the	O	695-698
initial	O	699-706
three	O	707-712
or	O	713-715
terminal	O	716-724
three	O	725-730
exons	O	731-736
of	O	737-739
the	O	740-743
gene	O	744-748
,	O	748-749
and	O	750-753
the	O	754-757
majority	O	758-766
of	O	767-769
which	O	770-775
were	O	776-780
unique	O	781-787
in	O	788-790
each	O	791-795
case	O	796-800
.	O	800-801

However	O	802-809
,	O	809-810
a	O	811-812
missense	O	813-821
mutation	O	822-830
which	O	831-836
results	O	837-844
in	O	845-847
substitution	O	848-860
of	O	861-863
the	O	864-867
arginine	O	868-876
at	O	877-879
WAS	B	880-883
codon	O	884-889
86	O	890-892
was	O	893-896
identified	O	897-907
in	O	908-910
three	O	911-916
boys	O	917-921
with	O	922-926
severe	O	927-933
WAS	B	934-937
as	O	938-940
well	O	941-945
as	O	946-948
in	O	949-951
one	O	952-955
boy	O	956-959
presenting	O	960-970
with	O	971-975
thrombocytopenia	B	976-992
alone	O	993-998
.	O	998-999

While	O	1000-1005
the	O	1006-1009
three	O	1010-1015
mutations	O	1016-1025
found	O	1026-1031
in	O	1032-1034
the	O	1035-1038
isolated	B	1039-1047
thrombocytopenia	I	1048-1064
patients	O	1065-1073
leave	O	1074-1079
the	O	1080-1083
reading	O	1084-1091
frame	O	1092-1097
intact	O	1098-1104
,	O	1104-1105
about	O	1106-1111
one	O	1112-1115
-	O	1115-1116
half	O	1116-1120
of	O	1121-1123
the	O	1124-1127
gene	O	1128-1132
alterations	O	1133-1144
detected	O	1145-1153
in	O	1154-1156
both	O	1157-1161
severe	O	1162-1168
and	O	1169-1172
attenuated	O	1173-1183
WAS	B	1184-1187
patients	O	1188-1196
result	O	1197-1203
in	O	1204-1206
frameshifted	O	1207-1219
transcript	O	1220-1230
and	O	1231-1234
premature	O	1235-1244
translation	O	1245-1256
termination	O	1257-1268
.	O	1268-1269

These	O	1270-1275
findings	O	1276-1284
therefore	O	1285-1294
confirm	O	1295-1302
the	O	1303-1306
association	O	1307-1318
of	O	1319-1321
WAS	B	1322-1325
with	O	1326-1330
WASP	O	1331-1335
mutation	O	1336-1344
and	O	1345-1348
identify	O	1349-1357
WASP	O	1358-1362
mutation	O	1363-1371
as	O	1372-1374
a	O	1375-1376
cause	O	1377-1382
for	O	1383-1386
isolated	O	1387-1395
congenital	B	1396-1406
thrombocytopenia	I	1407-1423
in	O	1424-1426
males	O	1427-1432
.	O	1432-1433

While	O	1434-1439
the	O	1440-1443
WASP	O	1444-1448
gene	O	1449-1453
defects	O	1454-1461
responsible	O	1462-1473
for	O	1474-1477
isolated	B	1478-1486
thrombocytopenia	I	1487-1503
and	O	1504-1507
other	O	1508-1513
mild	O	1514-1518
presentations	O	1519-1532
of	O	1533-1535
WAS	B	1536-1539
do	O	1540-1542
not	O	1543-1546
appear	O	1547-1553
distinct	O	1554-1562
from	O	1563-1567
those	O	1568-1573
resulting	O	1574-1583
in	O	1584-1586
severe	O	1587-1593
WAS	B	1594-1597
,	O	1597-1598
these	O	1599-1604
data	O	1605-1609
indicate	O	1610-1618
that	O	1619-1623
analysis	O	1624-1632
of	O	1633-1635
WASP	O	1636-1640
gene	O	1641-1645
mutation	O	1646-1654
provides	O	1655-1663
a	O	1664-1665
valuable	O	1666-1674
tool	O	1675-1679
for	O	1680-1683
distinguishing	O	1684-1698
the	O	1699-1702
spectrum	O	1703-1711
of	O	1712-1714
WAS	B	1715-1718
patients	O	1719-1727
and	O	1728-1731
the	O	1732-1735
subset	O	1736-1742
of	O	1743-1745
males	O	1746-1751
with	O	1752-1756
isolated	B	1757-1765
thrombocytopenia	I	1766-1782
who	O	1783-1786
represent	O	1787-1796
mild	O	1797-1801
cases	O	1802-1807
of	O	1808-1810
WAS	B	1811-1814
.	O	1814-1815
.	O	1814-1815

Huntington	B	0-10
disease	I	11-18
without	O	19-26
CAG	O	27-30
expansion	O	31-40
:	O	40-41
phenocopies	O	42-53
or	O	54-56
errors	O	57-63
in	O	64-66
assignment	O	67-77
?	O	77-78

Huntington	B	79-89
disease	I	90-97
(	O	98-99
HD	B	99-101
)	O	101-102
has	O	103-106
been	O	107-111
shown	O	112-117
to	O	118-120
be	O	121-123
associated	O	124-134
with	O	135-139
an	O	140-142
expanded	O	143-151
CAG	O	152-155
repeat	O	156-162
within	O	163-169
a	O	170-171
novel	O	172-177
gene	O	178-182
on	O	183-185
4p16	O	186-190
.	O	190-191
3	O	192-193
(	O	194-195
IT15	O	195-199
)	O	199-200
.	O	200-201

A	O	202-203
total	O	204-209
of	O	210-212
30	O	213-215
of	O	216-218
1	O	219-220
,	O	220-221
022	O	222-225
affected	O	226-234
persons	O	235-242
(	O	243-244
2	O	244-245
.	O	245-246

9	O	247-248
%	O	248-249
of	O	250-252
our	O	253-256
cohort	O	257-263
)	O	263-264
did	O	265-268
not	O	269-272
have	O	273-277
an	O	278-280
expanded	O	281-289
CAG	O	290-293
in	O	294-296
the	O	297-300
disease	O	301-308
range	O	309-314
.	O	314-315

The	O	316-319
reasons	O	320-327
for	O	328-331
not	O	332-335
observing	O	336-345
expansion	O	346-355
in	O	356-358
affected	O	359-367
individuals	O	368-379
are	O	380-383
important	O	384-393
for	O	394-397
determining	O	398-409
the	O	410-413
sensitivity	O	414-425
of	O	426-428
using	O	429-434
repeat	O	435-441
length	O	442-448
both	O	449-453
for	O	454-457
diagnosis	O	458-467
of	O	468-470
affected	O	471-479
patients	O	480-488
and	O	489-492
for	O	493-496
predictive	O	497-507
testing	O	508-515
programs	O	516-524
and	O	525-528
may	O	529-532
have	O	533-537
biological	O	538-548
relevance	O	549-558
for	O	559-562
the	O	563-566
understanding	O	567-580
of	O	581-583
the	O	584-587
molecular	O	588-597
mechanism	O	598-607
underlying	O	608-618
HD	B	619-621
.	O	621-622

Here	O	623-627
we	O	628-630
show	O	631-635
that	O	636-640
the	O	641-644
majority	O	645-653
(	O	654-655
18	O	655-657
)	O	657-658
of	O	659-661
the	O	662-665
individuals	O	666-677
with	O	678-682
normal	O	683-689
sized	O	690-695
alleles	O	696-703
represent	O	704-713
misdiagnosis	O	714-726
,	O	726-727
sample	O	728-734
mix	O	735-738
-	O	738-739
up	O	739-741
,	O	741-742
or	O	743-745
clerical	O	746-754
error	O	755-760
.	O	760-761

The	O	762-765
remaining	O	766-775
12	O	776-778
patients	O	779-787
represent	O	788-797
possible	O	798-806
phenocopies	O	807-818
for	O	819-822
HD	B	823-825
.	O	825-826

In	O	827-829
at	O	830-832
least	O	833-838
four	O	839-843
cases	O	844-849
,	O	849-850
family	O	851-857
studies	O	858-865
of	O	866-868
these	O	869-874
phenocopies	O	875-886
excluded	O	887-895
4p16	O	896-900
.	O	900-901

3	O	902-903
as	O	904-906
the	O	907-910
region	O	911-917
responsible	O	918-929
for	O	930-933
the	O	934-937
phenotype	O	938-947
.	O	947-948

Mutations	O	949-958
in	O	959-961
the	O	962-965
HD	B	966-968
gene	O	969-973
that	O	974-978
are	O	979-982
other	O	983-988
than	O	989-993
CAG	O	994-997
expansion	O	998-1007
have	O	1008-1012
not	O	1013-1016
been	O	1017-1021
excluded	O	1022-1030
for	O	1031-1034
the	O	1035-1038
remaining	O	1039-1048
eight	O	1049-1054
cases	O	1055-1060
;	O	1060-1061
however	O	1062-1069
,	O	1069-1070
in	O	1071-1073
as	O	1074-1076
many	O	1077-1081
as	O	1082-1084
seven	O	1085-1090
of	O	1091-1093
these	O	1094-1099
persons	O	1100-1107
,	O	1107-1108
retrospective	O	1109-1122
review	O	1123-1129
of	O	1130-1132
these	O	1133-1138
patients	O	1139-1147
clinical	O	1148-1156
features	O	1157-1165
identified	O	1166-1176
characteristics	O	1177-1192
not	O	1193-1196
typical	O	1197-1204
for	O	1205-1208
HD	B	1209-1211
.	O	1211-1212

This	O	1213-1217
study	O	1218-1223
shows	O	1224-1229
that	O	1230-1234
on	O	1235-1237
rare	O	1238-1242
occasions	O	1243-1252
mutations	O	1253-1262
in	O	1263-1265
other	O	1266-1271
,	O	1271-1272
as	O	1273-1275
-	O	1275-1276
yet	O	1276-1279
-	O	1275-1276
undefined	O	1280-1289
genes	O	1290-1295
can	O	1296-1299
present	O	1300-1307
with	O	1308-1312
a	O	1313-1314
clinical	O	1315-1323
phenotype	O	1324-1333
very	O	1334-1338
similar	O	1339-1346
to	O	1347-1349
that	O	1350-1354
of	O	1355-1357
HD	B	1358-1360

Allelic	O	0-7
exclusion	O	8-17
of	O	18-20
glucose	O	21-28
-	O	28-29
6	O	29-30
-	O	28-29
phosphate	O	31-40
dehydrogenase	O	41-54
in	O	55-57
platelets	O	58-67
and	O	68-71
T	O	72-73
lymphocytes	O	74-85
from	O	86-90
a	O	91-92
Wiskott	B	93-100
-	I	100-101
Aldrich	I	101-108
syndrome	I	109-117
carrier	O	118-125
.	O	125-126

An	O	127-129
obligate	O	130-138
carrier	O	139-146
of	O	147-149
the	O	150-153
Wiskott	B	154-161
-	I	161-162
Aldrich	I	162-169
syndrome	I	170-178
(	O	179-180
WAS	B	180-183
)	O	183-184
who	O	185-188
was	O	189-192
also	O	193-197
heterozygous	O	198-210
for	O	211-214
the	O	215-218
A	O	219-220
and	O	221-224
B	O	225-226
types	O	227-232
of	O	233-235
X	O	236-237
-	O	237-238
linked	O	238-244
glucose	O	245-252
-	O	252-253
6	O	253-254
-	O	252-253
phosphate	O	255-264
dehydrogenase	O	265-278
was	O	279-282
found	O	283-288
.	O	288-289

With	O	290-294
her	O	295-298
it	O	299-301
became	O	302-308
possible	O	309-317
to	O	318-320
determine	O	321-330
whether	O	331-338
allelic	O	339-346
exclusion	O	347-356
occurs	O	357-363
in	O	364-366
particular	O	367-377
cell	O	378-382
-	O	382-383
types	O	383-388
of	O	389-391
the	O	392-395
WAS	B	396-399
carrier	O	400-407
.	O	407-408

If	O	409-411
so	O	412-414
,	O	414-415
the	O	416-419
remaining	O	420-429
cells	O	430-435
of	O	436-438
a	O	439-440
particular	O	441-451
cell	O	452-456
-	O	456-457
type	O	457-461
would	O	462-467
express	O	468-475
only	O	476-480
the	O	481-484
normal	O	485-491
X	O	492-493
chromosome	O	494-504
and	O	505-508
only	O	509-513
one	O	514-517
glucose	O	518-525
-	O	525-526
6	O	526-527
-	O	525-526
phosphate	O	528-537
dehydrogenase	O	538-551
isoenzyme	O	552-561
would	O	562-567
be	O	568-570
demonstrable	O	571-583
.	O	583-584

This	O	585-589
carrier	O	590-597
had	O	598-601
only	O	602-606
the	O	607-610
B	O	611-612
isoenzyme	O	613-622
of	O	623-625
glucose	O	626-633
-	O	633-634
6	O	634-635
-	O	633-634
phosphate	O	636-645
dehydrogenase	O	646-659
in	O	660-662
platelets	O	663-672
and	O	673-676
thymus	O	677-683
-	O	683-684
derived	O	684-691
T	O	692-693
lymphocytes	O	694-705
,	O	705-706
although	O	707-715
both	O	716-720
isoenzymes	O	721-731
A	O	732-733
and	O	734-737
B	O	738-739
were	O	740-744
present	O	745-752
in	O	753-755
erythrocytes	O	756-768
and	O	769-772
neutrophils	O	773-784
.	O	784-785

These	O	786-791
findings	O	792-800
suggest	O	801-808
that	O	809-813
selection	O	814-823
against	O	824-831
the	O	832-835
WAS	B	836-839
gene	O	840-844
occurs	O	845-851
in	O	852-854
platelets	O	855-864
and	O	865-868
thymus	O	869-875
-	O	875-876
derived	O	876-883
T	O	884-885
lymphocytes	O	886-897
and	O	898-901
that	O	902-906
the	O	907-910
defects	O	911-918
associated	O	919-929
with	O	930-934
WAS	B	935-938
expressed	O	939-948
in	O	949-951
these	O	952-957
cell	O	958-962
-	O	962-963
types	O	963-968
may	O	969-972
be	O	973-975
implicated	O	976-986
in	O	987-989
the	O	990-993
genesis	O	994-1001
of	O	1002-1004
the	O	1005-1008
Wiskott	B	1009-1016
-	I	1016-1017
Aldrich	I	1017-1024
syndrome	I	1025-1033
.	O	1033-1034
.	O	1033-1034

A	O	0-1
novel	O	2-7
mutation	O	8-16
in	O	17-19
the	O	20-23
sodium	O	24-30
/	O	30-31
iodide	O	31-37
symporter	O	38-47
gene	O	48-52
in	O	53-55
the	O	56-59
largest	O	60-67
family	O	68-74
with	O	75-79
iodide	B	80-86
transport	I	87-96
defect	I	97-103
.	O	103-104

We	O	105-107
previously	O	108-118
reported	O	119-127
nine	O	128-132
children	O	133-141
with	O	142-146
an	O	147-149
autosomally	O	150-161
recessive	O	162-171
form	O	172-176
of	O	177-179
congenital	B	180-190
hypothyroidism	I	191-205
due	O	206-209
to	O	210-212
an	O	213-215
iodide	B	216-222
transport	I	223-232
defect	I	233-239
in	O	240-242
a	O	243-244
large	O	245-250
Hutterite	O	251-260
family	O	261-267
with	O	268-272
extensive	O	273-282
consanguinity	O	283-296
living	O	297-303
in	O	304-306
central	O	307-314
Canada	O	315-321
.	O	321-322

Since	O	323-328
the	O	329-332
original	O	333-341
report	O	342-348
,	O	348-349
we	O	350-352
have	O	353-357
diagnosed	O	358-367
congenital	B	368-378
hypothyroidism	I	379-393
by	O	394-396
newborn	O	397-404
TSH	O	405-408
screening	O	409-418
in	O	419-421
9	O	422-423
additional	O	424-434
children	O	435-443
from	O	444-448
the	O	449-452
family	O	453-459
.	O	459-460

We	O	461-463
performed	O	464-473
direct	O	474-480
sequencing	O	481-491
of	O	492-494
the	O	495-498
PCR	O	499-502
products	O	503-511
of	O	512-514
each	O	515-519
NIS	O	520-523
(	O	524-525
sodium	O	525-531
/	O	531-532
iodide	O	532-538
symporter	O	539-548
)	O	548-549
gene	O	550-554
exon	O	555-559
with	O	560-564
flanking	O	565-573
introns	O	574-581
amplified	O	582-591
from	O	592-596
genomic	O	597-604
DNA	O	605-608
extracted	O	609-618
from	O	619-623
peripheral	O	624-634
blood	O	635-640
cells	O	641-646
of	O	647-649
the	O	650-653
patients	O	654-662
.	O	662-663

We	O	664-666
identified	O	667-677
a	O	678-679
novel	O	680-685
NIS	O	686-689
gene	O	690-694
mutation	O	695-703
,	O	703-704
G395R	O	705-710
(	O	711-712
Gly395	O	712-718
-	O	718-719
-	O	718-719
>	O	721-722
Arg	O	723-726
;	O	726-727
GGA	O	728-731
-	O	731-732
-	O	731-732
>	O	734-735
AGA	O	736-739
)	O	739-740
,	O	740-741
in	O	742-744
10	O	745-747
patients	O	748-756
examined	O	757-765
in	O	766-768
the	O	769-772
present	O	773-780
study	O	781-786
.	O	786-787

All	O	788-791
of	O	792-794
the	O	795-798
parents	O	799-806
tested	O	807-813
were	O	814-818
heterozygous	O	819-831
for	O	832-835
the	O	836-839
mutation	O	840-848
,	O	848-849
suggesting	O	850-860
that	O	861-865
the	O	866-869
patients	O	870-878
were	O	879-883
homozygous	O	884-894
.	O	894-895

The	O	896-899
mutation	O	900-908
was	O	909-912
located	O	913-920
in	O	921-923
the	O	924-927
10th	O	928-932
transmembrane	O	933-946
helix	O	947-952
.	O	952-953

Expression	O	954-964
experiments	O	965-976
by	O	977-979
transfection	O	980-992
of	O	993-995
the	O	996-999
mutant	O	1000-1006
NIS	O	1007-1010
complimentary	O	1011-1024
DNA	O	1025-1028
into	O	1029-1033
COS	O	1034-1037
-	O	1037-1038
7	O	1038-1039
cells	O	1040-1045
showed	O	1046-1052
no	O	1053-1055
perchlorate	O	1056-1067
-	O	1067-1068
sensitive	O	1068-1077
iodide	O	1078-1084
uptake	O	1085-1091
,	O	1091-1092
confirming	O	1093-1103
that	O	1104-1108
the	O	1109-1112
mutation	O	1113-1121
is	O	1122-1124
the	O	1125-1128
direct	O	1129-1135
cause	O	1136-1141
of	O	1142-1144
the	O	1145-1148
iodide	B	1149-1155
transport	I	1156-1165
defect	I	1166-1172
in	O	1173-1175
these	O	1176-1181
patients	O	1182-1190
.	O	1190-1191

A	O	1192-1193
patient	O	1194-1201
who	O	1202-1205
showed	O	1206-1212
an	O	1213-1215
intermediate	O	1216-1228
saliva	O	1229-1235
/	O	1235-1236
serum	O	1236-1241
technetium	O	1242-1252
ratio	O	1253-1258
(	O	1259-1260
14	O	1260-1262
.	O	1262-1263

0	O	1264-1265
;	O	1265-1266
normal	O	1267-1273
,	O	1273-1274
>	O	1275-1276
or	O	1277-1279
=	O	1280-1281
20	O	1282-1284
)	O	1284-1285
and	O	1286-1289
was	O	1290-1293
considered	O	1294-1304
to	O	1305-1307
have	O	1308-1312
a	O	1313-1314
partial	O	1315-1322
or	O	1323-1325
less	O	1326-1330
severe	O	1331-1337
defect	O	1338-1344
in	O	1345-1347
the	O	1348-1351
previous	O	1352-1360
report	O	1361-1367
(	O	1368-1369
IX	O	1369-1371
-	O	1371-1372
24	O	1372-1374
)	O	1374-1375
did	O	1376-1379
not	O	1380-1383
have	O	1384-1388
a	O	1389-1390
NIS	O	1391-1394
gene	O	1395-1399
mutation	O	1400-1408
.	O	1408-1409

It	O	1410-1412
is	O	1413-1415
now	O	1416-1419
possible	O	1420-1428
to	O	1429-1431
use	O	1432-1435
gene	O	1436-1440
diagnostics	O	1441-1452
of	O	1453-1455
this	O	1456-1460
unique	O	1461-1467
NIS	O	1468-1471
mutation	O	1472-1480
to	O	1481-1483
identify	O	1484-1492
patients	O	1493-1501
with	O	1502-1506
congenital	B	1507-1517
hypothyroidism	I	1518-1532
due	O	1533-1536
to	O	1537-1539
an	O	1540-1542
iodide	B	1543-1549
transport	I	1550-1559
defect	I	1560-1566
in	O	1567-1569
this	O	1570-1574
family	O	1575-1581
and	O	1582-1585
to	O	1586-1588
determine	O	1589-1598
the	O	1599-1602
carrier	O	1603-1610
state	O	1611-1616
of	O	1617-1619
potential	O	1620-1629
parents	O	1630-1637
for	O	1638-1641
genetic	O	1642-1649
counseling	O	1650-1660
and	O	1661-1664
arranging	O	1665-1674
rapid	O	1675-1680
and	O	1681-1684
early	O	1685-1690
diagnosis	O	1691-1700
of	O	1701-1703
their	O	1704-1709
infants	O	1710-1717
.	O	1717-1718

Determination	O	0-13
of	O	14-16
the	O	17-20
mutations	O	21-30
responsible	O	31-42
for	O	43-46
the	O	47-50
Lesch	B	51-56
-	I	56-57
Nyhan	I	57-62
syndrome	I	63-71
in	O	72-74
17	O	75-77
subjects	O	78-86
.	O	86-87

Hypoxanthine	O	88-100
-	O	100-101
-	O	100-101
guanine	O	102-109
phosphoribosyltransferase	O	110-135
(	O	136-137
HPRT	O	137-141
)	O	141-142
is	O	143-145
a	O	146-147
purine	O	148-154
salvage	O	155-162
enzyme	O	163-169
that	O	170-174
catalyzes	O	175-184
the	O	185-188
conversion	O	189-199
of	O	200-202
hypoxanthine	O	203-215
to	O	216-218
inosine	O	219-226
monophosphate	O	227-240
and	O	241-244
guanine	O	245-252
to	O	253-255
guanosine	O	256-265
monophosphate	O	266-279
.	O	279-280

Previous	O	281-289
studies	O	290-297
of	O	298-300
mutant	O	301-307
HPRT	O	308-312
proteins	O	313-321
analyzed	O	322-330
at	O	331-333
the	O	334-337
molecular	O	338-347
level	O	348-353
have	O	354-358
shown	O	359-364
a	O	365-366
significant	O	367-378
heterogeneity	O	379-392
.	O	392-393

This	O	394-398
investigation	O	399-412
further	O	413-420
verifies	O	421-429
this	O	430-434
heterogeneity	O	435-448
and	O	449-452
identifies	O	453-463
insertions	O	464-474
,	O	474-475
deletions	O	476-485
,	O	485-486
and	O	487-490
point	O	491-496
mutations	O	497-506
.	O	506-507

The	O	508-511
direct	O	512-518
sequencing	O	519-529
of	O	530-532
the	O	533-536
polymerase	O	537-547
chain	O	548-553
reaction	O	554-562
-	O	562-563
amplified	O	563-572
product	O	573-580
of	O	581-583
reverse	O	584-591
-	O	591-592
transcribed	O	592-603
HPRT	O	604-608
mRNA	O	609-613
enabled	O	614-621
the	O	622-625
rapid	O	626-631
identification	O	632-646
of	O	647-649
the	O	650-653
mutations	O	654-663
found	O	664-669
in	O	670-672
17	O	673-675
previously	O	676-686
uncharacterized	O	687-702
cell	O	703-707
lines	O	708-713
derived	O	714-721
from	O	722-726
patients	O	727-735
with	O	736-740
the	O	741-744
Lesch	B	745-750
-	I	750-751
Nyhan	I	751-756
syndrome	I	757-765
.	O	765-766
.	O	765-766

A	O	0-1
new	O	2-5
CT	O	6-8
pattern	O	9-16
in	O	17-19
adrenoleukodystrophy	B	20-40
.	O	40-41

A	O	42-43
new	O	44-47
CT	O	48-50
pattern	O	51-58
was	O	59-62
observed	O	63-71
in	O	72-74
2	O	75-76
patients	O	77-85
with	O	86-90
adrenoleukodystrophy	B	91-111
(	O	112-113
ALD	B	113-116
)	O	116-117
.	O	117-118

This	O	119-123
pattern	O	124-131
,	O	131-132
which	O	133-138
the	O	139-142
authors	O	143-150
call	O	151-155
Type	O	156-160
II	O	161-163
,	O	163-164
is	O	165-167
characterized	O	168-181
by	O	182-184
the	O	185-188
absence	O	189-196
of	O	197-199
posterior	O	200-209
periventricular	O	210-225
areas	O	226-231
of	O	232-234
decreased	O	235-244
attenuation	O	245-256
around	O	257-263
the	O	264-267
trigone	O	268-275
on	O	276-278
non	O	279-282
-	O	282-283
contrast	O	283-291
scans	O	292-297
after	O	299-304
contrast	O	305-313
infusion	O	314-322
,	O	322-323
however	O	324-331
,	O	331-332
there	O	333-338
is	O	339-341
striking	O	342-350
enhancement	O	351-362
of	O	363-365
various	O	366-373
white	O	374-379
-	O	379-380
matter	O	380-386
structures	O	387-397
(	O	398-399
tracts	O	399-405
or	O	406-408
fiber	O	409-414
systems	O	415-422
)	O	422-423
such	O	424-428
as	O	429-431
the	O	432-435
internal	O	436-444
capsules	O	445-453
,	O	453-454
corpus	O	455-461
callosum	O	462-470
,	O	470-471
corona	O	472-478
radiata	O	479-486
,	O	486-487
forceps	O	488-495
major	O	496-501
,	O	501-502
and	O	503-506
cerebral	O	507-515
peduncles	O	516-525
.	O	525-526

This	O	527-531
is	O	532-534
different	O	535-544
from	O	545-549
numerous	O	550-558
previous	O	559-567
descriptions	O	568-580
of	O	581-583
the	O	584-587
CT	O	588-590
pattern	O	591-598
in	O	599-601
ALD	B	602-605
.	O	605-606

Type	B	607-611
II	I	612-614
ALD	I	615-618
does	O	619-623
not	O	624-627
appear	O	628-634
to	O	635-637
have	O	638-642
been	O	643-647
seen	O	648-652
in	O	653-655
any	O	656-659
other	O	660-665
leukoencephalopathy	B	666-685
and	O	686-689
is	O	690-692
probably	O	693-701
specific	O	702-710
for	O	711-714
a	O	715-716
phenotypic	O	717-727
variant	O	728-735
or	O	736-738
an	O	739-741
evolving	O	742-750
stage	O	751-756
of	O	757-759
ALD	B	760-763
.	O	763-764
.	O	763-764

Genetic	O	0-7
analysis	O	8-16
,	O	16-17
phenotypic	O	18-28
diagnosis	O	29-38
,	O	38-39
and	O	40-43
risk	O	44-48
of	O	49-51
venous	B	52-58
thrombosis	I	59-69
in	O	70-72
families	O	73-81
with	O	82-86
inherited	O	87-96
deficiencies	B	97-109
of	I	110-112
protein	I	113-120
S	I	121-122
.	O	122-123
Protein	B	124-131
S	I	132-133
deficiency	I	134-144
is	O	145-147
a	O	148-149
recognized	O	150-160
risk	O	161-165
factor	O	166-172
for	O	173-176
venous	B	177-183
thrombosis	I	184-194
.	O	194-195

Of	O	196-198
all	O	199-202
the	O	203-206
inherited	O	207-216
thrombophilic	B	217-230
conditions	I	231-241
,	O	241-242
it	O	243-245
remains	O	246-253
the	O	254-257
most	O	258-262
difficult	O	263-272
to	O	273-275
diagnose	O	276-284
because	O	285-292
of	O	293-295
phenotypic	O	296-306
variability	O	307-318
,	O	318-319
which	O	320-325
can	O	326-329
lead	O	330-334
to	O	335-337
inconclusive	O	338-350
results	O	351-358
.	O	358-359

We	O	360-362
have	O	363-367
overcome	O	368-376
this	O	377-381
problem	O	382-389
by	O	390-392
studying	O	393-401
a	O	402-403
cohort	O	404-410
of	O	411-413
patients	O	414-422
from	O	423-427
a	O	428-429
single	O	430-436
center	O	437-443
where	O	444-449
the	O	450-453
diagnosis	O	454-463
was	O	464-467
confirmed	O	468-477
at	O	478-480
the	O	481-484
genetic	O	485-492
level	O	493-498
.	O	498-499

Twenty	O	500-506
-	O	506-507
eight	O	507-512
index	O	513-518
patients	O	519-527
with	O	528-532
protein	B	533-540
S	I	541-542
deficiency	I	543-553
and	O	554-557
a	O	558-559
PROS1	B	560-565
gene	I	566-570
defect	I	571-577
were	O	578-582
studied	O	583-590
,	O	590-591
together	O	592-600
with	O	601-605
109	O	606-609
first	O	610-615
-	O	615-616
degree	O	616-622
relatives	O	623-632
.	O	632-633

To	O	634-636
avoid	O	637-642
selection	O	643-652
bias	O	653-657
,	O	657-658
we	O	659-661
confined	O	662-670
analysis	O	671-679
of	O	680-682
total	O	683-688
and	O	689-692
free	O	693-697
protein	O	698-705
S	O	706-707
levels	O	708-714
and	O	715-718
thrombotic	O	719-729
risk	O	730-734
to	O	735-737
the	O	738-741
patients	O	742-750
relatives	O	751-760
.	O	760-761

In	O	762-764
this	O	765-769
group	O	770-775
of	O	776-778
relatives	O	779-788
,	O	788-789
a	O	790-791
low	O	792-795
free	O	796-800
protein	O	801-808
S	O	809-810
level	O	811-816
was	O	817-820
the	O	821-824
most	O	825-829
reliable	O	830-838
predictor	O	839-848
of	O	849-851
a	O	852-853
PROS1	B	854-859
gene	I	860-864
defect	I	865-871
(	O	872-873
sensitivity	O	873-884
97	O	885-887
.	O	887-888

7	O	889-890
%	O	890-891
,	O	891-892
specificity	O	893-904
100	O	905-908
%	O	908-909
)	O	909-910
.	O	910-911

First	O	912-917
-	O	917-918
degree	O	918-924
relatives	O	925-934
with	O	935-939
a	O	940-941
PROS1	B	942-947
gene	I	948-952
defect	I	953-959
had	O	960-963
a	O	964-965
5	O	966-967
.	O	967-968
0	O	969-970
-	O	970-971
fold	O	971-975
higher	O	976-982
risk	O	983-987
of	O	988-990
thrombosis	B	991-1001
(	O	1002-1003
95	O	1003-1005
%	O	1005-1006
confidence	O	1007-1017
interval	O	1018-1026
,	O	1026-1027
1	O	1028-1029
.	O	1029-1030
5	O	1031-1032
-	O	1032-1033
16	O	1033-1035
.	O	1035-1036

8	O	1037-1038
)	O	1038-1039
than	O	1040-1044
those	O	1045-1050
with	O	1051-1055
a	O	1056-1057
normal	O	1058-1064
PROS1	O	1065-1070
gene	O	1071-1075
and	O	1076-1079
no	O	1080-1082
other	O	1083-1088
recognized	O	1089-1099
thrombophilic	B	1100-1113
defect	I	1114-1120
.	O	1120-1121

Although	O	1122-1130
pregnancy	O	1131-1140
/	O	1140-1141
puerperium	O	1141-1151
and	O	1152-1155
immobility	O	1156-1166
/	O	1166-1167
trauma	B	1167-1173
were	O	1174-1178
important	O	1179-1188
precipitating	O	1189-1202
factors	O	1203-1210
for	O	1211-1214
thrombosis	B	1215-1225
,	O	1225-1226
almost	O	1227-1233
half	O	1234-1238
of	O	1239-1241
the	O	1242-1245
events	O	1246-1252
were	O	1253-1257
spontaneous	O	1258-1269
.	O	1269-1270

Relatives	O	1271-1280
with	O	1281-1285
splice	O	1286-1292
-	O	1292-1293
site	O	1293-1297
or	O	1298-1300
major	O	1301-1306
structural	O	1307-1317
defects	B	1318-1325
in	I	1326-1328
the	I	1329-1332
PROS1	I	1333-1338
gene	I	1339-1343
were	O	1344-1348
more	O	1349-1353
likely	O	1354-1360
to	O	1361-1363
have	O	1364-1368
had	O	1369-1372
a	O	1373-1374
thrombotic	O	1375-1385
event	O	1386-1391
and	O	1392-1395
had	O	1396-1399
significantly	O	1400-1413
lower	O	1414-1419
total	O	1420-1425
and	O	1426-1429
free	O	1430-1434
protein	O	1435-1442
S	O	1443-1444
levels	O	1445-1451
than	O	1452-1456
those	O	1457-1462
relatives	O	1463-1472
having	O	1473-1479
missense	O	1480-1488
mutations	O	1489-1498
.	O	1498-1499

We	O	1500-1502
conclude	O	1503-1511
that	O	1512-1516
persons	O	1517-1524
with	O	1525-1529
PROS1	B	1530-1535
gene	I	1536-1540
defects	I	1541-1548
and	O	1549-1552
protein	B	1553-1560
S	I	1561-1562
deficiency	I	1563-1573
are	O	1574-1577
at	O	1578-1580
increased	O	1581-1590
risk	O	1591-1595
of	O	1596-1598
thrombosis	B	1599-1609
and	O	1610-1613
that	O	1614-1618
free	O	1619-1623
protein	O	1624-1631
S	O	1632-1633
estimation	O	1634-1644
offers	O	1645-1651
the	O	1652-1655
most	O	1656-1660
reliable	O	1661-1669
way	O	1670-1673
of	O	1674-1676
diagnosing	O	1677-1687
the	O	1688-1691
deficiency	O	1692-1702
.	O	1702-1703

(	O	1704-1705
Blood	O	1705-1710
.	O	1710-1711

2000	O	1712-1716
;	O	1716-1717
95	O	1718-1720
1935	O	1722-1726
-	O	1726-1727
1941	O	1727-1731
)	O	1731-1732
.	O	1732-1733

Severe	O	0-6
clinical	O	7-15
expression	O	16-26
in	O	27-29
X	B	30-31
-	I	31-32
linked	I	32-38
Emery	I	39-44
-	I	44-45
Dreifuss	I	45-53
muscular	I	54-62
dystrophy	I	63-72
.	O	72-73

X	B	74-75
-	I	75-76
linked	I	76-82
Emery	I	83-88
-	I	88-89
Dreifuss	I	89-97
muscular	I	98-106
dystrophy	I	107-116
(	O	117-118
EDMD	B	118-122
)	O	122-123
is	O	124-126
a	O	127-128
relatively	O	129-139
rare	O	140-144
benign	B	145-151
neuromuscular	I	152-165
disorder	I	166-174
which	O	175-180
can	O	181-184
vary	O	185-189
remarkably	O	190-200
in	O	201-203
onset	O	204-209
,	O	209-210
course	O	211-217
and	O	218-221
severity	O	222-230
.	O	230-231

In	O	232-234
the	O	235-238
present	O	239-246
study	O	247-252
,	O	252-253
a	O	254-255
TCTAC	O	256-261
deletion	O	262-270
spanning	O	271-279
the	O	280-283
nucleotides	O	284-295
631	O	296-299
-	O	299-300
635	O	300-303
of	O	304-306
the	O	307-310
emerin	O	311-317
gene	O	318-322
caused	O	323-329
an	O	330-332
unusually	O	333-342
severe	O	343-349
disease	O	350-357
phenotype	O	358-367
including	O	368-377
loss	B	378-382
of	I	383-385
ambulation	I	386-396
and	O	397-400
severe	O	401-407
muscle	B	408-414
wasting	I	415-422
in	O	423-425
two	O	426-429
affected	O	430-438
brothers	O	439-447
.	O	447-448

The	O	449-452
same	O	453-457
mutation	O	458-466
has	O	467-470
been	O	471-475
reported	O	476-484
previously	O	485-495
in	O	496-498
an	O	499-501
unrelated	O	502-511
family	O	512-518
showing	O	519-526
a	O	527-528
significantly	O	529-542
milder	O	543-549
phenotype	O	550-559
.	O	559-560

The	O	561-564
interfamilial	O	565-578
heterogeneity	O	579-592
in	O	593-595
distribution	O	596-608
and	O	609-612
in	O	613-615
severity	O	616-624
of	O	625-627
the	O	628-631
features	O	632-640
in	O	641-643
the	O	644-647
two	O	648-651
families	O	652-660
point	O	661-666
to	O	667-669
environmental	O	670-683
or	O	684-686
genetic	O	687-694
modification	O	695-707
as	O	708-710
the	O	711-714
cause	O	715-720
of	O	721-723
clinical	O	724-732
variability	O	733-744
in	O	745-747
Emery	B	748-753
-	I	753-754
Dreifuss	I	754-762
muscular	I	763-771
dystrophy	I	772-781
.	O	781-782
.	O	781-782

The	O	0-3
gene	O	4-8
for	O	9-12
spinal	B	13-19
cerebellar	I	20-30
ataxia	I	31-37
3	O	38-39
(	O	40-41
SCA3	O	41-45
)	O	45-46
is	O	47-49
located	O	50-57
in	O	58-60
a	O	61-62
region	O	63-69
of	O	70-72
approximately	O	73-86
3	O	87-88
cM	O	89-91
on	O	92-94
chromosome	O	95-105
14q24	O	106-111
.	O	111-112
3	O	112-113
-	O	113-114
q32	O	114-117
.	O	111-112
2	O	109-110
.	O	111-112

SCA3	O	121-125
,	O	125-126
the	O	127-130
gene	O	131-135
for	O	136-139
spinal	B	140-146
cerebellar	I	147-157
ataxia	I	158-164
3	O	165-166
,	O	166-167
was	O	168-171
recently	O	172-180
mapped	O	181-187
to	O	188-190
a	O	191-192
15	O	193-195
-	O	195-196
cM	O	196-198
interval	O	199-207
between	O	208-215
D14S67	O	216-222
and	O	223-226
D14S81	O	227-233
on	O	234-236
chromosome	O	237-247
14q	O	248-251
,	O	251-252
by	O	253-255
linkage	O	256-263
analysis	O	264-272
in	O	273-275
two	O	276-279
families	O	280-288
of	O	289-291
French	O	292-298
ancestry	O	299-307
.	O	307-308

The	O	309-312
SCA3	O	313-317
candidate	O	318-327
region	O	328-334
has	O	335-338
now	O	339-342
been	O	343-347
refined	O	348-355
by	O	356-358
linkage	O	359-366
analysis	O	367-375
with	O	376-380
four	O	381-385
new	O	386-389
microsatellite	O	390-404
markers	O	405-412
(	O	413-414
D14S256	O	414-421
,	O	421-422
D14S291	O	423-430
,	O	430-431
D14S280	O	432-439
,	O	439-440
and	O	441-444
AFM343vf1	O	445-454
)	O	454-455
in	O	456-458
the	O	459-462
same	O	463-467
two	O	468-471
families	O	472-480
,	O	480-481
in	O	482-484
which	O	485-490
19	O	491-493
additional	O	494-504
individuals	O	505-516
were	O	517-521
genotyped	O	522-531
,	O	531-532
and	O	533-536
in	O	537-539
a	O	540-541
third	O	542-547
French	O	548-554
family	O	555-561
.	O	561-562

Combined	O	563-571
two	O	572-575
-	O	575-576
point	O	576-581
linkage	O	582-589
analyses	O	590-598
show	O	599-603
that	O	604-608
the	O	609-612
new	O	613-616
markers	O	617-624
,	O	624-625
D14S280	O	626-633
and	O	634-637
AFM343vf1	O	638-647
,	O	647-648
are	O	649-652
tightly	O	653-660
linked	O	661-667
to	O	668-670
the	O	671-674
SCA3	O	675-679
locus	O	680-685
,	O	685-686
with	O	687-691
maximal	O	692-699
lod	O	700-703
scores	O	704-710
,	O	710-711
at	O	712-714
recombination	O	715-728
fraction	O	729-737
,	O	737-738
(	O	739-740
theta	O	740-745
)	O	745-746
=	O	747-748
.	O	748-749
00	O	750-752
,	O	752-753
of	O	754-756
7	O	757-758
.	O	758-759
05	O	760-762
and	O	763-766
13	O	767-769
.	O	769-770
70	O	771-773
,	O	773-774
respectively	O	775-787
.	O	787-788

Combined	O	789-797
multipoint	O	798-808
and	O	809-812
recombinant	O	813-824
haplotype	O	825-834
analyses	O	835-843
localize	O	844-852
the	O	853-856
SCA3	O	857-861
locus	O	862-867
to	O	868-870
a	O	871-872
3	O	873-874
-	O	874-875
cM	O	875-877
interval	O	878-886
flanked	O	887-894
by	O	895-897
D14S291	O	898-905
and	O	906-909
D14S81	O	910-916
.	O	916-917

The	O	918-921
same	O	922-926
allele	O	927-933
for	O	934-937
D14S280	O	938-945
segregates	O	946-956
with	O	957-961
the	O	962-965
disease	O	966-973
locus	O	974-979
in	O	980-982
the	O	983-986
three	O	987-992
kindreds	O	993-1001
.	O	1001-1002

This	O	1003-1007
allele	O	1008-1014
is	O	1015-1017
frequent	O	1018-1026
in	O	1027-1029
the	O	1030-1033
French	O	1034-1040
population	O	1041-1051
,	O	1051-1052
however	O	1053-1060
,	O	1060-1061
and	O	1062-1065
linkage	O	1066-1073
disequilibrium	O	1074-1088
is	O	1089-1091
not	O	1092-1095
clearly	O	1096-1103
established	O	1104-1115
.	O	1115-1116

The	O	1117-1120
SCA3	O	1121-1125
locus	O	1126-1131
remains	O	1132-1139
within	O	1140-1146
the	O	1147-1150
29	O	1151-1153
-	O	1153-1154
cM	O	1154-1156
region	O	1157-1163
on	O	1164-1166
14q24	O	1167-1172
.	O	1172-1173

3	O	1174-1175
-	O	1175-1176
q32	O	1176-1179
.	O	1179-1180
2	O	1181-1182
containing	O	1183-1193
the	O	1194-1197
gene	O	1198-1202
for	O	1203-1206
the	O	1207-1210
Machado	B	1211-1218
-	I	1218-1219
Joseph	I	1219-1225
disease	I	1226-1233
,	O	1233-1234
which	O	1235-1240
is	O	1241-1243
clinically	O	1244-1254
related	O	1255-1262
to	O	1263-1265
the	O	1266-1269
phenotype	O	1270-1279
determined	O	1280-1290
by	O	1291-1293
SCA3	O	1294-1298
,	O	1298-1299
but	O	1300-1303
it	O	1304-1306
cannot	O	1307-1313
yet	O	1314-1317
be	O	1318-1320
concluded	O	1321-1330
that	O	1331-1335
both	O	1336-1340
diseases	O	1341-1349
result	O	1350-1356
from	O	1357-1361
alterations	O	1362-1373
of	O	1374-1376
the	O	1377-1380
same	O	1381-1385
gene	O	1386-1390

Huntington	B	0-10
disease	I	11-18
and	O	19-22
childhood	O	23-32
-	O	32-33
onset	O	33-38
Tourette	B	39-47
syndrome	I	48-56
.	O	56-57

A	O	58-59
40	O	60-62
-	O	62-63
year	O	63-67
-	O	62-63
old	O	68-71
man	O	72-75
with	O	76-80
childhood	O	81-90
-	O	90-91
onset	O	91-96
Tourette	B	97-105
syndrome	I	106-114
(	O	115-116
TS	B	116-118
)	O	118-119
developed	O	120-129
Huntington	B	130-140
disease	I	141-148
(	O	149-150
HD	B	150-152
)	O	152-153
.	O	153-154

We	O	155-157
believe	O	158-165
this	O	166-170
to	O	171-173
be	O	174-176
the	O	177-180
first	O	181-186
reported	O	187-195
case	O	196-200
of	O	201-203
childhood	O	204-213
-	O	213-214
onset	O	214-219
TS	B	220-222
with	O	223-227
adult	O	228-233
onset	O	234-239
HD	B	240-242
.	O	242-243

Discovery	O	244-253
of	O	254-256
other	O	257-262
cases	O	263-268
with	O	269-273
both	O	274-278
disorders	O	279-288
may	O	289-292
provide	O	293-300
clues	O	301-306
to	O	307-309
the	O	310-313
pathophysiology	O	314-329
of	O	330-332
both	O	333-337
conditions	O	338-348
.	O	348-349
.	O	348-349

The	O	0-3
protein	O	4-11
deficient	O	12-21
in	O	22-24
Lowe	B	25-29
syndrome	I	30-38
is	O	39-41
a	O	42-43
phosphatidylinositol	O	44-64
-	O	64-65
4	O	65-66
,	O	66-67
5	O	67-68
-	O	64-65
bisphosphate	O	69-81
5	O	82-83
-	O	83-84
phosphatase	O	84-95
.	O	95-96

Lowe	B	97-101
syndrome	I	102-110
,	O	110-111
also	O	112-116
known	O	117-122
as	O	123-125
oculocerebrorenal	B	126-143
syndrome	I	144-152
,	O	152-153
is	O	154-156
caused	O	157-163
by	O	164-166
mutations	O	167-176
in	O	177-179
the	O	180-183
X	O	184-185
chromosome	O	186-196
-	O	196-197
encoded	O	197-204
OCRL	O	205-209
gene	O	210-214
.	O	214-215

The	O	216-219
OCRL	O	220-224
protein	O	225-232
is	O	233-235
51	O	236-238
%	O	238-239
identical	O	240-249
to	O	250-252
inositol	O	253-261
polyphosphate	O	262-275
5	O	276-277
-	O	277-278
phosphatase	O	278-289
II	O	290-292
(	O	293-294
5	O	294-295
-	O	295-296
phosphatase	O	296-307
II	O	308-310
)	O	310-311
from	O	312-316
human	O	317-322
platelets	O	323-332
over	O	333-337
a	O	338-339
span	O	340-344
of	O	345-347
744	O	348-351
aa	O	352-354
,	O	354-355
suggesting	O	356-366
that	O	367-371
OCRL	O	372-376
may	O	377-380
be	O	381-383
a	O	384-385
similar	O	386-393
enzyme	O	394-400
.	O	400-401

We	O	402-404
engineered	O	405-415
a	O	416-417
construct	O	418-427
of	O	428-430
the	O	431-434
OCRL	O	435-439
cDNA	O	440-444
that	O	445-449
encodes	O	450-457
amino	O	458-463
acids	O	464-469
homologous	O	470-480
to	O	481-483
the	O	484-487
platelet	O	488-496
5	O	497-498
-	O	498-499
phosphatase	O	499-510
for	O	511-514
expression	O	515-525
in	O	526-528
baculovirus	O	529-540
-	O	540-541
infected	O	541-549
Sf9	O	550-553
insect	O	554-560
cells	O	561-566
.	O	566-567

This	O	568-572
cDNA	O	573-577
encodes	O	578-585
aa	O	586-588
264	O	589-592
-	O	592-593
968	O	593-596
of	O	597-599
the	O	600-603
OCRL	O	604-608
protein	O	609-616
.	O	616-617

The	O	618-621
recombinant	O	622-633
protein	O	634-641
was	O	642-645
found	O	646-651
to	O	652-654
catalyze	O	655-663
the	O	664-667
reactions	O	668-677
also	O	678-682
carried	O	683-690
out	O	691-694
by	O	695-697
platelet	O	698-706
5	O	707-708
-	O	708-709
phosphatase	O	709-720
II	O	721-723
.	O	723-724

Thus	O	725-729
OCRL	O	730-734
converts	O	735-743
inositol	O	744-752
1	O	753-754
,	O	754-755
4	O	756-757
,	O	757-758
5	O	759-760
-	O	760-761
trisphosphate	O	761-774
to	O	775-777
inositol	O	778-786
1	O	787-788
,	O	788-789
4	O	790-791
-	O	791-792
bisphosphate	O	792-804
,	O	804-805
and	O	806-809
it	O	810-812
converts	O	813-821
inositol	O	822-830
1	O	831-832
,	O	832-833
3	O	834-835
,	O	835-836
4	O	837-838
,	O	838-839
5	O	840-841
-	O	841-842
tetrakisphosphate	O	842-859
to	O	860-862
inositol	O	863-871
1	O	872-873
,	O	873-874
3	O	875-876
,	O	876-877
4	O	878-879
-	O	879-880
trisphosphate	O	880-893
.	O	893-894

Most	O	895-899
important	O	900-909
,	O	909-910
the	O	911-914
enzyme	O	915-921
converts	O	922-930
phosphatidylinositol	O	931-951
4	O	952-953
,	O	953-954
5	O	955-956
-	O	956-957
bisphosphate	O	957-969
to	O	970-972
phosphatidylinositol	O	973-993
4	O	994-995
-	O	995-996
phosphate	O	996-1005
.	O	1005-1006

The	O	1007-1010
relative	O	1011-1019
ability	O	1020-1027
of	O	1028-1030
OCRL	O	1031-1035
to	O	1036-1038
catalyze	O	1039-1047
the	O	1048-1051
three	O	1052-1057
reactions	O	1058-1067
is	O	1068-1070
different	O	1071-1080
from	O	1081-1085
that	O	1086-1090
of	O	1091-1093
5	O	1094-1095
-	O	1095-1096
phosphatase	O	1096-1107
II	O	1108-1110
and	O	1111-1114
from	O	1115-1119
that	O	1120-1124
of	O	1125-1127
another	O	1128-1135
5	O	1136-1137
-	O	1137-1138
phosphatase	O	1138-1149
isoenzyme	O	1150-1159
from	O	1160-1164
platelets	O	1165-1174
,	O	1174-1175
5	O	1176-1177
-	O	1177-1178
phosphatase	O	1178-1189
I	O	1190-1191
.	O	1191-1192

The	O	1193-1196
recombinant	O	1197-1208
OCRL	O	1209-1213
protein	O	1214-1221
hydrolyzes	O	1222-1232
the	O	1233-1236
phospholipid	O	1237-1249
substrate	O	1250-1259
10	O	1260-1262
-	O	1262-1263
to	O	1264-1266
30	O	1267-1269
-	O	1269-1270
fold	O	1270-1274
better	O	1275-1281
than	O	1282-1286
5	O	1287-1288
-	O	1288-1289
phosphatase	O	1289-1300
II	O	1301-1303
,	O	1303-1304
and	O	1305-1308
5	O	1309-1310
-	O	1310-1311
phosphatase	O	1311-1322
I	O	1323-1324
does	O	1325-1329
not	O	1330-1333
cleave	O	1334-1340
the	O	1341-1344
lipid	O	1345-1350
at	O	1351-1353
all	O	1354-1357
.	O	1357-1358

We	O	1359-1361
also	O	1362-1366
show	O	1367-1371
that	O	1372-1376
OCRL	O	1377-1381
functions	O	1382-1391
as	O	1392-1394
a	O	1395-1396
phosphatidylinositol	O	1397-1417
4	O	1418-1419
,	O	1419-1420
5	O	1421-1422
-	O	1422-1423
bisphosphate	O	1423-1435
5	O	1436-1437
-	O	1437-1438
phosphatase	O	1438-1449
in	O	1450-1452
OCRL	O	1453-1457
-	O	1457-1458
expressing	O	1458-1468
Sf9	O	1469-1472
cells	O	1473-1478
.	O	1478-1479

These	O	1480-1485
results	O	1486-1493
suggest	O	1494-1501
that	O	1502-1506
OCRL	O	1507-1511
is	O	1512-1514
mainly	O	1515-1521
a	O	1522-1523
lipid	O	1524-1529
phosphatase	O	1530-1541
that	O	1542-1546
may	O	1547-1550
control	O	1551-1558
cellular	O	1559-1567
levels	O	1568-1574
of	O	1575-1577
a	O	1578-1579
critical	O	1580-1588
metabolite	O	1589-1599
,	O	1599-1600
phosphatidylinositol	O	1601-1621
4	O	1622-1623
,	O	1623-1624
5	O	1625-1626
-	O	1626-1627
bisphosphate	O	1627-1639
.	O	1639-1640

Deficiency	O	1641-1651
of	O	1652-1654
this	O	1655-1659
enzyme	O	1660-1666
apparently	O	1667-1677
causes	O	1678-1684
the	O	1685-1688
protean	O	1689-1696
manifestations	O	1697-1711
of	O	1712-1714
Lowe	B	1715-1719
syndrome	I	1720-1728
.	O	1728-1729
.	O	1728-1729

Microdeletions	O	0-14
at	O	15-17
chromosome	O	18-28
bands	O	29-34
1q32	O	35-39
-	O	39-40
q41	O	40-43
as	O	44-46
a	O	47-48
cause	O	49-54
of	O	55-57
Van	B	58-61
der	I	62-65
Woude	I	66-71
syndrome	I	72-80
.	O	80-81

Van	B	82-85
der	I	86-89
Woude	I	90-95
syndrome	I	96-104
(	O	105-106
VWS	B	106-109
)	O	109-110
is	O	111-113
an	O	114-116
autosomal	B	117-126
dominant	I	127-135
disorder	I	136-144
comprising	O	145-155
cleft	B	156-161
lip	I	162-165
and	O	166-169
/	O	169-170
or	O	170-172
cleft	B	173-178
palate	I	179-185
and	O	186-189
lip	B	190-193
pits	I	194-198
.	O	198-199

We	O	200-202
reported	O	203-211
previously	O	212-222
a	O	223-224
family	O	225-231
whose	O	232-237
underlying	O	238-248
mutation	O	249-257
is	O	258-260
a	O	261-262
500	O	263-266
-	O	266-267
800	O	267-270
kb	O	271-273
deletion	O	274-282
localized	O	283-292
to	O	293-295
chromosome	O	296-306
bands	O	307-312
1q32	O	313-317
-	O	317-318
q41	O	318-321
[	O	322-323
Sander	O	323-329
et	O	330-332
al	O	333-335
.	O	335-336
,	O	336-337
1994	O	338-342
Hum	O	344-347
Mol	O	348-351
Genet	O	352-357
3	O	358-359
576	O	361-364
-	O	364-365
578	O	365-368
]	O	368-369
.	O	369-370

Along	O	371-376
with	O	377-381
cleft	B	382-387
lip	I	388-391
/	I	391-392
palate	I	392-398
and	O	399-402
lip	B	403-406
pits	I	407-411
,	O	411-412
affected	O	413-421
relatives	O	422-431
exhibit	O	432-439
developmental	B	440-453
delays	I	454-460
,	O	460-461
suggesting	O	462-472
that	O	473-477
the	O	478-481
function	O	482-490
of	O	491-493
a	O	494-495
gene	O	496-500
nearby	O	501-507
may	O	508-511
also	O	512-516
be	O	517-519
disrupted	O	520-529
.	O	529-530

To	O	531-533
further	O	534-541
localize	O	542-550
the	O	551-554
VWS	B	555-558
gene	O	559-563
we	O	564-566
searched	O	567-575
for	O	576-579
other	O	580-585
deletions	O	586-595
that	O	596-600
cause	O	601-606
VWS	B	607-610
.	O	610-611

An	O	612-614
allele	O	615-621
loss	O	622-626
assay	O	627-632
was	O	633-636
performed	O	637-646
using	O	647-652
a	O	653-654
novel	O	655-660
highly	O	661-667
polymorphic	O	668-679
marker	O	680-686
,	O	686-687
D1S3753	O	688-695
.	O	695-696

From	O	697-701
a	O	702-703
panel	O	704-709
of	O	710-712
37	O	713-715
unrelated	O	716-725
individuals	O	726-737
,	O	737-738
we	O	739-741
detected	O	742-750
an	O	751-753
allele	O	754-760
loss	O	761-765
in	O	766-768
one	O	769-772
family	O	773-779
,	O	779-780
indicating	O	781-791
the	O	792-795
presence	O	796-804
of	O	805-807
a	O	808-809
deletion	O	810-818
.	O	818-819

In	O	820-822
this	O	823-827
family	O	828-834
,	O	834-835
the	O	836-839
phenotype	O	840-849
in	O	850-852
three	O	853-858
generations	O	859-870
of	O	871-873
affected	O	874-882
individuals	O	883-894
was	O	895-898
confined	O	899-907
to	O	908-910
the	O	911-914
cardinal	O	915-923
signs	O	924-929
of	O	930-932
VWS	B	933-936
.	O	936-937

Surprisingly	O	938-950
,	O	950-951
mapping	O	952-959
of	O	960-962
the	O	963-966
new	O	967-970
deletion	O	971-979
showed	O	980-986
that	O	987-991
it	O	992-994
extended	O	995-1003
0	O	1004-1005
.	O	1005-1006
2	O	1007-1008
-	O	1008-1009
1	O	1009-1010
Mb	O	1011-1013
beyond	O	1014-1020
the	O	1021-1024
proximal	O	1025-1033
breakpoint	O	1034-1044
for	O	1045-1048
the	O	1049-1052
deletion	O	1053-1061
described	O	1062-1071
previously	O	1072-1082
.	O	1082-1083

No	O	1084-1086
deletions	O	1087-1096
were	O	1097-1101
detected	O	1102-1110
in	O	1111-1113
seven	O	1114-1119
cases	O	1120-1125
of	O	1126-1128
popliteal	B	1129-1138
pterygia	I	1139-1147
syndrome	I	1148-1156
,	O	1156-1157
76	O	1158-1160
cases	O	1161-1166
of	O	1167-1169
mixed	O	1170-1175
syndromic	B	1176-1185
forms	I	1186-1191
of	I	1192-1194
cleft	I	1195-1200
lip	I	1201-1204
and	I	1205-1208
palate	I	1209-1215
,	O	1215-1216
and	O	1217-1220
178	O	1221-1224
cases	O	1225-1230
of	O	1231-1233
nonsyndromic	B	1234-1246
cleft	I	1247-1252
lip	I	1253-1256
and	I	1257-1260
palate	I	1261-1267
.	O	1267-1268

Mucopolysaccharidosis	B	0-21
type	I	22-26
IVA	I	27-30
:	O	30-31
common	O	32-38
double	O	39-45
deletion	O	46-54
in	O	55-57
the	O	58-61
N	O	62-63
-	O	63-64
acetylgalactosamine	O	64-83
-	O	63-64
6	O	84-85
-	O	63-64
sulfatase	O	86-95
gene	O	96-100
(	O	101-102
GALNS	O	102-107
)	O	107-108
.	O	108-109

Mucopolysaccharidosis	B	110-131
IVA	I	132-135
(	O	136-137
MPS	B	137-140
IVA	I	141-144
)	O	144-145
is	O	146-148
an	O	149-151
autosomal	B	152-161
recessive	I	162-171
disorder	I	172-180
caused	O	181-187
by	O	188-190
a	O	191-192
deficiency	B	193-203
in	I	204-206
N	I	207-208
-	I	208-209
acetylgalactosamine	I	209-228
-	I	208-209
6	I	229-230
-	I	208-209
sulfatase	I	231-240
(	O	241-242
GALNS	O	242-247
)	O	247-248
.	O	248-249

We	O	250-252
found	O	253-258
two	O	259-262
separate	O	263-271
deletions	O	272-281
of	O	282-284
nearly	O	285-291
8	O	292-293
.	O	293-294
0	O	295-296
and	O	297-300
6	O	301-302
.	O	302-303
0	O	304-305
kb	O	306-308
in	O	309-311
the	O	312-315
GALNS	O	316-321
gene	O	322-326
,	O	326-327
including	O	328-337
some	O	338-342
exons	O	343-348
.	O	348-349

There	O	350-355
are	O	356-359
Alu	O	360-363
repetitive	O	364-374
elements	O	375-383
near	O	384-388
the	O	389-392
breakpoints	O	393-404
of	O	405-407
the	O	408-411
8	O	412-413
.	O	413-414
0	O	415-416
-	O	416-417
kb	O	417-419
deletion	O	420-428
,	O	428-429
and	O	430-433
this	O	434-438
deletion	O	439-447
resulted	O	448-456
from	O	457-461
an	O	462-464
Alu	O	465-468
-	O	468-469
Alu	O	465-468
recombination	O	473-486
.	O	486-487

The	O	488-491
other	O	492-497
6	O	498-499
.	O	499-500
0	O	501-502
-	O	502-503
kb	O	503-505
deletion	O	506-514
involved	O	515-523
illegitimate	O	524-536
recombinational	O	537-552
events	O	553-559
between	O	560-567
incomplete	O	568-578
short	O	579-584
direct	O	585-591
repeats	O	592-599
of	O	600-602
8	O	603-604
bp	O	605-607
at	O	608-610
deletion	O	611-619
breakpoints	O	620-631
.	O	631-632

The	O	633-636
same	O	637-641
rearrangement	O	642-655
has	O	656-659
been	O	660-664
observed	O	665-673
in	O	674-676
a	O	677-678
heteroallelic	O	679-692
state	O	693-698
in	O	699-701
four	O	702-706
unrelated	O	707-716
patients	O	717-725
.	O	725-726

This	O	727-731
is	O	732-734
the	O	735-738
first	O	739-744
documentation	O	745-758
of	O	759-761
a	O	762-763
common	O	764-770
double	O	771-777
deletion	O	778-786
a	O	787-788
gene	O	789-793
that	O	794-798
is	O	799-801
not	O	802-805
a	O	806-807
member	O	808-814
of	O	815-817
a	O	818-819
gene	O	820-824
cluster	O	825-832
.	O	832-833

Segregation	O	0-11
analysis	O	12-20
of	O	21-23
a	O	24-25
marker	O	26-32
localised	O	33-42
Xp21	O	43-47
.	O	47-48
2	O	45-46
-	O	49-50
Xp21	O	43-47
.	O	47-48
3	O	55-56
in	O	57-59
Duchenne	B	60-68
and	I	69-72
Becker	I	73-79
muscular	I	80-88
dystrophy	I	89-98
families	O	99-107
.	O	107-108

A	O	109-110
DNA	O	111-114
marker	O	115-121
C7	O	122-124
,	O	124-125
localised	O	126-135
Xp21	O	136-140
.	O	140-141

1	O	142-143
-	O	143-144
Xp21	O	144-148
.	O	148-149

3	O	150-151
,	O	151-152
has	O	153-156
been	O	157-161
studied	O	162-169
in	O	170-172
kindreds	O	173-181
segregating	O	182-193
for	O	194-197
Duchenne	B	198-206
muscular	I	207-215
dystrophy	I	216-225
(	O	226-227
DMD	B	227-230
)	O	230-231
and	O	232-235
Becker	B	236-242
muscular	I	243-251
dystrophy	I	252-261
(	O	262-263
BMD	B	263-266
)	O	266-267
.	O	267-268

In	O	269-271
DMD	B	272-275
families	O	276-284
four	O	285-289
crossovers	O	290-300
were	O	301-305
observed	O	306-314
in	O	315-317
38	O	318-320
informative	O	321-332
meioses	O	333-340
between	O	341-348
C7	O	349-351
and	O	352-355
the	O	356-359
DMD	B	360-363
locus	O	364-369
(	O	370-371
theta	O	371-376
=	O	377-378
0	O	379-380
.	O	380-381
12	O	382-384
,	O	384-385
z	O	386-387
max	O	388-391
=	O	392-393
+	O	394-395
2	O	396-397
.	O	397-398
72	O	399-401
)	O	401-402
.	O	402-403

In	O	404-406
BMD	B	407-410
families	O	411-419
no	O	420-422
recombinants	O	423-435
were	O	436-440
observed	O	441-449
in	O	450-452
the	O	453-456
16	O	457-459
informative	O	460-471
meioses	O	472-479
studied	O	480-487
.	O	487-488

These	O	489-494
data	O	495-499
are	O	500-503
consistent	O	504-514
with	O	515-519
the	O	520-523
localisation	O	524-536
of	O	537-539
the	O	540-543
mutations	O	544-553
in	O	554-556
these	O	557-562
disorders	O	563-572
being	O	573-578
in	O	579-581
the	O	582-585
same	O	586-590
region	O	591-597
of	O	598-600
Xp21	O	601-605
.	O	605-606

Studies	O	607-614
in	O	615-617
families	O	618-626
also	O	627-631
segregating	O	632-643
for	O	644-647
the	O	648-651
DNA	O	652-655
marker	O	656-662
754	O	663-666
support	O	667-674
the	O	675-678
previously	O	679-689
reported	O	690-698
physical	O	699-707
order	O	708-713
of	O	714-716
these	O	717-722
loci	O	723-727
as	O	728-730
X	O	731-732
centromere	O	733-743
-	O	743-744
754	O	744-747
-	O	743-744
DMD	O	748-751
-	O	743-744
BMD	O	752-755
-	O	743-744
C7	O	756-758
-	O	743-744
X	O	759-760
telomere	O	761-769
.	O	769-770

A	O	771-772
recombination	O	773-786
fraction	O	787-795
of	O	796-798
0	O	799-800
.	O	800-801
11	O	802-804
(	O	805-806
z	O	806-807
max	O	808-811
=	O	812-813
+	O	814-815
5	O	816-817
.	O	817-818
58	O	819-821
)	O	821-822
was	O	823-826
found	O	827-832
between	O	833-840
DMD	O	841-844
-	O	844-845
754	O	845-848
by	O	849-851
combining	O	852-861
our	O	862-865
previously	O	866-876
published	O	877-886
data	O	887-891
with	O	892-896
the	O	897-900
data	O	901-905
presented	O	906-915
here	O	916-920
.	O	920-921

C7	O	922-924
and	O	925-928
754	O	929-932
thus	O	933-937
provide	O	938-945
good	O	946-950
bridging	O	951-959
markers	O	960-967
for	O	968-971
the	O	972-975
diagnosis	O	976-985
of	O	986-988
DMD	B	989-992
and	O	993-996
BMD	B	997-1000

Genetic	O	0-7
analysis	O	8-16
of	O	17-19
the	O	20-23
BRCA1	O	24-29
region	O	30-36
in	O	37-39
a	O	40-41
large	O	42-47
breast	O	48-54
/	O	54-55
ovarian	O	55-62
family	O	63-69
:	O	69-70
refinement	O	71-81
of	O	82-84
the	O	85-88
minimal	O	89-96
region	O	97-103
containing	O	104-114
BRCA1	O	115-120
.	O	120-121

We	O	122-124
have	O	125-129
analyzed	O	130-138
a	O	139-140
single	O	141-147
multi	O	148-153
-	O	153-154
affected	O	154-162
breast	B	163-169
/	I	169-170
ovarian	I	170-177
cancer	I	178-184
pedigree	O	185-193
(	O	194-195
BOV3	O	195-199
)	O	199-200
and	O	201-204
have	O	205-209
shown	O	210-215
consistent	O	216-226
inheritance	O	227-238
of	O	239-241
markers	O	242-249
on	O	250-252
chromosome	O	253-263
17q	O	264-267
with	O	268-272
the	O	273-276
disease	O	277-284
confirming	O	285-295
that	O	296-300
this	O	301-305
family	O	306-312
is	O	313-315
due	O	316-319
to	O	320-322
the	O	323-326
BRCA1	O	327-332
gene	O	333-337
.	O	337-338

Analysis	O	339-347
of	O	348-350
17q	O	351-354
haplotypes	O	355-365
shows	O	366-371
a	O	372-373
recombination	O	374-387
event	O	388-393
in	O	394-396
a	O	397-398
bilateral	O	399-408
breast	B	409-415
cancer	I	416-422
case	O	423-427
which	O	428-433
suggests	O	434-442
that	O	443-447
the	O	448-451
BRCA1	O	452-457
gene	O	458-462
lies	O	463-467
distal	O	468-474
to	O	475-477
D17S857	O	478-485
;	O	485-486
D17S857	O	487-494
is	O	495-497
thus	O	498-502
the	O	503-506
new	O	507-510
proximal	O	511-519
boundary	O	520-528
for	O	529-532
the	O	533-536
region	O	537-543
containing	O	544-554
BRCA1	O	555-560
.	O	560-561

Combining	O	562-571
this	O	572-576
information	O	577-588
with	O	589-593
previously	O	594-604
published	O	605-614
mapping	O	615-622
information	O	623-634
suggests	O	635-643
that	O	644-648
BRCA1	O	649-654
is	O	655-657
contained	O	658-667
in	O	668-670
a	O	671-672
region	O	673-679
estimated	O	680-689
at	O	690-692
1	O	693-694
-	O	694-695
1	O	693-694
.	O	696-697
5	O	698-699
Mb	O	700-702
in	O	703-705
length	O	706-712
.	O	712-713

All	O	714-717
seven	O	718-723
breast	B	724-730
tumour	I	731-737
/	O	737-738
blood	O	738-743
pairs	O	744-749
examined	O	750-758
from	O	759-763
this	O	764-768
family	O	769-775
show	O	776-780
loss	O	781-785
of	O	786-788
heterozygosity	O	789-803
in	O	804-806
the	O	807-810
tumours	B	811-818
.	O	818-819

The	O	820-823
allel	O	824-829
retained	O	830-838
in	O	839-841
each	O	842-846
tumour	B	847-853
was	O	854-857
from	O	858-862
the	O	863-866
disease	O	867-874
-	O	874-875
bearing	O	875-882
chromosome	O	883-893
implicating	O	894-905
BRCA1	O	906-911
as	O	912-914
a	O	915-916
tumour	B	917-923
suppressor	O	924-934
gene	O	935-939
.	O	939-940

We	O	941-943
have	O	944-948
sequenced	O	949-958
the	O	959-962
17	O	963-965
beta	O	966-970
-	O	970-971
oestradiol	O	971-981
dehydrogenase	O	982-995
genes	O	996-1001
(	O	1002-1003
EDH17B1	O	1003-1010
and	O	1011-1014
EDH17B2	O	1015-1022
)	O	1022-1023
which	O	1024-1029
have	O	1030-1034
been	O	1035-1039
suggested	O	1040-1049
as	O	1050-1052
candidate	O	1053-1062
genes	O	1063-1068
for	O	1069-1072
BRCA1	O	1073-1078
in	O	1079-1081
four	O	1082-1086
members	O	1087-1094
of	O	1095-1097
this	O	1098-1102
family	O	1103-1109
.	O	1109-1110

No	O	1111-1113
germline	O	1114-1122
mutations	O	1123-1132
were	O	1133-1137
detected	O	1138-1146
.	O	1146-1147

A	O	0-1
point	O	2-7
mutation	O	8-16
Thr	O	17-20
(	O	20-21
799	O	21-24
)	O	24-25
Met	O	25-28
on	O	29-31
the	O	32-35
alpha	O	36-41
(	O	41-42
2	O	42-43
)	O	43-44
integrin	O	45-53
leads	O	54-59
to	O	60-62
the	O	63-66
formation	O	67-76
of	O	77-79
new	O	80-83
human	O	84-89
platelet	O	90-98
alloantigen	O	99-110
Sit	O	111-114
(	O	114-115
a	O	115-116
)	O	116-117
and	O	118-121
affects	O	122-129
collagen	O	130-138
-	O	138-139
induced	O	139-146
aggregation	O	147-158
.	O	158-159

A	O	160-161
new	O	162-165
platelet	O	166-174
-	O	174-175
specific	O	175-183
alloantigen	O	184-195
,	O	195-196
termed	O	197-203
Sit	O	204-207
(	O	208-209
a	O	209-210
)	O	210-211
,	O	211-212
was	O	213-216
identified	O	217-227
in	O	228-230
a	O	231-232
severe	O	233-239
case	O	240-244
of	O	245-247
neonatal	B	248-256
alloimmune	I	257-267
thrombocytopenia	I	268-284
.	O	284-285

The	O	286-289
Sit	O	290-293
(	O	294-295
a	O	295-296
)	O	296-297
alloantigen	O	298-309
is	O	310-312
of	O	313-315
low	O	316-319
frequency	O	320-329
(	O	330-331
1	O	331-332
/	O	332-333
400	O	333-336
)	O	336-337
in	O	338-340
the	O	341-344
German	O	345-351
population	O	352-362
.	O	362-363

Immunochemical	O	364-378
studies	O	379-386
demonstrated	O	387-399
that	O	400-404
the	O	405-408
Sit	O	409-412
(	O	413-414
a	O	414-415
)	O	415-416
epitopes	O	417-425
reside	O	426-432
on	O	433-435
platelet	O	436-444
glycoprotein	O	445-457
(	O	458-459
GP	O	459-461
)	O	461-462
Ia	O	463-465
.	O	465-466

Nucleotide	O	467-477
sequence	O	478-486
analysis	O	487-495
of	O	496-498
GPIa	O	499-503
cDNA	O	504-508
derived	O	509-516
from	O	517-521
Sit	O	522-525
(	O	526-527
a	O	527-528
)	O	528-529
-	O	530-531
positive	O	531-539
platelets	O	540-549
showed	O	550-556
C	O	557-558
(	O	559-560
2531	O	560-564
)	O	564-565
-	O	566-567
-	O	566-567
>	O	569-570
T	O	571-572
(	O	573-574
2531	O	574-578
)	O	578-579
point	O	580-585
mutation	O	586-594
,	O	594-595
resulting	O	596-605
in	O	606-608
Thr	O	609-612
(	O	613-614
799	O	614-617
)	O	617-618
Met	O	619-622
dimorphism	O	623-633
.	O	633-634

Analysis	O	635-643
of	O	644-646
genomic	O	647-654
DNA	O	655-658
from	O	659-663
22	O	664-666
Sit	O	667-670
(	O	671-672
a	O	672-673
)	O	673-674
-	O	675-676
negative	O	676-684
normal	O	685-691
individuals	O	692-703
showed	O	704-710
that	O	711-715
the	O	716-719
Thr	O	720-723
(	O	724-725
799	O	725-728
)	O	728-729
is	O	730-732
encoded	O	733-740
by	O	741-743
ACG	O	744-747
(	O	748-749
2532	O	749-753
)	O	753-754
(	O	755-756
90	O	756-758
.	O	758-759

9	O	760-761
%	O	761-762
)	O	762-763
or	O	764-766
ACA	O	767-770
(	O	771-772
2532	O	772-776
)	O	776-777
(	O	778-779
9	O	779-780
.	O	780-781

1	O	782-783
%	O	783-784
)	O	784-785
.	O	785-786

To	O	787-789
establish	O	790-799
a	O	800-801
DNA	O	802-805
typing	O	806-812
technique	O	813-822
,	O	822-823
we	O	824-826
elucidated	O	827-837
the	O	838-841
organization	O	842-854
of	O	855-857
the	O	858-861
GPIa	O	862-866
gene	O	867-871
adjacent	O	872-880
to	O	881-883
the	O	884-887
polymorphic	O	888-899
bases	O	900-905
.	O	905-906

The	O	907-910
introns	O	911-918
(	O	919-920
421	O	920-923
bp	O	924-926
and	O	927-930
1	O	931-932
.	O	932-933
2	O	934-935
kb	O	936-938
)	O	938-939
encompass	O	940-949
a	O	950-951
142	O	952-955
-	O	955-956
bp	O	956-958
exon	O	959-963
with	O	964-968
the	O	969-972
2	O	973-974
polymorphic	O	975-986
bases	O	987-992
2531	O	993-997
and	O	998-1001
2532	O	1002-1006
.	O	1006-1007

Polymerase	O	1008-1018
chain	O	1019-1024
reaction	O	1025-1033
-	O	1033-1034
restriction	O	1034-1045
fragment	O	1046-1054
length	O	1055-1061
polymorphism	O	1062-1074
analysis	O	1075-1083
on	O	1084-1086
DNA	O	1087-1090
derived	O	1091-1098
from	O	1099-1103
100	O	1104-1107
donors	O	1108-1114
using	O	1115-1120
the	O	1121-1124
restriction	O	1125-1136
enzyme	O	1137-1143
Mae	O	1144-1147
III	O	1148-1151
showed	O	1152-1158
that	O	1159-1163
the	O	1164-1167
Met	O	1168-1171
(	O	1172-1173
799	O	1173-1176
)	O	1176-1177
form	O	1178-1182
of	O	1183-1185
GPIa	O	1186-1190
is	O	1191-1193
restricted	O	1194-1204
to	O	1205-1207
Sit	O	1208-1211
(	O	1212-1213
a	O	1213-1214
)	O	1214-1215
(	O	1216-1217
+	O	1217-1218
)	O	1218-1219
phenotype	O	1220-1229
.	O	1229-1230

Analysis	O	1231-1239
of	O	1240-1242
stable	O	1243-1249
Chinese	O	1250-1257
hamster	O	1258-1265
ovary	O	1266-1271
transfectants	O	1272-1285
expressing	O	1286-1296
allele	O	1297-1303
-	O	1303-1304
specific	O	1304-1312
recombinant	O	1313-1324
forms	O	1325-1330
of	O	1331-1333
GPIa	O	1334-1338
showed	O	1339-1345
that	O	1346-1350
anti	O	1351-1355
-	O	1355-1356
Sit	O	1356-1359
(	O	1360-1361
a	O	1361-1362
)	O	1362-1363
exclusively	O	1364-1375
reacted	O	1376-1383
with	O	1384-1388
the	O	1389-1392
Glu	O	1393-1396
(	O	1397-1398
505	O	1398-1401
)	O	1401-1402
Met	O	1403-1406
(	O	1407-1408
799	O	1408-1411
)	O	1411-1412
,	O	1412-1413
but	O	1414-1417
not	O	1418-1421
with	O	1422-1426
the	O	1427-1430
Glu	O	1431-1434
(	O	1435-1436
505	O	1436-1439
)	O	1439-1440
Thr	O	1441-1444
(	O	1445-1446
799	O	1446-1449
)	O	1449-1450
and	O	1451-1454
the	O	1455-1458
Lys	O	1459-1462
(	O	1463-1464
505	O	1464-1467
)	O	1467-1468
Thr	O	1469-1472
(	O	1473-1474
799	O	1474-1477
)	O	1477-1478
isoforms	O	1479-1487
.	O	1487-1488

In	O	1489-1491
contrast	O	1492-1500
,	O	1500-1501
anti	O	1502-1506
-	O	1506-1507
Br	O	1507-1509
(	O	1510-1511
a	O	1511-1512
)	O	1512-1513
(	O	1514-1515
HPA	O	1515-1518
-	O	1518-1519
5b	O	1519-1521
)	O	1521-1522
only	O	1523-1527
recognized	O	1528-1538
the	O	1539-1542
Lys	O	1543-1546
(	O	1547-1548
505	O	1548-1551
)	O	1551-1552
Thr	O	1553-1556
(	O	1557-1558
799	O	1558-1561
)	O	1561-1562
form	O	1563-1567
,	O	1567-1568
whereas	O	1569-1576
anti	O	1577-1581
-	O	1581-1582
Br	O	1582-1584
(	O	1585-1586
b	O	1586-1587
)	O	1587-1588
(	O	1589-1590
HPA	O	1590-1593
-	O	1593-1594
5a	O	1594-1596
)	O	1596-1597
reacted	O	1598-1605
with	O	1606-1610
both	O	1611-1615
Glu	O	1616-1619
(	O	1620-1621
505	O	1621-1624
)	O	1624-1625
Thr	O	1626-1629
(	O	1630-1631
799	O	1631-1634
)	O	1634-1635
and	O	1636-1639
Glu	O	1640-1643
(	O	1644-1645
505	O	1645-1648
)	O	1648-1649
Met	O	1650-1653
(	O	1654-1655
799	O	1655-1658
)	O	1658-1659
isoforms	O	1660-1668
.	O	1668-1669

These	O	1670-1675
results	O	1676-1683
demonstrated	O	1684-1696
that	O	1697-1701
the	O	1702-1705
Met	O	1706-1709
(	O	1710-1711
799	O	1711-1714
)	O	1714-1715
is	O	1716-1718
responsible	O	1719-1730
for	O	1731-1734
formation	O	1735-1744
of	O	1745-1747
the	O	1748-1751
Sit	O	1752-1755
(	O	1756-1757
a	O	1757-1758
)	O	1758-1759
alloantigenic	O	1760-1773
determinants	O	1774-1786
,	O	1786-1787
whereas	O	1788-1795
amino	O	1796-1801
acid	O	1802-1806
505	O	1807-1810
(	O	1811-1812
Lys	O	1812-1815
or	O	1816-1818
Glu	O	1819-1822
)	O	1822-1823
specifically	O	1824-1836
controls	O	1837-1845
the	O	1846-1849
expression	O	1850-1860
of	O	1861-1863
Br	O	1864-1866
(	O	1867-1868
a	O	1868-1869
)	O	1869-1870
and	O	1871-1874
Br	O	1875-1877
(	O	1878-1879
b	O	1879-1880
)	O	1880-1881
epitopes	O	1882-1890
,	O	1890-1891
respectively	O	1892-1904
.	O	1904-1905

Platelet	O	1906-1914
aggregation	O	1915-1926
responses	O	1927-1936
of	O	1937-1939
Sit	O	1940-1943
(	O	1944-1945
a	O	1945-1946
)	O	1946-1947
(	O	1948-1949
+	O	1949-1950
)	O	1950-1951
individuals	O	1952-1963
were	O	1964-1968
diminished	O	1969-1979
in	O	1980-1982
response	O	1983-1991
to	O	1992-1994
collagen	O	1995-2003
,	O	2003-2004
indicating	O	2005-2015
that	O	2016-2020
the	O	2021-2024
Thr	O	2025-2028
(	O	2029-2030
799	O	2030-2033
)	O	2033-2034
Met	O	2035-2038
mutation	O	2039-2047
affects	O	2048-2055
the	O	2056-2059
function	O	2060-2068
of	O	2069-2071
the	O	2072-2075
GPIa	O	2076-2080
/	O	2080-2081
IIa	O	2081-2084
complex	O	2085-2092

Estimation	O	0-10
of	O	11-13
the	O	14-17
male	O	18-22
to	O	23-25
female	O	26-32
ratio	O	33-38
of	O	39-41
mutation	O	42-50
rates	O	51-56
from	O	57-61
the	O	62-65
segregation	O	66-77
of	O	78-80
X	O	81-82
-	O	82-83
chromosomal	O	83-94
DNA	O	95-98
haplotypes	O	99-109
in	O	110-112
Duchenne	B	113-121
muscular	I	122-130
dystrophy	I	131-140
families	O	141-149
.	O	149-150

A	O	151-152
novel	O	153-158
procedure	O	159-168
is	O	169-171
presented	O	172-181
to	O	182-184
estimate	O	185-193
the	O	194-197
ratio	O	198-203
of	O	204-206
male	O	207-211
to	O	212-214
female	O	215-221
mutation	O	222-230
rates	O	231-236
for	O	237-240
Duchenne	B	241-249
muscular	I	250-258
dystrophy	I	259-268
(	O	269-270
DMD	B	270-273
)	O	273-274
.	O	274-275

X	O	276-277
-	O	277-278
specific	O	278-286
restriction	O	287-298
fragment	O	299-307
length	O	308-314
polymorphisms	O	315-328
are	O	329-332
used	O	333-337
to	O	338-340
establish	O	341-350
DNA	O	351-354
haplotypes	O	355-365
in	O	366-368
three	O	369-374
-	O	374-375
generation	O	375-385
DMD	B	386-389
families	O	390-398
.	O	398-399

From	O	400-404
the	O	405-408
proportion	O	409-419
of	O	420-422
DMD	B	423-426
patients	O	427-435
who	O	436-439
have	O	440-444
inherited	O	445-454
their	O	455-460
maternal	O	461-469
grandfathers	O	470-482
X	O	483-484
chromosome	O	485-495
,	O	495-496
the	O	497-500
ratio	O	501-506
of	O	507-509
mutation	O	510-518
rates	O	519-524
can	O	525-528
be	O	529-531
calculated	O	532-542
.	O	542-543

In	O	544-546
contrast	O	547-555
to	O	556-558
classical	O	559-568
methods	O	569-576
,	O	576-577
the	O	578-581
proposed	O	582-590
procedure	O	591-600
is	O	601-603
not	O	604-607
restricted	O	608-618
to	O	619-621
sporadic	O	622-630
or	O	631-633
familiar	O	634-642
cases	O	643-648
nor	O	649-652
is	O	653-655
any	O	656-659
information	O	660-671
on	O	672-674
the	O	675-678
carrier	O	679-686
status	O	687-693
of	O	694-696
female	O	697-703
relatives	O	704-713
required	O	714-722
.	O	722-723
.	O	722-723

Genetic	O	0-7
analysis	O	8-16
of	O	17-19
an	O	20-22
inherited	O	23-32
deficiency	B	33-43
of	I	44-46
the	I	47-50
third	I	51-56
component	I	57-66
of	I	67-69
complement	I	70-80
in	O	81-83
Brittany	O	84-92
spaniel	O	93-100
dogs	O	101-105
.	O	105-106

Genetically	O	107-118
determined	O	119-129
C3	B	130-132
deficiency	I	133-143
in	O	144-146
Brittany	O	147-155
spaniel	O	156-163
dogs	O	164-168
shares	O	169-175
a	O	176-177
number	O	178-184
of	O	185-187
biochemical	O	188-199
and	O	200-203
clinical	O	204-212
characteristics	O	213-228
with	O	229-233
the	O	234-237
human	O	238-243
disorder	O	244-252
.	O	252-253

In	O	254-256
humans	O	257-263
,	O	263-264
the	O	265-268
gene	O	269-273
for	O	274-277
C3	B	278-280
deficiency	I	281-291
is	O	292-294
a	O	295-296
null	O	297-301
gene	O	302-306
that	O	307-311
is	O	312-314
allelic	O	315-322
to	O	323-325
the	O	326-329
structural	O	330-340
gene	O	341-345
for	O	346-349
C3	O	350-352
and	O	353-356
is	O	357-359
not	O	360-363
linked	O	364-370
to	O	371-373
the	O	374-377
major	O	378-383
histocompatibility	O	384-402
locus	O	403-408
.	O	408-409

The	O	410-413
current	O	414-421
study	O	422-427
used	O	428-432
allotype	O	433-441
analysis	O	442-450
of	O	451-453
canine	O	454-460
C3	O	461-463
in	O	464-466
order	O	467-472
to	O	473-475
demonstrate	O	476-487
that	O	488-492
the	O	493-496
gene	O	497-501
for	O	502-505
C3	B	506-508
deficiency	I	509-519
in	O	520-522
these	O	523-528
dogs	O	529-533
is	O	534-536
also	O	537-541
a	O	542-543
null	O	544-548
gene	O	549-553
allelic	O	554-561
to	O	562-564
the	O	565-568
structural	O	569-579
gene	O	580-584
for	O	585-588
C3	O	589-591
.	O	591-592

In	O	593-595
addition	O	596-604
,	O	604-605
preliminary	O	606-617
pedigree	O	618-626
analysis	O	627-635
suggests	O	636-644
that	O	645-649
the	O	650-653
gene	O	654-658
for	O	659-662
canine	O	663-669
C3	B	670-672
deficiency	I	673-683
is	O	684-686
apparently	O	687-697
not	O	698-701
closely	O	702-709
linked	O	710-716
to	O	717-719
the	O	720-723
major	O	724-729
histocompatibility	O	730-748
complex	O	749-756
of	O	757-759
the	O	760-763
dog	O	764-767
.	O	767-768

Thus	O	769-773
,	O	773-774
it	O	775-777
appears	O	778-785
that	O	786-790
C3	B	791-793
deficiency	I	794-804
in	O	805-807
Brittany	O	808-816
spaniel	O	817-824
dogs	O	825-829
not	O	830-833
only	O	834-838
shares	O	839-845
biochemical	O	846-857
and	O	858-861
clinical	O	862-870
features	O	871-879
with	O	880-884
C3	B	885-887
deficiency	I	888-898
in	O	899-901
humans	O	902-908
,	O	908-909
but	O	910-913
also	O	914-918
shares	O	919-925
some	O	926-930
genetic	O	931-938
characteristics	O	939-954
with	O	955-959
the	O	960-963
human	O	964-969
disorder	O	970-978
.	O	978-979
.	O	978-979

A	O	0-1
novel	O	2-7
frameshift	O	8-18
mutation	O	19-27
in	O	28-30
the	O	31-34
McLeod	B	35-41
syndrome	I	42-50
gene	O	51-55
in	O	56-58
a	O	59-60
Japanese	O	61-69
family	O	70-76
.	O	76-77

We	O	78-80
report	O	81-87
a	O	88-89
novel	O	90-95
mutation	O	96-104
in	O	105-107
the	O	108-111
XK	O	112-114
gene	O	115-119
(	O	120-121
XK	O	121-123
)	O	123-124
in	O	125-127
a	O	128-129
Japanese	O	130-138
patient	O	139-146
with	O	147-151
McLeod	B	152-158
syndrome	I	159-167
.	O	167-168

A	O	169-170
50	O	171-173
-	O	173-174
year	O	174-178
-	O	173-174
old	O	179-182
man	O	183-186
showed	O	187-193
progressive	O	194-205
muscular	B	206-214
atrophy	I	215-222
,	O	222-223
choreic	B	224-231
movement	I	232-240
,	O	240-241
elevated	O	242-250
level	O	251-256
of	O	257-259
serum	O	260-265
creatinine	O	266-276
kinase	O	277-283
,	O	283-284
and	O	285-288
acanthocytosis	B	289-303
.	O	303-304

The	O	305-308
expression	O	309-319
level	O	320-325
of	O	326-328
all	O	329-332
the	O	333-336
Kell	O	337-341
antigens	O	342-350
in	O	351-353
erythrocyte	O	354-365
was	O	366-369
decreased	O	370-379
and	O	380-383
molecular	O	384-393
analysis	O	394-402
revealed	O	403-411
a	O	412-413
single	O	414-420
-	O	420-421
base	O	421-425
(	O	426-427
T	O	427-428
)	O	428-429
deletion	O	430-438
at	O	439-441
the	O	442-445
nucleotide	O	446-456
position	O	457-465
1095	O	466-470
in	O	471-473
XK	O	474-476
.	O	476-477

This	O	478-482
deletion	O	483-491
caused	O	492-498
a	O	499-500
frameshift	O	501-511
in	O	512-514
translation	O	515-526
,	O	526-527
leading	O	528-535
to	O	536-538
a	O	539-540
premature	O	541-550
stop	O	551-555
codon	O	556-561
at	O	562-564
the	O	565-568
amino	O	569-574
acid	O	575-579
position	O	580-588
408	O	589-592
.	O	592-593

We	O	594-596
conclude	O	597-605
this	O	606-610
single	O	611-617
-	O	617-618
base	O	618-622
deletion	O	623-631
causes	O	632-638
defective	O	639-648
Kx	O	649-651
protein	O	652-659
,	O	659-660
which	O	661-666
is	O	667-669
responsible	O	670-681
for	O	682-685
the	O	686-689
McLeod	B	690-696
phenotype	O	697-706
in	O	707-709
this	O	710-714
patient	O	715-722
.	O	722-723
.	O	722-723

Alpha	O	0-5
-	O	5-6
cardiac	O	6-13
actin	O	14-19
is	O	20-22
a	O	23-24
novel	O	25-30
disease	O	31-38
gene	O	39-43
in	O	44-46
familial	B	47-55
hypertrophic	I	56-68
cardiomyopathy	I	69-83
.	O	83-84

We	O	85-87
identified	O	88-98
the	O	99-102
alpha	O	103-108
-	O	108-109
cardiac	O	109-116
actin	O	117-122
gene	O	123-127
(	O	128-129
ACTC	O	129-133
)	O	133-134
as	O	135-137
a	O	138-139
novel	O	140-145
disease	O	146-153
gene	O	154-158
in	O	159-161
a	O	162-163
pedigree	O	164-172
suffering	O	173-182
from	O	183-187
familial	B	188-196
hypertrophic	I	197-209
cardiomyopathy	I	210-224
(	O	225-226
FHC	B	226-229
)	O	229-230
.	O	230-231

Linkage	O	232-239
analyses	O	240-248
excluded	O	249-257
all	O	258-261
the	O	262-265
previously	O	266-276
reported	O	277-285
FHC	B	286-289
loci	O	290-294
as	O	295-297
possible	O	298-306
disease	O	307-314
loci	O	315-319
in	O	320-322
the	O	323-326
family	O	327-333
studied	O	334-341
,	O	341-342
with	O	343-347
lod	O	348-351
scores	O	352-358
varying	O	359-366
between	O	367-374
-	O	375-376
2	O	376-377
.	O	377-378
5	O	379-380
and	O	381-384
-	O	385-386
6	O	386-387
.	O	387-388

0	O	389-390
0	O	391-392
.	O	392-393
Further	O	394-401
linkage	O	402-409
analyses	O	410-418
of	O	419-421
plausible	O	422-431
candidate	O	432-441
genes	O	442-447
highly	O	448-454
expressed	O	455-464
in	O	465-467
the	O	468-471
adult	O	472-477
human	O	478-483
heart	O	484-489
identified	O	490-500
ACTC	O	501-505
as	O	506-508
the	O	509-512
most	O	513-517
likely	O	518-524
disease	O	525-532
gene	O	533-537
,	O	537-538
showing	O	539-546
a	O	547-548
maximal	O	549-556
lod	O	557-560
score	O	561-566
of	O	567-569
3	O	570-571
.	O	571-572
6	O	573-574
6	O	575-576
.	O	576-577

Mutation	O	578-586
analysis	O	587-595
of	O	596-598
ACTC	O	599-603
revealed	O	604-612
an	O	613-615
Ala295Ser	O	616-625
mutation	O	626-634
in	O	635-637
exon	O	638-642
5	O	643-644
close	O	645-650
to	O	651-653
2	O	654-655
missense	O	656-664
mutations	O	665-674
recently	O	675-683
described	O	684-693
to	O	694-696
cause	O	697-702
the	O	703-706
inherited	O	707-716
form	O	717-721
of	O	722-724
idiopathic	B	725-735
dilated	I	736-743
cardiomyopathy	I	744-758
(	O	759-760
IDC	B	760-763
)	O	763-764
.	O	764-765

The	O	0-3
EWS	O	4-7
gene	O	8-12
,	O	12-13
involved	O	14-22
in	O	23-25
Ewing	B	26-31
family	I	32-38
of	I	39-41
tumors	I	42-48
,	O	48-49
malignant	B	50-59
melanoma	I	60-68
of	I	69-71
soft	I	72-76
parts	I	77-82
and	O	83-86
desmoplastic	B	87-99
small	I	100-105
round	I	106-111
cell	I	112-116
tumors	I	117-123
,	O	123-124
codes	O	125-130
for	O	131-134
an	O	135-137
RNA	O	138-141
binding	O	142-149
protein	O	150-157
with	O	158-162
novel	O	163-168
regulatory	O	169-179
domains	O	180-187
.	O	187-188

The	O	189-192
EWS	O	193-196
gene	O	197-201
,	O	201-202
which	O	203-208
maps	O	209-213
to	O	214-216
band	O	217-221
q12	O	222-225
of	O	226-228
human	O	229-234
chromosome	O	235-245
22	O	246-248
,	O	248-249
is	O	250-252
involved	O	253-261
in	O	262-264
a	O	265-266
wide	O	267-271
variety	O	272-279
of	O	280-282
human	O	283-288
solid	B	289-294
tumors	I	295-301
including	O	302-311
Ewing	B	312-317
sarcoma	I	318-325
,	O	325-326
related	O	327-334
primitive	O	335-344
neuroectodermal	B	345-360
tumors	I	361-367
,	O	367-368
malignant	B	369-378
melanoma	I	379-387
of	I	388-390
soft	I	391-395
parts	I	396-401
and	O	402-405
desmoplastic	B	406-418
small	I	419-424
round	I	425-430
cell	I	431-435
tumors	I	436-442
.	O	442-443

In	O	444-446
these	O	447-452
tumors	B	453-459
,	O	459-460
the	O	461-464
EWS	O	465-468
is	O	469-471
fused	O	472-477
to	O	478-480
genes	O	481-486
encoding	O	487-495
transcriptional	O	496-511
activators	O	512-522
/	O	522-523
repressors	O	523-533
,	O	533-534
like	O	535-539
Fli	O	540-543
-	O	543-544
1	O	544-545
or	O	546-548
erg	O	549-552
or	O	553-555
ATF	O	556-559
1	O	560-561
or	O	562-564
wt1	O	565-568
.	O	568-569

To	O	570-572
better	O	573-579
understand	O	580-590
the	O	591-594
function	O	595-603
of	O	604-606
the	O	607-610
EWS	O	611-614
protein	O	615-622
,	O	622-623
we	O	624-626
cloned	O	627-633
the	O	634-637
EWS	O	638-641
cDNA	O	642-646
.	O	646-647

Sequence	O	648-656
analysis	O	657-665
of	O	666-668
this	O	669-673
cDNA	O	674-678
revealed	O	679-687
differential	O	688-700
splicing	O	701-709
involving	O	710-719
two	O	720-723
exons	O	724-729
encoding	O	730-738
72	O	739-741
amino	O	742-747
acids	O	748-753
.	O	753-754

Both	O	755-759
alternatively	O	760-773
spliced	O	774-781
transcripts	O	782-793
,	O	793-794
EWS	O	795-798
and	O	799-802
EWS	O	803-806
-	O	806-807
b	O	807-808
,	O	808-809
are	O	810-813
expressed	O	814-823
in	O	824-826
a	O	827-828
variety	O	829-836
of	O	837-839
cells	O	840-845
.	O	845-846

Because	O	847-854
EWS	O	855-858
proteins	O	859-867
contain	O	868-875
putative	O	876-884
conserved	O	885-894
RNA	O	895-898
binding	O	899-906
motifs	O	907-913
,	O	913-914
we	O	915-917
studied	O	918-925
the	O	926-929
RNA	O	930-933
binding	O	934-941
properties	O	942-952
of	O	953-955
the	O	956-959
EWS	O	960-963
protein	O	964-971
.	O	971-972

The	O	973-976
EWS	O	977-980
-	O	980-981
b	O	981-982
protein	O	983-990
binds	O	991-996
to	O	997-999
RNA	O	1000-1003
in	O	1004-1006
vitro	O	1007-1012
and	O	1013-1016
,	O	1016-1017
specifically	O	1018-1030
,	O	1030-1031
to	O	1032-1034
poly	O	1035-1039
G	O	1040-1041
and	O	1042-1045
poly	O	1046-1050
U	O	1051-1052
.	O	1052-1053

The	O	1054-1057
RNA	O	1058-1061
binding	O	1062-1069
activity	O	1070-1078
was	O	1079-1082
localized	O	1083-1092
to	O	1093-1095
the	O	1096-1099
carboxy	O	1100-1107
terminal	O	1108-1116
86	O	1117-1119
amino	O	1120-1125
acids	O	1126-1131
,	O	1131-1132
which	O	1133-1138
constitute	O	1139-1149
RGG	O	1150-1153
box	O	1154-1157
.	O	1157-1158

Thus	O	1159-1163
the	O	1164-1167
amino	O	1168-1173
terminal	O	1174-1182
domain	O	1183-1189
of	O	1190-1192
EWS	O	1193-1196
(	O	1197-1198
NTD	O	1198-1201
-	O	1201-1202
EWS	O	1202-1205
)	O	1205-1206
,	O	1206-1207
which	O	1208-1213
is	O	1214-1216
involved	O	1217-1225
in	O	1226-1228
chromosome	O	1229-1239
translocation	O	1240-1253
may	O	1254-1257
regulate	O	1258-1266
the	O	1267-1270
specificity	O	1271-1282
of	O	1283-1285
RNA	O	1286-1289
binding	O	1290-1297
activity	O	1298-1306
of	O	1307-1309
EWS	O	1310-1313
.	O	1313-1314

An	O	1315-1317
EWS	O	1318-1321
-	O	1321-1322
erg	O	1322-1325
chimeric	O	1326-1334
protein	O	1335-1342
,	O	1342-1343
which	O	1344-1349
is	O	1350-1352
found	O	1353-1358
in	O	1359-1361
Ewings	B	1362-1368
sarcoma	I	1369-1376
cells	O	1377-1382
,	O	1382-1383
functions	O	1384-1393
as	O	1394-1396
a	O	1397-1398
transcriptional	O	1399-1414
activator	O	1415-1424
.	O	1424-1425

Mutational	O	1426-1436
analysis	O	1437-1445
of	O	1446-1448
EWS	O	1449-1452
-	O	1452-1453
erg	O	1453-1456
chimeric	O	1457-1465
protein	O	1466-1473
revealed	O	1474-1482
that	O	1483-1487
NTD	O	1488-1491
-	O	1491-1492
EWS	O	1492-1495
functions	O	1496-1505
as	O	1506-1508
a	O	1509-1510
regulatory	O	1511-1521
domain	O	1522-1528
for	O	1529-1532
the	O	1533-1536
transcriptional	O	1537-1552
activation	O	1553-1563
properties	O	1564-1574
of	O	1575-1577
EWS	O	1578-1581
-	O	1581-1582
erg	O	1582-1585
chimeric	O	1586-1594
protein	O	1595-1602
.	O	1602-1603
.	O	1602-1603

A	O	0-1
mutation	O	2-10
common	O	11-17
in	O	18-20
non	O	21-24
-	O	24-25
Jewish	O	25-31
Tay	B	32-35
-	I	35-36
Sachs	I	36-41
disease	I	42-49
:	O	49-50
frequency	O	51-60
and	O	61-64
RNA	O	65-68
studies	O	69-76
.	O	76-77

Tay	B	78-81
-	I	81-82
Sachs	I	82-87
disease	I	88-95
(	O	96-97
TSD	B	97-100
)	O	100-101
is	O	102-104
an	O	105-107
autosomal	B	108-117
recessive	I	118-127
genetic	I	128-135
disorder	I	136-144
resulting	O	145-154
from	O	155-159
mutation	O	160-168
of	O	169-171
the	O	172-175
HEXA	O	176-180
gene	O	181-185
encoding	O	186-194
the	O	195-198
alpha	O	199-204
-	O	204-205
subunit	O	205-212
of	O	213-215
the	O	216-219
lysosomal	O	220-229
enzyme	O	230-236
,	O	236-237
beta	O	238-242
-	O	242-243
N	O	243-244
-	O	242-243
acetylhexosaminidase	O	245-265
A	O	266-267
(	O	268-269
Hex	O	269-272
A	O	273-274
)	O	274-275
.	O	275-276

We	O	277-279
have	O	280-284
discovered	O	285-295
that	O	296-300
a	O	301-302
Tay	B	303-306
-	I	306-307
Sachs	I	307-312
mutation	O	313-321
,	O	321-322
IVS	O	323-326
-	O	326-327
9	O	327-328
+	O	329-330
1	O	331-332
G	O	333-334
-	O	334-335
-	O	334-335
>	O	337-338
A	O	339-340
,	O	340-341
first	O	342-347
detected	O	348-356
by	O	357-359
Akli	O	360-364
et	O	365-367
al	O	368-370
.	O	370-371
(	O	372-373
Genomics	O	373-381
11	O	382-384
124	O	386-389
-	O	389-390
134	O	390-393
,	O	393-394
1991	O	395-399
)	O	399-400
,	O	400-401
is	O	402-404
a	O	405-406
common	O	407-413
disease	O	414-421
allele	O	422-428
in	O	429-431
non	O	432-435
-	O	435-436
Jewish	O	436-442
Caucasians	O	443-453
(	O	454-455
10	O	455-457
/	O	457-458
58	O	458-460
alleles	O	461-468
examined	O	469-477
)	O	477-478
.	O	478-479

A	O	480-481
PCR	O	482-485
-	O	485-486
based	O	486-491
diagnostic	O	492-502
test	O	503-507
,	O	507-508
which	O	509-514
detects	O	515-522
an	O	523-525
NlaIII	O	526-532
site	O	533-537
generated	O	538-547
by	O	548-550
the	O	551-554
mutation	O	555-563
,	O	563-564
revealed	O	565-573
a	O	574-575
frequency	O	576-585
among	O	586-591
enzyme	O	592-598
-	O	598-599
defined	O	599-606
carriers	O	607-615
of	O	616-618
9	O	619-620
/	O	620-621
64	O	621-623
(	O	624-625
14	O	625-627
%	O	627-628
)	O	628-629
.	O	629-630

Most	O	631-635
of	O	636-638
those	O	639-644
carrying	O	645-653
the	O	654-657
allele	O	658-664
trace	O	665-670
their	O	671-676
origins	O	677-684
to	O	685-687
the	O	688-691
United	O	692-698
Kingdom	O	699-706
,	O	706-707
Ireland	O	708-715
,	O	715-716
or	O	717-719
Western	O	720-727
Europe	O	728-734
.	O	734-735

It	O	736-738
was	O	739-742
not	O	743-746
identified	O	747-757
among	O	758-763
12	O	764-766
Black	O	767-772
American	O	773-781
TSD	B	782-785
alleles	O	786-793
or	O	794-796
in	O	797-799
any	O	800-803
of	O	804-806
18	O	807-809
Ashkenazi	O	810-819
Jewish	O	820-826
,	O	826-827
enzyme	O	828-834
-	O	834-835
defined	O	835-842
carriers	O	843-851
who	O	852-855
did	O	856-859
not	O	860-863
carry	O	864-869
any	O	870-873
of	O	874-876
the	O	877-880
mutations	O	881-890
common	O	891-897
to	O	898-900
this	O	901-905
population	O	906-916
.	O	916-917

No	O	918-920
normally	O	921-929
spliced	O	930-937
RNA	O	938-941
was	O	942-945
detected	O	946-954
in	O	955-957
PCR	O	958-961
products	O	962-970
generated	O	971-980
from	O	981-985
reverse	O	986-993
transcription	O	994-1007
of	O	1008-1010
RNA	O	1011-1014
carrying	O	1015-1023
the	O	1024-1027
IVS	O	1028-1031
-	O	1031-1032
9	O	1032-1033
mutation	O	1034-1042
.	O	1042-1043

Instead	O	1044-1051
,	O	1051-1052
the	O	1053-1056
low	O	1057-1060
levels	O	1061-1067
of	O	1068-1070
mRNA	O	1071-1075
from	O	1076-1080
this	O	1081-1085
allele	O	1086-1092
were	O	1093-1097
comprised	O	1098-1107
of	O	1108-1110
aberrant	O	1111-1119
species	O	1120-1127
resulting	O	1128-1137
from	O	1138-1142
the	O	1143-1146
use	O	1147-1150
of	O	1151-1153
either	O	1154-1160
of	O	1161-1163
two	O	1164-1167
cryptic	O	1168-1175
donor	O	1176-1181
sites	O	1182-1187
,	O	1187-1188
one	O	1189-1192
truncating	O	1193-1203
exon	O	1204-1208
9	O	1209-1210
and	O	1211-1214
the	O	1215-1218
other	O	1219-1224
within	O	1225-1231
IVS	O	1232-1235
-	O	1235-1236
9	O	1236-1237
,	O	1237-1238
spliced	O	1239-1246
to	O	1247-1249
exon	O	1250-1254
10	O	1255-1257
.	O	1257-1258

Numerous	O	1259-1267
additional	O	1268-1278
splice	O	1279-1285
products	O	1286-1294
were	O	1295-1299
detected	O	1300-1308
,	O	1308-1309
most	O	1310-1314
involving	O	1315-1324
skipping	O	1325-1333
of	O	1334-1336
one	O	1337-1340
or	O	1341-1343
more	O	1344-1348
surrounding	O	1349-1360
exons	O	1361-1366
.	O	1366-1367

Together	O	1368-1376
with	O	1377-1381
a	O	1382-1383
recently	O	1384-1392
identified	O	1393-1403
allele	O	1404-1410
responsible	O	1411-1422
for	O	1423-1426
Hex	O	1427-1430
A	O	1431-1432
pseudodeficiency	O	1433-1449
(	O	1450-1451
Triggs	O	1451-1457
-	O	1457-1458
Raine	O	1458-1463
et	O	1464-1466
al	O	1467-1469
.	O	1469-1470

Am	O	1471-1473
J	O	1474-1475
Hum	O	1476-1479
Genet	O	1480-1485
,	O	1485-1486
1992	O	1487-1491
)	O	1491-1492
,	O	1492-1493
these	O	1494-1499
two	O	1500-1503
alleles	O	1504-1511
accounted	O	1512-1521
for	O	1522-1525
almost	O	1526-1532
50	O	1533-1535
%	O	1535-1536
(	O	1537-1538
29	O	1538-1540
/	O	1540-1541
64	O	1541-1543
)	O	1543-1544
of	O	1545-1547
TSD	B	1548-1551
or	O	1552-1554
carrier	O	1555-1562
alleles	O	1563-1570
ascertained	O	1571-1582
by	O	1583-1585
enzyme	O	1586-1592
screening	O	1593-1602
tests	O	1603-1608
in	O	1609-1611
non	O	1612-1615
-	O	1615-1616
Jewish	O	1616-1622
Caucasians	O	1623-1633
.	O	1633-1634
.	O	1633-1634

Characterization	O	0-16
of	O	17-19
the	O	20-23
myotonic	B	24-32
dystrophy	I	33-42
region	O	43-49
predicts	O	50-58
multiple	O	59-67
protein	O	68-75
isoform	O	76-83
-	O	83-84
encoding	O	84-92
mRNAs	O	93-98
.	O	98-99

The	O	100-103
mutation	O	104-112
underlying	O	113-123
myotonic	B	124-132
dystrophy	I	133-142
(	O	143-144
DM	B	144-146
)	O	146-147
has	O	148-151
been	O	152-156
identified	O	157-167
as	O	168-170
an	O	171-173
expansion	O	174-183
of	O	184-186
a	O	187-188
polymorphic	O	189-200
CTG	O	201-204
-	O	204-205
repeat	O	205-211
in	O	212-214
a	O	215-216
gene	O	217-221
encoding	O	222-230
protein	O	231-238
kinase	O	239-245
activity	O	246-254
.	O	254-255

Brain	O	256-261
and	O	262-265
heart	O	266-271
transcripts	O	272-283
of	O	284-286
the	O	287-290
DM	O	291-293
-	O	293-294
kinase	O	294-300
(	O	301-302
DMR	O	302-305
-	O	305-306
B15	O	306-309
)	O	309-310
gene	O	311-315
are	O	316-319
subject	O	320-327
to	O	328-330
alternative	O	331-342
RNA	O	343-346
splicing	O	347-355
in	O	356-358
both	O	359-363
human	O	364-369
and	O	370-373
mouse	O	374-379
.	O	379-380

The	O	381-384
unstable	O	385-393
[	O	394-395
CTG	O	395-398
]	O	398-399
5	O	400-401
-	O	401-402
30	O	402-404
motif	O	405-410
is	O	411-413
found	O	414-419
uniquely	O	420-428
in	O	429-431
humans	O	432-438
,	O	438-439
although	O	440-448
the	O	449-452
flanking	O	453-461
nucleotides	O	462-473
are	O	474-477
also	O	478-482
present	O	483-490
in	O	491-493
mouse	O	494-499
.	O	499-500

Characterization	O	501-517
of	O	518-520
the	O	521-524
DM	B	525-527
region	O	528-534
of	O	535-537
both	O	538-542
species	O	543-550
reveals	O	551-558
another	O	559-566
active	O	567-573
gene	O	574-578
(	O	579-580
DMR	O	580-583
-	O	583-584
N9	O	584-586
)	O	586-587
in	O	588-590
close	O	591-596
proximity	O	597-606
to	O	607-609
the	O	610-613
kinase	O	614-620
gene	O	621-625
.	O	625-626

DMR	O	627-630
-	O	630-631
N9	O	631-633
transcripts	O	634-645
,	O	645-646
mainly	O	647-653
expressed	O	654-663
in	O	664-666
brain	O	667-672
and	O	673-676
testis	O	677-683
,	O	683-684
possess	O	685-692
a	O	693-694
single	O	695-701
,	O	701-702
large	O	703-708
open	O	709-713
reading	O	714-721
frame	O	722-727
,	O	727-728
but	O	729-732
the	O	733-736
function	O	737-745
of	O	746-748
its	O	749-752
protein	O	753-760
product	O	761-768
is	O	769-771
unknown	O	772-779
.	O	779-780

Clinical	O	781-789
manifestation	O	790-803
of	O	804-806
DM	B	807-809
may	O	810-813
be	O	814-816
caused	O	817-823
by	O	824-826
the	O	827-830
expanded	O	831-839
CTG	O	840-843
-	O	843-844
repeat	O	844-850
compromising	O	851-863
the	O	864-867
(	O	868-869
alternative	O	869-880
)	O	880-881
expression	O	882-892
of	O	893-895
DM	O	896-898
-	O	898-899
kinase	O	899-905
or	O	906-908
DMR	O	909-912
-	O	912-913
N9	O	913-915
proteins	O	916-924
.	O	924-925
.	O	924-925

Paroxysmal	B	0-10
nocturnal	I	11-20
haemoglobinuria	I	21-36
with	O	37-41
coexisting	O	42-52
deficiency	B	53-63
of	I	64-66
the	I	67-70
ninth	I	71-76
component	I	77-86
of	I	87-89
complement	I	90-100
:	O	100-101
lack	O	102-106
of	O	107-109
massive	O	110-117
haemolytic	B	118-128
attack	I	129-135
.	O	135-136

A	O	137-138
47	O	139-141
-	O	141-142
year	O	142-146
-	O	141-142
old	O	147-150
woman	O	151-156
with	O	157-161
paroxysmal	B	162-172
nocturnal	I	173-182
haemoglobinuria	I	183-198
(	O	199-200
PNH	B	200-203
)	O	203-204
was	O	205-208
found	O	209-214
to	O	215-217
have	O	218-222
an	O	223-225
inherited	B	226-235
deficiency	I	236-246
in	I	247-249
the	I	250-253
ninth	I	254-259
complement	I	260-270
component	I	271-280
(	O	281-282
C9	O	282-284
)	O	284-285
.	O	285-286

In	O	287-289
complement	O	290-300
-	O	300-301
sensitivity	O	301-312
lysis	O	313-318
tests	O	319-324
,	O	324-325
80	O	326-328
%	O	328-329
of	O	330-332
her	O	333-336
erythrocytes	O	337-349
were	O	350-354
markedly	O	355-363
complement	O	364-374
-	O	374-375
sensitive	O	375-384
(	O	385-386
PNH	O	386-389
-	O	389-390
III	O	390-393
)	O	393-394
.	O	394-395

Laser	O	396-401
cytofluorimetry	O	402-417
with	O	418-422
a	O	423-424
monoclonal	O	425-435
antibody	O	436-444
against	O	445-452
decay	O	453-458
-	O	458-459
accelerating	O	459-471
factor	O	472-478
(	O	479-480
DAF	O	480-483
)	O	483-484
revealed	O	485-493
that	O	494-498
95	O	499-501
%	O	501-502
of	O	503-505
her	O	506-509
erythrocytes	O	510-522
were	O	523-527
DAF	O	528-531
-	O	531-532
negative	O	532-540
.	O	540-541

Surprisingly	O	542-554
,	O	554-555
she	O	556-559
has	O	560-563
suffered	O	564-572
only	O	573-577
mild	O	578-582
haemolysis	B	583-593
and	O	594-597
has	O	598-601
never	O	602-607
experienced	O	608-619
massive	O	620-627
spontaneous	O	628-639
haemolysis	B	640-650
.	O	650-651

Gross	O	652-657
haemoglobinuria	B	658-673
and	O	674-677
jaundice	B	678-686
occurred	O	687-695
only	O	696-700
after	O	701-706
receiving	O	707-716
postoperative	O	717-730
transfusion	O	731-742
of	O	743-745
whole	O	746-751
blood	O	752-757
.	O	757-758

In	O	759-761
her	O	762-765
serum	O	766-771
,	O	771-772
C9	O	773-775
was	O	776-779
not	O	780-783
detectable	O	784-794
either	O	795-801
by	O	802-804
immunological	O	805-818
or	O	819-821
by	O	822-824
functional	O	825-835
assays	O	836-842
.	O	842-843

Both	O	844-848
the	O	849-852
Ham	O	853-856
test	O	857-861
and	O	862-865
the	O	866-869
sugar	O	870-875
water	O	876-881
test	O	882-886
using	O	887-892
normal	O	893-899
human	O	900-905
serum	O	906-911
or	O	912-914
plasma	O	915-921
yielded	O	922-929
marked	O	930-936
haemolysis	O	937-947
of	O	948-950
the	O	951-954
patients	O	955-963
erythrocytes	O	964-976
.	O	976-977

When	O	978-982
the	O	983-986
patients	O	987-995
serum	O	996-1001
or	O	1002-1004
plasma	O	1005-1011
was	O	1012-1015
used	O	1016-1020
,	O	1020-1021
only	O	1022-1026
a	O	1027-1028
trace	O	1029-1034
of	O	1035-1037
lysis	O	1038-1043
was	O	1044-1047
detected	O	1048-1056
.	O	1056-1057

Addition	O	1058-1066
of	O	1067-1069
purified	O	1070-1078
human	O	1079-1084
C9	O	1085-1087
to	O	1088-1090
her	O	1091-1094
plasma	O	1095-1101
fully	O	1102-1107
restored	O	1108-1116
haemolysis	O	1117-1127
.	O	1127-1128

These	O	1129-1134
observations	O	1135-1147
indicated	O	1148-1157
that	O	1158-1162
C9	O	1163-1165
may	O	1166-1169
play	O	1170-1174
a	O	1175-1176
critical	O	1177-1185
role	O	1186-1190
in	O	1191-1193
haemolytic	B	1194-1204
attacks	I	1205-1212
in	O	1213-1215
patients	O	1216-1224
with	O	1225-1229
PNH	B	1230-1233
and	O	1234-1237
that	O	1238-1242
characteristic	O	1243-1257
haemolysis	B	1258-1268
in	O	1269-1271
PNH	B	1272-1275
may	O	1276-1279
be	O	1280-1282
tempered	O	1283-1291
by	O	1292-1294
coexisting	O	1295-1305
C9	B	1306-1308
deficiency	I	1309-1319
.	O	1319-1320
.	O	1319-1320

BRCA1	O	0-5
is	O	6-8
associated	O	9-19
with	O	20-24
a	O	25-26
human	O	27-32
SWI	O	33-36
/	O	36-37
SNF	O	37-40
-	O	40-41
related	O	41-48
complex	O	49-56
:	O	56-57
linking	O	58-65
chromatin	O	66-75
remodeling	O	76-86
to	O	87-89
breast	B	90-96
cancer	I	97-103
.	O	103-104

Germline	O	105-113
mutations	O	114-123
in	O	124-126
the	O	127-130
tumor	B	131-136
suppressor	O	137-147
gene	O	148-152
,	O	152-153
BRCA1	O	154-159
,	O	159-160
predispose	O	161-171
individuals	O	172-183
to	O	184-186
breast	B	187-193
and	I	194-197
ovarian	I	198-205
cancers	I	206-213
.	O	213-214

Using	O	215-220
a	O	221-222
combination	O	223-234
of	O	235-237
affinity	O	238-246
-	O	246-247
and	O	248-251
conventional	O	252-264
chromatographic	O	265-280
techniques	O	281-291
,	O	291-292
we	O	293-295
have	O	296-300
isolated	O	301-309
a	O	310-311
predominant	O	312-323
form	O	324-328
of	O	329-331
a	O	332-333
multiprotein	O	334-346
BRCA1	O	347-352
-	O	352-353
containing	O	353-363
complex	O	364-371
from	O	372-376
human	O	377-382
cells	O	383-388
displaying	O	389-399
chromatin	O	400-409
-	O	409-410
remodeling	O	410-420
activity	O	421-429
.	O	429-430

Mass	O	431-435
spectrometric	O	436-449
sequencing	O	450-460
of	O	461-463
components	O	464-474
of	O	475-477
this	O	478-482
complex	O	483-490
indicated	O	491-500
that	O	501-505
BRCA1	O	506-511
is	O	512-514
associated	O	515-525
with	O	526-530
a	O	531-532
SWI	O	533-536
/	O	536-537
SNF	O	537-540
-	O	540-541
related	O	541-548
complex	O	549-556
.	O	556-557

We	O	558-560
show	O	561-565
that	O	566-570
BRCA1	O	571-576
can	O	577-580
directly	O	581-589
interact	O	590-598
with	O	599-603
the	O	604-607
BRG1	O	608-612
subunit	O	613-620
of	O	621-623
the	O	624-627
SWI	O	628-631
/	O	631-632
SNF	O	632-635
complex	O	636-643
.	O	643-644

Moreover	O	645-653
,	O	653-654
p53	O	655-658
-	O	658-659
mediated	O	659-667
stimulation	O	668-679
of	O	680-682
transcription	O	683-696
by	O	697-699
BRCA1	O	700-705
was	O	706-709
completely	O	710-720
abrogated	O	721-730
by	O	731-733
either	O	734-740
a	O	741-742
dominant	O	743-751
-	O	751-752
negative	O	752-760
mutant	O	761-767
of	O	768-770
BRG1	O	771-775
or	O	776-778
the	O	779-782
cancer	B	783-789
-	O	789-790
causing	O	790-797
deletion	O	798-806
in	O	807-809
exon	O	810-814
11	O	815-817
of	O	818-820
BRCA1	O	821-826
.	O	826-827

These	O	828-833
findings	O	834-842
reveal	O	843-849
a	O	850-851
direct	O	852-858
function	O	859-867
for	O	868-871
BRCA1	O	872-877
in	O	878-880
transcriptional	O	881-896
control	O	897-904
through	O	905-912
modulation	O	913-923
of	O	924-926
chromatin	O	927-936
structure	O	937-946
.	O	946-947
.	O	946-947

Germinal	O	0-8
mosaicism	O	9-18
in	O	19-21
a	O	22-23
Duchenne	B	24-32
muscular	I	33-41
dystrophy	I	42-51
family	O	52-58
:	O	58-59
implications	O	60-72
for	O	73-76
genetic	O	77-84
counselling	O	85-96
.	O	96-97

In	O	98-100
this	O	101-105
study	O	106-111
we	O	112-114
describe	O	115-123
a	O	124-125
three	O	126-131
-	O	131-132
generation	O	132-142
family	O	143-149
in	O	150-152
which	O	153-158
two	O	159-162
siblings	O	163-171
were	O	172-176
affected	O	177-185
by	O	186-188
Duchenne	B	189-197
muscular	I	198-206
dystrophy	I	207-216
(	O	217-218
DMD	B	218-221
)	O	221-222
.	O	222-223

Immunohistochemical	O	224-243
analysis	O	244-252
of	O	253-255
muscle	O	256-262
dystrophin	O	263-273
and	O	274-277
haplotype	O	278-287
analysis	O	288-296
of	O	297-299
the	O	300-303
DMD	B	304-307
locus	O	308-313
revealed	O	314-322
that	O	323-327
the	O	328-331
X	O	332-333
chromosome	O	334-344
carrying	O	345-353
the	O	354-357
DMD	B	358-361
gene	O	362-366
was	O	367-370
transmitted	O	371-382
from	O	383-387
the	O	388-391
healthy	O	392-399
maternal	O	400-408
grandfather	O	409-420
to	O	421-423
his	O	424-427
three	O	428-433
daughters	O	434-443
,	O	443-444
including	O	445-454
the	O	455-458
probands	O	459-467
mother	O	468-474
.	O	474-475

These	O	476-481
findings	O	482-490
indicate	O	491-499
that	O	500-504
the	O	505-508
grandfather	O	509-520
was	O	521-524
a	O	525-526
germinal	O	527-535
mosaic	O	536-542
for	O	543-546
the	O	547-550
DMD	B	551-554
gene	O	555-559
.	O	559-560

The	O	561-564
definition	O	565-575
of	O	576-578
the	O	579-582
carrier	O	583-590
status	O	591-597
in	O	598-600
two	O	601-604
possible	O	605-613
carriers	O	614-622
led	O	623-626
us	O	627-629
to	O	630-632
give	O	633-637
accurate	O	638-646
genetic	O	647-654
counselling	O	655-666
and	O	667-670
to	O	671-673
prevent	O	674-681
the	O	682-685
birth	O	686-691
of	O	692-694
an	O	695-697
affected	O	698-706
boy	O	707-710
.	O	710-711

The	O	712-715
results	O	716-723
of	O	724-726
this	O	727-731
study	O	732-737
demonstrate	O	738-749
the	O	750-753
usefulness	O	754-764
of	O	765-767
haplotype	O	768-777
analysis	O	778-786
and	O	787-790
immunohistochemical	O	791-810
muscle	O	811-817
dystrophin	O	818-828
studies	O	829-836
to	O	837-839
detect	O	840-846
hidden	O	847-853
germinal	O	854-862
mosaicism	O	863-872
and	O	873-876
to	O	877-879
improve	O	880-887
genetic	O	888-895
counselling	O	896-907
.	O	907-908
.	O	907-908

Centrosome	O	0-10
amplification	O	11-24
and	O	25-28
a	O	29-30
defective	O	31-40
G2	O	41-43
-	O	43-44
M	O	44-45
cell	O	46-50
cycle	O	51-56
checkpoint	O	57-67
induce	O	68-74
genetic	O	75-82
instability	O	83-94
in	O	95-97
BRCA1	O	98-103
exon	O	104-108
11	O	109-111
isoform	O	112-119
-	O	119-120
deficient	O	120-129
cells	O	130-135
.	O	135-136

Germline	O	137-145
mutations	O	146-155
of	O	156-158
the	O	159-162
Brca1	O	163-168
tumor	B	169-174
suppressor	O	175-185
gene	O	186-190
predispose	O	191-201
women	O	202-207
to	O	208-210
breast	B	211-217
and	I	218-221
ovarian	I	222-229
cancers	I	230-237
.	O	237-238

To	O	239-241
study	O	242-247
mechanisms	O	248-258
underlying	O	259-269
BRCA1	O	270-275
-	O	275-276
related	O	276-283
tumorigenesis	O	284-297
,	O	297-298
we	O	299-301
derived	O	302-309
mouse	O	310-315
embryonic	O	316-325
fibroblast	O	326-336
cells	O	337-342
carrying	O	343-351
a	O	352-353
targeted	O	354-362
deletion	O	363-371
of	O	372-374
exon	O	375-379
11	O	380-382
of	O	383-385
the	O	386-389
Brca1	O	390-395
gene	O	396-400
.	O	400-401

We	O	402-404
show	O	405-409
that	O	410-414
the	O	415-418
mutant	O	419-425
cells	O	426-431
maintain	O	432-440
an	O	441-443
intact	O	444-450
G1	O	451-453
-	O	453-454
S	O	454-455
cell	O	456-460
cycle	O	461-466
checkpoint	O	467-477
and	O	478-481
proliferate	O	482-493
poorly	O	494-500
.	O	500-501

However	O	502-509
,	O	509-510
a	O	511-512
defective	O	513-522
G2	O	523-525
-	O	525-526
M	O	526-527
checkpoint	O	528-538
in	O	539-541
these	O	542-547
cells	O	548-553
is	O	554-556
accompanied	O	557-568
by	O	569-571
extensive	O	572-581
chromosomal	B	582-593
abnormalities	I	594-607
.	O	607-608

Mutant	O	609-615
fibroblasts	O	616-627
contain	O	628-635
multiple	O	636-644
,	O	644-645
functional	O	646-656
centrosomes	O	657-668
,	O	668-669
which	O	670-675
lead	O	676-680
to	O	681-683
unequal	O	684-691
chromosome	O	692-702
segregation	O	703-714
,	O	714-715
abnormal	O	716-724
nuclear	O	725-732
division	O	733-741
,	O	741-742
and	O	743-746
aneuploidy	B	747-757
.	O	757-758

These	O	759-764
data	O	765-769
uncover	O	770-777
an	O	778-780
essential	O	781-790
role	O	791-795
of	O	796-798
BRCA1	O	799-804
in	O	805-807
maintaining	O	808-819
genetic	O	820-827
stability	O	828-837
through	O	838-845
the	O	846-849
regulation	O	850-860
of	O	861-863
centrosome	O	864-874
duplication	O	875-886
and	O	887-890
the	O	891-894
G2	O	895-897
-	O	897-898
M	O	898-899
checkpoint	O	900-910
and	O	911-914
provide	O	915-922
a	O	923-924
molecular	O	925-934
basis	O	935-940
for	O	941-944
the	O	945-948
role	O	949-953
of	O	954-956
BRCA1	O	957-962
in	O	963-965
tumorigenesis	O	966-979
.	O	979-980
.	O	979-980

Aberrant	O	0-8
splicing	O	9-17
of	O	18-20
phenylalanine	O	21-34
hydroxylase	O	35-46
mRNA	O	47-51
:	O	51-52
the	O	53-56
major	O	57-62
cause	O	63-68
for	O	69-72
phenylketonuria	B	73-88
in	O	89-91
parts	O	92-97
of	O	98-100
southern	O	101-109
Europe	O	110-116
.	O	116-117

We	O	118-120
report	O	121-127
a	O	128-129
mutation	O	130-138
within	O	139-145
the	O	146-149
phenylalanine	O	150-163
hydroxylase	O	164-175
(	O	176-177
PAH	O	177-180
)	O	180-181
gene	O	182-186
that	O	187-191
causes	O	192-198
aberrant	O	199-207
splicing	O	208-216
of	O	217-219
the	O	220-223
mRNA	O	224-228
and	O	229-232
that	O	233-237
is	O	238-240
in	O	241-243
tight	O	244-249
association	O	250-261
with	O	262-266
chromosomal	O	267-278
haplotypes	O	279-289
6	O	290-291
,	O	291-292
10	O	293-295
,	O	295-296
and	O	297-300
36	O	301-303
.	O	303-304

Because	O	305-312
of	O	313-315
the	O	316-319
high	O	320-324
frequency	O	325-334
of	O	335-337
these	O	338-343
particular	O	344-354
haplotypes	O	355-365
in	O	366-368
Bulgaria	O	369-377
,	O	377-378
Italy	O	379-384
,	O	384-385
and	O	386-389
Turkey	O	390-396
,	O	396-397
it	O	398-400
appears	O	401-408
to	O	409-411
be	O	412-414
one	O	415-418
of	O	419-421
the	O	422-425
more	O	426-430
frequent	O	431-439
defects	O	440-447
in	O	448-450
the	O	451-454
PAH	O	455-458
gene	O	459-463
causing	O	464-471
classical	O	472-481
phenylketonuria	B	482-497
in	O	498-500
this	O	501-505
part	O	506-510
of	O	511-513
Europe	O	514-520
.	O	520-521

The	O	522-525
mutation	O	526-534
is	O	535-537
a	O	538-539
G	O	540-541
to	O	542-544
A	O	545-546
transition	O	547-557
at	O	558-560
position	O	561-569
546	O	570-573
in	O	574-576
intron	O	577-583
10	O	584-586
of	O	587-589
the	O	590-593
PAH	O	594-597
gene	O	598-602
,	O	602-603
11	O	604-606
bp	O	607-609
upstream	O	610-618
from	O	619-623
the	O	624-627
intron	O	628-634
10	O	635-637
/	O	637-638
exon	O	638-642
11	O	643-645
boundary	O	646-654
.	O	654-655

It	O	656-658
activates	O	659-668
a	O	669-670
cryptic	O	671-678
splice	O	679-685
site	O	686-690
and	O	691-694
results	O	695-702
in	O	703-705
an	O	706-708
in	O	709-711
-	O	711-712
frame	O	712-717
insertion	O	718-727
of	O	728-730
9	O	731-732
nucleotides	O	733-744
between	O	745-752
exon	O	753-757
10	O	758-760
and	O	761-764
exon	O	765-769
11	O	770-772
of	O	773-775
the	O	776-779
processed	O	780-789
mRNA	O	790-794
.	O	794-795

Normal	O	796-802
amounts	O	803-810
of	O	811-813
liver	O	814-819
PAH	O	820-823
protein	O	824-831
are	O	832-835
present	O	836-843
in	O	844-846
homozygous	O	847-857
patients	O	858-866
,	O	866-867
but	O	868-871
no	O	872-874
catalytic	O	875-884
activity	O	885-893
can	O	894-897
be	O	898-900
detected	O	901-909
.	O	909-910

This	O	911-915
loss	O	916-920
of	O	921-923
enzyme	O	924-930
activity	O	931-939
is	O	940-942
probably	O	943-951
caused	O	952-958
by	O	959-961
conformational	O	962-976
changes	O	977-984
resulting	O	985-994
from	O	995-999
the	O	1000-1003
insertion	O	1004-1013
of	O	1014-1016
three	O	1017-1022
additional	O	1023-1033
amino	O	1034-1039
acids	O	1040-1045
(	O	1046-1047
Gly	O	1047-1050
-	O	1050-1051
Leu	O	1051-1054
-	O	1050-1051
Gln	O	1055-1058
)	O	1058-1059
between	O	1060-1067
the	O	1068-1071
normal	O	1072-1078
sequences	O	1079-1088
encoded	O	1089-1096
by	O	1097-1099
exon	O	1100-1104
10	O	1105-1107
and	O	1108-1111
exon	O	1112-1116
11	O	1117-1119
.	O	1119-1120
.	O	1119-1120

Biochemical	O	0-11
and	O	12-15
structural	O	16-26
analysis	O	27-35
of	O	36-38
missense	O	39-47
mutations	O	48-57
in	O	58-60
N	O	61-62
-	O	62-63
acetylgalactosamine	O	63-82
-	O	62-63
6	O	83-84
-	O	62-63
sulfate	O	85-92
sulfatase	O	93-102
causing	O	103-110
mucopolysaccharidosis	B	111-132
IVA	I	133-136
phenotypes	O	137-147
.	O	147-148

Mucopolysaccharidosis	B	149-170
IVA	I	171-174
(	O	175-176
MPS	B	176-179
IVA	I	180-183
;	O	183-184
OMIM	O	185-189
#	O	190-191
253000	O	192-198
)	O	198-199
,	O	199-200
a	O	201-202
lysosomal	B	203-212
storage	I	213-220
disorder	I	221-229
caused	O	230-236
by	O	237-239
a	O	240-241
deficiency	B	242-252
of	I	253-255
N	I	256-257
-	I	258-259
acetylgalactosamine	I	259-278
-	I	258-259
6	I	279-280
-	I	258-259
sulfate	I	281-288
sulfatase	I	289-298
(	O	299-300
GALNS	O	300-305
)	O	305-306
,	O	306-307
has	O	308-311
variable	O	312-320
clinical	O	321-329
phenotypes	O	330-340
.	O	340-341

To	O	342-344
date	O	345-349
we	O	350-352
have	O	353-357
identified	O	358-368
65	O	369-371
missense	O	372-380
mutations	O	381-390
in	O	391-393
the	O	394-397
GALNS	O	398-403
gene	O	404-408
from	O	409-413
MPS	B	414-417
IVA	I	418-421
patients	O	422-430
,	O	430-431
but	O	432-435
the	O	436-439
correlation	O	440-451
between	O	452-459
genotype	O	460-468
and	O	469-472
phenotype	O	473-482
has	O	483-486
remained	O	487-495
unclear	O	496-503
.	O	503-504

We	O	505-507
studied	O	508-515
17	O	516-518
missense	O	519-527
mutations	O	528-537
using	O	538-543
biochemical	O	544-555
approaches	O	556-566
and	O	567-570
32	O	571-573
missense	O	574-582
mutations	O	583-592
,	O	592-593
using	O	594-599
structural	O	600-610
analyses	O	611-619
.	O	619-620

Fifteen	O	621-628
missense	O	629-637
mutations	O	638-647
and	O	648-651
two	O	652-655
newly	O	656-661
engineered	O	662-672
active	O	673-679
site	O	680-684
mutations	O	685-694
(	O	695-696
C79S	O	696-700
,	O	700-701
C79T	O	702-706
)	O	706-707
were	O	708-712
characterized	O	713-726
by	O	727-729
transient	O	730-739
expression	O	740-750
analysis	O	751-759
.	O	759-760

Mutant	O	761-767
proteins	O	768-776
,	O	776-777
except	O	778-784
for	O	785-788
C79S	O	789-793
and	O	794-797
C79T	O	798-802
,	O	802-803
were	O	804-808
destabilized	O	809-821
and	O	822-825
detected	O	826-834
as	O	835-837
insoluble	O	838-847
precursor	O	848-857
forms	O	858-863
while	O	864-869
the	O	870-873
C79S	O	874-878
and	O	879-882
C79T	O	883-887
mutants	O	888-895
were	O	896-900
of	O	901-903
a	O	904-905
soluble	O	906-913
mature	O	914-920
size	O	921-925
.	O	925-926

Mutants	O	927-934
found	O	935-940
in	O	941-943
the	O	944-947
severe	O	948-954
phenotype	O	955-964
had	O	965-968
no	O	969-971
activity	O	972-980
.	O	980-981

Mutants	O	982-989
found	O	990-995
in	O	996-998
the	O	999-1002
mild	O	1003-1007
phenotype	O	1008-1017
had	O	1018-1021
a	O	1022-1023
considerable	O	1024-1036
residual	O	1037-1045
activity	O	1046-1054
(	O	1055-1056
1	O	1056-1057
.	O	1057-1058

3	O	1059-1060
-	O	1060-1061
13	O	1061-1063
.	O	1063-1064

3	O	1065-1066
%	O	1066-1067
of	O	1068-1070
wild	O	1071-1075
-	O	1075-1076
type	O	1076-1080
GALNS	O	1081-1086
activity	O	1087-1095
)	O	1095-1096
.	O	1096-1097

Sulfatases	O	1098-1108
,	O	1108-1109
including	O	1110-1119
GALNS	O	1120-1125
,	O	1125-1126
are	O	1127-1130
members	O	1131-1138
of	O	1139-1141
a	O	1142-1143
highly	O	1144-1150
conserved	O	1151-1160
gene	O	1161-1165
family	O	1166-1172
sharing	O	1173-1180
an	O	1181-1183
extensive	O	1184-1193
sequence	O	1194-1202
homology	O	1203-1211
.	O	1211-1212

Thus	O	1213-1217
,	O	1217-1218
a	O	1219-1220
tertiary	O	1221-1229
structural	O	1230-1240
model	O	1241-1246
of	O	1247-1249
human	O	1250-1255
GALNS	O	1256-1261
was	O	1262-1265
constructed	O	1266-1277
from	O	1278-1282
the	O	1283-1286
X	O	1287-1288
-	O	1288-1289
ray	O	1289-1292
crystal	O	1293-1300
structure	O	1301-1310
of	O	1311-1313
N	O	1314-1315
-	O	1316-1317
acetylgalacto	O	1317-1330
-	O	1316-1317
samine	O	1331-1337
-	O	1316-1317
4	O	1338-1339
-	O	1316-1317
sulfatase	O	1340-1349
and	O	1350-1353
arylsulfatase	O	1354-1367
A	O	1368-1369
,	O	1369-1370
using	O	1371-1376
homology	O	1377-1385
modeling	O	1386-1394
,	O	1394-1395
and	O	1396-1399
32	O	1400-1402
missense	O	1403-1411
mutations	O	1412-1421
were	O	1422-1426
investigated	O	1427-1439
.	O	1439-1440

Consequently	O	1441-1453
,	O	1453-1454
we	O	1455-1457
propose	O	1458-1465
that	O	1466-1470
there	O	1471-1476
are	O	1477-1480
at	O	1481-1483
least	O	1484-1489
three	O	1490-1495
different	O	1496-1505
reasons	O	1506-1513
for	O	1514-1517
the	O	1518-1521
severe	O	1522-1528
phenotype	O	1529-1538
(	O	1540-1541
i	O	1541-1542
)	O	1542-1543
destruction	O	1544-1555
of	O	1556-1558
the	O	1559-1562
hydrophobic	O	1563-1574
core	O	1575-1579
or	O	1580-1582
modification	O	1583-1595
of	O	1596-1598
the	O	1599-1602
packing	O	1603-1610
;	O	1610-1611
(	O	1612-1613
ii	O	1613-1615
)	O	1615-1616
removal	O	1617-1624
of	O	1625-1627
a	O	1628-1629
salt	O	1630-1634
bridge	O	1635-1641
to	O	1642-1644
destabilize	O	1645-1656
the	O	1657-1660
entire	O	1661-1667
conformation	O	1668-1680
;	O	1680-1681
(	O	1682-1683
iii	O	1683-1686
)	O	1686-1687
modification	O	1688-1700
of	O	1701-1703
the	O	1704-1707
active	O	1708-1714
site	O	1715-1719
.	O	1719-1720

In	O	1721-1723
contrast	O	1724-1732
,	O	1732-1733
mild	O	1734-1738
mutations	O	1739-1748
were	O	1749-1753
mostly	O	1754-1760
located	O	1761-1768
on	O	1769-1771
the	O	1772-1775
surface	O	1776-1783
of	O	1784-1786
the	O	1787-1790
GALNS	O	1791-1796
protein	O	1797-1804
.	O	1804-1805

These	O	1806-1811
studies	O	1812-1819
shed	O	1820-1824
further	O	1825-1832
light	O	1833-1838
on	O	1839-1841
the	O	1842-1845
genotype	O	1846-1854
-	O	1854-1855
phenotype	O	1855-1864
correlation	O	1865-1876
of	O	1877-1879
MPS	B	1880-1883
IVA	I	1884-1887
and	O	1888-1891
structure	O	1892-1901
-	O	1901-1902
function	O	1902-1910
relationship	O	1911-1923
in	O	1924-1926
the	O	1927-1930
sulfatase	O	1931-1940
family	O	1941-1947
.	O	1947-1948

Wiskott	B	0-7
-	I	7-8
Aldrich	I	8-15
syndrome	I	16-24
:	O	24-25
cellular	O	26-34
impairments	O	35-46
and	O	47-50
their	O	51-56
implication	O	57-68
for	O	69-72
carrier	O	73-80
detection	O	81-90
.	O	90-91

A	O	92-93
family	O	94-100
in	O	101-103
which	O	104-109
two	O	110-113
male	O	114-118
siblings	O	119-127
were	O	128-132
affected	O	133-141
with	O	142-146
Wiskott	B	147-154
-	I	154-155
Aldrich	I	155-162
syndrome	I	163-171
(	O	172-173
WAS	B	173-176
)	O	176-177
was	O	178-181
studied	O	182-189
using	O	190-195
G	O	196-197
-	O	197-198
6	O	198-199
-	O	197-198
PD	O	200-202
isoenzymes	O	203-213
as	O	214-216
an	O	217-219
X	O	220-221
-	O	221-222
linked	O	222-228
marker	O	229-235
in	O	236-238
order	O	239-244
to	O	245-247
investigate	O	248-259
the	O	260-263
nature	O	264-270
of	O	271-273
cellular	O	274-282
abnormalities	O	283-296
.	O	296-297

Isolated	O	298-306
peripheral	O	307-317
blood	O	318-323
cell	O	324-328
types	O	329-334
from	O	335-339
the	O	340-343
doubly	O	344-350
heterozygous	O	351-363
mother	O	364-370
of	O	371-373
the	O	374-377
affected	O	378-386
males	O	387-392
seemingly	O	393-402
failed	O	403-409
to	O	410-412
express	O	413-420
the	O	421-424
G	O	425-426
-	O	426-427
6	O	427-428
-	O	426-427
PD	O	429-431
allele	O	432-438
in	O	439-441
cis	O	442-445
position	O	446-454
with	O	455-459
the	O	460-463
WAS	B	464-467
allele	O	468-474
while	O	475-480
her	O	481-484
cultured	O	485-493
skin	O	494-498
fibroblasts	O	499-510
expressed	O	511-520
both	O	521-525
G	O	526-527
-	O	527-528
6	O	528-529
-	O	527-528
PD	O	530-532
alleles	O	533-540
.	O	540-541

Additionally	O	542-554
,	O	554-555
a	O	556-557
histogram	O	558-567
analysis	O	568-576
of	O	577-579
platelet	O	580-588
size	O	589-593
revealed	O	594-602
a	O	603-604
single	O	605-611
population	O	612-622
of	O	623-625
abnormally	O	626-636
small	O	637-642
platelets	O	643-652
in	O	653-655
the	O	656-659
affected	O	660-668
propositus	O	669-679
,	O	679-680
whereas	O	681-688
the	O	689-692
heterozygous	O	693-705
mother	O	706-712
had	O	713-716
no	O	717-719
appreciable	O	720-731
small	O	732-737
platelet	O	738-746
subpopulation	O	747-760
.	O	760-761

In	O	762-764
vitro	O	765-770
culture	O	771-778
of	O	779-781
hemopoietic	O	782-793
progenitor	O	794-804
cells	O	805-810
of	O	811-813
the	O	814-817
heterozygous	O	818-830
mother	O	831-837
showed	O	838-844
that	O	845-849
the	O	850-853
majority	O	854-862
of	O	863-865
progenitor	O	866-876
cells	O	877-882
did	O	883-886
not	O	887-890
express	O	891-898
the	O	899-902
WAS	B	903-906
allele	O	907-913
.	O	913-914

However	O	915-922
,	O	922-923
a	O	924-925
small	O	926-931
number	O	932-938
of	O	939-941
cells	O	942-947
expressing	O	948-958
the	O	959-962
G	O	963-964
-	O	964-965
6	O	965-966
-	O	964-965
PD	O	967-969
type	O	970-974
linked	O	975-981
with	O	982-986
the	O	987-990
WAS	B	991-994
allele	O	995-1001
were	O	1002-1006
detected	O	1007-1015
.	O	1015-1016

The	O	1017-1020
proportion	O	1021-1031
of	O	1032-1034
the	O	1035-1038
latter	O	1039-1045
progenitors	O	1046-1057
was	O	1058-1061
significantly	O	1062-1075
higher	O	1076-1082
among	O	1083-1088
more	O	1089-1093
primitive	O	1094-1103
progenitors	O	1104-1115
(	O	1116-1117
those	O	1117-1122
giving	O	1123-1129
rise	O	1130-1134
to	O	1135-1137
later	O	1138-1143
appearing	O	1144-1153
colonies	O	1154-1162
)	O	1162-1163
.	O	1163-1164

This	O	1165-1169
observation	O	1170-1181
suggests	O	1182-1190
that	O	1191-1195
selection	O	1196-1205
against	O	1206-1213
cells	O	1214-1219
expressing	O	1220-1230
the	O	1231-1234
Wiskott	B	1235-1242
-	I	1242-1243
Aldrich	I	1243-1250
defect	I	1251-1257
takes	O	1258-1263
place	O	1264-1269
in	O	1270-1272
the	O	1273-1276
hemopoietic	O	1277-1288
system	O	1289-1295
of	O	1296-1298
the	O	1299-1302
heterozygous	O	1303-1315
female	O	1316-1322
and	O	1323-1326
offers	O	1327-1333
a	O	1334-1335
possible	O	1336-1344
means	O	1345-1350
of	O	1351-1353
carrier	O	1354-1361
detection	O	1362-1371
in	O	1372-1374
some	O	1375-1379
women	O	1380-1385
.	O	1385-1386

Linkage	O	1387-1394
studies	O	1395-1402
in	O	1403-1405
this	O	1406-1410
family	O	1411-1417
revealed	O	1418-1426
one	O	1427-1430
example	O	1431-1438
of	O	1439-1441
probable	O	1442-1450
recombination	O	1451-1464
between	O	1465-1472
the	O	1473-1476
loci	O	1477-1481
for	O	1482-1485
WAS	B	1486-1489
and	O	1490-1493
G	O	1494-1495
-	O	1495-1496
6	O	1496-1497
-	O	1495-1496
PD	O	1498-1500
among	O	1501-1506
three	O	1507-1512
informative	O	1513-1524
subjects	O	1525-1533
,	O	1533-1534
suggesting	O	1535-1545
that	O	1546-1550
these	O	1551-1556
two	O	1557-1560
loci	O	1561-1565
may	O	1566-1569
not	O	1570-1573
be	O	1574-1576
closely	O	1577-1584
linked	O	1585-1591
on	O	1592-1594
the	O	1595-1598
X	O	1599-1600
-	O	1600-1601
chromosome	O	1601-1611
.	O	1611-1612
.	O	1611-1612

Familial	B	0-8
deficiency	I	9-19
of	I	20-22
the	I	23-26
seventh	I	27-34
component	I	35-44
of	I	45-47
complement	I	48-58
associated	O	59-69
with	O	70-74
recurrent	O	75-84
meningococcal	B	85-98
infections	I	99-109
.	O	109-110

We	O	111-113
describe	O	114-122
an	O	123-125
11	O	126-128
-	O	128-129
year	O	129-133
-	O	128-129
old	O	134-137
girl	O	138-142
suffering	O	143-152
from	O	153-157
recurrent	B	158-167
meningitis	I	168-178
with	O	179-183
a	O	184-185
complete	O	186-194
absence	B	195-202
of	I	203-205
the	I	206-209
seventh	I	210-217
component	I	218-227
of	I	228-230
complement	O	231-241
(	O	242-243
C7	O	243-245
)	O	245-246
.	O	246-247

Diagnosis	O	248-257
was	O	258-261
established	O	262-273
by	O	274-276
haemolytic	O	277-287
titration	O	288-297
and	O	298-301
western	O	302-309
blotting	O	310-318
.	O	318-319

The	O	320-323
patients	O	324-332
serum	O	333-338
lacked	O	339-345
the	O	346-349
85	O	350-352
kDa	O	353-356
C7	O	357-359
chain	O	360-365
.	O	365-366

Haemolytic	O	367-377
activity	O	378-386
of	O	387-389
serum	O	390-395
was	O	396-399
reconstituted	O	400-413
with	O	414-418
either	O	419-425
pooled	O	426-432
normal	O	433-439
human	O	440-445
serum	O	446-451
or	O	452-454
with	O	455-459
purified	O	460-468
C7	O	469-471
.	O	471-472

The	O	473-476
relatives	O	477-486
(	O	487-488
parents	O	488-495
and	O	496-499
one	O	500-503
sister	O	504-510
)	O	510-511
had	O	512-515
half	O	516-520
-	O	520-521
normal	O	521-527
levels	O	528-534
of	O	535-537
both	O	538-542
immunochemically	O	543-559
and	O	560-563
functionally	O	564-576
determined	O	577-587
C7	O	588-590
,	O	590-591
indicating	O	592-602
a	O	603-604
heterozygous	O	605-617
state	O	618-623
for	O	624-627
C7	B	628-630
deficiency	I	631-641
.	O	641-642
.	O	641-642

Non	B	0-3
-	I	3-4
syndromic	I	4-13
hearing	I	14-21
loss	I	22-26
associated	O	27-37
with	O	38-42
enlarged	B	43-51
vestibular	I	52-62
aqueduct	I	63-71
is	O	72-74
caused	O	75-81
by	O	82-84
PDS	B	85-88
mutations	O	89-98
.	O	98-99

Enlarged	B	100-108
vestibular	I	109-119
aqueduct	I	120-128
(	O	129-130
EVA	B	130-133
)	O	133-134
,	O	134-135
known	O	136-141
as	O	142-144
the	O	145-148
most	O	149-153
common	O	154-160
form	O	161-165
of	O	166-168
inner	B	169-174
ear	I	175-178
abnormality	I	179-190
,	O	190-191
has	O	192-195
recently	O	196-204
been	O	205-209
of	O	210-212
particular	O	213-223
genetic	O	224-231
interest	O	232-240
because	O	241-248
this	O	249-253
anomaly	O	254-261
is	O	262-264
inherited	O	265-274
in	O	275-277
a	O	278-279
recessive	O	280-289
manner	O	290-296
.	O	296-297

The	O	298-301
locus	O	302-307
for	O	308-311
non	B	312-315
-	I	315-316
syndromic	I	316-325
sensorineural	I	326-339
hearing	I	340-347
loss	I	348-352
with	O	353-357
EVA	B	358-361
has	O	362-365
been	O	366-370
mapped	O	371-377
to	O	378-380
the	O	381-384
same	O	385-389
chromosomal	O	390-401
region	O	402-408
,	O	408-409
7q31	O	410-414
,	O	414-415
as	O	416-418
the	O	419-422
Pendred	B	423-430
syndrome	I	431-439
locus	O	440-445
.	O	445-446

In	O	447-449
the	O	450-453
present	O	454-461
study	O	462-467
,	O	467-468
seven	O	469-474
mutations	O	475-484
in	O	485-487
the	O	488-491
PDS	B	492-495
gene	O	496-500
(	O	501-502
PDS	O	502-505
)	O	505-506
,	O	506-507
the	O	508-511
gene	O	512-516
responsible	O	517-528
for	O	529-532
Pendred	B	533-540
syndrome	I	541-549
,	O	549-550
have	O	551-555
been	O	556-560
found	O	561-566
in	O	567-569
families	O	570-578
of	O	579-581
non	B	582-585
-	I	585-586
syndromic	I	586-595
sensorineural	I	596-609
hearing	I	610-617
loss	I	618-622
with	O	623-627
EVA	B	628-631
.	O	631-632

One	O	633-636
family	O	637-643
is	O	644-646
homozygous	O	647-657
,	O	657-658
three	O	659-664
families	O	665-673
are	O	674-677
compound	O	678-686
heterozygotes	O	687-700
,	O	700-701
and	O	702-705
two	O	706-709
families	O	710-718
are	O	719-722
heterozygous	O	723-735
but	O	736-739
with	O	740-744
no	O	745-747
other	O	748-753
mutation	O	754-762
detected	O	763-771
.	O	771-772

The	O	773-776
present	O	777-784
results	O	785-792
provide	O	793-800
evidence	O	801-809
that	O	810-814
mutations	O	815-824
in	O	825-827
PDS	O	828-831
cause	O	832-837
both	O	838-842
syndromic	B	843-852
and	I	853-856
non	I	857-860
-	I	860-861
syndromic	I	861-870
hearing	I	871-878
loss	I	879-883
.	O	883-884
.	O	883-884

Deletions	O	0-9
of	O	10-12
a	O	13-14
DNA	O	15-18
sequence	O	19-27
in	O	28-30
retinoblastomas	B	31-46
and	O	47-50
mesenchymal	B	51-62
tumors	I	63-69
:	O	69-70
organization	O	71-83
of	O	84-86
the	O	87-90
sequence	O	91-99
and	O	100-103
its	O	104-107
encoded	O	108-115
protein	O	116-123
.	O	123-124

Retinoblastoma	B	125-139
is	O	140-142
a	O	143-144
childhood	B	145-154
tumor	I	155-160
that	O	161-165
can	O	166-169
arise	O	170-175
because	O	176-183
of	O	184-186
mutant	O	187-193
alleles	O	194-201
acquired	O	202-210
as	O	211-213
somatic	O	214-221
or	O	222-224
germinal	O	225-233
mutations	O	234-243
.	O	243-244

The	O	245-248
mutant	O	249-255
allele	O	256-262
can	O	263-266
be	O	267-269
carried	O	270-277
in	O	278-280
the	O	281-284
germ	O	285-289
line	O	290-294
.	O	294-295

The	O	296-299
mutations	O	300-309
creating	O	310-318
these	O	319-324
alleles	O	325-332
act	O	333-336
by	O	337-339
inactivating	O	340-352
copies	O	353-359
of	O	360-362
a	O	363-364
recessive	O	365-374
oncogene	O	375-383
located	O	384-391
within	O	392-398
band	O	399-403
q14	O	404-407
of	O	408-410
chromosome	O	411-421
13	O	422-424
and	O	425-428
termed	O	429-435
the	O	436-439
RB1	O	440-443
locus	O	444-449
.	O	449-450

We	O	451-453
have	O	454-458
reported	O	459-467
isolation	O	468-477
of	O	478-480
a	O	481-482
cDNA	O	483-487
fragment	O	488-496
that	O	497-501
recognizes	O	502-512
chromosomal	O	513-524
sequences	O	525-534
possessing	O	535-545
many	O	546-550
of	O	551-553
the	O	554-557
attributes	O	558-568
of	O	569-571
the	O	572-575
retinoblastoma	B	576-590
gene	O	591-595
associated	O	596-606
with	O	607-611
the	O	612-615
RB1	O	616-619
locus	O	620-625
.	O	625-626

We	O	627-629
now	O	630-633
report	O	634-640
that	O	641-645
this	O	646-650
segment	O	651-658
is	O	659-661
additionally	O	662-674
the	O	675-678
target	O	679-685
of	O	686-688
somatic	O	689-696
mutations	O	697-706
in	O	707-709
mesenchymal	B	710-721
tumors	I	722-728
among	O	729-734
patients	O	735-743
having	O	744-750
no	O	751-753
apparent	O	754-762
predisposition	O	763-777
to	O	778-780
retinoblastoma	B	781-795
and	O	796-799
no	O	800-802
previous	O	803-811
evidence	O	812-820
of	O	821-823
retinoblastoma	B	824-838
.	O	838-839

These	O	840-845
tumors	B	846-852
provide	O	853-860
additional	O	861-871
evidence	O	872-880
that	O	881-885
the	O	886-889
cloned	O	890-896
sequences	O	897-906
are	O	907-910
representative	O	911-925
of	O	926-928
a	O	929-930
gene	O	931-935
that	O	936-940
is	O	941-943
a	O	944-945
frequent	O	946-954
target	O	955-961
of	O	962-964
inactivation	O	965-977
during	O	978-984
tumorigenesis	O	985-998
.	O	998-999

Sequence	O	1000-1008
analysis	O	1009-1017
of	O	1018-1020
this	O	1021-1025
cDNA	O	1026-1030
provides	O	1031-1039
little	O	1040-1046
insight	O	1047-1054
into	O	1055-1059
its	O	1060-1063
normal	O	1064-1070
functional	O	1071-1081
role	O	1082-1086
.	O	1086-1087
.	O	1086-1087

Genetically	O	0-11
determined	O	12-22
low	O	23-26
C4	O	27-29
:	O	29-30
a	O	31-32
predisposing	O	33-45
factor	O	46-52
to	O	53-55
autoimmune	B	56-66
chronic	I	67-74
active	I	75-81
hepatitis	I	82-91
.	O	91-92

Of	O	93-95
26	O	96-98
patients	O	99-107
with	O	108-112
autoimmune	B	113-123
chronic	I	124-131
active	I	132-138
hepatitis	I	139-148
(	O	149-150
CAH	B	150-153
)	O	153-154
starting	O	155-163
in	O	164-166
childhood	O	167-176
18	O	177-179
(	O	180-181
69	O	181-183
%	O	183-184
)	O	184-185
had	O	186-189
low	O	190-193
C4	O	194-196
and	O	197-200
5	O	201-202
(	O	203-204
19	O	204-206
%	O	206-207
)	O	207-208
had	O	209-212
low	O	213-216
C3	O	217-219
serum	O	220-225
levels	O	226-232
.	O	232-233

Impaired	O	234-242
hepatic	O	243-250
synthesis	O	251-260
and	O	261-264
immune	O	265-271
-	O	271-272
consumption	O	272-283
were	O	284-288
unlikely	O	289-297
since	O	298-303
transferrin	O	304-315
levels	O	316-322
were	O	323-327
normal	O	328-334
in	O	335-337
all	O	338-341
patients	O	342-350
,	O	350-351
albumin	O	352-359
levels	O	360-366
were	O	367-371
persistently	O	372-384
low	O	385-388
in	O	389-391
only	O	392-396
3	O	397-398
,	O	398-399
and	O	400-403
only	O	404-408
3	O	409-410
had	O	411-414
raised	O	415-421
levels	O	422-428
of	O	429-431
activation	O	432-442
fragment	O	443-451
C3d	O	452-455
.	O	455-456

C4d	O	457-460
was	O	461-464
normal	O	465-471
in	O	472-474
all	O	475-478
patients	O	479-487
studied	O	488-495
.	O	495-496

In	O	497-499
the	O	500-503
families	O	504-512
of	O	513-515
12	O	516-518
probands	O	519-527
with	O	528-532
low	O	533-536
C4	O	537-539
,	O	539-540
7	O	541-542
parents	O	543-550
had	O	551-554
low	O	555-558
C4	O	559-561
and	O	562-565
2	O	566-567
had	O	568-571
levels	O	572-578
which	O	579-584
were	O	585-589
at	O	590-592
the	O	593-596
lower	O	597-602
limit	O	603-608
of	O	609-611
normal	O	612-618
.	O	618-619

5	O	620-621
of	O	622-624
10	O	625-627
siblings	O	628-636
from	O	637-641
5	O	642-643
families	O	644-652
had	O	653-656
low	O	657-660
C4	O	661-663
.	O	663-664

These	O	665-670
results	O	671-678
suggest	O	679-686
that	O	687-691
low	O	692-695
C4	O	696-698
levels	O	699-705
in	O	706-708
CAH	B	709-712
are	O	713-716
genetically	O	717-728
determined	O	729-739
.	O	739-740

C4	O	741-743
phenotyping	O	744-755
in	O	756-758
20	O	759-761
patients	O	762-770
and	O	771-774
in	O	775-777
26	O	778-780
parents	O	781-788
showed	O	789-795
that	O	796-800
90	O	801-803
%	O	803-804
and	O	805-808
81	O	809-811
%	O	811-812
,	O	812-813
respectively	O	814-826
,	O	826-827
had	O	828-831
null	O	832-836
allotypes	O	837-846
at	O	847-849
either	O	850-856
the	O	857-860
C4A	O	861-864
or	O	865-867
C4B	O	868-871
locus	O	872-877
compared	O	878-886
with	O	887-891
59	O	892-894
%	O	894-895
in	O	896-898
controls	O	899-907
,	O	907-908
indicating	O	909-919
that	O	920-924
defective	O	925-934
expression	O	935-945
of	O	946-948
structural	O	949-959
genes	O	960-965
may	O	966-969
contribute	O	970-980
to	O	981-983
the	O	984-987
observed	O	988-996
C4	B	997-999
deficiency	I	1000-1010
.	O	1010-1011
.	O	1010-1011

Tight	O	0-5
linkage	O	6-13
between	O	14-21
myotonic	B	22-30
dystrophy	I	31-40
and	O	41-44
apolipoprotein	O	45-59
E	O	60-61
genes	O	62-67
revealed	O	68-76
with	O	77-81
allele	O	82-88
-	O	88-89
specific	O	89-97
oligonucleotides	O	98-114
.	O	114-115

In	O	116-118
16	O	119-121
families	O	122-130
with	O	131-135
myotonic	B	136-144
dystrophy	I	145-154
(	O	155-156
DM	B	156-158
)	O	158-159
a	O	160-161
novel	O	162-167
approach	O	168-176
based	O	177-182
on	O	183-185
use	O	186-189
of	O	190-192
allele	O	193-199
-	O	199-200
specific	O	200-208
oligonucleotides	O	209-225
has	O	226-229
been	O	230-234
employed	O	235-243
to	O	244-246
study	O	247-252
the	O	253-256
linkage	O	257-264
relationship	O	265-277
between	O	278-285
the	O	286-289
apolipoprotein	O	290-304
E	O	305-306
(	O	307-308
APOE	O	308-312
)	O	312-313
gene	O	314-318
and	O	319-322
DM	B	323-325
.	O	325-326

Synthetic	O	327-336
oligonucleotides	O	337-353
,	O	353-354
designed	O	355-363
to	O	364-366
discriminate	O	367-379
between	O	380-387
APOE	O	388-392
alleles	O	393-400
epsilon	O	401-408
3	O	409-410
and	O	411-414
epsilon	O	415-422
4	O	423-424
,	O	424-425
enabled	O	426-433
us	O	434-436
to	O	437-439
distinguish	O	440-451
heterozygous	O	452-464
carriers	O	465-473
in	O	474-476
a	O	477-478
hybridization	O	479-492
assay	O	493-498
.	O	498-499

In	O	500-502
a	O	503-504
subset	O	505-511
of	O	512-514
families	O	515-523
,	O	523-524
the	O	525-528
relevant	O	529-537
segment	O	538-545
of	O	546-548
the	O	549-552
APOE	O	553-557
gene	O	558-562
was	O	563-566
enzymatically	O	567-580
amplified	O	581-590
to	O	591-593
increase	O	594-602
the	O	603-606
sensitivity	O	607-618
of	O	619-621
the	O	622-625
method	O	626-632
.	O	632-633

For	O	634-637
DM	O	638-640
and	O	641-644
APOE	O	645-649
,	O	649-650
a	O	651-652
maximum	O	653-660
lod	O	661-664
score	O	665-670
(	O	671-672
zmax	O	672-676
of	O	677-679
7	O	680-681
.	O	681-682
47	O	683-685
was	O	686-689
obtained	O	690-698
at	O	699-701
a	O	702-703
recombination	O	704-717
frequency	O	718-727
(	O	728-729
theta	O	729-734
)	O	734-735
of	O	736-738
0	O	739-740
.	O	740-741
047	O	742-745
(	O	746-747
male	O	747-751
theta	O	752-757
=	O	758-759
female	O	760-766
theta	O	767-772
)	O	772-773
.	O	773-774

No	O	775-777
recombination	O	778-791
(	O	792-793
maximum	O	793-800
lod	O	801-804
score	O	805-810
of	O	811-813
5	O	814-815
.	O	815-816
61	O	817-819
at	O	820-822
theta	O	823-828
=	O	829-830
0	O	831-832
.	O	832-833
0	O	834-835
)	O	835-836
was	O	837-840
found	O	841-846
between	O	847-854
APOE	O	855-859
and	O	860-863
the	O	864-867
apolipoprotein	O	868-882
CII	O	883-886
(	O	887-888
APOC2	O	888-893
)	O	893-894
gene	O	895-899
.	O	899-900

These	O	901-906
results	O	907-914
suggest	O	915-922
that	O	923-927
,	O	927-928
in	O	929-931
addition	O	932-940
to	O	941-943
APOC2	O	944-949
,	O	949-950
APOE	O	951-955
is	O	956-958
a	O	959-960
useful	O	961-967
marker	O	968-974
for	O	975-978
presymptomatic	O	979-993
DM	B	994-996
diagnosis	O	997-1006
.	O	1006-1007

Confirmation	O	0-12
of	O	13-15
BRCA1	O	16-21
by	O	22-24
analysis	O	25-33
of	O	34-36
germline	O	37-45
mutations	O	46-55
linked	O	56-62
to	O	63-65
breast	B	66-72
and	I	73-76
ovarian	I	77-84
cancer	I	85-91
in	O	92-94
ten	O	95-98
families	O	99-107
.	O	107-108

We	O	109-111
provide	O	112-119
genetic	O	120-127
evidence	O	128-136
supporting	O	137-147
the	O	148-151
identity	O	152-160
of	O	161-163
the	O	164-167
candidate	O	168-177
gene	O	178-182
for	O	183-186
BRCA1	O	187-192
through	O	193-200
the	O	201-204
characterization	O	205-221
of	O	222-224
germline	O	225-233
mutations	O	234-243
in	O	244-246
63	O	247-249
breast	B	250-256
cancer	I	257-263
patients	O	264-272
and	O	273-276
10	O	277-279
ovarian	B	280-287
cancer	I	288-294
patients	O	295-303
in	O	304-306
ten	O	307-310
families	O	311-319
with	O	320-324
cancer	B	325-331
linked	O	332-338
to	O	339-341
chromosome	O	342-352
17q21	O	353-358
.	O	358-359

Nine	O	360-364
different	O	365-374
mutations	O	375-384
were	O	385-389
detected	O	390-398
by	O	399-401
screening	O	402-411
BRCA1	O	412-417
DNA	O	418-421
and	O	422-425
RNA	O	426-429
by	O	430-432
single	O	433-439
-	O	439-440
strand	O	440-446
conformation	O	447-459
polymorphism	O	460-472
analysis	O	473-481
and	O	482-485
direct	O	486-492
sequencing	O	493-503
.	O	503-504

Seven	O	505-510
mutations	O	511-520
lead	O	521-525
to	O	526-528
protein	O	529-536
truncations	O	537-548
at	O	549-551
sites	O	552-557
throughout	O	558-568
the	O	569-572
gene	O	573-577
.	O	577-578

One	O	579-582
missense	O	583-591
mutation	O	592-600
(	O	601-602
which	O	602-607
occurred	O	608-616
independently	O	617-630
in	O	631-633
two	O	634-637
families	O	638-646
)	O	646-647
leads	O	648-653
to	O	654-656
loss	O	657-661
of	O	662-664
a	O	665-666
cysteine	O	667-675
in	O	676-678
the	O	679-682
zinc	O	683-687
binding	O	688-695
domain	O	696-702
.	O	702-703

An	O	704-706
intronic	O	707-715
single	O	716-722
basepair	O	723-731
substitution	O	732-744
destroys	O	745-753
an	O	754-756
acceptor	O	757-765
site	O	766-770
and	O	771-774
activates	O	775-784
a	O	785-786
cryptic	O	787-794
splice	O	795-801
site	O	802-806
,	O	806-807
leading	O	808-815
to	O	816-818
a	O	819-820
59	O	821-823
basepair	O	824-832
insertion	O	833-842
and	O	843-846
chain	O	847-852
termination	O	853-864
.	O	864-865

The	O	866-869
four	O	870-874
families	O	875-883
with	O	884-888
both	O	889-893
breast	B	894-900
and	I	901-904
ovarian	I	905-912
cancer	I	913-919
had	O	920-923
chain	O	924-929
termination	O	930-941
mutations	O	942-951
in	O	952-954
the	O	955-958
N	O	959-960
-	O	960-961
terminal	O	961-969
half	O	970-974
of	O	975-977
the	O	978-981
protein	O	982-989
.	O	989-990
.	O	989-990

Genetic	O	0-7
instability	O	8-19
in	O	20-22
human	O	23-28
ovarian	B	29-36
cancer	I	37-43
cell	O	44-48
lines	O	49-54
.	O	54-55

We	O	56-58
have	O	59-63
analyzed	O	64-72
the	O	73-76
stability	O	77-86
of	O	87-89
microsatellites	O	90-105
in	O	106-108
cell	O	109-113
lines	O	114-119
derived	O	120-127
from	O	128-132
human	O	133-138
ovarian	B	139-146
cancers	I	147-154
and	O	155-158
found	O	159-164
that	O	165-169
5	O	170-171
out	O	172-175
of	O	176-178
10	O	179-181
of	O	182-184
the	O	185-188
ovarian	B	189-196
tumor	I	197-202
cell	O	203-207
lines	O	208-213
are	O	214-217
genetically	O	218-229
unstable	O	230-238
at	O	239-241
the	O	242-245
majority	O	246-254
of	O	255-257
the	O	258-261
loci	O	262-266
analyzed	O	267-275
.	O	275-276

In	O	277-279
clones	O	280-286
and	O	287-290
subclones	O	291-300
derived	O	301-308
serially	O	309-317
from	O	318-322
one	O	323-326
of	O	327-329
these	O	330-335
cell	O	336-340
lines	O	341-346
(	O	347-348
2774	O	348-352
;	O	352-353
serous	B	354-360
cystadenocarcinoma	I	361-379
)	O	379-380
,	O	380-381
a	O	382-383
very	O	384-388
high	O	389-393
proportion	O	394-404
of	O	405-407
microsatellites	O	408-423
distributed	O	424-435
in	O	436-438
many	O	439-443
different	O	444-453
regions	O	454-461
of	O	462-464
the	O	465-468
genome	O	469-475
change	O	476-482
their	O	483-488
size	O	489-493
in	O	494-496
a	O	497-498
mercurial	O	499-508
fashion	O	509-516
.	O	516-517

We	O	518-520
conclude	O	521-529
that	O	530-534
genomic	O	535-542
instability	O	543-554
in	O	555-557
ovarian	B	558-565
tumors	I	566-572
is	O	573-575
a	O	576-577
dynamic	O	578-585
and	O	586-589
ongoing	O	590-597
process	O	598-605
whose	O	606-611
high	O	612-616
frequency	O	617-626
may	O	627-630
have	O	631-635
been	O	636-640
previously	O	641-651
underestimated	O	652-666
by	O	667-669
PCR	O	670-673
-	O	673-674
based	O	674-679
allelotyping	O	680-692
of	O	693-695
bulk	O	696-700
tumor	B	701-706
tissue	O	707-713
.	O	713-714

We	O	715-717
have	O	718-722
identified	O	723-733
the	O	734-737
source	O	738-744
of	O	745-747
the	O	748-751
genetic	O	752-759
instability	O	760-771
in	O	772-774
one	O	775-778
ovarian	B	779-786
tumor	I	787-792
as	O	793-795
a	O	796-797
point	O	798-803
mutation	O	804-812
(	O	813-814
R524P	O	814-819
)	O	819-820
in	O	821-823
the	O	824-827
human	O	828-833
mismatch	O	834-842
-	O	842-843
repair	O	843-849
gene	O	850-854
MSH2	O	855-859
(	O	860-861
Salmonella	O	861-871
MutS	O	872-876
homologue	O	877-886
)	O	886-887
,	O	887-888
which	O	889-894
has	O	895-898
recently	O	899-907
been	O	908-912
shown	O	913-918
to	O	919-921
be	O	922-924
involved	O	925-933
in	O	934-936
hereditary	B	937-947
nonpolyposis	I	948-960
colorectal	I	961-971
cancer	I	972-978
.	O	978-979

Patient	O	980-987
2774	O	988-992
was	O	993-996
a	O	997-998
38	O	999-1001
-	O	1001-1002
year	O	1002-1006
-	O	1001-1002
old	O	1007-1010
heterozygote	O	1011-1023
,	O	1023-1024
and	O	1025-1028
her	O	1029-1032
normal	O	1033-1039
tissue	O	1040-1046
carried	O	1047-1054
both	O	1055-1059
mutant	O	1060-1066
and	O	1067-1070
wild	O	1071-1075
-	O	1075-1076
type	O	1076-1080
alleles	O	1081-1088
of	O	1089-1091
the	O	1092-1095
human	O	1096-1101
MSH2	O	1102-1106
gene	O	1107-1111
.	O	1111-1112

However	O	1113-1120
the	O	1121-1124
wild	O	1125-1129
-	O	1129-1130
type	O	1130-1134
allele	O	1135-1141
was	O	1142-1145
lost	O	1146-1150
at	O	1151-1153
some	O	1154-1158
point	O	1159-1164
early	O	1165-1170
during	O	1171-1177
tumorigenesis	O	1178-1191
so	O	1192-1194
that	O	1195-1199
DNA	O	1200-1203
isolated	O	1204-1212
either	O	1213-1219
from	O	1220-1224
the	O	1225-1228
patients	O	1229-1237
ovarian	B	1238-1245
tumor	I	1246-1251
or	O	1252-1254
from	O	1255-1259
the	O	1260-1263
2774	O	1264-1268
cell	O	1269-1273
line	O	1274-1278
carries	O	1279-1286
only	O	1287-1291
the	O	1292-1295
mutant	O	1296-1302
allele	O	1303-1309
of	O	1310-1312
the	O	1313-1316
human	O	1317-1322
MSH2	O	1323-1327
gene	O	1328-1332
.	O	1332-1333

The	O	1334-1337
genetic	O	1338-1345
instability	O	1346-1357
observed	O	1358-1366
in	O	1367-1369
the	O	1370-1373
tumor	B	1374-1379
and	O	1380-1383
cell	O	1384-1388
line	O	1389-1393
DNA	O	1394-1397
,	O	1397-1398
together	O	1399-1407
with	O	1408-1412
the	O	1413-1416
germ	O	1417-1421
-	O	1421-1422
line	O	1422-1426
mutation	O	1427-1435
in	O	1436-1438
a	O	1439-1440
mismatch	O	1441-1449
-	O	1449-1450
repair	O	1450-1456
gene	O	1457-1461
,	O	1461-1462
suggest	O	1463-1470
that	O	1471-1475
the	O	1476-1479
MSH2	O	1480-1484
gene	O	1485-1489
is	O	1490-1492
involved	O	1493-1501
in	O	1502-1504
the	O	1505-1508
onset	O	1509-1514
and	O	1515-1518
/	O	1518-1519
or	O	1519-1521
progression	O	1522-1533
in	O	1534-1536
a	O	1537-1538
subset	O	1539-1545
of	O	1546-1548
ovarian	B	1549-1556
cancer	I	1557-1563
.	O	1563-1564
.	O	1563-1564

Retroviral	O	0-10
-	O	10-11
mediated	O	11-19
gene	O	20-24
transfer	O	25-33
of	O	34-36
human	O	37-42
phenylalanine	O	43-56
hydroxylase	O	57-68
into	O	69-73
NIH	O	74-77
3T3	O	78-81
and	O	82-85
hepatoma	B	86-94
cells	O	95-100
.	O	100-101

Phenylketonuria	B	102-117
(	O	118-119
PKU	B	119-122
)	O	122-123
is	O	124-126
caused	O	127-133
by	O	134-136
deficiency	B	137-147
of	I	148-150
the	I	151-154
hepatic	I	155-162
enzyme	I	163-169
phenylalanine	I	170-183
hydroxylase	I	184-195
(	O	196-197
PAH	O	197-200
)	O	200-201
.	O	201-202

A	O	203-204
full	O	205-209
-	O	209-210
length	O	210-216
human	O	217-222
PAH	O	223-226
cDNA	O	227-231
sequence	O	232-240
has	O	241-244
been	O	245-249
inserted	O	250-258
into	O	259-263
pzip	O	264-268
-	O	268-269
neoSV	O	269-274
(	O	275-276
X	O	276-277
)	O	277-278
,	O	278-279
which	O	280-285
is	O	286-288
a	O	289-290
retroviral	O	291-301
vector	O	302-308
containing	O	309-319
the	O	320-323
bacterial	O	324-333
neo	O	334-337
gene	O	338-342
.	O	342-343

The	O	344-347
recombinant	O	348-359
has	O	360-363
been	O	364-368
transfected	O	369-380
into	O	381-385
psi	O	386-389
2	O	390-391
cells	O	392-397
,	O	397-398
which	O	399-404
provide	O	405-412
synthesis	O	413-422
of	O	423-425
the	O	426-429
retroviral	O	430-440
capsid	O	441-447
.	O	447-448

Recombinant	O	449-460
virus	O	461-466
was	O	467-470
detected	O	471-479
in	O	480-482
the	O	483-486
culture	O	487-494
medium	O	495-501
of	O	502-504
the	O	505-508
transfected	O	509-520
psi	O	521-524
2	O	525-526
cells	O	527-532
,	O	532-533
which	O	534-539
is	O	540-542
capable	O	543-550
of	O	551-553
transmitting	O	554-566
the	O	567-570
human	O	571-576
PAH	O	577-580
gene	O	581-585
into	O	586-590
mouse	O	591-596
NIH	O	597-600
3T3	O	601-604
cells	O	605-610
by	O	611-613
infection	O	614-623
leading	O	624-631
to	O	632-634
stable	O	635-641
incorporation	O	642-655
of	O	656-658
the	O	659-662
recombinant	O	663-674
provirus	O	675-683
.	O	683-684

Infected	O	685-693
cells	O	694-699
express	O	700-707
PAH	O	708-711
mRNA	O	712-716
,	O	716-717
immunoreactive	O	718-732
PAH	O	733-736
protein	O	737-744
,	O	744-745
and	O	746-749
exhibit	O	750-757
pterin	O	758-764
-	O	764-765
dependent	O	765-774
phenylalanine	O	775-788
hydroxylase	O	789-800
activity	O	801-809
.	O	809-810

The	O	811-814
recombinant	O	815-826
virus	O	827-832
is	O	833-835
also	O	836-840
capable	O	841-848
of	O	849-851
infecting	O	852-861
a	O	862-863
mouse	O	864-869
hepatoma	B	870-878
cell	O	879-883
line	O	884-888
that	O	889-893
does	O	894-898
not	O	899-902
normally	O	903-911
synthesize	O	912-922
PAH	O	923-926
.	O	926-927

PAH	O	928-931
activity	O	932-940
is	O	941-943
present	O	944-951
in	O	952-954
the	O	955-958
cellular	O	959-967
extracts	O	968-976
and	O	977-980
the	O	981-984
entire	O	985-991
hydroxylation	O	992-1005
system	O	1006-1012
is	O	1013-1015
reconstituted	O	1016-1029
in	O	1030-1032
the	O	1033-1036
hepatoma	B	1037-1045
cells	O	1046-1051
infected	O	1052-1060
with	O	1061-1065
the	O	1066-1069
recombinant	O	1070-1081
viruses	O	1082-1089
.	O	1089-1090

Thus	O	1091-1095
,	O	1095-1096
recombinant	O	1097-1108
viruses	O	1109-1116
containing	O	1117-1127
human	O	1128-1133
PAH	O	1134-1137
cDNA	O	1138-1142
provide	O	1143-1150
a	O	1151-1152
means	O	1153-1158
for	O	1159-1162
introducing	O	1163-1174
functional	O	1175-1185
PAH	O	1186-1189
into	O	1190-1194
mammalian	O	1195-1204
cells	O	1205-1210
of	O	1211-1213
hepatic	O	1214-1221
origin	O	1222-1228
and	O	1229-1232
can	O	1233-1236
potentially	O	1237-1248
be	O	1249-1251
introduced	O	1252-1262
into	O	1263-1267
whole	O	1268-1273
animals	O	1274-1281
as	O	1282-1284
a	O	1285-1286
model	O	1287-1292
for	O	1293-1296
somatic	O	1297-1304
gene	O	1305-1309
therapy	O	1310-1317
for	O	1318-1321
PKU	B	1322-1325
.	O	1325-1326
.	O	1325-1326

Characterisation	O	0-16
of	O	17-19
molecular	O	20-29
defects	O	30-37
in	O	38-40
X	B	41-42
-	I	42-43
linked	I	43-49
amelogenesis	I	50-62
imperfecta	I	63-73
(	O	74-75
AIH1	O	75-79
)	O	79-80
.	O	80-81

Amelogenins	O	82-93
are	O	94-97
an	O	98-100
heterogenous	O	101-113
family	O	114-120
of	O	121-123
proteins	O	124-132
produced	O	133-141
by	O	142-144
ameloblasts	O	145-156
of	O	157-159
the	O	160-163
enamel	O	164-170
organ	O	171-176
during	O	177-183
tooth	O	184-189
development	O	190-201
.	O	201-202

Disturbances	O	203-215
of	O	216-218
enamel	O	219-225
formation	O	226-235
occur	O	236-241
in	O	242-244
amelogenesis	B	245-257
imperfecta	I	258-268
,	O	268-269
a	O	270-271
clinically	O	272-282
heterogenous	O	283-295
group	O	296-301
of	O	302-304
inherited	B	305-314
disorders	I	315-324
characterised	O	325-338
by	O	339-341
defective	O	342-351
enamel	O	352-358
biomineralisation	O	359-376
.	O	376-377

An	O	378-380
amelogenin	O	381-391
gene	O	392-396
,	O	396-397
AMGX	O	398-402
,	O	402-403
has	O	404-407
been	O	408-412
mapped	O	413-419
to	O	420-422
the	O	423-426
short	O	427-432
of	O	433-435
the	O	436-439
X	O	440-441
chromosome	O	442-452
(	O	453-454
Xp22	O	454-458
.	O	458-459

1	O	460-461
-	O	461-462
p22	O	462-465
.	O	465-466

3	O	467-468
)	O	468-469
and	O	470-473
has	O	474-477
been	O	478-482
implicated	O	483-493
in	O	494-496
the	O	497-500
molecular	O	501-510
pathology	O	511-520
of	O	521-523
X	B	524-525
-	I	525-526
linked	I	526-532
amelogenesis	I	533-545
imperfecta	I	546-556
(	O	557-558
AIH1	B	558-562
)	O	562-563
.	O	563-564

We	O	565-567
have	O	568-572
identified	O	573-583
three	O	584-589
families	O	590-598
exhibiting	O	599-609
AIH1	B	610-614
and	O	615-618
screened	O	619-627
the	O	628-631
AMGX	O	632-636
gene	O	637-641
for	O	642-645
mutations	O	646-655
using	O	656-661
single	O	662-668
-	O	668-669
strand	O	669-675
conformational	O	676-690
polymorphism	O	691-703
analysis	O	704-712
and	O	713-716
DNA	O	717-720
sequencing	O	721-731
.	O	731-732

Three	O	733-738
novel	O	739-744
mutations	O	745-754
were	O	755-759
identified	O	760-770
a	O	772-773
C	O	774-775
-	O	775-776
T	O	776-777
substitution	O	778-790
in	O	791-793
exon	O	794-798
5	O	799-800
,	O	800-801
and	O	802-805
a	O	806-807
G	O	808-809
-	O	809-810
T	O	810-811
substitution	O	812-824
and	O	825-828
single	O	829-835
cytosine	O	836-844
deletion	O	845-853
in	O	854-856
exon	O	857-861
6	O	862-863
,	O	863-864
confirming	O	865-875
the	O	876-879
existence	O	880-889
of	O	890-892
extensive	O	893-902
allelic	O	903-910
heterogeneity	O	911-924
in	O	925-927
this	O	928-932
condition	O	933-942
.	O	942-943

The	O	944-947
identification	O	948-962
of	O	963-965
family	O	966-972
-	O	972-973
specific	O	973-981
mutations	O	982-991
will	O	992-996
enable	O	997-1003
early	O	1004-1009
identification	O	1010-1024
of	O	1025-1027
affected	O	1028-1036
individuals	O	1037-1048
and	O	1049-1052
correlation	O	1053-1064
of	O	1065-1067
clinical	O	1068-1076
phenotype	O	1077-1086
with	O	1087-1091
genotype	O	1092-1100
will	O	1101-1105
facilitate	O	1106-1116
an	O	1117-1119
objective	O	1120-1129
system	O	1130-1136
of	O	1137-1139
disease	O	1140-1147
classification	O	1148-1162
.	O	1162-1163

The	O	0-3
Pendred	B	4-11
syndrome	I	12-20
gene	O	21-25
encodes	O	26-33
a	O	34-35
chloride	O	36-44
-	O	44-45
iodide	O	45-51
transport	O	52-61
protein	O	62-69
.	O	69-70

Pendred	B	71-78
syndrome	I	79-87
is	O	88-90
the	O	91-94
most	O	95-99
common	O	100-106
form	O	107-111
of	O	112-114
syndromic	B	115-124
deafness	I	125-133
and	O	134-137
characterized	O	138-151
by	O	152-154
congenital	O	155-165
sensorineural	B	166-179
hearing	I	180-187
loss	I	188-192
and	O	193-196
goitre	B	197-203
.	O	203-204

This	O	205-209
disorder	O	210-218
was	O	219-222
mapped	O	223-229
to	O	230-232
chromosome	O	233-243
7	O	244-245
and	O	246-249
the	O	250-253
gene	O	254-258
causing	O	259-266
Pendred	B	267-274
syndrome	I	275-283
(	O	284-285
PDS	B	285-288
)	O	288-289
was	O	290-293
subsequently	O	294-306
identified	O	307-317
by	O	318-320
positional	O	321-331
cloning	O	332-339
.	O	339-340

PDS	O	341-344
encodes	O	345-352
a	O	353-354
putative	O	355-363
transmembrane	O	364-377
protein	O	378-385
designated	O	386-396
pendrin	O	397-404
.	O	404-405

Pendrin	O	406-413
is	O	414-416
closely	O	417-424
related	O	425-432
to	O	433-435
a	O	436-437
family	O	438-444
of	O	445-447
sulfate	O	448-455
transport	O	456-465
proteins	O	466-474
that	O	475-479
includes	O	480-488
the	O	489-492
rat	O	493-496
sulfate	O	497-504
-	O	504-505
anion	O	505-510
transporter	O	511-522
(	O	523-524
encoded	O	524-531
by	O	532-534
Sat	O	535-538
-	O	538-539
1	O	539-540
;	O	540-541
29	O	542-544
%	O	544-545
amino	O	546-551
acid	O	552-556
sequence	O	557-565
identity	O	566-574
)	O	574-575
,	O	575-576
the	O	577-580
human	O	581-586
diastrophic	B	587-598
dysplasia	I	599-608
sulfate	O	609-616
transporter	O	617-628
(	O	629-630
encoded	O	630-637
by	O	638-640
DTD	O	641-644
;	O	644-645
32	O	646-648
%	O	648-649
)	O	649-650
and	O	651-654
the	O	655-658
human	O	659-664
sulfate	O	665-672
transporter	O	673-684
downregulated	O	685-698
in	O	699-701
adenoma	B	702-709
(	O	710-711
encoded	O	711-718
by	O	719-721
DRA	O	722-725
;	O	725-726
45	O	727-729
%	O	729-730
)	O	730-731
.	O	731-732

On	O	733-735
the	O	736-739
basis	O	740-745
of	O	746-748
this	O	749-753
homology	O	754-762
and	O	763-766
the	O	767-770
presence	O	771-779
of	O	780-782
a	O	783-784
slightly	O	785-793
modified	O	794-802
sulfate	O	803-810
-	O	810-811
transporter	O	811-822
signature	O	823-832
sequence	O	833-841
comprising	O	842-852
its	O	853-856
putative	O	857-865
second	O	866-872
transmembrane	O	873-886
domain	O	887-893
,	O	893-894
pendrin	O	895-902
has	O	903-906
been	O	907-911
proposed	O	912-920
to	O	921-923
function	O	924-932
as	O	933-935
a	O	936-937
sulfate	O	938-945
transporter	O	946-957
.	O	957-958

We	O	959-961
were	O	962-966
unable	O	967-973
to	O	974-976
detect	O	977-983
evidence	O	984-992
of	O	993-995
sulfate	O	996-1003
transport	O	1004-1013
following	O	1014-1023
the	O	1024-1027
expression	O	1028-1038
of	O	1039-1041
pendrin	O	1042-1049
in	O	1050-1052
Xenopus	O	1053-1060
laevis	O	1061-1067
oocytes	O	1068-1075
by	O	1076-1078
microinjection	O	1079-1093
of	O	1094-1096
PDS	O	1097-1100
cRNA	O	1101-1105
or	O	1106-1108
in	O	1109-1111
Sf9	O	1112-1115
cells	O	1116-1121
following	O	1122-1131
infection	O	1132-1141
with	O	1142-1146
PDS	O	1147-1150
-	O	1150-1151
recombinant	O	1151-1162
baculovirus	O	1163-1174
.	O	1174-1175

The	O	1176-1179
rates	O	1180-1185
of	O	1186-1188
transport	O	1189-1198
for	O	1199-1202
iodide	O	1203-1209
and	O	1210-1213
chloride	O	1214-1222
were	O	1223-1227
significantly	O	1228-1241
increased	O	1242-1251
following	O	1252-1261
the	O	1262-1265
expression	O	1266-1276
of	O	1277-1279
pendrin	O	1280-1287
in	O	1288-1290
both	O	1291-1295
cell	O	1296-1300
systems	O	1301-1308
.	O	1308-1309

Our	O	1310-1313
results	O	1314-1321
demonstrate	O	1322-1333
that	O	1334-1338
pendrin	O	1339-1346
functions	O	1347-1356
as	O	1357-1359
a	O	1360-1361
transporter	O	1362-1373
of	O	1374-1376
chloride	O	1377-1385
and	O	1386-1389
iodide	O	1390-1396
,	O	1396-1397
but	O	1398-1401
not	O	1402-1405
sulfate	O	1406-1413
,	O	1413-1414
and	O	1415-1418
may	O	1419-1422
provide	O	1423-1430
insight	O	1431-1438
into	O	1439-1443
thyroid	O	1444-1451
physiology	O	1452-1462
and	O	1463-1466
the	O	1467-1470
pathophysiology	O	1471-1486
of	O	1487-1489
Pendred	B	1490-1497
syndrome	I	1498-1506
.	O	1506-1507
.	O	1506-1507

Linkage	O	0-7
relationship	O	8-20
of	O	21-23
C2	B	24-26
deficiency	I	27-37
,	O	37-38
HLA	O	39-42
and	O	43-46
glyoxalase	O	47-57
I	O	58-59
loci	O	60-64
.	O	64-65

Immunogenetic	O	66-79
analysis	O	80-88
of	O	89-91
a	O	92-93
homozygous	O	94-104
C2	B	105-107
-	I	107-108
deficient	I	108-117
individual	O	118-128
and	O	129-132
family	O	133-139
members	O	140-147
demonstrated	O	148-160
linkage	O	161-168
of	O	169-171
HLA	O	172-175
-	O	175-176
A25	O	176-179
,	O	179-180
B18	O	181-184
and	O	185-188
C2o	O	189-192
.	O	192-193

HLA	O	194-197
-	O	197-198
D	O	198-199
typing	O	200-206
showed	O	207-213
that	O	214-218
5	O	219-220
members	O	221-228
typed	O	229-234
with	O	235-239
homozygous	O	240-250
Dw2	O	251-254
typing	O	255-261
cells	O	262-267
from	O	268-272
an	O	273-275
individual	O	276-286
with	O	287-291
C2	B	292-294
deficiency	I	295-305
but	O	306-309
not	O	310-313
with	O	314-318
Dw2	O	319-322
typing	O	323-329
cells	O	330-335
from	O	336-340
2	O	341-342
individuals	O	343-354
with	O	355-359
normal	O	360-366
C2	O	367-369
.	O	369-370

The	O	371-374
homozygous	O	375-385
C2	B	386-388
-	I	388-389
deficient	I	389-398
propositus	O	399-409
and	O	410-413
brother	O	414-421
were	O	422-426
HLA	O	427-430
-	O	430-431
A	O	429-430
and	O	433-436
B	O	437-438
homozygous	O	439-449
but	O	450-453
heterozygous	O	454-466
at	O	467-469
the	O	470-473
HLA	O	474-477
-	O	477-478
D	O	478-479
and	O	480-483
glyoxalase	O	484-494
I	O	495-496
loci	O	497-501
.	O	501-502

Therefore	O	503-512
,	O	512-513
in	O	514-516
this	O	517-521
family	O	522-528
,	O	528-529
the	O	530-533
C2o	O	534-537
gene	O	538-542
is	O	543-545
linked	O	546-552
with	O	553-557
two	O	558-561
distinct	O	562-570
haplotypes	O	571-581
HLA	O	583-586
-	O	586-587
A25	O	587-590
,	O	590-591
B18	O	592-595
,	O	595-596
Dw2	O	597-600
,	O	600-601
GLO1	O	602-606
and	O	607-610
HLA	O	611-614
-	O	614-615
A25	O	615-618
,	O	618-619
B18	O	620-623
,	O	623-624
D	O	625-626
unknown	O	627-634
,	O	634-635
GL02	O	636-640
.	O	640-641

These	O	642-647
results	O	648-655
could	O	656-661
be	O	662-664
explained	O	665-674
by	O	675-677
an	O	678-680
ancestral	O	681-690
recombinant	O	691-702
event	O	703-708
,	O	708-709
which	O	710-715
occurred	O	716-724
between	O	725-732
the	O	733-736
C2o	O	737-740
locus	O	741-746
and	O	747-750
HLA	O	751-754
-	O	754-755
D	O	755-756
locus	O	757-762
in	O	763-765
which	O	766-771
C2o	O	772-775
segregated	O	776-786
with	O	787-791
HLA	O	792-795
-	O	795-796
B	O	796-797
.	O	797-798

This	O	799-803
would	O	804-809
suggest	O	810-817
that	O	818-822
the	O	823-826
locus	O	827-832
for	O	833-836
the	O	837-840
C2o	O	841-844
gene	O	845-849
maps	O	850-854
between	O	855-862
HLA	O	863-866
-	O	866-867
B	O	867-868
and	O	869-872
HLA	O	873-876
-	O	876-877
D	O	877-878
on	O	879-881
the	O	882-885
sixth	O	886-891
chromosome	O	892-902
.	O	902-903
.	O	902-903

A	O	0-1
71	O	2-4
-	O	4-5
kilodalton	O	5-15
protein	O	16-23
is	O	24-26
a	O	27-28
major	O	29-34
product	O	35-42
of	O	43-45
the	O	46-49
Duchenne	B	50-58
muscular	I	59-67
dystrophy	I	68-77
gene	O	78-82
in	O	83-85
brain	O	86-91
and	O	92-95
other	O	96-101
nonmuscle	O	102-111
tissues	O	112-119
.	O	119-120

The	O	121-124
known	O	125-130
Duchenne	B	131-139
muscular	I	140-148
dystrophy	I	149-158
(	O	159-160
DMD	B	160-163
)	O	163-164
gene	O	165-169
products	O	170-178
,	O	178-179
the	O	180-183
muscle	O	184-190
-	O	190-191
and	O	192-195
brain	O	196-201
-	O	201-202
type	O	202-206
dystrophin	O	207-217
isoforms	O	218-226
,	O	226-227
are	O	228-231
427	O	232-235
-	O	235-236
kDa	O	236-239
proteins	O	240-248
translated	O	249-259
from	O	260-264
14	O	265-267
-	O	267-268
kilobase	O	268-276
(	O	277-278
kb	O	278-280
)	O	280-281
mRNAs	O	282-287
.	O	287-288

Recently	O	289-297
we	O	298-300
described	O	301-310
a	O	311-312
6	O	313-314
.	O	314-315
5	O	316-317
-	O	317-318
kb	O	318-320
mRNA	O	321-325
that	O	326-330
also	O	331-335
is	O	336-338
transcribed	O	339-350
from	O	351-355
the	O	356-359
DMD	B	360-363
gene	O	364-368
.	O	368-369

Cloning	O	370-377
and	O	378-381
in	O	382-384
vitro	O	385-390
transcription	O	391-404
and	O	405-408
translation	O	409-420
of	O	421-423
the	O	424-427
entire	O	428-434
coding	O	435-441
region	O	442-448
show	O	449-453
that	O	454-458
the	O	459-462
6	O	463-464
.	O	464-465
5	O	466-467
-	O	467-468
kb	O	468-470
mRNA	O	471-475
encodes	O	476-483
a	O	484-485
70	O	486-488
.	O	488-489

8	O	490-491
-	O	491-492
kDa	O	492-495
protein	O	496-503
that	O	504-508
is	O	509-511
a	O	512-513
major	O	514-519
product	O	520-527
of	O	528-530
the	O	531-534
DMD	B	535-538
gene	O	539-543
.	O	543-544

It	O	545-547
contains	O	548-556
the	O	557-560
C	O	561-562
-	O	562-563
terminal	O	563-571
and	O	572-575
the	O	576-579
cysteine	O	580-588
-	O	588-589
rich	O	589-593
domains	O	594-601
of	O	602-604
dystrophin	O	605-615
,	O	615-616
seven	O	617-622
additional	O	623-633
amino	O	634-639
acids	O	640-645
at	O	646-648
the	O	649-652
N	O	653-654
terminus	O	655-663
,	O	663-664
and	O	665-668
some	O	669-673
modifications	O	674-687
formed	O	688-694
by	O	695-697
alternative	O	698-709
splicing	O	710-718
in	O	719-721
the	O	722-725
C	O	726-727
-	O	727-728
terminal	O	728-736
domain	O	737-743
.	O	743-744

It	O	745-747
lacks	O	748-753
the	O	754-757
entire	O	758-764
large	O	765-770
domain	O	771-777
of	O	778-780
spectrin	O	781-789
-	O	789-790
like	O	790-794
repeats	O	795-802
and	O	803-806
the	O	807-810
actin	O	811-816
-	O	816-817
binding	O	817-824
N	O	825-826
-	O	826-827
terminal	O	827-835
domain	O	836-842
of	O	843-845
dystrophin	O	846-856
.	O	856-857

This	O	858-862
protein	O	863-870
is	O	871-873
the	O	874-877
major	O	878-883
DMD	B	884-887
gene	O	888-892
product	O	893-900
in	O	901-903
brain	O	904-909
and	O	910-913
other	O	914-919
nonmuscle	O	920-929
tissues	O	930-937
but	O	938-941
is	O	942-944
undetectable	O	945-957
in	O	958-960
skeletal	O	961-969
muscle	O	970-976
extracts	O	977-985
.	O	985-986

Histidinemia	B	0-12
.	O	12-13

Classical	O	14-23
and	O	24-27
atypical	O	28-36
form	O	37-41
in	O	42-44
siblings	O	45-53
.	O	53-54

Two	O	55-58
brothers	O	59-67
,	O	67-68
6	O	69-70
and	O	71-74
13	O	75-77
years	O	78-83
old	O	84-87
,	O	87-88
had	O	89-92
histidinemia	B	93-105
.	O	105-106

On	O	107-109
the	O	110-113
basis	O	114-119
of	O	120-122
clinical	O	123-131
and	O	132-135
biochemical	O	136-147
observations	O	148-160
,	O	160-161
the	O	162-165
younger	O	166-173
boy	O	174-177
was	O	178-181
considered	O	182-192
to	O	193-195
have	O	196-200
a	O	201-202
classical	O	203-212
type	O	213-217
of	O	218-220
the	O	221-224
disease	O	225-232
,	O	232-233
while	O	234-239
the	O	240-243
older	O	244-249
boy	O	250-253
had	O	254-257
an	O	258-260
atypical	O	261-269
form	O	270-274
characterized	O	275-288
by	O	289-291
partial	O	292-299
impairment	O	300-310
of	O	311-313
the	O	314-317
skin	O	318-322
histidase	O	323-332
activity	O	333-341
and	O	342-345
a	O	346-347
moderately	O	348-358
prolonged	O	359-368
half	O	369-373
-	O	373-374
life	O	374-378
of	O	379-381
blood	O	382-387
histidine	O	388-397
.	O	397-398

The	O	399-402
mother	O	403-409
is	O	410-412
a	O	413-414
heterozygous	O	415-427
carrier	O	428-435
,	O	435-436
while	O	437-442
the	O	443-446
father	O	447-453
and	O	454-457
sister	O	458-464
seem	O	465-469
to	O	470-472
be	O	473-475
normal	O	476-482
.	O	482-483
.	O	482-483

Hypoxanthine	B	0-12
-	I	12-13
guanine	I	13-20
phosphoribosyltransferase	I	21-46
deficiency	I	47-57
:	O	57-58
analysis	O	59-67
of	O	68-70
HPRT	O	71-75
mutations	O	76-85
by	O	86-88
direct	O	89-95
sequencing	O	96-106
and	O	107-110
allele	O	111-117
-	O	117-118
specific	O	118-126
amplification	O	127-140
.	O	140-141

The	O	142-145
Lesch	B	146-151
-	I	151-152
Nyhan	I	152-157
syndrome	I	158-166
is	O	167-169
a	O	170-171
severe	O	172-178
X	B	179-180
chromosome	I	181-191
-	I	191-192
linked	I	192-198
human	I	199-204
disease	I	205-212
caused	O	213-219
by	O	220-222
a	O	223-224
virtual	O	225-232
absence	B	233-240
of	I	241-243
hypoxanthine	I	244-256
-	I	256-257
guanine	I	257-264
phosphoribosyltransferase	I	265-290
(	I	291-292
HPRT	I	292-296
)	I	296-297
activity	I	298-306
.	O	306-307

A	O	308-309
partial	O	310-317
deficiency	O	318-328
in	O	329-331
the	O	332-335
activity	O	336-344
of	O	345-347
this	O	348-352
enzyme	O	353-359
can	O	360-363
result	O	364-370
in	O	371-373
gouty	B	374-379
arthritis	I	380-389
.	O	389-390

To	O	391-393
determine	O	394-403
the	O	404-407
genetic	O	408-415
basis	O	416-421
for	O	422-425
reduction	O	426-435
or	O	436-438
loss	O	439-443
of	O	444-446
enzyme	O	447-453
activity	O	454-462
,	O	462-463
we	O	464-466
have	O	467-471
amplified	O	472-481
and	O	482-485
sequenced	O	486-495
the	O	496-499
coding	O	500-506
region	O	507-513
of	O	514-516
HPRT	O	517-521
cDNA	O	522-526
from	O	527-531
four	O	532-536
patients	O	537-545
one	O	547-550
with	O	551-555
Lesch	B	556-561
-	I	561-562
Nyhan	I	562-567
syndrome	I	568-576
(	O	577-578
HPRTPerth	O	578-587
)	O	587-588
and	O	589-592
three	O	593-598
with	O	599-603
partial	B	604-611
deficiencies	I	612-624
of	I	625-627
HPRT	I	628-632
activity	I	633-641
,	O	641-642
which	O	643-648
have	O	649-653
been	O	654-658
designated	O	659-669
HPRTUrangan	O	670-681
,	O	681-682
HPRTSwan	O	683-691
and	O	692-695
HPRTToowong	O	696-707
.	O	707-708

In	O	709-711
all	O	712-715
four	O	716-720
patients	O	721-729
,	O	729-730
the	O	731-734
only	O	735-739
mutation	O	740-748
identified	O	749-759
was	O	760-763
a	O	764-765
single	O	766-772
base	O	773-777
substitution	O	778-790
in	O	791-793
exons	O	794-799
2	O	800-801
or	O	802-804
3	O	805-806
of	O	807-809
the	O	810-813
coding	O	814-820
region	O	821-827
,	O	827-828
which	O	829-834
in	O	835-837
each	O	838-842
case	O	843-847
predicts	O	848-856
a	O	857-858
single	O	859-865
amino	O	866-871
acid	O	872-876
substitution	O	877-889
in	O	890-892
the	O	893-896
translated	O	897-907
protein	O	908-915
.	O	915-916

Each	O	917-921
base	O	922-926
change	O	927-933
was	O	934-937
confirmed	O	938-947
by	O	948-950
allele	O	951-957
-	O	957-958
specific	O	958-966
amplification	O	967-980
of	O	981-983
the	O	984-987
patients	O	988-996
genomic	O	997-1004
DNA	O	1005-1008
.	O	1008-1009

It	O	1010-1012
is	O	1013-1015
interesting	O	1016-1027
to	O	1028-1030
note	O	1031-1035
that	O	1036-1040
the	O	1041-1044
mutation	O	1045-1053
found	O	1054-1059
for	O	1060-1063
HPRTPerth	O	1064-1073
is	O	1074-1076
identical	O	1077-1086
to	O	1087-1089
that	O	1090-1094
reported	O	1095-1103
for	O	1104-1107
HPRTFlint	O	1108-1117
.	O	1117-1118

It	O	1119-1121
appears	O	1122-1129
that	O	1130-1134
the	O	1135-1138
two	O	1139-1142
mutations	O	1143-1152
are	O	1153-1156
de	O	1157-1159
novo	O	1160-1164
events	O	1165-1171
.	O	1171-1172
.	O	1171-1172

Sjogren	B	0-7
-	I	7-8
Larsson	I	8-15
syndrome	I	16-24
.	O	24-25

Impaired	O	26-34
fatty	O	35-40
alcohol	O	41-48
oxidation	O	49-58
in	O	59-61
cultured	O	62-70
fibroblasts	O	71-82
due	O	83-86
to	O	87-89
deficient	O	90-99
fatty	O	100-105
alcohol	O	106-113
:	O	113-114
nicotinamide	O	114-126
adenine	O	127-134
dinucleotide	O	135-147
oxidoreductase	O	148-162
activity	O	163-171
.	O	171-172

Lipid	O	173-178
metabolism	O	179-189
was	O	190-193
studied	O	194-201
in	O	202-204
cultured	O	205-213
skin	O	214-218
fibroblasts	O	219-230
from	O	231-235
patients	O	236-244
with	O	245-249
the	O	250-253
inherited	B	254-263
disorder	I	264-272
,	O	272-273
Sjogren	B	274-281
-	I	281-282
Larsson	I	282-289
syndrome	I	290-298
(	O	299-300
SLS	B	300-303
)	O	303-304
.	O	304-305

Intact	O	306-312
SLS	B	313-316
fibroblasts	O	317-328
incubated	O	329-338
in	O	339-341
the	O	342-345
presence	O	346-354
of	O	355-357
[	O	358-359
1	O	359-360
-	O	360-361
14C	O	361-364
]	O	364-365
palmitate	O	366-375
accumulated	O	376-387
more	O	388-392
radioactive	O	393-404
hexadecanol	O	405-416
than	O	417-421
did	O	422-425
normal	O	426-432
cells	O	433-438
,	O	438-439
whereas	O	440-447
incorporation	O	448-461
of	O	462-464
radioactivity	O	465-478
into	O	479-483
other	O	484-489
cellular	O	490-498
lipids	O	499-505
was	O	506-509
unaltered	O	510-519
.	O	519-520

The	O	521-524
hexadecanol	O	525-536
content	O	537-544
of	O	545-547
SLS	B	548-551
fibroblasts	O	552-563
was	O	564-567
abnormally	O	568-578
elevated	O	579-587
.	O	587-588

Hexadecanol	O	589-600
accumulation	O	601-613
was	O	614-617
not	O	618-621
due	O	622-625
to	O	626-628
increased	O	629-638
fatty	O	639-644
alcohol	O	645-652
synthesis	O	653-662
nor	O	663-666
its	O	667-670
deficient	O	671-680
utilization	O	681-692
for	O	693-696
glycerol	O	697-705
ether	O	706-711
synthesis	O	712-721
.	O	721-722

The	O	723-726
half	O	727-731
-	O	731-732
life	O	732-736
of	O	737-739
intracellular	O	740-753
hexadecanol	O	754-765
loaded	O	766-772
into	O	773-777
SLS	B	778-781
fibroblasts	O	782-793
was	O	794-797
increased	O	798-807
(	O	808-809
70	O	809-811
min	O	812-815
)	O	815-816
compared	O	817-825
with	O	826-830
normal	O	831-837
(	O	838-839
15	O	839-841
min	O	842-845
)	O	845-846
,	O	846-847
and	O	848-851
intact	O	852-858
SLS	B	859-862
fibroblasts	O	863-874
showed	O	875-881
impaired	O	882-890
oxidation	O	891-900
of	O	901-903
[	O	904-905
14C	O	905-908
]	O	908-909
-	O	910-911
hexadecanol	O	911-922
to	O	923-925
fatty	O	926-931
acid	O	932-936
.	O	936-937

Fatty	O	938-943
alcohol	O	944-951
NAD	O	953-956
+	O	957-958
oxidoreductase	O	959-973
,	O	973-974
the	O	975-978
enzyme	O	979-985
catalyzing	O	986-996
this	O	997-1001
reaction	O	1002-1010
,	O	1010-1011
was	O	1012-1015
deficient	O	1016-1025
in	O	1026-1028
SLS	B	1029-1032
fibroblasts	O	1033-1044
.	O	1044-1045

Mean	O	1046-1050
total	O	1051-1056
activity	O	1057-1065
in	O	1066-1068
SLS	B	1069-1072
fibroblasts	O	1073-1084
(	O	1085-1086
n	O	1086-1087
=	O	1088-1089
5	O	1090-1091
)	O	1091-1092
was	O	1093-1096
13	O	1097-1099
%	O	1099-1100
of	O	1101-1103
that	O	1104-1108
in	O	1109-1111
normal	O	1112-1118
fibroblasts	O	1119-1130
,	O	1130-1131
and	O	1132-1135
palmitoyl	O	1136-1145
CoA	O	1146-1149
-	O	1149-1150
inhibitable	O	1150-1161
activity	O	1162-1170
was	O	1171-1174
1	O	1175-1176
%	O	1176-1177
of	O	1178-1180
normal	O	1181-1187
.	O	1187-1188

Fibroblasts	O	1189-1200
from	O	1201-1205
two	O	1206-1209
obligate	O	1210-1218
SLS	B	1219-1222
heterozygotes	O	1223-1236
had	O	1237-1240
enzyme	O	1241-1247
activities	O	1248-1258
intermediate	O	1259-1271
between	O	1272-1279
that	O	1280-1284
in	O	1285-1287
normal	O	1288-1294
fibroblasts	O	1295-1306
and	O	1307-1310
individuals	O	1311-1322
with	O	1323-1327
SLS	B	1328-1331
.	O	1331-1332

These	O	1333-1338
results	O	1339-1346
suggest	O	1347-1354
that	O	1355-1359
the	O	1360-1363
primary	O	1364-1371
defect	O	1372-1378
in	O	1379-1381
SLS	B	1382-1385
is	O	1386-1388
deficiency	B	1389-1399
of	I	1400-1402
fatty	I	1403-1408
alcohol	I	1409-1416
NAD	I	1418-1421
+	I	1422-1423
oxidoreductase	I	1424-1438
.	O	1438-1439

SLS	B	1440-1443
represents	O	1444-1454
the	O	1455-1458
first	O	1459-1464
inherited	B	1465-1474
disorder	I	1475-1483
in	O	1484-1486
man	O	1487-1490
associated	O	1491-1501
with	O	1502-1506
an	O	1507-1509
isolated	O	1510-1518
abnormality	B	1519-1530
in	I	1531-1533
fatty	I	1534-1539
alcohol	I	1540-1547
metabolism	I	1548-1558
.	O	1558-1559
.	O	1558-1559

Glycerol	O	0-8
as	O	9-11
a	O	12-13
correlate	O	14-23
of	O	24-26
impaired	B	27-35
glucose	I	36-43
tolerance	I	44-53
:	O	53-54
dissection	O	55-65
of	O	66-68
a	O	69-70
complex	O	71-78
system	O	79-85
by	O	86-88
use	O	89-92
of	O	93-95
a	O	96-97
simple	O	98-104
genetic	O	105-112
trait	O	113-118
.	O	118-119

Glycerol	O	120-128
kinase	O	129-135
(	O	136-137
GK	O	137-139
)	O	139-140
represents	O	141-151
the	O	152-155
primary	O	156-163
entry	O	164-169
of	O	170-172
glycerol	O	173-181
into	O	182-186
glucose	O	187-194
and	O	195-198
triglyceride	O	199-211
metabolism	O	212-222
.	O	222-223

Impaired	B	224-232
glucose	I	233-240
tolerance	I	241-250
(	O	251-252
IGT	B	252-255
)	O	255-256
and	O	257-260
hypertriglyceridemia	B	261-281
are	O	282-285
associated	O	286-296
with	O	297-301
an	O	302-304
increased	O	305-314
risk	O	315-319
of	O	320-322
diabetes	B	323-331
mellitus	I	332-340
and	O	341-344
cardiovascular	B	345-359
disease	I	360-367
.	O	367-368

The	O	369-372
relationship	O	373-385
between	O	386-393
glycerol	O	394-402
and	O	403-406
the	O	407-410
risk	O	411-415
of	O	416-418
IGT	B	419-422
,	O	422-423
however	O	424-431
,	O	431-432
is	O	433-435
poorly	O	436-442
understood	O	443-453
.	O	453-454

We	O	455-457
therefore	O	458-467
undertook	O	468-477
the	O	478-481
study	O	482-487
of	O	488-490
fasting	O	491-498
plasma	O	499-505
glycerol	O	506-514
levels	O	515-521
in	O	522-524
a	O	525-526
cohort	O	527-533
of	O	534-536
1	O	537-538
,	O	538-539
056	O	540-543
unrelated	O	544-553
men	O	554-557
and	O	558-561
women	O	562-567
of	O	568-570
French	O	571-577
-	O	577-578
Canadian	O	578-586
descent	O	587-594
.	O	594-595

Family	O	596-602
screening	O	603-612
in	O	613-615
the	O	616-619
initial	O	620-627
cohort	O	628-634
identified	O	635-645
18	O	646-648
men	O	649-652
from	O	653-657
five	O	658-662
families	O	663-671
with	O	672-676
severe	O	677-683
hyperglycerolemia	B	684-701
(	O	702-703
values	O	703-709
above	O	710-715
2	O	716-717
.	O	717-718
0	O	719-720
mmol	O	721-725
/	O	725-726
liter	O	726-731
)	O	731-732
and	O	733-736
demonstrated	O	737-749
an	O	750-752
X	O	753-754
-	O	754-755
linked	O	755-761
pattern	O	762-769
of	O	770-772
inheritance	O	773-784
.	O	784-785

Linkage	O	786-793
analysis	O	794-802
of	O	803-805
the	O	806-809
data	O	810-814
from	O	815-819
12	O	820-822
microsatellite	O	823-837
markers	O	838-845
surrounding	O	846-857
the	O	858-861
Xp21	O	862-866
.	O	866-867
3	O	868-869
GK	O	870-872
gene	O	873-877
resulted	O	878-886
in	O	887-889
a	O	890-891
peak	O	892-896
LOD	O	897-900
score	O	901-906
of	O	907-909
3	O	910-911
.	O	911-912
46	O	913-915
,	O	915-916
centered	O	917-925
around	O	926-932
marker	O	933-939
DXS8039	O	940-947
.	O	947-948

In	O	949-951
addition	O	952-960
,	O	960-961
since	O	962-967
all	O	968-971
of	O	972-974
the	O	975-978
families	O	979-987
originated	O	988-998
in	O	999-1001
a	O	1002-1003
population	O	1004-1014
with	O	1015-1019
a	O	1020-1021
proven	O	1022-1028
founder	O	1029-1036
effect	O	1037-1043
-	O	1043-1044
the	O	1044-1047
Saguenay	O	1048-1056
Lac	O	1057-1060
-	O	1060-1061
St	O	1061-1063
.	O	1063-1064

-	O	1065-1066
Jean	O	1066-1070
region	O	1071-1077
of	O	1078-1080
Quebec	O	1081-1087
-	O	1087-1088
a	O	1088-1089
common	O	1090-1096
disease	O	1097-1104
haplotype	O	1105-1114
was	O	1115-1118
sought	O	1119-1125
.	O	1125-1126

Indeed	O	1127-1133
,	O	1133-1134
a	O	1135-1136
six	O	1137-1140
-	O	1140-1141
marker	O	1141-1147
haplotype	O	1148-1157
extending	O	1158-1167
over	O	1168-1172
a	O	1173-1174
region	O	1175-1181
of	O	1182-1184
5	O	1185-1186
.	O	1186-1187
5	O	1188-1189
cM	O	1190-1192
was	O	1193-1196
observed	O	1197-1205
in	O	1206-1208
all	O	1209-1212
families	O	1213-1221
.	O	1221-1222

Resequencing	O	1223-1235
of	O	1236-1238
the	O	1239-1242
GK	O	1243-1245
gene	O	1246-1250
in	O	1251-1253
family	O	1254-1260
members	O	1261-1268
led	O	1269-1272
to	O	1273-1275
the	O	1276-1279
discovery	O	1280-1289
of	O	1290-1292
a	O	1293-1294
N288D	O	1295-1300
missense	O	1301-1309
mutation	O	1310-1318
in	O	1319-1321
exon	O	1322-1326
10	O	1327-1329
,	O	1329-1330
which	O	1331-1336
resulted	O	1337-1345
in	O	1346-1348
the	O	1349-1352
substitution	O	1353-1365
of	O	1366-1368
a	O	1369-1370
highly	O	1371-1377
conserved	O	1378-1387
asparagine	O	1388-1398
residue	O	1399-1406
by	O	1407-1409
a	O	1410-1411
negatively	O	1412-1422
charged	O	1423-1430
aspartic	O	1431-1439
acid	O	1440-1444
.	O	1444-1445

Assignment	O	0-10
of	O	11-13
the	O	14-17
aspartylglucosaminidase	O	18-41
gene	O	42-46
(	O	47-48
AGA	O	48-51
)	O	51-52
to	O	53-55
4q33	O	56-60
-	O	60-61
-	O	60-61
-	O	60-61
-	O	60-61
q35	O	64-67
based	O	68-73
on	O	74-76
decreased	O	77-86
activity	O	87-95
in	O	96-98
a	O	99-100
girl	O	101-105
with	O	106-110
a	O	111-112
46	O	113-115
,	O	115-116
XX	O	116-118
,	O	115-116
del	O	119-122
(	O	122-123
4	O	113-114
)	O	124-125
(	O	122-123
q33	O	126-129
)	O	124-125
karyotype	O	131-140
.	O	140-141

Aspartylglucosaminuria	B	142-164
(	O	165-166
AGU	B	166-169
)	O	169-170
is	O	171-173
a	O	174-175
recessive	O	176-185
autosomally	O	186-197
inherited	O	198-207
lysosomal	B	208-217
storage	I	218-225
disorder	I	226-234
due	O	235-238
to	O	239-241
deficiency	B	242-252
of	I	253-255
the	I	256-259
enzyme	I	260-266
aspartylglucosaminidase	I	267-290
(	O	291-292
AGA	O	292-295
)	O	295-296
.	O	296-297

The	O	298-301
structural	O	302-312
gene	O	313-317
for	O	318-321
this	O	322-326
human	O	327-332
enzyme	O	333-339
(	O	340-341
AGA	O	341-344
)	O	344-345
has	O	346-349
been	O	350-354
assigned	O	355-363
to	O	364-366
the	O	367-370
region	O	371-377
4q21	O	378-382
-	O	382-383
-	O	382-383
-	O	382-383
-	O	382-383
qter	O	386-390
.	O	390-391

We	O	392-394
determined	O	395-405
the	O	406-409
AGA	O	410-413
activity	O	414-422
in	O	423-425
cultured	O	426-434
fibroblasts	O	435-446
of	O	447-449
a	O	450-451
girl	O	452-456
with	O	457-461
a	O	462-463
46	O	464-466
,	O	466-467
XX	O	468-470
,	O	470-471
del	O	472-475
(	O	476-477
4	O	477-478
)	O	478-479
(	O	480-481
q33	O	481-484
)	O	484-485
karyotype	O	486-495
.	O	495-496

The	O	497-500
results	O	501-508
indicate	O	509-517
that	O	518-522
the	O	523-526
girl	O	527-531
is	O	532-534
a	O	535-536
hemizygote	O	537-547
for	O	548-551
AGA	O	552-555
,	O	555-556
permitting	O	557-567
the	O	568-571
assignment	O	572-582
of	O	583-585
human	O	586-591
AGA	O	592-595
to	O	596-598
the	O	599-602
region	O	603-609
4q33	O	610-614
-	O	614-615
-	O	614-615
-	O	614-615
-	O	614-615
qter	O	618-622
.	O	622-623
.	O	622-623

Mutations	O	0-9
in	O	10-12
the	O	13-16
fibrinogen	O	17-27
aalpha	O	28-34
gene	O	35-39
account	O	40-47
for	O	48-51
the	O	52-55
majority	O	56-64
of	O	65-67
cases	O	68-73
of	O	74-76
congenital	B	77-87
afibrinogenemia	I	88-103
.	O	103-104

Congenital	B	105-115
afibrinogenemia	I	116-131
is	O	132-134
a	O	135-136
rare	O	137-141
,	O	141-142
autosomal	B	143-152
,	I	152-153
recessive	I	154-163
disorder	I	164-172
characterized	O	173-186
by	O	187-189
the	O	190-193
complete	O	194-202
absence	O	203-210
of	O	211-213
detectable	O	214-224
fibrinogen	O	225-235
.	O	235-236

We	O	237-239
previously	O	240-250
identified	O	251-261
the	O	262-265
first	O	266-271
causative	O	272-281
mutations	O	282-291
in	O	292-294
a	O	295-296
nonconsanguineous	O	297-314
Swiss	O	315-320
family	O	321-327
;	O	327-328
the	O	329-332
4	O	333-334
affected	O	335-343
persons	O	344-351
have	O	352-356
homozygous	O	357-367
deletions	O	368-377
of	O	378-380
approximately	O	381-394
11	O	395-397
kb	O	398-400
of	O	401-403
the	O	404-407
fibrinogen	O	408-418
alpha	O	419-424
(	O	425-426
FGA	O	426-429
)	O	429-430
gene	O	431-435
.	O	435-436

Haplotype	O	437-446
data	O	447-451
implied	O	452-459
that	O	460-464
these	O	465-470
deletions	O	471-480
occurred	O	481-489
on	O	490-492
distinct	O	493-501
ancestral	O	502-511
chromosomes	O	512-523
,	O	523-524
suggesting	O	525-535
that	O	536-540
this	O	541-545
region	O	546-552
may	O	553-556
be	O	557-559
susceptible	O	560-571
to	O	572-574
deletion	O	575-583
by	O	584-586
a	O	587-588
common	O	589-595
mechanism	O	596-605
.	O	605-606

We	O	607-609
subsequently	O	610-622
showed	O	623-629
that	O	630-634
all	O	635-638
the	O	639-642
deletions	O	643-652
were	O	653-657
identical	O	658-667
to	O	668-670
the	O	671-674
base	O	675-679
pair	O	680-684
and	O	685-688
probably	O	689-697
resulted	O	698-706
from	O	707-711
a	O	712-713
nonhomologous	O	714-727
recombination	O	728-741
mediated	O	742-750
by	O	751-753
7	O	754-755
-	O	755-756
bp	O	756-758
direct	O	759-765
repeats	O	766-773
.	O	773-774

In	O	775-777
this	O	778-782
study	O	783-788
,	O	788-789
we	O	790-792
have	O	793-797
collected	O	798-807
data	O	808-812
on	O	813-815
13	O	816-818
additional	O	819-829
unrelated	O	830-839
patients	O	840-848
to	O	849-851
identify	O	852-860
the	O	861-864
causative	O	865-874
mutations	O	875-884
and	O	885-888
to	O	889-891
determine	O	892-901
the	O	902-905
prevalence	O	906-916
of	O	917-919
the	O	920-923
11	O	924-926
-	O	926-927
kb	O	927-929
deletion	O	930-938
.	O	938-939

A	O	940-941
common	O	942-948
recurrent	O	949-958
mutation	O	959-967
,	O	967-968
at	O	969-971
the	O	972-975
donor	O	976-981
splice	O	982-988
site	O	989-993
of	O	994-996
FGA	O	997-1000
intron	O	1001-1007
4	O	1008-1009
(	O	1010-1011
IVS4	O	1011-1015
+	O	1016-1017
1	O	1018-1019
G	O	1020-1021
>	O	1022-1023
T	O	1024-1025
)	O	1025-1026
,	O	1026-1027
accounted	O	1028-1037
for	O	1038-1041
14	O	1042-1044
of	O	1045-1047
the	O	1048-1051
26	O	1052-1054
(	O	1055-1056
54	O	1056-1058
%	O	1058-1059
)	O	1059-1060
alleles	O	1061-1068
.	O	1068-1069

One	O	1070-1073
patient	O	1074-1081
was	O	1082-1085
heterozygous	O	1086-1098
for	O	1099-1102
the	O	1103-1106
previously	O	1107-1117
identified	O	1118-1128
deletion	O	1129-1137
.	O	1137-1138

Three	O	1139-1144
more	O	1145-1149
frameshift	O	1150-1160
mutations	O	1161-1170
,	O	1170-1171
2	O	1172-1173
nonsense	O	1174-1182
mutations	O	1183-1192
,	O	1192-1193
and	O	1194-1197
a	O	1198-1199
second	O	1200-1206
splice	O	1207-1213
site	O	1214-1218
mutation	O	1219-1227
were	O	1228-1232
also	O	1233-1237
identified	O	1238-1248
.	O	1248-1249

Consequently	O	1250-1262
,	O	1262-1263
86	O	1264-1266
%	O	1266-1267
of	O	1268-1270
afibrinogenemia	B	1271-1286
alleles	O	1287-1294
analyzed	O	1295-1303
to	O	1304-1306
date	O	1307-1311
have	O	1312-1316
truncating	O	1317-1327
mutations	O	1328-1337
of	O	1338-1340
FGA	O	1341-1344
,	O	1344-1345
though	O	1346-1352
mutations	O	1353-1362
in	O	1363-1365
all	O	1366-1369
3	O	1370-1371
fibrinogen	O	1372-1382
genes	O	1383-1388
,	O	1388-1389
FGG	O	1390-1393
,	O	1393-1394
FGA	O	1395-1398
,	O	1398-1399
and	O	1400-1403
FGB	O	1404-1407
,	O	1407-1408
might	O	1409-1414
be	O	1415-1417
predicted	O	1418-1427
to	O	1428-1430
cause	O	1431-1436
congenital	B	1437-1447
afibrinogenemia	I	1448-1463
.	O	1463-1464
.	O	1463-1464

Utilization	O	0-11
of	O	12-14
purines	O	15-22
by	O	23-25
an	O	26-28
HPRT	O	29-33
variant	O	34-41
in	O	42-44
an	O	45-47
intelligent	O	48-59
,	O	59-60
nonmutilative	O	61-74
patient	O	75-82
with	O	83-87
features	O	88-96
of	O	97-99
the	O	100-103
Lesch	B	104-109
-	I	109-110
Nyhan	I	110-115
syndrome	I	116-124
.	O	124-125

The	O	126-129
patient	O	130-137
,	O	137-138
H	O	139-140
.	O	140-141
Chr	O	142-145
.	O	145-146

B	O	147-148
.	O	148-149
,	O	149-150
was	O	151-154
among	O	155-160
the	O	161-164
first	O	165-170
reported	O	171-179
with	O	180-184
hyperuricemia	B	185-198
and	O	199-202
central	B	203-210
nervous	I	211-218
system	I	219-225
symptoms	I	226-234
.	O	234-235

He	O	236-238
has	O	239-242
been	O	243-247
found	O	248-253
to	O	254-256
have	O	257-261
a	O	262-263
variant	O	264-271
of	O	272-274
hypoxanthine	O	275-287
guanine	O	288-295
phosphoribosyl	O	296-310
transferase	O	311-322
(	O	323-324
HPRT	O	324-328
;	O	328-329
E	O	330-331
.	O	331-332
C	O	333-334
.	O	334-335
2	O	336-337
.	O	337-338
4	O	339-340
.	O	340-341
2	O	342-343
.	O	343-344
8	O	345-346
)	O	346-347
distinct	O	348-356
from	O	357-361
the	O	362-365
enzyme	O	366-372
present	O	373-380
in	O	381-383
patients	O	384-392
with	O	393-397
the	O	398-401
Lesch	B	402-407
-	I	407-408
Nyhan	I	408-413
syndrome	I	414-422
.	O	422-423

The	O	424-427
patient	O	428-435
had	O	436-439
chroeoathetosis	B	440-455
,	O	455-456
spasticity	B	457-467
,	O	467-468
dysarthric	B	469-479
speech	I	480-486
,	O	486-487
and	O	488-491
hyperuricemia	B	492-505
.	O	505-506

However	O	507-514
,	O	514-515
his	O	516-519
intelligence	O	520-532
was	O	533-536
normal	O	537-543
and	O	544-547
he	O	548-550
had	O	551-554
no	O	555-557
evidence	O	558-566
of	O	567-569
self	O	570-574
-	O	574-575
mutilation	O	575-585
.	O	585-586

There	O	587-592
was	O	593-596
no	O	597-599
activity	O	600-608
of	O	609-611
HPRT	O	612-616
in	O	617-619
the	O	620-623
lysates	O	624-631
of	O	632-634
erythrocytes	O	635-647
and	O	648-651
cultured	O	652-660
fibroblasts	O	661-672
when	O	673-677
analyzed	O	678-686
in	O	687-689
the	O	690-693
usual	O	694-699
manner	O	700-706
.	O	706-707

Using	O	708-713
a	O	714-715
newly	O	716-721
developed	O	722-731
method	O	732-738
for	O	739-742
the	O	743-746
study	O	747-752
of	O	753-755
purine	O	756-762
metabolism	O	763-773
in	O	774-776
intact	O	777-783
cultured	O	784-792
cells	O	793-798
,	O	798-799
this	O	800-804
patient	O	805-812
was	O	813-816
found	O	817-822
to	O	823-825
metabolize	O	826-836
some	O	837-841
9	O	842-843
%	O	843-844
of	O	845-847
8	O	848-849
-	O	849-850
14C	O	850-853
-	O	849-850
hypoxanthine	O	854-866
,	O	866-867
and	O	868-871
90	O	872-874
%	O	874-875
of	O	876-878
the	O	879-882
isotope	O	883-890
utilized	O	891-899
was	O	900-903
converted	O	904-913
to	O	914-916
adenine	O	917-924
and	O	925-928
guanine	O	929-936
nucleotides	O	937-948
.	O	948-949

In	O	950-952
contrast	O	953-961
,	O	961-962
cells	O	963-968
from	O	969-973
patients	O	974-982
with	O	983-987
the	O	988-991
Lesch	B	992-997
-	I	997-998
Nyhan	I	998-1003
syndrome	I	1004-1012
were	O	1013-1017
virtually	O	1018-1027
completely	O	1028-1038
unable	O	1039-1045
to	O	1046-1048
convert	O	1049-1056
hypoxanthine	O	1057-1069
to	O	1070-1072
nucleotides	O	1073-1084
.	O	1084-1085

The	O	1086-1089
patients	O	1090-1098
fibroblasts	O	1099-1110
were	O	1111-1115
even	O	1116-1120
more	O	1121-1125
efficient	O	1126-1135
in	O	1136-1138
the	O	1139-1142
metabolism	O	1143-1153
of	O	1154-1156
8	O	1157-1158
-	O	1158-1159
14C	O	1159-1162
-	O	1158-1159
guanine	O	1163-1170
,	O	1170-1171
which	O	1172-1177
was	O	1178-1181
utilized	O	1182-1190
to	O	1191-1193
the	O	1194-1197
extent	O	1198-1204
of	O	1205-1207
27	O	1208-1210
%	O	1210-1211
,	O	1211-1212
over	O	1213-1217
80	O	1218-1220
%	O	1220-1221
of	O	1222-1224
which	O	1225-1230
was	O	1231-1234
converted	O	1235-1244
to	O	1245-1247
guanine	O	1248-1255
and	O	1256-1259
adenine	O	1260-1267
nucleotides	O	1268-1279
.	O	1279-1280

The	O	1281-1284
growth	O	1285-1291
of	O	1292-1294
the	O	1295-1298
cultured	O	1299-1307
fibroblasts	O	1308-1319
of	O	1320-1322
this	O	1323-1327
patient	O	1328-1335
was	O	1336-1339
intermediate	O	1340-1352
in	O	1353-1355
media	O	1356-1361
containing	O	1362-1372
hypoxanthine	O	1373-1385
aminopterin	O	1386-1397
thymidine	O	1398-1407
(	O	1408-1409
HAT	O	1409-1412
)	O	1412-1413
,	O	1413-1414
whereas	O	1415-1422
the	O	1423-1426
growth	O	1427-1433
of	O	1434-1436
Lesch	B	1437-1442
-	I	1442-1443
Nyhan	I	1443-1448
cells	O	1449-1454
was	O	1455-1458
inhibited	O	1459-1468
and	O	1469-1472
normal	O	1473-1479
cells	O	1480-1485
grew	O	1486-1490
normally	O	1491-1499
.	O	1499-1500

Similarly	O	1501-1510
in	O	1511-1513
8	O	1514-1515
-	O	1515-1516
azaguanine	O	1516-1526
,	O	1526-1527
6	O	1528-1529
-	O	1529-1530
thioguanine	O	1530-1541
,	O	1541-1542
and	O	1543-1546
8	O	1547-1548
-	O	1548-1549
azahypoxanthine	O	1549-1564
,	O	1564-1565
the	O	1566-1569
growth	O	1570-1576
of	O	1577-1579
the	O	1580-1583
patients	O	1584-1592
cells	O	1593-1598
was	O	1599-1602
intermediate	O	1603-1615
between	O	1616-1623
normal	O	1624-1630
and	O	1631-1634
Lesch	B	1635-1640
-	I	1640-1641
Nyhan	I	1641-1646
cells	O	1647-1652
.	O	1652-1653

These	O	1654-1659
observations	O	1660-1672
provide	O	1673-1680
further	O	1681-1688
evidence	O	1689-1697
for	O	1698-1701
genetic	O	1702-1709
heterogeneity	O	1710-1723
among	O	1724-1729
patients	O	1730-1738
with	O	1739-1743
disorders	O	1744-1753
in	O	1754-1756
purine	O	1757-1763
metabolism	O	1764-1774
involving	O	1775-1784
the	O	1785-1788
HPRT	O	1789-1793
gene	O	1794-1798
.	O	1798-1799

They	O	1800-1804
document	O	1805-1813
that	O	1814-1818
this	O	1819-1823
famous	O	1824-1830
patient	O	1831-1838
did	O	1839-1842
not	O	1843-1846
have	O	1847-1851
the	O	1852-1855
Lesch	B	1856-1861
-	I	1861-1862
Nyhan	I	1862-1867
syndrome	I	1868-1876

Canavan	B	0-7
disease	I	8-15
:	O	15-16
mutations	O	17-26
among	O	27-32
Jewish	O	33-39
and	O	40-43
non	O	44-47
-	O	47-48
Jewish	O	48-54
patients	O	55-63
.	O	63-64

Canavan	B	65-72
disease	I	73-80
is	O	81-83
an	O	84-86
autosomal	B	87-96
recessive	I	97-106
leukodystrophy	I	107-121
caused	O	122-128
by	O	129-131
the	O	132-135
deficiency	B	136-146
of	I	147-149
aspartoacylase	I	150-164
(	O	165-166
ASPA	O	166-170
)	O	170-171
.	O	171-172

Sixty	O	173-178
-	O	178-179
four	O	179-183
probands	O	184-192
were	O	193-197
analyzed	O	198-206
for	O	207-210
mutations	O	211-220
in	O	221-223
the	O	224-227
ASPA	O	228-232
gene	O	233-237
.	O	237-238

Three	O	239-244
point	O	245-250
mutations	O	251-260
-	O	260-261
-	O	260-261
693C	O	262-266
-	O	260-261
-	O	260-261
>	O	269-270
A	O	271-272
,	O	272-273
854A	O	274-278
-	O	278-279
-	O	278-279
>	O	281-282
C	O	283-284
,	O	284-285
and	O	286-289
914C	O	290-294
-	O	294-295
-	O	294-295
>	O	297-298
A	O	299-300
-	O	300-301
-	O	300-301
were	O	302-306
identified	O	307-317
in	O	318-320
the	O	321-324
coding	O	325-331
sequence	O	332-340
.	O	340-341

The	O	342-345
693C	O	346-350
-	O	350-351
-	O	350-351
>	O	353-354
A	O	355-356
and	O	357-360
914C	O	361-365
-	O	365-366
-	O	365-366
>	O	368-369
A	O	370-371
base	O	372-376
changes	O	377-384
,	O	384-385
resulting	O	386-395
in	O	396-398
nonsense	O	399-407
tyr231	O	408-414
-	O	414-415
-	O	414-415
>	O	417-418
ter	O	419-422
and	O	423-426
missense	O	427-435
ala305	O	436-442
-	O	442-443
-	O	442-443
>	O	445-446
glu	O	447-450
mutations	O	451-460
,	O	460-461
respectively	O	462-474
,	O	474-475
lead	O	476-480
to	O	481-483
complete	O	484-492
loss	O	493-497
of	O	498-500
ASPA	O	501-505
activity	O	506-514
in	O	515-517
in	O	518-520
vitro	O	521-526
expression	O	527-537
studies	O	538-545
.	O	545-546

The	O	547-550
854A	O	551-555
-	O	555-556
-	O	555-556
>	O	558-559
C	O	560-561
transversion	O	562-574
converted	O	575-584
glu	O	585-588
to	O	589-591
ala	O	592-595
in	O	596-598
codon	O	599-604
285	O	605-608
.	O	608-609

The	O	610-613
glu285	O	614-620
-	O	620-621
-	O	620-621
>	O	623-624
ala	O	625-628
mutant	O	629-635
ASPA	O	636-640
has	O	641-644
2	O	645-646
.	O	646-647
5	O	648-649
%	O	649-650
of	O	651-653
the	O	654-657
activity	O	658-666
expressed	O	667-676
by	O	677-679
the	O	680-683
wild	O	684-688
-	O	688-689
type	O	689-693
enzyme	O	694-700
.	O	700-701

A	O	702-703
fourth	O	704-710
mutation	O	711-719
,	O	719-720
433	O	721-724
-	O	725-726
-	O	725-726
2	O	727-728
(	O	729-730
A	O	730-731
-	O	731-732
-	O	731-732
>	O	734-735
G	O	736-737
)	O	737-738
transition	O	739-749
,	O	749-750
was	O	751-754
identified	O	755-765
at	O	766-768
the	O	769-772
splice	O	773-779
-	O	779-780
acceptor	O	780-788
site	O	789-793
in	O	794-796
intron	O	797-803
2	O	804-805
.	O	805-806
The	O	807-810
splice	O	811-817
-	O	817-818
site	O	818-822
mutation	O	823-831
would	O	832-837
lead	O	838-842
to	O	843-845
skipping	O	846-854
of	O	855-857
exon	O	858-862
3	O	863-864
,	O	864-865
accompanied	O	866-877
by	O	878-880
a	O	881-882
frameshift	O	883-893
,	O	893-894
and	O	895-898
thus	O	899-903
would	O	904-909
produce	O	910-917
aberrant	O	918-926
ASPA	O	927-931
.	O	931-932

Of	O	933-935
the	O	936-939
128	O	940-943
unrelated	O	944-953
Canavan	B	954-961
chromosomes	O	962-973
analyzed	O	974-982
,	O	982-983
88	O	984-986
were	O	987-991
from	O	992-996
probands	O	997-1005
of	O	1006-1008
Ashkenazi	O	1009-1018
Jewish	O	1019-1025
descent	O	1026-1033
.	O	1033-1034

The	O	1035-1038
glu285	O	1039-1045
-	O	1045-1046
-	O	1045-1046
>	O	1048-1049
ala	O	1050-1053
mutation	O	1054-1062
was	O	1063-1066
predominant	O	1067-1078
(	O	1079-1080
82	O	1080-1082
.	O	1082-1083

9	O	1084-1085
%	O	1085-1086
)	O	1086-1087
in	O	1088-1090
this	O	1091-1095
population	O	1096-1106
,	O	1106-1107
followed	O	1108-1116
by	O	1117-1119
the	O	1120-1123
tyr231	O	1124-1130
-	O	1130-1131
-	O	1130-1131
>	O	1133-1134
ter	O	1135-1138
(	O	1139-1140
14	O	1140-1142
.	O	1142-1143

8	O	1144-1145
%	O	1145-1146
)	O	1146-1147
and	O	1148-1151
433	O	1152-1155
-	O	1156-1157
-	O	1156-1157
2	O	1158-1159
(	O	1160-1161
A	O	1161-1162
-	O	1162-1163
-	O	1162-1163
>	O	1165-1166
G	O	1167-1168
)	O	1168-1169
(	O	1170-1171
1	O	1171-1172
.	O	1172-1173

1	O	1174-1175
%	O	1175-1176
)	O	1176-1177
mutations	O	1178-1187
.	O	1187-1188

The	O	1189-1192
three	O	1193-1198
mutations	O	1199-1208
account	O	1209-1216
for	O	1217-1220
98	O	1221-1223
.	O	1223-1224
8	O	1225-1226
%	O	1226-1227
of	O	1228-1230
the	O	1231-1234
Canavan	B	1235-1242
chromosomes	O	1243-1254
of	O	1255-1257
Ashkenazi	O	1258-1267
Jewish	O	1268-1274
origin	O	1275-1281
.	O	1281-1282

The	O	1283-1286
ala305	O	1287-1293
-	O	1293-1294
-	O	1293-1294
>	O	1296-1297
glu	O	1298-1301
mutation	O	1302-1310
was	O	1311-1314
found	O	1315-1320
exclusively	O	1321-1332
in	O	1333-1335
non	O	1336-1339
-	O	1339-1340
Jewish	O	1340-1346
probands	O	1347-1355
of	O	1356-1358
European	O	1359-1367
descent	O	1368-1375
and	O	1376-1379
constituted	O	1380-1391
60	O	1392-1394
%	O	1394-1395
of	O	1396-1398
the	O	1399-1402
40	O	1403-1405
mutant	O	1406-1412
chromosomes	O	1413-1424
.	O	1424-1425

Predominant	O	1426-1437
occurrence	O	1438-1448
of	O	1449-1451
certain	O	1452-1459
mutations	O	1460-1469
among	O	1470-1475
Ashkenazi	O	1476-1485
Jewish	O	1486-1492
and	O	1493-1496
non	O	1497-1500
-	O	1500-1501
Jewish	O	1501-1507
patients	O	1508-1516
with	O	1517-1521
Canavan	B	1522-1529
disease	I	1530-1537
would	O	1538-1543
suggest	O	1544-1551
a	O	1552-1553
founding	O	1554-1562
-	O	1562-1563
father	O	1563-1569
effect	O	1570-1576
in	O	1577-1579
propagation	O	1580-1591
of	O	1592-1594
these	O	1595-1600
mutant	O	1601-1607
chromosomes	O	1608-1619

Identification	O	0-14
of	O	15-17
deletion	O	18-26
mutations	O	27-36
and	O	37-40
three	O	41-46
new	O	47-50
genes	O	51-56
at	O	57-59
the	O	60-63
familial	B	64-72
polyposis	I	73-82
locus	O	83-88
.	O	88-89

Small	O	90-95
(	O	96-97
100	O	97-100
-	O	100-101
260	O	101-104
kb	O	105-107
)	O	107-108
,	O	108-109
nested	O	110-116
deletions	O	117-126
were	O	127-131
characterized	O	132-145
in	O	146-148
DNA	O	149-152
from	O	153-157
two	O	158-161
unrelated	O	162-171
patients	O	172-180
with	O	181-185
familial	B	186-194
adenomatous	I	195-206
polyposis	I	207-216
coli	I	217-221
(	O	222-223
APC	B	223-226
)	O	226-227
.	O	227-228

Three	O	229-234
candidate	O	235-244
genes	O	245-250
located	O	251-258
within	O	259-265
the	O	266-269
deleted	O	270-277
region	O	278-284
were	O	285-289
ascertained	O	290-301
and	O	302-305
a	O	306-307
previous	O	308-316
candidate	O	317-326
gene	O	327-331
,	O	331-332
MCC	O	333-336
,	O	336-337
was	O	338-341
shown	O	342-347
to	O	348-350
be	O	351-353
located	O	354-361
outside	O	362-369
the	O	370-373
deleted	O	374-381
region	O	382-388
.	O	388-389

One	O	390-393
of	O	394-396
the	O	397-400
new	O	401-404
genes	O	405-410
contained	O	411-420
sequence	O	421-429
identical	O	430-439
to	O	440-442
SRP19	O	443-448
,	O	448-449
the	O	450-453
gene	O	454-458
coding	O	459-465
for	O	466-469
the	O	470-473
19	O	474-476
kd	O	477-479
component	O	480-489
of	O	490-492
the	O	493-496
ribosomal	O	497-506
signal	O	507-513
recognition	O	514-525
particle	O	526-534
.	O	534-535

The	O	536-539
second	O	540-546
,	O	546-547
provisionally	O	548-561
designated	O	562-572
DP1	O	573-576
(	O	577-578
deleted	O	578-585
in	O	586-588
polyposis	O	589-598
1	O	599-600
)	O	600-601
,	O	601-602
was	O	603-606
found	O	607-612
to	O	613-615
be	O	616-618
transcribed	O	619-630
in	O	631-633
the	O	634-637
same	O	638-642
orientation	O	643-654
as	O	655-657
MCC	O	658-661
.	O	661-662

Two	O	663-666
other	O	667-672
cDNAs	O	673-678
,	O	678-679
DP2	O	680-683
and	O	684-687
DP3	O	688-691
,	O	691-692
were	O	693-697
found	O	698-703
to	O	704-706
overlap	O	707-714
,	O	714-715
forming	O	716-723
a	O	724-725
single	O	726-732
gene	O	733-737
,	O	737-738
DP2	O	739-742
.	O	742-743
5	O	744-745
,	O	745-746
that	O	747-751
is	O	752-754
transcribed	O	755-766
in	O	767-769
the	O	770-773
same	O	774-778
orientation	O	779-790
as	O	791-793
SRP19	O	794-799
.	O	799-800

Genotype	O	0-8
-	O	8-9
phenotype	O	9-18
correlations	O	19-31
in	O	32-34
families	O	35-43
with	O	44-48
deletions	O	49-58
in	O	59-61
the	O	62-65
von	B	66-69
Hippel	I	70-76
-	I	76-77
Lindau	I	77-83
(	O	84-85
VHL	B	85-88
)	O	88-89
gene	O	90-94
.	O	94-95

Von	B	96-99
Hippel	I	100-106
-	I	106-107
Lindau	I	107-113
(	I	114-115
VHL	I	115-118
)	I	118-119
disease	I	120-127
is	O	128-130
a	O	131-132
hereditary	B	133-143
tumor	I	144-149
syndrome	I	150-158
characterized	O	159-172
by	O	173-175
predisposition	O	176-190
for	O	191-194
bilateral	B	195-204
and	I	205-208
multi	I	209-214
-	I	214-215
centric	I	215-222
hemangioblastoma	I	223-239
in	O	240-242
the	O	243-246
retina	O	247-253
and	O	254-257
central	O	258-265
nervous	O	266-273
system	O	274-280
,	O	280-281
pheochromocytoma	B	282-298
,	O	298-299
renal	B	300-305
cell	I	306-310
carcinoma	I	311-320
,	O	320-321
and	O	322-325
cysts	B	326-331
in	I	332-334
the	I	335-338
kidney	I	339-345
,	I	345-346
pancreas	I	347-355
,	I	355-356
and	I	357-360
epididymis	I	361-371
.	O	371-372

We	O	373-375
describe	O	376-384
five	O	385-389
families	O	390-398
for	O	399-402
which	O	403-408
direct	O	409-415
sequencing	O	416-426
of	O	427-429
the	O	430-433
coding	O	434-440
region	O	441-447
of	O	448-450
the	O	451-454
VHL	B	455-458
gene	O	459-463
had	O	464-467
failed	O	468-474
to	O	475-477
identify	O	478-486
the	O	487-490
family	O	491-497
-	O	497-498
specific	O	498-506
mutation	O	507-515
.	O	515-516

Further	O	517-524
molecular	O	525-534
analysis	O	535-543
revealed	O	544-552
deletions	O	553-562
involving	O	563-572
the	O	573-576
VHL	B	577-580
gene	O	581-585
in	O	586-588
each	O	589-593
of	O	594-596
these	O	597-602
families	O	603-611
.	O	611-612

In	O	613-615
four	O	616-620
families	O	621-629
,	O	629-630
partial	O	631-638
deletions	O	639-648
of	O	649-651
one	O	652-655
or	O	656-658
more	O	659-663
exons	O	664-669
were	O	670-674
detected	O	675-683
by	O	684-686
Southern	O	687-695
blot	O	696-700
analysis	O	701-709
.	O	709-710

In	O	711-713
the	O	714-717
fifth	O	718-723
family	O	724-730
,	O	730-731
FISH	O	732-736
analysis	O	737-745
demonstrated	O	746-758
the	O	759-762
deletion	O	763-771
of	O	772-774
the	O	775-778
entire	O	779-785
VHL	B	786-789
gene	O	790-794
.	O	794-795

Our	O	796-799
results	O	800-807
show	O	808-812
that	O	813-817
(	O	818-819
quantitative	O	819-831
)	O	831-832
Southern	O	833-841
blot	O	842-846
analysis	O	847-855
is	O	856-858
a	O	859-860
sensitive	O	861-870
method	O	871-877
for	O	878-881
detecting	O	882-891
germline	O	892-900
deletions	O	901-910
of	O	911-913
the	O	914-917
VHL	B	918-921
gene	O	922-926
and	O	927-930
should	O	931-937
be	O	938-940
implemented	O	941-952
in	O	953-955
routine	O	956-963
DNA	O	964-967
diagnosis	O	968-977
for	O	978-981
VHL	B	982-985
disease	I	986-993
.	O	993-994

Our	O	995-998
data	O	999-1003
support	O	1004-1011
the	O	1012-1015
previously	O	1016-1026
established	O	1027-1038
observation	O	1039-1050
that	O	1051-1055
families	O	1056-1064
with	O	1065-1069
a	O	1070-1071
germline	O	1072-1080
deletion	O	1081-1089
have	O	1090-1094
a	O	1095-1096
low	O	1097-1100
risk	O	1101-1105
for	O	1106-1109
pheochromocytoma	B	1110-1126
.	O	1126-1127

Further	O	1128-1135
unraveling	O	1136-1146
of	O	1147-1149
genotype	O	1150-1158
-	O	1158-1159
phenotype	O	1159-1168
correlations	O	1169-1181
in	O	1182-1184
VHL	B	1185-1188
disease	I	1189-1196
has	O	1197-1200
revealed	O	1201-1209
that	O	1210-1214
families	O	1215-1223
with	O	1224-1228
a	O	1229-1230
full	O	1231-1235
or	O	1236-1238
partial	O	1239-1246
deletion	O	1247-1255
of	O	1256-1258
the	O	1259-1262
VHL	B	1263-1266
gene	O	1267-1271
exhibit	O	1272-1279
a	O	1280-1281
phenotype	O	1282-1291
with	O	1292-1296
a	O	1297-1298
preponderance	O	1299-1312
of	O	1313-1315
central	B	1316-1323
nervous	I	1324-1331
system	I	1332-1338
hemangioblastoma	I	1339-1355
.	O	1355-1356
.	O	1355-1356

Understanding	O	0-13
the	O	14-17
molecular	O	18-27
basis	O	28-33
of	O	34-36
fragile	B	37-44
X	I	45-46
syndrome	I	47-55
.	O	55-56

Fragile	B	57-64
X	I	65-66
syndrome	I	67-75
,	O	75-76
a	O	77-78
common	O	79-85
form	O	86-90
of	O	91-93
inherited	B	94-103
mental	I	104-110
retardation	I	111-122
,	O	122-123
is	O	124-126
mainly	O	127-133
caused	O	134-140
by	O	141-143
massive	O	144-151
expansion	O	152-161
of	O	162-164
CGG	O	165-168
triplet	O	169-176
repeats	O	177-184
located	O	185-192
in	O	193-195
the	O	196-199
5	O	200-201
-	O	201-202
untranslated	O	202-214
region	O	215-221
of	O	222-224
the	O	225-228
fragile	B	229-236
X	I	237-238
mental	I	239-245
retardation	I	246-257
-	O	257-258
1	O	258-259
(	O	260-261
FMR1	O	261-265
)	O	265-266
gene	O	267-271
.	O	271-272

In	O	273-275
patients	O	276-284
with	O	285-289
fragile	B	290-297
X	I	298-299
syndrome	I	300-308
,	O	308-309
the	O	310-313
expanded	O	314-322
CGG	O	323-326
triplet	O	327-334
repeats	O	335-342
are	O	343-346
hypermethylated	O	347-362
and	O	363-366
the	O	367-370
expression	O	371-381
of	O	382-384
the	O	385-388
FMR1	O	389-393
gene	O	394-398
is	O	399-401
repressed	O	402-411
,	O	411-412
which	O	413-418
leads	O	419-424
to	O	425-427
the	O	428-431
absence	O	432-439
of	O	440-442
FMR1	O	443-447
protein	O	448-455
(	O	456-457
FMRP	O	457-461
)	O	461-462
and	O	463-466
subsequent	O	467-477
mental	B	478-484
retardation	I	485-496
.	O	496-497

FMRP	O	498-502
is	O	503-505
an	O	506-508
RNA	O	509-512
-	O	512-513
binding	O	513-520
protein	O	521-528
that	O	529-533
shuttles	O	534-542
between	O	543-550
the	O	551-554
nucleus	O	555-562
and	O	563-566
cytoplasm	O	567-576
.	O	576-577

This	O	578-582
protein	O	583-590
has	O	591-594
been	O	595-599
implicated	O	600-610
in	O	611-613
protein	O	614-621
translation	O	622-633
as	O	634-636
it	O	637-639
is	O	640-642
found	O	643-648
associated	O	649-659
with	O	660-664
polyribosomes	O	665-678
and	O	679-682
the	O	683-686
rough	O	687-692
endoplasmic	O	693-704
reticulum	O	705-714
.	O	714-715

We	O	716-718
discuss	O	719-726
here	O	727-731
the	O	732-735
recent	O	736-742
progress	O	743-751
made	O	752-756
towards	O	757-764
understanding	O	765-778
the	O	779-782
molecular	O	783-792
mechanism	O	793-802
of	O	803-805
CGG	O	806-809
repeat	O	810-816
expansion	O	817-826
and	O	827-830
physiological	O	831-844
function	O	845-853
(	O	854-855
s	O	855-856
)	O	856-857
of	O	858-860
FMRP	O	861-865
.	O	865-866

These	O	867-872
studies	O	873-880
will	O	881-885
not	O	886-889
only	O	890-894
help	O	895-899
to	O	900-902
illuminate	O	903-913
the	O	914-917
molecular	O	918-927
basis	O	928-933
of	O	934-936
the	O	937-940
general	O	941-948
class	O	949-954
of	O	955-957
human	O	958-963
diseases	O	964-972
with	O	973-977
trinucleotide	O	978-991
repeat	O	992-998
expansion	O	999-1008
but	O	1009-1012
also	O	1013-1017
provide	O	1018-1025
an	O	1026-1028
avenue	O	1029-1035
to	O	1036-1038
understand	O	1039-1049
aspects	O	1050-1057
of	O	1058-1060
human	O	1061-1066
cognition	O	1067-1076
and	O	1077-1080
intelligence	O	1081-1093
.	O	1093-1094
.	O	1093-1094

Glucose	B	0-7
-	I	7-8
6	I	8-9
-	I	7-8
phosphate	I	10-19
dehydrogenase	I	20-33
deficiency	I	34-44
in	O	45-47
Papua	O	48-53
New	O	54-57
Guinea	O	58-64
.	O	64-65

The	O	66-69
description	O	70-81
of	O	82-84
13	O	85-87
new	O	88-91
variants	O	92-100
.	O	100-101

A	O	102-103
total	O	104-109
of	O	110-112
362	O	113-116
males	O	117-122
from	O	123-127
various	O	128-135
regions	O	136-143
of	O	144-146
Papua	O	147-152
New	O	153-156
Guinea	O	157-163
were	O	164-168
screened	O	169-177
for	O	178-181
red	O	182-185
cell	O	186-190
glucose	O	191-198
-	O	198-199
6	O	199-200
-	O	198-199
phosphate	O	201-210
dehydrogenase	O	211-224
(	O	225-226
G6PD	O	226-230
)	O	230-231
activity	O	232-240
.	O	240-241

Twenty	O	242-248
-	O	248-249
six	O	249-252
G6PD	B	253-257
deficient	I	258-267
individuals	O	268-279
were	O	280-284
identified	O	285-295
.	O	295-296

Biochemical	O	297-308
characterization	O	309-325
of	O	326-328
G6PD	O	329-333
purified	O	334-342
from	O	343-347
these	O	348-353
subjects	O	354-362
has	O	363-366
revealed	O	367-375
13	O	376-378
new	O	379-382
variants	O	383-391
and	O	392-395
several	O	396-403
copies	O	404-410
of	O	411-413
previously	O	414-424
described	O	425-434
forms	O	435-440
of	O	441-443
G6PD	O	444-448
.	O	448-449

This	O	450-454
study	O	455-460
illustrates	O	461-472
the	O	473-476
extreme	O	477-484
heterogeneity	O	485-498
of	O	499-501
G6PD	B	502-506
deficiency	I	507-517
among	O	518-523
the	O	524-527
people	O	528-534
of	O	535-537
Papua	O	538-543
New	O	544-547
Guinea	O	548-554
.	O	554-555
.	O	554-555

Regional	O	0-8
mapping	O	9-16
of	O	17-19
the	O	20-23
phenylalanine	O	24-37
hydroxylase	O	38-49
gene	O	50-54
and	O	55-58
the	O	59-62
phenylketonuria	B	63-78
locus	O	79-84
in	O	85-87
the	O	88-91
human	O	92-97
genome	O	98-104
.	O	104-105

Phenylketonuria	B	106-121
(	O	122-123
PKU	B	123-126
)	O	126-127
is	O	128-130
an	O	131-133
autosomal	B	134-143
recessive	I	144-153
disorder	I	154-162
of	O	163-165
amino	O	166-171
acid	O	172-176
metabolism	O	177-187
caused	O	188-194
by	O	195-197
a	O	198-199
deficiency	B	200-210
of	I	211-213
the	I	214-217
hepatic	I	218-225
enzyme	I	226-232
phenylalanine	I	233-246
hydroxylase	I	247-258
(	O	259-260
PAH	O	260-263
;	O	263-264
phenylalanine	O	265-278
4	O	279-280
-	O	280-281
monooxygenase	O	281-294
,	O	294-295
EC	O	296-298
1	O	299-300
.	O	300-301
14	O	302-304
.	O	304-305
16	O	306-308
.	O	308-309
1	O	310-311
)	O	311-312
.	O	312-313

A	O	314-315
cDNA	O	316-320
clone	O	321-326
for	O	327-330
human	O	331-336
PAH	O	337-340
has	O	341-344
previously	O	345-355
been	O	356-360
used	O	361-365
to	O	366-368
assign	O	369-375
the	O	376-379
corresponding	O	380-393
gene	O	394-398
to	O	399-401
human	O	402-407
chromosome	O	408-418
12	O	419-421
.	O	421-422

To	O	423-425
define	O	426-432
the	O	433-436
regional	O	437-445
map	O	446-449
position	O	450-458
of	O	459-461
the	O	462-465
disease	O	466-473
locus	O	474-479
and	O	480-483
the	O	484-487
PAH	O	488-491
gene	O	492-496
on	O	497-499
human	O	500-505
chromosome	O	506-516
12	O	517-519
,	O	519-520
DNA	O	521-524
was	O	525-528
isolated	O	529-537
from	O	538-542
human	O	543-548
-	O	548-549
hamster	O	549-556
somatic	O	557-564
cell	O	565-569
hybrids	O	570-577
with	O	578-582
various	O	583-590
deletions	O	591-600
of	O	601-603
human	O	604-609
chromosome	O	610-620
12	O	621-623
and	O	624-627
was	O	628-631
analyzed	O	632-640
by	O	641-643
Southern	O	644-652
blot	O	653-657
analysis	O	658-666
using	O	667-672
the	O	673-676
human	O	677-682
cDNA	O	683-687
PAH	O	688-691
clone	O	692-697
as	O	698-700
a	O	701-702
hybridization	O	703-716
probe	O	717-722
.	O	722-723

From	O	724-728
these	O	729-734
results	O	735-742
,	O	742-743
together	O	744-752
with	O	753-757
detailed	O	758-766
biochemical	O	767-778
and	O	779-782
cytogenetic	O	783-794
characterization	O	795-811
of	O	812-814
the	O	815-818
hybrid	O	819-825
cells	O	826-831
,	O	831-832
the	O	833-836
region	O	837-843
on	O	844-846
chromosome	O	847-857
12	O	858-860
containing	O	861-871
the	O	872-875
human	O	876-881
PAH	O	882-885
gene	O	886-890
has	O	891-894
been	O	895-899
defined	O	900-907
as	O	908-910
12q14	O	911-916
.	O	916-917

3	O	918-919
-	O	919-920
-	O	919-920
-	O	919-920
-	O	919-920
qter	O	923-927
3	O	928-929
-	O	929-930
-	O	929-930
-	O	929-930
-	O	929-930
qter	O	933-937
.	O	937-938

The	O	939-942
PAH	O	943-946
map	O	947-950
position	O	951-959
on	O	960-962
chromosome	O	963-973
12	O	974-976
was	O	977-980
further	O	981-988
localized	O	989-998
by	O	999-1001
in	O	1002-1004
situ	O	1005-1009
hybridization	O	1010-1023
of	O	1024-1026
125I	O	1027-1031
-	O	1031-1032
labeled	O	1032-1039
human	O	1040-1045
PAH	O	1046-1049
cDNA	O	1050-1054
to	O	1055-1057
chromosomes	O	1058-1069
prepared	O	1070-1078
from	O	1079-1083
a	O	1084-1085
human	O	1086-1091
lymphoblastoid	O	1092-1106
cell	O	1107-1111
line	O	1112-1116
.	O	1116-1117

Results	O	1118-1125
of	O	1126-1128
these	O	1129-1134
experiments	O	1135-1146
demonstrated	O	1147-1159
that	O	1160-1164
the	O	1165-1168
region	O	1169-1175
on	O	1176-1178
chromosome	O	1179-1189
12	O	1190-1192
containing	O	1193-1203
the	O	1204-1207
PAH	O	1208-1211
gene	O	1212-1216
and	O	1217-1220
the	O	1221-1224
PKU	B	1225-1228
locus	O	1229-1234
in	O	1235-1237
man	O	1238-1241
is	O	1242-1244
12q22	O	1245-1250
-	O	1250-1251
-	O	1250-1251
-	O	1250-1251
-	O	1250-1251
12q24	O	1254-1259
.	O	1259-1260

1	O	1261-1262
.	O	1262-1263

These	O	1264-1269
results	O	1270-1277
not	O	1278-1281
only	O	1282-1286
provide	O	1287-1294
a	O	1295-1296
regionalized	O	1297-1309
map	O	1310-1313
position	O	1314-1322
for	O	1323-1326
a	O	1327-1328
major	O	1329-1334
human	O	1335-1340
disease	O	1341-1348
locus	O	1349-1354
but	O	1355-1358
also	O	1359-1363
can	O	1364-1367
serve	O	1368-1373
as	O	1374-1376
a	O	1377-1378
reference	O	1379-1388
point	O	1389-1394
for	O	1395-1398
linkage	O	1399-1406
analysis	O	1407-1415
with	O	1416-1420
other	O	1421-1426
DNA	O	1427-1430
markers	O	1431-1438
on	O	1439-1441
human	O	1442-1447
chromosome	O	1448-1458
12	O	1459-1461

Total	B	0-5
deficiency	I	6-16
of	I	17-19
plasma	I	20-26
cholesteryl	I	27-38
ester	I	39-44
transfer	I	45-53
protein	I	54-61
in	O	62-64
subjects	O	65-73
homozygous	O	74-84
and	O	85-88
heterozygous	O	89-101
for	O	102-105
the	O	106-109
intron	O	110-116
14	O	117-119
splicing	O	120-128
defect	O	129-135
.	O	135-136

The	O	137-140
molecular	O	141-150
basis	O	151-156
of	O	157-159
cholesteryl	B	160-171
ester	I	172-177
transfer	I	178-186
protein	I	187-194
(	I	195-196
CETP	I	196-200
)	I	200-201
deficiency	I	202-212
was	O	213-216
investigated	O	217-229
in	O	230-232
4	O	233-234
unrelated	O	235-244
CETP	B	245-249
-	I	249-250
deficient	I	250-259
families	O	260-268
.	O	268-269

The	O	270-273
high	O	274-278
density	O	279-286
lipoprotein	O	287-298
-	O	298-299
cholesterol	O	299-310
levels	O	311-317
of	O	318-320
the	O	321-324
probands	O	325-333
exceeded	O	334-342
150	O	343-346
mg	O	347-349
/	O	349-350
dl	O	350-352
.	O	352-353

The	O	354-357
plasma	O	358-364
of	O	365-367
the	O	368-371
probands	O	372-380
was	O	381-384
totally	O	385-392
deficient	O	393-402
in	O	403-405
CETP	O	406-410
activity	O	411-419
and	O	420-423
mass	O	424-428
.	O	428-429

The	O	430-433
genomic	O	434-441
DNA	O	442-445
of	O	446-448
the	O	449-452
patients	O	453-461
was	O	462-465
amplified	O	466-475
by	O	476-478
polymerase	O	479-489
chain	O	490-495
reaction	O	496-504
,	O	504-505
using	O	506-511
two	O	512-515
oligonucleotide	O	516-531
primers	O	532-539
located	O	540-547
in	O	548-550
the	O	551-554
intron	O	555-561
12	O	562-564
and	O	565-568
14	O	569-571
of	O	572-574
the	O	575-578
CETP	O	579-583
gene	O	584-588
,	O	588-589
and	O	590-593
the	O	594-597
amplified	O	598-607
products	O	608-616
were	O	617-621
directly	O	622-630
sequenced	O	631-640
.	O	640-641

Two	O	642-645
patients	O	646-654
were	O	655-659
homozygous	O	660-670
for	O	671-674
a	O	675-676
G	O	677-678
-	O	678-679
to	O	679-681
-	O	678-679
A	O	682-683
change	O	684-690
at	O	691-693
the	O	694-697
5	O	698-699
-	O	699-700
splice	O	700-706
donor	O	707-712
site	O	713-717
of	O	718-720
the	O	721-724
intron	O	725-731
14	O	732-734
.	O	734-735

The	O	736-739
G	O	740-741
-	O	741-742
to	O	742-744
-	O	741-742
A	O	745-746
change	O	747-753
would	O	754-759
cause	O	760-765
impaired	O	766-774
splicing	O	775-783
of	O	784-786
pre	O	787-790
-	O	790-791
messenger	O	791-800
RNA	O	801-804
.	O	804-805

The	O	806-809
other	O	810-815
two	O	816-819
probands	O	820-828
were	O	829-833
heterozygous	O	834-846
for	O	847-850
the	O	851-854
mutation	O	855-863
,	O	863-864
but	O	865-868
totally	O	869-876
lacked	O	877-883
CETP	O	884-888
.	O	888-889

Their	O	890-895
lipoprotein	O	896-907
patterns	O	908-916
were	O	917-921
also	O	922-926
similar	O	927-934
to	O	935-937
those	O	938-943
of	O	944-946
the	O	947-950
two	O	951-954
homozygotes	O	955-966
.	O	966-967

Thus	O	968-972
,	O	972-973
other	O	974-979
genetic	B	980-987
defects	I	988-995
or	O	996-998
metabolic	O	999-1008
factors	O	1009-1016
influencing	O	1017-1028
CETP	O	1029-1033
expression	O	1034-1044
are	O	1045-1048
implicated	O	1049-1059
.	O	1059-1060

The	O	1061-1064
data	O	1065-1069
suggest	O	1070-1077
that	O	1078-1082
the	O	1083-1086
G	O	1087-1088
-	O	1088-1089
to	O	1089-1091
-	O	1088-1089
A	O	1092-1093
mutation	O	1094-1102
may	O	1103-1106
be	O	1107-1109
common	O	1110-1116
in	O	1117-1119
human	O	1120-1125
plasma	O	1126-1132
CETP	B	1133-1137
deficiency	I	1138-1148
.	O	1148-1149

Furthermore	O	1150-1161
,	O	1161-1162
there	O	1163-1168
could	O	1169-1174
be	O	1175-1177
compound	O	1178-1186
heterozygotes	O	1187-1200
who	O	1201-1204
totally	O	1205-1212
lack	O	1213-1217
plasma	O	1218-1224
CETP	O	1225-1229
and	O	1230-1233
have	O	1234-1238
lipoprotein	O	1239-1250
profiles	O	1251-1259
similar	O	1260-1267
to	O	1268-1270
those	O	1271-1276
of	O	1277-1279
homozygotes	O	1280-1291
.	O	1291-1292
.	O	1291-1292

Heterogeneity	O	0-13
of	O	14-16
type	B	17-21
I	I	22-23
von	I	24-27
Willebrand	I	28-38
disease	I	39-46
:	O	46-47
evidence	O	48-56
for	O	57-60
a	O	61-62
subgroup	O	63-71
with	O	72-76
an	O	77-79
abnormal	O	80-88
von	B	89-92
Willebrand	I	93-103
factor	O	104-110
.	O	110-111

Type	B	112-116
I	I	117-118
von	I	119-122
Willebrand	I	123-133
disease	I	134-141
(	O	142-143
vWD	B	143-146
)	O	146-147
is	O	148-150
characterized	O	151-164
by	O	165-167
equally	O	168-175
low	O	176-179
plasma	O	180-186
concentrations	O	187-201
of	O	202-204
von	B	205-208
Willebrand	I	209-219
factor	O	220-226
antigen	O	227-234
(	O	235-236
vWF	O	236-239
Ag	O	241-243
)	O	243-244
and	O	245-248
ristocetin	O	249-259
cofactor	O	260-268
(	O	269-270
RiCof	O	270-275
)	O	275-276
and	O	277-280
by	O	281-283
the	O	284-287
presence	O	288-296
of	O	297-299
all	O	300-303
vWF	O	304-307
multimers	O	308-317
in	O	318-320
sodium	O	321-327
dodecyl	O	328-335
sulfate	O	336-343
(	O	344-345
SDS	O	345-348
)	O	348-349
-	O	350-351
agarose	O	351-358
gel	O	359-362
electrophoresis	O	363-378
.	O	378-379

For	O	380-383
17	O	384-386
patients	O	387-395
(	O	396-397
13	O	397-399
kindreds	O	400-408
)	O	408-409
diagnosed	O	410-419
with	O	420-424
these	O	425-430
criteria	O	431-439
,	O	439-440
we	O	441-443
have	O	444-448
studied	O	449-456
the	O	457-460
platelet	O	461-469
contents	O	470-478
of	O	479-481
vWF	O	482-485
Ag	O	487-489
and	O	490-493
RiCof	O	494-499
and	O	500-503
the	O	504-507
changes	O	508-515
of	O	516-518
these	O	519-524
in	O	525-527
plasma	O	528-534
after	O	535-540
DDAVP	O	541-546
infusion	O	547-555
.	O	555-556

Platelet	O	557-565
vWF	O	566-569
Ag	O	571-573
and	O	574-577
RiCof	O	578-583
were	O	584-588
normal	O	589-595
in	O	596-598
four	O	599-603
kindreds	O	604-612
(	O	613-614
called	O	614-620
"	O	621-622
platelet	O	623-631
normal	O	632-638
"	O	639-640
subgroup	O	641-649
)	O	649-650
;	O	650-651
following	O	652-661
1	O	662-663
-	O	663-664
deamino	O	664-671
-	O	663-664
8	O	672-673
-	O	663-664
D	O	674-675
-	O	663-664
arginine	O	676-684
vasopressin	O	685-696
;	O	696-697
plasma	O	698-704
vWF	O	705-708
Ag	O	710-712
,	O	712-713
RiCof	O	714-719
and	O	720-723
the	O	724-727
bleeding	O	728-736
time	O	737-741
(	O	742-743
BT	O	743-745
)	O	745-746
became	O	747-753
normal	O	754-760
.	O	760-761

In	O	762-764
six	O	765-768
kindreds	O	769-777
,	O	777-778
platelet	O	779-787
vWF	O	788-791
Ag	O	793-795
and	O	796-799
RiCof	O	800-805
were	O	806-810
equally	O	811-818
low	O	819-822
(	O	823-824
platelet	O	824-832
low	O	833-836
)	O	836-837
;	O	837-838
after	O	839-844
DDAVP	O	845-850
,	O	850-851
plasma	O	852-858
vWF	O	859-862
Ag	O	864-866
and	O	867-870
RiCof	O	871-876
remained	O	877-885
low	O	886-889
,	O	889-890
and	O	891-894
the	O	895-898
BT	O	899-901
was	O	902-905
prolonged	O	906-915
.	O	915-916

In	O	917-919
three	O	920-925
additional	O	926-936
kindreds	O	937-945
,	O	945-946
platelets	O	947-956
contained	O	957-966
normal	O	967-973
concentrations	O	974-988
of	O	989-991
vWF	O	992-995
Ag	O	997-999
,	O	999-1000
but	O	1001-1004
RiCof	O	1005-1010
was	O	1011-1014
very	O	1015-1019
low	O	1020-1023
(	O	1024-1025
platelet	O	1025-1033
discordant	O	1034-1044
)	O	1044-1045
;	O	1045-1046
even	O	1047-1051
though	O	1052-1058
a	O	1059-1060
complete	O	1061-1069
set	O	1070-1073
of	O	1074-1076
multimers	O	1077-1086
was	O	1087-1090
found	O	1091-1096
in	O	1097-1099
plasma	O	1100-1106
and	O	1107-1110
platelets	O	1111-1120
,	O	1120-1121
there	O	1122-1127
was	O	1128-1131
a	O	1132-1133
relatively	O	1134-1144
small	O	1145-1150
amount	O	1151-1157
of	O	1158-1160
large	O	1161-1166
multimers	O	1167-1176
.	O	1176-1177

After	O	1178-1183
DDAVP	O	1184-1189
,	O	1189-1190
plasma	O	1191-1197
vWF	O	1198-1201
Ag	O	1203-1205
became	O	1206-1212
normal	O	1213-1219
,	O	1219-1220
but	O	1221-1224
RiCof	O	1225-1230
remained	O	1231-1239
low	O	1240-1243
and	O	1244-1247
the	O	1248-1251
BT	O	1252-1254
was	O	1255-1258
very	O	1259-1263
prolonged	O	1264-1273
.	O	1273-1274

These	O	1275-1280
findings	O	1281-1289
demonstrated	O	1290-1302
that	O	1303-1307
there	O	1308-1313
can	O	1314-1317
be	O	1318-1320
an	O	1321-1323
abnormal	O	1324-1332
vWF	O	1333-1336
(	O	1337-1338
RiCof	O	1338-1343
less	O	1344-1348
than	O	1349-1353
vWF	O	1354-1357
Ag	O	1359-1361
)	O	1361-1362
even	O	1363-1367
in	O	1368-1370
type	B	1371-1375
I	I	1376-1377
vWD	I	1378-1381
,	O	1381-1382
coexisting	O	1383-1393
with	O	1394-1398
a	O	1399-1400
complete	O	1401-1409
set	O	1410-1413
of	O	1414-1416
vWF	O	1417-1420
multimers	O	1421-1430
(	O	1431-1432
platelet	O	1432-1440
discordant	O	1441-1451
)	O	1451-1452
;	O	1452-1453
that	O	1454-1458
the	O	1459-1462
abnormal	O	1463-1471
vWF	O	1472-1475
can	O	1476-1479
be	O	1480-1482
shown	O	1483-1488
more	O	1489-1493
clearly	O	1494-1501
in	O	1502-1504
platelets	O	1505-1514
than	O	1515-1519
in	O	1520-1522
plasma	O	1523-1529
or	O	1530-1532
else	O	1533-1537
in	O	1538-1540
plasma	O	1541-1547
after	O	1548-1553
DDAVP	O	1554-1559
infusion	O	1560-1568
;	O	1568-1569
and	O	1570-1573
that	O	1574-1578
DDAVP	O	1579-1584
normalizes	O	1585-1595
the	O	1596-1599
BT	O	1600-1602
only	O	1603-1607
in	O	1608-1610
those	O	1611-1616
patients	O	1617-1625
with	O	1626-1630
normal	O	1631-1637
platelet	O	1638-1646
levels	O	1647-1653
of	O	1654-1656
both	O	1657-1661
vWF	O	1662-1665
Ag	O	1667-1669
and	O	1670-1673
RiCof	O	1674-1679
(	O	1680-1681
platelet	O	1681-1689
normal	O	1690-1696
)	O	1696-1697
.	O	1697-1698
.	O	1697-1698

Characterization	O	0-16
of	O	17-19
a	O	20-21
YAC	O	22-25
containing	O	26-36
part	O	37-41
or	O	42-44
all	O	45-48
of	O	49-51
the	O	52-55
Norrie	B	56-62
disease	I	63-70
locus	O	71-76
.	O	76-77

It	O	78-80
has	O	81-84
been	O	85-89
shown	O	90-95
from	O	96-100
pulsed	O	101-107
-	O	107-108
field	O	108-113
gel	O	114-117
electrophoresis	O	118-133
(	O	134-135
PFGE	O	135-139
)	O	139-140
that	O	141-145
the	O	146-149
monoamine	O	150-159
oxidase	O	160-167
genes	O	168-173
A	O	174-175
and	O	176-179
B	O	180-181
(	O	182-183
MAOA	O	183-187
&	O	188-189
MAOB	O	190-194
)	O	194-195
and	O	196-199
DXS7	O	200-204
loci	O	205-209
are	O	210-213
physically	O	214-224
very	O	225-229
close	O	230-235
.	O	235-236

We	O	237-239
have	O	240-244
therefore	O	245-254
extended	O	255-263
studies	O	264-271
on	O	272-274
their	O	275-280
relationship	O	281-293
through	O	294-301
the	O	302-305
characterisation	O	306-322
of	O	323-325
a	O	326-327
650	O	328-331
kb	O	332-334
YAC	O	335-338
isolated	O	339-347
using	O	348-353
L1	O	354-356
.	O	356-357

28	O	358-360
(	O	361-362
recognising	O	362-373
the	O	374-377
DXS7	O	378-382
locus	O	383-388
)	O	388-389
as	O	390-392
a	O	393-394
probe	O	395-400
.	O	400-401

Restriction	O	402-413
mapping	O	414-421
of	O	422-424
the	O	425-428
YAC	O	429-432
indicates	O	433-442
that	O	443-447
it	O	448-450
contains	O	451-459
both	O	460-464
MAOA	O	465-469
and	O	470-473
MAOB	O	474-478
genes	O	479-484
in	O	485-487
addition	O	488-496
to	O	497-499
the	O	500-503
DXS7	O	504-508
locus	O	509-514
.	O	514-515

The	O	516-519
map	O	520-523
derived	O	524-531
from	O	532-536
the	O	537-540
YL1	O	541-544
.	O	544-545

28	O	546-548
-	O	548-549
YAC	O	549-552
is	O	553-555
compatible	O	556-566
both	O	567-571
with	O	572-576
the	O	577-580
map	O	581-584
from	O	585-589
an	O	590-592
independently	O	593-606
derived	O	607-614
YAC	O	615-618
carrying	O	619-627
MAOA	O	628-632
and	O	633-636
B	O	637-638
genes	O	639-644
and	O	645-648
with	O	649-653
the	O	654-657
long	O	658-662
range	O	663-668
genomic	O	669-676
map	O	677-680
for	O	681-684
the	O	685-688
region	O	689-695
.	O	695-696

A	O	697-698
series	O	699-705
of	O	706-708
subclones	O	709-718
prepared	O	719-727
from	O	728-732
a	O	733-734
phage	O	735-740
library	O	741-748
(	O	749-750
lambda	O	750-756
DASH	O	757-761
II	O	762-764
)	O	764-765
of	O	766-768
the	O	769-772
YAC	O	773-776
have	O	777-781
been	O	782-786
characterised	O	787-800
and	O	801-804
have	O	805-809
been	O	810-814
employed	O	815-823
to	O	824-826
determine	O	827-836
the	O	837-840
end	O	841-844
point	O	845-850
of	O	851-853
the	O	854-857
deletion	O	858-866
of	O	867-869
a	O	870-871
Norrie	B	872-878
disease	I	879-886
(	O	887-888
NDP	B	888-891
)	O	891-892
patient	O	893-900
who	O	901-904
has	O	905-908
been	O	909-913
shown	O	914-919
to	O	920-922
lack	O	923-927
both	O	928-932
DXS7	O	933-937
and	O	938-941
MAO	O	942-945
coding	O	946-952
sequences	O	953-962
.	O	962-963

The	O	964-967
pattern	O	968-975
of	O	976-978
retention	O	979-988
of	O	989-991
subclones	O	992-1001
in	O	1002-1004
the	O	1005-1008
deletion	O	1009-1017
patient	O	1018-1025
place	O	1026-1031
the	O	1032-1035
end	O	1036-1039
point	O	1040-1045
of	O	1046-1048
the	O	1049-1052
deletion	O	1053-1061
within	O	1062-1068
30	O	1069-1071
-	O	1071-1072
130	O	1072-1075
kb	O	1076-1078
of	O	1079-1081
the	O	1082-1085
proximal	O	1086-1094
end	O	1095-1098
of	O	1099-1101
the	O	1102-1105
YAC	O	1106-1109
.	O	1109-1110

By	O	1111-1113
combining	O	1114-1123
the	O	1124-1127
data	O	1128-1132
with	O	1133-1137
established	O	1138-1149
recombination	O	1150-1163
analysis	O	1164-1172
,	O	1172-1173
we	O	1174-1176
provide	O	1177-1184
evidence	O	1185-1193
that	O	1194-1198
all	O	1199-1202
or	O	1203-1205
part	O	1206-1210
of	O	1211-1213
the	O	1214-1217
NDP	O	1218-1221
lies	O	1222-1226
in	O	1227-1229
the	O	1230-1233
interval	O	1234-1242
of	O	1243-1245
approximately	O	1246-1259
250kb	O	1260-1265
within	O	1266-1272
the	O	1273-1276
YAC	O	1277-1280
.	O	1280-1281

Identification	O	0-14
of	O	15-17
mutations	O	18-27
in	O	28-30
Danish	O	31-37
choroideremia	B	38-51
families	O	52-60
.	O	60-61

We	O	62-64
have	O	65-69
searched	O	70-78
for	O	79-82
mutations	O	83-92
in	O	93-95
the	O	96-99
choroideremia	B	100-113
gene	O	114-118
(	O	119-120
CHM	B	120-123
)	O	123-124
in	O	125-127
patients	O	128-136
from	O	137-141
12	O	142-144
Danish	O	145-151
families	O	152-160
in	O	161-163
which	O	164-169
CHM	B	170-173
is	O	174-176
segregating	O	177-188
.	O	188-189

Employing	O	190-199
polymerase	O	200-210
chain	O	211-216
reaction	O	217-225
(	O	226-227
PCR	O	227-230
)	O	230-231
,	O	231-232
single	O	233-239
strand	O	240-246
conformation	O	247-259
polymorphism	O	260-272
(	O	273-274
SSCP	O	274-278
)	O	278-279
analysis	O	280-288
,	O	288-289
and	O	290-293
direct	O	294-300
DNA	O	301-304
sequencing	O	305-315
,	O	315-316
different	O	317-326
mutations	O	327-336
have	O	337-341
been	O	342-346
identified	O	347-357
in	O	358-360
6	O	361-362
patients	O	363-371
.	O	371-372

All	O	373-376
the	O	377-380
mutations	O	381-390
will	O	391-395
interfere	O	396-405
with	O	406-410
the	O	411-414
correct	O	415-422
translation	O	423-434
of	O	435-437
the	O	438-441
mRNA	O	442-446
predicting	O	447-457
a	O	458-459
truncated	O	460-469
protein	O	470-477
or	O	478-480
no	O	481-483
gene	O	484-488
product	O	489-496
at	O	497-499
all	O	500-503
.	O	503-504
.	O	503-504

G130V	O	0-5
,	O	5-6
a	O	7-8
common	O	9-15
FRDA	B	16-20
point	O	21-26
mutation	O	27-35
,	O	35-36
appears	O	37-44
to	O	45-47
have	O	48-52
arisen	O	53-59
from	O	60-64
a	O	65-66
common	O	67-73
founder	O	74-81
.	O	81-82

Friedreich	B	83-93
ataxia	I	94-100
(	O	101-102
FRDA	B	102-106
)	O	106-107
is	O	108-110
the	O	111-114
most	O	115-119
common	O	120-126
inherited	B	127-136
ataxia	I	137-143
.	O	143-144

About	O	145-150
98	O	151-153
%	O	153-154
of	O	155-157
mutant	O	158-164
alleles	O	165-172
have	O	173-177
an	O	178-180
expansion	O	181-190
of	O	191-193
a	O	194-195
GAA	O	196-199
trinucleotide	O	200-213
repeat	O	214-220
in	O	221-223
intron	O	224-230
1	O	231-232
of	O	233-235
the	O	236-239
affected	O	240-248
gene	O	249-253
,	O	253-254
FRDA	O	255-259
.	O	259-260

The	O	261-264
other	O	265-270
2	O	271-272
%	O	272-273
are	O	274-277
point	O	278-283
mutations	O	284-293
.	O	293-294

Of	O	295-297
the	O	298-301
17	O	302-304
point	O	305-310
mutations	O	311-320
so	O	321-323
far	O	324-327
described	O	328-337
,	O	337-338
three	O	339-344
appear	O	345-351
to	O	352-354
be	O	355-357
more	O	358-362
common	O	363-369
.	O	369-370

One	O	371-374
of	O	375-377
these	O	378-383
is	O	384-386
the	O	387-390
G130V	O	391-396
mutation	O	397-405
in	O	406-408
exon	O	409-413
4	O	414-415
of	O	416-418
FRDA	O	419-423
.	O	423-424

G130V	O	425-430
,	O	430-431
when	O	432-436
present	O	437-444
with	O	445-449
an	O	450-452
expanded	O	453-461
GAA	O	462-465
repeat	O	466-472
on	O	473-475
the	O	476-479
other	O	480-485
allele	O	486-492
,	O	492-493
is	O	494-496
associated	O	497-507
with	O	508-512
an	O	513-515
atypical	O	516-524
FRDA	B	525-529
phenotype	O	530-539
.	O	539-540

Haplotype	O	541-550
analysis	O	551-559
was	O	560-563
undertaken	O	564-574
on	O	575-577
the	O	578-581
four	O	582-586
families	O	587-595
who	O	596-599
have	O	600-604
been	O	605-609
described	O	610-619
with	O	620-624
this	O	625-629
mutation	O	630-638
.	O	638-639

The	O	640-643
results	O	644-651
suggest	O	652-659
a	O	660-661
common	O	662-668
founder	O	669-676
for	O	677-680
this	O	681-685
mutation	O	686-694
.	O	694-695

Although	O	696-704
marked	O	705-711
differences	O	712-723
in	O	724-726
extragenic	O	727-737
marker	O	738-744
haplotypes	O	745-755
were	O	756-760
seen	O	761-765
in	O	766-768
one	O	769-772
family	O	773-779
,	O	779-780
similar	O	781-788
intragenic	O	789-799
haplotyping	O	800-811
suggests	O	812-820
the	O	821-824
same	O	825-829
mutation	O	830-838
founder	O	839-846
for	O	847-850
this	O	851-855
family	O	856-862
with	O	863-867
the	O	868-871
differences	O	872-883
explicable	O	884-894
by	O	895-897
two	O	898-901
recombination	O	902-915
events	O	916-922
.	O	922-923
.	O	922-923

Frequency	O	0-9
of	O	10-12
exon	O	13-17
15	O	18-20
missense	O	21-29
mutation	O	30-38
(	O	39-40
442D	O	40-44
:	O	44-45
G	O	45-46
)	O	46-47
in	O	48-50
cholesteryl	O	51-62
ester	O	63-68
transfer	O	69-77
protein	O	78-85
gene	O	86-90
in	O	91-93
hyperalphalipoproteinemic	B	94-119
Japanese	O	120-128
subjects	O	129-137
.	O	137-138

Cholesteryl	O	139-150
ester	O	151-156
transfer	O	157-165
protein	O	166-173
(	O	174-175
CETP	O	175-179
)	O	179-180
transfers	O	181-190
cholesteryl	O	191-202
ester	O	203-208
from	O	209-213
high	O	214-218
density	O	219-226
lipoprotein	O	227-238
(	O	239-240
HDL	O	240-243
)	O	243-244
to	O	245-247
apo	O	248-251
B	O	252-253
-	O	253-254
containing	O	254-264
lipoproteins	O	265-277
.	O	277-278

The	O	279-282
hyperalphalipoproteinemia	B	283-308
caused	O	309-315
by	O	316-318
CETP	B	319-323
deficiency	I	324-334
is	O	335-337
fairly	O	338-344
common	O	345-351
in	O	352-354
Japan	O	355-360
and	O	361-364
one	O	365-368
of	O	369-371
the	O	372-375
most	O	376-380
common	O	381-387
mutations	O	388-397
in	O	398-400
the	O	401-404
CETP	O	405-409
gene	O	410-414
is	O	415-417
the	O	418-421
splicing	O	422-430
defect	O	431-437
of	O	438-440
the	O	441-444
intron	O	445-451
14	O	452-454
,	O	454-455
the	O	456-459
allelic	O	460-467
frequency	O	468-477
of	O	478-480
which	O	481-486
has	O	487-490
been	O	491-495
shown	O	496-501
to	O	502-504
be	O	505-507
0	O	508-509
.	O	509-510
0049	O	511-515
in	O	516-518
the	O	519-522
Japanese	O	523-531
general	O	532-539
population	O	540-550
.	O	550-551

Recently	O	552-560
,	O	560-561
we	O	562-564
have	O	565-569
reported	O	570-578
a	O	579-580
missense	O	581-589
mutation	O	590-598
in	O	599-601
exon	O	602-606
15	O	607-609
of	O	610-612
the	O	613-616
CETP	O	617-621
gene	O	622-626
(	O	627-628
442D	O	628-632
G	O	634-635
)	O	635-636
,	O	636-637
showing	O	638-645
a	O	646-647
dominant	O	648-656
effect	O	657-663
on	O	664-666
the	O	667-670
CETP	O	671-675
activity	O	676-684
and	O	685-688
HDL	O	689-692
-	O	692-693
cholesterol	O	693-704
level	O	705-710
.	O	710-711

In	O	712-714
the	O	715-718
current	O	719-726
study	O	727-732
,	O	732-733
we	O	734-736
determined	O	737-747
the	O	748-751
frequency	O	752-761
of	O	762-764
this	O	765-769
new	O	770-773
mutation	O	774-782
in	O	783-785
Japanese	O	786-794
hyperalphalipoproteinemic	B	795-820
(	O	821-822
HDL	O	822-825
-	O	825-826
cholesterol	O	826-837
>	O	838-839
or	O	840-842
=	O	843-844
100	O	845-848
mg	O	849-851
/	O	851-852
dl	O	852-854
)	O	854-855
subjects	O	856-864
.	O	864-865

A	O	866-867
rapid	O	868-873
and	O	874-877
easy	O	878-882
screening	O	883-892
method	O	893-899
for	O	900-903
this	O	904-908
new	O	909-912
mutation	O	913-921
was	O	922-925
developed	O	926-935
using	O	936-941
a	O	942-943
polymerase	O	944-954
chain	O	955-960
reaction	O	961-969
(	O	970-971
PCR	O	971-974
)	O	974-975
-	O	976-977
mediated	O	977-985
site	O	986-990
-	O	990-991
directed	O	991-999
mutagenesis	O	1000-1011
.	O	1011-1012

Among	O	1013-1018
117	O	1019-1022
Japanese	O	1023-1031
hyperalphalipoproteinemic	B	1032-1057
subjects	O	1058-1066
(	O	1067-1068
HDL	O	1068-1071
-	O	1071-1072
cholesterol	O	1072-1083
;	O	1083-1084
116	O	1085-1088
.	O	1088-1089

7	O	1090-1091
+	O	1092-1093
/	O	1093-1094
-	O	1094-1095
16	O	1096-1098
.	O	1098-1099
5	O	1100-1101
mg	O	1102-1104
/	O	1104-1105
dl	O	1105-1107
,	O	1107-1108
mean	O	1109-1113
+	O	1114-1115
/	O	1115-1116
-	O	1116-1117
S	O	1118-1119
.	O	1119-1120
D	O	1121-1122
.	O	1122-1123
)	O	1123-1124
without	O	1125-1132
the	O	1133-1136
intron	O	1137-1143
14	O	1144-1146
splice	O	1147-1153
defect	O	1154-1160
,	O	1160-1161
three	O	1162-1167
homozygotes	O	1168-1179
(	O	1180-1181
2	O	1181-1182
.	O	1182-1183

5	O	1184-1185
%	O	1185-1186
)	O	1186-1187
and	O	1188-1191
34	O	1192-1194
heterozygotes	O	1195-1208
(	O	1209-1210
29	O	1210-1212
.	O	1212-1213

1	O	1214-1215
%	O	1215-1216
)	O	1216-1217
were	O	1218-1222
found	O	1223-1228
to	O	1229-1231
have	O	1232-1236
the	O	1237-1240
442D	O	1241-1245
G	O	1247-1248
mutation	O	1249-1257
.	O	1257-1258

The	O	1259-1262
relative	O	1263-1271
allelic	O	1272-1279
frequency	O	1280-1289
of	O	1290-1292
this	O	1293-1297
mutation	O	1298-1306
was	O	1307-1310
calculated	O	1311-1321
to	O	1322-1324
be	O	1325-1327
0	O	1328-1329
.	O	1329-1330
17	O	1331-1333
.	O	1333-1334

One	O	1335-1338
of	O	1339-1341
the	O	1342-1345
homozygotes	O	1346-1357
for	O	1358-1361
the	O	1362-1365
442D	O	1366-1370
G	O	1372-1373
mutation	O	1374-1382
was	O	1383-1386
the	O	1387-1390
patient	O	1391-1398
previously	O	1399-1409
described	O	1410-1419
by	O	1420-1422
us	O	1423-1425
as	O	1426-1428
having	O	1429-1435
hyperalphalipoproteinemia	B	1436-1461
with	O	1462-1466
corneal	B	1467-1474
opacity	I	1475-1482
and	O	1483-1486
coronary	B	1487-1495
heart	I	1496-1501
disease	I	1502-1509
.	O	1509-1510

This	O	1511-1515
was	O	1516-1519
the	O	1520-1523
first	O	1524-1529
reported	O	1530-1538
subject	O	1539-1546
homozygous	O	1547-1557
for	O	1558-1561
the	O	1562-1565
CETP	B	1566-1570
deficiency	I	1571-1581
who	O	1582-1585
also	O	1586-1590
demonstrated	O	1591-1603
atherosclerotic	B	1604-1619
symptoms	I	1620-1628
.	O	1628-1629

In	O	1630-1632
homozygous	O	1633-1643
subjects	O	1644-1652
,	O	1652-1653
CETP	O	1654-1658
activity	O	1659-1667
ranged	O	1668-1674
from	O	1675-1679
37	O	1680-1682
%	O	1682-1683
to	O	1684-1686
62	O	1687-1689
%	O	1689-1690
of	O	1691-1693
the	O	1694-1697
normal	O	1698-1704
value	O	1705-1710
,	O	1710-1711
which	O	1712-1717
was	O	1718-1721
consistent	O	1722-1732
with	O	1733-1737
the	O	1738-1741
results	O	1742-1749
obtained	O	1750-1758
from	O	1759-1763
the	O	1764-1767
transient	O	1768-1777
expression	O	1778-1788
experiment	O	1789-1799
previously	O	1800-1810
reported	O	1811-1819
;	O	1819-1820
however	O	1821-1828
,	O	1828-1829
the	O	1830-1833
specific	O	1834-1842
activity	O	1843-1851
of	O	1852-1854
CETP	O	1855-1859
was	O	1860-1863
not	O	1864-1867
as	O	1868-1870
low	O	1871-1874
as	O	1875-1877
expected	O	1878-1886
.	O	1886-1887

(	O	1888-1889
ABSTRACT	O	1889-1897
TRUNCATED	O	1898-1907
AT	O	1908-1910
250	O	1911-1914
WORDS	O	1915-1920
)	O	1920-1921

Fibroblast	O	0-10
growth	O	11-17
factor	O	18-24
homologous	O	25-35
factor	O	36-42
2	O	43-44
(	O	45-46
FHF2	O	46-50
)	O	50-51
:	O	51-52
gene	O	53-57
structure	O	58-67
,	O	67-68
expression	O	69-79
and	O	80-83
mapping	O	84-91
to	O	92-94
the	O	95-98
Borjeson	B	99-107
-	I	107-108
Forssman	I	108-116
-	I	107-108
Lehmann	I	117-124
syndrome	I	125-133
region	O	134-140
in	O	141-143
Xq26	O	144-148
delineated	O	149-159
by	O	160-162
a	O	163-164
duplication	O	165-176
breakpoint	O	177-187
in	O	188-190
a	O	191-192
BFLS	B	193-197
-	O	197-198
like	O	198-202
patient	O	203-210
.	O	210-211

Borjeson	B	212-220
-	I	220-221
Forssman	I	221-229
-	I	220-221
Lehmann	I	230-237
syndrome	I	238-246
(	O	247-248
BFLS	B	248-252
)	O	252-253
is	O	254-256
a	O	257-258
syndromal	O	259-268
X	B	269-270
-	I	270-271
linked	I	271-277
mental	I	278-284
retardation	I	285-296
,	O	296-297
which	O	298-303
maps	O	304-308
by	O	309-311
linkage	O	312-319
to	O	320-322
the	O	323-326
q26	O	327-330
region	O	331-337
of	O	338-340
the	O	341-344
human	O	345-350
X	O	351-352
chromosome	O	353-363
.	O	363-364

We	O	365-367
have	O	368-372
identified	O	373-383
a	O	384-385
male	O	386-390
patient	O	391-398
with	O	399-403
BFLS	B	404-408
-	O	408-409
like	O	409-413
features	O	414-422
and	O	423-426
a	O	427-428
duplication	O	429-440
,	O	440-441
46	O	442-444
,	O	444-445
Y	O	446-447
,	O	447-448
dup	O	449-452
(	O	453-454
X	O	454-455
)	O	455-456
(	O	457-458
q26q28	O	458-464
)	O	464-465
,	O	465-466
inherited	O	467-476
from	O	477-481
his	O	482-485
phenotypically	O	486-500
normal	O	501-507
mother	O	508-514
.	O	514-515

Fluorescence	O	516-528
in	O	529-531
situ	O	532-536
hybridisation	O	537-550
using	O	551-556
yeast	O	557-562
artificial	O	563-573
chromosome	O	574-584
clones	O	585-591
from	O	592-596
Xq26	O	597-601
localised	O	602-611
the	O	612-615
duplication	O	616-627
breakpoint	O	628-638
to	O	639-641
an	O	642-644
approximately	O	645-658
400	O	659-662
-	O	662-663
kb	O	663-665
interval	O	666-674
in	O	675-677
the	O	678-681
Xq26	O	682-686
.	O	686-687
3	O	688-689
region	O	690-696
between	O	697-704
DXS155	O	705-711
and	O	712-715
DXS294	O	716-722
/	O	722-723
DXS730	O	723-729
.	O	729-730

Database	O	731-739
searches	O	740-748
and	O	749-752
analysis	O	753-761
of	O	762-764
available	O	765-774
genomic	O	775-782
DNA	O	783-786
sequence	O	787-795
from	O	796-800
the	O	801-804
region	O	805-811
revealed	O	812-820
the	O	821-824
presence	O	825-833
of	O	834-836
the	O	837-840
fibroblast	O	841-851
growth	O	852-858
factor	O	859-865
homologous	O	866-876
factor	O	877-883
gene	O	884-888
,	O	888-889
FHF2	O	890-894
,	O	894-895
within	O	896-902
the	O	903-906
duplication	O	907-918
breakpoint	O	919-929
interval	O	930-938
.	O	938-939

The	O	940-943
gene	O	944-948
structure	O	949-958
of	O	959-961
FHF2	O	962-966
was	O	967-970
determined	O	971-981
and	O	982-985
two	O	986-989
new	O	990-993
exons	O	994-999
were	O	1000-1004
identified	O	1005-1015
,	O	1015-1016
including	O	1017-1026
a	O	1027-1028
new	O	1029-1032
5	O	1033-1034
end	O	1035-1038
exon	O	1039-1043
,	O	1043-1044
1B	O	1045-1047
.	O	1047-1048

FHF2	O	1049-1053
is	O	1054-1056
a	O	1057-1058
large	O	1059-1064
gene	O	1065-1069
extending	O	1070-1079
over	O	1080-1084
approximately	O	1085-1098
200	O	1099-1102
kb	O	1103-1105
in	O	1106-1108
Xq26	O	1109-1113
.	O	1113-1114
3	O	1115-1116
and	O	1117-1120
is	O	1121-1123
composed	O	1124-1132
of	O	1133-1135
at	O	1136-1138
least	O	1139-1144
seven	O	1145-1150
exons	O	1151-1156
.	O	1156-1157

It	O	1158-1160
shows	O	1161-1166
tissue	O	1167-1173
-	O	1173-1174
specific	O	1174-1182
alternative	O	1183-1194
splicing	O	1195-1203
and	O	1204-1207
alternative	O	1208-1219
transcription	O	1220-1233
starts	O	1234-1240
.	O	1240-1241

Northern	O	1242-1250
blot	O	1251-1255
hybridisation	O	1256-1269
showed	O	1270-1276
highest	O	1277-1284
expression	O	1285-1295
in	O	1296-1298
brain	O	1299-1304
and	O	1305-1308
skeletal	O	1309-1317
muscle	O	1318-1324
.	O	1324-1325

The	O	1326-1329
FHF2	O	1330-1334
gene	O	1335-1339
localisation	O	1340-1352
and	O	1353-1356
tissue	O	1357-1363
-	O	1363-1364
specific	O	1364-1372
expression	O	1373-1383
pattern	O	1384-1391
suggest	O	1392-1399
it	O	1400-1402
to	O	1403-1405
be	O	1406-1408
a	O	1409-1410
candidate	O	1411-1420
gene	O	1421-1425
for	O	1426-1429
familial	O	1430-1438
cases	O	1439-1444
of	O	1445-1447
the	O	1448-1451
BFLS	B	1452-1456
syndrome	I	1457-1465
and	O	1466-1469
other	O	1470-1475
syndromal	O	1476-1485
and	O	1486-1489
non	O	1490-1493
-	O	1493-1494
specific	O	1494-1502
forms	O	1503-1508
of	O	1509-1511
X	B	1512-1513
-	I	1513-1514
linked	I	1514-1520
mental	I	1521-1527
retardation	I	1528-1539
mapping	O	1540-1547
to	O	1548-1550
the	O	1551-1554
region	O	1555-1561
.	O	1561-1562

Illegitimate	O	0-12
transcription	O	13-26
of	O	27-29
the	O	30-33
phenylalanine	O	34-47
hydroxylase	O	48-59
gene	O	60-64
in	O	65-67
lymphocytes	O	68-79
for	O	80-83
identification	O	84-98
of	O	99-101
mutations	O	102-111
in	O	112-114
phenylketonuria	B	115-130
.	O	130-131

Taking	O	132-138
advantage	O	139-148
of	O	149-151
the	O	152-155
illegitimate	O	156-168
transcription	O	169-182
of	O	183-185
the	O	186-189
phenylalanine	O	190-203
hydroxylase	O	204-215
(	O	216-217
PAH	O	217-220
)	O	220-221
gene	O	222-226
,	O	226-227
we	O	228-230
have	O	231-235
been	O	236-240
able	O	241-245
to	O	246-248
analyse	O	249-256
the	O	257-260
PAH	O	261-264
cDNA	O	265-269
sequence	O	270-278
of	O	279-281
hyperphenylalaninemic	B	282-303
children	O	304-312
in	O	313-315
circulating	O	316-327
lymphocytes	O	328-339
.	O	339-340

Using	O	341-346
this	O	347-351
approach	O	352-360
,	O	360-361
we	O	362-364
have	O	365-369
also	O	370-374
identified	O	375-385
3	O	386-387
novel	O	388-393
mutations	O	394-403
in	O	404-406
cDNA	O	407-411
from	O	412-416
liver	O	417-422
and	O	423-426
lymphocytes	O	427-438
of	O	439-441
two	O	442-445
patients	O	446-454
.	O	454-455

One	O	456-459
mutation	O	460-468
,	O	468-469
detected	O	470-478
by	O	479-481
the	O	482-485
abnormal	O	486-494
pattern	O	495-502
of	O	503-505
migration	O	506-515
of	O	516-518
an	O	519-521
amplified	O	522-531
fragment	O	532-540
,	O	540-541
is	O	542-544
a	O	545-546
C	O	547-548
to	O	549-551
T	O	552-553
transition	O	554-564
in	O	565-567
the	O	568-571
splice	O	572-578
acceptor	O	579-587
site	O	588-592
of	O	593-595
intron	O	596-602
10	O	603-605
,	O	605-606
which	O	607-612
resulted	O	613-621
in	O	622-624
the	O	625-628
skipping	O	629-637
of	O	638-640
exon	O	641-645
11	O	646-648
with	O	649-653
the	O	654-657
premature	O	658-667
termination	O	668-679
of	O	680-682
RNA	O	683-686
translation	O	687-698
downstream	O	699-709
from	O	710-714
exon	O	715-719
12	O	720-722
(	O	723-724
-	O	724-725
3	O	725-726
IVS10	O	727-732
)	O	732-733
.	O	733-734

The	O	735-738
other	O	739-744
two	O	745-748
mutations	O	749-758
are	O	759-762
missense	O	763-771
mutations	O	772-781
in	O	782-784
exons	O	785-790
10	O	791-793
and	O	794-797
11	O	798-800
(	O	801-802
respectively	O	802-814
,	O	814-815
L333F	O	816-821
and	O	822-825
E390G	O	826-831
)	O	831-832
.	O	832-833

The	O	834-837
present	O	838-845
study	O	846-851
supports	O	852-860
the	O	861-864
view	O	865-869
that	O	870-874
circulating	O	875-886
lymphocytes	O	887-898
give	O	899-903
easy	O	904-908
access	O	909-915
to	O	916-918
PAH	O	919-922
gene	O	923-927
transcripts	O	928-939
whose	O	940-945
nucleotide	O	946-956
sequence	O	957-965
is	O	966-968
identical	O	969-978
to	O	979-981
that	O	982-986
reported	O	987-995
in	O	996-998
liver	O	999-1004
and	O	1005-1008
therefore	O	1009-1018
represent	O	1019-1028
a	O	1029-1030
useful	O	1031-1037
tool	O	1038-1042
for	O	1043-1046
molecular	O	1047-1056
genetic	O	1057-1064
studies	O	1065-1072
in	O	1073-1075
phenylketonuria	B	1076-1091
.	O	1091-1092
.	O	1091-1092

Function	O	0-8
of	O	9-11
an	O	12-14
axonal	O	15-21
chemoattractant	O	22-37
modulated	O	38-47
by	O	48-50
metalloprotease	O	51-66
activity	O	67-75
.	O	75-76

The	O	77-80
axonal	O	81-87
chemoattractant	O	88-103
netrin	O	104-110
-	O	110-111
1	O	111-112
guides	O	113-119
spinal	O	120-126
commissural	O	127-138
axons	O	139-144
by	O	145-147
activating	O	148-158
its	O	159-162
receptor	O	163-171
DCC	O	172-175
(	O	176-177
Deleted	O	177-184
in	O	185-187
Colorectal	B	188-198
Cancer	I	199-205
)	O	206-207
.	O	207-208

We	O	209-211
have	O	212-216
found	O	217-222
that	O	223-227
chemical	O	228-236
inhibitors	O	237-247
of	O	248-250
metalloproteases	O	251-267
potentiate	O	268-278
netrin	O	279-285
-	O	285-286
mediated	O	286-294
axon	O	295-299
outgrowth	O	300-309
in	O	310-312
vitro	O	313-318
.	O	318-319

We	O	320-322
have	O	323-327
also	O	328-332
found	O	333-338
that	O	339-343
DCC	O	344-347
is	O	348-350
a	O	351-352
substrate	O	353-362
for	O	363-366
metalloprotease	O	367-382
-	O	382-383
dependent	O	383-392
ectodomain	O	393-403
shedding	O	404-412
,	O	412-413
and	O	414-417
that	O	418-422
the	O	423-426
inhibitors	O	427-437
block	O	438-443
proteolytic	O	444-455
processing	O	456-466
of	O	467-469
DCC	O	470-473
and	O	474-477
cause	O	478-483
an	O	484-486
increase	O	487-495
in	O	496-498
DCC	O	499-502
protein	O	503-510
levels	O	511-517
on	O	518-520
axons	O	521-526
within	O	527-533
spinal	O	534-540
cord	O	541-545
explants	O	546-554
.	O	554-555

Thus	O	556-560
,	O	560-561
potentiation	O	562-574
of	O	575-577
netrin	O	578-584
activity	O	585-593
by	O	594-596
inhibitors	O	597-607
may	O	608-611
result	O	612-618
from	O	619-623
stabilization	O	624-637
of	O	638-640
DCC	O	641-644
on	O	645-647
the	O	648-651
axons	O	652-657
,	O	657-658
and	O	659-662
proteolytic	O	663-674
activity	O	675-683
may	O	684-687
regulate	O	688-696
axon	O	697-701
migration	O	702-711
by	O	712-714
controlling	O	715-726
the	O	727-730
number	O	731-737
of	O	738-740
functional	O	741-751
extracellular	O	752-765
axon	O	766-770
guidance	O	771-779
receptors	O	780-789
.	O	789-790
.	O	789-790

Choroideremia	B	0-13
:	O	13-14
close	O	15-20
linkage	O	21-28
to	O	29-31
DXYS1	O	32-37
and	O	38-41
DXYS12	O	42-48
demonstrated	O	49-61
by	O	62-64
segregation	O	65-76
analysis	O	77-85
and	O	86-89
historical	O	90-100
-	O	100-101
genealogical	O	101-113
evidence	O	114-122
.	O	122-123

Linkage	O	124-131
studies	O	132-139
using	O	140-145
restriction	O	146-157
fragment	O	158-166
length	O	167-173
polymorphisms	O	174-187
were	O	188-192
conducted	O	193-202
in	O	203-205
the	O	206-209
X	B	210-211
-	I	211-212
linked	I	212-218
disorder	I	219-227
,	O	227-228
choroideremia	B	229-242
,	O	242-243
designated	O	244-254
TCD	B	255-258
for	O	259-262
Progressive	B	263-274
Tapeto	I	275-281
-	I	281-282
Choroidal	I	282-291
Dystrophy	I	292-301
.	O	301-302

Previously	O	303-313
demonstrated	O	314-326
close	O	327-332
linkage	O	333-340
with	O	341-345
locus	O	346-351
DXYS1	O	352-357
was	O	358-361
confirmed	O	362-371
(	O	372-373
lod	O	373-376
11	O	377-379
.	O	379-380
44	O	381-383
at	O	384-386
0	O	387-388
recombination	O	389-402
distance	O	403-411
)	O	411-412
.	O	412-413

In	O	414-416
addition	O	417-425
,	O	425-426
locus	O	427-432
DXYS12	O	433-439
was	O	440-443
found	O	444-449
to	O	450-452
be	O	453-455
closely	O	456-463
linked	O	464-470
with	O	471-475
TCD	B	476-479
(	O	480-481
lod	O	481-484
3	O	485-486
.	O	486-487
31	O	488-490
at	O	491-493
0	O	494-495
recombination	O	496-509
distance	O	510-518
)	O	518-519
.	O	519-520

The	O	521-524
disease	O	525-532
mainly	O	533-539
occurs	O	540-546
in	O	547-549
three	O	550-555
large	O	556-561
kindreds	O	562-570
in	O	571-573
remote	O	574-580
Northern	O	581-589
Finland	O	590-597
.	O	597-598

While	O	599-604
formal	O	605-611
genealogical	O	612-624
proof	O	625-630
is	O	631-633
lacking	O	634-641
,	O	641-642
all	O	643-646
presently	O	647-656
living	O	657-663
(	O	664-665
more	O	665-669
than	O	670-674
80	O	675-677
affected	O	678-686
males	O	687-692
and	O	693-696
120	O	697-700
carrier	O	701-708
females	O	709-716
)	O	716-717
probably	O	718-726
originate	O	727-736
from	O	737-741
a	O	742-743
common	O	744-750
founder	O	751-758
couple	O	759-765
born	O	766-770
in	O	771-773
1644	O	774-778
and	O	779-782
1646	O	783-787
,	O	787-788
twelve	O	789-795
generations	O	796-807
ago	O	808-811
.	O	811-812

All	O	813-816
36	O	817-819
patients	O	820-828
and	O	829-832
48	O	833-835
carriers	O	836-844
tested	O	845-851
from	O	852-856
the	O	857-860
three	O	861-866
kindreds	O	867-875
had	O	876-879
the	O	880-883
same	O	884-888
haplotype	O	889-898
(	O	899-900
TCD	B	900-903
/	O	903-904
DXYS1	O	904-909
,	O	909-910
11kb	O	911-915
/	O	915-916
DXYS12	O	916-922
,	O	922-923
1	O	924-925
.	O	925-926
6kb	O	927-930
)	O	930-931
.	O	931-932

Given	O	933-938
that	O	939-943
at	O	944-946
least	O	947-952
105	O	953-956
female	O	957-963
meioses	O	964-971
transmitting	O	972-984
TCD	B	985-988
have	O	989-993
occurred	O	994-1002
since	O	1003-1008
1650	O	1009-1013
in	O	1014-1016
these	O	1017-1022
kindreds	O	1023-1031
,	O	1031-1032
extremely	O	1033-1042
close	O	1043-1048
linkage	O	1049-1056
between	O	1057-1064
TCD	B	1065-1068
,	O	1068-1069
DXYS1	O	1070-1075
and	O	1076-1079
DXYS12	O	1080-1086
is	O	1087-1089
suggested	O	1090-1099
.	O	1099-1100

The	O	1101-1104
above	O	1105-1110
haplotype	O	1111-1120
is	O	1121-1123
a	O	1124-1125
very	O	1126-1130
useful	O	1131-1137
diagnostic	O	1138-1148
tool	O	1149-1153
in	O	1154-1156
these	O	1157-1162
TCD	B	1163-1166
families	O	1167-1175
.	O	1175-1176

We	O	1177-1179
suggest	O	1180-1187
that	O	1188-1192
our	O	1193-1196
historical	O	1197-1207
-	O	1207-1208
genealogical	O	1208-1220
approach	O	1221-1229
to	O	1230-1232
linkage	O	1233-1240
analysis	O	1241-1249
may	O	1250-1253
be	O	1254-1256
possible	O	1257-1265
elsewhere	O	1266-1275
in	O	1276-1278
similar	O	1279-1286
isolated	O	1287-1295
populations	O	1296-1307

Functional	O	0-10
consequences	O	11-23
of	O	24-26
mutations	O	27-36
in	O	37-39
the	O	40-43
early	O	44-49
growth	O	50-56
response	O	57-65
2	O	66-67
gene	O	68-72
(	O	73-74
EGR2	O	74-78
)	O	78-79
correlate	O	80-89
with	O	90-94
severity	O	95-103
of	O	104-106
human	O	107-112
myelinopathies	B	113-127
.	O	127-128

The	O	129-132
early	O	133-138
growth	O	139-145
response	O	146-154
2	O	155-156
gene	O	157-161
(	O	162-163
EGR2	O	163-167
)	O	167-168
is	O	169-171
a	O	172-173
Cys2His2zinc	O	174-186
finger	O	187-193
transcription	O	194-207
factor	O	208-214
which	O	215-220
is	O	221-223
thought	O	224-231
to	O	232-234
play	O	235-239
a	O	240-241
role	O	242-246
in	O	247-249
the	O	250-253
regulation	O	254-264
of	O	265-267
peripheral	O	268-278
nervous	O	279-286
system	O	287-293
myelination	O	294-305
.	O	305-306

This	O	307-311
idea	O	312-316
is	O	317-319
based	O	320-325
partly	O	326-332
on	O	333-335
the	O	336-339
phenotype	O	340-349
of	O	350-352
homozygous	O	353-363
Krox20	O	364-370
(	O	371-372
Egr2	O	372-376
)	O	376-377
knockout	O	378-386
mice	O	387-391
,	O	391-392
which	O	393-398
display	O	399-406
hypomyelination	B	407-422
of	I	423-425
the	I	426-429
PNS	I	430-433
and	O	434-437
a	O	438-439
block	O	440-445
of	O	446-448
Schwann	O	449-456
cells	O	457-462
at	O	463-465
an	O	466-468
early	O	469-474
stage	O	475-480
of	O	481-483
differentiation	O	484-499
.	O	499-500

Mutations	O	501-510
in	O	511-513
the	O	514-517
human	O	518-523
EGR2	O	524-528
gene	O	529-533
have	O	534-538
recently	O	539-547
been	O	548-552
associated	O	553-563
with	O	564-568
the	O	569-572
inherited	B	573-582
peripheral	I	583-593
neuropathies	I	594-606
Charcot	B	607-614
-	I	614-615
Marie	I	615-620
-	I	614-615
Tooth	I	621-626
type	I	627-631
1	I	632-633
,	O	633-634
Dejerine	B	635-643
-	I	643-644
Sottas	I	644-650
syndrome	I	651-659
and	O	660-663
congenital	B	664-674
hypomyelinating	I	675-690
neuropathy	I	691-701
.	O	701-702

Three	O	703-708
of	O	709-711
the	O	712-715
four	O	716-720
EGR2	O	721-725
mutations	O	726-735
are	O	736-739
dominant	O	740-748
and	O	749-752
occur	O	753-758
within	O	759-765
the	O	766-769
zinc	O	770-774
finger	O	775-781
DNA	O	782-785
-	O	785-786
binding	O	786-793
domain	O	794-800
.	O	800-801

The	O	802-805
fourth	O	806-812
mutation	O	813-821
is	O	822-824
recessive	O	825-834
and	O	835-838
affects	O	839-846
the	O	847-850
inhibitory	O	851-861
domain	O	862-868
(	O	869-870
R1	O	870-872
)	O	872-873
that	O	874-878
binds	O	879-884
the	O	885-888
NAB	O	889-892
transcriptional	O	893-908
co	O	909-911
-	O	911-912
repressors	O	912-922
.	O	922-923

A	O	924-925
combination	O	926-937
of	O	938-940
DNA	O	941-944
-	O	944-945
binding	O	945-952
assays	O	953-959
and	O	960-963
transcriptional	O	964-979
analysis	O	980-988
was	O	989-992
used	O	993-997
to	O	998-1000
determine	O	1001-1010
the	O	1011-1014
functional	O	1015-1025
consequences	O	1026-1038
of	O	1039-1041
these	O	1042-1047
mutations	O	1048-1057
.	O	1057-1058

The	O	1059-1062
zinc	O	1063-1067
finger	O	1068-1074
mutations	O	1075-1084
affect	O	1085-1091
DNA	O	1092-1095
binding	O	1096-1103
and	O	1104-1107
the	O	1108-1111
amount	O	1112-1118
of	O	1119-1121
residual	O	1122-1130
binding	O	1131-1138
directly	O	1139-1147
correlates	O	1148-1158
with	O	1159-1163
disease	O	1164-1171
severity	O	1172-1180
.	O	1180-1181

The	O	1182-1185
R1	O	1186-1188
domain	O	1189-1195
mutation	O	1196-1204
prevents	O	1205-1213
interaction	O	1214-1225
of	O	1226-1228
EGR2	O	1229-1233
with	O	1234-1238
the	O	1239-1242
NAB	O	1243-1246
co	O	1247-1249
-	O	1249-1250
repressors	O	1250-1260
and	O	1261-1264
thereby	O	1265-1272
increases	O	1273-1282
transcriptional	O	1283-1298
activity	O	1299-1307
.	O	1307-1308

These	O	1309-1314
data	O	1315-1319
provide	O	1320-1327
insight	O	1328-1335
into	O	1336-1340
the	O	1341-1344
possible	O	1345-1353
disease	O	1354-1361
mechanisms	O	1362-1372
underlying	O	1373-1383
EGR2	O	1384-1388
mutations	O	1389-1398
and	O	1399-1402
the	O	1403-1406
reason	O	1407-1413
for	O	1414-1417
varying	O	1418-1425
severity	O	1426-1434
and	O	1435-1438
differences	O	1439-1450
in	O	1451-1453
inheritance	O	1454-1465
patterns	O	1466-1474
.	O	1474-1475
.	O	1474-1475

Molecular	O	0-9
basis	O	10-15
of	O	16-18
human	O	19-24
von	B	25-28
Willebrand	I	29-39
disease	I	40-47
:	O	47-48
analysis	O	49-57
of	O	58-60
platelet	O	61-69
von	B	70-73
Willebrand	I	74-84
factor	O	85-91
mRNA	O	92-96
.	O	96-97
von	B	98-101
Willebrand	I	102-112
disease	I	113-120
(	O	121-122
vWD	B	122-125
)	O	125-126
,	O	126-127
the	O	128-131
most	O	132-136
common	O	137-143
inherited	B	144-153
bleeding	I	154-162
disorder	I	163-171
in	O	172-174
humans	O	175-181
,	O	181-182
can	O	183-186
result	O	187-193
from	O	194-198
either	O	199-205
a	O	206-207
quantitative	O	208-220
or	O	221-223
a	O	224-225
qualitative	O	226-237
defect	O	238-244
in	O	245-247
the	O	248-251
adhesive	O	252-260
glycoprotein	O	261-273
,	O	273-274
von	B	275-278
Willebrand	I	279-289
factor	O	290-296
(	O	297-298
vWF	O	298-301
)	O	301-302
.	O	302-303

Molecular	O	304-313
studies	O	314-321
of	O	322-324
vWD	B	325-328
have	O	329-333
been	O	334-338
limited	O	339-346
by	O	347-349
the	O	350-353
large	O	354-359
size	O	360-364
of	O	365-367
the	O	368-371
vWF	O	372-375
gene	O	376-380
and	O	381-384
difficulty	O	385-395
in	O	396-398
obtaining	O	399-408
the	O	409-412
vWF	O	413-416
mRNA	O	417-421
from	O	422-426
patients	O	427-435
.	O	435-436

By	O	437-439
use	O	440-443
of	O	444-446
an	O	447-449
adaptation	O	450-460
of	O	461-463
the	O	464-467
polymerase	O	468-478
chain	O	479-484
reaction	O	485-493
,	O	493-494
vWF	O	495-498
mRNA	O	499-503
was	O	504-507
amplified	O	508-517
and	O	518-521
sequenced	O	522-531
from	O	532-536
peripheral	O	537-547
blood	O	548-553
platelets	O	554-563
.	O	563-564

A	O	565-566
silent	O	567-573
vWF	O	574-577
allele	O	578-584
was	O	585-588
identified	O	589-599
,	O	599-600
resulting	O	601-610
from	O	611-615
a	O	616-617
cis	O	618-621
defect	O	622-628
in	O	629-631
vWF	O	632-635
mRNA	O	636-640
transcription	O	641-654
or	O	655-657
processing	O	658-668
.	O	668-669

In	O	670-672
two	O	673-676
type	B	677-681
IIA	I	682-685
vWD	I	686-689
patients	O	690-698
,	O	698-699
two	O	700-703
different	O	704-713
but	O	714-717
adjacent	O	718-726
missense	O	727-735
mutations	O	736-745
were	O	746-750
identified	O	751-761
,	O	761-762
the	O	763-766
locations	O	767-776
of	O	777-779
which	O	780-785
may	O	786-789
identify	O	790-798
an	O	799-801
important	O	802-811
vWF	O	812-815
functional	O	816-826
domain	O	827-833
.	O	833-834

Expression	O	835-845
in	O	846-848
heterologous	O	849-861
cells	O	862-867
of	O	868-870
recombinant	O	871-882
vWF	O	883-886
containing	O	887-897
one	O	898-901
of	O	902-904
these	O	905-910
latter	O	911-917
mutations	O	918-927
reproduced	O	928-938
the	O	939-942
characteristic	O	943-957
structural	O	958-968
abnormality	O	969-980
seen	O	981-985
in	O	986-988
type	B	989-993
IIA	I	994-997
vWD	I	998-1001
plasma	O	1002-1008
.	O	1008-1009
.	O	1008-1009

A	O	0-1
transgene	O	2-11
insertion	O	12-21
creating	O	22-30
a	O	31-32
heritable	O	33-42
chromosome	O	43-53
deletion	O	54-62
mouse	O	63-68
model	O	69-74
of	O	75-77
Prader	B	78-84
-	I	84-85
Willi	I	85-90
and	I	91-94
angelman	I	95-103
syndromes	I	104-113
.	O	113-114

Prader	B	115-121
-	I	121-122
Willi	I	122-127
syndrome	I	128-136
(	O	137-138
PWS	B	138-141
)	O	141-142
and	O	143-146
Angelman	B	147-155
syndrome	I	156-164
(	O	165-166
AS	B	166-168
)	O	168-169
result	O	170-176
from	O	177-181
the	O	182-185
loss	O	186-190
of	O	191-193
function	O	194-202
of	O	203-205
imprinted	O	206-215
genes	O	216-221
in	O	222-224
human	O	225-230
chromosome	O	231-241
15q11	O	242-247
-	O	247-248
q13	O	248-251
.	O	251-252

The	O	253-256
central	O	257-264
part	O	265-269
of	O	270-272
mouse	O	273-278
chromosome	O	279-289
7	O	290-291
is	O	292-294
homologous	O	295-305
to	O	306-308
human	O	309-314
15q11	O	315-320
-	O	320-321
q13	O	321-324
,	O	324-325
with	O	326-330
conservation	O	331-343
of	O	344-346
both	O	347-351
gene	O	352-356
order	O	357-362
and	O	363-366
imprinted	O	367-376
features	O	377-385
.	O	385-386

We	O	387-389
report	O	390-396
here	O	397-401
the	O	402-405
characterization	O	406-422
of	O	423-425
a	O	426-427
transgene	O	428-437
insertion	O	438-447
(	O	448-449
Epstein	O	449-456
-	O	456-457
Barr	O	457-461
virus	O	462-467
Latent	O	468-474
Membrane	O	475-483
Protein	O	484-491
2A	O	492-494
,	O	494-495
LMP2A	O	496-501
)	O	501-502
into	O	503-507
mouse	O	508-513
chromosome	O	514-524
7C	O	525-527
,	O	527-528
which	O	529-534
has	O	535-538
resulted	O	539-547
in	O	548-550
mouse	O	551-556
models	O	557-563
for	O	564-567
PWS	B	568-571
and	O	572-575
AS	B	576-578
dependent	O	579-588
on	O	589-591
the	O	592-595
sex	O	596-599
of	O	600-602
the	O	603-606
transmitting	O	607-619
parent	O	620-626
.	O	626-627

Epigenotype	O	628-639
(	O	640-641
allelic	O	641-648
expression	O	649-659
and	O	660-663
DNA	O	664-667
methylation	O	668-679
)	O	679-680
and	O	681-684
fluorescence	O	685-697
in	O	698-700
situ	O	701-705
hybridization	O	706-719
analyses	O	720-728
indicate	O	729-737
that	O	738-742
the	O	743-746
transgene	O	747-756
-	O	756-757
induced	O	757-764
mutation	O	765-773
has	O	774-777
generated	O	778-787
a	O	788-789
complete	O	790-798
deletion	O	799-807
of	O	808-810
the	O	811-814
PWS	B	815-818
/	O	818-819
AS	B	819-821
-	O	821-822
homologous	O	822-832
region	O	833-839
but	O	840-843
has	O	844-847
not	O	848-851
deleted	O	852-859
flanking	O	860-868
loci	O	869-873
.	O	873-874

Because	O	875-882
the	O	883-886
intact	O	887-893
chromosome	O	894-904
7	O	905-906
,	O	906-907
opposite	O	908-916
the	O	917-920
deleted	O	921-928
homolog	O	929-936
,	O	936-937
maintains	O	938-947
the	O	948-951
correct	O	952-959
imprint	O	960-967
in	O	968-970
somatic	O	971-978
cells	O	979-984
of	O	985-987
PWS	B	988-991
and	O	992-995
AS	B	996-998
mice	O	999-1003
and	O	1004-1007
establishes	O	1008-1019
the	O	1020-1023
correct	O	1024-1031
imprint	O	1032-1039
in	O	1040-1042
male	O	1043-1047
and	O	1048-1051
female	O	1052-1058
germ	O	1059-1063
cells	O	1064-1069
of	O	1070-1072
AS	B	1073-1075
mice	O	1076-1080
,	O	1080-1081
homologous	O	1082-1092
association	O	1093-1104
and	O	1105-1108
replication	O	1109-1120
asynchrony	O	1121-1131
are	O	1132-1135
not	O	1136-1139
part	O	1140-1144
of	O	1145-1147
the	O	1148-1151
imprinting	O	1152-1162
mechanism	O	1163-1172
.	O	1172-1173

This	O	1174-1178
heritable	O	1179-1188
-	O	1188-1189
deletion	O	1189-1197
mouse	O	1198-1203
model	O	1204-1209
will	O	1210-1214
be	O	1215-1217
particularly	O	1218-1230
useful	O	1231-1237
for	O	1238-1241
the	O	1242-1245
identification	O	1246-1260
of	O	1261-1263
the	O	1264-1267
etiological	O	1268-1279
genes	O	1280-1285
and	O	1286-1289
mechanisms	O	1290-1300
,	O	1300-1301
phenotypic	O	1302-1312
basis	O	1313-1318
,	O	1318-1319
and	O	1320-1323
investigation	O	1324-1337
of	O	1338-1340
therapeutic	O	1341-1352
approaches	O	1353-1363
for	O	1364-1367
PWS	B	1368-1371
.	O	1371-1372
.	O	1371-1372

Transgenic	O	0-10
mice	O	11-15
expressing	O	16-26
a	O	27-28
truncated	O	29-38
form	O	39-43
of	O	44-46
the	O	47-50
high	O	51-55
mobility	O	56-64
group	O	65-70
I	O	71-72
-	O	72-73
C	O	73-74
protein	O	75-82
develop	O	83-90
adiposity	O	91-100
and	O	101-104
an	O	105-107
abnormally	O	108-118
high	O	119-123
prevalence	O	124-134
of	O	135-137
lipomas	B	138-145
.	O	145-146

Chromosomal	O	147-158
translocations	O	159-173
in	O	174-176
human	O	177-182
lipomas	B	183-190
frequently	O	191-201
create	O	202-208
fusion	O	209-215
transcripts	O	216-227
encoding	O	228-236
high	O	237-241
mobility	O	242-250
group	O	251-256
(	O	257-258
HMG	O	258-261
)	O	261-262
I	O	263-264
-	O	264-265
C	O	265-266
DNA	O	267-270
-	O	270-271
binding	O	271-278
domains	O	279-286
and	O	287-290
C	O	291-292
-	O	292-293
terminal	O	293-301
sequences	O	302-311
from	O	312-316
different	O	317-326
presumed	O	327-335
transcription	O	336-349
factors	O	350-357
,	O	357-358
suggesting	O	359-369
a	O	370-371
potential	O	372-381
role	O	382-386
for	O	387-390
HMG	O	391-394
I	O	395-396
-	O	396-397
C	O	397-398
in	O	399-401
the	O	402-405
development	O	406-417
of	O	418-420
lipomas	B	421-428
.	O	428-429

To	O	430-432
evaluate	O	433-441
the	O	442-445
role	O	446-450
of	O	451-453
the	O	454-457
HMG	O	458-461
I	O	462-463
-	O	463-464
C	O	464-465
component	O	466-475
,	O	475-476
the	O	477-480
three	O	481-486
DNA	O	487-490
-	O	490-491
binding	O	491-498
domains	O	499-506
of	O	507-509
HMG	O	510-513
I	O	514-515
-	O	515-516
C	O	516-517
have	O	518-522
now	O	523-526
been	O	527-531
expressed	O	532-541
in	O	542-544
transgenic	O	545-555
mice	O	556-560
.	O	560-561

Despite	O	562-569
the	O	570-573
ubiquitous	O	574-584
expression	O	585-595
of	O	596-598
the	O	599-602
truncated	O	603-612
HMG	O	613-616
I	O	617-618
-	O	618-619
C	O	619-620
protein	O	621-628
,	O	628-629
the	O	630-633
transgenic	O	634-644
mice	O	645-649
develop	O	650-657
a	O	658-659
selective	O	660-669
abundance	O	670-679
of	O	680-682
fat	O	683-686
tissue	O	687-693
early	O	694-699
in	O	700-702
life	O	703-707
,	O	707-708
show	O	709-713
marked	O	714-720
adipose	B	721-728
tissue	I	729-735
inflammation	I	736-748
,	O	748-749
and	O	750-753
have	O	754-758
an	O	759-761
abnormally	O	762-772
high	O	773-777
incidence	O	778-787
of	O	788-790
lipomas	B	791-798
.	O	798-799

These	O	800-805
findings	O	806-814
demonstrate	O	815-826
that	O	827-831
the	O	832-835
DNA	O	836-839
-	O	839-840
binding	O	840-847
domains	O	848-855
of	O	856-858
HMG	O	859-862
I	O	863-864
-	O	864-865
C	O	865-866
,	O	866-867
in	O	868-870
the	O	871-874
absence	O	875-882
of	O	883-885
a	O	886-887
C	O	888-889
-	O	889-890
terminal	O	890-898
fusion	O	899-905
partner	O	906-913
,	O	913-914
are	O	915-918
sufficient	O	919-929
to	O	930-932
perturb	O	933-940
adipogenesis	O	941-953
and	O	954-957
predispose	O	958-968
to	O	969-971
lipomas	B	972-979
.	O	979-980

We	O	981-983
provide	O	984-991
data	O	992-996
supporting	O	997-1007
the	O	1008-1011
central	O	1012-1019
utility	O	1020-1027
of	O	1028-1030
this	O	1031-1035
animal	O	1036-1042
model	O	1043-1048
as	O	1049-1051
a	O	1052-1053
tool	O	1054-1058
to	O	1059-1061
understand	O	1062-1072
the	O	1073-1076
molecular	O	1077-1086
mechanisms	O	1087-1097
underlying	O	1098-1108
the	O	1109-1112
development	O	1113-1124
of	O	1125-1127
one	O	1128-1131
of	O	1132-1134
the	O	1135-1138
most	O	1139-1143
common	O	1144-1150
kind	O	1151-1155
of	O	1156-1158
human	O	1159-1164
benign	B	1165-1171
tumors	I	1172-1178
.	O	1178-1179
.	O	1178-1179

A	O	0-1
common	O	2-8
MSH2	O	9-13
mutation	O	14-22
in	O	23-25
English	O	26-33
and	O	34-37
North	O	38-43
American	O	44-52
HNPCC	B	53-58
families	O	59-67
:	O	67-68
origin	O	69-75
,	O	75-76
phenotypic	O	77-87
expression	O	88-98
,	O	98-99
and	O	100-103
sex	O	104-107
specific	O	108-116
differences	O	117-128
in	O	129-131
colorectal	B	132-142
cancer	I	143-149
.	O	149-150

The	O	151-154
frequency	O	155-164
,	O	164-165
origin	O	166-172
,	O	172-173
and	O	174-177
phenotypic	O	178-188
expression	O	189-199
of	O	200-202
a	O	203-204
germline	O	205-213
MSH2	O	214-218
gene	O	219-223
mutation	O	224-232
previously	O	233-243
identified	O	244-254
in	O	255-257
seven	O	258-263
kindreds	O	264-272
with	O	273-277
hereditary	B	278-288
non	I	289-292
-	I	292-293
polyposis	I	293-302
cancer	I	303-309
syndrome	I	310-318
(	O	319-320
HNPCC	B	320-325
)	O	325-326
was	O	327-330
investigated	O	331-343
.	O	343-344

The	O	345-348
mutation	O	349-357
(	O	358-359
A	O	359-360
-	O	360-361
-	O	360-361
>	O	363-364
T	O	365-366
at	O	367-369
nt943	O	370-375
+	O	376-377
3	O	378-379
)	O	379-380
disrupts	O	381-389
the	O	390-393
3	O	394-395
splice	O	396-402
site	O	403-407
of	O	408-410
exon	O	411-415
5	O	416-417
leading	O	418-425
to	O	426-428
the	O	429-432
deletion	O	433-441
of	O	442-444
this	O	445-449
exon	O	450-454
from	O	455-459
MSH2	O	460-464
mRNA	O	465-469
and	O	470-473
represents	O	474-484
the	O	485-488
only	O	489-493
frequent	O	494-502
MSH2	O	503-507
mutation	O	508-516
so	O	517-519
far	O	520-523
reported	O	524-532
.	O	532-533

Although	O	534-542
this	O	543-547
mutation	O	548-556
was	O	557-560
initially	O	561-570
detected	O	571-579
in	O	580-582
four	O	583-587
of	O	588-590
33	O	591-593
colorectal	B	594-604
cancer	I	605-611
families	O	612-620
analysed	O	621-629
from	O	630-634
eastern	O	635-642
England	O	643-650
,	O	650-651
more	O	652-656
extensive	O	657-666
analysis	O	667-675
has	O	676-679
reduced	O	680-687
the	O	688-691
frequency	O	692-701
to	O	702-704
four	O	705-709
of	O	710-712
52	O	713-715
(	O	716-717
8	O	717-718
%	O	718-719
)	O	719-720
English	O	721-728
HNPCC	B	729-734
kindreds	O	735-743
analysed	O	744-752
.	O	752-753

In	O	754-756
contrast	O	757-765
,	O	765-766
the	O	767-770
MSH2	O	771-775
mutation	O	776-784
was	O	785-788
identified	O	789-799
in	O	800-802
10	O	803-805
of	O	806-808
20	O	809-811
(	O	812-813
50	O	813-815
%	O	815-816
)	O	816-817
separately	O	818-828
identified	O	829-839
colorectal	B	840-850
families	O	851-859
from	O	860-864
Newfoundland	O	865-877
.	O	877-878

To	O	879-881
investigate	O	882-893
the	O	894-897
origin	O	898-904
of	O	905-907
this	O	908-912
mutation	O	913-921
in	O	922-924
colorectal	B	925-935
cancer	I	936-942
families	O	943-951
from	O	952-956
England	O	957-964
(	O	965-966
n	O	966-967
=	O	968-969
4	O	970-971
)	O	971-972
,	O	972-973
Newfoundland	O	974-986
(	O	987-988
n	O	988-989
=	O	990-991
10	O	992-994
)	O	994-995
,	O	995-996
and	O	997-1000
the	O	1001-1004
United	O	1005-1011
States	O	1012-1018
(	O	1019-1020
n	O	1020-1021
=	O	1022-1023
3	O	1024-1025
)	O	1025-1026
,	O	1026-1027
haplotype	O	1028-1037
analysis	O	1038-1046
using	O	1047-1052
microsatellite	O	1053-1067
markers	O	1068-1075
linked	O	1076-1082
to	O	1083-1085
MSH2	O	1086-1090
was	O	1091-1094
performed	O	1095-1104
.	O	1104-1105

Within	O	1106-1112
the	O	1113-1116
English	O	1117-1124
and	O	1125-1128
US	O	1129-1131
families	O	1132-1140
there	O	1141-1146
was	O	1147-1150
little	O	1151-1157
evidence	O	1158-1166
for	O	1167-1170
a	O	1171-1172
recent	O	1173-1179
common	O	1180-1186
origin	O	1187-1193
of	O	1194-1196
the	O	1197-1200
MSH2	O	1201-1205
splice	O	1206-1212
site	O	1213-1217
mutation	O	1218-1226
in	O	1227-1229
most	O	1230-1234
families	O	1235-1243
.	O	1243-1244

In	O	1245-1247
contrast	O	1248-1256
,	O	1256-1257
a	O	1258-1259
common	O	1260-1266
haplotype	O	1267-1276
was	O	1277-1280
identified	O	1281-1291
at	O	1292-1294
the	O	1295-1298
two	O	1299-1302
flanking	O	1303-1311
markers	O	1312-1319
(	O	1320-1321
CA5	O	1321-1324
and	O	1325-1328
D2S288	O	1329-1335
)	O	1335-1336
in	O	1337-1339
eight	O	1340-1345
of	O	1346-1348
the	O	1349-1352
Newfoundland	O	1353-1365
families	O	1366-1374
.	O	1374-1375

These	O	1376-1381
findings	O	1382-1390
suggested	O	1391-1400
a	O	1401-1402
founder	O	1403-1410
effect	O	1411-1417
within	O	1418-1424
Newfoundland	O	1425-1437
similar	O	1438-1445
to	O	1446-1448
that	O	1449-1453
reported	O	1454-1462
by	O	1463-1465
others	O	1466-1472
for	O	1473-1476
two	O	1477-1480
MLH1	O	1481-1485
mutations	O	1486-1495
in	O	1496-1498
Finnish	O	1499-1506
HNPCC	B	1507-1512
families	O	1513-1521
.	O	1521-1522

We	O	1523-1525
calculated	O	1526-1536
age	O	1537-1540
related	O	1541-1548
risks	O	1549-1554
of	O	1555-1557
all	O	1558-1561
,	O	1561-1562
colorectal	B	1563-1573
,	I	1573-1574
endometrial	I	1575-1586
,	I	1586-1587
and	I	1588-1591
ovarian	I	1592-1599
cancers	I	1600-1607
in	O	1608-1610
nt943	O	1611-1616
+	O	1617-1618
3	O	1619-1620
A	O	1621-1622
-	O	1622-1623
-	O	1622-1623
>	O	1625-1626
T	O	1627-1628
MSH2	O	1629-1633
mutation	O	1634-1642
carriers	O	1643-1651
(	O	1652-1653
n	O	1653-1654
=	O	1655-1656
76	O	1657-1659
)	O	1659-1660
for	O	1661-1664
all	O	1665-1668
patients	O	1669-1677
and	O	1678-1681
for	O	1682-1685
men	O	1686-1689
and	O	1690-1693
women	O	1694-1699
separately	O	1700-1710
.	O	1710-1711

For	O	1712-1715
both	O	1716-1720
sexes	O	1721-1726
combined	O	1727-1735
,	O	1735-1736
the	O	1737-1740
penetrances	O	1741-1752
at	O	1753-1755
age	O	1756-1759
60	O	1760-1762
years	O	1763-1768
for	O	1769-1772
all	O	1773-1776
cancers	B	1777-1784
and	O	1786-1789
for	O	1790-1793
colorectal	B	1794-1804
cancer	I	1805-1811
were	O	1812-1816
0	O	1817-1818
.	O	1818-1819
86	O	1820-1822
and	O	1823-1826
0	O	1827-1828
.	O	1828-1829
57	O	1830-1832
,	O	1832-1833
respectively	O	1834-1846
.	O	1846-1847

The	O	1848-1851
risk	O	1852-1856
of	O	1857-1859
colorectal	B	1860-1870
cancer	I	1871-1877
was	O	1878-1881
significantly	O	1882-1895
higher	O	1896-1902
(	O	1903-1904
p	O	1904-1905
<	O	1906-1907
0	O	1908-1909
.	O	1909-1910
01	O	1911-1913
)	O	1913-1914
in	O	1915-1917
males	O	1918-1923
than	O	1924-1928
females	O	1929-1936
(	O	1937-1938
0	O	1938-1939
.	O	1939-1940
63	O	1941-1943
v	O	1944-1945
0	O	1946-1947
.	O	1947-1948
30	O	1949-1951
and	O	1952-1955
0	O	1956-1957
.	O	1957-1958
84	O	1959-1961
v	O	1962-1963
0	O	1964-1965
.	O	1965-1966
44	O	1967-1969
at	O	1970-1972
ages	O	1973-1977
50	O	1978-1980
and	O	1981-1984
60	O	1985-1987
years	O	1988-1993
,	O	1993-1994
respectively	O	1995-2007
)	O	2007-2008
.	O	2008-2009

For	O	2010-2013
females	O	2014-2021
there	O	2022-2027
was	O	2028-2031
a	O	2032-2033
high	O	2034-2038
risk	O	2039-2043
of	O	2044-2046
endometrial	B	2047-2058
cancer	I	2059-2065
(	O	2066-2067
0	O	2067-2068
.	O	2068-2069
5	O	2070-2071
at	O	2072-2074
age	O	2075-2078
60	O	2079-2081
years	O	2082-2087
)	O	2087-2088
and	O	2089-2092
premenopausal	B	2093-2106
ovarian	I	2107-2114
cancer	I	2115-2121
(	O	2122-2123
0	O	2123-2124
.	O	2124-2125
2	O	2126-2127
at	O	2128-2130
50	O	2131-2133
years	O	2134-2139
)	O	2139-2140
.	O	2140-2141

These	O	2142-2147
intersex	O	2148-2156
differences	O	2157-2168
in	O	2169-2171
colorectal	B	2172-2182
cancer	I	2183-2189
risks	O	2190-2195
have	O	2196-2200
implications	O	2201-2213
for	O	2214-2217
screening	O	2218-2227
programmes	O	2228-2238
and	O	2239-2242
for	O	2243-2246
attempts	O	2247-2255
to	O	2256-2258
identify	O	2259-2267
colorectal	B	2268-2278
cancer	I	2279-2285
susceptibility	O	2286-2300
modifiers	O	2301-2310
.	O	2310-2311

Novel	O	0-5
mutation	O	6-14
at	O	15-17
the	O	18-21
initiation	O	22-32
codon	O	33-38
in	O	39-41
the	O	42-45
Norrie	B	46-52
disease	I	53-60
gene	O	61-65
in	O	66-68
two	O	69-72
Japanese	O	73-81
families	O	82-90
.	O	90-91

We	O	92-94
have	O	95-99
identified	O	100-110
a	O	111-112
new	O	113-116
mutation	O	117-125
of	O	126-128
Norrie	B	129-135
disease	I	136-143
(	O	144-145
ND	B	145-147
)	O	147-148
gene	O	149-153
in	O	154-156
two	O	157-160
Japanese	O	161-169
males	O	170-175
from	O	176-180
unrelated	O	181-190
families	O	191-199
;	O	199-200
they	O	201-205
showed	O	206-212
typical	O	213-220
ocular	O	221-227
features	O	228-236
of	O	237-239
ND	B	240-242
but	O	243-246
no	O	247-249
mental	B	250-256
retardation	I	257-268
or	O	269-271
hearing	B	272-279
impairment	I	280-290
.	O	290-291

A	O	292-293
mutation	O	294-302
was	O	303-306
found	O	307-312
in	O	313-315
both	O	316-320
patients	O	321-329
at	O	330-332
the	O	333-336
initiation	O	337-347
codon	O	348-353
of	O	354-356
exon	O	357-361
2	O	362-363
of	O	364-366
the	O	367-370
ND	B	371-373
gene	O	374-378
(	O	379-380
ATG	O	380-383
to	O	384-386
GTG	O	387-390
)	O	390-391
,	O	391-392
with	O	393-397
otherwise	O	398-407
normal	O	408-414
nucleotide	O	415-425
sequences	O	426-435
.	O	435-436

Their	O	437-442
mothers	O	443-450
had	O	451-454
the	O	455-458
normal	O	459-465
and	O	466-469
mutant	O	470-476
types	O	477-482
of	O	483-485
the	O	486-489
gene	O	490-494
,	O	494-495
which	O	496-501
was	O	502-505
expected	O	506-514
for	O	515-518
heterozygotes	O	519-532
of	O	533-535
the	O	536-539
disease	O	540-547
.	O	547-548

The	O	549-552
mutation	O	553-561
of	O	562-564
the	O	565-568
initiation	O	569-579
codon	O	580-585
would	O	586-591
cause	O	592-597
the	O	598-601
failure	O	602-609
of	O	610-612
ND	B	613-615
gene	O	616-620
expression	O	621-631
or	O	632-634
a	O	635-636
defect	O	637-643
in	O	644-646
translation	O	647-658
thereby	O	659-666
truncating	O	667-677
the	O	678-681
amino	O	682-687
terminus	O	688-696
of	O	697-699
ND	B	700-702
protein	O	703-710
.	O	710-711

In	O	712-714
view	O	715-719
of	O	720-722
the	O	723-726
rarity	O	727-733
and	O	734-737
marked	O	738-744
heterogeneity	O	745-758
of	O	759-761
mutations	O	762-771
in	O	772-774
the	O	775-778
ND	B	779-781
gene	O	782-786
,	O	786-787
the	O	788-791
present	O	792-799
apparently	O	800-810
unrelated	O	811-820
Japanese	O	821-829
families	O	830-838
who	O	839-842
have	O	843-847
lived	O	848-853
in	O	854-856
the	O	857-860
same	O	861-865
area	O	866-870
for	O	871-874
over	O	875-879
two	O	880-883
centuries	O	884-893
presumably	O	894-904
share	O	905-910
the	O	911-914
origin	O	915-921
of	O	922-924
the	O	925-928
mutation	O	929-937
.	O	937-938
.	O	937-938

Haplotype	O	0-9
and	O	10-13
phenotype	O	14-23
analysis	O	24-32
of	O	33-35
six	O	36-39
recurrent	O	40-49
BRCA1	O	50-55
mutations	O	56-65
in	O	66-68
61	O	69-71
families	O	72-80
:	O	80-81
results	O	82-89
of	O	90-92
an	O	93-95
international	O	96-109
study	O	110-115
.	O	115-116

Several	O	117-124
BRCA1	O	125-130
mutations	O	131-140
have	O	141-145
now	O	146-149
been	O	150-154
found	O	155-160
to	O	161-163
occur	O	164-169
in	O	170-172
geographically	O	173-187
diverse	O	188-195
breast	B	196-202
and	I	203-206
ovarian	I	207-214
cancer	I	215-221
families	O	222-230
.	O	230-231

To	O	232-234
investigate	O	235-246
mutation	O	247-255
origin	O	256-262
and	O	263-266
mutation	O	267-275
-	O	275-276
specific	O	276-284
phenotypes	O	285-295
due	O	296-299
to	O	300-302
BRCA1	O	303-308
,	O	308-309
we	O	310-312
constructed	O	313-324
a	O	325-326
haplotype	O	327-336
of	O	337-339
nine	O	340-344
polymorphic	O	345-356
markers	O	357-364
within	O	365-371
or	O	372-374
immediately	O	375-386
flanking	O	387-395
the	O	396-399
BRCA1	O	400-405
locus	O	406-411
in	O	412-414
a	O	415-416
set	O	417-420
of	O	421-423
61	O	424-426
breast	B	427-433
/	I	433-434
ovarian	I	434-441
cancer	I	442-448
families	O	449-457
selected	O	458-466
for	O	467-470
having	O	471-477
one	O	478-481
of	O	482-484
six	O	485-488
recurrent	O	489-498
BRCA1	O	499-504
mutations	O	505-514
.	O	514-515

Tests	O	516-521
of	O	522-524
both	O	525-529
mutations	O	530-539
and	O	540-543
family	O	544-550
-	O	550-551
specific	O	551-559
differences	O	560-571
in	O	572-574
age	O	575-578
at	O	579-581
diagnosis	O	582-591
were	O	592-596
not	O	597-600
significant	O	601-612
.	O	612-613

A	O	614-615
comparison	O	616-626
of	O	627-629
the	O	630-633
six	O	634-637
mutations	O	638-647
in	O	648-650
the	O	651-654
relative	O	655-663
proportions	O	664-675
of	O	676-678
cases	O	679-684
of	O	685-687
breast	B	688-694
and	I	695-698
ovarian	I	699-706
cancer	I	707-713
was	O	714-717
suggestive	O	718-728
of	O	729-731
an	O	732-734
effect	O	735-741
(	O	742-743
P	O	743-744
=	O	745-746
.	O	746-747
069	O	748-751
)	O	751-752
,	O	752-753
with	O	754-758
57	O	759-761
%	O	761-762
of	O	763-765
women	O	766-771
presumed	O	772-780
affected	O	781-789
because	O	790-797
of	O	798-800
the	O	801-804
1294	O	805-809
del	O	810-813
40	O	814-816
BRCA1	O	817-822
mutation	O	823-831
having	O	832-838
ovarian	B	839-846
cancer	I	847-853
,	O	853-854
compared	O	855-863
with	O	864-868
14	O	869-871
%	O	871-872
of	O	873-875
affected	O	876-884
women	O	885-890
with	O	891-895
the	O	896-899
splice	O	900-906
-	O	906-907
site	O	907-911
mutation	O	912-920
in	O	921-923
intron	O	924-930
5	O	931-932
of	O	933-935
BRCA1	O	936-941
.	O	941-942

For	O	943-946
the	O	947-950
BRCA1	O	951-956
mutations	O	957-966
studied	O	967-974
here	O	975-979
,	O	979-980
the	O	981-984
individual	O	985-995
mutations	O	996-1005
are	O	1006-1009
estimated	O	1010-1019
to	O	1020-1022
have	O	1023-1027
arisen	O	1028-1034
9	O	1035-1036
-	O	1036-1037
170	O	1037-1040
generations	O	1041-1052
ago	O	1053-1056
.	O	1056-1057

In	O	1058-1060
general	O	1061-1068
,	O	1068-1069
a	O	1070-1071
high	O	1072-1076
degree	O	1077-1083
of	O	1084-1086
haplotype	O	1087-1096
conservation	O	1097-1109
across	O	1110-1116
the	O	1117-1120
region	O	1121-1127
was	O	1128-1131
observed	O	1132-1140
,	O	1140-1141
with	O	1142-1146
haplotype	O	1147-1156
differences	O	1157-1168
most	O	1169-1173
often	O	1174-1179
due	O	1180-1183
to	O	1184-1186
mutations	O	1187-1196
in	O	1197-1199
the	O	1200-1203
short	O	1204-1209
-	O	1209-1210
tandem	O	1210-1216
-	O	1209-1210
repeat	O	1217-1223
markers	O	1224-1231
,	O	1231-1232
although	O	1233-1241
some	O	1242-1246
likely	O	1247-1253
instances	O	1254-1263
of	O	1264-1266
recombination	O	1267-1280
also	O	1281-1285
were	O	1286-1290
observed	O	1291-1299
.	O	1299-1300

For	O	1301-1304
several	O	1305-1312
of	O	1313-1315
the	O	1316-1319
instances	O	1320-1329
,	O	1329-1330
there	O	1331-1336
was	O	1337-1340
evidence	O	1341-1349
for	O	1350-1353
multiple	O	1354-1362
,	O	1362-1363
independent	O	1364-1375
,	O	1375-1376
BRCA1	O	1377-1382
mutational	O	1383-1393
events	O	1394-1400
.	O	1400-1401

A	O	0-1
new	O	2-5
glucose	O	6-13
-	O	13-14
6	O	14-15
-	O	13-14
phosphate	O	16-25
dehydrogenase	O	26-39
variant	O	40-47
(	O	48-49
G6PD	O	49-53
Nagano	O	54-60
)	O	60-61
associated	O	62-72
with	O	73-77
congenital	B	78-88
hemolytic	I	89-98
anemia	I	99-105
.	O	105-106

A	O	107-108
new	O	109-112
glucose	O	113-120
-	O	120-121
6	O	121-122
-	O	120-121
phosphate	O	123-132
dehydrogenase	O	133-146
(	O	147-148
G6PD	O	148-152
)	O	152-153
variant	O	154-161
associated	O	162-172
with	O	173-177
chronic	B	178-185
nonspherocytic	I	186-200
hemolytic	I	201-210
anemia	I	211-217
was	O	218-221
reported	O	222-230
.	O	230-231

The	O	232-235
patient	O	236-243
,	O	243-244
a	O	245-246
6	O	247-248
-	O	248-249
year	O	249-253
-	O	248-249
old	O	254-257
Japanese	O	258-266
male	O	267-271
,	O	271-272
was	O	273-276
noticed	O	277-284
to	O	285-287
have	O	288-292
hemolytic	B	293-302
anemia	I	303-309
soon	O	310-314
after	O	315-320
birth	O	321-326
,	O	326-327
and	O	328-331
a	O	332-333
diagnosis	O	334-343
of	O	344-346
G6PD	B	347-351
deficiency	I	352-362
was	O	363-366
made	O	367-371
at	O	372-374
the	O	375-378
age	O	379-382
of	O	383-385
2	O	386-387
.	O	387-388
He	O	389-391
had	O	392-395
episodes	O	396-404
of	O	405-407
hemolytic	B	408-417
crisis	I	418-424
several	O	425-432
times	O	433-438
after	O	439-444
upper	B	445-450
respiratory	I	451-462
infection	I	463-472
.	O	472-473

G6PD	O	474-478
activity	O	479-487
of	O	488-490
the	O	491-494
patient	O	495-502
was	O	503-506
5	O	507-508
.	O	508-509
5	O	510-511
%	O	511-512
of	O	513-515
normal	O	516-522
.	O	522-523

The	O	524-527
enzymatic	O	528-537
characteristics	O	538-553
were	O	554-558
examined	O	559-567
when	O	568-572
he	O	573-575
was	O	576-579
5	O	580-581
years	O	582-587
old	O	588-591
,	O	591-592
and	O	593-596
his	O	597-600
G6PD	O	601-605
showed	O	606-612
faster	O	613-619
-	O	619-620
than	O	620-624
-	O	619-620
normal	O	625-631
electrophoretic	O	632-647
mobility	O	648-656
,	O	656-657
low	O	658-661
Km	O	662-664
G6P	O	665-668
,	O	668-669
high	O	670-674
Km	O	675-677
NADP	O	678-682
,	O	682-683
low	O	684-687
Ki	O	688-690
NADPH	O	691-696
,	O	696-697
normal	O	698-704
utilization	O	705-716
of	O	717-719
substrate	O	720-729
analogues	O	730-739
,	O	739-740
heat	O	741-745
instability	O	746-757
,	O	757-758
and	O	759-762
a	O	763-764
normal	O	765-771
pH	O	772-774
optimum	O	775-782
curve	O	783-788
.	O	788-789

From	O	790-794
these	O	795-800
results	O	801-808
,	O	808-809
this	O	810-814
was	O	815-818
considered	O	819-829
to	O	830-832
be	O	833-835
a	O	836-837
new	O	838-841
variant	O	842-849
and	O	850-853
was	O	854-857
designated	O	858-868
G6PD	O	869-873
Nagano	O	874-880
.	O	880-881

Infection	O	882-891
-	O	891-892
induced	O	892-899
hemolysis	B	900-909
and	O	910-913
chronic	B	914-921
hemolytic	I	922-931
anemia	I	932-938
seem	O	939-943
to	O	944-946
be	O	947-949
due	O	950-953
to	O	954-956
markedly	O	957-965
impaired	O	966-974
enzyme	O	975-981
activity	O	982-990
and	O	991-994
thermal	O	995-1002
instability	O	1003-1014
.	O	1014-1015

Craniofrontonasal	B	0-17
dysplasia	I	18-27
.	O	27-28

We	O	29-31
report	O	32-38
on	O	39-41
nine	O	42-46
patients	O	47-55
with	O	56-60
craniofrontonasal	B	61-78
dysplasia	I	79-88
(	O	89-90
CFND	B	90-94
)	O	94-95
.	O	95-96

Seven	O	97-102
classical	O	103-112
cases	O	113-118
had	O	119-122
facial	O	123-129
features	O	130-138
suggestive	O	139-149
of	O	150-152
frontonasal	B	153-164
dysplasia	I	165-174
and	O	175-178
coronal	B	179-186
craniosynostosis	I	187-203
.	O	203-204

Extracranial	B	205-217
abnormalities	I	218-231
such	O	232-236
as	O	237-239
brittle	B	240-247
nails	I	248-253
with	I	254-258
prominent	I	259-268
longitudinal	I	269-281
grooves	I	282-289
or	O	290-292
syndactyly	B	293-303
of	I	304-306
fingers	I	307-314
and	I	315-318
toes	I	319-323
were	O	324-328
observed	O	329-337
in	O	338-340
individual	O	341-351
patients	O	352-360
.	O	360-361

In	O	362-364
two	O	365-368
families	O	369-377
the	O	378-381
father	O	382-388
of	O	389-391
classical	O	392-401
cases	O	402-407
showed	O	408-414
a	O	415-416
milder	O	417-423
pattern	O	424-431
of	O	432-434
abnormalities	O	435-448
,	O	448-449
consistent	O	450-460
with	O	461-465
the	O	466-469
diagnosis	O	470-479
.	O	479-480

We	O	481-483
present	O	484-491
a	O	492-493
2	O	494-495
-	O	495-496
to	O	497-499
13	O	500-502
-	O	502-503
year	O	503-507
follow	O	508-514
-	O	514-515
up	O	515-517
on	O	518-520
our	O	521-524
patients	O	525-533
.	O	533-534

Hypotonia	B	535-544
and	O	545-548
laxity	B	549-555
of	I	556-558
joints	I	559-565
are	O	566-569
common	O	570-576
and	O	577-580
may	O	581-584
necessitate	O	585-596
supportive	O	597-607
measures	O	608-616
.	O	616-617

Mild	O	618-622
developmental	B	623-636
delay	I	637-642
was	O	643-646
noted	O	647-652
in	O	653-655
three	O	656-661
out	O	662-665
of	O	666-668
six	O	669-672
classical	O	673-682
cases	O	683-688
studied	O	689-696
in	O	697-699
detail	O	700-706
.	O	706-707

Unlike	O	708-714
almost	O	715-721
all	O	722-725
other	O	726-731
X	B	732-733
-	I	733-734
linked	I	734-740
disorders	I	741-750
,	O	750-751
clinical	O	752-760
expression	O	761-771
in	O	772-774
CFND	B	775-779
is	O	780-782
generally	O	783-792
much	O	793-797
more	O	798-802
severe	O	803-809
in	O	810-812
females	O	813-820
than	O	821-825
in	O	826-828
males	O	829-834
.	O	834-835

In	O	836-838
contrast	O	839-847
to	O	848-850
previous	O	851-859
reports	O	860-867
of	O	868-870
this	O	871-875
condition	O	876-885
,	O	885-886
one	O	887-890
of	O	891-893
our	O	894-897
severely	O	898-906
affected	O	907-915
cases	O	916-921
is	O	922-924
a	O	925-926
male	O	927-931
.	O	931-932
.	O	931-932

A	O	0-1
new	O	2-5
mutation	O	6-14
in	O	15-17
the	O	18-21
proteolipid	O	22-33
protein	O	34-41
(	O	42-43
PLP	O	43-46
)	O	46-47
gene	O	48-52
in	O	53-55
a	O	56-57
German	O	58-64
family	O	65-71
with	O	72-76
Pelizaeus	B	77-86
-	I	86-87
Merzbacher	I	87-97
disease	I	98-105
.	O	105-106

A	O	107-108
C	O	109-110
-	O	110-111
to	O	111-113
-	O	110-111
T	O	114-115
transition	O	116-126
in	O	127-129
exon	O	130-134
4	O	135-136
of	O	137-139
the	O	140-143
PLP	O	144-147
gene	O	148-152
was	O	153-156
found	O	157-162
in	O	163-165
2	O	166-167
affected	O	168-176
males	O	177-182
and	O	183-186
two	O	187-190
obligate	O	191-199
carriers	O	200-208
in	O	209-211
a	O	212-213
German	O	214-220
family	O	221-227
with	O	228-232
Pelizaeus	B	233-242
-	I	242-243
Merzbacher	I	243-253
disease	I	254-261
.	O	261-262

The	O	263-266
mutation	O	267-275
,	O	275-276
which	O	277-282
causes	O	283-289
loss	O	290-294
of	O	295-297
an	O	298-300
HphI	O	301-305
site	O	306-310
and	O	311-314
changes	O	315-322
amino	O	323-328
acid	O	329-333
155	O	334-337
from	O	338-342
threonine	O	343-352
to	O	353-355
isoleucine	O	356-366
,	O	366-367
was	O	368-371
absent	O	372-378
from	O	379-383
108	O	384-387
normal	O	388-394
chromosomes	O	395-406
.	O	406-407

There	O	408-413
are	O	414-417
5	O	418-419
concordances	O	420-432
and	O	433-436
1	O	437-438
discrepancy	O	439-450
between	O	451-458
these	O	459-464
results	O	465-472
and	O	473-476
those	O	477-482
obtained	O	483-491
by	O	492-494
magnetic	O	495-503
resonance	O	504-513
imaging	O	514-521
in	O	522-524
this	O	525-529
family	O	530-536
.	O	536-537
.	O	536-537

The	O	0-3
Wiskott	B	4-11
-	I	11-12
Aldrich	I	12-19
syndrome	I	20-28
and	O	29-32
X	B	33-34
-	I	34-35
linked	I	35-41
congenital	I	42-52
thrombocytopenia	I	53-69
are	O	70-73
caused	O	74-80
by	O	81-83
mutations	O	84-93
of	O	94-96
the	O	97-100
same	O	101-105
gene	O	106-110
.	O	110-111

The	O	112-115
Wiskott	B	116-123
-	I	123-124
Aldrich	I	124-131
syndrome	I	132-140
(	O	141-142
WAS	B	142-145
)	O	145-146
is	O	147-149
an	O	150-152
X	B	153-154
-	I	154-155
linked	I	155-161
recessive	I	162-171
disorder	I	172-180
characterized	O	181-194
by	O	195-197
thrombocytopenia	B	198-214
,	O	214-215
small	O	216-221
platelets	O	222-231
,	O	231-232
eczema	B	233-239
,	O	239-240
recurrent	O	241-250
infections	O	251-261
,	O	261-262
and	O	263-266
immunodeficiency	B	267-283
.	O	283-284

Besides	O	285-292
the	O	293-296
classic	O	297-304
WAS	B	305-308
phenotype	O	309-318
,	O	318-319
there	O	320-325
is	O	326-328
a	O	329-330
group	O	331-336
of	O	337-339
patients	O	340-348
with	O	349-353
congenital	B	354-364
X	I	365-366
-	I	366-367
linked	I	367-373
thrombocytopenia	I	374-390
(	O	391-392
XLT	B	392-395
)	O	395-396
who	O	397-400
have	O	401-405
small	O	406-411
platelets	O	412-421
but	O	422-425
only	O	426-430
transient	O	431-440
eczema	B	441-447
,	O	447-448
if	O	449-451
any	O	452-455
,	O	455-456
and	O	457-460
minimal	O	461-468
immune	B	469-475
deficiency	I	476-486
.	O	486-487

Because	O	488-495
the	O	496-499
gene	O	500-504
responsible	O	505-516
for	O	517-520
WAS	B	521-524
has	O	525-528
been	O	529-533
sequenced	O	534-543
,	O	543-544
it	O	545-547
was	O	548-551
possible	O	552-560
to	O	561-563
correlate	O	564-573
the	O	574-577
WAS	B	578-581
phenotypes	O	582-592
with	O	593-597
WAS	B	598-601
gene	O	602-606
mutations	O	607-616
.	O	616-617

Using	O	618-623
a	O	624-625
fingerprinting	O	626-640
screening	O	641-650
technique	O	651-660
,	O	660-661
we	O	662-664
determined	O	665-675
the	O	676-679
approximate	O	680-691
location	O	692-700
of	O	701-703
the	O	704-707
mutation	O	708-716
in	O	717-719
13	O	720-722
unrelated	O	723-732
WAS	B	733-736
patients	O	737-745
with	O	746-750
mild	O	751-755
to	O	756-758
severe	O	759-765
clinical	O	766-774
symptoms	O	775-783
.	O	783-784

Direct	O	785-791
sequence	O	792-800
analysis	O	801-809
of	O	810-812
cDNA	O	813-817
and	O	818-821
genomic	O	822-829
DNA	O	830-833
obtained	O	834-842
from	O	843-847
patient	O	848-855
-	O	855-856
derived	O	856-863
cell	O	864-868
lines	O	869-874
showed	O	875-881
12	O	882-884
unique	O	885-891
mutations	O	892-901
distributed	O	902-913
throughout	O	914-924
the	O	925-928
WAS	B	929-932
gene	O	933-937
,	O	937-938
including	O	939-948
insertions	O	949-959
,	O	959-960
deletions	O	961-970
,	O	970-971
and	O	972-975
point	O	976-981
mutations	O	982-991
resulting	O	992-1001
in	O	1002-1004
amino	O	1005-1010
acid	O	1011-1015
substitutions	O	1016-1029
,	O	1029-1030
termination	O	1031-1042
,	O	1042-1043
exon	O	1044-1048
skipping	O	1049-1057
,	O	1057-1058
or	O	1059-1061
splicing	O	1062-1070
defects	O	1071-1078
.	O	1078-1079

Of	O	1080-1082
4	O	1083-1084
unrelated	O	1085-1094
patients	O	1095-1103
with	O	1104-1108
the	O	1109-1112
XLT	B	1113-1116
phenotype	O	1117-1126
,	O	1126-1127
3	O	1128-1129
had	O	1130-1133
missense	O	1134-1142
mutations	O	1143-1152
affecting	O	1153-1162
exon	O	1163-1167
2	O	1168-1169
and	O	1170-1173
1	O	1174-1175
had	O	1176-1179
a	O	1180-1181
splice	O	1182-1188
-	O	1188-1189
site	O	1189-1193
mutation	O	1194-1202
affecting	O	1203-1212
exon	O	1213-1217
9	O	1218-1219
.	O	1219-1220
Patients	O	1221-1229
with	O	1230-1234
classic	O	1235-1242
WAS	B	1243-1246
had	O	1247-1250
more	O	1251-1255
complex	O	1256-1263
mutations	O	1264-1273
,	O	1273-1274
resulting	O	1275-1284
in	O	1285-1287
termination	O	1288-1299
codons	O	1300-1306
,	O	1306-1307
frameshift	O	1308-1318
,	O	1318-1319
and	O	1320-1323
early	O	1324-1329
termination	O	1330-1341
.	O	1341-1342

These	O	1343-1348
findings	O	1349-1357
provide	O	1358-1365
direct	O	1366-1372
evidence	O	1373-1381
that	O	1382-1386
XLT	B	1387-1390
and	O	1391-1394
WAS	B	1395-1398
are	O	1399-1402
caused	O	1403-1409
by	O	1410-1412
mutations	O	1413-1422
of	O	1423-1425
the	O	1426-1429
same	O	1430-1434
gene	O	1435-1439
and	O	1440-1443
suggest	O	1444-1451
that	O	1452-1456
severe	O	1457-1463
clinical	O	1464-1472
phenotypes	O	1473-1483
are	O	1484-1487
associated	O	1488-1498
with	O	1499-1503
complex	O	1504-1511
mutations	O	1512-1521
.	O	1521-1522
.	O	1521-1522

A	O	0-1
3	O	2-3
-	O	3-4
base	O	4-8
pair	O	9-13
in	O	14-16
-	O	16-17
frame	O	17-22
deletion	O	23-31
of	O	32-34
the	O	35-38
phenylalanine	O	39-52
hydroxylase	O	53-64
gene	O	65-69
results	O	70-77
in	O	78-80
a	O	81-82
kinetic	O	83-90
variant	O	91-98
of	O	99-101
phenylketonuria	B	102-117
.	O	117-118

Phenylketonuria	B	119-134
(	O	135-136
PKU	B	136-139
)	O	139-140
is	O	141-143
an	O	144-146
autosomal	B	147-156
recessive	I	157-166
disease	I	167-174
due	O	175-178
to	O	179-181
deficiency	B	182-192
of	I	193-195
a	I	196-197
hepatic	I	198-205
enzyme	I	206-212
,	I	212-213
phenylalanine	I	214-227
hydroxylase	I	228-239
(	O	240-241
PAH	O	241-244
)	O	244-245
.	O	245-246

The	O	247-250
absence	O	251-258
of	O	259-261
PAH	O	262-265
activity	O	266-274
results	O	275-282
in	O	283-285
typical	O	286-293
PKU	B	294-297
while	O	298-303
persistence	O	304-315
of	O	316-318
a	O	319-320
residual	O	321-329
enzyme	O	330-336
activity	O	337-345
gives	O	346-351
rise	O	352-356
to	O	357-359
variant	O	360-367
forms	O	368-373
of	O	374-376
the	O	377-380
disease	O	381-388
.	O	388-389

We	O	390-392
report	O	393-399
here	O	400-404
a	O	405-406
3	O	407-408
-	O	408-409
base	O	409-413
pair	O	414-418
in	O	419-421
-	O	421-422
frame	O	422-427
deletion	O	428-436
of	O	437-439
the	O	440-443
PAH	O	444-447
gene	O	448-452
(	O	453-454
delta	O	454-459
194	O	460-463
)	O	463-464
in	O	465-467
a	O	468-469
mild	O	470-474
variant	O	475-482
,	O	482-483
with	O	484-488
markedly	O	489-497
reduced	O	498-505
affinity	O	506-514
of	O	515-517
the	O	518-521
enzyme	O	522-528
for	O	529-532
phenylalanine	O	533-546
(	O	547-548
Km	O	548-550
=	O	551-552
160	O	553-556
nM	O	557-559
)	O	559-560
,	O	560-561
and	O	562-565
we	O	566-568
provide	O	569-576
functional	O	577-587
evidence	O	588-596
for	O	597-600
responsibility	O	601-615
of	O	616-618
the	O	619-622
deletion	O	623-631
in	O	632-634
the	O	635-638
mutant	O	639-645
phenotype	O	646-655
.	O	655-656

Since	O	657-662
the	O	663-666
deletion	O	667-675
was	O	676-679
located	O	680-687
in	O	688-690
the	O	691-694
third	O	695-700
exon	O	701-705
of	O	706-708
the	O	709-712
gene	O	713-717
,	O	717-718
which	O	719-724
presents	O	725-733
no	O	734-736
homology	O	737-745
with	O	746-750
other	O	751-756
hydroxylases	O	757-769
,	O	769-770
we	O	771-773
suggest	O	774-781
that	O	782-786
exon	O	787-791
3	O	792-793
is	O	794-796
involved	O	797-805
in	O	806-808
the	O	809-812
specificity	O	813-824
of	O	825-827
the	O	828-831
enzyme	O	832-838
for	O	839-842
phenylalanine	O	843-856
.	O	856-857

Finally	O	858-865
,	O	865-866
since	O	867-872
none	O	873-877
of	O	878-880
the	O	881-884
98	O	885-887
PKU	B	888-891
patients	O	892-900
tested	O	901-907
were	O	908-912
found	O	913-918
to	O	919-921
carry	O	922-927
this	O	928-932
particular	O	933-943
deletion	O	944-952
,	O	952-953
our	O	954-957
study	O	958-963
suggests	O	964-972
that	O	973-977
this	O	978-982
molecular	O	983-992
event	O	993-998
probably	O	999-1007
occurred	O	1008-1016
recently	O	1017-1025
on	O	1026-1028
the	O	1029-1032
background	O	1033-1043
of	O	1044-1046
a	O	1047-1048
haplotype	O	1049-1058
2	O	1059-1060
gene	O	1061-1065
in	O	1066-1068
Portugal	O	1069-1077
.	O	1077-1078
.	O	1077-1078

Friedreich	B	0-10
ataxia	I	11-17
:	O	17-18
an	O	19-21
overview	O	22-30
.	O	30-31

Friedreich	B	32-42
ataxia	I	43-49
,	O	49-50
an	O	51-53
autosomal	B	54-63
recessive	I	64-73
neurodegenerative	I	74-91
disease	I	92-99
,	O	99-100
is	O	101-103
the	O	104-107
most	O	108-112
common	O	113-119
of	O	120-122
the	O	123-126
inherited	B	127-136
ataxias	I	137-144
.	O	144-145

The	O	146-149
recent	O	150-156
discovery	O	157-166
of	O	167-169
the	O	170-173
gene	O	174-178
that	O	179-183
is	O	184-186
mutated	O	187-194
in	O	195-197
this	O	198-202
condition	O	203-212
,	O	212-213
FRDA	O	214-218
,	O	218-219
has	O	220-223
led	O	224-227
to	O	228-230
rapid	O	231-236
advances	O	237-245
in	O	246-248
the	O	249-252
understanding	O	253-266
of	O	267-269
the	O	270-273
pathogenesis	O	274-286
of	O	287-289
Friedreich	B	290-300
ataxia	I	301-307
.	O	307-308

About	O	309-314
98	O	315-317
%	O	317-318
of	O	319-321
mutant	O	322-328
alleles	O	329-336
have	O	337-341
an	O	342-344
expansion	O	345-354
of	O	355-357
a	O	358-359
GAA	O	360-363
trinucleotide	O	364-377
repeat	O	378-384
in	O	385-387
intron	O	388-394
1	O	395-396
of	O	397-399
the	O	400-403
gene	O	404-408
.	O	408-409

This	O	410-414
leads	O	415-420
to	O	421-423
reduced	O	424-431
levels	O	432-438
of	O	439-441
the	O	442-445
protein	O	446-453
,	O	453-454
frataxin	O	455-463
.	O	463-464

There	O	465-470
is	O	471-473
mounting	O	474-482
evidence	O	483-491
to	O	492-494
suggest	O	495-502
that	O	503-507
Friedreich	B	508-518
ataxia	I	519-525
is	O	526-528
the	O	529-532
result	O	533-539
of	O	540-542
accumulation	O	543-555
of	O	556-558
iron	O	559-563
in	O	564-566
mitochondria	O	567-579
leading	O	580-587
to	O	588-590
excess	O	591-597
production	O	598-608
of	O	609-611
free	O	612-616
radicals	O	617-625
,	O	625-626
which	O	627-632
then	O	633-637
results	O	638-645
in	O	646-648
cellular	O	649-657
damage	O	658-664
and	O	665-668
death	O	669-674
.	O	674-675

Currently	O	676-685
there	O	686-691
is	O	692-694
no	O	695-697
known	O	698-703
treatment	O	704-713
that	O	714-718
alters	O	719-725
the	O	726-729
natural	O	730-737
course	O	738-744
of	O	745-747
the	O	748-751
disease	O	752-759
.	O	759-760

The	O	761-764
discovery	O	765-774
of	O	775-777
the	O	778-781
FRDA	B	782-786
gene	O	787-791
and	O	792-795
its	O	796-799
possible	O	800-808
function	O	809-817
has	O	818-821
raised	O	822-828
hope	O	829-833
that	O	834-838
rational	O	839-847
therapeutic	O	848-859
strategies	O	860-870
will	O	871-875
be	O	876-878
developed	O	879-888
.	O	888-889
.	O	888-889

Clinical	O	0-8
and	O	9-12
molecular	O	13-22
genetics	O	23-31
of	O	32-34
primary	B	35-42
dystonias	I	43-52
.	O	52-53

Primary	B	54-61
dystonias	I	62-71
are	O	72-75
movement	B	76-84
disorders	I	85-94
with	O	95-99
dystonia	B	100-108
as	O	109-111
a	O	112-113
major	O	114-119
symptom	O	120-127
.	O	127-128

They	O	129-133
are	O	134-137
frequently	O	138-148
inherited	O	149-158
as	O	159-161
Mendelian	O	162-171
traits	O	172-178
.	O	178-179

There	O	180-185
are	O	186-189
at	O	190-192
least	O	193-198
eight	O	199-204
clinically	O	205-215
distinct	O	216-224
autosomal	O	225-234
dominant	O	235-243
and	O	244-247
two	O	248-251
X	O	252-253
-	O	253-254
linked	O	254-260
recessive	O	261-270
forms	O	271-276
.	O	276-277

In	O	278-280
addition	O	281-289
,	O	289-290
pedigree	O	291-299
analyses	O	300-308
suggest	O	309-316
the	O	317-320
occurrence	O	321-331
of	O	332-334
an	O	335-337
autosomal	O	338-347
recessive	O	348-357
variant	O	358-365
.	O	365-366

The	O	367-370
clinical	O	371-379
classification	O	380-394
is	O	395-397
increasingly	O	398-410
being	O	411-416
replaced	O	417-425
by	O	426-428
a	O	429-430
genetic	O	431-438
one	O	439-442
.	O	442-443

To	O	444-446
date	O	447-451
gene	O	452-456
loci	O	457-461
have	O	462-466
been	O	467-471
identified	O	472-482
in	O	483-485
at	O	486-488
least	O	489-494
six	O	495-498
autosomal	O	499-508
dominant	O	509-517
forms	O	518-523
,	O	523-524
i	O	525-526
.	O	526-527
e	O	528-529
.	O	529-530
,	O	530-531
in	O	532-534
idiopathic	B	535-545
torsion	I	546-553
dystonia	I	554-562
(	O	563-564
9q34	O	564-568
)	O	568-569
,	O	569-570
focal	B	571-576
dystonia	I	577-585
(	O	586-587
18p	O	587-590
)	O	590-591
,	O	591-592
adult	O	593-598
-	O	598-599
onset	O	599-604
idiopathic	B	605-615
torsion	I	616-623
dystonia	I	624-632
of	O	633-635
mixed	O	636-641
type	O	642-646
(	O	647-648
8p21	O	648-652
-	O	652-653
q22	O	653-656
)	O	656-657
,	O	657-658
dopa	B	659-663
-	I	663-664
responsive	I	664-674
dystonia	I	675-683
(	O	684-685
14q22	O	685-690
.	O	690-691

1	O	692-693
-	O	693-694
q22	O	694-697
.	O	697-698

2	O	699-700
)	O	700-701
,	O	701-702
and	O	703-706
paroxysmal	B	707-717
dystonic	I	718-726
choreoathetosis	I	727-742
(	O	743-744
2q25	O	744-748
-	O	748-749
q33	O	749-752
;	O	752-753
1p21	O	754-758
-	O	758-759
p13	O	759-762
.	O	762-763

3	O	764-765
)	O	765-766
.	O	766-767

Gene	O	768-772
loci	O	773-777
in	O	778-780
the	O	781-784
X	O	785-786
-	O	786-787
linked	O	787-793
recessive	O	794-803
forms	O	805-810
have	O	811-815
been	O	816-820
assigned	O	821-829
to	O	830-832
Xq13	O	833-837
.	O	837-838
1	O	839-840
in	O	841-843
the	O	844-847
X	B	848-849
-	I	849-850
linked	I	850-856
dystonia	I	857-865
parkinsonism	I	866-878
syndrome	I	879-887
and	O	888-891
to	O	892-894
Xq22	O	895-899
in	O	900-902
X	B	903-904
-	I	904-905
linked	I	905-911
sensorineural	I	912-925
deafness	I	926-934
,	O	934-935
dystonia	B	936-944
,	O	944-945
and	O	946-949
mental	B	950-956
retardation	I	957-968
.	O	968-969

The	O	970-973
disease	O	974-981
genes	O	982-987
have	O	988-992
been	O	993-997
identified	O	998-1008
in	O	1009-1011
two	O	1012-1015
autosomal	O	1016-1025
dominant	O	1026-1034
forms	O	1035-1040
and	O	1041-1044
in	O	1045-1047
one	O	1048-1051
X	O	1052-1053
-	O	1053-1054
linked	O	1054-1060
recessive	O	1061-1070
form	O	1071-1075
.	O	1075-1076

Mutations	O	1077-1086
in	O	1087-1089
a	O	1090-1091
gene	O	1092-1096
coding	O	1097-1103
for	O	1104-1107
an	O	1108-1110
ATP	O	1111-1114
-	O	1114-1115
binding	O	1115-1122
protein	O	1123-1130
were	O	1131-1135
detected	O	1136-1144
in	O	1145-1147
idiopathic	B	1148-1158
torsion	I	1159-1166
dystonia	I	1167-1175
(	O	1176-1177
DYT1	O	1177-1181
)	O	1181-1182
,	O	1182-1183
and	O	1184-1187
the	O	1188-1191
GTP	O	1192-1195
cyclohydrolase	O	1196-1210
1	O	1211-1212
gene	O	1213-1217
is	O	1218-1220
mutated	O	1221-1228
in	O	1229-1231
dopa	B	1232-1236
-	I	1236-1237
responsive	I	1237-1247
dystonia	I	1248-1256
(	O	1257-1258
DYT5	O	1258-1262
)	O	1262-1263
.	O	1263-1264

In	O	1265-1267
sensorineural	B	1268-1281
deafness	I	1282-1290
,	O	1290-1291
dystonia	B	1292-1300
,	O	1300-1301
and	O	1302-1305
mental	B	1306-1312
retardation	I	1313-1324
,	O	1325-1326
mutations	O	1327-1336
were	O	1337-1341
found	O	1342-1347
in	O	1348-1350
the	O	1351-1354
gene	O	1355-1359
DDP	O	1360-1363
coding	O	1364-1370
for	O	1371-1374
a	O	1375-1376
polypeptide	O	1377-1388
of	O	1389-1391
unknown	O	1392-1399
function	O	1400-1408
.	O	1408-1409

This	O	1410-1414
article	O	1415-1422
reviews	O	1423-1430
the	O	1431-1434
clinical	O	1435-1443
and	O	1444-1447
molecular	O	1448-1457
genetics	O	1458-1466
of	O	1467-1469
primary	B	1470-1477
dystonias	I	1478-1487
,	O	1487-1488
critically	O	1489-1499
discusses	O	1500-1509
present	O	1510-1517
findings	O	1518-1526
,	O	1526-1527
and	O	1528-1531
proposes	O	1532-1540
referring	O	1541-1550
to	O	1551-1553
the	O	1554-1557
known	O	1558-1563
forms	O	1564-1569
,	O	1569-1570
most	O	1571-1575
of	O	1576-1578
which	O	1579-1584
can	O	1585-1588
be	O	1589-1591
distinguished	O	1592-1605
by	O	1606-1608
genetic	O	1609-1616
criteria	O	1617-1625
,	O	1625-1626
as	O	1627-1629
dystonias	B	1630-1639
1	I	1640-1641
-	I	1641-1642
12	I	1642-1644
.	O	1644-1645

Clinical	O	0-8
and	O	9-12
genetic	O	13-20
study	O	21-26
of	O	27-29
Friedreich	B	30-40
ataxia	I	41-47
in	O	48-50
an	O	51-53
Australian	O	54-64
population	O	65-75
.	O	75-76

Friedreich	B	77-87
ataxia	I	88-94
is	O	95-97
an	O	98-100
autosomal	B	101-110
recessive	I	111-120
disorder	I	121-129
caused	O	130-136
by	O	137-139
mutations	O	140-149
in	O	150-152
the	O	153-156
FRDA	B	157-161
gene	O	162-166
that	O	167-171
encodes	O	172-179
a	O	180-181
210	O	182-185
-	O	185-186
amino	O	186-191
acid	O	192-196
protein	O	197-204
called	O	205-211
frataxin	O	212-220
.	O	220-221

An	O	222-224
expansion	O	225-234
of	O	235-237
a	O	238-239
GAA	O	240-243
trinucleotide	O	244-257
repeat	O	258-264
in	O	265-267
intron	O	268-274
1	O	275-276
of	O	277-279
the	O	280-283
gene	O	284-288
is	O	289-291
present	O	292-299
in	O	300-302
more	O	303-307
than	O	308-312
95	O	313-315
%	O	315-316
of	O	317-319
mutant	O	320-326
alleles	O	327-334
.	O	334-335

Of	O	336-338
the	O	339-342
83	O	343-345
people	O	346-352
we	O	353-355
studied	O	356-363
who	O	364-367
have	O	368-372
mutations	O	373-382
in	O	383-385
FRDA	O	386-390
,	O	390-391
78	O	392-394
are	O	395-398
homozygous	O	399-409
for	O	410-413
an	O	414-416
expanded	O	417-425
GAA	O	426-429
repeat	O	430-436
;	O	436-437
the	O	438-441
other	O	442-447
five	O	448-452
patients	O	453-461
have	O	462-466
an	O	467-469
expansion	O	470-479
in	O	480-482
one	O	483-486
allele	O	487-493
and	O	494-497
a	O	498-499
point	O	500-505
mutation	O	506-514
in	O	515-517
the	O	518-521
other	O	522-527
.	O	527-528

Here	O	529-533
we	O	534-536
present	O	537-544
a	O	545-546
detailed	O	547-555
clinical	O	556-564
and	O	565-568
genetic	O	569-576
study	O	577-582
of	O	583-585
a	O	586-587
subset	O	588-594
of	O	595-597
51	O	598-600
patients	O	601-609
homozygous	O	610-620
for	O	621-624
an	O	625-627
expansion	O	628-637
of	O	638-640
the	O	641-644
GAA	O	645-648
repeat	O	649-655
.	O	655-656

We	O	657-659
found	O	660-665
a	O	666-667
correlation	O	668-679
between	O	680-687
the	O	688-691
size	O	692-696
of	O	697-699
the	O	700-703
smaller	O	704-711
of	O	712-714
the	O	715-718
two	O	719-722
expanded	O	723-731
alleles	O	732-739
and	O	740-743
age	O	744-747
at	O	748-750
onset	O	751-756
,	O	756-757
age	O	758-761
into	O	762-766
wheelchair	O	767-777
,	O	777-778
scoliosis	B	779-788
,	O	788-789
impaired	O	790-798
vibration	O	799-808
sense	O	809-814
,	O	814-815
and	O	816-819
the	O	820-823
presence	O	824-832
of	O	833-835
foot	B	836-840
deformity	I	841-850
.	O	850-851

There	O	852-857
was	O	858-861
no	O	862-864
significant	O	865-876
correlation	O	877-888
between	O	889-896
the	O	897-900
size	O	901-905
of	O	906-908
the	O	909-912
smaller	O	913-920
allele	O	921-927
and	O	928-931
cardiomyopathy	B	932-946
,	O	946-947
diabetes	B	948-956
mellitus	I	957-965
,	O	965-966
loss	B	967-971
of	I	972-974
proprioception	I	975-989
,	O	989-990
or	O	991-993
bladder	B	994-1001
symptoms	I	1002-1010
.	O	1010-1011

The	O	1012-1015
larger	O	1016-1022
allele	O	1023-1029
size	O	1030-1034
correlated	O	1035-1045
with	O	1046-1050
bladder	B	1051-1058
symptoms	I	1059-1067
and	O	1068-1071
the	O	1072-1075
presence	O	1076-1084
of	O	1085-1087
foot	B	1088-1092
deformity	I	1093-1102
.	O	1102-1103

The	O	1104-1107
duration	O	1108-1116
of	O	1117-1119
disease	O	1120-1127
is	O	1128-1130
correlated	O	1131-1141
with	O	1142-1146
wheelchair	O	1147-1157
use	O	1158-1161
and	O	1162-1165
the	O	1166-1169
presence	O	1170-1178
of	O	1179-1181
diabetes	B	1182-1190
,	O	1190-1191
scoliosis	B	1192-1201
,	O	1201-1202
bladder	B	1203-1210
symptoms	I	1211-1219
and	O	1220-1223
impaired	B	1224-1232
proprioception	I	1233-1247
,	O	1247-1248
and	O	1249-1252
vibration	O	1253-1262
sense	O	1263-1268
but	O	1269-1272
no	O	1273-1275
other	O	1276-1281
complications	O	1282-1295
studied	O	1296-1303
.	O	1303-1304
.	O	1303-1304

Recurrent	O	0-9
meningococcal	B	10-23
meningitis	I	24-34
with	O	35-39
absence	B	40-47
of	I	48-50
the	I	51-54
sixth	I	55-60
component	I	61-70
of	I	71-73
complement	I	74-84
:	O	84-85
an	O	86-88
evaluation	O	89-99
of	O	100-102
underlying	O	103-113
immunologic	O	114-125
mechanisms	O	126-136
.	O	136-137

A	O	138-139
51	O	140-142
/	O	142-143
2	O	143-144
-	O	144-145
year	O	145-149
-	O	144-145
old	O	150-153
black	O	154-159
girl	O	160-164
with	O	165-169
recurrent	O	170-179
meningococcal	B	180-193
meningitis	I	194-204
and	O	205-208
absence	B	209-216
of	I	217-219
the	I	220-223
sixth	I	224-229
component	I	230-239
of	I	240-242
complement	I	243-253
(	O	254-255
C6	O	255-257
)	O	257-258
is	O	259-261
reported	O	262-270
.	O	270-271

To	O	272-274
explore	O	275-282
the	O	283-286
pathogenesis	O	287-299
of	O	300-302
recurrent	O	303-312
neisserial	B	313-323
infections	I	324-334
in	O	335-337
C6	B	338-340
deficiency	I	341-351
,	O	351-352
a	O	353-354
detailed	O	355-363
analysis	O	364-372
of	O	373-375
her	O	376-379
immune	O	380-386
competence	O	387-397
was	O	398-401
conducted	O	402-411
.	O	411-412

Her	O	413-416
serum	O	417-422
had	O	423-426
normal	O	427-433
chemotactic	O	434-445
,	O	445-446
opsonic	O	447-454
,	O	454-455
alternative	O	456-467
complement	O	468-478
pathway	O	479-486
,	O	486-487
and	O	488-491
specific	O	492-500
antibody	O	501-509
activity	O	510-518
,	O	518-519
but	O	520-523
lacked	O	524-530
complement	O	531-541
-	O	541-542
mediated	O	542-550
bacteriolytic	O	551-564
activity	O	565-573
.	O	573-574

In	O	575-577
addition	O	578-586
,	O	586-587
her	O	588-591
C6	B	592-594
-	I	594-595
deficient	I	595-604
serum	O	605-610
was	O	611-614
indistinguishable	O	615-632
from	O	633-637
normal	O	638-644
serum	O	645-650
in	O	651-653
a	O	654-655
complement	O	656-666
-	O	666-667
dependent	O	667-676
assay	O	677-682
of	O	683-685
phagocyte	O	686-695
bactericidal	O	696-708
activity	O	709-717
.	O	717-718

Absent	O	719-725
bacteriolysis	O	726-739
remains	O	740-747
the	O	748-751
only	O	752-756
consistent	O	757-767
defect	O	768-774
associated	O	775-785
with	O	786-790
recurrent	O	791-800
neisserial	B	801-811
infections	I	812-822
and	O	823-826
absence	O	827-834
of	O	835-837
one	O	838-841
of	O	842-844
the	O	845-848
late	O	849-853
-	O	853-854
acting	O	854-860
complement	O	861-871
components	O	872-882
.	O	882-883
.	O	882-883

Mutation	O	0-8
of	O	9-11
the	O	12-15
sterol	O	16-22
27	O	23-25
-	O	25-26
hydroxylase	O	26-37
gene	O	38-42
(	O	43-44
CYP27	O	44-49
)	O	49-50
results	O	51-58
in	O	59-61
truncation	O	62-72
of	O	73-75
mRNA	O	76-80
expressed	O	81-90
in	O	91-93
leucocytes	O	94-104
in	O	105-107
a	O	108-109
Japanese	O	110-118
family	O	119-125
with	O	126-130
cerebrotendinous	B	131-147
xanthomatosis	I	148-161
.	O	161-162

OBJECTIVES	O	163-173
A	O	175-176
Japanese	O	177-185
family	O	186-192
with	O	193-197
cerebrotendinous	B	198-214
xanthomatosis	I	215-228
(	O	229-230
CTX	B	230-233
)	O	233-234
was	O	235-238
investigated	O	239-251
for	O	252-255
a	O	256-257
sequence	O	258-266
alteration	O	267-277
in	O	278-280
the	O	281-284
sterol	O	285-291
27	O	292-294
-	O	294-295
hydroxylase	O	295-306
gene	O	307-311
(	O	312-313
CYP27	O	313-318
)	O	318-319
.	O	319-320

The	O	321-324
expression	O	325-335
of	O	336-338
CYP27	O	339-344
has	O	345-348
been	O	349-353
mostly	O	354-360
explored	O	361-369
using	O	370-375
cultured	O	376-384
fibroblasts	O	385-396
,	O	396-397
prompting	O	398-407
the	O	408-411
examination	O	412-423
of	O	424-426
the	O	427-430
transcripts	O	431-442
from	O	443-447
blood	O	448-453
leucocytes	O	454-464
as	O	465-467
a	O	468-469
simple	O	470-476
and	O	477-480
rapid	O	481-486
technique	O	487-496
.	O	496-497

METHODS	O	498-505
An	O	507-509
alteration	O	510-520
in	O	521-523
CYP27	O	524-529
of	O	530-532
the	O	533-536
proband	O	537-544
was	O	545-548
searched	O	549-557
for	O	558-561
by	O	562-564
polymerase	O	565-575
chain	O	576-581
reaction	O	582-590
-	O	590-591
single	O	591-597
strand	O	598-604
conformation	O	605-617
polymorphism	O	618-630
(	O	631-632
PCR	O	632-635
-	O	635-636
SSCP	O	636-640
)	O	640-641
analysis	O	642-650
and	O	651-654
subsequent	O	655-665
sequencing	O	666-676
.	O	676-677

Samples	O	678-685
of	O	686-688
RNA	O	689-692
were	O	693-697
subjected	O	698-707
to	O	708-710
reverse	O	711-718
transcription	O	719-732
PCR	O	733-736
(	O	737-738
RT	O	738-740
-	O	740-741
PCR	O	741-744
)	O	744-745
and	O	746-749
the	O	750-753
product	O	754-761
of	O	762-764
the	O	765-768
proband	O	769-776
was	O	777-780
amplified	O	781-790
with	O	791-795
nested	O	796-802
primers	O	803-810
and	O	811-814
sequenced	O	815-824
.	O	824-825

RESULTS	O	826-833
A	O	835-836
homozygous	O	837-847
G	O	848-849
to	O	850-852
A	O	853-854
transition	O	855-865
at	O	866-868
the	O	869-872
5	O	873-874
end	O	875-878
of	O	879-881
intron	O	882-888
7	O	889-890
was	O	891-894
detected	O	895-903
in	O	904-906
the	O	907-910
patient	O	911-918
.	O	918-919

In	O	920-922
RT	O	923-925
-	O	925-926
PCR	O	926-929
analysis	O	930-938
,	O	938-939
only	O	940-944
a	O	945-946
truncated	O	947-956
transcript	O	957-967
was	O	968-971
detected	O	972-980
in	O	981-983
the	O	984-987
patient	O	988-995
,	O	995-996
whereas	O	997-1004
both	O	1005-1009
normal	O	1010-1016
and	O	1017-1020
truncated	O	1021-1030
transcripts	O	1031-1042
were	O	1043-1047
detected	O	1048-1056
in	O	1057-1059
the	O	1060-1063
siblings	O	1064-1072
.	O	1072-1073

The	O	1074-1077
sequencing	O	1078-1088
of	O	1089-1091
the	O	1092-1095
patients	O	1096-1104
cDNA	O	1105-1109
fragment	O	1110-1118
disclosed	O	1119-1128
a	O	1129-1130
direct	O	1131-1137
conjuction	O	1138-1148
of	O	1149-1151
exon	O	1152-1156
6	O	1157-1158
and	O	1159-1162
exon	O	1163-1167
8	O	1168-1169
.	O	1169-1170
CONCLUSION	O	1171-1181
The	O	1183-1186
mutation	O	1187-1195
at	O	1196-1198
splice	O	1199-1205
donor	O	1206-1211
site	O	1212-1216
and	O	1217-1220
the	O	1221-1224
truncation	O	1225-1235
of	O	1236-1238
mRNA	O	1239-1243
were	O	1244-1248
identical	O	1249-1258
with	O	1259-1263
those	O	1264-1269
of	O	1270-1272
a	O	1273-1274
recently	O	1275-1283
reported	O	1284-1292
Italian	O	1293-1300
patient	O	1301-1308
,	O	1308-1309
although	O	1310-1318
different	O	1319-1328
in	O	1329-1331
symptomatology	O	1332-1346
.	O	1346-1347

The	O	1348-1351
application	O	1352-1363
of	O	1364-1366
blood	O	1367-1372
leucocytes	O	1373-1383
can	O	1384-1387
be	O	1388-1390
a	O	1391-1392
simple	O	1393-1399
technique	O	1400-1409
on	O	1410-1412
analysing	O	1413-1422
a	O	1423-1424
constructive	O	1425-1437
abnormality	B	1438-1449
of	I	1450-1452
CYP27	I	1453-1458
mRNA	O	1459-1463
.	O	1463-1464
.	O	1463-1464

Frequent	O	0-8
detection	O	9-18
of	O	19-21
codon	O	22-27
877	O	28-31
mutation	O	32-40
in	O	41-43
the	O	44-47
androgen	O	48-56
receptor	O	57-65
gene	O	66-70
in	O	71-73
advanced	B	74-82
prostate	I	83-91
cancers	I	92-99
.	O	99-100

Prostatic	O	101-110
tissue	O	111-117
specimens	O	118-127
derived	O	128-135
from	O	136-140
transurethral	O	141-154
resections	O	155-165
of	O	166-168
patients	O	169-177
with	O	178-182
metastatic	B	183-193
prostate	I	194-202
cancer	I	203-209
were	O	210-214
analyzed	O	215-223
for	O	224-227
genetic	O	228-235
alterations	O	236-247
in	O	248-250
the	O	251-254
hormone	O	255-262
-	O	262-263
binding	O	263-270
domain	O	271-277
of	O	278-280
the	O	281-284
androgen	O	285-293
receptor	O	294-302
(	O	303-304
AR	O	304-306
)	O	306-307
gene	O	308-312
.	O	312-313

Direct	O	314-320
sequencing	O	321-331
of	O	332-334
the	O	335-338
polymerase	O	339-349
chain	O	350-355
reaction	O	356-364
-	O	364-365
derived	O	365-372
DNAs	O	373-377
of	O	378-380
6	O	381-382
of	O	383-385
24	O	386-388
specimens	O	389-398
revealed	O	399-407
a	O	408-409
codon	O	410-415
877	O	416-419
mutation	O	420-428
(	O	429-430
ACT	O	430-433
-	O	433-434
-	O	433-434
>	O	436-437
GCT	O	438-441
,	O	441-442
Thr	O	443-446
-	O	446-447
-	O	446-447
>	O	449-450
Ala	O	451-454
)	O	454-455
in	O	456-458
the	O	459-462
hormone	O	463-470
-	O	470-471
binding	O	471-478
domain	O	479-485
of	O	486-488
the	O	489-492
AR	O	493-495
gene	O	496-500
.	O	500-501

This	O	502-506
same	O	507-511
AR	O	512-514
mutation	O	515-523
has	O	524-527
been	O	528-532
reported	O	533-541
previously	O	542-552
in	O	553-555
a	O	556-557
metastatic	B	558-568
prostate	I	569-577
cancer	I	578-584
cell	O	585-589
line	O	590-594
,	O	594-595
LNCaP	O	596-601
,	O	601-602
where	O	603-608
this	O	609-613
mutation	O	614-622
confers	O	623-630
upon	O	631-635
the	O	636-639
AR	O	640-642
an	O	643-645
altered	O	646-653
ligand	O	654-660
-	O	660-661
binding	O	661-668
specificity	O	669-680
which	O	681-686
is	O	687-689
stimulated	O	690-700
by	O	701-703
estrogens	O	704-713
,	O	713-714
progestagens	O	715-727
,	O	727-728
and	O	729-732
antiandrogens	O	733-746
.	O	746-747

It	O	748-750
is	O	751-753
possible	O	754-762
that	O	763-767
analogous	O	768-777
to	O	778-780
an	O	781-783
activated	O	784-793
/	O	793-794
altered	O	794-801
growth	O	802-808
factor	O	809-815
receptor	O	816-824
oncogene	O	825-833
,	O	833-834
codon	O	835-840
877	O	841-844
mutant	O	845-851
AR	O	852-854
with	O	855-859
altered	O	860-867
ligand	O	868-874
binding	O	875-882
may	O	883-886
provide	O	887-894
a	O	895-896
selective	O	897-906
growth	O	907-913
advantage	O	914-923
in	O	924-926
the	O	927-930
genesis	O	931-938
of	O	939-941
a	O	942-943
subset	O	944-950
of	O	951-953
advanced	B	954-962
prostate	I	963-971
cancer	I	972-978
.	O	978-979

Although	O	980-988
estrogens	O	989-998
are	O	999-1002
used	O	1003-1007
infrequently	O	1008-1020
,	O	1020-1021
antiandrogens	O	1022-1035
are	O	1036-1039
used	O	1040-1044
increasingly	O	1045-1057
in	O	1058-1060
hormonal	O	1061-1069
therapy	O	1070-1077
for	O	1078-1081
patients	O	1082-1090
with	O	1091-1095
advanced	B	1096-1104
prostate	I	1105-1113
cancer	I	1114-1120
.	O	1120-1121

The	O	1122-1125
stimulatory	O	1126-1137
effect	O	1138-1144
of	O	1145-1147
these	O	1148-1153
therapeutic	O	1154-1165
agents	O	1166-1172
on	O	1173-1175
the	O	1176-1179
codon	O	1180-1185
877	O	1186-1189
mutant	O	1190-1196
AR	O	1197-1199
further	O	1200-1207
suggests	O	1208-1216
that	O	1217-1221
this	O	1222-1226
frequently	O	1227-1237
observed	O	1238-1246
AR	O	1247-1249
mutation	O	1250-1258
may	O	1259-1262
contribute	O	1263-1273
to	O	1274-1276
the	O	1277-1280
treatment	O	1281-1290
refractory	O	1291-1301
disease	O	1302-1309
.	O	1309-1310
.	O	1309-1310

ATM	O	0-3
-	O	3-4
dependent	O	4-13
phosphorylation	O	14-29
of	O	30-32
nibrin	O	33-39
in	O	40-42
response	O	43-51
to	O	52-54
radiation	O	55-64
exposure	O	65-73
.	O	73-74

Mutations	O	75-84
in	O	85-87
the	O	88-91
gene	O	92-96
ATM	O	97-100
are	O	101-104
responsible	O	105-116
for	O	117-120
the	O	121-124
genetic	B	125-132
disorder	I	133-141
ataxia	B	142-148
-	I	148-149
telangiectasia	I	149-163
(	O	164-165
A	B	165-166
-	I	166-167
T	I	167-168
)	O	168-169
,	O	169-170
which	O	171-176
is	O	177-179
characterized	O	180-193
by	O	194-196
cerebellar	B	197-207
dysfunction	I	208-219
,	O	219-220
radiosensitivity	O	221-237
,	O	237-238
chromosomal	O	239-250
instability	O	251-262
and	O	263-266
cancer	B	267-273
predisposition	O	274-288
.	O	288-289

Both	O	290-294
the	O	295-298
A	B	299-300
-	I	300-301
T	I	301-302
phenotype	O	303-312
and	O	313-316
the	O	317-320
similarity	O	321-331
of	O	332-334
the	O	335-338
ATM	O	339-342
protein	O	343-350
to	O	351-353
other	O	354-359
DNA	O	360-363
-	O	363-364
damage	O	364-370
sensors	O	371-378
suggests	O	379-387
a	O	388-389
role	O	390-394
for	O	395-398
ATM	O	399-402
in	O	403-405
biochemical	O	406-417
pathways	O	418-426
involved	O	427-435
in	O	436-438
the	O	439-442
recognition	O	443-454
,	O	454-455
signalling	O	456-466
and	O	467-470
repair	O	471-477
of	O	478-480
DNA	O	481-484
double	O	485-491
-	O	491-492
strand	O	492-498
breaks	O	499-505
(	O	506-507
DSBs	O	507-511
)	O	511-512
.	O	512-513

There	O	514-519
are	O	520-523
strong	O	524-530
parallels	O	531-540
between	O	541-548
the	O	549-552
pattern	O	553-560
of	O	561-563
radiosensitivity	O	564-580
,	O	580-581
chromosomal	O	582-593
instability	O	594-605
and	O	606-609
cancer	B	610-616
predisposition	O	617-631
in	O	632-634
A	B	635-636
-	I	636-637
T	I	637-638
patients	O	639-647
and	O	648-651
that	O	652-656
in	O	657-659
patients	O	660-668
with	O	669-673
Nijmegen	B	674-682
breakage	I	683-691
syndrome	I	692-700
(	O	701-702
NBS	B	702-705
)	O	705-706
.	O	706-707

The	O	708-711
protein	O	712-719
defective	O	720-729
in	O	730-732
NBS	B	733-736
,	O	736-737
nibrin	O	738-744
(	O	745-746
encoded	O	746-753
by	O	754-756
NBS1	O	757-761
)	O	761-762
,	O	762-763
forms	O	764-769
a	O	770-771
complex	O	772-779
with	O	780-784
MRE11	O	785-790
and	O	791-794
RAD50	O	795-800
(	O	801-802
refs	O	802-806
1	O	807-808
,	O	808-809
2	O	810-811
)	O	811-812
.	O	812-813

This	O	814-818
complex	O	819-826
localizes	O	827-836
to	O	837-839
DSBs	O	840-844
within	O	845-851
30	O	852-854
minutes	O	855-862
after	O	863-868
cellular	O	869-877
exposure	O	878-886
to	O	887-889
ionizing	O	890-898
radiation	O	899-908
(	O	909-910
IR	O	910-912
)	O	912-913
and	O	914-917
is	O	918-920
observed	O	921-929
in	O	930-932
brightly	O	933-941
staining	O	942-950
nuclear	O	951-958
foci	O	959-963
after	O	964-969
a	O	970-971
longer	O	972-978
period	O	979-985
of	O	986-988
time	O	989-993
.	O	993-994

The	O	995-998
overlap	O	999-1006
between	O	1007-1014
clinical	O	1015-1023
and	O	1024-1027
cellular	O	1028-1036
phenotypes	O	1037-1047
in	O	1048-1050
A	B	1051-1052
-	I	1052-1053
T	I	1053-1054
and	O	1055-1058
NBS	B	1059-1062
suggests	O	1063-1071
that	O	1072-1076
ATM	O	1077-1080
and	O	1081-1084
nibrin	O	1085-1091
may	O	1092-1095
function	O	1096-1104
in	O	1105-1107
the	O	1108-1111
same	O	1112-1116
biochemical	O	1117-1128
pathway	O	1129-1136
.	O	1136-1137

Here	O	1138-1142
we	O	1143-1145
demonstrate	O	1146-1157
that	O	1158-1162
nibrin	O	1163-1169
is	O	1170-1172
phosphorylated	O	1173-1187
within	O	1188-1194
one	O	1195-1198
hour	O	1199-1203
of	O	1204-1206
treatment	O	1207-1216
of	O	1217-1219
cells	O	1220-1225
with	O	1226-1230
IR	O	1231-1233
.	O	1233-1234

This	O	1235-1239
response	O	1240-1248
is	O	1249-1251
abrogated	O	1252-1261
in	O	1262-1264
A	B	1265-1266
-	I	1266-1267
T	I	1267-1268
cells	O	1269-1274
that	O	1275-1279
either	O	1280-1286
do	O	1287-1289
not	O	1290-1293
express	O	1294-1301
ATM	O	1302-1305
protein	O	1306-1313
or	O	1314-1316
express	O	1317-1324
near	O	1325-1329
full	O	1330-1334
-	O	1334-1335
length	O	1335-1341
mutant	O	1342-1348
protein	O	1349-1356
.	O	1356-1357

We	O	1358-1360
also	O	1361-1365
show	O	1366-1370
that	O	1371-1375
ATM	O	1376-1379
physically	O	1380-1390
interacts	O	1391-1400
with	O	1401-1405
and	O	1406-1409
phosphorylates	O	1410-1424
nibrin	O	1425-1431
on	O	1432-1434
serine	O	1435-1441
343	O	1442-1445
both	O	1446-1450
in	O	1451-1453
vivo	O	1454-1458
and	O	1459-1462
in	O	1463-1465
vitro	O	1466-1471
.	O	1471-1472

Phosphorylation	O	1473-1488
of	O	1489-1491
this	O	1492-1496
site	O	1497-1501
appears	O	1502-1509
to	O	1510-1512
be	O	1513-1515
functionally	O	1516-1528
important	O	1529-1538
because	O	1539-1546
mutated	O	1547-1554
nibrin	O	1555-1561
(	O	1562-1563
S343A	O	1563-1568
)	O	1568-1569
does	O	1570-1574
not	O	1575-1578
completely	O	1579-1589
complement	O	1590-1600
radiosensitivity	O	1601-1617
in	O	1618-1620
NBS	B	1621-1624
cells	O	1625-1630
.	O	1630-1631

ATM	O	1632-1635
phosphorylation	O	1636-1651
of	O	1652-1654
nibrin	O	1655-1661
does	O	1662-1666
not	O	1667-1670
affect	O	1671-1677
nibrin	O	1678-1684
-	O	1684-1685
MRE11	O	1685-1690
-	O	1684-1685
RAD50	O	1691-1696
association	O	1697-1708
as	O	1709-1711
revealed	O	1712-1720
by	O	1721-1723
radiation	O	1724-1733
-	O	1733-1734
induced	O	1734-1741
foci	O	1742-1746
formation	O	1747-1756
.	O	1756-1757

Our	O	1758-1761
data	O	1762-1766
provide	O	1767-1774
a	O	1775-1776
biochemical	O	1777-1788
explanation	O	1789-1800
for	O	1801-1804
the	O	1805-1808
similarity	O	1809-1819
in	O	1820-1822
phenotype	O	1823-1832
between	O	1833-1840
A	B	1841-1842
-	I	1842-1843
T	I	1843-1844
and	O	1845-1848
NBS	B	1849-1852
.	O	1852-1853
.	O	1852-1853

Detection	O	0-9
of	O	10-12
an	O	13-15
unstable	O	16-24
fragment	O	25-33
of	O	34-36
DNA	O	37-40
specific	O	41-49
to	O	50-52
individuals	O	53-64
with	O	65-69
myotonic	B	70-78
dystrophy	I	79-88
.	O	88-89

Myotonic	B	90-98
dystrophy	I	99-108
(	O	109-110
DM	B	110-112
)	O	112-113
is	O	114-116
the	O	117-120
most	O	121-125
common	O	126-132
form	O	133-137
of	O	138-140
adult	O	141-146
muscular	B	147-155
dystrophy	I	156-165
,	O	165-166
with	O	167-171
a	O	172-173
prevalence	O	174-184
of	O	185-187
2	O	188-189
-	O	189-190
14	O	190-192
per	O	193-196
100	O	197-200
,	O	200-201
000	O	202-205
individuals	O	206-217
.	O	217-218

The	O	219-222
disease	O	223-230
is	O	231-233
characterized	O	234-247
by	O	248-250
progressive	O	251-262
muscle	B	263-269
weakness	I	270-278
and	O	279-282
sustained	B	283-292
muscle	I	293-299
contraction	I	300-311
,	O	311-312
often	O	313-318
with	O	319-323
a	O	324-325
wide	O	326-330
range	O	331-336
of	O	337-339
accompanying	O	340-352
symptoms	O	353-361
.	O	361-362

The	O	363-366
age	O	367-370
at	O	371-373
onset	O	374-379
and	O	380-383
severity	O	384-392
of	O	393-395
the	O	396-399
disease	O	400-407
show	O	408-412
extreme	O	413-420
variation	O	421-430
,	O	430-431
both	O	432-436
within	O	437-443
and	O	444-447
between	O	448-455
families	O	456-464
.	O	464-465

Despite	O	466-473
its	O	474-477
clinical	O	478-486
variability	O	487-498
,	O	498-499
this	O	500-504
dominant	O	505-513
condition	O	514-523
segregates	O	524-534
as	O	535-537
a	O	538-539
single	O	540-546
locus	O	547-552
at	O	553-555
chromosome	O	556-566
19q13	O	567-572
.	O	572-573

3	O	574-575
in	O	576-578
every	O	579-584
population	O	585-595
studied	O	596-603
.	O	603-604

It	O	605-607
is	O	608-610
flanked	O	611-618
by	O	619-621
the	O	622-625
tightly	O	626-633
linked	O	634-640
genetic	O	641-648
markers	O	649-656
ERCC1	O	657-662
proximally	O	663-673
and	O	674-677
D19S51	O	678-684
distally	O	685-693
;	O	693-694
these	O	695-700
define	O	701-707
the	O	708-711
DM	B	712-714
critical	O	715-723
region	O	724-730
.	O	730-731

We	O	732-734
report	O	735-741
the	O	742-745
isolation	O	746-755
of	O	756-758
an	O	759-761
expressed	O	762-771
sequence	O	772-780
from	O	781-785
this	O	786-790
region	O	791-797
which	O	798-803
detects	O	804-811
a	O	812-813
DNA	O	814-817
fragment	O	818-826
that	O	827-831
is	O	832-834
larger	O	835-841
in	O	842-844
affected	O	845-853
individuals	O	854-865
than	O	866-870
in	O	871-873
normal	O	874-880
siblings	O	881-889
or	O	890-892
unaffected	O	893-903
controls	O	904-912
.	O	912-913

The	O	914-917
size	O	918-922
of	O	923-925
this	O	926-930
fragment	O	931-939
varies	O	940-946
between	O	947-954
affected	O	955-963
siblings	O	964-972
,	O	972-973
and	O	974-977
increases	O	978-987
in	O	988-990
size	O	991-995
through	O	996-1003
generations	O	1004-1015
in	O	1016-1018
parallel	O	1019-1027
with	O	1028-1032
increasing	O	1033-1043
severity	O	1044-1052
of	O	1053-1055
the	O	1056-1059
disease	O	1060-1067
.	O	1067-1068

We	O	1069-1071
postulate	O	1072-1081
that	O	1082-1086
this	O	1087-1091
unstable	O	1092-1100
DNA	O	1101-1104
sequence	O	1105-1113
is	O	1114-1116
the	O	1117-1120
molecular	O	1121-1130
feature	O	1131-1138
that	O	1139-1143
underlies	O	1144-1153
DM	B	1154-1156
.	O	1156-1157

Detection	O	0-9
of	O	10-12
a	O	13-14
novel	O	15-20
missense	O	21-29
mutation	O	30-38
and	O	39-42
second	O	43-49
recurrent	O	50-59
mutation	O	60-68
in	O	69-71
the	O	72-75
CACNA1A	O	76-83
gene	O	84-88
in	O	89-91
individuals	O	92-103
with	O	104-108
EA	B	109-111
-	I	111-112
2	I	112-113
and	O	114-117
FHM	B	118-121
.	O	121-122

Mutations	O	123-132
in	O	133-135
the	O	136-139
brain	O	140-145
specific	O	146-154
P	O	155-156
/	O	156-157
Q	O	157-158
type	O	159-163
Ca2	O	164-167
+	O	168-169
channel	O	170-177
alpha1	O	178-184
subunit	O	185-192
gene	O	193-197
,	O	197-198
CACNA1A	O	199-206
,	O	206-207
have	O	208-212
been	O	213-217
identified	O	218-228
in	O	229-231
three	O	232-237
clinically	O	238-248
distinct	O	249-257
disorders	O	258-267
,	O	267-268
viz	O	269-272
.	O	272-273

episodic	B	274-282
ataxia	I	283-289
type	I	290-294
2	I	295-296
(	O	297-298
EA	B	298-300
-	I	300-301
2	I	301-302
)	O	302-303
,	O	303-304
familial	B	305-313
hemiplegic	I	314-324
migraine	I	325-333
(	O	334-335
FHM	B	335-338
)	O	338-339
and	O	340-343
spinocerebellar	B	344-359
ataxia	I	360-366
6	I	367-368
(	O	369-370
SCA6	B	370-374
)	O	374-375
.	O	375-376

For	O	377-380
individuals	O	381-392
with	O	393-397
EA	B	398-400
-	I	400-401
2	I	401-402
,	O	402-403
the	O	404-407
mutations	O	408-417
described	O	418-427
thus	O	428-432
far	O	433-436
are	O	437-440
presumed	O	441-449
to	O	450-452
result	O	453-459
in	O	460-462
a	O	463-464
truncated	O	465-474
protein	O	475-482
product	O	483-490
.	O	490-491

Several	O	492-499
different	O	500-509
missense	O	510-518
mutations	O	519-528
have	O	529-533
been	O	534-538
identified	O	539-549
in	O	550-552
patients	O	553-561
with	O	562-566
FHM	B	567-570
.	O	570-571

At	O	572-574
least	O	575-580
two	O	581-584
of	O	585-587
these	O	588-593
mutations	O	594-603
have	O	604-608
been	O	609-613
identified	O	614-624
on	O	625-627
two	O	628-631
different	O	632-641
chromosome	O	642-652
19p13	O	653-658
haplotypes	O	659-669
and	O	670-673
thus	O	674-678
represent	O	679-688
recurrent	O	689-698
mutations	O	699-708
.	O	708-709

In	O	710-712
the	O	713-716
present	O	717-724
study	O	725-730
,	O	730-731
we	O	732-734
have	O	735-739
screened	O	740-748
several	O	749-756
individuals	O	757-768
for	O	769-772
mutations	O	773-782
in	O	783-785
all	O	786-789
47	O	790-792
exons	O	793-798
in	O	799-801
the	O	802-805
CACNA1A	O	806-813
gene	O	814-818
by	O	819-821
single	O	822-828
-	O	828-829
strand	O	829-835
conformation	O	836-848
analysis	O	849-857
.	O	857-858

We	O	859-861
have	O	862-866
characterised	O	867-880
a	O	881-882
novel	O	883-888
missense	O	889-897
mutation	O	898-906
,	O	906-907
G5260A	O	908-914
,	O	914-915
in	O	916-918
exon	O	919-923
32	O	924-926
in	O	927-929
a	O	930-931
family	O	932-938
segregating	O	939-950
for	O	951-954
EA	B	955-957
-	I	957-958
2	I	958-959
.	O	959-960

The	O	961-964
consequence	O	965-976
of	O	977-979
this	O	980-984
mutation	O	985-993
is	O	994-996
an	O	997-999
amino	O	1000-1005
acid	O	1006-1010
substitution	O	1011-1023
at	O	1024-1026
a	O	1027-1028
highly	O	1029-1035
conserved	O	1036-1045
position	O	1046-1054
within	O	1055-1061
the	O	1062-1065
CACNA1A	O	1066-1073
gene	O	1074-1078
.	O	1078-1079

This	O	1080-1084
represents	O	1085-1095
the	O	1096-1099
first	O	1100-1105
point	O	1106-1111
mutation	O	1112-1120
not	O	1121-1124
resulting	O	1125-1134
in	O	1135-1137
a	O	1138-1139
proposed	O	1140-1148
truncated	O	1149-1158
protein	O	1159-1166
.	O	1166-1167

Furthermore	O	1168-1179
,	O	1179-1180
this	O	1181-1185
mutation	O	1186-1194
has	O	1195-1198
been	O	1199-1203
detected	O	1204-1212
in	O	1213-1215
a	O	1216-1217
family	O	1218-1224
member	O	1225-1231
with	O	1232-1236
mild	O	1237-1241
clinical	O	1242-1250
signs	O	1251-1256
including	O	1257-1266
only	O	1267-1271
migraine	B	1272-1280
.	O	1280-1281

Additionally	O	1282-1294
,	O	1294-1295
a	O	1296-1297
second	O	1298-1304
previously	O	1305-1315
identified	O	1316-1326
recurrent	O	1327-1336
muta	O	1337-1341
tion	O	1342-1346
,	O	1346-1347
C2272T	O	1348-1354
,	O	1354-1355
in	O	1356-1358
exon	O	1359-1363
16	O	1364-1366
has	O	1367-1370
been	O	1371-1375
discovered	O	1376-1386
in	O	1387-1389
a	O	1390-1391
patient	O	1392-1399
with	O	1400-1404
FHM	B	1405-1408
.	O	1408-1409
.	O	1408-1409

Dominant	O	0-8
negative	O	9-17
effect	O	18-24
of	O	25-27
the	O	28-31
APC1309	O	32-39
mutation	O	40-48
:	O	48-49
a	O	50-51
possible	O	52-60
explanation	O	61-72
for	O	73-76
genotype	O	77-85
-	O	85-86
phenotype	O	86-95
correlations	O	96-108
in	O	109-111
familial	B	112-120
adenomatous	I	121-132
polyposis	I	133-142
.	O	142-143

Inactivation	O	144-156
of	O	157-159
the	O	160-163
adenomatous	B	164-175
polyposis	I	176-185
coli	I	186-190
(	O	191-192
APC	B	192-195
)	O	195-196
gene	O	197-201
product	O	202-209
initiates	O	210-219
colorectal	O	220-230
tumorigenesis	O	231-244
.	O	244-245

Patients	O	246-254
with	O	255-259
familial	B	260-268
APC	I	269-272
(	O	273-274
FAP	B	274-277
)	O	277-278
carry	O	279-284
germ	O	285-289
-	O	289-290
line	O	290-294
mutations	O	295-304
in	O	305-307
the	O	308-311
APC	B	312-315
gene	O	316-320
and	O	321-324
develop	O	325-332
multiple	O	333-341
colorectal	B	342-352
adenomas	I	353-361
and	O	362-365
subsequent	O	366-376
carcinomas	B	377-387
early	O	388-393
in	O	394-396
life	O	397-401
.	O	401-402

The	O	403-406
severity	O	407-415
of	O	416-418
the	O	419-422
disease	O	423-430
correlates	O	431-441
with	O	442-446
the	O	447-450
position	O	451-459
of	O	460-462
the	O	463-466
inherited	O	467-476
APC	B	477-480
mutation	O	481-489
(	O	490-491
genotype	O	491-499
-	O	499-500
phenotype	O	500-509
correlation	O	510-521
)	O	521-522
.	O	522-523

Together	O	524-532
with	O	533-537
the	O	538-541
fact	O	542-546
that	O	547-551
both	O	552-556
germ	O	557-561
-	O	561-562
line	O	562-566
and	O	567-570
sporadic	O	571-579
APC	B	580-583
mutations	O	584-593
cluster	O	594-601
in	O	602-604
the	O	605-608
central	O	609-616
region	O	617-623
of	O	624-626
the	O	627-630
APC	B	631-634
gene	O	635-639
,	O	639-640
this	O	641-645
points	O	646-652
to	O	653-655
a	O	656-657
dominant	O	658-666
negative	O	667-675
effect	O	676-682
of	O	683-685
certain	O	686-693
APC	B	694-697
mutants	O	698-705
.	O	705-706

Loss	O	707-711
of	O	712-714
APC	B	715-718
function	O	719-727
was	O	728-731
recently	O	732-740
shown	O	741-746
to	O	747-749
result	O	750-756
in	O	757-759
enhanced	O	760-768
beta	O	769-773
-	O	773-774
catenin	O	774-781
-	O	773-774
/	O	782-783
Tcf	O	783-786
-	O	773-774
mediated	O	787-795
transcription	O	796-809
in	O	810-812
colon	O	813-818
epithelial	O	819-829
cells	O	830-835
.	O	835-836

Here	O	837-841
,	O	841-842
we	O	843-845
provide	O	846-853
experimental	O	854-866
evidence	O	867-875
for	O	876-879
a	O	880-881
dominant	O	882-890
negative	O	891-899
effect	O	900-906
of	O	907-909
APC	B	910-913
gene	O	914-918
products	O	919-927
associated	O	928-938
with	O	939-943
severe	O	944-950
polyposis	B	951-960
.	O	960-961

Wild	O	962-966
-	O	966-967
type	O	967-971
APC	B	972-975
activity	O	976-984
in	O	985-987
beta	O	988-992
-	O	992-993
catenin	O	993-1000
-	O	992-993
/	O	1001-1002
Tcf	O	1002-1005
-	O	992-993
mediated	O	1006-1014
transcription	O	1015-1028
was	O	1029-1032
strongly	O	1033-1041
inhibited	O	1042-1051
by	O	1052-1054
a	O	1055-1056
mutant	O	1057-1063
APC	B	1064-1067
that	O	1068-1072
is	O	1073-1075
truncated	O	1076-1085
at	O	1086-1088
codon	O	1089-1094
1309	O	1095-1099
.	O	1099-1100

In	O	1101-1103
contrast	O	1104-1112
,	O	1112-1113
mutant	O	1114-1120
APC	B	1121-1124
gene	O	1125-1129
products	O	1130-1138
that	O	1139-1143
are	O	1144-1147
associated	O	1148-1158
with	O	1159-1163
attenuated	B	1164-1174
polyposis	I	1175-1184
(	O	1185-1186
codon	O	1186-1191
386	O	1192-1195
or	O	1196-1198
1465	O	1199-1203
)	O	1203-1204
interfered	O	1205-1215
only	O	1216-1220
weakly	O	1221-1227
with	O	1228-1232
wild	O	1233-1237
-	O	1237-1238
type	O	1238-1242
APC	B	1243-1246
activity	O	1247-1255
.	O	1255-1256

These	O	1257-1262
results	O	1263-1270
suggest	O	1271-1278
a	O	1279-1280
molecular	O	1281-1290
explanation	O	1291-1302
for	O	1303-1306
the	O	1307-1310
genotype	O	1311-1319
-	O	1319-1320
phenotype	O	1320-1329
correlation	O	1330-1341
in	O	1342-1344
FAP	B	1345-1348
patients	O	1349-1357
and	O	1358-1361
support	O	1362-1369
the	O	1370-1373
idea	O	1374-1378
that	O	1379-1383
colorectal	B	1384-1394
tumor	I	1395-1400
growth	O	1401-1407
might	O	1408-1413
be	O	1414-1416
,	O	1416-1417
in	O	1418-1420
part	O	1421-1425
,	O	1425-1426
driven	O	1427-1433
by	O	1434-1436
selection	O	1437-1446
for	O	1447-1450
a	O	1451-1452
mutation	O	1453-1461
in	O	1462-1464
the	O	1465-1468
mutation	O	1469-1477
cluster	O	1478-1485
region	O	1486-1492
.	O	1492-1493
.	O	1492-1493

Mutation	O	0-8
of	O	9-11
the	O	12-15
KIT	O	16-19
(	O	20-21
mast	O	21-25
/	O	25-26
stem	O	26-30
cell	O	31-35
growth	O	36-42
factor	O	43-49
receptor	O	50-58
)	O	58-59
protooncogene	O	60-73
in	O	74-76
human	O	77-82
piebaldism	B	83-93
.	O	93-94

Piebaldism	B	95-105
is	O	106-108
an	O	109-111
autosomal	B	112-121
dominant	I	122-130
genetic	I	131-138
disorder	I	139-147
characterized	O	148-161
by	O	162-164
cogenital	O	165-174
patches	O	175-182
of	O	183-185
skin	O	186-190
and	O	191-194
hair	O	195-199
from	O	200-204
which	O	205-210
melanocytes	O	211-222
are	O	223-226
completely	O	227-237
absent	O	238-244
.	O	244-245

A	O	246-247
similar	O	248-255
disorder	O	256-264
of	O	265-267
mouse	O	268-273
,	O	273-274
dominant	O	275-283
white	O	284-289
spotting	O	290-298
(	O	299-300
W	O	300-301
)	O	301-302
,	O	302-303
results	O	304-311
from	O	312-316
mutations	O	317-326
of	O	327-329
the	O	330-333
c	O	334-335
-	O	335-336
Kit	O	336-339
protooncogene	O	340-353
,	O	353-354
which	O	355-360
encodes	O	361-368
and	O	369-372
receptor	O	373-381
for	O	382-385
mast	O	386-390
/	O	390-391
stem	O	391-395
cell	O	396-400
growth	O	401-407
factor	O	408-414
.	O	414-415

We	O	416-418
identified	O	419-429
a	O	430-431
KIT	O	432-435
gene	O	436-440
mutation	O	441-449
in	O	450-452
a	O	453-454
proband	O	455-462
with	O	463-467
classic	O	468-475
autosomal	O	476-485
dominant	O	486-494
piebaldism	B	495-505
.	O	505-506

This	O	507-511
mutation	O	512-520
results	O	521-528
in	O	529-531
a	O	532-533
Gly	O	534-537
-	O	537-538
-	O	537-538
-	O	537-538
-	O	537-538
Arg	O	541-544
substitution	O	545-557
at	O	558-560
codon	O	561-566
664	O	567-570
,	O	570-571
within	O	572-578
the	O	579-582
tyrosine	O	583-591
kinase	O	592-598
domain	O	599-605
.	O	605-606

This	O	607-611
substitution	O	612-624
was	O	625-628
not	O	629-632
seen	O	633-637
in	O	638-640
any	O	641-644
normal	O	645-651
individuals	O	652-663
and	O	664-667
was	O	668-671
completely	O	672-682
linked	O	683-689
to	O	690-692
the	O	693-696
piebald	B	697-704
phenotype	O	705-714
in	O	715-717
the	O	718-721
probands	O	722-730
family	O	731-737
.	O	737-738

Piebaldism	B	739-749
in	O	750-752
this	O	753-757
family	O	758-764
thus	O	765-769
appears	O	770-777
to	O	778-780
be	O	781-783
the	O	784-787
human	O	788-793
homologue	O	794-803
to	O	804-806
dominant	O	807-815
white	O	816-821
spotting	O	822-830
(	O	831-832
W	O	832-833
)	O	833-834
of	O	835-837
the	O	838-841
mouse	O	842-847
.	O	847-848
.	O	847-848

An	O	0-2
arylsulfatase	O	3-16
A	O	17-18
(	O	19-20
ARSA	O	20-24
)	O	24-25
missense	O	26-34
mutation	O	35-43
(	O	44-45
T274M	O	45-50
)	O	50-51
causing	O	52-59
late	B	60-64
-	I	64-65
infantile	I	65-74
metachromatic	I	75-88
leukodystrophy	I	89-103
.	O	103-104

Metachromatic	B	105-118
leukodystrophy	I	119-133
(	O	134-135
MLD	B	135-138
)	O	138-139
is	O	140-142
an	O	143-145
autosomal	B	146-155
recessive	I	156-165
lysosomal	I	166-175
storage	I	176-183
disorder	I	184-192
caused	O	193-199
by	O	200-202
a	O	203-204
deficiency	B	205-215
of	I	216-218
arylsulfatase	I	219-232
A	I	233-234
(	O	235-236
ARSA	O	236-240
;	O	240-241
EC	O	242-244
3	O	245-246
.	O	246-247
1	O	248-249
.	O	249-250
6	O	251-252
.	O	252-253
8	O	254-255
)	O	255-256
.	O	256-257

The	O	258-261
8	O	262-263
ARSA	O	264-268
exons	O	269-274
and	O	275-278
adjacent	O	279-287
intron	O	288-294
boundaries	O	295-305
from	O	306-310
a	O	311-312
patient	O	313-320
with	O	321-325
late	B	326-330
-	I	330-331
infantile	I	331-340
metachromatic	I	341-354
leukodystrophy	I	355-369
were	O	370-374
polymerase	O	375-385
chain	O	386-391
reaction	O	392-400
(	O	401-402
PCR	O	402-405
)	O	405-406
amplified	O	407-416
in	O	417-419
seven	O	420-425
discrete	O	426-434
reactions	O	435-444
.	O	444-445

Amplified	O	446-455
ARSA	O	456-460
exons	O	461-466
were	O	467-471
analysed	O	472-480
for	O	481-484
the	O	485-488
presence	O	489-497
of	O	498-500
sequence	O	501-509
alterations	O	510-521
by	O	522-524
single	O	525-531
-	O	531-532
strand	O	532-538
conformation	O	539-551
polymorphism	O	552-564
analysis	O	565-573
,	O	573-574
followed	O	575-583
by	O	584-586
direct	O	587-593
sequencing	O	594-604
of	O	605-607
PCR	O	608-611
products	O	612-620
.	O	620-621

The	O	622-625
patient	O	626-633
was	O	634-637
found	O	638-643
to	O	644-646
be	O	647-649
homozygous	O	650-660
for	O	661-664
a	O	665-666
C	O	667-668
-	O	668-669
-	O	668-669
>	O	671-672
T	O	673-674
transition	O	675-685
in	O	686-688
exon	O	689-693
IV	O	694-696
that	O	697-701
results	O	702-709
in	O	710-712
the	O	713-716
substitution	O	717-729
of	O	730-732
a	O	733-734
highly	O	735-741
conserved	O	742-751
threonine	O	752-761
residue	O	762-769
at	O	770-772
amino	O	773-778
acid	O	779-783
274	O	784-787
with	O	788-792
a	O	793-794
methionine	O	795-805
(	O	806-807
T274M	O	807-812
)	O	812-813
.	O	813-814

Analysis	O	815-823
of	O	824-826
a	O	827-828
further	O	829-836
29	O	837-839
MLD	B	840-843
patients	O	844-852
revealed	O	853-861
the	O	862-865
presence	O	866-874
of	O	875-877
five	O	878-882
additional	O	883-893
homozygotes	O	894-905
for	O	906-909
T274M	O	910-915
.	O	915-916

All	O	917-920
6	O	921-922
T274M	O	923-928
homozygotes	O	929-940
(	O	941-942
representing	O	942-954
four	O	955-959
families	O	960-968
)	O	968-969
were	O	970-974
of	O	975-977
Lebanese	O	978-986
descent	O	987-994
,	O	994-995
and	O	996-999
all	O	1000-1003
were	O	1004-1008
known	O	1009-1014
to	O	1015-1017
be	O	1018-1020
the	O	1021-1024
result	O	1025-1031
of	O	1032-1034
consanguineous	O	1035-1049
marriages	O	1050-1059
.	O	1059-1060

The	O	1061-1064
altered	O	1065-1072
amino	O	1073-1078
acid	O	1079-1083
is	O	1084-1086
rigidly	O	1087-1094
conserved	O	1095-1104
among	O	1105-1110
10	O	1111-1113
sulfatases	O	1114-1124
from	O	1125-1129
Escherichia	O	1130-1141
coli	O	1142-1146
to	O	1147-1149
humans	O	1150-1156
;	O	1156-1157
therefore	O	1158-1167
,	O	1167-1168
it	O	1169-1171
is	O	1172-1174
most	O	1175-1179
likely	O	1180-1186
that	O	1187-1191
the	O	1192-1195
resultant	O	1196-1205
mutant	O	1206-1212
protein	O	1213-1220
will	O	1221-1225
have	O	1226-1230
little	O	1231-1237
or	O	1238-1240
no	O	1241-1243
enzyme	O	1244-1250
activity	O	1251-1259
.	O	1259-1260

This	O	1261-1265
is	O	1266-1268
consistent	O	1269-1279
with	O	1280-1284
the	O	1285-1288
very	O	1289-1293
low	O	1294-1297
ARSA	O	1298-1302
activity	O	1303-1311
measured	O	1312-1320
in	O	1321-1323
these	O	1324-1329
patients	O	1330-1338
and	O	1339-1342
their	O	1343-1348
uniformly	O	1349-1358
severe	O	1359-1365
clinical	O	1366-1374
presentation	O	1375-1387

Mutations	O	0-9
in	O	10-12
the	O	13-16
gene	O	17-21
for	O	22-25
X	B	26-27
-	I	27-28
linked	I	28-34
adrenoleukodystrophy	I	35-55
in	O	56-58
patients	O	59-67
with	O	68-72
different	O	73-82
clinical	O	83-91
phenotypes	O	92-102
.	O	102-103

Recently	O	104-112
,	O	112-113
the	O	114-117
gene	O	118-122
for	O	123-126
the	O	127-130
most	O	131-135
common	O	136-142
peroxisomal	B	143-154
disorder	I	155-163
,	O	163-164
X	B	165-166
-	I	166-167
linked	I	167-173
adrenoleukodystrophy	I	174-194
(	O	195-196
X	B	196-197
-	I	197-198
ALD	I	198-201
)	O	201-202
,	O	202-203
has	O	204-207
been	O	208-212
described	O	213-222
encoding	O	223-231
a	O	232-233
peroxisomal	O	234-245
membrane	O	246-254
transporter	O	255-266
protein	O	267-274
.	O	274-275

We	O	276-278
analyzed	O	279-287
the	O	288-291
entire	O	292-298
protein	O	299-306
-	O	306-307
coding	O	307-313
sequence	O	314-322
of	O	323-325
this	O	326-330
gene	O	331-335
by	O	336-338
reverse	O	339-346
-	O	346-347
transcription	O	347-360
PCR	O	361-364
,	O	364-365
SSCP	O	366-370
,	O	370-371
and	O	372-375
DNA	O	376-379
sequencing	O	380-390
in	O	391-393
five	O	394-398
patients	O	399-407
with	O	408-412
different	O	413-422
clinical	O	423-431
expression	O	432-442
of	O	443-445
X	B	446-447
-	I	447-448
ALD	I	448-451
and	O	452-455
in	O	456-458
their	O	459-464
female	O	465-471
relatives	O	472-481
;	O	481-482
these	O	483-488
clinical	O	489-497
expressions	O	498-509
were	O	510-514
cerebral	O	515-523
childhood	O	524-533
ALD	B	534-537
,	O	537-538
adrenomyeloneuropathy	B	539-560
(	O	561-562
AMN	B	562-565
)	O	565-566
,	O	566-567
and	O	568-571
"	O	572-573
Addison	B	574-581
disease	I	582-589
only	I	590-594
"	O	595-596
(	O	597-598
ADO	B	598-601
)	O	601-602
phenotype	O	603-612
.	O	612-613

In	O	614-616
the	O	617-620
three	O	621-626
patients	O	627-635
exhibiting	O	636-646
the	O	647-650
classical	O	651-660
picture	O	661-668
of	O	669-671
severe	O	672-678
childhood	O	679-688
ALD	B	689-692
we	O	693-695
identified	O	696-706
in	O	707-709
the	O	710-713
5	O	714-715
portion	O	716-723
of	O	724-726
the	O	727-730
X	B	731-732
-	I	732-733
ALD	I	733-736
gene	O	737-741
a	O	742-743
38	O	744-746
-	O	746-747
bp	O	747-749
deletion	O	750-758
that	O	759-763
causes	O	764-770
a	O	771-772
frameshift	O	773-783
mutation	O	784-792
,	O	792-793
a	O	794-795
3	O	796-797
-	O	797-798
bp	O	798-800
deletion	O	801-809
leading	O	810-817
to	O	818-820
a	O	821-822
deletion	O	823-831
of	O	832-834
an	O	835-837
amino	O	838-843
acid	O	844-848
in	O	849-851
the	O	852-855
ATP	O	856-859
-	O	859-860
binding	O	860-867
domain	O	868-874
of	O	875-877
the	O	878-881
ALD	B	882-885
protein	O	886-893
,	O	893-894
and	O	895-898
a	O	899-900
missense	O	901-909
mutation	O	910-918
.	O	918-919

In	O	920-922
the	O	923-926
patient	O	927-934
with	O	935-939
the	O	940-943
clinical	O	944-952
phenotype	O	953-962
of	O	963-965
AMN	B	966-969
,	O	969-970
a	O	971-972
nonsense	O	973-981
mutation	O	982-990
in	O	991-993
codon	O	994-999
212	O	1000-1003
,	O	1003-1004
along	O	1005-1010
with	O	1011-1015
a	O	1016-1017
second	O	1018-1024
site	O	1025-1029
mutation	O	1030-1038
at	O	1039-1041
codon	O	1042-1047
178	O	1048-1051
,	O	1051-1052
was	O	1053-1056
observed	O	1057-1065
.	O	1065-1066

Analysis	O	1067-1075
of	O	1076-1078
the	O	1079-1082
patient	O	1083-1090
with	O	1091-1095
the	O	1096-1099
ADO	B	1100-1103
phenotype	O	1104-1113
revealed	O	1114-1122
a	O	1123-1124
further	O	1125-1132
missense	O	1133-1141
mutation	O	1142-1150
at	O	1151-1153
a	O	1154-1155
highly	O	1156-1162
conserved	O	1163-1172
position	O	1173-1181
in	O	1182-1184
the	O	1185-1188
ALDP	O	1189-1193
/	O	1193-1194
PMP70	O	1194-1199
comparison	O	1200-1210
.	O	1210-1211

The	O	1212-1215
disruptive	O	1216-1226
nature	O	1227-1233
of	O	1234-1236
two	O	1237-1240
mutations	O	1241-1250
(	O	1251-1252
i	O	1252-1253
.	O	1253-1254

e	O	1255-1256
.	O	1256-1257
,	O	1257-1258
the	O	1259-1262
frameshift	O	1263-1273
and	O	1274-1277
the	O	1278-1281
nonsense	O	1282-1290
mutation	O	1291-1299
)	O	1299-1300
in	O	1301-1303
patients	O	1304-1312
with	O	1313-1317
biochemically	O	1318-1331
proved	O	1332-1338
childhood	O	1339-1348
ALD	B	1349-1352
and	O	1353-1356
AMN	B	1357-1360
further	O	1361-1368
strongly	O	1369-1377
supports	O	1378-1386
the	O	1387-1390
hypothesis	O	1391-1401
that	O	1402-1406
alterations	O	1407-1418
in	O	1419-1421
this	O	1422-1426
gene	O	1427-1431
play	O	1432-1436
a	O	1437-1438
crucial	O	1439-1446
role	O	1447-1451
in	O	1452-1454
the	O	1455-1458
pathogenesis	O	1459-1471
of	O	1472-1474
X	B	1475-1476
-	I	1476-1477
ALD	I	1477-1480
.	O	1480-1481

Since	O	1482-1487
the	O	1488-1491
current	O	1492-1499
biochemical	O	1500-1511
techniques	O	1512-1522
for	O	1523-1526
X	B	1527-1528
-	I	1528-1529
ALD	I	1529-1532
carrier	O	1533-1540
detection	O	1541-1550
in	O	1551-1553
affected	O	1554-1562
families	O	1563-1571
lack	O	1572-1576
sufficient	O	1577-1587
reliability	O	1588-1599
,	O	1599-1600
our	O	1601-1604
procedure	O	1605-1614
described	O	1615-1624
for	O	1625-1628
systematic	O	1629-1639
mutation	O	1640-1648
scanning	O	1649-1657
is	O	1658-1660
also	O	1661-1665
capable	O	1666-1673
of	O	1674-1676
improving	O	1677-1686
genetic	O	1687-1694
counseling	O	1695-1705
and	O	1706-1709
prenatal	O	1710-1718
diagnosis	O	1719-1728

Atelosteogenesis	B	0-16
type	I	17-21
II	I	22-24
is	O	25-27
caused	O	28-34
by	O	35-37
mutations	O	38-47
in	O	48-50
the	O	51-54
diastrophic	B	55-66
dysplasia	I	67-76
sulfate	O	77-84
-	O	84-85
transporter	O	85-96
gene	O	97-101
(	O	102-103
DTDST	O	103-108
)	O	108-109
:	O	109-110
evidence	O	111-119
for	O	120-123
a	O	124-125
phenotypic	O	126-136
series	O	137-143
involving	O	144-153
three	O	154-159
chondrodysplasias	B	160-177
.	O	177-178

Atelosteogenesis	B	179-195
type	I	196-200
II	I	201-203
(	O	204-205
AO	B	205-207
II	I	208-210
)	O	210-211
is	O	212-214
a	O	215-216
neonatally	O	217-227
lethal	O	228-234
chondrodysplasia	B	235-251
whose	O	252-257
clinical	O	258-266
and	O	267-270
histological	O	271-283
characteristics	O	284-299
resemble	O	300-308
those	O	309-314
of	O	315-317
another	O	318-325
chondrodysplasia	B	326-342
,	O	342-343
the	O	344-347
much	O	348-352
less	O	353-357
severe	O	358-364
diastrophic	B	365-376
dysplasia	I	377-386
(	O	387-388
DTD	B	388-391
)	O	391-392
.	O	392-393

The	O	394-397
similarity	O	398-408
suggests	O	409-417
a	O	418-419
shared	O	420-426
pathogenesis	O	427-439
involving	O	440-449
lesions	O	450-457
in	O	458-460
the	O	461-464
same	O	465-469
biochemical	O	470-481
pathway	O	482-489
and	O	490-493
perhaps	O	494-501
the	O	502-505
same	O	506-510
gene	O	511-515
.	O	515-516

DTD	B	517-520
is	O	521-523
caused	O	524-530
by	O	531-533
mutations	O	534-543
in	O	544-546
the	O	547-550
recently	O	551-559
identified	O	560-570
diastrophic	B	571-582
dysplasia	I	583-592
sulfate	O	593-600
-	O	600-601
transporter	O	601-612
gene	O	613-617
(	O	618-619
DTDST	O	619-624
)	O	624-625
.	O	625-626

Here	O	627-631
,	O	631-632
we	O	633-635
report	O	636-642
that	O	643-647
AOII	B	648-652
patients	O	653-661
also	O	662-666
have	O	667-671
DTDST	O	672-677
mutations	O	678-687
,	O	687-688
which	O	689-694
lead	O	695-699
to	O	700-702
defective	O	703-712
uptake	O	713-719
of	O	720-722
inorganic	O	723-732
sulfate	O	733-740
and	O	741-744
insufficient	O	745-757
sulfation	O	758-767
of	O	768-770
macromolecules	O	771-785
by	O	786-788
patient	O	789-796
mesenchymal	O	797-808
cells	O	809-814
in	O	815-817
vitro	O	818-823
.	O	823-824

Together	O	825-833
with	O	834-838
our	O	839-842
recent	O	843-849
observation	O	850-861
that	O	862-866
a	O	867-868
third	O	869-874
even	O	875-879
more	O	880-884
severe	O	885-891
chondrodysplasia	B	892-908
,	O	908-909
achondrogenesis	O	910-925
type	O	926-930
IB	O	931-933
,	O	933-934
is	O	935-937
also	O	938-942
caused	O	943-949
by	O	950-952
mutations	O	953-962
in	O	963-965
DTDST	O	966-971
,	O	971-972
these	O	973-978
results	O	979-986
demonstrate	O	987-998
a	O	999-1000
phenotypic	O	1001-1011
series	O	1012-1018
of	O	1019-1021
three	O	1022-1027
chondrodysplasias	B	1028-1045
of	O	1046-1048
increasing	O	1049-1059
severity	O	1060-1068
caused	O	1069-1075
by	O	1076-1078
lesions	O	1079-1086
in	O	1087-1089
a	O	1090-1091
single	O	1092-1098
sulfate	O	1099-1106
-	O	1106-1107
transporter	O	1107-1118
gene	O	1119-1123
.	O	1123-1124

The	O	1125-1128
severity	O	1129-1137
of	O	1138-1140
the	O	1141-1144
phenotype	O	1145-1154
appears	O	1155-1162
to	O	1163-1165
be	O	1166-1168
correlated	O	1169-1179
with	O	1180-1184
the	O	1185-1188
predicted	O	1189-1198
effect	O	1199-1205
of	O	1206-1208
the	O	1209-1212
mutations	O	1213-1222
on	O	1223-1225
the	O	1226-1229
residual	O	1230-1238
activity	O	1239-1247
of	O	1248-1250
the	O	1251-1254
DTDST	O	1255-1260
protein	O	1261-1268
.	O	1268-1269
.	O	1268-1269

Emerin	B	0-6
,	I	6-7
deficiency	I	8-18
of	O	19-21
which	O	22-27
causes	O	28-34
Emery	B	35-40
-	I	40-41
Dreifuss	I	41-49
muscular	I	50-58
dystrophy	I	59-68
,	O	68-69
is	O	70-72
localized	O	73-82
at	O	83-85
the	O	86-89
inner	O	90-95
nuclear	O	96-103
membrane	O	104-112
.	O	112-113

X	B	114-115
-	I	115-116
linked	I	116-122
recessive	I	123-132
Emery	I	133-138
-	I	138-139
Dreifuss	I	139-147
muscular	I	148-156
dystrophy	I	157-166
(	O	167-168
EDMD	B	168-172
)	O	172-173
is	O	174-176
an	O	177-179
inherited	B	180-189
muscle	I	190-196
disorder	I	197-205
characterized	O	206-219
by	O	220-222
the	O	223-226
clinical	O	227-235
triad	O	236-241
of	O	242-244
progressive	O	245-256
wasting	B	257-264
of	I	265-267
humero	I	268-274
-	I	274-275
peroneal	I	275-283
muscles	I	284-291
,	O	291-292
early	O	293-298
contractures	B	299-311
of	I	312-314
the	I	315-318
elbows	I	319-325
,	I	325-326
Achilles	I	327-335
tendons	I	336-343
and	I	344-347
postcervical	I	348-360
muscles	I	361-368
,	O	368-369
and	O	370-373
cardiac	B	374-381
conduction	I	382-392
block	I	393-398
with	O	399-403
a	O	404-405
high	O	406-410
risk	O	411-415
of	O	416-418
sudden	B	419-425
death	I	426-431
.	O	431-432

The	O	433-436
gene	O	437-441
for	O	442-445
EDMD	B	446-450
on	O	451-453
Xq28	O	454-458
encodes	O	459-466
a	O	467-468
novel	O	469-474
protein	O	475-482
named	O	483-488
emerin	O	489-495
that	O	496-500
localizes	O	501-510
at	O	511-513
the	O	514-517
nuclear	O	518-525
membrane	O	526-534
of	O	535-537
skeletal	O	538-546
,	O	546-547
cardiac	O	548-555
and	O	556-559
smooth	O	560-566
muscles	O	567-574
and	O	575-578
some	O	579-583
other	O	584-589
non	O	590-593
-	O	593-594
muscle	O	594-600
tissues	O	601-608
.	O	608-609

To	O	610-612
investigate	O	613-624
a	O	625-626
possible	O	627-635
physiological	O	636-649
role	O	650-654
for	O	655-658
emerin	O	659-665
,	O	665-666
we	O	667-669
examined	O	670-678
the	O	679-682
ultrastructural	O	683-698
localization	O	699-711
of	O	712-714
the	O	715-718
protein	O	719-726
in	O	727-729
human	O	730-735
skeletal	O	736-744
muscle	O	745-751
and	O	752-755
HeLa	O	756-760
cells	O	761-766
,	O	766-767
using	O	768-773
ultrathin	O	774-783
cryosections	O	784-796
.	O	796-797

We	O	798-800
found	O	801-806
that	O	807-811
the	O	812-815
immune	O	816-822
-	O	822-823
labeled	O	823-830
colloidal	O	831-840
gold	O	841-845
particles	O	846-855
were	O	856-860
localized	O	861-870
on	O	871-873
the	O	874-877
nucleoplasmic	O	878-891
surface	O	892-899
of	O	900-902
the	O	903-906
inner	O	907-912
nuclear	O	913-920
membrane	O	921-929
,	O	929-930
but	O	931-934
not	O	935-938
on	O	939-941
the	O	942-945
nuclear	O	946-953
pore	O	954-958
.	O	958-959

Emerin	O	960-966
stayed	O	967-973
on	O	974-976
the	O	977-980
cytoplasmic	O	981-992
surface	O	993-1000
of	O	1001-1003
the	O	1004-1007
nuclear	O	1008-1015
lamina	O	1016-1022
,	O	1022-1023
even	O	1024-1028
after	O	1029-1034
detergent	O	1035-1044
treatment	O	1045-1054
that	O	1055-1059
solubilizes	O	1060-1071
membrane	O	1072-1080
lipids	O	1081-1087
and	O	1088-1091
washes	O	1092-1098
out	O	1099-1102
membrane	O	1103-1111
proteins	O	1112-1120
.	O	1120-1121

These	O	1122-1127
results	O	1128-1135
suggest	O	1136-1143
that	O	1144-1148
emerin	O	1149-1155
anchors	O	1156-1163
at	O	1164-1166
the	O	1167-1170
inner	O	1171-1176
nuclear	O	1177-1184
membrane	O	1185-1193
through	O	1194-1201
the	O	1202-1205
hydrophobic	O	1206-1217
stretch	O	1218-1225
,	O	1225-1226
and	O	1227-1230
protrudes	O	1231-1240
from	O	1241-1245
the	O	1246-1249
hydrophilic	O	1250-1261
region	O	1262-1268
to	O	1269-1271
the	O	1272-1275
nucleoplasm	O	1276-1287
where	O	1288-1293
it	O	1294-1296
interacts	O	1297-1306
with	O	1307-1311
the	O	1312-1315
nuclear	O	1316-1323
lamina	O	1324-1330
.	O	1330-1331

We	O	1332-1334
speculate	O	1335-1344
that	O	1345-1349
emerin	O	1350-1356
contributes	O	1357-1368
to	O	1369-1371
maintain	O	1372-1380
the	O	1381-1384
nuclear	O	1385-1392
structure	O	1393-1402
and	O	1403-1406
stability	O	1407-1416
,	O	1416-1417
as	O	1418-1420
well	O	1421-1425
as	O	1426-1428
nuclear	O	1429-1436
functions	O	1437-1446
,	O	1446-1447
particularly	O	1448-1460
in	O	1461-1463
muscle	O	1464-1470
tissues	O	1471-1478
that	O	1479-1483
have	O	1484-1488
severe	O	1489-1495
stress	O	1496-1502
with	O	1503-1507
rigorous	O	1508-1516
contraction	O	1517-1528
-	O	1528-1529
relaxation	O	1529-1539
movements	O	1540-1549
and	O	1550-1553
calcium	O	1554-1561
flux	O	1562-1566
.	O	1566-1567
.	O	1566-1567

Identification	O	0-14
of	O	15-17
a	O	18-19
common	O	20-26
PEX1	O	27-31
mutation	O	32-40
in	O	41-43
Zellweger	B	44-53
syndrome	I	54-62
.	O	62-63

The	O	64-67
Zellweger	B	68-77
spectrum	I	78-86
of	I	87-89
disease	I	90-97
,	O	97-98
encompassing	O	99-111
Zellweger	B	112-121
syndrome	I	122-130
and	O	131-134
the	O	135-138
progressively	O	139-152
milder	O	153-159
phenotypes	O	160-170
of	O	171-173
neonatal	B	174-182
adrenoleukodystrophy	I	183-203
and	O	204-207
infantile	B	208-217
Refsum	I	218-224
disease	I	225-232
,	O	232-233
is	O	234-236
due	O	237-240
to	O	241-243
a	O	244-245
failure	O	246-253
to	O	254-256
form	O	257-261
functional	O	262-272
peroxisomes	O	273-284
.	O	284-285

Cell	O	286-290
fusion	O	291-297
complementation	O	298-313
studies	O	314-321
demonstrated	O	322-334
that	O	335-339
these	O	340-345
diseases	O	346-354
are	O	355-358
genetically	O	359-370
heterogeneous	O	371-384
,	O	384-385
with	O	386-390
two	O	391-394
-	O	394-395
thirds	O	395-401
of	O	402-404
all	O	405-408
patients	O	409-417
lying	O	418-423
within	O	424-430
a	O	431-432
single	O	433-439
complementation	O	440-455
group	O	456-461
,	O	461-462
CG1	O	463-466
.	O	466-467

Molecular	O	468-477
genetic	O	478-485
and	O	486-489
cell	O	490-494
biology	O	495-502
studies	O	503-510
have	O	511-515
shown	O	516-521
that	O	522-526
PEX1	O	527-531
is	O	532-534
deficient	O	535-544
in	O	545-547
many	O	548-552
CG1	O	553-556
patients	O	557-565
.	O	565-566

However	O	567-574
,	O	574-575
previous	O	576-584
studies	O	585-592
have	O	593-597
focused	O	598-605
on	O	606-608
mildly	O	609-615
affected	O	616-624
patients	O	625-633
and	O	634-637
there	O	638-643
is	O	644-646
still	O	647-652
no	O	653-655
report	O	656-662
of	O	663-665
two	O	666-669
mutant	O	670-676
PEX1	O	677-681
alleles	O	682-689
in	O	690-692
any	O	693-696
Zellweger	B	697-706
syndrome	I	707-715
patient	O	716-723
.	O	723-724

Furthermore	O	725-736
,	O	736-737
mutations	O	738-747
in	O	748-750
the	O	751-754
PMP70	O	755-760
gene	O	761-765
have	O	766-770
also	O	771-775
been	O	776-780
identified	O	781-791
in	O	792-794
two	O	795-798
Zellweger	B	799-808
syndrome	I	809-817
patients	O	818-826
from	O	827-831
CG1	O	832-835
,	O	835-836
raising	O	837-844
the	O	845-848
possibility	O	849-860
that	O	861-865
CG1	O	866-869
patients	O	870-878
may	O	879-882
represent	O	883-892
a	O	893-894
mixture	O	895-902
of	O	903-905
PEX1	O	906-910
-	O	910-911
deficient	O	911-920
and	O	921-924
PMP70	O	925-930
-	O	930-931
deficient	O	931-940
individuals	O	941-952
.	O	952-953

To	O	954-956
address	O	957-964
the	O	965-968
molecular	O	969-978
basis	O	979-984
of	O	985-987
disease	O	988-995
in	O	996-998
Zellweger	B	999-1008
syndrome	I	1009-1017
patients	O	1018-1026
from	O	1027-1031
CG1	O	1032-1035
,	O	1035-1036
we	O	1037-1039
examined	O	1040-1048
all	O	1049-1052
24	O	1053-1055
PEX1	O	1056-1060
exons	O	1061-1066
in	O	1067-1069
four	O	1070-1074
patients	O	1075-1083
,	O	1083-1084
including	O	1085-1094
both	O	1095-1099
patients	O	1100-1108
that	O	1109-1113
have	O	1114-1118
mutations	O	1119-1128
in	O	1129-1131
PMP70	O	1132-1137
.	O	1137-1138

PEX1	O	1139-1143
mutations	O	1144-1153
were	O	1154-1158
detected	O	1159-1167
in	O	1168-1170
all	O	1171-1174
four	O	1175-1179
patients	O	1180-1188
,	O	1188-1189
including	O	1190-1199
a	O	1200-1201
1	O	1202-1203
-	O	1203-1204
bp	O	1204-1206
insertion	O	1207-1216
(	O	1217-1218
c	O	1218-1219
.	O	1219-1220

2097insT	O	1221-1229
)	O	1229-1230
in	O	1231-1233
exon	O	1234-1238
13	O	1239-1241
that	O	1242-1246
was	O	1247-1250
present	O	1251-1258
in	O	1259-1261
three	O	1262-1267
of	O	1268-1270
the	O	1271-1274
four	O	1275-1279
patients	O	1280-1288
.	O	1288-1289

Subsequent	O	1290-1300
studies	O	1301-1308
demonstrated	O	1309-1321
that	O	1322-1326
this	O	1327-1331
mutation	O	1332-1340
is	O	1341-1343
present	O	1344-1351
in	O	1352-1354
one	O	1355-1358
-	O	1358-1359
half	O	1359-1363
of	O	1364-1366
all	O	1367-1370
CG1	O	1371-1374
patients	O	1375-1383
and	O	1384-1387
correlates	O	1388-1398
with	O	1399-1403
the	O	1404-1407
Zellweger	B	1408-1417
syndrome	I	1418-1426
phenotype	O	1427-1436
.	O	1436-1437

As	O	1438-1440
this	O	1441-1445
mutation	O	1446-1454
leads	O	1455-1460
to	O	1461-1463
a	O	1464-1465
loss	O	1466-1470
of	O	1471-1473
protein	O	1474-1481
function	O	1482-1490
its	O	1491-1494
frequency	O	1495-1504
makes	O	1505-1510
it	O	1511-1513
the	O	1514-1517
most	O	1518-1522
common	O	1523-1529
cause	O	1530-1535
of	O	1536-1538
Zellweger	B	1539-1548
syndrome	I	1549-1557
,	O	1557-1558
helping	O	1559-1566
to	O	1567-1569
explain	O	1570-1577
the	O	1578-1581
high	O	1582-1586
percentage	O	1587-1597
of	O	1598-1600
patients	O	1601-1609
that	O	1610-1614
belong	O	1615-1621
to	O	1622-1624
CG1	O	1625-1628
.	O	1628-1629

Polymorphisms	O	0-13
of	O	14-16
the	O	17-20
CYP2D6	O	21-27
gene	O	28-32
increase	O	33-41
susceptibility	O	42-56
to	O	57-59
ankylosing	B	60-70
spondylitis	I	71-82
.	O	82-83

Ankylosing	B	84-94
spondylitis	I	95-106
(	O	107-108
AS	B	108-110
)	O	110-111
is	O	112-114
a	O	115-116
common	O	117-123
and	O	124-127
highly	O	128-134
familial	O	135-143
rheumatic	B	144-153
disorder	I	154-162
.	O	162-163

The	O	164-167
sibling	O	168-175
recurrence	O	176-186
risk	O	187-191
ratio	O	192-197
for	O	198-201
the	O	202-205
disease	O	206-213
is	O	214-216
63	O	217-219
and	O	220-223
heritability	O	224-236
assessed	O	237-245
in	O	246-248
twins	O	249-254
>	O	255-256
90	O	257-259
%	O	259-260
.	O	260-261

Although	O	262-270
MHC	O	271-274
genes	O	275-280
,	O	280-281
including	O	282-291
HLA	O	292-295
-	O	295-296
B27	O	296-299
,	O	299-300
contribute	O	301-311
only	O	312-316
20	O	317-319
-	O	319-320
50	O	320-322
%	O	322-323
of	O	324-326
the	O	327-330
genetic	O	331-338
risk	O	339-343
for	O	344-347
the	O	348-351
disease	O	352-359
,	O	359-360
no	O	361-363
non	O	364-367
-	O	367-368
MHC	O	368-371
gene	O	372-376
has	O	377-380
yet	O	381-384
been	O	385-389
convincingly	O	390-402
demonstrated	O	403-415
to	O	416-418
influence	O	419-428
either	O	429-435
susceptibility	O	436-450
to	O	451-453
the	O	454-457
disease	O	458-465
or	O	466-468
its	O	469-472
phenotypic	O	473-483
expression	O	484-494
.	O	494-495

Previous	O	496-504
linkage	O	505-512
and	O	513-516
association	O	517-528
studies	O	529-536
have	O	537-541
suggested	O	542-551
the	O	552-555
presence	O	556-564
of	O	565-567
a	O	568-569
susceptibility	O	570-584
gene	O	585-589
for	O	590-593
AS	B	594-596
close	O	597-602
to	O	603-605
,	O	605-606
or	O	607-609
within	O	610-616
,	O	616-617
the	O	618-621
cytochrome	O	622-632
P450	O	633-637
2D6	O	638-641
gene	O	642-646
(	O	647-648
CYP2D6	O	648-654
,	O	654-655
debrisoquine	O	656-668
hydroxylase	O	669-680
)	O	680-681
located	O	682-689
at	O	690-692
chromosome	O	693-703
22q13	O	704-709
.	O	709-710
1	O	707-708
.	O	709-710

We	O	713-715
performed	O	716-725
a	O	726-727
linkage	O	728-735
study	O	736-741
of	O	742-744
chromosome	O	745-755
22	O	756-758
in	O	759-761
200	O	762-765
families	O	766-774
with	O	775-779
AS	B	780-782
affected	O	783-791
sibling	O	792-799
-	O	799-800
pairs	O	800-805
.	O	805-806

Association	O	807-818
of	O	819-821
alleles	O	822-829
of	O	830-832
the	O	833-836
CYP2D6	O	837-843
gene	O	844-848
was	O	849-852
examined	O	853-861
by	O	862-864
both	O	865-869
case	O	870-874
-	O	874-875
control	O	875-882
and	O	883-886
within	O	887-893
-	O	893-894
family	O	894-900
means	O	901-906
.	O	906-907

For	O	908-911
case	O	912-916
-	O	916-917
control	O	917-924
studies	O	925-932
,	O	932-933
617	O	934-937
unrelated	O	938-947
individuals	O	948-959
with	O	960-964
AS	B	965-967
(	O	968-969
361	O	969-972
probands	O	973-981
from	O	982-986
sibling	O	987-994
-	O	994-995
pair	O	995-999
and	O	1000-1003
parent	O	1004-1010
-	O	1010-1011
case	O	1011-1015
trio	O	1016-1020
families	O	1021-1029
and	O	1030-1033
256	O	1034-1037
unrelated	O	1038-1047
non	O	1048-1051
-	O	1051-1052
familial	O	1052-1060
sporadic	O	1061-1069
cases	O	1070-1075
)	O	1075-1076
and	O	1077-1080
402	O	1081-1084
healthy	O	1085-1092
ethnically	O	1093-1103
matched	O	1104-1111
controls	O	1112-1120
were	O	1121-1125
employed	O	1126-1134
.	O	1134-1135

For	O	1136-1139
within	O	1140-1146
-	O	1146-1147
family	O	1147-1153
association	O	1154-1165
studies	O	1166-1173
,	O	1173-1174
361	O	1175-1178
families	O	1179-1187
including	O	1188-1197
161	O	1198-1201
parent	O	1202-1208
-	O	1208-1209
case	O	1209-1213
trios	O	1214-1219
and	O	1220-1223
200	O	1224-1227
affected	O	1228-1236
sibling	O	1237-1244
-	O	1244-1245
pair	O	1245-1249
families	O	1250-1258
were	O	1259-1263
employed	O	1264-1272
.	O	1272-1273

Homozygosity	O	1274-1286
for	O	1287-1290
poor	O	1291-1295
metabolizer	O	1296-1307
alleles	O	1308-1315
was	O	1316-1319
found	O	1320-1325
to	O	1326-1328
be	O	1329-1331
associated	O	1332-1342
with	O	1343-1347
AS	B	1348-1350
.	O	1350-1351

Heterozygosity	O	1352-1366
for	O	1367-1370
the	O	1371-1374
most	O	1375-1379
frequent	O	1380-1388
poor	O	1389-1393
metabolizer	O	1394-1405
allele	O	1406-1412
(	O	1413-1414
CYP2D6	O	1414-1420
*	O	1420-1421
4	O	1421-1422
)	O	1422-1423
was	O	1424-1427
not	O	1428-1431
associated	O	1432-1442
with	O	1443-1447
increased	O	1448-1457
susceptibility	O	1458-1472
to	O	1473-1475
AS	B	1476-1478
.	O	1478-1479
Significant	O	1480-1491
within	O	1492-1498
-	O	1498-1499
family	O	1499-1505
association	O	1506-1517
of	O	1518-1520
CYP2D6	O	1521-1527
*	O	1527-1528
4	O	1528-1529
alleles	O	1530-1537
and	O	1538-1541
AS	B	1542-1544
was	O	1545-1548
demonstrated	O	1549-1561
.	O	1561-1562

Weak	O	1563-1567
linkage	O	1568-1575
was	O	1576-1579
also	O	1580-1584
demonstrated	O	1585-1597
between	O	1598-1605
CYP2D6	O	1606-1612
and	O	1613-1616
AS	B	1617-1619
.	O	1619-1620

We	O	1621-1623
postulate	O	1624-1633
that	O	1634-1638
altered	O	1639-1646
metabolism	O	1647-1657
of	O	1658-1660
a	O	1661-1662
natural	O	1663-1670
toxin	O	1671-1676
or	O	1677-1679
antigen	O	1680-1687
by	O	1688-1690
the	O	1691-1694
CYP2D6	O	1695-1701
gene	O	1702-1706
may	O	1707-1710
increase	O	1711-1719
susceptibility	O	1720-1734
to	O	1735-1737
AS	B	1738-1740
.	O	1740-1741

Molecular	O	0-9
analysis	O	10-18
of	O	19-21
the	O	22-25
genotype	O	26-34
-	O	34-35
phenotype	O	35-44
relationship	O	45-57
in	O	58-60
factor	B	61-67
X	I	68-69
deficiency	I	70-80
.	O	80-81

Factor	B	82-88
X	I	89-90
deficiency	I	91-101
is	O	102-104
a	O	105-106
rare	O	107-111
haemorrhagic	B	112-124
condition	I	125-134
,	O	134-135
normally	O	136-144
inherited	O	145-154
as	O	155-157
an	O	158-160
autosomal	O	161-170
recessive	O	171-180
trait	O	181-186
,	O	186-187
in	O	188-190
which	O	191-196
a	O	197-198
variable	O	199-207
clinical	O	208-216
presentation	O	217-229
correlates	O	230-240
poorly	O	241-247
with	O	248-252
laboratory	O	253-263
phenotype	O	264-273
.	O	273-274

The	O	275-278
factor	O	279-285
X	O	286-287
(	O	288-289
F10	O	289-292
)	O	292-293
genes	O	294-299
of	O	300-302
14	O	303-305
unrelated	O	306-315
individuals	O	316-327
with	O	328-332
factor	B	333-339
X	I	340-341
deficiency	I	342-352
(	O	353-354
12	O	354-356
familial	O	357-365
and	O	366-369
two	O	370-373
sporadic	O	374-382
cases	O	383-388
)	O	388-389
were	O	390-394
sequenced	O	395-404
yielding	O	405-413
a	O	414-415
total	O	416-421
of	O	422-424
13	O	425-427
novel	O	428-433
mutations	O	434-443
.	O	443-444

Family	O	445-451
studies	O	452-459
were	O	460-464
performed	O	465-474
in	O	475-477
order	O	478-483
to	O	484-486
distinguish	O	487-498
the	O	499-502
contributions	O	503-516
of	O	517-519
individual	O	520-530
mutant	O	531-537
F10	O	538-541
alleles	O	542-549
to	O	550-552
the	O	553-556
clinical	O	557-565
and	O	566-569
laboratory	O	570-580
phenotypes	O	581-591
.	O	591-592

Missense	O	593-601
mutations	O	602-611
were	O	612-616
studied	O	617-624
by	O	625-627
means	O	628-633
of	O	634-636
molecular	O	637-646
modelling	O	647-656
,	O	656-657
whereas	O	658-665
single	O	666-672
basepair	O	673-681
substitutions	O	682-695
in	O	696-698
splice	O	699-705
sites	O	706-711
and	O	712-715
the	O	716-719
5	O	720-721
flanking	O	722-730
region	O	731-737
were	O	738-742
examined	O	743-751
by	O	752-754
in	O	755-757
vitro	O	758-763
splicing	O	764-772
assay	O	773-778
and	O	779-782
luciferase	O	783-793
reporter	O	794-802
gene	O	803-807
assay	O	808-813
respectively	O	814-826
.	O	826-827

The	O	828-831
deletion	O	832-840
allele	O	841-847
of	O	848-850
a	O	851-852
novel	O	853-858
hexanucleotide	O	859-873
insertion	O	874-883
/	O	883-884
deletion	O	884-892
polymorphism	O	893-905
in	O	906-908
the	O	909-912
F10	O	913-916
gene	O	917-921
promoter	O	922-930
region	O	931-937
was	O	938-941
shown	O	942-947
by	O	948-950
reporter	O	951-959
gene	O	960-964
assay	O	965-970
,	O	970-971
to	O	972-974
reduce	O	975-981
promoter	O	982-990
activity	O	991-999
by	O	1000-1002
approximately	O	1003-1016
20	O	1017-1019
%	O	1019-1020
.	O	1020-1021

One	O	1022-1025
family	O	1026-1032
manifesting	O	1033-1044
an	O	1045-1047
autosomal	O	1048-1057
dominant	O	1058-1066
pattern	O	1067-1074
of	O	1075-1077
inheritance	O	1078-1089
possessed	O	1090-1099
three	O	1100-1105
clinically	O	1106-1116
affected	O	1117-1125
members	O	1126-1133
who	O	1134-1137
were	O	1138-1142
heterozygous	O	1143-1155
for	O	1156-1159
a	O	1160-1161
splice	O	1162-1168
-	O	1168-1169
site	O	1169-1173
mutation	O	1174-1182
that	O	1183-1187
was	O	1188-1191
predicted	O	1192-1201
to	O	1202-1204
lead	O	1205-1209
to	O	1210-1212
the	O	1213-1216
production	O	1217-1227
of	O	1228-1230
a	O	1231-1232
truncated	O	1233-1242
protein	O	1243-1250
product	O	1251-1258
.	O	1258-1259

A	O	1260-1261
model	O	1262-1267
which	O	1268-1273
accounts	O	1274-1282
for	O	1283-1286
the	O	1287-1290
dominant	O	1291-1299
negative	O	1300-1308
effect	O	1309-1315
of	O	1316-1318
this	O	1319-1323
lesion	O	1324-1330
is	O	1331-1333
presented	O	1334-1343
.	O	1343-1344

Variation	O	1345-1354
in	O	1355-1357
the	O	1358-1361
antigen	O	1362-1369
level	O	1370-1375
of	O	1376-1378
heterozygous	O	1379-1391
relatives	O	1392-1401
of	O	1402-1404
probands	O	1405-1413
was	O	1414-1417
found	O	1418-1423
to	O	1424-1426
be	O	1427-1429
significantly	O	1430-1443
higher	O	1444-1450
between	O	1451-1458
families	O	1459-1467
than	O	1468-1472
within	O	1473-1479
families	O	1480-1488
,	O	1488-1489
consistent	O	1490-1500
with	O	1501-1505
the	O	1506-1509
view	O	1510-1514
that	O	1515-1519
the	O	1520-1523
nature	O	1524-1530
of	O	1531-1533
the	O	1534-1537
F10	O	1538-1541
lesion	O	1542-1548
(	O	1549-1550
s	O	1550-1551
)	O	1551-1552
segregating	O	1553-1564
in	O	1565-1567
a	O	1568-1569
given	O	1570-1575
family	O	1576-1582
is	O	1583-1585
a	O	1586-1587
prime	O	1588-1593
determinant	O	1594-1605
of	O	1606-1608
the	O	1609-1612
laboratory	O	1613-1623
phenotype	O	1624-1633
.	O	1633-1634

By	O	1635-1637
contrast	O	1638-1646
,	O	1646-1647
no	O	1648-1650
such	O	1651-1655
relationship	O	1656-1668
could	O	1669-1674
be	O	1675-1677
discerned	O	1678-1687
between	O	1688-1695
laboratory	O	1696-1706
phenotype	O	1707-1716
and	O	1717-1720
polymorphism	O	1721-1733
genotype	O	1734-1742
.	O	1742-1743
.	O	1742-1743

Restoration	O	0-11
of	O	12-14
photoreceptor	O	15-28
ultrastructure	O	29-43
and	O	44-47
function	O	48-56
in	O	57-59
retinal	B	60-67
degeneration	I	68-80
slow	O	81-85
mice	O	86-90
by	O	91-93
gene	O	94-98
therapy	O	99-106
.	O	106-107

The	O	108-111
gene	O	112-116
Prph2	O	117-122
encodes	O	123-130
a	O	131-132
photoreceptor	O	133-146
-	O	146-147
specific	O	147-155
membrane	O	156-164
glycoprotein	O	165-177
,	O	177-178
peripherin	O	179-189
-	O	189-190
2	O	190-191
(	O	192-193
also	O	193-197
known	O	198-203
as	O	204-206
peripherin	O	207-217
/	O	217-218
rds	O	218-221
)	O	221-222
,	O	222-223
which	O	224-229
is	O	230-232
inserted	O	233-241
into	O	242-246
the	O	247-250
rims	O	251-255
of	O	256-258
photoreceptor	O	259-272
outer	O	273-278
segment	O	279-286
discs	O	287-292
in	O	293-295
a	O	296-297
complex	O	298-305
with	O	306-310
rom	O	311-314
-	O	314-315
1	O	315-316
(	O	317-318
ref	O	318-321
.	O	321-322

2	O	323-324
)	O	324-325
.	O	325-326

The	O	327-330
complex	O	331-338
is	O	339-341
necessary	O	342-351
for	O	352-355
the	O	356-359
stabilization	O	360-373
of	O	374-376
the	O	377-380
discs	O	381-386
,	O	386-387
which	O	388-393
are	O	394-397
renewed	O	398-405
constantly	O	406-416
throughout	O	417-427
life	O	428-432
,	O	432-433
and	O	434-437
which	O	438-443
contain	O	444-451
the	O	452-455
visual	O	456-462
pigments	O	463-471
necessary	O	472-481
for	O	482-485
photon	O	486-492
capture	O	493-500
.	O	500-501

Mutations	O	502-511
in	O	512-514
Prph2	O	515-520
have	O	521-525
been	O	526-530
shown	O	531-536
to	O	537-539
result	O	540-546
in	O	547-549
a	O	550-551
variety	O	552-559
of	O	560-562
photoreceptor	B	563-576
dystrophies	I	577-588
,	O	588-589
including	O	590-599
autosomal	B	600-609
dominant	I	610-618
retinitis	I	619-628
pigmentosa	I	629-639
and	O	640-643
macular	B	644-651
dystrophy	I	652-661
.	O	661-662

A	O	663-664
common	O	665-671
feature	O	672-679
of	O	680-682
these	O	683-688
diseases	O	689-697
is	O	698-700
the	O	701-704
loss	O	705-709
of	O	710-712
photoreceptor	O	713-726
function	O	727-735
,	O	735-736
also	O	737-741
seen	O	742-746
in	O	747-749
the	O	750-753
retinal	B	754-761
degeneration	I	762-774
slow	O	775-779
(	O	780-781
rds	O	781-784
or	O	785-787
Prph2	O	788-793
Rd2	O	794-797
/	O	797-798
Rd2	O	794-797
)	O	801-802
mouse	O	803-808
,	O	808-809
which	O	810-815
is	O	816-818
homozygous	O	819-829
for	O	830-833
a	O	834-835
null	O	836-840
mutation	O	841-849
in	O	850-852
Prph2	O	853-858
.	O	858-859

It	O	860-862
is	O	863-865
characterized	O	866-879
by	O	880-882
a	O	883-884
complete	O	885-893
failure	O	894-901
to	O	902-904
develop	O	905-912
photoreceptor	O	913-926
discs	O	927-932
and	O	933-936
outer	O	937-942
segments	O	943-951
,	O	951-952
downregulation	O	953-967
of	O	968-970
rhodopsin	O	971-980
and	O	981-984
apoptotic	O	985-994
loss	O	995-999
of	O	1000-1002
photoreceptor	O	1003-1016
cells	O	1017-1022
.	O	1022-1023

The	O	1024-1027
electroretinograms	O	1028-1046
(	O	1047-1048
ERGs	O	1048-1052
)	O	1052-1053
of	O	1054-1056
Prph2Rd2	O	1057-1065
/	O	1065-1066
Rd2	O	1062-1065
mice	O	1070-1074
have	O	1075-1079
greatly	O	1080-1087
diminished	O	1088-1098
a	O	1099-1100
-	O	1100-1101
wave	O	1101-1105
and	O	1106-1109
b	O	1110-1111
-	O	1111-1112
wave	O	1112-1116
amplitudes	O	1117-1127
,	O	1127-1128
which	O	1129-1134
decline	O	1135-1142
to	O	1143-1145
virtually	O	1146-1155
undetectable	O	1156-1168
concentrations	O	1169-1183
by	O	1184-1186
two	O	1187-1190
months	O	1191-1197
.	O	1197-1198

Subretinal	O	1199-1209
injection	O	1210-1219
of	O	1220-1222
recombinant	O	1223-1234
adeno	O	1235-1240
-	O	1240-1241
associated	O	1241-1251
virus	O	1252-1257
(	O	1258-1259
AAV	O	1259-1262
)	O	1262-1263
encoding	O	1264-1272
a	O	1273-1274
Prph2	O	1275-1280
transgene	O	1281-1290
results	O	1291-1298
in	O	1299-1301
stable	O	1302-1308
generation	O	1309-1319
of	O	1320-1322
outer	O	1323-1328
segment	O	1329-1336
structures	O	1337-1347
and	O	1348-1351
formation	O	1352-1361
of	O	1362-1364
new	O	1365-1368
stacks	O	1369-1375
of	O	1376-1378
discs	O	1379-1384
containing	O	1385-1395
both	O	1396-1400
perpherin	O	1401-1410
-	O	1410-1411
2	O	1411-1412
and	O	1413-1416
rhodopsin	O	1417-1426
,	O	1426-1427
which	O	1428-1433
in	O	1434-1436
many	O	1437-1441
cases	O	1442-1447
are	O	1448-1451
morphologically	O	1452-1467
similar	O	1468-1475
to	O	1476-1478
normal	O	1479-1485
outer	O	1486-1491
segments	O	1492-1500
.	O	1500-1501

Moreover	O	1502-1510
,	O	1510-1511
the	O	1512-1515
re	O	1516-1518
-	O	1518-1519
establishment	O	1519-1532
of	O	1533-1535
the	O	1536-1539
structural	O	1540-1550
integrity	O	1551-1560
of	O	1561-1563
the	O	1564-1567
photoreceptor	O	1568-1581
layer	O	1582-1587
also	O	1588-1592
results	O	1593-1600
in	O	1601-1603
electrophysiological	O	1604-1624
correction	O	1625-1635
.	O	1635-1636

These	O	1637-1642
studies	O	1643-1650
demonstrate	O	1651-1662
for	O	1663-1666
the	O	1667-1670
first	O	1671-1676
time	O	1677-1681
that	O	1682-1686
a	O	1687-1688
complex	O	1689-1696
ultrastructural	O	1697-1712
cell	O	1713-1717
defect	O	1718-1724
can	O	1725-1728
be	O	1729-1731
corrected	O	1732-1741
both	O	1742-1746
morphologically	O	1747-1762
and	O	1763-1766
functionally	O	1767-1779
by	O	1780-1782
in	O	1783-1785
vivo	O	1786-1790
gene	O	1791-1795
transfer	O	1796-1804
.	O	1804-1805
.	O	1804-1805

Phenylalanine	O	0-13
hydroxylase	O	14-25
gene	O	26-30
haplotypes	O	31-41
in	O	42-44
Polynesians	O	45-56
:	O	56-57
evolutionary	O	58-70
origins	O	71-78
and	O	79-82
absence	O	83-90
of	O	91-93
alleles	O	94-101
associated	O	102-112
with	O	113-117
severe	O	118-124
phenylketonuria	B	125-140
.	O	140-141

A	O	142-143
total	O	144-149
of	O	150-152
630	O	153-156
haplotypes	O	157-167
for	O	168-171
the	O	172-175
phenylalanine	O	176-189
hydroxylase	O	190-201
(	O	202-203
PAH	O	203-206
)	O	206-207
gene	O	208-212
locus	O	213-218
were	O	219-223
established	O	224-235
in	O	236-238
five	O	239-243
groups	O	244-250
of	O	251-253
Polynesians	O	254-265
comprising	O	266-276
Samoans	O	277-284
,	O	284-285
Tongans	O	286-293
,	O	293-294
Cook	O	295-299
Islanders	O	300-309
,	O	309-310
Maori	O	311-316
,	O	316-317
and	O	318-321
Niueans	O	322-329
.	O	329-330

Considerable	O	331-343
genetic	O	344-351
continuity	O	352-362
was	O	363-366
demonstrated	O	367-379
between	O	380-387
these	O	388-393
widely	O	394-400
dispersed	O	401-410
populations	O	411-422
,	O	422-423
since	O	424-429
three	O	430-435
common	O	436-442
haplotypes	O	443-453
(	O	454-455
4	O	455-456
,	O	456-457
1	O	458-459
,	O	459-460
and	O	461-464
7	O	465-466
)	O	466-467
constituted	O	468-479
over	O	480-484
95	O	485-487
%	O	487-488
of	O	489-491
alleles	O	492-499
.	O	499-500

A	O	501-502
control	O	503-510
group	O	511-516
of	O	517-519
individuals	O	520-531
from	O	532-536
Southeast	O	537-546
Asia	O	547-551
shared	O	552-558
the	O	559-562
same	O	563-567
major	O	568-573
haplotypes	O	574-584
,	O	584-585
4	O	586-587
,	O	587-588
1	O	589-590
,	O	590-591
and	O	592-595
7	O	596-597
,	O	597-598
with	O	599-603
Polynesians	O	604-615
.	O	615-616

These	O	617-622
data	O	623-627
provide	O	628-635
further	O	636-643
support	O	644-651
for	O	652-655
the	O	656-659
theories	O	660-668
of	O	669-671
genetic	O	672-679
homogeneity	O	680-691
and	O	692-695
of	O	696-698
Asian	O	699-704
affinities	O	705-715
of	O	716-718
the	O	719-722
Polynesian	O	723-733
precursor	O	734-743
populations	O	744-755
.	O	755-756

The	O	757-760
absence	O	761-768
of	O	769-771
severe	O	772-778
phenylketonuria	B	779-794
(	O	795-796
PKU	B	796-799
)	O	799-800
in	O	801-803
both	O	804-808
Polynesians	O	809-820
and	O	821-824
Southeast	O	825-834
Asians	O	835-841
is	O	842-844
consistent	O	845-855
with	O	856-860
the	O	861-864
lack	O	865-869
of	O	870-872
PAH	O	873-876
haplotypes	O	877-887
2	O	888-889
and	O	890-893
3	O	894-895
,	O	895-896
on	O	897-899
which	O	900-905
the	O	906-909
severe	O	910-916
PKU	B	917-920
mutants	O	921-928
have	O	929-933
arisen	O	934-940
among	O	941-946
Caucasians	O	947-957
.	O	957-958
.	O	957-958

cDNA	O	0-4
microarrays	O	5-16
detect	O	17-23
activation	O	24-34
of	O	35-37
a	O	38-39
myogenic	O	40-48
transcription	O	49-62
program	O	63-70
by	O	71-73
the	O	74-77
PAX3	O	78-82
-	O	82-83
FKHR	O	83-87
fusion	O	88-94
oncogene	O	95-103
.	O	103-104

Alveolar	B	105-113
rhabdomyosarcoma	I	114-130
is	O	131-133
an	O	134-136
aggressive	O	137-147
pediatric	B	148-157
cancer	I	158-164
of	I	165-167
striated	I	168-176
muscle	I	177-183
characterized	O	184-197
in	O	198-200
60	O	201-203
%	O	203-204
of	O	205-207
cases	O	208-213
by	O	214-216
a	O	217-218
t	O	219-220
(	O	221-222
2	O	222-223
;	O	223-224
13	O	225-227
)	O	227-228
(	O	229-230
q35	O	230-233
;	O	233-234
q14	O	235-238
)	O	238-239
.	O	239-240

This	O	241-245
results	O	246-253
in	O	254-256
the	O	257-260
fusion	O	261-267
of	O	268-270
PAX3	O	271-275
,	O	275-276
a	O	277-278
developmental	O	279-292
transcription	O	293-306
factor	O	307-313
required	O	314-322
for	O	323-326
limb	O	327-331
myogenesis	O	332-342
,	O	342-343
with	O	344-348
FKHR	O	349-353
,	O	353-354
a	O	355-356
member	O	357-363
of	O	364-366
the	O	367-370
forkhead	O	371-379
family	O	380-386
of	O	387-389
transcription	O	390-403
factors	O	404-411
.	O	411-412

The	O	413-416
resultant	O	417-426
PAX3	O	427-431
-	O	431-432
FKHR	O	432-436
gene	O	437-441
possesses	O	442-451
transforming	O	452-464
properties	O	465-475
;	O	475-476
however	O	477-484
,	O	484-485
the	O	486-489
effects	O	490-497
of	O	498-500
this	O	501-505
chimeric	O	506-514
oncogene	O	515-523
on	O	524-526
gene	O	527-531
expression	O	532-542
are	O	543-546
largely	O	547-554
unknown	O	555-562
.	O	562-563

To	O	564-566
investigate	O	567-578
the	O	579-582
actions	O	583-590
of	O	591-593
these	O	594-599
transcription	O	600-613
factors	O	614-621
,	O	621-622
both	O	623-627
Pax3	O	628-632
and	O	633-636
PAX3	O	637-641
-	O	641-642
FKHR	O	642-646
were	O	647-651
introduced	O	652-662
into	O	663-667
NIH	O	668-671
3T3	O	672-675
cells	O	676-681
,	O	681-682
and	O	683-686
the	O	687-690
resultant	O	691-700
gene	O	701-705
expression	O	706-716
changes	O	717-724
were	O	725-729
analyzed	O	730-738
with	O	739-743
a	O	744-745
murine	O	746-752
cDNA	O	753-757
microarray	O	758-768
containing	O	769-779
2	O	780-781
,	O	781-782
225	O	783-786
elements	O	787-795
.	O	795-796

We	O	797-799
found	O	800-805
that	O	806-810
PAX3	O	811-815
-	O	815-816
FKHR	O	816-820
but	O	821-824
not	O	825-828
PAX3	O	829-833
activated	O	834-843
a	O	844-845
myogenic	O	846-854
transcription	O	855-868
program	O	869-876
including	O	877-886
the	O	887-890
induction	O	891-900
of	O	901-903
transcription	O	904-917
factors	O	918-925
MyoD	O	926-930
,	O	930-931
Myogenin	O	932-940
,	O	940-941
Six1	O	942-946
,	O	946-947
and	O	948-951
Slug	O	952-956
as	O	957-959
well	O	960-964
as	O	965-967
a	O	968-969
battery	O	970-977
of	O	978-980
genes	O	981-986
involved	O	987-995
in	O	996-998
several	O	999-1006
aspects	O	1007-1014
of	O	1015-1017
muscle	O	1018-1024
function	O	1025-1033
.	O	1033-1034

Notable	O	1035-1042
among	O	1043-1048
this	O	1049-1053
group	O	1054-1059
were	O	1060-1064
the	O	1065-1068
growth	O	1069-1075
factor	O	1076-1082
gene	O	1083-1087
Igf2	O	1088-1092
and	O	1093-1096
its	O	1097-1100
binding	O	1101-1108
protein	O	1109-1116
Igfbp5	O	1117-1123
.	O	1123-1124

Relevance	O	1125-1134
of	O	1135-1137
this	O	1138-1142
model	O	1143-1148
was	O	1149-1152
suggested	O	1153-1162
by	O	1163-1165
verification	O	1166-1178
that	O	1179-1183
three	O	1184-1189
of	O	1190-1192
these	O	1193-1198
genes	O	1199-1204
(	O	1205-1206
IGFBP5	O	1206-1212
,	O	1212-1213
HSIX1	O	1214-1219
,	O	1219-1220
and	O	1221-1224
Slug	O	1225-1229
)	O	1229-1230
were	O	1231-1235
also	O	1236-1240
expressed	O	1241-1250
in	O	1251-1253
alveolar	B	1254-1262
rhabdomyosarcoma	I	1263-1279
cell	O	1280-1284
lines	O	1285-1290
.	O	1290-1291

This	O	1292-1296
study	O	1297-1302
utilizes	O	1303-1311
cDNA	O	1312-1316
microarrays	O	1317-1328
to	O	1329-1331
elucidate	O	1332-1341
the	O	1342-1345
pattern	O	1346-1353
of	O	1354-1356
gene	O	1357-1361
expression	O	1362-1372
induced	O	1373-1380
by	O	1381-1383
an	O	1384-1386
oncogenic	O	1387-1396
transcription	O	1397-1410
factor	O	1411-1417
and	O	1418-1421
demonstrates	O	1422-1434
the	O	1435-1438
profound	O	1439-1447
myogenic	O	1448-1456
properties	O	1457-1467
of	O	1468-1470
PAX3	O	1471-1475
-	O	1475-1476
FKHR	O	1476-1480
in	O	1481-1483
NIH	O	1484-1487
3T3	O	1488-1491
cells	O	1492-1497
.	O	1497-1498
.	O	1497-1498

Re	O	0-2
-	O	2-3
evaluation	O	3-13
of	O	14-16
the	O	17-20
sublocalization	O	21-36
of	O	37-39
esterase	O	40-48
D	O	49-50
and	O	51-54
its	O	55-58
relation	O	59-67
to	O	68-70
the	O	71-74
retinoblastoma	B	75-89
locus	O	90-95
by	O	96-98
in	O	99-101
situ	O	102-106
hybridization	O	107-120
.	O	120-121

In	O	122-124
situ	O	125-129
hybridization	O	130-143
of	O	144-146
a	O	147-148
cDNA	O	149-153
probe	O	154-159
for	O	160-163
the	O	164-167
esterase	O	168-176
D	O	177-178
gene	O	179-183
(	O	184-185
ESD	O	185-188
)	O	188-189
was	O	190-193
carried	O	194-201
out	O	202-205
on	O	206-208
human	O	209-214
chromosomes	O	215-226
.	O	226-227

The	O	228-231
probe	O	232-237
hybridized	O	238-248
most	O	249-253
strongly	O	254-262
to	O	263-265
13q14	O	266-271
.	O	271-272
2	O	273-274
and	O	275-278
13q14	O	279-284
.	O	284-285

3	O	286-287
.	O	287-288

This	O	289-293
observation	O	294-305
raises	O	306-312
doubts	O	313-319
concerning	O	320-330
the	O	331-334
most	O	335-339
recently	O	340-348
published	O	349-358
assignment	O	359-369
of	O	370-372
ESD	O	373-376
to	O	377-379
13q14	O	380-385
.	O	385-386
1	O	387-388
.	O	388-389

A	O	390-391
deletion	O	392-400
in	O	401-403
an	O	404-406
individual	O	407-417
with	O	418-422
retinoblastoma	B	423-437
was	O	438-441
reported	O	442-450
to	O	451-453
separate	O	454-462
the	O	463-466
closely	O	467-474
linked	O	475-481
ESD	O	482-485
and	O	486-489
retinoblastoma	B	490-504
(	O	505-506
RB1	O	506-509
)	O	509-510
loci	O	511-515
,	O	515-516
placing	O	517-524
ESD	O	525-528
proximal	O	529-537
to	O	538-540
RB1	O	541-544
.	O	544-545

Quantitative	O	546-558
in	O	559-561
situ	O	562-566
hybridization	O	567-580
studies	O	581-588
of	O	589-591
this	O	592-596
deletion	O	597-605
do	O	606-608
not	O	609-612
confirm	O	613-620
this	O	621-625
interpretation	O	626-640
.	O	640-641

Rather	O	642-648
,	O	648-649
they	O	650-654
suggest	O	655-662
that	O	663-667
ESD	O	668-671
is	O	672-674
missing	O	675-682
from	O	683-687
the	O	688-691
deleted	O	692-699
chromosome	O	700-710
13	O	711-713
and	O	714-717
duplicated	O	718-728
on	O	729-731
the	O	732-735
normal	O	736-742
homolog	O	743-750
.	O	750-751

From	O	752-756
these	O	757-762
findings	O	763-771
,	O	771-772
we	O	773-775
conclude	O	776-784
that	O	785-789
the	O	790-793
deletion	O	794-802
in	O	803-805
this	O	806-810
individual	O	811-821
cannot	O	822-828
be	O	829-831
used	O	832-836
to	O	837-839
determine	O	840-849
the	O	850-853
orientation	O	854-865
nor	O	866-869
the	O	870-873
sublocalization	O	874-889
of	O	890-892
ESD	O	893-896
and	O	897-900
RB1	O	901-904
within	O	905-911
the	O	912-915
13q14	O	916-921
region	O	922-928
.	O	928-929

The	O	0-3
DNA	O	4-7
double	O	8-14
-	O	14-15
strand	O	15-21
break	O	22-27
repair	O	28-34
gene	O	35-39
hMRE11	O	40-46
is	O	47-49
mutated	O	50-57
in	O	58-60
individuals	O	61-72
with	O	73-77
an	O	78-80
ataxia	B	81-87
-	I	87-88
telangiectasia	I	88-102
-	I	87-88
like	I	103-107
disorder	I	108-116
.	O	116-117

We	O	118-120
show	O	121-125
that	O	126-130
hypomorphic	O	131-142
mutations	O	143-152
in	O	153-155
hMRE11	O	156-162
,	O	162-163
but	O	164-167
not	O	168-171
in	O	172-174
ATM	O	175-178
,	O	178-179
are	O	180-183
present	O	184-191
in	O	192-194
certain	O	195-202
individuals	O	203-214
with	O	215-219
an	O	220-222
ataxia	B	223-229
-	I	229-230
telangiectasia	I	230-244
-	I	229-230
like	I	245-249
disorder	I	250-258
(	O	259-260
ATLD	B	260-264
)	O	264-265
.	O	265-266

The	O	267-270
cellular	O	271-279
features	O	280-288
resulting	O	289-298
from	O	299-303
these	O	304-309
hMRE11	O	310-316
mutations	O	317-326
are	O	327-330
similar	O	331-338
to	O	339-341
those	O	342-347
seen	O	348-352
in	O	353-355
A	B	356-357
-	I	357-358
T	I	358-359
as	O	360-362
well	O	363-367
as	O	368-370
NBS	B	371-374
and	O	375-378
include	O	379-386
hypersensitivity	B	387-403
to	I	404-406
ionizing	I	407-415
radiation	I	416-425
,	O	425-426
radioresistant	O	427-441
DNA	O	442-445
synthesis	O	446-455
,	O	455-456
and	O	457-460
abrogation	O	461-471
of	O	472-474
ATM	O	475-478
-	O	478-479
dependent	O	479-488
events	O	489-495
,	O	495-496
such	O	497-501
as	O	502-504
the	O	505-508
activation	O	509-519
of	O	520-522
Jun	O	523-526
kinase	O	527-533
following	O	534-543
exposure	O	544-552
to	O	553-555
gamma	O	556-561
irradiation	O	562-573
.	O	573-574

Although	O	575-583
the	O	584-587
mutant	O	588-594
hMre11	O	595-601
proteins	O	602-610
retain	O	611-617
some	O	618-622
ability	O	623-630
to	O	631-633
interact	O	634-642
with	O	643-647
hRad50	O	648-654
and	O	655-658
Nbs1	O	659-663
,	O	663-664
formation	O	665-674
of	O	675-677
ionizing	O	678-686
radiation	O	687-696
-	O	696-697
induced	O	697-704
hMre11	O	705-711
and	O	712-715
Nbs1	O	716-720
foci	O	721-725
was	O	726-729
absent	O	730-736
in	O	737-739
hMRE11	O	740-746
mutant	O	747-753
cells	O	754-759
.	O	759-760

These	O	761-766
data	O	767-771
demonstrate	O	772-783
that	O	784-788
ATM	O	789-792
and	O	793-796
the	O	797-800
hMre11	O	801-807
/	O	807-808
hRad50	O	808-814
/	O	807-808
Nbs1	O	815-819
protein	O	820-827
complex	O	828-835
act	O	836-839
in	O	840-842
the	O	843-846
same	O	847-851
DNA	O	852-855
damage	O	856-862
response	O	863-871
pathway	O	872-879
and	O	880-883
link	O	884-888
hMre11	O	889-895
to	O	896-898
the	O	899-902
complex	O	903-910
pathology	O	911-920
of	O	921-923
A	B	924-925
-	I	925-926
T	I	926-927
.	O	927-928
.	O	927-928

Duchenne	B	0-8
muscular	I	9-17
dystrophy	I	18-27
gene	O	28-32
expression	O	33-43
in	O	44-46
normal	O	47-53
and	O	54-57
diseased	O	58-66
human	O	67-72
muscle	O	73-79
.	O	79-80

A	O	81-82
probe	O	83-88
for	O	89-92
the	O	93-96
5	O	97-98
end	O	99-102
of	O	103-105
the	O	106-109
Duchenne	B	110-118
muscular	I	119-127
dystrophy	I	128-137
(	O	138-139
DMD	B	139-142
)	O	142-143
gene	O	144-148
was	O	149-152
used	O	153-157
to	O	158-160
study	O	161-166
expression	O	167-177
of	O	178-180
the	O	181-184
gene	O	185-189
in	O	190-192
normal	O	193-199
human	O	200-205
muscle	O	206-212
,	O	212-213
myogenic	O	214-222
cell	O	223-227
cultures	O	228-236
,	O	236-237
and	O	238-241
muscle	O	242-248
from	O	249-253
patients	O	254-262
with	O	263-267
DMD	B	268-271
.	O	271-272

Expression	O	273-283
was	O	284-287
found	O	288-293
in	O	294-296
RNA	O	297-300
from	O	301-305
normal	O	306-312
fetal	O	313-318
muscle	O	319-325
,	O	325-326
adult	O	327-332
cardiac	O	333-340
and	O	341-344
skeletal	O	345-353
muscle	O	354-360
,	O	360-361
and	O	362-365
cultured	O	366-374
muscle	O	375-381
after	O	382-387
myoblast	O	388-396
fusion	O	397-403
.	O	403-404

In	O	405-407
DMD	B	408-411
muscle	O	412-418
,	O	418-419
expression	O	420-430
of	O	431-433
this	O	434-438
portion	O	439-446
of	O	447-449
the	O	450-453
gene	O	454-458
was	O	459-462
also	O	463-467
revealed	O	468-476
by	O	477-479
in	O	480-482
situ	O	483-487
RNA	O	488-491
hybridization	O	492-505
,	O	505-506
particularly	O	507-519
in	O	520-522
regenerating	O	523-535
muscle	O	536-542
fibers	O	543-549
.	O	549-550
.	O	549-550

Localisation	O	0-12
of	O	13-15
the	O	16-19
Becker	B	20-26
muscular	I	27-35
dystrophy	I	36-45
gene	O	46-50
on	O	51-53
the	O	54-57
short	O	58-63
arm	O	64-67
of	O	68-70
the	O	71-74
X	O	75-76
chromosome	O	77-87
by	O	88-90
linkage	O	91-98
to	O	99-101
cloned	O	102-108
DNA	O	109-112
sequences	O	113-122
.	O	122-123

A	O	124-125
linkage	O	126-133
study	O	134-139
in	O	140-142
30	O	143-145
Becker	B	146-152
muscular	I	153-161
dystrophy	I	162-171
(	O	172-173
BMD	B	173-176
)	O	176-177
kindreds	O	178-186
using	O	187-192
three	O	193-198
cloned	O	199-205
DNA	O	206-209
sequences	O	210-219
from	O	220-224
the	O	225-228
X	O	229-230
chromosome	O	231-241
which	O	242-247
demonstrate	O	248-259
restriction	O	260-271
fragment	O	272-280
length	O	281-287
polymorphisms	O	288-301
(	O	302-303
RFLPs	O	303-308
)	O	308-309
,	O	309-310
suggests	O	311-319
that	O	320-324
the	O	325-328
BMD	B	329-332
gene	O	333-337
is	O	338-340
located	O	341-348
on	O	349-351
the	O	352-355
short	O	356-361
arm	O	362-365
of	O	366-368
the	O	369-372
X	O	373-374
chromosome	O	375-385
,	O	385-386
in	O	387-389
the	O	390-393
p21	O	394-397
region	O	398-404
.	O	404-405

The	O	406-409
genes	O	410-415
for	O	416-419
Becker	B	420-426
and	I	427-430
Duchenne	I	431-439
dystrophies	I	440-451
must	O	452-456
therefore	O	457-466
be	O	467-469
closely	O	470-477
linked	O	478-484
,	O	484-485
if	O	486-488
not	O	489-492
allelic	O	493-500
,	O	500-501
and	O	502-505
any	O	506-509
future	O	510-516
DNA	O	517-520
probes	O	521-527
found	O	528-533
to	O	534-536
be	O	537-539
of	O	540-542
practical	O	543-552
use	O	553-556
in	O	557-559
one	O	560-563
disorder	O	564-572
should	O	573-579
be	O	580-582
equally	O	583-590
applicable	O	591-601
to	O	602-604
the	O	605-608
other	O	609-614
.	O	614-615

The	O	616-619
linkage	O	620-627
analysis	O	628-636
also	O	637-641
provides	O	642-650
data	O	651-655
on	O	656-658
the	O	659-662
frequency	O	663-672
of	O	673-675
recombination	O	676-689
along	O	690-695
the	O	696-699
short	O	700-705
arm	O	706-709
of	O	710-712
the	O	713-716
X	O	717-718
chromosome	O	719-729
,	O	729-730
and	O	731-734
across	O	735-741
the	O	742-745
centromeric	O	746-757
region	O	758-764
.	O	764-765
.	O	764-765

Age	O	0-3
of	O	4-6
the	O	7-10
intronic	O	11-19
GAA	O	20-23
triplet	O	24-31
repeat	O	32-38
expansion	O	39-48
mutation	O	49-57
in	O	58-60
Friedreich	B	61-71
ataxia	I	72-78
.	O	78-79

Friedreich	B	80-90
ataxia	I	91-97
(	O	98-99
FRDA	B	99-103
)	O	103-104
,	O	104-105
the	O	106-109
most	O	110-114
frequently	O	115-125
inherited	B	126-135
ataxia	I	136-142
,	O	142-143
is	O	144-146
due	O	147-150
in	O	151-153
the	O	154-157
vast	O	158-162
majority	O	163-171
of	O	172-174
cases	O	175-180
to	O	181-183
a	O	184-185
large	O	186-191
expansion	O	192-201
of	O	202-204
an	O	205-207
intronic	O	208-216
GAA	O	217-220
repeat	O	221-227
.	O	227-228

Using	O	229-234
linkage	O	235-242
disequilibrium	O	243-257
analysis	O	258-266
based	O	267-272
on	O	273-275
haplotype	O	276-285
data	O	286-290
of	O	291-293
seven	O	294-299
polymorphic	O	300-311
markers	O	312-319
close	O	320-325
to	O	326-328
the	O	329-332
frataxin	O	333-341
gene	O	342-346
,	O	346-347
the	O	348-351
age	O	352-355
of	O	356-358
FRDA	B	359-363
founding	O	364-372
mutational	O	373-383
event	O	384-389
(	O	390-391
s	O	391-392
)	O	392-393
is	O	394-396
estimated	O	397-406
to	O	407-409
be	O	410-412
at	O	413-415
least	O	416-421
682	O	422-425
+	O	426-427
/	O	427-428
-	O	428-429
203	O	429-432
generations	O	433-444
(	O	445-446
95	O	446-448
%	O	448-449
confidence	O	450-460
interval	O	461-469
564	O	471-474
-	O	474-475
801	O	475-478
g	O	479-480
)	O	480-481
,	O	481-482
a	O	483-484
dating	O	485-491
which	O	492-497
is	O	498-500
consistent	O	501-511
with	O	512-516
little	O	517-523
or	O	524-526
no	O	527-529
negative	O	530-538
selection	O	539-548
and	O	549-552
provides	O	553-561
further	O	562-569
evidence	O	570-578
for	O	579-582
an	O	583-585
ancient	O	586-593
spread	O	594-600
of	O	601-603
a	O	604-605
pre	O	606-609
-	O	609-610
mutation	O	610-618
(	O	619-620
at	O	620-622
-	O	622-623
risk	O	623-627
alleles	O	628-635
)	O	635-636
in	O	637-639
western	O	640-647
Europe	O	648-654
.	O	654-655
.	O	654-655

The	O	0-3
human	O	4-9
MAGEL2	O	10-16
gene	O	17-21
and	O	22-25
its	O	26-29
mouse	O	30-35
homologue	O	36-45
are	O	46-49
paternally	O	50-60
expressed	O	61-70
and	O	71-74
mapped	O	75-81
to	O	82-84
the	O	85-88
Prader	B	89-95
-	I	95-96
Willi	I	96-101
region	O	102-108
.	O	108-109

Prader	B	110-116
-	I	116-117
Willi	I	117-122
syndrome	I	123-131
(	O	132-133
PWS	B	133-136
)	O	136-137
is	O	138-140
a	O	141-142
complex	O	143-150
neurogenetic	B	151-163
disorder	I	164-172
.	O	172-173

The	O	174-177
phenotype	O	178-187
is	O	188-190
likely	O	191-197
to	O	198-200
be	O	201-203
a	O	204-205
contiguous	B	206-216
gene	I	217-221
syndrome	I	222-230
involving	O	231-240
genes	O	241-246
which	O	247-252
are	O	253-256
paternally	O	257-267
expressed	O	268-277
only	O	278-282
,	O	282-283
located	O	284-291
in	O	292-294
the	O	295-298
human	O	299-304
15q11	O	305-310
-	O	310-311
q13	O	311-314
region	O	315-321
.	O	321-322

Four	O	323-327
mouse	O	328-333
models	O	334-340
of	O	341-343
PWS	B	344-347
have	O	348-352
been	O	353-357
reported	O	358-366
but	O	367-370
these	O	371-376
do	O	377-379
not	O	380-383
definitively	O	384-396
allow	O	397-402
the	O	403-406
delineation	O	407-418
of	O	419-421
the	O	422-425
critical	O	426-434
region	O	435-441
and	O	442-445
the	O	446-449
associated	O	450-460
genes	O	461-466
involved	O	467-475
in	O	476-478
the	O	479-482
aetiology	O	483-492
of	O	493-495
PWS	B	496-499
.	O	499-500

Moreover	O	501-509
,	O	509-510
targeted	O	511-519
mutagenesis	O	520-531
of	O	532-534
mouse	O	535-540
homologues	O	541-551
of	O	552-554
the	O	555-558
human	O	559-564
candidate	O	565-574
PWS	B	575-578
genes	O	579-584
does	O	585-589
not	O	590-593
appear	O	594-600
to	O	601-603
result	O	604-610
in	O	611-613
any	O	614-617
of	O	618-620
the	O	621-624
features	O	625-633
of	O	634-636
PWS	B	637-640
.	O	640-641

Therefore	O	642-651
,	O	651-652
the	O	653-656
isolation	O	657-666
of	O	667-669
new	O	670-673
genes	O	674-679
in	O	680-682
this	O	683-687
region	O	688-694
remains	O	695-702
crucial	O	703-710
for	O	711-714
a	O	715-716
better	O	717-723
understanding	O	724-737
of	O	738-740
the	O	741-744
molecular	O	745-754
basis	O	755-760
of	O	761-763
PWS	B	764-767
.	O	767-768

In	O	769-771
this	O	772-776
manuscript	O	777-787
,	O	787-788
we	O	789-791
report	O	792-798
the	O	799-802
characterization	O	803-819
of	O	820-822
MAGEL2	O	823-829
and	O	830-833
its	O	834-837
mouse	O	838-843
homologue	O	844-853
Magel2	O	854-860
.	O	860-861

These	O	862-867
are	O	868-871
located	O	872-879
in	O	880-882
the	O	883-886
human	O	887-892
15q11	O	893-898
-	O	898-899
q13	O	899-902
and	O	903-906
mouse	O	907-912
7C	O	913-915
regions	O	916-923
,	O	923-924
in	O	925-927
close	O	928-933
proximity	O	934-943
to	O	944-946
NDN	O	947-950
/	O	950-951
Ndn	O	951-954
.	O	954-955

By	O	956-958
northern	O	959-967
blot	O	968-972
analysis	O	973-981
we	O	982-984
did	O	985-988
not	O	989-992
detect	O	993-999
any	O	1000-1003
expression	O	1004-1014
of	O	1015-1017
MAGEL2	O	1018-1024
/	O	1024-1025
Magel2	O	1025-1031
but	O	1032-1035
by	O	1036-1038
RT	O	1039-1041
-	O	1041-1042
PCR	O	1042-1045
analysis	O	1046-1054
,	O	1054-1055
specific	O	1056-1064
expression	O	1065-1075
was	O	1076-1079
detected	O	1080-1088
in	O	1089-1091
fetal	O	1092-1097
and	O	1098-1101
adult	O	1102-1107
brain	O	1108-1113
and	O	1114-1117
in	O	1118-1120
placenta	O	1121-1129
.	O	1129-1130

Both	O	1131-1135
genes	O	1136-1141
are	O	1142-1145
intronless	O	1146-1156
with	O	1157-1161
tandem	O	1162-1168
direct	O	1169-1175
repeat	O	1176-1182
sequences	O	1183-1192
contained	O	1193-1202
within	O	1203-1209
a	O	1210-1211
CpG	O	1212-1215
island	O	1216-1222
in	O	1223-1225
the	O	1226-1229
5	O	1230-1231
-	O	1231-1232
untranscribed	O	1232-1245
region	O	1246-1252
.	O	1252-1253

The	O	1254-1257
transcripts	O	1258-1269
encode	O	1270-1276
putative	O	1277-1285
proteins	O	1286-1294
that	O	1295-1299
are	O	1300-1303
homologous	O	1304-1314
to	O	1315-1317
the	O	1318-1321
MAGE	O	1322-1326
proteins	O	1327-1335
and	O	1336-1339
NDN	O	1340-1343
.	O	1343-1344

Moreover	O	1345-1353
,	O	1353-1354
MAGEL2	O	1355-1361
/	O	1361-1362
Magel2	O	1362-1368
are	O	1369-1372
expressed	O	1373-1382
only	O	1383-1387
from	O	1388-1392
the	O	1393-1396
paternal	O	1397-1405
allele	O	1406-1412
in	O	1413-1415
brain	O	1416-1421
,	O	1421-1422
suggesting	O	1423-1433
a	O	1434-1435
potential	O	1436-1445
role	O	1446-1450
in	O	1451-1453
the	O	1454-1457
aetiology	O	1458-1467
of	O	1468-1470
PWS	B	1471-1474
and	O	1475-1478
its	O	1479-1482
mouse	O	1483-1488
model	O	1489-1494
,	O	1494-1495
respectively	O	1496-1508
.	O	1508-1509
.	O	1508-1509

Multiple	O	0-8
origins	O	9-16
for	O	17-20
phenylketonuria	B	21-36
in	O	37-39
Europe	O	40-46
.	O	46-47

Phenylketonuria	B	48-63
(	O	64-65
PKU	B	65-68
)	O	68-69
,	O	69-70
a	O	71-72
disorder	B	73-81
of	I	82-84
amino	I	85-90
acid	I	91-95
metabolism	I	96-106
prevalent	O	107-116
among	O	117-122
Caucasians	O	123-133
and	O	134-137
other	O	138-143
ethnic	O	144-150
groups	O	151-157
,	O	157-158
is	O	159-161
caused	O	162-168
primarily	O	169-178
by	O	179-181
a	O	182-183
deficiency	B	184-194
of	I	195-197
the	I	198-201
hepatic	I	202-209
enzyme	I	210-216
phenylalanine	I	217-230
hydroxylase	I	231-242
(	O	243-244
PAH	O	244-247
)	O	247-248
.	O	248-249

PKU	B	250-253
is	O	254-256
a	O	257-258
highly	O	259-265
heterogeneous	O	266-279
disorder	O	280-288
,	O	288-289
with	O	290-294
more	O	295-299
than	O	300-304
60	O	305-307
molecular	O	308-317
lesions	O	318-325
identified	O	326-336
in	O	337-339
the	O	340-343
PAH	O	344-347
gene	O	348-352
.	O	352-353

The	O	354-357
haplotype	O	358-367
associations	O	368-380
,	O	380-381
relative	O	382-390
frequencies	O	391-402
,	O	402-403
and	O	404-407
distributions	O	408-421
of	O	422-424
five	O	425-429
prevalent	O	430-439
PAH	O	440-443
mutations	O	444-453
(	O	454-455
R158Q	O	455-460
,	O	460-461
R261Q	O	462-467
,	O	467-468
IVS10nt546	O	469-479
,	O	479-480
R408W	O	481-486
,	O	486-487
and	O	488-491
IVS12n1	O	492-499
)	O	499-500
were	O	501-505
established	O	506-517
in	O	518-520
a	O	521-522
comprehensive	O	523-536
European	O	537-545
sample	O	546-552
population	O	553-563
and	O	564-567
subsequently	O	568-580
were	O	581-585
examined	O	586-594
to	O	595-597
determine	O	598-607
the	O	608-611
potential	O	612-621
roles	O	622-627
of	O	628-630
several	O	631-638
genetic	O	639-646
mechanisms	O	647-657
in	O	658-660
explaining	O	661-671
the	O	672-675
present	O	676-683
distribution	O	684-696
of	O	697-699
the	O	700-703
major	O	704-709
PKU	B	710-713
alleles	O	714-721
.	O	721-722

Each	O	723-727
of	O	728-730
these	O	731-736
five	O	737-741
mutations	O	742-751
was	O	752-755
strongly	O	756-764
associated	O	765-775
with	O	776-780
only	O	781-785
one	O	786-789
of	O	790-792
the	O	793-796
more	O	797-801
than	O	802-806
70	O	807-809
chromosomal	O	810-821
haplotypes	O	822-832
defined	O	833-840
by	O	841-843
eight	O	844-849
RFLPs	O	850-855
in	O	856-858
or	O	859-861
near	O	862-866
the	O	867-870
PAH	O	871-874
gene	O	875-879
.	O	879-880

These	O	881-886
findings	O	887-895
suggest	O	896-903
that	O	904-908
each	O	909-913
of	O	914-916
these	O	917-922
mutations	O	923-932
arose	O	933-938
through	O	939-946
a	O	947-948
single	O	949-955
founding	O	956-964
event	O	965-970
that	O	971-975
occurred	O	976-984
within	O	985-991
time	O	992-996
periods	O	997-1004
ranging	O	1005-1012
from	O	1013-1017
several	O	1018-1025
hundred	O	1026-1033
to	O	1034-1036
several	O	1037-1044
thousand	O	1045-1053
years	O	1054-1059
ago	O	1060-1063
.	O	1063-1064

From	O	1065-1069
the	O	1070-1073
significant	O	1074-1085
differences	O	1086-1097
observed	O	1098-1106
in	O	1107-1109
the	O	1110-1113
relative	O	1114-1122
frequencies	O	1123-1134
and	O	1135-1138
distributions	O	1139-1152
of	O	1153-1155
these	O	1156-1161
five	O	1162-1166
alleles	O	1167-1174
throughout	O	1175-1185
Europe	O	1186-1192
,	O	1192-1193
four	O	1194-1198
of	O	1199-1201
these	O	1202-1207
putative	O	1208-1216
founding	O	1217-1225
events	O	1226-1232
could	O	1233-1238
be	O	1239-1241
localized	O	1242-1251
to	O	1252-1254
specific	O	1255-1263
ethnic	O	1264-1270
subgroups	O	1271-1280
.	O	1280-1281

Together	O	1282-1290
,	O	1290-1291
these	O	1292-1297
data	O	1298-1302
suggest	O	1303-1310
that	O	1311-1315
there	O	1316-1321
were	O	1322-1326
multiple	O	1327-1335
,	O	1335-1336
geographically	O	1337-1351
and	O	1352-1355
ethnically	O	1356-1366
distinct	O	1367-1375
origins	O	1376-1383
for	O	1384-1387
PKU	B	1388-1391
within	O	1392-1398
the	O	1399-1402
European	O	1403-1411
population	O	1412-1422
.	O	1422-1423
.	O	1422-1423

Autoinhibition	O	0-14
and	O	15-18
activation	O	19-29
mechanisms	O	30-40
of	O	41-43
the	O	44-47
Wiskott	B	48-55
-	I	55-56
Aldrich	I	56-63
syndrome	I	64-72
protein	O	73-80
.	O	80-81

The	O	82-85
Rho	O	86-89
-	O	89-90
family	O	90-96
GTPase	O	97-103
,	O	103-104
Cdc42	O	105-110
,	O	110-111
can	O	112-115
regulate	O	116-124
the	O	125-128
actin	O	129-134
cytoskeleton	O	135-147
through	O	148-155
activation	O	156-166
of	O	167-169
Wiskott	B	170-177
-	I	177-178
Aldrich	I	178-185
syndrome	I	186-194
protein	O	195-202
(	O	203-204
WASP	O	204-208
)	O	208-209
family	O	210-216
members	O	217-224
.	O	224-225

Activation	O	226-236
relieves	O	237-245
an	O	246-248
autoinhibitory	O	249-263
contact	O	264-271
between	O	272-279
the	O	280-283
GTPase	O	284-290
-	O	290-291
binding	O	291-298
domain	O	299-305
and	O	306-309
the	O	310-313
carboxy	O	314-321
-	O	321-322
terminal	O	322-330
region	O	331-337
of	O	338-340
WASP	O	341-345
proteins	O	346-354
.	O	354-355

Here	O	356-360
we	O	361-363
report	O	364-370
the	O	371-374
autoinhibited	O	375-388
structure	O	389-398
of	O	399-401
the	O	402-405
GTPase	O	406-412
-	O	412-413
binding	O	413-420
domain	O	421-427
of	O	428-430
WASP	O	431-435
,	O	435-436
which	O	437-442
can	O	443-446
be	O	447-449
induced	O	450-457
by	O	458-460
the	O	461-464
C	O	465-466
-	O	466-467
terminal	O	467-475
region	O	476-482
or	O	483-485
by	O	486-488
organic	O	489-496
co	O	497-499
-	O	499-500
solvents	O	500-508
.	O	508-509

In	O	510-512
the	O	513-516
autoinhibited	O	517-530
complex	O	531-538
,	O	538-539
intramolecular	O	540-554
interactions	O	555-567
with	O	568-572
the	O	573-576
GTPase	O	577-583
-	O	583-584
binding	O	584-591
domain	O	592-598
occlude	O	599-606
residues	O	607-615
of	O	616-618
the	O	619-622
C	O	623-624
terminus	O	625-633
that	O	634-638
regulate	O	639-647
the	O	648-651
Arp2	O	652-656
/	O	656-657
3	O	657-658
actin	O	659-664
-	O	664-665
nucleating	O	665-675
complex	O	676-683
.	O	683-684

Binding	O	685-692
of	O	693-695
Cdc42	O	696-701
to	O	702-704
the	O	705-708
GTPase	O	709-715
-	O	715-716
binding	O	716-723
domain	O	724-730
causes	O	731-737
a	O	738-739
dramatic	O	740-748
conformational	O	749-763
change	O	764-770
,	O	770-771
resulting	O	772-781
in	O	782-784
disruption	O	785-795
of	O	796-798
the	O	799-802
hydrophobic	O	803-814
core	O	815-819
and	O	820-823
release	O	824-831
of	O	832-834
the	O	835-838
C	O	839-840
terminus	O	841-849
,	O	849-850
enabling	O	851-859
its	O	860-863
interaction	O	864-875
with	O	876-880
the	O	881-884
actin	O	885-890
regulatory	O	891-901
machinery	O	902-911
.	O	911-912

These	O	913-918
data	O	919-923
show	O	924-928
that	O	929-933
intrinsically	O	934-947
unstructured	O	948-960
peptides	O	961-969
such	O	970-974
as	O	975-977
the	O	978-981
GTPase	O	982-988
-	O	988-989
binding	O	989-996
domain	O	997-1003
of	O	1004-1006
WASP	O	1007-1011
can	O	1012-1015
be	O	1016-1018
induced	O	1019-1026
into	O	1027-1031
distinct	O	1032-1040
structural	O	1041-1051
and	O	1052-1055
functional	O	1056-1066
states	O	1067-1073
depending	O	1074-1083
on	O	1084-1086
context	O	1087-1094
.	O	1094-1095
.	O	1094-1095

Localisation	O	0-12
of	O	13-15
the	O	16-19
gene	O	20-24
for	O	25-28
Norrie	B	29-35
disease	I	36-43
to	O	44-46
between	O	47-54
DXS7	O	55-59
and	O	60-63
DXS426	O	64-70
on	O	71-73
Xp	O	74-76
.	O	76-77

A	O	78-79
highly	O	80-86
informative	O	87-98
microsatellite	O	99-113
marker	O	114-120
,	O	120-121
DXS426	O	122-128
,	O	128-129
which	O	130-135
maps	O	136-140
proximal	O	141-149
to	O	150-152
DXS7	O	153-157
in	O	158-160
the	O	161-164
interval	O	165-173
Xp11	O	174-178
.	O	178-179

4	O	180-181
-	O	181-182
Xp11	O	182-186
4	O	187-188
-	O	188-189
Xp11	O	189-193
.	O	193-194

23	O	195-197
,	O	197-198
has	O	199-202
been	O	203-207
used	O	208-212
to	O	213-215
refine	O	216-222
further	O	223-230
the	O	231-234
localisation	O	235-247
of	O	248-250
the	O	251-254
gene	O	255-259
for	O	260-263
Norrie	B	264-270
disease	I	271-278
(	O	279-280
NDP	B	280-283
)	O	283-284
.	O	284-285

The	O	286-289
results	O	290-297
from	O	298-302
a	O	303-304
multiply	O	305-313
informative	O	314-325
crossover	O	326-335
localize	O	336-344
the	O	345-348
NDP	B	349-352
gene	O	353-357
proximal	O	358-366
to	O	367-369
DXS7	O	370-374
.	O	374-375

In	O	376-378
conjunction	O	379-390
with	O	391-395
information	O	396-407
from	O	408-412
2	O	413-414
NDP	B	415-418
patients	O	419-427
who	O	428-431
have	O	432-436
a	O	437-438
deletion	O	439-447
for	O	448-451
DXS7	O	452-456
but	O	457-460
not	O	461-464
for	O	465-468
DSX426	O	469-475
,	O	475-476
our	O	477-480
data	O	481-485
indicate	O	486-494
that	O	495-499
the	O	500-503
NDP	B	504-507
gene	O	508-512
lies	O	513-517
between	O	518-525
DXS7	O	526-530
and	O	531-534
DXS426	O	535-541
on	O	542-544
proximal	O	545-553
Xp	O	554-556
.	O	556-557

Molecular	O	0-9
basis	O	10-15
of	O	16-18
human	O	19-24
mitochondrial	O	25-38
very	B	39-43
-	I	43-44
long	I	44-48
-	I	43-44
chain	I	49-54
acyl	I	55-59
-	I	59-60
CoA	I	60-63
dehydrogenase	I	64-77
deficiency	I	78-88
causing	O	89-96
cardiomyopathy	B	97-111
and	O	112-115
sudden	B	116-122
death	I	123-128
in	O	129-131
childhood	O	132-141
.	O	141-142

beta	O	143-147
-	O	147-148
Oxidation	O	148-157
of	O	158-160
long	O	161-165
-	O	165-166
chain	O	166-171
fatty	O	172-177
acids	O	178-183
provides	O	184-192
the	O	193-196
major	O	197-202
source	O	203-209
of	O	210-212
energy	O	213-219
in	O	220-222
the	O	223-226
heart	O	227-232
.	O	232-233

Defects	O	234-241
in	O	242-244
enzymes	O	245-252
of	O	253-255
the	O	256-259
beta	O	260-264
-	O	264-265
oxidation	O	265-274
pathway	O	275-282
cause	O	283-288
sudden	B	289-295
,	I	295-296
unexplained	I	297-308
death	I	309-314
in	O	315-317
childhood	O	318-327
,	O	327-328
acute	O	329-334
hepatic	B	335-342
encephalopathy	I	343-357
or	O	358-360
liver	B	361-366
failure	I	367-374
,	O	374-375
skeletal	B	376-384
myopathy	I	385-393
,	O	393-394
and	O	395-398
cardiomyopathy	B	399-413
.	O	413-414

Very	O	415-419
-	O	419-420
long	O	420-424
-	O	419-420
chain	O	425-430
acyl	O	431-435
-	O	435-436
CoA	O	436-439
dehydrogenase	O	440-453
[	O	454-455
VLCAD	O	455-460
;	O	460-461
very	O	462-466
-	O	466-467
long	O	467-471
-	O	466-467
chain	O	472-477
-	O	466-467
acyl	O	478-482
-	O	466-467
CoA	O	483-486
(	O	488-489
acceptor	O	489-497
)	O	497-498
2	O	499-500
,	O	500-501
3	O	502-503
-	O	503-504
oxidoreductase	O	504-518
,	O	518-519
EC	O	520-522
1	O	523-524
.	O	524-525
3	O	526-527
3	O	528-529
.	O	529-530
99	O	531-533
99	O	534-536
.	O	536-537

13	O	538-540
]	O	540-541
catalyzes	O	542-551
the	O	552-555
first	O	556-561
step	O	562-566
in	O	567-569
beta	O	570-574
-	O	574-575
oxidation	O	575-584
.	O	584-585

We	O	586-588
have	O	589-593
isolated	O	594-602
the	O	603-606
human	O	607-612
VLCAD	O	613-618
cDNA	O	619-623
and	O	624-627
gene	O	628-632
and	O	633-636
determined	O	637-647
the	O	648-651
complete	O	652-660
nucleotide	O	661-671
sequences	O	672-681
.	O	681-682

Polymerase	O	683-693
chain	O	694-699
reaction	O	700-708
amplification	O	709-722
of	O	723-725
VLCAD	O	726-731
mRNA	O	732-736
and	O	737-740
genomic	O	741-748
exons	O	749-754
defined	O	755-762
the	O	763-766
molecular	O	767-776
defects	O	777-784
in	O	785-787
two	O	788-791
patients	O	792-800
with	O	801-805
VLCAD	B	806-811
deficiency	I	812-822
who	O	823-826
presented	O	827-836
with	O	837-841
unexplained	O	842-853
cardiac	B	854-861
arrest	I	862-868
and	O	869-872
cardiomyopathy	B	873-887
.	O	887-888

In	O	889-891
one	O	892-895
,	O	895-896
a	O	897-898
homozygous	O	899-909
mutation	O	910-918
in	O	919-921
the	O	922-925
consensus	O	926-935
dinucleotide	O	936-948
of	O	949-951
the	O	952-955
donor	O	956-961
splice	O	962-968
site	O	969-973
(	O	974-975
g	O	975-976
+	O	977-978
1	O	979-980
-	O	980-981
-	O	980-981
>	O	983-984
a	O	985-986
)	O	986-987
was	O	988-991
associated	O	992-1002
with	O	1003-1007
universal	O	1008-1017
skipping	O	1018-1026
of	O	1027-1029
the	O	1030-1033
prior	O	1034-1039
exon	O	1040-1044
(	O	1045-1046
exon	O	1046-1050
11	O	1051-1053
)	O	1053-1054
.	O	1054-1055

The	O	1056-1059
second	O	1060-1066
patient	O	1067-1074
was	O	1075-1078
a	O	1079-1080
compound	O	1081-1089
heterozygote	O	1090-1102
,	O	1102-1103
with	O	1104-1108
a	O	1109-1110
missense	O	1111-1119
mutation	O	1120-1128
,	O	1128-1129
C1837	O	1130-1135
-	O	1135-1136
-	O	1135-1136
>	O	1138-1139
T	O	1140-1141
,	O	1141-1142
changing	O	1143-1151
the	O	1152-1155
arginine	O	1156-1164
at	O	1165-1167
residue	O	1168-1175
613	O	1176-1179
to	O	1180-1182
tryptophan	O	1183-1193
on	O	1194-1196
one	O	1197-1200
allele	O	1201-1207
and	O	1208-1211
a	O	1212-1213
single	O	1214-1220
base	O	1221-1225
deletion	O	1226-1234
at	O	1235-1237
the	O	1238-1241
intron	O	1242-1248
-	O	1248-1249
exon	O	1249-1253
6	O	1254-1255
boundary	O	1256-1264
as	O	1265-1267
the	O	1268-1271
second	O	1272-1278
mutation	O	1279-1287
.	O	1287-1288

This	O	1289-1293
initial	O	1294-1301
delineation	O	1302-1313
of	O	1314-1316
human	O	1317-1322
mutations	O	1323-1332
in	O	1333-1335
VLCAD	O	1336-1341
suggests	O	1342-1350
that	O	1351-1355
VLCAD	B	1356-1361
deficiency	I	1362-1372
reduces	O	1373-1380
myocardial	O	1381-1391
fatty	O	1392-1397
acid	O	1398-1402
beta	O	1403-1407
-	O	1407-1408
oxidation	O	1408-1417
and	O	1418-1421
energy	O	1422-1428
production	O	1429-1439
and	O	1440-1443
is	O	1444-1446
associated	O	1447-1457
with	O	1458-1462
cardiomyopathy	B	1463-1477
and	O	1478-1481
sudden	B	1482-1488
death	I	1489-1494
in	O	1495-1497
childhood	O	1498-1507
.	O	1507-1508

An	O	0-2
error	O	3-8
in	O	9-11
dystrophin	O	12-22
mRNA	O	23-27
processing	O	28-38
in	O	39-41
golden	B	42-48
retriever	I	49-58
muscular	I	59-67
dystrophy	I	68-77
,	O	77-78
an	O	79-81
animal	O	82-88
homologue	O	89-98
of	O	99-101
Duchenne	B	102-110
muscular	I	111-119
dystrophy	I	120-129
.	O	129-130

Golden	B	131-137
retriever	I	138-147
muscular	I	148-156
dystrophy	I	157-166
(	O	167-168
GRMD	B	168-172
)	O	172-173
is	O	174-176
a	O	177-178
spontaneous	O	179-190
,	O	190-191
X	O	192-193
-	O	193-194
linked	O	194-200
,	O	200-201
progressively	O	202-215
fatal	O	216-221
disease	O	222-229
of	O	230-232
dogs	O	233-237
and	O	238-241
is	O	242-244
also	O	245-249
a	O	250-251
homologue	O	252-261
of	O	262-264
Duchenne	B	265-273
muscular	I	274-282
dystrophy	I	283-292
(	O	293-294
DMD	B	294-297
)	O	297-298
.	O	298-299

Two	O	300-303
-	O	303-304
thirds	O	304-310
of	O	311-313
DMD	B	314-317
patients	O	318-326
carry	O	327-332
detectable	O	333-343
deletions	O	344-353
in	O	354-356
their	O	357-362
dystrophin	O	363-373
gene	O	374-378
.	O	378-379

The	O	380-383
defect	O	384-390
underlying	O	391-401
the	O	402-405
remaining	O	406-415
one	O	416-419
-	O	419-420
third	O	420-425
of	O	426-428
DMD	B	429-432
patients	O	433-441
is	O	442-444
undetermined	O	445-457
.	O	457-458

Analysis	O	459-467
of	O	468-470
the	O	471-474
canine	O	475-481
dystrophin	O	482-492
gene	O	493-497
in	O	498-500
normal	O	501-507
and	O	508-511
GRMD	B	512-516
dogs	O	517-521
has	O	522-525
failed	O	526-532
to	O	533-535
demonstrate	O	536-547
any	O	548-551
detectable	O	552-562
loss	O	563-567
of	O	568-570
exons	O	571-576
.	O	576-577

Here	O	578-582
,	O	582-583
we	O	584-586
have	O	587-591
demonstrated	O	592-604
a	O	605-606
RNA	O	607-610
processing	O	611-621
error	O	622-627
in	O	628-630
GRMD	B	631-635
that	O	636-640
results	O	641-648
from	O	649-653
a	O	654-655
single	O	656-662
base	O	663-667
change	O	668-674
in	O	675-677
the	O	678-681
3	O	682-683
consensus	O	684-693
splice	O	694-700
site	O	701-705
of	O	706-708
intron	O	709-715
6	O	716-717
.	O	717-718

The	O	719-722
seventh	O	723-730
exon	O	731-735
is	O	736-738
then	O	739-743
skipped	O	744-751
,	O	751-752
which	O	753-758
predicts	O	759-767
a	O	768-769
termination	O	770-781
of	O	782-784
the	O	785-788
dystrophin	O	789-799
reading	O	800-807
frame	O	808-813
within	O	814-820
its	O	821-824
N	O	825-826
-	O	826-827
terminal	O	827-835
domain	O	836-842
in	O	843-845
exon	O	846-850
8	O	851-852
.	O	852-853

This	O	854-858
is	O	859-861
the	O	862-865
first	O	866-871
example	O	872-879
of	O	880-882
dystrophin	B	883-893
deficiency	I	894-904
caused	O	905-911
by	O	912-914
a	O	915-916
splice	O	917-923
-	O	923-924
site	O	924-928
mutation	O	929-937
.	O	937-938
.	O	937-938

Serum	O	0-5
amyloid	O	6-13
A	O	14-15
and	O	16-19
P	O	20-21
protein	O	22-29
genes	O	30-35
in	O	36-38
familial	B	39-47
Mediterranean	I	48-61
fever	I	62-67
.	O	67-68

Two	O	69-72
recent	O	73-79
studies	O	80-87
have	O	88-92
suggested	O	93-102
the	O	103-106
involvement	O	107-118
of	O	119-121
serum	O	122-127
amyloid	O	128-135
A	O	136-137
(	O	138-139
SAA	O	139-142
)	O	142-143
and	O	144-147
P	O	148-149
(	O	150-151
APCS	O	151-155
)	O	155-156
genes	O	157-162
in	O	163-165
familial	B	166-174
Mediterranean	I	175-188
fever	I	189-194
(	O	195-196
MEF	B	196-199
)	O	199-200
.	O	200-201

To	O	202-204
test	O	205-209
the	O	210-213
role	O	214-218
of	O	219-221
SAA	O	222-225
and	O	226-229
APCS	O	230-234
in	O	235-237
MEF	B	238-241
and	O	242-245
MEF	B	246-249
-	I	249-250
amyloidosis	I	250-261
,	O	261-262
we	O	263-265
studied	O	266-273
17	O	274-276
informative	O	277-288
families	O	289-297
(	O	298-299
15	O	299-301
Armenians	O	302-311
,	O	311-312
2	O	313-314
non	O	315-318
-	O	318-319
Ashkenazi	O	319-328
Jews	O	329-333
)	O	333-334
and	O	335-338
8	O	339-340
MEF	B	341-344
patients	O	345-353
with	O	354-358
amyloidosis	B	359-370
using	O	371-376
a	O	377-378
candidate	O	379-388
gene	O	389-393
approach	O	394-402
.	O	402-403

No	O	404-406
evidence	O	407-415
for	O	416-419
any	O	420-423
MEF	B	424-427
-	O	427-428
associated	O	428-438
polymorphism	O	439-451
was	O	452-455
found	O	456-461
in	O	462-464
any	O	465-468
of	O	469-471
the	O	472-475
41	O	476-478
Armenian	O	479-487
and	O	488-491
Jewish	O	492-498
MEF	B	499-502
patients	O	503-511
tested	O	512-518
.	O	518-519

Our	O	520-523
family	O	524-530
studies	O	531-538
allowed	O	539-546
us	O	547-549
to	O	550-552
rule	O	553-557
out	O	558-561
tight	O	562-567
linkage	O	568-575
between	O	576-583
SAA	O	584-587
and	O	588-591
MEF	B	592-595
(	O	596-597
lod	O	597-600
score	O	601-606
=	O	607-608
-	O	609-610
2	O	610-611
.	O	611-612

16	O	613-615
,	O	615-616
theta	O	617-622
less	O	623-627
than	O	628-632
or	O	633-635
equal	O	636-641
to	O	642-644
0	O	645-646
.	O	646-647
06	O	648-650
)	O	650-651
.	O	651-652

For	O	653-656
APCS	O	657-661
we	O	662-664
found	O	665-670
that	O	671-675
the	O	676-679
allele	O	680-686
frequency	O	687-696
in	O	697-699
the	O	700-703
MEF	B	704-707
-	I	707-708
amyloidosis	I	708-719
patients	O	720-728
was	O	729-732
similar	O	733-740
to	O	741-743
that	O	744-748
in	O	749-751
18	O	752-754
unrelated	O	755-764
MEF	B	765-768
patients	O	769-777
without	O	778-785
amyloidosis	B	786-797
and	O	798-801
their	O	802-807
33	O	808-810
healthy	O	811-818
parents	O	819-826
.	O	826-827

Glucose	O	0-7
-	O	7-8
6	O	8-9
-	O	7-8
phosphate	O	10-19
dehydrogenase	O	20-33
variants	O	34-42
from	O	43-47
Italian	O	48-55
subjects	O	56-64
associated	O	65-75
with	O	76-80
severe	B	81-87
neonatal	I	88-96
jaundice	I	97-105
.	O	105-106

Screening	O	107-116
for	O	117-120
the	O	121-124
G6PD	B	125-129
deficiency	I	130-140
was	O	141-144
carried	O	145-152
out	O	153-156
at	O	157-159
the	O	160-163
Maternity	O	164-173
Division	O	174-182
of	O	183-185
the	O	186-189
Galliera	O	190-198
Hospital	O	199-207
in	O	208-210
Genoa	O	211-216
,	O	216-217
Italy	O	218-223
.	O	223-224

Two	O	225-228
groups	O	229-235
of	O	236-238
subjects	O	239-247
with	O	248-252
hyperbilirubinaemia	B	253-272
of	O	273-275
non	O	276-279
-	O	279-280
immunological	O	280-293
origin	O	294-300
were	O	301-305
examined	O	306-314
(	O	316-317
a	O	317-318
)	O	318-319
302	O	320-323
newborn	O	324-331
babies	O	332-338
of	O	339-341
Sardinian	O	342-351
extraction	O	352-362
(	O	363-364
on	O	364-366
cord	O	367-371
blood	O	372-377
)	O	377-378
and	O	379-382
(	O	383-384
b	O	384-385
)	O	385-386
201	O	387-390
newborn	O	391-398
babies	O	399-405
of	O	406-408
south	O	409-414
Italian	O	415-422
ancestry	O	423-431
(	O	432-433
on	O	433-435
peripheral	O	436-446
blood	O	447-452
)	O	452-453
.	O	453-454

Among	O	455-460
503	O	461-464
subjects	O	465-473
,	O	473-474
43	O	475-477
showed	O	478-484
an	O	485-487
enzyme	O	488-494
deficiency	O	495-505
;	O	505-506
in	O	507-509
39	O	510-512
the	O	513-516
defect	O	517-523
was	O	524-527
of	O	528-530
the	O	531-534
Mediterranean	O	535-548
type	O	549-553
.	O	553-554

In	O	555-557
one	O	558-561
case	O	562-566
,	O	566-567
previously	O	568-578
described	O	579-588
,	O	588-589
the	O	590-593
enzyme	O	594-600
was	O	601-604
of	O	605-607
the	O	608-611
A	O	612-613
-	O	613-614
type	O	615-619
.	O	619-620

In	O	621-623
the	O	624-627
remaining	O	628-637
cases	O	638-643
three	O	644-649
different	O	650-659
variants	O	660-668
were	O	669-673
identified	O	674-684
.	O	684-685

In	O	686-688
the	O	689-692
present	O	693-700
work	O	701-705
these	O	706-711
three	O	712-717
cases	O	718-723
,	O	723-724
each	O	725-729
with	O	730-734
severe	B	735-741
neonatal	I	742-750
jaundice	I	751-759
,	O	759-760
are	O	761-764
reported	O	765-773
.	O	773-774

Their	O	775-780
parents	O	781-788
originated	O	789-799
from	O	800-804
Calabria	O	805-813
,	O	813-814
from	O	815-819
Sardinia	O	820-828
and	O	829-832
from	O	833-837
Sicily	O	838-844
.	O	844-845

The	O	846-849
abnormal	O	850-858
enzymes	O	859-866
are	O	867-870
respectively	O	871-883
designated	O	884-894
as	O	895-897
GdDcbrousse	O	898-909
-	O	909-910
like	O	910-914
,	O	914-915
GdGallura	O	916-925
and	O	926-929
GdAgrigento	O	930-941
.	O	941-942
.	O	941-942

Loss	O	0-4
of	O	5-7
normal	O	8-14
allele	O	15-21
of	O	22-24
the	O	25-28
APC	B	29-32
gene	O	33-37
in	O	38-40
an	O	41-43
adrenocortical	B	44-58
carcinoma	I	59-68
from	O	69-73
a	O	74-75
patient	O	76-83
with	O	84-88
familial	B	89-97
adenomatous	I	98-109
polyposis	I	110-119
.	O	119-120

Endocrine	B	121-130
neoplasms	I	131-140
have	O	141-145
been	O	146-150
reported	O	151-159
occasionally	O	160-172
in	O	173-175
patients	O	176-184
with	O	185-189
familial	B	190-198
adenomatous	I	199-210
polyposis	I	211-220
(	O	221-222
FAP	B	222-225
)	O	225-226
.	O	226-227

An	O	228-230
adrenocorotical	B	231-246
carcinoma	I	247-256
was	O	257-260
studied	O	261-268
in	O	269-271
a	O	272-273
patient	O	274-281
with	O	282-286
a	O	287-288
family	O	289-295
history	O	296-303
of	O	304-306
FAP	B	307-310
.	O	310-311

Loss	O	312-316
of	O	317-319
heterozygosity	O	320-334
(	O	335-336
LOH	O	336-339
)	O	339-340
in	O	341-343
the	O	344-347
region	O	348-354
close	O	355-360
to	O	361-363
the	O	364-367
adenomatous	B	368-379
polyposis	I	380-389
coli	I	390-394
(	O	395-396
APC	B	396-399
)	O	399-400
gene	O	401-405
was	O	406-409
detected	O	410-418
in	O	419-421
this	O	422-426
carcinoma	B	427-436
,	O	436-437
and	O	438-441
evidence	O	442-450
was	O	451-454
obtained	O	455-463
that	O	464-468
there	O	469-474
was	O	475-478
a	O	479-480
loss	O	481-485
of	O	486-488
the	O	489-492
normal	O	493-499
allele	O	500-506
of	O	507-509
the	O	510-513
APC	B	514-517
gene	O	518-522
.	O	522-523

This	O	524-528
is	O	529-531
the	O	532-535
first	O	536-541
demonstration	O	542-555
of	O	556-558
LOH	O	559-562
at	O	563-565
the	O	566-569
APC	B	570-573
locus	O	574-579
in	O	580-582
adrenocortical	B	583-597
tumors	I	598-604
.	O	604-605

The	O	606-609
present	O	610-617
results	O	618-625
and	O	626-629
our	O	630-633
previous	O	634-642
data	O	643-647
on	O	648-650
LOH	O	651-654
in	O	655-657
a	O	658-659
recurring	O	660-669
desmoid	B	670-677
tumor	I	678-683
suggest	O	684-691
that	O	692-696
the	O	697-700
heterozygous	O	701-713
mutant	O	714-720
/	O	720-721
wild	O	721-725
-	O	725-726
type	O	726-730
condition	O	731-740
of	O	741-743
the	O	744-747
APC	B	748-751
gene	O	752-756
may	O	757-760
give	O	761-765
rise	O	766-770
to	O	771-773
benign	B	774-780
tumors	I	781-787
,	O	787-788
and	O	789-792
that	O	793-797
functional	O	798-808
loss	O	809-813
of	O	814-816
this	O	817-821
gene	O	822-826
leads	O	827-832
to	O	833-835
development	O	836-847
of	O	848-850
tumors	B	851-857
not	O	858-861
only	O	862-866
in	O	867-869
the	O	870-873
colon	O	874-879
but	O	880-883
also	O	884-888
in	O	889-891
other	O	892-897
various	O	898-905
parts	O	906-911
of	O	912-914
the	O	915-918
body	O	919-923
in	O	924-926
FAP	B	927-930
patients	O	931-939
.	O	939-940
.	O	939-940

Heterozygous	O	0-12
C2	B	13-15
-	I	15-16
deficiency	I	16-26
and	O	27-30
myasthenia	B	31-41
gravis	I	42-48
.	O	48-49

Complement	B	50-60
deficiency	I	61-71
states	O	72-78
in	O	79-81
myasthenia	B	82-92
gravis	I	93-99
(	O	100-101
MG	B	101-103
)	O	103-104
have	O	105-109
not	O	110-113
been	O	114-118
reported	O	119-127
previously	O	128-138
.	O	138-139

We	O	140-142
describe	O	143-151
a	O	152-153
19	O	154-156
-	O	156-157
year	O	157-161
-	O	156-157
old	O	162-165
woman	O	166-171
with	O	172-176
typical	O	177-184
MG	B	185-187
and	O	188-191
heterozygous	O	192-204
C2	B	205-207
deficiency	I	208-218
,	O	218-219
along	O	220-225
with	O	226-230
HLA	O	231-234
typing	O	235-241
of	O	242-244
the	O	245-248
patient	O	249-256
and	O	257-260
her	O	261-264
immediate	O	265-274
family	O	275-281
.	O	281-282
.	O	281-282

Large	O	0-5
heterozygous	O	6-18
deletion	O	19-27
masquerading	O	28-40
as	O	41-43
homozygous	O	44-54
missense	O	55-63
mutation	O	64-72
:	O	72-73
a	O	74-75
pitfall	O	76-83
in	O	84-86
diagnostic	O	87-97
mutation	O	98-106
analysis	O	107-115
.	O	115-116

The	O	117-120
clinical	O	121-129
use	O	130-133
of	O	134-136
molecular	O	137-146
analyses	O	147-155
in	O	156-158
recessive	B	159-168
disorders	I	169-178
relies	O	179-185
on	O	186-188
the	O	189-192
exact	O	193-198
characterization	O	199-215
of	O	216-218
both	O	219-223
mutant	O	224-230
alleles	O	231-238
in	O	239-241
the	O	242-245
affected	O	246-254
patient	O	255-262
.	O	262-263

This	O	264-268
can	O	269-272
be	O	273-275
problematic	O	276-287
when	O	288-292
only	O	293-297
part	O	298-302
of	O	303-305
the	O	306-309
gene	O	310-314
is	O	315-317
examined	O	318-326
or	O	327-329
when	O	330-334
relevant	O	335-343
DNA	O	344-347
alterations	O	348-359
are	O	360-363
not	O	364-367
recognized	O	368-378
by	O	379-381
standard	O	382-390
methods	O	391-398
.	O	398-399

We	O	400-402
present	O	403-410
a	O	411-412
child	O	413-418
in	O	419-421
whom	O	422-426
phenylketonuria	B	427-442
was	O	443-446
apparently	O	447-457
caused	O	458-464
by	O	465-467
homozygosity	O	468-480
for	O	481-484
the	O	485-488
mutation	O	489-497
E390G	O	498-503
in	O	504-506
exon	O	507-511
11	O	512-514
of	O	515-517
the	O	518-521
phenylalanine	O	522-535
hydroxylase	O	536-547
(	O	548-549
PAH	O	549-552
)	O	552-553
gene	O	554-558
.	O	558-559

However	O	560-567
,	O	567-568
the	O	569-572
clinical	O	573-581
severity	O	582-590
of	O	591-593
the	O	594-597
disease	O	598-605
was	O	606-609
not	O	610-613
quite	O	614-619
as	O	620-622
mild	O	623-627
as	O	628-630
expected	O	631-639
,	O	639-640
the	O	641-644
mutation	O	645-653
was	O	654-657
not	O	658-661
identified	O	662-672
in	O	673-675
the	O	676-679
father	O	680-686
despite	O	687-694
confirmed	O	695-704
paternity	O	705-714
,	O	714-715
and	O	716-719
the	O	720-723
paternal	O	724-732
allele	O	733-739
showed	O	740-746
a	O	747-748
highly	O	749-755
unusual	O	756-763
pattern	O	764-771
of	O	772-774
polymorphic	O	775-786
markers	O	787-794
in	O	795-797
the	O	798-801
PAH	O	802-805
gene	O	806-810
.	O	810-811

Presence	O	812-820
of	O	821-823
a	O	824-825
large	O	826-831
deletion	O	832-840
involving	O	841-850
exons	O	851-856
9	O	857-858
,	O	858-859
10	O	860-862
and	O	863-866
11	O	867-869
of	O	870-872
the	O	873-876
phenylalanine	O	877-890
hydroxylase	O	891-902
gene	O	903-907
was	O	908-911
confirmed	O	912-921
by	O	922-924
long	O	925-929
-	O	929-930
range	O	930-935
PCR	O	936-939
.	O	939-940

Diagnostic	O	941-951
DNA	O	952-955
analyses	O	956-964
should	O	965-971
include	O	972-979
a	O	980-981
comprehensive	O	982-995
examination	O	996-1007
of	O	1008-1010
the	O	1011-1014
whole	O	1015-1020
relevant	O	1021-1029
gene	O	1030-1034
in	O	1035-1037
the	O	1038-1041
patient	O	1042-1049
and	O	1050-1053
confirmation	O	1054-1066
of	O	1067-1069
carrier	O	1070-1077
status	O	1078-1084
in	O	1085-1087
both	O	1088-1092
parents	O	1093-1100
.	O	1100-1101
.	O	1100-1101

Two	O	0-3
point	O	4-9
mutations	O	10-19
are	O	20-23
responsible	O	24-35
for	O	36-39
G6PD	O	40-44
polymorphism	O	45-57
in	O	58-60
Sardinia	O	61-69
.	O	69-70

The	O	71-74
human	O	75-80
X	O	81-82
-	O	82-83
linked	O	83-89
gene	O	90-94
encoding	O	95-103
glucose	O	104-111
6	O	112-113
-	O	113-114
phosphate	O	114-123
dehydrogenase	O	124-137
(	O	138-139
G6PD	O	139-143
)	O	143-144
is	O	145-147
highly	O	148-154
polymorphic	O	155-166
;	O	166-167
more	O	168-172
than	O	173-177
300	O	178-181
G6PD	O	182-186
variants	O	187-195
have	O	196-200
been	O	201-205
identified	O	206-216
.	O	216-217

G6PD	B	218-222
deficiency	I	223-233
in	O	234-236
different	O	237-246
geographical	O	247-259
areas	O	260-265
appears	O	266-273
to	O	274-276
have	O	277-281
arisen	O	282-288
through	O	289-296
independent	O	297-308
mutational	O	309-319
events	O	320-326
,	O	326-327
but	O	328-331
within	O	332-338
the	O	339-342
same	O	343-347
population	O	348-358
it	O	359-361
may	O	362-365
also	O	366-370
be	O	371-373
heterogeneous	O	374-387
.	O	387-388

One	O	389-392
example	O	393-400
is	O	401-403
the	O	404-407
island	O	408-414
of	O	415-417
Sardinia	O	418-426
,	O	426-427
where	O	428-433
careful	O	434-441
clinical	O	442-450
and	O	451-454
biochemical	O	455-466
studies	O	467-474
have	O	475-479
identified	O	480-490
four	O	491-495
different	O	496-505
G6PD	O	506-510
variants	O	511-519
.	O	519-520

We	O	521-523
cloned	O	524-530
and	O	531-534
sequenced	O	535-544
the	O	545-548
four	O	549-553
G6PD	O	554-558
variants	O	559-567
from	O	568-572
Sardinia	O	573-581
and	O	582-585
found	O	586-591
that	O	592-596
only	O	597-601
two	O	602-605
mutations	O	606-615
are	O	616-619
responsible	O	620-631
for	O	632-635
G6PD	B	636-640
deficiency	I	641-651
in	O	652-654
this	O	655-659
area	O	660-664
one	O	666-669
mutation	O	670-678
is	O	679-681
the	O	682-685
cause	O	686-691
of	O	692-694
the	O	695-698
G6PD	B	699-703
Seattle	I	704-711
-	I	711-712
like	I	712-716
phenotype	I	717-726
,	O	726-727
a	O	728-729
milder	O	730-736
form	O	737-741
of	O	742-744
G6PD	B	745-749
deficiency	I	750-760
;	O	760-761
the	O	762-765
other	O	766-771
mutation	O	772-780
is	O	781-783
responsible	O	784-795
for	O	796-799
all	O	800-803
forms	O	804-809
of	O	810-812
very	O	813-817
severe	O	818-824
G6PD	B	825-829
deficiency	I	830-840
in	O	841-843
Sardinia	O	844-852
and	O	853-856
,	O	856-857
possibly	O	858-866
,	O	866-867
in	O	868-870
the	O	871-874
Mediterranean	O	875-888
.	O	888-889
.	O	888-889

Familial	B	0-8
discoid	I	9-16
lupus	I	17-22
erythematosus	I	23-36
associated	O	37-47
with	O	48-52
heterozygote	O	53-65
C2	B	66-68
deficiency	I	69-79
.	O	79-80

Two	O	81-84
siblings	O	85-93
with	O	94-98
chronic	B	99-106
discoid	I	107-114
lupus	I	115-120
erythematosus	I	121-134
and	O	135-138
several	O	139-146
family	O	147-153
members	O	154-161
were	O	162-166
found	O	167-172
with	O	173-177
heterozygous	O	178-190
C2	B	191-193
deficiency	I	194-204
.	O	204-205

An	O	206-208
association	O	209-220
with	O	221-225
histocompatibility	O	226-244
markers	O	245-252
HLA	O	253-256
-	O	256-257
B18	O	257-260
and	O	261-264
HLA	O	265-268
-	O	268-269
Dw2	O	269-272
was	O	273-276
demonstrated	O	277-289
,	O	289-290
and	O	291-294
the	O	295-298
slow	O	299-303
allotype	O	304-312
of	O	313-315
factor	O	316-322
B	O	323-324
was	O	325-328
present	O	329-336
.	O	336-337

Linkage	O	338-345
studies	O	346-353
in	O	354-356
this	O	357-361
family	O	362-368
suggested	O	369-378
a	O	379-380
close	O	381-386
linkage	O	387-394
between	O	395-402
the	O	403-406
C2	B	407-409
deficiency	I	410-420
gene	O	421-425
and	O	426-429
genes	O	430-435
coding	O	436-442
for	O	443-446
B18	O	447-450
,	O	450-451
Dw2	O	452-455
,	O	455-456
and	O	457-460
BfS	O	461-464
antigens	O	465-473
.	O	473-474

One	O	475-478
HLA	O	479-482
-	O	482-483
ACB	O	483-486
/	O	486-487
DBf	O	487-490
recombinant	O	491-502
was	O	503-506
observed	O	507-515
showing	O	516-523
closer	O	524-530
linkage	O	531-538
between	O	539-546
HLA	O	547-550
-	O	550-551
D	O	551-552
and	O	553-556
Bf	O	557-559
than	O	560-564
between	O	565-572
HLA	O	573-576
-	O	576-577
B	O	577-578
and	O	579-582
Bf	O	583-585
.	O	585-586
.	O	585-586

A	O	0-1
strong	O	2-8
candidate	O	9-18
for	O	19-22
the	O	23-26
breast	B	27-33
and	I	34-37
ovarian	I	38-45
cancer	I	46-52
susceptibility	O	53-67
gene	O	68-72
BRCA1	O	73-78
.	O	78-79

A	O	80-81
strong	O	82-88
candidate	O	89-98
for	O	99-102
the	O	103-106
17q	O	107-110
-	O	110-111
linked	O	111-117
BRCA1	O	118-123
gene	O	124-128
,	O	128-129
which	O	130-135
influences	O	136-146
susceptibility	O	147-161
to	O	162-164
breast	B	165-171
and	I	172-175
ovarian	I	176-183
cancer	I	184-190
,	O	190-191
has	O	192-195
been	O	196-200
identified	O	201-211
by	O	212-214
positional	O	215-225
cloning	O	226-233
methods	O	234-241
.	O	241-242

Probable	O	243-251
predisposing	O	252-264
mutations	O	265-274
have	O	275-279
been	O	280-284
detected	O	285-293
in	O	294-296
five	O	297-301
of	O	302-304
eight	O	305-310
kindreds	O	311-319
presumed	O	320-328
to	O	329-331
segregate	O	332-341
BRCA1	O	342-347
susceptibility	O	348-362
alleles	O	363-370
.	O	370-371

The	O	372-375
mutations	O	376-385
include	O	386-393
an	O	394-396
11	O	397-399
-	O	399-400
base	O	400-404
pair	O	405-409
deletion	O	410-418
,	O	418-419
a	O	420-421
1	O	422-423
-	O	423-424
base	O	424-428
pair	O	429-433
insertion	O	434-443
,	O	443-444
a	O	445-446
stop	O	447-451
codon	O	452-457
,	O	457-458
a	O	459-460
missense	O	461-469
substitution	O	470-482
,	O	482-483
and	O	484-487
an	O	488-490
inferred	O	491-499
regulatory	O	500-510
mutation	O	511-519
.	O	519-520

The	O	521-524
BRCA1	O	525-530
gene	O	531-535
is	O	536-538
expressed	O	539-548
in	O	549-551
numerous	O	552-560
tissues	O	561-568
,	O	568-569
including	O	570-579
breast	O	580-586
and	O	587-590
ovary	O	591-596
,	O	596-597
and	O	598-601
encodes	O	602-609
a	O	610-611
predicted	O	612-621
protein	O	622-629
of	O	630-632
1863	O	633-637
amino	O	638-643
acids	O	644-649
.	O	649-650

This	O	651-655
protein	O	656-663
contains	O	664-672
a	O	673-674
zinc	O	675-679
finger	O	680-686
domain	O	687-693
in	O	694-696
its	O	697-700
amino	O	701-706
-	O	706-707
terminal	O	707-715
region	O	716-722
,	O	722-723
but	O	724-727
is	O	728-730
otherwise	O	731-740
unrelated	O	741-750
to	O	751-753
previously	O	754-764
described	O	765-774
proteins	O	775-783
.	O	783-784

Identification	O	785-799
of	O	800-802
BRCA1	O	803-808
should	O	809-815
facilitate	O	816-826
early	O	827-832
diagnosis	O	833-842
of	O	843-845
breast	B	846-852
and	I	853-856
ovarian	I	857-864
cancer	I	865-871
susceptibility	O	872-886
in	O	887-889
some	O	890-894
individuals	O	895-906
as	O	907-909
well	O	910-914
as	O	915-917
a	O	918-919
better	O	920-926
understanding	O	927-940
of	O	941-943
breast	B	944-950
cancer	I	951-957
biology	O	958-965
.	O	965-966
.	O	965-966

Recombinations	O	0-14
in	O	15-17
individuals	O	18-29
homozygous	O	30-40
by	O	41-43
descent	O	44-51
localize	O	52-60
the	O	61-64
Friedreich	B	65-75
ataxia	I	76-82
locus	O	83-88
in	O	89-91
a	O	92-93
cloned	O	94-100
450	O	101-104
-	O	104-105
kb	O	105-107
interval	O	108-116
.	O	116-117

The	O	118-121
locus	O	122-127
for	O	128-131
Friedreich	B	132-142
ataxia	I	143-149
(	O	150-151
FRDA	B	151-155
)	O	155-156
,	O	156-157
a	O	158-159
severe	O	160-166
neurodegenerative	B	167-184
disease	I	185-192
,	O	192-193
is	O	194-196
tightly	O	197-204
linked	O	205-211
to	O	212-214
markers	O	215-222
D9S5	O	223-227
and	O	228-231
D9S15	O	232-237
,	O	237-238
and	O	239-242
analysis	O	243-251
of	O	252-254
rare	O	255-259
recombination	O	260-273
events	O	274-280
has	O	281-284
suggested	O	285-294
the	O	295-298
order	O	299-304
cen	O	305-308
-	O	308-309
FRDA	O	309-313
-	O	308-309
D9S5	O	314-318
-	O	308-309
D9S15	O	319-324
-	O	308-309
qter	O	325-329
.	O	329-330

We	O	331-333
report	O	334-340
here	O	341-345
the	O	346-349
construction	O	350-362
of	O	363-365
a	O	366-367
YAC	O	368-371
contig	O	372-378
extending	O	379-388
800	O	389-392
kb	O	393-395
centromeric	O	396-407
to	O	408-410
D9S5	O	411-415
and	O	416-419
the	O	420-423
isolation	O	424-433
of	O	434-436
five	O	437-441
new	O	442-445
microsatellite	O	446-460
markers	O	461-468
from	O	469-473
this	O	474-478
region	O	479-485
.	O	485-486

In	O	487-489
order	O	490-495
to	O	496-498
map	O	499-502
these	O	503-508
markers	O	509-516
with	O	517-521
respect	O	522-529
to	O	530-532
the	O	533-536
FRDA	B	537-541
locus	O	542-547
,	O	547-548
all	O	549-552
within	O	553-559
a	O	560-561
1	O	562-563
-	O	563-564
cM	O	564-566
confidence	O	567-577
interval	O	578-586
,	O	586-587
we	O	588-590
sought	O	591-597
to	O	598-600
increase	O	601-609
the	O	610-613
genetic	O	614-621
information	O	622-633
of	O	634-636
available	O	637-646
FRDA	B	647-651
families	O	652-660
by	O	661-663
considering	O	664-675
homozygosity	O	676-688
by	O	689-691
descent	O	692-699
and	O	700-703
association	O	704-715
with	O	716-720
founder	O	721-728
haplotypes	O	729-739
in	O	740-742
isolated	O	743-751
populations	O	752-763
.	O	763-764

This	O	765-769
approach	O	770-778
allowed	O	779-786
us	O	787-789
to	O	790-792
identify	O	793-801
one	O	802-805
phase	O	806-811
-	O	811-812
known	O	812-817
recombination	O	818-831
and	O	832-835
one	O	836-839
probable	O	840-848
historic	O	849-857
recombination	O	858-871
on	O	872-874
haplotypes	O	875-885
from	O	886-890
Reunion	O	891-898
Island	O	899-905
patients	O	906-914
,	O	914-915
both	O	916-920
of	O	921-923
which	O	924-929
place	O	930-935
three	O	936-941
of	O	942-944
the	O	945-948
five	O	949-953
markers	O	954-961
proximal	O	962-970
to	O	971-973
FRDA	B	974-978
.	O	978-979

This	O	980-984
represents	O	985-995
the	O	996-999
first	O	1000-1005
identification	O	1006-1020
of	O	1021-1023
close	O	1024-1029
FRDA	B	1030-1034
flanking	O	1035-1043
markers	O	1044-1051
on	O	1052-1054
the	O	1055-1058
centromeric	O	1059-1070
side	O	1071-1075
.	O	1075-1076

The	O	1077-1080
two	O	1081-1084
other	O	1085-1090
markers	O	1091-1098
allowed	O	1099-1106
us	O	1107-1109
to	O	1110-1112
narrow	O	1113-1119
the	O	1120-1123
breakpoint	O	1124-1134
of	O	1135-1137
a	O	1138-1139
previously	O	1140-1150
identified	O	1151-1161
distal	O	1162-1168
recombination	O	1169-1182
that	O	1183-1187
is	O	1188-1190
>	O	1191-1192
180	O	1193-1196
kb	O	1197-1199
from	O	1200-1204
D9S5	O	1205-1209
(	O	1210-1211
26P	O	1211-1214
)	O	1214-1215
.	O	1215-1216

Taken	O	1217-1222
together	O	1223-1231
,	O	1231-1232
the	O	1233-1236
results	O	1237-1244
place	O	1245-1250
the	O	1251-1254
FRDA	B	1255-1259
locus	O	1260-1265
in	O	1266-1268
a	O	1269-1270
450	O	1271-1274
-	O	1274-1275
kb	O	1275-1277
interval	O	1278-1286
,	O	1286-1287
which	O	1288-1293
is	O	1294-1296
small	O	1297-1302
enough	O	1303-1309
for	O	1310-1313
direct	O	1314-1320
search	O	1321-1327
of	O	1328-1330
candidate	O	1331-1340
genes	O	1341-1346
.	O	1346-1347

A	O	1348-1349
detailed	O	1350-1358
rare	O	1359-1363
cutter	O	1364-1370
restriction	O	1371-1382
map	O	1383-1386
and	O	1387-1390
a	O	1391-1392
cosmid	O	1393-1399
contig	O	1400-1406
covering	O	1407-1415
this	O	1416-1420
interval	O	1421-1429
were	O	1430-1434
constructed	O	1435-1446
and	O	1447-1450
should	O	1451-1457
facilitate	O	1458-1468
the	O	1469-1472
search	O	1473-1479
of	O	1480-1482
genes	O	1483-1488
in	O	1489-1491
this	O	1492-1496
region	O	1497-1503
.	O	1503-1504
.	O	1503-1504

Further	O	0-7
mapping	O	8-15
of	O	16-18
an	O	19-21
ataxia	B	22-28
-	I	28-29
telangiectasia	I	29-43
locus	O	44-49
to	O	50-52
the	O	53-56
chromosome	O	57-67
11q23	O	68-73
region	O	74-80
.	O	80-81

We	O	82-84
recently	O	85-93
mapped	O	94-100
the	O	101-104
gene	O	105-109
for	O	110-113
ataxia	B	114-120
-	I	120-121
telangiectasia	I	121-135
group	O	136-141
A	O	142-143
(	O	144-145
ATA	O	145-148
)	O	148-149
to	O	150-152
chromosome	O	153-163
11q22	O	164-169
-	O	169-170
23	O	170-172
by	O	173-175
linkage	O	176-183
analysis	O	184-192
,	O	192-193
using	O	194-199
the	O	200-203
genetic	O	204-211
markers	O	212-219
THY1	O	220-224
and	O	225-228
pYNB3	O	229-234
.	O	234-235

12	O	236-238
(	O	239-240
D11S144	O	240-247
)	O	247-248
.	O	248-249

The	O	250-253
most	O	254-258
likely	O	259-265
order	O	266-271
was	O	272-275
cent	O	276-280
-	O	280-281
AT	O	281-283
-	O	280-281
S144	O	284-288
-	O	280-281
THY1	O	289-293
.	O	293-294

The	O	295-298
present	O	299-306
paper	O	307-312
describes	O	313-322
further	O	323-330
mapping	O	331-338
of	O	339-341
the	O	342-345
AT	B	346-348
locus	O	349-354
by	O	355-357
means	O	358-363
of	O	364-366
a	O	367-368
panel	O	369-374
of	O	375-377
10	O	378-380
markers	O	381-388
that	O	389-393
span	O	394-398
approximately	O	399-412
60	O	413-415
cM	O	416-418
in	O	419-421
the	O	422-425
11q22	O	426-431
-	O	431-432
23	O	432-434
region	O	435-441
centered	O	442-450
around	O	451-457
S144	O	458-462
and	O	463-466
THY1	O	467-471
.	O	471-472

Location	O	473-481
scores	O	482-488
indicate	O	489-497
that	O	498-502
three	O	503-508
contiguous	O	509-519
subsegments	O	520-531
within	O	532-538
the	O	539-542
[	O	543-544
S144	O	544-548
-	O	548-549
THY1	O	549-553
]	O	553-554
segment	O	555-562
,	O	562-563
as	O	564-566
well	O	567-571
as	O	572-574
three	O	575-580
contiguous	O	581-591
segments	O	592-600
telomeric	O	601-610
to	O	611-613
THY1	O	614-618
,	O	618-619
are	O	620-623
each	O	624-628
unlikely	O	629-637
to	O	638-640
contain	O	641-648
the	O	649-652
AT	B	653-655
locus	O	656-661
,	O	661-662
while	O	663-668
the	O	669-672
more	O	673-677
centromeric	O	678-689
[	O	690-691
STMY	O	691-695
-	O	695-696
S144	O	696-700
]	O	700-701
segment	O	702-709
is	O	710-712
most	O	713-717
likely	O	718-724
to	O	725-727
contain	O	728-735
the	O	736-739
AT	B	740-742
locus	O	743-748
.	O	748-749

These	O	750-755
data	O	756-760
,	O	760-761
together	O	762-770
with	O	771-775
recent	O	776-782
refinements	O	783-794
in	O	795-797
the	O	798-801
linkage	O	802-809
and	O	810-813
physical	O	814-822
maps	O	823-827
of	O	828-830
11q22	O	831-836
-	O	836-837
23	O	837-839
,	O	839-840
place	O	841-846
the	O	847-850
AT	B	851-853
locus	O	854-859
at	O	860-862
11q23	O	863-868
.	O	868-869

Proliferation	O	0-13
-	O	13-14
related	O	14-21
expression	O	22-32
of	O	33-35
p19	O	36-39
/	O	39-40
nm23	O	40-44
nucleoside	O	45-55
diphosphate	O	56-67
kinase	O	68-74
.	O	74-75

High	O	76-80
level	O	81-86
expression	O	87-97
of	O	98-100
the	O	101-104
nm23	O	105-109
-	O	109-110
H1	O	110-112
gene	O	113-117
,	O	117-118
which	O	119-124
encodes	O	125-132
for	O	133-136
a	O	137-138
nucleoside	O	139-149
diphosphate	O	150-161
kinase	O	162-168
,	O	168-169
has	O	170-173
been	O	174-178
found	O	179-184
to	O	185-187
correlate	O	188-197
with	O	198-202
diminished	O	203-213
metastasis	O	214-224
in	O	225-227
some	O	228-232
tumors	B	233-239
but	O	240-243
not	O	244-247
in	O	248-250
others	O	251-257
.	O	257-258

We	O	259-261
have	O	262-266
previously	O	267-277
identified	O	278-288
the	O	289-292
protein	O	293-300
product	O	301-308
of	O	309-311
the	O	312-315
nm23	O	316-320
-	O	320-321
H1	O	321-323
gene	O	324-328
in	O	329-331
two	O	332-335
-	O	335-336
dimensional	O	336-347
electrophoretic	O	348-363
gels	O	364-368
and	O	369-372
have	O	373-377
designated	O	378-388
it	O	389-391
p19	O	392-395
/	O	395-396
nm23	O	396-400
.	O	400-401

In	O	402-404
neuroblastoma	B	405-418
,	O	418-419
higher	O	420-426
levels	O	427-433
of	O	434-436
p19	O	437-440
/	O	440-441
nm23	O	441-445
,	O	445-446
which	O	447-452
are	O	453-456
associated	O	457-467
with	O	468-472
amplification	O	473-486
of	O	487-489
the	O	490-493
N	O	494-495
-	O	495-496
myc	O	496-499
oncogene	O	500-508
,	O	508-509
large	O	510-515
tumor	B	516-521
mass	O	522-526
,	O	526-527
and	O	528-531
metastasis	O	532-542
,	O	542-543
were	O	544-548
observed	O	549-557
in	O	558-560
advanced	O	561-569
stage	O	570-575
tumors	B	576-582
compared	O	583-591
with	O	592-596
limited	O	597-604
stage	O	605-610
disease	O	611-618
.	O	618-619

Because	O	620-627
of	O	628-630
the	O	631-634
variable	O	635-643
expression	O	644-654
of	O	655-657
nm23	O	658-662
-	O	662-663
H1	O	663-665
in	O	666-668
different	O	669-678
tumors	B	679-685
,	O	685-686
we	O	687-689
have	O	690-694
investigated	O	695-707
the	O	708-711
relationship	O	712-724
between	O	725-732
amounts	O	733-740
of	O	741-743
the	O	744-747
protein	O	748-755
and	O	756-759
cell	O	760-764
proliferation	O	765-778
.	O	778-779

The	O	780-783
levels	O	784-790
of	O	791-793
p19	O	794-797
/	O	797-798
nm23	O	798-802
were	O	803-807
compared	O	808-816
between	O	817-824
resting	O	825-832
and	O	833-836
mitotically	O	837-848
stimulated	O	849-859
normal	O	860-866
human	O	867-872
PBLs	O	873-877
and	O	878-881
in	O	882-884
leukemia	B	885-893
cells	O	894-899
.	O	899-900

The	O	901-904
amount	O	905-911
of	O	912-914
p19	O	915-918
/	O	918-919
nm23	O	919-923
increased	O	924-933
in	O	934-936
normal	O	937-943
lymphocytes	O	944-955
in	O	956-958
response	O	959-967
to	O	968-970
mitotic	O	971-978
stimulation	O	979-990
and	O	991-994
paralleled	O	995-1005
the	O	1006-1009
increase	O	1010-1018
in	O	1019-1021
DNA	O	1022-1025
synthesis	O	1026-1035
.	O	1035-1036

In	O	1037-1039
leukemia	B	1040-1048
cells	O	1049-1054
obtained	O	1055-1063
from	O	1064-1068
patients	O	1069-1077
with	O	1078-1082
different	O	1083-1092
subtypes	O	1093-1101
of	O	1102-1104
acute	B	1105-1110
leukemia	I	1111-1119
,	O	1119-1120
p19	O	1121-1124
/	O	1124-1125
nm23	O	1125-1129
levels	O	1130-1136
were	O	1137-1141
also	O	1142-1146
increased	O	1147-1156
relative	O	1157-1165
to	O	1166-1168
resting	O	1169-1176
normal	O	1177-1183
lymphocytes	O	1184-1195
.	O	1195-1196

Treatment	O	1197-1206
of	O	1207-1209
mitotically	O	1210-1221
stimulated	O	1222-1232
lymphocytes	O	1233-1244
with	O	1245-1249
cyclosporin	O	1250-1261
,	O	1261-1262
which	O	1263-1268
inhibits	O	1269-1277
proliferation	O	1278-1291
,	O	1291-1292
blocked	O	1293-1300
the	O	1301-1304
increase	O	1305-1313
in	O	1314-1316
p19	O	1317-1320
/	O	1320-1321
nm23	O	1321-1325
;	O	1325-1326
treatment	O	1327-1336
of	O	1337-1339
the	O	1340-1343
leukemia	B	1344-1352
cell	O	1353-1357
line	O	1358-1362
HL	O	1363-1365
-	O	1365-1366
60	O	1366-1368
with	O	1369-1373
dimethylsulfoxide	O	1374-1391
,	O	1391-1392
which	O	1393-1398
induces	O	1399-1406
terminal	O	1407-1415
differentiation	O	1416-1431
,	O	1431-1432
resulted	O	1433-1441
in	O	1442-1444
diminished	O	1445-1455
levels	O	1456-1462
of	O	1463-1465
p19	O	1466-1469
/	O	1469-1470
nm23	O	1470-1474
.	O	1474-1475

Our	O	1476-1479
data	O	1480-1484
therefore	O	1485-1494
provide	O	1495-1502
evidence	O	1503-1511
that	O	1512-1516
nm23	O	1517-1521
-	O	1521-1522
H1	O	1522-1524
expression	O	1525-1535
is	O	1536-1538
related	O	1539-1546
to	O	1547-1549
cell	O	1550-1554
proliferative	O	1555-1568
activity	O	1569-1577
.	O	1577-1578
.	O	1577-1578

Carrier	O	0-7
detection	O	8-17
of	O	18-20
pyruvate	B	21-29
carboxylase	I	30-41
deficiency	I	42-52
in	O	53-55
fibroblasts	O	56-67
and	O	68-71
lymphocytes	O	72-83
.	O	83-84

Pyruvate	O	85-93
carboxylase	O	94-105
(	O	106-107
E	O	107-108
.	O	108-109

C	O	110-111
.	O	111-112
6	O	113-114
.	O	114-115
4	O	116-117
.	O	117-118
1	O	119-120
.	O	120-121
1	O	122-123
)	O	123-124
activity	O	125-133
was	O	134-137
determined	O	138-148
in	O	149-151
the	O	152-155
circulating	O	156-167
peripheral	O	168-178
lymphocytes	O	179-190
and	O	191-194
cultured	O	195-203
skin	O	204-208
fibroblasts	O	209-220
from	O	221-225
the	O	226-229
family	O	230-236
of	O	237-239
a	O	240-241
patient	O	242-249
with	O	250-254
hepatic	O	255-262
,	O	262-263
cerebral	O	264-272
,	O	272-273
renal	O	274-279
cortical	O	280-288
,	O	288-289
leukocyte	O	290-299
,	O	299-300
and	O	301-304
fibroblast	O	305-315
pyruvate	B	316-324
carboxylase	I	325-336
deficiency	I	337-347
(	O	348-349
PC	B	349-351
Portland	I	352-360
deficiency	I	361-371
)	O	371-372
.	O	372-373

Lymphocyte	O	374-384
activities	O	385-395
were	O	396-400
mother	O	402-408
,	O	408-409
33	O	410-412
-	O	412-413
-	O	412-413
39	O	414-416
%	O	416-417
;	O	417-418
father	O	419-425
,	O	425-426
11	O	427-429
-	O	429-430
-	O	429-430
29	O	431-433
%	O	433-434
;	O	434-435
brother	O	436-443
,	O	443-444
82	O	445-447
-	O	447-448
-	O	447-448
103	O	449-452
%	O	452-453
;	O	453-454
and	O	455-458
sister	O	459-465
,	O	465-466
38	O	467-469
-	O	469-470
-	O	469-470
48	O	471-473
%	O	473-474
of	O	475-477
the	O	478-481
lowest	O	482-488
normal	O	489-495
.	O	495-496

Fibroblasts	O	497-508
from	O	509-513
the	O	514-517
patients	O	518-526
mother	O	527-533
and	O	534-537
father	O	538-544
had	O	545-548
42	O	549-551
and	O	552-555
34	O	556-558
%	O	558-559
,	O	559-560
respectively	O	561-573
,	O	573-574
of	O	575-577
the	O	578-581
activity	O	582-590
of	O	591-593
the	O	594-597
lowest	O	598-604
normal	O	605-611
.	O	611-612

These	O	613-618
data	O	619-623
demonstrate	O	624-635
that	O	636-640
the	O	641-644
disease	O	645-652
is	O	653-655
inherited	O	656-665
in	O	666-668
an	O	669-671
autosomal	O	672-681
recessive	O	682-691
manner	O	692-698
and	O	699-702
that	O	703-707
lymphocytes	O	708-719
and	O	720-723
fibroblasts	O	724-735
can	O	736-739
be	O	740-742
used	O	743-747
to	O	748-750
detect	O	751-757
carriers	O	758-766
.	O	766-767

Neither	O	768-775
pyruvate	O	776-784
carboxylase	O	785-796
nor	O	797-800
mitochondrial	O	801-814
PEPCK	O	815-820
activity	O	821-829
in	O	830-832
lymphocytes	O	833-844
was	O	845-848
increased	O	849-858
by	O	859-861
a	O	862-863
21	O	864-866
-	O	866-867
hr	O	867-869
fast	O	870-874
.	O	874-875

Complex	B	0-7
glycerol	I	8-16
kinase	I	17-23
deficiency	I	24-34
:	O	34-35
molecular	O	36-45
-	O	45-46
genetic	O	46-53
,	O	53-54
cytogenetic	O	55-66
,	O	66-67
and	O	68-71
clinical	O	72-80
studies	O	81-88
of	O	89-91
five	O	92-96
Japanese	O	97-105
patients	O	106-114
.	O	114-115

Five	O	116-120
male	O	121-125
Japanese	O	126-134
patients	O	135-143
with	O	144-148
complex	B	149-156
glycerol	I	157-165
kinase	I	166-172
deficiency	I	173-183
(	O	184-185
CGKD	B	185-189
)	O	189-190
and	O	191-194
their	O	195-200
relatives	O	201-210
were	O	211-215
studied	O	216-223
clinically	O	224-234
,	O	234-235
cytogenetically	O	236-251
,	O	251-252
and	O	253-256
molecular	O	257-266
-	O	266-267
genetically	O	267-278
.	O	278-279

All	O	280-283
patients	O	284-292
had	O	293-296
muscular	B	297-305
dystrophy	I	306-315
or	O	316-318
muscle	B	319-325
weakness	I	326-334
,	O	334-335
mental	B	336-342
retardation	I	343-354
,	O	354-355
congenital	B	356-366
adrenal	I	367-374
hypoplasia	I	375-385
,	O	385-386
and	O	387-390
glycerol	B	391-399
kinase	I	400-406
deficiency	I	407-417
.	O	417-418

High	O	419-423
-	O	423-424
resolution	O	424-434
GTG	O	435-438
-	O	438-439
banded	O	439-445
chromosomes	O	446-457
showed	O	458-464
a	O	465-466
microdeletion	O	467-480
in	O	481-483
the	O	484-487
Xp21	O	488-492
region	O	493-499
in	O	500-502
all	O	503-506
four	O	507-511
patients	O	512-520
examined	O	521-529
and	O	530-533
in	O	534-536
all	O	537-540
five	O	541-545
mothers	O	546-553
.	O	553-554

Southern	O	555-563
hybridizations	O	564-578
,	O	578-579
after	O	580-585
digestions	O	586-596
by	O	597-599
restriction	O	600-611
endonucleases	O	612-625
,	O	625-626
with	O	627-631
various	O	632-639
cloned	O	640-646
DNAs	O	647-651
(	O	652-653
D2	O	653-655
,	O	655-656
99	O	657-659
-	O	659-660
6	O	660-661
,	O	661-662
B24	O	663-666
,	O	666-667
C7	O	668-670
,	O	670-671
L1	O	672-674
-	O	674-675
4	O	675-676
,	O	676-677
cDMD13	O	678-684
-	O	684-685
14	O	685-687
,	O	687-688
J66	O	689-692
-	O	692-693
HI	O	693-695
,	O	695-696
P20	O	697-700
,	O	700-701
J	O	702-703
-	O	703-704
Bir	O	704-707
,	O	707-708
ERT87	O	709-714
-	O	714-715
30	O	715-717
,	O	717-718
ERT87	O	719-724
-	O	724-725
15	O	725-727
,	O	727-728
ERT87	O	729-734
-	O	734-735
8	O	732-733
,	O	736-737
ERT87	O	738-743
-	O	743-744
1	O	744-745
,	O	745-746
XJ	O	747-749
-	O	749-750
1	O	750-751
.	O	751-752
1	O	753-754
,	O	754-755
754	O	756-759
,	O	759-760
cx5	O	761-764
.	O	764-765

7	O	766-767
,	O	767-768
and	O	769-772
OTC	O	773-776
-	O	776-777
1	O	777-778
)	O	778-779
that	O	780-784
are	O	785-788
located	O	789-796
around	O	797-803
Xp21	O	804-808
also	O	809-813
showed	O	814-820
a	O	821-822
deletion	O	823-831
in	O	832-834
the	O	835-838
genome	O	839-845
of	O	846-848
all	O	849-852
patients	O	853-861
and	O	862-865
mothers	O	866-873
.	O	873-874

Although	O	875-883
the	O	884-887
deletion	O	888-896
differed	O	897-905
in	O	906-908
size	O	909-913
among	O	914-919
patients	O	920-928
,	O	928-929
a	O	930-931
segment	O	932-939
commonly	O	940-948
absent	O	949-955
was	O	956-959
located	O	960-967
between	O	968-975
the	O	976-979
genomic	O	980-987
sequences	O	988-997
corresponding	O	998-1011
to	O	1012-1014
L1	O	1015-1017
-	O	1017-1018
4	O	1018-1019
and	O	1020-1023
cDMD13	O	1024-1030
-	O	1030-1031
14	O	1031-1033
.	O	1033-1034

This	O	1035-1039
finding	O	1040-1047
indicated	O	1048-1057
that	O	1058-1062
the	O	1063-1066
gene	O	1067-1071
coding	O	1072-1078
for	O	1079-1082
glycerol	O	1083-1091
kinase	O	1092-1098
(	O	1099-1100
GK	O	1100-1102
)	O	1102-1103
is	O	1104-1106
located	O	1107-1114
within	O	1115-1121
this	O	1122-1126
segment	O	1127-1134
.	O	1134-1135

A	O	1136-1137
comparison	O	1138-1148
of	O	1149-1151
the	O	1152-1155
clinical	O	1156-1164
manifestations	O	1165-1179
of	O	1180-1182
the	O	1183-1186
present	O	1187-1194
five	O	1195-1199
patients	O	1200-1208
and	O	1209-1212
reported	O	1213-1221
CGKD	B	1222-1226
or	O	1227-1229
Duchenne	B	1230-1238
muscular	I	1239-1247
dystrophy	I	1248-1257
(	O	1258-1259
DMD	B	1259-1262
)	O	1262-1263
patients	O	1264-1272
with	O	1273-1277
DNA	O	1278-1281
deletion	O	1282-1290
suggests	O	1291-1299
the	O	1300-1303
existence	O	1304-1313
of	O	1314-1316
a	O	1317-1318
certain	O	1319-1326
gene	O	1327-1331
responsible	O	1332-1343
for	O	1344-1347
gonadotropin	B	1348-1360
deficiency	I	1361-1371
(	O	1372-1373
GTD	B	1373-1376
)	O	1376-1377
.	O	1377-1378

The	O	1379-1382
result	O	1383-1389
of	O	1390-1392
the	O	1393-1396
present	O	1397-1404
study	O	1405-1410
and	O	1411-1414
results	O	1415-1422
of	O	1423-1425
previous	O	1426-1434
studies	O	1435-1442
suggest	O	1443-1450
that	O	1451-1455
genes	O	1456-1461
for	O	1462-1465
ornithine	O	1466-1475
transcarbamylase	O	1476-1492
(	O	1493-1494
OTC	O	1494-1497
)	O	1497-1498
,	O	1498-1499
DMD	B	1500-1503
,	O	1503-1504
and	O	1505-1508
GK	O	1509-1511
and	O	1512-1515
putative	O	1516-1524
genes	O	1525-1530
responsible	O	1531-1542
for	O	1543-1546
congenital	B	1547-1557
adrenal	I	1558-1565
hypoplasia	I	1566-1576
(	O	1577-1578
AHC	B	1578-1581
)	O	1581-1582
and	O	1583-1586
GTD	B	1587-1590
are	O	1591-1594
arranged	O	1595-1603
from	O	1604-1608
telomere	O	1609-1617
to	O	1618-1620
centromere	O	1621-1631
as	O	1632-1634
pter	O	1635-1639
-	O	1639-1640
-	O	1639-1640
GTD	O	1641-1644
-	O	1639-1640
-	O	1639-1640
AHC	O	1646-1649
-	O	1639-1640
-	O	1639-1640
GK	O	1651-1653
-	O	1639-1640
-	O	1639-1640
DMD	O	1655-1658
-	O	1639-1640
-	O	1639-1640
OTC	O	1660-1663
-	O	1639-1640
-	O	1639-1640
cen	O	1665-1668

Duchenne	B	0-8
muscular	I	9-17
dystrophy	I	18-27
and	O	28-31
myotonic	B	32-40
dystrophy	I	41-50
in	O	51-53
the	O	54-57
same	O	58-62
patient	O	63-70
.	O	70-71

We	O	72-74
report	O	75-81
on	O	82-84
the	O	85-88
first	O	89-94
patient	O	95-102
identified	O	103-113
with	O	114-118
myotonic	B	119-127
dystrophy	I	128-137
and	O	138-141
Duchenne	B	142-150
muscular	I	151-159
dystrophy	I	160-169
(	O	170-171
DMD	B	171-174
)	O	174-175
.	O	175-176

The	O	177-180
family	O	181-187
of	O	188-190
the	O	191-194
propositus	O	195-205
had	O	206-209
a	O	210-211
strong	O	212-218
history	O	219-226
of	O	227-229
myotonic	B	230-238
dystrophy	I	239-248
,	O	248-249
and	O	250-253
there	O	254-259
was	O	260-263
an	O	264-266
intrafamilial	O	267-280
pathological	O	281-293
expansion	O	294-303
of	O	304-306
the	O	307-310
responsible	O	311-322
CTG	O	323-326
repeat	O	327-333
between	O	334-341
the	O	342-345
mildly	O	346-352
affected	O	353-361
mother	O	362-368
(	O	369-370
160	O	370-373
repeats	O	374-381
;	O	381-382
normal	O	383-389
27	O	390-392
repeats	O	393-400
)	O	400-401
and	O	402-405
her	O	406-409
more	O	410-414
severely	O	415-423
affected	O	424-432
son	O	433-436
(	O	437-438
650	O	438-441
repeats	O	442-449
)	O	449-450
,	O	450-451
and	O	452-455
his	O	456-459
sister	O	460-466
(	O	467-468
650	O	468-471
repeats	O	472-479
)	O	479-480
.	O	480-481

The	O	482-485
propositus	O	486-496
was	O	497-500
an	O	501-503
isolated	O	504-512
case	O	513-517
of	O	518-520
Duchenne	B	521-529
muscular	I	530-538
dystrophy	I	539-548
with	O	549-553
marked	O	554-560
dystrophin	B	561-571
deficiency	I	572-582
in	O	583-585
muscle	O	586-592
biopsy	O	593-599
.	O	599-600

The	O	601-604
patient	O	605-612
was	O	613-616
still	O	617-622
ambulatory	O	623-633
post	O	634-638
age	O	639-642
16	O	643-645
.	O	645-646

Myotonic	B	647-655
dystrophy	I	656-665
could	O	666-671
interfere	O	672-681
to	O	682-684
some	O	685-689
extent	O	690-696
with	O	697-701
the	O	702-705
progression	O	706-717
of	O	718-720
Duchenne	B	721-729
dystrophy	I	730-739
.	O	739-740

However	O	741-748
,	O	748-749
other	O	750-755
interpretations	O	756-771
are	O	772-775
possible	O	776-784
.	O	784-785

Twelve	O	786-792
percent	O	793-800
of	O	801-803
dystrophin	O	804-814
revertant	O	815-824
fibers	O	825-831
as	O	832-834
observed	O	835-843
by	O	844-846
immunohistochemistry	O	847-867
could	O	868-873
be	O	874-876
sufficient	O	877-887
to	O	888-890
ameliorate	O	891-901
typical	O	902-909
DMD	B	910-913
clinical	O	914-922
severity	O	923-931
,	O	931-932
or	O	933-935
the	O	936-939
patient	O	940-947
may	O	948-951
present	O	952-959
a	O	960-961
somatic	O	962-969
mosaic	O	970-976
.	O	976-977

The	O	978-981
pathophysiological	O	982-1000
interactions	O	1001-1013
of	O	1014-1016
these	O	1017-1022
two	O	1023-1026
unlinked	O	1027-1035
disorders	O	1036-1045
are	O	1046-1049
discussed	O	1050-1059
at	O	1060-1062
the	O	1063-1066
clinical	O	1067-1075
and	O	1076-1079
histopathological	O	1080-1097
levels	O	1098-1104
.	O	1104-1105
.	O	1104-1105

Autosomal	O	0-9
recessive	O	10-19
transmission	O	20-32
of	O	33-35
hemophilia	B	36-46
A	I	47-48
due	O	49-52
to	O	53-55
a	O	56-57
von	B	58-61
Willebrand	I	62-72
factor	O	73-79
mutation	O	80-88
.	O	88-89

The	O	90-93
differential	O	94-106
diagnosis	O	107-116
of	O	117-119
the	O	120-123
genetic	B	124-131
bleeding	I	132-140
disorders	I	141-150
,	O	150-151
hemophilia	B	152-162
A	I	163-164
and	O	165-168
von	B	169-172
Willebrand	I	173-183
disease	I	184-191
,	O	191-192
is	O	193-195
occasionally	O	196-208
confounded	O	209-219
by	O	220-222
the	O	223-226
close	O	227-232
molecular	O	233-242
relationship	O	243-255
of	O	256-258
coagulation	O	259-270
factor	O	271-277
VIII	O	278-282
and	O	283-286
von	B	287-290
Willebrand	I	291-301
factor	O	302-308
(	O	309-310
vWF	O	310-313
)	O	313-314
.	O	314-315

This	O	316-320
report	O	321-327
describes	O	328-337
the	O	338-341
autosomal	O	342-351
inheritance	O	352-363
of	O	364-366
a	O	367-368
hemophilia	B	369-379
A	I	380-381
phenotype	O	382-391
due	O	392-395
to	O	396-398
a	O	399-400
mutation	O	401-409
of	O	410-412
vWF	O	413-416
that	O	417-421
results	O	422-429
in	O	430-432
defective	O	433-442
factor	O	443-449
VIII	O	450-454
binding	O	455-462
.	O	462-463

The	O	464-467
proband	O	468-475
was	O	476-479
a	O	480-481
female	O	482-488
patient	O	489-496
with	O	497-501
low	O	502-505
levels	O	506-512
of	O	513-515
factor	O	516-522
VIII	O	523-527
activity	O	528-536
.	O	536-537

Polymerase	O	538-548
chain	O	549-554
reaction	O	555-563
(	O	564-565
PCR	O	565-568
)	O	568-569
amplification	O	570-583
and	O	584-587
DNA	O	588-591
sequencing	O	592-602
were	O	603-607
employed	O	608-616
to	O	617-619
examine	O	620-627
exons	O	628-633
encoding	O	634-642
the	O	643-646
putative	O	647-655
factor	O	656-662
VIII	O	663-667
binding	O	668-675
domain	O	676-682
of	O	683-685
vWF	O	686-689
.	O	689-690

The	O	691-694
patient	O	695-702
was	O	703-706
found	O	707-712
to	O	713-715
be	O	716-718
homozygous	O	719-729
for	O	730-733
a	O	734-735
single	O	736-742
point	O	743-748
mutation	O	749-757
causing	O	758-765
a	O	766-767
Thr	O	768-771
-	O	771-772
-	O	771-772
>	O	774-775
Met	O	776-779
substitution	O	780-792
at	O	793-795
amino	O	796-801
acid	O	802-806
position	O	807-815
28	O	816-818
in	O	819-821
the	O	822-825
mature	O	826-832
vWF	O	833-836
subunit	O	837-844
.	O	844-845

The	O	846-849
phenotypic	O	850-860
expression	O	861-871
of	O	872-874
the	O	875-878
mutation	O	879-887
was	O	888-891
determined	O	892-902
to	O	903-905
be	O	906-908
recessive	O	909-918
because	O	919-926
heterozygous	O	927-939
family	O	940-946
members	O	947-954
were	O	955-959
clinically	O	960-970
unaffected	O	971-981
.	O	981-982

Recombinant	O	983-994
vWF	O	995-998
containing	O	999-1009
the	O	1010-1013
observed	O	1014-1022
amino	O	1023-1028
acid	O	1029-1033
substitution	O	1034-1046
was	O	1047-1050
expressed	O	1051-1060
in	O	1061-1063
COS	O	1064-1067
-	O	1067-1068
1	O	1068-1069
cells	O	1070-1075
.	O	1075-1076

The	O	1077-1080
mutant	O	1081-1087
vWF	O	1088-1091
was	O	1092-1095
processed	O	1096-1105
and	O	1106-1109
secreted	O	1110-1118
normally	O	1119-1127
,	O	1127-1128
and	O	1129-1132
was	O	1133-1136
functionally	O	1137-1149
equivalent	O	1150-1160
to	O	1161-1163
wild	O	1164-1168
-	O	1168-1169
type	O	1169-1173
vWF	O	1174-1177
in	O	1178-1180
its	O	1181-1184
ability	O	1185-1192
to	O	1193-1195
bind	O	1196-1200
to	O	1201-1203
platelets	O	1204-1213
.	O	1213-1214

However	O	1215-1222
,	O	1222-1223
the	O	1224-1227
mutant	O	1228-1234
failed	O	1235-1241
to	O	1242-1244
bind	O	1245-1249
factor	O	1250-1256
VIII	O	1257-1261
,	O	1261-1262
demonstrating	O	1263-1276
that	O	1277-1281
the	O	1282-1285
mutation	O	1286-1294
was	O	1295-1298
functionally	O	1299-1311
related	O	1312-1319
to	O	1320-1322
the	O	1323-1326
observed	O	1327-1335
hemophilia	B	1336-1346
phenotype	O	1347-1356
.	O	1356-1357

The	O	1358-1361
family	O	1362-1368
we	O	1369-1371
describe	O	1372-1380
demonstrates	O	1381-1393
the	O	1394-1397
recessive	O	1398-1407
inheritance	O	1408-1419
of	O	1420-1422
a	O	1423-1424
recently	O	1425-1433
recognized	O	1434-1444
class	O	1445-1450
of	O	1451-1453
genetic	O	1454-1461
bleeding	O	1462-1470
disorders	O	1471-1480
,	O	1480-1481
we	O	1482-1484
call	O	1485-1489
"	O	1490-1491
autosomal	O	1492-1501
hemophilia	B	1502-1512
.	O	1512-1513

"	O	1514-1515
We	O	1516-1518
conclude	O	1519-1527
that	O	1528-1532
vWF	O	1533-1536
mutation	O	1537-1545
may	O	1546-1549
be	O	1550-1552
an	O	1553-1555
under	O	1556-1561
recognized	O	1562-1572
cause	O	1573-1578
of	O	1579-1581
hemophilia	B	1582-1592
,	O	1592-1593
especially	O	1594-1604
in	O	1605-1607
cases	O	1608-1613
where	O	1614-1619
the	O	1620-1623
inheritance	O	1624-1635
pattern	O	1636-1643
is	O	1644-1646
not	O	1647-1650
consistent	O	1651-1661
with	O	1662-1666
X	O	1667-1668
-	O	1668-1669
linked	O	1669-1675
transmission	O	1676-1688
.	O	1688-1689

Determination	O	0-13
of	O	14-16
30	O	17-19
X	B	20-21
-	I	21-22
linked	I	22-28
adrenoleukodystrophy	I	29-49
mutations	O	50-59
,	O	59-60
including	O	61-70
15	O	71-73
not	O	74-77
previously	O	78-88
described	O	89-98
.	O	98-99

X	B	100-101
-	I	101-102
linked	I	102-108
Adrenoleukodystrophy	I	109-129
(	O	130-131
X	B	131-132
-	I	132-133
ALD	I	133-136
)	O	136-137
is	O	138-140
the	O	141-144
most	O	145-149
frequent	O	150-158
peroxisomal	B	159-170
disease	I	171-178
.	O	178-179

It	O	180-182
mainly	O	183-189
involves	O	190-198
the	O	199-202
nervous	O	203-210
system	O	211-217
white	O	218-223
matter	O	224-230
,	O	230-231
adrenal	O	232-239
cortex	O	240-246
and	O	247-250
testes	O	251-257
.	O	257-258

Several	O	259-266
distinct	O	267-275
clinical	O	276-284
phenotypes	O	285-295
are	O	296-299
known	O	300-305
.	O	305-306

The	O	307-310
principal	O	311-320
biochemical	O	321-332
abnormality	O	333-344
is	O	345-347
the	O	348-351
accumulation	O	352-364
of	O	365-367
saturated	O	368-377
very	O	378-382
-	O	382-383
long	O	383-387
-	O	382-383
chain	O	388-393
fatty	O	394-399
acids	O	400-405
(	O	406-407
VLCFAs	O	407-413
>	O	415-416
C22	O	417-420
0	O	422-423
,	O	423-424
mainly	O	425-431
C26	O	432-435
0	O	437-438
)	O	438-439
,	O	439-440
which	O	441-446
is	O	447-449
due	O	450-453
to	O	454-456
impaired	O	457-465
capacity	O	466-474
for	O	475-478
beta	O	479-483
-	O	483-484
oxidation	O	484-493
in	O	494-496
peroxisomes	O	497-508
.	O	508-509

Diagnosis	O	510-519
is	O	520-522
usually	O	523-530
based	O	531-536
on	O	537-539
the	O	540-543
VLCFA	O	544-549
levels	O	550-556
in	O	557-559
plasma	O	560-566
or	O	567-569
cultured	O	570-578
skin	O	579-583
fibroblasts	O	584-595
in	O	596-598
both	O	599-603
patients	O	604-612
and	O	613-616
carriers	O	617-625
.	O	625-626

In	O	627-629
0	O	630-631
.	O	631-632
1	O	633-634
%	O	634-635
of	O	636-638
affected	O	639-647
males	O	648-653
,	O	653-654
however	O	655-662
,	O	662-663
the	O	664-667
plasma	O	668-674
C26	O	675-678
0	O	680-681
level	O	682-687
is	O	688-690
borderline	O	691-701
normal	O	702-708
,	O	708-709
and	O	710-713
15	O	714-716
%	O	716-717
of	O	718-720
obligate	O	721-729
female	O	730-736
carriers	O	737-745
have	O	746-750
normal	O	751-757
results	O	758-765
.	O	765-766

Effective	O	767-776
mutation	O	777-785
detection	O	786-795
in	O	796-798
these	O	799-804
families	O	805-813
is	O	814-816
therefore	O	817-826
fundamental	O	827-838
to	O	839-841
unambiguously	O	842-855
determine	O	856-865
the	O	866-869
genetic	O	870-877
status	O	878-884
of	O	885-887
each	O	888-892
individual	O	893-903
at	O	904-906
risk	O	907-911
.	O	911-912

Of	O	913-915
particular	O	916-926
concern	O	927-934
are	O	935-938
female	O	939-945
members	O	946-953
of	O	954-956
kindreds	O	957-965
segregating	O	966-977
X	B	978-979
-	I	979-980
ALD	I	980-983
mutations	O	984-993
,	O	993-994
because	O	995-1002
normal	O	1003-1009
VLCFA	O	1010-1015
levels	O	1016-1022
do	O	1023-1025
not	O	1026-1029
guarantee	O	1030-1039
lack	O	1040-1044
of	O	1045-1047
carrier	O	1048-1055
status	O	1056-1062
.	O	1062-1063

We	O	1064-1066
describe	O	1067-1075
a	O	1076-1077
fast	O	1078-1082
method	O	1083-1089
for	O	1090-1093
detection	O	1094-1103
of	O	1104-1106
X	B	1107-1108
-	I	1108-1109
ALD	I	1109-1112
mutations	O	1113-1122
.	O	1122-1123

The	O	1124-1127
method	O	1128-1134
is	O	1135-1137
based	O	1138-1143
on	O	1144-1146
SSCP	O	1147-1151
analysis	O	1152-1160
of	O	1161-1163
nested	O	1164-1170
PCR	O	1171-1174
fragments	O	1175-1184
followed	O	1185-1193
by	O	1194-1196
sequence	O	1197-1205
-	O	1205-1206
determination	O	1206-1219
reactions	O	1220-1229
.	O	1229-1230

Using	O	1231-1236
this	O	1237-1241
methodology	O	1242-1253
we	O	1254-1256
have	O	1257-1261
found	O	1262-1267
X	B	1268-1269
-	I	1269-1270
ALD	I	1270-1273
mutations	O	1274-1283
in	O	1284-1286
30	O	1287-1289
kindreds	O	1290-1298
,	O	1298-1299
including	O	1300-1309
15	O	1310-1312
not	O	1313-1316
previously	O	1317-1327
reported	O	1328-1336
.	O	1336-1337

Mutations	O	0-9
in	O	10-12
the	O	13-16
BRCA1	O	17-22
gene	O	23-27
in	O	28-30
families	O	31-39
with	O	40-44
early	O	45-50
-	O	50-51
onset	O	51-56
breast	B	57-63
and	I	64-67
ovarian	I	68-75
cancer	I	76-82
.	O	82-83

We	O	84-86
analysed	O	87-95
50	O	96-98
probands	O	99-107
with	O	108-112
a	O	113-114
family	O	115-121
history	O	122-129
of	O	130-132
breast	B	133-139
and	I	140-143
/	I	143-144
or	I	144-146
ovarian	I	147-154
cancer	I	155-161
for	O	162-165
germline	O	166-174
mutations	O	175-184
in	O	185-187
the	O	188-191
coding	O	192-198
region	O	199-205
of	O	206-208
the	O	209-212
BRCA1	O	213-218
candidate	O	219-228
gene	O	229-233
,	O	233-234
using	O	235-240
single	O	241-247
-	O	247-248
strand	O	248-254
conformation	O	255-267
polymorphism	O	268-280
(	O	281-282
SSCP	O	282-286
)	O	286-287
analysis	O	288-296
on	O	297-299
PCR	O	300-303
-	O	303-304
amplified	O	304-313
genomic	O	314-321
DNA	O	322-325
.	O	325-326

A	O	327-328
total	O	329-334
of	O	335-337
eight	O	338-343
putative	O	344-352
disease	O	353-360
-	O	360-361
causing	O	361-368
alterations	O	369-380
were	O	381-385
identified	O	386-396
four	O	398-402
of	O	403-405
these	O	406-411
are	O	412-415
frameshifts	O	416-427
and	O	428-431
two	O	432-435
are	O	436-439
nonsense	O	440-448
mutations	O	449-458
.	O	458-459

In	O	460-462
addition	O	463-471
,	O	471-472
we	O	473-475
found	O	476-481
two	O	482-485
missense	O	486-494
mutations	O	495-504
,	O	504-505
one	O	506-509
of	O	510-512
which	O	513-518
changes	O	519-526
the	O	527-530
final	O	531-536
cysteine	O	537-545
of	O	546-548
the	O	549-552
BRCA1	O	553-558
zinc	O	559-563
finger	O	564-570
motif	O	571-576
to	O	577-579
glycine	O	580-587
.	O	587-588

These	O	589-594
data	O	595-599
are	O	600-603
consistent	O	604-614
with	O	615-619
a	O	620-621
tumour	B	622-628
suppressor	O	629-639
model	O	640-645
,	O	645-646
and	O	647-650
support	O	651-658
the	O	659-662
notion	O	663-669
that	O	670-674
this	O	675-679
candidate	O	680-689
gene	O	690-694
is	O	695-697
in	O	698-700
fact	O	701-705
BRCA1	O	706-711
.	O	711-712

The	O	713-716
heterogeneity	O	717-730
of	O	731-733
mutations	O	734-743
,	O	743-744
coupled	O	745-752
with	O	753-757
the	O	758-761
large	O	762-767
size	O	768-772
of	O	773-775
the	O	776-779
gene	O	780-784
,	O	784-785
indicates	O	786-795
that	O	796-800
clinical	O	801-809
application	O	810-821
of	O	822-824
BRCA1	O	825-830
mutation	O	831-839
testing	O	840-847
will	O	848-852
be	O	853-855
technically	O	856-867
challenging	O	868-879
.	O	879-880
.	O	879-880

Screening	O	0-9
for	O	10-13
carriers	O	14-22
of	O	23-25
Tay	B	26-29
-	I	29-30
Sachs	I	30-35
disease	I	36-43
among	O	44-49
Ashkenazi	O	50-59
Jews	O	60-64
.	O	64-65

A	O	66-67
comparison	O	68-78
of	O	79-81
DNA	O	82-85
-	O	85-86
based	O	86-91
and	O	92-95
enzyme	O	96-102
-	O	102-103
based	O	103-108
tests	O	109-114
.	O	114-115

BACKGROUND	O	116-126
AND	O	127-130
METHODS	O	131-138
.	O	138-139

The	O	140-143
prevention	O	144-154
of	O	155-157
Tay	B	158-161
-	I	161-162
Sachs	I	162-167
disease	I	168-175
(	O	176-177
GM2	B	177-180
gangliosidosis	I	181-195
,	I	195-196
type	I	197-201
1	I	202-203
)	O	203-204
depends	O	205-212
on	O	213-215
the	O	216-219
identification	O	220-234
of	O	235-237
carriers	O	238-246
of	O	247-249
the	O	250-253
gene	O	254-258
for	O	259-262
this	O	263-267
autosomal	B	268-277
recessive	I	278-287
disorder	I	288-296
.	O	296-297

We	O	298-300
compared	O	301-309
the	O	310-313
enzyme	O	314-320
-	O	320-321
based	O	321-326
test	O	327-331
widely	O	332-338
used	O	339-343
in	O	344-346
screening	O	347-356
for	O	357-360
Tay	B	361-364
-	I	364-365
Sachs	I	365-370
disease	I	371-378
with	O	379-383
a	O	384-385
test	O	386-390
based	O	391-396
on	O	397-399
analysis	O	400-408
of	O	409-411
DNA	O	412-415
.	O	415-416

We	O	417-419
developed	O	420-429
methods	O	430-437
to	O	438-440
detect	O	441-447
the	O	448-451
three	O	452-457
mutations	O	458-467
in	O	468-470
the	O	471-474
HEXA	O	475-479
gene	O	480-484
that	O	485-489
occur	O	490-495
with	O	496-500
high	O	501-505
frequency	O	506-515
among	O	516-521
Ashkenazi	O	522-531
Jews	O	532-536
two	O	538-541
mutations	O	542-551
cause	O	552-557
infantile	O	558-567
Tay	B	568-571
-	I	571-572
Sachs	I	572-577
disease	I	578-585
,	O	585-586
and	O	587-590
the	O	591-594
third	O	595-600
causes	O	601-607
the	O	608-611
adult	O	612-617
-	O	617-618
onset	O	618-623
form	O	624-628
of	O	629-631
the	O	632-635
disease	O	636-643
.	O	643-644

DNA	O	645-648
segments	O	649-657
containing	O	658-668
these	O	669-674
mutation	O	675-683
sites	O	684-689
were	O	690-694
amplified	O	695-704
with	O	705-709
the	O	710-713
polymerase	O	714-724
chain	O	725-730
reaction	O	731-739
and	O	740-743
analyzed	O	744-752
for	O	753-756
the	O	757-760
presence	O	761-769
of	O	770-772
the	O	773-776
mutations	O	777-786
.	O	786-787

RESULTS	O	788-795
.	O	795-796

Among	O	797-802
62	O	803-805
Ashkenazi	O	806-815
obligate	O	816-824
carriers	O	825-833
of	O	834-836
Tay	B	837-840
-	I	840-841
Sachs	I	841-846
disease	I	847-854
,	O	854-855
the	O	856-859
three	O	860-865
specific	O	866-874
mutations	O	875-884
accounted	O	885-894
for	O	895-898
all	O	899-902
but	O	903-906
one	O	907-910
of	O	911-913
the	O	914-917
mutant	O	918-924
alleles	O	925-932
(	O	933-934
98	O	934-936
percent	O	937-944
)	O	944-945
.	O	945-946

In	O	947-949
216	O	950-953
Ashkenazi	O	954-963
carriers	O	964-972
identified	O	973-983
by	O	984-986
the	O	987-990
enzyme	O	991-997
test	O	998-1002
,	O	1002-1003
DNA	O	1004-1007
analysis	O	1008-1016
showed	O	1017-1023
that	O	1024-1028
177	O	1029-1032
(	O	1033-1034
82	O	1034-1036
percent	O	1037-1044
)	O	1044-1045
had	O	1046-1049
one	O	1050-1053
of	O	1054-1056
the	O	1057-1060
identified	O	1061-1071
mutations	O	1072-1081
.	O	1081-1082

Of	O	1083-1085
the	O	1086-1089
177	O	1090-1093
,	O	1093-1094
79	O	1095-1097
percent	O	1098-1105
had	O	1106-1109
the	O	1110-1113
exon	O	1114-1118
11	O	1119-1121
insertion	O	1122-1131
mutation	O	1132-1140
,	O	1140-1141
18	O	1142-1144
percent	O	1145-1152
had	O	1153-1156
the	O	1157-1160
intron	O	1161-1167
12	O	1168-1170
splice	O	1171-1177
-	O	1177-1178
junction	O	1178-1186
mutation	O	1187-1195
,	O	1195-1196
and	O	1197-1200
3	O	1201-1202
percent	O	1203-1210
had	O	1211-1214
the	O	1215-1218
less	O	1219-1223
severe	O	1224-1230
exon	O	1231-1235
7	O	1236-1237
mutation	O	1238-1246
associated	O	1247-1257
with	O	1258-1262
adult	O	1263-1268
-	O	1268-1269
onset	O	1269-1274
disease	O	1275-1282
.	O	1282-1283

The	O	1284-1287
results	O	1288-1295
of	O	1296-1298
the	O	1299-1302
enzyme	O	1303-1309
tests	O	1310-1315
in	O	1316-1318
the	O	1319-1322
39	O	1323-1325
subjects	O	1326-1334
(	O	1335-1336
18	O	1336-1338
percent	O	1339-1346
)	O	1346-1347
who	O	1348-1351
were	O	1352-1356
defined	O	1357-1364
as	O	1365-1367
carriers	O	1368-1376
but	O	1377-1380
in	O	1381-1383
whom	O	1384-1388
DNA	O	1389-1392
analysis	O	1393-1401
did	O	1402-1405
not	O	1406-1409
identify	O	1410-1418
a	O	1419-1420
mutant	O	1421-1427
allele	O	1428-1434
were	O	1435-1439
probably	O	1440-1448
false	O	1449-1454
positive	O	1455-1463
(	O	1464-1465
although	O	1465-1473
there	O	1474-1479
remains	O	1480-1487
some	O	1488-1492
possibility	O	1493-1504
of	O	1505-1507
unidentified	O	1508-1520
mutations	O	1521-1530
)	O	1530-1531
.	O	1531-1532

In	O	1533-1535
addition	O	1536-1544
,	O	1544-1545
of	O	1546-1548
152	O	1549-1552
persons	O	1553-1560
defined	O	1561-1568
as	O	1569-1571
noncarriers	O	1572-1583
by	O	1584-1586
the	O	1587-1590
enzyme	O	1591-1597
-	O	1597-1598
based	O	1598-1603
test	O	1604-1608
,	O	1608-1609
1	O	1610-1611
was	O	1612-1615
identified	O	1616-1626
as	O	1627-1629
a	O	1630-1631
carrier	O	1632-1639
by	O	1640-1642
DNA	O	1643-1646
analysis	O	1647-1655
(	O	1656-1657
i	O	1657-1658
.	O	1658-1659
e	O	1660-1661
e	O	1662-1663
.	O	1663-1664
,	O	1664-1665
a	O	1666-1667
false	O	1668-1673
negative	O	1674-1682
enzyme	O	1683-1689
-	O	1689-1690
test	O	1690-1694
result	O	1695-1701
)	O	1701-1702
.	O	1702-1703

CONCLUSIONS	O	1704-1715
.	O	1715-1716

The	O	1717-1720
increased	O	1721-1730
specificity	O	1731-1742
and	O	1743-1746
predictive	O	1747-1757
value	O	1758-1763
of	O	1764-1766
the	O	1767-1770
DNA	O	1771-1774
-	O	1774-1775
based	O	1775-1780
test	O	1781-1785
make	O	1786-1790
it	O	1791-1793
a	O	1794-1795
useful	O	1796-1802
adjunct	O	1803-1810
to	O	1811-1813
the	O	1814-1817
diagnostic	O	1818-1828
tests	O	1829-1834
currently	O	1835-1844
used	O	1845-1849
to	O	1850-1852
screen	O	1853-1859
for	O	1860-1863
carriers	O	1864-1872
of	O	1873-1875
Tay	B	1876-1879
-	I	1879-1880
Sachs	I	1880-1885
disease	I	1886-1893
.	O	1893-1894

Adrenoleukodystrophy	B	0-20
gene	O	21-25
encodes	O	26-33
an	O	34-36
80	O	37-39
kDa	O	40-43
membrane	O	44-52
protein	O	53-60
.	O	60-61

An	O	62-64
antibody	O	65-73
against	O	74-81
the	O	82-85
synthetic	O	86-95
C	O	96-97
-	O	97-98
terminal	O	98-106
peptides	O	107-115
deduced	O	116-123
from	O	124-128
the	O	129-132
cDNA	O	133-137
of	O	138-140
the	O	141-144
gene	O	145-149
responsible	O	150-161
for	O	162-165
X	B	166-167
-	I	167-168
linked	I	168-174
adrenoleukodystrophy	I	175-195
(	O	196-197
ALD	B	197-200
)	O	200-201
was	O	202-205
produced	O	206-214
to	O	215-217
characterize	O	218-230
the	O	231-234
product	O	235-242
of	O	243-245
the	O	246-249
ALD	B	250-253
gene	O	254-258
.	O	258-259

The	O	260-263
antibody	O	264-272
reacted	O	273-280
with	O	281-285
the	O	286-289
80	O	290-292
kDa	O	293-296
band	O	297-301
protein	O	302-309
in	O	310-312
control	O	313-320
fibroblasts	O	321-332
,	O	332-333
while	O	334-339
no	O	340-342
bands	O	343-348
were	O	349-353
detected	O	354-362
in	O	363-365
the	O	366-369
fibroblasts	O	370-381
from	O	382-386
a	O	387-388
patient	O	389-396
with	O	397-401
ALD	B	402-405
(	O	406-407
#	O	407-408
163	O	409-412
)	O	412-413
,	O	413-414
in	O	415-417
which	O	418-423
mRNA	O	424-428
of	O	429-431
the	O	432-435
ALD	B	436-439
gene	O	440-444
was	O	445-448
undetectable	O	449-461
based	O	462-467
on	O	468-470
Northern	O	471-479
blot	O	480-484
analysis	O	485-493
.	O	493-494

The	O	495-498
293T	O	499-503
cells	O	504-509
transfected	O	510-521
with	O	522-526
the	O	527-530
full	O	531-535
-	O	535-536
coding	O	536-542
cDNA	O	543-547
inserted	O	548-556
in	O	557-559
the	O	560-563
expression	O	564-574
vector	O	575-581
produced	O	582-590
a	O	591-592
new	O	593-596
80	O	597-599
kDa	O	600-603
protein	O	604-611
,	O	611-612
as	O	613-615
detected	O	616-624
by	O	625-627
Western	O	628-635
blot	O	636-640
.	O	640-641

In	O	642-644
an	O	645-647
immunocytological	O	648-665
study	O	666-671
,	O	671-672
the	O	673-676
staining	O	677-685
was	O	686-689
in	O	690-692
a	O	693-694
punctate	O	695-703
pattern	O	704-711
,	O	711-712
in	O	713-715
the	O	716-719
normal	O	720-726
fibroblasts	O	727-738
.	O	738-739

However	O	740-747
,	O	747-748
there	O	749-754
was	O	755-758
no	O	759-761
punctate	O	762-770
staining	O	771-779
in	O	780-782
the	O	783-786
#	O	787-788
163	O	789-792
cells	O	793-798
.	O	798-799

These	O	800-805
data	O	806-810
thus	O	811-815
indicate	O	816-824
that	O	825-829
the	O	830-833
ALD	B	834-837
gene	O	838-842
encodes	O	843-850
an	O	851-853
80	O	854-856
kDa	O	857-860
membrane	O	861-869
protein	O	870-877
.	O	877-878
.	O	877-878

Preferential	O	0-12
germline	O	13-21
mutation	O	22-30
of	O	31-33
the	O	34-37
paternal	O	38-46
allele	O	47-53
in	O	54-56
retinoblastoma	B	57-71
.	O	71-72

The	O	73-76
event	O	77-82
triggering	O	83-93
malignant	O	94-103
proliferation	O	104-117
in	O	118-120
70	O	121-123
%	O	123-124
of	O	125-127
retinoblastoma	B	128-142
tumours	I	143-150
is	O	151-153
loss	O	154-158
of	O	159-161
heterozygosity	O	162-176
for	O	177-180
chromosome	O	181-191
13q14	O	192-197
,	O	197-198
whereby	O	199-206
the	O	207-210
normal	O	211-217
retinoblastoma	B	218-232
gene	O	233-237
(	O	238-239
RB1	O	239-242
)	O	242-243
allele	O	244-250
is	O	251-253
lost	O	254-258
and	O	259-262
an	O	263-265
already	O	266-273
mutated	O	274-281
RB1	O	282-285
allele	O	286-292
remains	O	293-300
in	O	301-303
the	O	304-307
tumour	B	308-314
.	O	314-315

The	O	316-319
first	O	320-325
allele	O	326-332
suffers	O	333-340
a	O	341-342
mutational	O	343-353
event	O	354-359
-	O	359-360
-	O	359-360
deletion	O	361-369
,	O	369-370
duplication	O	371-382
or	O	383-385
point	O	386-391
mutation	O	392-400
(	O	401-402
manuscript	O	402-412
in	O	413-415
preparation	O	416-427
)	O	427-428
-	O	429-430
-	O	429-430
either	O	431-437
in	O	438-440
the	O	441-444
germ	O	445-449
line	O	450-454
(	O	455-456
all	O	456-459
bilateral	O	460-469
patients	O	470-478
)	O	478-479
or	O	480-482
in	O	483-485
a	O	486-487
somatic	O	488-495
retinal	O	496-503
cell	O	504-508
(	O	509-510
most	O	510-514
unilateral	O	515-525
patients	O	526-534
)	O	534-535
.	O	535-536

Most	O	537-541
bilateral	O	542-551
patients	O	552-560
have	O	561-565
no	O	566-568
family	O	569-575
history	O	576-583
of	O	584-586
retinoblastoma	B	587-601
and	O	602-605
are	O	606-609
presumed	O	610-618
to	O	619-621
have	O	622-626
new	O	627-630
germline	O	631-639
mutations	O	640-649
which	O	650-655
arose	O	656-661
in	O	662-664
the	O	665-668
egg	O	669-672
,	O	672-673
sperm	O	674-679
or	O	680-682
early	O	683-688
embryo	O	689-695
.	O	695-696

We	O	697-699
have	O	700-704
determined	O	705-715
the	O	716-719
parental	O	720-728
origin	O	729-735
of	O	736-738
the	O	739-742
retained	O	743-751
allele	O	752-758
in	O	759-761
nine	O	762-766
retinoblastoma	B	767-781
tumours	I	782-789
from	O	790-794
eight	O	795-800
unrelated	O	801-810
non	O	811-814
-	O	814-815
familial	O	815-823
cases	O	824-829
by	O	830-832
using	O	833-838
RB1	O	839-842
-	O	842-843
linked	O	843-849
genetic	O	850-857
markers	O	858-865
.	O	865-866

Six	O	867-870
tumours	B	871-878
retained	O	879-887
the	O	888-891
paternal	O	892-900
allele	O	901-907
and	O	908-911
three	O	912-917
retained	O	918-926
the	O	927-930
maternal	O	931-939
allele	O	940-946
.	O	946-947

Of	O	948-950
the	O	951-954
three	O	955-960
unilateral	B	961-971
tumours	I	972-979
,	O	979-980
only	O	981-985
one	O	986-989
retained	O	990-998
the	O	999-1002
paternal	O	1003-1011
RB1	O	1012-1015
allele	O	1016-1022
.	O	1022-1023

Thus	O	1024-1028
,	O	1028-1029
there	O	1030-1035
is	O	1036-1038
no	O	1039-1041
evidence	O	1042-1050
that	O	1051-1055
the	O	1056-1059
paternal	O	1060-1068
RB1	O	1069-1072
allele	O	1073-1079
is	O	1080-1082
preferentially	O	1083-1097
retained	O	1098-1106
in	O	1107-1109
retinoblastoma	B	1110-1124
,	O	1124-1125
as	O	1126-1128
has	O	1129-1132
been	O	1133-1137
suggested	O	1138-1147
to	O	1148-1150
be	O	1151-1153
the	O	1154-1157
case	O	1158-1162
in	O	1163-1165
osteosarcoma	B	1166-1178
.	O	1178-1179

By	O	1180-1182
contrast	O	1183-1191
,	O	1191-1192
tumours	B	1193-1200
from	O	1201-1205
four	O	1206-1210
of	O	1211-1213
the	O	1214-1217
five	O	1218-1222
bilateral	O	1223-1232
patients	O	1233-1241
retained	O	1242-1250
the	O	1251-1254
paternal	O	1255-1263
RB1	O	1264-1267
allele	O	1268-1274
.	O	1274-1275

This	O	1276-1280
suggests	O	1281-1289
either	O	1290-1296
that	O	1297-1301
new	O	1302-1305
germline	O	1306-1314
RB1	O	1315-1318
mutations	O	1319-1328
arise	O	1329-1334
more	O	1335-1339
frequently	O	1340-1350
during	O	1351-1357
spermatogenesis	O	1358-1373
than	O	1374-1378
during	O	1379-1385
oogenesis	O	1386-1395
,	O	1395-1396
or	O	1397-1399
that	O	1400-1404
imprinting	O	1405-1415
in	O	1416-1418
the	O	1419-1422
early	O	1423-1428
embryo	O	1429-1435
affects	O	1436-1443
chromosomal	O	1444-1455
susceptibility	O	1456-1470
to	O	1471-1473
mutation	O	1474-1482
.	O	1482-1483
.	O	1482-1483

Mutations	O	0-9
at	O	10-12
the	O	13-16
ataxia	B	17-23
-	I	23-24
telangiectasia	I	24-38
locus	O	39-44
and	O	45-48
clinical	O	49-57
phenotypes	O	58-68
of	O	69-71
A	B	72-73
-	I	73-74
T	I	74-75
patients	O	76-84
.	O	84-85

Mutations	O	86-95
at	O	96-98
the	O	99-102
ataxia	B	103-109
-	I	109-110
telangiectasia	I	110-124
(	O	125-126
A	B	126-127
-	I	127-128
T	I	128-129
)	O	129-130
locus	O	131-136
on	O	137-139
chromosome	O	140-150
band	O	151-155
11q22	O	156-161
cause	O	162-167
a	O	168-169
distinctive	O	170-181
autosomal	B	182-191
recessive	I	192-201
syndrome	I	202-210
in	O	211-213
homozygotes	O	214-225
and	O	226-229
predispose	O	230-240
heterozygotes	O	241-254
to	O	255-257
cancer	B	258-264
,	O	264-265
ischemic	B	266-274
heart	I	275-280
disease	I	281-288
,	O	288-289
and	O	290-293
early	O	294-299
mortality	O	300-309
.	O	309-310

PCR	O	311-314
amplification	O	315-328
from	O	329-333
genomic	O	334-341
DNA	O	342-345
and	O	346-349
automated	O	350-359
sequencing	O	360-370
of	O	371-373
the	O	374-377
entire	O	378-384
coding	O	385-391
region	O	392-398
(	O	399-400
66	O	400-402
exons	O	403-408
)	O	408-409
and	O	410-413
splice	O	414-420
junctions	O	421-430
detected	O	431-439
77	O	440-442
mutations	O	443-452
(	O	453-454
85	O	454-456
%	O	456-457
)	O	457-458
in	O	459-461
90	O	462-464
A	B	465-466
-	I	466-467
T	I	467-468
chromosomes	O	469-480
.	O	480-481

Heteroduplex	O	482-494
analysis	O	495-503
detected	O	504-512
another	O	513-520
42	O	521-523
mutations	O	524-533
at	O	534-536
the	O	537-540
A	B	541-542
-	I	542-543
T	I	543-544
locus	O	545-550
.	O	550-551

Out	O	552-555
of	O	556-558
a	O	559-560
total	O	561-566
of	O	567-569
71	O	570-572
unique	O	573-579
mutations	O	580-589
,	O	589-590
50	O	591-593
were	O	594-598
found	O	599-604
only	O	605-609
in	O	610-612
a	O	613-614
single	O	615-621
family	O	622-628
,	O	628-629
and	O	630-633
51	O	634-636
had	O	637-640
not	O	641-644
been	O	645-649
reported	O	650-658
previously	O	659-669
.	O	669-670

Most	O	671-675
(	O	676-677
58	O	677-679
/	O	679-680
71	O	680-682
,	O	682-683
82	O	684-686
%	O	686-687
)	O	687-688
mutations	O	689-698
were	O	699-703
frameshift	O	704-714
and	O	715-718
nonsense	O	719-727
mutations	O	728-737
that	O	738-742
are	O	743-746
predicted	O	747-756
to	O	757-759
cause	O	760-765
truncation	O	766-776
of	O	777-779
the	O	780-783
A	B	784-785
-	I	785-786
T	I	786-787
protein	O	788-795
;	O	795-796
the	O	797-800
less	O	801-805
common	O	806-812
mutation	O	813-821
types	O	822-827
were	O	828-832
missense	O	833-841
(	O	842-843
9	O	843-844
/	O	844-845
71	O	845-847
,	O	847-848
13	O	849-851
%	O	851-852
)	O	852-853
,	O	853-854
splicing	O	855-863
(	O	864-865
3	O	865-866
/	O	866-867
71	O	867-869
,	O	869-870
4	O	871-872
%	O	872-873
)	O	873-874
and	O	875-878
one	O	879-882
in	O	883-885
-	O	885-886
frame	O	886-891
deletion	O	892-900
,	O	900-901
2546	O	902-906
3	O	907-908
(	O	909-910
1	O	910-911
/	O	911-912
71	O	912-914
,	O	914-915
1	O	916-917
%	O	917-918
)	O	918-919
.	O	919-920

The	O	921-924
mean	O	925-929
survival	O	930-938
and	O	939-942
height	O	943-949
distribution	O	950-962
of	O	963-965
134	O	966-969
A	B	970-971
-	I	971-972
T	I	972-973
patients	O	974-982
correlated	O	983-993
significantly	O	994-1007
with	O	1008-1012
the	O	1013-1016
specific	O	1017-1025
mutations	O	1026-1035
present	O	1036-1043
in	O	1044-1046
the	O	1047-1050
patients	O	1051-1059
.	O	1059-1060

Patients	O	1061-1069
homozygous	O	1070-1080
for	O	1081-1084
a	O	1085-1086
single	O	1087-1093
truncating	O	1094-1104
mutation	O	1105-1113
,	O	1113-1114
typically	O	1115-1124
near	O	1125-1129
the	O	1130-1133
N	O	1134-1135
-	O	1135-1136
terminal	O	1136-1144
end	O	1145-1148
of	O	1149-1151
the	O	1152-1155
gene	O	1156-1160
,	O	1160-1161
or	O	1162-1164
heterozygous	O	1165-1177
for	O	1178-1181
the	O	1182-1185
in	O	1186-1188
-	O	1188-1189
frame	O	1189-1194
deletion	O	1195-1203
2546	O	1204-1208
3	O	1209-1210
,	O	1210-1211
were	O	1212-1216
shorter	O	1217-1224
and	O	1225-1228
had	O	1229-1232
significantly	O	1233-1246
shorter	O	1247-1254
survival	O	1255-1263
than	O	1264-1268
those	O	1269-1274
heterozygous	O	1275-1287
for	O	1288-1291
a	O	1292-1293
splice	O	1294-1300
site	O	1301-1305
or	O	1306-1308
missense	O	1309-1317
mutation	O	1318-1326
,	O	1326-1327
or	O	1328-1330
heterozygous	O	1331-1343
for	O	1344-1347
two	O	1348-1351
truncating	O	1352-1362
mutations	O	1363-1372
.	O	1372-1373

Alterations	O	1374-1385
of	O	1386-1388
the	O	1389-1392
length	O	1393-1399
or	O	1400-1402
amino	O	1403-1408
acid	O	1409-1413
composition	O	1414-1425
of	O	1426-1428
the	O	1429-1432
A	B	1433-1434
-	I	1434-1435
T	I	1435-1436
gene	O	1437-1441
product	O	1442-1449
affect	O	1450-1456
the	O	1457-1460
A	B	1461-1462
-	I	1462-1463
T	I	1463-1464
clinical	O	1465-1473
phenotype	O	1474-1483
in	O	1484-1486
different	O	1487-1496
ways	O	1497-1501
.	O	1501-1502

Mutation	O	1503-1511
analysis	O	1512-1520
at	O	1521-1523
the	O	1524-1527
A	B	1528-1529
-	I	1529-1530
T	I	1530-1531
locus	O	1532-1537
may	O	1538-1541
help	O	1542-1546
estimate	O	1547-1555
the	O	1556-1559
prognosis	O	1560-1569
of	O	1570-1572
A	B	1573-1574
-	I	1574-1575
T	I	1575-1576
patients	O	1577-1585
.	O	1585-1586
.	O	1585-1586

Anticipation	O	0-12
resulting	O	13-22
in	O	23-25
elimination	O	26-37
of	O	38-40
the	O	41-44
myotonic	B	45-53
dystrophy	I	54-63
gene	O	64-68
:	O	68-69
a	O	70-71
follow	O	72-78
up	O	79-81
study	O	82-87
of	O	88-90
one	O	91-94
extended	O	95-103
family	O	104-110
.	O	110-111

We	O	112-114
have	O	115-119
re	O	120-122
-	O	122-123
examined	O	123-131
an	O	132-134
extended	O	135-143
myotonic	B	144-152
dystrophy	I	153-162
(	O	163-164
DM	B	164-166
)	O	166-167
family	O	168-174
,	O	174-175
previously	O	176-186
described	O	187-196
in	O	197-199
1955	O	200-204
,	O	204-205
in	O	206-208
order	O	209-214
to	O	215-217
study	O	218-223
the	O	224-227
long	O	228-232
term	O	233-237
effects	O	238-245
of	O	246-248
anticipation	O	249-261
in	O	262-264
DM	B	265-267
and	O	268-271
in	O	272-274
particular	O	275-285
the	O	286-289
implications	O	290-302
for	O	303-306
families	O	307-315
affected	O	316-324
by	O	325-327
this	O	328-332
disease	O	333-340
.	O	340-341

This	O	342-346
follow	O	347-353
up	O	354-356
study	O	357-362
provides	O	363-371
data	O	372-376
on	O	377-379
35	O	380-382
gene	O	383-387
carriers	O	388-396
and	O	397-400
46	O	401-403
asymptomatic	O	404-416
at	O	417-419
risk	O	420-424
family	O	425-431
members	O	432-439
in	O	440-442
five	O	443-447
generations	O	448-459
.	O	459-460

Clinical	O	461-469
anticipation	O	470-482
,	O	482-483
defined	O	484-491
as	O	492-494
the	O	495-498
cascade	O	499-506
of	O	507-509
mild	O	510-514
,	O	514-515
adult	O	516-521
,	O	521-522
childhood	O	523-532
,	O	532-533
or	O	534-536
congenital	B	537-547
disease	I	548-555
in	O	556-558
subsequent	O	559-569
generations	O	570-581
,	O	581-582
appeared	O	583-591
to	O	592-594
be	O	595-597
a	O	598-599
relentless	O	600-610
process	O	611-618
,	O	618-619
occurring	O	620-629
in	O	630-632
all	O	633-636
affected	O	637-645
branches	O	646-654
of	O	655-657
the	O	658-661
family	O	662-668
.	O	668-669

The	O	670-673
cascade	O	674-681
was	O	682-685
found	O	686-691
to	O	692-694
proceed	O	695-702
asynchronously	O	703-717
in	O	718-720
the	O	721-724
different	O	725-734
branches	O	735-743
,	O	743-744
mainly	O	745-751
because	O	752-759
of	O	760-762
an	O	763-765
unequal	O	766-773
number	O	774-780
of	O	781-783
generations	O	784-795
with	O	796-800
mild	O	801-805
disease	O	806-813
.	O	813-814

The	O	815-818
transition	O	819-829
from	O	830-834
the	O	835-838
mild	O	839-843
to	O	844-846
the	O	847-850
adult	O	851-856
type	O	857-861
was	O	862-865
associated	O	866-876
with	O	877-881
transmission	O	882-894
through	O	895-902
a	O	903-904
male	O	905-909
parent	O	910-916
.	O	916-917

Stable	O	918-924
transmission	O	925-937
of	O	938-940
the	O	941-944
asymptomatic	O	945-957
/	O	957-958
mild	O	958-962
phenotype	O	963-972
showed	O	973-979
a	O	980-981
female	O	982-988
transmission	O	989-1001
bias	O	1002-1006
.	O	1006-1007

We	O	1008-1010
further	O	1011-1018
examined	O	1019-1027
the	O	1028-1031
extent	O	1032-1038
and	O	1039-1042
causes	O	1043-1049
of	O	1050-1052
gene	O	1053-1057
loss	O	1058-1062
in	O	1063-1065
this	O	1066-1070
pedigree	O	1071-1079
.	O	1079-1080

Gene	O	1081-1085
loss	O	1086-1090
in	O	1091-1093
the	O	1094-1097
patient	O	1098-1105
group	O	1106-1111
was	O	1112-1115
complete	O	1116-1124
,	O	1124-1125
owing	O	1126-1131
to	O	1132-1134
infertility	B	1135-1146
of	O	1147-1149
the	O	1150-1153
male	O	1154-1158
patients	O	1159-1167
with	O	1168-1172
adult	O	1173-1178
onset	O	1179-1184
disease	O	1185-1192
and	O	1193-1196
the	O	1197-1200
fact	O	1201-1205
that	O	1206-1210
mentally	B	1211-1219
retarded	I	1220-1228
patients	O	1229-1237
did	O	1238-1241
not	O	1242-1245
procreate	O	1246-1255
.	O	1255-1256

Out	O	1257-1260
of	O	1261-1263
the	O	1264-1267
46	O	1268-1270
at	O	1271-1273
risk	O	1274-1278
subjects	O	1279-1287
in	O	1288-1290
the	O	1291-1294
two	O	1295-1298
youngest	O	1299-1307
generations	O	1308-1319
,	O	1319-1320
only	O	1321-1325
one	O	1326-1329
was	O	1330-1333
found	O	1334-1339
to	O	1340-1342
have	O	1343-1347
a	O	1348-1349
full	O	1350-1354
mutation	O	1355-1363
.	O	1363-1364

This	O	1365-1369
is	O	1370-1372
the	O	1373-1376
only	O	1377-1381
subject	O	1382-1389
who	O	1390-1393
may	O	1394-1397
transmit	O	1398-1406
the	O	1407-1410
gene	O	1411-1415
to	O	1416-1418
the	O	1419-1422
sixth	O	1423-1428
generation	O	1429-1439
.	O	1439-1440

No	O	1441-1443
protomutation	O	1444-1457
carriers	O	1458-1466
were	O	1467-1471
found	O	1472-1477
in	O	1478-1480
the	O	1481-1484
fourth	O	1485-1491
and	O	1492-1495
fifth	O	1496-1501
generations	O	1502-1513
.	O	1513-1514

Therefore	O	1515-1524
it	O	1525-1527
is	O	1528-1530
highly	O	1531-1537
probable	O	1538-1546
that	O	1547-1551
the	O	1552-1555
DM	B	1556-1558
gene	O	1559-1563
will	O	1564-1568
be	O	1569-1571
eliminated	O	1572-1582
from	O	1583-1587
this	O	1588-1592
pedigree	O	1593-1601
within	O	1602-1608
one	O	1609-1612
generation	O	1613-1623
.	O	1623-1624

The	O	1625-1628
high	O	1629-1633
population	O	1634-1644
frequency	O	1645-1654
of	O	1655-1657
DM	B	1658-1660
can	O	1661-1664
at	O	1665-1667
present	O	1668-1675
not	O	1676-1679
be	O	1680-1682
explained	O	1683-1692
by	O	1693-1695
the	O	1696-1699
contribution	O	1700-1712
of	O	1713-1715
asymptomatic	O	1716-1728
cases	O	1729-1734
in	O	1735-1737
the	O	1738-1741
younger	O	1742-1749
generations	O	1750-1761
of	O	1762-1764
known	O	1765-1770
families	O	1771-1779
,	O	1779-1780
but	O	1781-1784
is	O	1785-1787
probably	O	1788-1796
caused	O	1797-1803
by	O	1804-1806
the	O	1807-1810
events	O	1811-1817
in	O	1818-1820
the	O	1821-1824
ancestral	O	1825-1834
generations	O	1835-1846
.	O	1846-1847
.	O	1846-1847

Exon	O	0-4
9	O	5-6
mutations	O	7-16
in	O	17-19
the	O	20-23
WT1	O	24-27
gene	O	28-32
,	O	32-33
without	O	34-41
influencing	O	42-53
KTS	O	54-57
splice	O	58-64
isoforms	O	65-73
,	O	73-74
are	O	75-78
also	O	79-83
responsible	O	84-95
for	O	96-99
Frasier	B	100-107
syndrome	I	108-116
.	O	116-117

We	O	118-120
report	O	121-127
new	O	128-131
mutations	O	132-141
in	O	142-144
exon	O	145-149
9	O	150-151
of	O	152-154
the	O	155-158
WT1	O	159-162
gene	O	163-167
that	O	168-172
did	O	173-176
not	O	177-180
alter	O	181-186
the	O	187-190
ratio	O	191-196
of	O	197-199
+	O	200-201
/	O	201-202
-	O	202-203
KTS	O	204-207
splice	O	208-214
isoforms	O	215-223
in	O	224-226
two	O	227-230
unrelated	O	231-240
patients	O	241-249
with	O	250-254
Frasier	B	255-262
syndrome	I	263-271
(	O	272-273
FS	B	273-275
)	O	275-276
.	O	276-277

The	O	278-281
mutation	O	282-290
of	O	291-293
intron	O	294-300
9	O	301-302
inducing	O	303-311
defective	O	312-321
alternative	O	322-333
splicing	O	334-342
was	O	343-346
reported	O	347-355
to	O	356-358
be	O	359-361
responsible	O	362-373
for	O	374-377
this	O	378-382
syndrome	O	383-391
.	O	391-392

The	O	393-396
mutations	O	397-406
found	O	407-412
in	O	413-415
our	O	416-419
cases	O	420-425
occurred	O	426-434
in	O	435-437
the	O	438-441
same	O	442-446
exon	O	447-451
of	O	452-454
the	O	455-458
WT1	O	459-462
gene	O	463-467
as	O	468-470
detected	O	471-479
in	O	480-482
Denys	B	483-488
-	I	488-489
Drash	I	489-494
syndrome	I	495-503
(	O	504-505
DDS	B	505-508
)	O	508-509
and	O	510-513
could	O	514-519
not	O	520-523
be	O	524-526
explained	O	527-536
by	O	537-539
the	O	540-543
previously	O	544-554
proposed	O	555-563
mechanism	O	564-573
.	O	573-574

The	O	575-578
results	O	579-586
suggest	O	587-594
that	O	595-599
the	O	600-603
two	O	604-607
syndromes	O	608-617
originate	O	618-627
from	O	628-632
the	O	633-636
same	O	637-641
WT1	B	642-645
gene	I	646-650
abnormality	I	651-662
.	O	662-663

From	O	664-668
a	O	669-670
molecular	O	671-680
biological	O	681-691
point	O	692-697
of	O	698-700
view	O	701-705
,	O	705-706
we	O	707-709
concluded	O	710-719
that	O	720-724
the	O	725-728
two	O	729-732
diseases	O	733-741
were	O	742-746
not	O	747-750
separable	O	751-760
,	O	760-761
and	O	762-765
that	O	766-770
FS	B	771-773
should	O	774-780
be	O	781-783
included	O	784-792
as	O	793-795
an	O	796-798
atypical	O	799-807
form	O	808-812
of	O	813-815
DDS	B	816-819
.	O	819-820
.	O	819-820

Deficit	O	0-7
of	O	8-10
in	O	11-13
vivo	O	14-18
mitochondrial	O	19-32
ATP	O	33-36
production	O	37-47
in	O	48-50
patients	O	51-59
with	O	60-64
Friedreich	B	65-75
ataxia	I	76-82
.	O	82-83

Friedreich	B	84-94
ataxia	I	95-101
(	O	102-103
FRDA	B	103-107
)	O	107-108
,	O	108-109
the	O	110-113
most	O	114-118
common	O	119-125
of	O	126-128
the	O	129-132
inherited	B	133-142
ataxias	I	143-150
,	O	150-151
is	O	152-154
an	O	155-157
autosomal	B	158-167
recessive	I	168-177
degenerative	I	178-190
disorder	I	191-199
,	O	199-200
characterized	O	201-214
clinically	O	215-225
by	O	226-228
onset	O	229-234
before	O	235-241
the	O	242-245
age	O	246-249
of	O	250-252
25	O	253-255
of	O	256-258
progressive	B	259-270
gait	I	271-275
and	I	276-279
limb	I	280-284
ataxia	I	285-291
,	O	291-292
absence	B	293-300
of	I	301-303
deep	I	304-308
tendon	I	309-315
reflexes	I	316-324
,	O	324-325
extensor	B	326-334
plantar	I	335-342
responses	I	343-352
,	O	352-353
and	O	354-357
loss	B	358-362
of	I	363-365
position	I	366-374
and	I	375-378
vibration	I	379-388
sense	I	389-394
in	O	395-397
the	O	398-401
lower	O	402-407
limbs	O	408-413
.	O	413-414

FRDA	B	415-419
is	O	420-422
caused	O	423-429
by	O	430-432
a	O	433-434
GAA	O	435-438
triplet	O	439-446
expansion	O	447-456
in	O	457-459
the	O	460-463
first	O	464-469
intron	O	470-476
of	O	477-479
the	O	480-483
FRDA	B	484-488
gene	O	489-493
on	O	494-496
chromosome	O	497-507
9q13	O	508-512
in	O	513-515
97	O	516-518
%	O	518-519
of	O	520-522
patients	O	523-531
.	O	531-532

The	O	533-536
FRDA	B	537-541
gene	O	542-546
encodes	O	547-554
a	O	555-556
widely	O	557-563
expressed	O	564-573
210	O	574-577
-	O	577-578
aa	O	578-580
protein	O	581-588
,	O	588-589
frataxin	O	590-598
,	O	598-599
which	O	600-605
is	O	606-608
located	O	609-616
in	O	617-619
mitochondria	O	620-632
and	O	633-636
is	O	637-639
severely	O	640-648
reduced	O	649-656
in	O	657-659
FRDA	B	660-664
patients	O	665-673
.	O	673-674

Frataxin	O	675-683
function	O	684-692
is	O	693-695
still	O	696-701
unknown	O	702-709
but	O	710-713
the	O	714-717
knockout	O	718-726
of	O	727-729
the	O	730-733
yeast	O	734-739
frataxin	O	740-748
homologue	O	749-758
gene	O	759-763
(	O	764-765
YFH1	O	765-769
)	O	769-770
showed	O	771-777
a	O	778-779
severe	O	780-786
defect	O	787-793
of	O	794-796
mitochondrial	O	797-810
respiration	O	811-822
and	O	823-826
loss	O	827-831
of	O	832-834
mtDNA	O	835-840
associated	O	841-851
with	O	852-856
elevated	O	857-865
intramitochondrial	O	866-884
iron	O	885-889
.	O	889-890

Here	O	891-895
we	O	896-898
report	O	899-905
in	O	906-908
vivo	O	909-913
evidence	O	914-922
of	O	923-925
impaired	O	926-934
mitochondrial	O	935-948
respiration	O	949-960
in	O	961-963
skeletal	O	964-972
muscle	O	973-979
of	O	980-982
FRDA	B	983-987
patients	O	988-996
.	O	996-997

Using	O	998-1003
phosphorus	O	1004-1014
magnetic	O	1015-1023
resonance	O	1024-1033
spectroscopy	O	1034-1046
we	O	1047-1049
demonstrated	O	1050-1062
a	O	1063-1064
maximum	O	1065-1072
rate	O	1073-1077
of	O	1078-1080
muscle	O	1081-1087
mitochondrial	O	1088-1101
ATP	O	1102-1105
production	O	1106-1116
(	O	1117-1118
V	O	1118-1119
(	O	1120-1121
max	O	1121-1124
)	O	1124-1125
)	O	1124-1125
below	O	1127-1132
the	O	1133-1136
normal	O	1137-1143
range	O	1144-1149
in	O	1150-1152
all	O	1153-1156
12	O	1157-1159
FRDA	B	1160-1164
patients	O	1165-1173
and	O	1174-1177
a	O	1178-1179
strong	O	1180-1186
negative	O	1187-1195
correlation	O	1196-1207
between	O	1208-1215
mitochondrial	O	1216-1229
V	O	1230-1231
(	O	1232-1233
max	O	1233-1236
)	O	1236-1237
and	O	1238-1241
the	O	1242-1245
number	O	1246-1252
of	O	1253-1255
GAA	O	1256-1259
repeats	O	1260-1267
in	O	1268-1270
the	O	1271-1274
smaller	O	1275-1282
allele	O	1283-1289
.	O	1289-1290

Our	O	1291-1294
results	O	1295-1302
show	O	1303-1307
that	O	1308-1312
FRDA	B	1313-1317
is	O	1318-1320
a	O	1321-1322
nuclear	O	1323-1330
-	O	1330-1331
encoded	O	1331-1338
mitochondrial	B	1339-1352
disorder	I	1353-1361
affecting	O	1362-1371
oxidative	O	1372-1381
phosphorylation	O	1382-1397
and	O	1398-1401
give	O	1402-1406
a	O	1407-1408
rationale	O	1409-1418
for	O	1419-1422
treatments	O	1423-1433
aimed	O	1434-1439
to	O	1440-1442
improve	O	1443-1450
mitochondrial	O	1451-1464
function	O	1465-1473
in	O	1474-1476
this	O	1477-1481
condition	O	1482-1491
.	O	1491-1492
.	O	1491-1492

Chronic	B	0-7
nonspherocytic	I	8-22
hemolytic	I	23-32
anemia	I	33-39
(	O	40-41
CNSHA	B	41-46
)	O	46-47
and	O	48-51
glucose	B	52-59
6	I	60-61
phosphate	I	62-71
dehydrogenase	I	72-85
(	I	86-87
G6PD	I	87-91
)	I	91-92
deficiency	I	93-103
in	O	104-106
a	O	107-108
patient	O	109-116
with	O	117-121
familial	B	122-130
amyloidotic	I	131-142
polyneuropathy	I	143-157
(	O	158-159
FAP	B	159-162
)	O	162-163
.	O	163-164

Molecular	O	165-174
study	O	175-180
of	O	181-183
a	O	184-185
new	O	186-189
variant	O	190-197
(	O	198-199
G6PD	O	199-203
Clinic	O	204-210
)	O	210-211
with	O	212-216
markedly	O	217-225
acidic	O	226-232
pH	O	233-235
optimum	O	236-243
.	O	243-244

A	O	245-246
new	O	247-250
glucose	O	251-258
-	O	258-259
6	O	259-260
-	O	258-259
phosphate	O	261-270
dehydrogenase	O	271-284
(	O	285-286
G6PD	O	286-290
)	O	290-291
variant	O	292-299
with	O	300-304
severe	O	305-311
erythrocytic	B	312-324
G6PD	I	325-329
deficiency	I	330-340
and	O	341-344
a	O	345-346
unique	O	347-353
pH	O	354-356
optimum	O	357-364
is	O	365-367
described	O	368-377
in	O	378-380
a	O	381-382
young	O	383-388
patient	O	389-396
with	O	397-401
chronic	B	402-409
nonspherocytic	I	410-424
hemolytic	I	425-434
anemia	I	435-441
(	O	442-443
CNSHA	B	443-448
)	O	448-449
and	O	450-453
familial	B	454-462
amyloidotic	I	463-474
polyneuropathy	I	475-489
(	O	490-491
FAP	B	491-494
)	O	494-495
.	O	495-496

Chronic	B	497-504
hemolysis	I	505-514
was	O	515-518
present	O	519-526
in	O	527-529
the	O	530-533
absence	O	534-541
of	O	542-544
infections	O	545-555
,	O	555-556
oxidant	O	557-564
drugs	O	565-570
or	O	571-573
ingestion	O	574-583
of	O	584-586
faba	O	587-591
beans	O	592-597
.	O	597-598

Residual	O	599-607
enzyme	O	608-614
activity	O	615-623
was	O	624-627
about	O	628-633
2	O	634-635
.	O	635-636
6	O	637-638
%	O	638-639
and	O	640-643
63	O	644-646
%	O	646-647
of	O	648-650
normal	O	651-657
activity	O	658-666
in	O	667-669
erythrocytes	O	670-682
and	O	683-686
leucocytes	O	687-697
,	O	697-698
respectively	O	699-711
.	O	711-712

A	O	713-714
molecular	O	715-724
study	O	725-730
using	O	731-736
standard	O	737-745
methods	O	746-753
showed	O	754-760
G6PD	O	761-765
in	O	766-768
the	O	769-772
patient	O	773-780
to	O	781-783
have	O	784-788
normal	O	789-795
electrophoretic	O	796-811
mobility	O	812-820
(	O	821-822
at	O	822-824
pH	O	825-827
7	O	828-829
.	O	829-830
0	O	831-832
,	O	832-833
8	O	834-835
.	O	835-836
0	O	837-838
and	O	839-842
8	O	843-844
.	O	844-845
8	O	846-847
)	O	847-848
,	O	848-849
normal	O	850-856
apparent	O	857-865
affinity	O	866-874
for	O	875-878
substrates	O	879-889
(	O	890-891
Km	O	891-893
,	O	893-894
G6P	O	895-898
and	O	899-902
NADP	O	903-907
)	O	907-908
and	O	909-912
a	O	913-914
slightly	O	915-923
abnormal	O	924-932
utilization	O	933-944
of	O	945-947
substrate	O	948-957
analogues	O	958-967
(	O	968-969
decreased	O	969-978
deamino	O	979-986
-	O	986-987
NADP	O	987-991
and	O	992-995
increased	O	996-1005
2	O	1006-1007
-	O	1007-1008
deoxyglucose	O	1008-1020
-	O	1007-1008
6	O	1021-1022
-	O	1007-1008
phosphate	O	1023-1032
utilization	O	1033-1044
)	O	1044-1045
.	O	1045-1046

Heat	O	1047-1051
stability	O	1052-1061
was	O	1062-1065
found	O	1066-1071
to	O	1072-1074
be	O	1075-1077
markedly	O	1078-1086
decreased	O	1087-1096
(	O	1097-1098
8	O	1098-1099
%	O	1099-1100
of	O	1101-1103
residual	O	1104-1112
activity	O	1113-1121
after	O	1122-1127
20	O	1128-1130
min	O	1131-1134
of	O	1135-1137
incubation	O	1138-1148
at	O	1149-1151
46	O	1152-1154
degrees	O	1155-1162
C	O	1163-1164
)	O	1164-1165
and	O	1166-1169
a	O	1170-1171
particular	O	1172-1182
characteristic	O	1183-1197
of	O	1198-1200
this	O	1201-1205
enzyme	O	1206-1212
was	O	1213-1216
a	O	1217-1218
biphasic	O	1219-1227
pH	O	1228-1230
curve	O	1231-1236
with	O	1237-1241
a	O	1242-1243
greatly	O	1244-1251
increased	O	1252-1261
activity	O	1262-1270
at	O	1271-1273
low	O	1274-1277
pH	O	1278-1280
.	O	1280-1281

Although	O	1282-1290
molecular	O	1291-1300
characteristics	O	1301-1316
of	O	1317-1319
this	O	1320-1324
variant	O	1325-1332
closely	O	1333-1340
resemble	O	1341-1349
those	O	1350-1355
of	O	1356-1358
G6PD	O	1359-1363
Bangkok	O	1364-1371
and	O	1372-1375
G6PD	O	1376-1380
Duarte	O	1381-1387
,	O	1387-1388
it	O	1389-1391
can	O	1392-1395
be	O	1396-1398
distinguished	O	1399-1412
from	O	1413-1417
these	O	1418-1423
and	O	1424-1427
all	O	1428-1431
other	O	1432-1437
previously	O	1438-1448
reported	O	1449-1457
variants	O	1458-1466
by	O	1467-1469
virtue	O	1470-1476
of	O	1477-1479
its	O	1480-1483
unusual	O	1484-1491
pH	O	1492-1494
curve	O	1495-1500
.	O	1500-1501

Therefore	O	1502-1511
the	O	1512-1515
present	O	1516-1523
variant	O	1524-1531
has	O	1532-1535
been	O	1536-1540
designated	O	1541-1551
G6PD	O	1552-1556
Clinic	O	1557-1563
to	O	1564-1566
distinguish	O	1567-1578
it	O	1579-1581
from	O	1582-1586
other	O	1587-1592
G6PD	O	1593-1597
variants	O	1598-1606
previously	O	1607-1617
described	O	1618-1627

Regional	O	0-8
localization	O	9-21
of	O	22-24
polymorphic	O	25-36
DNA	O	37-40
loci	O	41-45
on	O	46-48
the	O	49-52
proximal	O	53-61
long	O	62-66
arm	O	67-70
of	O	71-73
the	O	74-77
X	O	78-79
chromosome	O	80-90
using	O	91-96
deletions	O	97-106
associated	O	107-117
with	O	118-122
choroideremia	B	123-136
.	O	136-137

In	O	138-140
two	O	141-144
unrelated	O	145-154
families	O	155-163
,	O	163-164
males	O	165-170
have	O	171-175
been	O	176-180
identified	O	181-191
who	O	192-195
suffer	O	196-202
from	O	203-207
choroideremia	B	208-221
and	O	222-225
at	O	226-228
the	O	229-232
same	O	233-237
time	O	238-242
have	O	243-247
an	O	248-250
interstitial	O	251-263
deletion	O	264-272
on	O	273-275
the	O	276-279
proximal	O	280-288
long	O	289-293
arm	O	294-297
of	O	298-300
the	O	301-304
X	O	305-306
chromosome	O	307-317
.	O	317-318

By	O	319-321
high	O	322-326
-	O	326-327
resolution	O	327-337
banding	O	338-345
we	O	346-348
have	O	349-353
characterized	O	354-367
the	O	368-371
deletion	O	372-380
chromosomes	O	381-392
as	O	393-395
del	O	396-399
(	O	400-401
X	O	401-402
)	O	402-403
(	O	404-405
q21	O	405-408
.	O	408-409

1	O	410-411
-	O	411-412
q21	O	412-415
1	O	416-417
-	O	417-418
q21	O	418-421
.	O	421-422

33	O	423-425
)	O	425-426
and	O	427-430
del	O	431-434
(	O	435-436
X	O	436-437
)	O	437-438
(	O	439-440
q21	O	440-443
.	O	443-444

2	O	445-446
-	O	446-447
q21	O	447-450
2	O	451-452
-	O	452-453
q21	O	453-456
.	O	456-457

31	O	458-460
)	O	460-461
respectively	O	462-474
.	O	474-475

By	O	476-478
Southern	O	479-487
blot	O	488-492
analysis	O	493-501
we	O	502-504
have	O	505-509
mapped	O	510-516
ten	O	517-520
different	O	521-530
polymorphic	O	531-542
DNA	O	543-546
loci	O	547-551
relative	O	552-560
to	O	561-563
the	O	564-567
position	O	568-576
of	O	577-579
the	O	580-583
deletion	O	584-592
and	O	593-596
the	O	597-600
choroideremia	B	601-614
locus	O	615-620
TCD	O	621-624
.	O	624-625

One	O	626-629
probe	O	630-635
,	O	635-636
p31	O	637-640
,	O	640-641
was	O	642-645
shown	O	646-651
to	O	652-654
cover	O	655-660
one	O	661-664
of	O	665-667
the	O	668-671
breakpoints	O	672-683
of	O	684-686
the	O	687-690
smallest	O	691-699
deletion	O	700-708
.	O	708-709

The	O	710-713
following	O	714-723
order	O	724-729
of	O	730-732
the	O	733-736
loci	O	737-741
was	O	742-745
suggested	O	746-755
by	O	756-758
deletion	O	759-767
mapping	O	768-775
cen	O	777-780
-	O	780-781
DXS106	O	781-787
-	O	780-781
DXS72	O	788-793
-	O	780-781
TCD	O	794-797
-	O	780-781
(	O	799-800
DXYS1	O	800-805
/	O	805-806
DXYS23	O	806-812
/	O	805-806
DXYS5	O	813-818
)	O	818-819
-	O	820-821
DXYS2	O	822-827
-	O	827-828
(	O	829-830
DXYS12	O	830-836
/	O	836-837
DXS3	O	837-841
)	O	841-842
-	O	843-844
(	O	845-846
DXS17	O	846-851
/	O	851-852
DXS101	O	852-858
)	O	858-859
-	O	860-861
Xqter	O	862-867
.	O	867-868

A	O	0-1
de	O	2-4
novo	O	5-9
unbalanced	O	10-20
reciprocal	O	21-31
translocation	O	32-45
identified	O	46-56
as	O	57-59
paternal	O	60-68
in	O	69-71
origin	O	72-78
in	O	79-81
the	O	82-85
Prader	B	86-92
-	I	92-93
Willi	I	93-98
syndrome	I	99-107
.	O	107-108

Interstitial	O	109-121
cytogenetic	O	122-133
deletions	O	134-143
involving	O	144-153
the	O	154-157
paternally	O	158-168
derived	O	169-176
chromosome	O	177-187
15q11	O	188-193
-	O	193-194
13	O	194-196
have	O	197-201
been	O	202-206
described	O	207-216
in	O	217-219
patients	O	220-228
with	O	229-233
the	O	234-237
Prader	B	238-244
-	I	244-245
Willi	I	245-250
syndrome	I	251-259
(	O	260-261
PWS	B	261-264
)	O	264-265
.	O	265-266

We	O	267-269
report	O	270-276
a	O	277-278
child	O	279-284
with	O	285-289
PWS	B	290-293
and	O	294-297
a	O	298-299
de	O	300-302
novo	O	303-307
unbalanced	O	308-318
karyotype	O	319-328
-	O	329-330
45	O	330-332
,	O	332-333
XY	O	334-336
,	O	336-337
-	O	338-339
9	O	339-340
,	O	340-341
-	O	342-343
15	O	343-345
,	O	345-346
+	O	347-348
der	O	349-352
(	O	353-354
9	O	354-355
)	O	355-356
t	O	357-358
(	O	359-360
9	O	360-361
;	O	361-362
15	O	363-365
)	O	365-366
(	O	367-368
q34	O	368-371
;	O	371-372
q13	O	373-376
)	O	376-377
.	O	377-378

Molecular	O	379-388
studies	O	389-396
with	O	397-401
the	O	402-405
DNA	O	406-409
probe	O	410-415
pML34	O	416-421
confirmed	O	422-431
that	O	432-436
only	O	437-441
a	O	442-443
single	O	444-450
Prader	B	451-457
Willi	I	458-463
critical	O	464-472
region	O	473-479
(	O	480-481
PWCR	O	481-485
15q11	O	487-492
.	O	492-493

2	O	494-495
-	O	495-496
q12	O	496-499
)	O	499-500
copy	O	501-505
was	O	506-509
present	O	510-517
.	O	517-518

Hybridisation	O	519-532
of	O	533-535
patient	O	536-543
and	O	544-547
parental	O	548-556
DNA	O	557-560
with	O	561-565
the	O	566-569
multi	O	570-575
-	O	575-576
allelic	O	576-583
probe	O	584-589
CMW1	O	590-594
,	O	594-595
which	O	596-601
maps	O	602-606
to	O	607-609
pter	O	610-614
-	O	614-615
15q13	O	615-620
,	O	620-621
showed	O	622-628
that	O	629-633
the	O	634-637
chromosome	O	638-648
involved	O	649-657
in	O	658-660
the	O	661-664
translocation	O	665-678
was	O	679-682
paternal	O	683-691
in	O	692-694
origin	O	695-701
.	O	701-702

This	O	703-707
is	O	708-710
the	O	711-714
first	O	715-720
example	O	721-728
of	O	729-731
a	O	732-733
paternally	O	734-744
-	O	744-745
derived	O	745-752
PWCR	O	753-757
allele	O	758-764
loss	O	765-769
caused	O	770-776
by	O	777-779
an	O	780-782
unbalanced	O	783-793
translocation	O	794-807
that	O	808-812
has	O	813-816
arisen	O	817-823
de	O	824-826
novo	O	827-831
.	O	831-832

Clinicopathologic	O	0-17
features	O	18-26
of	O	27-29
BRCA	B	30-34
-	I	34-35
linked	I	35-41
and	I	42-45
sporadic	I	46-54
ovarian	I	55-62
cancer	I	63-69
.	O	69-70

CONTEXT	O	71-78
Most	O	80-84
hereditary	B	85-95
ovarian	I	96-103
cancers	I	104-111
are	O	112-115
associated	O	116-126
with	O	127-131
germline	O	132-140
mutations	O	141-150
in	O	151-153
BRCA1	O	154-159
or	O	160-162
BRCA2	O	163-168
.	O	168-169

Attempts	O	170-178
to	O	179-181
define	O	182-188
the	O	189-192
clinical	O	193-201
significance	O	202-214
of	O	215-217
BRCA	O	218-222
mutation	O	223-231
status	O	232-238
in	O	239-241
ovarian	B	242-249
cancer	I	250-256
have	O	257-261
produced	O	262-270
conflicting	O	271-282
results	O	283-290
,	O	290-291
especially	O	292-302
regarding	O	303-312
survival	O	313-321
.	O	321-322

OBJECTIVE	O	323-332
To	O	334-336
determine	O	337-346
whether	O	347-354
hereditary	B	355-365
ovarian	I	366-373
cancers	I	374-381
have	O	382-386
distinct	O	387-395
clinical	O	396-404
and	O	405-408
pathological	O	409-421
features	O	422-430
compared	O	431-439
with	O	440-444
sporadic	B	445-453
(	I	454-455
nonhereditary	I	455-468
)	I	468-469
ovarian	I	470-477
cancers	I	478-485
.	O	485-486

DESIGN	O	487-493
AND	O	494-497
SETTING	O	498-505
Retrospective	O	507-520
cohort	O	521-527
study	O	528-533
of	O	534-536
a	O	537-538
consecutive	O	539-550
series	O	551-557
of	O	558-560
933	O	561-564
ovarian	B	565-572
cancers	I	573-580
diagnosed	O	581-590
and	O	591-594
treated	O	595-602
at	O	603-605
our	O	606-609
institution	O	610-621
,	O	621-622
which	O	623-628
is	O	629-631
a	O	632-633
comprehensive	O	634-647
cancer	B	648-654
center	O	655-661
as	O	662-664
designated	O	665-675
by	O	676-678
the	O	679-682
National	O	683-691
Cancer	B	692-698
Institute	O	699-708
,	O	708-709
over	O	710-714
a	O	715-716
12	O	717-719
-	O	719-720
year	O	720-724
period	O	725-731
(	O	732-733
December	O	733-741
1986	O	742-746
to	O	747-749
August	O	750-756
1998	O	757-761
)	O	761-762
.	O	762-763

PATIENTS	O	764-772
The	O	774-777
study	O	778-783
was	O	784-787
restricted	O	788-798
to	O	799-801
patients	O	802-810
of	O	811-813
Jewish	O	814-820
origin	O	821-827
because	O	828-835
of	O	836-838
the	O	839-842
ease	O	843-847
of	O	848-850
BRCA1	O	851-856
and	O	857-860
BRCA2	O	861-866
genotyping	O	867-877
in	O	878-880
this	O	881-885
ethnic	O	886-892
group	O	893-898
.	O	898-899

From	O	900-904
the	O	905-908
189	O	909-912
patients	O	913-921
who	O	922-925
identified	O	926-936
themselves	O	937-947
as	O	948-950
Jewish	O	951-957
,	O	957-958
88	O	959-961
hereditary	O	962-972
cases	O	973-978
were	O	979-983
identified	O	984-994
with	O	995-999
the	O	1000-1003
presence	O	1004-1012
of	O	1013-1015
a	O	1016-1017
germline	O	1018-1026
founder	O	1027-1034
mutation	O	1035-1043
in	O	1044-1046
BRCA1	O	1047-1052
or	O	1053-1055
BRCA2	O	1056-1061
.	O	1061-1062

The	O	1063-1066
remaining	O	1067-1076
101	O	1077-1080
cases	O	1081-1086
from	O	1087-1091
the	O	1092-1095
same	O	1096-1100
series	O	1101-1107
not	O	1108-1111
associated	O	1112-1122
with	O	1123-1127
a	O	1128-1129
BRCA	O	1130-1134
mutation	O	1135-1143
and	O	1144-1147
2	O	1148-1149
additional	O	1150-1160
groups	O	1161-1167
(	O	1168-1169
Gynecologic	O	1169-1180
Oncology	O	1181-1189
Group	O	1190-1195
protocols	O	1196-1205
52	O	1206-1208
and	O	1209-1212
111	O	1213-1216
)	O	1216-1217
with	O	1218-1222
ovarian	B	1223-1230
cancer	I	1231-1237
from	O	1238-1242
clinical	O	1243-1251
trials	O	1252-1258
(	O	1259-1260
for	O	1260-1263
the	O	1264-1267
survival	O	1268-1276
analysis	O	1277-1285
)	O	1285-1286
were	O	1287-1291
included	O	1292-1300
for	O	1301-1304
comparison	O	1305-1315
.	O	1315-1316

MAIN	O	1317-1321
OUTCOME	O	1322-1329
MEASURES	O	1330-1338
Age	O	1340-1343
at	O	1344-1346
diagnosis	O	1347-1356
,	O	1356-1357
surgical	O	1358-1366
stage	O	1367-1372
,	O	1372-1373
histologic	O	1374-1384
cell	O	1385-1389
type	O	1390-1394
and	O	1395-1398
grade	O	1399-1404
,	O	1404-1405
and	O	1406-1409
surgical	O	1410-1418
outcome	O	1419-1426
;	O	1426-1427
and	O	1428-1431
response	O	1432-1440
to	O	1441-1443
chemotherapy	O	1444-1456
and	O	1457-1460
survival	O	1461-1469
for	O	1470-1473
advanced	O	1474-1482
-	O	1482-1483
stage	O	1483-1488
(	O	1489-1490
II	O	1490-1492
and	O	1493-1496
IV	O	1497-1499
)	O	1499-1500
cases	O	1501-1506
.	O	1506-1507

RESULTS	O	1508-1515
Hereditary	B	1517-1527
cancers	I	1528-1535
were	O	1536-1540
rarely	O	1541-1547
diagnosed	O	1548-1557
before	O	1558-1564
age	O	1565-1568
40	O	1569-1571
years	O	1572-1577
and	O	1578-1581
were	O	1582-1586
common	O	1587-1593
after	O	1594-1599
age	O	1600-1603
60	O	1604-1606
years	O	1607-1612
,	O	1612-1613
with	O	1614-1618
mean	O	1619-1623
age	O	1624-1627
at	O	1628-1630
diagnosis	O	1631-1640
being	O	1641-1646
significantly	O	1647-1660
younger	O	1661-1668
for	O	1669-1672
BRCA1	O	1673-1678
-	O	1678-1679
vs	O	1680-1682
BRCA2	O	1683-1688
-	O	1688-1689
linked	O	1689-1695
patients	O	1696-1704
(	O	1705-1706
54	O	1706-1708
vs	O	1709-1711
62	O	1712-1714
years	O	1715-1720
;	O	1720-1721
P	O	1722-1723
=	O	1724-1725
.	O	1725-1726
04	O	1727-1729
)	O	1729-1730
.	O	1730-1731

Histology	O	1732-1741
,	O	1741-1742
grade	O	1743-1748
,	O	1748-1749
stage	O	1750-1755
,	O	1755-1756
and	O	1757-1760
success	O	1761-1768
of	O	1769-1771
cytoreductive	O	1772-1785
surgery	O	1786-1793
were	O	1794-1798
similar	O	1799-1806
for	O	1807-1810
hereditary	O	1811-1821
and	O	1822-1825
sporadic	O	1826-1834
cases	O	1835-1840
.	O	1840-1841

The	O	1842-1845
hereditary	O	1846-1856
group	O	1857-1862
had	O	1863-1866
a	O	1867-1868
longer	O	1869-1875
disease	O	1876-1883
-	O	1883-1884
free	O	1884-1888
interval	O	1889-1897
following	O	1898-1907
primary	O	1908-1915
chemotherapy	O	1916-1928
in	O	1929-1931
comparison	O	1932-1942
with	O	1943-1947
the	O	1948-1951
nonhereditary	O	1952-1965
group	O	1966-1971
,	O	1971-1972
with	O	1973-1977
a	O	1978-1979
median	O	1980-1986
time	O	1987-1991
to	O	1992-1994
recurrence	O	1995-2005
of	O	2006-2008
14	O	2009-2011
months	O	2012-2018
and	O	2019-2022
7	O	2023-2024
months	O	2025-2031
,	O	2031-2032
respectively	O	2033-2045
(	O	2046-2047
P	O	2047-2048
<	O	2049-2050
.	O	2050-2051
001	O	2052-2055
)	O	2055-2056
.	O	2056-2057

Those	O	2058-2063
with	O	2064-2068
hereditary	B	2069-2079
cancers	I	2080-2087
had	O	2088-2091
improved	O	2092-2100
survival	O	2101-2109
compared	O	2110-2118
with	O	2119-2123
the	O	2124-2127
nonhereditary	O	2128-2141
group	O	2142-2147
(	O	2148-2149
P	O	2149-2150
=	O	2151-2152
.	O	2152-2153
004	O	2154-2157
)	O	2157-2158
.	O	2158-2159

For	O	2160-2163
stage	B	2164-2169
III	I	2170-2173
cancers	I	2174-2181
,	O	2181-2182
BRCA	O	2183-2187
mutation	O	2188-2196
status	O	2197-2203
was	O	2204-2207
an	O	2208-2210
independent	O	2211-2222
prognostic	O	2223-2233
variable	O	2234-2242
(	O	2243-2244
P	O	2244-2245
=	O	2246-2247
.	O	2247-2248
03	O	2249-2251
)	O	2251-2252
.	O	2252-2253

CONCLUSIONS	O	2254-2265
Although	O	2267-2275
BRCA	B	2276-2280
-	I	2280-2281
associated	I	2281-2291
hereditary	I	2292-2302
ovarian	I	2303-2310
cancers	I	2311-2318
in	O	2319-2321
this	O	2322-2326
population	O	2327-2337
have	O	2338-2342
surgical	O	2343-2351
and	O	2352-2355
pathological	O	2356-2368
characteristics	O	2369-2384
similar	O	2385-2392
to	O	2393-2395
those	O	2396-2401
of	O	2402-2404
sporadic	B	2405-2413
cancers	I	2414-2421
,	O	2421-2422
advanced	B	2423-2431
-	I	2431-2432
stage	I	2432-2437
hereditary	I	2438-2448
cancer	I	2449-2455
patients	O	2456-2464
survive	O	2465-2472
longer	O	2473-2479
than	O	2480-2484
nonhereditary	B	2485-2498
cancer	I	2499-2505
patients	O	2506-2514
.	O	2514-2515

Age	O	2516-2519
penetrance	O	2520-2530
is	O	2531-2533
greater	O	2534-2541
for	O	2542-2545
BRCA1	B	2546-2551
-	I	2551-2552
linked	I	2552-2558
than	I	2559-2563
for	I	2564-2567
BRCA2	I	2568-2573
-	I	2573-2574
linked	I	2574-2580
cancers	I	2581-2588
in	O	2589-2591
this	O	2592-2596
population	O	2597-2607
.	O	2607-2608

Germline	O	0-8
intronic	O	9-17
and	O	18-21
exonic	O	22-28
mutations	O	29-38
in	O	39-41
the	O	42-45
Wilms	B	46-51
'	I	51-52
tumour	I	53-59
gene	O	60-64
(	O	65-66
WT1	O	66-69
)	O	69-70
affecting	O	71-80
urogenital	O	81-91
development	O	92-103
.	O	103-104

Denys	B	105-110
-	I	110-111
Drash	I	111-116
syndrome	I	117-125
is	O	126-128
a	O	129-130
rare	O	131-135
human	O	136-141
developmental	B	142-155
disorder	I	156-164
affecting	O	165-174
the	O	175-178
urogenital	O	179-189
system	O	190-196
and	O	197-200
leading	O	201-208
to	O	209-211
renal	B	212-217
failure	I	218-225
,	O	225-226
intersex	B	227-235
disorders	I	236-245
and	O	246-249
Wilms	B	250-255
tumour	I	256-262
.	O	262-263

In	O	264-266
this	O	267-271
report	O	272-278
,	O	278-279
four	O	280-284
individuals	O	285-296
with	O	297-301
this	O	302-306
syndrome	O	307-315
are	O	316-319
described	O	320-329
carrying	O	330-338
germline	O	339-347
point	O	348-353
mutations	O	354-363
in	O	364-366
the	O	367-370
Wilms	B	371-376
tumour	I	377-383
suppressor	O	384-394
gene	O	395-399
,	O	399-400
WT1	O	401-404
.	O	404-405

Three	O	406-411
of	O	412-414
these	O	415-420
mutations	O	421-430
were	O	431-435
in	O	436-438
the	O	439-442
zinc	O	443-447
finger	O	448-454
domains	O	455-462
of	O	463-465
WT1	O	466-469
.	O	469-470

The	O	471-474
fourth	O	475-481
occurred	O	482-490
within	O	491-497
intron	O	498-504
9	O	505-506
,	O	506-507
preventing	O	508-518
splicing	O	519-527
at	O	528-530
one	O	531-534
of	O	535-537
the	O	538-541
alternatively	O	542-555
chosen	O	556-562
splice	O	563-569
donor	O	570-575
sites	O	576-581
of	O	582-584
exon	O	585-589
9	O	590-591
when	O	592-596
assayed	O	597-604
in	O	605-607
vitro	O	608-613
.	O	613-614

These	O	615-620
results	O	621-628
provide	O	629-636
genetic	O	637-644
evidence	O	645-653
for	O	654-657
distinct	O	658-666
functional	O	667-677
roles	O	678-683
of	O	684-686
the	O	687-690
WT1	O	691-694
isoforms	O	695-703
in	O	704-706
urogenital	O	707-717
development	O	718-729
.	O	729-730
.	O	729-730

Analysis	O	0-8
of	O	9-11
deletions	O	12-21
in	O	22-24
DNA	O	25-28
from	O	29-33
patients	O	34-42
with	O	43-47
Becker	B	48-54
and	I	55-58
Duchenne	I	59-67
muscular	I	68-76
dystrophy	I	77-86
.	O	86-87

Duchenne	B	88-96
muscular	I	97-105
dystrophy	I	106-115
(	O	116-117
DMD	B	117-120
)	O	120-121
is	O	122-124
an	O	125-127
X	B	128-129
-	I	129-130
linked	I	130-136
recessive	I	137-146
genetic	I	147-154
disorder	I	155-163
for	O	164-167
which	O	168-173
the	O	174-177
biochemical	O	178-189
defect	O	190-196
is	O	197-199
as	O	200-202
yet	O	203-206
unknown	O	207-214
.	O	214-215

Recently	O	216-224
,	O	224-225
two	O	226-229
cloned	O	230-236
segments	O	237-245
of	O	246-248
human	O	249-254
X	O	255-256
-	O	256-257
chromosome	O	257-267
DNA	O	268-271
have	O	272-276
been	O	277-281
described	O	282-291
which	O	292-297
detect	O	298-304
structural	O	305-315
alterations	O	316-327
within	O	328-334
or	O	335-337
near	O	338-342
the	O	343-346
genetic	O	347-354
locus	O	355-360
responsible	O	361-372
for	O	373-376
the	O	377-380
disorder	O	381-389
.	O	389-390

Both	O	391-395
of	O	396-398
these	O	399-404
cloned	O	405-411
segments	O	412-420
were	O	421-425
described	O	426-435
as	O	436-438
tightly	O	439-446
linked	O	447-453
to	O	454-456
the	O	457-460
locus	O	461-466
and	O	467-470
were	O	471-475
capable	O	476-483
of	O	484-486
detecting	O	487-496
deletions	O	497-506
in	O	507-509
the	O	510-513
DNA	O	514-517
of	O	518-520
boys	O	521-525
affected	O	526-534
with	O	535-539
DMD	B	540-543
.	O	543-544

In	O	545-547
an	O	548-550
attempt	O	551-558
to	O	559-561
determine	O	562-571
more	O	572-576
precisely	O	577-586
the	O	587-590
occurrence	O	591-601
of	O	602-604
these	O	605-610
deletions	O	611-620
within	O	621-627
a	O	628-629
large	O	630-635
population	O	636-646
of	O	647-649
DMD	B	650-653
patients	O	654-662
and	O	663-666
the	O	667-670
accuracy	O	671-679
of	O	680-682
one	O	683-686
of	O	687-689
the	O	690-693
segments	O	694-702
,	O	702-703
DXS164	O	704-710
(	O	711-712
pERT87	O	712-718
)	O	718-719
,	O	719-720
in	O	721-723
determining	O	724-735
the	O	736-739
inheritance	O	740-751
of	O	752-754
the	O	755-758
DMD	B	759-762
X	O	763-764
chromosome	O	765-775
,	O	775-776
the	O	777-780
subclones	O	781-790
1	O	791-792
,	O	792-793
8	O	794-795
and	O	796-799
15	O	800-802
were	O	803-807
made	O	808-812
available	O	813-822
to	O	823-825
many	O	826-830
investigators	O	831-844
throughout	O	845-855
the	O	856-859
world	O	860-865
.	O	865-866

Here	O	867-871
we	O	872-874
describe	O	875-883
the	O	884-887
combined	O	888-896
results	O	897-904
of	O	905-907
more	O	908-912
than	O	913-917
20	O	918-920
research	O	921-929
laboratories	O	930-942
with	O	943-947
respect	O	948-955
to	O	956-958
the	O	959-962
occurrence	O	963-973
of	O	974-976
deletions	O	977-986
at	O	987-989
the	O	990-993
DXS164	O	994-1000
locus	O	1001-1006
in	O	1007-1009
DNA	O	1010-1013
samples	O	1014-1021
isolated	O	1022-1030
from	O	1031-1035
patients	O	1036-1044
with	O	1045-1049
DMD	B	1050-1053
and	O	1054-1057
Becker	B	1058-1064
muscular	I	1065-1073
dystrophy	I	1074-1083
(	O	1084-1085
BMD	B	1085-1088
)	O	1088-1089
.	O	1089-1090

The	O	1091-1094
results	O	1095-1102
indicate	O	1103-1111
that	O	1112-1116
the	O	1117-1120
DXS164	O	1121-1127
locus	O	1128-1133
apparently	O	1134-1144
recombines	O	1145-1155
with	O	1156-1160
DMD	B	1161-1164
5	O	1165-1166
%	O	1166-1167
of	O	1168-1170
the	O	1171-1174
time	O	1175-1179
,	O	1179-1180
but	O	1181-1184
is	O	1185-1187
probably	O	1188-1196
located	O	1197-1204
between	O	1205-1212
independent	O	1213-1224
sites	O	1225-1230
of	O	1231-1233
mutation	O	1234-1242
which	O	1243-1248
yield	O	1249-1254
DMD	B	1255-1258
.	O	1258-1259

The	O	1260-1263
breakpoints	O	1264-1275
of	O	1276-1278
some	O	1279-1283
deletions	O	1284-1293
are	O	1294-1297
delineated	O	1298-1308
within	O	1309-1315
the	O	1316-1319
DXS164	O	1320-1326
locus	O	1327-1332
,	O	1332-1333
and	O	1334-1337
it	O	1338-1340
is	O	1341-1343
evident	O	1344-1351
that	O	1352-1356
the	O	1357-1360
deletions	O	1361-1370
at	O	1371-1373
the	O	1374-1377
DMD	B	1378-1381
locus	O	1382-1387
are	O	1388-1391
frequent	O	1392-1400
and	O	1401-1404
extremely	O	1405-1414
large	O	1415-1420
.	O	1420-1421
.	O	1420-1421

Additional	O	0-10
case	O	11-15
of	O	16-18
female	O	19-25
monozygotic	O	26-37
twins	O	38-43
discordant	O	44-54
for	O	55-58
the	O	59-62
clinical	O	63-71
manifestations	O	72-86
of	O	87-89
Duchenne	B	90-98
muscular	I	99-107
dystrophy	I	108-117
due	O	118-121
to	O	122-124
opposite	O	125-133
X	O	134-135
-	O	135-136
chromosome	O	136-146
inactivation	O	147-159
.	O	159-160

A	O	161-162
pair	O	163-167
of	O	168-170
female	O	171-177
monozygotic	O	178-189
(	O	190-191
MZ	O	191-193
)	O	193-194
twins	O	195-200
,	O	200-201
heterozygous	O	202-214
carriers	O	215-223
for	O	224-227
a	O	228-229
deletion	O	230-238
in	O	239-241
the	O	242-245
DMD	B	246-249
gene	O	250-254
and	O	255-258
discordant	O	259-269
for	O	270-273
the	O	274-277
clinical	O	278-286
manifestations	O	287-301
of	O	302-304
Duchenne	B	305-313
muscular	I	314-322
dystrophy	I	323-332
,	O	332-333
were	O	334-338
analyzed	O	339-347
by	O	348-350
molecular	O	351-360
studies	O	361-368
,	O	368-369
in	O	370-372
situ	O	373-377
hybridization	O	378-391
,	O	391-392
and	O	393-396
methylation	O	397-408
pattern	O	409-416
of	O	417-419
X	O	420-421
chromosomes	O	422-433
to	O	434-436
search	O	437-443
for	O	444-447
opposite	O	448-456
X	O	457-458
inactivation	O	459-471
as	O	472-474
an	O	475-477
explanation	O	478-489
of	O	490-492
their	O	493-498
clinical	O	499-507
discordance	O	508-519
.	O	519-520

Results	O	521-528
in	O	529-531
lymphocytes	O	532-543
and	O	544-547
skin	O	548-552
fibroblast	O	553-563
cell	O	564-568
lines	O	569-574
suggest	O	575-582
a	O	583-584
partial	O	585-592
mirror	O	593-599
inactivation	O	600-612
with	O	613-617
the	O	618-621
normal	O	622-628
X	O	629-630
chromosome	O	631-641
preferentially	O	642-656
active	O	657-663
in	O	664-666
the	O	667-670
unaffected	O	671-681
twin	O	682-686
,	O	686-687
and	O	688-691
the	O	692-695
maternal	O	696-704
deleted	O	705-712
X	O	713-714
chromosome	O	715-725
preferentially	O	726-740
active	O	741-747
in	O	748-750
the	O	751-754
affected	O	755-763
twin	O	764-768
.	O	768-769

A	O	770-771
review	O	772-778
shows	O	779-784
that	O	785-789
MZ	O	790-792
female	O	793-799
twins	O	800-805
discordant	O	806-816
for	O	817-820
X	B	821-822
-	I	822-823
linked	I	823-829
diseases	I	830-838
are	O	839-842
not	O	843-846
uncommon	O	847-855
.	O	855-856

Twinning	O	857-865
and	O	866-869
X	O	870-871
inactivation	O	872-884
may	O	885-888
be	O	889-891
interrelated	O	892-904
and	O	905-908
could	O	909-914
explain	O	915-922
the	O	923-926
female	O	927-933
twins	O	934-939
discordant	O	940-950
for	O	951-954
X	O	955-956
-	O	956-957
linked	O	957-963
traits	O	964-970
.	O	970-971
.	O	970-971

Analbuminemia	B	0-13
in	O	14-16
a	O	17-18
neonate	O	19-26
.	O	26-27

A	O	28-29
small	O	30-35
-	O	35-36
for	O	36-39
-	O	35-36
gestational	O	40-51
-	O	35-36
age	O	52-55
infant	O	56-62
,	O	62-63
found	O	64-69
to	O	70-72
have	O	73-77
analbuminemia	B	78-91
in	O	92-94
the	O	95-98
neonatal	O	99-107
period	O	108-114
,	O	114-115
is	O	116-118
reported	O	119-127
and	O	128-131
the	O	132-135
twelve	O	136-142
cases	O	143-148
recorded	O	149-157
in	O	158-160
the	O	161-164
world	O	165-170
literature	O	171-181
are	O	182-185
reviewed	O	186-194
.	O	194-195

Patients	O	196-204
lacking	O	205-212
this	O	213-217
serum	O	218-223
protein	O	224-231
are	O	232-235
essentially	O	236-247
asymptomatic	O	248-260
,	O	260-261
apart	O	262-267
from	O	268-272
minimal	O	273-280
ankle	B	281-286
edema	I	287-292
and	O	293-296
ease	B	297-301
of	I	302-304
fatigue	I	305-312
.	O	312-313

Apparent	O	314-322
compensatory	O	323-335
mechanisms	O	336-346
which	O	347-352
come	O	353-357
into	O	358-362
play	O	363-367
when	O	368-372
serum	O	373-378
albumin	O	379-386
is	O	387-389
low	O	390-393
include	O	394-401
prolonged	O	402-411
half	O	412-416
-	O	416-417
life	O	417-421
of	O	422-424
albumin	O	425-432
and	O	433-436
transferrin	O	437-448
,	O	448-449
an	O	450-452
increase	O	453-461
in	O	462-464
serum	O	465-470
globulins	O	471-480
,	O	480-481
beta	O	482-486
lipoprotein	O	487-498
,	O	498-499
and	O	500-503
glycoproteins	O	504-517
,	O	517-518
arterial	B	519-527
hypotension	I	528-539
with	O	540-544
reduced	O	545-552
capillary	O	553-562
hydrostatic	O	563-574
pressure	O	575-583
,	O	583-584
and	O	585-588
the	O	589-592
ability	O	593-600
to	O	601-603
respond	O	604-611
with	O	612-616
rapid	O	617-622
sodium	O	623-629
and	O	630-633
chloride	O	634-642
diuresis	O	643-651
in	O	652-654
response	O	655-663
to	O	664-666
small	O	667-672
volume	O	673-679
changes	O	680-687
.	O	687-688

Examination	O	689-700
of	O	701-703
plasma	O	704-710
amino	O	711-716
acids	O	717-722
,	O	722-723
an	O	724-726
investigation	O	727-740
not	O	741-744
previously	O	745-755
reported	O	756-764
,	O	764-765
revealed	O	766-774
an	O	775-777
extremely	O	778-787
low	O	788-791
plasma	O	792-798
tryptophan	O	799-809
level	O	810-815
,	O	815-816
a	O	817-818
finding	O	819-826
which	O	827-832
may	O	833-836
be	O	837-839
important	O	840-849
in	O	850-852
view	O	853-857
of	O	858-860
the	O	861-864
role	O	865-869
of	O	870-872
tryptophan	O	873-883
in	O	884-886
albumin	O	887-894
synthesis	O	895-904
.	O	904-905
.	O	904-905

Homozygous	O	0-10
presence	O	11-19
of	O	20-22
the	O	23-26
crossover	O	27-36
(	O	37-38
fusion	O	38-44
gene	O	45-49
)	O	49-50
mutation	O	51-59
identified	O	60-70
in	O	71-73
a	O	74-75
type	B	76-80
II	I	81-83
Gaucher	I	84-91
disease	I	92-99
fetus	O	100-105
:	O	105-106
is	O	107-109
this	O	110-114
analogous	O	115-124
to	O	125-127
the	O	128-131
Gaucher	O	132-139
knock	O	140-145
-	O	145-146
out	O	146-149
mouse	O	150-155
model	O	156-161
?	O	161-162

Gaucher	B	163-170
disease	I	171-178
(	O	179-180
GD	B	180-182
)	O	182-183
is	O	184-186
an	O	187-189
inherited	O	190-199
deficiency	B	200-210
of	I	211-213
beta	I	214-218
-	I	218-219
glucocerebrosidase	I	219-237
(	O	238-239
EC	O	239-241
3	O	242-243
.	O	243-244
1	O	245-246
.	O	246-247
2	O	248-249
.	O	249-250
45	O	251-253
,	O	253-254
gene	O	255-259
symbol	O	260-266
GBA	O	267-270
)	O	270-271
.	O	271-272

In	O	273-275
type	B	276-280
I	I	281-282
GD	I	283-285
,	O	285-286
the	O	287-290
CNS	O	291-294
is	O	295-297
not	O	298-301
involved	O	302-310
(	O	311-312
nonneuronopathic	O	312-328
)	O	328-329
,	O	329-330
whereas	O	331-338
in	O	339-341
type	B	342-346
II	I	347-349
GD	I	350-352
(	O	353-354
acute	O	354-359
neuronopathic	O	360-373
)	O	373-374
CNS	O	375-378
involvement	O	379-390
is	O	391-393
early	O	394-399
and	O	400-403
rapidly	O	404-411
progressive	O	412-423
,	O	423-424
while	O	425-430
in	O	431-433
type	B	434-438
III	I	439-442
GD	I	443-445
(	O	446-447
subacute	O	447-455
neuronopathic	O	456-469
)	O	469-470
CNS	O	471-474
involvement	O	475-486
occurs	O	487-493
later	O	494-499
and	O	500-503
is	O	504-506
slowly	O	507-513
progressive	O	514-525
.	O	525-526

The	O	527-530
T6433C	O	531-537
(	O	538-539
L444P	O	539-544
)	O	544-545
substitution	O	546-558
is	O	559-561
prevalent	O	562-571
in	O	572-574
type	B	575-579
GD	I	580-582
II	I	583-585
.	O	585-586

It	O	587-589
may	O	590-593
occur	O	594-599
alone	O	600-605
as	O	606-608
a	O	609-610
single	O	611-617
base	O	618-622
-	O	622-623
pair	O	623-627
mutation	O	628-636
but	O	637-640
often	O	641-646
is	O	647-649
found	O	650-655
as	O	656-658
part	O	659-663
of	O	664-666
a	O	667-668
complex	O	669-676
allele	O	677-683
containing	O	684-694
additional	O	695-705
GBA	O	706-709
nucleotide	O	710-720
substitutions	O	721-734
,	O	734-735
G6468C	O	736-742
(	O	743-744
A456P	O	744-749
)	O	749-750
and	O	751-754
G6482C	O	755-761
(	O	762-763
V460V	O	763-768
)	O	768-769
,	O	769-770
without	O	771-778
(	O	779-780
recNciI	O	780-787
)	O	787-788
or	O	789-791
with	O	792-796
(	O	797-798
recTL	O	798-803
)	O	803-804
G5957C	O	805-811
(	O	812-813
D409H	O	813-818
)	O	818-819
.	O	819-820

This	O	821-825
complex	O	826-833
allele	O	834-840
is	O	841-843
presumed	O	844-852
to	O	853-855
have	O	856-860
formed	O	861-867
by	O	868-870
recombination	O	871-884
(	O	885-886
crossover	O	886-895
,	O	895-896
fusion	O	897-903
)	O	903-904
of	O	905-907
the	O	908-911
structural	O	912-922
gene	O	923-927
with	O	928-932
the	O	933-936
pseudogene	O	937-947
,	O	947-948
which	O	949-954
contains	O	955-963
the	O	964-967
mutated	O	968-975
sequences	O	976-985
.	O	985-986

Two	O	987-990
complex	O	991-998
alleles	O	999-1006
have	O	1007-1011
never	O	1012-1017
been	O	1018-1022
demonstrated	O	1023-1035
to	O	1036-1038
coexist	O	1039-1046
in	O	1047-1049
any	O	1050-1053
individual	O	1054-1064
.	O	1064-1065

We	O	1066-1068
devised	O	1069-1076
a	O	1077-1078
selective	O	1079-1088
PCR	O	1089-1092
method	O	1093-1099
for	O	1100-1103
the	O	1104-1107
specific	O	1108-1116
amplification	O	1117-1130
of	O	1131-1133
the	O	1134-1137
normal	O	1138-1144
and	O	1145-1148
/	O	1148-1149
or	O	1149-1151
fusion	O	1152-1158
gene	O	1159-1163
.	O	1163-1164

Using	O	1165-1170
this	O	1171-1175
procedure	O	1176-1185
we	O	1186-1188
demonstrated	O	1189-1201
the	O	1202-1205
fusion	O	1206-1212
gene	O	1213-1217
in	O	1218-1220
homozygous	O	1221-1231
form	O	1232-1236
for	O	1237-1240
the	O	1241-1244
first	O	1245-1250
time	O	1251-1255
,	O	1255-1256
in	O	1257-1259
a	O	1260-1261
Macedonian	O	1262-1272
/	O	1272-1273
Ashkenazi	O	1273-1282
Jewish	O	1283-1289
GD	B	1290-1292
type	I	1293-1297
II	I	1298-1300
fetus	O	1301-1306
.	O	1306-1307

Both	O	1308-1312
parents	O	1313-1320
were	O	1321-1325
carriers	O	1326-1334
of	O	1335-1337
the	O	1338-1341
recombination	O	1342-1355
.	O	1355-1356

This	O	1357-1361
was	O	1362-1365
confirmed	O	1366-1375
by	O	1376-1378
direct	O	1379-1385
sequence	O	1386-1394
analysis	O	1395-1403
.	O	1403-1404

A	O	1405-1406
previous	O	1407-1415
conceptus	O	1416-1425
in	O	1426-1428
this	O	1429-1433
family	O	1434-1440
was	O	1441-1444
stillborn	B	1445-1454
at	O	1455-1457
36	O	1458-1460
weeks	O	1461-1466
,	O	1466-1467
with	O	1468-1472
features	O	1473-1481
of	O	1482-1484
severe	O	1485-1491
type	B	1492-1496
II	I	1497-1499
GD	I	1500-1502
.	O	1502-1503

Neonates	O	1504-1512
showing	O	1513-1520
a	O	1521-1522
severe	O	1523-1529
clinical	O	1530-1538
phenotype	O	1539-1548
,	O	1548-1549
analogous	O	1550-1559
to	O	1560-1562
the	O	1563-1566
early	O	1567-1572
neonatal	O	1573-1581
lethal	O	1582-1588
disease	O	1589-1596
occurring	O	1597-1606
in	O	1607-1609
mice	O	1610-1614
homozygous	O	1615-1625
for	O	1626-1629
a	O	1630-1631
null	O	1632-1636
allele	O	1637-1643
produced	O	1644-1652
by	O	1653-1655
targeted	O	1656-1664
disruption	O	1665-1675
of	O	1676-1678
GBA	O	1679-1682
,	O	1682-1683
have	O	1684-1688
been	O	1689-1693
described	O	1694-1703
elsewhere	O	1704-1713
,	O	1713-1714
but	O	1715-1718
the	O	1719-1722
specific	O	1723-1731
mutations	O	1732-1741
in	O	1742-1744
these	O	1745-1750
cases	O	1751-1756
have	O	1757-1761
not	O	1762-1765
yet	O	1766-1769
been	O	1770-1774
characterized	O	1775-1788
.	O	1788-1789

(	O	1790-1791
ABSTRACT	O	1791-1799
TRUNCATED	O	1800-1809
AT	O	1810-1812
250	O	1813-1816
WORDS	O	1817-1822
)	O	1822-1823

Decrease	O	0-8
in	O	9-11
GTP	O	12-15
cyclohydrolase	O	16-30
I	O	31-32
gene	O	33-37
expression	O	38-48
caused	O	49-55
by	O	56-58
inactivation	O	59-71
of	O	72-74
one	O	75-78
allele	O	79-85
in	O	86-88
hereditary	B	89-99
progressive	I	100-111
dystonia	I	112-120
with	O	121-125
marked	O	126-132
diurnal	O	133-140
fluctuation	O	141-152
.	O	152-153

Hereditary	B	154-164
progressive	I	165-176
dystonia	I	177-185
with	O	186-190
marked	O	191-197
diurnal	O	198-205
fluctuation	O	206-217
(	O	218-219
HPD	B	219-222
;	O	222-223
dopa	B	224-228
-	I	228-229
responsive	I	229-239
dystonia	I	240-248
,	O	248-249
DRD	B	250-253
)	O	253-254
have	O	255-259
been	O	260-264
recently	O	265-273
found	O	274-279
to	O	280-282
be	O	283-285
caused	O	286-292
by	O	293-295
a	O	296-297
genetic	B	298-305
defect	I	306-312
in	O	313-315
the	O	316-319
GTP	O	320-323
cyclohydrolase	O	324-338
I	O	339-340
(	O	341-342
GCH1	O	342-346
)	O	346-347
gene	O	348-352
.	O	352-353

In	O	354-356
this	O	357-361
study	O	362-367
,	O	367-368
we	O	369-371
quantified	O	372-382
the	O	383-386
mRNA	O	387-391
level	O	392-397
of	O	398-400
GCH1	O	401-405
in	O	406-408
phytohemagglutinin	O	409-427
(	O	428-429
PHA	O	429-432
)	O	432-433
-	O	434-435
stimulated	O	435-445
mononuclear	O	446-457
blood	O	458-463
cells	O	464-469
from	O	470-474
one	O	475-478
Japanese	O	479-487
family	O	488-494
that	O	495-499
do	O	500-502
not	O	503-506
have	O	507-511
a	O	512-513
mutation	O	514-522
in	O	523-525
the	O	526-529
coding	O	530-536
region	O	537-543
or	O	544-546
splice	O	547-553
junctions	O	554-563
of	O	564-566
the	O	567-570
gene	O	571-575
.	O	575-576

The	O	577-580
results	O	581-588
showed	O	589-595
that	O	596-600
the	O	601-604
amounts	O	605-612
of	O	613-615
the	O	616-619
GCH1	O	620-624
mRNA	O	625-629
were	O	630-634
decreased	O	635-644
to	O	645-647
about	O	648-653
40	O	654-656
%	O	656-657
of	O	658-660
the	O	661-664
normal	O	665-671
level	O	672-677
in	O	678-680
both	O	681-685
patients	O	686-694
and	O	695-698
carriers	O	699-707
.	O	707-708

In	O	709-711
addition	O	712-720
,	O	720-721
we	O	722-724
found	O	725-730
that	O	731-735
the	O	736-739
GCH1	O	740-744
mRNA	O	745-749
was	O	750-753
transcribed	O	754-765
from	O	766-770
only	O	771-775
one	O	776-779
allele	O	780-786
,	O	786-787
indicating	O	788-798
that	O	799-803
the	O	804-807
other	O	808-813
allele	O	814-820
was	O	821-824
in	O	825-827
an	O	828-830
inactive	O	831-839
state	O	840-845
.	O	845-846

These	O	847-852
results	O	853-860
suggest	O	861-868
that	O	869-873
some	O	874-878
novel	O	879-884
mutations	O	885-894
should	O	895-901
exist	O	902-907
on	O	908-910
one	O	911-914
of	O	915-917
the	O	918-921
alleles	O	922-929
in	O	930-932
some	O	933-937
unknown	O	938-945
region	O	946-952
of	O	953-955
the	O	956-959
GCH1	O	960-964
gene	O	965-969
,	O	969-970
and	O	971-974
may	O	975-978
decrease	O	979-987
the	O	988-991
GCH1	O	992-996
mRNA	O	997-1001
causing	O	1002-1009
the	O	1010-1013
HPD	B	1014-1017
/	O	1017-1018
DRD	B	1018-1021
symptoms	O	1022-1030
.	O	1030-1031
.	O	1030-1031

Novel	O	0-5
mutations	O	6-15
in	O	16-18
the	O	19-22
Wiskott	B	23-30
-	I	30-31
Aldrich	I	31-38
syndrome	I	39-47
protein	O	48-55
gene	O	56-60
and	O	61-64
their	O	65-70
effects	O	71-78
on	O	79-81
transcriptional	O	82-97
,	O	97-98
translational	O	99-112
,	O	112-113
and	O	114-117
clinical	O	118-126
phenotypes	O	127-137
.	O	137-138

Wiskott	B	139-146
-	I	146-147
Aldrich	I	147-154
syndrome	I	155-163
(	O	164-165
WAS	B	165-168
)	O	168-169
is	O	170-172
an	O	173-175
X	B	176-177
-	I	177-178
linked	I	178-184
recessive	I	185-194
immunodeficiency	I	195-211
characterized	O	212-225
by	O	226-228
thrombocytopenia	B	229-245
,	O	245-246
eczema	B	247-253
,	O	253-254
and	O	255-258
recurrent	O	259-268
infections	O	269-279
,	O	279-280
and	O	281-284
caused	O	285-291
by	O	292-294
mutations	O	295-304
in	O	305-307
the	O	308-311
WAS	B	312-315
protein	O	316-323
(	O	324-325
WASP	O	325-329
)	O	329-330
gene	O	331-335
.	O	335-336

WASP	O	337-341
contains	O	342-350
several	O	351-358
functional	O	359-369
domains	O	370-377
through	O	378-385
which	O	386-391
it	O	392-394
interacts	O	395-404
with	O	405-409
proteins	O	410-418
involved	O	419-427
in	O	428-430
intracellular	O	431-444
signaling	O	445-454
and	O	455-458
regulation	O	459-469
of	O	470-472
the	O	473-476
actin	O	477-482
cytoskeleton	O	483-495
.	O	495-496

In	O	497-499
this	O	500-504
report	O	505-511
,	O	511-512
17	O	513-515
WASP	O	516-520
gene	O	521-525
mutations	O	526-535
were	O	536-540
identified	O	541-551
,	O	551-552
12	O	553-555
of	O	556-558
which	O	559-564
are	O	565-568
novel	O	569-574
.	O	574-575

DNA	O	576-579
of	O	580-582
affected	O	583-591
males	O	592-597
and	O	598-601
obligate	O	602-610
carriers	O	611-619
was	O	620-623
PCR	O	624-627
amplified	O	628-637
and	O	638-641
analyzed	O	642-650
by	O	651-653
SSCA	O	654-658
,	O	658-659
heteroduplex	O	660-672
analysis	O	673-681
,	O	681-682
and	O	683-686
direct	O	687-693
sequencing	O	694-704
.	O	704-705

The	O	706-709
effects	O	710-717
of	O	718-720
the	O	721-724
mutations	O	725-734
at	O	735-737
the	O	738-741
mRNA	O	742-746
and	O	747-750
protein	O	751-758
level	O	759-764
were	O	765-769
ascertained	O	770-781
by	O	782-784
RT	O	785-787
-	O	787-788
PCR	O	788-791
and	O	792-795
Western	O	796-803
blot	O	804-808
analyses	O	809-817
.	O	817-818

All	O	819-822
missense	O	823-831
mutations	O	832-841
were	O	842-846
located	O	847-854
in	O	855-857
exons	O	858-863
1	O	864-865
-	O	865-866
4	O	866-867
.	O	867-868

Most	O	869-873
of	O	874-876
the	O	877-880
nonsense	O	881-889
,	O	889-890
frameshift	O	891-901
and	O	902-905
splice	O	906-912
site	O	913-917
mutations	O	918-927
were	O	928-932
found	O	933-938
in	O	939-941
exons	O	942-947
6	O	948-949
-	O	949-950
11	O	950-952
.	O	952-953

Mutations	O	954-963
that	O	964-968
alter	O	969-974
splice	O	975-981
sites	O	982-987
led	O	988-991
to	O	992-994
the	O	995-998
synthesis	O	999-1008
of	O	1009-1011
several	O	1012-1019
types	O	1020-1025
of	O	1026-1028
mRNAs	O	1029-1034
,	O	1034-1035
a	O	1036-1037
fraction	O	1038-1046
of	O	1047-1049
which	O	1050-1055
represented	O	1056-1067
the	O	1068-1071
normally	O	1072-1080
spliced	O	1081-1088
product	O	1089-1096
.	O	1096-1097

The	O	1098-1101
presence	O	1102-1110
of	O	1111-1113
normally	O	1114-1122
spliced	O	1123-1130
transcripts	O	1131-1142
was	O	1143-1146
correlated	O	1147-1157
with	O	1158-1162
a	O	1163-1164
milder	O	1165-1171
phenotype	O	1172-1181
.	O	1181-1182

When	O	1183-1187
one	O	1188-1191
such	O	1192-1196
case	O	1197-1201
was	O	1202-1205
studied	O	1206-1213
by	O	1214-1216
Western	O	1217-1224
blotting	O	1225-1233
,	O	1233-1234
reduced	O	1235-1242
amounts	O	1243-1250
of	O	1251-1253
normal	O	1254-1260
-	O	1260-1261
size	O	1261-1265
WASP	O	1266-1270
were	O	1271-1275
present	O	1276-1283
.	O	1283-1284

In	O	1285-1287
other	O	1288-1293
cases	O	1294-1299
as	O	1300-1302
well	O	1303-1307
,	O	1307-1308
a	O	1309-1310
correlation	O	1311-1322
was	O	1323-1326
found	O	1327-1332
between	O	1333-1340
the	O	1341-1344
amount	O	1345-1351
of	O	1352-1354
normal	O	1355-1361
or	O	1362-1364
mutant	O	1365-1371
WASP	O	1372-1376
present	O	1377-1384
and	O	1385-1388
the	O	1389-1392
phenotypes	O	1393-1403
of	O	1404-1406
the	O	1407-1410
affected	O	1411-1419
individuals	O	1420-1431
.	O	1431-1432

No	O	1433-1435
protein	O	1436-1443
was	O	1444-1447
detected	O	1448-1456
in	O	1457-1459
two	O	1460-1463
individuals	O	1464-1475
with	O	1476-1480
severe	O	1481-1487
WAS	B	1488-1491
.	O	1491-1492

Reduced	O	1493-1500
levels	O	1501-1507
of	O	1508-1510
a	O	1511-1512
normal	O	1513-1519
-	O	1519-1520
size	O	1520-1524
WASP	O	1525-1529
with	O	1530-1534
a	O	1535-1536
missense	O	1537-1545
mutation	O	1546-1554
were	O	1555-1559
seen	O	1560-1564
in	O	1565-1567
two	O	1568-1571
individuals	O	1572-1583
with	O	1584-1588
XLT	B	1589-1592
.	O	1592-1593

It	O	1594-1596
is	O	1597-1599
concluded	O	1600-1609
that	O	1610-1614
mutation	O	1615-1623
analysis	O	1624-1632
at	O	1633-1635
the	O	1636-1639
DNA	O	1640-1643
level	O	1644-1649
is	O	1650-1652
not	O	1653-1656
sufficient	O	1657-1667
for	O	1668-1671
predicting	O	1672-1682
clinical	O	1683-1691
course	O	1692-1698
.	O	1698-1699

Studies	O	1700-1707
at	O	1708-1710
the	O	1711-1714
transcript	O	1715-1725
and	O	1726-1729
protein	O	1730-1737
level	O	1738-1743
are	O	1744-1747
needed	O	1748-1754
for	O	1755-1758
a	O	1759-1760
better	O	1761-1767
assessment	O	1768-1778
.	O	1778-1779
.	O	1778-1779

Incidence	O	0-9
and	O	10-13
characteristics	O	14-29
of	O	30-32
glucose	O	33-40
-	O	40-41
6	O	41-42
-	O	40-41
phosphate	O	43-52
dehydrogenase	O	53-66
variants	O	67-75
in	O	76-78
Japan	O	79-84
.	O	84-85

A	O	86-87
total	O	88-93
of	O	94-96
3000	O	97-101
men	O	102-105
living	O	106-112
in	O	113-115
Yamaguchi	O	116-125
were	O	126-130
screened	O	131-139
for	O	140-143
glucose	B	144-151
-	I	151-152
6	I	152-153
-	I	151-152
phosphate	I	154-163
dehydrogenase	I	164-177
(	I	178-179
G6PD	I	179-183
)	I	183-184
deficiency	I	185-195
using	O	196-201
Beutlers	O	202-210
spot	O	211-215
test	O	216-220
and	O	221-224
three	O	225-230
types	O	231-236
of	O	237-239
starch	O	240-246
gel	O	247-250
electrophoresis	O	251-266
.	O	266-267

These	O	268-273
electrophoresis	O	274-289
used	O	290-294
a	O	295-296
phosphate	O	297-306
buffer	O	307-313
system	O	314-320
at	O	321-323
pH	O	324-326
7	O	327-328
.	O	328-329
0	O	330-331
,	O	331-332
a	O	333-334
TRIS	O	335-339
-	O	339-340
EDTA	O	340-344
-	O	339-340
borate	O	345-351
buffer	O	352-358
system	O	359-365
at	O	366-368
pH	O	369-371
8	O	372-373
.	O	373-374
6	O	375-376
,	O	376-377
and	O	378-381
a	O	382-383
TRIS	O	384-388
-	O	388-389
hydrochloride	O	389-402
buffer	O	403-409
system	O	410-416
at	O	417-419
pH	O	420-422
8	O	423-424
.	O	424-425
.	O	424-425
Fifteen	O	427-434
G6PD	B	435-439
-	I	439-440
deficient	I	440-449
variants	O	450-458
were	O	459-463
found	O	464-469
at	O	470-472
the	O	473-476
rate	O	477-481
of	O	482-484
0	O	485-486
.	O	486-487
5	O	488-489
%	O	489-490
and	O	491-494
classified	O	495-505
into	O	506-510
four	O	511-515
groups	O	516-522
.	O	522-523

As	O	524-526
new	O	527-530
variants	O	531-539
,	O	539-540
G6PD	O	541-545
Konan	O	546-551
,	O	551-552
Kamiube	O	553-560
,	O	560-561
and	O	562-565
Kiwa	O	566-570
were	O	571-575
identified	O	576-586
.	O	586-587

These	O	588-593
three	O	594-599
variants	O	600-608
had	O	609-612
a	O	613-614
mild	O	615-619
to	O	620-622
moderate	O	623-631
G6PD	B	632-636
deficiency	I	637-647
and	O	648-651
were	O	652-656
not	O	657-660
associated	O	661-671
with	O	672-676
any	O	677-680
clinical	O	681-689
signs	O	690-695
.	O	695-696

G6PD	O	697-701
Konan	O	702-707
had	O	708-711
fast	O	712-716
electrophoretic	O	717-732
mobility	O	733-741
as	O	742-744
compared	O	745-753
with	O	754-758
normal	O	759-765
levels	O	766-772
,	O	772-773
G6PD	O	774-778
Kiwa	O	779-783
had	O	784-787
slightly	O	788-796
elevated	O	797-805
electrophoretic	O	806-821
mobility	O	822-830
,	O	830-831
and	O	832-835
G6PD	O	836-840
Kamiube	O	841-848
had	O	849-852
normal	O	853-859
electrophoretic	O	860-875
mobility	O	876-884
.	O	884-885

These	O	886-891
three	O	892-897
variants	O	898-906
had	O	907-910
normal	O	911-917
levels	O	918-924
of	O	925-927
Km	O	928-930
G6P	O	931-934
,	O	934-935
Km	O	936-938
NADP	O	939-943
,	O	943-944
and	O	945-948
Ki	O	949-951
NADPH	O	952-957
,	O	957-958
normal	O	959-965
utilizations	O	966-978
of	O	979-981
both	O	982-986
2	O	987-988
-	O	988-989
deoxy	O	989-994
-	O	988-989
G6P	O	995-998
and	O	999-1002
deamino	O	1003-1010
-	O	1010-1011
NAPD	O	1011-1015
,	O	1015-1016
normal	O	1017-1023
heat	O	1024-1028
stability	O	1029-1038
,	O	1038-1039
and	O	1040-1043
a	O	1044-1045
normal	O	1046-1052
pH	O	1053-1055
curve	O	1056-1061
.	O	1061-1062

The	O	1063-1066
other	O	1067-1072
variant	O	1073-1080
was	O	1081-1084
G6PD	O	1085-1089
Ube	O	1090-1093
,	O	1093-1094
which	O	1095-1100
we	O	1101-1103
had	O	1104-1107
previously	O	1108-1118
found	O	1119-1124
in	O	1125-1127
Yamaguchi	O	1128-1137
(	O	1138-1139
Nakashima	O	1139-1148
et	O	1149-1151
al	O	1152-1154
.	O	1154-1155
,	O	1155-1156
1977	O	1157-1161
)	O	1161-1162
.	O	1162-1163

One	O	1164-1167
boy	O	1168-1171
with	O	1172-1176
G6PD	O	1177-1181
Ube	O	1182-1185
was	O	1186-1189
Korean	O	1190-1196

Difference	O	0-10
in	O	11-13
methylation	O	14-25
patterns	O	26-34
within	O	35-41
the	O	42-45
D15S9	O	46-51
region	O	52-58
of	O	59-61
chromosome	O	62-72
15q11	O	73-78
-	O	78-79
13	O	79-81
in	O	82-84
first	O	85-90
cousins	O	91-98
with	O	99-103
Angelman	B	104-112
syndrome	I	113-121
and	O	122-125
Prader	B	126-132
-	I	132-133
Willi	I	133-138
syndrome	I	139-147
.	O	147-148

Abnormalities	O	149-162
of	O	163-165
chromosome	O	166-176
region	O	177-183
15q11	O	184-189
-	O	189-190
13	O	190-192
are	O	193-196
associated	O	197-207
with	O	208-212
Angelman	B	213-221
syndrome	I	222-230
(	O	231-232
AS	B	232-234
)	O	234-235
and	O	236-239
Prader	B	240-246
-	I	246-247
Willi	I	247-252
syndrome	I	253-261
(	O	262-263
PWS	B	263-266
)	O	266-267
.	O	267-268

Differences	O	269-280
between	O	281-288
the	O	289-292
methylation	O	293-304
patterns	O	305-313
of	O	314-316
the	O	317-320
region	O	321-327
of	O	328-330
chromosome	O	331-341
15q11	O	342-347
-	O	347-348
13	O	348-350
which	O	351-356
hybridizes	O	357-367
to	O	368-370
the	O	371-374
highly	O	375-381
conserved	O	382-391
DNA	O	392-395
,	O	395-396
DN34	O	397-401
,	O	401-402
in	O	403-405
normal	O	406-412
individuals	O	413-424
and	O	425-428
in	O	429-431
patients	O	432-440
with	O	441-445
AS	B	446-448
and	O	449-452
PWS	B	453-456
have	O	457-461
been	O	462-466
described	O	467-476
.	O	476-477

We	O	478-480
report	O	481-487
on	O	488-490
a	O	491-492
family	O	493-499
in	O	500-502
which	O	503-508
first	O	509-514
cousins	O	515-522
are	O	523-526
affected	O	527-535
by	O	536-538
AS	B	539-541
and	O	542-545
PWS	B	546-549
as	O	550-552
a	O	553-554
result	O	555-561
of	O	562-564
a	O	565-566
familial	O	567-575
paracentric	O	576-587
inversion	O	588-597
of	O	598-600
15q11	O	601-606
-	O	606-607
q13	O	607-610
.	O	610-611

The	O	612-615
results	O	616-623
of	O	624-626
the	O	627-630
studies	O	631-638
on	O	639-641
this	O	642-646
family	O	647-653
demonstrate	O	654-665
the	O	666-669
differences	O	670-681
in	O	682-684
the	O	685-688
methylation	O	689-700
patterns	O	701-709
in	O	710-712
the	O	713-716
2	O	717-718
conditions	O	719-729
and	O	730-733
the	O	734-737
phenomenon	O	738-748
of	O	749-751
genomic	O	752-759
imprinting	O	760-770
,	O	770-771
whereby	O	772-779
genetic	O	780-787
information	O	788-799
is	O	800-802
expressed	O	803-812
differently	O	813-824
dependent	O	825-834
on	O	835-837
the	O	838-841
parent	O	842-848
of	O	849-851
origin	O	852-858
.	O	858-859
.	O	858-859

Mutations	O	0-9
in	O	10-12
the	O	13-16
candidate	O	17-26
gene	O	27-31
for	O	32-35
Norrie	B	36-42
disease	I	43-50
.	O	50-51

Recently	O	52-60
,	O	60-61
we	O	62-64
and	O	65-68
others	O	69-75
have	O	76-80
isolated	O	81-89
a	O	90-91
candidate	O	92-101
gene	O	102-106
for	O	107-110
X	B	111-112
linked	I	113-119
Norrie	I	120-126
disease	I	127-134
(	O	135-136
ND	B	136-138
)	O	138-139
which	O	140-145
was	O	146-149
found	O	150-155
to	O	156-158
be	O	159-161
deleted	O	162-169
or	O	170-172
disrupted	O	173-182
in	O	183-185
several	O	186-193
patients	O	194-202
.	O	202-203

As	O	204-206
a	O	207-208
prerequisite	O	209-221
for	O	222-225
the	O	226-229
identification	O	230-244
of	O	245-247
point	O	248-253
mutations	O	254-263
in	O	264-266
the	O	267-270
ND	B	271-273
gene	O	274-278
we	O	279-281
have	O	282-286
established	O	287-298
the	O	299-302
exon	O	303-307
-	O	307-308
intron	O	308-314
structure	O	315-324
of	O	325-327
this	O	328-332
gene	O	333-337
.	O	337-338

In	O	339-341
17	O	342-344
unrelated	O	345-354
patients	O	355-363
and	O	364-367
15	O	368-370
controls	O	371-379
,	O	379-380
PCR	O	381-384
products	O	385-393
derived	O	394-401
from	O	402-406
the	O	407-410
promoter	O	411-419
region	O	420-426
,	O	426-427
exons	O	428-433
1	O	434-435
and	O	436-439
2	O	440-441
as	O	442-444
well	O	445-449
as	O	450-452
the	O	453-456
coding	O	457-463
part	O	464-468
of	O	469-471
exon	O	472-476
3	O	477-478
were	O	479-483
analysed	O	484-492
with	O	493-497
the	O	498-501
single	O	502-508
strand	O	509-515
conformation	O	516-528
polymorphism	O	529-541
(	O	542-543
SSCP	O	543-547
)	O	547-548
technique	O	549-558
.	O	558-559

In	O	560-562
12	O	563-565
patients	O	566-574
altered	O	575-582
PCR	O	583-586
fragments	O	587-596
were	O	597-601
detected	O	602-610
which	O	611-616
were	O	617-621
studied	O	622-629
in	O	630-632
detail	O	633-639
by	O	640-642
direct	O	643-649
sequencing	O	650-660
.	O	660-661

Eleven	O	662-668
different	O	669-678
mutations	O	679-688
were	O	689-693
found	O	694-699
,	O	699-700
and	O	701-704
all	O	705-708
but	O	709-712
one	O	713-716
are	O	717-720
likely	O	721-727
to	O	728-730
give	O	731-735
rise	O	736-740
to	O	741-743
significant	O	744-755
structural	O	756-766
changes	O	767-774
in	O	775-777
the	O	778-781
predicted	O	782-791
protein	O	792-799
.	O	799-800

These	O	801-806
findings	O	807-815
,	O	815-816
and	O	817-820
the	O	821-824
absence	O	825-832
of	O	833-835
functionally	O	836-848
relevant	O	849-857
base	O	858-862
changes	O	863-870
in	O	871-873
healthy	O	874-881
controls	O	882-890
,	O	890-891
emphasize	O	892-901
the	O	902-905
causal	O	906-912
role	O	913-917
of	O	918-920
this	O	921-925
candidate	O	926-935
gene	O	936-940
in	O	941-943
Norrie	B	944-950
disease	I	951-958
and	O	959-962
pave	O	963-967
the	O	968-971
way	O	972-975
for	O	976-979
reliable	O	980-988
diagnosis	O	989-998
and	O	999-1002
carrier	O	1003-1010
detection	O	1011-1020
.	O	1020-1021
.	O	1020-1021

A	O	0-1
single	O	2-8
amino	O	9-14
acid	O	15-19
substitution	O	20-32
(	O	33-34
G103D	O	34-39
)	O	39-40
in	O	41-43
the	O	44-47
type	O	48-52
II	O	53-55
collagen	O	56-64
triple	O	65-71
helix	O	72-77
produces	O	78-86
Kniest	B	87-93
dysplasia	I	94-103
.	O	103-104

Kniest	B	105-111
dysplasia	I	112-121
is	O	122-124
a	O	125-126
moderately	O	127-137
severe	O	138-144
chondrodysplasia	B	145-161
phenotype	O	162-171
that	O	172-176
results	O	177-184
from	O	185-189
mutations	O	190-199
in	O	200-202
the	O	203-206
gene	O	207-211
for	O	212-215
type	O	216-220
II	O	221-223
collagen	O	224-232
,	O	232-233
COL2A1	O	234-240
.	O	240-241

Characteristics	O	242-257
of	O	258-260
the	O	261-264
disorder	O	265-273
include	O	274-281
a	O	282-283
short	B	284-289
trunk	I	290-295
and	I	296-299
extremities	I	300-311
,	O	311-312
mid	B	313-316
-	I	316-317
face	I	317-321
hypoplasia	I	322-332
,	O	332-333
cleft	B	334-339
palate	I	340-346
,	O	346-347
myopia	B	348-354
,	O	354-355
retinal	B	356-363
detachment	I	364-374
,	O	374-375
and	O	376-379
hearing	B	380-387
loss	I	388-392
.	O	392-393

Recently	O	394-402
,	O	402-403
deletions	O	404-413
of	O	414-416
all	O	417-420
or	O	421-423
part	O	424-428
of	O	429-431
exon	O	432-436
12	O	437-439
have	O	440-444
been	O	445-449
identified	O	450-460
in	O	461-463
individuals	O	464-475
with	O	476-480
Kniest	B	481-487
dysplasia	I	488-497
,	O	497-498
suggesting	O	499-509
that	O	510-514
mutations	O	515-524
within	O	525-531
this	O	532-536
region	O	537-543
of	O	544-546
the	O	547-550
protein	O	551-558
may	O	559-562
primarily	O	563-572
result	O	573-579
in	O	580-582
the	O	583-586
Kniest	B	587-593
dysplasia	I	594-603
phenotype	O	604-613
.	O	613-614

We	O	615-617
used	O	618-622
SSCP	O	623-627
to	O	628-630
analyze	O	631-638
an	O	639-641
amplified	O	642-651
genomic	O	652-659
DNA	O	660-663
fragment	O	664-672
containing	O	673-683
exon	O	684-688
12	O	689-691
from	O	692-696
seven	O	697-702
individuals	O	703-714
with	O	715-719
Kniest	B	720-726
dysplasia	I	727-736
.	O	736-737

An	O	738-740
abnormality	O	741-752
was	O	753-756
identified	O	757-767
in	O	768-770
one	O	771-774
patient	O	775-782
.	O	782-783

DNA	O	784-787
sequence	O	788-796
analysis	O	797-805
demonstrated	O	806-818
that	O	819-823
the	O	824-827
patient	O	828-835
was	O	836-839
heterozygous	O	840-852
for	O	853-856
a	O	857-858
G	O	859-860
to	O	861-863
A	O	864-865
transition	O	866-876
that	O	877-881
implied	O	882-889
substitution	O	890-902
of	O	903-905
glycine103	O	906-916
of	O	917-919
the	O	920-923
triple	O	924-930
helical	O	931-938
domain	O	939-945
by	O	946-948
aspartate	O	949-958
.	O	958-959

The	O	960-963
mutation	O	964-972
was	O	973-976
not	O	977-980
observed	O	981-989
in	O	990-992
DNA	O	993-996
from	O	997-1001
either	O	1002-1008
of	O	1009-1011
the	O	1012-1015
clinically	O	1016-1026
unaffected	O	1027-1037
parents	O	1038-1045
of	O	1046-1048
the	O	1049-1052
proband	O	1053-1060
.	O	1060-1061

Protein	O	1062-1069
microsequencing	O	1070-1085
demonstrated	O	1086-1098
expression	O	1099-1109
of	O	1110-1112
the	O	1113-1116
abnormal	O	1117-1125
allele	O	1126-1132
in	O	1133-1135
cartilage	O	1136-1145
.	O	1145-1146

These	O	1147-1152
data	O	1153-1157
demonstrate	O	1158-1169
that	O	1170-1174
point	O	1175-1180
mutations	O	1181-1190
which	O	1191-1196
result	O	1197-1203
in	O	1204-1206
single	O	1207-1213
amino	O	1214-1219
acid	O	1220-1224
substitutions	O	1225-1238
can	O	1239-1242
produce	O	1243-1250
Kniest	B	1251-1257
dysplasia	I	1258-1267
and	O	1268-1271
further	O	1272-1279
support	O	1280-1287
the	O	1288-1291
hypothesis	O	1292-1302
that	O	1303-1307
alteration	O	1308-1318
of	O	1319-1321
a	O	1322-1323
domain	O	1324-1330
,	O	1330-1331
which	O	1332-1337
includes	O	1338-1346
the	O	1347-1350
region	O	1351-1357
encoded	O	1358-1365
by	O	1366-1368
exon	O	1369-1373
12	O	1374-1376
,	O	1376-1377
in	O	1378-1380
the	O	1381-1384
type	O	1385-1389
II	O	1390-1392
collagen	O	1393-1401
protein	O	1402-1409
leads	O	1410-1415
to	O	1416-1418
this	O	1419-1423
disorder	O	1424-1432
.	O	1432-1433
.	O	1432-1433

Linkage	O	0-7
analysis	O	8-16
of	O	17-19
5	O	20-21
novel	O	22-27
van	B	28-31
der	I	32-35
Woude	I	36-41
syndrome	I	42-50
kindreds	O	51-59
to	O	60-62
1q32	O	63-67
-	O	67-68
q41	O	68-71
markers	O	72-79
further	O	80-87
supports	O	88-96
locus	O	97-102
homogeneity	O	103-114
of	O	115-117
the	O	118-121
disease	O	122-129
trait	O	130-135
.	O	135-136

van	B	137-140
der	I	141-144
Woude	I	145-150
syndrome	I	151-159
(	O	160-161
vWS	B	161-164
,	O	164-165
MIM	O	166-169
119300	O	170-176
)	O	176-177
is	O	178-180
a	O	181-182
rare	O	183-187
autosomal	B	188-197
dominant	I	198-206
clefting	I	207-215
condition	I	216-225
with	O	226-230
cardinal	O	231-239
features	O	240-248
of	O	249-251
mucous	B	252-258
cysts	I	259-264
(	O	265-266
lower	B	266-271
-	I	271-272
lip	I	272-275
pits	I	276-280
)	O	280-281
and	O	282-285
clefts	B	286-292
to	I	293-295
the	I	296-299
lip	I	300-303
and	I	304-307
/	I	307-308
or	I	308-310
palate	I	311-317
.	O	317-318

The	O	319-322
vWS	B	323-326
gene	O	327-331
has	O	332-335
been	O	336-340
assigned	O	341-349
to	O	350-352
a	O	353-354
locus	O	355-360
in	O	361-363
1q32	O	364-368
-	O	368-369
q41	O	369-372
by	O	373-375
linkage	O	376-383
analysis	O	384-392
and	O	393-396
physical	O	397-405
mapping	O	406-413
.	O	413-414

We	O	415-417
have	O	418-422
investigated	O	423-435
5	O	436-437
novel	O	438-443
vWS	B	444-447
families	O	448-456
through	O	457-464
probands	O	465-473
attended	O	474-482
for	O	483-486
cleft	B	487-492
lip	I	493-496
and	I	497-500
/	I	500-501
or	I	501-503
palate	I	504-510
repair	O	511-517
at	O	518-520
the	O	521-524
Department	O	525-535
of	O	536-538
Maxillofacial	O	539-552
Surgery	O	553-560
of	O	561-563
Hopital	O	564-571
Trousseau	O	572-581
,	O	581-582
Paris	O	583-588
,	O	588-589
in	O	590-592
order	O	593-598
to	O	599-601
tentatively	O	602-613
refine	O	614-620
the	O	621-624
genetic	O	625-632
map	O	633-636
of	O	637-639
the	O	640-643
vWS	B	644-647
region	O	648-654
in	O	655-657
1q32	O	658-662
-	O	662-663
q41	O	663-666
and	O	667-670
possibly	O	671-679
identify	O	680-688
unlinked	O	689-697
pedigrees	O	698-707
.	O	707-708

Linkage	O	709-716
analysis	O	717-725
was	O	726-729
carried	O	730-737
out	O	738-741
to	O	742-744
6	O	745-746
microsatellite	O	747-761
markers	O	762-769
(	O	770-771
D1S249	O	771-777
,	O	777-778
D1S425	O	779-785
,	O	785-786
D1S491	O	787-793
,	O	793-794
D1S205	O	795-801
,	O	801-802
D1S414	O	803-809
,	O	809-810
D1S425	O	811-817
)	O	817-818
,	O	818-819
yielding	O	820-828
a	O	829-830
maximum	O	831-838
cumulative	O	839-849
LOD	O	850-853
score	O	854-859
of	O	860-862
Z	O	863-864
=	O	865-866
3	O	867-868
.	O	868-869
27	O	870-872
at	O	873-875
theta	O	876-881
=	O	882-883
0	O	884-885
.	O	885-886
00	O	887-889
for	O	890-893
D1S245	O	894-900
.	O	900-901

The	O	902-905
innermost	O	906-915
four	O	916-920
markers	O	921-928
were	O	929-933
found	O	934-939
to	O	940-942
be	O	943-945
tightly	O	946-953
linked	O	954-960
to	O	961-963
one	O	964-967
another	O	968-975
,	O	975-976
with	O	977-981
no	O	982-984
evidence	O	985-993
for	O	994-997
recombination	O	998-1011
.	O	1011-1012

Our	O	1013-1016
results	O	1017-1024
support	O	1025-1032
linkage	O	1033-1040
of	O	1041-1043
vWS	B	1044-1047
within	O	1048-1054
a	O	1055-1056
region	O	1057-1063
of	O	1064-1066
tightly	O	1067-1074
linked	O	1075-1081
markers	O	1082-1089
and	O	1090-1093
do	O	1094-1096
not	O	1097-1100
favour	O	1101-1107
locus	O	1108-1113
heterogeneity	O	1114-1127
of	O	1128-1130
the	O	1131-1134
disease	O	1135-1142
trait	O	1143-1148
.	O	1148-1149

Hypopigmentation	B	0-16
in	O	17-19
the	O	20-23
Prader	B	24-30
-	I	30-31
Willi	I	31-36
syndrome	I	37-45
.	O	45-46

Cutaneous	B	47-56
and	I	57-60
ocular	I	61-67
pigmentation	I	68-80
were	O	81-85
evaluated	O	86-95
in	O	96-98
29	O	99-101
individuals	O	102-113
with	O	114-118
the	O	119-122
Prader	B	123-129
-	I	129-130
Willi	I	130-135
syndrome	I	136-144
(	O	145-146
PWS	B	146-149
)	O	149-150
.	O	150-151

Criteria	O	152-160
for	O	161-164
hypopigmentation	B	165-181
included	O	182-190
the	O	191-194
presence	O	195-203
of	O	204-206
type	O	207-211
I	O	212-213
or	O	214-216
II	O	217-219
skin	O	220-224
,	O	224-225
the	O	226-229
lightest	O	230-238
skin	O	239-243
type	O	244-248
in	O	249-251
the	O	252-255
family	O	256-262
by	O	263-265
history	O	266-273
,	O	273-274
and	O	275-278
iris	O	279-283
translucency	O	284-296
on	O	297-299
globe	O	300-305
transillumination	O	306-323
.	O	323-324

On	O	325-327
the	O	328-331
basis	O	332-337
of	O	338-340
these	O	341-346
criteria	O	347-355
,	O	355-356
48	O	357-359
%	O	359-360
of	O	361-363
the	O	364-367
PWS	B	368-371
individuals	O	372-383
were	O	384-388
hypopigmented	B	389-402
.	O	402-403

The	O	404-407
presence	O	408-416
of	O	417-419
hypopigmentation	B	420-436
correlated	O	437-447
with	O	448-452
a	O	453-454
small	O	455-460
interstitial	O	461-473
deletion	O	474-482
on	O	483-485
the	O	486-489
proximal	O	490-498
long	O	499-503
arm	O	504-507
of	O	508-510
chromosome	O	511-521
15	O	522-524
;	O	524-525
however	O	526-533
,	O	533-534
this	O	535-539
deletion	O	540-548
was	O	549-552
also	O	553-557
found	O	558-563
in	O	564-566
individuals	O	567-578
who	O	579-582
did	O	583-586
not	O	587-590
meet	O	591-595
the	O	596-599
full	O	600-604
criteria	O	605-613
for	O	614-617
hypopigmentation	B	618-634
.	O	634-635

Hairbulb	O	636-644
tyrosinase	O	645-655
activity	O	656-664
and	O	665-668
glutathione	O	669-680
content	O	681-688
,	O	688-689
as	O	690-692
well	O	693-697
as	O	698-700
urine	O	701-706
cysteinyldopa	O	707-720
excretion	O	721-730
,	O	730-731
were	O	732-736
low	O	737-740
in	O	741-743
PWS	B	744-747
individuals	O	748-759
with	O	760-764
and	O	765-768
without	O	769-776
hypopigmentation	B	777-793
and	O	794-797
did	O	798-801
not	O	802-805
separate	O	806-814
these	O	815-820
two	O	821-824
groups	O	825-831
.	O	831-832

We	O	833-835
conclude	O	836-844
that	O	845-849
hypopigmentation	B	850-866
is	O	867-869
found	O	870-875
in	O	876-878
a	O	879-880
significant	O	881-892
proportion	O	893-903
of	O	904-906
individuals	O	907-918
with	O	919-923
PWS	B	924-927
and	O	928-931
that	O	932-936
the	O	937-940
hypopigmentation	B	941-957
may	O	958-961
be	O	962-964
associated	O	965-975
with	O	976-980
a	O	981-982
deletion	O	983-991
of	O	992-994
the	O	995-998
long	O	999-1003
arm	O	1004-1007
of	O	1008-1010
chromosome	O	1011-1021
15	O	1022-1024
.	O	1024-1025

The	O	1026-1029
mechanism	O	1030-1039
for	O	1040-1043
the	O	1044-1047
hypopigmentation	B	1048-1064
is	O	1065-1067
unknown	O	1068-1075
.	O	1075-1076
.	O	1075-1076

Deficiency	B	0-10
of	I	11-13
the	I	14-17
fifth	I	18-23
component	I	24-33
of	I	34-36
complement	I	37-47
in	O	48-50
human	O	51-56
subjects	O	57-65
.	O	65-66

Clinical	O	67-75
,	O	75-76
genetic	O	77-84
and	O	85-88
immunologic	O	89-100
studies	O	101-108
in	O	109-111
a	O	112-113
large	O	114-119
kindred	O	120-127
.	O	127-128

The	O	129-132
discovery	O	133-142
of	O	143-145
a	O	146-147
large	O	148-153
kindred	O	154-161
with	O	162-166
a	O	167-168
heritable	O	169-178
deficiency	B	179-189
of	I	190-192
the	I	193-196
fifth	I	197-202
component	I	203-212
of	I	213-215
complement	I	216-226
(	O	227-228
C5	O	228-230
)	O	230-231
has	O	232-235
permitted	O	236-245
the	O	246-249
accumulation	O	250-262
of	O	263-265
new	O	266-269
clinical	O	270-278
,	O	278-279
genetic	O	280-287
and	O	288-291
immunologic	O	292-303
data	O	304-308
concerning	O	309-319
the	O	320-323
role	O	324-328
of	O	329-331
C5	O	332-334
in	O	335-337
human	O	338-343
subjects	O	344-352
.	O	352-353

The	O	354-357
proband	O	358-365
,	O	365-366
who	O	367-370
has	O	371-374
had	O	375-378
nine	O	379-383
episodes	O	384-392
of	O	393-395
disseminated	O	396-408
gonococcal	B	409-419
infection	I	420-429
,	O	429-430
has	O	431-434
a	O	435-436
hemolytic	O	437-446
C5	O	447-449
level	O	450-455
of	O	456-458
approximately	O	459-472
0	O	473-474
.	O	474-475
5	O	476-477
per	O	478-481
cent	O	482-486
of	O	487-489
normal	O	490-496
.	O	496-497

No	O	498-500
C5	O	501-503
protein	O	504-511
was	O	512-515
detectable	O	516-526
,	O	526-527
but	O	528-531
low	O	532-535
levels	O	536-542
of	O	543-545
functional	O	546-556
C5	O	557-559
activity	O	560-568
could	O	569-574
be	O	575-577
found	O	578-583
using	O	584-589
a	O	590-591
sensitive	O	592-601
bactericidal	O	602-614
assay	O	615-620
.	O	620-621

The	O	622-625
probands	O	626-634
twin	O	635-639
as	O	640-642
well	O	643-647
as	O	648-650
another	O	651-658
sister	O	659-665
also	O	666-670
had	O	671-674
extremely	O	675-684
low	O	685-688
levels	O	689-695
of	O	696-698
hemolytic	O	699-708
C5	O	709-711
(	O	712-713
approximately	O	713-726
0	O	727-728
.	O	728-729
5	O	730-731
per	O	732-735
cent	O	736-740
normal	O	741-747
)	O	747-748
,	O	748-749
but	O	750-753
both	O	754-758
these	O	759-764
subjects	O	765-773
have	O	774-778
been	O	779-783
healthy	O	784-791
.	O	791-792

Hemolytic	O	793-802
complement	O	803-813
and	O	814-817
bacteriolytic	O	818-831
activity	O	832-840
could	O	841-846
be	O	847-849
restored	O	850-858
by	O	859-861
the	O	862-865
addition	O	866-874
of	O	875-877
purified	O	878-886
C5	O	887-889
.	O	889-890

No	O	891-893
chemotactic	O	894-905
activity	O	906-914
for	O	915-918
polymorphonuclear	O	919-936
leukocytes	O	937-947
could	O	948-953
be	O	954-956
generated	O	957-966
in	O	967-969
the	O	970-973
C5	B	974-976
-	I	976-977
deficient	I	977-986
serums	O	987-993
upon	O	994-998
activation	O	999-1009
of	O	1010-1012
either	O	1013-1019
the	O	1020-1023
classic	O	1024-1031
or	O	1032-1034
alternative	O	1035-1046
pathways	O	1047-1055
,	O	1055-1056
again	O	1057-1062
demonstrating	O	1063-1076
the	O	1077-1080
importance	O	1081-1091
of	O	1092-1094
C5	O	1095-1097
in	O	1098-1100
human	O	1101-1106
subjects	O	1107-1115
for	O	1116-1119
the	O	1120-1123
production	O	1124-1134
of	O	1135-1137
chemotactic	O	1138-1149
factors	O	1150-1157
.	O	1157-1158

The	O	1159-1162
chemotactic	O	1163-1174
responsiveness	O	1175-1189
of	O	1190-1192
the	O	1193-1196
patients	O	1197-1205
polymorphonuclear	O	1206-1223
leukocytes	O	1224-1234
and	O	1235-1238
monocytes	O	1239-1248
to	O	1249-1251
preformed	O	1252-1261
chemotactic	O	1262-1273
factors	O	1274-1281
was	O	1282-1285
not	O	1286-1289
depressed	O	1290-1299
.	O	1299-1300

Twenty	O	1301-1307
-	O	1307-1308
two	O	1308-1311
of	O	1312-1314
32	O	1315-1317
other	O	1318-1323
family	O	1324-1330
members	O	1331-1338
from	O	1339-1343
three	O	1344-1349
generations	O	1350-1361
had	O	1362-1365
depressed	O	1366-1375
whole	O	1376-1381
hemolytic	O	1382-1391
complement	O	1392-1402
levels	O	1403-1409
.	O	1409-1410

In	O	1411-1413
19	O	1414-1416
of	O	1417-1419
30	O	1420-1422
family	O	1423-1429
members	O	1430-1437
,	O	1437-1438
levels	O	1439-1445
of	O	1446-1448
hemolytic	O	1449-1458
C5	O	1459-1461
ranged	O	1462-1468
from	O	1469-1473
13	O	1474-1476
to	O	1477-1479
64	O	1480-1482
per	O	1483-1486
cent	O	1487-1491
of	O	1492-1494
normal	O	1495-1501
.	O	1501-1502

No	O	1503-1505
linkage	O	1506-1513
for	O	1514-1517
C5	B	1518-1520
deficiency	I	1521-1531
and	O	1532-1535
the	O	1536-1539
A	O	1540-1541
or	O	1542-1544
B	O	1545-1546
loci	O	1547-1551
of	O	1552-1554
the	O	1555-1558
major	O	1559-1564
histocompatibility	O	1565-1583
complex	O	1584-1591
could	O	1592-1597
be	O	1598-1600
found	O	1601-1606
.	O	1606-1607

These	O	1608-1613
data	O	1614-1618
suggest	O	1619-1626
an	O	1627-1629
autosomal	O	1630-1639
codominant	O	1640-1650
mode	O	1651-1655
of	O	1656-1658
inheritance	O	1659-1670
of	O	1671-1673
C5	B	1674-1676
deficiency	I	1677-1687
.	O	1687-1688

Deficiency	B	1689-1699
of	I	1700-1702
C5	I	1703-1705
is	O	1706-1708
compatible	O	1709-1719
with	O	1720-1724
good	O	1725-1729
health	O	1730-1736
,	O	1736-1737
but	O	1738-1741
it	O	1742-1744
can	O	1745-1748
be	O	1749-1751
associated	O	1752-1762
with	O	1763-1767
repeated	O	1768-1776
disseminated	O	1777-1789
gonococcal	B	1790-1800
infection	I	1801-1810

A	O	0-1
new	O	2-5
glucose	O	6-13
-	O	13-14
6	O	14-15
-	O	13-14
phosphate	O	16-25
dehydrogenase	O	26-39
variant	O	40-47
,	O	47-48
G6PD	O	49-53
Orissa	O	54-60
(	O	61-62
44	O	62-64
Ala	O	65-68
-	O	68-69
-	O	68-69
>	O	70-71
Gly	O	71-74
)	O	74-75
,	O	75-76
is	O	77-79
the	O	80-83
major	O	84-89
polymorphic	O	90-101
variant	O	102-109
in	O	110-112
tribal	O	113-119
populations	O	120-131
in	O	132-134
India	O	135-140
.	O	140-141

Deficiency	B	142-152
of	I	153-155
glucose	I	156-163
-	I	163-164
6	I	164-165
-	I	163-164
phosphate	I	166-175
dehydrogenase	I	176-189
(	O	190-191
G6PD	O	191-195
)	O	195-196
is	O	197-199
usually	O	200-207
found	O	208-213
at	O	214-216
high	O	217-221
frequencies	O	222-233
in	O	234-236
areas	O	237-242
of	O	243-245
the	O	246-249
world	O	250-255
where	O	256-261
malaria	B	262-269
has	O	270-273
been	O	274-278
endemic	O	279-286
.	O	286-287

The	O	288-291
frequency	O	292-301
and	O	302-305
genetic	O	306-313
basis	O	314-319
of	O	320-322
G6PD	B	323-327
deficiency	I	328-338
have	O	339-343
been	O	344-348
studied	O	349-356
in	O	357-359
Africa	O	360-366
,	O	366-367
around	O	368-374
the	O	375-378
Mediterranean	O	379-392
,	O	392-393
and	O	394-397
in	O	398-400
the	O	401-404
Far	O	405-408
East	O	409-413
,	O	413-414
but	O	415-418
little	O	419-425
such	O	426-430
information	O	431-442
is	O	443-445
available	O	446-455
about	O	456-461
the	O	462-465
situation	O	466-475
in	O	476-478
India	O	479-484
.	O	484-485

To	O	486-488
determine	O	489-498
the	O	499-502
extent	O	503-509
of	O	510-512
heterogeneity	O	513-526
of	O	527-529
G6PD	O	530-534
,	O	534-535
we	O	536-538
have	O	539-543
studied	O	544-551
several	O	552-559
different	O	560-569
Indian	O	570-576
populations	O	577-588
by	O	589-591
screening	O	592-601
for	O	602-605
G6PD	B	606-610
deficiency	I	611-621
,	O	621-622
followed	O	623-631
by	O	632-634
molecular	O	635-644
analysis	O	645-653
of	O	654-656
deficient	O	657-666
alleles	O	667-674
.	O	674-675

The	O	676-679
frequency	O	680-689
of	O	690-692
G6PD	B	693-697
deficiency	I	698-708
varies	O	709-715
between	O	716-723
3	O	724-725
%	O	725-726
and	O	727-730
15	O	731-733
%	O	733-734
in	O	735-737
different	O	738-747
tribal	O	748-754
and	O	755-758
urban	O	759-764
groups	O	765-771
.	O	771-772

Remarkably	O	773-783
,	O	783-784
a	O	785-786
previously	O	787-797
unreported	O	798-808
deficient	O	809-818
variant	O	819-826
,	O	826-827
G6PD	O	828-832
Orissa	O	833-839
(	O	840-841
44	O	841-843
Ala	O	844-847
-	O	847-848
-	O	847-848
>	O	850-851
Gly	O	852-855
)	O	855-856
,	O	856-857
is	O	858-860
responsible	O	861-872
for	O	873-876
most	O	877-881
of	O	882-884
the	O	885-888
G6PD	B	889-893
deficiency	I	894-904
in	O	905-907
tribal	O	908-914
Indian	O	915-921
populations	O	922-933
but	O	934-937
is	O	938-940
not	O	941-944
found	O	945-950
in	O	951-953
urban	O	954-959
populations	O	960-971
,	O	971-972
where	O	973-978
most	O	979-983
of	O	984-986
the	O	987-990
G6PD	B	991-995
deficiency	I	996-1006
is	O	1007-1009
due	O	1010-1013
to	O	1014-1016
the	O	1017-1020
G6PD	O	1021-1025
Mediterranean	O	1026-1039
(	O	1040-1041
188	O	1041-1044
Ser	O	1045-1048
-	O	1048-1049
-	O	1048-1049
>	O	1051-1052
Phe	O	1053-1056
)	O	1056-1057
variant	O	1058-1065
.	O	1065-1066

The	O	1067-1070
KmNADP	O	1071-1077
of	O	1078-1080
G6PD	O	1081-1085
Orissa	O	1086-1092
is	O	1093-1095
fivefold	O	1096-1104
higher	O	1105-1111
than	O	1112-1116
that	O	1117-1121
of	O	1122-1124
the	O	1125-1128
normal	O	1129-1135
enzyme	O	1136-1142
.	O	1142-1143

This	O	1144-1148
may	O	1149-1152
be	O	1153-1155
due	O	1156-1159
to	O	1160-1162
the	O	1163-1166
fact	O	1167-1171
that	O	1172-1176
the	O	1177-1180
alanine	O	1181-1188
residue	O	1189-1196
that	O	1197-1201
is	O	1202-1204
replaced	O	1205-1213
by	O	1214-1216
glycine	O	1217-1224
is	O	1225-1227
part	O	1228-1232
of	O	1233-1235
a	O	1236-1237
putative	O	1238-1246
coenzyme	O	1247-1255
-	O	1255-1256
binding	O	1256-1263
site	O	1264-1268
.	O	1268-1269
.	O	1268-1269

Germline	O	0-8
mutations	O	9-18
in	O	19-21
the	O	22-25
Wilms	B	26-31
'	I	31-32
tumor	I	33-38
suppressor	O	39-49
gene	O	50-54
are	O	55-58
associated	O	59-69
with	O	70-74
abnormal	O	75-83
urogenital	O	84-94
development	O	95-106
in	O	107-109
Denys	B	110-115
-	I	115-116
Drash	I	116-121
syndrome	I	122-130
.	O	130-131

Denys	B	132-137
-	I	137-138
Drash	I	138-143
syndrome	I	144-152
is	O	153-155
a	O	156-157
rare	O	158-162
human	O	163-168
condition	O	169-178
in	O	179-181
which	O	182-187
severe	O	188-194
urogenital	B	195-205
aberrations	I	206-217
result	O	218-224
in	O	225-227
renal	B	228-233
failure	I	234-241
,	O	241-242
pseudohermaphroditism	B	243-264
,	O	264-265
and	O	266-269
Wilms	B	270-275
tumor	I	276-281
(	O	282-283
nephroblastoma	B	283-297
)	O	297-298
.	O	298-299

To	O	300-302
investigate	O	303-314
its	O	315-318
possible	O	319-327
role	O	328-332
,	O	332-333
we	O	334-336
have	O	337-341
analyzed	O	342-350
the	O	351-354
coding	O	355-361
exons	O	362-367
of	O	368-370
the	O	371-374
Wilms	B	375-380
tumor	I	381-386
suppressor	O	387-397
gene	O	398-402
(	O	403-404
WT1	O	404-407
)	O	407-408
for	O	409-412
germline	O	413-421
mutations	O	422-431
.	O	431-432

In	O	433-435
ten	O	436-439
independent	O	440-451
cases	O	452-457
of	O	458-460
Denys	B	461-466
-	I	466-467
Drash	I	467-472
syndrome	I	473-481
,	O	481-482
point	O	483-488
mutations	O	489-498
in	O	499-501
the	O	502-505
zinc	O	506-510
finger	O	511-517
domains	O	518-525
of	O	526-528
one	O	529-532
WT1	O	533-536
gene	O	537-541
copy	O	542-546
were	O	547-551
found	O	552-557
.	O	557-558

Nine	O	559-563
of	O	564-566
these	O	567-572
mutations	O	573-582
are	O	583-586
found	O	587-592
within	O	593-599
exon	O	600-604
9	O	605-606
(	O	607-608
zinc	O	608-612
finger	O	613-619
III	O	620-623
)	O	623-624
;	O	624-625
the	O	626-629
remaining	O	630-639
mutation	O	640-648
is	O	649-651
in	O	652-654
exon	O	655-659
8	O	660-661
(	O	662-663
zinc	O	663-667
finger	O	668-674
II	O	675-677
)	O	677-678
.	O	678-679

These	O	680-685
mutations	O	686-695
directly	O	696-704
affect	O	705-711
DNA	O	712-715
sequence	O	716-724
recognition	O	725-736
.	O	736-737

In	O	738-740
two	O	741-744
families	O	745-753
analyzed	O	754-762
,	O	762-763
the	O	764-767
mutations	O	768-777
were	O	778-782
shown	O	783-788
to	O	789-791
arise	O	792-797
de	O	798-800
novo	O	801-805
.	O	805-806

Wilms	B	807-812
tumors	I	813-819
from	O	820-824
three	O	825-830
individuals	O	831-842
and	O	843-846
one	O	847-850
juvenile	O	851-859
granulosa	O	860-869
cell	O	870-874
tumor	B	875-880
demonstrate	O	881-892
reduction	O	893-902
to	O	903-905
homozygosity	O	906-918
for	O	919-922
the	O	923-926
mutated	O	927-934
WT1	O	935-938
allele	O	939-945
.	O	945-946

Our	O	947-950
results	O	951-958
provide	O	959-966
evidence	O	967-975
of	O	976-978
a	O	979-980
direct	O	981-987
role	O	988-992
for	O	993-996
WT1	O	997-1000
in	O	1001-1003
Denys	B	1004-1009
-	I	1009-1010
Drash	I	1010-1015
syndrome	I	1016-1024
and	O	1025-1028
thus	O	1029-1033
urogenital	O	1034-1044
system	O	1045-1051
development	O	1052-1063
.	O	1063-1064
.	O	1063-1064

Molecular	O	0-9
basis	O	10-15
of	O	16-18
feline	O	19-25
beta	B	26-30
-	I	30-31
glucuronidase	I	31-44
deficiency	I	45-55
:	O	55-56
an	O	57-59
animal	O	60-66
model	O	67-72
of	O	73-75
mucopolysaccharidosis	B	76-97
VII	I	98-101
.	O	101-102

A	O	103-104
family	O	105-111
of	O	112-114
domestic	O	115-123
cats	O	124-128
was	O	129-132
found	O	133-138
that	O	139-143
exhibited	O	144-153
clinical	O	154-162
and	O	163-166
biochemical	O	167-178
abnormalities	O	179-192
consistent	O	193-203
with	O	204-208
mucopolysaccharidosis	B	209-230
VII	I	231-234
,	O	234-235
an	O	236-238
autosomal	B	239-248
recessive	I	249-258
lysosomal	I	259-268
storage	I	269-276
disorder	I	277-285
caused	O	286-292
by	O	293-295
beta	B	296-300
-	I	300-301
glucuronidase	I	301-314
deficiency	I	315-325
.	O	325-326

beta	O	327-331
-	O	331-332
Glucuronidase	O	332-345
activity	O	346-354
was	O	355-358
undetectable	O	359-371
in	O	372-374
affected	O	375-383
cat	O	384-387
fibroblasts	O	388-399
and	O	400-403
restored	O	404-412
by	O	413-415
retroviral	O	416-426
gene	O	427-431
transfer	O	432-440
of	O	441-443
rat	O	444-447
beta	O	448-452
-	O	452-453
glucuronidase	O	453-466
cDNA	O	467-471
.	O	471-472

beta	O	473-477
-	O	477-478
Glucuronidase	O	478-491
mRNA	O	492-496
was	O	497-500
normal	O	501-507
in	O	508-510
affected	O	511-519
cat	O	520-523
testis	O	524-530
by	O	531-533
Northern	O	534-542
blot	O	543-547
analysis	O	548-556
.	O	556-557

Normal	O	558-564
feline	O	565-571
beta	O	572-576
-	O	576-577
glucuronidase	O	577-590
cDNA	O	591-595
was	O	596-599
cloned	O	600-606
and	O	607-610
characterized	O	611-624
,	O	624-625
and	O	626-629
amplified	O	630-639
from	O	640-644
affected	O	645-653
cat	O	654-657
fibroblasts	O	658-669
by	O	670-672
reverse	O	673-680
transcription	O	681-694
coupled	O	695-702
polymerase	O	703-713
chain	O	714-719
reaction	O	720-728
.	O	728-729

There	O	730-735
was	O	736-739
a	O	740-741
G	O	742-743
-	O	743-744
to	O	744-746
-	O	743-744
A	O	747-748
transition	O	749-759
in	O	760-762
the	O	763-766
affected	O	767-775
cat	O	776-779
cDNA	O	780-784
that	O	785-789
predicted	O	790-799
an	O	800-802
E351K	O	803-808
substitution	O	809-821
,	O	821-822
destroyed	O	823-832
a	O	833-834
BssSI	O	835-840
site	O	841-845
,	O	845-846
and	O	847-850
eliminated	O	851-861
GUSB	O	862-866
enzymatic	O	867-876
activity	O	877-885
in	O	886-888
expression	O	889-899
studies	O	900-907
.	O	907-908

Multiple	O	909-917
species	O	918-925
comparison	O	926-936
and	O	937-940
the	O	941-944
crystal	O	945-952
structure	O	953-962
of	O	963-965
human	O	966-971
beta	O	972-976
-	O	976-977
glucuronidase	O	977-990
indicated	O	991-1000
that	O	1001-1005
E351	O	1006-1010
is	O	1011-1013
a	O	1014-1015
highly	O	1016-1022
conserved	O	1023-1032
residue	O	1033-1040
most	O	1041-1045
likely	O	1046-1052
essential	O	1053-1062
in	O	1063-1065
maintenance	O	1066-1077
of	O	1078-1080
the	O	1081-1084
enzymes	O	1085-1092
conformation	O	1093-1105
.	O	1105-1106

BssSI	O	1107-1112
digestion	O	1113-1122
of	O	1123-1125
polymerase	O	1126-1136
chain	O	1137-1142
reaction	O	1143-1151
products	O	1152-1160
amplified	O	1161-1170
from	O	1171-1175
genomic	O	1176-1183
DNA	O	1184-1187
indicated	O	1188-1197
that	O	1198-1202
affected	O	1203-1211
cats	O	1212-1216
were	O	1217-1221
homozygous	O	1222-1232
and	O	1233-1236
cats	O	1237-1241
with	O	1242-1246
half	O	1247-1251
-	O	1251-1252
normal	O	1252-1258
beta	O	1259-1263
-	O	1263-1264
glucuronidase	O	1264-1277
activity	O	1278-1286
were	O	1287-1291
heterozygous	O	1292-1304
for	O	1305-1308
the	O	1309-1312
missense	O	1313-1321
mutation	O	1322-1330
.	O	1330-1331

Carriers	O	1332-1340
identified	O	1341-1351
in	O	1352-1354
this	O	1355-1359
manner	O	1360-1366
produced	O	1367-1375
affected	O	1376-1384
kittens	O	1385-1392
in	O	1393-1395
prospective	O	1396-1407
breedings	O	1408-1417
,	O	1417-1418
and	O	1419-1422
a	O	1423-1424
feline	O	1425-1431
MPS	B	1432-1435
VII	I	1436-1439
breeding	O	1440-1448
colony	O	1449-1455
has	O	1456-1459
been	O	1460-1464
established	O	1465-1476
.	O	1476-1477
.	O	1476-1477

Loss	O	0-4
-	O	4-5
of	O	5-7
-	O	4-5
function	O	8-16
mutations	O	17-26
in	O	27-29
the	O	30-33
cathepsin	O	34-43
C	O	44-45
gene	O	46-50
result	O	51-57
in	O	58-60
periodontal	B	61-72
disease	I	73-80
and	O	81-84
palmoplantar	B	85-97
keratosis	I	98-107
.	O	107-108

Papillon	B	109-117
-	I	117-118
Lefevre	I	118-125
syndrome	I	126-134
,	O	134-135
or	O	136-138
keratosis	B	139-148
palmoplantaris	I	149-163
with	O	164-168
periodontopathia	B	169-185
(	O	186-187
PLS	B	187-190
,	O	190-191
MIM	O	192-195
245000	O	196-202
)	O	202-203
,	O	203-204
is	O	205-207
an	O	208-210
autosomal	B	211-220
recessive	I	221-230
disorder	I	231-239
that	O	240-244
is	O	245-247
mainly	O	248-254
ascertained	O	255-266
by	O	267-269
dentists	O	270-278
because	O	279-286
of	O	287-289
the	O	290-293
severe	O	294-300
periodontitis	B	301-314
that	O	315-319
afflicts	O	320-328
patients	O	329-337
.	O	337-338

Both	O	339-343
the	O	344-347
deciduous	O	348-357
and	O	358-361
permanent	O	362-371
dentitions	O	372-382
are	O	383-386
affected	O	387-395
,	O	395-396
resulting	O	397-406
in	O	407-409
premature	O	410-419
tooth	B	420-425
loss	I	426-430
.	O	430-431

Palmoplantar	B	432-444
keratosis	I	445-454
,	O	454-455
varying	O	456-463
from	O	464-468
mild	O	469-473
psoriasiform	O	474-486
scaly	O	487-492
skin	O	493-497
to	O	498-500
overt	O	501-506
hyperkeratosis	B	507-521
,	O	521-522
typically	O	523-532
develops	O	533-541
within	O	542-548
the	O	549-552
first	O	553-558
three	O	559-564
years	O	565-570
of	O	571-573
life	O	574-578
.	O	578-579

Keratosis	B	580-589
also	O	590-594
affects	O	595-602
other	O	603-608
sites	O	609-614
such	O	615-619
as	O	620-622
elbows	O	623-629
and	O	630-633
knees	O	634-639
.	O	639-640

Most	O	641-645
PLS	B	646-649
patients	O	650-658
display	O	659-666
both	O	667-671
periodontitis	B	672-685
and	O	686-689
hyperkeratosis	B	690-704
.	O	704-705

Some	O	706-710
patients	O	711-719
have	O	720-724
only	O	725-729
palmoplantar	B	730-742
keratosis	I	743-752
or	O	753-755
periodontitis	B	756-769
,	O	769-770
and	O	771-774
in	O	775-777
rare	O	778-782
individuals	O	783-794
the	O	795-798
periodontitis	B	799-812
is	O	813-815
mild	O	816-820
and	O	821-824
of	O	825-827
late	O	828-832
onset	O	833-838
.	O	838-839

The	O	840-843
PLS	O	844-847
locus	O	848-853
has	O	854-857
been	O	858-862
mapped	O	863-869
to	O	870-872
chromosome	O	873-883
11q14	O	884-889
-	O	889-890
q21	O	890-893
(	O	894-895
refs	O	895-899
7	O	900-901
,	O	901-902
8	O	903-904
,	O	904-905
9	O	906-907
)	O	907-908
.	O	908-909

Using	O	910-915
homozygosity	O	916-928
mapping	O	929-936
in	O	937-939
eight	O	940-945
small	O	946-951
consanguineous	O	952-966
families	O	967-975
,	O	975-976
we	O	977-979
have	O	980-984
narrowed	O	985-993
the	O	994-997
candidate	O	998-1007
region	O	1008-1014
to	O	1015-1017
a	O	1018-1019
1	O	1020-1021
.	O	1021-1022
2	O	1023-1024
-	O	1024-1025
cM	O	1025-1027
interval	O	1028-1036
between	O	1037-1044
D11S4082	O	1045-1053
and	O	1054-1057
D11S931	O	1058-1065
.	O	1065-1066

The	O	1067-1070
gene	O	1071-1075
(	O	1076-1077
CTSC	O	1077-1081
)	O	1081-1082
encoding	O	1083-1091
the	O	1092-1095
lysosomal	O	1096-1105
protease	O	1106-1114
cathepsin	O	1115-1124
C	O	1125-1126
(	O	1127-1128
or	O	1128-1130
dipeptidyl	O	1131-1141
aminopeptidase	O	1142-1156
I	O	1157-1158
)	O	1158-1159
lies	O	1160-1164
within	O	1165-1171
this	O	1172-1176
interval	O	1177-1185
.	O	1185-1186

We	O	1187-1189
defined	O	1190-1197
the	O	1198-1201
genomic	O	1202-1209
structure	O	1210-1219
of	O	1220-1222
CTSC	O	1223-1227
and	O	1228-1231
found	O	1232-1237
mutations	O	1238-1247
in	O	1248-1250
all	O	1251-1254
eight	O	1255-1260
families	O	1261-1269
.	O	1269-1270

In	O	1271-1273
two	O	1274-1277
of	O	1278-1280
these	O	1281-1286
families	O	1287-1295
we	O	1296-1298
used	O	1299-1303
a	O	1304-1305
functional	O	1306-1316
assay	O	1317-1322
to	O	1323-1325
demonstrate	O	1326-1337
an	O	1338-1340
almost	O	1341-1347
total	O	1348-1353
loss	O	1354-1358
of	O	1359-1361
cathepsin	O	1362-1371
C	O	1372-1373
activity	O	1374-1382
in	O	1383-1385
PLS	B	1386-1389
patients	O	1390-1398
and	O	1399-1402
reduced	O	1403-1410
activity	O	1411-1419
in	O	1420-1422
obligate	O	1423-1431
carriers	O	1432-1440
.	O	1440-1441

Brca1	B	0-5
deficiency	I	6-16
results	O	17-24
in	O	25-27
early	O	28-33
embryonic	B	34-43
lethality	I	44-53
characterized	O	54-67
by	O	68-70
neuroepithelial	B	71-86
abnormalities	I	87-100
.	O	100-101

The	O	102-105
breast	B	106-112
and	I	113-116
ovarian	I	117-124
cancer	I	125-131
susceptibility	O	132-146
gene	O	147-151
,	O	151-152
BRCA1	O	153-158
,	O	158-159
has	O	160-163
been	O	164-168
cloned	O	169-175
and	O	176-179
shown	O	180-185
to	O	186-188
encode	O	189-195
a	O	196-197
zinc	O	198-202
-	O	202-203
finger	O	203-209
protein	O	210-217
of	O	218-220
unknown	O	221-228
function	O	229-237
.	O	237-238

Mutations	O	239-248
in	O	249-251
BRCA1	O	252-257
account	O	258-265
for	O	266-269
at	O	270-272
least	O	273-278
80	O	279-281
%	O	281-282
of	O	283-285
families	O	286-294
with	O	295-299
both	O	300-304
breast	B	305-311
and	I	312-315
ovarian	I	316-323
cancer	I	324-330
,	O	330-331
as	O	332-334
well	O	335-339
as	O	340-342
some	O	343-347
non	O	348-351
-	O	351-352
familial	O	352-360
sporadic	O	361-369
ovarian	B	370-377
cancers	I	378-385
.	O	385-386

The	O	387-390
loss	O	391-395
of	O	396-398
wild	O	399-403
-	O	403-404
type	O	404-408
BRCA1	O	409-414
in	O	415-417
tumours	B	418-425
of	O	426-428
individuals	O	429-440
carrying	O	441-449
one	O	450-453
nonfunctional	O	454-467
BRCA1	O	468-473
allele	O	474-480
suggests	O	481-489
that	O	490-494
BRCA1	O	495-500
encodes	O	501-508
a	O	509-510
tumour	B	511-517
suppressor	O	518-528
that	O	529-533
may	O	534-537
inhibit	O	538-545
the	O	546-549
proliferation	O	550-563
of	O	564-566
mammary	O	567-574
epithelial	O	575-585
cells	O	586-591
.	O	591-592

To	O	593-595
examine	O	596-603
the	O	604-607
role	O	608-612
of	O	613-615
BRCA1	O	616-621
in	O	622-624
normal	O	625-631
tissue	O	632-638
growth	O	639-645
and	O	646-649
differentiation	O	650-665
,	O	665-666
and	O	667-670
to	O	671-673
generate	O	674-682
a	O	683-684
potential	O	685-694
model	O	695-700
for	O	701-704
the	O	705-708
cancer	B	709-715
susceptibility	O	716-730
associated	O	731-741
with	O	742-746
loss	O	747-751
of	O	752-754
BRCA1	O	755-760
function	O	761-769
,	O	769-770
we	O	771-773
have	O	774-778
created	O	779-786
a	O	787-788
mouse	O	789-794
line	O	795-799
carrying	O	800-808
a	O	809-810
mutation	O	811-819
in	O	820-822
one	O	823-826
Brca1	O	827-832
allele	O	833-839
.	O	839-840

Analysis	O	841-849
of	O	850-852
mice	O	853-857
homozygous	O	858-868
for	O	869-872
the	O	873-876
mutant	O	877-883
allele	O	884-890
indicate	O	891-899
that	O	900-904
Brca1	O	905-910
is	O	911-913
critical	O	914-922
for	O	923-926
normal	O	927-933
development	O	934-945
,	O	945-946
as	O	947-949
these	O	950-955
mice	O	956-960
died	O	961-965
in	O	966-968
utero	O	969-974
between	O	975-982
10	O	983-985
and	O	986-989
13	O	990-992
days	O	993-997
of	O	998-1000
gestation	O	1001-1010
(	O	1011-1012
E10	O	1012-1015
-	O	1015-1016
E13	O	1016-1019
)	O	1019-1020
.	O	1020-1021

Abnormalities	O	1022-1035
in	O	1036-1038
Brca1	B	1039-1044
-	I	1044-1045
deficient	I	1045-1054
embryos	O	1055-1062
were	O	1063-1067
most	O	1068-1072
evident	O	1073-1080
in	O	1081-1083
the	O	1084-1087
neural	O	1088-1094
tube	O	1095-1099
,	O	1099-1100
with	O	1101-1105
40	O	1106-1108
%	O	1108-1109
of	O	1110-1112
the	O	1113-1116
embryos	O	1117-1124
presenting	O	1125-1135
with	O	1136-1140
varying	O	1141-1148
degrees	O	1149-1156
of	O	1157-1159
spina	B	1160-1165
bifida	I	1166-1172
and	O	1173-1176
anencephaly	B	1177-1188
.	O	1188-1189

In	O	1190-1192
addition	O	1193-1201
,	O	1201-1202
the	O	1203-1206
neuroepithelium	O	1207-1222
in	O	1223-1225
Brca1	B	1226-1231
-	I	1231-1232
deficient	I	1232-1241
embryos	O	1242-1249
appeared	O	1250-1258
disorganized	O	1259-1271
,	O	1271-1272
with	O	1273-1277
signs	O	1278-1283
of	O	1284-1286
both	O	1287-1291
rapid	O	1292-1297
proliferation	O	1298-1311
and	O	1312-1315
excessive	O	1316-1325
cell	O	1326-1330
death	O	1331-1336
.	O	1336-1337
.	O	1336-1337

X	B	0-1
linked	I	2-8
recessive	I	9-18
thrombocytopenia	I	19-35
.	O	35-36

A	O	37-38
Saudi	O	39-44
Arab	O	45-49
boy	O	50-53
presented	O	54-63
in	O	64-66
early	O	67-72
childhood	O	73-82
with	O	83-87
thrombocytopenia	B	88-104
,	O	104-105
morphologically	O	106-121
large	O	122-127
and	O	128-131
normal	O	132-138
sized	O	139-144
platelets	O	145-154
,	O	154-155
increased	O	156-165
mean	O	166-170
platelet	O	171-179
volume	O	180-186
,	O	186-187
and	O	188-191
a	O	192-193
hypermegakaryocytic	O	194-213
bone	O	214-218
marrow	O	219-225
.	O	225-226

There	O	227-232
was	O	233-236
no	O	237-239
clinical	O	240-248
and	O	249-252
laboratory	O	253-263
evidence	O	264-272
of	O	273-275
any	O	276-279
significant	O	280-291
immunological	B	292-305
abnormalities	I	306-319
.	O	319-320

Similar	O	321-328
findings	O	329-337
in	O	338-340
two	O	341-344
other	O	345-350
brothers	O	351-359
suggested	O	360-369
strongly	O	370-378
that	O	379-383
they	O	384-388
were	O	389-393
all	O	394-397
suffering	O	398-407
from	O	408-412
an	O	413-415
X	B	416-417
linked	I	418-424
recessive	I	425-434
thrombocytopenic	I	435-451
disorder	I	452-460
.	O	460-461

Results	O	462-469
of	O	470-472
DNA	O	473-476
analysis	O	477-485
with	O	486-490
the	O	491-494
probe	O	495-500
M27	O	501-504
beta	O	505-509
are	O	510-513
consistent	O	514-524
with	O	525-529
X	O	530-531
linkage	O	532-539
and	O	540-543
indicate	O	544-552
also	O	553-557
that	O	558-562
the	O	563-566
locus	O	567-572
of	O	573-575
the	O	576-579
relevant	O	580-588
gene	O	589-593
lies	O	594-598
close	O	599-604
to	O	605-607
or	O	608-610
is	O	611-613
identical	O	614-623
to	O	624-626
the	O	627-630
locus	O	631-636
of	O	637-639
the	O	640-643
gene	O	644-648
for	O	649-652
the	O	653-656
Wiskott	B	657-664
-	I	664-665
Aldrich	I	665-672
syndrome	I	673-681
(	O	682-683
WAS	B	683-686
)	O	686-687
.	O	687-688

Because	O	689-696
of	O	697-699
various	O	700-707
features	O	708-716
which	O	717-722
include	O	723-730
the	O	731-734
presence	O	735-743
of	O	744-746
large	O	747-752
and	O	753-756
normal	O	757-763
sized	O	764-769
platelets	O	770-779
(	O	780-781
rather	O	781-787
than	O	788-792
small	O	793-798
platelets	O	799-808
)	O	808-809
and	O	810-813
freedom	O	814-821
from	O	822-826
significant	O	827-838
immune	B	839-845
deficiencies	I	846-858
,	O	858-859
it	O	860-862
is	O	863-865
likely	O	866-872
that	O	873-877
the	O	878-881
X	B	882-883
linked	I	884-890
recessive	I	891-900
thrombocytopenia	I	901-917
in	O	918-920
this	O	921-925
family	O	926-932
is	O	933-935
an	O	936-938
isolated	O	939-947
entity	O	948-954
quite	O	955-960
distinct	O	961-969
from	O	970-974
the	O	975-978
classical	O	979-988
WAS	B	989-992
phenotype	O	993-1002
.	O	1002-1003

However	O	1004-1011
,	O	1011-1012
a	O	1013-1014
modified	O	1015-1023
expression	O	1024-1034
of	O	1035-1037
the	O	1038-1041
WAS	B	1042-1045
gene	O	1046-1050
producing	O	1051-1060
a	O	1061-1062
mild	O	1063-1067
phenotypic	O	1068-1078
variant	O	1079-1086
cannot	O	1087-1093
be	O	1094-1096
excluded	O	1097-1105
entirely	O	1106-1114
.	O	1114-1115
.	O	1114-1115

Genetics	O	0-8
of	O	9-11
cerebrotendinous	B	12-28
xanthomatosis	I	29-42
(	O	43-44
CTX	B	44-47
)	O	47-48
:	O	48-49
an	O	50-52
autosomal	O	53-62
recessive	O	63-72
trait	O	73-78
with	O	79-83
high	O	84-88
gene	O	89-93
frequency	O	94-103
in	O	104-106
Sephardim	O	107-116
of	O	117-119
Moroccan	O	120-128
origin	O	129-135
.	O	135-136

We	O	137-139
described	O	140-149
6	O	150-151
patients	O	152-160
(	O	161-162
from	O	162-166
3	O	167-168
families	O	169-177
)	O	177-178
affected	O	179-187
with	O	188-192
cerebrotendinous	B	193-209
xanthomatosis	I	210-223
(	O	224-225
CTX	B	225-228
)	O	228-229
.	O	229-230

All	O	231-234
are	O	235-238
Sephardic	O	239-248
Jews	O	249-253
of	O	254-256
Moroccan	O	257-265
extraction	O	266-276
.	O	276-277

In	O	278-280
view	O	281-285
of	O	286-288
the	O	289-292
small	O	293-298
number	O	299-305
of	O	306-308
CTX	B	309-312
patients	O	313-321
diagnosed	O	322-331
in	O	332-334
the	O	335-338
world	O	339-344
(	O	345-346
a	O	346-347
total	O	348-353
of	O	354-356
50	O	357-359
including	O	360-369
our	O	370-373
6	O	374-375
patients	O	376-384
)	O	384-385
,	O	385-386
we	O	387-389
are	O	390-393
probably	O	394-402
dealing	O	403-410
with	O	411-415
an	O	416-418
ethnic	O	419-425
subgroup	O	426-434
with	O	435-439
a	O	440-441
high	O	442-446
CTX	O	447-450
gene	O	451-455
frequency	O	456-465
,	O	465-466
which	O	467-472
we	O	473-475
have	O	476-480
estimated	O	481-490
to	O	491-493
be	O	494-496
1	O	497-498
/	O	498-499
108	O	499-502
.	O	502-503

Since	O	504-509
there	O	510-515
are	O	516-519
differences	O	520-531
in	O	532-534
expression	O	535-545
in	O	546-548
this	O	549-553
disease	O	554-561
,	O	561-562
we	O	563-565
recommend	O	566-575
cholestanol	O	576-587
study	O	588-593
in	O	594-596
cases	O	597-602
of	O	603-605
undiagnosed	O	606-617
cataract	B	618-626
or	O	627-629
tendinous	B	630-639
xanthomas	I	640-649
in	O	650-652
childhood	O	653-662
or	O	663-665
early	O	666-671
adolescence	O	672-683
.	O	683-684

The	O	685-688
diagnosis	O	689-698
in	O	699-701
CTX	B	702-705
is	O	706-708
important	O	709-718
not	O	719-722
only	O	723-727
for	O	728-731
genetic	O	732-739
counseling	O	740-750
,	O	750-751
but	O	752-755
also	O	756-760
in	O	761-763
veiw	O	764-768
of	O	769-771
possible	O	772-780
treatment	O	781-790
.	O	790-791
.	O	790-791

A	O	0-1
missense	O	2-10
mutation	O	11-19
in	O	20-22
the	O	23-26
cholesteryl	O	27-38
ester	O	39-44
transfer	O	45-53
protein	O	54-61
gene	O	62-66
with	O	67-71
possible	O	72-80
dominant	O	81-89
effects	O	90-97
on	O	98-100
plasma	O	101-107
high	O	108-112
density	O	113-120
lipoproteins	O	121-133
.	O	133-134

Plasma	O	135-141
HDL	O	142-145
are	O	146-149
a	O	150-151
negative	O	152-160
risk	O	161-165
factor	O	166-172
for	O	173-176
atherosclerosis	B	177-192
.	O	192-193

Cholesteryl	O	194-205
ester	O	206-211
transfer	O	212-220
protein	O	221-228
(	O	229-230
CETP	O	230-234
;	O	234-235
476	O	236-239
amino	O	240-245
acids	O	246-251
)	O	251-252
transfers	O	253-262
cholesteryl	O	263-274
ester	O	275-280
from	O	281-285
HDL	O	286-289
to	O	290-292
other	O	293-298
lipoproteins	O	299-311
.	O	311-312

Subjects	O	313-321
with	O	322-326
homozygous	O	327-337
CETP	B	338-342
deficiency	I	343-353
caused	O	354-360
by	O	361-363
a	O	364-365
gene	O	366-370
splicing	O	371-379
defect	O	380-386
have	O	387-391
markedly	O	392-400
elevated	O	401-409
HDL	O	410-413
;	O	413-414
however	O	415-422
,	O	422-423
heterozygotes	O	424-437
have	O	438-442
only	O	443-447
mild	O	448-452
increases	O	453-462
in	O	463-465
HDL	O	466-469
.	O	469-470

We	O	471-473
describe	O	474-482
two	O	483-486
probands	O	487-495
with	O	496-500
a	O	501-502
CETP	O	503-507
missense	O	508-516
mutation	O	517-525
(	O	526-527
442	O	527-530
D	O	531-532
G	O	534-535
)	O	535-536
.	O	536-537

Although	O	538-546
heterozygous	O	547-559
,	O	559-560
they	O	561-565
have	O	566-570
threefold	O	571-580
increases	O	581-590
in	O	591-593
HDL	O	594-597
concentration	O	598-611
and	O	612-615
markedly	O	616-624
decreased	O	625-634
plasma	O	635-641
CETP	O	642-646
mass	O	647-651
and	O	652-655
activity	O	656-664
,	O	664-665
suggesting	O	666-676
that	O	677-681
the	O	682-685
mutation	O	686-694
has	O	695-698
dominant	O	699-707
effects	O	708-715
on	O	716-718
CETP	O	719-723
and	O	724-727
HDL	O	728-731
in	O	732-734
vivo	O	735-739
.	O	739-740

Cellular	O	741-749
expression	O	750-760
of	O	761-763
mutant	O	764-770
cDNA	O	771-775
results	O	776-783
in	O	784-786
secretion	O	787-796
of	O	797-799
only	O	800-804
30	O	805-807
%	O	807-808
of	O	809-811
wild	O	812-816
type	O	817-821
CETP	O	822-826
activity	O	827-835
.	O	835-836

Moreover	O	837-845
,	O	845-846
coexpression	O	847-859
of	O	860-862
wild	O	863-867
type	O	868-872
and	O	873-876
mutant	O	877-883
cDNAs	O	884-889
leads	O	890-895
to	O	896-898
inhibition	O	899-909
of	O	910-912
wild	O	913-917
type	O	918-922
secretion	O	923-932
and	O	933-936
activity	O	937-945
.	O	945-946

The	O	947-950
dominant	O	951-959
effects	O	960-967
of	O	968-970
the	O	971-974
CETP	O	975-979
missense	O	980-988
mutation	O	989-997
during	O	998-1004
cellular	O	1005-1013
expression	O	1014-1024
probably	O	1025-1033
explains	O	1034-1042
why	O	1043-1046
the	O	1047-1050
probands	O	1051-1059
have	O	1060-1064
markedly	O	1065-1073
increased	O	1074-1083
HDL	O	1084-1087
in	O	1088-1090
the	O	1091-1094
heterozygous	O	1095-1107
state	O	1108-1113
,	O	1113-1114
and	O	1115-1118
suggests	O	1119-1127
that	O	1128-1132
the	O	1133-1136
active	O	1137-1143
molecular	O	1144-1153
species	O	1154-1161
of	O	1162-1164
CETP	O	1165-1169
may	O	1170-1173
be	O	1174-1176
multimeric	O	1177-1187
.	O	1187-1188
.	O	1187-1188

Huntington	B	0-10
disease	I	11-18
:	O	18-19
no	O	20-22
evidence	O	23-31
for	O	32-35
locus	O	36-41
heterogeneity	O	42-55
.	O	55-56

A	O	57-58
total	O	59-64
of	O	65-67
63	O	68-70
families	O	71-79
with	O	80-84
Huntington	B	85-95
disease	I	96-103
(	O	104-105
HD	B	105-107
)	O	107-108
were	O	109-113
examined	O	114-122
for	O	123-126
linkage	O	127-134
between	O	135-142
HD	B	143-145
and	O	146-149
G8	O	150-152
(	O	153-154
D4S10	O	154-159
)	O	159-160
.	O	160-161

The	O	162-165
families	O	166-174
included	O	175-183
57	O	184-186
Caucasian	O	187-196
,	O	196-197
four	O	198-202
Black	O	203-208
American	O	209-217
,	O	217-218
and	O	219-222
two	O	223-226
Japanese	O	227-235
.	O	235-236

The	O	237-240
combined	O	241-249
maximum	O	250-257
lod	O	258-261
score	O	262-267
was	O	268-271
87	O	272-274
.	O	274-275

69	O	276-278
at	O	279-281
theta	O	282-287
=	O	288-289
0	O	290-291
.	O	291-292
04	O	293-295
(	O	296-297
99	O	297-299
%	O	299-300
confidence	O	301-311
interval	O	312-320
0	O	321-322
.	O	322-323
018	O	324-327
-	O	327-328
0	O	324-325
.	O	329-330

071	O	331-334
)	O	334-335
.	O	335-336

The	O	337-340
maximum	O	341-348
frequency	O	349-358
of	O	359-361
recombination	O	362-375
was	O	376-379
0	O	380-381
.	O	381-382
03	O	383-385
in	O	386-388
males	O	389-394
and	O	395-398
0	O	399-400
.	O	400-401
05	O	402-404
in	O	405-407
females	O	408-415
.	O	415-416

Fifty	O	417-422
-	O	422-423
seven	O	423-428
families	O	429-437
gave	O	438-442
positive	O	443-451
lod	O	452-455
scores	O	456-462
;	O	462-463
five	O	464-468
small	O	469-474
families	O	475-483
gave	O	484-488
mildly	O	489-495
negative	O	496-504
lod	O	505-508
scores	O	509-515
.	O	515-516

The	O	517-520
maximum	O	521-528
likelihood	O	529-539
estimate	O	540-548
of	O	549-551
alpha	O	552-557
,	O	557-558
the	O	559-562
proportion	O	563-573
of	O	574-576
linked	O	577-583
loci	O	584-588
,	O	588-589
was	O	590-593
1	O	594-595
.	O	595-596
0	O	597-598
with	O	599-603
a	O	604-605
lower	O	606-611
99	O	612-614
%	O	614-615
confidence	O	616-626
interval	O	627-635
of	O	636-638
0	O	639-640
.	O	640-641
88	O	642-644
.	O	644-645

These	O	646-651
data	O	652-656
suggest	O	657-664
that	O	665-669
there	O	670-675
is	O	676-678
only	O	679-683
one	O	684-687
HD	B	688-690
locus	O	691-696
,	O	696-697
although	O	698-706
a	O	707-708
second	O	709-715
rare	O	716-720
locus	O	721-726
cannot	O	727-733
be	O	734-736
ruled	O	737-742
out	O	743-746
.	O	746-747

Homozygous	O	0-10
and	O	11-14
heterozygous	O	15-27
deletions	O	28-37
of	O	38-40
the	O	41-44
von	B	45-48
Willebrand	I	49-59
factor	O	60-66
gene	O	67-71
in	O	72-74
patients	O	75-83
and	O	84-87
carriers	O	88-96
of	O	97-99
severe	B	100-106
von	I	107-110
Willebrand	I	111-121
disease	I	122-129
.	O	129-130

Severe	B	131-137
von	I	138-141
Willebrand	I	142-152
disease	I	153-160
is	O	161-163
characterized	O	164-177
by	O	178-180
undetectable	O	181-193
or	O	194-196
trace	O	197-202
quantities	O	203-213
of	O	214-216
von	B	217-220
Willebrand	I	221-231
factor	O	232-238
in	O	239-241
plasma	O	242-248
and	O	249-252
tissue	O	253-259
stores	O	260-266
.	O	266-267

We	O	268-270
have	O	271-275
studied	O	276-283
the	O	284-287
genomic	O	288-295
DNA	O	296-299
of	O	300-302
10	O	303-305
affected	O	306-314
individuals	O	315-326
from	O	327-331
six	O	332-335
families	O	336-344
with	O	345-349
this	O	350-354
disorder	O	355-363
using	O	364-369
probes	O	370-376
from	O	377-381
the	O	382-385
5	O	386-387
and	O	388-391
3	O	392-393
ends	O	394-398
of	O	399-401
the	O	402-405
vWF	O	406-409
cDNA	O	410-414
and	O	415-418
with	O	419-423
a	O	424-425
probe	O	426-431
extending	O	432-441
from	O	442-446
the	O	447-450
5	O	451-452
end	O	453-456
into	O	457-461
the	O	462-465
central	O	466-473
region	O	474-480
.	O	480-481

Southern	O	482-490
blots	O	491-496
of	O	497-499
restriction	O	500-511
endonuclease	O	512-524
digests	O	525-532
and	O	533-536
gene	O	537-541
dosage	O	542-548
analysis	O	549-557
measurements	O	558-570
carried	O	571-578
out	O	579-582
with	O	583-587
quantitative	O	588-600
slot	O	601-605
blots	O	606-611
of	O	612-614
undigested	O	615-625
genomic	O	626-633
DNA	O	634-637
separated	O	638-647
these	O	648-653
patients	O	654-662
into	O	663-667
three	O	668-673
groups	O	674-680
.	O	680-681

The	O	682-685
first	O	686-691
group	O	692-697
consisted	O	698-707
of	O	708-710
a	O	711-712
family	O	713-719
with	O	720-724
complete	O	725-733
homozygous	O	734-744
deletions	O	745-754
of	O	755-757
the	O	758-761
vWF	O	762-765
gene	O	766-770
in	O	771-773
the	O	774-777
four	O	778-782
probands	O	783-791
.	O	791-792

Gene	O	793-797
dosage	O	798-804
analysis	O	805-813
was	O	814-817
consistent	O	818-828
with	O	829-833
heterozygous	O	834-846
deletions	O	847-856
in	O	857-859
both	O	860-864
of	O	865-867
the	O	868-871
asymptomatic	O	872-884
parents	O	885-892
and	O	893-896
four	O	897-901
asymptomatic	O	902-914
siblings	O	915-923
of	O	924-926
this	O	927-931
kindred	O	932-939
(	O	940-941
P	O	941-942
less	O	943-947
than	O	948-952
0	O	953-954
.	O	954-955
01	O	956-958
)	O	958-959
.	O	959-960

The	O	961-964
second	O	965-971
group	O	972-977
was	O	978-981
comprised	O	982-991
of	O	992-994
a	O	995-996
family	O	997-1003
in	O	1004-1006
which	O	1007-1012
there	O	1013-1018
was	O	1019-1022
a	O	1023-1024
complete	O	1025-1033
heterozygous	O	1034-1046
deletion	O	1047-1055
of	O	1056-1058
the	O	1059-1062
vWF	O	1063-1066
gene	O	1067-1071
in	O	1072-1074
the	O	1075-1078
proband	O	1079-1086
and	O	1087-1090
one	O	1091-1094
asymptomatic	O	1095-1107
parent	O	1108-1114
,	O	1114-1115
suggesting	O	1116-1126
that	O	1127-1131
a	O	1132-1133
different	O	1134-1143
type	O	1144-1148
of	O	1149-1151
genetic	B	1152-1159
abnormality	I	1160-1171
was	O	1172-1175
inherited	O	1176-1185
from	O	1186-1190
the	O	1191-1194
other	O	1195-1200
parent	O	1201-1207
.	O	1207-1208

Thus	O	1209-1213
,	O	1213-1214
the	O	1215-1218
patient	O	1219-1226
appeared	O	1227-1235
to	O	1236-1238
be	O	1239-1241
doubly	O	1242-1248
heterozygous	O	1249-1261
for	O	1262-1265
interacting	O	1266-1277
genetic	B	1278-1285
abnormalities	I	1286-1299
affecting	O	1300-1309
vWF	O	1310-1313
expression	O	1314-1324
.	O	1324-1325

In	O	1326-1328
the	O	1329-1332
third	O	1333-1338
group	O	1339-1344
,	O	1344-1345
no	O	1346-1348
gene	O	1349-1353
deletions	O	1354-1363
could	O	1364-1369
be	O	1370-1372
detected	O	1373-1381
.	O	1381-1382

Alloantibodies	O	1383-1397
developed	O	1398-1407
only	O	1408-1412
in	O	1413-1415
the	O	1416-1419
kindred	O	1420-1427
with	O	1428-1432
homozygous	O	1433-1443
deletions	O	1444-1453
.	O	1453-1454

These	O	1455-1460
techniques	O	1461-1471
should	O	1472-1478
prove	O	1479-1484
useful	O	1485-1491
in	O	1492-1494
identifying	O	1495-1506
carriers	O	1507-1515
of	O	1516-1518
severe	B	1519-1525
von	I	1526-1529
Willebrand	I	1530-1540
disease	I	1541-1548
and	O	1549-1552
also	O	1553-1557
in	O	1558-1560
defining	O	1561-1569
patients	O	1570-1578
predictably	O	1579-1590
at	O	1591-1593
risk	O	1594-1598
of	O	1599-1601
developing	O	1602-1612
alloantibodies	O	1613-1627
to	O	1628-1630
vWF	O	1631-1634
.	O	1634-1635

Spectrum	O	0-8
of	O	9-11
germline	O	12-20
mutations	O	21-30
in	O	31-33
the	O	34-37
RB1	O	38-41
gene	O	42-46
:	O	46-47
a	O	48-49
study	O	50-55
of	O	56-58
232	O	59-62
patients	O	63-71
with	O	72-76
hereditary	B	77-87
and	I	88-91
non	I	92-95
hereditary	I	96-106
retinoblastoma	I	107-121
.	O	121-122

Germline	O	123-131
mutations	O	132-141
in	O	142-144
the	O	145-148
RB1	O	149-152
gene	O	153-157
confer	O	158-164
hereditary	O	165-175
predisposition	O	176-190
to	O	191-193
retinoblastoma	B	194-208
.	O	208-209

We	O	210-212
have	O	213-217
performed	O	218-227
a	O	228-229
mutation	O	230-238
survey	O	239-245
of	O	246-248
the	O	249-252
RB1	O	253-256
gene	O	257-261
in	O	262-264
232	O	265-268
patients	O	269-277
with	O	278-282
hereditary	B	283-293
or	I	294-296
non	I	297-300
hereditary	I	301-311
retinoblastoma	I	312-326
.	O	326-327

We	O	328-330
systematically	O	331-345
explored	O	346-354
all	O	355-358
27	O	359-361
exons	O	362-367
and	O	368-371
flanking	O	372-380
sequences	O	381-390
as	O	391-393
well	O	394-398
as	O	399-401
the	O	402-405
promotor	O	406-414
.	O	414-415

All	O	416-419
types	O	420-425
of	O	426-428
point	O	429-434
mutations	O	435-444
are	O	445-448
represented	O	449-460
and	O	461-464
are	O	465-468
found	O	469-474
unequally	O	475-484
distributed	O	485-496
along	O	497-502
the	O	503-506
RB1	O	507-510
gene	O	511-515
sequence	O	516-524
.	O	524-525

In	O	526-528
the	O	529-532
population	O	533-543
we	O	544-546
studied	O	547-554
,	O	554-555
exons	O	556-561
3	O	562-563
,	O	563-564
8	O	565-566
,	O	566-567
18	O	568-570
and	O	571-574
19	O	575-577
are	O	578-581
preferentially	O	582-596
altered	O	597-604
.	O	604-605

The	O	606-609
range	O	610-615
of	O	616-618
frequency	O	619-628
of	O	629-631
detection	O	632-641
of	O	642-644
germline	O	645-653
mutations	O	654-663
is	O	664-666
about	O	667-672
20	O	673-675
%	O	675-676
,	O	676-677
indicating	O	678-688
that	O	689-693
other	O	694-699
mechanisms	O	700-710
of	O	711-713
inactivation	O	714-726
of	O	727-729
RB1	O	730-733
should	O	734-740
be	O	741-743
involved	O	744-752
.	O	752-753

The	O	754-757
spectrum	O	758-766
of	O	767-769
mutations	O	770-779
presented	O	780-789
here	O	790-794
should	O	795-801
help	O	802-806
to	O	807-809
improve	O	810-817
the	O	818-821
clinical	O	822-830
management	O	831-841
of	O	842-844
retinoblastoma	B	845-859
and	O	860-863
to	O	864-866
understand	O	867-877
the	O	878-881
molecular	O	882-891
mechanisms	O	892-902
leading	O	903-910
to	O	911-913
tumorigenesis	O	914-927
.	O	927-928
.	O	927-928

Pelizaeus	B	0-9
-	I	9-10
Merzbacher	I	10-20
disease	I	21-28
:	O	28-29
an	O	30-32
X	B	33-34
-	I	34-35
linked	I	35-41
neurologic	I	42-52
disorder	I	53-61
of	I	62-64
myelin	I	65-71
metabolism	I	72-82
with	O	83-87
a	O	88-89
novel	O	90-95
mutation	O	96-104
in	O	105-107
the	O	108-111
gene	O	112-116
encoding	O	117-125
proteolipid	O	126-137
protein	O	138-145
.	O	145-146

The	O	147-150
nosology	O	151-159
of	O	160-162
the	O	163-166
inborn	B	167-173
errors	I	174-180
of	I	181-183
myelin	I	184-190
metabolism	I	191-201
has	O	202-205
been	O	206-210
stymied	O	211-218
by	O	219-221
the	O	222-225
lack	O	226-230
of	O	231-233
molecular	O	234-243
genetic	O	244-251
analysis	O	252-260
.	O	260-261

Historically	O	262-274
,	O	274-275
Pelizaeus	B	276-285
-	I	285-286
Merzbacher	I	286-296
disease	I	297-304
has	O	305-308
encompassed	O	309-320
a	O	321-322
host	O	323-327
of	O	328-330
neurologic	B	331-341
disorders	I	342-351
that	O	352-356
present	O	357-364
with	O	365-369
a	O	370-371
deficit	B	372-379
of	I	380-382
myelin	I	383-389
,	O	389-390
the	O	391-394
membrane	O	395-403
elaborated	O	404-414
by	O	415-417
glial	O	418-423
cells	O	424-429
that	O	430-434
encircles	O	435-444
and	O	445-448
successively	O	449-461
enwraps	O	462-469
axons	O	470-475
.	O	475-476

We	O	477-479
describe	O	480-488
here	O	489-493
a	O	494-495
Pelizaeus	B	496-505
-	I	505-506
Merzbacher	I	506-516
pedigree	O	517-525
of	O	526-528
the	O	529-532
classical	O	533-542
type	O	543-547
,	O	547-548
with	O	549-553
X	O	554-555
-	O	555-556
linked	O	556-562
inheritance	O	563-574
,	O	574-575
a	O	576-577
typical	O	578-585
clinical	O	586-594
progression	O	595-606
,	O	606-607
and	O	608-611
a	O	612-613
pathologic	O	614-624
loss	O	625-629
of	O	630-632
myelinating	O	633-644
cells	O	645-650
and	O	651-654
myelin	O	655-661
in	O	662-664
the	O	665-668
central	O	669-676
nervous	O	677-684
system	O	685-691
.	O	691-692

To	O	693-695
discriminate	O	696-708
variants	O	709-717
of	O	718-720
Pelizaeus	B	721-730
-	I	730-731
Merzbacher	I	731-741
disease	I	742-749
,	O	749-750
a	O	751-752
set	O	753-756
of	O	757-759
oligonucleotide	O	760-775
primers	O	776-783
was	O	784-787
constructed	O	788-799
to	O	800-802
polymerase	O	803-813
-	O	813-814
chain	O	814-819
-	O	813-814
reaction	O	820-828
(	O	829-830
PCR	O	830-833
)	O	833-834
amplify	O	835-842
and	O	843-846
sequence	O	847-855
the	O	856-859
gene	O	860-864
encoding	O	865-873
proteolipid	O	874-885
protein	O	886-893
(	O	894-895
PLP	O	895-898
)	O	898-899
,	O	899-900
a	O	901-902
structural	O	903-913
protein	O	914-921
that	O	922-926
comprises	O	927-936
half	O	937-941
of	O	942-944
the	O	945-948
protein	O	949-956
of	O	957-959
the	O	960-963
myelin	O	964-970
sheath	O	971-977
.	O	977-978

The	O	979-982
PLP	O	983-986
gene	O	987-991
in	O	992-994
one	O	995-998
of	O	999-1001
two	O	1002-1005
affected	O	1006-1014
males	O	1015-1020
and	O	1021-1024
the	O	1025-1028
carrier	O	1029-1036
mother	O	1037-1043
of	O	1044-1046
this	O	1047-1051
family	O	1052-1058
exhibited	O	1059-1068
a	O	1069-1070
single	O	1071-1077
base	O	1078-1082
difference	O	1083-1093
in	O	1094-1096
the	O	1097-1100
more	O	1101-1105
than	O	1106-1110
2	O	1111-1112
kb	O	1113-1115
of	O	1116-1118
the	O	1119-1122
PLP	O	1123-1126
gene	O	1127-1131
sequenced	O	1132-1141
,	O	1141-1142
a	O	1143-1144
C	O	1145-1146
-	O	1146-1147
-	O	1146-1147
-	O	1146-1147
-	O	1146-1147
T	O	1150-1151
transition	O	1152-1162
that	O	1163-1167
would	O	1168-1173
create	O	1174-1180
a	O	1181-1182
serine	O	1183-1189
substitution	O	1190-1202
for	O	1203-1206
proline	O	1207-1214
at	O	1215-1217
the	O	1218-1221
carboxy	O	1222-1229
end	O	1230-1233
of	O	1234-1236
the	O	1237-1240
protein	O	1241-1248
.	O	1248-1249

Our	O	1250-1253
results	O	1254-1261
delineate	O	1262-1271
the	O	1272-1275
clinical	O	1276-1284
features	O	1285-1293
of	O	1294-1296
Pelizaeus	B	1297-1306
-	I	1306-1307
Merzbacher	I	1307-1317
disease	I	1318-1325
,	O	1325-1326
define	O	1327-1333
the	O	1334-1337
possible	O	1338-1346
molecular	O	1347-1356
pathology	O	1357-1366
of	O	1367-1369
this	O	1370-1374
dysmyelinating	B	1375-1389
disorder	I	1390-1398
,	O	1398-1399
and	O	1400-1403
address	O	1404-1411
the	O	1412-1415
molecular	O	1416-1425
classification	O	1426-1440
of	O	1441-1443
inborn	B	1444-1450
errors	I	1451-1457
of	I	1458-1460
myelin	I	1461-1467
metabolism	I	1468-1478
.	O	1478-1479

Patients	O	1480-1488
with	O	1489-1493
the	O	1494-1497
classical	O	1498-1507
form	O	1508-1512
(	O	1513-1514
type	O	1514-1518
I	O	1519-1520
)	O	1520-1521
and	O	1522-1525
the	O	1526-1529
more	O	1530-1534
severely	O	1535-1543
affected	O	1544-1552
,	O	1552-1553
connatal	O	1554-1562
variant	O	1563-1570
of	O	1571-1573
Pelizaeus	B	1574-1583
-	I	1583-1584
Merzbacher	I	1584-1594
disease	I	1595-1602
(	I	1603-1604
type	I	1604-1608
II	I	1609-1611
)	I	1611-1612
would	O	1613-1618
be	O	1619-1621
predicted	O	1622-1631
to	O	1632-1634
display	O	1635-1642
mutation	O	1643-1651
at	O	1652-1654
the	O	1655-1658
PLP	O	1659-1662
locus	O	1663-1668
.	O	1668-1669

The	O	1670-1673
other	O	1674-1679
variants	O	1680-1688
(	O	1689-1690
types	O	1690-1695
III	O	1696-1699
-	O	1699-1700
VI	O	1700-1702
)	O	1702-1703
,	O	1703-1704
which	O	1705-1710
have	O	1711-1715
sometimes	O	1716-1725
been	O	1726-1730
categorized	O	1731-1742
as	O	1743-1745
Pelizaeus	B	1746-1755
-	I	1755-1756
Merzbacher	I	1756-1766
disease	I	1767-1774
,	O	1774-1775
may	O	1776-1779
represent	O	1780-1789
mutations	O	1790-1799
in	O	1800-1802
genes	O	1803-1808
encoding	O	1809-1817
other	O	1818-1823
structural	O	1824-1834
myelin	O	1835-1841
proteins	O	1842-1850
or	O	1851-1853
proteins	O	1854-1862
critical	O	1863-1871
to	O	1872-1874
myelination	O	1875-1886
.	O	1886-1887
.	O	1886-1887

CAG	O	0-3
expansions	O	4-14
in	O	15-17
a	O	18-19
novel	O	20-25
gene	O	26-30
for	O	31-34
Machado	B	35-42
-	I	42-43
Joseph	I	43-49
disease	I	50-57
at	O	58-60
chromosome	O	61-71
14q32	O	72-77
.	O	77-78
1	O	72-73
.	O	77-78

We	O	81-83
have	O	84-88
identified	O	89-99
a	O	100-101
novel	O	102-107
gene	O	108-112
containing	O	113-123
CAG	O	124-127
repeats	O	128-135
and	O	136-139
mapped	O	140-146
it	O	147-149
to	O	150-152
chromosome	O	153-163
14q32	O	164-169
.	O	169-170

1	O	171-172
,	O	172-173
the	O	174-177
genetic	O	178-185
locus	O	186-191
for	O	192-195
Machado	B	196-203
-	I	203-204
Joseph	I	204-210
disease	I	211-218
(	O	219-220
MJD	B	220-223
)	O	223-224
.	O	224-225

In	O	226-228
normal	O	229-235
individuals	O	236-247
the	O	248-251
gene	O	252-256
contains	O	257-265
between	O	266-273
13	O	274-276
and	O	277-280
36	O	281-283
CAG	O	284-287
repeats	O	288-295
,	O	295-296
whereas	O	297-304
most	O	305-309
of	O	310-312
the	O	313-316
clinically	O	317-327
diagnosed	O	328-337
patients	O	338-346
and	O	347-350
all	O	351-354
of	O	355-357
the	O	358-361
affected	O	362-370
members	O	371-378
of	O	379-381
a	O	382-383
family	O	384-390
with	O	391-395
the	O	396-399
clinical	O	400-408
and	O	409-412
pathological	O	413-425
diagnosis	O	426-435
of	O	436-438
MJD	B	439-442
show	O	443-447
expansion	O	448-457
of	O	458-460
the	O	461-464
repeat	O	465-471
-	O	471-472
number	O	472-478
(	O	479-480
from	O	480-484
68	O	485-487
-	O	487-488
79	O	488-490
)	O	490-491
.	O	491-492

Southern	O	493-501
blot	O	502-506
analyses	O	507-515
and	O	516-519
genomic	O	520-527
cloning	O	528-535
demonstrates	O	536-548
the	O	549-552
existence	O	553-562
of	O	563-565
related	O	566-573
genes	O	574-579
.	O	579-580

These	O	581-586
results	O	587-594
raise	O	595-600
the	O	601-604
possibility	O	605-616
that	O	617-621
similar	O	622-629
abnormalities	O	630-643
in	O	644-646
related	O	647-654
genes	O	655-660
may	O	661-664
give	O	665-669
rise	O	670-674
to	O	675-677
diseases	O	678-686
similar	O	687-694
to	O	695-697
MJD	B	698-701
.	O	701-702

Conservation	O	0-12
of	O	13-15
the	O	16-19
Duchenne	B	20-28
muscular	I	29-37
dystrophy	I	38-47
gene	O	48-52
in	O	53-55
mice	O	56-60
and	O	61-64
humans	O	65-71
.	O	71-72

A	O	73-74
portion	O	75-82
of	O	83-85
the	O	86-89
Duchenne	B	90-98
muscular	I	99-107
dystrophy	I	108-117
(	O	118-119
DMD	B	119-122
)	O	122-123
gene	O	124-128
transcript	O	129-139
from	O	140-144
human	O	145-150
fetal	O	151-156
skeletal	O	157-165
muscle	O	166-172
and	O	173-176
mouse	O	177-182
adult	O	183-188
heart	O	189-194
was	O	195-198
sequenced	O	199-208
,	O	208-209
representing	O	210-222
approximately	O	223-236
25	O	237-239
percent	O	240-247
of	O	248-250
the	O	251-254
total	O	255-260
,	O	260-261
14	O	262-264
-	O	264-265
kb	O	265-267
DMD	B	268-271
transcript	O	272-282
.	O	282-283

The	O	284-287
nucleic	O	288-295
acid	O	296-300
and	O	301-304
predicted	O	305-314
amino	O	315-320
acid	O	321-325
sequences	O	326-335
from	O	336-340
the	O	341-344
two	O	345-348
species	O	349-356
are	O	357-360
nearly	O	361-367
90	O	368-370
percent	O	371-378
homologous	O	379-389
.	O	389-390

The	O	391-394
amino	O	395-400
acid	O	401-405
sequence	O	406-414
that	O	415-419
is	O	420-422
predicted	O	423-432
from	O	433-437
this	O	438-442
portion	O	443-450
of	O	451-453
the	O	454-457
DMD	B	458-461
gene	O	462-466
indicates	O	467-476
that	O	477-481
the	O	482-485
protein	O	486-493
product	O	494-501
might	O	502-507
serve	O	508-513
a	O	514-515
structural	O	516-526
role	O	527-531
in	O	532-534
muscle	O	535-541
,	O	541-542
but	O	543-546
the	O	547-550
abundance	O	551-560
and	O	561-564
tissue	O	565-571
distribution	O	572-584
of	O	585-587
the	O	588-591
messenger	O	592-601
RNA	O	602-605
suggests	O	606-614
that	O	615-619
the	O	620-623
DMD	B	624-627
protein	O	628-635
is	O	636-638
not	O	639-642
nebulin	O	643-650
.	O	650-651
.	O	650-651

Deficiency	B	0-10
of	I	11-13
the	I	14-17
murine	I	18-24
fifth	I	25-30
complement	I	31-41
component	I	42-51
(	I	52-53
C5	I	53-55
)	I	55-56
.	O	56-57

A	O	58-59
2	O	60-61
-	O	61-62
base	O	62-66
pair	O	67-71
gene	O	72-76
deletion	O	77-85
in	O	86-88
a	O	89-90
5	O	91-92
'	O	92-93
-	O	93-94
exon	O	94-98
.	O	98-99

To	O	100-102
ascertain	O	103-112
the	O	113-116
molecular	O	117-126
mechanism	O	127-136
that	O	137-141
causes	O	142-148
murine	O	149-155
C5	B	156-158
deficiency	I	159-169
,	O	169-170
genomic	O	171-178
and	O	179-182
cDNA	O	183-187
libraries	O	188-197
were	O	198-202
constructed	O	203-214
from	O	215-219
mouse	O	220-225
liver	O	226-231
DNA	O	232-235
and	O	236-239
mRNA	O	240-244
employing	O	245-254
the	O	255-258
congenic	O	259-267
strains	O	268-275
B10	O	276-279
.	O	279-280

D2	O	281-283
/	O	283-284
nSnJ	O	284-288
and	O	289-292
B10	O	293-296
.	O	296-297

D2	O	298-300
/	O	300-301
oSnJ	O	301-305
that	O	306-310
are	O	311-314
sufficient	O	315-325
and	O	326-329
deficient	B	330-339
for	I	340-343
C5	I	344-346
,	O	346-347
respectively	O	348-360
.	O	360-361

Genomic	O	362-369
fragments	O	370-379
were	O	380-384
isolated	O	385-393
which	O	394-399
correspond	O	400-410
to	O	411-413
PvuII	O	414-419
and	O	420-423
HindIII	O	424-431
restriction	O	432-443
fragment	O	444-452
length	O	453-459
polymorphisms	O	460-473
associated	O	474-484
with	O	485-489
C5	B	490-492
deficiency	I	493-503
.	O	503-504

Sequence	O	505-513
analyses	O	514-522
demonstrated	O	523-535
that	O	536-540
each	O	541-545
of	O	546-548
these	O	549-554
polymorphisms	O	555-568
resulted	O	569-577
from	O	578-582
single	O	583-589
base	O	590-594
pair	O	595-599
substitutions	O	600-613
and	O	614-617
that	O	618-622
neither	O	623-630
substitution	O	631-643
would	O	644-649
probably	O	650-658
cause	O	659-664
or	O	665-667
contribute	O	668-678
to	O	679-681
the	O	682-685
C5	B	686-688
deficiency	I	689-699
.	O	699-700

Sequence	O	701-709
analyses	O	710-718
of	O	719-721
C5	O	722-724
sufficient	O	725-735
and	O	736-739
deficient	O	740-749
cDNAs	O	750-755
revealed	O	756-764
a	O	765-766
2	O	767-768
base	O	769-773
-	O	773-774
pair	O	774-778
deletion	O	779-787
in	O	788-790
the	O	791-794
deficient	O	795-804
cDNAs	O	805-810
.	O	810-811

The	O	812-815
"	O	816-817
TA	O	818-820
"	O	821-822
deletion	O	823-831
was	O	832-835
located	O	836-843
near	O	844-848
the	O	849-852
5	O	853-854
end	O	855-858
of	O	859-861
the	O	862-865
cDNA	O	866-870
.	O	870-871

This	O	872-876
deletion	O	877-885
shifts	O	886-892
the	O	893-896
reading	O	897-904
frame	O	905-910
of	O	911-913
the	O	914-917
C5	O	918-920
mRNA	O	921-925
so	O	926-928
that	O	929-933
the	O	934-937
termination	O	938-949
codon	O	950-955
UGA	O	956-959
is	O	960-962
present	O	963-970
4	O	971-972
base	O	973-977
pairs	O	978-983
downstream	O	984-994
from	O	995-999
the	O	1000-1003
deletion	O	1004-1012
.	O	1012-1013

Genomic	O	1014-1021
DNA	O	1022-1025
was	O	1026-1029
amplified	O	1030-1039
and	O	1040-1043
sequenced	O	1044-1053
corresponding	O	1054-1067
to	O	1068-1070
the	O	1071-1074
area	O	1075-1079
surrounding	O	1080-1091
the	O	1092-1095
2	O	1096-1097
-	O	1097-1098
base	O	1098-1102
pair	O	1103-1107
deletion	O	1108-1116
.	O	1116-1117

Six	O	1118-1121
C5	B	1122-1124
-	I	1124-1125
deficient	I	1125-1134
strains	O	1135-1142
,	O	1142-1143
A	O	1144-1145
/	O	1145-1146
HeJ	O	1146-1149
,	O	1149-1150
AKR	O	1151-1154
/	O	1154-1155
J	O	1155-1156
,	O	1156-1157
DBA	O	1158-1161
/	O	1161-1162
2J	O	1162-1164
,	O	1164-1165
NZB	O	1166-1169
/	O	1169-1170
B1NJ	O	1170-1174
,	O	1174-1175
SWR	O	1176-1179
/	O	1179-1180
J	O	1180-1181
,	O	1181-1182
and	O	1183-1186
B10	O	1187-1190
.	O	1190-1191

D2	O	1192-1194
/	O	1194-1195
oSnJ	O	1195-1199
,	O	1199-1200
and	O	1201-1204
four	O	1205-1209
C5	O	1210-1212
-	O	1212-1213
sufficient	O	1213-1223
strains	O	1224-1231
,	O	1231-1232
Balb	O	1233-1237
/	O	1237-1238
CJ	O	1238-1240
,	O	1240-1241
C57Bl	O	1242-1247
/	O	1247-1248
6J	O	1248-1250
,	O	1250-1251
DBA	O	1252-1255
/	O	1255-1256
1J	O	1256-1258
,	O	1258-1259
and	O	1260-1263
B10	O	1264-1267
.	O	1267-1268

D2	O	1269-1271
/	O	1271-1272
nSnJ	O	1272-1276
,	O	1276-1277
were	O	1278-1282
analyzed	O	1283-1291
.	O	1291-1292

The	O	1293-1296
sequencing	O	1297-1307
data	O	1308-1312
revealed	O	1313-1321
that	O	1322-1326
the	O	1327-1330
2	O	1331-1332
base	O	1333-1337
pairs	O	1338-1343
were	O	1344-1348
deleted	O	1349-1356
from	O	1357-1361
the	O	1362-1365
C5	O	1366-1368
gene	O	1369-1373
of	O	1374-1376
each	O	1377-1381
deficient	O	1382-1391
mouse	O	1392-1397
tested	O	1398-1404
but	O	1405-1408
not	O	1409-1412
from	O	1413-1417
the	O	1418-1421
C5	O	1422-1424
gene	O	1425-1429
of	O	1430-1432
any	O	1433-1436
sufficient	O	1437-1447
mouse	O	1448-1453
.	O	1453-1454

These	O	1455-1460
data	O	1461-1465
demonstrate	O	1466-1477
that	O	1478-1482
1	O	1484-1485
)	O	1485-1486
there	O	1487-1492
is	O	1493-1495
an	O	1496-1498
identical	O	1499-1508
2	O	1509-1510
-	O	1510-1511
base	O	1511-1515
pair	O	1516-1520
deletion	O	1521-1529
in	O	1530-1532
an	O	1533-1535
exon	O	1536-1540
of	O	1541-1543
the	O	1544-1547
C5	O	1548-1550
gene	O	1551-1555
in	O	1556-1558
several	O	1559-1566
different	O	1567-1576
C5	B	1577-1579
-	I	1579-1580
deficient	I	1580-1589
mouse	O	1590-1595
strains	O	1596-1603
;	O	1603-1604
2	O	1605-1606
)	O	1606-1607
the	O	1608-1611
mRNA	O	1612-1616
transcribed	O	1617-1628
from	O	1629-1633
the	O	1634-1637
C5D	O	1638-1641
gene	O	1642-1646
retains	O	1647-1654
this	O	1655-1659
deletion	O	1660-1668
;	O	1668-1669
and	O	1670-1673
3	O	1674-1675
)	O	1675-1676
this	O	1677-1681
mutation	O	1682-1690
should	O	1691-1697
result	O	1698-1704
in	O	1705-1707
C5	B	1708-1710
protein	I	1711-1718
deficiency	I	1719-1729
.	O	1729-1730

Recurrent	O	0-9
meningitis	B	10-20
in	O	21-23
a	O	24-25
patient	O	26-33
with	O	34-38
congenital	B	39-49
deficiency	I	50-60
of	I	61-63
the	I	64-67
C9	I	68-70
component	I	71-80
of	I	81-83
complement	I	84-94
.	O	94-95

First	O	96-101
case	O	102-106
of	O	107-109
C9	B	110-112
deficiency	I	113-123
in	O	124-126
Europe	O	127-133
.	O	133-134

We	O	135-137
describe	O	138-146
the	O	147-150
first	O	151-156
cases	O	157-162
,	O	162-163
to	O	164-166
our	O	167-170
knowledge	O	171-180
,	O	180-181
of	O	182-184
C9	B	185-187
deficiency	I	188-198
in	O	199-201
Europe	O	202-208
that	O	209-213
were	O	214-218
detected	O	219-227
in	O	228-230
a	O	231-232
Swiss	O	233-238
family	O	239-245
,	O	245-246
of	O	247-249
which	O	250-255
two	O	256-259
members	O	260-267
-	O	267-268
-	O	267-268
one	O	269-272
with	O	273-277
a	O	278-279
complete	O	280-288
deficiency	O	289-299
and	O	300-303
the	O	304-307
other	O	308-313
with	O	314-318
approximately	O	319-332
half	O	333-337
-	O	337-338
normal	O	338-344
C9	O	345-347
levels	O	348-354
-	O	354-355
-	O	354-355
experienced	O	356-367
bacterial	B	368-377
meningitis	I	378-388
.	O	388-389

The	O	390-393
index	O	394-399
patient	O	400-407
,	O	407-408
a	O	409-410
56	O	411-413
-	O	413-414
year	O	414-418
-	O	413-414
old	O	419-422
white	O	423-428
man	O	429-432
with	O	433-437
a	O	438-439
history	O	440-447
of	O	448-450
purulent	B	451-459
meningitis	I	460-470
at	O	471-473
the	O	474-477
age	O	478-481
of	O	482-484
23	O	485-487
years	O	488-493
,	O	493-494
presented	O	495-504
with	O	505-509
an	O	510-512
acute	B	513-518
meningococcal	I	519-532
meningitis	I	533-543
.	O	543-544

No	O	545-547
impairment	B	548-558
of	I	559-561
cellular	I	562-570
immunity	I	571-579
or	O	580-582
immunoglobulin	B	583-597
deficiency	I	598-608
could	O	609-614
be	O	615-617
found	O	618-623
.	O	623-624

Complement	O	625-635
assays	O	636-642
showed	O	643-649
a	O	650-651
complete	B	652-660
deficiency	I	661-671
of	I	672-674
the	I	675-678
C9	I	679-681
component	I	682-691
,	O	691-692
while	O	693-698
the	O	699-702
other	O	703-708
individual	O	709-719
component	O	720-729
levels	O	730-736
were	O	737-741
normal	O	742-748
and	O	749-752
the	O	753-756
hemolytic	O	757-766
activity	O	767-775
(	O	776-777
measured	O	777-785
using	O	786-791
the	O	792-795
CH50	O	796-800
assay	O	801-806
)	O	806-807
was	O	808-811
only	O	812-816
slightly	O	817-825
reduced	O	826-833
.	O	833-834

A	O	835-836
family	O	837-843
study	O	844-849
revealed	O	850-858
complete	B	859-867
C9	I	868-870
deficiency	I	871-881
in	O	882-884
the	O	885-888
patients	O	889-897
healthy	O	898-905
brother	O	906-913
and	O	914-917
half	O	918-922
-	O	922-923
normal	O	923-929
C9	O	930-932
concentrations	O	933-947
in	O	948-950
his	O	951-954
sister	O	955-961
,	O	961-962
his	O	963-966
son	O	967-970
(	O	971-972
who	O	972-975
also	O	976-980
had	O	981-984
experienced	O	985-996
an	O	997-999
episode	O	1000-1007
of	O	1008-1010
bacterial	B	1011-1020
meningitis	I	1021-1031
)	O	1031-1032
,	O	1032-1033
and	O	1034-1037
his	O	1038-1041
niece	O	1042-1047
,	O	1047-1048
consistent	O	1049-1059
with	O	1060-1064
an	O	1065-1067
inherited	O	1068-1077
C9	B	1078-1080
deficiency	I	1081-1091
.	O	1091-1092

This	O	1093-1097
first	O	1098-1103
case	O	1104-1108
of	O	1109-1111
recurrent	B	1112-1121
meningitis	I	1122-1132
in	O	1133-1135
a	O	1136-1137
white	O	1138-1143
patient	O	1144-1151
with	O	1152-1156
complete	B	1157-1165
C9	I	1166-1168
deficiency	I	1169-1179
suggests	O	1180-1188
that	O	1189-1193
this	O	1194-1198
complement	B	1199-1209
defect	I	1210-1216
may	O	1217-1220
also	O	1221-1225
be	O	1226-1228
a	O	1229-1230
risk	O	1231-1235
factor	O	1236-1242
for	O	1243-1246
bacterial	B	1247-1256
,	I	1256-1257
especially	I	1258-1268
neisserial	I	1269-1279
,	I	1279-1280
infections	I	1281-1291
.	O	1291-1292
.	O	1291-1292

Bone	O	0-4
marrow	O	5-11
transplant	O	12-22
in	O	23-25
adrenoleukodystrophy	B	26-46
.	O	46-47

An	O	48-50
allogeneic	O	51-61
bone	O	62-66
marrow	O	67-73
transplant	O	74-84
(	O	85-86
BMT	O	86-89
)	O	89-90
from	O	91-95
a	O	96-97
normal	O	98-104
HLA	O	105-108
identical	O	109-118
sibling	O	119-126
donor	O	127-132
was	O	133-136
performed	O	137-146
in	O	147-149
a	O	150-151
13	O	152-154
-	O	154-155
year	O	155-159
-	O	154-155
old	O	160-163
boy	O	164-167
with	O	168-172
rapidly	O	173-180
progressive	O	181-192
adrenoleukodystrophy	B	193-213
(	O	214-215
ALD	B	215-218
)	O	218-219
.	O	219-220

Engraftment	O	221-232
and	O	233-236
complete	O	237-245
hematologic	O	246-257
recovery	O	258-266
occurred	O	267-275
within	O	276-282
4	O	283-284
weeks	O	285-290
,	O	290-291
but	O	292-295
neurologic	B	296-306
deterioration	I	307-320
continued	O	321-330
.	O	330-331

The	O	332-335
patient	O	336-343
died	O	344-348
of	O	349-351
an	O	352-354
adenovirus	B	355-365
infection	I	366-375
141	O	376-379
days	O	380-384
after	O	385-390
BMT	O	391-394
.	O	394-395

ALD	B	396-399
is	O	400-402
characterized	O	403-416
by	O	417-419
abnormally	O	420-430
high	O	431-435
plasma	O	436-442
levels	O	443-449
of	O	450-452
very	O	453-457
long	O	458-462
chain	O	463-468
fatty	O	469-474
acids	O	475-480
(	O	481-482
VLCFA	O	482-487
)	O	487-488
as	O	489-491
a	O	492-493
result	O	494-500
of	O	501-503
impaired	O	504-512
capacity	O	513-521
to	O	522-524
degrade	O	525-532
them	O	533-537
.	O	537-538

Ten	O	539-542
days	O	543-547
after	O	548-553
BMT	O	554-557
,	O	557-558
the	O	559-562
white	O	563-568
blood	O	569-574
cell	O	575-579
VLCFA	O	580-585
levels	O	586-592
and	O	593-596
enzyme	O	597-603
activity	O	604-612
became	O	613-619
normal	O	620-626
;	O	626-627
after	O	628-633
3	O	634-635
months	O	636-642
,	O	642-643
there	O	644-649
was	O	650-653
progressive	O	654-665
reduction	O	666-675
of	O	676-678
plasma	O	679-685
VLCFA	O	686-691
to	O	692-694
levels	O	695-701
only	O	702-706
slightly	O	707-715
above	O	716-721
normal	O	722-728
.	O	728-729
.	O	728-729

Increased	O	0-9
incidence	O	10-19
of	O	20-22
cataracts	B	23-32
in	O	33-35
male	O	36-40
subjects	O	41-49
deficient	B	50-59
in	I	60-62
glucose	I	63-70
-	I	70-71
6	I	71-72
-	I	70-71
phosphate	I	73-82
dehydrogenase	I	83-96
.	O	96-97

Glucose	B	98-105
-	I	105-106
6	I	106-107
-	I	105-106
phosphate	I	108-117
dehydrogenase	I	118-131
(	I	132-133
G6PD	I	133-137
)	I	137-138
deficiency	I	139-149
in	O	150-152
RBCs	O	153-157
was	O	158-161
found	O	162-167
significantly	O	168-181
more	O	182-186
frequently	O	187-197
in	O	198-200
210	O	201-204
male	O	205-209
cataractous	B	210-221
patients	O	222-230
than	O	231-235
in	O	236-238
672	O	239-242
control	O	243-250
subjects	O	251-259
of	O	260-262
Sardinian	O	263-272
origin	O	273-279
.	O	279-280

The	O	281-284
frequency	O	285-294
of	O	295-297
the	O	298-301
deficiency	O	302-312
was	O	313-316
increasingly	O	317-329
higher	O	330-336
in	O	337-339
presenile	O	340-349
cataracts	B	350-359
.	O	359-360

In	O	361-363
the	O	364-367
G6PD	B	368-372
-	I	372-373
deficient	I	373-382
group	O	383-388
,	O	388-389
the	O	390-393
incidence	O	394-403
of	O	404-406
cortical	B	407-415
and	I	416-419
total	I	420-425
cataracts	I	426-435
was	O	436-439
also	O	440-444
increased	O	445-454
.	O	454-455

It	O	456-458
is	O	459-461
suggested	O	462-471
that	O	472-476
decrease	O	477-485
of	O	486-488
the	O	489-492
G6PD	O	493-497
activity	O	498-506
in	O	507-509
the	O	510-513
lens	O	514-518
,	O	518-519
which	O	520-525
accompanies	O	526-537
its	O	538-541
deficiency	O	542-552
in	O	553-555
the	O	556-559
erythrocyte	O	560-571
,	O	571-572
might	O	573-578
play	O	579-583
a	O	584-585
role	O	586-590
in	O	591-593
the	O	594-597
cataracto	O	598-607
-	O	607-608
genesis	O	608-615
of	O	616-618
these	O	619-624
patients	O	625-633
.	O	633-634

Moreover	O	635-643
,	O	643-644
G6PD	B	645-649
deficiency	I	650-660
should	O	661-667
be	O	668-670
added	O	671-676
to	O	677-679
other	O	680-685
conditions	O	686-696
,	O	696-697
such	O	698-702
as	O	703-705
the	O	706-709
galactosemic	B	710-722
states	O	723-729
and	O	730-733
riboflavin	B	734-744
deficiency	I	745-755
,	O	755-756
where	O	757-762
cataracts	B	763-772
represent	O	773-782
a	O	783-784
sensitive	O	785-794
indicator	O	795-804
of	O	805-807
metabolic	B	808-817
abnormalities	I	818-831
of	O	832-834
the	O	835-838
RBC	O	839-842
.	O	842-843
.	O	842-843

Von	B	0-3
Hippel	I	4-10
-	I	10-11
Lindau	I	11-17
disease	I	18-25
maps	O	26-30
to	O	31-33
the	O	34-37
region	O	38-44
of	O	45-47
chromosome	O	48-58
3	O	59-60
associated	O	61-71
with	O	72-76
renal	B	77-82
cell	I	83-87
carcinoma	I	88-97
.	O	97-98

Von	B	99-102
Hippel	I	103-109
-	I	109-110
Lindau	I	110-116
disease	I	117-124
(	O	125-126
VHL	B	126-129
)	O	129-130
is	O	131-133
an	O	134-136
autosomal	B	137-146
dominant	I	147-155
disorder	I	156-164
with	O	165-169
inherited	O	170-179
susceptibility	O	180-194
to	O	195-197
various	O	198-205
forms	O	206-211
of	O	212-214
cancer	B	215-221
,	O	221-222
including	O	223-232
hemangioblastomas	B	233-250
of	O	251-253
the	O	254-257
central	O	258-265
nervous	O	266-273
system	O	274-280
,	O	280-281
phaeochromocytomas	B	282-300
,	O	300-301
pancreatic	B	302-312
malignancies	I	313-325
,	O	325-326
and	O	327-330
renal	B	331-336
cell	I	337-341
carcinomas	I	342-352
.	O	352-353

Renal	B	354-359
cell	I	360-364
carcinomas	I	365-375
constitute	O	376-386
a	O	387-388
particularly	O	389-401
frequent	O	402-410
cause	O	411-416
of	O	417-419
death	O	420-425
in	O	426-428
this	O	429-433
disorder	O	434-442
,	O	442-443
occurring	O	444-453
as	O	454-456
bilateral	B	457-466
and	I	467-470
multifocal	I	471-481
tumours	I	482-489
,	O	489-490
and	O	491-494
presenting	O	495-505
at	O	506-508
an	O	509-511
earlier	O	512-519
age	O	520-523
than	O	524-528
in	O	529-531
sporadic	O	532-540
,	O	540-541
non	O	542-545
-	O	545-546
familial	O	546-554
cases	O	555-560
of	O	561-563
this	O	564-568
tumour	B	569-575
type	O	576-580
.	O	580-581

We	O	582-584
report	O	585-591
here	O	592-596
that	O	597-601
the	O	602-605
VHL	B	606-609
gene	O	610-614
is	O	615-617
linked	O	618-624
to	O	625-627
the	O	628-631
locus	O	632-637
encoding	O	638-646
the	O	647-650
human	O	651-656
homologoue	O	657-667
of	O	668-670
the	O	671-674
RAF1	O	675-679
oncogene	O	680-688
,	O	688-689
which	O	690-695
maps	O	696-700
to	O	701-703
chromosome	O	704-714
3p25	O	715-719
(	O	720-721
ref	O	721-724
.	O	724-725

4	O	726-727
)	O	727-728
.	O	728-729

Crossovers	O	730-740
with	O	741-745
the	O	746-749
VHL	B	750-753
locus	O	754-759
suggest	O	760-767
that	O	768-772
the	O	773-776
defect	O	777-783
responsible	O	784-795
for	O	796-799
the	O	800-803
VHL	B	804-807
phenotype	O	808-817
is	O	818-820
not	O	821-824
a	O	825-826
mutation	O	827-835
in	O	836-838
the	O	839-842
RAF1	O	843-847
gene	O	848-852
itself	O	853-859
.	O	859-860

An	O	861-863
alternative	O	864-875
or	O	876-878
prior	O	879-884
event	O	885-890
to	O	891-893
oncogene	O	894-902
activation	O	903-913
in	O	914-916
tumour	B	917-923
formation	O	924-933
may	O	934-937
be	O	938-940
the	O	941-944
inactivation	O	945-957
of	O	958-960
a	O	961-962
putative	O	963-971
tumour	B	972-978
suppressor	O	979-989
which	O	990-995
can	O	996-999
be	O	1000-1002
associated	O	1003-1013
with	O	1014-1018
both	O	1019-1023
the	O	1024-1027
inherited	B	1028-1037
and	I	1038-1041
sporadic	I	1042-1050
forms	I	1051-1056
of	I	1057-1059
the	I	1060-1063
cancer	I	1064-1070
.	O	1070-1071

Sporadic	B	1072-1080
renal	I	1081-1086
cell	I	1087-1091
carcinomas	I	1092-1102
have	O	1103-1107
previously	O	1108-1118
been	O	1119-1123
associated	O	1124-1134
with	O	1135-1139
the	O	1140-1143
loss	O	1144-1148
of	O	1149-1151
regions	O	1152-1159
on	O	1160-1162
chromosome	O	1163-1173
3p	O	1174-1176
(	O	1177-1178
refs	O	1178-1182
5	O	1183-1184
,	O	1184-1185
6	O	1186-1187
)	O	1187-1188
.	O	1188-1189

Consequently	O	1190-1202
,	O	1202-1203
sporadic	O	1204-1212
and	O	1213-1216
VHL	O	1217-1220
-	O	1220-1221
associated	O	1221-1231
forms	O	1232-1237
of	O	1238-1240
renal	B	1241-1246
cell	I	1247-1251
carcinoma	I	1252-1261
might	O	1262-1267
both	O	1268-1272
result	O	1273-1279
from	O	1280-1284
alterations	O	1285-1296
causing	O	1297-1304
loss	O	1305-1309
of	O	1310-1312
function	O	1313-1321
of	O	1322-1324
the	O	1325-1328
same	O	1329-1333
tumour	B	1334-1340
suppressor	O	1341-1351
gene	O	1352-1356
on	O	1357-1359
this	O	1360-1364
chromosome	O	1365-1375
.	O	1375-1376
.	O	1375-1376

Tightly	O	0-7
linked	O	8-14
flanking	O	15-23
markers	O	24-31
for	O	32-35
the	O	36-39
Lowe	B	40-44
oculocerebrorenal	I	45-62
syndrome	I	63-71
,	O	71-72
with	O	73-77
application	O	78-89
to	O	90-92
carrier	O	93-100
assessment	O	101-111
.	O	111-112

The	O	113-116
Lowe	B	117-121
oculocerebrorenal	I	122-139
syndrome	I	140-148
(	O	149-150
OCRL	B	150-154
)	O	154-155
is	O	156-158
characterized	O	159-172
by	O	173-175
congenital	O	176-186
cataract	B	187-195
,	O	195-196
mental	B	197-203
retardation	I	204-215
,	O	215-216
and	O	217-220
defective	B	221-230
renal	I	231-236
tubular	I	237-244
function	I	245-253
.	O	253-254

A	O	255-256
map	O	257-260
assignment	O	261-271
of	O	272-274
OCRL	B	275-279
to	O	280-282
Xq24	O	283-287
-	O	287-288
q26	O	288-291
has	O	292-295
been	O	296-300
made	O	301-305
previously	O	306-316
by	O	317-319
linkage	O	320-327
analysis	O	328-336
with	O	337-341
DXS42	O	342-347
at	O	348-350
Xq24	O	351-355
-	O	355-356
q26	O	356-359
(	O	360-361
theta	O	361-366
=	O	367-368
0	O	369-370
,	O	370-371
z	O	372-373
=	O	374-375
5	O	376-377
.	O	377-378
09	O	379-381
)	O	381-382
and	O	383-386
with	O	387-391
DXS10	O	392-397
at	O	398-400
Xq26	O	401-405
(	O	406-407
theta	O	407-412
=	O	413-414
0	O	415-416
,	O	416-417
z	O	418-419
=	O	420-421
6	O	422-423
.	O	423-424

45	O	425-427
)	O	427-428
.	O	428-429

Two	O	430-433
additional	O	434-444
families	O	445-453
were	O	454-458
studied	O	459-466
and	O	467-470
three	O	471-476
additional	O	477-487
polymorphisms	O	488-501
were	O	502-506
identified	O	507-517
at	O	518-520
DXS42	O	521-526
by	O	527-529
using	O	530-535
a	O	536-537
35	O	538-540
-	O	540-541
kb	O	541-543
sequence	O	544-552
isolated	O	553-561
with	O	562-566
the	O	567-570
probe	O	571-576
detecting	O	577-586
the	O	587-590
original	O	591-599
polymorphism	O	600-612
at	O	613-615
DXS42	O	616-621
.	O	621-622

With	O	623-627
additional	O	628-638
OCRL	B	639-643
families	O	644-652
made	O	653-657
informative	O	658-669
for	O	670-673
DXS42	O	674-679
,	O	679-680
theta	O	681-686
remained	O	687-695
0	O	696-697
with	O	698-702
z	O	703-704
=	O	705-706
6	O	707-708
.	O	708-709

63	O	710-712
;	O	712-713
and	O	714-717
for	O	718-721
DXS10	O	722-727
theta	O	728-733
=	O	734-735
0	O	736-737
.	O	737-738
03	O	739-741
and	O	742-745
z	O	746-747
=	O	748-749
7	O	750-751
.	O	751-752
07	O	753-755
.	O	755-756

Evidence	O	757-765
for	O	766-769
placing	O	770-777
OCRL	O	778-782
at	O	783-785
Xq25	O	786-790
also	O	791-795
comes	O	796-801
from	O	802-806
a	O	807-808
female	O	809-815
with	O	816-820
Lowe	B	821-825
syndrome	I	826-834
and	O	835-838
an	O	839-841
X	O	842-843
;	O	843-844
3	O	845-846
translocation	O	847-860
.	O	860-861

We	O	862-864
have	O	865-869
used	O	870-874
the	O	875-878
Xq25	O	879-883
breakpoint	O	884-894
in	O	895-897
this	O	898-902
patient	O	903-910
to	O	911-913
determine	O	914-923
the	O	924-927
position	O	928-936
of	O	937-939
OCRL	O	940-944
relative	O	945-953
to	O	954-956
the	O	957-960
two	O	961-964
linked	O	965-971
markers	O	972-979
.	O	979-980

Each	O	981-985
derivative	O	986-996
chromosome	O	997-1007
was	O	1008-1011
isolated	O	1012-1020
away	O	1021-1025
from	O	1026-1030
its	O	1031-1034
normal	O	1035-1041
counterpart	O	1042-1053
in	O	1054-1056
somatic	O	1057-1064
cell	O	1065-1069
hybrids	O	1070-1077
.	O	1077-1078

DXS42	O	1079-1084
was	O	1085-1088
mapped	O	1089-1095
to	O	1096-1098
the	O	1099-1102
derivative	O	1103-1113
chromosome	O	1114-1124
X	O	1125-1126
containing	O	1127-1137
Xpterq25	O	1138-1146
,	O	1146-1147
and	O	1148-1151
DXS10	O	1152-1157
was	O	1158-1161
mapped	O	1162-1168
to	O	1169-1171
the	O	1172-1175
derivative	O	1176-1186
chromosome	O	1187-1197
3	O	1198-1199
containing	O	1200-1210
Xq25	O	1211-1215
-	O	1215-1216
qter	O	1216-1220
.	O	1220-1221

The	O	1222-1225
markers	O	1226-1233
DXS10	O	1234-1239
and	O	1240-1243
DXS42	O	1244-1249
therefore	O	1250-1259
show	O	1260-1264
tight	O	1265-1270
linkage	O	1271-1278
with	O	1279-1283
OCRL	B	1284-1288
in	O	1289-1291
six	O	1292-1295
families	O	1296-1304
and	O	1305-1308
flank	O	1309-1314
the	O	1315-1318
Xq25	O	1319-1323
breakpoint	O	1324-1334
in	O	1335-1337
a	O	1338-1339
female	O	1340-1346
patient	O	1347-1354
with	O	1355-1359
an	O	1360-1362
X	O	1363-1364
;	O	1364-1365
3	O	1366-1367
translocation	O	1368-1381
.	O	1381-1382

Linkage	O	1383-1390
analysis	O	1391-1399
with	O	1400-1404
flanking	O	1405-1413
markers	O	1414-1421
was	O	1422-1425
used	O	1426-1430
to	O	1431-1433
assess	O	1434-1440
OCRL	B	1441-1445
carrier	O	1446-1453
status	O	1454-1460
in	O	1461-1463
women	O	1464-1469
at	O	1470-1472
risk	O	1473-1477
.	O	1477-1478

Results	O	1479-1486
,	O	1486-1487
when	O	1488-1492
compared	O	1493-1501
with	O	1502-1506
carrier	O	1507-1514
determination	O	1515-1528
by	O	1529-1531
ophthalmologic	O	1532-1546
examination	O	1547-1558
,	O	1558-1559
indicated	O	1560-1569
that	O	1570-1574
the	O	1575-1578
slit	O	1579-1583
-	O	1583-1584
lamp	O	1584-1588
exam	O	1589-1593
can	O	1594-1597
be	O	1598-1600
a	O	1601-1602
sensitive	O	1603-1612
and	O	1613-1616
specific	O	1617-1625
method	O	1626-1632
of	O	1633-1635
carrier	O	1636-1643
determination	O	1644-1657
in	O	1658-1660
many	O	1661-1665
cases	O	1666-1671

Abnormal	O	0-8
development	O	9-20
of	O	21-23
Purkinje	O	24-32
cells	O	33-38
and	O	39-42
lymphocytes	O	43-54
in	O	55-57
Atm	O	58-61
mutant	O	62-68
mice	O	69-73
.	O	73-74

Motor	B	75-80
incoordination	I	81-95
,	O	95-96
immune	B	97-103
deficiencies	I	104-116
,	O	116-117
and	O	118-121
an	O	122-124
increased	O	125-134
risk	O	135-139
of	O	140-142
cancer	B	143-149
are	O	150-153
the	O	154-157
characteristic	O	158-172
features	O	173-181
of	O	182-184
the	O	185-188
hereditary	B	189-199
disease	I	200-207
ataxia	B	208-214
-	I	214-215
telangiectasia	I	215-229
(	O	230-231
A	B	231-232
-	I	232-233
T	I	233-234
)	O	234-235
,	O	235-236
which	O	237-242
is	O	243-245
caused	O	246-252
by	O	253-255
mutations	O	256-265
in	O	266-268
the	O	269-272
ATM	O	273-276
gene	O	277-281
.	O	281-282

Through	O	283-290
gene	O	291-295
targeting	O	296-305
,	O	305-306
we	O	307-309
have	O	310-314
generated	O	315-324
a	O	325-326
line	O	327-331
of	O	332-334
Atm	O	335-338
mutant	O	339-345
mice	O	346-350
,	O	350-351
Atm	O	352-355
(	O	356-357
y	O	357-358
/	O	358-359
y	O	357-358
)	O	360-361
mice	O	362-366
.	O	366-367

In	O	368-370
contrast	O	371-379
to	O	380-382
other	O	383-388
Atm	O	389-392
mutant	O	393-399
mice	O	400-404
,	O	404-405
Atm	O	406-409
(	O	410-411
y	O	411-412
/	O	412-413
y	O	411-412
)	O	414-415
mice	O	416-420
show	O	421-425
a	O	426-427
lower	O	428-433
incidence	O	434-443
of	O	444-446
thymic	B	447-453
lymphoma	I	454-462
and	O	463-466
survive	O	467-474
beyond	O	475-481
a	O	482-483
few	O	484-487
months	O	488-494
of	O	495-497
age	O	498-501
.	O	501-502

Atm	O	503-506
(	O	507-508
y	O	508-509
/	O	509-510
y	O	508-509
)	O	511-512
mice	O	513-517
exhibit	O	518-525
deficits	O	526-534
in	O	535-537
motor	O	538-543
learning	O	544-552
indicative	O	553-563
of	O	564-566
cerebellar	B	567-577
dysfunction	I	578-589
.	O	589-590

Even	O	591-595
though	O	596-602
we	O	603-605
found	O	606-611
no	O	612-614
gross	O	615-620
cerebellar	B	621-631
degeneration	I	632-644
in	O	645-647
older	O	648-653
Atm	O	654-657
(	O	658-659
y	O	659-660
/	O	660-661
y	O	659-660
)	O	662-663
animals	O	664-671
,	O	671-672
ectopic	O	673-680
and	O	681-684
abnormally	O	685-695
differentiated	O	696-710
Purkinje	O	711-719
cells	O	720-725
were	O	726-730
apparent	O	731-739
in	O	740-742
mutant	O	743-749
mice	O	750-754
of	O	755-757
all	O	758-761
ages	O	762-766
.	O	766-767

These	O	768-773
findings	O	774-782
establish	O	783-792
that	O	793-797
some	O	798-802
neuropathological	B	803-820
abnormalities	I	821-834
seen	O	835-839
in	O	840-842
A	B	843-844
-	I	844-845
T	I	845-846
patients	O	847-855
also	O	856-860
are	O	861-864
present	O	865-872
in	O	873-875
Atm	O	876-879
mutant	O	880-886
mice	O	887-891
.	O	891-892

In	O	893-895
addition	O	896-904
,	O	904-905
we	O	906-908
report	O	909-915
a	O	916-917
previously	O	918-928
unrecognized	O	929-941
effect	O	942-948
of	O	949-951
Atm	B	952-955
deficiency	I	956-966
on	O	967-969
development	O	970-981
or	O	982-984
maintenance	O	985-996
of	O	997-999
CD4	O	1000-1003
(	O	1004-1005
+	O	1005-1006
)	O	1006-1007
8	O	1008-1009
(	O	1010-1011
+	O	1011-1012
)	O	1012-1013
thymocytes	O	1014-1024
.	O	1024-1025

We	O	1026-1028
discuss	O	1029-1036
these	O	1037-1042
findings	O	1043-1051
in	O	1052-1054
the	O	1055-1058
context	O	1059-1066
of	O	1067-1069
the	O	1070-1073
hypothesis	O	1074-1084
that	O	1085-1089
abnormal	O	1090-1098
development	O	1099-1110
of	O	1111-1113
Purkinje	O	1114-1122
cells	O	1123-1128
and	O	1129-1132
lymphocytes	O	1133-1144
contributes	O	1145-1156
to	O	1157-1159
the	O	1160-1163
pathogenesis	O	1164-1176
of	O	1177-1179
A	B	1180-1181
-	I	1181-1182
T	I	1182-1183
.	O	1183-1184
.	O	1183-1184

Both	O	0-4
mutations	O	5-14
in	O	15-17
G6PD	O	18-22
A	O	23-24
-	O	24-25
are	O	26-29
necessary	O	30-39
to	O	40-42
produce	O	43-50
the	O	51-54
G6PD	B	55-59
deficient	I	60-69
phenotype	O	70-79
.	O	79-80

The	O	81-84
high	O	85-89
prevalence	O	90-100
of	O	101-103
glucose	B	104-111
6	I	112-113
-	I	113-114
phosphate	I	114-123
dehydrogenase	I	124-137
(	I	138-139
G6PD	I	139-143
)	I	143-144
deficiency	I	145-155
in	O	156-158
African	O	159-166
populations	O	167-178
is	O	179-181
due	O	182-185
almost	O	186-192
entirely	O	193-201
to	O	202-204
the	O	205-208
enzyme	O	209-215
variant	O	216-223
A	O	224-225
-	O	225-226
,	O	226-227
which	O	228-233
differs	O	234-241
from	O	242-246
the	O	247-250
wild	O	251-255
-	O	255-256
type	O	256-260
G6PD	O	261-265
B	O	266-267
by	O	268-270
two	O	271-274
amino	O	275-280
acid	O	281-285
replacements	O	286-298
,	O	298-299
68	O	300-302
Val	O	303-306
-	O	306-307
-	O	306-307
>	O	309-310
Met	O	311-314
and	O	315-318
126	O	319-322
Asn	O	323-326
-	O	326-327
-	O	326-327
>	O	329-330
Asp	O	331-334
.	O	334-335

The	O	336-339
non	O	340-343
-	O	343-344
deficient	O	344-353
polymorphic	O	354-365
variant	O	366-373
G6PD	O	374-378
A	O	379-380
contains	O	381-389
only	O	390-394
the	O	395-398
mutation	O	399-407
126	O	408-411
Asn	O	412-415
-	O	415-416
-	O	415-416
>	O	418-419
Asp	O	420-423
.	O	423-424

The	O	425-428
frequencies	O	429-440
of	O	441-443
the	O	444-447
G6PD	O	448-452
A	O	453-454
and	O	455-458
of	O	459-461
the	O	462-465
G6PD	O	466-470
A	O	471-472
-	O	472-473
genes	O	474-479
in	O	480-482
parts	O	483-488
of	O	489-491
Africa	O	492-498
are	O	499-502
both	O	503-507
about	O	508-513
0	O	514-515
.	O	515-516
2	O	517-518
.	O	518-519
The	O	520-523
68	O	524-526
Val	O	527-530
-	O	530-531
-	O	530-531
>	O	533-534
Met	O	535-538
mutation	O	539-547
has	O	548-551
not	O	552-555
been	O	556-560
found	O	561-566
in	O	567-569
a	O	570-571
B	O	572-573
background	O	574-584
.	O	584-585

This	O	586-590
could	O	591-596
be	O	597-599
because	O	600-607
the	O	608-611
68	O	612-614
Val	O	615-618
-	O	618-619
-	O	618-619
>	O	621-622
Met	O	623-626
mutation	O	627-635
happened	O	636-644
to	O	645-647
arise	O	648-653
in	O	654-656
an	O	657-659
A	O	660-661
gene	O	662-666
in	O	667-669
the	O	670-673
first	O	674-679
instance	O	680-688
,	O	688-689
or	O	690-692
because	O	693-700
the	O	701-704
68	O	705-707
Val	O	708-711
-	O	711-712
-	O	711-712
>	O	714-715
Met	O	716-719
mutation	O	720-728
alone	O	729-734
is	O	735-737
not	O	738-741
sufficient	O	742-752
to	O	753-755
cause	O	756-761
G6PD	B	762-766
deficiency	I	767-777
.	O	777-778

We	O	779-781
have	O	782-786
approached	O	787-797
this	O	798-802
question	O	803-811
by	O	812-814
producing	O	815-824
G6PD	O	825-829
B	O	830-831
,	O	831-832
A	O	833-834
,	O	834-835
A	O	836-837
-	O	837-838
,	O	838-839
and	O	840-843
G6PD	O	844-848
68	O	849-851
Val	O	852-855
-	O	855-856
-	O	855-856
>	O	858-859
Met	O	860-863
in	O	864-866
a	O	867-868
bacterial	O	869-878
expression	O	879-889
system	O	890-896
and	O	897-900
analysing	O	901-910
their	O	911-916
biochemical	O	917-928
properties	O	929-939
.	O	939-940

With	O	941-945
each	O	946-950
single	O	951-957
mutation	O	958-966
we	O	967-969
found	O	970-975
a	O	976-977
slight	O	978-984
decrease	O	985-993
in	O	994-996
both	O	997-1001
the	O	1002-1005
specific	O	1006-1014
activity	O	1015-1023
and	O	1024-1027
the	O	1028-1031
yield	O	1032-1037
of	O	1038-1040
enzyme	O	1041-1047
when	O	1048-1052
compared	O	1053-1061
to	O	1062-1064
G6PD	O	1065-1069
B	O	1070-1071
.	O	1071-1072
When	O	1073-1077
both	O	1078-1082
mutations	O	1083-1092
were	O	1093-1097
introduced	O	1098-1108
together	O	1109-1117
,	O	1117-1118
there	O	1119-1124
was	O	1125-1128
a	O	1129-1130
roughly	O	1131-1138
additive	O	1139-1147
effect	O	1148-1154
on	O	1155-1157
specific	O	1158-1166
activity	O	1167-1175
,	O	1175-1176
but	O	1177-1180
a	O	1181-1182
much	O	1183-1187
more	O	1188-1192
drastic	O	1193-1200
effect	O	1201-1207
on	O	1208-1210
enzyme	O	1211-1217
yield	O	1218-1223
(	O	1224-1225
4	O	1225-1226
%	O	1226-1227
of	O	1228-1230
normal	O	1231-1237
)	O	1237-1238
.	O	1238-1239

This	O	1240-1244
synergistic	O	1245-1256
effect	O	1257-1263
was	O	1264-1267
also	O	1268-1272
demonstrated	O	1273-1285
on	O	1286-1288
thermal	O	1289-1296
stability	O	1297-1306
,	O	1306-1307
especially	O	1308-1318
at	O	1319-1321
low	O	1322-1325
NADP	O	1326-1330
concentrations	O	1331-1345
.	O	1345-1346

Comparable	O	1347-1357
results	O	1358-1365
were	O	1366-1370
produced	O	1371-1379
when	O	1380-1384
the	O	1385-1388
replacement	O	1389-1400
119	O	1401-1404
Gln	O	1405-1408
-	O	1408-1409
-	O	1408-1409
>	O	1411-1412
Glu	O	1413-1416
was	O	1417-1420
studied	O	1421-1428
instead	O	1429-1436
of	O	1437-1439
126	O	1440-1443
Asn	O	1444-1447
-	O	1447-1448
-	O	1447-1448
>	O	1450-1451
Asp	O	1452-1455
.	O	1455-1456

We	O	1457-1459
infer	O	1460-1465
that	O	1466-1470
the	O	1471-1474
coexistence	O	1475-1486
of	O	1487-1489
the	O	1490-1493
two	O	1494-1497
mutations	O	1498-1507
is	O	1508-1510
responsible	O	1511-1522
for	O	1523-1526
enzyme	B	1527-1533
deficiency	I	1534-1544
in	I	1545-1547
G6PD	I	1548-1552
A	O	1553-1554
-	O	1554-1555
because	O	1556-1563
they	O	1564-1568
act	O	1569-1572
synergistically	O	1573-1588
in	O	1589-1591
causing	O	1592-1599
instability	O	1600-1611
of	O	1612-1614
the	O	1615-1618
enzyme	O	1619-1625
.	O	1625-1626

Detection	O	0-9
of	O	10-12
98	O	13-15
%	O	15-16
of	O	17-19
DMD	B	20-23
/	O	23-24
BMD	B	24-27
gene	O	28-32
deletions	O	33-42
by	O	43-45
polymerase	O	46-56
chain	O	57-62
reaction	O	63-71
.	O	71-72

We	O	73-75
describe	O	76-84
oligonucleotide	O	85-100
primer	O	101-107
sequences	O	108-117
that	O	118-122
can	O	123-126
be	O	127-129
used	O	130-134
to	O	135-137
amplify	O	138-145
eight	O	146-151
exons	O	152-157
plus	O	158-162
the	O	163-166
muscle	O	167-173
promoter	O	174-182
of	O	183-185
the	O	186-189
dystrophin	O	190-200
gene	O	201-205
in	O	206-208
a	O	209-210
single	O	211-217
multiplex	O	218-227
polymerase	O	228-238
chain	O	239-244
reaction	O	245-253
(	O	254-255
PCR	O	255-258
)	O	258-259
.	O	259-260

When	O	261-265
used	O	266-270
in	O	271-273
conjunction	O	274-285
with	O	286-290
an	O	291-293
existing	O	294-302
primer	O	303-309
set	O	310-313
,	O	313-314
these	O	315-320
two	O	321-324
multiplex	O	325-334
reactions	O	335-344
detect	O	345-351
about	O	352-357
98	O	358-360
%	O	360-361
of	O	362-364
deletions	O	365-374
in	O	375-377
patients	O	378-386
with	O	387-391
Duchenne	B	392-400
or	I	401-403
Becker	I	404-410
muscular	I	411-419
dystrophy	I	420-429
(	O	430-431
DMD	B	431-434
,	O	434-435
BMD	B	436-439
)	O	439-440
.	O	440-441

Furthermore	O	442-453
,	O	453-454
these	O	455-460
primers	O	461-468
amplify	O	469-476
most	O	477-481
of	O	482-484
the	O	485-488
exons	O	489-494
in	O	495-497
the	O	498-501
deletion	O	502-510
prone	O	511-516
"	O	517-518
hot	O	519-522
spot	O	523-527
"	O	528-529
region	O	530-536
around	O	537-543
exons	O	544-549
44	O	550-552
to	O	553-555
53	O	556-558
,	O	558-559
allowing	O	560-568
determination	O	569-582
of	O	583-585
deletion	O	586-594
endpoints	O	595-604
and	O	605-608
prediction	O	609-619
of	O	620-622
mutational	O	623-633
effects	O	634-641
on	O	642-644
the	O	645-648
translational	O	649-662
reading	O	663-670
frame	O	671-676
.	O	676-677

Thus	O	678-682
,	O	682-683
use	O	684-687
of	O	688-690
these	O	691-696
PCR	O	697-700
-	O	700-701
based	O	701-706
assays	O	707-713
will	O	714-718
allow	O	719-724
deletion	O	725-733
detection	O	734-743
and	O	744-747
prenatal	O	748-756
diagnosis	O	757-766
for	O	767-770
most	O	771-775
DMD	B	776-779
/	O	779-780
BMD	B	780-783
patients	O	784-792
in	O	793-795
a	O	796-797
fraction	O	798-806
of	O	807-809
the	O	810-813
time	O	814-818
required	O	819-827
for	O	828-831
Southern	O	832-840
blot	O	841-845
analysis	O	846-854
.	O	854-855
.	O	854-855

Recombination	O	0-13
events	O	14-20
that	O	21-25
locate	O	26-32
myotonic	B	33-41
dystrophy	I	42-51
distal	O	52-58
to	O	59-61
APOC2	O	62-67
on	O	68-70
19q	O	71-74
.	O	74-75

We	O	76-78
previously	O	79-89
reported	O	90-98
a	O	99-100
recombination	O	101-114
in	O	115-117
an	O	118-120
individual	O	121-131
with	O	132-136
myotonic	B	137-145
dystrophy	I	146-155
(	O	156-157
DM	B	157-159
)	O	159-160
which	O	161-166
placed	O	167-173
the	O	174-177
markers	O	178-185
D19S19	O	186-192
and	O	193-196
APOC2	O	197-202
on	O	203-205
the	O	206-209
same	O	210-214
side	O	215-219
of	O	220-222
the	O	223-226
DM	B	227-229
locus	O	230-235
.	O	235-236

Haplotyping	O	237-248
of	O	249-251
this	O	252-256
family	O	257-263
with	O	264-268
more	O	269-273
recently	O	274-282
characterized	O	283-296
probes	O	297-303
which	O	304-309
are	O	310-313
either	O	314-320
tightly	O	321-328
linked	O	329-335
to	O	336-338
DM	B	339-341
or	O	342-344
distal	O	345-351
to	O	352-354
the	O	355-358
linkage	O	359-366
group	O	367-372
at	O	373-375
q13	O	376-379
.	O	379-380
2	O	381-382
shows	O	383-388
that	O	389-393
the	O	394-397
DM	B	398-400
locus	O	401-406
is	O	407-409
distal	O	410-416
to	O	417-419
APOC2	O	420-425
.	O	425-426

This	O	427-431
is	O	432-434
confirmed	O	435-444
by	O	445-447
other	O	448-453
recombinants	O	454-466
where	O	467-472
DM	B	473-475
segregates	O	476-486
with	O	487-491
distal	O	492-498
probes	O	499-505
.	O	505-506

Additional	O	507-517
marker	O	518-524
to	O	525-527
marker	O	528-534
recombinations	O	535-549
in	O	550-552
unaffected	O	553-563
individuals	O	564-575
are	O	576-579
reported	O	580-588
and	O	589-592
support	O	593-600
the	O	601-604
order	O	605-610
and	O	611-614
orientation	O	615-626
of	O	627-629
the	O	630-633
DM	B	634-636
linkage	O	637-644
group	O	645-650
as	O	651-653
pter	O	654-658
-	O	658-659
(	O	660-661
INSR	O	661-665
,	O	665-666
LDLR	O	667-671
,	O	671-672
S9	O	673-675
)	O	675-676
-	O	677-678
(	O	679-680
S19	O	680-683
,	O	683-684
BCL3	O	685-689
,	O	689-690
APOC2	O	691-696
)	O	696-697
-	O	698-699
(	O	700-701
CKMM	O	701-705
,	O	705-706
DM	O	707-709
)	O	709-710
-	O	711-712
(	O	713-714
S22	O	714-717
,	O	717-718
+	O	719-720
+	O	721-722
+	O	723-724
PRKCG	O	725-730
)	O	730-731
-	O	732-733
qter	O	733-737
.	O	737-738

The	O	739-742
data	O	743-747
presented	O	748-757
here	O	758-762
cannot	O	763-769
determine	O	770-779
whether	O	780-787
DM	B	788-790
is	O	791-793
proximal	O	794-802
or	O	803-805
distal	O	806-812
to	O	813-815
CKMM	O	816-820
.	O	820-821

The	O	822-825
consequences	O	826-838
of	O	839-841
this	O	842-846
probe	O	847-852
order	O	853-858
for	O	859-862
antenatal	O	863-872
diagnosis	O	873-882
and	O	883-886
future	O	887-893
research	O	894-902
aiming	O	903-909
to	O	910-912
isolate	O	913-920
the	O	921-924
gene	O	925-929
which	O	930-935
is	O	936-938
affected	O	939-947
in	O	948-950
DM	B	951-953
are	O	954-957
discussed	O	958-967
.	O	967-968

New	O	0-3
mutations	O	4-13
,	O	13-14
polymorphisms	O	15-28
,	O	28-29
and	O	30-33
rare	O	34-38
variants	O	39-47
in	O	48-50
the	O	51-54
ATM	O	55-58
gene	O	59-63
detected	O	64-72
by	O	73-75
a	O	76-77
novel	O	78-83
SSCP	O	84-88
strategy	O	89-97
.	O	97-98

The	O	99-102
gene	O	103-107
for	O	108-111
ataxia	B	112-118
-	I	118-119
telangiectasia	I	119-133
,	O	133-134
ATM	O	135-138
,	O	138-139
spans	O	140-145
about	O	146-151
150	O	152-155
kb	O	156-158
of	O	159-161
genomic	O	162-169
DNA	O	170-173
.	O	173-174

ATM	O	175-178
mutations	O	179-188
are	O	189-192
found	O	193-198
along	O	199-204
the	O	205-208
entire	O	209-215
gene	O	216-220
,	O	220-221
with	O	222-226
no	O	227-229
evidence	O	230-238
of	O	239-241
a	O	242-243
mutational	O	244-254
hot	O	255-258
spot	O	259-263
.	O	263-264

Using	O	265-270
DNA	O	271-274
as	O	275-277
the	O	278-281
starting	O	282-290
material	O	291-299
,	O	299-300
we	O	301-303
screened	O	304-312
the	O	313-316
ATM	O	317-320
gene	O	321-325
in	O	326-328
92	O	329-331
A	B	332-333
-	I	333-334
T	I	334-335
patients	O	336-344
,	O	344-345
using	O	346-351
an	O	352-354
optimized	O	355-364
single	O	365-371
-	O	371-372
strand	O	372-378
conformation	O	379-391
polymorphism	O	392-404
(	O	405-406
SSCP	O	406-410
)	O	410-411
technique	O	412-421
that	O	422-426
detected	O	427-435
all	O	436-439
previously	O	440-450
known	O	451-456
mutations	O	457-466
in	O	467-469
the	O	470-473
polymerase	O	474-484
chain	O	485-490
reaction	O	491-499
(	O	500-501
PCR	O	501-504
)	O	504-505
segments	O	506-514
being	O	515-520
analyzed	O	521-529
.	O	529-530

To	O	531-533
expedite	O	534-542
screening	O	543-552
,	O	552-553
we	O	554-556
sequentially	O	557-569
loaded	O	570-576
the	O	577-580
SSCP	O	581-585
gels	O	586-590
with	O	591-595
three	O	596-601
different	O	602-611
sets	O	612-616
of	O	617-619
PCR	O	620-623
products	O	624-632
that	O	633-637
were	O	638-642
pretested	O	643-652
to	O	653-655
avoid	O	656-661
overlapping	O	662-673
patterns	O	674-682
.	O	682-683

Many	O	684-688
of	O	689-691
the	O	692-695
DNA	O	696-699
changes	O	700-707
we	O	708-710
detected	O	711-719
were	O	720-724
intragenic	O	725-735
polymorphisms	O	736-749
.	O	749-750

Of	O	751-753
an	O	754-756
expected	O	757-765
177	O	766-769
unknown	O	770-777
mutations	O	778-787
,	O	787-788
we	O	789-791
detected	O	792-800
approximately	O	801-814
70	O	815-817
%	O	817-818
,	O	818-819
mostly	O	820-826
protein	O	827-834
truncating	O	835-845
mutations	O	846-855
(	O	856-857
that	O	857-861
would	O	862-867
have	O	868-872
been	O	873-877
detectable	O	878-888
by	O	889-891
protein	O	892-899
truncation	O	900-910
testing	O	911-918
if	O	919-921
RNA	O	922-925
starting	O	926-934
material	O	935-943
had	O	944-947
been	O	948-952
available	O	953-962
)	O	962-963
.	O	963-964

Mutations	O	965-974
have	O	975-979
now	O	980-983
been	O	984-988
defined	O	989-996
for	O	997-1000
every	O	1001-1006
exon	O	1007-1011
of	O	1012-1014
the	O	1015-1018
ATM	O	1019-1022
gene	O	1023-1027
.	O	1027-1028

Herein	O	1029-1035
,	O	1035-1036
we	O	1037-1039
present	O	1040-1047
35	O	1048-1050
new	O	1051-1054
mutations	O	1055-1064
and	O	1065-1068
34	O	1069-1071
new	O	1072-1075
intragenic	O	1076-1086
polymorphisms	O	1087-1100
or	O	1101-1103
rare	O	1104-1108
variants	O	1109-1117
within	O	1118-1124
the	O	1125-1128
ATM	O	1129-1132
gene	O	1133-1137
.	O	1137-1138

This	O	1139-1143
is	O	1144-1146
the	O	1147-1150
most	O	1151-1155
comprehensive	O	1156-1169
compilation	O	1170-1181
of	O	1182-1184
ATM	O	1185-1188
polymorphisms	O	1189-1202
assembled	O	1203-1212
to	O	1213-1215
date	O	1216-1220
.	O	1220-1221

Defining	O	1222-1230
polymorphic	O	1231-1242
sites	O	1243-1248
as	O	1249-1251
well	O	1252-1256
as	O	1257-1259
mutations	O	1260-1269
in	O	1270-1272
the	O	1273-1276
ATM	O	1277-1280
gene	O	1281-1285
will	O	1286-1290
be	O	1291-1293
of	O	1294-1296
great	O	1297-1302
importance	O	1303-1313
in	O	1314-1316
designing	O	1317-1326
automated	O	1327-1336
methods	O	1337-1344
for	O	1345-1348
detecting	O	1349-1358
mutations	O	1359-1368
.	O	1368-1369
.	O	1368-1369

Chromosome	O	0-10
breakage	O	11-19
in	O	20-22
the	O	23-26
Prader	B	27-33
-	I	33-34
Willi	I	34-39
and	I	40-43
Angelman	I	44-52
syndromes	I	53-62
involves	O	63-71
recombination	O	72-85
between	O	86-93
large	O	94-99
,	O	99-100
transcribed	O	101-112
repeats	O	113-120
at	O	121-123
proximal	O	124-132
and	O	133-136
distal	O	137-143
breakpoints	O	144-155
.	O	155-156

Prader	B	157-163
-	I	163-164
Willi	I	164-169
syndrome	I	170-178
(	O	179-180
PWS	B	180-183
)	O	183-184
and	O	185-188
Angelman	B	189-197
syndrome	I	198-206
(	O	207-208
AS	B	208-210
)	O	210-211
are	O	212-215
distinct	O	216-224
neurobehavioral	B	225-240
disorders	I	241-250
that	O	251-255
most	O	256-260
often	O	261-266
arise	O	267-272
from	O	273-277
a	O	278-279
4	O	280-281
-	O	281-282
Mb	O	282-284
deletion	O	285-293
of	O	294-296
chromosome	O	297-307
15q11	O	308-313
-	O	313-314
q13	O	314-317
during	O	318-324
paternal	O	325-333
or	O	334-336
maternal	O	337-345
gametogenesis	O	346-359
,	O	359-360
respectively	O	361-373
.	O	373-374

At	O	375-377
a	O	378-379
de	O	380-382
novo	O	383-387
frequency	O	388-397
of	O	398-400
approximately	O	401-414
.	O	414-415

67	O	416-418
-	O	418-419
1	O	419-420
/	O	420-421
10	O	421-423
,	O	423-424
000	O	425-428
births	O	429-435
,	O	435-436
these	O	437-442
deletions	O	443-452
represent	O	453-462
a	O	463-464
common	O	465-471
structural	O	472-482
chromosome	O	483-493
change	O	494-500
in	O	501-503
the	O	504-507
human	O	508-513
genome	O	514-520
.	O	520-521

To	O	522-524
elucidate	O	525-534
the	O	535-538
mechanism	O	539-548
underlying	O	549-559
these	O	560-565
events	O	566-572
,	O	572-573
we	O	574-576
characterized	O	577-590
the	O	591-594
regions	O	595-602
that	O	603-607
contain	O	608-615
two	O	616-619
proximal	O	620-628
breakpoint	O	629-639
clusters	O	640-648
and	O	649-652
a	O	653-654
distal	O	655-661
cluster	O	662-669
.	O	669-670

Novel	O	671-676
DNA	O	677-680
sequences	O	681-690
potentially	O	691-702
associated	O	703-713
with	O	714-718
the	O	719-722
breakpoints	O	723-734
were	O	735-739
positionally	O	740-752
cloned	O	753-759
from	O	760-764
YACs	O	765-769
within	O	770-776
or	O	777-779
near	O	780-784
these	O	785-790
regions	O	791-798
.	O	798-799

Analyses	O	800-808
of	O	809-811
rodent	O	812-818
-	O	818-819
human	O	819-824
somatic	O	825-832
-	O	832-833
cell	O	833-837
hybrids	O	838-845
,	O	845-846
YAC	O	847-850
contigs	O	851-858
,	O	858-859
and	O	860-863
FISH	O	864-868
of	O	869-871
normal	O	872-878
or	O	879-881
rearranged	O	882-892
chromosomes	O	893-904
15	O	905-907
identified	O	908-918
duplicated	O	919-929
sequences	O	930-939
(	O	940-941
the	O	941-944
END	O	945-948
repeats	O	949-956
)	O	956-957
at	O	958-960
or	O	961-963
near	O	964-968
the	O	969-972
breakpoints	O	973-984
.	O	984-985

The	O	986-989
END	O	990-993
-	O	993-994
repeat	O	994-1000
units	O	1001-1006
are	O	1007-1010
derived	O	1011-1018
from	O	1019-1023
large	O	1024-1029
genomic	O	1030-1037
duplications	O	1038-1050
of	O	1051-1053
a	O	1054-1055
novel	O	1056-1061
gene	O	1062-1066
(	O	1067-1068
HERC2	O	1068-1073
)	O	1073-1074
,	O	1074-1075
many	O	1076-1080
copies	O	1081-1087
of	O	1088-1090
which	O	1091-1096
are	O	1097-1100
transcriptionally	O	1101-1118
active	O	1119-1125
in	O	1126-1128
germline	O	1129-1137
tissues	O	1138-1145
.	O	1145-1146

One	O	1147-1150
of	O	1151-1153
five	O	1154-1158
PWS	B	1159-1162
/	O	1162-1163
AS	B	1163-1165
patients	O	1166-1174
analyzed	O	1175-1183
to	O	1184-1186
date	O	1187-1191
has	O	1192-1195
an	O	1196-1198
identifiable	O	1199-1211
,	O	1211-1212
rearranged	O	1213-1223
HERC2	O	1224-1229
transcript	O	1230-1240
derived	O	1241-1248
from	O	1249-1253
the	O	1254-1257
deletion	O	1258-1266
event	O	1267-1272
.	O	1272-1273

We	O	1274-1276
postulate	O	1277-1286
that	O	1287-1291
the	O	1292-1295
END	O	1296-1299
repeats	O	1300-1307
flanking	O	1308-1316
15q11	O	1317-1322
-	O	1322-1323
q13	O	1323-1326
mediate	O	1327-1334
homologous	O	1335-1345
recombination	O	1346-1359
resulting	O	1360-1369
in	O	1370-1372
deletion	O	1373-1381
.	O	1381-1382

Furthermore	O	1383-1394
,	O	1394-1395
we	O	1396-1398
propose	O	1399-1406
that	O	1407-1411
active	O	1412-1418
transcription	O	1419-1432
of	O	1433-1435
these	O	1436-1441
repeats	O	1442-1449
in	O	1450-1452
male	O	1453-1457
and	O	1458-1461
female	O	1462-1468
germ	O	1469-1473
cells	O	1474-1479
may	O	1480-1483
facilitate	O	1484-1494
the	O	1495-1498
homologous	O	1499-1509
recombination	O	1510-1523
process	O	1524-1531
.	O	1531-1532

A	O	0-1
4	O	2-3
-	O	3-4
megabase	O	4-12
YAC	O	13-16
contig	O	17-23
that	O	24-28
spans	O	29-34
the	O	35-38
Langer	B	39-45
-	I	45-46
Giedion	I	46-53
syndrome	I	54-62
region	O	63-69
on	O	70-72
human	O	73-78
chromosome	O	79-89
8q24	O	90-94
.	O	94-95
1	O	95-96
:	O	96-97

use	O	98-101
in	O	102-104
refining	O	105-113
the	O	114-117
location	O	118-126
of	O	127-129
the	O	130-133
trichorhinophalangeal	B	134-155
syndrome	I	156-164
and	O	165-168
multiple	O	169-177
exostoses	O	178-187
genes	O	188-193
(	O	194-195
TRPS1	O	195-200
and	O	201-204
EXT1	O	205-209
)	O	209-210
.	O	210-211

We	O	212-214
have	O	215-219
constructed	O	220-231
a	O	232-233
physical	O	234-242
map	O	243-246
covering	O	247-255
over	O	256-260
4	O	261-262
Mb	O	263-265
of	O	266-268
human	O	269-274
chromosome	O	275-285
8q24	O	286-290
.	O	290-291
1	O	292-293
and	O	294-297
used	O	298-302
this	O	303-307
map	O	308-311
to	O	312-314
refine	O	315-321
the	O	322-325
locations	O	326-335
of	O	336-338
the	O	339-342
genes	O	343-348
responsible	O	349-360
for	O	361-364
Langer	B	365-371
-	I	371-372
Giedion	I	372-379
syndrome	I	380-388
.	O	388-389

The	O	390-393
map	O	394-397
is	O	398-400
composed	O	401-409
of	O	410-412
overlapping	O	413-424
YAC	O	425-428
clones	O	429-435
that	O	436-440
were	O	441-445
identified	O	446-456
and	O	457-460
ordered	O	461-468
in	O	469-471
relation	O	472-480
to	O	481-483
sequence	O	484-492
tagged	O	493-499
sites	O	500-505
mapped	O	506-512
to	O	513-515
the	O	516-519
Langer	O	520-526
-	O	526-527
Giedion	O	527-534
chromosomal	O	535-546
region	O	547-553
on	O	554-556
somatic	O	557-564
cell	O	565-569
hybrids	O	570-577
.	O	577-578

The	O	579-582
minimal	O	583-590
region	O	591-597
of	O	598-600
overlap	O	601-608
of	O	609-611
Langer	B	612-618
-	I	618-619
Giedion	I	619-626
syndrome	I	627-635
deletions	O	636-645
,	O	645-646
previously	O	647-657
identified	O	658-668
by	O	669-671
analysis	O	672-680
of	O	681-683
15	O	684-686
patients	O	687-695
,	O	695-696
was	O	697-700
placed	O	701-707
on	O	708-710
the	O	711-714
map	O	715-718
by	O	719-721
analysis	O	722-730
of	O	731-733
2	O	734-735
patients	O	736-744
whose	O	745-750
deletions	O	751-760
define	O	761-767
the	O	768-771
endpoints	O	772-781
.	O	781-782

The	O	783-786
chromosome	O	787-797
8	O	798-799
breakpoint	O	800-810
of	O	811-813
a	O	814-815
balanced	O	816-824
t	O	825-826
(	O	827-828
8	O	828-829
;	O	829-830
9	O	831-832
)	O	832-833
(	O	834-835
q24	O	835-838
.	O	838-839

11	O	840-842
;	O	842-843
q33	O	844-847
.	O	847-848
3	O	849-850
)	O	850-851
translocation	O	852-865
from	O	866-870
a	O	871-872
patient	O	873-880
with	O	881-885
trichorhinophalangeal	B	886-907
syndrome	I	908-916
(	O	917-918
TRPS	B	918-922
I	O	923-924
)	O	924-925
was	O	926-929
found	O	930-935
to	O	936-938
be	O	939-941
located	O	942-949
just	O	950-954
within	O	955-961
the	O	962-965
proximal	O	966-974
end	O	975-978
of	O	979-981
the	O	982-985
minimal	O	986-993
deletion	O	994-1002
region	O	1003-1009
.	O	1009-1010

A	O	1011-1012
deletion	O	1013-1021
of	O	1022-1024
8q24	O	1025-1029
.	O	1029-1030

11	O	1031-1033
-	O	1033-1034
q24	O	1034-1037
.	O	1037-1038

3	O	1039-1040
in	O	1041-1043
a	O	1044-1045
patient	O	1046-1053
with	O	1054-1058
multiple	O	1059-1067
exostoses	O	1068-1077
was	O	1078-1081
found	O	1082-1087
to	O	1088-1090
overlap	O	1091-1098
the	O	1099-1102
distal	O	1103-1109
end	O	1110-1113
of	O	1114-1116
the	O	1117-1120
LGS	B	1121-1124
deletion	O	1125-1133
region	O	1134-1140
,	O	1140-1141
indicating	O	1142-1152
that	O	1153-1157
the	O	1158-1161
EXT1	O	1162-1166
gene	O	1167-1171
is	O	1172-1174
distal	O	1175-1181
to	O	1182-1184
the	O	1185-1188
TRPS1	O	1189-1194
gene	O	1195-1199
and	O	1200-1203
supporting	O	1204-1214
the	O	1215-1218
hypothesis	O	1219-1229
that	O	1230-1234
Langer	B	1235-1241
-	I	1241-1242
Giedion	I	1242-1249
syndrome	I	1250-1258
is	O	1259-1261
due	O	1262-1265
to	O	1266-1268
loss	O	1269-1273
of	O	1274-1276
functional	O	1277-1287
copies	O	1288-1294
of	O	1295-1297
both	O	1298-1302
the	O	1303-1306
TRPS1	O	1307-1312
and	O	1313-1316
the	O	1317-1320
EXT1	O	1321-1325
genes	O	1326-1331

Genetic	O	0-7
mapping	O	8-15
of	O	16-18
the	O	19-22
breast	B	23-29
-	I	29-30
ovarian	I	30-37
cancer	I	38-44
syndrome	I	45-53
to	O	54-56
a	O	57-58
small	O	59-64
interval	O	65-73
on	O	74-76
chromosome	O	77-87
17q12	O	88-93
-	O	93-94
21	O	94-96
:	O	96-97
exclusion	O	98-107
of	O	108-110
candidate	O	111-120
genes	O	121-126
EDH17B2	O	127-134
and	O	135-138
RARA	O	139-143
.	O	143-144

A	O	145-146
susceptibility	O	147-161
gene	O	162-166
for	O	167-170
hereditary	B	171-181
breast	I	182-188
-	I	188-189
ovarian	I	189-196
cancer	I	197-203
,	O	203-204
BRCA1	O	205-210
,	O	210-211
has	O	212-215
been	O	216-220
assigned	O	221-229
by	O	230-232
linkage	O	233-240
analysis	O	241-249
to	O	250-252
chromosome	O	253-263
17q21	O	264-269
.	O	269-270

Candidate	O	271-280
genes	O	281-286
in	O	287-289
this	O	290-294
region	O	295-301
include	O	302-309
EDH17B2	O	310-317
,	O	317-318
which	O	319-324
encodes	O	325-332
estradiol	O	333-342
17	O	343-345
beta	O	346-350
-	O	350-351
hydroxysteroid	O	351-365
dehydrogenase	O	366-379
II	O	380-382
(	O	383-384
17	O	384-386
beta	O	387-391
-	O	391-392
HSD	O	392-395
II	O	396-398
)	O	398-399
,	O	399-400
and	O	401-404
RARA	O	405-409
,	O	409-410
the	O	411-414
gene	O	415-419
for	O	420-423
retinoic	O	424-432
acid	O	433-437
receptor	O	438-446
alpha	O	447-452
.	O	452-453

We	O	454-456
have	O	457-461
typed	O	462-467
22	O	468-470
breast	B	471-477
and	I	478-481
breast	I	482-488
-	I	488-489
ovarian	I	489-496
cancer	I	497-503
families	O	504-512
with	O	513-517
eight	O	518-523
polymorphisms	O	524-537
from	O	538-542
the	O	543-546
chromosome	O	547-557
17q12	O	558-563
-	O	563-564
21	O	564-566
region	O	567-573
,	O	573-574
including	O	575-584
two	O	585-588
in	O	589-591
the	O	592-595
EDH17B2	O	596-603
gene	O	604-608
.	O	608-609

Genetic	O	610-617
recombination	O	618-631
with	O	632-636
the	O	637-640
breast	B	641-647
cancer	I	648-654
trait	O	655-660
excludes	O	661-669
RARA	O	670-674
from	O	675-679
further	O	680-687
consideration	O	688-701
as	O	702-704
a	O	705-706
candidate	O	707-716
gene	O	717-721
for	O	722-725
BRCA1	O	726-731
.	O	731-732

Both	O	733-737
BRCA1	O	738-743
and	O	744-747
EDH17B2	O	748-755
map	O	756-759
to	O	760-762
a	O	763-764
6	O	765-766
cM	O	767-769
interval	O	770-778
(	O	779-780
between	O	780-787
THRA1	O	788-793
and	O	794-797
D17S579	O	798-805
)	O	805-806
and	O	807-810
no	O	811-813
recombination	O	814-827
was	O	828-831
observed	O	832-840
between	O	841-848
the	O	849-852
two	O	853-856
genes	O	857-862
.	O	862-863

However	O	864-871
,	O	871-872
direct	O	873-879
sequencing	O	880-890
of	O	891-893
overlapping	O	894-905
PCR	O	906-909
products	O	910-918
containing	O	919-929
the	O	930-933
entire	O	934-940
EDH17B2	O	941-948
gene	O	949-953
in	O	954-956
four	O	957-961
unrelated	O	962-971
affected	O	972-980
women	O	981-986
did	O	987-990
not	O	991-994
uncover	O	995-1002
any	O	1003-1006
sequence	O	1007-1015
variation	O	1016-1025
,	O	1025-1026
other	O	1027-1032
than	O	1033-1037
previously	O	1038-1048
described	O	1049-1058
polymorphisms	O	1059-1072
.	O	1072-1073

Mutations	O	1074-1083
in	O	1084-1086
the	O	1087-1090
EDH17B2	O	1091-1098
gene	O	1099-1103
,	O	1103-1104
therefore	O	1105-1114
do	O	1115-1117
not	O	1118-1121
appear	O	1122-1128
to	O	1129-1131
be	O	1132-1134
responsible	O	1135-1146
for	O	1147-1150
the	O	1151-1154
hereditary	B	1155-1165
breast	I	1166-1172
-	I	1172-1173
ovarian	I	1173-1180
cancer	I	1181-1187
syndrome	I	1188-1196
.	O	1196-1197

Single	O	1198-1204
meiotic	O	1205-1212
crossovers	O	1213-1223
in	O	1224-1226
affected	O	1227-1235
women	O	1236-1241
suggest	O	1242-1249
that	O	1250-1254
BRCA1	O	1255-1260
is	O	1261-1263
flanked	O	1264-1271
by	O	1272-1274
the	O	1275-1278
loci	O	1279-1283
RARA	O	1284-1288
and	O	1289-1292
D17S78	O	1293-1299
.	O	1299-1300
.	O	1299-1300

Hereditary	B	0-10
C2	I	11-13
deficiency	I	14-24
associated	O	25-35
with	O	36-40
common	O	41-47
variable	O	48-56
immunodeficiency	B	57-73
.	O	73-74

Homozygous	O	75-85
C2	B	86-88
deficiency	I	89-99
in	O	100-102
a	O	103-104
19	O	105-107
-	O	107-108
year	O	108-112
-	O	107-108
old	O	113-116
boy	O	117-120
was	O	121-124
associated	O	125-135
with	O	136-140
variable	O	141-149
immunodeficiency	B	150-166
manifested	O	167-177
by	O	178-180
marked	O	181-187
hypoimmunoglobulinemia	B	188-210
and	O	211-214
impaired	O	215-223
antibody	O	224-232
responses	O	233-242
,	O	242-243
normal	O	244-250
circulating	O	251-262
B	O	263-264
lymphocytes	O	265-276
,	O	276-277
and	O	278-281
subnormal	O	282-291
T	O	292-293
-	O	293-294
cell	O	294-298
functions	O	299-308
.	O	308-309

Neither	O	310-317
antilymphocytic	O	318-333
autoantibodies	O	334-348
nor	O	349-352
chromosomal	B	353-364
abnormalities	I	365-378
were	O	379-383
found	O	384-389
.	O	389-390

Serum	O	391-396
immunoglobulin	O	397-411
levels	O	412-418
were	O	419-423
within	O	424-430
normal	O	431-437
limits	O	438-444
in	O	445-447
his	O	448-451
parents	O	452-459
and	O	460-463
brother	O	464-471
who	O	472-475
were	O	476-480
heterozygous	O	481-493
for	O	494-497
C2	B	498-500
deficiency	I	501-511
.	O	511-512

The	O	513-516
patients	O	517-525
lymphocytes	O	526-537
were	O	538-542
homozygous	O	543-553
at	O	554-556
the	O	557-560
HLA	O	561-564
-	O	564-565
D	O	565-566
locus	O	567-572
but	O	573-576
expressed	O	577-586
an	O	587-589
antigen	O	590-597
different	O	598-607
from	O	608-612
DW2	O	613-616
.	O	616-617
.	O	616-617

Isolation	O	0-9
of	O	10-12
molecular	O	13-22
probes	O	23-29
associated	O	30-40
with	O	41-45
the	O	46-49
chromosome	O	50-60
15	O	61-63
instability	O	64-75
in	O	76-78
the	O	79-82
Prader	B	83-89
-	I	89-90
Willi	I	90-95
syndrome	I	96-104
.	O	104-105

Flow	O	106-110
cytometry	O	111-120
and	O	121-124
recombinant	O	125-136
DNA	O	137-140
techniques	O	141-151
have	O	152-156
been	O	157-161
used	O	162-166
to	O	167-169
obtain	O	170-176
reagents	O	177-185
for	O	186-189
a	O	190-191
molecular	O	192-201
analysis	O	202-210
of	O	211-213
the	O	214-217
Prader	B	218-224
-	I	224-225
Willi	I	225-230
syndrome	I	231-239
(	O	240-241
PWS	B	241-244
)	O	244-245
.	O	245-246

HindIII	O	247-254
total	O	255-260
-	O	260-261
digest	O	261-267
libraries	O	268-277
were	O	278-282
prepared	O	283-291
in	O	292-294
lambda	O	295-301
phage	O	302-307
Charon	O	308-314
21A	O	315-318
from	O	319-323
flow	O	324-328
-	O	328-329
sorted	O	329-335
inverted	O	336-344
duplicated	O	345-355
no	O	356-358
.	O	358-359
15	O	360-362
human	O	363-368
chromosomes	O	369-380
and	O	381-384
propagated	O	385-395
on	O	396-398
recombination	O	399-412
-	O	412-413
proficient	O	413-423
(	O	424-425
LE392	O	425-430
)	O	430-431
and	O	432-435
recBC	O	436-441
-	O	441-442
,	O	442-443
sbcB	O	444-448
-	O	448-449
(	O	450-451
DB1257	O	451-457
)	O	457-458
bacteria	O	459-467
.	O	467-468

Twelve	O	469-475
distinct	O	476-484
chromosome	O	485-495
15	O	496-498
-	O	498-499
specific	O	499-507
probes	O	508-514
have	O	515-519
been	O	520-524
isolated	O	525-533
.	O	533-534

Eight	O	535-540
localized	O	541-550
to	O	551-553
the	O	554-557
region	O	558-564
15q11	O	565-570
-	O	570-571
-	O	570-571
-	O	570-571
-	O	570-571
13	O	574-576
.	O	576-577

Four	O	578-582
of	O	583-585
these	O	586-591
eight	O	592-597
sublocalized	O	598-610
to	O	611-613
band	O	614-618
15q11	O	619-624
.	O	624-625
2	O	626-627
and	O	628-631
are	O	632-635
shown	O	636-641
to	O	642-644
be	O	645-647
deleted	O	648-655
in	O	656-658
DNA	O	659-662
of	O	663-665
one	O	666-669
of	O	670-672
two	O	673-676
patients	O	677-685
examined	O	686-694
with	O	695-699
the	O	700-703
PWS	B	704-707
.	O	707-708

Heteroduplex	O	709-721
analysis	O	722-730
of	O	731-733
two	O	734-737
of	O	738-740
these	O	741-746
clones	O	747-753
,	O	753-754
which	O	755-760
grew	O	761-765
on	O	766-768
DB1257	O	769-775
but	O	776-779
not	O	780-783
on	O	784-786
LE392	O	787-792
,	O	792-793
revealed	O	794-802
stem	O	803-807
-	O	807-808
loop	O	808-812
structures	O	813-823
in	O	824-826
the	O	827-830
inserts	O	831-838
,	O	838-839
indicative	O	840-850
of	O	851-853
inverted	O	854-862
,	O	862-863
repeated	O	864-872
DNA	O	873-876
elements	O	877-885
.	O	885-886

Such	O	887-891
DNA	O	892-895
repeats	O	896-903
might	O	904-909
account	O	910-917
for	O	918-921
some	O	922-926
of	O	927-929
the	O	930-933
cloning	O	934-941
instability	O	942-953
of	O	954-956
DNA	O	957-960
segments	O	961-969
from	O	970-974
proximal	O	975-983
15q	O	984-987
.	O	987-988

Analysis	O	989-997
of	O	998-1000
the	O	1001-1004
genetic	O	1005-1012
and	O	1013-1016
physical	O	1017-1025
instability	O	1026-1037
associated	O	1038-1048
with	O	1049-1053
the	O	1054-1057
repeated	O	1058-1066
sequences	O	1067-1076
we	O	1077-1079
have	O	1080-1084
isolated	O	1085-1093
from	O	1094-1098
band	O	1099-1103
15q11	O	1104-1109
.	O	1109-1110
2	O	1111-1112
may	O	1113-1116
elucidate	O	1117-1126
the	O	1127-1130
molecular	O	1131-1140
basis	O	1141-1146
for	O	1147-1150
the	O	1151-1154
instability	O	1155-1166
of	O	1167-1169
this	O	1170-1174
chromosomal	O	1175-1186
region	O	1187-1193
in	O	1194-1196
patients	O	1197-1205
with	O	1206-1210
the	O	1211-1214
PWS	B	1215-1218
or	O	1219-1221
other	O	1222-1227
diseases	O	1228-1236
associated	O	1237-1247
with	O	1248-1252
chromosomal	B	1253-1264
abnormalities	I	1265-1278
in	O	1279-1281
the	O	1282-1285
proximal	O	1286-1294
long	O	1295-1299
arm	O	1300-1303
of	O	1304-1306
human	O	1307-1312
chromosome	O	1313-1323
15	O	1324-1326

Myotonic	B	0-8
dystrophy	I	9-18
:	O	18-19
evidence	O	20-28
for	O	29-32
a	O	33-34
possible	O	35-43
dominant	O	44-52
-	O	52-53
negative	O	53-61
RNA	O	62-65
mutation	O	66-74
.	O	74-75

The	O	76-79
trinucleotide	O	80-93
expansion	O	94-103
mutation	O	104-112
causing	O	113-120
myotonic	B	121-129
dystrophy	I	130-139
is	O	140-142
in	O	143-145
the	O	146-149
3	O	150-151
untranslated	O	152-164
region	O	165-171
of	O	172-174
a	O	175-176
protein	O	177-184
kinase	O	185-191
gene	O	192-196
.	O	196-197

The	O	198-201
molecular	O	202-211
mechanisms	O	212-222
by	O	223-225
which	O	226-231
the	O	232-235
expanded	O	236-244
repeat	O	245-251
causes	O	252-258
the	O	259-262
clinically	O	263-273
variable	O	274-282
and	O	283-286
multisystemic	B	287-300
disease	I	301-308
,	O	308-309
myotonic	B	310-318
dystrophy	I	319-328
,	O	328-329
are	O	330-333
not	O	334-337
understood	O	338-348
.	O	348-349

It	O	350-352
has	O	353-356
been	O	357-361
particularly	O	362-374
difficult	O	375-384
to	O	385-387
rationalize	O	388-399
the	O	400-403
dominant	O	404-412
inheritance	O	413-424
with	O	425-429
the	O	430-433
fact	O	434-438
that	O	439-443
the	O	444-447
expansion	O	448-457
mutation	O	458-466
lies	O	467-471
outside	O	472-479
of	O	480-482
the	O	483-486
protein	O	487-494
-	O	494-495
encoding	O	495-503
gene	O	504-508
elements	O	509-517
,	O	517-518
and	O	519-522
should	O	523-529
not	O	530-533
be	O	534-536
translated	O	537-547
into	O	548-552
protein	O	553-560
.	O	560-561

Here	O	562-566
we	O	567-569
use	O	570-573
muscle	O	574-580
biopsies	O	581-589
from	O	590-594
classical	O	595-604
adult	O	605-610
-	O	610-611
onset	O	611-616
myotonic	B	617-625
dystrophy	I	626-635
patients	O	636-644
to	O	645-647
study	O	648-653
the	O	654-657
accumulation	O	658-670
of	O	671-673
transcripts	O	674-685
from	O	686-690
both	O	691-695
the	O	696-699
normal	O	700-706
and	O	707-710
expanded	O	711-719
DM	B	720-722
kinase	O	723-729
genes	O	730-735
in	O	736-738
patient	O	739-746
muscle	O	747-753
,	O	753-754
and	O	755-758
compare	O	759-766
the	O	767-770
results	O	771-778
to	O	779-781
normal	O	782-788
and	O	789-792
myopathic	B	793-802
controls	O	803-811
.	O	811-812

We	O	813-815
found	O	816-821
relatively	O	822-832
small	O	833-838
decreases	O	839-848
of	O	849-851
DM	B	852-854
kinase	O	855-861
RNA	O	862-865
in	O	866-868
the	O	869-872
total	O	873-878
RNA	O	879-882
pool	O	883-887
from	O	888-892
muscle	O	893-899
;	O	899-900
however	O	901-908
,	O	908-909
these	O	910-915
reductions	O	916-926
were	O	927-931
not	O	932-935
disease	O	936-943
specific	O	944-952
.	O	952-953

Analysis	O	954-962
of	O	963-965
poly	O	966-970
(	O	971-972
A	O	972-973
)	O	973-974
+	O	975-976
RNA	O	977-980
showed	O	981-987
dramatic	O	988-996
decreases	O	997-1006
of	O	1007-1009
both	O	1010-1014
the	O	1015-1018
mutant	O	1019-1025
and	O	1026-1029
normal	O	1030-1036
DM	B	1037-1039
kinase	O	1040-1046
RNAs	O	1047-1051
,	O	1051-1052
and	O	1053-1056
these	O	1057-1062
changes	O	1063-1070
were	O	1071-1075
disease	O	1076-1083
-	O	1083-1084
specific	O	1084-1092
.	O	1092-1093

Our	O	1094-1097
findings	O	1098-1106
are	O	1107-1110
consistent	O	1111-1121
with	O	1122-1126
a	O	1127-1128
novel	O	1129-1134
molecular	O	1135-1144
pathogenetic	O	1145-1157
mechanism	O	1158-1167
for	O	1168-1171
myotonic	B	1172-1180
dystrophy	I	1181-1190
both	O	1192-1196
the	O	1197-1200
normal	O	1201-1207
and	O	1208-1211
expanded	O	1212-1220
DM	B	1221-1223
kinase	O	1224-1230
genes	O	1231-1236
are	O	1237-1240
transcribed	O	1241-1252
in	O	1253-1255
patient	O	1256-1263
muscle	O	1264-1270
,	O	1270-1271
but	O	1272-1275
the	O	1276-1279
abnormal	O	1280-1288
expansion	O	1289-1298
-	O	1298-1299
containing	O	1299-1309
RNA	O	1310-1313
has	O	1314-1317
a	O	1318-1319
dominant	O	1320-1328
effect	O	1329-1335
on	O	1336-1338
RNA	O	1339-1342
metabolism	O	1343-1353
by	O	1354-1356
preventing	O	1357-1367
the	O	1368-1371
accumulation	O	1372-1384
of	O	1385-1387
poly	O	1388-1392
(	O	1393-1394
A	O	1394-1395
)	O	1395-1396
+	O	1397-1398
RNA	O	1399-1402
.	O	1402-1403

The	O	1404-1407
ability	O	1408-1415
of	O	1416-1418
the	O	1419-1422
expansion	O	1423-1432
mutation	O	1433-1441
to	O	1442-1444
alter	O	1445-1450
accumulation	O	1451-1463
of	O	1464-1466
poly	O	1467-1471
(	O	1472-1473
A	O	1473-1474
)	O	1474-1475
+	O	1476-1477
RNA	O	1478-1481
in	O	1482-1484
trans	O	1485-1490
suggests	O	1491-1499
that	O	1500-1504
myotonic	B	1505-1513
dystrophy	I	1514-1523
may	O	1524-1527
be	O	1528-1530
the	O	1531-1534
first	O	1535-1540
example	O	1541-1548
of	O	1549-1551
a	O	1552-1553
dominant	O	1554-1562
-	O	1562-1563
negative	O	1563-1571
mutation	O	1572-1580
manifested	O	1581-1591
at	O	1592-1594
the	O	1595-1598
RNA	O	1599-1602
level	O	1603-1608
.	O	1608-1609
.	O	1608-1609

Isolation	O	0-9
of	O	10-12
the	O	13-16
gene	O	17-21
for	O	22-25
McLeod	B	26-32
syndrome	I	33-41
that	O	42-46
encodes	O	47-54
a	O	55-56
novel	O	57-62
membrane	O	63-71
transport	O	72-81
protein	O	82-89
.	O	89-90

McLeod	B	91-97
syndrome	I	98-106
is	O	107-109
an	O	110-112
X	B	113-114
-	I	114-115
linked	I	115-121
multisystem	I	122-133
disorder	I	134-142
characterized	O	143-156
by	O	157-159
abnormalities	O	160-173
in	O	174-176
the	O	177-180
neuromuscular	O	181-194
and	O	195-198
hematopoietic	O	199-212
systems	O	213-220
.	O	220-221

We	O	222-224
have	O	225-229
assembled	O	230-239
a	O	240-241
cosmid	O	242-248
contig	O	249-255
of	O	256-258
360	O	259-262
kb	O	263-265
that	O	266-270
encompasses	O	271-282
the	O	283-286
McLeod	B	287-293
gene	O	294-298
locus	O	299-304
.	O	304-305

A	O	306-307
50	O	308-310
kb	O	311-313
deletion	O	314-322
was	O	323-326
detected	O	327-335
by	O	336-338
screening	O	339-348
DNA	O	349-352
from	O	353-357
patients	O	358-366
with	O	367-371
radiolabeled	O	372-384
whole	O	385-390
cosmids	O	391-398
,	O	398-399
and	O	400-403
two	O	404-407
transcription	O	408-421
units	O	422-427
were	O	428-432
identified	O	433-443
within	O	444-450
this	O	451-455
deletion	O	456-464
.	O	464-465

The	O	466-469
mRNA	O	470-474
expression	O	475-485
pattern	O	486-493
of	O	494-496
one	O	497-500
of	O	501-503
them	O	504-508
,	O	508-509
designated	O	510-520
as	O	521-523
XK	O	524-526
,	O	526-527
correlates	O	528-538
closely	O	539-546
to	O	547-549
the	O	550-553
McLeod	B	554-560
phenotype	O	561-570
.	O	570-571

XK	O	572-574
encodes	O	575-582
a	O	583-584
novel	O	585-590
protein	O	591-598
with	O	599-603
structural	O	604-614
characteristics	O	615-630
of	O	631-633
prokaryotic	O	634-645
and	O	646-649
eukaryotic	O	650-660
membrane	O	661-669
transport	O	670-679
proteins	O	680-688
.	O	688-689

Nucleotide	O	690-700
sequence	O	701-709
analysis	O	710-718
of	O	719-721
XK	O	722-724
from	O	725-729
two	O	730-733
unrelated	O	734-743
McLeod	B	744-750
patients	O	751-759
has	O	760-763
identified	O	764-774
point	O	775-780
mutations	O	781-790
at	O	791-793
conserved	O	794-803
splice	O	804-810
donor	O	811-816
and	O	817-820
acceptor	O	821-829
sites	O	830-835
.	O	835-836

These	O	837-842
findings	O	843-851
provide	O	852-859
direct	O	860-866
evidence	O	867-875
that	O	876-880
XK	O	881-883
is	O	884-886
responsible	O	887-898
for	O	899-902
McLeod	B	903-909
syndrome	I	910-918
.	O	918-919
.	O	918-919

Molecular	O	0-9
basis	O	10-15
of	O	16-18
very	B	19-23
long	I	24-28
chain	I	29-34
acyl	I	35-39
-	I	39-40
CoA	I	40-43
dehydrogenase	I	44-57
deficiency	I	58-68
in	O	69-71
three	O	72-77
Israeli	O	78-85
patients	O	86-94
:	O	94-95
identification	O	96-110
of	O	111-113
a	O	114-115
complex	O	116-123
mutant	O	124-130
allele	O	131-137
with	O	138-142
P65L	O	143-147
and	O	148-151
K247Q	O	152-157
mutations	O	158-167
,	O	167-168
the	O	169-172
former	O	173-179
being	O	180-185
an	O	186-188
exonic	O	189-195
mutation	O	196-204
causing	O	205-212
exon	O	213-217
3	O	218-219
skipping	O	220-228
.	O	228-229

Very	B	230-234
long	I	235-239
chain	I	240-245
acyl	I	246-250
-	I	250-251
CoA	I	251-254
dehydrogenase	I	255-268
(	I	269-270
VLCAD	I	270-275
)	I	275-276
deficiency	I	277-287
is	O	288-290
a	O	291-292
life	O	293-297
-	O	297-298
threatening	O	298-309
disorder	O	310-318
of	O	319-321
mitochondrial	O	322-335
fatty	O	336-341
acid	O	342-346
beta	O	347-351
-	O	351-352
oxidation	O	352-361
.	O	361-362

We	O	363-365
identified	O	366-376
four	O	377-381
novel	O	382-387
mutations	O	388-397
in	O	398-400
three	O	401-406
unrelated	O	407-416
patients	O	417-425
.	O	425-426

All	O	427-430
patients	O	431-439
had	O	440-443
the	O	444-447
severe	O	448-454
childhood	O	455-464
form	O	465-469
of	O	470-472
VLCAD	B	473-478
deficiency	I	479-489
with	O	490-494
early	O	495-500
onset	O	501-506
and	O	507-510
high	O	511-515
mortality	O	516-525
.	O	525-526

Immunoblot	O	527-537
analysis	O	538-546
revealed	O	547-555
that	O	556-560
VLCAD	O	561-566
protein	O	567-574
was	O	575-578
undetectable	O	579-591
in	O	592-594
patients	O	595-603
2	O	604-605
and	O	606-609
3	O	610-611
,	O	611-612
whereas	O	613-620
normal	O	621-627
-	O	627-628
size	O	628-632
VLCAD	O	633-638
protein	O	639-646
and	O	647-650
an	O	651-653
aberrant	O	654-662
form	O	663-667
of	O	668-670
VLCAD	O	671-676
(	O	677-678
4kDa	O	678-682
smaller	O	683-690
)	O	690-691
were	O	692-696
detected	O	697-705
in	O	706-708
patient	O	709-716
1	O	717-718
.	O	718-719

As	O	720-722
expected	O	723-731
,	O	731-732
null	O	733-737
mutations	O	738-747
were	O	748-752
found	O	753-758
in	O	759-761
patients	O	762-770
2	O	771-772
and	O	773-776
3	O	777-778
patient	O	780-787
2	O	788-789
is	O	790-792
homozygous	O	793-803
for	O	804-807
a	O	808-809
frameshift	O	810-820
mutation	O	821-829
,	O	829-830
del	O	831-834
4	O	835-836
bp	O	837-839
at	O	840-842
798	O	843-846
-	O	846-847
801	O	847-850
,	O	850-851
and	O	852-855
patient	O	856-863
3	O	864-865
is	O	866-868
homozygous	O	869-879
for	O	880-883
a	O	884-885
nonsense	O	886-894
mutation	O	895-903
65C	O	904-907
>	O	908-909
A	O	910-911
(	O	912-913
S22X	O	913-917
)	O	917-918
.	O	918-919

Patient	O	920-927
1	O	928-929
was	O	930-933
homozygous	O	934-944
for	O	945-948
a	O	949-950
complex	O	951-958
mutant	O	959-965
allele	O	966-972
containing	O	973-983
two	O	984-987
alterations	O	988-999
,	O	999-1000
including	O	1001-1010
a	O	1011-1012
194C	O	1013-1017
>	O	1018-1019
T	O	1020-1021
transition	O	1022-1032
(	O	1033-1034
P65L	O	1034-1038
)	O	1038-1039
and	O	1040-1043
739A	O	1044-1048
>	O	1049-1050
C	O	1051-1052
transversion	O	1053-1065
(	O	1066-1067
K247Q	O	1067-1072
)	O	1072-1073
;	O	1073-1074
in	O	1075-1077
the	O	1078-1081
case	O	1082-1086
of	O	1087-1089
P65L	O	1090-1094
,	O	1094-1095
the	O	1096-1099
amino	O	1100-1105
acid	O	1106-1110
change	O	1111-1117
does	O	1118-1122
not	O	1123-1126
reduce	O	1127-1133
enzyme	O	1134-1140
activity	O	1141-1149
.	O	1149-1150

However	O	1151-1158
,	O	1158-1159
the	O	1160-1163
nucleotide	O	1164-1174
change	O	1175-1181
resulted	O	1182-1190
in	O	1191-1193
exon	O	1194-1198
3	O	1199-1200
skipping	O	1201-1209
,	O	1209-1210
whereas	O	1211-1218
the	O	1219-1222
latter	O	1223-1229
K247Q	O	1230-1235
mutation	O	1236-1244
had	O	1245-1248
a	O	1249-1250
drastic	O	1251-1258
effect	O	1259-1265
on	O	1266-1268
enzyme	O	1269-1275
activity	O	1276-1284
.	O	1284-1285

We	O	1286-1288
verified	O	1289-1297
these	O	1298-1303
events	O	1304-1310
by	O	1311-1313
in	O	1314-1316
vivo	O	1317-1321
splicing	O	1322-1330
experiments	O	1331-1342
and	O	1343-1346
transient	O	1347-1356
expression	O	1357-1367
analysis	O	1368-1376
of	O	1377-1379
mutant	O	1380-1386
cDNAs	O	1387-1392
.	O	1392-1393

The	O	1394-1397
P65L	O	1398-1402
mutation	O	1403-1411
locates	O	1412-1419
11	O	1420-1422
bases	O	1423-1428
upstream	O	1429-1437
of	O	1438-1440
a	O	1441-1442
splice	O	1443-1449
donor	O	1450-1455
site	O	1456-1460
of	O	1461-1463
intron	O	1464-1470
3	O	1471-1472
.	O	1472-1473

This	O	1474-1478
is	O	1479-1481
an	O	1482-1484
example	O	1485-1492
of	O	1493-1495
an	O	1496-1498
exonic	O	1499-1505
mutation	O	1506-1514
which	O	1515-1520
affects	O	1521-1528
exon	O	1529-1533
-	O	1533-1534
splicing	O	1534-1542
.	O	1542-1543
.	O	1542-1543

Amino	O	0-5
-	O	5-6
terminal	O	6-14
fragments	O	15-24
of	O	25-27
mutant	O	28-34
huntingtin	O	35-45
show	O	46-50
selective	O	51-60
accumulation	O	61-73
in	O	74-76
striatal	O	77-85
neurons	O	86-93
and	O	94-97
synaptic	O	98-106
toxicity	O	107-115
.	O	115-116

Huntington	B	117-127
disease	I	128-135
(	O	136-137
HD	B	137-139
)	O	139-140
is	O	141-143
caused	O	144-150
by	O	151-153
expansion	O	154-163
of	O	164-166
a	O	167-168
glutamine	O	169-178
repeat	O	179-185
in	O	186-188
the	O	189-192
amino	O	193-198
-	O	198-199
terminal	O	199-207
region	O	208-214
of	O	215-217
huntingtin	O	218-228
.	O	228-229

Despite	O	230-237
its	O	238-241
widespread	O	242-252
expression	O	253-263
,	O	263-264
mutant	O	265-271
huntingtin	O	272-282
induces	O	283-290
selective	O	291-300
neuronal	O	301-309
loss	O	310-314
in	O	315-317
striatal	O	318-326
neurons	O	327-334
.	O	334-335

Here	O	336-340
we	O	341-343
report	O	344-350
that	O	351-355
,	O	355-356
in	O	357-359
mutant	O	360-366
mice	O	367-371
expressing	O	372-382
HD	B	383-385
repeats	O	386-393
,	O	393-394
the	O	395-398
production	O	399-409
and	O	410-413
aggregation	O	414-425
of	O	426-428
N	O	429-430
-	O	430-431
terminal	O	431-439
huntingtin	O	440-450
fragments	O	451-460
preferentially	O	461-475
occur	O	476-481
in	O	482-484
HD	B	485-487
-	O	487-488
affected	O	488-496
neurons	O	497-504
and	O	505-508
their	O	509-514
processes	O	515-524
and	O	525-528
axonal	O	529-535
terminals	O	536-545
.	O	545-546

N	O	547-548
-	O	548-549
terminal	O	549-557
fragments	O	558-567
of	O	568-570
mutant	O	571-577
huntingtin	O	578-588
form	O	589-593
aggregates	O	594-604
and	O	605-608
induce	O	609-615
neuritic	B	616-624
degeneration	I	625-637
in	O	638-640
cultured	O	641-649
striatal	O	650-658
neurons	O	659-666
.	O	666-667

N	O	668-669
-	O	669-670
terminal	O	670-678
mutant	O	679-685
huntingtin	O	686-696
also	O	697-701
binds	O	702-707
to	O	708-710
synaptic	O	711-719
vesicles	O	720-728
and	O	729-732
inhibits	O	733-741
their	O	742-747
glutamate	O	748-757
uptake	O	758-764
in	O	765-767
vitro	O	768-773
.	O	773-774

The	O	775-778
specific	O	779-787
processing	O	788-798
and	O	799-802
accumulation	O	803-815
of	O	816-818
toxic	O	819-824
fragments	O	825-834
of	O	835-837
N	O	838-839
-	O	839-840
terminal	O	840-848
huntingtin	O	849-859
in	O	860-862
HD	B	863-865
-	O	865-866
affected	O	866-874
striatal	O	875-883
neurons	O	884-891
,	O	891-892
especially	O	893-903
in	O	904-906
their	O	907-912
neuronal	O	913-921
processes	O	922-931
and	O	932-935
axonal	O	936-942
terminals	O	943-952
,	O	952-953
may	O	954-957
contribute	O	958-968
to	O	969-971
the	O	972-975
selective	O	976-985
neuropathology	O	986-1000
of	O	1001-1003
HD	B	1004-1006
.	O	1006-1007
.	O	1006-1007

Phenotypic	O	0-10
variation	O	11-20
including	O	21-30
retinitis	B	31-40
pigmentosa	I	41-51
,	O	51-52
pattern	B	53-60
dystrophy	I	61-70
,	O	70-71
and	O	72-75
fundus	B	76-82
flavimaculatus	I	83-97
in	O	98-100
a	O	101-102
single	O	103-109
family	O	110-116
with	O	117-121
a	O	122-123
deletion	O	124-132
of	O	133-135
codon	O	136-141
153	O	142-145
or	O	146-148
154	O	149-152
of	O	153-155
the	O	156-159
peripherin	O	160-170
/	O	170-171
RDS	O	171-174
gene	O	175-179
.	O	179-180

BACKGROUND	O	181-191
AND	O	192-195
OBJECTIVES	O	196-206
Mutations	O	208-217
of	O	218-220
the	O	221-224
peripherin	O	225-235
/	O	235-236
RDS	O	236-239
gene	O	240-244
have	O	245-249
been	O	250-254
reported	O	255-263
in	O	264-266
autosomal	B	267-276
dominant	I	277-285
retinitis	I	286-295
pigmentosa	I	296-306
,	O	306-307
pattern	O	308-315
macular	B	316-323
dystrophy	I	324-333
,	O	333-334
and	O	335-338
retinitis	B	339-348
punctata	I	349-357
albescens	I	358-367
.	O	367-368

We	O	369-371
report	O	372-378
herein	O	379-385
the	O	386-389
occurrence	O	390-400
of	O	401-403
three	O	404-409
separate	O	410-418
phenotypes	O	419-429
within	O	430-436
a	O	437-438
single	O	439-445
family	O	446-452
with	O	453-457
a	O	458-459
novel	O	460-465
3	O	466-467
-	O	467-468
base	O	468-472
pair	O	473-477
deletion	O	478-486
of	O	487-489
codon	O	490-495
153	O	496-499
or	O	500-502
154	O	503-506
of	O	507-509
the	O	510-513
peripherin	O	514-524
/	O	524-525
RDS	O	525-528
gene	O	529-533
.	O	533-534

DESIGN	O	535-541
Case	O	543-547
reports	O	548-555
with	O	556-560
clinical	O	561-569
features	O	570-578
,	O	578-579
fluorescein	O	580-591
angiography	O	592-603
,	O	603-604
kinetic	O	605-612
perimetry	O	613-622
,	O	622-623
electrophysiological	O	624-644
studies	O	645-652
,	O	652-653
and	O	654-657
molecular	O	658-667
genetics	O	668-676
.	O	676-677

SETTING	O	678-685
University	O	687-697
medical	O	698-705
centers	O	706-713
.	O	713-714

PATIENTS	O	715-723
A	O	725-726
75	O	727-729
-	O	729-730
year	O	730-734
-	O	729-730
old	O	735-738
woman	O	739-744
,	O	744-745
her	O	746-749
two	O	750-753
daughters	O	754-763
(	O	764-765
aged	O	765-769
44	O	770-772
and	O	773-776
50	O	777-779
years	O	780-785
)	O	785-786
,	O	786-787
and	O	788-791
her	O	792-795
49	O	796-798
-	O	798-799
year	O	799-803
-	O	798-799
old	O	804-807
son	O	808-811
were	O	812-816
screened	O	817-825
for	O	826-829
peripherin	O	830-840
/	O	840-841
RDS	O	841-844
mutations	O	845-854
because	O	855-862
of	O	863-865
the	O	866-869
presence	O	870-878
of	O	879-881
multiple	O	882-890
phenotypes	O	891-901
within	O	902-908
the	O	909-912
same	O	913-917
family	O	918-924
.	O	924-925

RESULTS	O	926-933
The	O	935-938
mother	O	939-945
presented	O	946-955
at	O	956-958
age	O	959-962
63	O	963-965
years	O	966-971
with	O	972-976
a	O	977-978
profoundly	O	979-989
abnormal	O	990-998
electroretinogram	O	999-1016
(	O	1017-1018
ERG	O	1018-1021
)	O	1021-1022
and	O	1023-1026
adult	O	1027-1032
-	O	1032-1033
onset	O	1033-1038
retinitis	B	1039-1048
pigmentosa	I	1049-1059
that	O	1060-1064
progressed	O	1065-1075
dramatically	O	1076-1088
over	O	1089-1093
12	O	1094-1096
years	O	1097-1102
,	O	1102-1103
with	O	1104-1108
marked	O	1109-1115
loss	O	1116-1120
of	O	1121-1123
peripheral	O	1124-1134
visual	O	1135-1141
field	O	1142-1147
.	O	1147-1148

One	O	1149-1152
daughter	O	1153-1161
developed	O	1162-1171
pattern	B	1172-1179
macular	I	1180-1187
dystrophy	I	1188-1197
at	O	1198-1200
age	O	1201-1204
31	O	1205-1207
years	O	1208-1213
.	O	1213-1214

At	O	1215-1217
age	O	1218-1221
44	O	1222-1224
years	O	1225-1230
,	O	1230-1231
her	O	1232-1235
ERG	O	1236-1239
was	O	1240-1243
moderately	O	1244-1254
abnormal	O	1255-1263
but	O	1264-1267
her	O	1268-1271
clinical	O	1272-1280
disease	O	1281-1288
was	O	1289-1292
limited	O	1293-1300
to	O	1301-1303
the	O	1304-1307
macula	O	1308-1314
.	O	1314-1315

Another	O	1316-1323
daughter	O	1324-1332
presented	O	1333-1342
at	O	1343-1345
age	O	1346-1349
42	O	1350-1352
years	O	1353-1358
with	O	1359-1363
macular	B	1364-1371
degeneration	I	1372-1384
and	O	1385-1388
over	O	1389-1393
10	O	1394-1396
years	O	1397-1402
developed	O	1403-1412
the	O	1413-1416
clinical	O	1417-1425
picture	O	1426-1433
of	O	1434-1436
fundus	B	1437-1443
flavimaculatus	I	1444-1458
.	O	1458-1459

Her	O	1460-1463
peripheral	O	1464-1474
visual	O	1475-1481
field	O	1482-1487
was	O	1488-1491
preserved	O	1492-1501
but	O	1502-1505
her	O	1506-1509
ERG	O	1510-1513
was	O	1514-1517
moderately	O	1518-1528
abnormal	O	1529-1537
.	O	1537-1538

The	O	1539-1542
son	O	1543-1546
had	O	1547-1550
onset	O	1551-1556
of	O	1557-1559
macular	B	1560-1567
degeneration	I	1568-1580
at	O	1581-1583
age	O	1584-1587
44	O	1588-1590
years	O	1591-1596
.	O	1596-1597

Pericentral	B	1598-1609
scotomas	I	1610-1618
were	O	1619-1623
present	O	1624-1631
and	O	1632-1635
the	O	1636-1639
ERG	O	1640-1643
was	O	1644-1647
markedly	O	1648-1656
abnormal	O	1657-1665
.	O	1665-1666

Fluorescein	O	1667-1678
angiography	O	1679-1690
revealed	O	1691-1699
punctate	O	1700-1708
pigment	O	1709-1716
epithelial	O	1717-1727
transmission	O	1728-1740
defects	O	1741-1748
.	O	1748-1749

CONCLUSIONS	O	1750-1761
A	O	1763-1764
3	O	1765-1766
-	O	1766-1767
base	O	1767-1771
pair	O	1772-1776
deletion	O	1777-1785
of	O	1786-1788
codon	O	1789-1794
153	O	1795-1798
or	O	1799-1801
154	O	1802-1805
of	O	1806-1808
the	O	1809-1812
peripherin	O	1813-1823
/	O	1823-1824
RDS	O	1824-1827
gene	O	1828-1832
can	O	1833-1836
produce	O	1837-1844
clinically	O	1845-1855
disparate	O	1856-1865
phenotypes	O	1866-1876
even	O	1877-1881
within	O	1882-1888
the	O	1889-1892
same	O	1893-1897
family	O	1898-1904
.	O	1904-1905
.	O	1904-1905

Missense	O	0-8
mutation	O	9-17
in	O	18-20
the	O	21-24
alternative	O	25-36
splice	O	37-43
region	O	44-50
of	O	51-53
the	O	54-57
PAX6	O	58-62
gene	O	63-67
in	O	68-70
eye	B	71-74
anomalies	I	75-84
.	O	84-85

The	O	86-89
PAX6	O	90-94
gene	O	95-99
is	O	100-102
involved	O	103-111
in	O	112-114
ocular	O	115-121
morphogenesis	O	122-135
,	O	135-136
and	O	137-140
PAX6	O	141-145
mutations	O	146-155
have	O	156-160
been	O	161-165
detected	O	166-174
in	O	175-177
various	O	178-185
types	O	186-191
of	O	192-194
ocular	B	195-201
anomalies	I	202-211
,	O	211-212
including	O	213-222
aniridia	B	223-231
,	O	231-232
Peters	B	233-239
anomaly	I	240-247
,	O	247-248
corneal	B	249-256
dystrophy	I	257-266
,	O	266-267
congenital	B	268-278
cataract	I	279-287
,	O	287-288
and	O	289-292
foveal	B	293-299
hypoplasia	I	300-310
.	O	310-311

The	O	312-315
gene	O	316-320
encodes	O	321-328
a	O	329-330
transcriptional	O	331-346
regulator	O	347-356
that	O	357-361
recognizes	O	362-372
target	O	373-379
genes	O	380-385
through	O	386-393
its	O	394-397
paired	O	398-404
-	O	404-405
type	O	405-409
DNA	O	410-413
-	O	413-414
binding	O	414-421
domain	O	422-428
.	O	428-429

The	O	430-433
paired	O	434-440
domain	O	441-447
is	O	448-450
composed	O	451-459
of	O	460-462
two	O	463-466
distinct	O	467-475
DNA	O	476-479
-	O	479-480
binding	O	480-487
subdomains	O	488-498
,	O	498-499
the	O	500-503
N	O	504-505
-	O	505-506
terminal	O	506-514
subdomain	O	515-524
(	O	525-526
NTS	O	526-529
)	O	529-530
and	O	531-534
the	O	535-538
C	O	539-540
-	O	540-541
terminal	O	541-549
subdomain	O	550-559
(	O	560-561
CTS	O	561-564
)	O	564-565
,	O	565-566
which	O	567-572
bind	O	573-577
respective	O	578-588
consensus	O	589-598
DNA	O	599-602
sequences	O	603-612
.	O	612-613

The	O	614-617
human	O	618-623
PAX6	O	624-628
gene	O	629-633
produces	O	634-642
two	O	643-646
alternative	O	647-658
splice	O	659-665
isoforms	O	666-674
that	O	675-679
have	O	680-684
the	O	685-688
distinct	O	689-697
structure	O	698-707
of	O	708-710
the	O	711-714
paired	O	715-721
domain	O	722-728
.	O	728-729

The	O	730-733
insertion	O	734-743
,	O	743-744
into	O	745-749
the	O	750-753
NTS	O	754-757
,	O	757-758
of	O	759-761
14	O	762-764
additional	O	765-775
amino	O	776-781
acids	O	782-787
encoded	O	788-795
by	O	796-798
exon	O	799-803
5a	O	804-806
abolishes	O	807-816
the	O	817-820
DNA	O	821-824
-	O	824-825
binding	O	825-832
activity	O	833-841
of	O	842-844
the	O	845-848
NTS	O	849-852
and	O	853-856
unmasks	O	857-864
the	O	865-868
DNA	O	869-872
-	O	872-873
binding	O	873-880
ability	O	881-888
of	O	889-891
the	O	892-895
CTS	O	896-899
.	O	899-900

Thus	O	901-905
,	O	905-906
exon	O	907-911
5a	O	912-914
appears	O	915-922
to	O	923-925
function	O	926-934
as	O	935-937
a	O	938-939
molecular	O	940-949
switch	O	950-956
that	O	957-961
specifies	O	962-971
target	O	972-978
genes	O	979-984
.	O	984-985

We	O	986-988
ascertained	O	989-1000
a	O	1001-1002
novel	O	1003-1008
missense	O	1009-1017
mutation	O	1018-1026
in	O	1027-1029
four	O	1030-1034
pedigrees	O	1035-1044
with	O	1045-1049
Peters	B	1050-1056
anomaly	I	1057-1064
,	O	1064-1065
congenital	B	1066-1076
cataract	I	1077-1085
,	O	1085-1086
Axenfeldt	B	1087-1096
anomaly	I	1097-1104
,	O	1104-1105
and	O	1106-1109
/	O	1109-1110
or	O	1110-1112
foveal	B	1113-1119
hypoplasia	I	1120-1130
,	O	1130-1131
which	O	1132-1137
,	O	1137-1138
to	O	1139-1141
our	O	1142-1145
knowledge	O	1146-1155
,	O	1155-1156
is	O	1157-1159
the	O	1160-1163
first	O	1164-1169
mutation	O	1170-1178
identified	O	1179-1189
in	O	1190-1192
the	O	1193-1196
splice	O	1197-1203
-	O	1203-1204
variant	O	1204-1211
region	O	1212-1218
.	O	1218-1219

A	O	1220-1221
T	O	1222-1223
-	O	1223-1224
-	O	1223-1224
>	O	1226-1227
A	O	1228-1229
transition	O	1230-1240
at	O	1241-1243
the	O	1244-1247
20th	O	1248-1252
nucleotide	O	1253-1263
position	O	1264-1272
of	O	1273-1275
exon	O	1276-1280
5a	O	1281-1283
results	O	1284-1291
in	O	1292-1294
a	O	1295-1296
Val	O	1297-1300
-	O	1300-1301
-	O	1300-1301
>	O	1303-1304
Asp	O	1305-1308
(	O	1309-1310
GTC	O	1310-1313
-	O	1313-1314
-	O	1313-1314
>	O	1316-1317
GAC	O	1318-1321
)	O	1321-1322
substitution	O	1323-1335
at	O	1336-1338
the	O	1339-1342
7th	O	1343-1346
codon	O	1347-1352
of	O	1353-1355
the	O	1356-1359
alternative	O	1360-1371
splice	O	1372-1378
region	O	1379-1385
.	O	1385-1386

Functional	O	1387-1397
analyses	O	1398-1406
demonstrated	O	1407-1419
that	O	1420-1424
the	O	1425-1428
V54D	O	1429-1433
mutation	O	1434-1442
slightly	O	1443-1451
increased	O	1452-1461
NTS	O	1462-1465
binding	O	1466-1473
and	O	1474-1477
decreased	O	1478-1487
CTS	O	1488-1491
transactivation	O	1492-1507
activity	O	1508-1516
to	O	1517-1519
almost	O	1520-1526
half	O	1527-1531
.	O	1531-1532
.	O	1531-1532

A	O	0-1
detailed	O	2-10
multipoint	O	11-21
map	O	22-25
of	O	26-28
human	O	29-34
chromosome	O	35-45
4	O	46-47
provides	O	48-56
evidence	O	57-65
for	O	66-69
linkage	O	70-77
heterogeneity	O	78-91
and	O	92-95
position	O	96-104
-	O	104-105
specific	O	105-113
recombination	O	114-127
rates	O	128-133
.	O	133-134

Utilizing	O	135-144
the	O	145-148
CEPH	O	149-153
reference	O	154-163
panel	O	164-169
and	O	170-173
genotypic	O	174-183
data	O	184-188
for	O	189-192
53	O	193-195
markers	O	196-203
,	O	203-204
we	O	205-207
have	O	208-212
constructed	O	213-224
a	O	225-226
20	O	227-229
-	O	229-230
locus	O	230-235
multipoint	O	236-246
genetic	O	247-254
map	O	255-258
of	O	259-261
human	O	262-267
chromosome	O	268-278
4	O	279-280
.	O	280-281
New	O	282-285
RFLPs	O	286-291
are	O	292-295
reported	O	296-304
for	O	305-308
four	O	309-313
loci	O	314-318
.	O	318-319

The	O	320-323
map	O	324-327
integrates	O	328-338
a	O	339-340
high	O	341-345
-	O	345-346
resolution	O	346-356
genetic	O	357-364
map	O	365-368
of	O	369-371
4p16	O	372-376
into	O	377-381
a	O	382-383
continuous	O	384-394
map	O	395-398
extending	O	399-408
to	O	409-411
4q31	O	412-416
and	O	417-420
an	O	421-423
unlinked	O	424-432
cluster	O	433-440
of	O	441-443
three	O	444-449
loci	O	450-454
at	O	455-457
4q35	O	458-462
.	O	462-463

The	O	464-467
20	O	468-470
linked	O	471-477
markers	O	478-485
form	O	486-490
a	O	491-492
continuous	O	493-503
linkage	O	504-511
group	O	512-517
of	O	518-520
152	O	521-524
cM	O	525-527
in	O	528-530
males	O	531-536
and	O	537-540
202	O	541-544
cM	O	545-547
in	O	548-550
females	O	551-558
.	O	558-559

Likely	O	560-566
genetic	O	567-574
locations	O	575-584
are	O	585-588
provided	O	589-597
for	O	598-601
25	O	602-604
polymorphic	O	605-616
anonymous	O	617-626
sequences	O	627-636
and	O	637-640
28	O	641-643
gene	O	644-648
-	O	648-649
specific	O	649-657
RFLPs	O	658-663
.	O	663-664

The	O	665-668
map	O	669-672
was	O	673-676
constructed	O	677-688
employing	O	689-698
the	O	699-702
LINKAGE	O	703-710
and	O	711-714
CRIMAP	O	715-721
computational	O	722-735
methodologies	O	736-749
to	O	750-752
build	O	753-758
the	O	759-762
multipoint	O	763-773
map	O	774-777
via	O	778-781
a	O	782-783
stepwise	O	784-792
algorithm	O	793-802
.	O	802-803

A	O	804-805
detailed	O	806-814
10	O	815-817
-	O	817-818
point	O	818-823
map	O	824-827
of	O	828-830
the	O	831-834
4p16	O	835-839
region	O	840-846
constructed	O	847-858
from	O	859-863
the	O	864-867
CEPH	O	868-872
panel	O	873-878
provides	O	879-887
evidence	O	888-896
for	O	897-900
heterogeneity	O	901-914
in	O	915-917
the	O	918-921
linkage	O	922-929
maps	O	930-934
constructed	O	935-946
from	O	947-951
families	O	952-960
segregating	O	961-972
for	O	973-976
Huntington	B	977-987
disease	I	988-995
(	O	996-997
HD	B	997-999
)	O	999-1000
.	O	1000-1001

It	O	1002-1004
additionally	O	1005-1017
provides	O	1018-1026
evidence	O	1027-1035
for	O	1036-1039
position	O	1040-1048
-	O	1048-1049
specific	O	1049-1057
recombination	O	1058-1071
frequencies	O	1072-1083
in	O	1084-1086
the	O	1087-1090
telomeric	O	1091-1100
region	O	1101-1107
of	O	1108-1110
4p	O	1111-1113
.	O	1113-1114
.	O	1113-1114

The	O	0-3
murine	O	4-10
homolog	O	11-18
of	O	19-21
the	O	22-25
human	O	26-31
breast	B	32-38
and	I	39-42
ovarian	I	43-50
cancer	I	51-57
susceptibility	O	58-72
gene	O	73-77
Brca1	O	78-83
maps	O	84-88
to	O	89-91
mouse	O	92-97
chromosome	O	98-108
11D	O	109-112
.	O	112-113

The	O	114-117
recently	O	118-126
cloned	O	127-133
human	O	134-139
breast	B	140-146
and	I	147-150
ovarian	I	151-158
cancer	I	159-165
susceptibility	O	166-180
gene	O	181-185
,	O	185-186
BRCA1	O	187-192
,	O	192-193
is	O	194-196
located	O	197-204
on	O	205-207
human	O	208-213
chromosome	O	214-224
17q21	O	225-230
.	O	230-231

We	O	232-234
have	O	235-239
isolated	O	240-248
murine	O	249-255
genomic	O	256-263
clones	O	264-270
containing	O	271-281
Brca1	O	282-287
as	O	288-290
a	O	291-292
first	O	293-298
step	O	299-303
in	O	304-306
generating	O	307-317
a	O	318-319
mouse	O	320-325
model	O	326-331
for	O	332-335
the	O	336-339
loss	O	340-344
of	O	345-347
BRCA1	O	348-353
function	O	354-362
.	O	362-363

A	O	364-365
mouse	O	366-371
genomic	O	372-379
library	O	380-387
was	O	388-391
screened	O	392-400
using	O	401-406
probes	O	407-413
corresponding	O	414-427
to	O	428-430
exon	O	431-435
11	O	436-438
of	O	439-441
the	O	442-445
human	O	446-451
BRCA1	O	452-457
gene	O	458-462
.	O	462-463

Two	O	464-467
overlapping	O	468-479
mouse	O	480-485
clones	O	486-492
were	O	493-497
identified	O	498-508
that	O	509-513
hybridized	O	514-524
to	O	525-527
human	O	528-533
BRCA1	O	534-539
exons	O	540-545
9	O	546-547
-	O	547-548
12	O	548-550
.	O	550-551

Sequence	O	552-560
analysis	O	561-569
of	O	570-572
1	O	573-574
.	O	574-575
4	O	576-577
kb	O	578-580
of	O	581-583
the	O	584-587
region	O	588-594
of	O	595-597
these	O	598-603
clones	O	604-610
corresponding	O	611-624
to	O	625-627
part	O	628-632
of	O	633-635
human	O	636-641
exon	O	642-646
11	O	647-649
revealed	O	650-658
72	O	659-661
%	O	661-662
nucleic	O	663-670
acid	O	671-675
identity	O	676-684
but	O	685-688
only	O	689-693
50	O	694-696
%	O	696-697
amino	O	698-703
acid	O	704-708
identity	O	709-717
with	O	718-722
the	O	723-726
human	O	727-732
gene	O	733-737
.	O	737-738

The	O	739-742
longest	O	743-750
of	O	751-753
the	O	754-757
mouse	O	758-763
Brca1	O	764-769
genomic	O	770-777
clones	O	778-784
maps	O	785-789
to	O	790-792
chromosome	O	793-803
11D	O	804-807
,	O	807-808
as	O	809-811
determined	O	812-822
by	O	823-825
two	O	826-829
-	O	829-830
color	O	830-835
fluorescence	O	836-848
in	O	849-851
situ	O	852-856
hybridization	O	857-870
.	O	870-871

The	O	872-875
synteny	O	876-883
to	O	884-886
human	O	887-892
chromosome	O	893-903
17	O	904-906
was	O	907-910
confirmed	O	911-920
by	O	921-923
cohybridization	O	924-939
with	O	940-944
the	O	945-948
mouse	O	949-954
probe	O	955-960
for	O	961-964
the	O	965-968
NF1	O	969-972
-	O	972-973
gene	O	973-977
.	O	977-978

This	O	979-983
comparative	O	984-995
study	O	996-1001
confirms	O	1002-1010
that	O	1011-1015
the	O	1016-1019
relative	O	1020-1028
location	O	1029-1037
of	O	1038-1040
the	O	1041-1044
BRCA1	O	1045-1050
gene	O	1051-1055
has	O	1056-1059
been	O	1060-1064
conserved	O	1065-1074
between	O	1075-1082
mice	O	1083-1087
and	O	1088-1091
humans	O	1092-1098
.	O	1098-1099

High	O	0-4
residual	O	5-13
arylsulfatase	O	14-27
A	O	28-29
(	O	30-31
ARSA	O	31-35
)	O	35-36
activity	O	37-45
in	O	46-48
a	O	49-50
patient	O	51-58
with	O	59-63
late	B	64-68
-	I	68-69
infantile	I	69-78
metachromatic	I	79-92
leukodystrophy	I	93-107
.	O	107-108

We	O	109-111
identified	O	112-122
a	O	123-124
patient	O	125-132
suffering	O	133-142
from	O	143-147
late	B	148-152
-	I	152-153
infantile	I	153-162
metachromatic	I	163-176
leukodystrophy	I	177-191
(	O	192-193
MLD	B	193-196
)	O	196-197
who	O	198-201
has	O	202-205
a	O	206-207
residual	O	208-216
arylsulfatase	O	217-230
A	O	231-232
(	O	233-234
ARSA	O	234-238
)	O	238-239
activity	O	240-248
of	O	249-251
about	O	252-257
10	O	258-260
%	O	260-261
.	O	261-262

Fibroblasts	O	263-274
of	O	275-277
the	O	278-281
patient	O	282-289
show	O	290-294
significant	O	295-306
sulfatide	O	307-316
degradation	O	317-328
activity	O	329-337
exceeding	O	338-347
that	O	348-352
of	O	353-355
adult	B	356-361
MLD	I	362-365
patients	O	366-374
.	O	374-375

Analysis	O	376-384
of	O	385-387
the	O	388-391
ARSA	O	392-396
gene	O	397-401
in	O	402-404
this	O	405-409
patient	O	410-417
revealed	O	418-426
heterozygosity	O	427-441
for	O	442-445
two	O	446-449
new	O	450-453
mutant	O	454-460
alleles	O	461-468
in	O	470-472
one	O	473-476
allele	O	477-483
,	O	483-484
deletion	O	485-493
of	O	494-496
C	O	497-498
447	O	499-502
in	O	503-505
exon	O	506-510
2	O	511-512
leads	O	513-518
to	O	519-521
a	O	522-523
frameshift	O	524-534
and	O	535-538
to	O	539-541
a	O	542-543
premature	O	544-553
stop	O	554-558
codon	O	559-564
at	O	565-567
amino	O	568-573
acid	O	574-578
position	O	579-587
105	O	588-591
;	O	591-592
in	O	593-595
the	O	596-599
second	O	600-606
allele	O	607-613
,	O	613-614
a	O	615-616
G	O	617-618
-	O	618-619
-	O	618-619
>	O	621-622
A	O	623-624
transition	O	625-635
in	O	636-638
exon	O	639-643
5	O	644-645
causes	O	646-652
a	O	653-654
Gly309	O	655-661
-	O	661-662
-	O	661-662
>	O	664-665
Ser	O	666-669
substitution	O	670-682
.	O	682-683

Transient	O	684-693
expression	O	694-704
of	O	705-707
the	O	708-711
mutant	O	712-718
Ser309	O	719-725
-	O	725-726
ARSA	O	726-730
resulted	O	731-739
in	O	740-742
only	O	743-747
13	O	748-750
%	O	750-751
enzyme	O	752-758
activity	O	759-767
of	O	768-770
that	O	771-775
observed	O	776-784
in	O	785-787
cells	O	788-793
expressing	O	794-804
normal	O	805-811
ARSA	O	812-816
.	O	816-817

The	O	818-821
mutant	O	822-828
ARSA	O	829-833
is	O	834-836
correctly	O	837-846
targeted	O	847-855
to	O	856-858
the	O	859-862
lysosomes	O	863-872
but	O	873-876
is	O	877-879
unstable	O	880-888
.	O	888-889

These	O	890-895
findings	O	896-904
are	O	905-908
in	O	909-911
contrast	O	912-920
to	O	921-923
previous	O	924-932
results	O	933-940
showing	O	941-948
that	O	949-953
the	O	954-957
late	B	958-962
-	I	962-963
infantile	I	963-972
type	I	973-977
of	I	978-980
MLD	I	981-984
is	O	985-987
always	O	988-994
associated	O	995-1005
with	O	1006-1010
the	O	1011-1014
complete	O	1015-1023
absence	O	1024-1031
of	O	1032-1034
ARSA	O	1035-1039
activity	O	1040-1048
.	O	1048-1049

The	O	1050-1053
expression	O	1054-1064
of	O	1065-1067
the	O	1068-1071
mutant	O	1072-1078
ARSA	O	1079-1083
protein	O	1084-1091
may	O	1092-1095
be	O	1096-1098
influenced	O	1099-1109
by	O	1110-1112
particular	O	1113-1123
features	O	1124-1132
of	O	1133-1135
oligodendrocytes	O	1136-1152
,	O	1152-1153
such	O	1154-1158
that	O	1159-1163
the	O	1164-1167
level	O	1168-1173
of	O	1174-1176
mutant	O	1177-1183
enzyme	O	1184-1190
is	O	1191-1193
lower	O	1194-1199
in	O	1200-1202
these	O	1203-1208
cells	O	1209-1214
than	O	1215-1219
in	O	1220-1222
others	O	1223-1229
.	O	1229-1230
.	O	1229-1230

De	O	0-2
novo	O	3-7
deletions	O	8-17
of	O	18-20
SNRPN	O	21-26
exon	O	27-31
1	O	32-33
in	O	34-36
early	O	37-42
human	O	43-48
and	O	49-52
mouse	O	53-58
embryos	O	59-66
result	O	67-73
in	O	74-76
a	O	77-78
paternal	O	79-87
to	O	88-90
maternal	O	91-99
imprint	O	100-107
switch	O	108-114
.	O	114-115

Prader	B	116-122
-	I	122-123
Willi	I	123-128
syndrome	I	129-137
(	O	138-139
PWS	B	139-142
)	O	142-143
is	O	144-146
a	O	147-148
neurogenetic	B	149-161
disease	I	162-169
characterized	O	170-183
by	O	184-186
infantile	B	187-196
hypotonia	I	197-206
,	O	206-207
gonadal	B	208-215
hypoplasia	I	216-226
,	O	226-227
obsessive	O	228-237
behaviour	O	238-247
and	O	248-251
neonatal	O	252-260
feeding	O	261-268
difficulties	O	269-281
followed	O	282-290
by	O	291-293
hyperphagia	B	294-305
,	O	305-306
leading	O	307-314
to	O	315-317
profound	O	318-326
obesity	B	327-334
.	O	334-335

PWS	B	336-339
is	O	340-342
due	O	343-346
to	O	347-349
a	O	350-351
lack	O	352-356
of	O	357-359
paternal	O	360-368
genetic	O	369-376
information	O	377-388
at	O	389-391
15q11	O	392-397
-	O	397-398
q13	O	398-401
(	O	402-403
ref	O	403-406
.	O	406-407

2	O	408-409
)	O	409-410
.	O	410-411

Five	O	412-416
imprinted	O	417-426
,	O	426-427
paternally	O	428-438
expressed	O	439-448
genes	O	449-454
map	O	455-458
to	O	459-461
the	O	462-465
PWS	B	466-469
region	O	470-476
,	O	476-477
MKRN3	O	478-483
(	O	484-485
ref	O	485-488
.	O	488-489

3	O	490-491
)	O	491-492
,	O	492-493
NDN	O	494-497
(	O	498-499
ref	O	499-502
.	O	502-503

4	O	504-505
)	O	505-506
,	O	506-507
NDNL1	O	508-513
(	O	514-515
ref	O	515-518
.	O	518-519

5	O	520-521
)	O	521-522
,	O	522-523
SNRPN	O	524-529
(	O	530-531
refs	O	531-535
6	O	536-537
-	O	537-538
8	O	538-539
)	O	539-540
and	O	541-544
IPW	O	545-548
(	O	549-550
ref	O	550-553
.	O	553-554

9	O	555-556
)	O	556-557
,	O	557-558
as	O	559-561
well	O	562-566
as	O	567-569
two	O	570-573
poorly	O	574-580
characterized	O	581-594
framents	O	595-603
designated	O	604-614
PAR	O	615-618
-	O	618-619
1	O	619-620
and	O	621-624
PAR	O	625-628
-	O	628-629
5	O	629-630
(	O	631-632
ref	O	632-635
.	O	635-636

10	O	637-639
)	O	639-640
.	O	640-641

Imprinting	O	642-652
of	O	653-655
this	O	656-660
region	O	661-667
involves	O	668-676
a	O	677-678
bipartite	O	679-688
imprinting	O	689-699
centre	O	700-706
(	O	707-708
IC	O	708-710
)	O	710-711
,	O	711-712
which	O	713-718
overlaps	O	719-727
SNRPN	O	728-733
(	O	734-735
refs	O	735-739
10	O	740-742
,	O	742-743
11	O	744-746
)	O	746-747
.	O	747-748

Deletion	O	749-757
of	O	758-760
the	O	761-764
SNRPN	O	765-770
promoter	O	771-779
/	O	779-780
exon	O	780-784
1	O	785-786
region	O	787-793
(	O	794-795
the	O	795-798
PWS	B	799-802
IC	O	803-805
element	O	806-813
)	O	813-814
appears	O	815-822
to	O	823-825
impair	O	826-832
the	O	833-836
establishment	O	837-850
of	O	851-853
the	O	854-857
paternal	O	858-866
imprint	O	867-874
in	O	875-877
the	O	878-881
male	O	882-886
germ	O	887-891
line	O	892-896
and	O	897-900
leads	O	901-906
to	O	907-909
PWS	B	910-913
.	O	913-914

Here	O	915-919
we	O	920-922
report	O	923-929
a	O	930-931
PWS	B	932-935
family	O	936-942
in	O	943-945
which	O	946-951
the	O	952-955
father	O	956-962
is	O	963-965
mosaic	O	966-972
for	O	973-976
an	O	977-979
IC	O	980-982
deletion	O	983-991
on	O	992-994
his	O	995-998
paternal	O	999-1007
chromosome	O	1008-1018
.	O	1018-1019

The	O	1020-1023
deletion	O	1024-1032
chromosome	O	1033-1043
has	O	1044-1047
acquired	O	1048-1056
a	O	1057-1058
maternal	O	1059-1067
methylation	O	1068-1079
imprint	O	1080-1087
in	O	1088-1090
his	O	1091-1094
somatic	O	1095-1102
cells	O	1103-1108
.	O	1108-1109

We	O	1110-1112
have	O	1113-1117
made	O	1118-1122
identical	O	1123-1132
findings	O	1133-1141
in	O	1142-1144
chimaeric	O	1145-1154
mice	O	1155-1159
generated	O	1160-1169
from	O	1170-1174
two	O	1175-1178
independent	O	1179-1190
embryonic	O	1191-1200
stem	O	1201-1205
(	O	1206-1207
ES	O	1207-1209
)	O	1209-1210
cell	O	1211-1215
lines	O	1216-1221
harbouring	O	1222-1232
a	O	1233-1234
similar	O	1235-1242
deletion	O	1243-1251
.	O	1251-1252

Our	O	1253-1256
studies	O	1257-1264
demonstrate	O	1265-1276
that	O	1277-1281
the	O	1282-1285
PWS	B	1286-1289
IC	O	1290-1292
element	O	1293-1300
is	O	1301-1303
not	O	1304-1307
only	O	1308-1312
required	O	1313-1321
for	O	1322-1325
the	O	1326-1329
establishment	O	1330-1343
of	O	1344-1346
the	O	1347-1350
paternal	O	1351-1359
imprint	O	1360-1367
,	O	1367-1368
but	O	1369-1372
also	O	1373-1377
for	O	1378-1381
its	O	1382-1385
postzygotic	O	1386-1397
maintenance	O	1398-1409
.	O	1409-1410
.	O	1409-1410

Molecular	O	0-9
characterization	O	10-26
of	O	27-29
two	O	30-33
galactosemia	B	34-46
mutations	O	47-56
:	O	56-57
correlation	O	58-69
of	O	70-72
mutations	O	73-82
with	O	83-87
highly	O	88-94
conserved	O	95-104
domains	O	105-112
in	O	113-115
galactose	O	116-125
-	O	125-126
1	O	126-127
-	O	125-126
phosphate	O	128-137
uridyl	O	138-144
transferase	O	145-156
.	O	156-157

Galactosemia	B	158-170
is	O	171-173
an	O	174-176
autosomal	B	177-186
recessive	I	187-196
disorder	I	197-205
of	I	206-208
human	I	209-214
galactose	I	215-224
metabolism	I	225-235
caused	O	236-242
by	O	243-245
deficiency	B	246-256
of	I	257-259
the	I	260-263
enzyme	I	264-270
galactose	I	271-280
-	I	280-281
1	I	281-282
-	I	280-281
phosphate	I	283-292
uridyl	I	293-299
transferase	I	300-311
(	O	312-313
GALT	O	313-317
)	O	317-318
.	O	318-319

The	O	320-323
molecular	O	324-333
basis	O	334-339
of	O	340-342
this	O	343-347
disorder	O	348-356
is	O	357-359
at	O	360-362
present	O	363-370
not	O	371-374
well	O	375-379
understood	O	380-390
.	O	390-391

We	O	392-394
report	O	395-401
here	O	402-406
two	O	407-410
missense	O	411-419
mutations	O	420-429
which	O	430-435
result	O	436-442
in	O	443-445
low	O	446-449
or	O	450-452
undetectable	O	453-465
enzymatic	O	466-475
activity	O	476-484
.	O	484-485

First	O	486-491
,	O	491-492
we	O	493-495
identified	O	496-506
at	O	507-509
nucleotide	O	510-520
591	O	521-524
a	O	525-526
transition	O	527-537
which	O	538-543
substitutes	O	544-555
glutamine	O	556-565
188	O	566-569
by	O	570-572
arginine	O	573-581
.	O	581-582

The	O	583-586
mutated	O	587-594
glutamine	O	595-604
is	O	605-607
not	O	608-611
only	O	612-616
highly	O	617-623
conserved	O	624-633
in	O	634-636
evolution	O	637-646
(	O	647-648
conserved	O	648-657
also	O	658-662
in	O	663-665
Escherichia	O	666-677
coli	O	678-682
and	O	683-686
Saccharomyces	O	687-700
cerevisiae	O	701-711
)	O	711-712
,	O	712-713
but	O	714-717
is	O	718-720
also	O	721-725
two	O	726-729
amino	O	730-735
acid	O	736-740
residues	O	741-749
downstream	O	750-760
from	O	761-765
the	O	766-769
active	O	770-776
site	O	777-781
histidine	O	782-791
-	O	791-792
proline	O	792-799
-	O	791-792
histidine	O	782-791
triad	O	810-815
and	O	816-819
results	O	820-827
in	O	828-830
about	O	831-836
10	O	837-839
%	O	839-840
of	O	841-843
normal	O	844-850
enzymatic	O	851-860
activity	O	861-869
.	O	869-870

The	O	871-874
arginine	O	875-883
188	O	884-887
mutation	O	888-896
is	O	897-899
the	O	900-903
most	O	904-908
common	O	909-915
galactosemia	B	916-928
mutation	O	929-937
characterized	O	938-951
to	O	952-954
date	O	955-959
.	O	959-960

It	O	961-963
accounts	O	964-972
for	O	973-976
one	O	977-980
-	O	980-981
fourth	O	981-987
of	O	988-990
the	O	991-994
galactosemia	B	995-1007
alleles	O	1008-1015
studied	O	1016-1023
.	O	1023-1024

Second	O	1025-1031
,	O	1031-1032
we	O	1033-1035
report	O	1036-1042
the	O	1043-1046
substitution	O	1047-1059
of	O	1060-1062
arginine	O	1063-1071
333	O	1072-1075
by	O	1076-1078
tryptophan	O	1079-1089
,	O	1089-1090
caused	O	1091-1097
by	O	1098-1100
a	O	1101-1102
transition	O	1103-1113
at	O	1114-1116
nucleotide	O	1117-1127
1025	O	1128-1132
.	O	1132-1133

The	O	1134-1137
area	O	1138-1142
surrounding	O	1143-1154
this	O	1155-1159
missense	O	1160-1168
mutation	O	1169-1177
is	O	1178-1180
the	O	1181-1184
most	O	1185-1189
highly	O	1190-1196
conserved	O	1197-1206
domain	O	1207-1213
in	O	1214-1216
the	O	1217-1220
homologous	O	1221-1231
enzymes	O	1232-1239
from	O	1240-1244
E	O	1245-1246
.	O	1246-1247
coli	O	1248-1252
,	O	1252-1253
yeast	O	1254-1259
,	O	1259-1260
and	O	1261-1264
humans	O	1265-1271
,	O	1271-1272
and	O	1273-1276
this	O	1277-1281
mutation	O	1282-1290
results	O	1291-1298
in	O	1299-1301
undetectable	O	1302-1314
enzymatic	O	1315-1324
activity	O	1325-1333
,	O	1333-1334
suggesting	O	1335-1345
that	O	1346-1350
this	O	1351-1355
is	O	1356-1358
a	O	1359-1360
severe	O	1361-1367
mutation	O	1368-1376
.	O	1376-1377

This	O	1378-1382
second	O	1383-1389
mutation	O	1390-1398
appears	O	1399-1406
to	O	1407-1409
be	O	1410-1412
rare	O	1413-1417
,	O	1417-1418
since	O	1419-1424
it	O	1425-1427
was	O	1428-1431
found	O	1432-1437
only	O	1438-1442
in	O	1443-1445
the	O	1446-1449
patient	O	1450-1457
we	O	1458-1460
sequenced	O	1461-1470
.	O	1470-1471

Our	O	1472-1475
data	O	1476-1480
provide	O	1481-1488
further	O	1489-1496
evidence	O	1497-1505
for	O	1506-1509
the	O	1510-1513
heterogeneity	O	1514-1527
of	O	1528-1530
galactosemia	B	1531-1543
at	O	1544-1546
the	O	1547-1550
molecular	O	1551-1560
level	O	1561-1566
,	O	1566-1567
heterogeneity	O	1568-1581
which	O	1582-1587
might	O	1588-1593
be	O	1594-1596
related	O	1597-1604
to	O	1605-1607
the	O	1608-1611
variable	O	1612-1620
clinical	O	1621-1629
outcome	O	1630-1637
observed	O	1638-1646
in	O	1647-1649
this	O	1650-1654
disorder	O	1655-1663
.	O	1663-1664
.	O	1663-1664

Neurophysiologic	O	0-16
follow	O	17-23
-	O	23-24
up	O	24-26
of	O	27-29
long	O	30-34
-	O	34-35
term	O	35-39
dietary	O	40-47
treatment	O	48-57
in	O	58-60
adult	O	61-66
-	O	66-67
onset	O	67-72
adrenoleukodystrophy	B	73-93
.	O	93-94
OBJECTIVE	O	95-104
To	O	106-108
monitor	O	109-116
the	O	117-120
effects	O	121-128
of	O	129-131
dietary	O	132-139
treatment	O	140-149
in	O	150-152
adult	O	153-158
-	O	158-159
onset	O	159-164
adrenoleukodystrophy	B	165-185
(	O	186-187
ALD	B	187-190
)	O	190-191
by	O	192-194
means	O	195-200
of	O	201-203
somatosensory	O	204-217
evoked	O	218-224
potentials	O	225-235
(	O	236-237
SEPs	O	237-241
)	O	241-242
and	O	243-246
motor	O	247-252
evoked	O	253-259
potentials	O	260-270
(	O	271-272
MEPs	O	272-276
)	O	276-277
.	O	277-278

BACKGROUND	O	279-289
SEPs	O	291-295
and	O	296-299
MEPs	O	300-304
have	O	305-309
proved	O	310-316
useful	O	317-323
in	O	324-326
revealing	O	327-336
signs	O	337-342
of	O	343-345
progressively	O	346-359
severe	O	360-366
,	O	366-367
central	O	368-375
dying	B	376-381
-	I	381-382
back	I	382-386
axonopathy	I	387-397
in	O	398-400
early	O	401-406
stages	O	407-413
of	O	414-416
adult	O	417-422
-	O	422-423
onset	O	423-428
ALD	B	429-432
.	O	432-433

METHODS	O	434-441
Eight	O	443-448
patients	O	449-457
with	O	458-462
adult	O	463-468
-	O	468-469
onset	O	469-474
ALD	B	475-478
underwent	O	479-488
clinical	O	489-497
examination	O	498-509
,	O	509-510
brain	O	511-516
and	O	517-520
spine	O	521-526
MRI	O	527-530
,	O	530-531
and	O	532-535
SEP	O	536-539
and	O	540-543
MEP	O	544-547
studies	O	548-555
before	O	556-562
and	O	563-566
after	O	567-572
3	O	573-574
years	O	575-580
of	O	581-583
Lorenzos	O	584-592
oil	O	593-596
dietary	O	597-604
therapy	O	605-612
.	O	612-613

RESULTS	O	614-621
Before	O	623-629
treatment	O	630-639
,	O	639-640
brain	O	641-646
MRI	O	647-650
was	O	651-654
normal	O	655-661
in	O	662-664
five	O	665-669
patients	O	670-678
.	O	678-679

Three	O	680-685
of	O	686-688
these	O	689-694
patients	O	695-703
had	O	704-707
pure	O	708-712
spinal	B	713-719
SEP	I	720-723
abnormalities	I	724-737
and	O	738-741
in	O	742-744
the	O	745-748
remaining	O	749-758
two	O	759-762
patients	O	763-771
SEPs	O	772-776
showed	O	777-783
signs	O	784-789
of	O	790-792
involvement	O	793-804
of	O	805-807
both	O	808-812
the	O	813-816
spinal	O	817-823
and	O	824-827
cerebral	O	828-836
somatosensory	O	837-850
tracts	O	851-857
.	O	857-858

After	O	859-864
treatment	O	865-874
,	O	874-875
the	O	876-879
three	O	880-885
patients	O	886-894
with	O	895-899
pure	O	900-904
spinal	B	905-911
abnormalities	I	912-925
showed	O	926-932
clinical	O	933-941
and	O	942-945
neurophysiologic	O	946-962
worsening	O	963-972
,	O	972-973
whereas	O	974-981
the	O	982-985
two	O	986-989
patients	O	990-998
with	O	999-1003
a	O	1004-1005
more	O	1006-1010
advanced	O	1011-1019
stage	O	1020-1025
of	O	1026-1028
disease	O	1029-1036
(	O	1037-1038
exhibited	O	1038-1047
by	O	1048-1050
SEPs	O	1051-1055
)	O	1055-1056
showed	O	1057-1063
substantially	O	1064-1077
unchanged	O	1078-1087
clinical	O	1088-1096
and	O	1097-1100
neurophysiologic	O	1101-1117
features	O	1118-1126
.	O	1126-1127

The	O	1128-1131
patients	O	1132-1140
with	O	1141-1145
abnormal	O	1146-1154
brain	O	1155-1160
MRI	O	1161-1164
at	O	1165-1167
the	O	1168-1171
onset	O	1172-1177
of	O	1178-1180
treatment	O	1181-1190
showed	O	1191-1197
clinical	O	1198-1206
and	O	1207-1210
neurophysiologic	O	1211-1227
worsening	O	1228-1237
.	O	1237-1238

CONCLUSIONS	O	1239-1250
Lorenzos	O	1252-1260
oil	O	1261-1264
therapy	O	1265-1272
had	O	1273-1276
no	O	1277-1279
effect	O	1280-1286
on	O	1287-1289
patients	O	1290-1298
with	O	1299-1303
evidence	O	1304-1312
of	O	1313-1315
inflammatory	B	1316-1328
brain	I	1329-1334
lesions	I	1335-1342
.	O	1342-1343

Moreover	O	1344-1352
,	O	1352-1353
in	O	1354-1356
patients	O	1357-1365
without	O	1366-1373
clear	O	1374-1379
signs	O	1380-1385
of	O	1386-1388
inflammatory	O	1389-1401
damage	O	1402-1408
,	O	1408-1409
this	O	1410-1414
treatment	O	1415-1424
does	O	1425-1429
not	O	1430-1433
modify	O	1434-1440
significantly	O	1441-1454
the	O	1455-1458
natural	O	1459-1466
course	O	1467-1473
of	O	1474-1476
the	O	1477-1480
disease	O	1481-1488
.	O	1488-1489

However	O	1490-1497
,	O	1497-1498
because	O	1499-1506
effective	O	1507-1516
treatments	O	1517-1527
should	O	1528-1534
begin	O	1535-1540
before	O	1541-1547
the	O	1548-1551
onset	O	1552-1557
of	O	1558-1560
severe	O	1561-1567
neurologic	O	1568-1578
symptoms	O	1579-1587
,	O	1587-1588
SEPs	O	1589-1593
and	O	1594-1597
MEPs	O	1598-1602
should	O	1603-1609
be	O	1610-1612
considered	O	1613-1623
to	O	1624-1626
evaluate	O	1627-1635
the	O	1636-1639
effectiveness	O	1640-1653
of	O	1654-1656
other	O	1657-1662
experimental	O	1663-1675
treatments	O	1676-1686
in	O	1687-1689
the	O	1690-1693
patient	O	1694-1701
with	O	1702-1706
a	O	1707-1708
negative	O	1709-1717
brain	O	1718-1723
MRI	O	1724-1727
.	O	1727-1728

The	O	0-3
molecular	O	4-13
basis	O	14-19
of	O	20-22
Sjogren	B	23-30
-	I	30-31
Larsson	I	31-38
syndrome	I	39-47
:	O	47-48
mutation	O	49-57
analysis	O	58-66
of	O	67-69
the	O	70-73
fatty	O	74-79
aldehyde	O	80-88
dehydrogenase	O	89-102
gene	O	103-107
.	O	107-108

Sjogren	B	109-116
-	I	116-117
Larsson	I	117-124
syndrome	I	125-133
(	O	134-135
SLS	B	135-138
)	O	138-139
is	O	140-142
an	O	143-145
autosomal	B	146-155
recessive	I	156-165
disorder	I	166-174
characterized	O	175-188
by	O	189-191
ichthyosis	B	192-202
,	O	202-203
mental	B	204-210
retardation	I	211-222
,	O	222-223
spasticity	B	224-234
,	O	234-235
and	O	236-239
deficient	B	240-249
activity	I	250-258
of	I	259-261
fatty	I	262-267
aldehyde	I	268-276
dehydrogenase	I	277-290
(	O	291-292
FALDH	O	292-297
)	O	297-298
.	O	298-299

To	O	300-302
define	O	303-309
the	O	310-313
molecular	O	314-323
defects	O	324-331
causing	O	332-339
SLS	B	340-343
,	O	343-344
we	O	345-347
performed	O	348-357
mutation	O	358-366
analysis	O	367-375
of	O	376-378
the	O	379-382
FALDH	O	383-388
gene	O	389-393
in	O	394-396
probands	O	397-405
from	O	406-410
63	O	411-413
kindreds	O	414-422
with	O	423-427
SLS	B	428-431
.	O	431-432

Among	O	433-438
these	O	439-444
patients	O	445-453
,	O	453-454
49	O	455-457
different	O	458-467
mutations	O	468-477
-	O	477-478
including	O	478-487
10	O	488-490
deletions	O	491-500
,	O	500-501
2	O	502-503
insertions	O	504-514
,	O	514-515
22	O	516-518
amino	O	519-524
acid	O	525-529
substitutions	O	530-543
,	O	543-544
3	O	545-546
nonsense	O	547-555
mutations	O	556-565
,	O	565-566
9	O	567-568
splice	O	569-575
-	O	575-576
site	O	576-580
defects	O	581-588
,	O	588-589
and	O	590-593
3	O	594-595
complex	O	596-603
mutations	O	604-613
-	O	613-614
were	O	614-618
found	O	619-624
.	O	624-625

All	O	626-629
of	O	630-632
the	O	633-636
patients	O	637-645
with	O	646-650
SLS	B	651-654
were	O	655-659
found	O	660-665
to	O	666-668
carry	O	669-674
mutations	O	675-684
.	O	684-685

Nineteen	O	686-694
of	O	695-697
the	O	698-701
missense	O	702-710
mutations	O	711-720
resulted	O	721-729
in	O	730-732
a	O	733-734
severe	O	735-741
reduction	O	742-751
of	O	752-754
FALDH	O	755-760
enzyme	O	761-767
catalytic	O	768-777
activity	O	778-786
when	O	787-791
expressed	O	792-801
in	O	802-804
mammalian	O	805-814
cells	O	815-820
,	O	820-821
but	O	822-825
one	O	826-829
mutation	O	830-838
(	O	839-840
798G	O	840-844
-	O	844-845
-	O	844-845
>	O	847-848
C	O	849-850
[	O	851-852
K266N	O	852-857
]	O	857-858
)	O	858-859
seemed	O	860-866
to	O	867-869
have	O	870-874
a	O	875-876
greater	O	877-884
effect	O	885-891
on	O	892-894
mRNA	O	895-899
stability	O	900-909
.	O	909-910

The	O	911-914
splice	O	915-921
-	O	921-922
site	O	922-926
mutations	O	927-936
led	O	937-940
to	O	941-943
exon	O	944-948
skipping	O	949-957
or	O	958-960
utilization	O	961-972
of	O	973-975
cryptic	O	976-983
acceptor	O	984-992
-	O	992-993
splice	O	993-999
sites	O	1000-1005
.	O	1005-1006

Thirty	O	1007-1013
-	O	1013-1014
seven	O	1014-1019
mutations	O	1020-1029
were	O	1030-1034
private	O	1035-1042
,	O	1042-1043
and	O	1044-1047
12	O	1048-1050
mutations	O	1051-1060
were	O	1061-1065
seen	O	1066-1070
in	O	1071-1073
two	O	1074-1077
or	O	1078-1080
more	O	1081-1085
probands	O	1086-1094
of	O	1095-1097
European	O	1098-1106
or	O	1107-1109
Middle	O	1110-1116
Eastern	O	1117-1124
descent	O	1125-1132
.	O	1132-1133

Four	O	1134-1138
single	O	1139-1145
-	O	1145-1146
nucleotide	O	1146-1156
polymorphisms	O	1157-1170
(	O	1171-1172
SNPs	O	1172-1176
)	O	1176-1177
were	O	1178-1182
found	O	1183-1188
in	O	1189-1191
the	O	1192-1195
FALDH	O	1196-1201
gene	O	1202-1206
.	O	1206-1207

At	O	1208-1210
least	O	1211-1216
four	O	1217-1221
of	O	1222-1224
the	O	1225-1228
common	O	1229-1235
mutations	O	1236-1245
(	O	1246-1247
551C	O	1247-1251
-	O	1251-1252
-	O	1251-1252
>	O	1254-1255
T	O	1256-1257
,	O	1257-1258
682C	O	1259-1263
-	O	1263-1264
-	O	1263-1264
>	O	1266-1267
T	O	1268-1269
,	O	1269-1270
733G	O	1271-1275
-	O	1275-1276
-	O	1275-1276
>	O	1278-1279
A	O	1280-1281
,	O	1281-1282
and	O	1283-1286
798	O	1287-1290
+	O	1291-1292
1delG	O	1293-1298
)	O	1298-1299
were	O	1300-1304
associated	O	1305-1315
with	O	1316-1320
multiple	O	1321-1329
SNP	O	1330-1333
haplotypes	O	1334-1344
,	O	1344-1345
suggesting	O	1346-1356
that	O	1357-1361
these	O	1362-1367
mutations	O	1368-1377
originated	O	1378-1388
independently	O	1389-1402
on	O	1403-1405
more	O	1406-1410
than	O	1411-1415
one	O	1416-1419
occasion	O	1420-1428
or	O	1429-1431
were	O	1432-1436
ancient	O	1437-1444
SLS	B	1445-1448
genes	O	1449-1454
that	O	1455-1459
had	O	1460-1463
undergone	O	1464-1473
intragenic	O	1474-1484
recombination	O	1485-1498
.	O	1498-1499

Our	O	1500-1503
results	O	1504-1511
demonstrate	O	1512-1523
that	O	1524-1528
SLS	B	1529-1532
is	O	1533-1535
caused	O	1536-1542
by	O	1543-1545
a	O	1546-1547
strikingly	O	1548-1558
heterogeneous	O	1559-1572
group	O	1573-1578
of	O	1579-1581
mutations	O	1582-1591
in	O	1592-1594
the	O	1595-1598
FALDH	O	1599-1604
gene	O	1605-1609
and	O	1610-1613
provide	O	1614-1621
a	O	1622-1623
framework	O	1624-1633
for	O	1634-1637
understanding	O	1638-1651
the	O	1652-1655
genetic	O	1656-1663
basis	O	1664-1669
of	O	1670-1672
SLS	B	1673-1676
and	O	1677-1680
the	O	1681-1684
development	O	1685-1696
of	O	1697-1699
DNA	O	1700-1703
-	O	1703-1704
based	O	1704-1709
diagnostic	O	1710-1720
tests	O	1721-1726
.	O	1726-1727
.	O	1726-1727

Severe	B	0-6
-	I	6-7
glucose	I	7-14
-	I	6-7
6	I	15-16
-	I	6-7
phosphate	I	17-26
dehydrogenase	I	27-40
(	I	41-42
G6PD	I	42-46
)	I	46-47
deficiency	I	48-58
associated	O	59-69
with	O	70-74
chronic	O	75-82
hemolytic	B	83-92
anemia	I	93-99
,	O	99-100
granulocyte	B	101-112
dysfunction	I	113-124
,	O	124-125
and	O	126-129
increased	O	130-139
susceptibility	O	140-154
to	O	155-157
infections	O	158-168
:	O	168-169
description	O	170-181
of	O	182-184
a	O	185-186
new	O	187-190
molecular	O	191-200
variant	O	201-208
(	O	209-210
G6PD	O	210-214
Barcelona	O	215-224
)	O	224-225
.	O	225-226

Molecular	O	227-236
,	O	236-237
kinetic	O	238-245
,	O	245-246
and	O	247-250
functional	O	251-261
studies	O	262-269
were	O	270-274
carried	O	275-282
out	O	283-286
on	O	287-289
erythrocytes	O	290-302
and	O	303-306
leukocytes	O	307-317
in	O	318-320
a	O	321-322
Spanish	O	323-330
male	O	331-335
with	O	336-340
G6PD	B	341-345
deficiency	I	346-356
,	O	356-357
congenital	B	358-368
nonspherocytic	I	369-383
hemolytic	I	384-393
anemia	I	394-400
(	O	401-402
CNSHA	B	402-407
)	O	407-408
,	O	408-409
and	O	410-413
increased	O	414-423
susceptibility	O	424-438
to	O	439-441
infections	O	442-452
.	O	452-453

G6PD	O	454-458
activity	O	459-467
was	O	468-471
absent	O	472-478
in	O	479-481
patients	O	482-490
red	O	491-494
cells	O	495-500
and	O	501-504
was	O	505-508
about	O	509-514
2	O	515-516
%	O	516-517
of	O	518-520
normal	O	521-527
in	O	528-530
leukocytes	O	531-541
.	O	541-542

Molecular	O	543-552
studies	O	553-560
using	O	561-566
standard	O	567-575
methods	O	576-583
(	O	584-585
WHO	O	585-588
,	O	588-589
1967	O	590-594
)	O	594-595
showed	O	596-602
G6PD	O	603-607
in	O	608-610
the	O	611-614
patient	O	615-622
to	O	623-625
have	O	626-630
a	O	631-632
slightly	O	633-641
fast	O	642-646
electrophoretic	O	647-662
mobility	O	663-671
at	O	672-674
pH	O	675-677
8	O	678-679
.	O	679-680
0	O	681-682
with	O	683-687
otherwise	O	688-697
normal	O	698-704
properties	O	705-715
(	O	716-717
heat	O	717-721
stability	O	722-731
at	O	732-734
46	O	735-737
degrees	O	738-745
C	O	746-747
,	O	747-748
apparent	O	749-757
affinity	O	758-766
for	O	767-770
substrates	O	771-781
,	O	781-782
optimum	O	783-790
pH	O	791-793
,	O	793-794
and	O	795-798
utilization	O	799-810
of	O	811-813
substrate	O	814-823
analogues	O	824-833
)	O	833-834
.	O	834-835

Other	O	836-841
tests	O	842-847
showed	O	848-854
the	O	855-858
patients	O	859-867
granulocytes	O	868-880
to	O	881-883
engulf	O	884-890
latex	O	891-896
particles	O	897-906
normally	O	907-915
,	O	915-916
but	O	917-920
to	O	921-923
have	O	924-928
impaired	O	929-937
reduction	O	938-947
of	O	948-950
nitroblue	O	951-960
tetrazolium	O	961-972
and	O	973-976
ferricytochrome	O	977-992
-	O	992-993
c	O	982-983
as	O	995-997
well	O	998-1002
as	O	1003-1005
reduced	O	1006-1013
iodination	O	1014-1024
.	O	1024-1025

Chemotaxis	O	1026-1036
and	O	1037-1040
random	O	1041-1047
migration	O	1048-1057
of	O	1058-1060
the	O	1061-1064
patients	O	1065-1073
granulocytes	O	1074-1086
were	O	1087-1091
normal	O	1092-1098
as	O	1099-1101
were	O	1102-1106
myeloperoxidase	O	1107-1122
,	O	1122-1123
leukocyte	O	1124-1133
alkaline	O	1134-1142
phosphatase	O	1143-1154
(	O	1155-1156
LAP	O	1156-1159
)	O	1159-1160
,	O	1160-1161
and	O	1162-1165
ultrastructural	O	1166-1181
features	O	1182-1190
.	O	1190-1191

The	O	1192-1195
molecular	O	1196-1205
characteristics	O	1206-1221
of	O	1222-1224
G6PD	O	1225-1229
in	O	1230-1232
the	O	1233-1236
patient	O	1237-1244
differed	O	1245-1253
from	O	1254-1258
those	O	1259-1264
of	O	1265-1267
all	O	1268-1271
previously	O	1272-1282
reported	O	1283-1291
variants	O	1292-1300
associated	O	1301-1311
with	O	1312-1316
CNSHA	B	1317-1322
,	O	1322-1323
so	O	1324-1326
the	O	1327-1330
present	O	1331-1338
variant	O	1339-1346
was	O	1347-1350
provisionally	O	1351-1364
called	O	1365-1371
G6PD	O	1372-1376
Barcelona	O	1377-1386
to	O	1387-1389
distinguish	O	1390-1401
it	O	1402-1404
from	O	1405-1409
other	O	1410-1415
G6PD	O	1416-1420
variants	O	1421-1429
previously	O	1430-1440
described	O	1441-1450
.	O	1450-1451

Possible	O	1452-1460
mechanisms	O	1461-1471
for	O	1472-1475
the	O	1476-1479
severe	O	1480-1486
deficiency	B	1487-1497
of	I	1498-1500
G6PD	I	1501-1505
in	O	1506-1508
erythrocytes	O	1509-1521
and	O	1522-1525
granulocytes	O	1526-1538
was	O	1539-1542
investigated	O	1543-1555
by	O	1556-1558
studies	O	1559-1566
on	O	1567-1569
the	O	1570-1573
immunologic	O	1574-1585
specific	O	1586-1594
activity	O	1595-1603
of	O	1604-1606
the	O	1607-1610
mutant	O	1611-1617
enzyme	O	1618-1624
.	O	1624-1625

Mutations	O	0-9
at	O	10-12
the	O	13-16
PAX6	O	17-21
locus	O	22-27
are	O	28-31
found	O	32-37
in	O	38-40
heterogeneous	O	41-54
anterior	B	55-63
segment	I	64-71
malformations	I	72-85
including	O	86-95
Peters	B	96-102
'	I	102-103
anomaly	I	104-111
.	O	111-112

Mutation	O	113-121
or	O	122-124
deletion	O	125-133
of	O	134-136
the	O	137-140
PAX6	O	141-145
gene	O	146-150
underlies	O	151-160
many	O	161-165
cases	O	166-171
of	O	172-174
aniridia	B	175-183
.	O	183-184

Three	O	185-190
lines	O	191-196
of	O	197-199
evidence	O	200-208
now	O	209-212
converge	O	213-221
to	O	222-224
implicate	O	225-234
PAX6	O	235-239
more	O	240-244
widely	O	245-251
in	O	252-254
anterior	B	255-263
segment	I	264-271
malformations	I	272-285
including	O	286-295
Peters	B	296-302
anomaly	I	303-310
.	O	310-311

First	O	312-317
,	O	317-318
a	O	319-320
child	O	321-326
with	O	327-331
Peters	B	332-338
anomaly	I	339-346
is	O	347-349
deleted	O	350-357
for	O	358-361
one	O	362-365
copy	O	366-370
of	O	371-373
PAX6	O	374-378
.	O	378-379

Second	O	380-386
,	O	386-387
affected	O	388-396
members	O	397-404
of	O	405-407
a	O	408-409
family	O	410-416
with	O	417-421
dominantly	O	422-432
inherited	O	433-442
anterior	B	443-451
segment	I	452-459
malformations	I	460-473
,	O	473-474
including	O	475-484
Peters	B	485-491
anomaly	I	492-499
are	O	500-503
heterozygous	O	504-516
for	O	517-520
an	O	521-523
R26G	O	524-528
mutation	O	529-537
in	O	538-540
the	O	541-544
PAX6	O	545-549
paired	O	550-556
box	O	557-560
.	O	560-561

Third	O	562-567
,	O	567-568
a	O	569-570
proportion	O	571-581
of	O	582-584
Sey	O	585-588
/	O	588-589
+	O	589-590
Smalleye	O	591-599
mice	O	600-604
,	O	604-605
heterozygous	O	606-618
for	O	619-622
a	O	623-624
nonsense	O	625-633
mutation	O	634-642
in	O	643-645
murine	O	646-652
Pax	O	653-656
-	O	656-657
6	O	657-658
,	O	658-659
have	O	660-664
an	O	665-667
ocular	O	668-674
phenotype	O	675-684
resembling	O	685-695
Peters	B	696-702
anomaly	I	703-710
.	O	710-711

We	O	712-714
therefore	O	715-724
propose	O	725-732
that	O	733-737
a	O	738-739
variety	O	740-747
of	O	748-750
anterior	B	751-759
segment	I	760-767
anomalies	I	768-777
may	O	778-781
be	O	782-784
associated	O	785-795
with	O	796-800
PAX6	O	801-805
mutations	O	806-815
.	O	815-816
.	O	815-816

In	O	0-2
Swedish	O	3-10
families	O	11-19
with	O	20-24
hereditary	B	25-35
prostate	I	36-44
cancer	I	45-51
,	O	51-52
linkage	O	53-60
to	O	61-63
the	O	64-67
HPC1	O	68-72
locus	O	73-78
on	O	79-81
chromosome	O	82-92
1q24	O	93-97
-	O	97-98
25	O	98-100
is	O	101-103
restricted	O	104-114
to	O	115-117
families	O	118-126
with	O	127-131
early	O	132-137
-	O	137-138
onset	O	138-143
prostate	B	144-152
cancer	I	153-159
.	O	159-160

Prostate	B	161-169
cancer	I	170-176
clusters	O	177-185
in	O	186-188
some	O	189-193
families	O	194-202
,	O	202-203
and	O	204-207
an	O	208-210
estimated	O	211-220
5	O	221-222
%	O	222-223
-	O	224-225
10	O	225-227
%	O	227-228
of	O	229-231
all	O	232-235
cases	O	236-241
are	O	242-245
estimated	O	246-255
to	O	256-258
result	O	259-265
from	O	266-270
inheritance	O	271-282
of	O	283-285
prostate	O	286-294
cancer	O	295-301
-	O	301-302
susceptibility	O	302-316
genes	O	317-322
.	O	322-323

We	O	324-326
previously	O	327-337
reported	O	338-346
evidence	O	347-355
of	O	356-358
linkage	O	359-366
to	O	367-369
the	O	370-373
1q24	O	374-378
-	O	378-379
25	O	379-381
region	O	382-388
(	O	389-390
HPC1	O	390-394
)	O	394-395
in	O	396-398
91	O	399-401
North	O	402-407
American	O	408-416
and	O	417-420
Swedish	O	421-428
families	O	429-437
each	O	438-442
with	O	443-447
multiple	O	448-456
cases	O	457-462
of	O	463-465
prostate	B	466-474
cancer	I	475-481
(	O	482-483
Smith	O	483-488
et	O	489-491
al	O	492-494
.	O	494-495
1996	O	496-500
)	O	500-501
.	O	501-502

In	O	503-505
the	O	506-509
present	O	510-517
report	O	518-524
we	O	525-527
analyze	O	528-535
40	O	536-538
(	O	539-540
12	O	540-542
original	O	543-551
and	O	552-555
28	O	556-558
newly	O	559-564
identified	O	565-575
)	O	575-576
Swedish	O	577-584
families	O	585-593
with	O	594-598
hereditary	B	599-609
prostate	I	610-618
cancer	I	619-625
(	O	626-627
HPC	B	627-630
)	O	630-631
that	O	632-636
,	O	636-637
on	O	638-640
the	O	641-644
basis	O	645-650
of	O	651-653
40	O	654-656
markers	O	657-664
spanning	O	665-673
a	O	674-675
25	O	676-678
-	O	678-679
cM	O	679-681
interval	O	682-690
within	O	691-697
1q24	O	698-702
-	O	702-703
25	O	703-705
,	O	705-706
have	O	707-711
evidence	O	712-720
of	O	721-723
linkage	O	724-731
.	O	731-732

In	O	733-735
the	O	736-739
complete	O	740-748
set	O	749-752
of	O	753-755
families	O	756-764
,	O	764-765
a	O	766-767
maximum	O	768-775
two	O	776-779
-	O	779-780
point	O	780-785
LOD	O	786-789
score	O	790-795
of	O	796-798
1	O	799-800
.	O	800-801
10	O	802-804
was	O	805-808
observed	O	809-817
at	O	818-820
D1S413	O	821-827
(	O	828-829
at	O	829-831
a	O	832-833
recombination	O	834-847
fraction	O	848-856
[	O	857-858
theta	O	858-863
]	O	863-864
of	O	865-867
.	O	867-868

1	O	869-870
)	O	870-871
,	O	871-872
with	O	873-877
a	O	878-879
maximum	O	880-887
NPL	O	888-891
(	O	892-893
nonparametric	O	893-906
linkage	O	907-914
)	O	914-915
Z	O	916-917
score	O	918-923
of	O	924-926
1	O	927-928
.	O	928-929
64	O	930-932
at	O	933-935
D1S202	O	936-942
(	O	943-944
P	O	944-945
=	O	946-947
.	O	947-948
05	O	949-951
)	O	951-952
.	O	952-953

The	O	954-957
evidence	O	958-966
of	O	967-969
linkage	O	970-977
to	O	978-980
this	O	981-985
region	O	986-992
originated	O	993-1003
almost	O	1004-1010
exclusively	O	1011-1022
from	O	1023-1027
the	O	1028-1031
subset	O	1032-1038
of	O	1039-1041
12	O	1042-1044
early	O	1045-1050
-	O	1050-1051
onset	O	1051-1056
(	O	1057-1058
age	O	1058-1061
<	O	1062-1063
65	O	1064-1066
years	O	1067-1072
)	O	1072-1073
families	O	1074-1082
,	O	1082-1083
which	O	1084-1089
yielded	O	1090-1097
a	O	1098-1099
maximum	O	1100-1107
LOD	O	1108-1111
score	O	1112-1117
of	O	1118-1120
2	O	1121-1122
.	O	1122-1123
38	O	1124-1126
at	O	1127-1129
D1S413	O	1130-1136
(	O	1137-1138
straight	O	1138-1146
theta	O	1147-1152
=	O	1153-1154
0	O	1155-1156
)	O	1156-1157
and	O	1158-1161
an	O	1162-1164
NPL	O	1165-1168
Z	O	1169-1170
score	O	1171-1176
of	O	1177-1179
1	O	1180-1181
.	O	1181-1182
95	O	1183-1185
at	O	1186-1188
D1S422	O	1189-1195
(	O	1196-1197
P	O	1197-1198
=	O	1199-1200
.	O	1200-1201
03	O	1202-1204
)	O	1204-1205
.	O	1205-1206

Estimates	O	1207-1216
from	O	1217-1221
heterogeneity	O	1222-1235
tests	O	1236-1241
suggest	O	1242-1249
that	O	1250-1254
,	O	1254-1255
within	O	1256-1262
Sweden	O	1263-1269
,	O	1269-1270
as	O	1271-1273
many	O	1274-1278
as	O	1279-1281
50	O	1282-1284
%	O	1284-1285
of	O	1286-1288
early	O	1289-1294
-	O	1294-1295
onset	O	1295-1300
families	O	1301-1309
had	O	1310-1313
evidence	O	1314-1322
of	O	1323-1325
linkage	O	1326-1333
to	O	1334-1336
the	O	1337-1340
HPC1	O	1341-1345
region	O	1346-1352
.	O	1352-1353

These	O	1354-1359
results	O	1360-1367
are	O	1368-1371
consistent	O	1372-1382
with	O	1383-1387
the	O	1388-1391
hypothesis	O	1392-1402
of	O	1403-1405
linkage	O	1406-1413
to	O	1414-1416
HPC1	O	1417-1421
in	O	1422-1424
a	O	1425-1426
subset	O	1427-1433
of	O	1434-1436
families	O	1437-1445
with	O	1446-1450
prostate	B	1451-1459
cancer	I	1460-1466
,	O	1466-1467
particularly	O	1468-1480
those	O	1481-1486
with	O	1487-1491
an	O	1492-1494
early	O	1495-1500
age	O	1501-1504
at	O	1505-1507
diagnosis	O	1508-1517
.	O	1517-1518

Localisation	O	0-12
of	O	13-15
the	O	16-19
myotonic	B	20-28
dystrophy	I	29-38
locus	O	39-44
to	O	45-47
19q13	O	48-53
.	O	53-54
2	O	54-55
-	O	55-56
19q13	O	48-53
.	O	53-54
3	O	52-53

and	O	64-67
its	O	68-71
relationship	O	72-84
to	O	85-87
twelve	O	88-94
polymorphic	O	95-106
loci	O	107-111
on	O	112-114
19q	O	115-118
.	O	118-119

The	O	120-123
order	O	124-129
of	O	130-132
fourteen	O	133-141
polymorphic	O	142-153
markers	O	154-161
localised	O	162-171
to	O	172-174
the	O	175-178
long	O	179-183
arm	O	184-187
of	O	188-190
human	O	191-196
chromosome	O	197-207
19	O	208-210
has	O	211-214
been	O	215-219
established	O	220-231
by	O	232-234
multipoint	O	235-245
mapping	O	246-253
in	O	254-256
a	O	257-258
set	O	259-262
of	O	263-265
40	O	266-268
CEPH	O	269-273
(	O	274-275
Centre	O	275-281
dEtude	O	282-288
de	O	289-291
Polymorphisme	O	292-305
Humain	O	306-312
,	O	312-313
Paris	O	314-319
)	O	319-320
reference	O	321-330
families	O	331-339
.	O	339-340

We	O	341-343
report	O	344-350
here	O	351-355
the	O	356-359
linkage	O	360-367
relationship	O	368-380
of	O	381-383
the	O	384-387
myotonic	B	388-396
dystrophy	I	397-406
(	O	407-408
DM	B	408-410
)	O	410-411
locus	O	412-417
to	O	418-420
twelve	O	421-427
of	O	428-430
these	O	431-436
markers	O	437-444
as	O	445-447
studied	O	448-455
in	O	456-458
45	O	459-461
families	O	462-470
with	O	471-475
DM	B	476-478
.	O	478-479

The	O	480-483
resulting	O	484-493
genetic	O	494-501
map	O	502-505
is	O	506-508
supported	O	509-518
by	O	519-521
the	O	522-525
localisation	O	526-538
of	O	539-541
the	O	542-545
DNA	O	546-549
markers	O	550-557
in	O	558-560
a	O	561-562
panel	O	563-568
of	O	569-571
somatic	O	572-579
cell	O	580-584
hybrids	O	585-592
.	O	592-593

Ten	O	594-597
of	O	598-600
the	O	601-604
twelve	O	605-611
markers	O	612-619
have	O	620-624
been	O	625-629
shown	O	630-635
to	O	636-638
be	O	639-641
proximal	O	642-650
to	O	651-653
the	O	654-657
DM	B	658-660
gene	O	661-665
and	O	666-669
two	O	670-673
,	O	673-674
PRKCG	O	675-680
and	O	681-684
D19S22	O	685-691
,	O	691-692
distal	O	693-699
but	O	700-703
at	O	704-706
distances	O	707-716
of	O	717-719
approximately	O	720-733
25	O	734-736
cM	O	737-739
and	O	740-743
15	O	744-746
cM	O	747-749
,	O	749-750
respectively	O	751-763
.	O	763-764

The	O	765-768
closest	O	769-776
proximal	O	777-785
markers	O	786-793
are	O	794-797
APOC2	O	798-803
(	O	804-805
apolipoprotein	O	805-819
C	O	820-821
-	O	821-822
II	O	822-824
)	O	824-825
and	O	826-829
CKM	O	830-833
(	O	834-835
creatine	O	835-843
kinase	O	844-850
,	O	850-851
muscle	O	852-858
)	O	858-859
approximately	O	860-873
3	O	874-875
cM	O	876-878
and	O	879-882
2	O	883-884
cM	O	885-887
from	O	888-892
the	O	893-896
DM	B	897-899
gene	O	900-904
respectively	O	905-917
,	O	917-918
in	O	919-921
the	O	922-925
order	O	926-931
APOC2	O	932-937
-	O	937-938
CKM	O	938-941
-	O	937-938
DM	O	942-944
.	O	944-945

The	O	946-949
distance	O	950-958
between	O	959-966
APOC2	O	967-972
,	O	972-973
CKM	O	974-977
and	O	978-981
DM	B	982-984
(	O	985-986
of	O	986-988
the	O	989-992
order	O	993-998
of	O	999-1001
2	O	1002-1003
million	O	1004-1011
base	O	1012-1016
pairs	O	1017-1022
)	O	1022-1023
and	O	1024-1027
their	O	1028-1033
known	O	1034-1039
orientation	O	1040-1051
should	O	1052-1058
permit	O	1059-1065
directional	O	1066-1077
chromosome	O	1078-1088
walking	O	1089-1096
and	O	1097-1100
jumping	O	1101-1108
.	O	1108-1109

The	O	1110-1113
data	O	1114-1118
presented	O	1119-1128
here	O	1129-1133
should	O	1134-1140
enable	O	1141-1147
us	O	1148-1150
to	O	1151-1153
determine	O	1154-1163
whether	O	1164-1171
or	O	1172-1174
not	O	1175-1178
new	O	1179-1182
markers	O	1183-1190
are	O	1191-1194
distal	O	1195-1201
to	O	1202-1204
APOC2	O	1205-1210
/	O	1210-1211
CKM	O	1211-1214
and	O	1215-1218
thus	O	1219-1223
potentially	O	1224-1235
flank	O	1236-1241
the	O	1242-1245
DM	B	1246-1248
gene	O	1249-1253
.	O	1253-1254
.	O	1253-1254

A	O	0-1
recurrent	O	2-11
expansion	O	12-21
of	O	22-24
a	O	25-26
maternal	O	27-35
allele	O	36-42
with	O	43-47
36	O	48-50
CAG	O	51-54
repeats	O	55-62
causes	O	63-69
Huntington	B	70-80
disease	I	81-88
in	O	89-91
two	O	92-95
sisters	O	96-103
.	O	103-104

Large	O	105-110
intergenerational	O	111-128
repeat	O	129-135
expansions	O	136-146
of	O	147-149
the	O	150-153
CAG	O	154-157
trinucleotide	O	158-171
repeat	O	172-178
in	O	179-181
the	O	182-185
HD	B	186-188
gene	O	189-193
have	O	194-198
been	O	199-203
well	O	204-208
documented	O	209-219
for	O	220-223
the	O	224-227
male	O	228-232
germline	O	233-241
.	O	241-242

We	O	243-245
describe	O	246-254
a	O	255-256
recurrent	O	257-266
large	O	267-272
expansion	O	273-282
of	O	283-285
a	O	286-287
maternal	O	288-296
allele	O	297-303
with	O	304-308
36	O	309-311
CAG	O	312-315
repeats	O	316-323
(	O	324-325
to	O	325-327
66	O	328-330
and	O	331-334
57	O	335-337
repeats	O	338-345
,	O	345-346
respectively	O	347-359
,	O	359-360
in	O	361-363
two	O	364-367
daughters	O	368-377
)	O	377-378
associated	O	379-389
with	O	390-394
onset	O	395-400
of	O	401-403
Huntington	B	404-414
disease	I	415-422
(	O	423-424
HD	B	424-426
)	O	426-427
in	O	428-430
the	O	431-434
second	O	435-441
and	O	442-445
third	O	446-451
decade	O	452-458
in	O	459-461
a	O	462-463
family	O	464-470
without	O	471-478
history	O	479-486
of	O	487-489
HD	B	490-492
.	O	492-493

Our	O	494-497
findings	O	498-506
give	O	507-511
evidence	O	512-520
of	O	521-523
a	O	524-525
gonadal	O	526-533
mosaicism	O	534-543
in	O	544-546
the	O	547-550
unaffected	O	551-561
mother	O	562-568
.	O	568-569

We	O	570-572
hypothesize	O	573-584
that	O	585-589
large	O	590-595
expansions	O	596-606
also	O	607-611
occur	O	612-617
in	O	618-620
the	O	621-624
female	O	625-631
germline	O	632-640
and	O	641-644
that	O	645-649
a	O	650-651
negative	O	652-660
selection	O	661-670
of	O	671-673
oocytes	O	674-681
with	O	682-686
long	O	687-691
repeats	O	692-699
might	O	700-705
explain	O	706-713
the	O	714-717
different	O	718-727
instability	O	728-739
behavior	O	740-748
of	O	749-751
the	O	752-755
male	O	756-760
and	O	761-764
the	O	765-768
female	O	769-775
germlines	O	776-785
.	O	785-786
.	O	785-786

Germline	O	0-8
E	O	9-10
-	O	10-11
cadherin	O	11-19
gene	O	20-24
(	O	25-26
CDH1	O	26-30
)	O	30-31
mutations	O	32-41
predispose	O	42-52
to	O	53-55
familial	B	56-64
gastric	I	65-72
cancer	I	73-79
and	O	80-83
colorectal	B	84-94
cancer	I	95-101
.	O	101-102

Inherited	O	103-112
mutations	O	113-122
in	O	123-125
the	O	126-129
E	O	130-131
-	O	131-132
cadherin	O	132-140
gene	O	141-145
(	O	146-147
CDH1	O	147-151
)	O	151-152
were	O	153-157
described	O	158-167
recently	O	168-176
in	O	177-179
three	O	180-185
Maori	O	186-191
kindreds	O	192-200
with	O	201-205
familial	B	206-214
gastric	I	215-222
cancer	I	223-229
.	O	229-230

Familial	B	231-239
gastric	I	240-247
cancer	I	248-254
is	O	255-257
genetically	O	258-269
heterogeneous	O	270-283
and	O	284-287
it	O	288-290
is	O	291-293
not	O	294-297
clear	O	298-303
what	O	304-308
proportion	O	309-319
of	O	320-322
gastric	B	323-330
cancer	I	331-337
susceptibility	O	338-352
in	O	353-355
non	O	356-359
-	O	359-360
Maori	O	360-365
populations	O	366-377
is	O	378-380
due	O	381-384
to	O	385-387
germline	O	388-396
CDH1	O	397-401
mutations	O	402-411
.	O	411-412

Therefore	O	413-422
,	O	422-423
we	O	424-426
screened	O	427-435
eight	O	436-441
familial	B	442-450
gastric	I	451-458
cancer	I	459-465
kindreds	O	466-474
of	O	475-477
British	O	478-485
and	O	486-489
Irish	O	490-495
origin	O	496-502
for	O	503-506
germline	O	507-515
CDH1	O	516-520
mutations	O	521-530
,	O	530-531
by	O	532-534
SSCP	O	535-539
analysis	O	540-548
of	O	549-551
all	O	552-555
16	O	556-558
exons	O	559-564
and	O	565-568
flanking	O	569-577
sequences	O	578-587
.	O	587-588

Each	O	589-593
family	O	594-600
contained	O	601-610
(	O	612-613
i	O	613-614
)	O	614-615
two	O	616-619
cases	O	620-625
of	O	626-628
gastric	B	629-636
cancer	I	637-643
in	O	644-646
first	O	647-652
degree	O	653-659
relatives	O	660-669
with	O	670-674
one	O	675-678
affected	O	679-687
before	O	688-694
age	O	695-698
50	O	699-701
years	O	702-707
;	O	707-708
or	O	709-711
(	O	712-713
ii	O	713-715
)	O	715-716
three	O	717-722
or	O	723-725
more	O	726-730
cases	O	731-736
of	O	737-739
gastric	B	740-747
cancer	I	748-754
.	O	754-755

Novel	O	756-761
germline	O	762-770
CDH1	O	771-775
mutations	O	776-785
(	O	786-787
a	O	787-788
nonsense	O	789-797
and	O	798-801
a	O	802-803
splice	O	804-810
site	O	811-815
)	O	815-816
were	O	817-821
detected	O	822-830
in	O	831-833
two	O	834-837
families	O	838-846
(	O	847-848
25	O	848-850
%	O	850-851
)	O	851-852
.	O	852-853

Both	O	854-858
mutations	O	859-868
were	O	869-873
predicted	O	874-883
to	O	884-886
truncate	O	887-895
the	O	896-899
E	O	900-901
-	O	901-902
cadherin	O	902-910
protein	O	911-918
in	O	919-921
the	O	922-925
signal	O	926-932
peptide	O	933-940
domain	O	941-947
.	O	947-948

In	O	949-951
one	O	952-955
family	O	956-962
there	O	963-968
was	O	969-972
evidence	O	973-981
of	O	982-984
non	O	985-988
-	O	988-989
penetrance	O	989-999
and	O	1000-1003
susceptibility	O	1004-1018
to	O	1019-1021
both	O	1022-1026
gastric	B	1027-1034
and	I	1035-1038
colorectal	I	1039-1049
cancer	I	1050-1056
;	O	1056-1057
thus	O	1058-1062
,	O	1062-1063
in	O	1064-1066
addition	O	1067-1075
to	O	1076-1078
six	O	1079-1082
cases	O	1083-1088
of	O	1089-1091
gastric	B	1092-1099
cancer	I	1100-1106
,	O	1106-1107
a	O	1108-1109
CDH1	O	1110-1114
mutation	O	1115-1123
carrier	O	1124-1131
developed	O	1132-1141
colorectal	B	1142-1152
cancer	I	1153-1159
at	O	1160-1162
age	O	1163-1166
30	O	1167-1169
years	O	1170-1175
.	O	1175-1176

We	O	1177-1179
have	O	1180-1184
confirmed	O	1185-1194
that	O	1195-1199
germline	O	1200-1208
mutations	O	1209-1218
in	O	1219-1221
the	O	1222-1225
CDH1	O	1226-1230
gene	O	1231-1235
cause	O	1236-1241
familial	B	1242-1250
gastric	I	1251-1258
cancer	I	1259-1265
in	O	1266-1268
non	O	1269-1272
-	O	1272-1273
Maori	O	1273-1278
populations	O	1279-1290
.	O	1290-1291

However	O	1292-1299
,	O	1299-1300
only	O	1301-1305
a	O	1306-1307
minority	O	1308-1316
of	O	1317-1319
familial	O	1320-1328
gastric	B	1329-1336
cancers	I	1337-1344
can	O	1345-1348
be	O	1349-1351
accounted	O	1352-1361
for	O	1362-1365
by	O	1366-1368
CDH1	O	1369-1373
mutations	O	1374-1383
.	O	1383-1384

Loss	O	1385-1389
of	O	1390-1392
E	O	1393-1394
-	O	1394-1395
cadherin	O	1395-1403
function	O	1404-1412
has	O	1413-1416
been	O	1417-1421
implicated	O	1422-1432
in	O	1433-1435
the	O	1436-1439
pathogenesis	O	1440-1452
of	O	1453-1455
sporadic	O	1456-1464
colorectal	B	1465-1475
and	I	1476-1479
other	I	1480-1485
cancers	I	1486-1493
,	O	1493-1494
and	O	1495-1498
our	O	1499-1502
findings	O	1503-1511
provide	O	1512-1519
evidence	O	1520-1528
that	O	1529-1533
germline	O	1534-1542
CDH1	O	1543-1547
mutations	O	1548-1557
predispose	O	1558-1568
to	O	1569-1571
early	O	1572-1577
onset	O	1578-1583
colorectal	B	1584-1594
cancer	I	1595-1601
.	O	1601-1602

Thus	O	1603-1607
,	O	1607-1608
CDH1	O	1609-1613
should	O	1614-1620
be	O	1621-1623
investigated	O	1624-1636
as	O	1637-1639
a	O	1640-1641
cause	O	1642-1647
of	O	1648-1650
inherited	O	1651-1660
susceptibility	O	1661-1675
to	O	1676-1678
both	O	1679-1683
gastric	B	1684-1691
and	I	1692-1695
colorectal	I	1696-1706
cancers	I	1707-1714
.	O	1714-1715

Germinal	O	0-8
mosaicism	O	9-18
in	O	19-21
Duchenne	B	22-30
muscular	I	31-39
dystrophy	I	40-49
.	O	49-50

We	O	51-53
have	O	54-58
identified	O	59-69
a	O	70-71
Duchenne	B	72-80
muscular	I	81-89
dystrophy	I	90-99
(	O	100-101
DMD	B	101-104
)	O	104-105
pedigree	O	106-114
where	O	115-120
the	O	121-124
disease	O	125-132
is	O	133-135
associated	O	136-146
with	O	147-151
a	O	152-153
molecular	O	154-163
deletion	O	164-172
within	O	173-179
the	O	180-183
DMD	B	184-187
locus	O	188-193
.	O	193-194

We	O	195-197
have	O	198-202
examined	O	203-211
the	O	212-215
meiotic	O	216-223
segregation	O	224-235
products	O	236-244
of	O	245-247
the	O	248-251
common	O	252-258
female	O	259-265
ancestor	O	266-274
using	O	275-280
marker	O	281-287
restriction	O	288-299
fragment	O	300-308
length	O	309-315
polymorphisms	O	316-329
(	O	330-331
RFLPs	O	331-336
)	O	336-337
detected	O	338-346
by	O	347-349
probes	O	350-356
that	O	357-361
lie	O	362-365
within	O	366-372
this	O	373-377
deletion	O	378-386
.	O	386-387

These	O	388-393
studies	O	394-401
show	O	402-406
that	O	407-411
this	O	412-416
female	O	417-423
has	O	424-427
transmitted	O	428-439
three	O	440-445
distinct	O	446-454
types	O	455-460
of	O	461-463
X	O	464-465
chromosome	O	466-476
to	O	477-479
her	O	480-483
offspring	O	484-493
.	O	493-494

This	O	495-499
observation	O	500-511
may	O	512-515
be	O	516-518
explained	O	519-528
by	O	529-531
postulating	O	532-543
that	O	544-548
the	O	549-552
mutation	O	553-561
arose	O	562-567
as	O	568-570
a	O	571-572
postzygotic	O	573-584
deletion	O	585-593
within	O	594-600
this	O	601-605
common	O	606-612
ancestor	O	613-621
,	O	621-622
who	O	623-626
was	O	627-630
consequently	O	631-643
germinally	O	644-654
mosaic	O	655-661
.	O	661-662
.	O	661-662

Expression	O	0-10
of	O	11-13
the	O	14-17
murine	O	18-24
Duchenne	B	25-33
muscular	I	34-42
dystrophy	I	43-52
gene	O	53-57
in	O	58-60
muscle	O	61-67
and	O	68-71
brain	O	72-77
.	O	77-78

Complementary	O	79-92
DNA	O	93-96
clones	O	97-103
were	O	104-108
isolated	O	109-117
that	O	118-122
represent	O	123-132
the	O	133-136
5	O	137-138
terminal	O	139-147
2	O	148-149
.	O	149-150
5	O	151-152
kilobases	O	153-162
of	O	163-165
the	O	166-169
murine	O	170-176
Duchenne	B	177-185
muscular	I	186-194
dystrophy	I	195-204
(	O	205-206
Dmd	O	206-209
)	O	209-210
messenger	O	211-220
RNA	O	221-224
(	O	225-226
mRNA	O	226-230
)	O	230-231
.	O	231-232

Mouse	O	233-238
Dmd	O	239-242
mRNA	O	243-247
was	O	248-251
detectable	O	252-262
in	O	263-265
skeletal	O	266-274
and	O	275-278
cardiac	O	279-286
muscle	O	287-293
and	O	294-297
at	O	298-300
a	O	301-302
level	O	303-308
approximately	O	309-322
90	O	323-325
percent	O	326-333
lower	O	334-339
in	O	340-342
brain	O	343-348
.	O	348-349

Dmd	O	350-353
mRNA	O	354-358
is	O	359-361
also	O	362-366
present	O	367-374
,	O	374-375
but	O	376-379
at	O	380-382
much	O	383-387
lower	O	388-393
than	O	394-398
normal	O	399-405
levels	O	406-412
,	O	412-413
in	O	414-416
both	O	417-421
the	O	422-425
muscle	O	426-432
and	O	433-436
brain	O	437-442
of	O	443-445
three	O	446-451
different	O	452-461
strains	O	462-469
of	O	470-472
dystrophic	B	473-483
mdx	O	484-487
mice	O	488-492
.	O	492-493

The	O	494-497
identification	O	498-512
of	O	513-515
Dmd	O	516-519
mRNA	O	520-524
in	O	525-527
brain	O	528-533
raises	O	534-540
the	O	541-544
possibility	O	545-556
of	O	557-559
a	O	560-561
relation	O	562-570
between	O	571-578
human	O	579-584
Duchenne	B	585-593
muscular	I	594-602
dystrophy	I	603-612
(	O	613-614
DMD	B	614-617
)	O	617-618
gene	O	619-623
expression	O	624-634
and	O	635-638
the	O	639-642
mental	B	643-649
retardation	I	650-661
found	O	662-667
in	O	668-670
some	O	671-675
DMD	B	676-679
males	O	680-685
.	O	685-686

These	O	687-692
results	O	693-700
also	O	701-705
provide	O	706-713
evidence	O	714-722
that	O	723-727
the	O	728-731
mdx	O	732-735
mutations	O	736-745
are	O	746-749
allelic	O	750-757
variants	O	758-766
of	O	767-769
mouse	O	770-775
Dmd	O	776-779
gene	O	780-784
mutations	O	785-794
.	O	794-795

Human	O	0-5
peroxisomal	O	6-17
targeting	O	18-27
signal	O	28-34
-	O	34-35
1	O	35-36
receptor	O	37-45
restores	O	46-54
peroxisomal	O	55-66
protein	O	67-74
import	O	75-81
in	O	82-84
cells	O	85-90
from	O	91-95
patients	O	96-104
with	O	105-109
fatal	O	110-115
peroxisomal	B	116-127
disorders	I	128-137
.	O	137-138

Two	O	139-142
peroxisomal	O	143-154
targeting	O	155-164
signals	O	165-172
,	O	172-173
PTS1	O	174-178
and	O	179-182
PTS2	O	183-187
,	O	187-188
are	O	189-192
involved	O	193-201
in	O	202-204
the	O	205-208
import	O	209-215
of	O	216-218
proteins	O	219-227
into	O	228-232
the	O	233-236
peroxisome	O	237-247
matrix	O	248-254
.	O	254-255

Human	O	256-261
patients	O	262-270
with	O	271-275
fatal	O	276-281
generalized	O	282-293
peroxisomal	B	294-305
deficiency	I	306-316
disorders	I	317-326
fall	O	327-331
into	O	332-336
at	O	337-339
least	O	340-345
nine	O	346-350
genetic	O	351-358
complementation	O	359-374
groups	O	375-381
.	O	381-382

Cells	O	383-388
from	O	389-393
many	O	394-398
of	O	399-401
these	O	402-407
patients	O	408-416
are	O	417-420
deficient	O	421-430
in	O	431-433
the	O	434-437
import	O	438-444
of	O	445-447
PTS1	O	448-452
-	O	452-453
containing	O	453-463
proteins	O	464-472
,	O	472-473
but	O	474-477
the	O	478-481
causes	O	482-488
of	O	489-491
the	O	492-495
protein	O	496-503
-	O	503-504
import	O	504-510
defect	O	511-517
in	O	518-520
these	O	521-526
patients	O	527-535
are	O	536-539
unknown	O	540-547
.	O	547-548

We	O	549-551
have	O	552-556
cloned	O	557-563
and	O	564-567
sequenced	O	568-577
the	O	578-581
human	O	582-587
cDNA	O	588-592
homologue	O	593-602
(	O	603-604
PTS1R	O	604-609
)	O	609-610
of	O	611-613
the	O	614-617
Pichia	O	618-624
pastoris	O	625-633
PAS8	O	634-638
gene	O	639-643
,	O	643-644
the	O	645-648
PTS1	O	649-653
receptor	O	654-662
(	O	663-664
McCollum	O	664-672
,	O	672-673
D	O	674-675
.	O	675-676
,	O	676-677
E	O	678-679
.	O	679-680
Monosov	O	681-688
,	O	688-689
and	O	690-693
S	O	694-695
.	O	695-696
Subramani	O	697-706
.	O	706-707

1993	O	708-712
.	O	712-713

J	O	714-715
.	O	715-716
Cell	O	717-721
Biol	O	722-726
.	O	726-727

121	O	728-731
761	O	733-736
-	O	736-737
774	O	737-740
)	O	740-741
.	O	741-742

The	O	743-746
PTS1R	O	747-752
mRNA	O	753-757
is	O	758-760
expressed	O	761-770
in	O	771-773
all	O	774-777
human	O	778-783
tissues	O	784-791
examined	O	792-800
.	O	800-801

Antibodies	O	802-812
to	O	813-815
the	O	816-819
human	O	820-825
PTS1R	O	826-831
recognize	O	832-841
this	O	842-846
protein	O	847-854
in	O	855-857
human	O	858-863
,	O	863-864
monkey	O	865-871
,	O	871-872
rat	O	873-876
,	O	876-877
and	O	878-881
hamster	O	882-889
cells	O	890-895
.	O	895-896

The	O	897-900
protein	O	901-908
is	O	909-911
localized	O	912-921
mainly	O	922-928
in	O	929-931
the	O	932-935
cytosol	O	936-943
but	O	944-947
is	O	948-950
also	O	951-955
found	O	956-961
to	O	962-964
be	O	965-967
associated	O	968-978
with	O	979-983
peroxisomes	O	984-995
.	O	995-996

Part	O	997-1001
of	O	1002-1004
the	O	1005-1008
peroxisomal	O	1009-1020
PTS1R	O	1021-1026
protein	O	1027-1034
is	O	1035-1037
tightly	O	1038-1045
bound	O	1046-1051
to	O	1052-1054
the	O	1055-1058
peroxisomal	O	1059-1070
membrane	O	1071-1079
.	O	1079-1080

Antibodies	O	1081-1091
to	O	1092-1094
PTS1R	O	1095-1100
inhibit	O	1101-1108
peroxisomal	O	1109-1120
protein	O	1121-1128
-	O	1128-1129
import	O	1129-1135
of	O	1136-1138
PTS1	O	1139-1143
-	O	1143-1144
containing	O	1144-1154
proteins	O	1155-1163
in	O	1164-1166
a	O	1167-1168
permeabilized	O	1169-1182
CHO	O	1183-1186
cell	O	1187-1191
system	O	1192-1198
.	O	1198-1199

In	O	1200-1202
vitro	O	1203-1208
-	O	1208-1209
translated	O	1209-1219
PTS1R	O	1220-1225
protein	O	1226-1233
specifically	O	1234-1246
binds	O	1247-1252
a	O	1253-1254
serine	O	1255-1261
-	O	1261-1262
lysine	O	1262-1268
-	O	1261-1262
leucine	O	1269-1276
-	O	1261-1262
peptide	O	1277-1284
.	O	1284-1285

A	O	1286-1287
PAS8	O	1288-1292
-	O	1292-1293
PTS1R	O	1293-1298
fusion	O	1299-1305
protein	O	1306-1313
complements	O	1314-1325
the	O	1326-1329
P	O	1330-1331
.	O	1331-1332
pastoris	O	1333-1341
pas8	O	1342-1346
mutant	O	1347-1353
.	O	1353-1354

The	O	1355-1358
PTS1R	O	1359-1364
cDNA	O	1365-1369
also	O	1370-1374
complements	O	1375-1386
the	O	1387-1390
PTS1	B	1391-1395
protein	I	1396-1403
-	I	1403-1404
import	I	1404-1410
defect	I	1411-1417
in	O	1418-1420
skin	O	1421-1425
fibroblasts	O	1426-1437
from	O	1438-1442
patients	O	1443-1451
-	O	1451-1452
-	O	1451-1452
belonging	O	1453-1462
to	O	1463-1465
complementation	O	1466-1481
group	O	1482-1487
two	O	1488-1491
-	O	1491-1492
-	O	1491-1492
diagnosed	O	1493-1502
as	O	1503-1505
having	O	1506-1512
neonatal	B	1513-1521
adrenoleukodystrophy	I	1522-1542
or	O	1543-1545
Zellweger	B	1546-1555
syndrome	I	1556-1564
.	O	1564-1565

The	O	1566-1569
PTS1R	O	1570-1575
gene	O	1576-1580
has	O	1581-1584
been	O	1585-1589
localized	O	1590-1599
to	O	1600-1602
a	O	1603-1604
chromosomal	O	1605-1616
location	O	1617-1625
where	O	1626-1631
no	O	1632-1634
other	O	1635-1640
peroxisomal	B	1641-1652
disorder	I	1653-1661
genes	O	1662-1667
are	O	1668-1671
known	O	1672-1677
to	O	1678-1680
map	O	1681-1684
.	O	1684-1685

Our	O	1686-1689
findings	O	1690-1698
represent	O	1699-1708
the	O	1709-1712
only	O	1713-1717
case	O	1718-1722
in	O	1723-1725
which	O	1726-1731
the	O	1732-1735
molecular	O	1736-1745
basis	O	1746-1751
of	O	1752-1754
the	O	1755-1758
protein	B	1759-1766
-	I	1766-1767
import	I	1767-1773
deficiency	I	1774-1784
in	O	1785-1787
human	O	1788-1793
peroxisomal	B	1794-1805
disorders	I	1806-1815
is	O	1816-1818
understood	O	1819-1829
.	O	1829-1830

X	B	0-1
-	I	1-2
linked	I	2-8
spastic	I	9-16
paraplegia	I	17-27
and	O	28-31
Pelizaeus	B	32-41
-	I	41-42
Merzbacher	I	42-52
disease	I	53-60
are	O	61-64
allelic	B	65-72
disorders	I	73-82
at	O	83-85
the	O	86-89
proteolipid	O	90-101
protein	O	102-109
locus	O	110-115
.	O	115-116

Three	O	117-122
forms	O	123-128
of	O	129-131
X	B	132-133
-	I	133-134
linked	I	134-140
spastic	I	141-148
paraplegia	I	149-159
(	O	160-161
SPG	B	161-164
)	O	164-165
have	O	166-170
been	O	171-175
defined	O	176-183
.	O	183-184

One	O	185-188
locus	O	189-194
(	O	195-196
SPG	O	196-199
1	O	200-201
)	O	201-202
maps	O	203-207
to	O	208-210
Xq28	O	211-215
while	O	216-221
two	O	222-225
clinically	O	226-236
distinct	O	237-245
forms	O	246-251
map	O	252-255
to	O	256-258
Xq22	O	259-263
(	O	264-265
SPG2	O	265-269
)	O	269-270
.	O	270-271

A	O	272-273
rare	O	274-278
X	B	279-280
-	I	280-281
linked	I	281-287
dysmyelinating	I	288-302
disorder	I	303-311
of	O	312-314
the	O	315-318
central	O	319-326
nervous	O	327-334
system	O	335-341
,	O	341-342
Pelizaeus	B	343-352
-	I	352-353
Merzbacher	I	353-363
disease	I	364-371
(	O	372-373
PMD	B	373-376
)	O	376-377
,	O	377-378
has	O	379-382
also	O	383-387
been	O	388-392
mapped	O	393-399
to	O	400-402
Xq21	O	403-407
-	O	407-408
q22	O	408-411
,	O	411-412
and	O	413-416
is	O	417-419
caused	O	420-426
by	O	427-429
mutations	O	430-439
in	O	440-442
the	O	443-446
proteolipid	O	447-458
protein	O	459-466
gene	O	467-471
(	O	472-473
PLP	O	473-476
)	O	476-477
which	O	478-483
encodes	O	484-491
two	O	492-495
myelin	O	496-502
proteins	O	503-511
,	O	511-512
PLP	O	513-516
and	O	517-520
DM20	O	521-525
.	O	525-526

While	O	527-532
narrowing	O	533-542
the	O	543-546
genetic	O	547-554
interval	O	555-563
containing	O	564-574
SPG2	O	575-579
in	O	580-582
a	O	583-584
large	O	585-590
pedigree	O	591-599
,	O	599-600
we	O	601-603
found	O	604-609
that	O	610-614
PLP	O	615-618
was	O	619-622
the	O	623-626
closest	O	627-634
marker	O	635-641
to	O	642-644
the	O	645-648
disease	O	649-656
locus	O	657-662
,	O	662-663
implicating	O	664-675
PLP	O	676-679
as	O	680-682
a	O	683-684
possible	O	685-693
candidate	O	694-703
gene	O	704-708
.	O	708-709

We	O	710-712
have	O	713-717
found	O	718-723
that	O	724-728
a	O	729-730
point	O	731-736
mutation	O	737-745
(	O	746-747
His139Tyr	O	747-756
)	O	756-757
in	O	758-760
exon	O	761-765
3B	O	766-768
of	O	769-771
an	O	772-774
affected	O	775-783
male	O	784-788
produces	O	789-797
a	O	798-799
mutant	O	800-806
PLP	O	807-810
but	O	811-814
a	O	815-816
normal	O	817-823
DM20	O	824-828
,	O	828-829
and	O	830-833
segregates	O	834-844
with	O	845-849
the	O	850-853
disease	O	854-861
(	O	862-863
Zmax	O	863-867
=	O	868-869
6	O	870-871
.	O	871-872

63	O	873-875
,	O	875-876
theta	O	877-882
=	O	883-884
0	O	885-886
.	O	886-887
00	O	888-890
)	O	890-891
.	O	891-892

It	O	893-895
appears	O	896-903
,	O	903-904
therefore	O	905-914
,	O	914-915
that	O	916-920
SPG2	O	921-925
and	O	926-929
PMD	B	930-933
are	O	934-937
allelic	B	938-945
disorders	I	946-955

